FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Russo, V
   Cardillo, G
   Viggiano, GV
   Mangiacapra, S
   Cavalli, A
   Fontanella, A
   Agrusta, F
   Bellizzi, A
   Amitrano, M
   Iannuzzo, M
   Sacco, C
   Lodigiani, C
   Di Micco, P
AF Russo, Vincenzo
   Cardillo, Giuseppe
   Viggiano, Giuseppe Vito
   Mangiacapra, Sara
   Cavalli, Antonella
   Fontanella, Andrea
   Agrusta, Federica
   Bellizzi, Annamaria
   Amitrano, Maria
   Iannuzzo, Mariateresa
   Sacco, Chiara
   Lodigiani, Corrado
   Di Micco, Pierpaolo
TI Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter
   Real-World Experience
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
LA English
DT Article
AB The use of heparin has been shown to decrease the mortality in hospitalized patients with severe COVID-19. The aim of our study was to evaluate the clinical impact of venous thromboembolism prophylaxis with fondaparinux versus enoxaparin among 100 hospitalized COVID-19 patients. The incidence of pulmonary embolism, deep venous thrombosis, major bleeding (MB), clinically relevant non-MB, acute respiratory distress syndrome, and in-hospital mortality was compared between patients on fondaparinux versus enoxaparin therapy. The 2 groups were homogeneous for demographic, laboratory, and clinical characteristics. In a median follow-up of 28 (IQR: 12-45) days, no statistically significant difference in venous thromboembolism (14.5% vs. 5.3%; P = 0.20), MB and clinically relevant non-MB (3.2% vs. 5.3%, P = 0.76), ARDS (17.7% vs. 15.8%; P = 0.83), and in-hospital mortality (9.7% vs. 10.5%; P = 0.97) has been shown between the enoxaparin group versus the fondaparinux group. Our preliminary results support the hypothesis of a safe and effective use of fondaparinux among patients with COVID-19 hospitalized in internal medicine units.
C1 [Russo, Vincenzo] Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Via Leonardo Bianchi, I-80131 Naples, Italy.
   [Cardillo, Giuseppe] Medylab Inst, Adv Biochem Unit, Lusciano, CE, Italy.
   [Viggiano, Giuseppe Vito; Agrusta, Federica] Marazzini Hosp, Emergency Med Unit, Modena, Italy.
   [Mangiacapra, Sara; Amitrano, Maria] Moscati Hosp, Internal Med Unit, Avellino, Italy.
   [Cavalli, Antonella; Bellizzi, Annamaria] Frangipane Hosp, Internal Med Unit, Ariano Irpino, Italy.
   [Fontanella, Andrea; Iannuzzo, Mariateresa; Di Micco, Pierpaolo] Fatebenefratelli Hosp, Internal Med Unit, Naples, Italy.
   [Sacco, Chiara; Lodigiani, Corrado] Humanitas Res Hosp & Univ, Thrombosis & Hemorrag Ctr, Rozzano, Italy.
RP Russo, V (corresponding author), Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Via Leonardo Bianchi, I-80131 Naples, Italy.
EM vincenzo.russo@unicampania.it
RI Russo, Vincenzo/ABH-1766-2020; Cardillo, Giuseppe/N-3296-2019
OI Cardillo, Giuseppe/0000-0001-6414-8475
CR Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Di Micco P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051371
   Kaatz S, 2015, J THROMB HAEMOST, V13, P2119, DOI 10.1111/jth.13140
   Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Kumar A, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012184
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Russo V, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061944
   Russo V, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104965
   Russo V, 2020, J CARDIOVASC PHARM, V76, P138, DOI 10.1097/FJC.0000000000000854
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Zhang Z, 2017, J THROMB THROMBOLYS, V43, P540, DOI 10.1007/s11239-017-1473-5
NR 14
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0160-2446
EI 1533-4023
J9 J CARDIOVASC PHARM
JI J. Cardiovasc. Pharmacol.
PD OCT
PY 2020
VL 76
IS 4
BP 369
EP 371
DI 10.1097/FJC.0000000000000893
PG 3
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA OP0VO
UT WOS:000587798900001
PM 33027192
DA 2021-01-01
ER

PT J
AU Li, QY
   Cheng, Q
   Zhao, ZL
   Dai, NN
   Zeng, L
   Zhu, L
   Guo, W
   Li, C
   Wang, JH
   Li, S
   Shen, N
   Ge, QG
AF Li, Qiuyu
   Cheng, Qin
   Zhao, Zhiling
   Dai, Nini
   Zeng, Lin
   Zhu, Lan
   Guo, Wei
   Li, Chao
   Wang, Junhong
   Li, Shu
   Shen, Ning
   Ge, Qinggang
TI Novel coronavirus infection and acute kidney injury in two renal
   transplant recipients: a case report
SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
LA English
DT Article
DE Novel coronavirus infection; renal transplantation; acute kidney injury;
   pneumonia; immunosuppressive therapy; methylprednisolone; case report
ID WUHAN
AB Background
   The causative virus of coronavirus disease 2019 (COVID-19) may cause severe fatal pneumonia. The clinical presentation includes asymptomatic infection, severe pneumonia, and acute respiratory failure. Data pertaining to acute renal injury due to COVID-19 in patients who have undergone renal transplantation are scarce. We herein report two cases of COVID-19 along with acute kidney injury following kidney transplantation.
   Case presentation: Two patients with COVID-19 underwent renal transplantation and were subsequently diagnosed with acute kidney injury. The first patient presented with progressive respiratory symptoms and acute renal injury. He was treated with diuretics and suspension of immunosuppressive therapy; however, the patient died. The second patient presented with respiratory tract symptoms, hypoxemia, and progressive deterioration of renal function followed by improvement. Her mycophenolate mofetil was stopped after admission, and tacrolimus was discontinued 10 days later. Moxifloxacin and methylprednisolone were continued in combination with albumin and gamma globulin infusion. A diuretic was administered, and prednisone was gradually reduced along with tacrolimus. The patient exhibited a satisfactory clinical recovery.
   Conclusion
   Patients who develop COVID-19 after kidney transplantation are at risk of acute kidney injury, and their prednisone, immunosuppressant, and gamma globulin treatment must be adjusted according to their condition.
C1 [Li, Qiuyu; Cheng, Qin; Dai, Nini; Shen, Ning] Peking Univ Third Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China.
   [Zhao, Zhiling; Li, Chao; Ge, Qinggang] Peking Univ Third Hosp, Dept Crit Care Med, 49 Huayuanbeilu Rd, Beijing 100191, Peoples R China.
   [Zeng, Lin] Peking Univ Third Hosp, Res Ctr Clin Epidemiol, Beijing, Peoples R China.
   [Zhu, Lan] Huazhong Univ Sci & Technol, Inst Organ Transplantat, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Guo, Wei] Peking Univ Third Hosp, Dept Radiol, Beijing, Peoples R China.
   [Wang, Junhong; Li, Shu] Peking Univ Third Hosp, Dept Emergency, Beijing, Peoples R China.
RP Ge, QG (corresponding author), Peking Univ Third Hosp, Dept Crit Care Med, 49 Huayuanbeilu Rd, Beijing 100191, Peoples R China.
EM qingganggelin@126.com
OI Dai, Nini/0000-0003-0429-1645
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81900641]; Medjaden Academy & Research
   Foundation for Young Scientists [nCoV_MJA20200228]; Special Campaign to
   Fight Novel Coronary Pneumonia (COVID-19)(2020) of Subject Construction
   Project of Peking University Health Science Center [BMU2020HKYZX011];
   Fundamental Research Funds for the Central University: the Special
   Research Fund of PKU for Prevention and Control of COVID-19
   [BMU2020HKYZX011]; National R&D Program of China [2020YFC0844500,
   2020YFC0844900]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81900641), the Medjaden Academy & Research Foundation
   for Young Scientists (Grant No. nCoV_MJA20200228), the Special Campaign
   to Fight Novel Coronary Pneumonia (COVID-19)(2020) of Subject
   Construction Project of Peking University Health Science Center (Grant
   No. BMU2020HKYZX011), the Fundamental Research Funds for the Central
   University: the Special Research Fund of PKU for Prevention and Control
   of COVID-19 (Grant No. BMU2020HKYZX011), and the National R&D Program of
   China (Grant Nos. 2020YFC0844500 and 2020YFC0844900).
CR Arabi YM, 2017, NEW ENGL J MED, V376, P584, DOI 10.1056/NEJMsr1408795
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Cukuranovic J, 2012, SCI WORLD J, DOI 10.1100/2012/820621
   Farkash EA, 2020, J AM SOC NEPHROL, V31, P1683, DOI 10.1681/ASN.2020040432
   Gori A, 2020, AM J TRANSPLANT, V20, P1939, DOI 10.1111/ajt.15853
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kissling S, 2020, KIDNEY INT, V98, P228, DOI 10.1016/j.kint.2020.04.006
   Larsen CP, 2020, KIDNEY INT REP, V5, P935, DOI 10.1016/j.ekir.2020.04.002
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Mubarak M, 2020, IMMUNOPATHOL PERSA, V6, DOI 10.34172/ipp.2020.18
   Oliva A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002243
   Peleg Y, 2020, KIDNEY INT REP, V5, P940, DOI 10.1016/j.ekir.2020.04.017
   Singbartl K, 2019, SEMIN NEPHROL, V39, P96, DOI 10.1016/j.semnephrol.2018.10.007
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   TOLOUIAN R, 2020, J RENAL INJ PREV, V9, pe19, DOI DOI 10.34172/JRIP.2020.19
   W ZP Y, 2020, J NEPHROPATHOL, V9, DOI [http://dx.doi.org/10.34172/jnp.2020.37, DOI 10.34172/JNP.2020.37]
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Yalameha B, 2020, J NEPHROPHARMACOL, V9, pe22
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Santovena AZ, 2015, TRANSPL P, V47, P62, DOI 10.1016/j.transproceed.2014.11.020
   Zhang H, 2020, EUR UROL, V77, P742, DOI 10.1016/j.eururo.2020.03.030
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 29
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-0605
EI 1473-2300
J9 J INT MED RES
JI J. Int. Med. Res.
PD OCT
PY 2020
VL 48
IS 10
AR 0300060520964009
DI 10.1177/0300060520964009
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OP7RX
UT WOS:000588285400001
PM 33100064
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, N
   Zhang, M
   Su, HJ
   Huang, ZL
   Lin, YB
AF Wang, Nan
   Zhang, Min
   Su, Huajun
   Huang, Zhonglue
   Lin, Yongbo
TI Fibrinolysis is a reasonable alternative for STEMI care during the
   COVID-19 pandemic
SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
LA English
DT Article
DE Coronavirus disease 2019; ST-segment elevation myocardial infarction;
   fibrinolysis; primary percutaneous coronary intervention; safety;
   efficacy
ID ELEVATION MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; TASK-FORCE;
   MANAGEMENT
AB Objective
   No data are available to develop uniform recommendations for reperfusion therapies in ST-segment elevation myocardial infarction (STEMI) during the coronavirus disease 2019 (COVID-19) pandemic. We aimed to fill the evidence gap regarding STEMI reperfusion strategy during the COVID-19 era.
   Methods
   Clinical characteristics and outcomes for 17 patients with STEMI who received fibrinolysis during the COVID-19 pandemic were compared with 20 patients who received primary percutaneous coronary intervention (PPCI), and were further compared with another 41 patients who received PPCI in the pre-COVID-19 period.
   Results
   In patients with STEMI, fibrinolysis achieved a comparable in-hospital and 30-day primary composite end point, as compared with those who received PPCI during the COVID-19 pandemic. No major bleeding was detected in either group. Compared patients with STEMI who received PPCI in the pre-COVID-19 period, we found a remarkable extension of chest pain onset-to-first medical contact (FMC) and FMC-to-wire crossing times, significantly increased number and length of stents, and much worse thrombolysis in myocardial infarction flow in patients with STEMI who received PPCI during the COVID-19 pandemic.
   Conclusion
   Owing to its considerable efficacy and safety and advantages in conserving medical resources, we recommend fibrinolysis as a reasonable alternative for STEMI care during the COVID-19 pandemic.
C1 [Wang, Nan] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Peoples R China.
   [Zhang, Min] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiol, Wuhan 430022, Peoples R China.
   [Zhang, Min] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Key Lab Biol Targeted Therapy,Minist Educ, Wuhan, Peoples R China.
   [Su, Huajun; Huang, Zhonglue] Union Jiangbei Hosp, Dept Cardiol, Wuhan, Peoples R China.
   [Lin, Yongbo] Peoples Hosp Dongxihu Dist, Dept Cardiol, Wuhan, Peoples R China.
RP Zhang, M (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Cardiol, Wuhan 430022, Peoples R China.; Zhang, M (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Key Lab Biol Targeted Therapy,Minist Educ, Wuhan, Peoples R China.
EM zm429800@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81600187, 81800891]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by the National Natural Science Foundation of China 81600187
   (to M.Z.) and 81800891 (to N.W.).
CR Berwanger O, 2018, JAMA CARDIOL, V3, P391, DOI 10.1001/jamacardio.2018.0612
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ibanez B, 2018, EUR HEART J, V39, P119, DOI 10.1093/eurheartj/ehx393
   Jing ZC, 2020, EUR HEART J, V41, P1791, DOI 10.1093/eurheartj/ehaa258
   O'Gara PT, 2013, J AM COLL CARDIOL, V61, pE78, DOI 10.1016/j.jacc.2012.11.019
   Poston JT, 2020, JAMA-J AM MED ASSOC, V323, P1839, DOI 10.1001/jama.2020.4914
   Siontis KC, 2016, AM J CARDIOL, V117, P1904, DOI 10.1016/j.amjcard.2016.03.036
   Szerlip M, 2020, CATHETER CARDIO INTE, V96, P586, DOI 10.1002/ccd.28887
   Vora AN, 2015, JAMA INTERN MED, V175, P207, DOI 10.1001/jamainternmed.2014.6573
   Wang HB, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016838
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiong TY, 2020, EUR HEART J, V41, P1798, DOI 10.1093/eurheartj/ehaa231
   Zeng J, 2020, INTENS CARE MED, V46, P1111, DOI 10.1007/s00134-020-05993-9
   Zhang L, 2020, EUR HEART J, V41, P1788, DOI 10.1093/eurheartj/ehaa266
   Zhao LR, 2018, HEART VESSELS, V33, P507, DOI 10.1007/s00380-017-1097-x
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 18
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-0605
EI 1473-2300
J9 J INT MED RES
JI J. Int. Med. Res.
PD OCT
PY 2020
VL 48
IS 10
AR 0300060520966151
DI 10.1177/0300060520966151
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OP5KX
UT WOS:000588125800001
PM 33108941
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Iversen, J
   Sabin, K
   Chang, J
   Thomas, RM
   Prestage, G
   Strathdee, SA
   Maher, L
AF Iversen, Jenny
   Sabin, Keith
   Chang, Judy
   Morgan Thomas, Ruth
   Prestage, Garrett
   Strathdee, Steffanie A.
   Maher, Lisa
TI COVID-19, HIV and key populations: cross-cutting issues and the need for
   population-specific responses
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Article
DE COVID&#8208; 19; HIV; key populations; physical distancing;
   vulnerability; health equity
ID HEALTH
AB Introduction Key populations at elevated risk to contract or transmit HIV may also be at higher risk of COVID-19 complications and adverse outcomes associated with public health prevention measures. However, the conditions faced by specific populations vary according to social, structural and environmental factors, including stigma and discrimination, criminalization, social and economic safety nets and the local epidemiology of HIV and COVID-19, which determine risk of exposure and vulnerability to adverse health outcomes, as well as the ability to comply with measures such as physical distancing. This commentary identifies common vulnerabilities and cross-cutting themes in terms of the impacts of COVID-19 on key populations before addressing issues and concerns specific to particular populations.
   Discussion Cross-cutting themes include direct impacts such as disrupted access to essential medicines, commodities and services such as anti-retroviral treatment, HIV pre-exposure prophylaxis, opioid agonist treatment, viral load monitoring, HIV and sexually transmitted infections testing, condoms and syringes. Indirect impacts include significant collateral damage arising from prevention measures which restrict human rights, increase or impose criminal penalties, and expand police powers to target vulnerable and criminalized populations. Significant heterogeneity in the COVID-19 pandemic, the underlying HIV epidemic and the ability of key populations to protect themselves means that people who inject drugs and sex workers face particular challenges, including indirect impacts as a result of police targeting, loss of income and sometimes both. Geographical variations mean that transgender people and men who have sex with men in regions like Africa and the middle east remain criminalized, as well as stigmatized and discriminated against, increasing their vulnerability to adverse outcomes in relation to COVID-19.
   Conclusions Disruptions to both licit and illicit supply chains, loss of income and livelihoods and changes in behaviour as a result of lockdowns and physical distancing have the potential to exacerbate the impacts of the COVID-19 pandemic on key populations. While these impacts will vary significantly, human-rights approaches to COVID-19 emergency laws and public health prevention measures that are population-specific and sensitive, will be key to reducing adverse health outcomes and ensuring that no one is left behind.
C1 [Iversen, Jenny; Prestage, Garrett; Maher, Lisa] UNSW Sydney, Fac Med, Kirby Inst Infect & Immun, Sydney, NSW, Australia.
   [Sabin, Keith] Joint United Nations Programme HIV AIDS UNAIDS, Geneva, Switzerland.
   [Chang, Judy] Int Network People Who Use Drugs, London, England.
   [Morgan Thomas, Ruth] Global Network Sex Work Projects, Edinburgh, Midlothian, Scotland.
   [Strathdee, Steffanie A.] Univ Calif San Diego, Dept Med, Global Hlth Sci, La Jolla, CA 92093 USA.
RP Maher, L (corresponding author), UNSW Sydney, 6th Floor,Wallace Wurth Bldg, Sydney, NSW 2052, Australia.
EM lmaher@kirby.unsw.edu.au
OI Iversen, Jenny/0000-0002-0062-7300; Strathdee,
   Steffanie/0000-0002-7724-691X; Maher, Lisa/0000-0001-6020-6519
FU UNSW Sydney Strategic Fellowship; Australian National Health and Medical
   Research Council Senior Research FellowshipNational Health and Medical
   Research Council of Australia
FX JI is supported by a UNSW Sydney Strategic Fellowship and LM is
   supported by the award of an Australian National Health and Medical
   Research Council Senior Research Fellowship. Funders had no role in
   writing of this commentary. The corresponding author had final
   responsibility for the decision to submit for publication.
CR [Anonymous], 2020, COVID 19 HIGHL URG E
   [Anonymous], DWINDL DRUG SUPPL DT
   DeBeck K, 2017, LANCET HIV, V4, pE357, DOI 10.1016/S2352-3018(17)30073-5
   Deering KN, 2014, AM J PUBLIC HEALTH, V104, pE42, DOI 10.2105/AJPH.2014.301909
   Doherty M, 2020, P AIDS 2020 VIRT JUL
   Dolan K, 2016, LANCET, V388, P1089, DOI 10.1016/S0140-6736(16)30466-4
   Drain PK, 2020, LANCET, V22
   Dunlop A, 2020, HARM REDUCT J, V17, DOI 10.1186/s12954-020-00370-7
   Ferguson N, 2020, REPORT 9 IMPACT NONP
   Global Commission on HIV and the Law, 2018, GLOB COMM HIV LAW RI
   Global Network of Sex Work Projects (NSWP) and UNAIDS, SEX WORK MUST NOT BE
   GNP+, STAT COVID 19 CRIM
   Hammoud MA, 2020, JAIDS-J ACQ IMM DEF, V85, P309, DOI 10.1097/QAI.0000000000002462
   Hawks L, 2020, JAMA INTERN MED, V180, P1041, DOI 10.1001/jamainternmed.2020.1856
   International Network of People who use Drugs (INPUD), 2020, INPUD ONL SURV COVID
   International Network of People who use Drugs (INPUD), TIM COVID 19 CIV SOC
   Iversen J, 2019, J HEPATOL, V70, P33, DOI 10.1016/j.jhep.2018.09.030
   John Hopkins University, 2020, MORT AN DOES MORT DI
   Joint United Nations Programme on HIV/AIDS (UNAIDS), UNAIDS DAT 2020
   Maher L, 2015, HEALTH HUM RIGHTS, V17, P102, DOI 10.2307/healhumarigh.17.1.102
   Poteat T, 2019, CURR OPIN HIV AIDS, V14, P393, DOI 10.1097/COH.0000000000000563
   Poteat T, 2016, JAIDS-J ACQ IMM DEF, V72, pS210, DOI 10.1097/QAI.0000000000001087
   Prestage G, 2018, INT J DRUG POLICY, V55, P169, DOI 10.1016/j.drugpo.2018.01.020
   Puras D, 2020, LANCET, V395, P1888, DOI 10.1016/S0140-6736(20)31255-1
   Sanchez TH, 2020, AIDS BEHAV, V24, P2024, DOI 10.1007/s10461-020-02894-2
   Shannon K, 2018, LANCET, V392, P698, DOI 10.1016/S0140-6736(18)31439-9
   Sohn AH, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25557
   Strathdee S, 2020, AIDS
   UNAIDS, RIGHTS TIM COVID 19
   UNAIDS, RIGHTS PAND LOCKD RI
   United Nations Committee on Economic Social and Cultural Rights, GEN COMM 25 2020 SCI
   United Nations Office of the High Commissioner for Human Rights (OHCHR) and WHO, INT GUID COVID 19 FO
   United Nations Office of the High Commissioner on Human Rights (OHCHR), COVID 19 STAT SHOULD
   US Centers for Disease Control (CDC), COVID 19 GROUPS HIGH
   Verster A, WHO GUIDANCE COVID 1
   Wallace M, 2020, MMWR-MORBID MORTAL W, V69, P587, DOI 10.15585/mmwr.mm6919e1
   Wilkinson L, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25503
   World Health Organization, 2014, CONS GUID HIV PREV D
NR 38
TC 0
Z9 0
U1 1
U2 1
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2020
VL 23
IS 10
AR e25632
DI 10.1002/jia2.25632
PG 6
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA OP4QI
UT WOS:000588066500004
PM 33119183
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Salciccia, S
   Del Giudice, F
   Eisenberg, ML
   Mastroianni, CM
   De Berardinis, E
   Ricciuti, GP
   Maggi, M
   Sciarra, A
AF Salciccia, Stefano
   Del Giudice, Francesco
   Eisenberg, Michael L.
   Mastroianni, Claudio M.
   De Berardinis, Ettore
   Ricciuti, Gian Piero
   Maggi, Martina
   Sciarra, Alessandro
TI Androgen-deprivation therapy and SARS-Cov-2 infection: the potential
   double-face role of testosterone
SO THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM
LA English
DT Letter
DE androgen-deprivation therapy; COVID-19; hypogonadism; testosterone
ID RISK
C1 [Salciccia, Stefano] Univ Sapienza, Dept Urol, Viale Policlin 155, I-00161 Rome, Italy.
   [Del Giudice, Francesco; De Berardinis, Ettore; Ricciuti, Gian Piero; Maggi, Martina; Sciarra, Alessandro] Sapienza Rome Univ, Policlin Umberto I Hosp, Dept Maternal Infant & Urol Sci, Rome, Italy.
   [Del Giudice, Francesco; Eisenberg, Michael L.] Stanford Univ, Dept Urol, Sch Med, Stanford, CA 94305 USA.
   [Mastroianni, Claudio M.] Sapienza Rome Univ, Policlin Umberto I Hosp, Dept Publ Hlth & Infect Dis, Rome, Italy.
RP Salciccia, S (corresponding author), Univ Sapienza, Dept Urol, Viale Policlin 155, I-00161 Rome, Italy.
EM stefano.salciccia@uniroma1.it
CR Caffo O, 2020, ANN ONCOL, V31, P1415, DOI 10.1016/j.annonc.2020.06.005
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jones TH, 2010, TRENDS ENDOCRIN MET, V21, P496, DOI 10.1016/j.tem.2010.03.002
   Klein EA, J UROLOGY, DOI [10.1097/JU.0000000000001338, DOI 10.1097/JU.0000000000001338.]
   La Vignera S, 2020, THER ADV ENDOCRINOL, V11, DOI 10.1177/2042018820942385
   Mohan SS, 2015, CLIN ENDOCRINOL, V83, P268, DOI 10.1111/cen.12738
   Montano LM, 2014, J ENDOCRINOL, V222, P1, DOI 10.1530/JOE-14-0074
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Moore BJB, SCIENCE, V368, P473
   Pozzilli P, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154252
   Rastrelli G, ANDROLOGY, DOI [10.1111/andr.12821., DOI 10.1111/ANDR.12821.]
   Salciccia S, ENDOCRINE, DOI [10.1007/s12020-020-02515-x., DOI 10.1007/S12020-020-02515-X.]
   Trigunaite A, 2015, CELL IMMUNOL, V294, P87, DOI 10.1016/j.cellimm.2015.02.004
NR 15
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 2042-0188
EI 2042-0196
J9 THER ADV ENDOCRINOL
JI Ther. Adv. Endocrinol. Metab.
PD OCT
PY 2020
VL 11
AR 2042018820969019
DI 10.1177/2042018820969019
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OP4JF
UT WOS:000588046500001
PM 33194171
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Robson, B
AF Robson, B.
TI The use of knowledge management tools in viroinformatics. Example study
   of a highly conserved sequence motif in Nsp3 of SARS-CoV-2 as a
   therapeutic target
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Knowledge management; Coronavirus; SARS-CoV-2; COVID-19; Mutations;
   Conservation; Bioinformatics; Therapeutic; X domain; Macro domain
ID RESPIRATORY SYNDROME CORONAVIRUS; DECISION SUPPORT.; INFERENCE;
   ADP-RIBOSE-1''-MONOPHOSPHATASE; INHIBITION; LANGUAGE; PROTEASE; COMPLEX;
   ESCAPE; DOMAIN
AB Knowledge management tools that assist in systematic review and exploration of scientific knowledge generally are of obvious potential importance in evidence based medicine in general, but also to the design of therapeutics based on the protein subsequences and fold motifs of virus proteins as considered here. Rapid access to bundles (clusters) of related elements of knowledge gathered from diverse sources on the Internet and from growing knowledge repositories seem particularly helpful when exploring less obvious therapeutic targets in viruses (for which knowledge new to the researcher is important), and when using the following concept. Subsequences of amino acid residue sequences of proteins that are conserved across strains and species are (a) more likely to be important targets and (b) less likely to exhibit escape mutations that would make them resistant to vaccines and therapeutic agents. However, the terms "conserved" and even "highly conserved" used by authors are matters of degree, depending on how distant from SARS-CoV-2 they wished to go in comparing other sequences. The binding site to the human ACE2 protein as virus receptor and human antibody CR3022 binding site on the spike glycoprotein are rather variable by the criteria used in the present and preceding studies. To look for more strongly conserved targets, open reading frames of SARS-CoV-2 were examined for extremely highly conserved regions, meaning recognizable across many viruses and organisms. Most prominent is a motif found in SARSCoV-2 non-structural protein 3 (Nsp3). It relates to a fold called type called the macro domain and has remarkably wide distribution across organisms including humans with significant homologies involving three especially conserved subsequences (a) VVVNAANVYLKHGGGVAGALNK, (b) LHVVGPNVNKG, and (c) PLLSAGIFG. Careful study of the variations of these and of the more variable sequences between and around them might provide a finer "scalpel" to ensure inhibition of a vital function of the virus without impairing the functions of related host macro domains.
C1 [Robson, B.] Ingine Inc, Cleveland, OH 44106 USA.
   [Robson, B.] Dirac Fdn, Witney, Oxon, England.
RP Robson, B (corresponding author), Ingine Inc, Cleveland, OH 44106 USA.; Robson, B (corresponding author), Dirac Fdn, Witney, Oxon, England.
EM barryrobson@ingine.com
CR Adachi M, 2009, P NATL ACAD SCI USA, V106, P4641, DOI 10.1073/pnas.0809400106
   Alhammad YMO, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040384
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bianchi A, 2012, PROTEINS, V80, P1418, DOI 10.1002/prot.24038
   Bosch BJ, 2008, J VIROL, V82, P2580, DOI 10.1128/JVI.02287-07
   Cohen FS, 2016, BIOPHYS J, V110, P1028, DOI 10.1016/j.bpj.2016.02.006
   Dawkins R., 1976, SELFISH GENE
   Deckelman S, 2014, COMMUN INF SYST, V14, P135, DOI 10.4310/CIS.2014.v14.n3.a1
   Dong E, 2020, LANCET INFECT DIS
   Egloff MP, 2006, J VIROL, V80, P8493, DOI 10.1128/JVI.00713-06
   Fehr AR, 2020, GENE DEV, V34, P341, DOI 10.1101/gad.334425.119
   Forni D, 2015, SCI REP-UK, V5, DOI 10.1038/srep14480
   Frick DN, 2020, BIOCHEMISTRY-US, V59, P2608, DOI 10.1021/acs.biochem.0c00309
   Gordon DE, 2020, SARS COV 2 HUMAN PRO
   Grunewald ME, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007756
   Guo TT, 2019, NAT MICROBIOL, V4, P1872, DOI 10.1038/s41564-019-0428-3
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kumaran D, 2005, PROTEIN SCI, V14, P719, DOI 10.1110/ps.041132005
   Kuri T, 2011, J GEN VIROL, V92, P1899, DOI 10.1099/vir.0.031856-0
   Lesk A.M., 2019, INTRO BIOINFORMATICS
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu IJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082081
   Lu R., 2020, GENOMIC CHARACTERIZA, DOI [10.1016/S0140-6736(20)30251-30258, DOI 10.1016/S0140-6736(20)30251-30258]
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   National institutes of Health National Library of Medicine, BLAST
   Peck KM, 2018, J VIROL, V92, DOI 10.1128/JVI.01031-17
   Poltronieri P., 2017, EIDTORIAL CHALLENGES, V8, P14
   Putics A, 2005, J VIROL, V79, P12721, DOI 10.1128/JVI.79.20.12721-12731.2005
   Rack JGM, 2016, ANNU REV BIOCHEM, V85, P431, DOI 10.1146/annurev-biochem-060815-014935
   Robson B, 2020, COMPUT BIOL MED, V122, DOI 10.1016/j.compbiomed.2020.103849
   Robson B, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103749
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Robson B, 2018, COMPUT BIOL MED, V95, P147, DOI 10.1016/j.compbiomed.2018.02.013
   Robson B., 2013, COMPUT BIOL MED, V1, P43
   Robson B., 2020, PRELIMINARY BIOINFOR, DOI [10.13140/RG.2.2.18275.09761, DOI 10.13140/RG.2.2.18275.09761]
   Robson B, 2020, COMPUT BIOL MED, V117, DOI 10.1016/j.compbiomed.2020.103621
   Robson B, 2019, COMPUT BIOL MED, V108, P382, DOI 10.1016/j.compbiomed.2019.04.005
   Robson B, 2016, COMPUT BIOL MED, V79, P299, DOI 10.1016/j.compbiomed.2016.10.009
   Robson B, 2016, COMPUT BIOL MED, V73, P71, DOI 10.1016/j.compbiomed.2016.02.010
   Robson B, 2015, COMPUT BIOL MED, V56, P107, DOI 10.1016/j.compbiomed.2014.10.011
   Robson B, 2014, COMPUT BIOL MED, V51, P183, DOI 10.1016/j.compbiomed.2014.03.014
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10
   Soua R, 2018, GLOB INFORM INFRAS
   Staines R., PHARMAPHORUM
   Tan JZ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000428
   Tang JW, 2007, J CLIN VIROL, V38, P19, DOI 10.1016/j.jcv.2006.10.001
   Webb T.E., 2020, IMMUNOL LETT, P38
   Wertheim JO, 2013, J VIROL, V87, P7039, DOI 10.1128/JVI.03273-12
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
NR 53
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD OCT
PY 2020
VL 125
AR 103963
DI 10.1016/j.compbiomed.2020.103963
PG 33
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA OO4MM
UT WOS:000587354800007
PM 32828990
OA Green Published
DA 2021-01-01
ER

PT J
AU Li, JH
   Wei, Q
   Li, WX
   McCowen, KC
   Xiong, W
   Liu, J
   Jiang, WLJ
   Marin, T
   Thomas, RL
   He, M
   Gongol, B
   Hepokoski, M
   Yuan, JXJ
   Shyy, JYJ
   Xiong, N
   Malhotra, A
AF Li, Jinghong
   Wei, Qi
   Li, Willis X.
   McCowen, Karen C.
   Xiong, Wei
   Liu, Jiao
   Jiang, Wenlijun
   Marin, Traci
   Thomas, Robert L.
   He, Ming
   Gongol, Brendan
   Hepokoski, Mark
   Yuan, Jason X-J
   Shyy, John Y-J
   Xiong, Nian
   Malhotra, Atul
TI METFORMIN USE IN DIABETES PRIOR TO HOSPITALIZATION: EFFECTS ON MORTALITY
   IN COVID-19
SO ENDOCRINE PRACTICE
LA English
DT Article
ID ASSOCIATION; GLUCOSE; DISEASE
AB Objective: Although type 2 diabetes mellitus (T2DM) has been reported as a risk factor for coronavirus disease 2019 (COVID-19), the effect of pharmacologic agents used to treat T2DM, such as metformin, on COVID-19 outcomes remains unclear. Metformin increases the expression of angiotensin converting enzyme 2, a known receptor for severe acute respiratory syndrome coronavirus 2. Data from people with T2DM hospitalized for COVID-19 were used to test the hypothesis that metformin use is associated with improved survival in this population.
   Methods: Retrospective analyses were performed on de-identified clinical data fmm a major hospital in Wuhan, China, that included patients with T2DM hospitalized for COVID-19 during the recent epidemic. One hundred and thirty-one patients diagnosed with COVID-19 and T2DM were used in this study. The primary outcome was mortality. Demographic, clinical characteristics, laboratory data, diabetes medications, and respiratory therapy data were also included in the analysis.
   Results: Of these 131 patients, 37 used metformin with or without other antidiabetes medications. Among the 37 metformin-taking patients, 35 (94.6%) survived and 2 (5.4%) did not survive. The mortality rates in the metformin-taking group versus the non-metformin group were 5.4% (2/37) versus 22.3% (21/94). Using multivariate analysis, metformin was found to be an independent predictor of survival in this cohort (P = .02).
   Conclusion: This study reveals a significant association between metformin use and survival in people with T2DM diagnosed with COVID-19. These clinical data are consistent with potential benefits of the use of metformin for COVID-19 patients with T2DM.
C1 [Li, Jinghong; Li, Willis X.; McCowen, Karen C.; Thomas, Robert L.; He, Ming; Gongol, Brendan; Hepokoski, Mark; Yuan, Jason X-J; Shyy, John Y-J; Malhotra, Atul] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Wei, Qi; Xiong, Wei; Liu, Jiao; Jiang, Wenlijun; Xiong, Nian] Wuhan Red Cross Hosp, Dept Endocrinol, Wuhan, Hubei, Peoples R China.
   [Marin, Traci] Victor Valley Coll, Dept Hlth Sci, Victorville, CA USA.
   [Xiong, Nian] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Hubei, Peoples R China.
RP Xiong, N (corresponding author), 392 Hongkong Rd, Wuhan 430015, Hubei, Peoples R China.; Shyy, JYJ (corresponding author), 9500 Gilman Dr,MC 0613K, La Jolla, CA 92093 USA.
EM jshyy@health.ucsd.edu; nianxiong@hust.edu.cn
RI Li, Willis/AAL-7212-2020
OI Li, Willis/0000-0001-9041-7341
FU National Heart, Lung, and Blood Institute of the National Institutes of
   Health grants (NIH) [R01 HL108735, HL140898, R01 HL085188, K24 HL132105,
   T32 HL134632]; National Key R&D Program of China [2018YFC1314700];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81873782]
FX This study was supported in part by the National Heart, Lung, and Blood
   Institute of the National Institutes of Health grants (NIH R01 HL108735,
   HL140898 to Shyy; NIH R01 HL085188, K24 HL132105, T32 HL134632 to
   Malhotra); National Key R&D Program of China 2018YFC1314700, National
   Natural Science Foundation of China 81873782 to Xiong.
CR Beigel J. H., 2020, N ENGL J MED
   Bergmark BA, 2019, CIRCULATION, V140, P1004, DOI 10.1161/CIRCULATIONAHA.119.040144
   Berlin DA, 2020, N ENGL J MED
   Bramante C, 2020, OBSERVATIONAL STUDY
   El Messaoudi S, 2011, CURR OPIN LIPIDOL, V22, P445, DOI 10.1097/MOL.0b013e32834ae1a7
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gabir MM, 2000, DIABETES CARE, V23, P1113, DOI 10.2337/diacare.23.8.1113
   GARCIA E Y, 1950, J Philipp Med Assoc, V26, P287
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Jarcho JA, 2020, NEW ENGL J MED, V382, P2462, DOI 10.1056/NEJMe2012924
   Kavanagh BP, 2010, NEW ENGL J MED, V363, P2540, DOI 10.1056/NEJMcp1001115
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li Y, 2013, BIOMED REP, V1, P57, DOI 10.3892/br.2012.18
   Luo P, 2020, AM J TROP MED HYG, V103, P69, DOI 10.4269/ajtmh.20-0375
   Malhotra A, 2006, NEW ENGL J MED, V354, P516, DOI 10.1056/NEJMe058304
   Malhotra A, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101425
   McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8
   Norrie JD, 2020, LANCET, V395, P1525, DOI 10.1016/S0140-6736(20)31023-0
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Pernicova I, 2014, NAT REV ENDOCRINOL, V10, P143, DOI 10.1038/nrendo.2013.256
   Ramnath VR, 2020, CHEST, V158, P873, DOI 10.1016/j.chest.2020.05.548
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Schadle P, 2020, EXP CLIN ENDOCRINOL
   TSAKIRIS AG, 1969, J APPL PHYSIOL, V27, P817
   Ursini F, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108167
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Venter M, 2020, J CLIN PATHOL, V73, P370, DOI 10.1136/jclinpath-2020-206685
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang J, 2018, AM J RESP CRIT CARE, V198, P509, DOI 10.1164/rccm.201712-2570OC
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 33
TC 0
Z9 0
U1 2
U2 2
PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS
PI JACKSONVILLE
PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA
SN 1530-891X
EI 1934-2403
J9 ENDOCR PRACT
JI Endocr. Pract.
PD OCT
PY 2020
VL 26
IS 10
BP 1166
EP 1172
DI 10.4158/EP-2020-0466
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OO5KJ
UT WOS:000587416900013
DA 2021-01-01
ER

PT J
AU Binois, Y
   Hachad, H
   Salem, JE
   Charpentier, J
   Lebrun-Vignes, B
   Pene, F
   Cariou, A
   Chiche, JD
   Mira, JP
   Nguyen, LS
AF Binois, Yannick
   Hachad, Hafsah
   Salem, Joe-Elie
   Charpentier, Julien
   Lebrun-Vignes, Benedicte
   Pene, Frederic
   Cariou, Alain
   Chiche, Jean-Daniel
   Mira, Jean-Paul
   Nguyen, Lee S.
TI Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy
   in Patients With COVID-19
SO KIDNEY INTERNATIONAL REPORTS
LA English
DT Letter
C1 [Binois, Yannick; Hachad, Hafsah; Charpentier, Julien; Pene, Frederic; Cariou, Alain; Chiche, Jean-Daniel; Mira, Jean-Paul; Nguyen, Lee S.] Cochin Univ Hosp, Assistance Publ Hop Paris Ctr, Intens Care Med Dept, Paris, France.
   [Salem, Joe-Elie; Lebrun-Vignes, Benedicte; Nguyen, Lee S.] Sorbonne Univ, Assistance Publ Hop Paris Pitie Salpetrier, INSERM, Clin Invest Ctr Paris Est, Paris, France.
   [Lebrun-Vignes, Benedicte] Univ Paris Est Creteil, EpiDermE, Creteil, France.
   [Nguyen, Lee S.] Ctr Med Chirurg Ambroise Pare Res & Innovat, Neuilly Sur Seine, France.
RP Nguyen, LS (corresponding author), Cochin Univ Hosp, AP HP, Intens Care Med Dept, F-75014 Paris, France.
EM nguyen.lee@icloud.com
CR Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Gabarre P, 2020, INTENS CARE MED, V46, P1339, DOI 10.1007/s00134-020-06153-9
   Lindquist M, 2007, DRUG SAFETY, V30, P635, DOI 10.2165/00002018-200730070-00014
   Nguyen LS, 2020, CIRCULATION, V142, P303, DOI 10.1161/CIRCULATIONAHA.120.048238
   Parkhie SM, 2010, CLIN J AM SOC NEPHRO, V5, P798, DOI 10.2215/CJN.08211109
   Peele K Abraham, 2020, Inform Med Unlocked, V19, P100345, DOI 10.1016/j.imu.2020.100345
   Robbins-Juarez SY, 2020, KIDNEY INT REP, V5, P1149, DOI 10.1016/j.ekir.2020.06.013
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
NR 9
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2468-0249
J9 KIDNEY INT REP
JI Kidney Int. Rep.
PD OCT
PY 2020
VL 5
IS 10
BP 1787
EP 1790
DI 10.1016/j.ekir.2020.07.035
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA OF3QO
UT WOS:000581127000024
PM 32838087
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Maldonado, YA
   O'Leary, ST
   Banerjee, R
   Barnett, ED
   Campbell, JD
   Caserta, MT
   Gerber, JS
   Kourtis, AP
   Lynfield, R
   Munoz, FM
   Nolt, D
   Nyquist, AC
   Steinbach, WJ
   Zangwill, KM
   Zaoutis, TE
AF Maldonado, Yvonne A.
   O'Leary, Sean T.
   Banerjee, Ritu
   Barnett, Elizabeth D.
   Campbell, James D.
   Caserta, Mary T.
   Gerber, Jeffrey S.
   Kourtis, Athena P.
   Lynfield, Ruth
   Munoz, Flor M.
   Nolt, Dawn
   Nyquist, Ann-Christine
   Steinbach, William J.
   Zangwill, Kenneth M.
   Zaoutis, Theoklis E.
CA Comm Infect Dis
TI Recommendations for Prevention and Control of Influenza in Children,
   2020-2021
SO PEDIATRICS
LA English
DT Article
ID PREGNANCY BIRTH-DEFECTS; VACCINE EFFECTIVENESS; UNITED-STATES; SEASONAL
   INFLUENZA; OSELTAMIVIR TREATMENT; SPONTANEOUS-ABORTION; CONFIRMED
   INFLUENZA; PRETERM DELIVERY; PRIMARY-CARE; PHASE 4
AB This statement updates the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccine and antiviral medications in the prevention and treatment of influenza in children during the 2020-2021 season. The American Academy of Pediatrics (AAP) recommends routine influenza immunization of all children without medical contraindications, starting at 6 months of age. Influenza vaccination is an important intervention to protect vulnerable populations and reduce the burden of respiratory illnesses during the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) pandemic. Any licensed, recommended, age-appropriate vaccine available can be administered, without preference for one product or formulation over another. Antiviral treatment of influenza with any licensed, recommended, age-appropriate influenza antiviral medication is recommended for children with suspected or confirmed influenza who are hospitalized, have severe or progressive disease, or have underlying conditions that increase their risk of complications of influenza. Antiviral treatment may be considered for any previously healthy, symptomatic outpatient not at high risk for influenza complications in whom an influenza diagnosis is confirmed or suspected, if treatment can be initiated within 48 hours of illness onset, and for children whose siblings or household contacts either are younger than 6 months or have a high-risk condition that predisposes them to complications of influenza.
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P277
   Baker M, 2020, VACCINE, V38, P2166, DOI 10.1016/j.vaccine.2020.01.046
   Belongia EA, 2015, VACCINE, V33, P246, DOI 10.1016/j.vaccine.2014.06.052
   Biggerstaff M, 2018, AM J EPIDEMIOL, V187, P1040, DOI 10.1093/aje/kwx334
   Blyth CC, 2020, VACCINE, V38, P2779, DOI 10.1016/j.vaccine.2020.02.031
   Bradley JS, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2016-2727
   Castilla J, 2013, EUROSURVEILLANCE, V18, P17
   Castrodale L., 2009, Morbidity and Mortality Weekly Report, V58, P1341
   Centers for Disease Control and Prevention, US FLU VE DAT 2018 2
   Centers for Disease Control and Prevention, COVIDVIEW WEEKL SURV
   Centers for Disease Control and Prevention, INFLUENZA
   Centers for Disease Control and Prevention, FLU VACC COV
   Centers for Disease Control and Prevention, WEEK US INFL SURV RE
   Centers for Disease Control and Prevention, VACCINE
   Chambers CD, 2016, VACCINE, V34, P4443, DOI 10.1016/j.vaccine.2016.06.054
   Chambers CD, 2013, VACCINE, V31, P5026, DOI 10.1016/j.vaccine.2013.08.097
   Chan-Tack KM, 2015, ANTIVIR THER, V20, P561, DOI 10.3851/IMP2944
   Chung JR, CLIN INFECT DIS, DOI 10.1093/cid/ciz1244
   Claeys C, 2018, LANCET CHILD ADOLESC, V2, P338, DOI 10.1016/S2352-4642(18)30062-2
   Tran D, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4643
   Dawood FS, 2020, MMWR-MORBID MORTAL W, V69, P177, DOI 10.15585/mmwr.mm6907a1
   Dawood FS, 2016, ANTIVIR RES, V133, P85, DOI 10.1016/j.antiviral.2016.07.007
   Dee DL, 2011, ANN EPIDEMIOL, V21, P623, DOI 10.1016/j.annepidem.2011.03.002
   Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1
   Dominguez A, 2018, EPIDEMIOL INFECT, V146, P799, DOI 10.1017/S0950268818000663
   Donahue JG, 2019, VACCINE, V37, P6673, DOI 10.1016/j.vaccine.2019.09.035
   Donahue JG, 2017, VACCINE, V35, P5314, DOI 10.1016/j.vaccine.2017.06.069
   Duffy J, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0320
   Feldstein LR, J PEDIAT INFECT DIS, DOI 10.1093/jpids/piaa017
   Ferdinands JM, 2019, CLIN INFECT DIS, V69, P190, DOI 10.1093/cid/ciy1084
   Ferdinands JM, 2017, CLIN INFECT DIS, V64, P544, DOI 10.1093/cid/ciw816
   Ferdinands JM, 2014, J INFECT DIS, V210, P674, DOI 10.1093/infdis/jiu185
   Flannery B, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4244
   Garten R, 2018, MMWR-MORBID MORTAL W, V67, P634, DOI 10.15585/mmwr.mm6722a4
   Gounder PP, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu031
   Greenhawt M, 2018, ANN ALLERG ASTHMA IM, V120, P49, DOI 10.1016/j.anai.2017.10.020
   Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1
   Grohskopf LA, 2018, MMWR-MORBID MORTAL W, V67, P643, DOI 10.15585/mmwr.mm6722a5
   Gubareva LV, 2019, EUROSURVEILLANCE, V24, P13, DOI 10.2807/1560-7917.ES.2019.24.3.1800666
   Halasa NB, 2015, J PEDIAT INF DIS SOC, V4, P214, DOI 10.1093/jpids/piu061
   Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197
   Hennessy TW, 2016, EPIDEMIOL INFECT, V144, P315, DOI 10.1017/S0950268815001211
   Heo YA, 2018, DRUGS, V78, P693, DOI 10.1007/s40265-018-0899-1
   Howard A, 2018, J PEDIAT INF DIS SOC, V7, pE172, DOI 10.1093/jpids/piy033
   Hsu J, 2012, ANN INTERN MED, V156, P512, DOI 10.7326/0003-4819-156-7-201204030-00411
   Ince WL, J INFECT DIS, DOI 10.1093/infdis/jiaa164
   Influenza vaccination during pregnancy, 2018, OBSTET GYNECOL, V131, pe109, DOI DOI 10.1097/AOG.0000000000002588
   Jain VK, 2017, J PEDIATR INFECT DIS, V6, P9, DOI 10.1093/jpids/piw068
   Jefferson T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008965.pub3
   Kalligeros M, 2020, VACCINE, V38, P2893, DOI 10.1016/j.vaccine.2020.02.049
   Katzen J, 2019, CLIN INFECT DIS, V69, P52, DOI 10.1093/cid/ciy860
   Kelso JM, 2013, ANN ALLERG ASTHMA IM, V111, P301, DOI 10.1016/j.anai.2013.07.030
   Kissling E, 2013, EUROSURVEILLANCE, V18, P33
   Kissling E, 2016, EURO SURV, V21, P16
   Koszalka P, 2019, ANTIVIR RES, V164, P91, DOI 10.1016/j.antiviral.2019.02.007
   Li L, J CLIN PHARM THER, DOI 10.1111/jcpt.13203
   Louie JK, 2013, PEDIATRICS, V132, pE1539, DOI 10.1542/peds.2013-2149
   Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480
   Mallory RM, 2020, VACCINE, V38, P1001, DOI 10.1016/j.vaccine.2019.11.055
   Malosh RE, 2018, CLIN INFECT DIS, V66, P1492, DOI 10.1093/cid/cix1040
   Miyakawa R, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-2608
   Munoz FM, 2018, VACCINE, V36, P8054, DOI 10.1016/j.vaccine.2018.10.088
   Muthuri SG, 2014, LANCET RESP MED, V2, P395, DOI 10.1016/S2213-2600(14)70041-4
   Nordin JD, 2019, VACCINE, V37, P4055, DOI 10.1016/j.vaccine.2019.05.081
   Nordin JD, 2014, J PEDIATR-US, V164, P1051, DOI 10.1016/j.jpeds.2014.01.037
   Nunes MC, 2018, HUM VACC IMMUNOTHER, V14, P758, DOI 10.1080/21645515.2017.1345385
   Nunes Marta C, 2018, F1000Res, V7, P122, DOI 10.12688/f1000research.12473.1
   Omer SB, 2018, PEDIATR INFECT DIS J, V37, P436, DOI [10.1097/inf.0000000000001914, 10.1097/INF.0000000000001914]
   Omoto S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27890-4
   Pebody RG, 2020, VACCINE, V38, P158, DOI 10.1016/j.vaccine.2019.10.035
   Pebody RG, 2013, EUROSURVEILLANCE, V18, P25
   Pebody RG, 2020, VACCINE, V38, P489, DOI 10.1016/j.vaccine.2019.10.071
   Petrie JG, 2016, J INFECT DIS, V214, P1142, DOI 10.1093/infdis/jiw105
   Polyzos KA, 2015, OBSTET GYNECOL, V126, P1075, DOI 10.1097/AOG.0000000000001068
   Puig-Barbera J, 2017, VACCINE, V35, P5799, DOI 10.1016/j.vaccine.2017.09.035
   Radin JM, 2016, VACCINE, V34, P3907, DOI 10.1016/j.vaccine.2016.05.034
   Ramirez J, 2018, CLIN INFECT DIS, V67, P736, DOI 10.1093/cid/ciy163
   Ray GT, 2020, CLIN INFECT DIS, V70, P1484, DOI 10.1093/cid/ciz706
   Ray GT, 2019, CLIN INFECT DIS, V68, P1623, DOI 10.1093/cid/ciy770
   Robertson CA, 2019, PEDIATR INFECT DIS J, V38, P323, DOI 10.1097/INF.0000000000002227
   Robison SG, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2883
   Schlaudecker EP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070867
   Segaloff HE, 2019, CLIN INFECT DIS, V69, P2153, DOI 10.1093/cid/ciz125
   Sentinel, 2017, INFL VACC FEBR SEIZ
   Shakib JH, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2360
   Sheffield JS, 2012, OBSTET GYNECOL, V120, P532, DOI 10.1097/AOG.0b013e318263a278
   Shope TR, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-3690
   Steinhoff MC, 2017, LANCET INFECT DIS, V17, P981, DOI 10.1016/S1473-3099(17)30252-9
   Takashita E, 2020, ANTIVIR RES, V175, DOI 10.1016/j.antiviral.2020.104718
   Takashita E, 2019, EUROSURVEILLANCE, V24, P9, DOI 10.2807/1560-7917.ES.2019.24.12.1900170
   Takashita E, 2019, EUROSURVEILLANCE, V24, P18, DOI 10.2807/1560-7917.ES.2019.24.3.1800698
   Takeuchi S, 2019, PHARMACOEPIDEM DR S, V28, P434, DOI 10.1002/pds.4721
   Tapia MD, 2016, LANCET INFECT DIS, V16, P1026, DOI 10.1016/S1473-3099(16)30054-8
   Thompson CA, 2014, AM J HEALTH-SYST PH, V71, P1432, DOI 10.2146/news140063
   Thompson MG, 2019, CLIN INFECT DIS, V68, P1444, DOI 10.1093/cid/ciy737
   Turner PJ, 2020, J ALLERGY CLIN IMMUN, V145, P1157, DOI 10.1016/j.jaci.2019.12.010
   US Food and Drug Administration, 2018, AFL QUADR
   US Food and Drug Administration, 2018, FLUZ QUADR
   Uyeki TM, 2019, CLIN INFECT DIS, V68, pE1, DOI 10.1093/cid/ciy866
   Uyeki TM, 2018, CLIN INFECT DIS, V66, P1501, DOI 10.1093/cid/cix1150
   Venkatesan S, 2017, CLIN INFECT DIS, V64, P1328, DOI 10.1093/cid/cix127
   Vesikari T, 2018, LANCET RESP MED, V6, P345, DOI [10.1016/S2213-2600(18)30108-5, 10.1016/s2213-2600(18)30108-5]
   Walter EB, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-1909
   WANG K, 2012, COCHRANE DB SYST REV, V18, DOI DOI 10.1002/14651858.CD002744.PUB3
   Wang X, 2020, LANCET GLOB HEALTH, V8, pE497, DOI 10.1016/S2214-109X(19)30545-5
   World Health Organization, REC COMP INFL VIR VA
   Xu XY, 2019, MMWR-MORBID MORTAL W, V68, P544, DOI 10.15585/mmwr.mm6824a3
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
NR 108
TC 1
Z9 1
U1 0
U2 0
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD OCT
PY 2020
VL 146
IS 4
AR e2020024588
DI 10.1542/peds.2020-024588
PG 29
WC Pediatrics
SC Pediatrics
GA OG1VI
UT WOS:000581680200029
PM 32900875
OA Bronze
DA 2021-01-01
ER

PT J
AU Cavicchi, C
   Vagnoni, E
AF Cavicchi, Caterina
   Vagnoni, Emidia
TI Sustainable Business Models in Hybrids: A Conceptual Framework for
   Community Pharmacies' Business Owners
SO SUSTAINABILITY
LA English
DT Article
DE sustainable business model; community pharmacies; pharmacy practice;
   public health; COVID-19
ID MANAGEMENT; HEALTH; PROFESSION; INNOVATION; DESIGN; FIELD; TOOL; UK
AB Community pharmacies have recently been asked to contribute to sustainable healthcare systems through active participation in an integrated model of care and by playing a major educational role for environmental conservation. Therefore, dramatic changes in their institutional context have led to increasing competition in the drugs retail sector and a shift toward a service-oriented business. These factors urge rethinking of the business model of these hybrid organizations, which combine a profit-oriented, social, and more recently addressed, environmental identity. This paper aims at discussing a sustainable business model (SBM) that could allow community pharmacies to contribute to public health through pharmacists' current role and development of that role. The effects of the COVID-19 pandemic suggest that human health should be at the center of the sustainable development agenda; the pandemic raises questions about the traditional role of community pharmacies, such as extending patient-oriented services. The SBM for community pharmacies represents an opportunity to enhance their role among the healthcare workforce, especially in a time of global pandemics. In addition, the SBM can support community pharmacies to integrate sustainability in day-to-day pharmacy practice, although it should be customized based on the contextual characteristics of the business and on differences between countries, such as health policies and regulations.
C1 [Cavicchi, Caterina; Vagnoni, Emidia] Univ Ferrara, Dept Econ & Management, I-44121 Ferrara, Italy.
RP Cavicchi, C (corresponding author), Univ Ferrara, Dept Econ & Management, I-44121 Ferrara, Italy.
EM cvccrn@unife.it; vgnmde@unife.it
CR Abdelkafi N, 2016, ORGAN ENVIRON, V29, P74, DOI 10.1177/1086026615592930
   ALARIFI MN, 2013, PHARM PHARM, V4, P63, DOI DOI 10.4236/PP.2013.41009
   Allee V, 2009, LEARN ORGAN, V16, P427, DOI 10.1108/09696470910993918
   Anderson C, 2000, PATIENT EDUC COUNS, V39, P285, DOI 10.1016/S0738-3991(99)00025-7
   Anderson C, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-45
   Baden-Fuller C, 2013, LONG RANGE PLANN, V46, P419, DOI 10.1016/j.lrp.2013.08.023
   Bader L, 2020, RES SOC ADMIN PHARM, V16, P724, DOI 10.1016/j.sapharm.2019.06.017
   Bernsten C, 2001, DRUG AGING, V18, P63, DOI 10.2165/00002512-200118010-00005
   Birkin F, 2009, BUS STRATEG ENVIRON, V18, P64, DOI 10.1002/bse.568
   Birkin F, 2009, BUS STRATEG ENVIRON, V18, P277, DOI 10.1002/bse.581
   Bocken NMP, 2014, J CLEAN PROD, V65, P42, DOI 10.1016/j.jclepro.2013.11.039
   Bocken N, 2013, CORP GOV-INT J BUS S, V13, P482, DOI 10.1108/CG-06-2013-0078
   Breen L., 2017, P BRIT AC MAN C WARW
   Bukhari Nadia, 2020, J Pharm Policy Pract, V13, P8, DOI 10.1186/s40545-020-00210-w
   Cadogan C. A., 2020, RES SOC ADM PHARM
   Campbell J., 2008, PHARM PRACTICE, P41
   Castaldo S, 2016, RES SOC ADMIN PHARM, V12, P699, DOI 10.1016/j.sapharm.2015.10.001
   Chesbrough H, 2010, LONG RANGE PLANN, V43, P354, DOI 10.1016/j.lrp.2009.07.010
   Cranor Carole W, 2003, J Am Pharm Assoc (Wash), V43, P173, DOI 10.1331/108658003321480713
   Daughton CG, 2003, ENVIRON HEALTH PERSP, V111, P757, DOI 10.1289/ehp.5947
   Daughton Christian G, 2011, Expert Rev Clin Pharmacol, V4, P211, DOI 10.1586/ecp.11.6
   Dentchev N, 2018, J CLEAN PROD, V194, P695, DOI 10.1016/j.jclepro.2018.05.156
   Dugani S, 2016, CAN MED ASSOC J, V188, pE213, DOI 10.1503/cmaj.151241
   Elkington J., 1997, CANNIBALS FORKS TRIP
   Ensing HT, 2019, RES SOC ADMIN PHARM, V15, P267, DOI 10.1016/j.sapharm.2018.05.001
   Evans S, 2017, BUS STRATEG ENVIRON, V26, P597, DOI 10.1002/bse.1939
   Fjeldstad OD, 2018, LONG RANGE PLANN, V51, P32, DOI 10.1016/j.lrp.2017.07.008
   Franco-Trigo L, 2017, RES SOC ADMIN PHARM, V13, P539, DOI 10.1016/j.sapharm.2016.06.009
   Frumkin H., 2007, GREEN HEALTHCARE I H, DOI [10.17226/11878, DOI 10.17226/11878]
   Garrett DG, 2005, J AM PHARM ASSOC, V45, P130, DOI 10.1331/1544345053623492
   Gavilan D, 2014, RES SOC ADMIN PHARM, V10, pE125, DOI 10.1016/j.sapharm.2014.02.008
   Geissdoerfer M, 2018, J CLEAN PROD, V198, P401, DOI 10.1016/j.jclepro.2018.06.240
   Gotz K, 2010, GREEN SUSTAINABLE PH, P149
   Hakovirta M, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12093727
   HEPLER CD, 1990, AM J HOSP PHARM, V47, P533, DOI 10.1093/ajhp/47.3.533
   International Federation of Pharmacists, 2017, ADV GLOB PHARM WORKF
   Joldersma C., 2002, PUBL MANAG REV, V4, P83, DOI DOI 10.1080/14616670110101708
   Joyce A, 2016, J CLEAN PROD, V135, P1474, DOI 10.1016/j.jclepro.2016.06.067
   Kehrer James P, 2013, Can Pharm J (Ott), V146, P321, DOI 10.1177/1715163513506370
   Koster Ellen S, 2021, Res Social Adm Pharm, V17, P2002, DOI 10.1016/j.sapharm.2020.07.001
   Kotchen M, 2009, J ENVIRON MANAGE, V90, P1476, DOI 10.1016/j.jenvman.2008.10.002
   Kozminski M, 2011, J AM PHARM ASSOC, V51, P173, DOI 10.1331/JAPhA.2011.10188
   Kreisberg J., 2007, INTEGRAT MED, V6, P50
   Kummerer K, 2007, GREEN CHEM, V9, P899, DOI 10.1039/b618298b
   Kurunmaki L, 2004, ACCOUNT ORG SOC, V29, P327, DOI 10.1016/S0361-3682(02)00069-7
   Laasch O, 2018, LONG RANGE PLANN, V51, P158, DOI 10.1016/j.lrp.2017.09.002
   Ludeke-Freund F, 2018, SUSTAIN PROD CONSUMP, V15, P145, DOI 10.1016/j.spc.2018.06.004
   Ludeke-Freund F, 2017, J CLEAN PROD, V168, P1668, DOI 10.1016/j.jclepro.2017.08.093
   Mair J, 2015, ORGAN STUD, V36, P713, DOI 10.1177/0170840615580007
   Miller P, 2008, ACCOUNT ORG SOC, V33, P942, DOI 10.1016/j.aos.2007.02.005
   Mossialos E, 2015, HEALTH POLICY, V119, P628, DOI 10.1016/j.healthpol.2015.02.007
   Moullin JC, 2013, RES SOC ADMIN PHARM, V9, P989, DOI 10.1016/j.sapharm.2013.02.005
   Munroe WP, 1997, CLIN THER, V19, P113, DOI 10.1016/S0149-2918(97)80078-1
   Nadeem M.F., IS PARADIGM COMMUNIT
   Nazar H, 2019, RES SOC ADMIN PHARM, V15, P292, DOI 10.1016/j.sapharm.2018.04.036
   Nosratabadi S, 2019, SUSTAINABILITY-BASEL, V11, DOI 10.3390/su11061663
   Nunes FG, 2017, J SMALL BUS ENTERP D, V24, P34, DOI 10.1108/JSBED-05-2016-0069
   Osterwalder A., 2010, BUSINESS MODEL GENER
   Osterwalder A, 2011, RESPONSIBLE MANAGEME, P61
   OTTEWILL R, 2000, ED TRAINING, V42, P246, DOI DOI 10.1108/00400910010373697
   Park J J, 1996, J Am Pharm Assoc (Wash), VNS36, P443
   Pena C, 2011, INT PHARM J, V27, P1
   Perepelkin J, 2011, INT J PHARM HEALTHC, V5, P175, DOI 10.1108/17506121111172194
   Pieroni MPP, 2019, J CLEAN PROD, V215, P198, DOI 10.1016/j.jclepro.2019.01.036
   Pioch E.A., 2004, INT J RETAILING DIST, V32, P532
   Porter ME, 2011, HARVARD BUS REV, V89, P2, DOI DOI 10.1111/J.1467-9310.2011.00672.X
   Roome N, 2016, ORGAN ENVIRON, V29, P11, DOI 10.1177/1086026615595084
   Root D., 2017, PHARM WAY FORWARD PU, P1
   Rutter V, 2018, J PHARM POLICY PRACT, V11, DOI 10.1186/s40545-018-0140-3
   Saramunee K, 2014, RES SOC ADMIN PHARM, V10, P272, DOI 10.1016/j.sapharm.2012.05.006
   Schaltegger S, 2016, ORGAN ENVIRON, V29, P3, DOI 10.1177/1086026615599806
   SCHAPER M., 2002, INT SMALL BUS J, V20, P235, DOI DOI 10.1177/0266242602203001
   Schmidt R, 2004, INT J RETAIL DISTRIB, V32, P354, DOI DOI 10.1108/09590550410541471
   Schommer JC, 2019, J AM PHARM ASSOC, V59, P306, DOI 10.1016/j.japh.2018.10.009
   Short S.W., 2012, IFIP INT C ADV PROD, P175
   Singleton J., 2013, J PHARM, V94, P64
   Singleton JA, 2014, RES SOC ADMIN PHARM, V10, P459, DOI 10.1016/j.sapharm.2013.05.010
   Sobczak E, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12114648
   Spieth P, 2019, LONG RANGE PLANN, V52, P427, DOI 10.1016/j.lrp.2018.04.004
   Stubbs W, 2008, ORGAN ENVIRON, V21, P103, DOI 10.1177/1086026608318042
   Teece DJ, 2010, LONG RANGE PLANN, V43, P172, DOI 10.1016/j.lrp.2009.07.003
   Thach AV, 2013, J ENVIRON MANAGE, V127, P23, DOI 10.1016/j.jenvman.2013.04.025
   Turner K, 2019, RES SOC ADMIN PHARM, V15, P1118, DOI 10.1016/j.sapharm.2018.09.015
   Upward A, 2016, ORGAN ENVIRON, V29, P97, DOI 10.1177/1086026615592933
   Vagnoni E, 2018, INT J HEALTH PLAN M, V33, P1146, DOI 10.1002/hpm.2596
   Van Mil J, 2006, HARVARD HLTH POLICY, V7, P155
   Velo G, 2010, DRUG SAFETY, V33, P963, DOI 10.2165/11539380-000000000-00000
   Webster L., 2014, PHARM PRACTICE TODAY, P358
   Wermeille J, 2004, PHARM WORLD SCI, V26, P18, DOI 10.1023/B:PHAR.0000013465.24857.a8
   Wick J.Y., GETTING GREEN HOWS P
   Wiedenmayer K., 2006, DEV PHARM PRACTICE F
   Woodard LJ, 2018, PUBLIC HEALTH, V155, P69, DOI 10.1016/j.puhe.2017.11.010
   Xie Y, 2012, SUPPLY CHAIN MANAG, V17, P40, DOI 10.1108/13598541211212195
NR 93
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2071-1050
J9 SUSTAINABILITY-BASEL
JI Sustainability
PD OCT
PY 2020
VL 12
IS 19
AR 8125
DI 10.3390/su12198125
PG 18
WC Green & Sustainable Science & Technology; Environmental Sciences;
   Environmental Studies
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA OO2OU
UT WOS:000587224300001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Ianevski, A
   Yao, RA
   Biza, S
   Zusinaite, E
   Mannik, A
   Kivi, G
   Planken, A
   Kurg, K
   Tombak, EM
   Ustav, M
   Shtaida, N
   Kulesskiy, E
   Jo, E
   Yang, J
   Lysvand, H
   Loseth, K
   Oksenych, V
   Aas, PA
   Tenson, T
   Vitkauskiene, A
   Windisch, MP
   Fenstad, MH
   Nordbo, SA
   Ustav, M
   Bjoras, M
   Kainov, DE
AF Ianevski, Aleksandr
   Yao, Rouan
   Biza, Svetlana
   Zusinaite, Eva
   Mannik, Andres
   Kivi, Gaily
   Planken, Anu
   Kurg, Kristiina
   Tombak, Eva-Maria
   Ustav, Mart, Jr.
   Shtaida, Nastassia
   Kulesskiy, Evgeny
   Jo, Eunji
   Yang, Jaewon
   Lysvand, Hilde
   Loseth, Kirsti
   Oksenych, Valentyn
   Aas, Per Arne
   Tenson, Tanel
   Vitkauskiene, Astra
   Windisch, Marc P.
   Fenstad, Mona Hoysaeter
   Nordbo, Svein Arne
   Ustav, Mart
   Bjoras, Magnar
   Kainov, Denis E.
TI Identification and Tracking of Antiviral Drug Combinations
SO VIRUSES-BASEL
LA English
DT Article
DE antivirals; antiviral drug combinations; broad-spectrum antivirals;
   virus
ID ENTRY
AB Combination therapies have become a standard for the treatment for HIV and hepatitis C virus (HCV) infections. They are advantageous over monotherapies due to better efficacy, reduced toxicity, as well as the ability to prevent the development of resistant viral strains and to treat viral co-infections. Here, we identify new synergistic combinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), echovirus 1 (EV1), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1) in vitro. We observed synergistic activity of nelfinavir with convalescent serum and with purified neutralizing antibody 23G7 against SARS-CoV-2 in human lung epithelial Calu-3 cells. We also demonstrated synergistic activity of nelfinavir with EIDD-2801 or remdesivir in Calu-3 cells. In addition, we showed synergistic activity of vemurafenib with emetine, homoharringtonine, anisomycin, or cycloheximide against EV1 infection in human lung epithelial A549 cells. We also found that combinations of sofosbuvir with brequinar or niclosamide are synergistic against HCV infection in hepatocyte-derived Huh-7.5 cells, and that combinations of monensin with lamivudine or tenofovir are synergistic against HIV-1 infection in human cervical TZM-bl cells. These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status.
C1 [Ianevski, Aleksandr; Yao, Rouan; Biza, Svetlana; Lysvand, Hilde; Loseth, Kirsti; Oksenych, Valentyn; Aas, Per Arne; Fenstad, Mona Hoysaeter; Nordbo, Svein Arne; Bjoras, Magnar; Kainov, Denis E.] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, N-7028 Trondheim, Norway.
   [Zusinaite, Eva; Shtaida, Nastassia; Tenson, Tanel; Kainov, Denis E.] Univ Tartu, Inst Technol, EE-50090 Tartu, Estonia.
   [Mannik, Andres; Kivi, Gaily; Planken, Anu; Kurg, Kristiina; Tombak, Eva-Maria; Ustav, Mart, Jr.; Ustav, Mart] Icosagen Cell Factory OU, EE-61713 Kambja Vald Tartumaa, Estonia.
   [Kulesskiy, Evgeny; Kainov, Denis E.] Univ Helsinki, Inst Mol Med Finland, FIMM, Helsinki 00014, Finland.
   [Jo, Eunji; Yang, Jaewon; Windisch, Marc P.] Inst Pasteur Korea, Appl Mol Virol Lab, Sampyeong Dong 696, Seongnam Si 463400, Gyeonggi Do, South Korea.
   [Vitkauskiene, Astra] Lithuanian Univ Hlth Sci, Dept Lab Med, LT-44307 Kaunas, Lithuania.
   [Fenstad, Mona Hoysaeter] St Olavs Hosp, Dept Med Microbiol, N-7006 Trondheim, Norway.
   [Nordbo, Svein Arne] St Olavs Hosp, Dept Immunol & Transfus Med, N-7006 Trondheim, Norway.
RP Kainov, DE (corresponding author), Norwegian Univ Sci & Technol, Dept Clin & Mol Med, N-7028 Trondheim, Norway.; Kainov, DE (corresponding author), Univ Tartu, Inst Technol, EE-50090 Tartu, Estonia.; Kainov, DE (corresponding author), Univ Helsinki, Inst Mol Med Finland, FIMM, Helsinki 00014, Finland.
EM aleksandr.ianevski@ntnu.no; rouany@stud.ntnu.no;
   svetlana.biza@yandex.ru; eva.zusinaite@ut.ee; andres.mannik@icosagen.ee;
   gaily.kivi@icosagen.ee; anu.planken@icosagen.ee;
   kristiina.kurg@icosagen.ee; eva-maria.tombak@icosagen.ee;
   mart.ustav@icosagen.ee; nastassia.shtaida@ut.ee;
   evgeny.kulesskiy@helsinki.fi; eunji.jo@ip-korea.org;
   jaewon.yang@ip-korea.org; hilde.lysvand@ntnu.no; kirsti.loseth@ntnu.no;
   valentyn.oksenych@ntnu.no; per.a.aas@ntnu.no; tanel.tenson@ut.ee;
   astra.vitkauskiene@kaunoklinikos.lt; marc.windisch@ip-korea.org;
   Mona.Hoyseter.Fenstad@stolav.no; svein.a.nordbo@ntnu.no;
   mart.ustav@icosagen.ee; magnar.bjoras@ntnu.no; denis.kainov@ntnu.no
RI ; Tenson, Tanel/I-6431-2015
OI Oksenych, Valentyn/0000-0002-5088-3791; Fenstad, Mona
   Hoysaeter/0000-0002-9102-8409; Tenson, Tanel/0000-0002-0260-3601
FU European Regional Development FundEuropean Union (EU); Mobilitas Pluss
   Project [MOBTT39]; National Research Foundation of Korea (NRF) - Korean
   government (MSIT) [NRF-2017M3A9G6068246]
FX This research was funded the European Regional Development Fund, the
   Mobilitas Pluss Project MOBTT39 (to D.K.). This work was financially
   supported by a National Research Foundation of Korea (NRF) grant funded
   by the Korean government (MSIT) (NRF-2017M3A9G6068246).
CR Andersen PI, 2020, INT J INFECT DIS, V93, P268, DOI 10.1016/j.ijid.2020.02.018
   Andersen PI, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100964
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Bosl K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02186
   Bulanova D, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100271
   Chaudhuri S, 2018, ANTIVIR RES, V155, P76, DOI 10.1016/j.antiviral.2018.05.005
   Del Bufalo F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00526
   Fu Y, 2016, ANTIVIR RES, V133, P23, DOI 10.1016/j.antiviral.2016.07.008
   Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X
   Ianevski A, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060642
   Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216
   Ianevski A, 2019, DRUG DISCOV TODAY, V24, P1224, DOI 10.1016/j.drudis.2019.04.006
   Ianevski A, 2018, ANTIVIR RES, V154, P174, DOI 10.1016/j.antiviral.2018.04.016
   Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Kivi G, 2016, BMC BIOTECHNOL, V16, DOI 10.1186/s12896-016-0232-6
   Kuivanen S, 2017, ANTIVIR RES, V139, P117, DOI 10.1016/j.antiviral.2016.12.022
   Lamb YN, 2020, DRUGS, V80, P1355, DOI 10.1007/s40265-020-01378-w
   Lee M, 2017, SCI REP-UK, V7, DOI 10.1038/srep44676
   Lee M, 2016, ANTIVIR RES, V132, P287, DOI 10.1016/j.antiviral.2016.07.002
   Potdar S, 2020, BIOINFORMATICS, V36, P3602, DOI 10.1093/bioinformatics/btaa138
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Smura T, 2013, INFECT GENET EVOL, V16, P234, DOI 10.1016/j.meegid.2013.02.011
   Toots M, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax5866
   Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
   Zhang CH, 2005, CHINESE MED J-PEKING, V118, P493
NR 27
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD OCT
PY 2020
VL 12
IS 10
AR 1178
DI 10.3390/v12101178
PG 15
WC Virology
SC Virology
GA OO5YZ
UT WOS:000587455300001
PM 33080984
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tesfaye, W
   Abrha, S
   Sinnollareddy, M
   Arnold, B
   Brown, A
   Matthew, C
   Oguoma, VM
   Peterson, GM
   Thomas, J
AF Tesfaye, Wubshet
   Abrha, Solomon
   Sinnollareddy, Mahipal
   Arnold, Bruce
   Brown, Andrew
   Matthew, Cynthia
   Oguoma, Victor M.
   Peterson, Gregory M.
   Thomas, Jackson
TI How Do We Combat Bogus Medicines in the Age of the COVID-19 Pandemic?
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID QUALITY; DRUGS; RISKS
AB The COVID-19 pandemic has brought concurrent challenges. The increased incidence of fake and falsified product distribution is one of these problems with tremendous impact, especially in low- and middle-income countries. Up to a tenth of medicines including antibiotics and antimalarial drugs in the African market are considered falsified. Pandemics make this worse by creating an ecosystem of confusion, distraction, and vulnerability stemming from the pandemic as health systems become more stressed and the workload of individuals increased. These environments create opportunities for substandard and falsified medicines to be more easily introduced into the marketplace by unscrupulous operators. In this work we discuss some of the challenges with fake or falsified product distribution in the context of COVID-19 and proposed strategies to best manage this problem.
C1 [Tesfaye, Wubshet; Oguoma, Victor M.] Univ Canberra, Hlth Res Inst, Canberra, ACT, Australia.
   [Abrha, Solomon; Matthew, Cynthia; Peterson, Gregory M.; Thomas, Jackson] Univ Canberra, Canberra, ACT, Australia.
   [Abrha, Solomon] Mekelle Univ, Mekele, Ethiopia.
   [Sinnollareddy, Mahipal] Therapeut Goods Adm, Canberra, ACT, Australia.
   [Arnold, Bruce] Univ Canberra, Canberra Law Sch, Canberra, ACT, Australia.
   [Brown, Andrew] IntraHlth Int, Durham, NC USA.
   [Peterson, Gregory M.] Univ Tasmania, Hobart, Tas, Australia.
RP Thomas, J (corresponding author), Univ Canberra Bruce, Fac Hlth, Kirrinari St, Canberra, ACT 2601, Australia.
EM wubshet.tesfaye@canberra.edu.au; solomon.bezabh@canberra.edu.au;
   sinnollareddy@health.gov.au; bruce.arnold@canberra.edu.au;
   abrown@intrahealth.org; cynthia.matthew@canberra.edu.au;
   victor.oguoma@canberra.edu.au; g.peterson@utas.edu.au;
   jackson.thomas@canberra.edu.au
RI ; Oguoma, Victor/I-9177-2014
OI Thomas, Jackson/0000-0002-0699-788X; Oguoma, Victor/0000-0001-9505-7197;
   Arnold, Bruce/0000-0003-0536-0446; Tesfaye, Wubshet/0000-0001-7208-2330
CR Bate R, 2012, PHAKE DEADLY WORLD F
   Beigel J. H., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2007764., DOI 10.1056/NEJMOA2007764., 10.1056/nejmoa2007764.]
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   CHAVES A, 2008, SUFFOLK TRANSNATL LA, V32, P631
   Davison M, 2011, PHARM ANTICOUNTERFEI
   Emily Tucker MD, 2020, CONVERSATION
   Erku DA, 2020, RES SOC ADMIN PHARM, DOI [10.1016/j.sapharm.2020.04.032, DOI 10.1016/J.SAPHARM.2020.04.032.]
   Gostin LO, 2013, COUNTERING PROBLEM F
   Grech J, 2018, J PHARMACEUT BIOMED, V147, P612, DOI 10.1016/j.jpba.2017.04.056
   Guerin Philippe J, 2020, F1000Res, V9, P225, DOI 10.12688/f1000research.23057.1
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436, 10. 1056/NEJMoa2021436., DOI 10.1056/NEJMOA2021436.]
   Iacobucci G, 2020, BMJ-BRIT MED J, V370, DOI [10.1136/bmj.m3224, 10.1136/bmj.m2224]
   Koczwara A, 2017, J PHARM SCI-US, V106, P2921, DOI 10.1016/j.xphs.2017.05.018
   Lakavage A, 2020, STAT
   Ledford H, 2020, NATURE, V582, P160, DOI 10.1038/d41586-020-01695-w
   Mehta B, 2020, JAMA HLTH FOR APR 10
   MSH, 2020, MED TECHN PHARM SERV
   Mullin R, 2020, CHEM ENG NEWS, V98
   Nawrat A, 2020, PHARM TECHNOL
   Nayyar GML, 2019, AM J TROP MED HYG, V100, P1058, DOI 10.4269/ajtmh.18-0981
   Newton PN, 2020, LANCET GLOB HEALTH, V8, pE754, DOI 10.1016/S2214-109X(20)30136-4
   OECD, 2016, ILL TRAD
   OECD, 2020, COVID 19 CRIS UND NE
   Pisani Elizabeth, 2019, Wellcome Open Res, V4, P70, DOI 10.12688/wellcomeopenres.15236.1
   Rahman MS, 2018, TROP MED INT HEALTH, V23, P1294, DOI 10.1111/tmi.13161
   RECOVERY, 2020, PREL RES RECOVERY TR
   Roth L, 2018, GLOBALIZATION HEALTH, V14, DOI 10.1186/s12992-018-0360-y
   Schwitzer G, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j1262
   Servick K, 2020, SCIENCE, V368, P1041, DOI 10.1126/science.368.6495.1041
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Thomas J, 2018, CLIN PHARMACOL THER, V104, P1059, DOI 10.1002/cpt.1199
   USAID, 2020, USAID GLOB HLTH SUPP
   USP, 2020, PROM QUAL MED PQM PR
   Vickers S, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000725
   Walker EJ, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5521-7
   WHO, 2018, TANZ IS 1 AFR COUNTR
   WHO, 2020, FALS CHLOR PROD CIRC
   WHO, 2017, 1 10 MED PROD DEV CO
   WHO, 2018, SUBST FALS MED PROD
   WHO, 2020, WHO DISC HYDR LOP RI
   World Health Organization, 2017, STUD PUBL HLTH SOC I
NR 41
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2020
VL 103
IS 4
BP 1360
EP 1363
DI 10.4269/ajtmh.20-0903
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA OE9CC
UT WOS:000580818500010
PM 32815510
OA Green Accepted, Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Rayner, CR
   Dron, L
   Park, JJH
   Decloedt, EH
   Cotton, MF
   Niranjan, V
   Smith, PF
   Dodds, MG
   Brown, F
   Reis, G
   Wesche, D
   Mills, EJ
AF Rayner, Craig R.
   Dron, Louis
   Park, Jay J. H.
   Decloedt, Eric H.
   Cotton, Mark F.
   Niranjan, Vis
   Smith, Patrick F.
   Dodds, Michael G.
   Brown, Fran
   Reis, Gilmar
   Wesche, David
   Mills, Edward J.
TI Accelerating Clinical Evaluation of Repurposed Combination Therapies for
   COVID-19
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
AB As the global COVID-19 pandemic continues, unabated and clinical trials demonstrate limited effective pharmaceutical interventions, there is a pressing need to accelerate treatment evaluations. Among options for accelerated development is the evaluation of drug combinations in the absence of prior monotherapy data. This approach is appealing for a number of reasons. First, combining two or more drugs with related or complementary therapeutic effects permits a multipronged approach addressing the variable pathways of the disease. Second, if an individual component of a combination offers a therapeutic effect, then in the absence of antagonism, a trial of combination therapy should still detect individual efficacy. Third, this strategy is time saving. Rather than taking a stepwise approach to evaluating monotherapies, this strategy begins with testing all relevant therapeutic options. Finally, given the severity of the current pandemic and the absence of treatment options, the likelihood of detecting a treatment effect with combination therapy maintains scientific enthusiasm for evaluating repurposed treatments. Antiviral combination selection can be facilitated by insights regarding SARS-CoV-2 pathophysiology and cell cycle dynamics, supported by infectious disease and clinical pharmacology expert advice. We describe a clinical evaluation strategy using adaptive combination platform trials to rapidly test combination therapies to treat COVID-19.
C1 [Rayner, Craig R.] Monash Univ, Monash Inst Pharmaceut Sci, Melbourne, Vic, Australia.
   [Rayner, Craig R.; Smith, Patrick F.; Dodds, Michael G.; Brown, Fran; Wesche, David] Certara, 100 Overlook Ctr, Princeton, NJ 08540 USA.
   [Dron, Louis; Mills, Edward J.] Cytel Inc, Vancouver, BC, Canada.
   [Dron, Louis; Park, Jay J. H.; Mills, Edward J.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
   [Park, Jay J. H.] Univ British Columbia, Dept Med, Expt Med, Vancouver, BC, Canada.
   [Decloedt, Eric H.] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Med, Div Clin Pharmacol, Cape Town, South Africa.
   [Cotton, Mark F.] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Paediat & Child Hlth, Family Clin Res Unit, Cape Town, South Africa.
   [Niranjan, Vis] RxMD, Chennai, Tamil Nadu, India.
   [Reis, Gilmar] PUC Minas Med Sch Med Contagem, Belo Horizonte, MG, Brazil.
RP Rayner, CR (corresponding author), Certara, 100 Overlook Ctr, Princeton, NJ 08540 USA.
EM craig.rayner@certara.com; louis.dron@cytel.com; jay.park@cytel.com;
   ericdecloedt@sun.ac.za; mcot@sun.ac.za; vis.niranjan@rxmd.com;
   patrick.smith@certara.com; michael.dodds@certara.com;
   fran.brown@certara.com; greisbh@uol.com.br; david.wesche@certara.com;
   millsej@mcmaster.ca
OI Niranjan, Viswanathan/0000-0002-2538-7980; Smith,
   Patrick/0000-0002-6003-0805
CR Adaptive Platform Trials Coalition, 2019, Nat Rev Drug Discov, V18, P797, DOI 10.1038/s41573-019-0034-3
   Angus DC, 2020, ANN AM THORAC SOC, V17, P879, DOI 10.1513/AnnalsATS.202003-192SD
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhatt DL, 2016, NEW ENGL J MED, V375, P65, DOI 10.1056/NEJMra1510061
   Dodds MG, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14486
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Havlir DV, 2000, J INFECT DIS, V182, P321, DOI 10.1086/315683
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Morita M, 2007, INT J ONCOL, V30, P187
   Park JJH, 2020, J CLIN EPIDEMIOL, V125, P1, DOI 10.1016/j.jclinepi.2020.04.025
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1
   The RECOVERY Trial, 2020, CLIN BEN US LOP RIT
   Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8
   United States Food Drug Administration, 2013, GUID IND COD 2 MOR N
   World Health Organization, 2020, SOL CLIN TRIAL COVID
NR 16
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2020
VL 103
IS 4
BP 1364
EP 1366
DI 10.4269/ajtmh.20-0995
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA OE9CC
UT WOS:000580818500011
PM 32828137
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Ahmadi, A
   Essar, MY
   Lin, X
   Adebisi, YA
   Lucero-Prisno, DE
AF Ahmadi, Attaullah
   Essar, Mohammad Yasir
   Lin, Xu
   Adebisi, Yusuff Adebayo
   Lucero-Prisno, Don Eliseo, III
TI Polio in Afghanistan: The Current Situation amid COVID-19
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
AB Polio is a deadly viral disease that has been paralyzing many children in Afghanistan. Despite fundamental efforts, primarily vaccination, to reduce the number of cases in Afghanistan, there are still many children who are deprived of the vaccine every year. Afghanistan is one of the two remaining countries endemic for polio, and the country has undergone various challenges that have hampered the eradication of this disease. The underlying challenges include inaccessibility of unsecured areas, illiteracy, refusal, and, most recently, COVID-19. The country is in the midst of a battle against COVID-19, and polio has almost entirely been neglected. Sadly, polio cases are increasing in the country, particularly in polio-free provinces. After an initial lockdown, many businesses have been allowed to resume, but the mass polio vaccination campaign has not restarted. New cases of polio will surge if endemic regions remain unvaccinated or inaccessible. To curb the further spread of polio, Afghanistan needs to resume nationwide house-to-house vaccination as restrictions due to COVID-19 are loosened.
C1 [Ahmadi, Attaullah; Essar, Mohammad Yasir] Kabul Univ Med Sci, Ata Turk Ave, Kabul 1004, Afghanistan.
   [Lin, Xu] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Thorac Surg, Hangzhou, Peoples R China.
   [Adebisi, Yusuff Adebayo] Univ Ibadan, Fac Pharm, Ibadan, Nigeria.
   [Lucero-Prisno, Don Eliseo, III] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London, England.
   [Lucero-Prisno, Don Eliseo, III] Univ Philippines, Fac Management & Dev Studies, Open Univ, Los Banos, Philippines.
RP Ahmadi, A (corresponding author), Kabul Univ Med Sci, Ata Turk Ave, Kabul 1004, Afghanistan.
EM attaullah.ahmadi@gmail.com; yasir.essar@gmail.com; linxu_001@zju.edu.cn;
   adebisiyusuff23@yahoo.com; doneliseo.prisno@upou.edu.ph
OI Adebisi, Yusuff Adebayo/0000-0002-2381-0984; Lucero-Prisno, Don Eliseo
   III/0000-0002-2179-6365
CR AFP, 2020, NEW POL CAS AFGH COR
   Akinwotu E, 2020, POLIO CAMPAIGN AFRIC
   Chang A, 2012, ERADICATING POLIO AF
   GPEI, 2020, POL PREV
   GPEI, 2020, AFGHANISTAN
   Martinez M, 2018, MMWR-MORBID MORTAL W, V67, P833, DOI 10.15585/mmwr.mm6730a6
   Office of the President of Afghanistan, 2020, GRAD REL RESTR
   RFERL, 2016, 3 POL WORK KILL E AF
   Roberts L, 2020, PANDEMIC FORCES POLI
   Simpson DM, 2014, J INFECT DIS, V210, pS162, DOI 10.1093/infdis/jiu022
   UNAMA, 2020, AFGH ANN REP PROT CI
   UNICEF, 2020, POL ER REACH EV CHIL
   World Health Organization, 2018, AFGH POL ER IN
   World Health Organization, 2019, POL
   Yusufzai A, 2020, LANCET CHILD ADOLESC, V4, P17, DOI 10.1016/S2352-4642(19)30382-7
NR 15
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2020
VL 103
IS 4
BP 1367
EP 1369
DI 10.4269/ajtmh.20-1010
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA OE9CC
UT WOS:000580818500012
PM 32861265
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Lier, AJ
   Tuan, JJ
   Davis, MW
   Paulson, N
   McManus, D
   Campbell, S
   Peaper, DR
   Topal, JE
AF Lier, Audun J.
   Tuan, Jessica J.
   Davis, Matthew W.
   Paulson, Nathan
   McManus, Dayna
   Campbell, Sheldon
   Peaper, David R.
   Topal, Jeffrey E.
TI Case Report: Disseminated Strongyloidiasis in a Patient with COVID-19
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID STERCORALIS; INFECTION
AB The SARS-CoV-2 virus has emerged and rapidly evolved into a current global pandemic. Although bacterial and fungal coinfections have been associated with COVID-19, little is known about parasitic infection. We report a case of a COVID-19 patient who developed disseminated strongyloidiasis following treatment with high-dose corticosteroids and tocilizumab. Screening for Strongyloides infection should be pursued in individuals with COVID-19 who originate from endemic regions before initiating immunosuppressive therapy.
C1 [Lier, Audun J.; Tuan, Jessica J.; Topal, Jeffrey E.] Yale Univ, Dept Internal Med, Sect Infect Dis, Sch Med, 333 Cedar St,POB 208022, New Haven, CT 06520 USA.
   [Davis, Matthew W.; McManus, Dayna; Topal, Jeffrey E.] Yale New Haven Med Ctr, Dept Pharm Serv, 20 York St, New Haven, CT 06504 USA.
   [Paulson, Nathan; Campbell, Sheldon; Peaper, David R.] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA.
RP Lier, AJ (corresponding author), Yale Univ, Dept Internal Med, Sect Infect Dis, Sch Med, 333 Cedar St,POB 208022, New Haven, CT 06520 USA.
EM audun.lier@yale.edu; jessica.tuan@yale.edu; matthew.davis2@ynhh.org;
   nathan.paulson@yale.edu; dayna.mcmanus@ynhh.org;
   sheldon.campbell@yale.edu; david.peaper@yale.edu; jeffrey.topal@ynhh.org
CR Buonfrate D, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-78
   CDC, STRONGYLOIDIASIS
   GANN PH, 1994, J INFECT DIS, V169, P1076, DOI 10.1093/infdis/169.5.1076
   Guevara AG, 2020, AM J TROP MED HYG, V102, P346, DOI 10.4269/ajtmh.19-0565
   Keiser PB, 2004, CLIN MICROBIOL REV, V17, P208, DOI 10.1128/CMR.17.1.208-217.2004
   Machado ER, 2011, AM J TROP MED HYG, V84, P957, DOI 10.4269/ajtmh.2011.10-0490
   Mukaigawara M, 2020, EMERG INFECT DIS, V26, P401, DOI 10.3201/eid2603.190571
   Nutman TB, 2017, PARASITOLOGY, V144, P263, DOI 10.1017/S0031182016000834
   Pornsuriyasak Prapaporn, 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P531
   Quest Diagnostics, STRONG ANT
   Rodriguez EA, 2015, AM J CASE REP, V16, P95, DOI 10.12659/AJCR.892759
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Zhang GQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104364
NR 13
TC 2
Z9 2
U1 2
U2 2
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2020
VL 103
IS 4
BP 1590
EP 1592
DI 10.4269/ajtmh.20-0699
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA OE9CC
UT WOS:000580818500048
PM 32830642
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Rivas, N
   Espinoza, M
   Loban, A
   Luque, O
   Jurado, J
   Henry-Hurtado, N
   Goodridge, A
AF Rivas, Neyla
   Espinoza, Mario
   Loban, Alejandra
   Luque, Odemaris
   Jurado, Julio
   Henry-Hurtado, Nicolas
   Goodridge, Amador
TI Case Report: COVID-19 Recovery from Triple Infection with Mycobacterium
   tuberculosis, HIV, and SARS-CoV-2
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
AB COVID-19, designated as SARS-CoV-2, has caused millions of infections worldwide, including in patients with concomitant infections. Here, we report two unusual cases of patients with triple infections of SARS-CoV-2, Mycobacterium tuberculosis, and HIV. Both cases were confirmed through microbiological and immunological studies. The acute respiratory phase in both patients was treated with supplemental oxygen. Antituberculosis and antiretroviral therapies were started simultaneously. In 2 weeks, both patients demonstrated clinical improvement and recovery from COVID-19. Our findings suggest that even in cases of triple infection, clinical management together with respiratory therapy contributes to patient survival.
C1 [Rivas, Neyla; Espinoza, Mario; Loban, Alejandra; Jurado, Julio; Henry-Hurtado, Nicolas] Complejo Hosp Dr Manuel Amador Guerrero, Serv Med Interna, Caja Seguro Social, Colon, Panama.
   [Luque, Odemaris] Minist Salud, Programa Reg Control TB, Colon, Panama.
   [Goodridge, Amador] Inst Invest Cient & Serv Alta Tecnol INDICASAT AI, TB Biomarker Res Unit, Edificio 219,Bldg 208, Panama City 99999, Panama.
RP Goodridge, A (corresponding author), Inst Invest Cient & Serv Alta Tecnol INDICASAT AI, TB Biomarker Res Unit, Edificio 219,Bldg 208, Panama City 99999, Panama.
EM neyriv2229@gmail.com; mario-btr@hotmail.com; alejandraloban@gmail.com;
   odeque261@gmail.com; juldenju@yahoo.com; nic_henh@hotmail.com;
   agoodridge@indicasat.org.pa
FU Sistema Nacional de Investigadores de Panama -SNI, Secretaria Nacional
   de Ciencia Tecnologia e Innovacion-SENACYT
FX This study was funded by Sistema Nacional de Investigadores de Panama
   -SNI, Secretaria Nacional de Ciencia Tecnologia e Innovacion-SENACYT.
CR Cavalcanti AB, 2020, N ENGL J MED
   Davies M-A, 2020, WHY TB DEATHS MAY IN
   DelAmo J, 2020, ANN INTERN MED, V173, P1
   Gervasoni C, 2020, CLIN INFECT DIS
   Guo W, 2020, SSRN
   Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z
   Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266
   Liu Y, 2020, ACTIVE LATENT TUBERC, DOI [10.1101/2020.03.10.20033795, DOI 10.1101/2020.03.10.20033795]
   Min Ong CW, 2020, EUR RESPIR J
   Moreno R, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.43
   Tadolini M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01398-2020
   Vizcarra P, 2020, LANCET HIV, V7, pE554, DOI 10.1016/S2352-3018(20)30164-8
   WHO, 2019, TB HIV FACT SHEET
   Xu Z, 2020, LANCET HIV, V7, pE524, DOI 10.1016/S2352-3018(20)30163-6
NR 14
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2020
VL 103
IS 4
BP 1597
EP 1599
DI 10.4269/ajtmh.20-0756
PG 3
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA OE9CC
UT WOS:000580818500050
PM 32815513
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abd-Elsalam, S
   Esmail, ES
   Khalaf, M
   Abdo, EF
   Medhat, MA
   Abd El Ghafar, MS
   Ahmed, OA
   Soliman, S
   Serangawy, GN
   Alboraie, M
AF Abd-Elsalam, Sherief
   Esmail, Eslam Saber
   Khalaf, Mai
   Abdo, Ehab Fawzy
   Medhat, Mohammed A.
   Abd El Ghafar, Mohamed Samir
   Ahmed, Ossama Ashraf
   Soliman, Shaimaa
   Serangawy, Ghada N.
   Alboraie, Mohamed
TI Hydroxychloroquine in the Treatment of COVID-19: A Multicenter
   Randomized Controlled Study
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID CORONAVIRUS; SARS; MERS
AB The COVID-19 pandemic is showing an exponential growth, mandating an urgent need to develop an effective treatment. Indeed, to date, a well-established therapy is still lacking. We aimed to evaluate the safety and efficacy of hydroxychloroquine (HCQ) added to standard care in patients with COVID-19. This was a multicenter, randomized controlled trial conducted at three major university hospitals in Egypt. One hundred ninety-four patients with confirmed diagnosis of COVID-19 were included in the study after signing informed consent. They were equally randomized into two arms: 97 patients administrated HCQ plus standard care (HCQ group) and 97 patients administered only standard care as a control arm (control group). The primary endpoints were recovery within 28 days, need for mechanical ventilation, or death. The two groups were matched for age and gender. There was no significant difference between them regarding any of the baseline characteristics or laboratory parameters. Four patients (4.1%) in the HCQ group and 5 (5.2%) patients in the control group needed mechanical ventilation (P = 0.75). The overall mortality did not differ between the two groups, as six patients (6.2%) died in the HCQ group and 5 (5.2%) died in the control group (P = 0.77). Univariate logistic regression analysis showed that HCQ treatment was not significantly associated with decreased mortality in COVID-19 patients. So, adding HCQ to standard care did not add significant benefit, did not decrease the need for ventilation, and did not reduce mortality rates in COVID-19 patients.
C1 [Abd-Elsalam, Sherief; Esmail, Eslam Saber; Khalaf, Mai] Tanta Univ, Fac Med, Dept Trop Med & Infect Dis, El Giash St, Tanta 31527, Egypt.
   [Abdo, Ehab Fawzy; Medhat, Mohammed A.] Assiut Univ, Fac Med, Dept Gastroenterol & Trop Med, Assiut, Egypt.
   [Abd El Ghafar, Mohamed Samir] Tanta Univ, Fac Med, Dept Anesthesia Surg Intens Care & Pain Med, Tanta, Egypt.
   [Ahmed, Ossama Ashraf] Ain Shams Univ, Dept Internal Med, Cairo, Egypt.
   [Soliman, Shaimaa] Menoufia Univ, Publ Hlth & Community Med, Menoufia, Egypt.
   [Serangawy, Ghada N.] Tanta Univ, Fac Med, Dept Forens Med & Toxicol, Tanta, Egypt.
   [Alboraie, Mohamed] Al Azhar Univ, Dept Internal Med, Cairo, Egypt.
RP Abd-Elsalam, S (corresponding author), Tanta Univ, Fac Med, Dept Trop Med & Infect Dis, El Giash St, Tanta 31527, Egypt.
EM sherif.abdelbaky@med.tanta.edu.eg; eslam.esmail@med.tanta.edu.eg;
   mai.a.khalaf@med.tanta.edu.eg; mostafa99@yahoo.com; mmedhat83@gmail.com;
   mohamed.abdelghafar1@med.tanta.edu.eg; ossamaashraf@yahoo.com;
   shaimaasherif@hotmail.com; elashryheba@yahoo.com; alboraie@azhar.edu.eg
RI abd-elsalam, sherief/L-3274-2018; Medhat, Mohammed/ABG-5850-2020;
   Alboraie, Mohamed/F-5688-2011
OI abd-elsalam, sherief/0000-0003-4366-2218; Medhat,
   Mohammed/0000-0002-3866-2283; Alboraie, Mohamed/0000-0002-8490-9822
CR Abd-Elsalam Sherief, 2020, Infect Disord Drug Targets, DOI 10.2174/1871526520666200726224802
   Abena PM, 2020, AM J TROP MED HYG, V102, P1184, DOI 10.4269/ajtmh.20-0290
   Alexander PE, 2020, J CLIN EPIDEMIOL, V123, P120, DOI 10.1016/j.jclinepi.2020.04.016
   Avidan MS, 2020, NEW ENGL J MED, V383, P1087, DOI 10.1056/NEJMc2023617
   Bhandari Sudhir, 2020, J Assoc Physicians India, V68, P13
   Bhatnagar T, 2020, INDIAN J MED RES, DOI [10.4103/ijmr.IJMR_502_20, DOI 10.4103/IJMR.IJMR_502_20]
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Egyptian Ministry of Health and Population (MOH), 2020, DIAGN TREATM PROT CO
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gnegel G, 2020, AM J TROP MED HYG, V103, P73, DOI 10.4269/ajtmh.20-0363
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Mohamed AA, 2020, INFECT DISORD DRUG T, DOI [10.2174/187152652066, DOI 10.2174/187152652066]
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Sarin SK, 2020, HEPATOL INT, V14, P690, DOI 10.1007/s12072-020-10072-8
   Sarma P, 2020, J MED VIROL, V92, P776, DOI 10.1002/jmv.25898
   Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Udwadia Zarir F, 2020, J Assoc Physicians India, V68, P48
   WHO, 2020, CLIN MAN SEV AC RESP
   Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 29
TC 6
Z9 6
U1 1
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2020
VL 103
IS 4
BP 1635
EP 1639
DI 10.4269/ajtmh.20-0873
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA OE9CC
UT WOS:000580818500057
PM 32828135
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Cipriani, A
   Zorzi, A
   Ceccato, D
   Capone, F
   Parolin, M
   Donato, F
   Fioretto, P
   Pesavento, R
   Previato, L
   Maffei, P
   Saller, A
   Avogaro, A
   Sarais, C
   Gregori, D
   Iliceto, S
   Vettor, R
AF Cipriani, Alberto
   Zorzi, Alessandro
   Ceccato, Davide
   Capone, Federico
   Parolin, Matteo
   Donato, Filippo
   Fioretto, Paola
   Pesavento, Raffaele
   Previato, Lorenzo
   Maffei, Pietro
   Saller, Alois
   Avogaro, Angelo
   Sarais, Cristiano
   Gregori, Dario
   Iliceto, Sabino
   Vettor, Roberto
TI Arrhythmic profile and 24-hour QT interval variability in COVID-19
   patients treated with hydroxychloroquine and azithromycin
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Coronavirus; COVID-19; Severe acute respiratory syndrome; Ventricular
   arrhythmia; Sudden death
ID CHLOROQUINE; PHARMACOKINETICS; PLAQUENIL
AB Background: Hydroxychloroquine and azithromycin combination therapy is often prescribed for coronavirus disease 2019 (COVID-19). Electrocardiographic (ECG) monitoring is warranted because both medications cause corrected QT-interval (QTc) prolongation. Whether QTc duration significantly varies during the day, potentially requiring multiple ECGs, remains to be established.
   Methods: We performed 12-lead ECGs and 12-lead 24-h Holter ECG monitoring in all patients aged <80 years admitted to our medical unit for COVID-19, in oral therapy with hydroxychloroquine (200 mg, twice daily) and azithromycin (500 mg, once daily) for at least 3 days. A group of healthy individuals matched for age and sex served as control.
   Results: Out of 126 patients, 22 (median age 64, 82% men) met the inclusion criteria. ECG after therapy showed longer QTc-interval than before therapy (450 vs 426 ms, p=.02). Four patients had a QTc >= 480 ms: they showed higher values of aspartate aminotransferase (52 vs 30 U/L, p=.03) and alanine aminotransferase (108 vs 33 U/L, p < .01) compared with those with QTc < 480 ms. At 24-h Holter ECGmonitoring, 1 COVID-19 patient and no control had >= 1 run of non-sustained ventricular tachycardia (p = .4). No patients showed "R on T" premature ventricular beats. Analysis of 24-h QTc dynamics revealed that COVID-19 patients had higher QTc values than controls, with no significant hourly variability.
   Conclusion: Therapy with hydroxychloroquine and azithromycin prolongs QTc interval in patients with COVID19, particularly in those with high levels of transaminases. Because QTc duration remains stable during the 24 h, multiple daily ECG are not recommendable. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Cipriani, Alberto; Zorzi, Alessandro; Donato, Filippo; Sarais, Cristiano; Gregori, Dario; Iliceto, Sabino] Dept Cardiothoracovasc Sci & Publ Hlth, Padua, Italy.
   [Ceccato, Davide; Capone, Federico; Parolin, Matteo; Fioretto, Paola; Pesavento, Raffaele; Previato, Lorenzo; Maffei, Pietro; Saller, Alois; Avogaro, Angelo; Vettor, Roberto] Univ Padua, Dept Med, Med Sch, Padua, Italy.
RP Cipriani, A (corresponding author), Univ Padua, Med Sch, Dept Cardiothoracovasc Sci & Publ Hlth, Via Giustiniani 2, I-35128 Padua, Italy.
EM alberto.cipriani@unipd.it
RI Zorzi, Alessandro/I-9334-2019; Cipriani, Alberto/B-6495-2018
OI Zorzi, Alessandro/0000-0002-3578-0583; Capone,
   Federico/0000-0001-8127-5564; Cipriani, Alberto/0000-0001-7842-6202
CR Bernardi M, 1998, HEPATOLOGY, V27, P28, DOI 10.1002/hep.510270106
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cortegiani A., 2020, J CRIT CARE, DOI [10.1016/j.jcrc.2020.03.005 S0883-9441(20)30390-7, DOI 10.1016/J.JCRC.2020.03.005S0883-9441(20)30390-7]
   Cubeddu LX, 2016, CURR CARDIOL REV, V12, P141, DOI 10.2174/1573403X12666160301120217
   FOULDS G, 1990, J ANTIMICROB CHEMOTH, V25, P73, DOI 10.1093/jac/25.suppl_A.73
   Furst DE, 1996, LUPUS, V5, pS11, DOI 10.1177/096120339600500104
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Gorelik E, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/aac.00438-18, 10.1128/AAC.00438-18]
   HAMILTON EB, 1962, ARTHRITIS RHEUM, V5, P502, DOI 10.1002/art.1780050507
   Howard PA, 2013, ANN PHARMACOTHER, V47, P1547, DOI 10.1177/1060028013504905
   Khobragade SB, 2013, J PHARMACOL PHARMACO, V4, P116, DOI 10.4103/0976-500X.110892
   Maisch Nicole M, 2014, J Pharm Pract, V27, P496
   Molnar J, 1996, J AM COLL CARDIOL, V27, P76, DOI 10.1016/0735-1097(95)00426-2
   MULLINS JF, 1956, JAMA-J AM MED ASSOC, V161, P879, DOI 10.1001/jama.1956.62970090020017k
   Sanchez-Capula JA, 2001, J PHARMACOL EXP THER, V297, P437
   Simpson T.F., 2020, JAMA INTERN MED
   Sordillo PP, 2015, IN VIVO, V29, P619
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2017, WHO EV REV GROUP CAR
   World Health Organization, 15 WHO
NR 21
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD OCT 1
PY 2020
VL 316
BP 280
EP 284
DI 10.1016/j.ijcard.2020.05.036
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OE5OA
UT WOS:000580578300058
PM 32439366
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Liu, XJ
   Mesch, GS
AF Liu, Xue-Jing
   Mesch, Gustavo S.
TI The Adoption of Preventive Behaviors during the COVID-19 Pandemic in
   China and Israel
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE COVID19; social distance; preventive behaviors; 3C&#8217; s model
ID RISK PERCEPTION; VACCINE HESITANCY; HEALTH; TRUST; BELIEF; INFLUENZA;
   DISEASE; COMMUNICATION; PERSPECTIVE; RESPONSES
AB The COVID-19 pandemic represents a massive global health crisis. The rapid transmission rate of the virus, as well as the lack of effective medications and vaccines, has posed serious challenges to controlling the spread of the disease. Dealing with this public health crisis has required major changes in people's behavior, including the adoption of social distancing measures such as avoiding meeting with family members and friends, crowded places, and public transportation. The purpose of this study is to investigate the factors associated with the adoption of these behaviors in China and Israel. We relied on the 3Cs model that has been used to predict the adoption of a specific preventive behavior (vaccinations) with the goal of testing its applicability to other preventive behaviors such as in response to the COVID-19 pandemic. The model indicates that confidence in social institutions, complacency (fear of and assessments about the risk of becoming ill) and constraints (levels of self-efficacy and confidence in being able to engage in the behaviors) are predictors of adopting preventive behaviors. Data were collected in China and Israel through an online survey of the population (n = 1406). We used latent variables and structural equation modeling to test the hypotheses derived from the 3Cs model. The findings indicate that there are some differences in the types of preventive behaviors adopted in the two countries. In Israel, higher levels of confidence predicted the adoption of avoidant behaviors and more constraints predicted engaging in fewer avoidant behaviors. In China, more constraints also contributed to the adoption of fewer avoidant behaviors, but people's level of confidence fully mediated this result. The multi-group analysis indicated that the conceptualized model fits the Chinese and Israeli data reasonably well. The findings suggest that the 3Cs model can be generalized from getting vaccinated to adopting avoidant behaviors and that the model can be used across cultures and countries.
C1 [Liu, Xue-Jing] Univ Haifa, Sch Publ Hlth, IL-31905 Haifa, Israel.
   [Liu, Xue-Jing] East China Normal Univ, Joint Translat Inst Sci & Technol, Shanghai 200062, Peoples R China.
   [Mesch, Gustavo S.] Univ Haifa, Dept Sociol, IL-31905 Haifa, Israel.
RP Mesch, GS (corresponding author), Univ Haifa, Dept Sociol, IL-31905 Haifa, Israel.
EM xliu@campus.haifa.ac.il; gustavo@soc.haifa.ac.il
OI Liu, Xue-Jing/0000-0002-2508-0495; Mesch, Gustavo/0000-0002-9470-621X
CR Alsulaiman S.A, 2018, J INT CRISIS RISK CO, V1, P3, DOI [10.30658/jicrcr.1.1.3, DOI 10.30658/JICRCR.1.1.3.]
   Askelson NM, 2010, J SCH NURS, V26, P194, DOI 10.1177/1059840510366022
   Bachmann R, 1998, TRUST ORG CONCEPTUAL, P298
   BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191
   Bandura A., 1986, SOCIAL FDN THOUGHT A, P23
   BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497
   Becker M, 1974, HLTH ED MONOGRAPHS, V2, P324, DOI [10.1177/109019817400200401, DOI 10.1177/109019817400200407]
   Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601
   Blair RA, 2017, SOC SCI MED, V172, P89, DOI 10.1016/j.socscimed.2016.11.016
   Brewer NT, 2007, ANN BEHAV MED, V34, P95, DOI 10.1007/BF02879925
   Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136
   Bults M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-2
   Cahyanto I, 2016, TOUR MANAG PERSPECT, V20, P195, DOI 10.1016/j.tmp.2016.09.004
   Cairns G, 2013, J HEALTH COMMUN, V18, P1550, DOI 10.1080/10810730.2013.840696
   Champion V. L., 2008, HLTH BEHAV HLTH ED T, P45
   Champion VL, 2008, J HEALTH PSYCHOL, V13, P827, DOI 10.1177/1359105308093867
   Cowling BJ, 2010, J INFECT DIS, V202, P867, DOI 10.1086/655811
   Drottz-Sjoberg B.-M, 1991, PERCEPTION RISK STUD
   Durham DP, 2012, RISK ANAL, V32, P2020, DOI 10.1111/j.1539-6924.2012.01823.x
   Dussaillant F, 2014, DISASTERS, V38, P808, DOI 10.1111/disa.12077
   Fadda M, 2017, J PUBLIC HEALTH RES, V6, P100, DOI 10.4081/jphr.2017.955
   Farooq A, 2019, IFIP ADV INF COMM TE, V562, P238, DOI 10.1007/978-3-030-22312-0_17
   Farooq Ali, 2020, J Med Internet Res, V22, pe19128, DOI 10.2196/19128
   Fischhoff B, 2018, RISK ANAL, V38, P71, DOI 10.1111/risa.12794
   FOLKES VS, 1988, J CONSUM RES, V15, P13, DOI 10.1086/209141
   Funk S, 2010, J R SOC INTERFACE, V7, P1247, DOI 10.1098/rsif.2010.0142
   Gelfand MJ, 2017, PERSPECT PSYCHOL SCI, V12, P800, DOI 10.1177/1745691617708631
   Gelfand MJ, 2011, SCIENCE, V332, P1100, DOI 10.1126/science.1197754
   Giddens Anthony, 2013, CONSEQUENCES MODERNI
   Gilson L, 2003, SOC SCI MED, V56, P1453, DOI 10.1016/S0277-9536(02)00142-9
   Green L.W, 1980, HLTH ED PLANNING DIA, P306
   Ibuka Y, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-296
   JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101
   Johnson RA, 2007, APPL MULTIVARIATE CO
   Kelvin DJ, 2020, J INFECT DEV COUNTR, V14, P1, DOI 10.3855/jidc.12496
   Kitayama S, 2018, PERS SOC PSYCHOL B, V44, P809, DOI 10.1177/0146167217748603
   Kraus B, 2019, BIOL PSYCHOL, V146, DOI 10.1016/j.biopsycho.2019.107733
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Leung GM, 2005, CLIN INFECT DIS, V40, P1713, DOI 10.1086/429923
   Liao QY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013350
   Loewenstein GF, 2001, PSYCHOL BULL, V127, P267, DOI 10.1037//0033-2909.127.2.267
   Luszczynska A, 2005, J PSYCHOL, V139, P439, DOI 10.3200/JRLP.139.5.439-457
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Meltzer MI, 1999, EMERG INFECT DIS, V5, P659, DOI 10.3201/eid0505.990507
   MIDDLEKAUFF GW, 1978, AM J PSYCHIAT, V135, P878
   Mishler W, 2001, COMP POLIT STUD, V34, P30, DOI 10.1177/0010414001034001002
   Moxham-Hall V, PUBLIC OPINION TRUST
   Perkins DD, 1995, AM J COMMUN PSYCHOL, V23, P569, DOI 10.1007/BF02506982
   Pike J, 2020, ECOHEALTH, V17, P217, DOI 10.1007/s10393-020-01479-8
   Prentice-Dunn S, 1986, HLTH ED RES, V1, P153, DOI DOI 10.1093/HER/1.3.153
   Rappapon J., 1984, PREVENTION HUMAN SER, V3, P1, DOI DOI 10.1300/J293V03N02_
   ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403
   ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203
   Rubin GJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2651
   Schwarzer R., 1996, PREDICTING HLTH BEHA, V163, P196, DOI DOI 10.4324/9781315800820-10
   Sibley CG, 2020, AM PSYCHOL, V75, P618, DOI 10.1037/amp0000662
   Sjoberg L, 2000, QUAL QUANT, V34, P407, DOI 10.1023/A:1004838806793
   Slater M, 2019, ATTENTION ATTITUDE A, P273
   Smith RD, 2006, SOC SCI MED, V63, P3113, DOI 10.1016/j.socscimed.2006.08.004
   Smith RD, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4571
   Sundaram N, 2020, HUM VACC IMMUNOTHER, V16, P1835, DOI 10.1080/21645515.2019.1697596
   Triandis Harry C., 2018, INDIVIDUALISM COLLEC
   TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124
   van der Pligt J, 1996, EUR PSYCHOL, V1, P34, DOI 10.1027/1016-9040.1.1.34
   van der Weerd W, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-575
   van Prooijen JW, 2014, J EXP SOC PSYCHOL, V55, P63, DOI 10.1016/j.jesp.2014.06.006
   VELICER WF, 1985, J PERS SOC PSYCHOL, V48, P1279, DOI 10.1037/0022-3514.48.5.1279
   Ward PR, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00022
   WHO, NOV COR CHIN
   World Health Organization (WHO), TIM COVID 19
   Yzer M, 2017, INT ENCY MEDIA EFF, V50, P1
   Zydney J.M, 2012, ENCY SCI LEARN, V2, P3095, DOI [10.1007/978-1-4419-1428-6_5752, DOI 10.1007/978-1-4419-1428-6_5752]
NR 73
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD OCT
PY 2020
VL 17
IS 19
AR 7170
DI 10.3390/ijerph17197170
PG 18
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OO1XS
UT WOS:000587179900001
PM 33007985
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Crolley, VE
   Hanna, D
   Joharatnam-Hogan, N
   Chopra, N
   Bamac, E
   Desai, M
   Lam, YC
   Dipro, S
   Kanani, R
   Benson, J
   Wilson, W
   Fox, TA
   Shiu, KK
   Forster, M
   Bridgewater, J
   Hochhauser, D
   Khan, K
AF Crolley, Valerie E.
   Hanna, Daire
   Joharatnam-Hogan, Nalinie
   Chopra, Neha
   Bamac, Ekin
   Desai, Meera
   Lam, Yuk-Chun
   Dipro, Sabiq
   Kanani, Ruhi
   Benson, Jack
   Wilson, William
   Fox, Thomas A.
   Shiu, Kai-Keen
   Forster, Martin
   Bridgewater, John
   Hochhauser, Daniel
   Khan, Khurum
TI COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes
   from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London)
   cohort study
SO THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
LA English
DT Article
DE cancer; chemotherapy; COVID-19; coronavirus; hormone therapy;
   immunotherapy; novel coronavirus; oncology; SACT; SARS-CoV-2; systemic
   anti-cancer treatment; tumour; targeted treatment
ID MORTALITY
AB Background:
   Patients with cancer are hypothesised to be at increased risk of contracting COVID-19, leading to changes in treatment pathways in those treated with systemic anti-cancer treatments (SACT). This study investigated the outcomes of patients receiving SACT to assess whether they were at greater risk of contracting COVID-19 or having more severe outcomes.
   Methods:
   Data was collected from all patients receiving SACT in two cancer centres as part of CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London). The primary outcome was the effect of clinical characteristics on the incidence and severity of COVID-19 infection in patients on SACT. We used univariable and multivariable models to analyse outcomes, adjusting for age, gender and comorbidities.
   Results:
   A total of 2871 patients receiving SACT from 2 March to 31 May 2020 were analysed; 68 (2.4%) were diagnosed with COVID-19. Cancer patients receiving SACT were more likely to die if they contracted COVID-19 than those who did not [adjusted (adj.) odds ratio (OR) 9.84; 95% confidence interval (CI) 5.73-16.9]. Receiving chemotherapy increased the risk of developing COVID-19 (adj. OR 2.99; 95% CI = 1.72-5.21), with high dose chemotherapy significantly increasing risk (adj. OR 2.36, 95% CI 1.35-6.48), as did the presence of comorbidities (adj. OR 2.29; 95% CI 1.19-4.38), and having a respiratory or intrathoracic neoplasm (adj. OR 2.12; 95% CI 1.04-4.36). Receiving targeted treatment had a protective effect (adj. OR 0.53; 95% CI 0.30-0.95). Treatment intent (curative versus palliative), hormonal- or immunotherapy and solid versus haematological cancers had no significant effect on risk.
   Conclusion:
   Patients on SACT are more likely to die if they contract COVID-19. Those on chemotherapy, particularly high dose chemotherapy, are more likely to contract COVID-19, while targeted treatment appears to be protective.
C1 [Khan, Khurum] Univ Coll London Hosp, Gastrointestinal Oncol Serv & Canc Unknown Primar, UCL Canc Inst, 250 Euston Rd, London NW1 2PG, England.
   [Crolley, Valerie E.; Dipro, Sabiq; Kanani, Ruhi; Benson, Jack; Khan, Khurum] North Middlesex Univ Hosp, 250 Euston Rd, London NW1 2PG, England.
   [Khan, Khurum] North London Canc Res Network, 250 Euston Rd, London NW1 2PG, England.
   [Khan, Khurum] UCL Canc Inst, 72 Huntley St, London WC1E 6DD, England.
   [Hanna, Daire; Joharatnam-Hogan, Nalinie; Chopra, Neha; Bamac, Ekin; Desai, Meera; Lam, Yuk-Chun; Fox, Thomas A.; Shiu, Kai-Keen; Forster, Martin; Bridgewater, John; Hochhauser, Daniel] Univ Coll NHS Fdn Trust, London, England.
   [Wilson, William] Canc Res UK, Oxford, England.
   [Wilson, William] UCL Canc Trials Ctr, London, England.
   [Joharatnam-Hogan, Nalinie; Forster, Martin; Bridgewater, John; Hochhauser, Daniel] UCL, London, England.
RP Khan, K (corresponding author), Univ Coll London Hosp, Gastrointestinal Oncol Serv & Canc Unknown Primar, UCL Canc Inst, 250 Euston Rd, London NW1 2PG, England.; Khan, K (corresponding author), North Middlesex Univ Hosp, 250 Euston Rd, London NW1 2PG, England.; Khan, K (corresponding author), North London Canc Res Network, 250 Euston Rd, London NW1 2PG, England.; Khan, K (corresponding author), UCL Canc Inst, 72 Huntley St, London WC1E 6DD, England.
EM khurum.khan1@nhs.net
OI Crolley, Valerie/0000-0001-7263-4051
CR Assaad S, 2020, EUR J CANCER, V135, P251, DOI 10.1016/j.ejca.2020.05.028
   Atkins JL, 2020, J GERONTOL A-BIOL, V75, P2224, DOI 10.1093/gerona/glaa183
   Bi JP, 2020, J INFECTION, V81, pE22, DOI 10.1016/j.jinf.2020.07.018
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   El-Sharkawi D, 2020, BRIT J HAEMATOL, V190, P336, DOI 10.1111/bjh.16956
   Gambichler T, 2020, J IMMUNOTHER CANCER, V8, P1
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Jee J, 2020, J CLIN ONCOL, V38, P3538, DOI 10.1200/JCO.20.01307
   Joharatnam-Hogan N, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920956803
   Joharatnam-Hogan N, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01649-z
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   London Datastore, 2020, COR COVID 19 CAS
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   National Institute for Health and Care Excellence, 2020, COVID 19 RAP GUID DE
   Office of National Statistics, 2020, COR COVID 19 INF SUR
   Pinato DJ, 2020, CANCER DISCOV, V10, P1465, DOI 10.1158/2159-8290.CD-20-0773
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Robilotti Elizabeth V, 2020, medRxiv, DOI 10.1101/2020.05.04.20086322
   Robinson AG, 2020, NAT REV CLIN ONCOL, V17, P386, DOI 10.1038/s41571-020-0394-y
   Sud A, 2020, SSRN ELECT J, V22
   World Health Organisation, 2020, COVID 19 INF
   World Health Organisation, 2020, US CHEST IM COVID 19
   World Health Organisation, 2020, UK COVID 19 INF STAT
   World Health Organization, 2015, INT STAT CLASS DIS R
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 29
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1758-8340
EI 1758-8359
J9 THER ADV MED ONCOL
JI Ther. Adv. Med. Oncol.
PD OCT
PY 2020
VL 12
AR 1758835920971147
DI 10.1177/1758835920971147
PG 14
WC Oncology
SC Oncology
GA ON5IW
UT WOS:000586735500001
PM 33178336
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ackerman, EE
   Shoemaker, JE
AF Ackerman, Emily E.
   Shoemaker, Jason E.
TI Network Controllability-Based Prioritization of Candidates for
   SARS-CoV-2 Drug Repositioning
SO VIRUSES-BASEL
LA English
DT Article
DE SARS-CoV-2; drug repositioning; COVID-19; network biology; virus-host
   interactions
ID VITAMIN-E; RECEPTOR; COMPLEX; LIGANDS; NKG2D
AB In a short time, the COVID-19 pandemic has left the world with over 25 million cases and staggering death tolls that are still rising. Treatments for SARS-CoV-2 infection are desperately needed as there are currently no approved drug therapies. With limited knowledge of viral mechanisms, a network controllability method of prioritizing existing drugs for repurposing efforts is optimal for quickly moving through the drug approval pipeline using limited, available, virus-specific data. Based on network topology and controllability, 16 proteins involved in translation, cellular transport, cellular stress, and host immune response are predicted as regulators of the SARS-CoV-2 infected cell. Of the 16, eight are prioritized as possible drug targets where two, PVR and SCARB1, are previously unexplored. Known compounds targeting these genes are suggested for viral inhibition study. Prioritized proteins in agreement with previous analysis and viral inhibition studies verify the ability of network controllability to predict biologically relevant candidates.
C1 [Ackerman, Emily E.; Shoemaker, Jason E.] Univ Pittsburgh, Dept Chem & Petr Engn, Pittsburgh, PA 15260 USA.
   [Shoemaker, Jason E.] Univ Pittsburgh, McGowan Inst Regenerat Med MIRM, Pittsburgh, PA 15260 USA.
   [Shoemaker, Jason E.] Univ Pittsburgh, Sch Med, Dept Computat & Syst Biol, Pittsburgh, PA 15260 USA.
RP Shoemaker, JE (corresponding author), Univ Pittsburgh, Dept Chem & Petr Engn, Pittsburgh, PA 15260 USA.; Shoemaker, JE (corresponding author), Univ Pittsburgh, McGowan Inst Regenerat Med MIRM, Pittsburgh, PA 15260 USA.; Shoemaker, JE (corresponding author), Univ Pittsburgh, Sch Med, Dept Computat & Syst Biol, Pittsburgh, PA 15260 USA.
EM eea16@pitt.edu; jason.shoemaker@pitt.edu
RI Shoemaker, Jason/B-8137-2011
OI Shoemaker, Jason/0000-0003-3315-7103
FU Howard Hughes Medical InstituteHoward Hughes Medical Institute; James H.
   Gilliam Fellowships for Advanced Study program
FX Thank you to the Howard Hughes Medical Institute for supporting this
   project through the James H. Gilliam Fellowships for Advanced Study
   program.
CR Ackerman EE, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2917-z
   Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200
   Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727
   Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788
   Cava C, 2020, BMC PHARMACOL TOXICO, V21, DOI 10.1186/s40360-020-00444-z
   Ellinger B, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-23951/v1, DOI 10.21203/RS.3.RS-23951/V1]
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gordon D.E., 2020, NATURE NATURE, V583, P1
   Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036
   Hayek MG, 1997, J INFECT DIS, V176, P273, DOI 10.1086/517265
   Hopcroft J. E., 1973, SIAM Journal on Computing, V2, P225, DOI 10.1137/0202019
   Jia T, 2013, SCI REP-UK, V3, DOI 10.1038/srep02354
   Jia T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3002
   Jiang M., 2017, EUR J ENV CIV ENG, V7, P1, DOI DOI 10.1038/srep42781
   Jung H, 2012, J EXP MED, V209, P2409, DOI 10.1084/jem.20120565
   Kawasaki Y, 2002, J BIOL CHEM, V277, P27559, DOI 10.1074/jbc.M202879200
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Liao LX, 2017, P NATL ACAD SCI USA, V114, pE5986, DOI 10.1073/pnas.1706778114
   Liu YY, 2011, NATURE, V473, P167, DOI 10.1038/nature10011
   Morita M, 2012, MOL CELL BIOL, V32, P3585, DOI 10.1128/MCB.00455-12
   Oldstone MBA, 2014, CURR TOP MICROBIOL, V378, P129, DOI 10.1007/978-3-319-05879-5_6
   Perrin-Cocon L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02480-z
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Riva Laura, 2020, bioRxiv, DOI 10.1101/2020.04.16.044016
   Samarajiwa SA, 2009, NUCLEIC ACIDS RES, V37, pD852, DOI 10.1093/nar/gkn732
   Scannell JW, 2012, NAT REV DRUG DISCOV, V11, P191, DOI 10.1038/nrd3681
   Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529
   Sloan KE, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-73
   Sontag E. D., 1998, MATH CONTROL THEORY
   Stead RL, 2013, FEBS LETT, V587, P2623, DOI 10.1016/j.febslet.2013.06.045
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Touret F., 2020, SCI REP, V10, P1
   Uchil PD, 2013, J VIROL, V87, P257, DOI 10.1128/JVI.01804-12
   van Nieuwenhuijze A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02234
   Vinayagam A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001699
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Witt W, 2000, J LIPID RES, V41, P2009
   World Health Organization, COR DIS COVID 19 WEE
   Yang Y, 2008, MOL CANCER THER, V7, P952, DOI 10.1158/1535-7163.MCT-07-2045
   Yu JK, 2009, BIOINFORMATICS, V25, P105, DOI 10.1093/bioinformatics/btn597
   Zhang XZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep38209
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 42
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD OCT
PY 2020
VL 12
IS 10
AR 1087
DI 10.3390/v12101087
PG 14
WC Virology
SC Virology
GA OO6AE
UT WOS:000587458600001
PM 32993136
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Barrasa, H
   Rello, J
   Tejada, S
   Martin, A
   Balziskueta, G
   Vinuesa, C
   Fernandez-Miret, B
   Villagra, A
   Vallejo, A
   San Sebastian, A
   Cabanes, S
   Iribarren, S
   Fonseca, F
   Maynar, J
AF Barrasa, Helena
   Rello, Jordi
   Tejada, Sofia
   Martin, Alejandro
   Balziskueta, Goiatz
   Vinuesa, Cristina
   Fernandez-Miret, Borja
   Villagra, Ana
   Vallejo, Ana
   San Sebastian, Ana
   Cabanes, Sara
   Iribarren, Sebastian
   Fonseca, Fernando
   Maynar, Javier
CA Alava COVID-19 Study Investigators
TI SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day
   survival in Vitoria
SO ANAESTHESIA CRITICAL CARE & PAIN MEDICINE
LA English
DT Article
DE COVID-19; Pneumonia; Procalcitonin; ARDS
AB Purpose: Community transmission of SARS-CoV-2 was detected in Spain in February 2020, with 216% intensive care unit (ICU) capacity expanded in Vitoria by March 18th, 2020.
   Methods: We identified patients from the two public hospitals in Vitoria who were admitted to ICU with confirmed infection by SARS-CoV-2. Data reported here were available in April 6th, 2020. Mortality was assessed in those who completed 15-days of ICU stay.
   Results: We identified 48 patients (27 males) with confirmed SARS-CoV-2. Median [interquartile range (IQR)] age of patients was 63 [51-75] years. Symptoms began a median of 7 [5-12] days before ICU admission. The most common comorbidities identified were obesity (48%), arterial hypertension (44%) and chronic lung disease (37%). All patients were admitted by hypoxemic respiratory failure and none received non-invasive mechanical ventilation. Forty-five (94%) underwent intubation, 3 (6%) high flow nasal therapy (HFNT), 1 (2%) extracorporeal membrane oxygenation (ECMO) and 22 (46%) required prone position. After 15 days, 14/45 (31%) intubated patients died (13% within one week), 10/45 (22%) were extubated, and 21/45 (47%) underwent mechanical ventilation. Six patients had documented super-infection. Procalcitonin plasma above 0.5 [J,g/L was associated with 16% vs. 19% (p = 0.78) risk of death after 7 days.
   Conclusion: This early experience with SARS-CoV-2 in Spain suggests that a strategy of right oxygenation avoiding non-invasive mechanical ventilation was life-saving. Seven-day mortality in SARS-CoV-2 requiring intubation was lower than 15%, with 80% of patients still requiring mechanical ventilation. After 15 days of ICU admission, half of patients remained intubated, whereas one third died. (C) 2020 Societe francaise d'anesthesie et de reanimation (Sfar). Published by Elsevier Masson SAS. All rights reserved.
C1 [Barrasa, Helena; Martin, Alejandro; Balziskueta, Goiatz; Vinuesa, Cristina; Fernandez-Miret, Borja; Villagra, Ana; Vallejo, Ana; San Sebastian, Ana; Cabanes, Sara; Iribarren, Sebastian; Fonseca, Fernando; Maynar, Javier] Hosp Univ Alava, Crit Care Dept, Gasteiz, Spain.
   [Rello, Jordi; Tejada, Sofia] Inst Salud Carlos II, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain.
   [Rello, Jordi; Tejada, Sofia] Vall dHebron Inst Res, Clin Res Pneumonia & Sepsis CRIPS, Barcelona, Spain.
   [Rello, Jordi] Univ Montpellier Nimes, CHU Nimes, Clin Res, Nimes, France.
RP Tejada, S (corresponding author), Inst Salud Carlos II, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain.; Tejada, S (corresponding author), Vall dHebron Inst Res, Clin Res Pneumonia & Sepsis CRIPS, Barcelona, Spain.
EM stmagraner@gmail.com
RI Barrasa, Helena/W-5284-2018
OI Barrasa, Helena/0000-0003-2841-6035; Tejada, Sofia/0000-0002-2000-6587;
   Castano Avila, Sergio/0000-0001-6213-7713
FU CIBERES, Instituto Salud Carlos III, Madrid, Spain [CB06-06-036]; fondos
   FEDEREuropean Union (EU)
FX This work was funded in part by CIBERES, Instituto Salud Carlos III,
   Madrid, Spain (CB06-06-036 and fondos FEDER).
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Cohen IG, 2020, JAMA-J AM MED ASSOC, V323, P1901, DOI 10.1001/jama.2020.5442
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Iba T, 2019, J THROMB HAEMOST, V17, P1989, DOI 10.1111/jth.14578
   Jansson M, 2020, INTENS CRIT CARE NUR, V57, DOI 10.1016/j.iccn.2020.102812
   Lippi G, 2020, CLIN CHIM ACTA, V505, P190, DOI 10.1016/j.cca.2020.03.004
   Rello J, 2020, ANAESTH CRIT CARE PA, V39, P167, DOI 10.1016/j.accpm.2020.03.001
   Rello J, 2009, CRIT CARE, V13, DOI 10.1186/cc8044
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   WHO, 2020, CLIN MAN SEV AC RESP
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 27
Z9 27
U1 0
U2 1
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 2352-5568
J9 ANAESTH CRIT CARE PA
JI Anaesth. Crit. Care Pain Med.
PD OCT
PY 2020
VL 39
IS 5
BP 553
EP 561
DI 10.1016/j.accpm.2020.04.001
PG 9
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA OE6PM
UT WOS:000580650500005
PM 32278670
OA Green Published
DA 2021-01-01
ER

PT J
AU Charbonneau, H
   Mrozek, S
   Pradere, B
   Cornu, JN
   Misrai, V
AF Charbonneau, Helene
   Mrozek, Segolene
   Pradere, Benjamin
   Cornu, Jean-Nicolas
   Misrai, Vincent
TI How to resume elective surgery in light of COVID-19 post-pandemic
   propofol shortage: The common concern of anaesthesists and surgeons
SO ANAESTHESIA CRITICAL CARE & PAIN MEDICINE
LA English
DT Letter
DE COVID-19; Surgery; Drugs shortage; Propofol; Regional Anaesthesia
C1 [Charbonneau, Helene] Clin Pasteur, Dept Anaesthesia & Crit Care, F-31300 Toulouse, France.
   [Mrozek, Segolene] Univ Hosp Toulouse, Dept Anaesthesia & Crit Care, Toulouse, France.
   [Pradere, Benjamin] Univ Hosp Tours, Dept Urol, Tours, France.
   [Cornu, Jean-Nicolas] Univ Hosp Rouen, Dept Urol, Rouen, France.
   [Misrai, Vincent] Clin Pasteur, Dept Urol, F-31300 Toulouse, France.
RP Charbonneau, H (corresponding author), Clin Pasteur, Dept Anaesthesia & Crit Care, F-31300 Toulouse, France.
EM hcharbonneau@clinique-pasteur.com
CR Cozowicz C, 2015, BRIT J ANAESTH, V115, P57, DOI 10.1093/bja/aev381
   Lyu H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181970
   Nepogodiev D, 2020, BRIT J SURG, V107, P1440, DOI 10.1002/bjs.11746
   Pourrat X, 2020, ANAESTH CRIT CARE PA, V39, P367, DOI 10.1016/j.accpm.2020.04.012
   Schraag S, 2018, BMC ANESTHESIOL, V18, DOI 10.1186/s12871-018-0632-3
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 2352-5568
J9 ANAESTH CRIT CARE PA
JI Anaesth. Crit. Care Pain Med.
PD OCT
PY 2020
VL 39
IS 5
BP 593
EP 594
DI 10.1016/j.accpm.2020.07.007
PG 2
WC Anesthesiology; Critical Care Medicine
SC Anesthesiology; General & Internal Medicine
GA OE6PM
UT WOS:000580650500016
PM 32753363
OA Green Published
DA 2021-01-01
ER

PT J
AU Pylinska-Dabrowska, D
   Starzynska, A
   Cubala, WJ
   Ragin, K
   Alterio, D
   Jereczek-Fossa, BA
AF Pylinska-Dabrowska, Dorota
   Starzynska, Anna
   Cubala, Wieslaw Jerzy
   Ragin, Karolina
   Alterio, Daniela
   Jereczek-Fossa, Barbara Alicja
TI Psychological Functioning of Patients Undergoing Oral Surgery Procedures
   during the Regime Related with SARS-CoV-2 Pandemic
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE dental anxiety; pandemic; dentistry; oral surgery; dental care;
   SARS-CoV-2; COVID-19
ID DENTAL FEAR; ANXIETY
AB The coronavirus pandemic has become a huge global challenge medically, economically and psychologically. The COVID-19 pandemic shows that the population can experience general psychological distress. The sanitary regime in dental offices and lack of vaccine for coronavirus may have an impact on the level of dental anxiety among patients undergoing oral surgery procedures. A clinical study was conducted between November 2019 and September 2020. A total of 175 patients (n = 175) were enrolled in the research. The aim of the study was to assess the attitude of patients towards the new situation related to the reduced availability of dental offices providing oral surgery procedures. The level of anxiety associated with surgical intervention was measured using a self-made COVID-19 questionnaire and the MDAS scale. The ED-5Q questionnaire and EQ-VAS scale were also used in this research. The study showed that 21.9% of respondents presented with increased anxiety about a dental visit compared with the time before the pandemic. This epidemiological situation has led to an overwhelming increase in moderate dental anxiety (M: 11.4) among patients undergoing oral surgery procedures. The quality of patients' health (EQ-VAS) related to the impact of the coronavirus pandemic and the quarantine decreased by 10 percentage points. Oral surgeons should be prepared for more anxious patients in dental offices during the pandemic.
C1 [Pylinska-Dabrowska, Dorota; Starzynska, Anna; Ragin, Karolina] Med Univ Gdansk, Dept Oral Surg, PL-80211 Gdansk, Poland.
   [Cubala, Wieslaw Jerzy] Med Univ Gdansk, Dept Adult Psychiat, PL-80211 Gdansk, Poland.
   [Alterio, Daniela; Jereczek-Fossa, Barbara Alicja] Univ Milan, Dept Oncol & Hematooncol, I-20122 Milan, Italy.
   [Jereczek-Fossa, Barbara Alicja] IRCCS, IEO European Inst Oncol, Div Radiotherapy, I-20141 Milan, Italy.
RP Pylinska-Dabrowska, D; Starzynska, A (corresponding author), Med Univ Gdansk, Dept Oral Surg, PL-80211 Gdansk, Poland.
EM 37670@gumed.edu.pl; ast@gumed.edu.pl; wieslaw.cubala@gumed.edu.pl;
   karolina.ragin@gumed.edu.pl; daniela.alterio@ieo.it;
   barbara.jereczek@ieo.it
RI Starzynska, Anna/ABI-4599-2020; Cubala, Wieslaw/N-6113-2018
OI Starzynska, Anna/0000-0001-6900-0429; Cubala,
   Wieslaw/0000-0001-6343-8454; Pylinska-Dabrowska,
   Dorota/0000-0002-3617-2213
CR Ahmad MF, 2017, J OBSTET GYNAECOL, V37, P906, DOI 10.1080/01443615.2017.1312302
   [Anonymous], 2020, PUBLIC HLTH ENGLAND
   Armfield JM, 2013, AUST DENT J, V58, P390, DOI 10.1111/adj.12118
   Armfield JM, 2006, AUST DENT J, V51, P78, DOI 10.1111/j.1834-7819.2006.tb00405.x
   Arslan S, 2011, ERCIYES MED J, V33, P295
   Balestroni Gianluigi, 2012, Monaldi Arch Chest Dis, V78, P155
   CORAH NL, 1969, J DENT RES, V48, P596, DOI 10.1177/00220345690480041801
   Cotrin P, 2020, ORTHOD CRANIOFAC RES, V23, P455, DOI 10.1111/ocr.12395
   Dave M, 2020, LANCET, V395, P1257, DOI 10.1016/S0140-6736(20)30806-0
   Davenne E, 2020, Rev Med Liege, V75, P218
   Egbor PE, 2014, LIBYAN J MED, V9, DOI 10.3402/ljm.v9.25433
   Erten H, 2006, QUINTESSENCE INT, V37, P304
   Everts J, 2013, ANTIPODE, V45, P809, DOI 10.1111/j.1467-8330.2012.01021.x
   Fu WN, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-00913-3
   Humphris G M, 1995, Community Dent Health, V12, P143
   Humphris Gerry M, 2009, BMC Oral Health, V9, P20, DOI 10.1186/1472-6831-9-20
   Humphris GM, 2000, INT DENT J, V50, P367, DOI 10.1111/j.1875-595X.2000.tb00570.x
   Leutgeb V, 2013, EUR J ORAL SCI, V121, P465, DOI 10.1111/eos.12079
   Lin C-Y, 2020, SOCIAL HLTH BEHAV, V3, P1, DOI [10.4103/SHB.SHB_11_20, DOI 10.4103/SHB.SHB_11_20]
   PELOSO Renan Morais, 2020, Braz. oral res., V34, pe84, DOI 10.1590/1807-3107bor-2020.vol34.0084
   Vazquez LMR, 2008, MED ORAL PATOL ORAL, V13, pE253
   Bonafe FSS, 2016, BRAZ ORAL RES, V30, DOI [10.1590/1807-3107BOR-2016.vol30.0138, 10.1590/1807-3107bor-2016.vol30.0138]
   Statement on the second meeting of the International Health Regulations, 2005, EM COMM REG OUTBR NO
   Taani DSMQ, 2002, J ORAL REHABIL, V29, P604
   Taani DSMQ, 2001, INT DENT J, V51, P62, DOI 10.1002/j.1875-595X.2001.tb00823.x
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   VASSEND O, 1993, BEHAV RES THER, V31, P659, DOI 10.1016/0005-7967(93)90119-F
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang JK, 2020, IEEE T AUTOM SCI ENG, V17, P2063, DOI [10.1109/TASE.2020.2987397, 10.1109/TASE.2020.2976560, 10.1007/s11845-020-02218-2, 10.1007/978-981-13-8237-6_1]
   Zhang YF, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072381
NR 30
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD OCT
PY 2020
VL 9
IS 10
AR 3344
DI 10.3390/jcm9103344
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA ON8TR
UT WOS:000586966400001
PM 33081004
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mohammadi, S
   Heidarizadeh, M
   Entesari, M
   Esmailpour, A
   Esmailpour, M
   Moradi, R
   Sakhaee, N
   Doustkhah, E
AF Mohammadi, Saeedeh
   Heidarizadeh, Mohammad
   Entesari, Mehrnaz
   Esmailpour, Ayoub
   Esmailpour, Mohammad
   Moradi, Rasoul
   Sakhaee, Nader
   Doustkhah, Esmail
TI In silico Investigation on the Inhibiting Role of Nicotine/Caffeine by
   Blocking the S Protein of SARS-CoV-2 Versus ACE2 Receptor
SO MICROORGANISMS
LA English
DT Article
DE anti-COVID-19; nicotine and caffeine; ACE2 human receptors
ID MOLECULAR-DYNAMICS SIMULATION; FORCE-FIELD; DRUG-DELIVERY; DOCKING;
   BINDING; DESIGN; VIRUS; CFF93
AB In this paper, we studied the in silico interaction of angiotensin-converting enzyme 2 (ACE2) human receptor with two bioactive compounds, i.e., nicotine and caffeine, via molecular dynamic (MD) simulations. The simulations reveal the efficient blocking of ACE2 by caffeine and nicotine in the exposure to the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We have selected the two most important active sites of ACE2-S protein, i.e., 6LZG and 6VW1, which are critically responsible in the interaction of S protein to the receptor and thus, we investigated their interaction with nicotine and caffeine through MD simulations. Caffeine and nicotine are interesting structures for interactions because of their similar structure to the candidate antiviral drugs. Our results reveal that caffeine or nicotine in a specific molar ratio to 6LZG shows a very strong interaction and indicate that caffeine is more efficient in the interaction with 6LZG and further blocking of this site against S protein binding. Further, we investigated the interaction of ACE2 receptor- S protein with nicotine or caffeine when mixed with candidate or approved antiviral drugs for SARS-CoV-2 therapy. Our MD simulations suggest that the combination of caffeine with ribavirin shows a stronger interaction with 6VW1, while in case of favipiravir+nicotine, 6LZG shows potent efficacy of these interaction, proposing the potent efficacy of these combinations for blocking ACE2 receptor against SARS-CoV-2.
C1 [Mohammadi, Saeedeh; Esmailpour, Ayoub] Shahid Rajaee Teacher Training Univ, Dept Phys, Tehran 1678815811, Iran.
   [Mohammadi, Saeedeh; Esmailpour, Mohammad] Azarbaijan Shahid Madani Univ, Dept Phys, Tabriz 53714161, Iran.
   [Heidarizadeh, Mohammad] Univ Maragheh, Fac Sci, Dept Microbiol, POB 55181-83111, Maragheh, Iran.
   [Entesari, Mehrnaz] Zanjan Univ, Dept Genet Engn & Mol Genet, Zanjan 4537138791, Iran.
   [Moradi, Rasoul] Khazar Univ, Sch Engn & Appl Sci, Dept Chem Engn, AZ-1096 Baku, Azerbaijan.
   [Sakhaee, Nader] Univ Illinois, Dept Chem, 1209 W Calif St, Urbana, IL 61801 USA.
   [Doustkhah, Esmail] Natl Inst Mat Sci NIMS, Int Ctr Mat Nanoarchitechton WPI MANA, 1-1 Namiki, Tsukuba, Ibaraki 3050044, Japan.
RP Doustkhah, E (corresponding author), Natl Inst Mat Sci NIMS, Int Ctr Mat Nanoarchitechton WPI MANA, 1-1 Namiki, Tsukuba, Ibaraki 3050044, Japan.
EM s.mohammadi427@gmail.com; hz.mohamad@yahoo.com;
   mehrnaz.entesari@gmail.com; Esmailpour@sru.ac.ir;
   esmailpour@azaruniv.ac.ir; rasoulmoradi84@gmail.com;
   nsakhaee@illinois.edu; esmaildostkhah@gmail.com
RI Doustkhah Heragh, Esmaeil/I-7553-2014
OI Doustkhah Heragh, Esmaeil/0000-0003-1459-1756; Moradi,
   Rasoul/0000-0001-8652-9738
FU Shahid Rajaee Teacher Training University
FX This research was supported by Shahid Rajaee Teacher Training
   University.
CR Alonso H, 2006, MED RES REV, V26, P531, DOI 10.1002/med.20067
   Amaro RE, 2018, BIOPHYS J, V114, P2271, DOI 10.1016/j.bpj.2018.02.038
   ANDREA TA, 1983, J CHEM PHYS, V79, P4576, DOI 10.1063/1.446373
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Audipudi A.V., 2020, MED PLANTS BIODIVERS, P501
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Chandler D, 2005, NATURE, V437, P640, DOI 10.1038/nature04162
   Chang KS, 2010, J MEMBRANE SCI, V354, P93, DOI 10.1016/j.memsci.2010.02.076
   Chen SJ, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8091259
   Contini C, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8081228
   Durdagi S, 2008, BIOORGAN MED CHEM, V16, P9957, DOI 10.1016/j.bmc.2008.10.039
   Eslami M, 2016, EUR J PHARM SCI, V82, P79, DOI 10.1016/j.ejps.2015.11.014
   Ewald PP, 1921, ANN PHYS-BERLIN, V64, P253
   Farsalinos K, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320935765
   Farsalinos K, 2020, INTERN EMERG MED, V15, P845, DOI 10.1007/s11739-020-02355-7
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Forrey C, 2014, SOFT MATTER, V10, P7480, DOI 10.1039/c4sm01297f
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holland J.H, 1975, ADAPTATION NATURAL A
   Holmes L, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124322
   Hussain M, 2020, J MED VIROL, V92, P1580, DOI 10.1002/jmv.25832
   HWANG MJ, 1994, J AM CHEM SOC, V116, P2515, DOI 10.1021/ja00085a036
   Johansson MU, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-173
   Kalyaanamoorthy S, 2011, DRUG DISCOV TODAY, V16, P831, DOI 10.1016/j.drudis.2011.07.006
   Khalilov R., 2020, Advances in Biology & Earth Sciences, V5, P7
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   KITAMURA S, 1987, ENVIRON HEALTH PERSP, V72, P283, DOI 10.2307/3430305
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752310
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li B, 2008, IND ENG CHEM RES, V47, P4440, DOI 10.1021/ie0708935
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li QX, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8081250
   Lu GW, 2012, PROTEIN CELL, V3, P803, DOI 10.1007/s13238-012-2811-1
   MacRaild CA, 2007, J MOL BIOL, V368, P822, DOI 10.1016/j.jmb.2007.02.055
   Meng L, 2020, J DENT RES, V99, P481, DOI 10.1177/0022034520914246
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Oakes JM, 2018, AM J PHYSIOL-REG I, V315, pR895, DOI 10.1152/ajpregu.00099.2018
   Sethi A, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8081097
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   SUN H, 1994, J AM CHEM SOC, V116, P2978, DOI 10.1021/ja00086a030
   SUN H, 1995, MACROMOLECULES, V28, P701, DOI 10.1021/ma00107a006
   Van Norman Gail A, 2016, JACC Basic Transl Sci, V1, P170, DOI 10.1016/j.jacbts.2016.03.002
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 50
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-2607
J9 MICROORGANISMS
JI Microorganisms
PD OCT
PY 2020
VL 8
IS 10
AR 1600
DI 10.3390/microorganisms8101600
PG 14
WC Microbiology
SC Microbiology
GA ON9HP
UT WOS:000587002600001
PM 33080900
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hollingsworth, B
   Okamoto, KW
   Lloyd, AL
AF Hollingsworth, Brandon
   Okamoto, Kenichi W.
   Lloyd, Alun L.
TI After the honeymoon, the divorce: Unexpected outcomes of disease control
   measures against endemic infections
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID TRANSMISSION; TEMPERATURE; MEASLES; VACCINE
AB Author summary Many common endemic infections lack effective, inexpensive vaccinations, and control relies instead on transmission reduction, e.g. mosquito population reduction for dengue. Often, these controls are used with the immediate goal of decreasing the current incidence with little importance placed on what will happen at later points in time, and much less what will happen once the control is stopped. Here, by looking at the cumulative incidence since the beginning of the control period, instead of the instantaneous incidence, we show that when controls are stopped, or fail, the resulting outbreaks can be large enough to completely eliminate any benefit of the control. We call this result thedivorce effect. Further, we show that this result is not limited to specific transmission pathways or epidemiological parameters, but is instead tied directly to the reduction of herd immunity inherent in non-immunizing controls. Lastly, by evaluating programs to minimize the magnitude of the divorce effect, we show that without maintaining herd immunity, or successfully continuing control for decades, it is impossible to keep the costs of post-control outbreaks from outweighing the benefits of the control program. We note that our results have significance in the context of non-pharmaceutical interventions aimed at COVID-19.
   The lack of effective vaccines for many endemic diseases often forces policymakers to rely on non-immunizing control measures, such as vector control, to reduce the massive burden of these diseases. Controls can have well-known counterintuitive effects on endemic infections, including the honeymoon effect, in which partially effective controls cause not only a greater initial reduction in infection than expected, but also large outbreaks during control resulting from accumulation of susceptibles. Unfortunately, many control measures cannot be maintained indefinitely, and the results of cessation are poorly understood. Here, we examine the results of stopped or failed non-immunizing control measures in endemic settings. By using a mathematical model to compare the cumulative number of cases expected with and without control, we show that deployment of control can lead to a larger total number of infections,counting from the time that control started, than without any control-thedivorce effect. This result is directly related to the population-level loss of immunity resulting from non-immunizing controls and is seen in a variety of models when non-immunizing controls are used against an infection that confers immunity. Finally, we examine three control plans for minimizing the magnitude of the divorce effect in seasonal infections and show that they are incapable of eliminating the divorce effect. While we do not suggest stopping control programs that rely on non-immunizing controls, our results strongly argue that the accumulation of susceptibility should be considered before deploying such controls against endemic infections when indefinite use of the control is unlikely. We highlight that our results are particularly germane to endemic mosquito-borne infections, such as dengue virus, both for routine management involving vector control and for field trials of novel control approaches, and in the context of non-pharmaceutical interventions aimed at COVID-19.
C1 [Hollingsworth, Brandon; Lloyd, Alun L.] North Carolina State Univ, Biomath Grad Program, Raleigh, NC 27695 USA.
   [Okamoto, Kenichi W.] Univ St Thomas, Dept Biol, St Paul, MN USA.
   [Lloyd, Alun L.] North Carolina State Univ, Dept Math, Raleigh, NC 27695 USA.
RP Lloyd, AL (corresponding author), North Carolina State Univ, Biomath Grad Program, Raleigh, NC 27695 USA.; Lloyd, AL (corresponding author), North Carolina State Univ, Dept Math, Raleigh, NC 27695 USA.
EM alun_lloyd@ncsu.edu
OI Hollingsworth, Brandon/0000-0002-1772-8191; Lloyd,
   Alun/0000-0002-6389-6321
FU National Science FoundationNational Science Foundation (NSF)
   [RTG/DMS-1246991]; National Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [R01-AI139085, R01-AI091980, P01-AI098670]; W. M. Keck FoundationW.M.
   Keck Foundation; NC State Drexel Endowment
FX This work has been supported by grants from the National Science
   Foundation (RTG/DMS-1246991), the National Institutes of Health (grants
   R01-AI139085, R01-AI091980 and P01-AI098670), the W. M. Keck Foundation
   and the NC State Drexel Endowment. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839
   Bacaer N, 2009, B MATH BIOL, V71, P1954, DOI 10.1007/s11538-009-9433-7
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bowman LR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004551
   Dell AI, 2011, P NATL ACAD SCI USA, V108, P10591, DOI 10.1073/pnas.1015178108
   Dowdle W R, 1998, Bull World Health Organ, V76 Suppl 2, P22
   Ferguson NM, 1996, P NATL ACAD SCI USA, V93, P7231, DOI 10.1073/pnas.93.14.7231
   Ferguson NM, 1996, MATH BIOSCI, V138, P101, DOI 10.1016/S0025-5564(96)00127-7
   Grenfell BT, 1992, J R STAT SOC B, DOI [10.1111/j.2517-6161.1992.tb01888.x, DOI 10.1111/J.2517-6161.1992.TB01888.X]
   Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X
   Heesterbeek H, 2015, SCIENCE, V347, P1216, DOI 10.1126/science.aaa4339
   Hladish TJ, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006570
   Klepac P, 2015, EPIDEMICS-NETH, V10, P97, DOI 10.1016/j.epidem.2014.12.001
   KNOX EG, 1980, INT J EPIDEMIOL, V9, P13, DOI 10.1093/ije/9.1.13
   MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P419, DOI 10.1017/S0950268800067170
   Mordecai EA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005568
   Mordecai EA, 2013, ECOL LETT, V16, P22, DOI 10.1111/ele.12015
   Okamoto KW, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004695
   Pandey A, 2015, EPIDEMIOL INFECT, V143, P1276, DOI 10.1017/S0950268814001939
   Towers S, 2011, J THEOR BIOL, V289, P259, DOI 10.1016/j.jtbi.2011.08.011
NR 20
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD OCT
PY 2020
VL 16
IS 10
AR e1008292
DI 10.1371/journal.pcbi.1008292
PG 21
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA OL2IA
UT WOS:000585163600002
PM 33075052
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tomaszewski, T
   DeVries, RS
   Dong, MY
   Bhatia, G
   Norsworthy, MD
   Zheng, XY
   Caetano-Anolles, G
AF Tomaszewski, Tre
   DeVries, Ryan S.
   Dong, Mengyi
   Bhatia, Gitanshu
   Norsworthy, Miles D.
   Zheng, Xuying
   Caetano-Anolles, Gustavo
TI New Pathways of Mutational Change in SARS-CoV-2 Proteomes Involve
   Regions of Intrinsic Disorder Important for Virus Replication and
   Release
SO EVOLUTIONARY BIOINFORMATICS
LA English
DT Article
DE Nucleocapsid protein; spike protein; SARS-CoV-2; mutation; entropy
ID PROTEIN; CORONAVIRUS; EXORIBONUCLEASE; SERVER
AB The massive worldwide spread of the SARS-CoV-2 virus is fueling the COVID-19 pandemic. Since the first whole-genome sequence was published in January 2020, a growing database of tens of thousands of viral genomes has been constructed. This offers opportunities to study pathways of molecular change in the expanding viral population that can help identify molecular culprits of virulence and virus spread. Here we investigate the genomic accumulation of mutations at various time points of the early pandemic to identify changes in mutationally highly active genomic regions that are occurring worldwide. We used the Wuhan NC_045512.2 sequence as a reference and sampled 15 342 indexed sequences from GISAID, translating them into proteins and grouping them by month of deposition. The per-position amino acid frequencies and Shannon entropies of the coding sequences were calculated for each month, and a map of intrinsic disorder regions and binding sites was generated. The analysis revealed dominant variants, most of which were located in loop regions and on the surface of the proteins. Mutation entropy decreased between March and April of 2020 after steady increases at several sites, including the D614G mutation site of the spike (S) protein that was previously found associated with higher case fatality rates and at sites of the NSP12 polymerase and the NSP13 helicase proteins. Notable expanding mutations include R203K and G204R of the nucleocapsid (N) protein inter-domain linker region and G251V of the viroporin encoded by ORF3a between March and April. The regions spanning these mutations exhibited significant intrinsic disorder, which was enhanced and decreased by the N-protein and viroporin 3a protein mutations, respectively. These results predict an ongoing mutational shift from the spike and replication complex to other regions, especially to encoded molecules known to represent major beta-interferon antagonists. The study provides valuable information for therapeutics and vaccine design, as well as insight into mutation tendencies that could facilitate preventive control.
C1 [Tomaszewski, Tre; DeVries, Ryan S.] Univ Illinois, Dept Informat Sci, Urbana, IL 61801 USA.
   [Dong, Mengyi] Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA.
   [Bhatia, Gitanshu] Univ Illinois, Dept Agr & Biol Engn, Urbana, IL 61801 USA.
   [Norsworthy, Miles D.] Univ Illinois, Beckman Inst, Urbana, IL 61801 USA.
   [Zheng, Xuying; Caetano-Anolles, Gustavo] Univ Illinois, Dept Crop Sci, Urbana, IL 61801 USA.
RP Caetano-Anolles, G (corresponding author), Univ Illinois, Dept Crop Sci, Evolutionary Bioinformat Lab, CR Woese Inst Genom Biol, 332 NSRC,1101 Peabody Dr, Urbana, IL 61801 USA.; Caetano-Anolles, G (corresponding author), Univ Illinois, Illinois Informat Inst, 332 NSRC,1101 Peabody Dr, Urbana, IL 61801 USA.
EM gca@illinois.edu
OI Caetano-Anolles, Gustavo/0000-0001-5854-4121
FU Office of Research at the University of Illinois at Urbana-Champaign;
   Office of International Programs in the College of Agricultural,
   Consumer and Environmental Sciences at the University of Illinois at
   Urbana-Champaign;  [CPSC 567]
FX This study began as a class research project in CPSC 567, a course in
   bioinformatics and systems biology taught by G.C.-A. at the University
   of Illinois in the spring of 2020. We dedicate this work to the
   frontline medical professionals who have been saving the life of others
   with limited protective equipment, selflessly, and at their own peril.
   We also thank public health professionals and scientists for making
   real-time data and sequences readily accessible to the public. COVID-19
   research in the laboratory of G.C.-A is supported by the Office of
   Research and Office of International Programs in the College of
   Agricultural, Consumer and Environmental Sciences at the University of
   Illinois at Urbana-Champaign.
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   Boni MF, 2020, EVOLUTIONARY ORIGINS, DOI [10.1101/2020.03.30.015008, DOI 10.1101/2020.03.30.015008]
   Castano-Rodriguez C, 2018, MBIO, V9, DOI 10.1128/mBio.02325-17
   Cavanagh D, 2005, AVIAN PATHOL, V34, P439, DOI 10.1080/03079450500367682
   CDC, 2016, DIS WEEK SARS
   Chang C, 2020, RCSB PDB 6WKP CRYSTA
   Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7
   Domingo E, 2012, MICROBIOL MOL BIOL R, V76, P159, DOI 10.1128/MMBR.05023-11
   Dosztanyi Z, 2009, BIOINFORMATICS, V25, P2745, DOI 10.1093/bioinformatics/btp518
   Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910
   Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+
   Eckerle LD, 2007, J VIROL, V81, P12135, DOI 10.1128/JVI.01296-07
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Erdos Gabor, 2020, Curr Protoc Bioinformatics, V70, pe99, DOI 10.1002/cpbi.99
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gabriella D, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106519
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Goh GKM, 2020, MICROB PATHOGENESIS, V144, DOI 10.1016/j.micpath.2020.104177
   Goh GKM, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020331
   Gsponer J, 2008, SCIENCE, V322, P1365, DOI 10.1126/science.1163581
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915
   Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366
   Hou XW, 2018, ELIFE, V7, DOI 10.7554/eLife.36758
   JHU CSSE, 2020, COR COVID 19 2019 NC
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   John T, 2020, CNN
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Kern David M, 2020, bioRxiv, DOI 10.1101/2020.06.17.156554
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lau SKP, 2020, EMERG INFECT DIS, V26, P1542, DOI 10.3201/eid2607.200092
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Nieva JL, 2012, NAT REV MICROBIOL, V10, P563, DOI 10.1038/nrmicro2820
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Meszaros B, 2018, NUCLEIC ACIDS RES, V46, pW329, DOI 10.1093/nar/gky384
   Minasov G, 2020, RCSB PDB 6WJI 2 05 A
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   Pan K, 2011, J R SOC INTERFACE, V8, P1644, DOI 10.1098/rsif.2011.0105
   Qiu Y., 2020, STEMEDICINE, V1, pe39, DOI DOI 10.37175/stemedicine.v1i2.39
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003760
   Tilocca B, 2020, MICROBES INFECT, V22, P188, DOI 10.1016/j.micinf.2020.04.002
   Trivedi R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52532-8
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Whitehead S, 2020, CDC DIRECTOR MODELS
   WHO, 2020, WHO EMRO MERS SIT UP
   Woo J, 2019, BIOCHEM BIOPH RES CO, V520, P499, DOI 10.1016/j.bbrc.2019.09.115
   World Health Organization, 2020, WHO TIM COVID 19
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wright PE, 2009, CURR OPIN STRUC BIOL, V19, P31, DOI 10.1016/j.sbi.2008.12.003
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 66
TC 0
Z9 0
U1 3
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1176-9343
J9 EVOL BIOINFORM
JI Evol. Bioinform.
PD OCT
PY 2020
VL 16
AR 1176934320965149
DI 10.1177/1176934320965149
PG 18
WC Evolutionary Biology; Mathematical & Computational Biology
SC Evolutionary Biology; Mathematical & Computational Biology
GA OM9WQ
UT WOS:000586365500001
PM 33149541
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sada, M
   Saraya, T
   Ishii, H
   Okayama, K
   Hayashi, Y
   Tsugawa, T
   Nishina, A
   Murakami, K
   Kuroda, M
   Ryo, A
   Kimura, H
AF Sada, Mitsuru
   Saraya, Takeshi
   Ishii, Haruyuki
   Okayama, Kaori
   Hayashi, Yuriko
   Tsugawa, Takeshi
   Nishina, Atsuyoshi
   Murakami, Koichi
   Kuroda, Makoto
   Ryo, Akihide
   Kimura, Hirokazu
TI Detailed Molecular Interactions of Favipiravir with SARS-CoV-2,
   SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico
SO MICROORGANISMS
LA English
DT Article
DE favipiravir; COVID-19; SARS-CoV-2; influenza; RdRp; in silico
ID T-705 FAVIPIRAVIR; INFECTION; DOCKING
AB Favipiravir was initially developed as an antiviral drug against influenza and is currently used in clinical trials against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (COVID-19). This agent is presumably involved in RNA chain termination during influenza virus replication, although the molecular interactions underlying its potential impact on the coronaviruses including SARS-CoV-2, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV) remain unclear. We performed in silico studies to elucidate detailed molecular interactions between favipiravir and the SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza virus RNA-dependent RNA polymerases (RdRp). As a result, no interactions between favipiravir ribofuranosyl-5 '-triphosphate (F-RTP), the active form of favipiravir, and the active sites of RdRps (PB1 proteins) from influenza A (H1N1)pdm09 virus were found, yet the agent bound to the tunnel of the replication genome of PB1 protein leading to the inhibition of replicated RNA passage. In contrast, F-RTP bound to the active sites of coronavirus RdRp in the presence of the agent and RdRp. Further, the agent bound to the replicated RNA terminus in the presence of agent, magnesium ions, nucleotide triphosphate, and RdRp proteins. These results suggest that favipiravir exhibits distinct mechanisms of action against influenza virus and various coronaviruses.
C1 [Sada, Mitsuru] Gunma Paz Univ, Adv Med Sci Res Ctr, Shibukawa, Gunma 3770008, Japan.
   [Sada, Mitsuru; Saraya, Takeshi; Ishii, Haruyuki] Kyorin Univ Hosp Med, Dept Resp Med, Mitaka, Tokyo 1818611, Japan.
   [Okayama, Kaori; Hayashi, Yuriko] Gumma Paz Univ, Fac Hlth Sci, Sch Med Technol, Takasaki, Gumma 3700006, Japan.
   [Tsugawa, Takeshi] Sapporo Med Univ, Dept Pediat, Sch Med, Sapporo, Hokkaido 0608543, Japan.
   [Nishina, Atsuyoshi] Nihon Univ, Coll Sci & Technol, Tokyo 1010062, Japan.
   [Murakami, Koichi] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo 1628640, Japan.
   [Kuroda, Makoto] Natl Inst Infect Dis, Pathogen Genom Ctr, Tokyo 2080011, Japan.
   [Ryo, Akihide; Kimura, Hirokazu] Yokohama City Univ, Dept Microbiol, Sch Med, Yokohama, Kanagawa 2360004, Japan.
   [Kimura, Hirokazu] Gunma Paz Univ, Dept Hlth Sci, Grad Sch Hlth Sci, Takasaki, Gumma 3700006, Japan.
RP Kimura, H (corresponding author), Yokohama City Univ, Dept Microbiol, Sch Med, Yokohama, Kanagawa 2360004, Japan.; Kimura, H (corresponding author), Gunma Paz Univ, Dept Hlth Sci, Grad Sch Hlth Sci, Takasaki, Gumma 3700006, Japan.
EM rainbow_orchestra716@yahoo.co.jp; saraya@ks.kyorin-u.ac.jp;
   h141@ks.kyorin-u.ac.jp; okayama@paz.ac.jp; hayashi@paz.ac.jp;
   tsugawat@sapmed.ac.jp; nishina.atsuyoshi@nihon-u.ac.jp;
   kmuraka@niid.go.jp; makokuro@niid.go.jp; aryo@yokohama-cu.ac.jp;
   kimhiro@nih.go.jp
OI Saraya, Takeshi/0000-0003-0502-8128
FU AMED [JP20fk0108103]
FX This research was supported by AMED (https://www.amed.go.jp/) under
   Grant Number JP20fk0108103. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Arias A, 2014, ELIFE, V3, DOI 10.7554/eLife.03679
   Bai CQ, 2016, CLIN INFECT DIS, V63, P1288, DOI 10.1093/cid/ciw571
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Eloy P, 2020, CLIN PHARMACOL THER, V108, P188, DOI 10.1002/cpt.1877
   Esposito Silvano, 2020, Infez Med, V28, P198
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Furuta Y, 2002, ANTIMICROB AGENTS CH, V46, P977, DOI 10.1128/AAC.46.4.977-981.2002
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Goldhill DH, 2018, P NATL ACAD SCI USA, V115, P11613, DOI 10.1073/pnas.1811345115
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hagar M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113922
   Harismah K, 2020, ADV J CHEM B, V2, P55
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   Kimura H, 2020, J ALLERGY CLIN IMMUN, V146, P330, DOI 10.1016/j.jaci.2020.05.029
   Li CF, 2014, SCI REP-UK, V4, DOI 10.1038/srep07192
   Mahumud RA, 2020, INFECTION, DOI 10.1007/s15010-020-01502-8
   Oestereich L, 2014, ANTIVIR RES, V105, P17, DOI 10.1016/j.antiviral.2014.02.014
   Raabe VN, 2017, CLIN INFECT DIS, V65, P855, DOI 10.1093/cid/cix406
   Raborn R Taylor, 2019, Methods Mol Biol, V1858, P99, DOI 10.1007/978-1-4939-8775-7_9
   Sangawa H, 2013, ANTIMICROB AGENTS CH, V57, P5202, DOI 10.1128/AAC.00649-13
   Shannon A, 2020, bioRxiv, DOI 10.1101/2020.05.15.098731
   Shiraki K, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107512
   SMITH TJ, 1995, J MOL GRAPHICS, V13, P122, DOI 10.1016/0263-7855(94)00019-O
   Smither SJ, 2014, ANTIVIR RES, V104, P153, DOI 10.1016/j.antiviral.2014.01.012
   Takashita Emi, 2020, Cold Spring Harb Perspect Med, DOI 10.1101/cshperspect.a038687
   te Velthuis AJW, 2016, NAT REV MICROBIOL, V14, P479, DOI 10.1038/nrmicro.2016.87
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Webb B., 2014, CURR PROTOC BIOINF, V47, DOI [10.1002/0471250953.bi0506s47, DOI 10.1088/1751-8113/47/31/315202]
   WHO, COR DIS COVID 19
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 36
TC 0
Z9 0
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-2607
J9 MICROORGANISMS
JI Microorganisms
PD OCT
PY 2020
VL 8
IS 10
AR 1610
DI 10.3390/microorganisms8101610
PG 9
WC Microbiology
SC Microbiology
GA OM8CI
UT WOS:000586245100001
PM 33092045
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Weiss, J
   Bajraktari-Sylejmani, G
   Haefeli, WE
AF Weiss, Johanna
   Bajraktari-Sylejmani, Gzona
   Haefeli, Walter E.
TI Interaction of Hydroxychloroquine with Pharmacokinetically Important
   Drug Transporters
SO PHARMACEUTICS
LA English
DT Article
DE hydroxychloroquine; drug-drug interaction; drug transporters;
   inhibition; induction; P-glycoprotein; BCRP; OATP
ID ARYL-HYDROCARBON RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CANCER
   RESISTANCE PROTEIN; PREGNANE-X RECEPTOR; P-GLYCOPROTEIN;
   LUPUS-ERYTHEMATOSUS; CHLOROQUINE; EXPRESSION; MODULATION; INTESTINE
AB (1) Background: Hydroxychloroquine is used to treat malaria and autoimmune diseases, and its potential use against COVID-19 is currently under investigation. Thus far, information on interactions of hydroxychloroquine with drug transporters mediating drug-drug interactions is limited. We assessed the inhibition of important efflux (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP)) and uptake transporters (organic anion transporting polypeptide (OATP)-1B1, OATP1B3, OATP2B1) by hydroxychloroquine, tested its P-gp and BCRP substrate characteristics, and evaluated the induction of pharmacokinetically relevant genes regulated by the nuclear pregnane X (PXR) (CYP3A4, ABCB1) and aryl hydrocarbon receptor (AhR) (CYP1A1, CYP1A2). (2) Methods: Transporter inhibition was evaluated in transporter over-expressing cell lines using fluorescent probe substrates. P-gp and BCRP substrate characteristics were assessed by comparing growth inhibition of over-expressing and parental cell lines. Possible mRNA induction was analysed in LS180 cells by quantitative real-time PCR. (3) Results: Hydroxychloroquine did not inhibit BCRP or the OATPs tested but inhibited P-gp at concentrations exceeding 10 mu M. P-gp overexpressing cells were 5.2-fold more resistant to hydroxychloroquine than control cells stressing its substrate characteristics. Hydroxychloroquine did not induce genes regulated by PXR or AhR. (4) Conclusions: This is the first evidence that hydroxychloroquine's interaction potential with drug transporters is low, albeit bioavailability of simultaneously orally administered P-gp substrates might be increased by hydroxychloroquine.
C1 [Weiss, Johanna; Bajraktari-Sylejmani, Gzona; Haefeli, Walter E.] Heidelberg Univ Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
RP Weiss, J (corresponding author), Heidelberg Univ Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.
EM johanna.weiss@med.uni-heidelberg.de;
   gzona.bajraktari-sylejmani@med.uni-heidelberg.de;
   walter.emil.haefeli@med.uni-heidelberg.de
OI Haefeli, Walter/0000-0003-0672-6876
CR Albermann N, 2005, BIOCHEM PHARMACOL, V70, P949, DOI 10.1016/j.bcp.2005.06.018
   Ayed-Boussema I, 2011, ENVIRON TOXICOL PHAR, V31, P79, DOI 10.1016/j.etap.2010.09.008
   BOESCH D, 1991, CANCER RES, V51, P4226
   Cerveny L, 2007, DRUG METAB DISPOS, V35, P1032, DOI 10.1124/dmd.106.014456
   Costedoat-Chalumeau N, 2006, ARTHRITIS RHEUM, V54, P3284, DOI 10.1002/art.22156
   CUTLER DJ, 1993, AGENT ACTION SUPPL, V44, P139
   Dvorak Z, 2008, BIOCHEM PHARMACOL, V75, P580, DOI 10.1016/j.bcp.2007.09.013
   Easterbrook M, 1999, INT OPHTHALMOL CLIN, V39, P49, DOI 10.1097/00004397-199903920-00005
   Frances C, 2012, ARCH DERMATOL, V148, P479, DOI 10.1001/archdermatol.2011.2558
   Frohlich M, 2004, BIOCHEM PHARMACOL, V68, P2409, DOI 10.1016/j.bcp.2004.08.026
   Grosser G, 2015, ARCH TOXICOL, V89, P2253, DOI 10.1007/s00204-014-1379-3
   Hashem AM, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101735
   Kansal A, 2016, CLIN RHEUMATOL, V35, P341, DOI 10.1007/s10067-015-3079-7
   Konig J, 2013, PHARMACOL REV, V65, P944, DOI 10.1124/pr.113.007518
   Konig J, 2000, J BIOL CHEM, V275, P23161, DOI 10.1074/jbc.M001448200
   Konig J, 2000, AM J PHYSIOL-GASTR L, V278, pG156, DOI 10.1152/ajpgi.2000.278.1.G156
   LEDEN I, 1982, ACTA MED SCAND, V211, P411
   Lee JY, 2016, ARTHRITIS RHEUMATOL, V68, P184, DOI 10.1002/art.39402
   Li Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0938-5
   Liu CX, 2015, CURR DRUG METAB, V16, P732, DOI 10.2174/138920021609151201112629
   Liu XD, 2019, ADV EXP MED BIOL, V1141, P241, DOI 10.1007/978-981-13-7647-4_5
   McFeely SJ, 2019, PHARMACOL THERAPEUT, V196, P204, DOI 10.1016/j.pharmthera.2018.12.009
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Nakanishi T, 2015, CURR DRUG METAB, V16, P753, DOI 10.2174/138920021609151201113537
   Olsen NJ, 2013, SEMIN ARTHRITIS RHEU, V43, P264, DOI 10.1016/j.semarthrit.2013.01.001
   Panc A.G., 2014, J MED LIFE, V7, P322
   Pavek P, 2005, J PHARMACOL EXP THER, V312, P144, DOI 10.1124/jpet.104.073916
   Peters T, 2006, N-S ARCH PHARMACOL, V372, P291, DOI 10.1007/s00210-005-0022-5
   Plantone D, 2018, CLIN DRUG INVEST, V38, P653, DOI 10.1007/s40261-018-0656-y
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Ramadoss Preeti, 2005, Expert Opin Drug Metab Toxicol, V1, P9, DOI 10.1517/17425255.1.1.9
   Rolain JM, 2007, INT J ANTIMICROB AG, V30, P297, DOI 10.1016/j.ijantimicag.2007.05.015
   Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Somer M, 2000, BRIT J CLIN PHARMACO, V49, P549, DOI 10.1046/j.1365-2125.2000.00197.x
   Tan KP, 2010, MOL PHARMACOL, V78, P175, DOI 10.1124/mol.110.065078
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Wahie S, 2011, J INVEST DERMATOL, V131, P1981, DOI 10.1038/jid.2011.167
   Weiss J, 2003, J PHARMACOL EXP THER, V305, P197, DOI 10.1124/jpet.102.046532
   Weiss J, 2007, J ANTIMICROB CHEMOTH, V59, P238, DOI 10.1093/jac/dkl474
   Weiss Johanna, 2014, Pharmaceutics, V6, P632, DOI 10.3390/pharmaceutics6040632
   Weiss J, 2013, BIOCHEM PHARMACOL, V85, P265, DOI 10.1016/j.bcp.2012.11.020
   Weiss J, 2010, INT REV CEL MOL BIO, V280, P219, DOI 10.1016/S1937-6448(10)80005-X
   Xu CH, 2016, J PHARM SCI-US, V105, P884, DOI 10.1002/jps.24663
   Yamagishi Tetsuo, 2013, J Biol Chem, V288, P31761, DOI 10.1074/jbc.M113.514091
   Zhang L, 2008, XENOBIOTICA, V38, P709, DOI [10.1080/00498250802017715, 10.1080/00498250802017715 ]
   Zisowsky J, 2007, BIOCHEM PHARMACOL, V73, P298, DOI 10.1016/j.bcp.2006.10.003
NR 48
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD OCT
PY 2020
VL 12
IS 10
AR 919
DI 10.3390/pharmaceutics12100919
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OM8OV
UT WOS:000586277600001
PM 32992777
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bartoszek, A
   Walkowiak, D
   Bartoszek, A
   Kardas, G
AF Bartoszek, Adrian
   Walkowiak, Dariusz
   Bartoszek, Agnieszka
   Kardas, Grzegorz
TI Mental Well-Being (Depression, Loneliness, Insomnia, Daily Life Fatigue)
   during COVID-19 Related Home-Confinement-A Study from Poland
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE COVID-19; depression; loneliness; insomnia; fatigue; home confinement;
   isolation
ID HEALTH; DISORDERS; SEVERITY
AB The COVID-19 pandemic is a great threat to both physical and mental health as it may lead to psychological stress connected with an economic crisis, threat of unemployment, or fear of losing family members. Emerging data shows that the general public may be vulnerable to the pandemic-related stress and experience frequently prevalent anxiety. A study involving 471 subjects (85.6% female) was conducted online during the COVID-19 pandemic. We used the following scales: Insomnia Severity Index (ISI), Beck Depression Inventory (BDI), Revised University of California, Los Angeles (R-UCLA) Loneliness Scale, and Daily Life Fatigue scale (DLF). Women had higher mean scores of depression, loneliness, and daily life fatigue and more often than males started exercising. Among people professionally active before the pandemic, there were more cases of increased alcohol consumption than among students. No differences in alcohol consumption patterns were found between genders. People living alone had higher scores of loneliness and daily life fatigue compared to those living with someone. Respondents who started taking any new drugs during COVID-19 home confinement had higher outcomes in all questionnaires. During home confinement, high scores of depression, insomnia, loneliness, and everyday fatigue were observed.
C1 [Bartoszek, Adrian] Med Univ Lodz, Fac Med, PL-90001 Lodz, Poland.
   [Bartoszek, Adrian] Med Univ Lublin, Dept Pathophysiol, PL-20090 Lublin, Poland.
   [Walkowiak, Dariusz] Poznan Univ Med Sci, Dept Org & Management Hlth Care, PL-60356 Poznan, Poland.
   [Bartoszek, Agnieszka] Med Univ Lublin, Dept Family Med & Community Nursing, PL-20081 Lublin, Poland.
   [Kardas, Grzegorz] Med Univ Lodz, Clin Internal Med Asthma & Allergy, PL-90001 Lodz, Poland.
RP Bartoszek, A (corresponding author), Med Univ Lodz, Fac Med, PL-90001 Lodz, Poland.; Bartoszek, A (corresponding author), Med Univ Lublin, Dept Pathophysiol, PL-20090 Lublin, Poland.
EM adrianbartoszek96@gmail.com; dariuszwalkowiak@ump.edu.pl;
   agabartoszek@wp.pl; kardas7@gmail.com
OI Bartoszek, Agnieszka/0000-0003-0974-0761; Bartoszek,
   Adrian/0000-0002-6840-7320
CR Altena E, 2020, J SLEEP RES, V29, DOI 10.1111/jsr.13052
   Andrzejewska K., 2018, Medycyna Og�lna i Nauki o Zdrowiu, V24, P126
   Assary E, 2018, SEMIN CELL DEV BIOL, V77, P133, DOI 10.1016/j.semcdb.2017.10.016
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004
   Berg-Weger M, 2020, J NUTR HEALTH AGING, V24, P456, DOI 10.1007/s12603-020-1366-8
   Brydsten A, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-0950-1
   Casagrande M, 2020, SLEEP MED, V75, P12, DOI 10.1016/j.sleep.2020.05.011
   Clay JM, 2020, LANCET PUBLIC HEALTH, V5, pE259, DOI 10.1016/S2468-2667(20)30088-8
   Dawel A, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.579985
   Elhai JD, 2020, J AFFECT DISORDERS, V274, P576, DOI 10.1016/j.jad.2020.05.080
   Epstein D., 2020, EUR J CASE REP INTER, P7, DOI [10.12890/2020_00165132399450, DOI 10.12890/2020_00165132399450]
   Finlay I, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1987
   Gonzalez-Sanguino C, 2020, BRAIN BEHAV IMMUN, V87, P172, DOI 10.1016/j.bbi.2020.05.040
   Guastello SJ, 2014, AM PSYCHOL, V69, P628, DOI 10.1037/a0036980
   Harter M, 2007, PSYCHOTHER PSYCHOSOM, V76, P354, DOI 10.1159/000107563
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Hutton K, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-394
   Kay-Stacey M, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i2123
   Kwiatkowska MM, 2018, CURR ISS PERSONAL PS, V6, P164, DOI 10.5114/CIPP.2017.69681
   Li Y, 2020, J CLIN SLEEP MED, V16, P1417, DOI 10.5664/jcsm.8524
   Losada-Baltar A., 2020, J GERONTOL B-PSYCHOL, DOI 10.1093/geronb/gbaa04832282920
   Luo M, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113190
   Mazza M, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113046
   Milken Institute, COVID 19 TREATM VACC
   Morgul E, 2020, INT J SOC PSYCHIATR, DOI 10.1177/0020764020941889
   Pappa S, 2020, BRAIN BEHAV IMMUN, V88, P901, DOI 10.1016/j.bbi.2020.05.026
   Patel SS, 2020, DISASTER MED PUBLIC, V14, pE13, DOI 10.1017/dmp.2020.145
   Pierce M, 2020, LANCET PSYCHIAT, V7, P883, DOI 10.1016/S2215-0366(20)30308-4
   Salari N, 2020, GLOBALIZATION HEALTH, V16, DOI 10.1186/s12992-020-00589-w
   Scott KM, 2014, JAMA PSYCHIAT, V71, P1400, DOI 10.1001/jamapsychiatry.2014.1337
   Szczesniak D, 2020, BRAIN BEHAV IMMUN, V87, P161, DOI 10.1016/j.bbi.2020.05.027
   Szmyd Bartosz, 2020, Sleep Med Rev, V55, P101380, DOI 10.1016/j.smrv.2020.101380
   Tull MT, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113098
   Urbaska J., 2010, ZMCZENIE YCIEM CODZI
   Vindegaard N, 2020, BRAIN BEHAV IMMUN, V89, P531, DOI 10.1016/j.bbi.2020.05.048
   Voitsidis P, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113076
   Whittemore PB, 2020, AM J INFECT CONTROL, V48, P1042, DOI 10.1016/j.ajic.2020.06.193
   World Health Organization, 125 WHO
   Zawadzki B, 2009, PSYCHOL ETOL GEN, V19, P71
   Zhang CX, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00306
   Zhang WR, 2020, PSYCHOTHER PSYCHOSOM, V89, P242, DOI 10.1159/000507639
   Zubatsky M, 2020, J AM GERIATR SOC, V68, P1678, DOI 10.1111/jgs.16553
NR 44
TC 1
Z9 1
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD OCT
PY 2020
VL 17
IS 20
AR 7417
DI 10.3390/ijerph17207417
PG 12
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OL7WH
UT WOS:000585544600001
PM 33053787
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kierat, W
   Augustyn, W
   Koper, P
   Pawlyta, M
   Chrusciel, A
   Wyrwol, B
AF Kierat, Wojciech
   Augustyn, Weronika
   Koper, Piotr
   Pawlyta, Miroslawa
   Chrusciel, Arkadiusz
   Wyrwol, Bernard
TI The Use of UVC Irradiation to Sterilize Filtering Facepiece Masks
   Limiting Airborne Cross-Infection
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE ultraviolet germicidal irradiation; UVGI; HEPA filter sterilization;
   SARS-CoV-2
ID BACILLUS-ATROPHAEUS; INACTIVATION; DECONTAMINATION; EFFICACY
AB In addition to looking for effective drugs and a vaccine, which are necessary to save and protect human health, it is also important to limit, or at least to slow, the spread of coronavirus. One important element in this action is the use of individual protective devices such as filtering facepiece masks. Currently, masks that use a mechanical filter, such as a HEPA (High Efficiency Particulate Air) filter, are often used. In some countries that do not have a well-developed healthcare system or in exceptional situations, there is a real and pressing need to restore filters for reuse. This article presents technical details for a very simple device for sterilization, including of HEPA polymer filters. The results of biological and microscopic tests confirming the effectiveness of the sterilization performed in the device are presented. The compact and portable design of the device also allows its use to disinfect other small surfaces, for example a small fragment of a floor, table, or bed.
C1 [Kierat, Wojciech; Wyrwol, Bernard] Silesian Tech Univ, Dept Digital Syst, PL-44100 Gliwice, Poland.
   [Augustyn, Weronika] Silesian Tech Univ, Dept Environm Biotechnol, PL-44100 Gliwice, Poland.
   [Koper, Piotr] Silesian Tech Univ, Dept Heating Ventilat & Dust Removal Technol, PL-44100 Gliwice, Poland.
   [Pawlyta, Miroslawa] Silesian Tech Univ, Dept Engn Mat & Biomat, PL-44100 Gliwice, Poland.
   [Chrusciel, Arkadiusz] MEXEO Inst Technol, PL-47225 Kedzierzyn Kozle, Poland.
RP Kierat, W (corresponding author), Silesian Tech Univ, Dept Digital Syst, PL-44100 Gliwice, Poland.
EM wojciech.kierat@polsl.pl; weronika.augustyn@mexeo.pl;
   piotr.koper@polsl.pl; miroslawa.pawlyta@polsl.pl;
   arkadiusz.chrusciel@mexeo.pl; bernard.wyrwol@polsl.pl
RI Koper, Piotr/ABG-8618-2020; Pawlyta, Miroslawa/AAL-7325-2020; Kierat,
   Wojciech/T-5013-2018
OI Koper, Piotr/0000-0001-5709-443X; Pawlyta,
   Miroslawa/0000-0001-9072-3306; Kierat, Wojciech/0000-0002-6167-6579;
   Augustyn, Weronika/0000-0002-4426-4695
FU National Centre for Research and Development, Poland, POIR/EFRR
   2014-2020 [01.01.01-00-1104/17-00]; Implementation Doctorate Program-2nd
   edition at the Faculty of Energy and Environmental Engineering of the
   Silesian University of Technology; Faculty of Automatic Control,
   Electronics and Computer Science of the Silesian University of
   Technology
FX The works were supported by the National Centre for Research and
   Development, Poland, POIR/EFRR 2014-2020, Project No.
   01.01.01-00-1104/17-00, and by the Implementation Doctorate Program-2nd
   edition at the Faculty of Energy and Environmental Engineering of the
   Silesian University of Technology, and from the funds of the Faculty of
   Automatic Control, Electronics and Computer Science of the Silesian
   University of Technology.
CR Bedell K, 2016, INFECT CONT HOSP EP, V37, P598, DOI 10.1017/ice.2015.348
   Blazquez E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212332
   Buonanno M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67211-2
   Cai CJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.12099
   CHANG JCH, 1985, APPL ENVIRON MICROB, V49, P1361, DOI 10.1128/AEM.49.6.1361-1365.1985
   Derraik J.G.B., 2020, RAPID EVIDENCE SUMMA, V2020, DOI [10.1101/2020.04.02.20051409, DOI 10.1101/2020.04.02.20051409]
   Fisher EM, 2011, J APPL MICROBIOL, V110, P287, DOI 10.1111/j.1365-2672.2010.04881.x
   Gillis JR, 2010, PHARM TECH, V34, P1
   Guerrini G.L., 2020, VIRUS, DOI [10.13140/RG.2.2.14041.88163, DOI 10.13140/RG.2.2.14041.88163]
   Halfmann H, 2007, J PHYS D APPL PHYS, V40, P5907, DOI 10.1088/0022-3727/40/19/019
   Hamzavi IH, 2020, J AM ACAD DERMATOL, V82, P1511, DOI 10.1016/j.jaad.2020.03.085
   International Organization for Standardization, 2017, 1113812017 ISO
   Lindsley WG, 2015, J OCCUP ENVIRON HYG, V12, P509, DOI 10.1080/15459624.2015.1018518
   Luna VA, 2008, J APPL MICROBIOL, V104, P489, DOI 10.1111/j.1365-2672.2007.03569.x
   Mills D, 2018, AM J INFECT CONTROL, V46, pE49, DOI 10.1016/j.ajic.2018.02.018
   Mohammadipanah F, 2016, J PHARM INNOV, V11, P323, DOI 10.1007/s12247-016-9260-y
   Oliveira EA, 2010, WASTE MANAGE, V30, P2327, DOI 10.1016/j.wasman.2010.05.002
   Ponnaiya B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192053
   Pozzobon Victor, 2020, Biotechnology Reports, V25, pe00399, DOI 10.1016/j.btre.2019.e00399
   Russell AD, 1999, J HOSP INFECT, V43, pS57, DOI 10.1016/S0195-6701(99)90066-X
   Rutala WA, 2008, GUIDELINE DISINFECTI
   Sella SRBR, 2015, CRIT REV BIOTECHNOL, V35, P533, DOI 10.3109/07388551.2014.922915
   Stawicki S., 2020, INT J ACAD MED, V6
   Toomey E., 2020, EXTENDED USE REUSE S, DOI [10.1101/2020.06.04.20121947, DOI 10.1101/2020.06.04.20121947]
   Tseng CC, 2007, J OCCUP ENVIRON HYG, V4, P400, DOI 10.1080/15459620701329012
   Viscusi DJ, 2009, ANN OCCUP HYG, V53, P815, DOI 10.1093/annhyg/mep070
   Welch D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21058-w
   Wong T, 2016, AM J INFECT CONTROL, V44, P416, DOI 10.1016/j.ajic.2015.10.016
NR 28
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD OCT
PY 2020
VL 17
IS 20
AR 7396
DI 10.3390/ijerph17207396
PG 14
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OL7JO
UT WOS:000585511500001
PM 33050590
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Felsenstein, S
   Willis, E
   Lythgoe, H
   McCann, L
   Cleary, A
   Mahmood, K
   Porter, D
   Jones, J
   McDonagh, J
   Chieng, A
   Varnier, G
   Hughes, S
   Boullier, M
   Ryan, F
   Awogbemi, O
   Soda, G
   Duong, P
   Pain, C
   Riley, P
   Hedrich, CM
AF Felsenstein, Susanna
   Willis, Emily
   Lythgoe, Hannah
   McCann, Liza
   Cleary, Andrew
   Mahmood, Kamran
   Porter, David
   Jones, Jessica
   McDonagh, Janet
   Chieng, Alice
   Varnier, Giulia
   Hughes, Stephen
   Boullier, Mary
   Ryan, Fiona
   Awogbemi, Olumoyin
   Soda, Giridhar
   Duong, Phuoc
   Pain, Clare
   Riley, Phil
   Hedrich, Christian M.
TI Presentation, Treatment Response and Short-Term Outcomes in Paediatric
   Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2
   (PIMS-TS)
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE childhood; paediatric; COVID-19; PIMS-TS; MIS-C; treatment;
   inflammation; SARS-CoV-2; coronavirus
ID CORONAVIRUS DISEASE; KAWASAKI-DISEASE; CHILDREN; COVID-19; DIAGNOSIS
AB The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the pathogen responsible for Coronavirus Disease 2019 (COVID-19). Whilst most children and young people develop mild symptoms, recent reports suggest a novel paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS). Case definition and classification are preliminary, treatment is empiric and disease-associated outcomes are unclear. Here, we report 29 patients with PIMS-TS who were diagnosed, admitted and treated in the English North West between March and June 2020. Consistent with patterns observed internationally, cases peaked approximately 4 weeks after the initial surge of COVID-19-like symptoms in the UK population. Clinical symptoms included fever (100%), skin rashes (72%), cardiovascular involvement (86%), conjunctivitis (62%) and respiratory involvement (21%). Some patients had clinical features partially resembling Kawasaki disease (KD), toxic shock syndrome and cytokine storm syndrome. Male gender (69%), black, Asian and other minority ethnicities (BAME, 59%) were over-represented. Immune modulating treatment was used in all, including intravenous immunoglobulin (IVIG), corticosteroids and cytokine blockers. Notably, 32% of patients treated with IVIG alone went into remission. The rest required additional treatment, usually corticosteroids, with the exception of two patients who were treated with TNF inhibition and IL-1 blockade, respectively. Another patient received IL-1 inhibition as primary therapy, with associated rapid and sustained remission. Randomized and prospective studies are needed to investigate efficacy and safety of treatment, especially as resources of IVIG may be depleted secondary to high demand during future waves of COVID-19.
C1 [Felsenstein, Susanna; Porter, David] Alder Hey Childrens NHS Fdn Trust Hosp, Dept Infect Dis & Immunol, Liverpool L14 5AB, Merseyside, England.
   [Willis, Emily; McDonagh, Janet; Chieng, Alice; Varnier, Giulia; Hughes, Stephen; Riley, Phil] Royal Manchester Childrens Hosp, Dept Rheumatol, Manchester M13 9WL, Lancs, England.
   [Lythgoe, Hannah; McCann, Liza; Cleary, Andrew; Mahmood, Kamran; Pain, Clare; Hedrich, Christian M.] Alder Hey Childrens NHS Fdn Trust Hosp, Dept Rheumatol, Liverpool L14 5AB, Merseyside, England.
   [Jones, Jessica] Alder Hey Childrens NHS Fdn Trust Hosp, Dept Microbiol, Liverpool L14 5AB, Merseyside, England.
   [Boullier, Mary; Ryan, Fiona; Awogbemi, Olumoyin] Alder Hey Childrens NHS Fdn Trust Hosp, Dept Gen Paediat, Liverpool L14 5AB, Merseyside, England.
   [Soda, Giridhar] Royal Manchester Childrens Hosp, Dept Cardiol, Manchester M13 9WL, Lancs, England.
   [Duong, Phuoc] Alder Hey Childrens NHS Fdn Trust Hosp, Dept Cardiol, Liverpool L14 5AB, Merseyside, England.
   [Hedrich, Christian M.] Univ Liverpool, Inst Translat Med, Dept Womens & Childrens Hlth, Liverpool L69 3BX, Merseyside, England.
RP Felsenstein, S (corresponding author), Alder Hey Childrens NHS Fdn Trust Hosp, Dept Infect Dis & Immunol, Liverpool L14 5AB, Merseyside, England.; Hedrich, CM (corresponding author), Alder Hey Childrens NHS Fdn Trust Hosp, Dept Rheumatol, Liverpool L14 5AB, Merseyside, England.; Hedrich, CM (corresponding author), Univ Liverpool, Inst Translat Med, Dept Womens & Childrens Hlth, Liverpool L69 3BX, Merseyside, England.
EM Susanna.Felsenstein@alderhey.nhs.uk; Emily.Willis@mft.nhs.uk;
   Hanna.Lythgoe@alderhey.nhs.uk; Liza.McCann@alderhey.nhs.uk;
   Gavin.Cleary@alderhey.nhs.uk; Kamran.Mahmood@alderhey.nhs.uk;
   David.Porter@alderhey.nhs.uk; jessica.jones@alderhey.nhs.uk;
   janet.mcdonagh@manchester.ac.uk; Alice.Chieng@mft.nhs.uk;
   giuliavarnier@gmail.com; stephen.hughes@mft.nhs.uk;
   mary.boullier@alderhey.nhs.uk; fiona.ryan@alderhey.nhs.uk;
   olumoyin.awogbemi@alderhey.nhs.uk; giridhar.soda@alderhey.nhs.uk;
   Phuoc.Duong@alderhey.nhs.uk; Clare.Pain@alderhey.nhs.uk;
   Phil.Riley@mft.nhs.uk; christian.hedrich@liverpool.ac.uk
OI McDonagh, janet/0000-0002-4555-7270; Hedrich,
   Christian/0000-0002-1295-6179
FU Versus Arthritis Centre for Epidemiology (UK)Versus Arthritis [21755];
   National Institute for Health Research, Manchester Biomedical Research
   CentreNational Institute for Health Research (NIHR)
FX The authors wish to thank Melissa Pronold, for critical revision of the
   manuscript and statistical methods, as well as Charlie Pickles and Saabi
   Ahmad for their kind support with out-of-hours data collection. Janet
   McDonagh was supported by Versus Arthritis Centre for Epidemiology (UK
   grant: 21755) and the National Institute for Health Research, Manchester
   Biomedical Research Centre.
CR Abdel-Mannan O, 2020, JAMA NEUROL, V77, P1440, DOI 10.1001/jamaneurol.2020.2687
   Advanced Life Support Group, 2016, ADV PAED LIF SUPP PR
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   American Academy of Pediatrics, 2020, MULT INFL SYNDR CHIL
   Antunez-Montes Omar Yassef, 2021, Pediatr Infect Dis J, V40, pe1, DOI 10.1097/INF.0000000000002949
   Antwi-Amoabeng D, 2020, J MED VIROL, V92, P2516, DOI 10.1002/jmv.26038
   Arvin AM, 2020, NATURE, DOI 10.1038/s41586-020-2538-8
   Pereira MFB, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e2209
   Belhadjer Z, 2020, CIRCULATION, V142, P429, DOI 10.1161/CIRCULATIONAHA.120.048360
   Belot A, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.22.2001010
   Bertoncelli Deborah, 2020, Acta Biomed, V91, P177, DOI 10.23750/abm.v91i2.9655
   Bhat C.S., 2020, INDIAN PEDIAT
   Blondiaux E, 2020, RADIOLOGY, V297, pE283, DOI 10.1148/radiol.2020202288
   Buja LM, 2020, CARDIOVASC PATHOL, V48, DOI 10.1016/j.carpath.2020.107233
   Capone CA, 2020, J PEDIATR-US, V224, P141, DOI [10.1018/j.jpeds.2020.08.044, 10.1016/j.jpeds.2020.06.044]
   Carter MJ, 2020, NAT MED, V26, P1701, DOI 10.1038/s41591-020-1054-6
   Centers for Disease Control and Prevention, 2020, MULT INFL SYNDR CHIL
   Cheung EW, 2020, JAMA-J AM MED ASSOC, V324, P294, DOI 10.1001/jama.2020.10374
   Chiotos K, 2020, J PEDIAT INF DIS SOC, V9, P393, DOI 10.1093/jpids/piaa069
   Consiglio CR, 2020, CELL, V183, P968, DOI 10.1016/j.cell.2020.09.016
   D'Amore F, 2020, AM J NEURORADIOL, V41, P1800, DOI 10.3174/ajnr.A6679
   Davies P, 2020, LANCET CHILD ADOLESC, V4, P669, DOI 10.1016/S2352-4642(20)30215-7
   de Farias ECF, 2020, PEDIATR INFECT DIS J, V39, pE374, DOI 10.1097/INF.0000000000002865
   Dhanalakshmi K, 2020, INDIAN PEDIAT
   Diorio C, 2020, J CLIN INVEST, V130, P5967, DOI 10.1172/JCI140970
   ECDC, 2020, PAED INFL MULT SYNDR
   England P.H., 2020, WEEKLY CORONAVIRUS D
   European Centre for Disease, 2020, COVID 19 CHILDR ROL
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680
   Filocamo G, 2020, INT J INFECT DIS, V96, P607, DOI 10.1016/j.ijid.2020.05.026
   Galeotti C, 2020, NAT REV RHEUMATOL, V16, P413, DOI 10.1038/s41584-020-0448-7
   Godfred-Cato S, 2020, MMWR-MORBID MORTAL W, V69, P1074, DOI 10.15585/mmwr.mm6932e2
   Gotzinger F, 2020, LANCET CHILD ADOLESC, V4, P653, DOI 10.1016/S2352-4642(20)30177-2
   Grimaud M, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00690-8
   Gruber CN, 2020, CELL, V183, P982, DOI 10.1016/j.cell.2020.09.034
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Hameed Shema, 2021, Radiology, V298, pE1, DOI 10.1148/radiol.2020202543
   Harkness A, 2020, ECHO RES PRACT, V7, pX1, DOI 10.1530/ERP-19-0050e
   Hedrich CM, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00198
   Henry BM, 2020, CLIN BIOCHEM, V81, P1, DOI 10.1016/j.clinbiochem.2020.05.012
   Jain S, 2020, INDIAN PEDIAT
   Kaushik S, 2020, J PEDIATR-US, V224, P24, DOI 10.1016/j.jpeds.2020.06.045
   Khesrani LS, 2020, J PEDIAT SURG CASE R, V61, DOI 10.1016/j.epsc.2020.101604
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Lee PY, 2020, J ALLERGY CLIN IMMUN, V146, P1194, DOI 10.1016/j.jaci.2020.07.033
   Lee PY, 2020, J CLIN INVEST, V130, P5942, DOI 10.1172/JCI141113
   Licciardi F, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1711
   Lin J, 2020, AM J NEURORADIOL, V41, P2017, DOI 10.3174/ajnr.A6755
   Liu XY, 2020, ACTA PHARMACOL SIN B, V10, P1205, DOI 10.1016/j.apsb.2020.04.008
   Mamishi S, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S095026882000196X
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   Miller IF, 2020, NAT MED, V26, P1212, DOI 10.1038/s41591-020-0952-y
   Miller J, 2020, GASTROENTEROLOGY, V159, P1571, DOI 10.1053/j.gastro.2020.05.079
   Moraleda Cinta, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1042
   Muniz JCG, 2013, CIRC-CARDIOVASC IMAG, V6, P239, DOI 10.1161/CIRCIMAGING.112.000159
   National Institutes of Health, 2020, RADX RAD PRED VIR AS
   Nicin L, 2020, EUR HEART J, V41, P1804, DOI 10.1093/eurheartj/ehaa311
   Novack M.L, 2020, NATRIURETIC PEPTIDE
   Pain CE, 2020, LANCET RHEUMATOL, V2, pE376, DOI 10.1016/S2665-9913(20)30137-5
   Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008
   Pouletty M, 2020, ANN RHEUM DIS, V79, P999, DOI 10.1136/annrheumdis-2020-217960
   Ramcharan T, 2020, PEDIATR CARDIOL, V41, P1391, DOI 10.1007/s00246-020-02391-2
   Ravelli A, 2016, ARTHRITIS RHEUMATOL, V68, P566, DOI 10.1002/art.39332
   Riollano-Cruz M, 2020, J MED VIROL, DOI 10.1002/jmv.26224
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Roncati L, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108487
   Rowley AH, 2020, NAT REV IMMUNOL, V20, P453, DOI 10.1038/s41577-020-0367-5
   Royal College of Paediatrics and Child Health, 2020, GUID PAED MULT INFL
   Schnabel A, 2019, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00421
   Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003
   Shi YL, 2020, ACTA PHARMACOL SIN B, V10, P1239, DOI 10.1016/j.apsb.2020.04.006
   Stringhini S, 2020, LANCET, V396, P313, DOI 10.1016/S0140-6736(20)31304-0
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Torres Juan P, 2020, Int J Infect Dis, V100, P75, DOI 10.1016/j.ijid.2020.08.062
   Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094
   University of Oxford, 2020, REC RAND EV COVID 19
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Vernuccio F, 2020, CLIN RADIOL, V75, P804, DOI 10.1016/j.crad.2020.07.019
   Ward H, 2020, ANTIBODY PREVALENCE, DOI [10.1101/2020.08/12/20173690, DOI 10.1101/2020.08/12/20173690]
   Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369
   World Health Organization, 2020, SCI BRIEF
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 86
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD OCT
PY 2020
VL 9
IS 10
AR 3293
DI 10.3390/jcm9103293
PG 20
WC Medicine, General & Internal
SC General & Internal Medicine
GA OL3VD
UT WOS:000585270400001
PM 33066459
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rodilla, E
   Saura, A
   Jimenez, I
   Mendizabal, A
   Pineda-Cantero, A
   Lorenzo-Hernandez, E
   Fidalgo-Montero, MD
   Lopez-Cuervo, JF
   Gil-Sanchez, R
   Rabadan-Pejenaute, E
   Abella-Vazquez, L
   Giner-Galvan, V
   Solis-Marquinez, MN
   Boixeda, R
   Pena-Fernandez, AD
   Carrasco-Sanchez, FJ
   Gonzalez-Moraleja, J
   Torres-Pena, JD
   Guisado-Espartero, ME
   Escobar-Sevilla, J
   Guzman-Garcia, M
   Martin-Escalante, MD
   Martinez-Gonzalez, AL
   Casas-Rojo, JM
   Gomez-Huelgas, R
AF Rodilla, Enrique
   Saura, Alberto
   Jimenez, Iratxe
   Mendizabal, Andrea
   Pineda-Cantero, Araceli
   Lorenzo-Hernandez, Elizabeth
   Fidalgo-Montero, Maria del Pilar
   Lopez-Cuervo, Joaquin Fernandez
   Gil-Sanchez, Ricardo
   Rabadan-Pejenaute, Elisa
   Abella-Vazquez, Lucy
   Giner-Galvan, Vicente
   Solis-Marquinez, Marta Nataya
   Boixeda, Ramon
   Pena-Fernandez, Andres de la
   Carrasco-Sanchez, Francisco Javier
   Gonzalez-Moraleja, Julio
   Torres-Pena, Jose David
   Guisado-Espartero, Maria Esther
   Escobar-Sevilla, Joaquin
   Guzman-Garcia, Marcos
   Martin-Escalante, Maria Dolores
   Martinez-Gonzalez, Angel Luis
   Casas-Rojo, Jose Manuel
   Gomez-Huelgas, Ricardo
TI Association of Hypertension with All-Cause Mortality among Hospitalized
   Patients with COVID-19
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE hypertension; COVID-19; angiotensin-converting enzyme inhibitors
   (ACEIs); angiotensin II receptor blockers (ARBs); all-cause mortality
ID CONVERTING ENZYME 2; ACE2
AB It is unclear to which extent the higher mortality associated with hypertension in the coronavirus disease (COVID-19) is due to its increased prevalence among older patients or to specific mechanisms. Cross-sectional, observational, retrospective multicenter study, analyzing 12226 patients who required hospital admission in 150 Spanish centers included in the nationwide SEMI-COVID-19 Network. We compared the clinical characteristics of survivors versus non-survivors. The mean age of the study population was 67.5 +/- 16.1 years, 42.6% were women. Overall, 2630 (21.5%) subjects died. The most common comorbidity was hypertension (50.9%) followed by diabetes (19.1%), and atrial fibrillation (11.2%). Multivariate analysis showed that after adjusting for gender (males, OR: 1.5, p = 0.0001), age tertiles (second and third tertiles, OR: 2.0 and 4.7, p = 0.0001), and Charlson Comorbidity Index scores (second and third tertiles, OR: 4.7 and 8.1, p = 0.0001), hypertension was significantly predictive of all-cause mortality when this comorbidity was treated with angiotensin-converting enzyme inhibitors (ACEIs) (OR: 1.6, p = 0.002) or other than renin-angiotensin-aldosterone blockers (OR: 1.3, p = 0.001) or angiotensin II receptor blockers (ARBs) (OR: 1.2, p = 0.035). The preexisting condition of hypertension had an independent prognostic value for all-cause mortality in patients with COVID-19 who required hospitalization. ARBs showed a lower risk of lethality in hypertensive patients than other antihypertensive drugs.
C1 [Rodilla, Enrique; Saura, Alberto; Jimenez, Iratxe; Mendizabal, Andrea] CEU Univ, Univ Hosp Sagunto, Univ Cardenal Herrera CEU, Dept Internal Med, Sagunto 46520, Spain.
   [Pineda-Cantero, Araceli; Lorenzo-Hernandez, Elizabeth; Gomez-Huelgas, Ricardo] Reg Univ Hosp Malaga, Dept Internal Med, Malaga 29010, Spain.
   [Fidalgo-Montero, Maria del Pilar] Henares Hosp, Dept Internal Med, Coslada 28822, Madrid, Spain.
   [Lopez-Cuervo, Joaquin Fernandez] Torrevieja Univ Hosp, Dept Internal Med, Torrevieja 03186, Alicante, Spain.
   [Gil-Sanchez, Ricardo] La Fe Univ Hosp, Dept Internal Med, Valencia 46026, Spain.
   [Rabadan-Pejenaute, Elisa] San Pedro Hosp, Dept Internal Med, Logrono 26006, La Rioja, Spain.
   [Abella-Vazquez, Lucy] Ntra Sra Candelaria Univ Hosp, Dept Internal Med, Santa Cruz De Tenerife 38010, Spain.
   [Giner-Galvan, Vicente] Miguel Hernandez Univ, San Juan De Alicante Univ Hosp, Dept Internal Med, Hypertens & Cardiometabol Risk Unit, Alacant, Alicante, Spain.
   [Solis-Marquinez, Marta Nataya] San Agustin Univ Hosp, Dept Internal Med, Aviles 33410, Asturias, Spain.
   [Boixeda, Ramon] Mataro Hosp, Dept Internal Med, Barcelona 08304, Spain.
   [Pena-Fernandez, Andres de la] Son Llatzer Univ Hosp, Dept Internal Med, Palma de Mallorca 07198, Spain.
   [Carrasco-Sanchez, Francisco Javier] Juan Ramon Jimenez Hosp, Dept Internal Med, Huelva 21005, Spain.
   [Gonzalez-Moraleja, Julio] Virgen Salud Hosp, Dept Internal Med, Toledo 45004, Spain.
   [Torres-Pena, Jose David] Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Lipids & Atherosclerosis Unit,Dept Internal Med, Cordoba 14004, Spain.
   [Torres-Pena, Jose David] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Cordoba 14004, Spain.
   [Guisado-Espartero, Maria Esther] Infanta Margarita Hosp, Dept Internal Med, Cabra 14940, Cordoba, Spain.
   [Escobar-Sevilla, Joaquin] Virgen Las Nieves Univ Hosp, Dept Internal Med, Granada 18014, Spain.
   [Guzman-Garcia, Marcos] San Juan Cruz Hosp, Dept Internal Med, Ubeda 23400, Jaen, Spain.
   [Martin-Escalante, Maria Dolores] Costa Sol Hosp, Dept Internal Med, Marbella 29603, Malaga, Spain.
   [Martinez-Gonzalez, Angel Luis] Leon Univ Hosp Complex, Dept Internal Med, Leon 24008, Spain.
   [Casas-Rojo, Jose Manuel] Infanta Cristina Univ Hosp, Dept Internal Med, Parla 28981, Madrid, Spain.
RP Rodilla, E (corresponding author), CEU Univ, Univ Hosp Sagunto, Univ Cardenal Herrera CEU, Dept Internal Med, Sagunto 46520, Spain.
EM enrique.rodilla@uchceu.es; albertosaura@hotmail.com;
   iratxej@hotmail.com; andreamendi@hotmail.com; arapineda9@gmail.com;
   eli.lorenzo.hernandez@gmail.com; garrotefidalgo@telefonica.net;
   joaquinfernandezcuervo11@gmail.com; rigilsan@gmail.com;
   elisapeje@gmail.com; abellavazquez@gmail.com; ginervicgal@gmail.com;
   natayasolis@gmail.com; rboixeda@ub.edu; adelapen@hsll.es;
   fjcarrascos@icloud.com; juliogmoraleja@gmail.com; azarel_00@hotmail.com;
   guesm53@hotmail.com; escobarsevillaj@gmail.com; m_guzman00@hotmail.es;
   mmartinescalante@gmail.com; garufa125@gmail.com; jm.casas@gmail.com;
   ricardogomezhuelgas@hotmail.com
RI Sanchez, Francisco Javier Carrasco/T-9558-2019; Rodilla,
   Enrique/L-1284-2014; Pena, Jose D. Torres/ABH-3312-2020
OI Sanchez, Francisco Javier Carrasco/0000-0002-9275-7056; Rodilla,
   Enrique/0000-0003-3669-4270; Pena, Jose D. Torres/0000-0003-1366-5549;
   Gomez Huelgas, Ricardo/0000-0002-9909-3555; Rabadan,
   Elisa/0000-0002-5942-0611; Casas Rojo, Jose Manuel/0000-0002-6649-4301;
   Gonzalez-Moraleja, Julio/0000-0002-4507-8990; Boixeda,
   Ramon/0000-0002-5330-9971; Saura, Alberto/0000-0003-2537-3324; Martin
   Escalante, Maria Dolores/0000-0003-1932-8682; Guisado Espartero, M
   Esther/0000-0002-9920-1835
CR ACC, 2020, HFSA ACC AHA STAT AD
   [Anonymous], 33 RENAVE CNE CNM IS
   [Anonymous], 2011, GLOBAL ATLAS CARDIOV
   Casas-Rojo JM, 2020, REV CLIN ESP, V220, P480, DOI 10.1016/j.rce.2020.07.003
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chow CK, 2013, JAMA-J AM MED ASSOC, V310, P959, DOI 10.1001/jama.2013.184182
   Drummond GR, 2019, NAT REV IMMUNOL, V19, P517, DOI 10.1038/s41577-019-0160-5
   European Society of Cardiology (ESC), 2020, POS STAT ESC COUNC H
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fosbol EL, 2020, JAMA-J AM MED ASSOC, V324, P168, DOI 10.1001/jama.2020.11301
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iaccarino G, 2020, HYPERTENSION, V76, P366, DOI 10.1161/HYPERTENSIONAHA.120.15324
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Sisnieguez CEL, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01148-2020
   Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033
   Lind L, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007061
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Rao C, 2020, B WORLD HEALTH ORGAN, V98, P298, DOI 10.2471/BLT.20.257600
   Saavedra JM, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104832
   Santos RAS, 2018, PHYSIOL REV, V98, P505, DOI 10.1152/physrev.00023.2016
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339
   World Health Organization, CLIN MAN SEV AC RESP
   Zhang YX, 2020, NAT REV CARDIOL, V17, P170, DOI 10.1038/s41569-019-0260-8
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 30
TC 2
Z9 2
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD OCT
PY 2020
VL 9
IS 10
AR 3136
DI 10.3390/jcm9103136
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA OL4CH
UT WOS:000585289800001
PM 32998337
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Brown, AS
   Ackerley, DF
   Calcott, MJ
AF Brown, Alistair S.
   Ackerley, David F.
   Calcott, Mark J.
TI High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease
   Using a FRET-Biosensor
SO MOLECULES
LA English
DT Article
DE SARS-CoV-2; COVID-19; 3CLPro; cysteine protease; ebselen; apomorphine;
   aporphine
ID HEPATITIS-C VIRUS; SARS-COV 3CL(PRO); PD 404,182
AB The global SARS-CoV-2 pandemic started late 2019 and currently continues unabated. The lag-time for developing vaccines means it is of paramount importance to be able to quickly develop and repurpose therapeutic drugs. Protein-based biosensors allow screening to be performed using routine molecular laboratory equipment without a need for expensive chemical reagents. Here we present a biosensor for the 3-chymotrypsin-like cysteine protease from SARS-CoV-2, comprising a FRET-capable pair of fluorescent proteins held in proximity by a protease cleavable linker. We demonstrate the utility of this biosensor for inhibitor discovery by screening 1280 compounds from the Library of Pharmaceutically Active Compounds collection. The screening identified 65 inhibitors, with the 20 most active exhibiting sub-micromolar inhibition of 3CL(pro) in follow-up EC50 assays. The top hits included several compounds not previously identified as 3CL(pro) inhibitors, in particular five members of a family of aporphine alkaloids that offer promise as new antiviral drug leads.
C1 [Brown, Alistair S.; Ackerley, David F.; Calcott, Mark J.] Victoria Univ Wellington, Sch Biol Sci, Wellington 6012, New Zealand.
RP Calcott, MJ (corresponding author), Victoria Univ Wellington, Sch Biol Sci, Wellington 6012, New Zealand.
EM alistair.brown@vuw.ac.nz; david.ackerley@vuw.ac.nz;
   mark.calcott@vuw.ac.nz
OI Ackerley, David/0000-0002-6188-9902
FU Royal Society of New Zealand Marsden FundRoyal Society of New
   ZealandMarsden Fund (NZ) [18-VUW-082]; Health Research Council of New
   ZealandHealth Research Council of New Zealand [18-532]
FX This work was supported by the Royal Society of New Zealand Marsden Fund
   (grant 18-VUW-082 to M.J.C.) and Health Research Council of New Zealand
   (grant 18-532 to D.F.A.).
CR [Anonymous], 2020, COR DIS COVID 19 DAS
   Auffret M, 2019, EUR J PHARMACOL, V843, P66, DOI 10.1016/j.ejphar.2018.10.052
   Birck MR, 2000, J AM CHEM SOC, V122, P9334, DOI 10.1021/ja002142z
   Chamoun AM, 2012, ANTIMICROB AGENTS CH, V56, P672, DOI 10.1128/AAC.05722-11
   Chamoun-Emanuelli AM, 2014, ANTIMICROB AGENTS CH, V58, P687, DOI 10.1128/AAC.02000-13
   Chen LL, 2006, BIOORGAN MED CHEM, V14, P8295, DOI 10.1016/j.bmc.2006.09.014
   Chockalingam K, 2010, ANTIVIR RES, V86, pA32, DOI 10.1016/j.antiviral.2010.02.369
   Chuck CP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013197
   Feng BY, 2006, NAT PROTOC, V1, P550, DOI 10.1038/nprot.2006.77
   Ghebremariam YT, 2014, J PHARMACOL EXP THER, V348, P69, DOI 10.1124/jpet.113.206847
   Groen K, 2019, CANCER MANAG RES, V11, P2663, DOI 10.2147/CMAR.S150653
   Grosset KA, 2013, EUR J NEUROL, V20, P1445, DOI 10.1111/ene.12091
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kelly JA, 2020, J BIOL CHEM, V295, P10741, DOI 10.1074/jbc.AC120.013449
   Kilianski A, 2013, J VIROL, V87, P11955, DOI 10.1128/JVI.02105-13
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8
   Menendez CA, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd0345
   Menni C, 2020, NAT MED, V26, P1037, DOI 10.1038/s41591-020-0916-2
   Muth M, 2019, BBA-GEN SUBJECTS, V1863, P577, DOI 10.1016/j.bbagen.2019.01.001
   Nagai T, 2004, BIOCHEM BIOPH RES CO, V319, P72, DOI 10.1016/j.bbrc.2004.04.147
   Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878
   Pawlotsky JM, 2013, CURR TOP MICROBIOL, V369, P321, DOI 10.1007/978-3-642-27340-7_13
   Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v
   Ritz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146021
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Sies H, 2020, FREE RADICAL BIO MED, V156, P107, DOI 10.1016/j.freeradbiomed.2020.06.032
   Wilkins MR, 1999, METH MOL B, V112, P531
   Wu AD, 2015, VIRUS RES, V208, P56, DOI 10.1016/j.virusres.2015.05.018
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 32
TC 0
Z9 0
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD OCT
PY 2020
VL 25
IS 20
AR 4666
DI 10.3390/molecules25204666
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OL9PM
UT WOS:000585662100001
PM 33066278
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Plonka, W
   Paneth, A
   Paneth, P
AF Plonka, Wojciech
   Paneth, Agata
   Paneth, Piotr
TI Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Protein-Human
   ACE2 Receptor Interface
SO MOLECULES
LA English
DT Article
DE SARS-CoV-2; aminothioureas; docking; QSAR; ADMET
ID ANTICONVULSANT ACTIVITY; ANTIBACTERIAL ACTIVITY; SEARCH;
   THIOSEMICARBAZIDE; PREDICTION; ALGORITHM; TRIAZOLE; BINDING
AB Docking of over 160 aminothiourea derivatives at the SARS-CoV-2 S-protein-human ACE2 receptor interface, whose structure became available recently, has been evaluated for its complex stabilizing potency and subsequently subjected to quantitative structure-activity relationship (QSAR) analysis. The structural variety of the studied compounds, that include 3 different forms of the N-N-C(S)-N skeleton and combinations of 13 different substituents alongside the extensive length of the interface, resulted in the failure of the QSAR analysis, since different molecules were binding to different parts of the interface. Subsequently, absorption, distribution, metabolism, and excretion (ADME) analysis on all studied compounds, followed by a toxicity analysis using statistical models for selected compounds, was carried out to evaluate their potential use as lead compounds for drug design. Combined, these studies highlighted two molecules among the studied compounds, i.e., 5-(pyrrol-2-yl)-2-(2-methoxyphenylamino)-1,3,4-thiadiazole and 1-(cyclopentanoyl)-4-(3-iodophenyl)-thiosemicarbazide, as the best candidates for the development of future drugs.
C1 [Plonka, Wojciech] Univ Hamburg, Ctr Bioinformat ZBH, D-20146 Hamburg, Germany.
   [Plonka, Wojciech] FQS Fujitsu Poland, Parkowa 11, PL-33332 Krakow, Poland.
   [Paneth, Agata] Med Univ Lublin, Fac Pharm, Dept Organ Chem, Chodzki 4a, PL-20093 Lublin, Poland.
   [Paneth, Piotr] Lodz Univ Technol, Fac Chem, Inst Appl Radiat Chem, Zeromskiego 116, PL-90924 Lodz, Poland.
   [Paneth, Piotr] Lodz Univ Technol, Int Ctr Res Innovat Biobased Mat ICRI BioM Int Re, Zeromskiego 116, PL-90924 Lodz, Poland.
RP Paneth, P (corresponding author), Lodz Univ Technol, Fac Chem, Inst Appl Radiat Chem, Zeromskiego 116, PL-90924 Lodz, Poland.; Paneth, P (corresponding author), Lodz Univ Technol, Int Ctr Res Innovat Biobased Mat ICRI BioM Int Re, Zeromskiego 116, PL-90924 Lodz, Poland.
EM w.plonka@fqs.pl; agata.paneth@umlub.pl; piotr.paneth@p.lodz.pl
OI Paneth, Piotr/0000-0002-3091-8387; Paneth, Agata/0000-0002-8198-7702
FU Foundation for Polish ScienceFoundation for Polish Science
FX This research was partly supported by the Foundation for Polish Science
   via the grantMABPLUS/2019/11.
CR Alexander SPH, 2020, BRIT J PHARMACOL, V177, P4942, DOI 10.1111/bph.15094
   Ali Amanat, 2020, Sci Rep, V10, P14214, DOI 10.1038/s41598-020-71188-3
   Bai C, 2020, J PHYS CHEM B, V124, P5907, DOI 10.1021/acs.jpcb.0c04317
   Baxter CA, 1998, PROTEINS, V33, P367, DOI 10.1002/(SICI)1097-0134(19981115)33:3<367::AID-PROT6>3.0.CO;2-W
   Cao JZ, 2015, ANTIVIR RES, V114, P1, DOI 10.1016/j.antiviral.2014.11.010
   Chan KK, 2020, SCIENCE, V369, P1261, DOI 10.1126/science.abc0870
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Daina A, 2016, CHEMMEDCHEM, V11, P1117, DOI 10.1002/cmdc.201600182
   Datta PK, 2020, THERANOSTICS, V10, P7448, DOI 10.7150/thno.48076
   Dennington R.K., 2016, GAUSSVIEW VERSION 6
   Dzitko K, 2014, ANTIMICROB AGENTS CH, V58, P7583, DOI 10.1128/AAC.03832-14
   Dzitko K, 2014, MOLECULES, V19, P9926, DOI 10.3390/molecules19079926
   Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e
   Fraczek T, 2016, J ENZYM INHIB MED CH, V31, P481, DOI 10.3109/14756366.2015.1039531
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Hyperchem, 2010, PROGRAM
   Jain A.K., 2018, MODELS METHODS IN VI, P45
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Kapron B, 2018, ANTI-CANCER AGENT ME, V18, P529, DOI 10.2174/1871520617666171023142958
   Kapron B, 2017, INT J MED SCI, V14, P741, DOI 10.7150/ijms.20001
   Keramagi AR, 2018, 3 BIOTECH, V8, DOI 10.1007/s13205-018-1303-2
   Kramer B, 1999, PROTEINS, V37, P228, DOI 10.1002/(SICI)1097-0134(19991101)37:2<228::AID-PROT8>3.0.CO;2-8
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Leadl T, 2017, PROGRAM BIOSOLVEIT G
   LEE S, 2002, PROB SOL, V2003, P418
   Li Y, 2014, J CHEM INF MODEL, V54, P1717, DOI 10.1021/ci500081m
   Lim PL, 2013, CURR INFECT DIS REP, V15, P295, DOI 10.1007/s11908-013-0344-2
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Macrae CF, 2020, J APPL CRYSTALLOGR, V53, P226, DOI 10.1107/S1600576719014092
   Mercurio I, 2020, CELL MOL LIFE SCI, DOI 10.1007/s00018-020-03580-1
   Novick PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079568
   Paneth A., 2020, SCI REP, DOI [10.21203/rs.3.rs-23928/v1, DOI 10.21203/RS.3.RS-23928/V1]
   Paneth A, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12020064
   Paneth A, 2019, MOLECULES, V24, DOI 10.3390/molecules24081618
   Paneth A, 2019, MOLECULES, V24, DOI 10.3390/molecules24030614
   Paneth A, 2017, J MOL MODEL, V23, DOI 10.1007/s00894-017-3489-3
   Paneth A, 2017, BIOMED PHARMACOTHER, V88, P1235, DOI 10.1016/j.biopha.2017.02.001
   Paneth A, 2016, CNS NEUROL DISORD-DR, V15, P730, DOI 10.2174/1871527315666160321110818
   Paneth A, 2016, J ENZYM INHIB MED CH, V31, P434, DOI 10.3109/14756366.2015.1036050
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Plech T, 2015, J ENZYM INHIB MED CH, V30, P1021, DOI 10.3109/14756366.2014.995179
   Plech T, 2015, EUR J MED CHEM, V97, P94, DOI 10.1016/j.ejmech.2015.04.058
   Plech T, 2015, CHEM BIOL DRUG DES, V85, P315, DOI 10.1111/cbdd.12392
   Plech T, 2014, EUR J MED CHEM, V86, P690, DOI 10.1016/j.ejmech.2014.09.034
   Plech T, 2014, MOLECULES, V19, P11279, DOI 10.3390/molecules190811279
   Siwek A, 2014, J ENZYM INHIB MED CH, V29, P243, DOI 10.3109/14756366.2013.768987
   Siwek A, 2013, J MOL MODEL, V19, P1319, DOI 10.1007/s00894-012-1679-6
   Smith M., 2020, CHEMRXIV UNPUB, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Teixido E, 2020, ENVIRON TOXICOL CHEM, V39, P30, DOI 10.1002/etc.4607
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vilar S, 2008, CURR TOP MED CHEM, V8, P1555, DOI 10.2174/156802608786786624
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang YJ, 2020, P NATL ACAD SCI USA, V117, P13967, DOI 10.1073/pnas.2008209117
   Wildman SA, 1999, J CHEM INF COMP SCI, V39, P868, DOI 10.1021/ci990307l
   Wujec M, 2014, MOLECULES, V19, P4745, DOI 10.3390/molecules19044745
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 61
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD OCT
PY 2020
VL 25
IS 20
AR 4645
DI 10.3390/molecules25204645
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OL8OV
UT WOS:000585592800001
PM 33053830
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Singh, R
   Gautam, A
   Chandel, S
   Ghosh, A
   Dey, D
   Roy, S
   Ravichandiran, V
   Ghosh, D
AF Singh, Rajveer
   Gautam, Anupam
   Chandel, Shivani
   Ghosh, Arijit
   Dey, Dhritiman
   Roy, Syamal
   Ravichandiran, Velayutham
   Ghosh, Dipanjan
TI Protease Inhibitory Effect of Natural Polyphenolic Compounds on
   SARS-CoV-2: An In Silico Study
SO MOLECULES
LA English
DT Article
DE polyphenols; SARS-CoV-2; molecular docking; molecular dynamic
   simulation; MM-PBSA
ID MANGIFERIN; MODEL; ACTIVATION; DOCKING; GROMACS; TOOL
AB The current pandemic, caused by SARS-CoV-2 virus, is a severe challenge for human health and the world economy. There is an urgent need for development of drugs that can manage this pandemic, as it has already infected 19 million people and led to the death of around 711,277 people worldwide. At this time, in-silico studies are providing lots of preliminary data about potential drugs, which can be a great help in further in-vitro and in-vivo studies. Here, we have selected three polyphenolic compounds, mangiferin, glucogallin, and phlorizin. These compounds are isolated from different natural sources but share structural similarities and have been reported for their antiviral activity. The objective of this study is to analyze and predict the anti-protease activity of these compounds on SARS-CoV-2main protease (Mpro) and TMPRSS2 protein. Both the viral protein and the host protein play an important role in the viral life cycle, such as post-translational modification and viral spike protein priming. This study has been performed by molecular docking of the compounds using PyRx with AutoDock Vina on the two aforementioned targets chosen for this study, i.e., SARS-CoV-2 Mpro and TMPRSS2. The compounds showed good binding affinity and are further analyzed by (Molecular dynamic) MD and Molecular Mechanics Poisson-Boltzmann Surface Area MM-PBSA study. The MD-simulation study has predicted that these natural compounds will have a great impact on the stabilization of the binding cavity of the Mpro of SARS-CoV-2. The predicted pharmacokinetic parameters also show that these compounds are expected to have good solubility and absorption properties. Further predictions for these compounds also showed no involvement in drug-drug interaction and no toxicity.
C1 [Singh, Rajveer; Chandel, Shivani; Dey, Dhritiman; Roy, Syamal; Ravichandiran, Velayutham; Ghosh, Dipanjan] Natl Inst Pharmaceut Educ & Res, Kolkata 70054, India.
   [Gautam, Anupam] Univ Tubingen, Inst Bioinformat & Med Informat, Sand 14, D-72076 Tubingen, Germany.
   [Gautam, Anupam] Int Max Planck Res Sch Mol Organisms, D-72076 Tubingen, Germany.
   [Ghosh, Arijit] Univ Calcutta, Dept Chem, Kolkata 700009, India.
RP Ghosh, D (corresponding author), Natl Inst Pharmaceut Educ & Res, Kolkata 70054, India.
EM rajveersidhu94@gmail.com; anupam.gautam@uni-tuebingen.de;
   chandelshivani48@gmail.com; jitbiochem71@gmail.com;
   dhritimandey@gmail.com; drsyamalroy@yahoo.com;
   directorniperkolkata@gmail.com; dipanjan4u@gmail.com
OI GHOSH, DIPANJAN/0000-0003-3266-9262; Gautam, Anupam/0000-0002-6460-6525;
   Ghosh, Arijit/0000-0001-5530-1909
FU Department of Pharmaceuticals, Ministry of Fertilizer, Government of
   India; DBT, Govt. of IndiaDepartment of Biotechnology (DBT) India
   [BT/PR26301/GET/119/258/2017]; Govt. of West Bengal Department of
   Biotechnology WBDBT [BT/P/Budget/RD-74/2017]
FX The authors would like to give their thanks to the Department of
   Pharmaceuticals, Ministry of Fertilizer, Government of India for
   providing the fellowship to Mr. Rajveer Singh and Miss Shivani Chandel.
   We also thank the DBT, Govt. of India [grant number
   BT/PR26301/GET/119/258/2017] and the Govt. of West Bengal Department of
   Biotechnology WBDBT [grant numbers BT/P/Budget/RD-74/2017] for their
   support.
CR Antonio AD, 2020, RSC ADV, V10, P23379, DOI 10.1039/d0ra03774e
   Arun KG, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/10799893.2020.1715432, 10.1080/07391102.2020.1779819]
   Aryaeian Naheed, 2017, Med J Islam Repub Iran, V31, P134, DOI 10.14196/mjiri.31.134
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Boonstra S, 2016, J PHYS CHEM B, V120, P3692, DOI 10.1021/acs.jpcb.6b01316
   Bouarab-Chibane L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00829
   Carocho M, 2013, ANTI-CANCER AGENT ME, V13, P1236, DOI 10.2174/18715206113139990301
   Chaipan C, 2009, J VIROL, V83, P3200, DOI 10.1128/JVI.02205-08
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   Ghosh R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779818
   Guex N, 2009, ELECTROPHORESIS, V30, pS162, DOI 10.1002/elps.200900140
   Gupta P, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-80
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Havranek B, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1776158, 10.1080/07391102.2020.1805018]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   King A, 1999, J AM DIET ASSOC, V99, P213, DOI 10.1016/S0002-8223(99)00051-6
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lee S, 2014, J PHYS CHEM B, V118, P547, DOI 10.1021/jp410344g
   Leegwater Emiel, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa883
   Majumder R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1817787
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Muruganandan S, 2005, TOXICOLOGY, V215, P57, DOI 10.1016/j.tox.2005.06.008
   Ngwa W, 2020, MOLECULES, V25, DOI 10.3390/molecules25112707
   Oliver S, 2016, POLYM CHEM-UK, V7, P1529, DOI 10.1039/c5py01912e
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Pouysegu L., 2013, NATURAL PRODUCTS PHY, P1975, DOI DOI 10.1007/978-3-642-22144-6_65
   Santos KB, 2020, J CHEM INF MODEL, V60, P667, DOI 10.1021/acs.jcim.9b00905
   Spagnuolo C, 2016, CURR TOP MED CHEM, V16, P1943, DOI 10.2174/1568026616666160204122449
   Studer G, 2020, BIOINFORMATICS, V36, P1765, DOI 10.1093/bioinformatics/btz828
   Studer G, 2014, BIOINFORMATICS, V30, pI505, DOI 10.1093/bioinformatics/btu457
   Tangney CC, 2013, CURR ATHEROSCLER REP, V15, DOI 10.1007/s11883-013-0324-x
   Vieira AB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071759
   Vyas VK, 2012, INDIAN J PHARM SCI, V74, P1, DOI 10.4103/0250-474X.102537
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Zeng W., 2020, BIORXIV, DOI [10.1101/2020.07.08.193144, DOI 10.1101/2020.07.08.193144]
   ZHENG MS, 1990, CHINESE MED J-PEKING, V103, P160
   ZHU XM, 1993, ACTA PHARM SINIC, V14, P452
NR 39
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD OCT
PY 2020
VL 25
IS 20
AR 4604
DI 10.3390/molecules25204604
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OM0BB
UT WOS:000585692800001
PM 33050360
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tomani, JCD
   Kagisha, V
   Tchinda, AT
   Jansen, O
   Ledoux, A
   Vanhamme, L
   Frederich, M
   Muganga, R
   Souopgui, J
AF Tomani, Jean Claude Didelot
   Kagisha, Vedaste
   Tchinda, Alembert Tiabou
   Jansen, Olivia
   Ledoux, Allison
   Vanhamme, Luc
   Frederich, Michel
   Muganga, Raymond
   Souopgui, Jacob
TI The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus
   noldeae Baker f. Derived Constituents Provides a Link to Its
   Anti-Inflammatory Therapeutic Potentials
SO MOLECULES
LA English
DT Article
DE asthma; Hibiscus noldeae; bio-guided fractionation; Inflammasome;
   IL-1&#946; IL-6; THP-1; RAW264; 7; macrophage
ID CYTOKINE STORM; MEDICINAL-PLANTS; COVID-19; ACTIVATION; MECHANISM
AB The activation of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome and/or its components is associated with the physio-pathogenesis of many respiratory diseases including asthma, COPD (chronic obstructive pulmonary disease), SARS Cov-2 (severe acute respiratory syndrome coronavirus 2), and in several autoimmune diseases. Hibiscus noldeae Baker f. has been widely reported to be traditionally used in the treatment of different ailments, some of which are of inflammatory background such as asthma, wounds, headache, etc. However, the claims have not been supported by evidence at the molecular and functional levels. Here, we report on the bio-guided fractionation of H. noldeae and assessment of the inhibitory properties of some fractions and purified compounds on NLRP3 inflammasome and Interleukin 6 (IL-6). The activation of the NLRP3 inflammasome was determined by detecting the activity of caspase-1 and the production of Interleukin 1 beta (IL-1 beta) in Lipopolysaccharide (LPS) and ATP-stimulated Tamm-Horsfall Protein 1 (THP-1) macrophages, while the production of IL-6 was studied in LPS-stimulated RAW264.7 mouse macrophages. It was observed that hexane and ethyl acetate fractions of the crude extract of the aerial parts of H. noldeae, as well as caffeic acid, isoquercetin, and ER2.4 and ER2.7 fractions revealed significant inhibitory effects on Caspase-1 activities, and on IL-1 beta and IL-6 production. The ER2.4 and ER2.7 fractions downregulated the production of IL-1 beta and IL-6, in a similar range as the caspase-1 inhibitor AC-YVAD-CHO and the drug Dexamethasone, both used as controls, respectively. Overall, our work does provide the very first scientific based evidence for Hibiscus noldeae anti-inflammatory effects and widespread use by traditional healers in Rwanda for a variety of ailments.
C1 [Tomani, Jean Claude Didelot; Kagisha, Vedaste; Muganga, Raymond] Univ Rwanda, Coll Med & Hlth Sci, Sch Med & Pharm, POB 3286, Kigali, Rwanda.
   [Tomani, Jean Claude Didelot; Vanhamme, Luc; Souopgui, Jacob] Univ Libre Bruxelles, Inst Mol Biol & Med, Dept Mol Biol, B-6041 Gosselies, Belgium.
   [Kagisha, Vedaste; Jansen, Olivia; Ledoux, Allison; Frederich, Michel] Univ Liege, Lab Pharmacognosy, Ctr Interdisciplinary Res Medicines CIRM, B36, B-4000 Liege, Belgium.
   [Tchinda, Alembert Tiabou] Inst Med Res & Med Plants Studies, Ctr Res Med Plants & Tradit Med, Lab Phytochem, POB 6163, Yaounde, Cameroon.
RP Souopgui, J (corresponding author), Univ Libre Bruxelles, Inst Mol Biol & Med, Dept Mol Biol, B-6041 Gosselies, Belgium.
EM Jean.Claude.Tomani@ulb.ac.be; kagishavedaste@gmail.com;
   talembert@gmail.com; ojansen@ulg.ac.be; allison.ledoux@ulg.ac.be;
   Luc.Vanhamme@ulb.ac.be; M.Frederich@uliege.be; rmuganga@yahoo.fr;
   jsouopgu@ulb.ac.be
OI FREDERICH, Michel/0000-0002-0770-9990
FU Academie de Recherche et d'Enseignement Superieur (ARES)
   [ARS-PRD2015Rwanda]; ARS-PRD2015 Rwanda; Les Amis des Instituts Pasteur
   a Bruxelles
FX This research was funded by the "Academie de Recherche et d'Enseignement
   Superieur (ARES)", grant number "ARS-PRD2015Rwanda to M.F." J.C.D.T. was
   funded via ARS-PRD2015 Rwanda and by "Les Amis des Instituts Pasteur a
   Bruxelles".
CR Akbar S., 2020, HDB 200 MED PLANTS C
   Besnard AG, 2012, J MOL CELL BIOL, V4, P3, DOI 10.1093/jmcb/mjr042
   Borthwick LA, 2016, SEMIN IMMUNOPATHOL, V38, P517, DOI 10.1007/s00281-016-0559-z
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Chifundera K, 2001, FITOTERAPIA, V72, P351, DOI 10.1016/S0367-326X(00)00294-X
   Da Cunha FM, 2004, FREE RADICAL RES, V38, P1241, DOI 10.1080/10715760400016139
   Derek K.C., 2015, ALLERGY ASTHMA CL IM, V2015, P11
   Dhimolea E, 2010, MABS-AUSTIN, V2, P3, DOI 10.4161/mabs.2.1.10328
   Dinarello CA, 2010, CELL, V140, P935, DOI 10.1016/j.cell.2010.02.043
   Dubois H, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007709
   Formica JV, 1995, FOOD CHEM TOXICOL, V33, P1061, DOI 10.1016/0278-6915(95)00077-1
   Global Asthma Network, 2018, GLOB ASTHM REP 2018
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Gurib-Fakim Ameenah, 2006, Molecular Aspects of Medicine, V27, P1, DOI 10.1016/j.mam.2005.07.008
   Kapepula PM, 2017, NAT PROD RES, V31, P2885, DOI 10.1080/14786419.2017.1305382
   Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
   Kiboneka A., 2019, RHINOSINUSITIS, DOI [10.5772/intechopen.86964, DOI 10.5772/INTECHOPEN.86964]
   Kozloski G.A., 2020, MAT METHODS, V10, P2869, DOI [10.13070/mm.en.10.2869, DOI 10.13070/MM.EN.10.2869]
   Lee HE, 2016, SCI REP-UK, V6, DOI 10.1038/srep38622
   LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Lin X., 2017, J ADV THER MED INNOV, V2, P35
   Madouri F, 2015, J MOL CELL BIOL, V7, P351, DOI 10.1093/jmcb/mjv012
   Marciniuk D., 2013, RESP DIS WORLD REALI, V53
   McGeough MD, 2012, J IMMUNOL, V189, P2707, DOI 10.4049/jimmunol.1101737
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002
   Peltzer N, 2019, TRENDS IMMUNOL, V40, P387, DOI 10.1016/j.it.2019.03.006
   Pinkerton JW, 2017, MOL IMMUNOL, V86, P44, DOI 10.1016/j.molimm.2017.01.014
   Priem D, 2020, TRENDS IMMUNOL, V41, P421, DOI 10.1016/j.it.2020.03.001
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Reddy NS, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-128
   Rogerio A., 2017, AUSTIN J ASTHMA, V1, P1002
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Schramm DD, 1998, J NUTR BIOCHEM, V9, P560, DOI 10.1016/S0955-2863(98)00051-5
   Sogo T, 2015, BIOFACTORS, V41, P58, DOI 10.1002/biof.1201
   Sollberger G, 2014, INNATE IMMUN-LONDON, V20, P115, DOI 10.1177/1753425913484374
   Sun XJ, 2020, CYTOKINE GROWTH F R, V53, P38, DOI 10.1016/j.cytogfr.2020.04.002
   Telefo PB, 2011, J ETHNOPHARMACOL, V136, P178, DOI 10.1016/j.jep.2011.04.036
   Theofani E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101615
   Tomani JCD, 2018, J ETHNOPHARMACOL, V227, P29, DOI 10.1016/j.jep.2018.08.016
   Vasudeva N, 2008, PHARM BIOL, V46, P145, DOI 10.1080/13880200701575320
   Wanderer AA, 2008, ISR MED ASSOC J, V10, P837
   Wang HL, 2017, RSC ADV, V7, P28931, DOI 10.1039/c7ra02562a
   Ye H, 2016, EXP MOL PATHOL, V101, P341, DOI 10.1016/j.yexmp.2016.11.005
   Yemele MD, 2015, J ETHNOPHARMACOL, V160, P14, DOI 10.1016/j.jep.2014.11.017
NR 46
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD OCT
PY 2020
VL 25
IS 20
AR 4693
DI 10.3390/molecules25204693
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OM0FE
UT WOS:000585704100001
PM 33066442
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alouane, T
   Laamarti, M
   Essabbar, A
   Hakmi, M
   Bouricha, E
   Chemao-Elfihri, MW
   Kartti, S
   Boumajdi, N
   Bendani, H
   Laamarti, R
   Ghrifi, F
   Allam, L
   Aanniz, T
   Ouadghiri, M
   El Hafidi, N
   El Jaoudi, R
   Benrahma, H
   Attar, JE
   Mentag, R
   Sbabou, L
   Nejjari, C
   Amzazi, S
   Belyamani, L
   Ibrahimi, A
AF Alouane, Tarek
   Laamarti, Meriem
   Essabbar, Abdelomunim
   Hakmi, Mohammed
   Bouricha, El Mehdi
   Chemao-Elfihri, M. W.
   Kartti, Souad
   Boumajdi, Nasma
   Bendani, Houda
   Laamarti, Rokia
   Ghrifi, Fatima
   Allam, Loubna
   Aanniz, Tarik
   Ouadghiri, Mouna
   El Hafidi, Naima
   El Jaoudi, Rachid
   Benrahma, Houda
   Attar, Jalil El
   Mentag, Rachid
   Sbabou, Laila
   Nejjari, Chakib
   Amzazi, Saaid
   Belyamani, Lahcen
   Ibrahimi, Azeddine
TI Genomic Diversity and Hotspot Mutations in 30,983 SARS-CoV-2 Genomes:
   Moving Toward a Universal Vaccine for the "Confined Virus"?
SO PATHOGENS
LA English
DT Article
DE COVID-19; SARS-CoV-2; genomic diversity; divergence; hotspot mutations;
   spike protein; vaccine
ID SARS-COV; CORONAVIRUS; INHIBITION; SEQUENCE; PROGRAM; PROTEIN; GENES
AB The COVID-19 pandemic has been ongoing since its onset in late November 2019 in Wuhan, China. Understanding and monitoring the genetic evolution of the virus, its geographical characteristics, and its stability are particularly important for controlling the spread of the disease and especially for the development of a universal vaccine covering all circulating strains. From this perspective, we analyzed 30,983 complete SARS-CoV-2 genomes from 79 countries located in the six continents and collected from 24 December 2019, to 13 May 2020, according to the GISAID database. Our analysis revealed the presence of 3206 variant sites, with a uniform distribution of mutation types in different geographic areas. Remarkably, a low frequency of recurrent mutations has been observed; only 169 mutations (5.27%) had a prevalence greater than 1% of genomes. Nevertheless, fourteen non-synonymous hotspot mutations (>10%) have been identified at different locations along the viral genome; eight in ORF1ab polyprotein (in nsp2, nsp3, transmembrane domain, RdRp, helicase, exonuclease, and endoribonuclease), three in nucleocapsid protein, and one in each of three proteins: Spike, ORF3a, and ORF8. Moreover, 36 non-synonymous mutations were identified in the receptor-binding domain (RBD) of the spike protein with a low prevalence (<1%) across all genomes, of which only four could potentially enhance the binding of the SARS-CoV-2 spike protein to the human ACE2 receptor. These results along with intra-genomic divergence of SARS-CoV-2 could indicate that unlike the influenza virus or HIV viruses, SARS-CoV-2 has a low mutation rate which makes the development of an effective global vaccine very likely.
C1 [Alouane, Tarek; Laamarti, Meriem; Essabbar, Abdelomunim; Hakmi, Mohammed; Bouricha, El Mehdi; Chemao-Elfihri, M. W.; Kartti, Souad; Boumajdi, Nasma; Bendani, Houda; Ghrifi, Fatima; Allam, Loubna; Aanniz, Tarik; Ouadghiri, Mouna; El Hafidi, Naima; El Jaoudi, Rachid; Ibrahimi, Azeddine] Mohammed Vth Univ, Med Biotechnol Lab MedBiotech, Bioinova Res Ctr, Rabat Med & Pharm Sch, Rabat 10100, Morocco.
   [Laamarti, Rokia] Moroccan Fdn Sci Innovat & Res MAScIR, Ctr Med Biotechnol, Rabat 10100, Morocco.
   [Benrahma, Houda] Mohammed VI Univ Hlth Sci UM6SS, Fac Med, Casablanca 82403, Morocco.
   [Attar, Jalil El] City Ctr Hay Riad, Riad Lab, Rabat 10112, Morocco.
   [Mentag, Rachid] Natl Inst Agr Res, Reg Ctr Agr Res Rabat, Biotechnol Unit, Rabat 10101, Morocco.
   [Sbabou, Laila] Mohammed Univ, Fac Sci, Ctr Plant & Microbial Biotechnol Biodivers & Envi, Microbiol & Mol Biol Team, Rabat 10000, Morocco.
   [Nejjari, Chakib] Mohammed VI Univ Hlth Sci UM6SS, Int Sch Publ Hlth, Casablanca 82403, Morocco.
   [Amzazi, Saaid] Mohammed V Univ, Lab Human Pathol Biol, Fac Sci, Rabat 10000, Morocco.
   [Belyamani, Lahcen] Mohammed Vth Univ, Rabat Med & Pharm Sch, Mil Hosp Mohammed 5, Emergency Dept, Rabat 10112, Morocco.
RP Ibrahimi, A (corresponding author), Mohammed Vth Univ, Med Biotechnol Lab MedBiotech, Bioinova Res Ctr, Rabat Med & Pharm Sch, Rabat 10100, Morocco.
EM tarek.alouane@um5s.net.ma; m_laamarti@yahoo.com;
   abdelmounim.essabbar@um5s.net.ma; gml.hakmi@gmail.com;
   elmehdi.bouricha@gmail.com; souad.kartti@um5s.net.ma;
   nassma.boumajdi@gmail.com; hbendani.houda@gmail.com;
   r.laamarti@mascir.ma; fatima.ghrifi@um5s.net.ma;
   louabna.allam@um5s.net.ma; t.aanniz@um5s.net.ma;
   mouna.ouadghiri@um5.ac.ma; n.elhafidi@um5s.net.ma;
   r.eljaoudi@um5s.net.ma; hbenrahma@um6ss.ma; laboratoireriad@gmail.com;
   rachid.mentag@inra.ma; l.sbabou@um5s.net.ma; cnejjari@um6ss.ma;
   amzazi@gmail.com; l.belyamani@um5s.net.ma; a.ibrahimi@um5s.net.ma
OI Bouricha, El mehdi/0000-0002-6988-4647; Mentag,
   Rachid/0000-0002-2040-637X; Alouane, Tarek/0000-0003-3438-2388;
   Benrahma, Houda/0000-0002-7523-2581; CHEMAO-ELFIHRI, Mohammed
   Walid/0000-0002-8624-5839; BELYAMANI, LAHCEN/0000-0003-1464-6649;
   AANNIZ, Tarik/0000-0003-3308-2607
FU Moroccan Ministry of Higher Education and Scientific Research (COVID-19
   Program); Institute of Cancer Research (IRC)
FX This research was funded by Moroccan Ministry of Higher Education and
   Scientific Research (COVID-19 Program), and Institute of Cancer Research
   (IRC).
CR Abidha CA, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa031
   Alm E, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.32.2001410
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Chattopadhyay S, 2009, P NATL ACAD SCI USA, V106, P12412, DOI 10.1073/pnas.0906217106
   Chen JH, 2020, J MOL BIOL, V432, P5212, DOI 10.1016/j.jmb.2020.07.009
   Chen W, 2020, VIROL SIN, V35, P359, DOI 10.1007/s12250-020-00221-6
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Cuevas JM, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002251
   Deng XD, 2020, SCIENCE, V369, P582, DOI 10.1126/science.abb9263
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Ghosh S, 2020, EXCLI J, V19, P528, DOI 10.17179/excli2020-1328
   Grant Oliver C, 2020, bioRxiv, DOI 10.1101/2020.04.07.030445
   Grubaugh ND, 2020, CELL, V182, P794, DOI 10.1016/j.cell.2020.06.040
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hodgson J, 2020, NAT BIOTECHNOL, V38, P523, DOI 10.1038/d41587-020-00005-z
   Hu J., 2020, BIORXIV, DOI [10.1101/2020.06.20.161323, DOI 10.1101/2020.06.20.161323]
   Isabel Sandra, 2020, Sci Rep, V10, P14031, DOI 10.1038/s41598-020-70827-z
   Islam MR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70812-6
   Katsidzira Leolin, 2020, Clin Infect Dis, V71, P2180, DOI 10.1093/cid/ciaa552
   Kiyotani K, 2020, J HUM GENET, V65, P569, DOI 10.1038/s10038-020-0771-5
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Koyama T, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050324
   Laamarti M, 2020, LARGE SCALE GENOMIC, DOI [10.1101/2020.05.03.074567, DOI 10.1101/2020.05.03.074567]
   Lai A., 2020, MOL TRACING SARS COV, DOI [10.1101/2020.07.06.20147140, DOI 10.1101/2020.07.06.20147140]
   Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300
   LEVANDOWSKY M, 1971, NATURE, V234, P34, DOI 10.1038/234034a0
   Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li T, 2005, GENE THER, V12, P751, DOI 10.1038/sj.gt.3302479
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158
   Li XJ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb9153
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Mackenzie JS, 2020, MICROBIOL AUST, V41, P45, DOI 10.1071/MA20013
   Malik YA, 2020, MALAYS J PATHOL, V42, P3
   Loembe MM, 2020, NAT MED, V26, P999, DOI 10.1038/s41591-020-0961-x
   Noy-Porat T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18159-4
   Ortiz-Prado E, 2020, DIAGN MICR INFEC DIS, V98, DOI 10.1016/j.diagmicrobio.2020.115094
   Ou J, 2020, BIORXIV, DOI [10.1101/2020.03.15.991844, DOI 10.1101/2020.03.15.991844]
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Poterico JA, 2020, J MED VIROL, V92, P2139, DOI 10.1002/jmv.26001
   Rausch JW, 2020, P NATL ACAD SCI USA, V117, P24614, DOI 10.1073/pnas.2017726117
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802
   Sagulenko P, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vex042
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sheikh JA, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104330
   Shi Y, 2005, CELL RES, V15, P193, DOI 10.1038/sj.cr.7290286
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Stefanelli P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.13.2000305
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tang L., 2020, SARS COV 2 SPIKE PRO, DOI [10.20944/preprints202005.0407.v1., DOI 10.20944/PREPRINTS202005.0407.V1]
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   UKKONEN E, 1992, THEOR COMPUT SCI, V92, P191, DOI 10.1016/0304-3975(92)90143-4
   Uludag H, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00916
   Wang K, 2020, SARS COV 2 INVADES H, V3, P14, DOI DOI 10.1101/2020.03.14.988345
   Weng GQ, 2019, NUCLEIC ACIDS RES, V47, pW322, DOI 10.1093/nar/gkz397
   Wong AHM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01706-x
   Worobey M, 2020, SCIENCE, V370, P564, DOI 10.1126/science.abc8169
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu CJ, 2005, ANTIVIR RES, V65, P45, DOI 10.1016/j.antiviral.2004.09.005
   Xiong XL, 2020, NAT STRUCT MOL BIOL, DOI 10.1038/s41594-020-0478-5
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 65
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-0817
J9 PATHOGENS
JI Pathogens
PD OCT
PY 2020
VL 9
IS 10
AR 829
DI 10.3390/pathogens9100829
PG 19
WC Microbiology
SC Microbiology
GA OL4AB
UT WOS:000585283800001
PM 33050463
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Feikin, DR
   Widdowson, MA
   Mulholland, K
AF Feikin, Daniel R.
   Widdowson, Marc-Alain
   Mulholland, Kim
TI Estimating the Percentage of a Population Infected with SARS-CoV-2 Using
   the Number of Reported Deaths: A Policy Planning Tool
SO PATHOGENS
LA English
DT Article
DE SARS-CoV-2; coronavirus; Covid19; sero-prevalence; serology; low- and
   middle-income countries
ID SURVEILLANCE; RESPONSES; AFRICA
AB The magnitude of future waves of Covid19 in a population will depend, in part, on the percentage of that population already infected, recovered, and presumably immune. Sero-epidemiological surveys can define the prevalence of SARS-CoV-2 antibodies in various populations. However, sero-surveys are resource-intensive and methodologically challenging, limiting widespread use. We propose a relatively simple method for calculating the percentage of a population infected, which depends on the number of reported Covid19 deaths, a figure usually more reliable and less dependent on variable testing practices than the total number of reported Covid19 cases, and the infection fatality rate, a figure that is relatively stable in similar populations. The method can be applied in different sized areas, such as states, districts, or cities. Such an approach can provide useful, real-time estimates of probable population immunity in settings unable to undertake multiple sero-surveys. This method is applicable to low- and lower-middle-income country (LMIC) settings where sero-survey data will likely be limited; however, better estimates of infection fatality rates and Covid19 death counts in LMICs are needed to improve the method's accuracy. Information on the percentage of a population infected will help public health authorities in planning for future waves of Covid19, including where to most effectively deploy vaccines.
C1 [Widdowson, Marc-Alain] Inst Trop Med, B-2000 Antwerp, Belgium.
   [Mulholland, Kim] Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Melbourne, Vic 3051, Australia.
   [Mulholland, Kim] London Sch Hyg & Trop Med, London WC1E 7HT, England.
EM Drf3217@gmail.com; mawiddowson@itg.be; kim.Mulholland@lshtm.ac.uk
CR [Anonymous], ECONOMIST
   Aron J., PANDEMIC PRIMER EXCE
   Arora Rahul K, 2020, Lancet Infect Dis, DOI 10.1016/S1473-3099(20)30631-9
   Bendavid E, 2020, COVID 19 ANTIBODY SE, DOI [10.1101/2020.04.14.20062463, DOI 10.1101/2020.04.14.20062463]
   Bobrovitz N, 2020, LESSONS RAPID SYSTEM, DOI [10.1101/2020.05.10.20097451, DOI 10.1101/2020.05.10.20097451]
   Bradshaw D., REPORT WEEKLY DEATHS
   Britton T., 2020, DIS INDUCED HERD IMM, DOI [10.1101/2020.05.06.20093336, DOI 10.1101/2020.05.06.20093336]
   Bryant JE, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc6347
   Carey ME, 2020, CLIN INFECT DIS, V71, pS102, DOI 10.1093/cid/ciaa367
   Centers for Disease Control and Prevention, INT GUID COVID 19 AN
   Chakravarty S., 2020, ESTIMATING MISSING D, DOI [10.1101/2020.07.29.20164392, DOI 10.1101/2020.07.29.20164392]
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chibwana Marah Grace, 2020, medRxiv, DOI 10.1101/2020.07.30.20164970
   Chow Carson C, 2020, medRxiv, DOI 10.1101/2020.04.29.20083485
   Clark A, 2020, LANCET GLOB HEALTH, V8, P1003, DOI 10.1016/S2214-109X(20)30264-3
   Coates MM, 2019, GLOBAL HEALTH ACTION, V12, DOI 10.1080/16549716.2019.1608013
   Delius G.W., 2020, MORE PREVALENT LESS, DOI [10.1101/2020.04.19.20071811, DOI 10.1101/2020.04.19.20071811]
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Grewelle R, 2020, ESTIMATING GLOBAL IN, DOI [10.1101/2020.05.11.20098780, DOI 10.1101/2020.05.11.20098780]
   Havers F.P., 2020, SEROPREVALENCE ANTIB, DOI [10.1101/2020.06.25.20140384, DOI 10.1101/2020.06.25.20140384]
   Huang Angkana T, 2020, medRxiv, DOI 10.1101/2020.04.14.20065771
   Kenya Ministry of Health, SIT REP JUL 27
   Kenya National Bureau of Statistics, 2009 CENS OP DAT
   Kolthur-Seeheram U., MUMBAI SEROSURVEY TE
   Laxminarayan R., 2020, SCIENCE, DOI [10.11261/science.abd7672, DOI 10.11261/SCIENCE.ABD7672]
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Lourenco J, 2020, FUNDAMENTAL PRINCIPL, DOI [10.1101/2020.03.24.20042291, DOI 10.1101/2020.03.24.20042291]
   Majiya H, 2020, SEROPREVALENCE COVID, DOI [10.1101/2020.08.04.20168112, DOI 10.1101/2020.08.04.20168112]
   Meyerowitz-Katz G., 2020, SYSTEMATIC REV METAA, DOI [10.1101/2020.05.03.20089854, DOI 10.1101/2020.05.03.20089854, 10.1101/2020.05.03.20089854.]
   Modi C, 2020, DEADLY IS COVID 19 R, DOI [10.1101/2020.04.15.20067074, DOI 10.1101/2020.04.15.20067074]
   Nordling L, 2020, SCIENCE, V369, P756, DOI 10.1126/science.369.6505.756
   O'Driscoll M., 2020, AGE SPECIFIC MORTALI, DOI [10.1101/2020.08.24.20180851, DOI 10.1101/2020.08.24.20180851]
   Ojal J., 2020, REVEALING EXTENT COV, DOI [10.1101/2020.09.02.20186817, DOI 10.1101/2020.09.02.20186817]
   Payne DC, 2020, MMWR-MORBID MORTAL W, V69, P714, DOI [10.15585/mmwr.mm6923e4, 10.15585/mmwr.mm6923e4externalicon]
   Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5
   RTVE, RAD COR RES ANC MAS
   Russell Timothy W, 2020, Euro Surveill, V25, DOI 10.2807/1560-7917.ES.2020.25.12.2000256
   Seow G., 2020, LONGITUDINAL EVALUAT, DOI [10.1101/2020.07.09.20148429., 10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   Streeck HBS, 2020, INFECT FATALITY RATE, DOI [10.1101/2020.05.04.20090076, DOI 10.1101/2020.05.04.20090076]
   Stringhini S, 2020, LANCET, V396, P313, DOI 10.1016/S0140-6736(20)31304-0
   Uyoga S, 2020, SEROPREVALENCE ANTI, DOI [10.1101/2020.07.27.20162693, DOI 10.1101/2020.07.27.20162693]
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wajnberg A, 2020, HUMORAL IMMUNE RESPO, DOI [10.1101/2020.04.30.20085613, DOI 10.1101/2020.04.30.20085613]
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 46 WHO
   World Health Organization, SOL 2 GLOB SER STUD
   Worldometer, COVID19 COR PAND
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang ZQ, 2020, J INFECTION, V81, P170, DOI 10.1016/j.jinf.2020.03.018
NR 50
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-0817
J9 PATHOGENS
JI Pathogens
PD OCT
PY 2020
VL 9
IS 10
AR 838
DI 10.3390/pathogens9100838
PG 11
WC Microbiology
SC Microbiology
GA OL5NS
UT WOS:000585387100001
PM 33066231
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU McKeigue, PM
   Weir, A
   Bishop, J
   McGurnaghan, SJ
   Kennedy, S
   McAllister, D
   Robertson, C
   Wood, R
   Lone, N
   Murray, J
   Caparrotta, TM
   Smith-Palmer, A
   Goldberg, D
   McMenamin, J
   Ramsay, C
   Hutchinson, S
   Colhoun, HM
AF McKeigue, Paul M.
   Weir, Amanda
   Bishop, Jen
   McGurnaghan, Stuart J.
   Kennedy, Sharon
   McAllister, David
   Robertson, Chris
   Wood, Rachael
   Lone, Nazir
   Murray, Janet
   Caparrotta, Thomas M.
   Smith-Palmer, Alison
   Goldberg, David
   McMenamin, Jim
   Ramsay, Colin
   Hutchinson, Sharon
   Colhoun, Helen M.
CA Public Hlth Scotland COVID-19 Hlth
TI Rapid Epidemiological Analysis of Comorbidities and Treatments as risk
   factors for COVID-19 in Scotland (REACT-SCOT): A population-based
   case-control study
SO PLOS MEDICINE
LA English
DT Article
AB Background The objectives of this study were to identify risk factors for severe coronavirus disease 2019 (COVID-19) and to lay the basis for risk stratification based on demographic data and health records. Methods and findings The design was a matched case-control study. Severe COVID-19 was defined as either a positive nucleic acid test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the national database followed by entry to a critical care unit or death within 28 days or a death certificate with COVID-19 as underlying cause. Up to 10 controls per case matched for sex, age, and primary care practice were selected from the national population register. For this analysis-based on ascertainment of positive test results up to 6 June 2020, entry to critical care up to 14 June 2020, and deaths registered up to 14 June 2020-there were 36,948 controls and 4,272 cases, of which 1,894 (44%) were care home residents. All diagnostic codes from the past 5 years of hospitalisation records and all drug codes from prescriptions dispensed during the past 240 days were extracted. Rate ratios for severe COVID-19 were estimated by conditional logistic regression. In a logistic regression using the age-sex distribution of the national population, the odds ratios for severe disease were 2.87 for a 10-year increase in age and 1.63 for male sex. In the case-control analysis, the strongest risk factor was residence in a care home, with rate ratio 21.4 (95% CI 19.1-23.9,p= 8 x 10(-644)). Univariate rate ratios for conditions listed by public health agencies as conferring high risk were 2.75 (95% CI 1.96-3.88,p= 6 x 10(-9)) for type 1 diabetes, 1.60 (95% CI 1.48-1.74,p= 8 x 10(-30)) for type 2 diabetes, 1.49 (95% CI 1.37-1.61,p= 3 x 10(-21)) for ischemic heart disease, 2.23 (95% CI 2.08-2.39,p= 4 x 10(-109)) for other heart disease, 1.96 (95% CI 1.83-2.10, p = 2 x 10(-78)) for chronic lower respiratory tract disease, 4.06 (95% CI 3.15-5.23,p= 3 x 10(-27)) for chronic kidney disease, 5.4 (95% CI 4.9-5.8,p= 1 x 10(-354)) for neurological disease, 3.61 (95% CI 2.60-5.00,p= 2 x 10(-14)) for chronic liver disease, and 2.66 (95% CI 1.86-3.79,p= 7 x 10(-8)) for immune deficiency or suppression. Seventy-eight percent of cases and 52% of controls had at least one listed condition (51% of cases and 11% of controls under age 40). Severe disease was associated with encashment of at least one prescription in the past 9 months and with at least one hospital admission in the past 5 years (rate ratios 3.10 [95% CI 2.59-3.71] and 2.75 [95% CI 2.53-2.99], respectively) even after adjusting for the listed conditions. In those without listed conditions, significant associations with severe disease were seen across many hospital diagnoses and drug categories. Age and sex provided 2.58 bits of information for discrimination. A model based on demographic variables, listed conditions, hospital diagnoses, and prescriptions provided an additional 1.07 bits (C-statistic 0.804). A limitation of this study is that records from primary care were not available. Conclusions We have shown that, along with older age and male sex, severe COVID-19 is strongly associated with past medical history across all age groups. Many comorbidities beyond the risk conditions designated by public health agencies contribute to this.
   A risk classifier that uses all the information available in health records, rather than only a limited set of conditions, will more accurately discriminate between low-risk and high-risk individuals who may require shielding until the epidemic is over.
   Author summaryWhy was this study done? Most people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not become seriously ill: risk of severe or fatal disease is associated with older age, male sex, and conditions designated by public health agencies, including asthma, diabetes, and heart disease. Studies reported so far have focused on these "listed conditions" but have not examined medical records systematically to identify possible risk factors for severe coronavirus disease 2019 (COVID-19). The objectives of this study were to identify risk factors for severe COVID-19 and to lay the basis for risk stratification based on electronic health records. What did the researchers do and find? Using Scotland's capability for linking electronic health records, we report the first systematic study of the relationship of severe or fatal COVID-19 to preexisting health conditions and other risk factors. Residents in care homes were 21 times more likely to develop severe disease than people of the same age and sex not living in care homes. The conditions associated with increased risk include not only those already designated by public health agencies-asthma, diabetes, heart disease, disabling neurological disease, kidney disease-but other diagnoses that are associated with frailty and poor health such as strokes and a history of falls. In those without any listed conditions, use of prescribed drugs acting on the digestive system or nervous system is associated with increased risk of severe COVID-19. What do these findings mean? The risk to younger individuals without any recent history of hospital admission or use of prescription drugs is very low. This study lays a basis for calculating a risk score based on electronic health records for every individual in the population and using it to advise those at high risk of severe disease to shield themselves when there is a COVID-19 epidemic in their locality.
C1 [McKeigue, Paul M.; Lone, Nazir] Univ Edinburgh, Coll Med & Vet Med, Usher Inst, Edinburgh, Midlothian, Scotland.
   [McKeigue, Paul M.; Weir, Amanda; Bishop, Jen; McAllister, David; Murray, Janet; Smith-Palmer, Alison; Goldberg, David; McMenamin, Jim; Ramsay, Colin; Hutchinson, Sharon; Colhoun, Helen M.] Publ Hlth Scotland, Glasgow, Lanark, Scotland.
   [McGurnaghan, Stuart J.; Caparrotta, Thomas M.; Colhoun, Helen M.] Univ Edinburgh, Coll Med & Vet Med, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland.
   [Kennedy, Sharon; Wood, Rachael] Publ Hlth Scotland, NHS Informat Serv Div, Edinburgh, Midlothian, Scotland.
   [McAllister, David] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland.
   [Robertson, Chris] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland.
   [Hutchinson, Sharon] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland.
RP McKeigue, PM (corresponding author), Univ Edinburgh, Coll Med & Vet Med, Usher Inst, Edinburgh, Midlothian, Scotland.; McKeigue, PM (corresponding author), Publ Hlth Scotland, Glasgow, Lanark, Scotland.
EM paul.mckeigue@ed.ac.uk
OI McGurnaghan, Stuart/0000-0002-3292-4633; McAllister,
   David/0000-0003-3550-1764; Lone, Nazir I/0000-0003-2707-2779; Robertson,
   Chris/0000-0001-6848-5241; Wood, Rachael/0000-0003-4453-623X
FU Public Health Scotland; MRCMedical Research Council UK (MRC)
FX I have read the journal's policy and the authors of this manuscript have
   the following competing interests:HC receives research support and
   honoraria and is a member of advisory panels or speaker bureaus for
   Sanofi Aventis, Regeneron, Novartis, Novo-Nordisk and Eli Lilly. HC
   receives or has recently received non-binding research support from
   AstraZeneca and NovoNordisk. SH received honoraria from Gilead. TMC is a
   Diabetes UK `Sir George Alberti Clinical Research Fellow' (Grant number:
   18/0005786), although the views represented in this article are his own
   and not those of Diabetes UK. CR reports grants from Public Health
   Scotland, grants from MRC, during the conduct of the study; and Member
   of Chief Medical Officer of Scotland Scientific Advisory Group for
   COVID19 Member of SPI-M a subgroup of the UK Scientific Advisory Group
   for Epidemics Member of MHRA Advisory Group for Vaccine Safety. All
   other co-authors declare that no competing interest exists.
CR Alvarez-Madrazo S, 2016, INT J EPIDEMIOL, V45, P714, DOI 10.1093/ije/dyw060
   BRESLOW NE, 1978, AM J EPIDEMIOL, V108, P299, DOI 10.1093/oxfordjournals.aje.a112623
   Bunnik BADvan, 2020, SEGMENTATION SHIELDI
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Ghebreyesus T, 2020, WHO DIRECTOR GEN OPE
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Ho FK, 2020, MODIFIABLE NONMODIFI
   McGoogan C, 2020, TELEGRAPH
   McKeigue P, 2019, STAT METHODS MED RES, V28, P1841, DOI 10.1177/0962280218776989
   McKeigue PM, 2020, EVALUATION STRATIFY
   Niedzwiedz CL, 2020, ETHNIC SOCIOECONOMIC
   Therneau TM, 2000, STAT BIOL HEALTH
   Williamson EJ, 2020, NATURE, P1
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 0
Z9 0
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1277
EI 1549-1676
J9 PLOS MED
JI PLos Med.
PD OCT
PY 2020
VL 17
IS 10
AR e1003374
DI 10.1371/journal.pmed.1003374; 10.1371/journal.pmed.1003374.r001;
   10.1371/journal.pmed.1003374.r002; 10.1371/journal.pmed.1003374.r003;
   10.1371/journal.pmed.1003374.r004; 10.1371/journal.pmed.1003374.r005
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA OL2OF
UT WOS:000585180400003
PM 33079969
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Kishaba, T
   Maeda, A
   Nabeya, D
   Nagano, H
AF Kishaba, Tomoo
   Maeda, Akiko
   Nabeya, Daijiro
   Nagano, Hiroaki
TI Potential Predictors of Poor Prognosis among Critical COVID-19 Pneumonia
   Patients Requiring Tracheal Intubation
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE body mass index; COVID-19 pneumonia; ratio of the partial pressure of
   oxygen to fractional inspiratory oxygen concentration; SARS-CoV-2;
   tracheal intubation
ID CORONAVIRUS; PATHOGENESIS
AB Coronavirus disease 2019 (COVID-19) is a global public health concern that can be classified as mild, moderate, severe, or critical, based on disease severity. Since the identification of critical patients is crucial for developing effective management strategies, we evaluated clinical characteristics, laboratory data, treatment provided, and oxygenation to identify potential predictors of mortality among critical COVID-19 pneumonia patients. We retrospectively utilized data from seven critical patients who were admitted to our hospital during April 2020 and required mechanical ventilation. The primary endpoint was to clarify potential predictor of mortality. All patients were older than 70 years, five were men, six had hypertension, and three ultimately died. Compared with survivors, non-survivors tended to be never smokers (0 pack-years vs. 30 pack-years, p = 0.08), to have higher body mass index (31.3 kg/m(2) vs. 25.3 kg/m(2), p = 0.06), to require earlier tracheal intubation after symptom onset (2.7 days vs. 5.5 days, p = 0.07), and had fewer lymphocytes on admission (339 /mu L vs. 518 /mu L, p = 0.05). During the first week after tracheal intubation, non-survivors displayed lower values for minimum ratio of the partial pressure of oxygen to fractional inspiratory oxygen concentration (P/F ratio) (44 mmHg vs. 122 mmHg, p < 0.01) and poor response to intensive therapy compared with survivors. In summary, we show that obesity and lymphopenia could predict the severity of COVID-19 pneumonia and that the trend of lower P/F ratio during the first week of mechanical ventilation could provide useful prognostic information.
C1 [Kishaba, Tomoo; Maeda, Akiko; Nabeya, Daijiro; Nagano, Hiroaki] Okinawa Chubu Hosp, Dept Resp Med, 281 Miyazato, Uruma, Okinawa 9042293, Japan.
RP Kishaba, T (corresponding author), Okinawa Chubu Hosp, Dept Resp Med, 281 Miyazato, Uruma, Okinawa 9042293, Japan.
EM kishabatomoo@gmail.com
CR Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Breakey N., 2020, SWISS MED WEEKLY, V150
   Casimiro I, 2020, OBES SCI PRACT, V6, P215, DOI 10.1002/osp4.396
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Colafrancesco S, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102573
   Danser AHJ, 2020, HYPERTENSION, V75, P1382, DOI [10.1161/HYPERTENSIONAHA.120.15082, 10.1161/HYPERTENSIONAHA.120.15082.)]
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dixon L, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000789
   Honce R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01071
   Hong YC, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.147
   Kim GU, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.04.040
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Liu MY, 2020, J TRANSL INTERN MED, V8, P9, DOI 10.2478/jtim-2020-0003
   Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Tamara A, 2020, DIABETES METAB SYND, V14, P655, DOI 10.1016/j.dsx.2020.05.020
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 18
TC 0
Z9 0
U1 0
U2 0
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD OCT
PY 2020
VL 252
IS 2
BP 103
EP 107
DI 10.1620/tjem.252.103
PG 5
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA OL5TZ
UT WOS:000585403400002
PM 32938838
OA Other Gold
DA 2021-01-01
ER

PT J
AU Garrone, O
   Denaro, N
   Ruatta, F
   Vanella, P
   Granetto, C
   Vandone, AM
   Occelli, M
   Cauchi, C
   Ricci, V
   Fea, E
   Di Costanzo, G
   Colantonio, I
   Crosetto, N
   Merlano, MC
AF Garrone, Ornella
   Denaro, Nerina
   Ruatta, Fiorella
   Vanella, Paola
   Granetto, Cristina
   Vandone, Anna Maria
   Occelli, Marcella
   Cauchi, Carolina
   Ricci, Vincenzo
   Fea, Elena
   Di Costanzo, Gianna
   Colantonio, Ida
   Crosetto, Nicola
   Merlano, Marco C.
TI Treating patients with cancer amidst the COVID-19 pandemic: experience
   of a regional hospital in the Piedmont region in northern Italy
SO TUMORI J
LA English
DT Article
DE COVID-19; cancer; pandemic; treatment; management
ID CARE
AB Background: The coronavirus disease 2019 (COVID-19) pandemic is posing an unprecedented dilemma to oncologists worldwide, forcing them to decide whether to continue or suspend treatments in order to protect their most vulnerable patients from infection. After the first report from China, the outbreak spread rapidly worldwide. To, date no clear indications on how to treat patients with cancer with COVID-19 infection are available. Methods: We report data on 21 patients with cancer referred to a single medical oncology unit of a general hospital from mid-March to April 23, 2020. Results: Nine patients were on active cancer therapy during the infection and all stopped medical treatments. Overall 8 patients developed pneumonia and 6 patients died of COVID-19. Conclusion: The management of patients with cancer during the pandemic should be carefully balanced and discussed among oncologists and other key professionals involved in the treatment of this vulnerable group of patients, in order to balance the risk of treatment and the risk of infection.
C1 [Garrone, Ornella; Denaro, Nerina; Ruatta, Fiorella; Vanella, Paola; Granetto, Cristina; Vandone, Anna Maria; Occelli, Marcella; Cauchi, Carolina; Ricci, Vincenzo; Fea, Elena; Di Costanzo, Gianna; Colantonio, Ida; Merlano, Marco C.] Azienda Osped S Croce & Carle Osped Insegnamento, Med Oncol, VM Coppino 26, I-12100 Cuneo, Italy.
   [Crosetto, Nicola] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden.
RP Garrone, O (corresponding author), Azienda Osped S Croce & Carle Osped Insegnamento, Med Oncol, VM Coppino 26, I-12100 Cuneo, Italy.
EM ornella.garrone@gmail.com
CR Agalar C, 2020, TURK J MED SCI, V50, P578, DOI 10.3906/sag-2004-132
   Comber H, 2005, Ir Med J, V98, P238
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Kamboj M, 2009, LANCET ONCOL, V10, P589, DOI 10.1016/S1470-2045(09)70069-5
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Miyashita H, 2020, ANN ONCOL, V17, P386
   Sharma DC, 2020, LANCET ONCOL, V21, P884, DOI 10.1016/S1470-2045(20)30312-0
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Wang QX, 2020, INFECT CONT HOSP EP, V41, P772, DOI 10.1017/ice.2020.185
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
NR 10
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-8916
EI 2038-2529
J9 TUMORI J
JI Tumori J.
PD OCT
PY 2020
VL 106
IS 5
BP 427
EP 431
DI 10.1177/0300891620942313
PG 5
WC Oncology
SC Oncology
GA OK4YR
UT WOS:000584658400014
PM 32703089
DA 2021-01-01
ER

PT J
AU Wang, R
   Hozumi, Y
   Zheng, YH
   Yin, CC
   Wei, GW
AF Wang, Rui
   Hozumi, Yuta
   Zheng, Yong-Hui
   Yin, Changchuan
   Wei, Guo-Wei
TI Host Immune Response Driving SARS-CoV-2 Evolution
SO VIRUSES-BASEL
LA English
DT Article
DE SARS-CoV-2; COVID-19; APOBEC; ADAR; gene editing
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS; MECHANISMS; OUTBREAK
AB The transmission and evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of paramount importance in controlling and combating the coronavirus disease 2019 (COVID-19) pandemic. Currently, over 15,000 SARS-CoV-2 single mutations have been recorded, which have a great impact on the development of diagnostics, vaccines, antibody therapies, and drugs. However, little is known about SARS-CoV-2's evolutionary characteristics and general trend. In this work, we present a comprehensive genotyping analysis of existing SARS-CoV-2 mutations. We reveal that host immune response via APOBEC and ADAR gene editing gives rise to near 65% of recorded mutations. Additionally, we show that children under age five and the elderly may be at high risk from COVID-19 because of their overreaction to the viral infection. Moreover, we uncover that populations of Oceania and Africa react significantly more intensively to SARS-CoV-2 infection than those of Europe and Asia, which may explain why African Americans were shown to be at increased risk of dying from COVID-19, in addition to their high risk of COVID-19 infection caused by systemic health and social inequities. Finally, our study indicates that for two viral genome sequences of the same origin, their evolution order may be determined from the ratio of mutation type, C > T over T > C.
C1 [Wang, Rui; Hozumi, Yuta; Wei, Guo-Wei] Michigan State Univ, Dept Math, E Lansing, MI 48824 USA.
   [Zheng, Yong-Hui] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.
   [Yin, Changchuan] Univ Illinois, Dept Math Stat & Comp Sci, Chicago, IL 60607 USA.
   [Wei, Guo-Wei] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
   [Wei, Guo-Wei] Michigan State Univ, Dept Elect & Comp Engn, E Lansing, MI 48824 USA.
RP Wei, GW (corresponding author), Michigan State Univ, Dept Math, E Lansing, MI 48824 USA.; Wei, GW (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.; Wei, GW (corresponding author), Michigan State Univ, Dept Elect & Comp Engn, E Lansing, MI 48824 USA.
EM wangru25@msu.edu; hozumiyu@msu.edu; zhengyo@msu.edu; cyin1@uic.edu;
   weig@msu.edu
OI Zheng, Yong-Hui/0000-0002-1098-7385; Wei, Guowei/0000-0001-8132-5998
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM126189, AI145504]; NSFNational
   Science Foundation (NSF) [DMS-1721024, DMS-1761320, IIS1900473];
   MICHIGAN ECONOMIC DEVELOPMENT CORPORATION; GEORGE MASON UNIVERSITY
   [PD45722]; BRISTOL-MYERS SQUIBBBristol-Myers Squibb; PFIZERPfizer
FX This research was funded by NIH grants number GM126189 and AI145504, NSF
   grants number DMS-1721024, DMS-1761320, and IIS1900473, MICHIGAN
   ECONOMIC DEVELOPMENT CORPORATION, GEORGE MASON UNIVERSITY award PD45722,
   BRISTOL-MYERS SQUIBB, and PFIZER.
CR Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   [Anonymous], 2020, 193 WHO
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bar-On YM, 2020, ELIFE, V9, DOI 10.7554/eLife.57309
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Blackshields G, 2010, ALGORITHM MOL BIOL, V5, DOI 10.1186/1748-7188-5-21
   Chen JH, 2020, J MOL BIOL, V432, P5212, DOI 10.1016/j.jmb.2020.07.009
   Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163
   Di Giorgio S, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb5813
   Drexler JF, 2010, J VIROL, V84, P11336, DOI 10.1128/JVI.00650-10
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Gonzales-van Horn SR, 2017, CELL HOST MICROBE, V21, P661, DOI 10.1016/j.chom.2017.05.008
   Grubaugh ND, 2020, CELL, V182, P794, DOI 10.1016/j.cell.2020.06.040
   Harris RS, 2015, VIROLOGY, V479, P131, DOI 10.1016/j.virol.2015.03.012
   Hewagama A, 2009, GENES IMMUN, V10, P509, DOI 10.1038/gene.2009.12
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu D, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0155-5
   Khan KA, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.200636
   Klein SL, 2012, BIOESSAYS, V34, P1050, DOI 10.1002/bies.201200099
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Liu MC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04273-x
   Matyasek R, 2020, GENES-BASEL, V11, DOI 10.3390/genes11070761
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Nishikura K, 2016, NAT REV MOL CELL BIO, V17, P83, DOI 10.1038/nrm.2015.4
   Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702
   Samuel CE, 2011, VIROLOGY, V411, P180, DOI 10.1016/j.virol.2010.12.004
   Sanjuan R, 2016, CELL MOL LIFE SCI, V73, P4433, DOI 10.1007/s00018-016-2299-6
   Sevajol M, 2014, VIRUS RES, V194, P90, DOI 10.1016/j.virusres.2014.10.008
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   SIEVERS F, 2014, CURR PROTOC BIOINFOR, V48, P3, DOI DOI 10.1002/0471250953.BI0313S48
   Simmonds P, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00408-20.
   Smith HC, 2012, SEMIN CELL DEV BIOL, V23, P258, DOI 10.1016/j.semcdb.2011.10.004
   Soding J, 2005, BIOINFORMATICS, V21, P951, DOI 10.1093/bioinformatics/bti125
   Song PP, 2020, CLIN CHIM ACTA, V509, P280, DOI 10.1016/j.cca.2020.06.017
   Stefl S, 2013, J MOL BIOL, V425, P3919, DOI 10.1016/j.jmb.2013.07.014
   SUN DT, 2020, GENOMICS, DOI DOI 10.1016/J.YGENO.2020.09.028
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Wang Rui, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00501
   Wang YQ, 2018, J THORAC DIS, V10, pS2260, DOI 10.21037/jtd.2018.03.80
   Wu F., 2020, NEUTRALIZING ANTIBOD, DOI [10.2139/ssrn.3566211, DOI 10.2139/SSRN.3566211]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao XD, 2003, BIOCHEM BIOPH RES CO, V312, P1159, DOI 10.1016/j.bbrc.2003.11.054
   Yin CC, 2020, GENOMICS, V112, P3588, DOI 10.1016/j.ygeno.2020.04.016
   Yue P, 2005, J MOL BIOL, V353, P459, DOI 10.1016/j.jmb.2005.08.020
   Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 48
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD OCT
PY 2020
VL 12
IS 10
AR 1095
DI 10.3390/v12101095
PG 20
WC Virology
SC Virology
GA OL5OB
UT WOS:000585388000001
PM 32992592
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lin, CH
   Yang, CY
   Ou, SC
   Wang, ML
   Lo, CY
   Tsai, TL
   Wu, HY
AF Lin, Ching-Hung
   Yang, Cheng-Yao
   Ou, Shan-Chia
   Wang, Meilin
   Lo, Chen-Yu
   Tsai, Tsung-Lin
   Wu, Hung-Yi
TI The Impacts of Antivirals on the Coronavirus Genome Structure and
   Subsequent Pathogenicity, Virus Fitness and Antiviral Design
SO BIOMEDICINES
LA English
DT Article
DE coronavirus; genome structure; pathogenicity; remdesivir; innate
   immunity; antiviral drug; spike protein
ID MUTATIONAL ROBUSTNESS; CONFERRING RESISTANCE; SPIKE PROTEIN; EVOLUTION;
   OSELTAMIVIR; REMDESIVIR; VIRULENCE; RESPONSES; VARIANTS; CAPACITY
AB With the global threat of SARS-CoV-2, much effort has been focused on treatment and disease control. However, how coronaviruses react to the treatments and whether the surviving viruses have altered their characteristics are also unanswered questions with medical importance. To this end, bovine coronavirus (BCoV), which is in the same genus as SARS-CoV-2, was used as a test model and the findings were as follows. With the treatment of antiviral remdesivir, the selected BCoV variant with an altered genome structure developed resistance, but its pathogenicity was not increased in comparison to that of wild type (wt) BCoV. Under the selection pressure of innate immunity, the genome structure was also altered; however, neither resistance developed nor pathogenicity increased for the selected BCoV variant. Furthermore, both selected BCoV variants showed a better efficiency in adapting to alternative host cells than wt BCoV. In addition, the previously unidentified feature that the spike protein was a common target for mutations under different antiviral treatments might pose a problem for vaccine development because spike protein is a common target for antibody and vaccine designs. The findings derived from this fundamental research may contribute to the disease control and treatments against coronaviruses, including SARS-CoV-2.
C1 [Lin, Ching-Hung; Yang, Cheng-Yao; Lo, Chen-Yu; Tsai, Tsung-Lin; Wu, Hung-Yi] Natl Chung Hsing Univ, Coll Vet Med, Grad Inst Vet Pathobiol, Taichung 40227, Taiwan.
   [Ou, Shan-Chia] Natl Chung Hsing Univ, Coll Vet Med, Grad Inst Microbiol & Publ Hlth, Taichung 40227, Taiwan.
   [Wang, Meilin] Chung Shan Med Univ, Dept Microbiol & Immunol, Taichung 40201, Taiwan.
RP Wu, HY (corresponding author), Natl Chung Hsing Univ, Coll Vet Med, Grad Inst Vet Pathobiol, Taichung 40227, Taiwan.
EM tw23whale@hotmail.com; yangchengyao@nchu.edu.tw;
   scou@dragon.nchu.edu.tw; wml@csmu.edu.tw; axfbji7917@gmail.com;
   windtaker10@msn.com; hwu2@dragon.nchu.edu.tw
OI Tsai, Tsung Lin/0000-0002-7585-0574; Wu, Hung-Yi/0000-0002-1260-6259;
   Yang, Cheng-Yao/0000-0002-8694-9561; Ou, Shan-Chia/0000-0002-0857-9008;
   Lin, Ching-Hung/0000-0003-3880-1148
FU Ministry of Science and Technology (MOST), R.O.C.
FX This work was supported by grants 106-2313-B-005-046-MY3 and
   109-2313-B-005-013-MY3 from the Ministry of Science and Technology
   (MOST), R.O.C. (https://www.most.gov.tw/?l=ch). Funding for open access
   charge: Ministry of Science and Technology (MOST), R.O.C.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Alonso M, 2011, J CLIN VIROL, V51, P150, DOI 10.1016/j.jcv.2011.03.009
   Amirian ES, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100128
   Baz M, 2010, J INFECT DIS, V201, P740, DOI 10.1086/650464
   BEAN WJ, 1992, J VIROL, V66, P1129, DOI 10.1128/JVI.66.2.1129-1138.1992
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Brunelle MN, 2005, HEPATOLOGY, V41, P1391, DOI 10.1002/hep.20723
   Cahn P, 2010, J ANTIMICROB CHEMOTH, V65, P213, DOI 10.1093/jac/dkp422
   Cavanagh D, 1997, AVIAN PATHOL, V26, P63, DOI 10.1080/03079459708419194
   Chen B, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0190-2
   Chen H, 2016, MOL MED REP, V13, P2689, DOI 10.3892/mmr.2016.4848
   Chotiyaputta W, 2012, J VIRAL HEPATITIS, V19, P205, DOI 10.1111/j.1365-2893.2011.01494.x
   Croteau G, 1997, J VIROL, V71, P1089, DOI 10.1128/JVI.71.2.1089-1096.1997
   de Visser JAGM, 2003, EVOLUTION, V57, P1959, DOI 10.1554/02-750R
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Domingo E, 2002, J VIROL, V76, P463, DOI 10.1128/JVI.76.1.463-465.2002
   DOMINGO E, 1978, CELL, V13, P735, DOI 10.1016/0092-8674(78)90223-4
   Draghi JA, 2010, NATURE, V463, P353, DOI 10.1038/nature08694
   Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910
   EIGEN M, 1993, SCI AM, V269, P42, DOI 10.1038/scientificamerican0793-42
   Ellis S, 2018, J VIROL, V92, DOI 10.1128/JVI.01473-18
   Falkowska E, 2007, J VIROL, V81, P8072, DOI 10.1128/JVI.00459-07
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hulswit RJG, 2019, P NATL ACAD SCI USA, V116, P2681, DOI 10.1073/pnas.1809667116
   Jiang M, 2013, ANTIMICROB AGENTS CH, V57, P6236, DOI 10.1128/AAC.01578-13
   Keep S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020330
   King A. M., 2012, VIRUS TAXONOMY CLASS
   KING B, 1982, J VIROL, V42, P700, DOI 10.1128/JVI.42.2.700-707.1982
   Koev G, 2008, EXPERT OPIN INV DRUG, V17, P303, DOI [10.1517/13543784.17.3.303, 10.1517/13543784.17.3.303 ]
   Kossyvakis A, 2017, EUR J CLIN MICROBIOL, V36, P361, DOI 10.1007/s10096-016-2809-3
   LAPPS W, 1987, VIROLOGY, V157, P47, DOI 10.1016/0042-6822(87)90312-6
   Lauring AS, 2012, CELL HOST MICROBE, V12, P623, DOI 10.1016/j.chom.2012.10.008
   Loo YM, 2007, J INTERF CYTOK RES, V27, P697
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   McKinley ET, 2008, VACCINE, V26, P1274, DOI 10.1016/j.vaccine.2008.01.006
   Montville R, 2005, PLOS BIOL, V3, P1939, DOI 10.1371/journal.pbio.0030381
   Renzette N, 2014, J VIROL, V88, P272, DOI 10.1128/JVI.01067-13
   Robinson M, 2011, P NATL ACAD SCI USA, V108, P10290, DOI 10.1073/pnas.1101515108
   Schmolke M, 2010, CELL MICROBIOL, V12, P873, DOI 10.1111/j.1462-5822.2010.01475.x
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007789
   Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218
   TOMPKINS WA, 1974, J NATL CANCER I, V52, P1101, DOI 10.1093/jnci/52.4.1101
   Triana-Baltzer GB, 2011, J ANTIMICROB CHEMOTH, V66, P15, DOI 10.1093/jac/dkq387
   Tsai TL, 2018, J VIROL, V92, DOI 10.1128/JVI.01162-18
   van der Vries E, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003343
   VAUTHEROT JF, 1981, J GEN VIROL, V56, P451, DOI 10.1099/0022-1317-56-2-451
   Von Hahn T, 2007, GASTROENTEROLOGY, V132, P667, DOI 10.1053/j.gastro.2006.12.008
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Wu HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070548
   Wu HY, 2010, P NATL ACAD SCI USA, V107, P12257, DOI 10.1073/pnas.1000378107
   Wu HY, 2006, J VIROL, V80, P2183, DOI 10.1128/JVI.80.5.2183-2193.2006
   Xiao YH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00354-5
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 58
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD OCT
PY 2020
VL 8
IS 10
AR 376
DI 10.3390/biomedicines8100376
PG 18
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OK2HT
UT WOS:000584472400001
PM 32987828
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dee, EC
   Mahal, BA
   Arega, MA
   D'Amico, AV
   Mouw, KW
   Nguyen, PL
   Muralidhar, V
AF Dee, Edward Christopher
   Mahal, Brandon A.
   Arega, Melaku A.
   D'Amico, Anthony V.
   Mouw, Kent W.
   Nguyen, Paul L.
   Muralidhar, Vinayak
TI Relative Timing of Radiotherapy and Androgen Deprivation for Prostate
   Cancer and Implications for Treatment During the COVID-19 Pandemic
SO JAMA ONCOLOGY
LA English
DT Letter
AB This cohort study uses National Cancer Database data from 2004 to 2014 to examine the association between overall survival and timing of radiotherapy relative to androgen deprivation therapy in patients with prostate cancer.
C1 [Dee, Edward Christopher; D'Amico, Anthony V.; Mouw, Kent W.; Nguyen, Paul L.; Muralidhar, Vinayak] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
   [Dee, Edward Christopher; Arega, Melaku A.] Harvard Med Sch, Boston, MA 02115 USA.
   [Mahal, Brandon A.] Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA.
   [Mahal, Brandon A.] Univ Miami, Sylvester Comprehens Canc Ctr, Off Community Outreach & Engagement, Miami, FL USA.
RP Muralidhar, V (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
EM vmuralidhar@bwh.harvard.edu
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   DevelopmentUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [R21 HD095240-01]
FX The Eunice Kennedy Shriver National Institute of Child Health and Human
   Development (R21 HD095240-01) funded this work.
CR DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504
   Malone S, 2020, J CLIN ONCOL, V38, P593, DOI 10.1200/JCO.19.01904
   Mohler JL, 2019, J NATL COMPR CANC NE, V17, P479, DOI 10.6004/jnccn.2019.0023
   Roach M, 2018, LANCET ONCOL, V19, P1504, DOI 10.1016/S1470-2045(18)30528-X
   Winchester DP, 2010, ANN SURG ONCOL, V17, P4, DOI 10.1245/s10434-009-0771-3
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2437
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD OCT
PY 2020
VL 6
IS 10
BP 1630
EP 1632
DI 10.1001/jamaoncol.2020.3545
PG 3
WC Oncology
SC Oncology
GA OI3VB
UT WOS:000583209400022
PM 32789489
OA Bronze
DA 2021-01-01
ER

PT J
AU Karlsson, JOG
   Jynge, P
   Ignarro, LJ
AF Karlsson, Jan Olof G.
   Jynge, Per
   Ignarro, Louis J.
TI May Mangafodipir or Other SOD Mimetics Contribute to Better Care in
   COVID-19 Patients?
SO ANTIOXIDANTS
LA English
DT Article
DE mangafodipir; inflammation; SARS-CoV-2; COVID-19; MnSOD-mimetic; nitric
   oxide; superoxide
ID NITRIC-OXIDE
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by massive inflammation of the arterial endothelium accompanied by vasoconstriction and widespread pulmonary micro thrombi. As a result, due to the destruction of nitric oxide ((NO)-N-center dot) by inflammatory superoxide (O-2(center dot-)), pulmonary (NO)-N-center dot concentration ceases, resulting in uncontrolled platelet aggregation and massive thrombosis, which kills the patients. Introducing (NO)-N-center dot by inhalation (INO) may replace the loss of endothelium-derived (NO)-N-center dot. The first results from clinical trials with INO in SARS-CoV-2 patients show a rapid and sustained improvement in cardiopulmonary function and decreased inflammation. An ongoing phase III study is expected to confirm the method's efficacy. INO may hence become a first line treatment in SARS-CoV-2 patients. However, due to the rapid inactivation of (NO)-N-center dot by deoxyhemoglobin to nitrate, pulmonary administration of (NO)-N-center dot will not protect remote organs. Another INO-related pharmacological approach to protect SARS-CoV-2 patients from developing life-threatening disease is to inhibit the O-2(center dot-)-driven destruction of (NO)-N-center dot by neutralizing inflammatory O-2(center dot-). By making use of low molecular weight compounds that mimic the action of the enzyme manganese superoxide dismutase (MnSOD). The MnSOD mimetics of the so-called porphyrin type (e.g., AEOL 10150), salen type (e.g., EUK-8) and cyclic polyamine type (e.g., M40419, today known as GC4419 and avasopasem manganese) have all been shown to positively affect the inflammatory response in lung epithelial cells in preclinical models of chronic obstructive pulmonary disease. The Manganese diPyridoxyL EthylDiamine (MnPLED)-type mangafodipir (manganese dipyridoxyl diphosphate-MnDPDP), a magnetic resonance imaging (MRI) contrast agent that possesses MnSOD mimetic activity, has shown promising results in various forms of inflammation, in preclinical as well as clinical settings. Intravenously administration of mangafodipir will, in contrast to INO, reach remote organs and may hence become an important supplement to INO. From the authors' viewpoint, it appears logical to test mangafodipr in COVID-19 patients at risk of developing life-threatening SARS-CoV-2. Five days after submission of the current manuscript, Galera Pharmaceuticals Inc. announced the dosing of the first patient in a randomized, double-blind pilot phase II clinical trial with GC4419 for COVID-19. The study was first posted on ClinicalTrials.gov (Identifier: NCT04555096) 18 September 2020.
C1 [Karlsson, Jan Olof G.] Linkoping Univ, Div Drug Res Pharmacol, SE-58183 Linkoping, Sweden.
   [Jynge, Per] Gjovik Hosp, Innlandet Trust Hosp, NO-2819 Gjovik, Norway.
   [Ignarro, Louis J.] Univ Calif Los Angeles, Sch Med, Dept Pharmacol, 264 El Camino Dr, Beverly Hills, CA 90212 USA.
RP Karlsson, JOG (corresponding author), Linkoping Univ, Div Drug Res Pharmacol, SE-58183 Linkoping, Sweden.
EM janolof.karlsson@ktias.com; per.jynge.ha@gmail.com; lignarro@gmail.com
FU Medical Research Council of Southeast Sweden [FORSS-85191];
   Karlsson-Tuner Invest AS, Norway
FX This work was supported by grants from the Medical Research Council of
   Southeast Sweden (FORSS-85191) and Karlsson-Tuner Invest AS, Norway.
CR Alexandre J, 2006, J NATL CANCER I, V98, P236, DOI 10.1093/jnci/djj049
   Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
   Bedda S, 2003, J HEPATOL, V39, P765, DOI 10.1016/S0168-8278(03)00325-8
   Chen LN, 2004, CLIN INFECT DIS, V39, P1531, DOI 10.1086/425357
   Giesecke J, 2020, LANCET, V395, pE98, DOI 10.1016/S0140-6736(20)31035-7
   Ignarro LJ, 2019, BRIT J PHARMACOL, V176, P131, DOI 10.1111/bph.14540
   Karlsson JOG, 2015, DRUG DISCOV TODAY, V20, P411, DOI 10.1016/j.drudis.2014.11.008
   Morrison EE, 2019, EBIOMEDICINE, V46, P423, DOI 10.1016/j.ebiom.2019.07.013
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Safaee Fakhr Bijan, 2020, Obstet Gynecol, V136, P1109, DOI 10.1097/AOG.0000000000004128
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 13
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD OCT
PY 2020
VL 9
IS 10
AR 971
DI 10.3390/antiox9100971
PG 4
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA OJ6LE
UT WOS:000584069500001
PM 33050459
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Longhitano, Y
   Racca, F
   Zanza, C
   Muncinelli, M
   Guagliano, A
   Peretti, E
   Minerba, AC
   Mari, M
   Boverio, R
   Salio, M
   Chichino, G
   Franceschi, F
   Piccioni, A
   Abenavoli, L
   Salvini, M
   Artico, M
AF Longhitano, Yaroslava
   Racca, Fabrizio
   Zanza, Christian
   Muncinelli, Marina
   Guagliano, Alberto
   Peretti, Elisa
   Minerba, Anna Chiara
   Mari, Marta
   Boverio, Riccardo
   Salio, Mario
   Chichino, Guido
   Franceschi, Francesco
   Piccioni, Andrea
   Abenavoli, Ludovico
   Salvini, Mauro
   Artico, Marco
TI Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with
   Three Different Anticoagulation Protocols: Prospective Observational
   Study
SO BIOLOGY-BASEL
LA English
DT Article
DE Covid-19; acute respiratory failure; deep vein thrombosis; coagulopathy;
   venous thromboembolism; thromboprophylaxis
ID DEEP-VEIN THROMBOSIS; COVID-19; PNEUMONIA; BURDEN
AB Simple Summary
   The aims of this study are: (1) to analyze the risk of vein thrombosis and pulmonary embolism in patients affected by pneumonia due to Covid-19; (2) to evaluate conditions that could increase this risk; (3) to verify the efficacy of different doses of antithrombotic drugs to prevent these life-threatening complications. Seventy-four patients were enrolled (44 men and 30 women, average age 68.6). All of them were screened with lower limb ultrasound. Laboratory analyses including D-dimers were tested the same day. In case of clinical suspicion of pulmonary embolism, they performed a CT pulmonary angiography. A total of 28.4% (21 patients) were diagnosed with deep vein thrombosis or pulmonary embolism. This finding confirms that these patients were at increased risk of venous thromboembolism, as already reported from other studies. Mechanical ventilation, higher d-dimer levels, longer length of hospitalization and admission to intensive care unit showed to be statistically associated with thromboembolic events. In addition, the study showed that an intermediate or high dose of anticoagulation did not decrease the risk of thromboembolic events compared to lower doses. On the other hand, six patients reported severe bleeding that could be caused by higher doses of anticoagulant drugs.
   The purpose of this study is to assess thrombotic risk in CoViD-19/pneumonia patients with acute respiratory failure and to compare populations treated with three different antithrombotic prophylaxis protocols. The primary outcome is to analyze the prevalence of thrombotic events in hospitalized patients, while the secondary outcome is to analyze the correlation between different anticoagulation targets with thrombotic events. All patients referred to our hospital for acute respiratory failure due to COVID-19 pneumonia between 18 and 31 May 2020 were included. Seventy-four patients were enrolled (44 men and 30 women, average age 68.6). Diagnosis of venous thromboembolism was made in 21 cases (28.4%) and thrombotic events were associated with positive pressure ventilation support (p = 0.024) and hospitalization in ICU (p < 0.0001). These patients presented higher levels of D-dimer (p < 0.0001) and their hospital length of stay was >16 days longer. Forty-seven out of 74 patients (63.5%) received intermediate or therapeutic dose of anticoagulation, while twenty-seven patients (34.5%) received standard antithrombotic prophylaxis. The analysis showed that an intermediate or therapeutic dose of anticoagulation did not decrease the prevalence of thrombotic events. On the other hand, six patients reported severe hemorrhagic complications. Despite intermediate or therapeutic-dose of anticoagulation, a high number of patients with acute respiratory failure secondary to COVID-19 developed thrombotic complications.
C1 [Longhitano, Yaroslava; Racca, Fabrizio; Zanza, Christian] Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Dept Anesthesiol & Crit Care Med, I-15121 Alessandria, Italy.
   [Zanza, Christian] Pietro & Michele Ferrero Hosp, Dept Anesthesia Crit Care & Emergency Med, I-12051 Verduno Alba, Italy.
   [Zanza, Christian; Franceschi, Francesco; Piccioni, Andrea] IRCCS Catholic Univ Sacred Heart, Dept Anesthesiol & Emergency Sci, Policlin Gemelli, I-00168 Rome, Italy.
   [Muncinelli, Marina; Guagliano, Alberto; Peretti, Elisa; Minerba, Anna Chiara; Mari, Marta; Salvini, Mauro] Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Dept Vasc Surg, I-15121 Alessandria, Italy.
   [Boverio, Riccardo] Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Dept Emergency Med, I-15121 Alessandria, Italy.
   [Salio, Mario; Chichino, Guido] Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Dept Internal Med, I-15121 Alessandria, Italy.
   [Abenavoli, Ludovico] Magnae Grecia Univ Catanzaro, Dept Hlth Sci, I-88100 Catanzaro, Italy.
   [Artico, Marco] Sapienza Univ Rome, Dept Sensory Organs, Policlin Umberto 1, I-00155 Rome, Italy.
RP Zanza, C (corresponding author), Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Dept Anesthesiol & Crit Care Med, I-15121 Alessandria, Italy.; Zanza, C (corresponding author), Pietro & Michele Ferrero Hosp, Dept Anesthesia Crit Care & Emergency Med, I-12051 Verduno Alba, Italy.; Zanza, C (corresponding author), IRCCS Catholic Univ Sacred Heart, Dept Anesthesiol & Emergency Sci, Policlin Gemelli, I-00168 Rome, Italy.
EM lon.yaro@gmail.com; fracca@ospedale.al.it; christian.zanza@live.it;
   mmuncinelli@ospedale.al.it; aguagliano@ospedale.al.it;
   elisa.peretti@libero.it; aminerba@ospedale.al.it;
   marta.mari.88@alice.it; rboverio@ospedale.al.it;
   mario.salio@ospedale.al.it; guido.chichino@ospedale.al.it;
   francesco.franceschi@unicatt.it; andrea.piccioni@policlinicogemelli.it;
   l.abenavoli@unicz.it; msalvini@ospedale.al.it; marco.artico@uniroma1.it
OI MONTEBIANCO ABENAVOLI, Ludovico/0000-0002-5922-1524; Mari,
   Marta/0000-0001-9372-7767; Longhitano, Yaroslava/0000-0001-8831-1361
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Artifoni M, 2020, J THROMB THROMBOLYS, V50, P211, DOI 10.1007/s11239-020-02146-z
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Caprini JA, 2005, DM-DIS MON, V51, P70, DOI 10.1016/j.disamonth.2005.02.003
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chi G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082489
   Chi G, 2019, INTENS CARE MED, V45, P477, DOI 10.1007/s00134-019-05565-6
   Chi G, 2017, THROMB HAEMOSTASIS, V117, P2389, DOI 10.1160/TH17-08-0538
   Ciavarella A, 2020, THROMB RES, V191, P29, DOI 10.1016/j.thromres.2020.04.023
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Demelo-Rodriguez P, 2020, THROMB RES, V192, P23, DOI 10.1016/j.thromres.2020.05.018
   Geerts W, 2002, J CRIT CARE, V17, P95, DOI 10.1053/jcrc.2002.33941
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kaplan D, 2015, CHEST, V148, P1224, DOI 10.1378/chest.15-0287
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Longhitano Y, 2020, EUR REV MED PHARMACO, V24, P9154, DOI 10.26355/eurrev_202009_22864
   Marongiu F, 2020, J THROMB HAEMOST, V18, P1511, DOI 10.1111/jth.14818
   Marongiu F, 2019, SEMIN THROMB HEMOST, V45, P778, DOI 10.1055/s-0039-1696942
   MCKELVIE PA, 1994, MED J AUSTRALIA, V160, P127, DOI 10.5694/j.1326-5377.1994.tb126557.x
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Nahum J, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10478
   Parke RL, 2011, RESP CARE, V56, P1151, DOI 10.4187/respcare.01106
   Patel R, 2005, J CRIT CARE, V20, P341, DOI 10.1016/j.jcrc.2005.09.014
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Porfidia A, 2020, J THROMB THROMBOLYS, V50, P68, DOI 10.1007/s11239-020-02125-4
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Santoliquido A, 2020, J THROMB HAEMOST, V18, P2358, DOI 10.1111/jth.14992
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vitacca M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00632-2020
   White D, 2020, J THROMB THROMBOLYS, V50, P287, DOI 10.1007/s11239-020-02145-0
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Zhai ZG, 2020, THROMB HAEMOSTASIS, V120, P937, DOI 10.1055/s-0040-1710019
NR 40
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-7737
J9 BIOLOGY-BASEL
JI Biology-Basel
PD OCT
PY 2020
VL 9
IS 10
AR 310
DI 10.3390/biology9100310
PG 12
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA OJ8SD
UT WOS:000584222800001
PM 32987902
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sattayaprasert, P
   Vasireddi, SK
   Bektik, E
   Jeon, O
   Hajjiri, M
   Mackall, JA
   Moravec, CS
   Alsberg, E
   Fu, JD
   Laurita, KR
AF Sattayaprasert, Prasongchai
   Vasireddi, Sunil K.
   Bektik, Emre
   Jeon, Oju
   Hajjiri, Mohammad
   Mackall, Judith A.
   Moravec, Christine S.
   Alsberg, Eben
   Fu, Jidong
   Laurita, Kenneth R.
TI Human Cardiac Mesenchymal Stem Cells Remodel in Disease and Can Regulate
   Arrhythmia Substrates
SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
LA English
DT Article
DE arrhythmia; COVID-19; insulin-like growth factor 1; mesenchymal stem
   cell; interleukin-6
ID HEART-FAILURE; VENTRICULAR MYOCYTES; STROMAL CELLS; INTERLEUKIN-6;
   MEDIATORS; MECHANISM; ALTERNANS; CYTOKINES; COVID-19; THERAPY
AB Background:
   The mesenchymal stem cell (MSC), known to remodel in disease and have an extensive secretome, has recently been isolated from the human heart. However, the effects of normal and diseased cardiac MSCs on myocyte electrophysiology remain unclear. We hypothesize that in disease the inflammatory secretome of cardiac human MSCs (hMSCs) remodels and can regulate arrhythmia substrates.
   Methods:
   hMSCs were isolated from patients with or without heart failure from tissue attached to extracted device leads and from samples taken from explanted/donor hearts. Failing hMSCs or nonfailing hMSCs were cocultured with normal human cardiac myocytes derived from induced pluripotent stem cells. Using fluorescent indicators, action potential duration, Ca2+ alternans, and spontaneous calcium release (SCR) incidence were determined.
   Results:
   Failing and nonfailing hMSCs from both sources exhibited similar trilineage differentiation potential and cell surface marker expression as bone marrow hMSCs. Compared with nonfailing hMSCs, failing hMSCs prolonged action potential duration by 24% (P0.001, n=15), increased Ca2+ alternans by 300% (P0.001, n=18), and promoted spontaneous calcium release activity (n=14, P0.013) in human cardiac myocytes derived from induced pluripotent stem cells. Failing hMSCs exhibited increased secretion of inflammatory cytokines IL (interleukin)-1 beta (98%, P0.0001) and IL-6 (460%, P0.02) compared with nonfailing hMSCs. IL-1 beta or IL-6 in the absence of hMSCs prolonged action potential duration but only IL-6 increased Ca2+ alternans and promoted spontaneous calcium release activity in human cardiac myocytes derived from induced pluripotent stem cells, replicating the effects of failing hMSCs. In contrast, nonfailing hMSCs prevented Ca2+ alternans in human cardiac myocytes derived from induced pluripotent stem cells during oxidative stress. Finally, nonfailing hMSCs exhibited >25x higher secretion of IGF (insulin-like growth factor)-1 compared with failing hMSCs. Importantly, IGF-1 supplementation or anti-IL-6 treatment rescued the arrhythmia substrates induced by failing hMSCs.
   Conclusions:
   We identified device leads as a novel source of cardiac hMSCs. Our findings show that cardiac hMSCs can regulate arrhythmia substrates by remodeling their secretome in disease. Importantly, therapy inhibiting (anti-IL-6) or mimicking (IGF-1) the cardiac hMSC secretome can rescue arrhythmia substrates.
C1 [Sattayaprasert, Prasongchai; Vasireddi, Sunil K.; Hajjiri, Mohammad; Laurita, Kenneth R.] Case Western Reserve Univ, Heart & Vasc Res Ctr, MetroHlth Campus,2500 MetroHlth Dr,6th Floor, Cleveland, OH 44109 USA.
   [Bektik, Emre] Harvard Med Sch, Boston Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
   [Jeon, Oju; Alsberg, Eben] Univ Illinois, Dept Biomed Engn, Chicago, IL USA.
   [Alsberg, Eben] Univ Illinois, Dept Orthopaed, Chicago, IL USA.
   [Alsberg, Eben] Univ Illinois, Dept Pharmacol, Chicago, IL USA.
   [Alsberg, Eben] Univ Illinois, Dept Mech & Ind Engn, Chicago, IL USA.
   [Mackall, Judith A.] Univ Hosp Cleveland Med Ctr, Harrington Heart & Vasc Inst, Cleveland, OH USA.
   [Moravec, Christine S.] Cleveland Clin Fdn, Cardiovasc & Metab Sci, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Fu, Jidong] Ohio State Univ, Dept Physiol & Cell Biol, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA.
RP Laurita, KR (corresponding author), Case Western Reserve Univ, Heart & Vasc Res Ctr, MetroHlth Campus,2500 MetroHlth Dr,6th Floor, Cleveland, OH 44109 USA.
EM kenneth.laurita@case.edu
RI Jeon, Oju/K-7227-2018
OI Jeon, Oju/0000-0003-3972-9272; Bektik, Emre/0000-0002-3558-2886;
   Alsberg, Eben/0000-0002-3487-4625
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [HL123012];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [HL139006, HL149369]; American Heart
   AssociationAmerican Heart Association [17CPOST33650005]
FX This work was supported in part by grants from National Institutes of
   Health (NIH) HL123012, NIH HL149369 (Dr Laurita), NIH HL139006 (Dr Fu),
   and American Heart Association 17CPOST33650005 (Dr Vasireddi), and
   generous support from Curtis and Sara Moll (Dr Mackall).
CR Afzal MR, 2015, CIRC RES, V117, P558, DOI 10.1161/CIRCRESAHA.114.304792
   Ali A, 2019, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01866
   Anker SD, 2004, HEART, V90, P464, DOI 10.1136/hrt.2002.007005
   Aromolaran AS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208321
   BASSANI JWM, 1994, J PHYSIOL-LONDON, V476, P279, DOI 10.1113/jphysiol.1994.sp020130
   BEUCKELMANN DJ, 1993, CIRC RES, V73, P379, DOI 10.1161/01.RES.73.2.379
   Brooke G, 2008, TRANSFUS MED HEMOTH, V35, P279, DOI 10.1159/000143158
   Cai QX, 2020, ALLERGY, V75, P1742, DOI 10.1111/all.14309
   Caplan AI, 2016, J CELL PHYSIOL, V231, P1413, DOI 10.1002/jcp.25255
   Cheng K, 2014, JACC-HEART FAIL, V2, P49, DOI 10.1016/j.jchf.2013.08.008
   Cieslik KA, 2015, FASEB J, V29, P3160, DOI 10.1096/fj.14-268136
   Cutler MJ, 2012, CIRCULATION, V126, P2095, DOI 10.1161/CIRCULATIONAHA.111.071480
   De Jesus NM, 2017, HEART RHYTHM, V14, P727, DOI 10.1016/j.hrthm.2017.01.027
   DeSantiago J, 2012, J MOL CELL CARDIOL, V52, P1249, DOI 10.1016/j.yjmcc.2012.03.008
   Garikipati VNS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192244
   Gullestad L, 2012, CARDIOLOGY, V122, P23, DOI 10.1159/000338166
   Hartman MHT, 2018, TRENDS CARDIOVAS MED, V28, P369, DOI 10.1016/j.tcm.2018.02.003
   Imazio M, 2016, NAT REV CARDIOL, V13, P99, DOI 10.1038/nrcardio.2015.115
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Li ZW, 2010, FEBS J, V277, P3688, DOI 10.1111/j.1742-4658.2010.07770.x
   Liu M, 2014, HEART ASIA, V6, P130, DOI 10.1136/heartasia-2013-010484
   Love Z, 2007, J NUCL MED, V48, P2011, DOI 10.2967/jnumed.107.043166
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mayfield AE, 2017, THERANOSTICS, V7, P4850, DOI 10.7150/thno.19435
   Mayourian J, 2017, CIRC RES, V121, P411, DOI 10.1161/CIRCRESAHA.117.310796
   McPheeters MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183761
   Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monsanto MM, 2017, CIRC RES, V121, P113, DOI 10.1161/CIRCRESAHA.116.310494
   Naftali-Shani N, 2017, CIRCULATION, V135, P2271, DOI 10.1161/CIRCULATIONAHA.116.023527
   Pastore JM, 1999, CIRCULATION, V99, P1385, DOI 10.1161/01.CIR.99.10.1385
   Price MJ, 2006, INT J CARDIOL, V111, P231, DOI 10.1016/j.ijcard.2005.07.036
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Ridker PM, 2016, CIRC RES, V118, P145, DOI 10.1161/CIRCRESAHA.115.306656
   Sapp JL, 2020, CAN J CARDIOL, V36, P948, DOI 10.1016/j.cjca.2020.04.003
   Sattayaprasert P, 2016, J MOL CELL CARDIOL, V98, P138, DOI 10.1016/j.yjmcc.2016.05.014
   Savi M, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110729
   Scott LJ, 2017, DRUGS, V77, P1029, DOI 10.1007/s40265-017-0752-y
   Subramani B, 2016, CYTOTECHNOLOGY, V68, P2061, DOI 10.1007/s10616-016-9946-5
   Sukhanov S, 2007, ARTERIOSCL THROM VAS, V27, P2684, DOI 10.1161/ATVBAHA.107.156257
   Valdivia CR, 2005, J MOL CELL CARDIOL, V38, P475, DOI 10.1016/j.yjmcc.2004.12.012
   Vasquez C, 2010, CIRC RES, V107, P1011, DOI 10.1161/CIRCRESAHA.110.227421
   Wagner WG, 2007, STEM CELLS, V25, P2638, DOI 10.1634/stemcells.2007-0280
NR 43
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3149
EI 1941-3084
J9 CIRC-ARRHYTHMIA ELEC
JI Circ.-Arrhythmia Electrophysiol.
PD OCT
PY 2020
VL 13
IS 10
BP 1132
EP 1144
DI 10.1161/CIRCEP.120.008740
PG 13
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OJ3YA
UT WOS:000583899800012
PM 32755466
DA 2021-01-01
ER

PT J
AU Friedman, DM
   Kim, M
   Costedoat-Chalumeau, N
   Clancy, R
   Copel, J
   Phoon, CK
   Cuneo, BF
   Cohen, R
   Masson, M
   Wainwright, BJ
   Zahr, N
   Saxena, A
   Izmirly, PM
   Buyon, JP
AF Friedman, Deborah M.
   Kim, Mimi
   Costedoat-Chalumeau, Nathalie
   Clancy, Robert
   Copel, Joshua
   Phoon, Colin K.
   Cuneo, Bettina F.
   Cohen, Rebecca
   Masson, Mala
   Wainwright, Benjamin J.
   Zahr, Noel
   Saxena, Amit
   Izmirly, Peter M.
   Buyon, Jill P.
TI Electrocardiographic QT Intervals in Infants Exposed to
   Hydroxychloroquine Throughout Gestation
SO CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY
LA English
DT Article
DE COVID-19; hydroxychloroquine; heart block; incidence; pregnancy
ID CARDIAC MANIFESTATIONS; RISK; FETUSES; MOTHERS
AB BACKGROUND: Based on inhibition of viral replication and limited reports on clinical efficacy, hydroxychloroquine is being considered as prophylaxis and treatment of coronavirus disease-19 (COVID-19). Although hydroxychloroquine is generally considered safe during pregnancy based on studies in patients with systemic lupus erythematosus and other rheumatic conditions, there may still be reluctance to institute this antimalarial during pregnancy for the sole purpose of antiviral therapy.
   METHODS: To provide data regarding any potential fetal/neonatal cardiotoxicity, we leveraged a unique opportunity in which neonatal ECGs and hydroxychloroquine blood levels were available in a recently completed study evaluating the efficacy of hydroxychloroquine 400 mg daily to prevent the recurrence of congenital heart block associated with anti-SSA/Ro (anti-Sjogren's Syndrome A/Ro) antibodies.
   RESULTS: Forty-five ECGs were available for corrected QT interval (QTc) measurement, and levels of hydroxychloroquine were assessed during each trimester of pregnancy and in the cord blood, providing unambiguous assurance of drug exposure. Overall, there was no correlation between cord blood levels of hydroxychloroquine and the neonatal QTc (R=0.02, P=0.86) or the mean of hydroxychloroquine values obtained throughout each individual pregnancy and the QTc (R=0.04, P=0.80). In total 5 (11% [95% CI, 4%-24%]) neonates had prolongation of the QTc >2 SD above historical healthy controls (2 markedly and 3 marginally) but ECGs were otherwise normal.
   CONCLUSIONS: In aggregate, these data provide reassurances that the maternal use of hydroxychloroquine is associated with a low incidence of infant QTc prolongation. However, if included in clinical COVID-19 studies, early postnatal ECGs should be considered.
   REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01379573.
   GRAPHIC ABSTRACT: A graphic abstract is available for this article.
C1 [Clancy, Robert; Phoon, Colin K.; Cohen, Rebecca; Masson, Mala; Wainwright, Benjamin J.; Saxena, Amit; Izmirly, Peter M.] NYU, Sch Med, 550 First Ave,MSB 625, New York, NY 10016 USA.
   [Buyon, Jill P.] NYU, Sch Med, 550 First Ave,MSB 601, New York, NY 10016 USA.
   [Friedman, Deborah M.] New York Med Coll, Valhalla, NY 10595 USA.
   [Kim, Mimi] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Costedoat-Chalumeau, Nathalie] Cochin Hosp, Paris, France.
   [Copel, Joshua] Yale Sch Med, New Haven, CT USA.
   [Cuneo, Bettina F.] Univ Colorado, Sch Med, Aurora, CO USA.
   [Zahr, Noel] Pitie Salpetriere Univ Hosp, Paris, France.
RP Izmirly, PM (corresponding author), NYU, Sch Med, 550 First Ave,MSB 625, New York, NY 10016 USA.; Buyon, JP (corresponding author), NYU, Sch Med, 550 First Ave,MSB 601, New York, NY 10016 USA.
EM peter.izmirly@nyulangone.org; jill.buyon@nyulangone.org
OI Copel, Joshua/0000-0002-8961-0758; Izmirly, Peter/0000-0001-5445-2182;
   Buyon, Jill/0000-0002-3852-7129; Saxena, Amit/0000-0003-0098-1083
FU Lupus Foundation of Minnesota; Lupus Foundation of America (LIFELINE
   Grant); Eunice Kennedy Shriver National Institute of Child Health and
   Human DevelopmentUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [R03HD069986, R01HD079951]
FX This research was supported by the Lupus Foundation of Minnesota, the
   Lupus Foundation of America (LIFELINE Grant), and the Eunice Kennedy
   Shriver National Institute of Child Health and Human Development
   (R03HD069986, Dr Buyon; R01HD079951, Dr Buyon.).
CR Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Costedoat-Chalumcau N, 2002, ARTHRITIS RHEUM, V46, P1123, DOI 10.1002/art.10150
   Costedoat-Chalumeau N, 2005, AUTOIMMUN REV, V4, P111, DOI 10.1016/j.autrev.2004.11.009
   Costedoat-Chalumeau N, 2004, ARTHRITIS RHEUM-US, V50, P3187, DOI 10.1002/art.20554
   Costedoat-Chalumeau N, 2003, ARTHRITIS RHEUM, V48, P3207, DOI 10.1002/art.11304
   Costedoat-Chalumeau N, 2019, CLIN PHARMACOL THER, V106, P374, DOI 10.1002/cpt.1194
   Costedoat-Chalumeau N, 2013, ANN RHEUM DIS, V72, P1786, DOI 10.1136/annrheumdis-2012-202322
   Diav-Citrin O, 2013, REPROD TOXICOL, V39, P58, DOI 10.1016/j.reprotox.2013.04.005
   Friedman D, 2017, CLIN EXP RHEUMATOL, V35, P857
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gerosa M, 2007, RHEUMATOLOGY, V46, P1285, DOI 10.1093/rheumatology/kem073
   Izmirly P, 2020, J AM COLL CARDIOL, V76, P292, DOI 10.1016/j.jacc.2020.05.045
   Izmirly PM, 2012, CIRCULATION, V126, P76, DOI 10.1161/CIRCULATIONAHA.111.089268
   Izmirly PM, 2010, ANN RHEUM DIS, V69, P1827, DOI 10.1136/ard.2009.119263
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Noe G, 2019, THER DRUG MONIT, V41, P476, DOI 10.1097/FTD.0000000000000614
   Reed JH, 2012, ARTHRIT CARE RES, V64, P1373, DOI 10.1002/acr.21704
   Rijnbeek PR, 2001, EUR HEART J, V22, P702, DOI 10.1053/euhj.2000.2399
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Sammaritano LR, 2020, ARTHRITIS RHEUMATOL, DOI 10.1002/art.41191
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Schwartz PJ, 2009, CIRCULATION, V120, P1761, DOI 10.1161/CIRCULATIONAHA.109.863209
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 25
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3149
EI 1941-3084
J9 CIRC-ARRHYTHMIA ELEC
JI Circ.-Arrhythmia Electrophysiol.
PD OCT
PY 2020
VL 13
IS 10
BP 1213
EP 1219
AR e008686
DI 10.1161/CIRCEP.120.008686
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OJ3YA
UT WOS:000583899800010
PM 32907357
DA 2021-01-01
ER

PT J
AU Serviddio, G
   Villani, R
   Stallone, G
   Scioscia, G
   Foschino-Barbaro, MP
   Lacedonia, D
AF Serviddio, Gaetano
   Villani, Rosanna
   Stallone, Giovanni
   Scioscia, Giulia
   Foschino-Barbaro, Maria Pia
   Lacedonia, Donato
TI Tocilizumab and liver injury in patients with COVID-19
SO THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
LA English
DT Article
DE COVID-19; hepatotoxicity; IL-6; SARS-CoV-2; tocilizumab
AB Current mortality rate in patients with COVID-19 disease is about 2%, whereas 5% of patients require admission to the intensive care unit. It is assumed that interleukin (IL)-6 may be involved in the pathogenesis of severe COVID-19 infections; therefore, in the absence of a specific antiviral therapy, some authors have suggested that tocilizumab - a drug used to block the signal transduction pathway of IL-6 - could have beneficial effects in the management of severe COVID-19 disease. However, mild-to-moderate elevation in transaminases and drug-induced liver injury have been observed in patients treated with tocilizumab. We present seven cases of patients with elevated liver enzymes [up to five times the upper limit of normal (ULN)] at baseline who received tocilizumab for life-threatening COVID-19 disease. All patients had no history of liver or pulmonary disease and were admitted for acute hypoxemic respiratory failure, dyspnea and fever due to COVID-19 bilateral pneumonia. IL-6 was available in six patients, and was significantly increased particularly in those with severe impairment of lung function. All patients received tocilizumab (8 mg/kg/day) for two consecutive days because of lack of improvement after hydroxychloroquine, azithromycin and lopinavir/ritonavir treatment. After tocilizumab administration, clinical condition rapidly improved and liver function test normalized within 3 weeks of treatment. Tocilizumab may be effective for the treatment of severe COVID-19 disease, even in patients with elevated liver function tests. Further studies are needed to evaluate the impact of tocilizumab use on liver function tests in patients with pre-existing chronic liver disease.
C1 [Serviddio, Gaetano; Villani, Rosanna] Univ Foggia, CURE Univ Ctr Liver Dis Res & Treatment, Dept Med & Surg Sci, Viale Pinto 1, I-71122 Foggia, Italy.
   [Stallone, Giovanni] Univ Foggia, Dept Med & Surg Sci, Nephrol Dialysis & Transplantat Unit, Foggia, Italy.
   [Scioscia, Giulia; Foschino-Barbaro, Maria Pia; Lacedonia, Donato] Univ Foggia, Inst Resp Dis, Dept Med & Surg Sci, Foggia, Italy.
RP Serviddio, G (corresponding author), Univ Foggia, CURE Univ Ctr Liver Dis Res & Treatment, Dept Med & Surg Sci, Viale Pinto 1, I-71122 Foggia, Italy.
EM gaetano.serviddio@unifg.it
CR Adams DH, 2006, AM J PATHOL, V168, P1057, DOI 10.2353/ajpath.2006.051296
   Anger F, 2017, RHEUMATOLOGY, V56, P1628, DOI 10.1093/rheumatology/kex221
   Aziz M, 2020, J MED VIROL, V92, P2283, DOI 10.1002/jmv.25948
   Cai QX, 2020, J HEPATOL, V73, P566, DOI 10.1016/j.jhep.2020.04.006
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009
   Chai X, 2020, SPECIFIC ACE2 EXPRES
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Gatti M, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14459
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Grifoni E, 2020, J INFECTION, V81, P52
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang SP, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00347
   Koskinas J, 2008, WORLD J GASTROENTERO, V14, P1389, DOI 10.3748/wjg.14.1389
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mazzitelli M, 2020, J MED VIROL, DOI 10.1002/jmv.26016
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Morena V, 2020, EUR J INTERN MED, V76, P36, DOI 10.1016/j.ejim.2020.05.011
   Muhovic D, 2020, LIVER INT, V40, P1901, DOI 10.1111/liv.14516
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Somers Emily C, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa954
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 27
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1756-283X
EI 1756-2848
J9 THER ADV GASTROENTER
JI Ther. Adv. Gastroenterol.
PD OCT
PY 2020
VL 13
AR 1756284820959183
DI 10.1177/1756284820959183
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OI5NG
UT WOS:000583324400001
PM 33101458
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ray, PR
   Wangzhou, AD
   Ghneim, N
   Yousuf, MS
   Paige, C
   Tavares-Ferreira, D
   Mwirigi, JM
   Shiers, S
   Sankaranarayanan, I
   McFarland, AJ
   Neerukonda, SV
   Davidson, S
   Dussor, G
   Burton, MD
   Price, TJ
AF Ray, Pradipta R.
   Wangzhou, Andi
   Ghneim, Nizar
   Yousuf, Muhammad S.
   Paige, Candler
   Tavares-Ferreira, Diana
   Mwirigi, Juliet M.
   Shiers, Stephanie
   Sankaranarayanan, Ishwarya
   McFarland, Amelia J.
   Neerukonda, Sanjay V.
   Davidson, Steve
   Dussor, Gregory
   Burton, Michael D.
   Price, Theodore J.
TI A pharmacological interactome between COVID-19 patient samples and human
   sensory neurons reveals potential drivers of neurogenic pulmonary
   dysfunction
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
ID HOST-DEFENSE; NERVOUS-SYSTEM; PHOSPHORYLATION; INFLAMMATION;
   NOCICEPTORS; PROTEIN; NERVES; LUNG; CCL2; ACTIVATION
AB The SARS-CoV-2 virus infects cells of the airway and lungs in humans causing the disease COVID-19. This disease is characterized by cough, shortness of breath, and in severe cases causes pneumonia and acute respiratory distress syndrome (ARDS) which can be fatal. Bronchial alveolar lavage fluid (BALF) and plasma from mild and severe cases of COVID-19 have been profiled using protein measurements and bulk and single cell RNA sequencing. Onset of pneumonia and ARDS can be rapid in COVID-19, suggesting a potential neuronal involvement in pathology and mortality. We hypothesized that SARS-CoV-2 infection drives changes in immune cell-derived factors that then interact with receptors expressed by the sensory neuronal innervation of the lung to further promote important aspects of disease severity, including ARDS. We sought to quantify how immune cells might interact with sensory innervation of the lung in COVID-19 using published data from patients, existing RNA sequencing datasets from human dorsal root ganglion neurons and other sources, and a genome-wide ligand-receptor pair database curated for pharmacological interactions relevant for neuro-immune interactions. Our findings reveal a landscape of ligand-receptor interactions in the lung caused by SARS-CoV-2 viral infection and point to potential interventions to reduce the burden of neurogenic inflammation in COVID-19 pulmonary disease. In particular, our work highlights opportunities for clinical trials with existing or under development rheumatoid arthritis and other (e.g. CCL2, CCR5 or EGFR inhibitors) drugs to treat high risk or severe COVID-19 cases.
C1 [Ray, Pradipta R.; Wangzhou, Andi; Ghneim, Nizar; Yousuf, Muhammad S.; Paige, Candler; Tavares-Ferreira, Diana; Mwirigi, Juliet M.; Shiers, Stephanie; Sankaranarayanan, Ishwarya; McFarland, Amelia J.; Neerukonda, Sanjay V.; Dussor, Gregory; Burton, Michael D.; Price, Theodore J.] Univ Texas Dallas, Sch Behav & Brain Sci, Richardson, TX 75083 USA.
   [Ray, Pradipta R.; Wangzhou, Andi; Ghneim, Nizar; Yousuf, Muhammad S.; Paige, Candler; Tavares-Ferreira, Diana; Mwirigi, Juliet M.; Shiers, Stephanie; Sankaranarayanan, Ishwarya; McFarland, Amelia J.; Neerukonda, Sanjay V.; Dussor, Gregory; Price, Theodore J.] Ctr Adv Pain Studies, Pain Neurobiol Res Grp, Richardson, TX USA.
   [Burton, Michael D.] Ctr Adv Pain Studies, Neuroimmunol & Behav Res Grp, Richardson, TX USA.
   [Davidson, Steve] Univ Cincinnati, Coll Med, Dept Anesthesiol, Cincinnati, OH 45221 USA.
RP Ray, PR; Price, TJ (corresponding author), 800 W Campbell Rd,Mailcode,BSB14-102, Richardson, TX 75080 USA.
EM prr105020@utdallas.edu; theodore.price@utdallas.edu
RI Yousuf, Muhammad Saad/AAW-1533-2020
OI Neerukonda, Sanjay/0000-0003-1966-7932
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [NS065926, NS115441]
FX This work was supported by NIH grants NS065926 and NS115441 to TJP.
CR Aguilar-Valles A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04883-5
   Amorim IS, 2018, J NEUROSCI, V38, P2118, DOI 10.1523/JNEUROSCI.2673-17.2018
   Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638
   Andratsch M, 2009, J NEUROSCI, V29, P13473, DOI 10.1523/JNEUROSCI.1822-09.2009
   Banerjee S, 2002, J VIROL, V76, P5937, DOI 10.1128/JVI.76.12.5937-5948.2002
   Baral P, 2018, NAT MED, V24, P417, DOI 10.1038/nm.4501
   Belkouch M, 2011, J NEUROSCI, V31, P18381, DOI 10.1523/JNEUROSCI.3386-11.2011
   Bonvini SJ, 2016, J ALLERGY CLIN IMMUN, V138, P249, DOI 10.1016/j.jaci.2015.10.044
   Bryant P, 2003, J SURG RES, V112, P152, DOI 10.1016/S0022-4804(03)00154-9
   Canning B J, 2009, Handb Exp Pharmacol, P139, DOI 10.1007/978-3-540-79090-7_5
   Canning BJ, 2001, RESP PHYSIOL, V125, P113, DOI 10.1016/S0034-5687(00)00208-5
   Canning Brendan J, 2002, Curr Allergy Asthma Rep, V2, P210, DOI 10.1007/s11882-002-0021-2
   Canning BJ, 2011, PULM PHARMACOL THER, V24, P295, DOI 10.1016/j.pupt.2011.01.008
   Carbon S, 2009, BIOINFORMATICS, V25, P288, DOI 10.1093/bioinformatics/btn615
   Chavan SS, 2018, AM J TRANSPLANT, V18, P556, DOI 10.1111/ajt.14515
   Chen IY, 2010, J VIROL, V84, P7703, DOI 10.1128/JVI.02560-09
   Chiu IM, 2012, NAT NEUROSCI, V15, P1063, DOI 10.1038/nn.3144
   Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143
   Darling TK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01473
   Devesa I, 2011, J INFLAMM RES, V4, P67, DOI 10.2147/JIR.S12978
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dubin AE, 2010, J CLIN INVEST, V120, P3760, DOI 10.1172/JCI42843
   Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955
   Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107
   Garceau D, 2019, PULM PHARMACOL THER, V56, P56, DOI 10.1016/j.pupt.2019.03.007
   Gordon D.E., 2020, SARS COV 2 HUMAN POT
   Guptill V, 2011, ANESTHESIOLOGY, V114, P1190, DOI 10.1097/ALN.0b013e318212515b
   Hadley SH, 2014, MOL PHARMACOL, V85, P839, DOI 10.1124/mol.113.091272
   Han Y, 2020, LACTATE DEHYDROGENAS
   Hanamura K, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2002457
   Held KS, 2004, VIROLOGY, V329, P251, DOI 10.1016/j.virol.2004.09.006
   Henderson NT, 2018, MOL CELL NEUROSCI, V91, P108, DOI 10.1016/j.mcn.2018.07.002
   Hensellek S, 2007, MOL CELL NEUROSCI, V36, P381, DOI 10.1016/j.mcn.2007.07.010
   Herdy B, 2012, NAT IMMUNOL, V13, P543, DOI 10.1038/ni.2291
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang L, 2020, BLOOD SINGLE CELL IM
   Kaelberer M.M., 2020, AM J PHYSL LUNG CELL
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   KUMMER W, 1992, NEUROSCIENCE, V49, P715, DOI 10.1016/0306-4522(92)90239-X
   Kupari J, 2019, CELL REP, V27, P2508, DOI 10.1016/j.celrep.2019.04.096
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Lachmann A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03751-6
   Levinson JN, 2005, NEURON, V48, P171, DOI 10.1016/j.neuron.2005.09.017
   Lewis TC, 2012, CLIN EXP ALLERGY, V42, P1734, DOI 10.1111/cea.12005
   Liang Z., 2019, 813980 BIORXIV
   Liao M., 2020, LANDSCAPE LUNG BRONC
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Martin LJ, 2017, J CLIN INVEST, V127, P3359, DOI 10.1172/JCI87406
   Megat S, 2019, J NEUROSCI, V39, P393, DOI 10.1523/JNEUROSCI.2661-18.2018
   Michieletto D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08333-8
   Mizutani T, 2004, BIOCHEM BIOPH RES CO, V319, P1228, DOI 10.1016/j.bbrc.2004.05.107
   Moy JK, 2017, J NEUROSCI, V37, P7481, DOI 10.1523/JNEUROSCI.0220-17.2017
   Narula M, 2014, J THORAC DIS, V6, pS712, DOI 10.3978/j.issn.2072-1439.2014.03.15
   North RY, 2019, BRAIN, V142, P1215, DOI 10.1093/brain/awz063
   Ramilowski JA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8866
   Ray P, 2018, PAIN, V159, P1325, DOI 10.1097/j.pain.0000000000001217
   Rayamajhi Manira, 2013, Methods Mol Biol, V1040, P85, DOI 10.1007/978-1-62703-523-1_7
   Reich SH, 2018, J MED CHEM, V61, P3516, DOI 10.1021/acs.jmedchem.7b01795
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Ruhl C.R., 2020, CELL
   Sann H, 1998, Z RHEUMATOL, V57, P8
   Shiers S, 2020, NEUROPSYCHOPHARMACOL, V45, P524, DOI 10.1038/s41386-019-0537-y
   Si YJ, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13322
   SPRINGALL DR, 1987, J AUTONOM NERV SYST, V20, P155, DOI 10.1016/0165-1838(87)90113-5
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Talbot S, 2015, NEURON, V87, P341, DOI 10.1016/j.neuron.2015.06.007
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Trujillo JA, 2013, J VIROL, V87, P2376, DOI 10.1128/JVI.03089-12
   Usoskin D, 2015, NAT NEUROSCI, V18, P145, DOI 10.1038/nn.3881
   Wallrapp A, 2019, IMMUNITY, V51, P709, DOI 10.1016/j.immuni.2019.09.005
   Wan Y, 2020, J VIROL, V94
   Wangzhou A., 2020, PHARM INTERACTOME PL
   Woolf CJ, 2007, NEURON, V55, P353, DOI 10.1016/j.neuron.2007.07.016
   Xiong Y., 2020, SSRN ELECT J
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yates B, 2017, NUCLEIC ACIDS RES, V45, pD619, DOI 10.1093/nar/gkw1033
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou Yonggang, 2020, ABERRANT PATHOGENIC
NR 79
TC 2
Z9 2
U1 2
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD OCT
PY 2020
VL 89
BP 559
EP 568
DI 10.1016/j.bbi.2020.05.078
PG 10
WC Immunology; Neurosciences; Psychiatry
SC Immunology; Neurosciences & Neurology; Psychiatry
GA OH9GJ
UT WOS:000582897600058
PM 32497778
OA Green Published
DA 2021-01-01
ER

PT J
AU Quaquarini, E
   Saltalamacchia, G
   Presti, D
   Caldana, G
   Tibollo, V
   Malovini, A
   Palumbo, R
   Teragni, CM
   Balletti, E
   Mollica, L
   Biscaldi, E
   Frascaroli, M
   Bernardo, A
   Sottotetti, F
AF Quaquarini, Erica
   Saltalamacchia, Giuseppe
   Presti, Daniele
   Caldana, Giulia
   Tibollo, Valentina
   Malovini, Alberto
   Palumbo, Raffaella
   Teragni, Cristina Maria
   Balletti, Emanuela
   Mollica, Ludovica
   Biscaldi, Elisa
   Frascaroli, Mara
   Bernardo, Antonio
   Sottotetti, Federico
TI Impact of COVID-19 Outbreak on Cancer Patient Care and Treatment: Data
   from an Outpatient Oncology Clinic in Lombardy (Italy)
SO CANCERS
LA English
DT Article
DE cancer; containment measures; lockdown; SARS-CoV-2; systemic treatment
ID OUTCOMES
AB Simple Summary
   Cancer has been reported as a major risk factor for adverse outcomes and death during COVID-19 pandemic. The aim of this study was to investigate the management of cancer patients and oncological treatments during the COVID-19 pandemic and to describe the containment measures performed in ICS Maugeri outpatient clinic (Pavia, Italy). A comparison with the same period of the four previous years was performed. A significant reduction in access for therapy was seen between the year 2020 and 2019 but not between 2020 and 2018, 2017, or 2016. In 2020, the "pandemic fear" was the most common cause of treatment delay. Only few patients developed COVID-19. A significant reduction in radiological exams was found in 2020 versus all the other years considered. The low incidence of COVID-19 among our cancer patients, along with the hospital policy to control infection, enabled safe cancer treatment and a continuum of care in most patients.
   Lombardy was the first area in Italy to have an outbreak of coronavirus disease 19 (COVID-19) at the beginning of 2020. In this context, cancer has been reported as a major risk factor for adverse outcomes and death, so oncology societies have quickly released guidelines on cancer care during the pandemic. The aim of this study was to investigate the management of cancer patients and oncological treatments during the COVID-19 pandemic and to describe the containment measures performed in our outpatient clinic at Pavia (Lombardy). A comparison with the same period of the four previous years (2019, 2018, 2017, and 2016) was also performed. Using our electronic databases, we evaluated the number and characteristics of patients accessing the hospital for anticancer drug infusion from 24 February, 2020 to 30 April, 2020 and the number of radiological exams performed. Although a significant reduction in access for therapy was seen when compared with 2019 (2590 versus 2974, access rate ratio (ARR) = 0.85, p < 0.001), no significant differences in access numbers and ARR was evident between 2020 and 2018, 2017, or 2016 (2590 versus 2626 (ARR = 0.07), 2660 (ARR = 0.99), and 2694 (ARR = 0.96), respectively, p > 0.05). In 2020, 63 patients delayed treatment: 38% for "pandemic fear", 18% for travel restrictions, 13% for quarantine, 18% for flu syndrome other than COVID-19, and 13% for worsening of clinical conditions and death. Only 7/469 patients developed COVID-19. A significant reduction in radiological exams was found in 2020 versus all the other years considered (211 versus 360, 355, 385, 390 for the years 2020, 2019, 2018, 2017, and 2016, respectively, p < 0.001). The low incidence of COVID-19 among our cancer patients, along with the hospital policy to control infection, enabled safe cancer treatment and a continuum of care in most patients, while a small fraction of patients experienced a therapeutic delay due to patient-related reasons.
C1 [Quaquarini, Erica; Saltalamacchia, Giuseppe; Presti, Daniele; Palumbo, Raffaella; Teragni, Cristina Maria; Balletti, Emanuela; Mollica, Ludovica; Bernardo, Antonio; Sottotetti, Federico] IRCCS SpA SB, ICS Maugeri, Med Oncol Unit, I-27100 Pavia, Italy.
   [Quaquarini, Erica] Univ Pavia, Expt Med Sch, I-27100 Pavia, Italy.
   [Caldana, Giulia; Biscaldi, Elisa; Frascaroli, Mara] IRCCS SpA SB, ICS Maugeri, Translat Oncol Unit, I-27100 Pavia, Italy.
   [Tibollo, Valentina; Malovini, Alberto] IRCCS SpA SB, ICS Maugeri, Lab Informat & Syst Engn Clin Res, I-27100 Pavia, Italy.
RP Quaquarini, E (corresponding author), IRCCS SpA SB, ICS Maugeri, Med Oncol Unit, I-27100 Pavia, Italy.; Quaquarini, E (corresponding author), Univ Pavia, Expt Med Sch, I-27100 Pavia, Italy.
EM erica.quaquarini@icsmaugeri.it; giuseppe.saltalamacchia@icsmaugeri.it;
   daniele.presti@icsmaugeri.it; giulia.caldana@icsmaugeri.it;
   valentina.tibollo@icsmaugeri.it; alberto.malovini@icsmaugeri.it;
   raffaella.palumbo@icsmaugeri.it; cristina.teragni@icsmaugeri.it;
   emanuela.balletti@icsmaugeri.it; ludovica.mollica@icsmaugeri.it;
   elisa.biscaldi@icsmaugeri.it; mara.frascaroli@icsmaugeri.it;
   antonio.bernardo@icsmaugeri.it; federico.sottotetti@icsmaugeri.it
RI QUAQUARINI, Erica/F-9945-2019
OI QUAQUARINI, Erica/0000-0001-9099-5352
CR Allegra A, 2020, CANCERS, V12, DOI 10.3390/cancers12061581
   Blasi L, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1046
   Brunetti O, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00734
   Curigliano G, 2020, BREAST, V52, P8, DOI 10.1016/j.breast.2020.04.006
   Curigliano G, 2020, ONCOLOGIST, V25, P463, DOI 10.1634/theoncologist.2020-0267
   de Marinis F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00665
   Deckx L, 2015, PSYCHO-ONCOLOGY, V24, P1521, DOI 10.1002/pon.3818
   Deckx L, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0071-7
   Frederick JT, 2007, AM J PREV MED, V33, P222, DOI 10.1016/j.amepre.2007.04.035
   Iavarone M, 2020, ANN ONCOL, V31, P1084, DOI 10.1016/j.annonc.2020.04.007
   Indini A, 2020, EUR J CANCER, V132, P17, DOI 10.1016/j.ejca.2020.03.024
   Lambertini M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000759
   Marandino L, 2020, JCO ONCOL PRACT, V16, P295, DOI 10.1200/OP.20.00237
   Maringe C, 2020, LANCET ONCOL, V21, P1023, DOI 10.1016/S1470-2045(20)30388-0
   Minstretta F.A., 2020, CANCERS, V12, P1513, DOI [10.3390/cancers12061513, DOI 10.3390/CANCERS12061513]
   Nguyen NP, 2020, CANCERS, V12, DOI 10.3390/cancers12051287
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pietrantonio F, 2020, CLIN COLORECTAL CANC, V19, P156, DOI 10.1016/j.clcc.2020.05.004
   Poggio Francesca, 2020, JCO Oncol Pract, V16, pe1304, DOI 10.1200/OP.20.00297
   Robinson AG, 2020, NAT REV CLIN ONCOL, V17, P386, DOI 10.1038/s41571-020-0394-y
   Trapani D, 2020, EUR J CANCER, V132, P199, DOI 10.1016/j.ejca.2020.04.017
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Valenza F, 2020, TUMORI J, V106, P193, DOI 10.1177/0300891620923790
   Viale G, 2020, ONCOLOGIST, V25, pE1013, DOI 10.1634/theoncologist.2020-0316
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
NR 25
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD OCT
PY 2020
VL 12
IS 10
AR 2941
DI 10.3390/cancers12102941
PG 16
WC Oncology
SC Oncology
GA OJ8FH
UT WOS:000584189400001
PM 33053782
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dores, AR
   Geraldo, A
   Carvalho, IP
   Barbosa, F
AF Dores, Artemisa R.
   Geraldo, Andreia
   Carvalho, Irene P.
   Barbosa, Fernando
TI The Use of New Digital Information and Communication Technologies in
   Psychological Counseling during the COVID-19 Pandemic
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE digital information and communication technologies; psychological
   counseling; therapy; COVID-19; coronavirus SARS-CoV-2; digital literacy
ID COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; GENERALIZED
   ANXIETY DISORDER; INTERNET-BASED TREATMENT; DEPRESSION; ATTITUDES;
   INTERVENTIONS; ACTIVATION
AB The use of digital information and communication technologies (ICTs) has enabled many professionals to continue to provide their services during the COVID-19 pandemic. However, little is known about the adoption of ICTs by psychologists and the impact of such technologies on their practice. This study aimed to explore psychologists' practices related with the use of ICTs before and during the COVID-19 lockdown, to identify the main changes that the pandemic has brought and the impact that such changes have had on their practice with clients, and also identify the factors that potentially have affected such changes. The Portuguese Psychologists Association announced the study, and 108 psychologists responded to an online survey during the mandatory lockdown. The results showed that these professionals continued to provide their services due to having adopted ICTs. Comparing with face-to-face interventions, psychologists recognized that additional precautions/knowledge were needed to use such technologies. Despite the challenges identified, they described the experience with the use of ICTs as positive, meeting clients' adherence, and yielding positive results. Psychologists with the most years of professional experience maintained their services the most, but those with average experience showed the most favorable attitudes toward the use of technologies and web-based interventions.
C1 [Dores, Artemisa R.] Polytech Inst Porto, Sch Hlth, Rehabil Res Ctr, P-4200072 Porto, Portugal.
   [Dores, Artemisa R.; Geraldo, Andreia; Barbosa, Fernando] Univ Porto, Lab Neuropsychophysiol, Fac Psychol & Educ Sci, P-4200135 Porto, Portugal.
   [Carvalho, Irene P.] Univ Porto FMUP, Sch Med, CINTESIS, P-4200319 Porto, Portugal.
   [Carvalho, Irene P.] Univ Porto FMUP, Sch Med, Dept Clin Neurosci & Mental Hlth, P-4200319 Porto, Portugal.
RP Dores, AR (corresponding author), Polytech Inst Porto, Sch Hlth, Rehabil Res Ctr, P-4200072 Porto, Portugal.; Dores, AR (corresponding author), Univ Porto, Lab Neuropsychophysiol, Fac Psychol & Educ Sci, P-4200135 Porto, Portugal.
EM artemisa@ess.ipp.pt; g.andreia9@gmail.com; irenec@med.up.pt;
   fbarbosa@fpce.up.pt
RI Carvalho, Irene Palmares/L-8031-2013
OI Carvalho, Irene Palmares/0000-0001-7981-4442; Dores, Artemisa
   R/0000-0003-4595-9816; Geraldo, Andreia/0000-0002-5394-4588
FU Fundacao para a Ciencia e Tecnologia (FCT)Portuguese Foundation for
   Science and Technology [UIDB/05210/2020, SFRH/BD/138723/2018]
FX This research was supported by Fundacao para a Ciencia e Tecnologia
   (FCT) through R&D Units funding (UIDB/05210/2020), and through a
   doctoral grant (SFRH/BD/138723/2018) awarded to Andreia Geraldo.
CR Agboola SO, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4009
   Andersson G, 2016, ANNU REV CLIN PSYCHO, V12, P157, DOI 10.1146/annurev-clinpsy-021815-093006
   Andersson G, 2014, WORLD PSYCHIATRY, V13, P4, DOI 10.1002/wps.20083
   Andersson G, 2013, J AFFECT DISORDERS, V151, P986, DOI 10.1016/j.jad.2013.08.022
   Andersson G, 2012, PSYCHOTHER PSYCHOSOM, V81, P344, DOI 10.1159/000339371
   Andersson Gerhard, 2009, Cognitive Behaviour Therapy, V38, P196, DOI 10.1080/16506070903318960
   [Anonymous], EARL VIEW EC IMP PAN
   Barak A, 2008, J TECHNOL HUMAN SERV, V26, P109, DOI 10.1080/15228830802094429
   Bekes V, 2020, J PSYCHOTHER INTEGR, V30, P238, DOI 10.1037/int0000214
   Berger Thomas, 2011, Cognitive Behaviour Therapy, V40, P251, DOI 10.1080/16506073.2011.616531
   Bruno R, 2015, INT J MENT HEALTH, V44, P107, DOI 10.1080/00207411.2015.1009784
   Carlbring P, 2006, COMPUT HUM BEHAV, V22, P545, DOI 10.1016/j.chb.2004.10.009
   Carlbring P, 2007, BRIT J PSYCHIAT, V190, P123, DOI 10.1192/bjp.bp.105.020107
   Carlbring P, 2013, J AFFECT DISORDERS, V148, P331, DOI 10.1016/j.jad.2012.12.020
   Carlbring P, 2011, BEHAV RES THER, V49, P18, DOI 10.1016/j.brat.2010.10.002
   Cipolletta S, 2018, PSYCHOTHER RES, V28, P909, DOI 10.1080/10503307.2016.1259533
   Diario da Republica Eletronico (DRE, 2020, DIARIO REPUBLIC 0318
   Dores A.R., 2017, REV ESTUD INVESTIG P, DOI [10.17979/reipe.2017.0.09.2451, DOI 10.17979/REIPE.2017.0.09.2451]
   Dowling M, 2013, J TECHNOL HUMAN SERV, V31, P1, DOI 10.1080/15228835.2012.728508
   Drda-Kuhn K., 2019, DIGITAL DIVERSITY BI, P321, DOI [10.1007/978-3-658-26753-77, DOI 10.1007/978-3-658-26753-77]
   Evans DJ, 2014, S AFR J PSYCHOL, V44, P162, DOI 10.1177/0081246314527874
   Feijt MA, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9485
   Glueckauf RL, 2018, PROF PSYCHOL-RES PR, V49, P205, DOI 10.1037/pro0000188
   Hadjiconstantinou M, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5991
   Hedman E, 2013, ACTA PSYCHIAT SCAND, V128, P457, DOI 10.1111/acps.12079
   Helou S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17134866
   IBMCorp, 2017, IBM SPSS STAT WINDOW, V25
   Kuijpers W, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2281
   Lamela D., 2017, THESIS
   LimesurveyGmbH, 2019, LIMESURVEY OP SOURC
   Loucas CE, 2014, BEHAV RES THER, V63, P122, DOI 10.1016/j.brat.2014.09.011
   Ly KH, 2014, INTERNET INTERV, V1, P95, DOI DOI 10.1016/J.INVENT.2014.06.003
   Ly KH, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-62
   Mansson KNT, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.22
   Mendes-Santos C, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/16817
   Mohr DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070086
   Mora L, 2008, COMPUT HUM BEHAV, V24, P3052, DOI 10.1016/j.chb.2008.05.011
   Muhleisen M., 2018, FINANC DEV, V55, P5
   O'Mahen HA, 2014, PSYCHOL MED, V44, P1675, DOI 10.1017/S0033291713002092
   Olthuis JV, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011565.pub2
   OPP, 21CEOPP2015 OPP
   OPP, NUM ASS CENS MEMBR E
   OPP, LINH OR PRAT PROF OP
   Paxling Bjorn, 2011, Cognitive Behaviour Therapy, V40, P159, DOI 10.1080/16506073.2011.576699
   Perini S, 2009, AUST NZ J PSYCHIAT, V43, P571, DOI 10.1080/00048670902873722
   Perle JG, 2013, J CLIN PSYCHOL, V69, P100, DOI 10.1002/jclp.21912
   Pierce Bradford S, 2020, Am Psychol, DOI 10.1037/amp0000722
   Richards D, 2013, J CLIN PSYCHOL, V69, P994, DOI 10.1002/jclp.21974
   Richards D, 2012, CLIN PSYCHOL REV, V32, P329, DOI 10.1016/j.cpr.2012.02.004
   Ruwaard Jeroen, 2009, Cognitive Behaviour Therapy, V38, P206, DOI 10.1080/16506070802408086
   Schroder J, 2017, COGNITIVE THER RES, V41, P745, DOI 10.1007/s10608-017-9850-0
   Schroder J, 2016, DIALOGUES CLIN NEURO, V18, P203
   Schuster R, 2018, J MED INTERNET RES, V20, DOI 10.2196/11007
   Simms DC, 2011, CAN PSYCHOL, V52, P41, DOI 10.1037/a0022275
   Spence J, 2011, DEPRESS ANXIETY, V28, P541, DOI 10.1002/da.20835
   Topooco N, 2017, INTERNET INTERV, V8, P1, DOI 10.1016/j.invent.2017.01.001
   Uscher-Pines L, 2020, PSYCHIAT SERV, V71, P1143, DOI 10.1176/appi.ps.202000250
   Vernmark K, 2010, BEHAV RES THER, V48, P368, DOI 10.1016/j.brat.2010.01.005
   Vigerland S, 2014, INTERNET INTERV, V1, P111, DOI DOI 10.1016/J.INVENT.2014.06.002
   Wagner B, 2014, J AFFECT DISORDERS, V152, P113, DOI 10.1016/j.jad.2013.06.032
   Wangberg SC, 2007, CYBERPSYCHOL BEHAV, V10, P418, DOI 10.1089/cpb.2006.9937
   WHO, 2005, 58 WORLD HLTH ASS, P108
   Wolvers MDJ, 2015, JMIR RES PROTOC, V4, DOI 10.2196/resprot.4363
   Zetterqvist Kristofer, 2003, Cognitive Behaviour Therapy, V32, P151, DOI 10.1080/16506070302316
NR 64
TC 0
Z9 0
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD OCT
PY 2020
VL 17
IS 20
AR 7663
DI 10.3390/ijerph17207663
PG 24
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OI0YH
UT WOS:000583011900001
PM 33096650
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bezzio, C
   Pellegrini, L
   Manes, G
   Arena, I
   Picascia, D
   Della Corte, C
   Devani, M
   Schettino, M
   Saibeni, S
AF Bezzio, Cristina
   Pellegrini, Lucienne
   Manes, Gianpiero
   Arena, Ilaria
   Picascia, Desiree
   Della Corte, Cristina
   Devani, Massimo
   Schettino, Mario
   Saibeni, Simone
TI Biologic Therapies May Reduce the Risk of COVID-19 in Patients With
   Inflammatory Bowel Disease
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Letter
DE inflammatory bowel disease; Crohn disease; ulcerative colitis; COVID-19;
   coronavirus; biologics; therapy
C1 [Bezzio, Cristina; Pellegrini, Lucienne; Manes, Gianpiero; Arena, Ilaria; Picascia, Desiree; Della Corte, Cristina; Devani, Massimo; Schettino, Mario; Saibeni, Simone] ASST Rhodense, Rho Hosp, Gastroenterol Unit, Corso Europa 250, I-20017 Rho, MI, Italy.
RP Bezzio, C (corresponding author), ASST Rhodense, Rho Hosp, Gastroenterol Unit, Corso Europa 250, I-20017 Rho, MI, Italy.
EM cribezzio03@yahoo.it
RI Saibeni, Simone/AAA-3663-2019
OI Saibeni, Simone/0000-0001-5677-2534
CR Axelrad Jordan E, 2020, Inflamm Bowel Dis, DOI 10.1093/ibd/izaa162
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Macaluso Fabio Salvatore, 2020, Gastroenterology, DOI 10.1053/j.gastro.2020.05.026
   Neurath MF, 2020, GUT, V69, P1335, DOI 10.1136/gutjnl-2020-321269
   Taxonera C, 2020, ALIMENT PHARM THER, V52, P276, DOI 10.1111/apt.15804
NR 5
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD OCT
PY 2020
VL 26
IS 10
SI SI
BP E107
EP E109
DI 10.1093/ibd/izaa242
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OH6CP
UT WOS:000582675800001
PM 32869831
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Liang, Y
   Fan, N
   Zhong, XL
   Fan, WH
AF Liang, Yi
   Fan, Na
   Zhong, Xiaoling
   Fan, Wenhui
TI A Case Report of a Patient with Severe Type of Coronavirus Disease 2019
   (COVID-19) Treated by Hyperbaric Oxygen: CT Dynamic Changes
SO IRANIAN JOURNAL OF RADIOLOGY
LA English
DT Article
DE COVID-19; Hyperbaric Oxygen Therapy; Computed Tomography
AB Coronavirus disease 2019 (COVID-19) is currentlya pandemic affecting the world, and there is no specific therapeutic drug available. Hypoxemia is a common clinical manifestation of severe patients, and oxygen therapy is the main treatment. This article reports for the first time the computed tomography (CT) imaging dynamic changes in a case of 69-year-old male with severe type of COVID-19 treated by hyperbaric oxygen, which provides a more effective regimen for severe COVID-19 patients with hypoxemia. We emphasize that hyperbaric oxygen treatment for COVID-19 is a preliminary attempt, and more clinical studies are required to confirm its efficacy.
C1 [Liang, Yi; Fan, Na; Fan, Wenhui] Wuhan Brain Hosp, Gen Hosp Yangtze River Shipping, Dept Radiol, Huiji Rd 5, Wuhan, Peoples R China.
   [Zhong, Xiaoling] Wuhan Brain Hosp, Gen Hosp Yangtze River Shipping, Dept Hyperbar Oxygen Therapy, Wuhan, Peoples R China.
RP Fan, WH (corresponding author), Wuhan Brain Hosp, Gen Hosp Yangtze River Shipping, Dept Radiol, Huiji Rd 5, Wuhan, Peoples R China.
EM fanwenhui6709@163.com
CR Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM NOV COR
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   World Health Organization, 2020, COR DIS
NR 5
TC 0
Z9 0
U1 3
U2 3
PU KOWSAR PUBL
PI HOENSBROEK
PA PATERSWEG 22,, HOENSBROEK, LIMBURG 6431 GC, NETHERLANDS
SN 1735-1065
EI 2008-2711
J9 IRAN J RADIOL
JI Iran. J. Radiol.
PD OCT
PY 2020
VL 17
IS 4
AR e104475
DI 10.5812/iranjradiol.104475
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA OH2YQ
UT WOS:000582435900006
OA Other Gold
DA 2021-01-01
ER

PT J
AU Sasangohar, F
   Bradshaw, MR
   Carlson, MM
   Flack, JN
   Fowler, JC
   Freeland, D
   Head, J
   Marder, K
   Orme, W
   Weinstein, B
   Kolman, JM
   Kash, B
   Madan, A
AF Sasangohar, Farzan
   Bradshaw, Major R.
   Carlson, Marianne Millen
   Flack, James N.
   Fowler, James C.
   Freeland, Diana
   Head, John
   Marder, Kate
   Orme, William
   Weinstein, Benjamin
   Kolman, Jacob M.
   Kash, Bita
   Madan, Alok
TI Adapting an Outpatient Psychiatric Clinic to Telehealth During the
   COVID-19 Pandemic: A Practice Perspective
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE telemedicine; psychiatry; preventive psychiatry; SARS virus; pandemic;
   prevention; COVID-19; telehealth; perspective
ID MENTAL-HEALTH-SERVICES; TELEPSYCHIATRY; CARE
AB As the demand for telepsychiatry increases during the COVID-19 pandemic, the strengths and challenges of telepsychiatry implementation must be articulated to improve clinical practices in the long term. Currently, observations within US contexts are lacking; therefore, we report on the rapid implementation of telepsychiatry and workflow experiences in a psychiatric practice based within a large health care system in southeast Texas with a national catchment area. We discuss the logistics of the implementation, including modes of communication, scheduling, coordination, and capacity; the psychological effects of web-based services, including both the loss of the physical therapeutic environment and the unique interpersonal dynamics experienced in the virtual environment; and postadoption patterns of engagement with our services and with other clinical functions affected by the rapid adaptation to telemedicine. Our art therapy group programming serves as an applied case study, demonstrating the value of a well-managed web-based program (eg, patients were receptive and well-engaged, and they appreciated the continuity of accessible service) as well as the challenges (eg, the need for backup plans and technological fallbacks, managing interruptions and telecommunication learning curves, and working around the difference in resources for art and music therapy between a well-stocked clinical setting versus clients' home spaces). We conclude from our experience that the overall strengths of telepsychiatry include receptive and well-engaged responses from patients as well as the expansion of boundaries, which provides a directly contextualized view into patients' home lives. Challenges and corresponding recommendations include the need for more careful safety planning for high-risk patients; maintaining professional boundaries in the newly informal virtual setting; designing the physical space to both frame the patient encounter and maintain work-life balance for the therapist; allowing for delays and interruptions (including an initial acclimation session); and preserving interprofessional care team collaboration when the physical locations that normally facilitate such encounters are not accessible. We believe that careful observations of the strengths and challenges of telepsychiatry during this pandemic will better inform practices that are considering telepsychiatry adoption both within pandemic contexts and more broadly thereafter.
C1 [Sasangohar, Farzan; Kolman, Jacob M.; Kash, Bita] Houston Methodist Hosp, Ctr Outcomes Res, 6565 Fannin St, Houston, TX 77030 USA.
   [Bradshaw, Major R.; Carlson, Marianne Millen; Flack, James N.; Fowler, James C.; Freeland, Diana; Head, John; Marder, Kate; Orme, William; Weinstein, Benjamin; Madan, Alok] Houston Methodist Hosp, Behav Hlth Clin, Houston, TX 77030 USA.
RP Sasangohar, F (corresponding author), Houston Methodist Hosp, Ctr Outcomes Res, 6565 Fannin St, Houston, TX 77030 USA.
EM sasangohar@tamu.edu
OI Sasangohar, Farzan/0000-0001-9962-5470; Kolman,
   Jacob/0000-0003-3205-1462; Head, John/0000-0002-9266-2495; Orme,
   William/0000-0001-9980-476X
CR Acierno R, 2016, DEPRESS ANXIETY, V33, P415, DOI 10.1002/da.22476
   American Psychiatric Association The American Telemedicine Association, 2018, BEST PRACT VID BAS T
   Augusterfer EF, 2015, INT REV PSYCHIATR, V27, P540, DOI 10.3109/09540261.2015.1082985
   Chakrabarti S, 2015, WORLD J PSYCHIATR, V5, P286, DOI 10.5498/wjp.v5.i3.286
   Chen JA, 2020, GEN HOSP PSYCHIAT, V66, P89, DOI 10.1016/j.genhosppsych.2020.07.002
   Corruble Emmanuelle, 2020, J Clin Psychiatry, V81, DOI 10.4088/JCP.20com13361
   Cosic K, 2020, PSYCHIAT DANUB, V32, P25, DOI 10.24869/psyd.2020.25
   Cowan Allison, 2020, Innov Clin Neurosci, V17, P23
   Dursun OB, 2020, TELEMED E-HEALTH, DOI 10.1089/tmj.2020.0237
   Fagiolini Andrea, 2020, J Clin Psychiatry, V81, DOI 10.4088/JCP.20com13357
   Fish Allison, 2011, AMIA Annu Symp Proc, V2011, P417
   Fowler JC, 2019, PSYCHOTHERAPY, V56, P91, DOI 10.1037/pst0000174
   Haxhihamza K, 2020, TELEMED E-HEALTH, DOI 10.1089/tmj.2020.0256
   Heschel A., 2005, THE SABBATH
   Hubley S, 2016, WORLD J PSYCHIATR, V6, P269, DOI 10.5498/wjp.v6.i2.269
   Kahn MW, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2010377
   Kalin ML, 2020, AM J PSYCHIAT, V177, P636, DOI 10.1176/appi.ajp.2020.20040372
   Kash BA, 2019, COR PROJECT REPORT A
   Koopman RJ, 2014, TELEMED E-HEALTH, V20, P253, DOI 10.1089/tmj.2013.0188
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Looi JCL, 2020, AUSTRALAS PSYCHIATRY, V28, P508, DOI 10.1177/1039856220930675
   O'Brien M, 2020, IRISH J PSYCHOL MED, V37, P250, DOI 10.1017/ipm.2020.54
   Ohannessian R, 2020, JMIR PUBLIC HLTH SUR, V6, P121, DOI 10.2196/18810
   Olwill C, 2020, Ir J Psychol Med, P1, DOI 10.1017/ipm.2020.51
   Percudani M, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112980
   Prisco Vincenzo, 2020, Recenti Progressi in Medicina, V111, P411, DOI 10.1701/3407.33923
   Rao AJ, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102074
   Reay RE, 2020, AUSTRALAS PSYCHIATRY, V28, P514, DOI 10.1177/1039856220943032
   Sasangohar F, 2013, P 57 ANN M HUM FACT, P1745, DOI [10.1177/1541931213571389, DOI 10.1177/1541931213571389]
   Sasangohar F, 2020, ANESTH ANALG, V131, P106, DOI 10.1213/ANE.0000000000004866
   Teixeira ALS, 2020, REV PSIQUIATR SALUD, V13, P174, DOI [10.1016/j.rpsm.2020.06.001, 10.1016/j.rpsm.2070.06.001]
   Sharma A, 2020, J CHILD ADOL PSYCHOP, V30, P404, DOI 10.1089/cap.2020.0062
   Shaw RJ, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-106
   Smith K, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/21108
   Sousa Avinash De, 2020, Indian J Public Health, V64, pS245, DOI 10.4103/ijph.IJPH_511_20
   Uscher-Pines L, 2014, TELEMED E-HEALTH, V20, P990, DOI 10.1089/tmj.2014.0015
   Usman M, 2020, Ir J Psychol Med, P1, DOI 10.1017/ipm.2020.86
   Wright JH, 2020, PSYCHOTHER PSYCHOSOM, V89, P130, DOI 10.1159/000507376
   Yellowlees P, 2020, PSYCHIAT SERV, V71, P749, DOI 10.1176/appi.ps.202000230
   Zhou JY, 2020, AM J PSYCHIAT, V177, P574, DOI 10.1176/appi.ajp.2020.20030304
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
   Zulfic Z, 2020, AUST NZ J PSYCHIAT, DOI 10.1177/0004867420937788
NR 42
TC 0
Z9 0
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD OCT 1
PY 2020
VL 22
IS 10
AR e22523
DI 10.2196/22523
PG 9
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA OH4FH
UT WOS:000582525800004
PM 32936768
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Romer, D
   Jamieson, KH
AF Romer, Daniel
   Jamieson, Kathleen Hall
TI Conspiracy theories as barriers to controlling the spread of COVID-19 in
   the US
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE Conspiracy theories; COVID-19; Prevention; Vaccination; Political
   ideology; Media use; Vaccination misinformation
ID MISINFORMATION; BELIEFS
AB Rationale: The COVID-19 pandemic poses extraordinary challenges to public health.
   Objective: Because the novel coronavirus is highly contagious, the widespread use of preventive measures such as masking, physical distancing, and eventually vaccination is needed to bring it under control. We hypothesized that accepting conspiracy theories that were circulating in mainstream and social media early in the COVID-19 pandemic in the US would be negatively related to the uptake of preventive behaviors and also of vaccination when a vaccine becomes available.
   Method: A national probability survey of US adults (N = 1050) was conducted in the latter half of March 2020 and a follow-up with 840 of the same individuals in July 2020. The surveys assessed adoption of preventive measures recommended by public health authorities, vaccination intentions, conspiracy beliefs, perceptions of threat, belief about the safety of vaccines, political ideology, and media exposure patterns.
   Results: Belief in three COVID-19-related conspiracy theories was highly stable across the two periods and inversely related to the (a) perceived threat of the pandemic, (b) taking of preventive actions, including wearing a face mask, (c) perceived safety of vaccination, and (d) intention to be vaccinated against COVID-19. Conspiracy beliefs in March predicted subsequent mask-wearing and vaccination intentions in July even after controlling for action taken and intentions in March. Although adopting preventive behaviors was predicted by political ideology and conservative media reliance, vaccination intentions were less related to political ideology. Mainstream television news use predicted adopting both preventive actions and vaccination.
   Conclusions: Because belief in COVID-related conspiracy theories predicts resistance to both preventive behaviors and future vaccination for the virus, it will be critical to confront both conspiracy theories and vaccination misinformation to prevent further spread of the virus in the US. Reducing those barriers will require continued messaging by public health authorities on mainstream media and in particular on politically conservative outlets that have supported COVID-related conspiracy theories.
C1 [Romer, Daniel; Jamieson, Kathleen Hall] Univ Penn, Annenberg Publ Policy Ctr, 202 S 36th ST, Philadelphia, PA 19104 USA.
RP Romer, D (corresponding author), Univ Penn, Annenberg Publ Policy Ctr, 202 S 36th ST, Philadelphia, PA 19104 USA.
EM dan.romer@appc.upenn.edu; kathleen.jamieson@asc.upenn.edu
FU Annenberg Public Policy Center of the University of Pennsylvania
FX This research was funded by the Annenberg Public Policy Center of the
   University of Pennsylvania. We thank the team at Qualtrics for their
   implementation of both waves of the survey and Dr. Kenneth Winneg and
   Gary Gehman of the APPC for their assistance in developing the survey.
CR Albeverio S, 2020, STOCH DYNAM, V20, DOI 10.1142/S0219493720500318
   Allcott H, 2020, POLARIZATION PUBLIC
   Barua Z., 2020, DISASTER SCI, DOI [10.1016/j.pdisas.2020.100119, DOI 10.1016/J.PDISAS.2020.100119]
   Bollen KA, 2009, STRUCT EQU MODELING, V16, P498, DOI 10.1080/10705510903008253
   CDC, 2020, HLTH EQ CONS RAC ETH
   CDC, 2020, AD RISK SEV ILLN COV
   Centers for Disease Control and Prevention (CDC), 2020, REC REG US CLOTH FAC
   Chan MPS, 2017, PSYCHOL SCI, V28, P1531, DOI 10.1177/0956797617714579
   Crocker J, 1999, PERS SOC PSYCHOL B, V25, P941, DOI 10.1177/01461672992511003
   Cummings W., 2020, I WAS QUITE SERIOUS
   Douglas KM, 2019, POLIT PSYCHOL, V40, P3, DOI 10.1111/pops.12568
   Eggertson L, 2010, CAN MED ASSOC J, V182, pE199, DOI 10.1503/cmaj.109-3179
   Elflein J., 2020, PROPORTION ADULTS US
   Funke D., 2020, RUSH LIMBAUGH IS SPR
   Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433
   Gregory J., 2020, TRAIL DECEIT 13 MOST
   Hahl O, 2018, AM SOCIOL REV, V83, P1, DOI 10.1177/0003122417749632
   Harambam J, 2015, PUBLIC UNDERST SCI, V24, P466, DOI 10.1177/0963662514559891
   Hofstadter Richard, 2008, PARANOID STYLE AM PO
   Hornsey MJ, 2020, J EXP SOC PSYCHOL, V88, DOI 10.1016/j.jesp.2019.103947
   Howard J., 2020, P NATL ACAD SCI USA, P1, DOI [10.1073/pnas, DOI 10.1073/PNAS]
   Imhoff R, 2020, SOC PSYCHOL PERS SCI, V11, P1110, DOI 10.1177/1948550620934692
   Infotagion, 2020, FACTCHECK IS COVID19
   Jamieson Kathleen Hall, 2020, HARVARD KENNEDY SCH, DOI [10.37016/mr-2020-012, DOI 10.37016/MR-2020-012, 10.37016/mr-2020-012.]
   Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1
   Jolley D, 2017, J APPL SOC PSYCHOL, V47, P459, DOI 10.1111/jasp.12453
   Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Lee B.Y., 2020, COVID19 WAS NOT BIOE
   Lewandowsky S, 2012, PSYCHOL SCI PUBL INT, V13, P106, DOI 10.1177/1529100612451018
   Miller JM, 2020, CAN J POLIT SCI, V53, P319, DOI 10.1017/S0008423920000517
   Montanaro D., 2020, FACT CHECK TRUMP COM
   Motta M, 2020, CAN J POLIT SCI, V53, P335, DOI 10.1017/S0008423920000396
   Muthen L.K., 1998, MPLUS USERS GUIDE
   Muthen L.K., 2002, USE MONTE CARLO STUD
   National Opinion Research Center, 2020, AM NORC
   Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017
   Oliver JE, 2014, JAMA INTERN MED, V174, P817, DOI 10.1001/jamainternmed.2014.190
   Pew Research Center, 2020, REP DEM OV EV FUETH
   Rogers R. W., 1983, SOCIAL PSYCHOPHYSIOL, P153, DOI DOI 10.1093/DEAFED/ENT031
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Singer PM, 2020, J PUBLIC HEALTH POL, V41, P399, DOI 10.1057/s41271-020-00243-0
   Strecher V.J., 1997, HLTH BEHAV HLTH ED T, P41
   Uscinski J.E., 2020, HARVARD KENNEDY SCH, V1, P23, DOI [10.37016/mr-2020-015, DOI 10.37016/MR-2020-015]
   Uscinski J. E., 2014, AM CONSPIRACY THEORI
   Uscinski J.E., 2017, ARGUMENTA, P1, DOI DOI 10.23811/53.ARG2017.USC
   Uscinski JE, 2016, POLIT RES QUART, V69, P57, DOI 10.1177/1065912915621621
   Wood MJ, 2012, SOC PSYCHOL PERS SCI, V3, P767, DOI 10.1177/1948550611434786
   World Health Organization, 2008, OUTBR COMM PLANN GUI
NR 49
TC 2
Z9 2
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD OCT
PY 2020
VL 263
AR 113356
DI 10.1016/j.socscimed.2020.113356
PG 8
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA OD4WI
UT WOS:000579852400010
PM 32967786
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Procopio, G
   Cancelliere, A
   Trecarichi, EM
   Mazzitelli, M
   Arrighi, E
   Perri, G
   Serapide, F
   Pelaia, C
   Lio, E
   Busceti, MT
   Pelle, MC
   Ricchio, M
   Scaglione, V
   Davoli, C
   Fusco, P
   La Gamba, V
   Torti, C
   Pelaia, G
AF Procopio, Giada
   Cancelliere, Anna
   Trecarichi, Enrico Maria
   Mazzitelli, Maria
   Arrighi, Eugenio
   Perri, Graziella
   Serapide, Francesca
   Pelaia, Corrado
   Lio, Elena
   Busceti, Maria Teresa
   Pelle, Maria Chiara
   Ricchio, Marco
   Scaglione, Vincenzo
   Davoli, Chiara
   Fusco, Paolo
   La Gamba, Valentina
   Torti, Carlo
   Pelaia, Girolamo
TI Oxygen therapy via high flow nasal cannula in severe respiratory failure
   caused by Sars-Cov-2 infection: a real-life observational study
SO THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
LA English
DT Article
DE continuous positive airway pressure; COVID-19; high-flow nasal cannula;
   respiratory failure; SARS-CoV-2
ID DELIVERY; AIR
AB The worldwide spread of coronavirus disease 2019 (COVID-19), caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization (WHO) in March 2020. According to clinical studies carried out in China and Italy, most patients experience mild or moderate symptoms; about a fifth of subjects develop a severe and critical disease, and may suffer from interstitial pneumonia, possibly associated with acute respiratory distress syndrome (ARDS) and death. In patients who develop respiratory failure, timely conventional oxygen therapy through nasal catheter plays a crucial role, but it can be used only in mild forms. Continuous positive airway pressure (CPAP) support or non-invasive mechanical ventilation (NIV) are uncomfortable, and require significant man-machine cooperation. Herein we describe our experience of five patients with COVID-19, who were treated with high-flow nasal cannula (HFNC) after failure of CPAP or NIV, and discuss the role of HFNC in COVID-19 patients. Our findings suggest that HFNC can be used successfully in selected patients with COVID-19-related ARDS. The reviews of this paper are available via the supplemental material section.
C1 [Procopio, Giada] Magna Graecia Univ Catanzaro, Infect & Trop Dis Unit, Viale Europa, I-88100 Catanzaro, Italy.
   [Cancelliere, Anna; Trecarichi, Enrico Maria; Mazzitelli, Maria; Arrighi, Eugenio; Perri, Graziella; Serapide, Francesca; Lio, Elena; Pelle, Maria Chiara; Ricchio, Marco; Scaglione, Vincenzo; Davoli, Chiara; Fusco, Paolo; La Gamba, Valentina; Torti, Carlo] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Infect & Trop Dis Unit, Catanzaro, Italy.
   [Pelaia, Corrado; Busceti, Maria Teresa] Magna Graecia Univ Hosp Catanzaro, Resp Dis Unit, Catanzaro, Italy.
   [Pelaia, Girolamo] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
RP Procopio, G (corresponding author), Magna Graecia Univ Catanzaro, Infect & Trop Dis Unit, Viale Europa, I-88100 Catanzaro, Italy.
EM procopiogiada@libero.it
OI Procopio, Giada/0000-0001-5148-3610
CR Agarwal A, 2020, CAN J ANESTH, V67, P1217, DOI 10.1007/s12630-020-01740-2
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Borghesi A, 2020, RADIOL MED, V125, P509, DOI 10.1007/s11547-020-01200-3
   Chanques G, 2013, MINERVA ANESTESIOL, V79, P1344
   Coe AB, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232707
   Cortegiani A, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2473-y
   Delclaux C, 2000, JAMA-J AM MED ASSOC, V284, P2352, DOI 10.1001/jama.284.18.2352
   Dysart K, 2009, RESP MED, V103, P1400, DOI 10.1016/j.rmed.2009.04.007
   Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC
   Gaeckle NT, 2020, AM J RESP CRIT CARE, DOI [10.1164/rccm.202006-2309OC., DOI 10.1164/RCCM.202006-2309OC.]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geng SK, 2020, HEART LUNG, V49, P444, DOI 10.1016/j.hrtlng.2020.03.018
   He G, 2020, ZHEJIANG DA XUE XUE, P49
   Hui DS, 2007, CHEST, V132, P540, DOI 10.1378/chest.07-0636
   Hui DS, 2006, CHEST, V130, P730, DOI 10.1378/chest.130.3.730
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Karamouzos V, 2020, MONALDI ARCH CHEST D, P90
   Kotoda M, 2020, J HOSP INFECT, V104, P534, DOI 10.1016/j.jhin.2019.11.010
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Li J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00892-2020
   Lu X, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020393
   Mauri T, 2017, AM J RESP CRIT CARE, V195, P1207, DOI 10.1164/rccm.201605-0916OC
   Mazzitelli M, 2020, MEDITERR J HEMATOL I, V12, DOI 10.4084/MJHID.2020.054
   Mazzitelli M, 2020, J MED VIROL, DOI 10.1002/jmv.26016
   Percorso assistenziale per il paziente affetto da COVID-19, SEZ 2 RACC GEST LOC
   Raoof S, 2020, CHEST, DOI [10.1016/j.chest.2020.07.013., DOI 10.1016/J.CHEST.2020.07.013.]
   Remy KE, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02892-9
   Renda T, 2018, BRIT J ANAESTH, V120, P18, DOI 10.1016/j.bja.2017.11.010
   Roca O, 2019, AM J RESP CRIT CARE, V199, P1368, DOI 10.1164/rccm.201803-0589OC
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Slessarev M, 2020, CAN J ANESTH, V67, P1288, DOI 10.1007/s12630-020-01661-0
   Spoletini G, 2015, CHEST, V148, P253, DOI 10.1378/chest.14-2871
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang K, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00653-z
   WHO, 2020, CLIN MAN SEV AC RESP
   Winck JC, 2020, PULMONOLOGY, V26, P213, DOI 10.1016/j.pulmoe.2020.04.013
NR 36
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1753-4658
EI 1753-4666
J9 THER ADV RESPIR DIS
JI Ther. Adv. Respir. Dis.
PD OCT
PY 2020
VL 14
AR 1753466620963016
DI 10.1177/1753466620963016
PG 10
WC Respiratory System
SC Respiratory System
GA OI5YJ
UT WOS:000583353300001
PM 33070706
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cinar, G
   Sancaoglu, C
   Inan, B
   Dincer, I
   Cakici, M
   Sayin, T
   Azap, A
   Akar, AR
AF Cinar, Gule
   Sancaoglu, Cahit
   Inan, Bahadir
   Dincer, Irem
   Cakici, Mehmet
   Sayin, Tamer
   Azap, Alpay
   Akar, Ahmet Ruchan
TI Heart transplant recipient survivor from COVID-19: The first case of
   Turkey
SO TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND
   CARDIOVASCULAR SURGERY
LA English
DT Article
DE COVID-19; heart transplantation; immunocompromised
AB Any highly infectious and rapidly spreading disease is a primary concern for immunocompromised solid organ transplant recipients. The number of data about the spectrum of clinical illness, the treatment modalities, and the outcomes of COVID-19 in this vulnerable population is scant and still remains empirical. Herein, we report the first COVID-19 case of a heart transplant recipient in Turkey who presented with fever, postnasal discharge, and myalgias for two days. The possibility of lung involvement was ruled out by thoracic computed tomography. Despite stable vital signs, we reduced the intensity of immunosuppressive therapy and maintained home self-isolation promptly. We also commenced a five-day course of hydroxychloroquine 200 mg q12h initially. After confirmation of real-time reverse-transcriptase-polymerasechain-reaction testing of the nasopharyngeal swab positive for COVID-19, the patient was hospitalized. After a loading dose of favipiravir 1,600 mg b.i. d., the patient received a five-day course of favipiravir 600 mg q12h. He was discharged with cure after 23 days of hospital isolation and treatment. In conclusion, treatment process can be affected by the daily electrocardiography, hand-held portable echocardiography, myocardial injury markers, and pulse oximeter for self-monitoring in the follow-up of previous heart transplant recipients suffering from COVID-19. The lack of treatment protocols in the solid organ transplant recipients with COVID-19 infection and the controversies about the protective effect of immunosuppression invite a global and update discussion.
C1 [Cinar, Gule; Azap, Alpay] Ankara Univ, Dept Infect Dis & Clin Microbiol, Sch Med, Ankara, Turkey.
   [Sancaoglu, Cahit; Inan, Bahadir; Cakici, Mehmet; Akar, Ahmet Ruchan] Ankara Univ, Dept Cardiovasc Surg, Sch Med, Ankara, Turkey.
   [Dincer, Irem; Sayin, Tamer] Ankara Univ, Dept Cardiol, Sch Med, Ankara, Turkey.
RP Akar, AR (corresponding author), Ankara Univ, Tip Fak, Kalp & Damar Cerrahisi Anabilim Dali, TR-06590 Ankara, Turkey.
EM akarruchan@gmail.com
RI Akar, Ahmet Ruchan/C-9905-2009
OI Akar, Ahmet Ruchan/0000-0002-5191-5505
CR Aslam S, 2020, J HEART LUNG TRANSPL, V39, P408, DOI 10.1016/j.healun.2020.03.007
   Bonow RO, 2020, JAMA CARDIOL, V5, P751, DOI 10.1001/jamacardio.2020.1105
   Cai Q, 2020, ENGINEERING BEIJING
   Chen C, 2020, FAVIPIRAVIR VERSUS A
   DeFilippis EM, 2020, CIRCULATION, V141, P2048, DOI 10.1161/CIRCULATIONAHA.120.047096
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Hsu JJ, 2020, AM J TRANSPLANT, V20, P1911, DOI 10.1111/ajt.15936
   Jankelson L, 2020, HEART RHYTHM, V17, P1472, DOI 10.1016/j.hrthm.2020.05.008
   Johnson KM, 2020, PHARMACOTHERAPY, V40, P517, DOI 10.1002/phar.2410
   Latif F, 2020, JAMA CARDIOL
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Russell MR, 2020, J HEART LUNG TRANSPL, V39, P732, DOI 10.1016/j.healun.2020.04.021
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Shiraki K, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107512
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Zou L, 2020, ARCH PHARM RES, V43, P765, DOI 10.1007/s12272-020-01258-7
NR 19
TC 0
Z9 0
U1 0
U2 0
PU BAYCINAR MEDICAL PUBL-BAYCINAR TIBBI YAYINCILIK
PI ATASEHIR
PA ORNEK MH DR SUPHI EZGI SK SARAY APT NO 11 D 6, ATASEHIR, ISTANBUL 34704,
   TURKEY
SN 1301-5680
J9 TURK GOGUS KALP DAMA
JI Turk Gogus Kalp Damar Cerrahisi Derg.
PD OCT
PY 2020
VL 28
IS 4
BP 674
EP 679
DI 10.5606/tgkdc.dergisi.2020.20291
PG 6
WC Surgery
SC Surgery
GA OH6PA
UT WOS:000582714700015
DA 2021-01-01
ER

PT J
AU Lee, YR
   Kang, MK
   Song, JE
   Kim, HJ
   Kweon, YO
   Tak, WY
   Jang, SY
   Park, JG
   Lee, C
   Hwang, JS
   Jang, BK
   Suh, JI
   Chung, WJ
   Kim, BS
   Park, SY
AF Lee, Yu Rim
   Kang, Min Kyu
   Song, Jeong Eun
   Kim, Hyun Jung
   Kweon, Young Oh
   Tak, Won Young
   Jang, Se Young
   Park, Jung Gil
   Lee, Changhyeong
   Hwang, Jae Seok
   Jang, Byoung Kuk
   Suh, Jeong Ill
   Chung, Woo Jin
   Kim, Byung Seok
   Park, Soo Young
TI Clinical outcomes of coronavirus disease 2019 in patients with
   pre-existing liver diseases: A multicenter study in South Korea
SO CLINICAL AND MOLECULAR HEPATOLOGY
LA English
DT Article
DE Liver diseases; Liver cirrhosis; Prognosis; Mortality; COVID-19
ID CIRRHOSIS; INFECTIONS; MANAGEMENT; FAILURE; RISK
AB Background/Aims: Although coronavirus disease 2019 (COVID-19) has spread rapidly worldwide, the implication of pre-existing liver disease on the outcome of COVID-19 remains unresolved.
   Methods: A total of 1,005 patients who were admitted to five tertiary hospitals in South Korea with laboratory-confirmed COVID-19 were included in this study. Clinical outcomes in COVID-19 patients with coexisting liver disease as well as the predictors of disease severity and mortality of COVID-19 were assessed.
   Results: Of the 47 patients (4.7%) who had liver-related comorbidities, 14 patients (1.4%) had liver cirrhosis. Liver cirrhosis was more common in COVID-19 patients with severe pneumonia than in those with non-severe pneumonia (4.5% vs. 0.9%, P=0.006). Compared to patients without liver cirrhosis, a higher proportion of patients with liver cirrhosis required oxygen therapy; were admitted to the intensive care unit; had septic shock, acute respiratory distress syndrome, or acute kidney injury; and died (P<0.05). The overall survival rate was significantly lower in patients with liver cirrhosis than in those without liver cirrhosis (log-rank test, P=0.003). Along with old age and diabetes, the presence of liver cirrhosis was found to be an independent predictor of severe disease (odds ratio, 4.52; 95% confidence interval [CI], 1.20-17.02; P=0.026) and death (hazard ratio, 2.86; 95% CI, 1.04-9.30; P=0.042) in COVID-19 patients.
   Conclusions: This study suggests liver cirrhosis is a significant risk factor for COVID-19. Stronger personal protection and more intensive treatment for COVID-19 are recommended in these patients.
C1 [Lee, Yu Rim; Kweon, Young Oh; Tak, Won Young; Jang, Se Young; Park, Soo Young] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea.
   [Lee, Yu Rim; Kweon, Young Oh; Tak, Won Young; Jang, Se Young; Park, Soo Young] Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea.
   [Lee, Yu Rim; Kang, Min Kyu; Song, Jeong Eun; Kim, Hyun Jung; Kweon, Young Oh; Tak, Won Young; Jang, Se Young; Park, Jung Gil; Lee, Changhyeong; Hwang, Jae Seok; Jang, Byoung Kuk; Suh, Jeong Ill; Chung, Woo Jin; Kim, Byung Seok; Park, Soo Young] Daegu Gyeongbuk Liver Study Grp, Daegu, South Korea.
   [Kang, Min Kyu; Park, Jung Gil] Yeungnam Univ, Coll Med, Dept Internal Med, Daegu, South Korea.
   [Song, Jeong Eun; Lee, Changhyeong; Kim, Byung Seok] Daegu Catholic Univ, Sch Med, Dept Internal Med, 33 Duryugongwon Ro 17 Gil, Daegu 42472, South Korea.
   [Kim, Hyun Jung; Hwang, Jae Seok; Jang, Byoung Kuk; Chung, Woo Jin] Keimyung Univ, Sch Med, Dept Internal Med, 1035 Dalgubeul Daero, Daegu 42601, South Korea.
   [Suh, Jeong Ill] Dongguk Univ, Gyeongju Hosp, Coll Med, Dept Internal Med, Gyeongju, South Korea.
RP Kim, BS (corresponding author), Daegu Catholic Univ, Sch Med, Dept Internal Med, 33 Duryugongwon Ro 17 Gil, Daegu 42472, South Korea.; Chung, WJ (corresponding author), Keimyung Univ, Sch Med, Dept Internal Med, 1035 Dalgubeul Daero, Daegu 42601, South Korea.; Park, SY (corresponding author), Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, 130 Dongdeok Ro, Daegu 41944, South Korea.
EM chung50@dsmc.or.kr; kbs9225@cu.ac.kr; psyoung0419@gmail.com
CR Albillos A, 2014, J HEPATOL, V61, P1385, DOI 10.1016/j.jhep.2014.08.010
   [Anonymous], KDIGO CLIN PRACTICE
   Asrani SK, 2019, J HEPATOL, V70, P151, DOI 10.1016/j.jhep.2018.09.014
   Bernardi M, 2015, J HEPATOL, V63, P1272, DOI 10.1016/j.jhep.2015.07.004
   Bernsmeier C, 2015, GASTROENTEROLOGY, V148, P603, DOI 10.1053/j.gastro.2014.11.045
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung W, 2015, CLIN MOL HEPATOL, V21, P14, DOI 10.3350/cmh.2015.21.1.14
   EASL Clinical Practice, 2018, J HEPATOL, V69, P406, DOI DOI 10.1016/j.jhep.2018.03.024
   Fernandez J, 2012, HEPATOLOGY, V55, P1551, DOI 10.1002/hep.25532
   Fernandez J, 2012, J HEPATOL, V56, pS1, DOI 10.1016/S0168-8278(12)60002-6
   Gacouin A, 2016, SHOCK, V45, P16, DOI 10.1097/SHK.0000000000000487
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Iavarone M, 2020, J HEPATOL, V73, P1063, DOI 10.1016/j.jhep.2020.06.001
   Ji D, 2020, J HEPATOL, V73, P451, DOI 10.1016/j.jhep.2020.03.044
   Korea Centers for Disease Control and Prevention ( KCDC), UPD COVID 19 KOR JUN
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e132
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Lee JH, 2010, DIGEST LIVER DIS, V42, P503, DOI 10.1016/j.dld.2009.08.002
   Qi Xiaolong, 2020, Gut, DOI 10.1136/gutjnl-2020-321666
   Sun J, 2020, LIVER INT, V40, P1278, DOI 10.1111/liv.14470
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, LAB TEST COR VIR DIS
   World Health Organization, 2020, LAB TEST HUM SUSP CA
   World Health Organization (WHO), 134 WHO
   Yeom SK, 2015, WORLD J HEPATOL, V7, P2069, DOI 10.4254/wjh.v7.i17.2069
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
NR 29
TC 0
Z9 0
U1 0
U2 0
PU KOREAN ASSOC STUDY LIVER
PI SEOUL
PA RM A1210, 53 MAPO-DAERO, MAPOTRAPALACE, DOWHA-DONG, MAPO-GU, SEOUL,
   04158, SOUTH KOREA
SN 2287-2728
EI 2287-285X
J9 CLIN MOL HEPATOL
JI Clin. Mol. Hepatol.
PD OCT
PY 2020
VL 26
IS 4
BP 562
EP 576
DI 10.3350/cmh.2020.0126
PG 15
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OE4OA
UT WOS:000580510600018
PM 33053932
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kanekura, T
   Kawahara, K
AF Kanekura, Takuro
   Kawahara, Koichi
TI Adsorptive granulocyte and monocyte apheresis: A potentially relevant
   therapeutic option for COVID-19
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE SARS-CoV-2; COVID-19; Adsorptive granulocyte and monocyte apheresis
ID MYELOID LINEAGE LEUKOCYTES; PSORIATIC-ARTHRITIS; NEUTROPHILS; DEPLETION
AB The overproduction of proinflammatory cytokines and subsequent thromboembolism are major problems of coronavirus disease 2019 (COVID-19). Adsorptive granulocyte and monocyte apheresis (GMA), used for ulcerative colitis, is an extracorporeal therapy designed to remove activated myeloid lineage cells. Previous studies have demonstrated that GMA decreases proinflammatory cytokines and neutrophil-platelet aggregates. The effect of GMA on COVID-19 in a patient with ulcerative colitis was recently reported. The modes of action of GMA together with the findings of this case report indicate that GMA could be a relevant treatment option for COVID-19. (c) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Kanekura, Takuro] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Dermatol, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
   [Kawahara, Koichi] Osaka Inst Technol, Dept Biomed Engn, Lab Funct Foods, Asahi Ku, 5-16-1 Omiya, Osaka 5358585, Japan.
RP Kanekura, T (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Dermatol, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM takurok@m2.kufm.kagoshima-u.ac.jp
CR Ikeda S, 2013, J AM ACAD DERMATOL, V68, P609, DOI 10.1016/j.jaad.2012.09.037
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kanekura T, 2006, THER APHER DIAL, V10, P247, DOI 10.1111/j.1744-9987.2006.00369.x
   Kanekura T, 2018, J DERMATOL, V45, P943, DOI 10.1111/1346-8138.14471
   Kanekura T, 2017, J DERMATOL, V44, P1353, DOI 10.1111/1346-8138.13975
   Kashiwagi N, 2002, DIGEST DIS SCI, V47, P1334, DOI 10.1023/A:1015330816364
   Roldan FP, 2020, REV ESP ENFERM DIG, V112, DOI 10.17235/reed.2020.7156/2020
   Piccardoni P, 2001, BLOOD, V98, P108, DOI 10.1182/blood.V98.1.108
   Saniabadi AR, 2003, THER APHER DIAL, V7, P48, DOI 10.1046/j.1526-0968.2003.00012.x
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD OCT
PY 2020
VL 99
BP 1
EP 2
DI 10.1016/j.ijid.2020.07.025
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA OH1IP
UT WOS:000582325600001
PM 32721534
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zheng, F
   Zhou, YW
   Zhou, ZG
   Ye, F
   Huang, BY
   Huang, YX
   Ma, J
   Zuo, Q
   Tan, X
   Xie, J
   Niu, PH
   Wang, WL
   Xu, Y
   Peng, F
   Zhou, N
   Cai, CL
   Tang, W
   Xiao, XQ
   Li, Y
   Zhou, ZG
   Jiang, YF
   Xie, YL
   Tan, WJ
   Gong, GZ
AF Zheng, Fang
   Zhou, Yanwen
   Zhou, Zhiguo
   Ye, Fei
   Huang, Baoying
   Huang, Yaxiong
   Ma, Jing
   Zuo, Qi
   Tan, Xin
   Xie, Jun
   Niu, Peihua
   Wang, Wenlong
   Xu, Yun
   Peng, Feng
   Zhou, Ning
   Cai, Chunlin
   Tang, Wei
   Xiao, Xinqiang
   Li, Yi
   Zhou, Zhiguang
   Jiang, Yongfang
   Xie, Yuanlin
   Tan, Wenjie
   Gong, Guozhong
TI SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A
   randomized, open-label, parallel-group trial
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Novaferon; Antiviral drug; Lopinavir/Ritonavir;
   Viral clearance; Aerosolized inhalation
ID CORONAVIRUS; PNEUMONIA; OUTBREAK
AB Background: The antiviral effects of Novaferon, a potent antiviral protein drug, on COVID-19 was evaluated in the laboratory, and in a randomized, open-label, parallel-group trial.
   Methods: In the laboratory, Novaferon's inhibition of viral replication in cells infected with SARS-CoV-2, and prevention of SARS-CoV-2 entry into healthy cells was determined. Antiviral effects of Novaferon in COVID-19 patients with treatment of Novaferon, Novaferon plus Lopinavir/Ritonavir, or Lopinavir/Ritonavir were evaluated. The primary endpoint was the SARS-CoV-2 clearance rates on day six of treatment, and the secondary endpoint was the time to SARS-CoV-2 clearance.
   Results: Novaferon inhibited viral replication (EC50 = 1.02 ng/ml), and prevented viral infection (EC50 = 0.10 ng/ml). Results from the 89 enrolled COVID-19 patients showed that both Novaferon and Novaferon plus Lopinavir/Ritonavir groups had significantly higher viral clearance rates on day six than Lopinavir/Ritonavir group (50.0% vs. 24.1%, p = 0.0400, and 60.0% vs. 24.1%, p = 0.0053). The median time to viral clearance was six days, six days, and nine days for three groups, respectively, a 3-day reduction in both the Novaferon and Novaferon plus Lopinavir/Ritonavir groups compared with the Lopinavir/Ritonavir group.
   Conclusions: Novaferon exhibited anti-SARS-CoV-2 effects in vitro and in COVID-19 patients. These data justify further evaluation of Novaferon. (c) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Zheng, Fang; Huang, Yaxiong; Cai, Chunlin; Tang, Wei; Xie, Yuanlin] First Hosp Changsha, Dept Infect Dis, Changsha, Peoples R China.
   [Zhou, Zhiguo] First Hosp Changsha, Dept Resp Med, Changsha, Peoples R China.
   [Zuo, Qi] First Hosp Changsha, Dept Intens Care Unit, Changsha, Peoples R China.
   [Tan, Xin] First Hosp Changsha, Dept Pediat, Changsha, Peoples R China.
   [Xie, Jun] First Hosp Changsha, Dept Internal Med, Changsha, Peoples R China.
   [Ma, Jing; Wang, Wenlong; Xu, Yun; Peng, Feng; Zhou, Ning; Xiao, Xinqiang; Li, Yi; Jiang, Yongfang; Gong, Guozhong] Cent South Univ, Dept Infect Dis, Xiangya Hosp 2, Changsha 410011, Peoples R China.
   [Zhou, Zhiguang] Cent South Univ, Key Lab Diabet Immunol, Natl Clin Res Ctr Metab Dis, Minist Educ,Xiangya Hosp 2, Changsha, Peoples R China.
   [Ye, Fei; Huang, Baoying; Niu, Peihua; Tan, Wenjie] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China.
RP Jiang, YF; Xie, YL; Tan, WJ; Gong, GZ (corresponding author), Cent South Univ, Dept Infect Dis, Xiangya Hosp 2, Changsha 410011, Peoples R China.
EM jiangyongfang@csu.edu.cn; 1286779459@qq.com; tanwj@ivdc.chinacdc.cn;
   gongguozhong@csu.edu.cn
FU National Science and Technology Major Project [2017ZX10202201,
   2017ZX10202203]; National Key Research and Development Program of China
   [2016YFD0500301]; Natural Science Foundation of Hunan ProvinceNatural
   Science Foundation of Hunan Province [2018JJ2452]; Specialized Science
   and Technology Project of Hunan Province [2020SK3013]
FX We thank all medical and management staff, who came from hospitals
   across Changsha City and worked at the First Hospital of Changsha, for
   their courage and dedication to COVID-19 patient care and their help in
   the hospital's overall operations during this difficult time. We
   especially thank Dr. Charlie Chen of SRD ClinMax Corporation for
   conducting the statistical analysis. This work was supported by the
   National Science and Technology Major Project (2017ZX10202201,
   2017ZX10202203), the National Key Research and Development Program of
   China (No. 2016YFD0500301), the Natural Science Foundation of Hunan
   Province (2018JJ2452) and Specialized Science and Technology Project of
   Hunan Province (2020SK3013).
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Daxian W, 2015, J HEPATOL, V62, pS521, DOI 10.1016/S0168-8278(15)30757-1
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li M, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-8
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Wang H, 2011, Patent, Patent No. [US 7,625,555 B2, 7625555]
   WHO, REP WHO CHIN JOINT M
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 76 WHO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu K, 2020, ZHEJIANG XUEXUE BAO, DOI [10.3785/j.issn.1008-9292.02.02, DOI 10.3785/J.ISSN.1008-9292.02.02]
   Zhang L, 2020, J MED VIROL, DOI [10.1002/jmv.2570.7, DOI 10.1002/JMV.2570.7]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 3
Z9 3
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD OCT
PY 2020
VL 99
BP 84
EP 91
DI 10.1016/j.ijid.2020.07.053
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA OH1IP
UT WOS:000582325600018
PM 32758689
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Finzi, E
AF Finzi, Eric
TI Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four
   patients
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; Zinc; Treatment; Case Series
ID COMMON COLD; LOZENGES; CURE
AB Coronavirus 2019 (COVID-19) is a pandemic with substantial mortality and no accepted therapy. We report here on four consecutive outpatients with clinical characteristics (CDC case definition) of and/or laboratory-confirmed COVID-19 who were treated with high dose zinc salt oral lozenges. All four patients experienced significant improvement in objective and symptomatic disease measures after one day of high dose therapy suggesting that zinc therapy was playing a role in clinical recovery. A mechanism for zinc's effects is proposed based on previously published studies on SARS- CoV-1, and randomized controlled trials assessing zinc shortening of common cold duration. The limited sample size and study design preclude a definitive statement about the effectiveness of zinc as a treatment for COVID-19 but suggest the variables to be addressed to confirm these initial findings in future trials. (C) 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Finzi, Eric] George Washington Sch Med 1, 2120 L St, Washington, DC 20037 USA.
RP Finzi, E (corresponding author), George Washington Sch Med 1, 2120 L St, Washington, DC 20037 USA.
EM Finzieric8@gmail.com
CR Carlucci P, 2020, HYDROXYCHLOROQUINE A, DOI [10.1101/2020.05.02.20080036, DOI 10.1101/2020.05.02.20080036]
   Derwand R, MED HYPOTHESES, V6
   Eby GA, 2004, BIOSCIENCE REP, V24, P23, DOI 10.1023/B:BIRE.0000037754.71063.41
   Eby GA, 2010, MED HYPOTHESES, V74, P482, DOI 10.1016/j.mehy.2009.10.017
   Hemila Harri, 2017, JRSM Open, V8, p2054270417694291, DOI 10.1177/2054270417694291
   Lanke K, 2007, J GEN VIROL, V88, P1206, DOI 10.1099/vir.0.82634-0
   Prasad AS, 2000, ANN INTERN MED, V133, P245, DOI 10.7326/0003-4819-133-4-200008150-00006
   Shittu Mujeeb Olushola, 2020, Infez Med, V28, P192
   Skalny A.V., 2020, INT J MOL MED
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
NR 10
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD OCT
PY 2020
VL 99
BP 307
EP 309
DI 10.1016/j.ijid.2020.06.006
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA OH1IP
UT WOS:000582325600059
PM 32522597
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Keske, S
   Tekin, S
   Sait, B
   Irkoren, P
   Kapmaz, M
   Cimen, C
   Ugur, S
   Celebi, I
   Bakir, VO
   Palaoglu, E
   Senturk, E
   Caglayan, B
   Cakar, N
   Tabak, L
   Ergonul, O
AF Keske, Siran
   Tekin, Suda
   Sait, Bilgin
   Irkoren, Pelin
   Kapmaz, Mahir
   Cimen, Cansu
   Ugur, Semra
   Celebi, Irfan
   Bakir, Veli Oguzalp
   Palaoglu, Erhan
   Senturk, Evren
   Caglayan, Benan
   Cakar, Nahit
   Tabak, Levent
   Ergonul, Onder
TI Appropriate use of tocilizumab in COVID-19 infection
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Tocilizumab; COVID-19; Cytokines; Interleukin-6; Therapy
ID CYTOKINE; HEALTH
AB Objective: This study aimed to describe the effectiveness and optimum use of tocilizumab (TCZ) treatment by the support of clinical, laboratory and radiologic observations.
   Methods: All patients were followed up in the hospital with daily interleukin-6 (IL-6), C-reactive protein (CRP), ferritin, D-dimer, full blood count, and procalcitonin. Thoracic computed tomography (CT) was performed on admission, when oxygen support was necessary, and seven days after TCZ started. Disease course of the patients was grouped as severe or critical, according to their clinical, laboratory and radiologic evaluations.
   Results: Forty-three patients were included: 70% were male; the median age was 64 years (minimum-maximum: 27-94); and six (14%) patients died. The median duration of oxygen support before the onset of TCZ was shorter among the severe patient group than the critical patient group (1 vs. 4 days, p < 0.001). Three cases of 21 (14%) who received TCZ in the ward were transferred to ICU, and none of them died. The levels of IL-6, CRP, ferritin, D-dimer, and procalcitonin were significantly lower in the severe cases group than the critical cases group (p = 0.025, p = 0.002, p = 0.008, p = 0.002, and p = 0.001, respectively). Radiological improvement was observed in severe cases on the seventh day of TCZ. Secondary bacterial infection was detected in 41% of critical cases, but none of the severe ones.
   Conclusion: Earlier use of TCZ in COVID-19 infection was beneficial for survival, length of hospitalization and duration of oxygen support. The recommendation for administration of TCZ was based on an increase in requirement of oxygen support, progression in thoracic CT, and elevation of inflammation markers, including IL-6, CRP, ferritin, and D-dimer, and decrease in % lymphocytes. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Keske, Siran; Cimen, Cansu] Amer Hosp, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey.
   [Tekin, Suda; Irkoren, Pelin; Kapmaz, Mahir; Ergonul, Onder] Koc Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey.
   [Sait, Bilgin] Amer Hosp, Dept Internal Med, Istanbul, Turkey.
   [Ugur, Semra; Senturk, Evren; Cakar, Nahit] Koc Univ, Sch Med, Dept Anesthesiol, Istanbul, Turkey.
   [Ugur, Semra; Senturk, Evren; Cakar, Nahit] Koc Univ, Sch Med, Intens Care Unit, Istanbul, Turkey.
   [Bakir, Veli Oguzalp] Koc Univ, Coll Engn, Dept Ind Engn, Istanbul, Turkey.
   [Palaoglu, Erhan] Amer Hosp, Clin Lab, Istanbul, Turkey.
   [Caglayan, Benan; Tabak, Levent] Koc Univ, Sch Med, Dept Chest Dis, Istanbul, Turkey.
   [Celebi, Irfan] Amer Hosp, Dept Radiol, Istanbul, Turkey.
   [Celebi, Irfan] Beykent Univ, Sch Med, Istanbul, Turkey.
RP Ergonul, O (corresponding author), Koc Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey.
EM oergonul@ku.edu.tr
RI Senturk, Evren/AAZ-5036-2020; Keske, Siran/AAG-3483-2019
OI Senturk, Evren/0000-0002-4985-562X; Keske, Siran/0000-0003-3823-4454
CR Alzghari SK, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104380
   [Anonymous], 2020, GLOB SURV COVID 19 C
   [Anonymous], 2020, DIAGNOSIS TREATMENT
   Cantini F, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8909834
   Chen X, 2020, CHINA PERSPECT-SER, P1
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   Ciotti M, 2020, CHEMOTHERAPY, V64, P215, DOI [10.1159/000507423, 10.1080/10408363.2020.1783198]
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Nishimoto N, 2000, ANN RHEUM DIS, V59, P21, DOI 10.1136/ard.59.suppl_1.i21
   Ruan Q, 2020, INTENSIVE CARE MED
   Sciascia S, 2020, CLIN EXP RHEUMATOL
   Tanaka T, 2014, SEMIN IMMUNOL, V26, P88, DOI 10.1016/j.smim.2014.01.009
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu X., 2020, P NATL ACAD SCI US
   Ye Q., 2020, J INFECT
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 23
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD OCT
PY 2020
VL 99
BP 338
EP 343
DI 10.1016/j.ijid.2020.07.036
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA OH1IP
UT WOS:000582325600066
PM 32726724
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gendrot, M
   Duflot, I
   Boxberger, M
   Delandre, O
   Jardot, P
   Le Bideau, M
   Andreani, J
   Fonta, I
   Mosnier, J
   Rolland, C
   Hutter, S
   La Scola, B
   Pradines, B
AF Gendrot, Mathieu
   Duflot, Isabelle
   Boxberger, Manon
   Delandre, Oceane
   Jardot, Priscilla
   Le Bideau, Marion
   Andreani, Julien
   Fonta, Isabelle
   Mosnier, Joel
   Rolland, Clara
   Hutter, Sebastien
   La Scola, Bernard
   Pradines, Bruno
TI Antimalarial artemisinin-based combination therapies (ACT) and COVID-19
   in Africa: In vitro inhibition of SARS-CoV-2 replication by
   mefloquine-artesunate
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE SARS-CoV-2; COVID-19; Antiviral; Antimalarial drug; in vitro; malaria
ID PHARMACOKINETICS; AMODIAQUINE
AB Objectives: At the end of November 2019, a novel coronavirus responsible for respiratory tract infections (COVID-19) emerged in China. Despitedrastic containment measures,this virus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spread in Asia and Europe. The pandemic is ongoing with a particular hotspot in Southern Europe and America; many studies predicted a similar epidemic in Africa, as is currently seen in Europe and the United States of America. However, reported data have not confirmed these predictions. One of the hypotheses that could explain the later emergence and spread of COVID-19 pandemic in African countries is the use of antimalarial drugs to treat malaria, and specifically, artemisinin-based combination therapy (ACT).
   Methods: The antiviral activity of fixed concentrations of ACT at concentrations consistent with those observed in human plasma when ACT is administered at oral doses for uncomplicated malaria treatment was evaluated in vitro against a clinically isolated SARS-CoV-2 strain (IHUMI-3) in Vero E6 cells.
   Results: Mefloquine-artesunate exerted the highest antiviral activity with% inhibition of 72.1 +/- 18.3% atexpected maximum blood concentration (C-max) for each ACT drug at doses commonly administered in malaria treatment. All the other combinations, artesunate-amodiaquine, artemether-lumefantrine, artesunate-pyronaridine, or dihydroartemisinin-piperaquine, showed antiviral inhibition in the same ranges (27.1 to 34.1 %).
   Conclusions: Antimalarial drugs for which concentration data in the lungs are available are concentrated from 10 to 160 fold more in the lungs than in blood. These in vitro results reinforce the hypothesis that antimalarial drugs could be effective as an anti-COVID-19 treatment. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Gendrot, Mathieu; Delandre, Oceane; Fonta, Isabelle; Mosnier, Joel; Pradines, Bruno] Inst Rech Biomed Armees, Dept Microbiol & Malad Infect, Unite Parasitol & Entomol, Marseille, France.
   [Gendrot, Mathieu; Delandre, Oceane; Fonta, Isabelle; Mosnier, Joel; Hutter, Sebastien; Pradines, Bruno] Aix Marseille Univ, AP HM, VITROME, IRD,SSA, Marseille, France.
   [Gendrot, Mathieu; Duflot, Isabelle; Boxberger, Manon; Delandre, Oceane; Jardot, Priscilla; Le Bideau, Marion; Andreani, Julien; Fonta, Isabelle; Mosnier, Joel; Rolland, Clara; Hutter, Sebastien; La Scola, Bernard; Pradines, Bruno] IHU Mediterranee Infect, Marseille, France.
   [Duflot, Isabelle; Boxberger, Manon; Jardot, Priscilla; Le Bideau, Marion; Andreani, Julien; Rolland, Clara; La Scola, Bernard] Aix Marseille Univ, AP HM, MEPHI, IRD, Marseille, France.
   [Fonta, Isabelle; Mosnier, Joel; Pradines, Bruno] Ctr Natl Reference Paludisme, Marseille, France.
RP Pradines, B (corresponding author), IHU Mediterranee Infect, Inst Rech Biomed Armees, Unite Parasitol & Entomol, 19-21 Blvd Jean Moulin, F-13005 Marseille, France.
EM bruno.pradines@gmail.com
RI Gendrot, Mathieu/ABI-6205-2020
FU Institut Hospitalo-Universitaire (IHU) Mediterranee Infection, the
   National Research Agency [ANR-10-IAHU-03]; L'Occitane Society
FX This study was supported by the Institut Hospitalo-Universitaire (IHU)
   Mediterranee Infection, the National Research Agency under the program
   "Investissements d'avenir", reference ANR-10-IAHU-03. M Boxberger was
   supported by L'Occitane Society.
CR Ali S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-275
   Amrane S, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101632
   Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Ashley EA, 2007, TROP MED INT HEALTH, V12, P201, DOI 10.1111/j.1365-3156.2006.01785.x
   Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Diop BZ, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002699
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Haider N, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000424
   Hanboonkunupakarn B, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00060-19
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang ZW, 2020, SCI TOTAL ENVIRON, V736, DOI 10.1016/j.scitotenv.2020.139487
   Izoulet M., COUNTRIES WHICH PRIM, DOI [10.2139/ssrn.3575899, DOI 10.2139/SSRN.3575899]
   Jittamala P, 2015, ANTIMICROB AGENTS CH, V59, P505, DOI 10.1128/AAC.03829-14
   JONES R, 1994, FORENSIC SCI INT, V68, P29, DOI 10.1016/0379-0738(94)90376-X
   Katoh S, 2020, ARCH ACAD EMERG MED, V8
   Kobia Francis, 2020, AAS Open Res, V3, P4, DOI 10.12688/aasopenres.13061.1
   Navaratnam V, 2009, EUR J CLIN PHARMACOL, V65, P809, DOI 10.1007/s00228-009-0656-1
   Park SH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/590707
   Pearson CAB, 2020, EUROSURVEILLANCE, DOI [10.2807/1560-7917, DOI 10.2807/1560-7917]
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   SUN MY, 2020, SSRN ELECT J, DOI DOI 10.2139/SSRN.3551767
   Valea I, 2014, J ANTIMICROB CHEMOTH, V69, P2499, DOI 10.1093/jac/dku154
   WINSTANLEY PA, 1988, J PHARM PHARMACOL, V40, P343, DOI 10.1111/j.2042-7158.1988.tb05264.x
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu H, 2007, RHEUMATOLOGY, V46, P920, DOI 10.1093/rheumatology/kem014
NR 29
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD OCT
PY 2020
VL 99
BP 437
EP 440
DI 10.1016/j.ijid.2020.08.032
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA OH1IP
UT WOS:000582325600084
PM 32805422
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Klopfenstein, T
   Zayet, S
   Lohse, A
   Selles, P
   Zahra, H
   Kadiane-Oussou, NJ
   Toko, L
   Royer, PY
   Balblanc, JC
   Gendrin, V
   Conrozier, T
AF Klopfenstein, Timothee
   Zayet, Souheil
   Lohse, Anne
   Selles, Phillippe
   Zahra, Hajer
   Kadiane-Oussou, N'dri Juliette
   Toko, Lynda
   Royer, Pierre-Yves
   Balblanc, Jean-Charles
   Gendrin, Vincent
   Conrozier, Thierry
CA HNF Hosp Tocilizumab
TI Impact of tocilizumab on mortality and/or invasive mechanical
   ventilation requirement in a cohort of 206 COVID-19 patients
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Tocilizumab; Mortality; Invasive mechanical
   ventilation
AB Introduction: No therapy has proven to be effective yet to reduce mortality and/or invasive mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment.
   Methods: We conducted a retrospective case-control study in the Nord Franche-Comte Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: mortality and/or IMV requirement.
   Results: Thirty patients were treated with TCZ and 176 patients were treated without TCZ. TCZ was used in patients in critical condition (oxygen therapy flow at TCZ onset was 10.5 L/min and 14/30 patients had >= 50% lung involvement on CT scan) as a rescue treatment (8/30 patients who died were not admitted in USC in regard to their comorbidities). However, mortality and/or IMV requirement were lower in patients with TCZ than in patients without TCZ (27% vs 52%, p = 0.009).
   Conclusion: Despite the small sample size in the TCZ group, this result suggests that TCZ reduces mortality and/or IMV requirement in patients with severe SARS-CoV-2 pneumonia. This notion needs to be confirmed and spread in the medical community. (C) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Klopfenstein, Timothee; Zayet, Souheil; Kadiane-Oussou, N'dri Juliette; Toko, Lynda; Royer, Pierre-Yves; Gendrin, Vincent] Nord Franche Comte Hosp, Dept Infect Dis, F-90400 Trevenans, France.
   [Lohse, Anne; Balblanc, Jean-Charles; Conrozier, Thierry] Nord Franche Comte Hosp, Dept Rheumatol, F-90400 Trevenans, France.
   [Selles, Phillippe] Nord Franche Comte Hosp, Dept Med Informat, F-90400 Trevenans, France.
   [Zahra, Hajer] Nord Franche Comte Hosp, Diabetol & Endocrinol Dept, F-90400 Trevenans, France.
RP Klopfenstein, T; Zayet, S (corresponding author), Nord Franche Comte Hosp, Dept Infect Dis, F-90400 Trevenans, France.
EM timothee.klopfenstein@hnfc.fr; souheil.zayet@hnfc.fr
CR [Anonymous], 2020, TOCILIZUMAB TREATMEN
   Bernard Stoecklin S, 2020, EURO SURVEILL B EUR, V25
   Capra R, 2020, EUR J INTERN MED
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Fu B, 2020, J TRANSL MED, P18
   Henry BM, 2020, CLIN CHEM LAB MED, V10
   JIN ZR, 2020, INTENS CARE MED, V6, DOI DOI 10.1061/AJRUA6.0001034
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Phua J, 2020, LANCET RESP MED, V6
   Rossotti R, 2020, J INFECT, V8
   Saleh K, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-0898-8
   Siddiqi HK, 2020, J HEART LUNG TRANSPL
   Somers EC, 2020, CLIN INFECT DIS PUBL, V11
   Weiss P, 2020, LANCET LOND ENGL, V28, P1014
   Xu Z, 2020, LANCET RESP MED, V18
   Ye Q, 2020, J INFECTION
   Zayet S, 2020, INFECTION, DOI 10.1007/s15010-020-01442-3
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD OCT
PY 2020
VL 99
BP 491
EP 495
DI 10.1016/j.ijid.2020.08.024
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA OH1IP
UT WOS:000582325600094
PM 32798660
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ciampi, E
   Uribe-San-Martin, R
   Soler, B
   Fernandez, R
   Garcia, P
   Navarrete-Asenjo, C
   Tirapegui, JM
   Torres, R
   Polanco, J
   Suarez, F
   Cuello, MJ
   Carcamo, C
AF Ciampi, Ethel
   Uribe-San-Martin, Reinaldo
   Soler, Bernardita
   Fernandez, Ramiro
   Garcia, Pia
   Navarrete-Asenjo, Claudio
   Miguel Tirapegui, Jose
   Torres, Ruben
   Polanco, Juan
   Suarez, Felipe
   Jose Cuello, Maria
   Carcamo, Claudia
TI COVID-19 in MS and NMOSD: A multicentric online national survey in Chile
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Letter
DE COVID-19; Multiple sclerosis; Nmosd; Disease-modifying therapy;
   Immunotherapy
C1 [Ciampi, Ethel; Uribe-San-Martin, Reinaldo; Soler, Bernardita; Carcamo, Claudia] Pontificia Univ Catolica Chile, Neurol, Santiago, Chile.
   [Ciampi, Ethel; Uribe-San-Martin, Reinaldo; Soler, Bernardita] Hosp Dr Sotero del Rio, Neurol, Santiago, Chile.
   [Fernandez, Ramiro] Hosp Clin Magallanes, Neurol, Punta Arenas, Chile.
   [Garcia, Pia] Hosp Dr Hernan Henriquez Aravena, Neurol, Temuco, Chile.
   [Navarrete-Asenjo, Claudio] Univ Austral Chile, Hosp Reg Base Valdivia, Neurol, Valdivia, Chile.
   [Miguel Tirapegui, Jose] Hosp Dr Eduardo Schutz Schroeder, Neurol, Puerto Montt, Chile.
   [Torres, Ruben] Univ Concepcion, Fac Med, Clin Univ Concepcion, Neurol,Hosp Guillermo Grant Benavente, Concepcion, Chile.
   [Polanco, Juan] Hosp San Jose Osorno, Neurol, Osorno, Chile.
   [Suarez, Felipe] Univ Austral Chile, Hosp San Jose Osorno, Clin Alemana Osorno, Neurol, Osorno, Chile.
   [Jose Cuello, Maria] Hosp Reg Copiapo, Neurol, Copiapo, Chile.
RP Ciampi, E; Carcamo, C (corresponding author), Pontificia Univ Catolica Chile, Neurol, Santiago, Chile.; Ciampi, E (corresponding author), Hosp Dr Sotero del Rio, Neurol, Santiago, Chile.
EM ethelciampi@gmail.com; ccarcamo@med.puc.cl
OI Ciampi, Ethel/0000-0002-7330-5433
CR Bowen JD, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000783
   Brownlee W, 2020, NEUROLOGY, V94, P949, DOI 10.1212/WNL.0000000000009507
   Ciampi E, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102204
   Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581
   Sahraian Mohammad Ali, 2020, Mult Scler Relat Disord, V44, P102245, DOI 10.1016/j.msard.2020.102245
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
NR 6
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD OCT
PY 2020
VL 45
AR 102392
DI 10.1016/j.msard.2020.102392
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA OG9YR
UT WOS:000582230900038
PM 32683306
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU De Angelis, M
   Petracca, M
   Lanzillo, R
   Morra, VB
   Moccia, M
AF De Angelis, Marcello
   Petracca, Maria
   Lanzillo, Roberta
   Morra, Vincenzo Brescia
   Moccia, Marcello
TI Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis:
   Two cases and implications for clinical practice
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Letter
DE Multiple sclerosis; Cladribine; COVID-19; Lymphocytes
AB Background: The use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) could affect COVID-19 outcomes by modulating the immune response, which, in turn, might favor viral replication and/or confer protection from COVID-19 induced inflammatory response
   Case report: We report on two MS patients treated with cladribine, with heterogeneous demographics and clinical features, who developed mild or no symptoms from COVID-19 and produced anti-SARS-CoV-2 anti-bodies, notwithstanding low lymphocyte levels.
C1 [De Angelis, Marcello; Petracca, Maria; Lanzillo, Roberta; Morra, Vincenzo Brescia; Moccia, Marcello] Federico II Univ Naples, Multiple Sclerosis Clin Care & Res Ctr, Dept Neurosci Reprod Sci & Odontostomatol, Via Sergio Pansini 5, I-80131 Naples, Italy.
RP Moccia, M (corresponding author), Federico II Univ Naples, Multiple Sclerosis Clin Care & Res Ctr, Dept Neurosci Reprod Sci & Odontostomatol, Via Sergio Pansini 5, I-80131 Naples, Italy.
EM marcello.moccia@unina.it
RI Moccia, Marcello/N-6987-2015
OI Moccia, Marcello/0000-0003-2613-3090; Lanzillo,
   Roberta/0000-0001-6388-8180
CR Bastos ML, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2516
   Berger JR, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000761
   Buonomo A, 2020, MULT SCLER RELAT DIS, V44
   Cook S, 2011, MULT SCLER J, V17, P578, DOI 10.1177/1352458510391344
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073
   Minotti C, 2020, J INFECTION, V81, pE61, DOI 10.1016/j.jinf.2020.04.026
   Montero-Escribano P, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102185
   Parrotta E, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000835
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Stuve O, 2019, THER ADV NEUROL DISO, V12, DOI 10.1177/1756286419854986
NR 10
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD OCT
PY 2020
VL 45
AR 102452
DI 10.1016/j.msard.2020.102452
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA OG9YR
UT WOS:000582230900090
PM 32823148
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Iannetta, M
   Cesta, N
   Stingone, C
   Malagnino, V
   Teti, E
   Vitale, P
   De Simone, G
   Rossi, B
   Ansaldo, L
   Compagno, M
   Spalliera, I
   Di Lorenzo, A
   Landi, D
   Nicoletti, CG
   Marfia, GA
   Andreoni, M
   Sarmati, L
AF Iannetta, Marco
   Cesta, Novella
   Stingone, Christof
   Malagnino, Vincenzo
   Teti, Elisabetta
   Vitale, Pietro
   De Simone, Giuseppe
   Rossi, Benedetta
   Ansaldo, Lorenzo
   Compagno, Mirko
   Spalliera, Ilaria
   Di Lorenzo, Andrea
   Landi, Doriana
   Nicoletti, Carolina Gabri
   Marfia, Girolama Alessandra
   Andreoni, Massimo
   Sarmati, Loredana
TI Mild clinical manifestations of SARS-CoV-2 related pneumonia in two
   patients with multiple sclerosis under treatment with ocrelizumab
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Letter
DE COVID-19; Disease modifying therapies; DMT; DMD; MS; IL-6
ID COVID-19
AB Background: Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS).
   Objectives: to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment.
   Methods: Case series.
   Results: Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae.
   Conclusion: Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.
C1 [Iannetta, Marco; Cesta, Novella; Stingone, Christof; Malagnino, Vincenzo; Teti, Elisabetta; Vitale, Pietro; De Simone, Giuseppe; Rossi, Benedetta; Ansaldo, Lorenzo; Compagno, Mirko; Spalliera, Ilaria; Di Lorenzo, Andrea; Landi, Doriana; Nicoletti, Carolina Gabri; Marfia, Girolama Alessandra; Andreoni, Massimo; Sarmati, Loredana] Tor Vergata Univ, Dept Syst Med, Rome, Italy.
   [Iannetta, Marco; Stingone, Christof; Malagnino, Vincenzo; Teti, Elisabetta; Andreoni, Massimo; Sarmati, Loredana] Policlin Tor Vergata, Infect Dis Clin, Rome, Italy.
   [Landi, Doriana; Nicoletti, Carolina Gabri; Marfia, Girolama Alessandra] Policlin Tor Vergata, Multiple Sclerosis & Res Unit, Rome, Italy.
RP Iannetta, M (corresponding author), Tor Vergata Univ, Dept Syst Med, Rome, Italy.; Iannetta, M (corresponding author), Policlin Tor Vergata, Infect Dis Clin, Rome, Italy.
EM marco.iannetta@uniroma2.it
RI Iannetta, Marco/B-5596-2017
OI Iannetta, Marco/0000-0002-6938-8627; Malagnino,
   Vincenzo/0000-0002-6561-5298
CR Barr TA, 2012, J EXP MED, V209, P1001, DOI 10.1084/jem.20111675
   Barzegar M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000753
   Borriello G, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102165
   Conte William L, 2020, Mult Scler Relat Disord, V44, P102315, DOI 10.1016/j.msard.2020.102315
   Foerch C, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102180
   Ghajarzadeh M, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102222
   Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277
   Hughes R, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102192
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   Lucchini Matteo, 2020, Mult Scler Relat Disord, V44, P102323, DOI 10.1016/j.msard.2020.102323
   Meca-Lallana Virginia, 2020, Mult Scler Relat Disord, V44, P102306, DOI 10.1016/j.msard.2020.102306
   Montero-Escribano P, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102185
   Novi G, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101430
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Suwanwongse K, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102201
   Tallantyre EC, 2018, J NEUROL, V265, P1115, DOI 10.1007/s00415-018-8812-0
   Thornton Jeanine Rempe, 2020, Mult Scler Relat Disord, V44, P102341, DOI 10.1016/j.msard.2020.102341
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD OCT
PY 2020
VL 45
AR 102442
DI 10.1016/j.msard.2020.102442
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA OG9YR
UT WOS:000582230900084
PM 32777745
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Nesbitt, C
   Rath, L
   Yeh, WZ
   Zhong, M
   Wesselingh, R
   Monif, M
   Richards, J
   Minh, VB
   Jokubaitis, VG
   Skibina, O
   Butzkueven, H
   van der Walt, A
AF Nesbitt, Cassie
   Rath, Louise
   Yeh, Wei Zhen
   Zhong, Michael
   Wesselingh, Robb
   Monif, Mastura
   Richards, Janene
   Viet Bui Minh
   Jokubaitis, Vilija G.
   Skibina, Olga
   Butzkueven, Helmut
   van der Walt, Anneke
TI MSCOVID19: Using social media to achieve rapid dissemination of health
   information
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Letter
AB Background and Objective: : The global COVID-19 pandemic creates an obvious acute health care resourcing and response problem. The different timing of pandemic peak in geographically distinct locations creates a short window of response opportunity. Rapid dissemination of medical information from early affected areas to later ones is therefore crucial to optimise planning. Formulating the best system response for at-risk patient populations is especially complex. People with multiple sclerosis (pwMS) are exposed to long-term immunosuppressive disease modifying treatments (DMTs) and, in theory, could be at increased risk of contracting the virus and developing complications. Social media, such as Twitter, can provide a global platform to rapidly share information and individual experiences.
   Methods and Results: : This report summarizes the case experience of pwMS with COVID-19 infection in the first month of the pandemic as reported on Twitter using the #MSCOVID19 hashtag. 26 individual cases of COVID-19 in pwMS were reported from Europe and the United States of America. The cases involved a combination of relapsing and progressive MS phenotypes treated with a range of DMT (5 anti CD20 therapy, 4 cladribine, 4 fingolimod, 4 injectables, 3 alemtuzumab, 2 dimethyl fumarate, 2 untreated, 1 teriflunomide, 1 natalizumab). The cases shared present the earliest reported data on outcomes of COVID-19 infection in pwMS. Whilst limited, the cautiously reassuring nature of these early cases assisted in clinical management by allowing neurologists to continuously reassess their approach to DMT management.
C1 [Nesbitt, Cassie; Rath, Louise; Yeh, Wei Zhen; Zhong, Michael; Wesselingh, Robb; Monif, Mastura; Richards, Janene; Viet Bui Minh; Jokubaitis, Vilija G.; Skibina, Olga; Butzkueven, Helmut; van der Walt, Anneke] Alfred Hlth, Clin Neurosci, Melbourne, Vic, Australia.
   [Nesbitt, Cassie; Yeh, Wei Zhen; Zhong, Michael; Wesselingh, Robb; Monif, Mastura; Jokubaitis, Vilija G.; Butzkueven, Helmut; van der Walt, Anneke] Monash Univ, Cent Clin Sch, Dept Neurosci, Melbourne, Vic, Australia.
RP Nesbitt, C (corresponding author), Alfred Hlth, Clin Neurosci, Melbourne, Vic, Australia.; Nesbitt, C (corresponding author), Monash Univ, Cent Clin Sch, Dept Neurosci, Melbourne, Vic, Australia.
EM msniadmin@alfred.org.au
OI Jokubaitis, Vilija/0000-0002-3942-4340
CR Amor S, 2020, ANN NEUROL, V87, P794, DOI 10.1002/ana.25770
   Baud D., 2020, LANCET INFECT DIS
   Broadley S., 2020, UPDATED ADVICE PERSO
   Kostkova P, 2014, ACM TRANS MANAG INF, V5, DOI 10.1145/2597892
   Panagiotopoulos P, 2016, TECHNOL FORECAST SOC, V111, P86, DOI 10.1016/j.techfore.2016.06.010
   Wu Z, 2020, JAMA
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 7
TC 1
Z9 1
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD OCT
PY 2020
VL 45
AR 102338
DI 10.1016/j.msard.2020.102338
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA OG9YR
UT WOS:000582230900013
PM 32629402
DA 2021-01-01
ER

PT J
AU Radulovic, L
   Erakovic, J
   Roganovic, M
AF Radulovic, Ljiljana
   Erakovic, Jevto
   Roganovic, Milovan
TI Attitudes of patients with relapsing-remitting form of multiple
   sclerosis using disease-modifying drugs in Montenegro regarding COVID-19
   pandemic
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Article
DE COVID-19; Multiple sclerosis; DMD; Montenegro; Neurology
AB Background: In the days of the reorganization of healthcare systems due to SARS-Cov2 pandemic, patients suffering from chronic diseases are being often neglected. The aim of our study was to examine the attitudes and behaviors of patient suffering from relapsing-remitting form of multiple sclerosis using disease-modifying drugs in Montenegro in relation to the current pandemic.
   Methods: The research was conducted through an online-generated questionnaire during the peak of the pandemic.
   Results: There is a high level of concern about COVID-19 (3.22 +/- 1.23), especially about safety behavior intensification (3.80 +/- 1.29). Possibility of relapse during pandemic was considered as moderate (2.06 +/- 1.42), but relapse symptoms would be reported by the majority of subjects (1.55 +/- 1.23). Our unemployed patients statistically more often reported that they had more frequent mood changes, but also that they felt more energy loss. Surprisingly, there was no difference among the subjects according to smoking status. According therapy groups there was significant difference between the groups regarding some variables: patients using ocrelizumab are most concerned about COVID-19; patients using interferon beta la i.m. statistically more often have frequent changes in their mood, memory problems, poor appetite, feeling of nausea or upset stomach and patients on fingolimod have bigger afraid of coming to regular visits.
   Conclusion: Our patients showed concern about their disease future status in the current epidemic era, but also showed a high degree of trust in physicians and the overall health system.
C1 [Radulovic, Ljiljana; Erakovic, Jevto; Roganovic, Milovan] Clin Ctr Montenegro, Clin Neurol, Ljubljanska Bb, Podgorica 81000, Montenegro.
   [Radulovic, Ljiljana] Univ Montenegro, Fac Med, Dept Neurol, Krusevac Bb, Podgorica 81000, Montenegro.
   [Roganovic, Milovan] Univ Montenegro, Fac Med, Dept Med Biochem, Krusevac Bb, Podgorica 81000, Montenegro.
RP Radulovic, L (corresponding author), Clin Ctr Montenegro, Clin Neurol, Ljubljanska Bb, Podgorica 81000, Montenegro.; Radulovic, L (corresponding author), Univ Montenegro, Fac Med, Dept Neurol, Krusevac Bb, Podgorica 81000, Montenegro.
EM ljiljana.radulovic@kccg.me
RI Roganovic, Milovan/AAN-3070-2020
CR [Anonymous], 2020, MONT WHO COR DIS COV
   Brownlee W., 2020, NEUROL
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073
   Harbo HF, 2013, THER ADV NEUROL DISO, V6, P237, DOI 10.1177/1756285613488434
   Huang I, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00453-4
   Lemus HN, 2018, NEUROL CLIN, V36, P1, DOI 10.1016/j.ncl.2017.08.002
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Marrie RA, 2015, MULT SCLER J, V21, P305, DOI 10.1177/1352458514564487
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Reich DS, 2018, NEW ENGL J MED, V378, P169, DOI 10.1056/NEJMra1401483
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, P2020, DOI 10.1038/s41392-020-0159-1
   Yang J, 2020, NEUROLOGY, V94
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD OCT
PY 2020
VL 45
AR 102380
DI 10.1016/j.msard.2020.102380
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA OG9YR
UT WOS:000582230900030
PM 32683304
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Stojanov, A
   Malobabic, M
   Milosevic, V
   Stojanov, J
   Vojinovic, S
   Stanojevic, G
   Stevic, M
AF Stojanov, Aleksandar
   Malobabic, Marina
   Milosevic, Vuk
   Stojanov, Jelena
   Vojinovic, Slobodan
   Stanojevic, Goran
   Stevic, Milos
TI Psychological status of patients with relapsing-remitting multiple
   sclerosis during coronavirus disease-2019 outbreak
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Article
DE COVID-19; Relapsing-remitting multiple sclerosis; Quality of life;
   Depression; Anxiety
ID QUALITY-OF-LIFE; ACUTE RESPIRATORY SYNDROME; ANXIETY; SCALE; ONSET
AB Background: The coronavirus disease 2019 (COVID-19) is a global health emergency. The aim was to investigate the impact of COVID-19 pandemic on the psychological status of patients with relapsing-remitting multiple sclerosis (RAMS).
   Methods: Data on the socio-demographic and clinical characteristics of 95 RAMS patients were collected. We used a self-designed questionnaire, the Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54), Hamilton scales for the assessment of anxiety (HAM-A), and depression (HAM-D). Patients who were tested one year ago were reassessed using the same questionnaires during the COVID-19 outbreak. Group of 99 healthy individuals (HC) were tested, using the same questionnaires.
   Results: The main concerns in RAMS patients were that someone that they know could be infected with COVID-19 (78.5%), or could die due to the infection (33.8%), and the lack of specific treatment options (25.8%). The main concerns about the RAMS status were that their disease would be worse if they get infected with COVID-19 (36.4%), that they would experience some difficulties in drug availability (43.6%), that they could not go to the hospital as usual (72.4%). Results on all questionnaires were worse in RAMS patients than in HC (p < 0.01). We noticed a statistically significant difference between the results obtained a year ago and the results from April 2020 in HAM-A (p < 0.05).
   Conclusions: There is an impact of the COVID-19 pandemic on the psychological status of RAMS patients. Healthcare organizations need to provide professional therapeutic advice and psychosocial support for this population of patients during the pandemic.
C1 [Stojanov, Aleksandar; Malobabic, Marina; Milosevic, Vuk; Vojinovic, Slobodan] Clin Ctr Nis, Clin Neurol, Dr Zoran Djindjic Blvd, Nish 18000, Serbia.
   [Stojanov, Jelena] Special Psychiat Hosp Gornja Toponica, Nish, Serbia.
   [Vojinovic, Slobodan; Stanojevic, Goran; Stevic, Milos] Univ Nis, Med Fac, Nish, Serbia.
RP Stojanov, A (corresponding author), Clin Ctr Nis, Clin Neurol, Dr Zoran Djindjic Blvd, Nish 18000, Serbia.
EM astojanov1986@gmail.com
RI Stojanov, Aleksandar/V-5300-2019
OI Stojanov, Aleksandar/0000-0002-6462-3528; Stanojevic,
   Goran/0000-0001-9401-7097
CR Ahmed MZ, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102092
   Artemiadis AK, 2011, NEUROEPIDEMIOLOGY, V36, P109, DOI 10.1159/000323953
   Biernacki T, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1466
   Boeschoten RE, 2017, J NEUROL SCI, V372, P331, DOI 10.1016/j.jns.2016.11.067
   Chan AOM, 2004, OCCUP MED-OXFORD, V54, P190, DOI 10.1093/occmed/kqh027
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x
   Howard J, 2016, NEUROL CLIN, V34, P919, DOI 10.1016/j.ncl.2016.06.016
   Inojosa Hernan, 2019, J Neurol, DOI 10.1007/s00415-019-09489-5
   KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
   Kwek SK, 2006, J PSYCHOSOM RES, V60, P513, DOI 10.1016/j.jpsychores.2005.08.020
   Lanzillo R, 2016, EUR J PAEDIATR NEURO, V20, P158, DOI 10.1016/j.ejpn.2015.08.005
   Moghadasi AN, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102138
   Ozamiz-Etxebarria N, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00054020, 10.1590/0102-311x00054020]
   Ozdin S, 2020, INT J SOC PSYCHIATR, V66, P504, DOI 10.1177/0020764020927051
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Ruet A, 2013, J NEUROL, V260, P776, DOI 10.1007/s00415-012-6705-1
   Solaro C, 2018, CNS DRUGS, V32, P117, DOI 10.1007/s40263-018-0489-5
   Stojanov J, 2020, J POSTGRAD MED, V66, P23, DOI 10.4103/jpgm.JPGM_499_19
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   VICKREY BG, 1995, QUAL LIFE RES, V4, P187, DOI 10.1007/BF02260859
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yalachkov Y, 2019, MULT SCLER RELAT DIS, V30, P33, DOI 10.1016/j.msard.2019.01.049
   Zhang YF, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072381
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 25
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD OCT
PY 2020
VL 45
AR 102407
DI 10.1016/j.msard.2020.102407
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA OG9YR
UT WOS:000582230900053
PM 32702641
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tomczak, A
   Han, MH
AF Tomczak, Anna
   Han, May H.
TI The impact of COVID-19 on patients with neuromyelitis optica spectrum
   disorder; a pilot study
SO MULTIPLE SCLEROSIS AND RELATED DISORDERS
LA English
DT Article
DE Neuromyelitis optica spectrum disorder; COVID-19; Pandemic; Infection
ID EVENTS
AB Neuromyelitis optica spectrum disorder (NMOSD) is a CNS neuroinflammatory disorder, mediated by the pathogenic autoantibody aquaporin-4 (AQP4-IgG). Current treatment includes long-term use of immunomodulatory therapies, leading to increased rates of infections among this population. It is of interest therefore, to study how the COVID-19 pandemic affects NMOSD patients in terms of their disease activity. A 15-point questionnaire was administered to 33 participants living in Northern California with NMOSD, MS and other related disorders. Although none of the participants were diagnosed with COVID-19, our results show that 2 participants with NMOSD experienced new onset of neurological symptoms and 2 experienced worsening of previous neurological symptoms - suggesting a possible effect of pandemic-related stress on this CNS autoimmune disorder.
C1 [Tomczak, Anna; Han, May H.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
   [Han, May H.] Stanford Univ, Multiple Sclerosis Ctr, Neuroimunol Div, Stanford, CA 94305 USA.
RP Han, MH (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.; Han, MH (corresponding author), Stanford Univ, Multiple Sclerosis Ctr, Neuroimunol Div, Stanford, CA 94305 USA.
EM mayhan@stanford.edu
CR Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Cook LJ, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000583
   Gluck T, 2005, J RHEUMATOL, V32, P1473
   Golan D, 2008, ANN NEUROL, V64, P143, DOI 10.1002/ana.21409
   GRANT I, 1989, J NEUROL NEUROSUR PS, V52, P8, DOI 10.1136/jnnp.52.1.8
   Kanamori Y, 2017, J NEUROL NEUROSUR PS, V88, P362, DOI 10.1136/jnnp-2016-313890
   Kessler RA, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000269
   Mohr DC, 2006, BRAIN BEHAV IMMUN, V20, P27, DOI 10.1016/j.bbi.2005.03.011
   Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729
   Yamout B, 2010, J NEUROL SCI, V288, P42, DOI 10.1016/j.jns.2009.10.012
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2211-0348
EI 2211-0356
J9 MULT SCLER RELAT DIS
JI Mult. Scler. Relat. Disord.
PD OCT
PY 2020
VL 45
AR 102347
DI 10.1016/j.msard.2020.102347
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA OG9YR
UT WOS:000582230900017
PM 32645636
OA Bronze
DA 2021-01-01
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Moderna Company wins the race for a certified Covid-19 vaccine
SO PRZEMYSL CHEMICZNY
LA Polish
DT Letter
NR 0
TC 0
Z9 0
U1 5
U2 5
PU WYDAWNICTWO SIGMA-N O T SP Z O O
PI WARSAW
PA UL RATUSZOWA 11, PO BOX 1004, 00-950 WARSAW, POLAND
SN 0033-2496
J9 PRZEM CHEM
JI Przem. Chem.
PD OCT
PY 2020
VL 99
IS 10
BP 1436
EP 1436
PG 1
WC Chemistry, Multidisciplinary; Engineering, Chemical
SC Chemistry; Engineering
GA OH2IJ
UT WOS:000582392700031
DA 2021-01-01
ER

PT J
AU Yepes-Perez, AF
   Herrera-Calderon, O
   Sanchez-Aparicio, JE
   Tiessler-Sala, L
   Marechal, JD
   Cardona-G, W
AF Yepes-Perez, Andres F.
   Herrera-Calderon, Oscar
   Sanchez-Aparicio, Josee-Emilio
   Tiessler-Sala, Laura
   Marechal, Jean-Didier
   Cardona-G, Wilson
TI Investigating Potential Inhibitory Effect of Uncaria tomentosa (Cat's
   Claw) against the Main Protease 3CL(pro) of SARS-CoV-2 by Molecular
   Modeling
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID QUINOVIC ACID GLYCOSIDES; PERMEABILITY; TRITERPENES; PROANTHOCYANIDINS;
   MECHANISM; FRAMEWORK; DOCKING; HEALTH; BARK
AB COVID-19 is a disease caused by severe acute respiratory syndrome coronavirus 2. Presently, there is no effective treatment for COVID-19. As part of the worldwide efforts to find efficient therapies and preventions, it has been reported the crystalline structure of the SARS-CoV-2 main protease M-pro(also called 3CL(pro)) bound to a synthetic inhibitor, which represents a major druggable target. The druggability of M(pro)could be used for discovering drugs to treat COVID-19. A multilevel computational study was carried out to evaluate the potential antiviral properties of the components of the medicinal herbUncaria tomentosa(Cat's claw), focusing on the inhibition of M-pro. Thein silicoapproach starts with protein-ligand docking of 26 Cat's claw key components, followed by ligand pathway calculations, molecular dynamics simulations, and MM-GBSA calculation of the free energy of binding for the best docked candidates. The structural bioinformatics approaches led to identification of three bioactive compounds ofUncaria tomentosa(speciophylline, cadambine, and proanthocyanidin B2) with potential therapeutic effects by strong interaction with 3CL(pro). Additionally,in silicodrug-likeness indices for these components were calculated and showed good predicted therapeutic profiles of these phytochemicals. Our findings suggest the potential effectiveness of Cat's claw as complementary and/or alternative medicine for COVID-19 treatment.
C1 [Yepes-Perez, Andres F.; Cardona-G, Wilson] Univ Antioquia UdeA, Chem Colombian Plants, Inst Chem, Fac Exact & Nat Sci, Calle 70 52-21, Medellin 1226, Colombia.
   [Herrera-Calderon, Oscar] Univ Nacl Mayor San Marcos, Acad Dept Pharmacol Bromatol & Toxicol, Fac Pharm & Biochem, Jr Puno 1002, Lima 15001, Peru.
   [Sanchez-Aparicio, Josee-Emilio; Tiessler-Sala, Laura; Marechal, Jean-Didier] Univ Autonoma Barcelona, Insilichem, Dept Quim, Edifici Cn, Barcelona 08193, Spain.
RP Yepes-Perez, AF (corresponding author), Univ Antioquia UdeA, Chem Colombian Plants, Inst Chem, Fac Exact & Nat Sci, Calle 70 52-21, Medellin 1226, Colombia.; Herrera-Calderon, O (corresponding author), Univ Nacl Mayor San Marcos, Acad Dept Pharmacol Bromatol & Toxicol, Fac Pharm & Biochem, Jr Puno 1002, Lima 15001, Peru.; Marechal, JD (corresponding author), Univ Autonoma Barcelona, Insilichem, Dept Quim, Edifici Cn, Barcelona 08193, Spain.
EM andresf.yepes@udea.edu.co; oherreracalderon@gmail.com;
   joseemilio.sanchez@uab.cat; laura.tiessler@uab.cat;
   jeandidier.marechal@uab.cat; wilson.cardona1@udea.edu.co
RI Herrera-Calderon, Oscar/L-5712-2017; Marechal, Jean-Didier/A-8936-2012
OI Herrera-Calderon, Oscar/0000-0001-7264-0961; Tiessler-Sala,
   Laura/0000-0002-6344-9839; Cardona G, Wilson I/0000-0002-5374-1211;
   Yepes Perez, Andres Felipe/0000-0001-6975-5119; Sanchez-Aparicio,
   Jose-Emilio/0000-0002-3397-8393; Marechal,
   Jean-Didier/0000-0002-8344-9043
FU Spanish MINECO [CTQ2017-87889-P]
FX J.-E.S.-A., L.T.-S., and J.-D.M. gratefully acknowledge the financial
   support from the Spanish MINECO (CTQ2017-87889-P). The authors would
   like to thank Universidad de Antioquia, Universidad Nacional Mayor de
   San Marcos, and Universitat Autnoma de Barcelona.
CR Aguinaga JY, 2014, J TOXICOL-US, V2014, DOI 10.1155/2014/412437
   Akesson C, 2003, PHYTOMEDICINE, V10, P23, DOI 10.1078/094471103321648629
   Allen-Hall L, 2010, J ETHNOPHARMACOL, V127, P685, DOI 10.1016/j.jep.2009.12.004
   Alonso-Cotchico L, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00211
   Amawi H, 2020, THER DELIV, V11, P245, DOI 10.4155/tde-2020-0035
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], 2020, CALCULATION MOL PROP
   Aquino R, 1997, PHYTOCHEMISTRY, V45, P1035, DOI 10.1016/S0031-9422(96)00716-9
   AQUINO R, 1989, J NAT PROD, V52, P679, DOI 10.1021/np50064a002
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004
   Ben-Shabat S, 2020, DRUG DELIV TRANSL RE, V10, P354, DOI 10.1007/s13346-019-00691-6
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Broccatelli F, 2016, MOL PHARMACEUT, V13, P4199, DOI 10.1021/acs.molpharmaceut.6b00836
   BROWN RT, 1991, TETRAHEDRON LETT, V32, P1987, DOI 10.1016/0040-4039(91)85020-6
   Bussmann RW, 2010, J ETHNOPHARMACOL, V132, P101, DOI 10.1016/j.jep.2010.07.048
   Caon T, 2014, FOOD CHEM TOXICOL, V66, P30, DOI 10.1016/j.fct.2014.01.013
   Case D., 2018, AMBER 2018
   CERRI R, 1988, J NAT PROD, V51, P257, DOI 10.1021/np50056a010
   ChemAxon, 2016, CHEMAXON SOFTW SOL S
   Chen SL, 2016, CHIN MED-UK, V11, DOI 10.1186/s13020-016-0108-7
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Dennis C. J., 2020, ANTIRETROVIRAL DRUG
   Eastman P, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005659
   Eastman P, 2010, COMPUT SCI ENG, V12, P34, DOI 10.1109/MCSE.2010.27
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Fintelman-Rodrigues N, 2020, ATAZANAVIR INHIBITS
   Flores-Sanchez IJ, 2002, PLANT CELL PHYSIOL, V43, P1502, DOI 10.1093/pcp/pcf181
   Frisch M. J., 2013, GAUSSIAN 09 REVISION
   Fujii W, 2013, TETRAHEDRON LETT, V54, P7188, DOI 10.1016/j.tetlet.2013.10.113
   Gao K., 2020, MACHINE INTELLIGENCE
   Goncalves C, 2005, PHYTOCHEMISTRY, V66, P89, DOI 10.1016/j.phytochem.2004.10.025
   Gonzales Gustavo F, 2010, Evid Based Complement Alternat Med, V7, P271, DOI 10.1093/ecam/nen042
   Gonzalez-Aleman R, 2020, J CHEM INF MODEL, V60, P467, DOI 10.1021/acs.jcim.9b00558
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   Haider Z., 2020, SILICO DISCOVERY NOV
   Heitzman ME, 2005, PHYTOCHEMISTRY, V66, P5, DOI 10.1016/j.phytochem.2004.10.022
   Herrera-Calderon O., 2017, ANN RES REV BIOL, V21, P1, DOI [10.9734/arrb/2017/37045, DOI 10.9734/ARRB/2017/37045]
   Hunold A, 2020, BIOMED ENG ONLINE, V19, DOI 10.1186/s12938-020-00792-1
   Irvine JD, 1999, J PHARM SCI, V88, P28, DOI 10.1021/js9803205
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Keplinger K, 1999, J ETHNOPHARMACOL, V64, P23, DOI 10.1016/S0378-8741(98)00096-8
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI 10.20944/preprints202003.0226.v1
   Kitajima M, 2000, TETRAHEDRON, V56, P547, DOI 10.1016/S0040-4020(99)01048-0
   Kosmider A, 2017, MOLECULES, V22, DOI 10.3390/molecules22040620
   Kumar Y, 2020, J INFECT PUBLIC HEAL, V13, P1210, DOI 10.1016/j.jiph.2020.06.016
   Laus G, 1997, PHYTOCHEMISTRY, V45, P855, DOI 10.1016/S0031-9422(97)00061-7
   Lima-Junior R. S., 2013, NATURAL PRODUCT COMM, V8, DOI 10.1177/1934578x1300801112
   Lipinski CA, 2012, ADV DRUG DELIVER REV, V64, P4, DOI 10.1016/j.addr.2012.09.019
   Lipson SM, 2017, FOOD ENVIRON VIROL, V9, P434, DOI 10.1007/s12560-017-9299-z
   Lock O, 2016, NAT PROD COMMUN, V11, P315
   de Paula LCL, 2015, J ALTERN COMPLEM MED, V21, P22, DOI 10.1089/acm.2014.0127
   Galera RM, 2008, EUR J CLIN PHARMACOL, V64, P1235, DOI 10.1007/s00228-008-0551-1
   Lupala C. S., 2020, COMPUTATIONAL SIMULA
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Montoro P, 2004, PHYTOCHEM ANALYSIS, V15, P55, DOI 10.1002/pca.740
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Navan C., 2020, POSSIBLE DRUG CANDID
   Hoyos MN, 2015, MOLECULES, V20, P22703, DOI 10.3390/molecules201219875
   Navarro M, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090339
   Navarro M, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6030060
   Peele K Abraham, 2020, Inform Med Unlocked, V19, P100345, DOI 10.1016/j.imu.2020.100345
   Penaloza E. M. C., 2015, QUIMICA NOVA, V38
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pierrot D, 2019, DRUG DEVELOP RES, V80, P133, DOI 10.1002/ddr.21494
   Prajapat M., 2020, SCHOLARS INT J BIOCH, V3, P143, DOI [10.36348/sijb.2020.v03i06.005, DOI 10.36348/SIJB.2020.V03I06.005]
   Rasoanaivo P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-S1-S4
   Reis SRIN, 2008, INT IMMUNOPHARMACOL, V8, P468, DOI 10.1016/j.intimp.2007.11.010
   Rodriguez-Guerra Pedregal J., 2018, OMMPROTOCOL COMMAND
   Sanchez-Aparicio JE, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133155
   Sandoval M, 2000, FREE RADICAL BIO MED, V29, P71, DOI 10.1016/S0891-5849(00)00327-0
   Santos A, 2012, ADCAIJ-ADV DISTRIB C, V1, P2
   Schrodinger, 2018, PYMOL MOL VIS SYST
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Snow AD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38645-0
   Song LF, 2019, J CHEM INF MODEL, V59, P3128, DOI 10.1021/acs.jcim.9b00105
   Tetko IV, 2004, J MED CHEM, V47, P5601, DOI 10.1021/jm049509l
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vera-Reyes I, 2015, FRONT ENV SCI-SWITZ, V3, DOI 10.3389/fenvs.2015.00027
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang Q, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1817786
   Wang XDR.PovysilG., 2020, TRANSCRIPTIONAL INHI, DOI 1020944/preprints2020030360v1
   Williams J E, 2001, Altern Med Rev, V6, P567
   Williamson J, 2015, AM J TROP MED HYG, V92, P857, DOI 10.4269/ajtmh.14-0536
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang HB, 2019, BIOINFORMATICS, V35, P1067, DOI 10.1093/bioinformatics/bty707
   YEPEZ AM, 1991, PHYTOCHEMISTRY, V30, P1635, DOI 10.1016/0031-9422(91)84223-F
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu S, 2018, PHARM BIOL, V56, P548, DOI 10.1080/13880209.2018.1499780
NR 91
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD OCT 1
PY 2020
VL 2020
AR 4932572
DI 10.1155/2020/4932572
PG 14
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA OF9JS
UT WOS:000581514800005
PM 33029165
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Castillo, ME
   Costa, LME
   Barrios, JMV
   Diaz, JFA
   Miranda, JL
   Bouillon, R
   Gomez, JMQ
AF Entrenas Castillo, Marta
   Entrenas Costa, Luis Manuel
   Vaquero Barrios, Jose Manuel
   Alcala Diaz, Juan Francisco
   Lopez Miranda, Jose
   Bouillon, Roger
   Quesada Gomez, Jose Manuel
TI Effect of calcifediol treatment and best available therapy versus best
   available therapy on intensive care unit admission and mortality among
   patients hospitalized for COVID-19: A pilot randomized clinical study
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Vitamin D; Vitamin D3 or cholecalciferol;
   Calcifediol or 25-hydroxyvitamin D3; 1 alpha, 25(OH)2D or 1 alpha,
   25-dihydroxyvitamin D or calcitriol; Acute respiratory distress syndrome
   (ARDS); Cytokine/Chemokine storm; Renin-angiotensin system;
   Hypercoagulability; Hydroxychloroquine; Chloroquine; Covidiol;
   Neutrophil activity; Vitamin D endocrine system; Cuboidal alveolar
   coating cells type II; Cathelicidin peptide; Defensins; TLR co-receptor
   CD14; Vitamin D receptor
ID RESPIRATORY-DISTRESS-SYNDROME; COMMUNITY-ACQUIRED PNEUMONIA; VITAMIN-D;
   CORONAVIRUS; GUIDELINES
AB Objective: The vitamin D endocrine system may have a variety of actions on cells and tissues involved in COVID-19 progression especially by decreasing the Acute Respiratory Distress Syndrome. Calcifediol can rapidly in- crease serum 25OHD concentration. We therefore evaluated the effect of calcifediol treatment, on Intensive Care Unit Admission and Mortality rate among Spanish patients hospitalized for COVID-19.
   Design: Parallel pilot randomized open label, double-masked clinical trial.
   Setting: University hospital setting (Reina Sofia University Hospital, Cordoba Spain.)
   Participants: 76 consecutive patients hospitalized with COVID-19 infection, clinical picture of acute respiratory infection, confirmed by a radiographic pattern of viral pneumonia and by a positive SARS-CoV-2 PCR with CURB65 severity scale (recommending hospital admission in case of total score > 1).
   Procedures: All hospitalized patients received as best available therapy the same standard care, (per hospital protocol), of a combination of hydroxychloroquine (400 mg every 12 h on the first day, and 200 mg every 12 h for the following 5 days), azithromycin (500 mg orally for 5 days. Eligible patients were allocated at a 2 calcifediol:1 no calcifediol ratio through electronic randomization on the day of admission to take oral calcifediol (0.532 mg), or not. Patients in the calcifediol treatment group continued with oral calcifediol (0.266 mg) on day 3 and 7, and then weekly until discharge or ICU admission. Outcomes of effectiveness included rate of ICU admission and deaths.
   Results: Of 50 patients treated with calcifediol, one required admission to the ICU (2%), while of 26 untreated patients, 13 required admission (50 %) p value X-2 Fischer test p < 0.001. Univariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment versus without Calcifediol treatment: 0.02 (95 %CI 0.002-0.17). Multivariate Risk Estimate Odds Ratio for ICU in patients with Calcifediol treatment vs Without Calcifediol treatment ICU (adjusting by Hypertension and T2DM): 0.03 (95 %CI: 0.003-0.25). Of the patients treated with calcifediol, none died, and all were discharged, without complications. The 13 patients not treated with calcifediol, who were not admitted to the ICU, were discharged. Of the 13 patients admitted to the ICU, two died and the remaining 11 were discharged.
   Conclusion: Our pilot study demonstrated that administration of a high dose of Calcifediol or 25-hydroxyvitamin D, a main metabolite of vitamin D endocrine system, significantly reduced the need for ICU treatment of patients requiring hospitalization due to proven COVID-19. Calcifediol seems to be able to reduce severity of the disease, but larger trials with groups properly matched will be required to show a definitive answer.
C1 [Entrenas Castillo, Marta; Entrenas Costa, Luis Manuel; Vaquero Barrios, Jose Manuel] Univ Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC 9, UGC Neumol, Hosp Univ Reina Sofia, Avda Menendez 10 Pidal S-N, Cordoba 1400411, Spain.
   [Alcala Diaz, Juan Francisco; Lopez Miranda, Jose] Univ Cordoba, CIBER Fisiopatol Obesidad & Nutr, Dept Med Interna, Hosp Univ Reina Sofia,IMIBIC,Fdn Progreso & Salud, Avda Menendez Pidal S-N, Cordoba 1400414, Spain.
   [Bouillon, Roger] Katholieke Univ Leuven, Lab Clin & Expt Endocrinol, Dept Chron Dis Metab & Ageing, Herestr ON1-902, B-3000 Leuven, Belgium.
   [Quesada Gomez, Jose Manuel] Univ Cordoba, Hosp Univ Reina Sofia, Fdn Progreso & Salud, IMIBIC,CIBER Fragilidad & Envejecimiento Saludabl, Avda Menendez Pidal S-N, Cordoba 1814004, Spain.
RP Costa, LME (corresponding author), Univ Cordoba, Inst Maimonides Invest Biomed Cordoba IMIBIC 9, UGC Neumol, Hosp Univ Reina Sofia, Avda Menendez 10 Pidal S-N, Cordoba 1400411, Spain.
EM lmentrenas@uco.es
OI Entrenas Costa, Luis Manuel/0000-0003-0664-5531
CR Andrukhov O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090301
   Bauchner H, 2020, JAMA-J AM MED ASSOC, V323, P2262, DOI 10.1001/jama.2020.8115
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Bouillon R, 2019, J BONE MINER RES, V34, P1985, DOI 10.1002/jbmr.3884
   Bouillon R, 2019, ENDOCR REV, V40, P1109, DOI 10.1210/er.2018-00126
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   D'Avolio A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051359
   Fan E, 2018, JAMA-J AM MED ASSOC, V319, P698, DOI 10.1001/jama.2017.21907
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gobierno De Espana Ministerio De Sanidad, 2020, CONS BIEN SOC DOC TE
   Grant WB, 2018, J STEROID BIOCHEM, V177, P266, DOI 10.1016/j.jsbmb.2017.08.009
   Hansdottir S, 2008, J IMMUNOL, V181, P7090, DOI 10.4049/jimmunol.181.10.7090
   Heaney RP, 2014, NUTR REV, V72, P48, DOI 10.1111/nure.12090
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8
   Jolliffe DA, 2020, AM J RESP CRIT CARE, V202, P371, DOI 10.1164/rccm.201909-1867OC
   Kong J, 2013, MOL ENDOCRINOL, V27, P2116, DOI 10.1210/me.2013-1146
   Laird E, 2020, IR MED J, V113
   Li RR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8297
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159
   Martineau AR, 2020, LANCET DIABETES ENDO, V8, P735, DOI 10.1016/S2213-8587(20)30268-0
   Martinez-Moreno JM, 2016, FASEB J, V30, P1367, DOI 10.1096/fj.15-272872
   Mata-Granados JM, 2010, J STEROID BIOCHEM, V121, P452, DOI 10.1016/j.jsbmb.2010.03.078
   Mata-Granados J. M., 2008, CLIN BIOCHEM, V41, P676, DOI DOI 10.1016/J.325465
   Panagiotou G, 2020, CLIN ENDOCRINOL, V93, P508, DOI 10.1111/cen.14276
   Quesada-Gomez JM, 2018, OSTEOPOROSIS INT, V29, P1697, DOI 10.1007/s00198-018-4520-y
   Quesada-Gomez JM, 2020, J STEROID BIOCHEM, V202, DOI 10.1016/j.jsbmb.2020.105719
   Rafique A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215383
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Russo S, 2011, CALCIFIED TISSUE INT, V89, P252, DOI 10.1007/s00223-011-9513-1
   Schulz KF, 2011, INT J SURG, V9, P672, DOI [10.1016/j.ijsu.2011.09.004, 10.1016/j.jclinepi.2010.02.005]
   Shi YY, 2016, MOL MED REP, V13, P1186, DOI 10.3892/mmr.2015.4685
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Viechtbauer W, 2015, J CLIN EPIDEMIOL, V68, P1375, DOI 10.1016/j.jclinepi.2015.04.014
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zheng SX, 2020, BIOCHEM PHARMACOL, V177, DOI 10.1016/j.bcp.2020.113955
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 40
TC 12
Z9 12
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD OCT
PY 2020
VL 203
AR 105751
DI 10.1016/j.jsbmb.2020.105751
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA OC9OC
UT WOS:000579483300007
PM 32871238
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Onchonga, D
   Omwoyo, J
   Nyamamba, D
AF Onchonga, David
   Omwoyo, Joshua
   Nyamamba, Duke
TI Assessing the prevalence of self-medication among healthcare workers
   before and during the 2019 SARS-CoV-2 (COVID-19) pandemic in Kenya
SO SAUDI PHARMACEUTICAL JOURNAL
LA English
DT Article
DE Self-medication; Prevalence; Healthcare workers; 2019 SARS-CoV-2; Kenya;
   COVID-19
ID CORONAVIRUS; RISKS
AB Background: Self-medication plays a key role in public health as it influences both negatively and positively on the health of individuals and the existing healthcare systems. This is especially the case during public health emergencies like the 2019 SARS-CoV-2 disease.
   Objectives: The study aimed at assessing the prevalence of self-medication before and during the outbreak of COVID-19 pandemic among healthcare workers and its associated factors.
   Methods: Stratified sampling was used to select 379 study respondents. The authors developed an online questionnaire, pretested and submitted to various online professional groups of different cadres of healthcare workers. Collected data was analysed using descriptive and inferential statistics. The data was presented in tables, graphs, percentages, and cross-tabulation with different variables. Multivariable logistic regression was used to ascertain factors that influence an individual's desire to self-medicate and associations were considered significant at p < 0.05.
   Results: The overall prevalence of self-medication increased from 36.2% (n = 137) before the pandemic to 60.4% (n = 229) during the pandemic. The respondents' gender, level of education, age, marital status, participation in physical activity, and drug reaction events, were significantly associated with selfmedication before and during the outbreak (P < 0.05). Multivariable logistic regression analyses showed that participants engaging in physical activities, working during the day and being healthy were less likely to self-medicate (p < 0.01).
   Conclusion: Self-medication is an important health issue, especially during the COVID-19 pandemic. Continuous awareness creation and sensitization could help in reducing self-medication practices among healthcare workers. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.
C1 [Onchonga, David] Univ Pecs, Fac Hlth Sci, Sch Hlth Sci, Mihaly Utca 4, H-7621 Pecs, Hungary.
   [Onchonga, David; Omwoyo, Joshua; Nyamamba, Duke] Minist Hlth Samburu Cty, Nairobi, Kenya.
RP Onchonga, D (corresponding author), Univ Pecs, Fac Hlth Sci, Sch Hlth Sci, Mihaly Utca 4, H-7621 Pecs, Hungary.
EM onchonga.david@etk.pte.hu; joshu2064@gmail.com; nyamamba1@gmail.com
OI David, Onchonga/0000-0003-4461-797X
CR Auta A, 2012, N AM J MED SCI, V4, P24, DOI 10.4103/1947-2714.92899
   Bamgboye E A, 2006, Afr J Med Med Sci, V35, P411
   Bennadi Darshana, 2013, J Basic Clin Pharm, V5, P19, DOI 10.4103/0976-0105.128253
   Bogren M, 2020, SEX REPROD HEALTHC, V23, DOI 10.1016/j.srhc.2019.100481
   Ruiz ME, 2010, CURR DRUG SAF, V5, P315, DOI 10.2174/157488610792245966
   Figueiras A, 2000, EUR J EPIDEMIOL, V16, P19, DOI 10.1023/A:1007608702063
   Gutema GB, 2011, J APPL PHARM SCI, V1, P183, DOI DOI 10.1186/S40360-018-0205-6
   Holmes KV, 2003, J CLIN INVEST, V111, P1605, DOI [10.1172/JCI18819, 10.1172/JCI200318819]
   Huffman MA, 2001, BIOSCIENCE, V51, P651, DOI 10.1641/0006-3568(2001)051[0651:SMBITA]2.0.CO;2
   Hughes CM, 2001, DRUG SAFETY, V24, P1027, DOI 10.2165/00002018-200124140-00002
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lei XS, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010068
   Lopez Jose J, 2009, Rev Salud Publica (Bogota), V11, P432
   Mandal S., 2015, ASIAN PAC J TROP DIS, V5, pS184
   Menary KR, 2011, J ANXIETY DISORD, V25, P335, DOI 10.1016/j.janxdis.2010.10.006
   Omolase C., 2011, ANN IBADAN POSTGRADU, V5, P64, DOI DOI 10.4314/AIPM.V5I2.64032
   Onchonga D, 2020, SAUDI PHARM J, V28, P903, DOI 10.1016/j.jsps.2020.06.007
   Onchonga D, 2020, SEX REPROD HEALTHC, V25, DOI 10.1016/j.srhc.2020.100512
   Onchonga D, 2020, SEX REPROD HEALTHC, V24, DOI 10.1016/j.srhc.2020.100510
   Osaboro E., 2013, EUR J GEN DENT, V2, P54, DOI [DOI 10.4103/2278-9626.106813, 10.4103/2278-9626.106813]
   Parulekar M, 2016, J PHARM TECHNOL RES, V4, P103, DOI [10.15415/jptrm.2016.42007, DOI 10.15415/JPTRM.2016.42007]
   Powis M.G., 1996, J SOC ADMIN PHARM, V13, P188
   Rotenberg A.R.R.B.R.H.G.L., 2009, SELF MED NURSING WOR, DOI [10.1590/S0104-11692009000600014, DOI 10.1590/S0104-11692009000600014]
   Sawalha A.F., 2007, ISLAMIC U J, V15
   Selvaraj Kalaiselvi, 2014, Perspect Clin Res, V5, P32, DOI 10.4103/2229-3485.124569
   Shankar P R, 2002, BMC Fam Pract, V3, P17, DOI 10.1186/1471-2296-3-17
   Sharma R., 2005, Indian Journal of Pharmacology, V37, P40
   Smith SK, 1996, BRIT MED J, V312, P592
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   WHO ( World Health Organization), 2020, 81 WHO
   Wijesinghe Pushpa R, 2012, WHO South East Asia J Public Health, V1, P28, DOI 10.4103/2224-3151.206911
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 32
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319-0164
EI 2213-7475
J9 SAUDI PHARM J
JI Saudi Pharm. J.
PD OCT
PY 2020
VL 28
IS 10
BP 1149
EP 1154
DI 10.1016/j.jsps.2020.08.003
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OG0US
UT WOS:000581611000001
PM 32837218
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nelsen, G
   Pigott, H
   Hopkinson, C
   Formea, CM
AF Nelsen, Greg
   Pigott, Heidi
   Hopkinson, Caleb
   Formea, Christine M.
TI Considerations for development of pharmacy support models for COVID-19
   alternate care sites
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
DE alternate care site; COVID-19; disaster medicine; disaster pharmacy;
   disaster planning; pandemic
AB Purpose. Guidance on alternate care site planning based on the experience of a health-system pharmacy department in preparing for an expected surge in coronavirus disease 2019 (COVID-19) cases is provided.
   Summary. In disaster response situations such as the COVID-19 pandemic, healthcare institutions may be compelled to transition to a contingency care model in which staffing and supply levels are no longer consistent with daily practice norms and, while usual patient care practices are maintained, establishment of alternate care sites (eg, a convention center) may be necessitated by high patient volumes. Available resources to assist hospitals and health systems in alternate care site planning include online guidance posted within the COVID-19 resources section of the US Army Corps of Engineers website, which provides recommended medication and supply lists; and the Federal Healthcare Resilience Task Force's alternate care site toolkit, a comprehensive resource for all aspects of alternate care site planning, including pharmacy services. Important pharmacy planning issues include security and storage of drugs, state board of pharmacy and Drug Enforcement Administration licensing considerations, and staff credentialing, education, and training. Key medication management issues to be addressed in alternate site care planning include logistical challenges of supply chain maintenance, optimal workflow for compounded sterile preparations (eg, on-site preparation vs off-site preparation and delivery from a nearby hospital), and infusion pump availability and suitability to patient acuity levels.
   Conclusion. Planning for and operation of alternate care sites in disaster response situations should include involvement of pharmacists in key decision-making processes at the earliest planning stages.
C1 [Nelsen, Greg] Primary Childrens Med Ctr, Dept Pharm, Intermt Healthcare, Salt Lake City, UT 84113 USA.
   [Pigott, Heidi] Intermt Healthcare, Salt Lake City, UT USA.
   [Hopkinson, Caleb] Utah Valley Hosp, Dept Pharm, Intermt Healthcare, Provo, UT USA.
   [Formea, Christine M.] Intermt Healthcare, Dept Pharm & Intermt Precis Genom, Salt Lake City, UT USA.
RP Nelsen, G (corresponding author), Primary Childrens Med Ctr, Dept Pharm, Intermt Healthcare, Salt Lake City, UT 84113 USA.
EM gregory.nelsen@gmail.com
CR American Medical Association, DEA EAS SOM CONTR SU
   Assistant Secretary of Preparedness and Response US Department of Health and Human Services, TOP COLL PHARM TRAC
   B. Braun Medical Inc, GRAV FLOW DRIP RAT T
   ClinCalc LLC, TOP 200 2020
   Institute of Medicine, 2010, CRIS STAND CAR SUMM
   US Army Corps of Engineers, ALT CAR SIT ACS
NR 6
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-2082
EI 1535-2900
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD OCT 1
PY 2020
VL 77
IS 19
BP 1592
EP 1597
DI 10.1093/ajhp/zxaa214
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OF1NH
UT WOS:000580983200012
OA Green Accepted
DA 2021-01-01
ER

PT J
AU Merchan, C
   Soliman, J
   Ahuja, T
   Arnouk, S
   Keeley, K
   Tracy, J
   Guerra, G
   DaCosta, K
   Papadopoulos, J
   Dabestani, A
AF Merchan, Cristian
   Soliman, Joshua
   Ahuja, Tania
   Arnouk, Serena
   Keeley, Kelsey
   Tracy, Joanna
   Guerra, Gabriel
   DaCosta, Kristopher
   Papadopoulos, John
   Dabestani, Arash
TI COVID-19 pandemic preparedness: A practical guide from an operational
   pharmacy perspective
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
DE COVID-19; pharmacotherapy; pharmacy
AB Purpose. To describe our medical center's pharmacy services preparedness process and offer guidance to assist other institutions in preparing for surges of critically ill patients such as those experienced during the coronavirus disease 2019 (COVID-19) pandemic.
   Summary. The leadership of a department of pharmacy at an urban medical center in the US epicenter of the COVID-19 pandemic proactively created a pharmacy action plan in anticipation of a surge in admissions of critically ill patients with COVID-19. It was essential to create guidance documents outlining workflow, provide comprehensive staff education, and repurpose non-intensive care unit (ICU)-trained clinical pharmacotherapy specialists to work in ICUs. Teamwork was crucial to ensure staff safety, develop complete scheduling, maintain adequate drug inventory and sterile compounding, optimize the electronic health record and automated dispensing cabinets to help ensure appropriate prescribing and effective management of medication supplies, and streamline the pharmacy workflow to ensure that all patients received pharmacotherapeutic regimens in a timely fashion.
   Conclusion. Each hospital should view the COVID-19 crisis as an opportunity to internally review and enhance workflow processes, initiatives that can continue even after the resolution of the COVID-19 pandemic.
C1 [Merchan, Cristian; Soliman, Joshua; Ahuja, Tania; Arnouk, Serena; Keeley, Kelsey; Tracy, Joanna; Guerra, Gabriel; DaCosta, Kristopher; Papadopoulos, John; Dabestani, Arash] NYU Langone Hlth, Dept Pharm, New York, NY 10016 USA.
RP Merchan, C (corresponding author), NYU Langone Hlth, Dept Pharm, New York, NY 10016 USA.
EM cristian.merchan@nyulangone.org
CR American Society of Health-System Pharmacists, FIELD SURG HOSP ICU
   American Society of Health-System Pharmacists, DRUG SHORT
   American Society of Health-System Pharmacists, ASHP COVID 19 PAND A
   American Society of Health-System Pharmacists, COVID 19 BI WEEKL PH
   [Anonymous], 2016, Am J Health Syst Pharm, V73, P410, DOI 10.2146/ajhp150540
   Center for Drug Evaluation and Research US Food and Drug Administration, COMP POL CLAR DRUG I
   Flynn AJ, 2018, AM J HEALTH-SYST PH, V75, P31
   Fox Erin R, 2018, Am J Health Syst Pharm, V75, P1742, DOI 10.2146/ajhp180441
   Hua XL, 2020, J AM PHARM ASSOC, V60, P431, DOI 10.1016/j.japh.2020.04.006
   Institute for Safe Medication Practices, 2020, AC CAR ISMP MED SAF
   Lam JH, 2017, AM J HEALTH-SYST PH, V74, P1130, DOI 10.2146/ajhp160819
   O'Neil DP, 2016, AM J HEALTH-SYST PH, V73, P975, DOI 10.2146/ajhp150423
   Troiano David, 2015, Am J Health Syst Pharm, V72, P1499, DOI 10.2146/sp150014
   U.S. Pharmacopeial Convention, OP CONS STER COMP CO
   WHO, COR DIS COVID 19 PAN
   Ying Wang, 2021, Res Social Adm Pharm, V17, P1978, DOI 10.1016/j.sapharm.2020.04.001
NR 16
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-2082
EI 1535-2900
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD OCT 1
PY 2020
VL 77
IS 19
BP 1598
EP 1605
DI 10.1093/ajhp/zxaa212
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OF1NH
UT WOS:000580983200013
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bell, DJ
   Self, MM
   Davis, C
   Conway, F
   Washburn, JJ
   Crepeau-Hobson, F
AF Bell, Debora J.
   Self, Mariella M.
   Davis, Claytie, III
   Conway, Francine
   Washburn, Jason J.
   Crepeau-Hobson, Franci
TI Health Service Psychology Education and Training in the Time of
   COVID-19: Challenges and Opportunities
SO AMERICAN PSYCHOLOGIST
LA English
DT Article
DE health service psychology; education and training; COVID-19; pandemic
ID PROFESSIONAL PSYCHOLOGY; COMPETENCE; DIVERSITY; SUPERVISION; MODEL
AB The COVID-19 pandemic has posed unprecedented challenges to health service psychology (HSP) education and training but also presents tremendous opportunities for growth that will persist well past the resolution of this public health crisis. The present article addresses three aims in understanding the challenges and opportunities faced by the HSP education and training community. First, it describes challenges to HSP education and training created by the COVID-19 pandemic, including the need to maintain the integrity of training; facilitate trainee progress; continue clinical service delivery; manage the safety and wellbeing of trainees, faculty, staff, and clients/patients; and adhere to national and local emergency orders. Second, the article summarizes guidance from training organization leadership regarding training program and clinical site responses to these challenges. Several principle-based recommendations called upon training programs to prioritize trainees and their training needs, while urging balance and flexibility in meeting the multiple demands of training programs, institutions, and the public. Third, the article discusses key opportunities for improvement in HSP education and training, including more effective use of competency evaluations; distance technologies in therapy, supervision, and admissions; and reconsideration of internship and degree timing and HSP's identity as a health care profession; and the potential for comprehensive review and redesign of HSP education and training. Embracing these opportunities may help ensure that HSP education and training is preparing its graduates to meet the psychological health care needs of the future.
C1 [Bell, Debora J.] Univ Missouri, Dept Psychol Sci, 210 McAlester Hall, Columbia, MO 65211 USA.
   [Self, Mariella M.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   [Davis, Claytie, III] Univ Calif Berkeley, Counseling & Psychol Serv, Berkeley, CA 94720 USA.
   [Conway, Francine] Rutgers Univ New Brunswick, Grad Sch Appl & Profess Psychol, New Brunswick, NJ USA.
   [Washburn, Jason J.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Evanston, IL 60208 USA.
   [Crepeau-Hobson, Franci] Univ Colorado, Sch Educ & Human Dev, Denver, CO 80202 USA.
RP Bell, DJ (corresponding author), Univ Missouri, Dept Psychol Sci, 210 McAlester Hall, Columbia, MO 65211 USA.
EM belldeb@missouri.edu
OI Crepeau-Hobson, Franci/0000-0002-3696-0981
FU Council of Chairs of Training Councils; Association of Psychology
   Postdoctoral and Internship Centers; Council of University Directors of
   Clinical Psychology; Council of Directors of School Psychology Programs
FX Debora J. Bell is current chair of the Council of Chairs of Training
   Councils. Mariella M. Self is past chair of the Association of
   Psychology Postdoctoral and Internship Centers. Claytie Davis III is
   current chair of the Association of Psychology Postdoctoral and
   Internship Centers. Francine Conway is current president of the National
   Council of Schools and Programs of Professional Psychology. Jason J.
   Washburn is current chair of the Council of University Directors of
   Clinical Psychology. Franci Crepeau-Hobson is current chair of the
   Council of Directors of School Psychology Programs.
CR American Medical Association, 2020, AM MED ASS COD MED E
   American Psychological Association, 2017, ETH PRINC PSYCH COD
   American Psychological Association, 2015, STAND ACCR HLTH SERV
   American Psychological Association, 2010, MOD ACT STAT LIC PSY
   Association of American Medical Colleges, 2020, UPD INT GUID MED STU
   Association of Psychology Postdoctoral and Internship Centers, 2016, 2016 APPIC MATCH S 1
   Association of Psychology Postdoctoral and Internship Centers, 2020, COVID 19 RES TRAIN C
   Association of Psychology Postdoctoral and Internship Centers, 2020, COVID 19 INF APPIC F
   Association of Psychology Postdoctoral and Internship Centers, 2020, APPIC POSTD COMM STA
   Association of Psychology Postdoctoral and Internship Centers, 2020, APPIC BOARD DIR COVI
   Association of State and Provincial Boards of Psychology, 2020, SUP HOURS LIC VIA TE
   Bajpai S, 2019, J MED INTERNET RES, V21, DOI 10.2196/12912
   Baker J., 2020, ED TRAINING HLTH SER
   Barnett JE, 2018, CLIN PSYCHOL-SCI PR, V25, DOI 10.1111/cpsp.12233
   Boggs KR, 2000, COUNS PSYCHOL, V28, P672, DOI 10.1177/0011000000285005
   Burmeister JM, 2013, OBESITY, V21, P918, DOI 10.1002/oby.20171
   Callahan JL, 2018, TRAIN EDUC PROF PSYC, V12, P245, DOI 10.1037/tep0000208
   Callahan JL, 2018, TRAIN EDUC PROF PSYC, V12, P273, DOI 10.1037/tep0000203
   Centers for Disease Control and Prevention, 2020, COVID VIEW WEEKL SUR
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 STRESS
   Council of Chairs of Training Councils, 2020, STAT ED TRAIN CONS C
   Fouad NA, 2009, TRAIN EDUC PROF PSYC, V3, pS5, DOI 10.1037/a0015832
   Garfin DR, 2020, HEALTH PSYCHOL, V39, P355, DOI 10.1037/hea0000875
   Grus CL, 2019, TRAIN EDUC PROF PSYC, V13, P84, DOI 10.1037/tep0000227
   Huber SJ, 2004, AM J BIOETHICS, V4, pW5
   Hughes Mark T, 2004, Virtual Mentor, V6, DOI 10.1001/virtualmentor.2004.6.5.ccas1-0405
   Ingram PB, 2019, TRAIN EDUC PROF PSYC, V13, P254, DOI 10.1037/tep0000249
   Inman AG, 2019, J CLIN PSYCHOL, V75, P292, DOI 10.1002/jclp.22722
   Jordan SE, 2019, TRAIN EDUC PROF PSYC, V13, P323, DOI 10.1037/tep0000245
   Kreiter CD, 2013, TEACH LEARN MED, V25, pS50, DOI 10.1080/10401334.2013.842910
   Loewy MI, 2009, COUNS PSYCHOL, V37, P705, DOI 10.1177/0011000009331942
   Martin P, 2018, J TELEMED TELECARE, V24, P271, DOI 10.1177/1357633X17698868
   McCord CE, 2015, COUNS PSYCHOL Q, V28, P324, DOI 10.1080/09515070.2015.1053433
   Meghani D. T., 2019, TRAIN EDUC PROF PSYC, DOI [10.1037/tep0000291, DOI 10.1037/TEP0000291]
   Murphy B., 2020, COVID 19 STATES CALL
   Price SD, 2017, TRAIN EDUC PROF PSYC, V11, P128, DOI 10.1037/tep0000133
   Roberts MC, 2018, TRAIN EDUC PROF PSYC, V12, P286, DOI 10.1037/tep0000219
   Rozensky RH, 2013, AM PSYCHOL, V68, P703, DOI 10.1037/a0033771
   Secon H., 2020, BUSINESS INSIDER
   Simpson S, 2015, AUST PSYCHOL, V50, P285, DOI 10.1111/ap.12131
   Smith-Schoenwalder C., 2020, US NEWS WORLD REPORT
   Souza CLE, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01557
   Wood JAV, 2005, PROF PSYCHOL-RES PR, V36, P173, DOI 10.1037/0735-7028.36.2.173
   World Health Organization, 2020, MENT HLTH PSYCH CONS
   Wynia MK, 2007, AM J BIOETHICS, V7, P1, DOI 10.1080/15265160701307613
NR 45
TC 1
Z9 1
U1 1
U2 1
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0003-066X
EI 1935-990X
J9 AM PSYCHOL
JI Am. Psychol.
PD OCT
PY 2020
VL 75
IS 7
BP 919
EP 932
DI 10.1037/amp0000673
PG 14
WC Psychology, Multidisciplinary
SC Psychology
GA OE3NH
UT WOS:000580440900005
PM 32584062
DA 2021-01-01
ER

PT J
AU Marfella, R
   Paolisso, P
   Sardu, C
   Bergamaschi, L
   D'Angelo, EC
   Barbieri, M
   Rizzo, MR
   Messina, V
   Maggi, P
   Coppola, N
   Pizzi, C
   Biffi, M
   Viale, P
   Galie, N
   Paolisso, G
AF Marfella, R.
   Paolisso, P.
   Sardu, C.
   Bergamaschi, L.
   D'Angelo, E. C.
   Barbieri, M.
   Rizzo, M. R.
   Messina, V
   Maggi, P.
   Coppola, N.
   Pizzi, C.
   Biffi, M.
   Viale, P.
   Galie, N.
   Paolisso, G.
TI Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19
   patients
SO DIABETES & METABOLISM
LA English
DT Article
DE Covid-19; Diabetes mellitus; Interleukin-6
AB Tocilizumab (TCZ) is used for treating moderate-to-severe Covid-19 pneumonia by targeting interleukin-6 receptors (IL-6Rs) and reducing cytokine release. Yet, in spite of this therapy, patients with vs. patients without diabetes have an adverse disease course. In fact, glucose homoeostasis has influenced the outcomes of diabetes patients with infectious diseases. Of the 475 Covid-19-positive patients admitted to infectious disease departments (University of Bologna, University Vanvitelli of Napoli, San Sebastiano Caserta Hospital) in Italy since 1 March 2020, 31 (39.7%) hyperglycaemic and 47 (60.3%) normoglycaemic patients (blood glucose levels >= 140 mg/dL) were retrospectively evaluated at admission and during their hospital stay. Of note, 20 (64%) hyperglycaemic and 11 (23.4%) normoglycaemic patients had diabetes (P < 0.01). At admission, hyperglycaemic vs. normoglycaemic patients had fivefold higher IL-6 levels, which persisted even after TCZ administration (P < 0.05). Intriguingly, in a risk-adjusted Cox regression analysis, TCZ in hyperglycaemic patients failed to attenuate risk of severe outcomes as it did in normoglycaemic patients (P < 0.009). Also, in hyperglycaemic patients, higher IL-6 plasma levels reduced the effects of TCZ, while adding IL-6 levels to the Cox regression model led to loss of significance (P < 0.07) of its effects. Moreover, there was evidence that optimal Covid-19 infection management with TCZ is not achieved during hyperglycaemia in both diabetic and non-diabetic patients. These data may be of interest to currently ongoing clinical trials of TCZ effects in Covid-19 patients and of optimal control of glycaemia in this patient subset. Crown Copyright (C) 2020 Published by Elsevier Masson SAS. All rights reserved.
C1 [Marfella, R.; Sardu, C.; Barbieri, M.; Rizzo, M. R.; Paolisso, G.] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci DAMSS, I-80138 Naples, Italy.
   [Paolisso, P.; Bergamaschi, L.; D'Angelo, E. C.; Pizzi, C.; Biffi, M.; Galie, N.] Univ Bologna, Dept Expt Diagnost & Specialty Med DIMES, Unit Cardiol, Bologna, Italy.
   [Sardu, C.] Int Univ Hlth & Med Sci St Camillus, Dept Med Sci, Rome, Italy.
   [Messina, V] St Anna Hosp, Dept Infect Dis, Caserta, Italy.
   [Maggi, P.; Coppola, N.] Univ Campania Luigi Vanvitelli, Dept Mental & Phys Hlth & Prevent Med, I-80138 Naples, Italy.
   [Viale, P.] Univ Bologna, S Orsola Hosp, Dept Med & Surg Sci, Unit Infect Dis, Bologna, Italy.
RP Sardu, C (corresponding author), Univ Campania Luigi Vanvitelli, DAMSS, Internal Med, Piazza Miraglia 2, I-80138 Naples, Italy.
EM drsarducele@gmail.com
OI Bergamaschi, Luca/0000-0001-8186-9717; Messina,
   Vincenzo/0000-0003-1323-5127; Paolisso, Pasquale/0000-0002-7017-778X
CR Aizu M, 2018, MOD RHEUMATOL, V28, P592, DOI 10.1080/14397595.2017.1370766
   Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Alzghari SK, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104380
   American Diabetes Association, 2015, Diabetes Care, V38 Suppl, pS8, DOI 10.2337/dc15-S005
   Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9
   Esposito K, 2002, CIRCULATION, V106, P2067, DOI 10.1161/01.CIR.0000034509.14906.AE
   JAIN SK, 1993, DIABETIC MED, V10, P27, DOI 10.1111/j.1464-5491.1993.tb01992.x
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Maddaloni E, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3321
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 10
TC 23
Z9 24
U1 1
U2 1
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 1262-3636
EI 1878-1780
J9 DIABETES METAB
JI Diabetes Metab.
PD OCT
PY 2020
VL 46
IS 5
BP 403
EP 405
DI 10.1016/j.diabet.2020.05.005
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OE6RN
UT WOS:000580655800010
PM 32447102
OA Green Published
DA 2021-01-01
ER

PT J
AU Masia, M
   Fernandez-Gonzalez, M
   Padilla, S
   Ortega, P
   Garcia, JA
   Agullo, V
   Garcia-Abellan, J
   Telenti, G
   Guillen, L
   Gutierrez, F
AF Masia, Mar
   Fernandez-Gonzalez, Marta
   Padilla, Sergio
   Ortega, Piedad
   Garcia, Jose A.
   Agullo, Vanesa
   Garcia-Abellan, Javier
   Telenti, Guillermo
   Guillen, Lucia
   Gutierrez, Felix
TI Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral
   kinetics and antibody responses in patients with COVID-19: A prospective
   cohort study
SO EBIOMEDICINE
LA English
DT Article
DE Tocilizumab; SARS-CoV-2; COVID-19; Viral kinetics; Antibody responses;
   Anti-cytokine therapy; S-IgG; N-IgG
ID PATIENTS RECEIVING TOCILIZUMAB; RHEUMATOID-ARTHRITIS; LOAD; IMMUNE; IL-6
AB Background: The virological and immunological effects of the immunomodulatory drugs used for COVID-19 remain unknown. We evaluated the impact of interleukin (IL)-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and the antibody response in patients with COVID-19.
   Methods: Prospective cohort study in patients admitted with COVID-19. Serial nasopharyngeal and plasma samples were measured for SARS-CoV-2 RNA and S-IgG/N-IgG titers, respectively.
   Findings: 138 patients with confirmed infection were included; 76 (55%) underwent IL-6 blockade. Median initial SOFA (p = 0.016) and SARS-CoV-2 viral load (p<0.001, Mann-Whitney-Wilcoxon test) were significantly higher among anti-IL-6 users. Patients under IL-6 blockade showed delayed viral clearance in the Kaplan-Meier curves (HR 0.35 [95%CI] [0.15.0.81], log-rank p = 0.014), but an adjusted propensity score matching model did not demonstrate a significant relationship of IL-6 blockade with viral clearance (HR 1.63 [0.35.7.7]). Cox regression showed an inverse association between SARS-CoV-2 RNA clearance and the initial viral load (HR 0.35 [0 .11.0.89]). Patients under the IL-6 blocker showed shorter median time to seropositivity, higher peak antibody titers, and higher cumulative proportion of seropositivity in the Kaplan Meier curves (HR 3.1 [1.9.5] for S-IgG; and HR 3.0 [1.9.4.9] for N-IgG; log-rank p<0.001 for both). However, no significant differences between groups were found in either S-IgG (HR 1.56 [0.41.6.0]) nor N-IgG (HR 0.96 [0.26.3.5]) responses in an adjusted propensity score analysis.
   Interpretation: Our results suggest that in patients infected with SARS-CoV-2, IL-6 blockade does not impair the viral specific antibody responses. Although a delayed viral clearance was observed, it was driven by a higher initial viral load. The study supports the safety of this therapy in patients with COVID-19.
   Funding: Instituto de salud Carlos III (Spain). (c) 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
C1 [Masia, Mar; Fernandez-Gonzalez, Marta; Padilla, Sergio; Ortega, Piedad; Agullo, Vanesa; Garcia-Abellan, Javier; Telenti, Guillermo; Guillen, Lucia; Gutierrez, Felix] Hosp Gen Univ Elche, Cami Almazara 11, Alicante 03203, Spain.
   [Masia, Mar; Gutierrez, Felix] Univ Miguel Hernandez, Cami Almazara 11, Alicante 03203, Spain.
   [Garcia, Jose A.] Univ Miguel Hernandez, Operat Res Ctr, Alicante, Spain.
RP Masia, M; Gutierrez, F (corresponding author), Hosp Gen Univ Elche, Cami Almazara 11, Alicante 03203, Spain.; Masia, M; Gutierrez, F (corresponding author), Univ Miguel Hernandez, Cami Almazara 11, Alicante 03203, Spain.
EM marmasia@umh.es; gutierrez_fel@gva.es
RI Gutierrez, Felix/Q-7880-2018; Fernandez-Gonzalez, Marta/U-7492-2017
OI Gutierrez, Felix/0000-0002-9485-6867; Telenti,
   Guillermo/0000-0002-1571-6090; GARCIA GOMEZ, JOSE
   ALBERTO/0000-0002-1203-7260; Fernandez-Gonzalez,
   Marta/0000-0001-9949-8504
FU Plan Nacional Research + Development + Innovation (R+D+I)
   [RD16/0025/0038]; Instituto de Salud Carlos III - Subdireccion General
   de Evaluacion y Fondo Europeo de Desarrollo Regional; Instituto de Salud
   Carlos III (Fondo de Investigaciones Sanitarias)Instituto de Salud
   Carlos III [PI16/01740, PI18/01861, CM19/00160, COV20-00005]
FX This work was supported by the RD16/0025/0038 project as a part of the
   Plan Nacional Research + Development + Innovation (R+D+I) and cofinanced
   by Instituto de Salud Carlos III - Subdireccion General de Evaluacion y
   Fondo Europeo de Desarrollo Regional; Instituto de Salud Carlos III
   (Fondo de Investigaciones Sanitarias [Grant No. PI16/01740; PI18/01861];
   CM19/00160; COV20-00005]). This study would not have been possible
   without the collaboration of all the patients, and the medical and
   nursing staff who were involved in their attention (COVID19-Elx Group).
CR Bingham CO, 2015, ANN RHEUM DIS, V74, P818, DOI 10.1136/annrheumdis-2013-204427
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Chen X, 2020, CHINA PERSPECT-SER, P1
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Guaraldi G., 2020, LANCET RHEUMATOL
   Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254-003-0012-2
   Kapetanovic MC, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4358
   Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806
   KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0
   Kubandova Z, 2010, JOINT BONE SPINE, V77, P623, DOI 10.1016/j.jbspin.2010.07.009
   Lee SK, 2011, J EXP MED, V208, P1377, DOI 10.1084/jem.20102065
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Mihara M, 2005, INT IMMUNOPHARMACOL, V5, P1731, DOI 10.1016/j.intimp.2005.05.010
   Mori S, 2012, ANN RHEUM DIS, V71, P2006, DOI 10.1136/annrheumdis-2012-201950
   Mourgues C, 2016, JOINT BONE SPINE, V83, P412, DOI 10.1016/j.jbspin.2015.07.009
   MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332
   Nagashima T, 2012, RHEUMATOL INT, V32, P2231, DOI 10.1007/s00296-011-2060-2
   Qian GD, 2020, INT J NEUROSCI, DOI [10.1080/00207454.2020.1758088, 10.1080/23744235.2020.1748705]
   Ramshaw IA, 1997, IMMUNOL REV, V159, P119, DOI 10.1111/j.1600-065X.1997.tb01011.x
   Rose-John S, 2017, NAT REV RHEUMATOL, V13, P399, DOI 10.1038/nrrheum.2017.83
   Scherlinger M, 2018, JOINT BONE SPINE, V85, P259, DOI 10.1016/j.jbspin.2017.02.010
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   van Duin D, 2011, EMERG INFECT DIS, V17, P754, DOI [10.3201/eid1704.101057, 10.3201/eid1706.101057]
   Watanabe K, 2020, SOC SCI COMPUT REV, DOI 10.1177/0894439320907027
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang YC, 2020, EMERG MICROBES INFEC, V9, P833, DOI 10.1080/22221751.2020.1756699
   Zhao S, 2020, INFECT DIS-NOR, V52, P284, DOI 10.1080/23744235.2020.1717598
   Zheng S, 2020, BMJ
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 30
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD OCT
PY 2020
VL 60
AR 102999
DI 10.1016/j.ebiom.2020.102999
PG 9
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA OE5LQ
UT WOS:000580572100023
PM 32950003
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Brenna, OV
   Torretta, S
   Pignataro, L
   Di Berardino, F
AF Brenna, Oreste Vittore
   Torretta, Sara
   Pignataro, Lorenzo
   Di Berardino, Federica
TI Cationic drugs and COVID-19
SO INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
LA English
DT Article
DE cationic drugs; COVID-19; emergency; infection; pandemic
ID TMPRSS2
AB Given the sharp spreading of COVID-19 pandemic all around the world, our attention was brought to consider that that many cationic drugs (i.e. those characterized by the presence, at physiological pH value, of one or more cationic groups, both primary, secondary, tertiary and guanidinic aminic groups) could have any effect in impairing SARS-CoV2 entry in the host cell. This could open to new therapeutic chances against COVID-19.
C1 [Brenna, Oreste Vittore] Univ Milan, Dept Food Environm & Nutrit Sci, Milan, Italy.
   [Torretta, Sara; Pignataro, Lorenzo; Di Berardino, Federica] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy.
   [Torretta, Sara; Pignataro, Lorenzo; Di Berardino, Federica] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
RP Torretta, S (corresponding author), Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Otolaryngol & Head & Neck Surg Unit, Via F Sforza 35, I-20100 Milan, Italy.; Torretta, S (corresponding author), Univ Milan, Dept Clin Sci & Community Hlth, Via F Sforza 35, I-20100 Milan, Italy.
EM sara.torretta@unimi.it
RI Torretta, Sara/B-3993-2017
OI Torretta, Sara/0000-0002-8461-6042
CR Farsalinos Konstantinos, 2020, Toxicol Rep, V7, P658, DOI 10.1016/j.toxrep.2020.04.012
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iacobellis G, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108125
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   OHKUMA S, 1986, J CELL BIOL, V102, P959, DOI 10.1083/jcb.102.3.959
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Varki A, 2012, ANN NY ACAD SCI, V1253, P16, DOI 10.1111/j.1749-6632.2012.06517.x
NR 10
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0394-6320
EI 2058-7384
J9 INT J IMMUNOPATH PH
JI Int. J. Immunopathol. Pharmacol.
PD OCT
PY 2020
VL 34
AR 2058738420966078
DI 10.1177/2058738420966078
PG 3
WC Immunology; Pathology; Pharmacology & Pharmacy
SC Immunology; Pathology; Pharmacology & Pharmacy
GA OG8NF
UT WOS:000582133000001
PM 33045858
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Carsana, L
   Sonzogni, A
   Nasr, A
   Rossi, RS
   Pellegrinelli, A
   Zerbi, P
   Rech, R
   Colombo, R
   Antinori, S
   Corbellino, M
   Galli, M
   Catena, E
   Tosoni, A
   Gianatti, A
   Nebuloni, M
AF Carsana, Luca
   Sonzogni, Aurelio
   Nasr, Ahmed
   Rossi, Roberta Simona
   Pellegrinelli, Alessandro
   Zerbi, Pietro
   Rech, Roberto
   Colombo, Riccardo
   Antinori, Spinello
   Corbellino, Mario
   Galli, Massimo
   Catena, Emanuele
   Tosoni, Antonella
   Gianatti, Andrea
   Nebuloni, Manuela
TI Pulmonary post-mortem findings in a series of COVID-19 cases from
   northern Italy: a two-centre descriptive study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; SARS; PATHOLOGY; LUNG
AB Background COVID-19 is characterised by respiratory symptoms, which deteriorate into respiratory failure in a substantial proportion of cases, requiring intensive care in up to a third of patients admitted to hospital. Analysis of the pathological features in the lung tissues of patients who have died with COVID-19 could help us to understand the disease pathogenesis and clinical outcomes.
   Methods We systematically analysed lung tissue samples from 38 patients who died from COVID-19 in two hospitals in northern Italy between Feb 29 and March 24, 2020. The most representative areas identified at macroscopic examination were selected, and tissue blocks (median seven, range five to nine) were taken from each lung and fixed in 10% buffered formalin for at least 48 h. Tissues were assessed with use of haematoxylin and eosin staining, immunohistochemical staining for inflammatory infiltrate and cellular components (including staining with antibodies against CD68, CD3, CD45, CD61, TTF1, p40, and Ki-67), and electron microscopy to identify virion localisation.
   Findings All cases showed features of the exudative and proliferative phases of diffuse alveolar damage, which included capillary congestion (in all cases), necrosis of pneumocytes (in all cases), hyaline membranes (in 33 cases), interstitial and intra-alveolar oedema (in 37 cases), type 2 pneumocyte hyperplasia (in all cases), squamous metaplasia with atypia (in 21 cases), and platelet-fibrin thrombi (in 33 cases). The inflammatory infiltrate, observed in all cases, was largely composed of macrophages in the alveolar lumina (in 24 cases) and lymphocytes in the interstitium (in 31 cases). Electron microscopy revealed that viral particles were predominantly located in the pneumocytes.
   Interpretation The predominant pattern of lung lesions in patients with COVID-19 patients is diffuse alveolar damage, as described in patients infected with severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses. Hyaline membrane formation and pneumocyte atypical hyperplasia are frequent. Importantly, the presence of platelet-fibrin thrombi in small arterial vessels is consistent with coagulopathy, which appears to be common in patients with COVID-19 and should be one of the main targets of therapy. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Carsana, Luca; Rossi, Roberta Simona; Pellegrinelli, Alessandro; Zerbi, Pietro; Tosoni, Antonella; Nebuloni, Manuela] Luigi Sacco Hosp, Pathol Unit, Milan, Italy.
   [Rech, Roberto; Colombo, Riccardo; Catena, Emanuele] Luigi Sacco Hosp, Dept Anaesthesiol, Milan, Italy.
   [Rech, Roberto; Colombo, Riccardo; Catena, Emanuele] Luigi Sacco Hosp, Intens Care Unit, Milan, Italy.
   [Antinori, Spinello; Corbellino, Mario; Galli, Massimo] Luigi Sacco Hosp, Dept Infect Dis, Milan, Italy.
   [Sonzogni, Aurelio; Nasr, Ahmed; Gianatti, Andrea] Papa Giovanni XXIII Hosp, Dept Pathol, Bergamo, Italy.
   [Nasr, Ahmed] Univ Milano Bicocca, Dept Pathol, Milan, Italy.
   [Zerbi, Pietro; Antinori, Spinello; Galli, Massimo; Nebuloni, Manuela] Univ Milan, Dept Biomed & Clin Sci, Milan, Italy.
RP Nebuloni, M (corresponding author), Univ Milan, Luigi Sacco Hosp, Pathol Unit, I-20157 Milan, Italy.
EM manuela.nebuloni@unimi.it
RI ; Zerbi, Pietro/L-1518-2017
OI Colombo, Riccardo/0000-0002-9616-803X; Zerbi, Pietro/0000-0001-7611-2605
CR Alsaad KO, 2018, HISTOPATHOLOGY, V72, P516, DOI 10.1111/his.13379
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Camprubi-Rimblas M, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.08
   Fineschi Vittorio, 2020, Pathologica, V112, P64, DOI 10.32074/1591-951X-13-20
   Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hwang DM, 2005, MODERN PATHOL, V18, P1, DOI 10.1038/modpathol.3800247
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Mandal RV, 2007, EXP MOL PATHOL, V83, P327, DOI 10.1016/j.yexmp.2007.08.005
   Ogando NS, 2020, BIORXIV, DOI [10.1101/2020.04.20.049924, DOI 10.1101/2020.04.20.049924]
   Shieh WJ, 2005, HUM PATHOL, V36, P303, DOI 10.1016/j.humpath.2004.11.006
   Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 90
Z9 92
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD OCT
PY 2020
VL 20
IS 10
BP 1135
EP 1140
DI 10.1016/S1473-3099(20)30434-5
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA OD7UL
UT WOS:000580053900036
PM 32526193
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sadria, M
   Layton, AT
AF Sadria, Mehrshad
   Layton, Anita T.
TI Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II
   Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID SEX-DIFFERENCES; LUNG FIBROSIS; SYSTEM; KIDNEY; ACE2
AB Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) are frequently prescribed for a range of diseases including hypertension, proteinuric chronic kidney disease, and heart failure. There is evidence indicating that these drugs upregulate ACE2, a key component of the renin-angiotensin system (RAS) and is found on the cells of a number of tissues, including the epithelial cells in the lungs. While ACE2 has a beneficial role in many diseases such as hypertension, diabetes, and cardiovascular disease, it also serves as a receptor for both SARS-CoV and SARS-CoV-2 via binding with the spike protein of the virus, thereby allowing it entry into host cells. Thus, it has been suggested that these therapies can theoretically increase the risk of SARS- CoV-2 infection and cause more severe COVID-19. Given the success of ACEi and ARBs in cardiovascular diseases, we seek to gain insights into the implications of these medications in the pathogenesis of COVID-19. To that end, we have developed a mathematical model that represents the RAS, binding of ACE2 with SARS-CoV-2 and the subsequent cell entry, and the host's acute inflammatory response. The model can simulate different levels of SARS-CoV-2 exposure, and represent the effect of commonly prescribed anti-hypertensive medications, ACEi and ARB, and predict tissue damage. Model simulations indicate that whether the extent of tissue damage may be exacerbated by ACEi or ARB treatment depends on a number of factors, including the level of existing inflammation, dosage, and the effect of the drugs on ACE2 protein abundance. The findings of this study can serve as the first step in the development of appropriate and more comprehensive guidelines for the prescription of ACEi and ARB in the current and future coronavirus pandemics.
C1 [Sadria, Mehrshad; Layton, Anita T.] Univ Waterloo, Dept Appl Math, Waterloo, ON, Canada.
   [Layton, Anita T.] Univ Waterloo, Dept Biol, Cheriton Sch Comp Sci, Waterloo, ON, Canada.
   [Layton, Anita T.] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada.
RP Layton, AT (corresponding author), Univ Waterloo, Dept Appl Math, Waterloo, ON, Canada.; Layton, AT (corresponding author), Univ Waterloo, Dept Biol, Cheriton Sch Comp Sci, Waterloo, ON, Canada.; Layton, AT (corresponding author), Univ Waterloo, Sch Pharm, Waterloo, ON, Canada.
EM anita.layton@uwaterloo.ca
FU Canada 150 Research Chair program; NSERC Discovery awardNatural Sciences
   and Engineering Research Council of Canada
FX This research was supported by the Canada 150 Research Chair program
   (A.T.L.) and the NSERC Discovery award (A.T.L.). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahmed S, 2019, AM J PHYSL RENAL PHY
   Chappell MC, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2013.00201
   Chappell MC, 2012, COMPR PHYSIOL, V2, P2733, DOI 10.1002/cphy.c120002
   Chen Y, 2017, AM J PHYSIOL-RENAL, V313, pF174, DOI 10.1152/ajprenal.00482.2016
   Clarke NE, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/307315
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Ferreira AJ, 2009, AM J RESP CRIT CARE, V179, P1048, DOI 10.1164/rccm.200811-1678OC
   GILLUM RF, 1979, HYPERTENSION, V1, P468, DOI 10.1161/01.HYP.1.5.468
   Gomez CR, 2005, CURR OPIN IMMUNOL, V17, P457, DOI 10.1016/j.coi.2005.07.013
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu R, 2020, AM J PHYSL RENAL PHY
   Hu R, 2019, AM J PHYSIOL-RENAL, V317, pF1462, DOI 10.1152/ajprenal.00352.2019
   Jiang JS, 2012, NEONATOLOGY, V101, P47, DOI 10.1159/000329451
   Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200
   Layton AT, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.13050
   Layton AT, 2018, AM J PHYSIOL-RENAL, V314, pF969, DOI 10.1152/ajprenal.00551.2017
   Leete J, 2019, COMPUT BIOL MED, V104, P139, DOI 10.1016/j.compbiomed.2018.11.002
   Leete J, 2018, COMPUT CHEM ENG, V112, P253, DOI 10.1016/j.compchemeng.2018.02.009
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Reynolds A, 2006, J THEOR BIOL, V242, P220, DOI 10.1016/j.jtbi.2006.02.016
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Sadria M, 2020, SCI REPORTS
   Savoia C, 2006, CURR OPIN NEPHROL HY, V15, P152, DOI 10.1097/01.mnh.0000203189.57513.76
   Shenoy V, 2010, AM J RESP CRIT CARE, V182, P1065, DOI 10.1164/rccm.200912-1840OC
   South AM, 2020, NAT REV NEPHROL, V16, P305, DOI 10.1038/s41581-020-0279-4
   Sparks MA, 2014, COMPR PHYSIOL, V4, P1201, DOI 10.1002/cphy.c130040
   Wagenaar GTM, 2013, AM J PHYSIOL-LUNG C, V305, pL341, DOI 10.1152/ajplung.00360.2012
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Warner FJ, 2005, J BIOL CHEM, V280, P39353, DOI 10.1074/jbc.M508914200
   Wysocki J, 2010, HYPERTENSION, V55, P90, DOI 10.1161/HYPERTENSIONAHA.109.138420
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zuo Yu, 2020, medRxiv, DOI 10.1101/2020.04.09.20059626
NR 32
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD OCT
PY 2020
VL 16
IS 10
AR e1008235
DI 10.1371/journal.pcbi.1008235
PG 16
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA OG3LT
UT WOS:000581790800003
PM 33031368
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lindholm, PF
   Ramsey, G
   Kwaan, HC
AF Lindholm, Paul F.
   Ramsey, Glenn
   Kwaan, Hau C.
TI Passive Immunity for Coronavirus Disease 2019: A Commentary on
   Therapeutic Aspects Including Convalescent Plasma
SO SEMINARS IN THROMBOSIS AND HEMOSTASIS
LA English
DT Article
DE COVID-19; MERS; SARS; immunity; immunoglobulin; convalescent plasma
ID ACUTE RESPIRATORY SYNDROME; RECEPTOR-BINDING DOMAIN; NEUTRALIZING
   ANTIBODIES; SPIKE PROTEIN; MONOCLONAL-ANTIBODIES; SARS CORONAVIRUS;
   VIRUS-INFECTION; MERS; INFLUENZA; PNEUMONIA
AB In the ongoing pandemic of coronavirus disease 2019 (COVID-19), the novel virus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is infecting a naive population. The innate immunity of the infected patient is unable to mount an effective defense, resulting in a severe illness with substantial morbidity and mortality. As most treatment modalities including antivirals and anti-inflammatory agents are mostly ineffective, an immunological approach is needed. The mechanism of innate immunity to this viral illness is not fully understood. Passive immunity becomes an important avenue for the management of these patients. In this article, the immune responses of COVID-19 patients are reviewed. As SARS-CoV-2 has many characteristics in common with two other viruses, SARS-CoV that cause severe acute respiratory syndrome (SARS) and MERS-CoV (Middle East respiratory syndrome coronavirus) that causes Middle East respiratory syndrome (MERS), the experiences learned from the use of passive immunity in treatment can be applied to COVID-19. The immune response includes the appearance of immunoglobulin M followed by immunoglobulin G and neutralizing antibodies. Convalescent plasma obtained from patients recovered from the illness with high titers of neutralizing antibodies was successful in treating many COVID-19 patients. The factors that determine responses as compared with those seen in SARS and MERS are also reviewed. As there are no approved vaccines against all three viruses, it remains a challenge in the ongoing development for an effective vaccine for COVID-19.
C1 [Lindholm, Paul F.; Ramsey, Glenn] Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 East Chicago Ave,Ward 3-140 W127, Chicago, IL 60611 USA.
   [Kwaan, Hau C.] Northwestern Univ, Dept Med, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Lindholm, PF (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 East Chicago Ave,Ward 3-140 W127, Chicago, IL 60611 USA.
EM P-lindholm@northwestern.edu
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Arabi Y, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1490-9
   Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5
   Arabi YM, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3846-x
   Beigel JH, 2019, LANCET RESP MED, V7, P941, DOI 10.1016/S2213-2600(19)30199-7
   Beigel JH, 2017, LANCET RESP MED, V5, P500, DOI 10.1016/S2213-2600(17)30174-1
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cormier M, 2020, BRIT J HAEMATOL, V189, P39, DOI 10.1111/bjh.16377
   Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Giwa Al, 2020, Emerg Med Pract, V22, P1
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   He WQ, 2016, P NATL ACAD SCI USA, V113, P11931, DOI 10.1073/pnas.1609316113
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   He YX, 2004, J IMMUNOL, V173, P4050, DOI 10.4049/jimmunol.173.6.4050
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2013, CHEST, V144, P712, DOI 10.1378/chest.13-0571
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Hung IFN, 2010, CLIN INFECT DIS, V51, P274, DOI 10.1086/653940
   Kim TW, 2004, J VIROL, V78, P4638, DOI 10.1128/JVI.78.9.4638-4645.2004
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Ko JH, 2017, DIAGN MICR INFEC DIS, V89, P106, DOI 10.1016/j.diagmicrobio.2017.07.006
   Kuchar E, 2015, ADV EXP MED BIOL, V857, P25, DOI 10.1007/5584_2015_110
   Kumar D, 2020, MOL IMMUNOL, V121, P99, DOI 10.1016/j.molimm.2020.03.005
   Lau YL, 2005, CURR OPIN IMMUNOL, V17, P404, DOI 10.1016/j.coi.2005.05.009
   Leung T F, 2003, Paediatr Respir Rev, V4, P334, DOI 10.1016/S1526-0542(03)00088-5
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Lin QQ, 2020, J MICROBIOL IMMUNOL, V53, P821, DOI 10.1016/j.jmii.2020.03.015
   Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   McGuire LW, 1919, J AMER MED ASSOC, V72, P709, DOI 10.1001/jama.1919.02610100017007
   Murin CD, 2019, NAT MICROBIOL, V4, P734, DOI 10.1038/s41564-019-0392-y
   Newton AH, 2016, SEMIN IMMUNOPATHOL, V38, P471, DOI 10.1007/s00281-016-0558-0
   Nurtop E, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1118-8
   Nurtop E, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1105-5
   O'Malley J J, 1919, JAMA-J AM MED ASSOC, V72, P34
   Payne S, 2017, VIRUSES: FROM UNDERSTANDING TO INVESTIGATION, P37, DOI 10.1016/B978-0-12-803109-4.00004-0
   Pelegrin M, 2015, TRENDS MICROBIOL, V23, P653, DOI 10.1016/j.tim.2015.07.005
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sanborn G, 1920, BOSTON MED SURG J, V183, P171
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991
   Tang J, 2015, HUM VACC IMMUNOTHER, V11, P1244, DOI 10.1080/21645515.2015.1021527
   Tang XC, 2015, IMMUNOTHERAPY-UK, V7, P591, DOI [10.2217/IMT.15.33, 10.2217/imt.15.33]
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   Tirado SMC, 2003, VIRAL IMMUNOL, V16, P69, DOI 10.1089/088282403763635465
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   U. S. FDA, INV COVID 19 CONV PL
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang F, 2020, EMERG MICROBES INFEC, V9, P664, DOI 10.1080/22221751.2020.1742076
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577
   Zhang JS, 2005, J MED VIROL, V77, P147, DOI 10.1002/jmv.20431
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 78
TC 3
Z9 3
U1 3
U2 3
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0094-6176
EI 1098-9064
J9 SEMIN THROMB HEMOST
JI Semin. Thromb. Hemost.
PD OCT
PY 2020
VL 46
IS 07
BP 796
EP 803
DI 10.1055/s-0040-1712157
PG 8
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA OG3XQ
UT WOS:000581821700008
PM 32526774
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Singh, JA
   Edwards, NL
AF Singh, Jasvinder A.
   Edwards, N. Lawrence
TI Gout management and outcomes during the COVID-19 pandemic: a
   cross-sectional internet survey
SO THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
LA English
DT Article
DE COVID-19; disease management; gout; internet; medication use;
   psychological distress; quality of life; resilience; survey
ID QUALITY-OF-LIFE; PSYCHOMETRIC PROPERTIES; SCREENING SCALE; SERUM URATE;
   DEPRESSION; ANXIETY
AB Aim: We aimed to assess the gout management during the COVID-19 pandemic.
   Methods: We assessed medication use, healthcare utilization, gout-specific health-related quality of life (HRQoL) on the Gout Impact Scale (GIS), psychological distress using the patient health questionnaire-4 (PHQ-4), and resilience in people with self-reported physician-diagnosed gout during the COVID-19 pandemic in a cross-sectional Internet survey.
   Results: Among the 122 survey respondents with physician-diagnosed gout, 82% were prescribed urate-lowering therapy (ULT) and 66% were taking ULT daily; mean age was 54.2 years [standard deviation (SD), 13.8], 65% were male, and 79% were White. More regular use of gout medication was reported during the COVID-19 pandemic: allopurinol, 44%; colchicine, 37%; non-steroidal anti-inflammatory drugs, 36%. Gout flares were common: 63% had > 1 gout flare monthly; 11% went to emergency room/urgent care; and 2% were hospitalized with gout flares. Between 41% and 56% of respondents reported more difficulty with gout management and related functional status related to COVID-19; 17-37% had difficulty with healthcare access for gout. HRQOL deficits were evident for gout concern overall, 79.4 (SD, 25); unmet gout treatment need, 64.5 (SD, 27.1); and gout concern during flare, 67.3 (SD, 27.1); but less so for gout medication side effects, 48.9 (SD, 27.4). Psychological distress was moderate in 19% and severe in 15% (mild, 22%; normal, 45%). Resilience score on Connor-Davidson Resilience Scale (CD-RISC2) was 5.6 (SD, 1.8; range 0-8). Compared with no/mild psychological distress, moderate-severe psychological distress during the COVID-19 pandemic was significantly associated with more difficulty getting gout medication filled (p = 0.02), flares treated (p = 0.005), and receiving gout education (p = 0.001).
   Conclusion: Healthcare gaps, psychological distress, and HRQoL deficits were commonly reported by people with gout during the COVID-19 pandemic. Interventions to address these challenges for people with gout during the COVID-19 pandemic are needed.
C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA.
   [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, 510 20th St South, Birmingham, AL 35233 USA.
   [Singh, Jasvinder A.; Edwards, N. Lawrence] Univ Florida, Dept Med, Div Rheumatol Immunol & Allergy, Gainesville, FL 32611 USA.
RP Singh, JA (corresponding author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA.; Singh, JA (corresponding author), Birmingham VA Med Ctr, Med Serv, 510 20th St South, Birmingham, AL 35233 USA.; Singh, JA (corresponding author), Univ Florida, Dept Med, Div Rheumatol Immunol & Allergy, Gainesville, FL 32611 USA.
EM Jasvinder.md@gmail.com
RI singh, jasvinder/A-6697-2009
OI singh, jasvinder/0000-0003-3485-0006
FU Division of Rheumatology at the University of Alabama at Birmingham
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: this material
   is the result of work supported by research funds from the Division of
   Rheumatology at the University of Alabama at Birmingham and the
   resources and use of facilities at the Birmingham VA Medical Center,
   Alabama, USA.
CR Chen-Xu M, 2019, ARTHRITIS RHEUMATOL, V71, P991, DOI 10.1002/art.40807
   Chudasama YV, 2020, DIABETES METAB SYND, V14, P965, DOI 10.1016/j.dsx.2020.06.042
   Dominick KL, 2002, AGING CLIN EXP RES, V14, P499, DOI 10.1007/BF03327351
   FitzGerald JD, 2020, ARTHRITIS RHEUMATOL, V72, P879, DOI 10.1002/art.41247
   Halpern R, 2009, JCR-J CLIN RHEUMATOL, V15, P3, DOI 10.1097/RHU.0b013e3181945d2c
   Hirsch JD, 2010, PATIENT-RELAT OUTCOM, V1, P1, DOI 10.2147/PROM.S8310
   Khanna D, 2011, RHEUMATOLOGY, V50, P1331, DOI 10.1093/rheumatology/ker023
   Khanna PP, 2011, RHEUMATOLOGY, V50, P740, DOI 10.1093/rheumatology/keq346
   Khubchandani J, 2016, ARCH PSYCHIAT NURS, V30, P457, DOI 10.1016/j.apnu.2016.01.014
   Kroenke K, 2009, PSYCHOSOMATICS, V50, P613, DOI 10.1176/appi.psy.50.6.613
   Michaud Kaleb, 2020, ACR Open Rheumatol, V2, P335, DOI 10.1002/acr2.11148
   Mills SD, 2015, HISPANIC J BEHAV SCI, V37, P560, DOI 10.1177/0739986315608126
   Richette P, 2017, ANN RHEUM DIS, V76, P29, DOI [10.1136/annrheumdis-2016-210356, 10.1136/annrheumdis-2016-209707]
   Rockwell KL, 2020, AM J MANAG CARE, V26, P147, DOI 10.37765/ajmc.2020.42784
   Roddy E, 2007, ANN RHEUM DIS, V66, P1311, DOI 10.1136/ard.2007.070755
   Shoji A, 2004, ARTHRIT RHEUM-ARTHR, V51, P321, DOI 10.1002/art.20405
   Singh JA, JCR-J CLIN RHEUMATOL, DOI [10.1097/RHU.0000000000000981., DOI 10.1097/RHU.0000000000000981.]
   Singh JA, 2018, CLIN RHEUMATOL, V37, P2557, DOI 10.1007/s10067-018-4243-7
   Spaetgens B, 2014, RHEUMATOLOGY, V53, P678, DOI 10.1093/rheumatology/ket423
   Sundy JS, 2011, JAMA-J AM MED ASSOC, V306, P711, DOI [10.1001/jama.2011.116, 10.1001/jama.2011.1169]
   Vaishnavi S, 2007, PSYCHIAT RES, V152, P293, DOI 10.1016/j.psychres.2007.01.006
   Voils CI, 2012, MED CARE, V50, P1013, DOI 10.1097/MLR.0b013e318269e121
NR 22
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1759-720X
EI 1759-7218
J9 THER ADV MUSCULOSKEL
JI Ther. Adv. Musculoskelet. Dis.
PD OCT
PY 2020
VL 12
AR 1759720X20966124
DI 10.1177/1759720X20966124
PG 8
WC Rheumatology
SC Rheumatology
GA OG0UN
UT WOS:000581610500001
PM 33133248
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Croasdell, G
AF Croasdell, G.
TI Alzheimer's Association International Conference 2020
SO DRUGS OF THE FUTURE
LA English
DT Article
DE Masupirdine; NTRX-07; AR-1001; BI-425809; LY-3372689
AB The Alzheimer's Association International Conference (AAIC) is the world's largest scientific platform to discuss Alzheimer's disease and dementia aimed at advancing science in these research areas. Despite the COVID-19 pandemic preventing an in-person meeting this year, the virtual alternative set up by the association, continued with this aim, noting that this option had the potential to reach a larger global audience, with the information made available through free registration to the event. The conference consisted of over 50 live sessions, 100 on-demand sessions with live Q&A and over 2,800 posters, covered with a different theme each day; additionally there were networking opportunities through dedicated chatrooms in a 'networking lounge' and a virtual exhibition hall with approximately 60 exhibitors available live to discuss their products. This report covers presentations on drugs in development presented throughout the conference.
C1 [Croasdell, G.] Clarivate, London, England.
RP Croasdell, G (corresponding author), Clarivate, London, England.
EM gary.croasdell@clarivate.com
NR 0
TC 0
Z9 0
U1 2
U2 2
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD OCT
PY 2020
VL 45
IS 10
BP 755
EP 759
DI 10.1358/dof.2020.45.10.3223381
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OF1BT
UT WOS:000580953200006
DA 2021-01-01
ER

PT J
AU Chen, GY
   Li, JH
   Jiang, YC
   Chen, HH
   Pan, R
AF Chen, Gaoyan
   Li, Junhua
   Jiang, Yongchao
   Chen, Haihua
   Pan, Rui
TI Characteristics of Eight Pediatric Patients with Coronavirus Disease
   2019
SO IRANIAN JOURNAL OF PEDIATRICS
LA English
DT Article
DE Child; Infection; Coronavirus; Pneumonia; Treatment
AB Background: Coronavirus Disease 2019 (COVID-19) has attracted global attention for unexpected rapid transmission among countries. Currently, little is known about the attributes of pediatric patients with COVID-19.
   Objectives: To describe the characteristics of pediatric patients with COVID-19.
   Methods: We retrospectively analyzed the epidemiological, laboratory, imaging, and clinical data of pediatric patients with COVID-19 from January 31 to February 24, 2020.
   Results: A total of eight patients with COVID-19 were enrolled in this study. Two patients had underlying diseases. Seven children (87.5%) belonged to a family cluster outbreak. The most common symptoms were fever (50%), cough (37.5%), expectoration (37.5%), and Sore throat (37.5%). For the laboratory findings, all patients had positive nCoV-RNA results, three patients (37.5%) with abnormal white blood cell counts, and six patients (75%) with higher lymphocyte counts. Chest computed tomography (CT) showed ground-glass opacity or patchy shadows in 7 patients (87.5%). All patients received antiviral therapy. Additionally, four patients (50%) were treated with antibiotics, one with glucocorticoid atomization (12.5%), one with interferon atomization (12.5%), four patients (50%) with traditional Chinese medicine. All patients discharged within three weeks, without poor prognosis or recurrence after 14 days follow-up.
   Conclusions: Pediatric patients with COVID-19 were mainly transfected through family cluster outbreaks. The clinical manifestations were mild without a typical pattern. High-resolution CT and nCoV-RNA tests have great value for early-stage diagnosis. Antiviral therapy is effective in treating viral pneumonia.
C1 [Chen, Gaoyan; Li, Junhua; Jiang, Yongchao; Chen, Haihua; Pan, Rui] Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Pediat, Affiliated Hosp, 136 Jinzhou St, Xiangyang City 441021, Peoples R China.
RP Pan, R (corresponding author), Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Pediat, Affiliated Hosp, 136 Jinzhou St, Xiangyang City 441021, Peoples R China.
EM prdoctor1979@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81703910]
FX This work was supported by the National Natural Science Foundation of
   China [grant number 81703910].
CR [Anonymous], 2020, ZHONGGUO DANG DAI ER, V22, P96
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Hamilton KA, 2018, WATER RES, V134, P261, DOI 10.1016/j.watres.2017.12.022
   Li Zhong-zhi, 2003, Zhonghua Er Ke Za Zhi, V41, P574
   National Health Commission of People's Republique of China, 2020, DAIL BRIEF NOV COR
   Shen KL, 2020, WORLD J PEDIATR, V16, P219, DOI 10.1007/s12519-020-00344-6
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   Song FX, 2020, RADIOLOGY, V295, P210, DOI 10.1148/radiol.2020200274
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Swerdlow DL, 2020, JAMA-J AM MED ASSOC, V323, P1129, DOI 10.1001/jama.2020.1960
   Thabet F, 2015, SAUDI MED J, V36, P484, DOI 10.15537/smj.2015.4.10243
   Wang D, 2020, Zhonghua Er Ke Za Zhi, V58, P269, DOI 10.3760/cma.j.cn112140-20200225-00138
   Wang X F, 2020, Zhonghua Er Ke Za Zhi, V58, pE008, DOI 10.3760/cma.j.issn.0578-1310.2020.0008
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 17
TC 0
Z9 0
U1 5
U2 5
PU KOWSAR CORP
PI TEHRAN
PA PO BOX 14155-3651, TEHRAN, 14155, IRAN
SN 2008-2142
EI 2008-2150
J9 IRAN J PEDIATR
JI Iran. J. Pediatr.
PD OCT
PY 2020
VL 30
IS 5
AR e103337
DI 10.5812/ijp.103337
PG 5
WC Pediatrics
SC Pediatrics
GA OE5SO
UT WOS:000580590100005
OA Other Gold
DA 2021-01-01
ER

PT J
AU Mendelson, M
   Boloko, L
   Boutall, A
   Cairncross, L
   Calligaro, G
   Coccia, C
   Dave, JA
   de Villiers, M
   Dlamini, S
   Frankenfeld, P
   Gina, P
   Gule, MV
   Hoare, J
   Hofmeyr, R
   Hsiao, M
   Joubert, I
   Kahn, T
   Krause, R
   Kroopman, A
   Levin, D
   Maughan, D
   Mazondwa, S
   Meintjes, G
   Nordien, R
   Ntusi, N
   Papavarnavas, N
   Peter, J
   Pickard, H
   Raubenheimer, P
   Said-Hartley, Q
   Singh, P
   Wasserman, S
AF Mendelson, M.
   Boloko, L.
   Boutall, A.
   Cairncross, L.
   Calligaro, G.
   Coccia, C.
   Dave, J. A.
   de Villiers, M.
   Dlamini, S.
   Frankenfeld, P.
   Gina, P.
   Gule, M., V
   Hoare, J.
   Hofmeyr, R.
   Hsiao, M.
   Joubert, I
   Kahn, T.
   Krause, R.
   Kroopman, A.
   Levin, D.
   Maughan, D.
   Mazondwa, S.
   Meintjes, G.
   Nordien, R.
   Ntusi, N.
   Papavarnavas, N.
   Peter, J.
   Pickard, H.
   Raubenheimer, P.
   Said-Hartley, Q.
   Singh, P.
   Wasserman, S.
CA Groote Schuur Hosp COVID-19 Respon
TI Clinical management of COVID-19: Experiences of the COVID-19 epidemic
   from Groote Schuur Hospital, Cape Town, South Africa
SO SAMJ SOUTH AFRICAN MEDICAL JOURNAL
LA English
DT Article
ID FLOW NASAL CANNULA; VENOUS THROMBOEMBOLISM; OXYGEN-THERAPY
AB The SARS-CoV-2 pandemic has presented clinicians with an enormous challenge in managing a respiratory virus that is not only capable of causing severe pneumonia and acute respiratory distress syndrome, but also multisystem disease. The extraordinary pace of clinical research, and particularly the surge in adaptive trials of new and repurposed treatments, have provided rapid answers to questions of whether such treatments work, and has resulted in corticosteroids taking centre stage in the management of hospitalised patients requiring oxygen support. Some treatment modalities, such as the role of anticoagulation to prevent and treat potential thromboembolic complications, remain controversial, as does the use of high-level oxygen support, outside of an intensive care unit setting. In this article, we describe the clinical management of COVID-19 patients admitted to Groote Schuur Hospital, a major tertiary level hospital at the epicentre of South Africa's SARS-CoV-2 epidemic during its first 4 months.
C1 [Mendelson, M.; Dlamini, S.; Meintjes, G.; Wasserman, S.] Univ Cape Town, Fac Hlth Sci, Div Infect Dis & HIV Med, Cape Town, South Africa.
   [Mendelson, M.; Boloko, L.; Calligaro, G.; Coccia, C.; Dave, J. A.; de Villiers, M.; Dlamini, S.; Frankenfeld, P.; Gina, P.; Gule, M., V; Kahn, T.; Levin, D.; Maughan, D.; Mazondwa, S.; Meintjes, G.; Nordien, R.; Ntusi, N.; Papavarnavas, N.; Peter, J.; Raubenheimer, P.; Singh, P.; Wasserman, S.] Univ Cape Town, Fac Hlth Sci, Dept Med, Cape Town, South Africa.
   [Boutall, A.; Cairncross, L.; Pickard, H.] Univ Cape Town, Fac Hlth Sci, Div Gen Surg, Cape Town, South Africa.
   [Calligaro, G.] Univ Cape Town, Fac Hlth Sci, Div Pulmonol, Cape Town, South Africa.
   [Dave, J. A.] Univ Cape Town, Fac Hlth Sci, Div Endocrinol, Cape Town, South Africa.
   [Hoare, J.] Univ Cape Town, Fac Hlth Sci, Dept Psychiat, Cape Town, South Africa.
   [Hofmeyr, R.] Univ Cape Town, Fac Hlth Sci, Dept Anaesthesia & Perioperat Med, Cape Town, South Africa.
   [Hsiao, M.] Univ Cape Town, Dept Pathol, Div Med Virol, Cape Town, South Africa.
   [Hsiao, M.] Natl Hlth Lab Serv, Groote Schuur Hosp Complex, Cape Town, South Africa.
   [Joubert, I] Univ Cape Town, Fac Hlth Sci, Div Crit Care Med, Cape Town, South Africa.
   [Krause, R.] Univ Cape Town, Fac Hlth Sci, Sch Publ Hlth & Family Med, Cape Town, South Africa.
   [Kroopman, A.] Univ Cape Town, Fac Hlth Sci, Div Emergency Med, Cape Town, South Africa.
   [Levin, D.] Univ Cape Town, Fac Hlth Sci, Div Gastroenterol, Cape Town, South Africa.
   [Peter, J.] Univ Cape Town, Fac Hlth Sci, Div Allergy & Clin Immunol, Cape Town, South Africa.
   [Said-Hartley, Q.] Univ Cape Town, Fac Hlth Sci, Dept Radiol, Cape Town, South Africa.
RP Mendelson, M (corresponding author), Univ Cape Town, Fac Hlth Sci, Div Infect Dis & HIV Med, Cape Town, South Africa.; Mendelson, M (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Med, Cape Town, South Africa.
EM marc.mendelson@uct.ac.za
OI Hoare, Jacqueline/0000-0002-6963-3557
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   [Anonymous], 2020, STATEMENT CHIEF INVE
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arendse J., 2020, OPERATIONAL GUIDE IM
   Artifoni M, 2020, J THROMB THROMBOLYS, V50, P211, DOI 10.1007/s11239-020-02146-z
   Barnes GD, 2020, J THROMB THROMBOLYS, V50, P72, DOI 10.1007/s11239-020-02138-z
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Beun R, 2020, INT J LAB HEMATOL, V42, P19, DOI 10.1111/ijlh.13230
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Cantador E, 2020, J THROMB THROMBOLYS, V50, P543, DOI 10.1007/s11239-020-02176-7
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Geng SK, 2020, HEART LUNG, V49, P444, DOI 10.1016/j.hrtlng.2020.03.018
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Kingma K, 2017, EMERG MED AUSTRALAS, V29, P650, DOI 10.1111/1742-6723.12874
   Lalla U, 2020, SAMJ S AFR MED J, V110, P432, DOI 10.7196/SAMJ.2020.v110i6.14882
   Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046
   Li J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00892-2020
   Li J, 2020, RESP CARE, V65, P545, DOI 10.4187/respcare.07663
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Lippi G, 2020, CLIN CHIM ACTA, V505, P190, DOI 10.1016/j.cca.2020.03.004
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Malato A, 2015, BLOOD TRANSFUS-ITALY, V13, P559, DOI 10.2450/2015.0277-14
   Mauri T, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2039-4
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Pesavento R, 2020, J THROMB HAEMOST, V18, P2629, DOI 10.1111/jth.15022
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rocha AT, 2006, OBES SURG, V16, P1645, DOI 10.1381/096089206779319383
   Rochwerg B, 2019, INTENS CARE MED, V45, P1171, DOI 10.1007/s00134-019-05658-2
   Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103
   The Association of Palliative Care Practitioners of SA, 2020, PROV PALL CAR S AFR
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   White D, 2020, J THROMB THROMBOLYS, V50, P287, DOI 10.1007/s11239-020-02145-0
   WHO, 2020, WHO2019NCOVCLINICAL2
   Williamson E., 2020, OPENSAFELY FACTORS A, DOI [10.1101/2020.05.06.20092999, DOI 10.1101/2020.05.06.20092999]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 44
TC 0
Z9 0
U1 2
U2 2
PU SA MEDICAL ASSOC
PI PRETORIA
PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA
SN 0256-9574
EI 2078-5135
J9 SAMJ S AFR MED J
JI SAMJ S. Afr. Med. J.
PD OCT
PY 2020
VL 110
IS 10
BP 973
EP 981
DI 10.7196/SAMJ.2020.v110i10.15157
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA OE5ZB
UT WOS:000580607300009
PM 33205723
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Wollenstein-Betech, S
   Cassandras, CG
   Paschalidis, IC
AF Wollenstein-Betech, Salomon
   Cassandras, Christos G.
   Paschalidis, Ioannis Ch
TI Personalized predictive models for symptomatic COVID-19 patients using
   basic preconditions: Hospitalizations, mortality, and the need for an
   ICU or ventilator
SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS
LA English
DT Article
DE Predictive models; COVID-19; Coronavirus; SARS-CoV-2; Hospitalization;
   Mortality; ICU; Ventilator; Electronic health records (EHRs)
ID CHEST CT; SELECTION
AB Background: The rapid global spread of the SARS-CoV-2 virus has provoked a spike in demand for hospital care. Hospital systems across the world have been over-extended, including in Northern Italy, Ecuador, and New York City, and many other systems face similar challenges. As a result, decisions on how to best allocate very limited medical resources and design targeted policies for vulnerable subgroups have come to the forefront. Specifically, under consideration are decisions on who to test, who to admit into hospitals, who to treat in an Intensive Care Unit (ICU), and who to support with a ventilator. Given today's ability to gather, share, analyze and process data, personalized predictive models based on demographics and information regarding prior conditions can be used to (1) help decision-makers allocate limited resources, when needed, (2) advise individuals how to better protect themselves given their risk profile, (3) differentiate social distancing guidelines based on risk, and (4) prioritize vaccinations once a vaccine becomes available.
   Objective: To develop personalized models that predict the following events: (1) hospitalization, (2) mortality, (3) need for ICU, and (4) need for a ventilator. To predict hospitalization, it is assumed that one has access to a patient's basic preconditions, which can be easily gathered without the need to be at a hospital and hence serve citizens and policy makers to assess individual risk during a pandemic. For the remaining models, different versions developed include different sets of a patient's features, with some including information on how the disease is progressing (e.g., diagnosis of pneumonia).
   Materials and Methods: National data from a publicly available repository, updated daily, containing information from approximately 91,000 patients in Mexico were used. The data for each patient include demographics, prior medical conditions, SARS-CoV-2 test results, hospitalization, mortality and whether a patient has developed pneumonia or not. Several classification methods were applied and compared, including robust versions of logistic regression, and support vector machines, as well as random forests and gradient boosted decision trees.
   Results: Interpretable methods (logistic regression and support vector machines) perform just as well as more complex models in terms of accuracy and detection rates, with the additional benefit of elucidating variables on which the predictions are based. Classification accuracies reached 72 %, 79 %, 89 %, and 90 % for predicting hospitalization, mortality, need for ICU and need for a ventilator, respectively. The analysis reveals the most important preconditions for making the predictions. For the four models derived, these are: (1) for hospitalization:age, pregnancy, diabetes, gender, chronic renal insufficiency, and immunosuppression; (2) for mortality: age, immunosuppression, chronic renal insufficiency, obesity and diabetes; (3) for ICU need: development of pneumonia (if available), age, obesity, diabetes and hypertension; and (4) for ventilator need: ICU and pneumonia (if available), age, obesity, and hypertension.
C1 [Wollenstein-Betech, Salomon; Cassandras, Christos G.; Paschalidis, Ioannis Ch] Boston Univ, Dept Elect & Comp Engn, Div Syst Engn, 8 St Marys St, Boston, MA 02215 USA.
   [Paschalidis, Ioannis Ch] Boston Univ, Dept Biomed Engn, 44 Cummington Mall, Boston, MA 02215 USA.
RP Paschalidis, IC (corresponding author), Boston Univ, Dept Elect & Comp Engn, 8 St Marys St, Boston, MA 02215 USA.
EM yannisp@bu.edu
FU NSFNational Science Foundation (NSF) [IIS-1914792, DMS-1664644,
   CNS-1645681]; ONR under MURI [N00014-19-1-2571]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R01-GM135930]
FX Research partially supported by the NSF under grants IIS-1914792,
   DMS-1664644, and CNS-1645681, by the ONR under MURI grant
   N00014-19-1-2571, and by the NIH under grant R01-GM135930.
CR [Anonymous], 2020, LINEAMIENTO ESTANDAR
   [Anonymous], SAL COV PRED MEX
   [Anonymous], DAT AB DIR GEN EP
   [Anonymous], 2020, ANN COVID 19 OUTBR P
   [Anonymous], CLIN PROGRESSION PAT
   [Anonymous], 2020, COVID 19 GLOBAL CASE
   Bernheim A, 2020, RADIOLOGY, V295, P685, DOI 10.1148/radiol.2020200463
   Brisimi TS, 2019, STAT METHODS MED RES, V28, P3667, DOI 10.1177/0962280218810911
   Brisimi TS, 2018, P IEEE, V106, P690, DOI 10.1109/JPROC.2017.2789319
   Brisimi TS, 2018, INT J MED INFORM, V112, P59, DOI 10.1016/j.ijmedinf.2018.01.007
   Chen RD, 2018, J MACH LEARN RES, V19
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Du XS, 2020, INT J MED INFORM, V139, DOI 10.1016/j.ijmedinf.2020.104140
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guyon I, 2002, MACH LEARN, V46, P389, DOI 10.1023/A:1012487302797
   Huang ZY, 2020, INT J MED INFORM, V139, DOI 10.1016/j.ijmedinf.2020.104141
   Morel D, 2020, INT J MED INFORM, V139, DOI 10.1016/j.ijmedinf.2020.104136
   Ng AY, 2004, P 21 INT C MACH LEAR, P78, DOI [10.1145/1015330.1015435, DOI 10.1145/1015330.1015435]
   Sanchez-Pinto LN, 2018, INT J MED INFORM, V116, P10, DOI 10.1016/j.ijmedinf.2018.05.006
   Steyerberg EW, 2009, CLIN PREDICTION MODE, DOI [10. 1007/978-0-387-77244-8., DOI 10.1007/978-0-387-77244-8, 10.1007/978-0-387-77244-8]
   Tartaglione E., 2020, UNVEILING COVID 19 C
   The New York Times Coronavirus Map, NY TIMES
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
NR 26
TC 1
Z9 1
U1 6
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1386-5056
EI 1872-8243
J9 INT J MED INFORM
JI Int. J. Med. Inform.
PD OCT
PY 2020
VL 142
AR 104258
DI 10.1016/j.ijmedinf.2020.104258
PG 8
WC Computer Science, Information Systems; Health Care Sciences & Services;
   Medical Informatics
SC Computer Science; Health Care Sciences & Services; Medical Informatics
GA OD4BC
UT WOS:000579796800010
PM 32927229
OA Green Published
DA 2021-01-01
ER

PT J
AU Chang, JPC
   Pariante, CM
   Su, KP
AF Chang, Jane Pei-Chen
   Pariante, Carmine M.
   Su, Kuan-Pin
TI Omega-3 fatty acids in the psychological and physiological resilience
   against COVID-19
SO PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS
LA English
DT Article
DE Omega-3; Covid-19; Immunomodulation
ID FATTY-ACID COMPOSITIONS; DOUBLE-BLIND; DISORDER
AB As the infected cases of COVID-19 reach more than 20 million with more than 778,000 deaths globally, an increase in psychiatric disorders including anxiety and depression has been reported. Scientists globally have been searching for novel therapies and vaccines to fight against COVID-19. Improving innate immunity has been suggested to block progression of COVID-19 at early stages, while omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been shown to have immunomodulation effects. Moreover, n-3 PUFAs have also been shown to improve mood disorders, thus, future research is warranted to test if n-3 PUFAs may have the potential to improve our immunity to counteract both physical and mental impact of COVID-19.
C1 [Chang, Jane Pei-Chen; Su, Kuan-Pin] China Med Univ Hosp, Mind Body Interface Lab MBI Lab, Taichung, Taiwan.
   [Chang, Jane Pei-Chen; Su, Kuan-Pin] China Med Univ Hosp, Dept Psychiat, 2 Yuh Der Rd, Taichung 404, Taiwan.
   [Chang, Jane Pei-Chen; Su, Kuan-Pin] China Med Univ, Coll Med, Taichung, Taiwan.
   [Chang, Jane Pei-Chen; Pariante, Carmine M.; Su, Kuan-Pin] Kings Coll London, Inst Psychiat Psychol & Neurosci, London, England.
   [Su, Kuan-Pin] China Med Univ, An Nan Hosp, Tainan, Taiwan.
RP Su, KP (corresponding author), China Med Univ Hosp, Dept Psychiat, 2 Yuh Der Rd, Taichung 404, Taiwan.
EM cobolsu@gmail.com
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [MOST 106-2314-B-039-027-MY3, 108-2320-B-039-048,
   108-2813-C039-133-B, 108-2314-B-039-016]; National Health Research
   Institutes, TaiwanNational Health Research Institutes - Taiwan
   [NHRI-EX108-10528NI]; University of Macau, China [MYRG2018-00242-ICMS];
   Higher Education Sprout Project by the Ministry of Education (MOE),
   Taiwan [CMRCeCMA-3]; China Medical University, Taichung, TaiwanChina
   Medical University [CMU108-SR-106]; China Medical University Hospital,
   Taichung, Taiwan [CMU104-S16-01, CMU103-BC-4-1, CRS-108-048,
   DMR-108-216, DMR-109-102, DMR-HHC-109-11, DMR-HHC-109-12]; Medical
   Research Council (UK)Medical Research Council UK (MRC) [MR/L014815/1,
   MR/J002739/1]; National Institute for Health Research (NIHR) Mental
   Health Biomedical Research Centre at South London and Maudsley NHS
   Foundation Trust and King's College London
FX Drs Chang and Su are supported by the following grants: MOST
   106-2314-B-039-027-MY3, 108-2320-B-039-048, 108-2813-C039-133-B and
   108-2314-B-039-016 from the Ministry of Science and Technology, Taiwan;
   NHRI-EX108-10528NI from the National Health Research Institutes, Taiwan;
   MYRG2018-00242-ICMS from University of Macau, China; CMRCeCMA-3 from
   Higher Education Sprout Project by the Ministry of Education (MOE),
   Taiwan; CMU108-SR-106 from the China Medical University, Taichung,
   Taiwan; and CMU104-S16-01, CMU103-BC-4-1, CRS-108-048, DMR-108-216,
   DMR-109-102, DMR-HHC-109-11, DMR-HHC-109-12 from the China Medical
   University Hospital, Taichung, Taiwan. Dr. Pariante is supported by the
   grants "Immunopsychiatry: a consortium to test the opportunity for
   immunotherapeutics in psychiatry' (MR/L014815/1) and 'Persistent Fatigue
   Induced by Interferon-alpha: A New Immunological Model for Chronic
   Fatigue Syndrome' (MR/J002739/1), from the Medical Research Council
   (UK), and by the National Institute for Health Research (NIHR) Mental
   Health Biomedical Research Centre at South London and Maudsley NHS
   Foundation Trust and King's College London.
CR Chang J., 2010, J PSYCHIAT, V24, P168
   Chang JPC, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0633-0
   Chang JPC, 2018, NEUROPSYCHOPHARMACOL, V43, P534, DOI 10.1038/npp.2017.160
   Chiu CC, 2008, PROG NEURO-PSYCHOPH, V32, P1538, DOI 10.1016/j.pnpbp.2008.05.015
   Freeman MP, 2006, PROSTAG LEUKOTR ESS, V75, P291, DOI 10.1016/j.plefa.2006.07.007
   Gutierrez S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205028
   Guu TW, 2020, PSYCHOTHER PSYCHOSOM, V89, P49, DOI [10.1159/000504232, 10.1159/000502652]
   Hodes GE, 2016, NEUROBIOL STRESS, V4, P15, DOI 10.1016/j.ynstr.2016.03.003
   Kim SW, 2020, BRAIN BEHAV IMMUN, V87, P4, DOI 10.1016/j.bbi.2020.03.025
   Lin PY, 2012, MOL PSYCHIATR, V17, P1161, DOI 10.1038/mp.2012.111
   Lin PY, 2012, J CLIN PSYCHIAT, V73, P1245, DOI 10.4088/JCP.11r07546
   Lin PY, 2010, BIOL PSYCHIAT, V68, P140, DOI 10.1016/j.biopsych.2010.03.018
   Lippi G., 2020, J MED VIROL
   Matricardi PM, 2020, PEDIAT ALLERG IMM-UK, V31, P454, DOI 10.1111/pai.13271
   Miller AH, 2010, BRAIN BEHAV IMMUN, V24, P1, DOI 10.1016/j.bbi.2009.09.009
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Rokni M, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2107
   Su KP, 2008, J CLIN PSYCHIAT, V69, P644, DOI 10.4088/JCP.v69n0418
   Su KP, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.2327
   Su KP, 2014, BIOL PSYCHIAT, V76, P559, DOI 10.1016/j.biopsych.2014.01.008
   Su KP, 2009, NEUROSIGNALS, V17, P144, DOI 10.1159/000198167
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0952-3278
EI 1532-2823
J9 PROSTAG LEUKOTR ESS
JI Prostaglandins Leukot. Essent. Fatty Acids
PD OCT
PY 2020
VL 161
AR 102177
DI 10.1016/j.plefa.2020.102177
PG 3
WC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
SC Biochemistry & Molecular Biology; Cell Biology; Endocrinology &
   Metabolism
GA OD6AG
UT WOS:000579933800003
PM 33031994
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ramirez, GA
   Gerosa, M
   Beretta, L
   Bellocchi, C
   Argolini, LM
   Moroni, L
   Della Torre, E
   Artusi, C
   Nicolosi, S
   Caporali, R
   Bozzolo, EP
   Dagna, L
AF Ramirez, Giuseppe A.
   Gerosa, Maria
   Beretta, Lorenzo
   Bellocchi, Chiara
   Argolini, Lorenza M.
   Moroni, Luca
   Della Torre, Emanuel
   Artusi, Carolina
   Nicolosi, Selene
   Caporali, Roberto
   Bozzolo, Enrica P.
   Dagna, Lorenzo
CA SMILE Milan Lupus Consortium
TI COVID-19 in systemic lupus erythematosus: Data from a survey on 417
   patients
SO SEMINARS IN ARTHRITIS AND RHEUMATISM
LA English
DT Article
DE COVID-19; Coronavirus; Systemic lupus erythematosus; Epidemiology;
   Hydroxychloroquine; Web
ID THERAPY; HYDROXYCHLOROQUINE; HOSPITALIZATIONS; RISK
AB Background: Systemic lupus erythematosus (SLE) is a chronic disease characterised by autoimmunity and increased susceptibility to infections. COVID-19 is a systemic viral disease currently spreading as a pandemic. Little is known about the impact of COVID-19 in patients with SLE.
   Objective: to acquire information on the impact of COVID-19 in SLE.
   Methods: A 26-item anonymous questionnaire investigating demographics, SLE clinical features, COVID-19 diagnoses and changes in treatments and daily habits was administered to patients with SLE from three referral centres through www.surveymonkey.com over 10 days. Data from the survey were compared to those from published estimates about the general population.
   Results: Four-hundred-seventeen patients responded to the survey. More than 60% of subjects complained of symptoms that are also associated to COVID-19. Fourteen COVID-19 diagnoses (five confirmed by polymerase chain reaction) were reported, in contrast to a 0.73% prevalence of confirmed cases in Lombardy. One hospitalisation was reported. Fever, anosmia, dry cough, a self-reported history of neuropsychiatric SLE and a recent contact with confirmed COVID-19 cases were more strongly associated with COVID-19, as were symptoms and lower compliance to behavioural preventive measures in patients' contacts. No protective effect was seen in subjects on hydroxychloroquine.
   Conclusion: COVID-19 morbidity might only moderately be increased in most patients with SLE, although limited information can be inferred on more severe cases. Hydroxychloroquine apparently seems not to confer protection to infection per se, although other beneficial roles cannot be excluded. Containment policies and behavioural preventive measures could have a major role in limiting the impact of COVID-19 in patients with SLE. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Ramirez, Giuseppe A.; Moroni, Luca; Della Torre, Emanuel; Dagna, Lorenzo] Univ Vita Salute San Raffaele, Via Olgettina 60, I-20134 Milan, Italy.
   [Ramirez, Giuseppe A.; Moroni, Luca; Della Torre, Emanuel; Bozzolo, Enrica P.; Dagna, Lorenzo] IRCCS Osped San Raffaele, Unit Immunol Rheumatol Allergy & Rare Dis, Via Olgettina 60, I-20134 Milan, Italy.
   [Gerosa, Maria; Argolini, Lorenza M.; Artusi, Carolina; Caporali, Roberto] Univ Milan, Dept Clin Sci Community Hlth, Milan, Italy.
   [Gerosa, Maria; Argolini, Lorenza M.; Artusi, Carolina; Caporali, Roberto] Univ Milan, Res Ctr Adult & Pediat Rheumat Dis, Milan, Italy.
   [Gerosa, Maria; Argolini, Lorenza M.; Artusi, Carolina; Caporali, Roberto] ASST Gaetano Pini CTO, Unit Clin Rheumatol, Milan, Italy.
   [Beretta, Lorenzo; Bellocchi, Chiara; Nicolosi, Selene] Fdn IRCCS Ca Granda Policlin, Referral Ctr Syst Autoimmune Dis, Milan, Italy.
   [Bellocchi, Chiara] Univ Milan, Milan, Italy.
RP Ramirez, GA (corresponding author), Univ Vita Salute San Raffaele, Via Olgettina 60, I-20134 Milan, Italy.; Ramirez, GA (corresponding author), IRCCS Osped San Raffaele, Unit Immunol Rheumatol Allergy & Rare Dis, Via Olgettina 60, I-20134 Milan, Italy.
EM ramirez.giuseppealvise@hsr.it
RI Ramirez, Giuseppe Alvise/K-4923-2018
OI Ramirez, Giuseppe Alvise/0000-0002-2889-366X; Moroni,
   Luca/0000-0001-8988-9106
FU B.I.R.D. Foundation Europe, Costozza di Longare (VI), Italy
FX We are indebted with the patients who kindly accepted to take this
   survey and spend part of their time in answering our questions even in
   this difficult time. We thank Dr. Andrea Lombardi (Fondazione IRCCS Ca'
   Granda Ospedale Maggiore Policlinico) for his advice about the content
   of the questionnaire employed in this study. We are also grateful to the
   B.I.R.D. Foundation Europe, Costozza di Longare (VI), Italy for its
   support to the School of Allergy and Immunology of the Universit~a
   Vita-Salute San Raffaele, Milan, Italy.
CR Campos LMA, 2013, ARTHRIT CARE RES, V65, P1121, DOI 10.1002/acr.21948
   Chang CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep37817
   Ciceri F., 2020, CRIT CARE RESUSC
   Costedoat-Chalumeau N, 2014, PRESSE MED, V43, pE167, DOI 10.1016/j.lpm.2014.03.007
   Danza A, 2013, LUPUS, V22, P1286, DOI 10.1177/0961203313493032
   DeNatale G, 2020, COVID 19 INFECT ITAL
   Dorner T, 2010, NAT REV RHEUMATOL, V6, P10, DOI 10.1038/nrrheum.2009.235
   Draborg A, 2016, CURR OPIN RHEUMATOL, V28, P398, DOI 10.1097/BOR.0000000000000289
   European-Commission, 2014, ART 29 DAT PROT WORK
   Fasano S, 2017, J RHEUMATOL, V44, P1032, DOI 10.3899/jrheum.161351
   Favalli EG, 2020, ANN RHEUM DIS
   Garcia-Romo GS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001201
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gianfrancesco M, 2020, LANCET RHEUMATOL
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Joob B, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis-2020-217506
   Katsuyama T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01088
   Kotliarov Y, 2020, NAT MED, DOI 10.1038/s41591-020-0769-8
   Kubo S, 2017, ARTHRITIS RHEUMATOL, V69, P2029, DOI 10.1002/art.40180
   Lee J, 2013, RHEUMATOLOGY, V52, P905, DOI 10.1093/rheumatology/kes391
   Lood C, 2016, NAT MED, V22, P146, DOI 10.1038/nm.4027
   Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-6
   Mathian A, 2020, ANN RHEUM DIS
   McDonnell TCR, 2018, RHEUMATOL ADV PRACT, V2, DOI 10.1093/rap/rky003
   Mehta B, 2020, JAMA HLTH FORUM
   Molina JM, 2020, MED MAL INFECT
   Morawski PA, 2017, TRENDS IMMUNOL, V38, P373, DOI 10.1016/j.it.2017.02.001
   Naing L, 2006, ARCH OROFAC SCI, V1, P9
   PERL A, 1995, ARTHRITIS RHEUM, V38, P1660, DOI 10.1002/art.1780381119
   PETRI M, 1992, J RHEUMATOL, V19, P1559
   Riccardo F, TASK FORCE COVID 19
   Rosenbaum L, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2015556
   Ruiz-Irastorza G, 2008, RHEUMATOLOGY, V47, P920, DOI 10.1093/rheumatology/ken121
   Ruiz-Irastorza G, 2006, LUPUS, V15, P577, DOI 10.1177/0961203306071872
   Sawalha AH, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108410
   Signorelli Carlo, 2020, Acta Biomed, V91, P175, DOI 10.23750/abm.v91i3-S.9511
   Siso A, 2008, LUPUS, V17, P281, DOI 10.1177/0961203307086503
   Societa, 2020, SOC ITALIANADI MALAT
   Tomelleri A, 2020, ANN RHEUM DIS
   Villanueva E, 2011, J IMMUNOL, V187, P538, DOI 10.4049/jimmunol.1100450
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, 2020, HOM CAR PAT COVID 19
NR 43
TC 0
Z9 0
U1 3
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0049-0172
EI 1532-866X
J9 SEMIN ARTHRITIS RHEU
JI Semin. Arthritis Rheum.
PD OCT
PY 2020
VL 50
IS 5
BP 1150
EP 1157
DI 10.1016/j.semarthrit.2020.06.012
PG 8
WC Rheumatology
SC Rheumatology
GA OE5XB
UT WOS:000580602000049
PM 32927376
OA Green Published
DA 2021-01-01
ER

PT J
AU Fox, TA
   Troy-Barnes, E
   Kirkwood, AA
   Chan, WY
   Day, JW
   Chavda, SJ
   Kumar, EA
   David, K
   Tomkins, O
   Sanchez, E
   Scully, M
   Khwaja, A
   Lambert, J
   Singer, M
   Roddie, C
   Morris, EC
   Yong, KL
   Thomson, KJ
   Ardeshna, KM
AF Fox, Thomas A.
   Troy-Barnes, Ethan
   Kirkwood, Amy A.
   Chan, Wei Yee
   Day, James W.
   Chavda, Selina J.
   Kumar, Emil A.
   David, Kate
   Tomkins, Oliver
   Sanchez, Emilie
   Scully, Marie
   Khwaja, Asim
   Lambert, Jonathan
   Singer, Mervyn
   Roddie, Claire
   Morris, Emma C.
   Yong, Kwee L.
   Thomson, Kirsty J.
   Ardeshna, Kirit M.
TI Clinical outcomes and risk factors for severe COVID-19 in patients with
   haematological disorders receiving chemo- or immunotherapy
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE Covid-19; chemotherapy; risk factors
ID CHEMOTHERAPY; CANCER
AB Haematology patients receiving chemo- or immunotherapy are considered to be at greater risk of COVID-19-related morbidity and mortality. We aimed to identify risk factors for COVID-19 severity and assess outcomes in patients where COVID-19 complicated the treatment of their haematological disorder. A retrospective cohort study was conducted in 55 patients with haematological disorders and COVID-19, including 52 with malignancy, two with bone marrow failure and one immune-mediated thrombotic thrombocytopenic purpura (TTP). COVID-19 diagnosis coincided with a new diagnosis of a haematological malignancy in four patients. Among patients, 82% were on systemic anti-cancer therapy (SACT) at the time of COVID-19 diagnosis. Of hospitalised patients, 37% (19/51) died while all four outpatients recovered. Risk factors for severe disease or mortality were similar to those in other published cohorts. Raised C-reactive protein at diagnosis predicted an aggressive clinical course. The majority of patients recovered from COVID-19, despite receiving recent SACT. This suggests that SACT, where urgent, should be administered despite intercurrent COVID-19 infection, which should be managed according to standard pathways. Delay or modification of therapy should be considered on an individual basis. Long-term follow-up studies in larger patient cohorts are required to assess the efficacy of treatment strategies employed during the pandemic.
C1 [Fox, Thomas A.; Troy-Barnes, Ethan; Chan, Wei Yee; Day, James W.; Chavda, Selina J.; Kumar, Emil A.; Tomkins, Oliver; Scully, Marie; Khwaja, Asim; Lambert, Jonathan; Roddie, Claire; Morris, Emma C.; Yong, Kwee L.; Thomson, Kirsty J.; Ardeshna, Kirit M.] Univ Coll London NHS Fdn Trust, Dept Haematol, London, England.
   [Fox, Thomas A.; Day, James W.; Morris, Emma C.] UCL, UCL Inst Immun & Transplantat, London, England.
   [Kirkwood, Amy A.] UCL, UCL Canc Inst, CR UK & UCL Canc Trials Ctr, London, England.
   [Chan, Wei Yee; Chavda, Selina J.; Khwaja, Asim; Roddie, Claire; Yong, Kwee L.] UCL Canc Inst, Dept Haematol, London, England.
   [Kumar, Emil A.] Queen Mary Univ London, Ctr Canc Genom & Computat Biol, Barts Canc Inst, London, England.
   [David, Kate; Sanchez, Emilie] Univ Coll London NHS Fdn Trust, Dept Clin Virol, London, England.
   [Scully, Marie; Lambert, Jonathan; Singer, Mervyn; Roddie, Claire; Morris, Emma C.; Yong, Kwee L.; Thomson, Kirsty J.; Ardeshna, Kirit M.] UCL, UCLH NIHR Biomed Res Ctr, London, England.
   [Singer, Mervyn] UCL, Bloomsbury Inst Intens Care Med, London, England.
   [Morris, Emma C.] Royal Free London Hosp NHS Fdn Trust, Dept Immunol, London, England.
RP Fox, TA (corresponding author), Univ Coll London NHS Fdn Trust, Dept Haematol, London, England.
EM t.fox@ucl.ac.uk
OI Tomkins, Oliver/0000-0002-1059-2906
CR Andrew JW, 2020, BRIT J HAEMATOL, DOI [10.1111/bjh.16962, DOI 10.1111/BJH.16962]
   Aries JA, 2020, BRIT J HAEMATOL, V190, pE64, DOI 10.1111/bjh.16852
   Booth S, EUR J HAEMATOL
   Brissot E, 2020, BONE MARROW TRANSPL, DOI 10.1038/s41409-020-0970-x
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Dai M, 2020, CANCER DISCOV
   DiNardo CD, 2019, BLOOD, V133, P7, DOI 10.1182/blood-2018-08-868752
   Docherty A.B., 2020, FEATURES 16749 HOSP, DOI [10.1101/2020.04.23.20076042thisversion, DOI 10.1101/2020.04.23.20076042]
   El-Sharkawi D, 2020, BRIT J HAEMATOL, V190, P336, DOI 10.1111/bjh.16956
   Fielding A., STUDY OLDER ADULTS A
   Gosain R, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00934-7
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Intensive Care National Audit & Research Centre, 2020, ICNARC REP COVID 19
   Kanellopoulos A, 2020, BRIT J HAEMATOL, V190, pE67, DOI 10.1111/bjh.16856
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Martin-Moro F, 2020, BRIT J HAEMATOL, V190, pE16, DOI 10.1111/bjh.16801
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   National Institute for Health and Care Excellence, COVID 19 RAP GUID DE
   Perl AE, 2019, NEW ENGL J MED, V381, P1728, DOI 10.1056/NEJMoa1902688
   Shah V, 2020, BRIT J HAEMATOL, V190, pE279, DOI 10.1111/bjh.16935
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 30
TC 7
Z9 7
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD OCT
PY 2020
VL 191
IS 2
BP 194
EP 206
DI 10.1111/bjh.17027
PG 13
WC Hematology
SC Hematology
GA OC4IZ
UT WOS:000579122700020
PM 32678948
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Jehi, L
   Ji, XG
   Milinovich, A
   Erzurum, S
   Rubin, BP
   Gordon, S
   Young, JB
   Kattan, MW
AF Jehi, Lara
   Ji, Xinge
   Milinovich, Alex
   Erzurum, Serpil
   Rubin, Brian P.
   Gordon, Steve
   Young, James B.
   Kattan, Michael W.
TI Individualizing Risk Prediction for Positive Coronavirus Disease 2019
   Testing Results From 11,672 Patients
SO CHEST
LA English
DT Article
DE COVID-19; infectious disease; predictive modeling; testing
AB BACKGROUND: Coronavirus disease 2019 (COVID-19) is sweeping the globe. Despite multiple case-series, actionable knowledge to tailor decision-making proactively is missing.
   RESEARCH QUESTION: Can a statistical model accurately predict infection with COVID-19?
   STUDY DESIGN AND METHODS: We developed a prospective registry of all patients tested for COVID-19 in Cleveland Clinic to create individualized risk prediction models. We focus here on the likelihood of a positive nasal or oropharyngeal COVID-19 test. A least absolute shrinkage and selection operator logistic regression algorithm was constructed that removed variables that were not contributing to the model's cross-validated concordance index. After external validation in a temporally and geographically distinct cohort, the statistical prediction model was illustrated as a nomogram and deployed in an online risk calculator.
   RESULT In the development cohort, 11,672 patients fulfilled study criteria, including 818 patients (7.0%) who tested positive for COVID-19; in the validation cohort, 2295 patients fulfilled criteria, including 290 patients who tested positive for COVID-19. Male, African American, older patients, and those with known COVID-19 exposure were at higher risk of being positive for COVID-19. Risk was reduced in those who had pneumococcal polysaccharide or influenza vaccine or who were on melatonin, paroxetine, or carvedilol. Our model had favorable discrimination (c-statistic = 0.863 in the development cohort and 0.840 in the validation cohort) and calibration. We present sensitivity, specificity, negative predictive value, and positive predictive value at different prediction cutoff points. The calculator is freely available at ftps://riskcalc.org/COVID-19.
   INTERPRETATION: Prediction of a COVID-19 positive test is possible and could help direct health-care resources. We demonstrate relevance of age, race, sex, and socioeconomic characteristics in COVID-19 susceptibility and suggest a potential modifying role of certain common vaccinations and drugs that have been identified in drug-repurposing studies.
C1 [Jehi, Lara] Cleveland Clin, Neurol Inst, Cleveland, OH 44106 USA.
   [Ji, Xinge; Milinovich, Alex; Kattan, Michael W.] Cleveland Clin, Quantitat Hlth Sci Dept, Lerner Res Inst, Cleveland, OH 44106 USA.
   [Erzurum, Serpil] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA.
   [Rubin, Brian P.] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44106 USA.
   [Gordon, Steve] Cleveland Clin, Infect Dis Dept, Cleveland, OH 44106 USA.
   [Young, James B.] Cleveland Clin, Cardiol, Cleveland, OH 44106 USA.
RP Jehi, L (corresponding author), 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM jehil@ccf.org
RI Milinovich, Alex/AAA-7353-2019
OI Milinovich, Alex/0000-0003-0585-1480
FU Cleveland Clinic; National Institutes of Health/National Center for
   Advancing Translational Sciences [UL1TR002548]
FX This study was funded by the Cleveland Clinic and National Institutes of
   Health/National Center for Advancing Translational Sciences [Grant
   UL1TR002548].
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Goff PH, 2015, J VIROL, V89, P3221, DOI 10.1128/JVI.03337-14
   HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Kattan Michael W, 2018, Diagn Progn Res, V2, P7, DOI 10.1186/s41512-018-0029-2
   Kattan Michael W, 2002, Semin Urol Oncol, V20, P79
   Li YL, 2020, INFECT DIS-NOR, DOI 10.1080/23744235.2020.1810308
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Milinovich A, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.13
   Ogbadu J, 2020, EXP GERONTOL, V135, DOI 10.1016/j.exger.2020.110892
   Sharfstein JM, 2020, JAMA-J AM MED ASSOC, V323, P1437, DOI 10.1001/jama.2020.3864
   Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7
   Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu Y, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7932046
   Yang CF, 2020, FRONT NEUROANAT, V14, DOI 10.3389/fnana.2020.00058
   Yang X, 2020, LANCET RESP MED, V8, pE26
   Yoon HE, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6731093
   Zhang J.J., 2020, ALLERGY
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 26
TC 10
Z9 10
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD OCT
PY 2020
VL 158
IS 4
BP 1364
EP 1375
DI 10.1016/j.chest.2020.05.580
PG 12
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA OC7JF
UT WOS:000579331500042
PM 32533957
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Madney, YM
   Esquinas, AM
   Saeed, H
   Harb, HS
   Abdelrahim, MEA
AF Madney, Yasmin M.
   Esquinas, Antonio M.
   Saeed, Haitham
   Harb, Hadeer S.
   Abdelrahim, Mohamed E. A.
TI Improving the Safety of High-Flow Therapies in the Management of
   Patients With COVID-19
SO CHEST
LA English
DT Letter
C1 [Madney, Yasmin M.; Saeed, Haitham; Harb, Hadeer S.; Abdelrahim, Mohamed E. A.] Beni Suef Univ, Fac Pharm, Dept Clin Pharm, Qism Bani Suef 62511, Bani Suef Gover, Egypt.
   [Esquinas, Antonio M.] Hosp M Meseguer, Intens Care Unit, Murcia, Spain.
RP Abdelrahim, MEA (corresponding author), Beni Suef Univ, Fac Pharm, Dept Clin Pharm, Qism Bani Suef 62511, Bani Suef Gover, Egypt.
EM mohamedemam9@yahoo.com
RI Harb, Hadeer S./ABG-2891-2020
OI Harb, Hadeer S./0000-0003-2259-9686; M.Madney, Y./0000-0003-4105-7874
CR Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Leonard S, 2020, CHEST, V158, P1046, DOI 10.1016/j.chest.2020.03.043
   Lucchini A, 2020, INTENS CRIT CARE NUR, V58, DOI 10.1016/j.iccn.2020.102859
   Oberkampf WL, 2002, PROG AEROSP SCI, V38, P209, DOI 10.1016/S0376-0421(02)00005-2
   World Health Organization, 2020, INF PREV CONTR HLTH
NR 6
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD OCT
PY 2020
VL 158
IS 4
BP 1788
EP 1789
DI 10.1016/j.chest.2020.06.040
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA OC7JF
UT WOS:000579331500094
PM 33036099
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Whittle, JS
   Dungan, GC
   DeBellis, RJ
AF Whittle, Jessica S.
   Dungan, George C., II
   DeBellis, Ronald J.
TI Improving the Safety of High-Flow Therapies in the Management of
   Patients With COVID-19 Response
SO CHEST
LA English
DT Letter
C1 [Whittle, Jessica S.] Univ Tennessee, Coll Med, Knoxville, TN 37996 USA.
   [Dungan, George C., II; DeBellis, Ronald J.] Vapotherm Inc, Dept Sci & Innovat, Exeter, NH USA.
   [Dungan, George C., II] Canisius Coll, Educ & Human Serv, Buffalo, NY 14208 USA.
   [Dungan, George C., II] CIRUS, Sydney, NSW, Australia.
RP DeBellis, RJ (corresponding author), 100 Domain Dr, Exeter, NH 03833 USA.
EM rjdebellis@gmail.com
CR Doshi P, 2018, ANN EMERG MED, V72, P73, DOI 10.1016/j.annemergmed.2017.12.006
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Leonard S, 2020, CHEST, V158, P1046, DOI 10.1016/j.chest.2020.03.043
   Miller TL, 2016, J PULMON RESPIR MED, V6, P376, DOI [10.4172/2161-105X.1000376, DOI 10.4172/2161-105X.1000376]
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD OCT
PY 2020
VL 158
IS 4
BP 1789
EP 1790
DI 10.1016/j.chest.2020.06.039
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA OC7JF
UT WOS:000579331500095
PM 33036100
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gomez, CC
   Rodriguez, OP
   Torne, ML
   Santaolalla, CE
   Jimenez, JFM
   Fernandez, JG
   Perales, JMC
   Heili-Frades, SB
   Monreal, MF
   Nilsson, JMD
   Arias, EL
   Rocamora, JLS
   Garrote, JI
   Serrano, MJZ
   Martinez, MG
   Munoz, EF
   San Andres, OM
   Cervera, GR
   Serra, AM
   Martinez, GH
   Lopez, CD
   Gas, OR
   Roca, RF
   Berrocal, AR
   Ortola, CF
AF Cinesi Gomez, Cesar
   Penuelas Rodriguez, Oscar
   Lujan Torne, Manel
   Egea Santaolalla, Carlos
   Masa Jimenez, Juan Fernando
   Garcia Fernandez, Javier
   Carratala Perales, Jose Manuel
   Beatrice Heili-Frades, Sarah
   Ferrer Monreal, Miquel
   de Andres Nilsson, Jose M.
   Lista Arias, Eva
   Sanchez Rocamora, Juan Luis
   Ignacio Garrote, Jose
   Zamorano Serrano, Miguel J.
   Gonzalez Martinez, Monica
   Farrero Munoz, Eva
   Mediano San Andres, Olga
   Rialp Cervera, Gemma
   Mas Serra, Arantxa
   Hernandez Martinez, Gonzalo
   de Haro Lopez, Candelaria
   Roca Gas, Oriol
   Ferrer Roca, Ricard
   Romero Berrocal, Antonio
   Ferrando Ortola, Carlos
TI Clinical consensus recommendations regarding non-invasive respiratory
   support in the adult patient with acute respiratory failure secondary to
   SARS-CoV-2 infection
SO MEDICINA INTENSIVA
LA Spanish
DT Article
DE Non-invasive mechanical ventilation; High-flow nasal therapy;
   Aerosol-generating procedures; Infection control
ID POSITIVE-PRESSURE VENTILATION; AIR
AB Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, that was first recognized in Wuhan, China, in December 2019. Currently, the World Health Organization (WHO) has defined the infection as a global pandemic and is a health and social emergency for the management of this new infection. While most people with COVID-19 develop only mild or uncomplicated illness, approximately 14% develop severe disease that requires hospitalization and oxygen support, and 5% require admission to an intensive care unit. In severe cases, COVID-19 can be complicated by the acute respiratory distress syndrome (ARDS), sepsis and septic shock, and multiorgan failure. This consensus document has been prepared on evidence-informed guidelines developed by a multidisciplinary panel of health care providers from four Spanish scientific societies (Spanish Society of Intensive Care Medicine [SEMI CYUC], Spanish Society of Pulmonologists [SEPAR], Spanish Society of Emergency [SEMES], Spanish Society of Anesthesiology, Reanimation, and Pain [SEDAR]) with experience in the clinical management of patients with COVID-19 and other viral infections, including SARS, as well as sepsis and ARDS. The document provides clinical recommendations for the noninvasive respiratory support (noninvasive ventilation, high flow oxygen therapy with nasal cannula) in any patient with suspected or confirmed presentation of COVID-19 with acute respiratory failure.
   This consensus guidance should serve as a foundation for optimized supportive care to ensure the best possible chance for survival and to allow for reliable comparison of investigational therapeutic interventions as part of randomized controlled trials. (C) 2020 Elsevier Espana, S.L.U. y SEMICYUC. All rights reserved.
C1 [Cinesi Gomez, Cesar] Serv Murciano Salud, Direcc Gen Asistencia Sanitaria, Med Urgencias & Emergencias, Murcia, Spain.
   [Penuelas Rodriguez, Oscar] Hosp Univ Getafe, Serv Med Intens & Grandes Quemados, CIBERES, CIBER Enfermedades Resp, Madrid, Spain.
   [Lujan Torne, Manel] Univ Autonoma Barcelona, Hosp Sabadell, Serv Neumol, Corp Parc Tauli,Ctr Invest Biomed Red,CIBERES, Barcelona, Spain.
   [Egea Santaolalla, Carlos] Hosp Univ Araba, OSI Araba, Unidad Func Sueno, Vitoria, Spain.
   [Masa Jimenez, Juan Fernando] Hosp San Pedro Alcantara, Serv Neumol, CIBER Enfermedades Resp CIBERES, Inst Univ Invest Biosanitaria Extremadura INUBE, Caceres, Spain.
   [Garcia Fernandez, Javier] Hosp Univ Puerta de Hierro, Serv Anestesia Cuidados Crit Quirurg & Dolor, Madrid, Spain.
   [Carratala Perales, Jose Manuel] Hosp Gen Alicante, Serv Urgencias, Unidad Corta Estancia & Hospitalizac Domicilio, Inst Invest Sanitaria & Biomed Alicante ISABIAL,F, Alicante, Spain.
   [Beatrice Heili-Frades, Sarah] Hosp Univ Fdn Jimenez Diaz, CIBERES, REVA, Unidad Neumol,Responsable UCIR,EMDOS, Madrid, Spain.
   [Ferrer Monreal, Miquel] Univ Barcelona, Hosp Clin Barcelona, Inst Clin Resp, IDIBAPS,CIBERES CB06 06 0028,Serv Pneumol, Barcelona, Spain.
   [de Andres Nilsson, Jose M.] Hosp Royo Villanova, Serv Urgencias, Zaragoza, Spain.
   [Lista Arias, Eva] Parc Tauli Hosp Univ, Serv Urgencias, Barcelona, Spain.
   [Sanchez Rocamora, Juan Luis] Hosp Gen Villarrobledo, Serv Urgencias, Albacete, Spain.
   [Ignacio Garrote, Jose] Eliance, Serv Emergencias GUETS, SESCAM, Madrid, Spain.
   [Zamorano Serrano, Miguel J.] Hosp Ramon & Cajal, Serv Urgencias, Madrid, Spain.
   [Gonzalez Martinez, Monica] Univ Cantabria, Hosp Univ Marques de Valdecilla, IDIVAL, Unidad Sueno & Ventilac,Neumol, Santander, Spain.
   [Farrero Munoz, Eva] Hosp Univ Bellvitge, Serv Pneumol, Barcelona, Spain.
   [Mediano San Andres, Olga] Hosp Univ Guadalajara, Neumol, Unidad Sueno, Guadalajara, Spain.
   [Rialp Cervera, Gemma] Hosp Univ Son Llatzer, Serv Med Intens, Palma De Mallorca, Spain.
   [Mas Serra, Arantxa] Hosp St Joan Despi Moises Broggi, Serv Med Intens, Barcelona, Spain.
   [Mas Serra, Arantxa] Hosp Gen Hospitalet, Barcelona, Spain.
   [Hernandez Martinez, Gonzalo] Hosp Univ Virgen de la Salud, Serv Med Intens, Toledo, Spain.
   [de Haro Lopez, Candelaria] Corp Sanitaria & Univ Parc Tauli, Area Crit, Inst Salud Carlos III, CIBER Enfermedades Resp CIBERES, Barcelona, Spain.
   [Roca Gas, Oriol] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Serv Med Intens, Inst Salud Carlos III,Inst Recerca Vall dHebron,C, Barcelona, Spain.
   [Ferrer Roca, Ricard] Hosp Univ Vall dHebron, Serv Med Intens, Shock Organ Dysfunct & Resuscitat Res Grp,CIBERES, Vall dHebron Inst Recerca,CIBER Enfermedades Resp, Barcelona, Spain.
   [Romero Berrocal, Antonio] Hosp Univ Puerta de Hierro, Serv Anestesia & Reanimac, Madrid, Spain.
   [Ferrando Ortola, Carlos] Hosp Clin Barcelona, Serv Anestesia & Cuidados Intens, Area Cuidados Intens Quirurg, Barcelona, Spain.
RP Rodriguez, OP (corresponding author), Hosp Univ Getafe, Serv Med Intens & Grandes Quemados, CIBERES, CIBER Enfermedades Resp, Madrid, Spain.
EM openuelas@gmail.com
OI HEILI-FRADES, SARAH/0000-0003-4901-6487; Gonzalez,
   Monica/0000-0003-1516-0181; Romero Berrocal,
   Antonio/0000-0003-4003-0709; Lujan, Manel/0000-0001-9033-7712
CR [Anonymous], 2019, RAT US PERS PROT EQ
   Belenguer-Muncharaz A, 2011, MED INTENSIVA, V35, P470, DOI 10.1016/j.medin.2011.04.001
   Bouadma L, 2020, INTENS CARE MED, V46, P579, DOI 10.1007/s00134-020-05967-x
   CDC, 2020, COR DIS 2019 COVID 1
   Cheung JC-H, 2020, LANCET RESP MED, DOI [10.1016/S2213-2600(20)30084-9, DOI 10.1016/52213-2600(20)30084-9]
   Cheung TMT, 2004, CHEST, V126, P845, DOI 10.1378/chest.126.3.845
   Cortegiani A, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3514-1
   Davidson C, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2016-000133
   Duan J, 2017, INTENS CARE MED, V43, P192, DOI 10.1007/s00134-016-4601-3
   Estenssoro E, 2010, AM J RESP CRIT CARE, V182, P41, DOI [10.1164/201001-0037OC, 10.1164/rccm.201001-0037OC]
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Guan WJ, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa7002032, DOI 10.1056/NEJM0A7002032]
   Hui DS, 2006, CHEST, V130, P730, DOI 10.1378/chest.130.3.730
   Hui DS, 2009, CHEST, V136, P998, DOI 10.1378/chest.09-0434
   Jefferson T, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006207.pub4
   Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1
   Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496
   Lellouche F, 2014, INTENS CARE MED, V40, P211
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Malave Adriel, 2010, Virtual Mentor, V12, P719, DOI 10.1001/virtualmentor.2010.12.9.cprl1-1009
   Masclans JR, 2013, CLIN MICROBIOL INFEC, V19, P249, DOI 10.1111/j.1469-0691.2012.03797.x
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   NAGASE FNI, 2019, INT J CHRONIC OBSTR, V14, DOI DOI 10.1186/S13023-019-1104-7
   Nin N, 2011, J CRIT CARE, V26, P186, DOI 10.1016/j.jcrc.2010.05.031
   Organization W.H., 2019, CLIN MAN SEV AC RESP
   Park JE, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5484-8
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Pisani L, 2014, SEMIN RESP CRIT CARE, V35, P501, DOI 10.1055/s-0034-1383864
   Respiratory care committee of Chinese Thoracic Society, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V17, pE020, DOI 10.3760/cma.j.issn.1001-0939.2020.0020
   Ricard JD, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022983
   Roca O, 2019, AM J RESP CRIT CARE, V199, P1368, DOI 10.1164/rccm.201803-0589OC
   Roca O, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1263-z
   Rochwerg B, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02426-2016
   Rodriguez A, 2017, RESP CARE, V62, P1307, DOI 10.4187/respcare.05481
   Scala R, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0008-2018
   Scala R, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0310-5
   Tonetti T, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.07.08
   Tramm R, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010381.pub2
   Tran K, 2011, AEROSOL GENERATING P
   Uyeki TM, 2019, CLIN INFECT DIS, V68, pE1, DOI 10.1093/cid/ciy866
   World Health Organization, COR DIS COVID 19 OUT
   Wright BJ, 2014, EMERG MED CLIN N AM, V32, P871, DOI 10.1016/j.emc.2014.07.012
   Yang X, 2020, LANCET RESP MED, DOI 10.1016/S2213-2600(20)30079-5
   Yuste Maria Eugenia, 2019, Rev. bras. ter. intensiva, V31, P156, DOI [10.5935/0103-507X.20190026, 10.5935/0103-507x.20190026]
   Zhao HY, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1760-8
NR 45
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0210-5691
EI 1578-6749
J9 MED INTENSIVA
JI Med. Intensiv.
PD OCT
PY 2020
VL 44
IS 7
BP 429
EP 438
DI 10.1016/j.medin.2020.03.005
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA OC7GJ
UT WOS:000579323400005
PM 32312600
OA Green Published
DA 2021-01-01
ER

PT J
AU Rut, W
   Lv, ZY
   Zmudzinski, M
   Patchett, S
   Nayak, D
   Snipas, SJ
   El Oualid, F
   Huang, TT
   Bekes, M
   Drag, M
   Olsen, SK
AF Rut, Wioletta
   Lv, Zongyang
   Zmudzinski, Mikolaj
   Patchett, Stephanie
   Nayak, Digant
   Snipas, Scott J.
   El Oualid, Farid
   Huang, Tony T.
   Bekes, Miklos
   Drag, Marcin
   Olsen, Shaun K.
TI Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2
   papain-like protease: A framework for anti-COVID-19 drug design
SO SCIENCE ADVANCES
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; UBIQUITIN-BASED PROBES; SARS-COV;
   MERS; SPECIFICITY; RECOGNITION; DIUBIQUITIN; DOMAIN
AB Viral papain-like cysteine protease (PLpro, NSP3) is essential for SARS-CoV-2 replication and represents a promising target for the development of antiviral drugs. Here, we used a combinatorial substrate library and performed comprehensive activity profiling of SARS-CoV-2 PLpro. On the scaffold of the best hits from positional scanning, we designed optimal fluorogenic substrates and irreversible inhibitors with a high degree of selectivity for SARS PLpro. We determined crystal structures of two of these inhibitors in complex with SARS-CoV-2 PLpro that reveals their inhibitory mechanisms and provides a molecular basis for the observed substrate specificity profiles. Last, we demonstrate that SARS-CoV-2 PLpro harbors deISGylating activity similar to SARSCoV-1 PLpro but its ability to hydrolyze K48-linked Ub chains is diminished, which our sequence and structure analysis provides a basis for. Together, this work has revealed the molecular rules governing PLpro substrate specificity and provides a framework for development of inhibitors with potential therapeutic value or drug repurposing.
C1 [Rut, Wioletta; Zmudzinski, Mikolaj; Drag, Marcin] Wroclaw Univ Sci & Technol, Dept Chem Biol & Bioimaging, Wyb Wyspianskiego 27, PL-50370 Wroclaw, Poland.
   [Lv, Zongyang; Nayak, Digant; Olsen, Shaun K.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
   [Lv, Zongyang; Nayak, Digant; Olsen, Shaun K.] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.
   [Lv, Zongyang; Nayak, Digant; Huang, Tony T.; Olsen, Shaun K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem & Struct Biol, San Antonio, TX 78229 USA.
   [Patchett, Stephanie] NYU, Dept Biochem & Mol Pharmacol, Sch Med, New York, NY 10016 USA.
   [Snipas, Scott J.; Drag, Marcin] Sanford Burnham Prebys Med Discovery Inst, 10901 North Torrey Pines Rd, La Jolla, CA 92037 USA.
   [El Oualid, Farid] UbiQ Bio BV, NL-1098 XH Amsterdam, Netherlands.
   [Bekes, Miklos] Arvinas Inc, 5 Sci Pk, New Haven, CT 06511 USA.
RP Rut, W; Drag, M (corresponding author), Wroclaw Univ Sci & Technol, Dept Chem Biol & Bioimaging, Wyb Wyspianskiego 27, PL-50370 Wroclaw, Poland.; Olsen, SK (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.; Olsen, SK (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.; Drag, M (corresponding author), Sanford Burnham Prebys Med Discovery Inst, 10901 North Torrey Pines Rd, La Jolla, CA 92037 USA.; Bekes, M (corresponding author), Arvinas Inc, 5 Sci Pk, New Haven, CT 06511 USA.
EM wioletta.rut@pwr.edu.pl; miklosbekes@icloud.com; marcin.drag@pwr.edu.pl;
   olsens@uthscsa.edu
RI ; Nayak, Digant/AAJ-1823-2020
OI Zmudzinski, Mikolaj/0000-0002-9792-9160; Snipas,
   Scott/0000-0002-4239-6862; Nayak, Digant/0000-0003-3680-0846
FU National Science Center grant in Poland [2015/17/N/ST5/03072]; European
   Union under the European Regional Development Fund [TEAM/2017-4/32];
   Foundation for Polish ScienceFoundation for Polish Science; National
   Institute of General Medical Sciences from the NIH [P30 GM124165]; DOE
   Office of ScienceUnited States Department of Energy (DOE)
   [DE-AC0206CH11357]; Office of the Vice President for Research at the
   Medical University of South Carolina; NIH Shared Instrumentation
   AwardUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [S10 RR027139-01]; CPRIT [RR200030];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 GM115568, ES025166, GM099040]
FX This project was supported by the National Science Center grant
   2015/17/N/ST5/03072 (Preludium 9) in Poland (W.R.) and the
   "TEAM/2017-4/32" project, which is carried out within the TEAM program
   of the Foundation for Polish Science, cofinanced by the European Union
   under the European Regional Development Fund (M.D.). W.R. is a
   beneficiary of a START scholarship from the Foundation for Polish
   Science. This work is based on research conducted at the Northeastern
   Collaborative Access Team beamlines, which are funded by the National
   Institute of General Medical Sciences from the NIH (P30 GM124165). This
   research used resources of the Advanced Photon Source, a U.S. Department
   of Energy (DOE) Office of Science User Facility operated for the DOE
   Office of Science by Argonne National Laboratory under contract no.
   DE-AC0206CH11357. The x-ray crystallography facility used for this work
   is supported by the Office of the Vice President for Research at the
   Medical University of South Carolina. The liquid handling robot used was
   purchased via an NIH Shared Instrumentation Award (S10 RR027139-01).
   Research reported in this publication was supported by CPRIT RR200030
   and NIH R01 GM115568 (S.K.O.), ES025166 (T.T.H.), and GM099040 (S.J.S.).
   Z.L. is a Hollings Cancer Center Postdoctoral Fellow, and S.P. is an
   American Cancer Society Postdoctoral Fellow (PF-18-23501-RMC). The
   content of this study is solely the responsibility of the authors and
   does not necessarily represent the official views of the NIH.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Aleshin AE, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.388678
   Anson B. J., 2020, BROAD SPECTRUM INHIB, DOI [10.21203/rs.3.rs-26344/v1, DOI 10.21203/RS.3.RS-26344/V1]
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Barretto N, 2006, ADV EXP MED BIOL, V581, P37
   Basters A, 2017, NAT STRUCT MOL BIOL, V24, P270, DOI 10.1038/nsmb.3371
   Bekes M, 2016, MOL CELL, V62, P572, DOI 10.1016/j.molcel.2016.04.016
   Bekes M, 2015, BIOCHEM J, V468, P215, DOI 10.1042/BJ20141170
   Calistri A, 2014, CELLS-BASEL, V3, P386, DOI 10.3390/cells3020386
   Clementz MA, 2010, J VIROL, V84, P4619, DOI 10.1128/JVI.02406-09
   de Jong A, 2012, CHEMBIOCHEM, V13, P2251, DOI 10.1002/cbic.201200497
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Drag M, 2008, BIOCHEM J, V415, P367, DOI 10.1042/BJ20080779
   Drag M, 2010, NAT REV DRUG DISCOV, V9, P690, DOI 10.1038/nrd3053
   Ekkebus R, 2013, J AM CHEM SOC, V135, P2867, DOI 10.1021/ja309802n
   El Oualid F, 2010, ANGEW CHEM INT EDIT, V49, P10149, DOI 10.1002/anie.201005995
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Flierman D, 2016, CELL CHEM BIOL, V23, P472, DOI 10.1016/j.chembiol.2016.03.009
   Freitas BT, 2020, ACS INFECT DIS, V6, P2099, DOI 10.1021/acsinfecdis.0c00168
   Frieman M, 2009, J VIROL, V83, P6689, DOI 10.1128/JVI.02220-08
   Han YS, 2005, BIOCHEMISTRY-US, V44, P10349, DOI 10.1021/bi0504761
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Hewings DS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03511-6
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kasperkiewicz P, 2017, FEBS J, V284, P1518, DOI 10.1111/febs.14001
   Klemm T., 2020, BIORXIV
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Lindner HA, 2007, ARCH BIOCHEM BIOPHYS, V466, P8, DOI 10.1016/j.abb.2007.07.006
   Maly DJ, 2002, J ORG CHEM, V67, P910, DOI 10.1021/jo016140o
   Mielech AM, 2014, VIROLOGY, V450, P64, DOI 10.1016/j.virol.2013.11.040
   Mulder MPC, 2014, CHEMBIOCHEM, V15, P946, DOI 10.1002/cbic.201402012
   Poreba M, 2017, NAT PROTOC, V12, P2189, DOI 10.1038/nprot.2017.091
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Rut W., 2020, BIORXIV
   Rut W, 2020, CHEM SCI, V11, P6058, DOI 10.1039/d0sc01347a
   Rut W, 2020, ANTIVIR RES, V175, DOI 10.1016/j.antiviral.2020.104731
   Rut W, 2018, J MED CHEM, V61, P5222, DOI 10.1021/acs.jmedchem.8b00026
   Rut W, 2017, ANTIVIR RES, V139, P88, DOI 10.1016/j.antiviral.2016.12.018
   Shin D., 2020, INHIBITION PAPAIN PR, DOI [10.21203/ rs.3.rs-27134/v1, DOI 10.21203/RS.3.RS-27134/V1]
   Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092
   Vedrenne E, 2005, SYNLETT, P670, DOI 10.1055/s-2005-862375
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
NR 49
TC 0
Z9 0
U1 2
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD OCT
PY 2020
VL 6
IS 42
AR eabd4596
DI 10.1126/sciadv.abd4596
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA OC4YU
UT WOS:000579164600041
PM 33067239
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pan, XY
   Zhou, PF
   Fan, TJ
   Wu, Y
   Zhang, J
   Shi, XY
   Shang, WJ
   Fang, LJ
   Jiang, XM
   Shi, J
   Sun, Y
   Zhao, SJ
   Gong, R
   Chen, Z
   Xiao, GF
AF Pan, Xiaoyan
   Zhou, Pengfei
   Fan, Tiejiong
   Wu, Yan
   Zhang, Jing
   Shi, Xiaoyue
   Shang, Weijuan
   Fang, Lijuan
   Jiang, Xiaming
   Shi, Jian
   Sun, Yuan
   Zhao, Shaojuan
   Gong, Rui
   Chen, Ze
   Xiao, Gengfu
TI Immunoglobulin fragment F(ab ')(2) against RBD potently neutralizes
   SARS-CoV-2 in vitro
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE SARS-CoV-2; Neutralizing antibody; Receptor-binding domain;
   Immunoglobulin fragment; COVID-19
ID INFLUENZA-A H5N1; CONVALESCENT PLASMA; PNEUMONIA OUTBREAK; CORONAVIRUS;
   INFECTION; DISEASE; ENHANCEMENT; ANTIBODIES; PROTECTS; EFFICACY
AB COVID-19, which is caused by the emerging human coronavirus SARS-CoV-2, has become a global pandemic that poses a serious threat to human health. To date, no vaccines or specific antiviral drugs have been approved for the treatment of this disease in clinic. Herein, therapeutic antibodies for SARS-CoV-2 were obtained from hyperimmune equine plasma. First, a recombinant SARS-CoV-2 spike protein receptor-binding domain (RBD) was obtained in gram-level quantities through high-cell density fermentation of Chinese hamster ovary cells. Then, the binding of the RBD to the SARS-CoV-2 receptor, human angiotensin-converting enzyme 2, was verified by several biochemical methods. The efficacy of the RBD in triggering antibody response in vivo was subsequently tested in both mice and equines, and the results showed that the RBD triggered high-titer neutralizing antibody production in vivo. Immunoglobulin F(ab')(2) fragments were prepared from equine antisera via removal of the Fc region from the immunoglobulins. Finally, a neutralization test with live virus demonstrated that RBD-specific F (ab')(2) inhibited SARS-CoV-2 with an EC50 of 0.07 mu g/ml and an EC80 of 0.18 mu g/ml, showing a potent inhibitory effect on SARS-CoV-2. These results highlight RBD-specific equine immunoglobulin F(ab')(2) fragment as a candidate for the treatment of SARS-CoV-2.
C1 [Pan, Xiaoyan; Wu, Yan; Shang, Weijuan; Jiang, Xiaming; Sun, Yuan; Xiao, Gengfu] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.
   [Zhou, Pengfei; Zhang, Jing; Fang, Lijuan; Shi, Jian] Wuhan YZY Biopharma Co Ltd, Wuhan 430075, Peoples R China.
   [Fan, Tiejiong; Shi, Xiaoyue; Chen, Ze] Shanghai Serum Biotechnol Co Ltd, Shanghai 201701, Peoples R China.
   [Jiang, Xiaming; Sun, Yuan; Zhao, Shaojuan; Xiao, Gengfu] Univ Chinese Acad Sci, Beijing 100039, Peoples R China.
   [Zhao, Shaojuan; Gong, Rui] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, CAS Key Lab Special Pathogens & Biosafety, Wuhan 430071, Peoples R China.
RP Xiao, GF (corresponding author), Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.; Chen, Z (corresponding author), Shanghai Serum Biotechnol Co Ltd, Shanghai 201701, Peoples R China.
EM chenze2005@hotmail.com; xiaogf@wh.iov.cn
OI , Yuan/0000-0001-8244-7436
FU National Ministry of Science and Technology Emergency Project
   [2020YFC0841400]; Hubei Provincial Department of Science and Technology
   Emergency Project [2020FCA003]; Wuhan National Biosafety Laboratory of
   the Chinese Academy of Sciences
FX This study was financially supported by grants from the National
   Ministry of Science and Technology Emergency Project (2020YFC0841400)
   and the Hubei Provincial Department of Science and Technology Emergency
   Project (2020FCA003). This study was also supported by the Wuhan
   National Biosafety Laboratory of the Chinese Academy of Sciences.
CR Ankcorn M, 2019, J HEPATOL, V71, P434, DOI 10.1016/j.jhep.2019.04.008
   Bal C, 2015, LANCET INFECT DIS, V15, P285, DOI 10.1016/S1473-3099(14)71072-2
   Brown JF, 2018, J INFECT DIS, V218, P555, DOI 10.1093/infdis/jiy199
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Corti D, 2016, SCIENCE, V351, P1339, DOI 10.1126/science.aad5224
   de Alwis R, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004386
   Du LY, 2009, VIROLOGY, V393, P144, DOI 10.1016/j.virol.2009.07.018
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Hastie KM, 2017, SCIENCE, V356, P923, DOI 10.1126/science.aam7260
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jaume M, 2012, Hong Kong Med J, V18 Suppl 2, P31
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Jolly PE, 2000, VIROLOGY, V273, P52, DOI 10.1006/viro.2000.0401
   Kraft CS, 2015, CLIN INFECT DIS, V61, P496, DOI 10.1093/cid/civ334
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lu JH, 2005, ACTA PHARMACOL SIN, V26, P1479, DOI 10.1111/j.1745-7254.2005.00210.x
   Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2
   MONTEFIORI DC, 1990, J VIROL, V64, P113, DOI 10.1128/JVI.64.1.113-119.1990
   Pan XY, 2020, ANTIVIR RES, V174, DOI 10.1016/j.antiviral.2019.104666
   Pan XY, 2018, ANTIVIR RES, V156, P21, DOI 10.1016/j.antiviral.2018.06.002
   Ratanabanangkoon K, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004565
   Rockman S, 2017, EBIOMEDICINE, V19, P119, DOI 10.1016/j.ebiom.2017.04.010
   RUGGIERO HA, 1986, PRESSE MED, V15, P2239
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Tang L, 2004, DNA CELL BIOL, V23, P391, DOI 10.1089/104454904323145272
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   Totura AL, 2019, EXPERT OPIN DRUG DIS, V14, P397, DOI 10.1080/17460441.2019.1581171
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang H., 2019, J VIROL, V93
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wong H.K., 2020, VOX SANG, V10, P12927
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Zhang Q, 2020, J MED VIROL, V92, P540, DOI [10.1002/jmv.25733, 10.1080/07391102.2020.1771421]
   Zhang Z, 2005, TRANSFUSION, V45, P1160, DOI 10.1111/j.1537-2995.2005.00179.x
   Zheng M, 2020, CELL MOL IMMUNOL, V17, P536, DOI 10.1038/s41423-020-0385-z
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 43
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD OCT
PY 2020
VL 182
AR 104868
DI 10.1016/j.antiviral.2020.104868
PG 10
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA OA6IT
UT WOS:000577887000006
PM 32659292
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Cui, FY
   Zhou, HSS
AF Cui, Feiyun
   Zhou, H. Susan
TI Diagnostic methods and potential portable biosensors for coronavirus
   disease 2019
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE COVID-19; SARS-CoV-2; Biosensors for virus detection; Lateral flow
   immunochromatographic strip; AI assisted diagnosis
ID VIRAL LOAD; SILVER NANOPARTICLES; NUCLEOCAPSID PROTEIN; SERS SUBSTRATE;
   OUTBREAK; ACID; SMARTPHONE; SARS-COV-2; PNEUMONIA; SPECIMENS
AB Timely detection and diagnosis are urgently needed to guide epidemiological measures, infection control, antiviral treatment, and vaccine research. In this review, biomarkers/indicators for diagnosis of coronavirus disease 2019 (COVID-19) or detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the environment are summarized and discussed. It is concluded that the detection methods targeting antibodies are not suitable for screening of early and asymptomatic cases since most patients had an antibody response at about 10 days after onset of symptoms. However, antibody detection methods can be combined with quantitative realtime reverse transcriptase-polymerase chain reaction (RT-qPCR) to significantly improve the sensitivity and specificity of diagnosis, and boost vaccine research. Fast, sensitive and accurate detection methods targeting antigens need to be developed urgently. Various specimens for diagnosis or detection are compared and analyzed. Among them, deep throat saliva and induced sputum are desired for RT-qPCR test or other early detection technologies. Chest computerized tomography (CT) scan, RT-qPCR, lateral flow immunochromatographic strip (LFICS) for diagnosis of COVID-19 are summarized and compared. Specially, potential electrochemical (EC) biosensor, surface enhanced Raman scattering (SERS)-based biosensor, field-effect transistor (FET)-based biosensor, surface plasmon resonance (SPR)-based biosensor and artificial intelligence (AI) assisted diagnosis of COVID-19 are emphasized. Finally, some commercialized portable detection device, current challenges and future directions are discussed.
C1 [Cui, Feiyun; Zhou, H. Susan] Worcester Polytech Inst, Dept Chem Engn, 100 Inst Rd, Worcester, MA 01609 USA.
RP Zhou, HSS (corresponding author), Worcester Polytech Inst, Dept Chem Engn, 100 Inst Rd, Worcester, MA 01609 USA.
EM szhou@wpi.edu
RI Zhou, Hong Susan/AAP-6521-2020; Cui, Feiyun/ABE-7502-2020
OI Zhou, Hong Susan/0000-0002-6659-6965; 
FU National Science FoundationNational Science Foundation (NSF)
   [CBET1805514]
FX This work was supported by National Science Foundation (CBET1805514) to
   HSZ.
CR Abad-Valle P, 2005, BIOSENS BIOELECTRON, V20, P2251, DOI 10.1016/j.bios.2004.10.019
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Anusha JR, 2019, BIOSENS BIOELECTRON, V142, DOI 10.1016/j.bios.2019.111511
   Bai H., 2020, LANDSCAPE CORONAVIRU, DOI [10.31219/osf.io/6eagn., DOI 10.31219/OSF.IO/6EAGN]
   Bai HX, 2020, RADIOLOGY, V296, pE46, DOI 10.1148/radiol.2020200823
   Bin SY, 2016, CLIN INFECT DIS, V62, P755, DOI 10.1093/cid/civ1020
   Broughton JP, 2020, NAT BIOTECHNOL, V38, P870, DOI 10.1038/s41587-020-0513-4
   Broughton JP, 2020, RAPID DETECTION 2019
   Che XY, 2004, J CLIN MICROBIOL, V42, P2629, DOI 10.1128/JCM.42.6.2629-2635.2004
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Corman V. M., 2020, EURO SURVEILL, V25
   Cui FY, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20040996
   Cui FY, 2019, J ELECTROCHEM SOC, V167, DOI 10.1149/2.0252003JES
   Diao B, 2020, DIAGNOSIS ACUTE RESP
   Ding X., 2020, BIORXIV
   Fahy JV, 1998, CLIN EXP ALLERGY, V28, P1047, DOI 10.1046/j.1365-2222.1998.00330.x
   Fang Y., 2020, RADIOLOGY, DOI DOI 10.1148/RADI0L.2020200432
   Guo JH, 2018, SENSOR ACTUAT B-CHEM, V275, P446, DOI 10.1016/j.snb.2018.08.042
   Guo JH, 2017, ANAL CHEM, V89, P8609, DOI 10.1021/acs.analchem.7b02531
   Guo JH, 2017, BIOSENS BIOELECTRON, V94, P415, DOI 10.1016/j.bios.2017.03.026
   Guo JH, 2016, ANAL CHEM, V88, P11986, DOI 10.1021/acs.analchem.6b04345
   Guo JC, 2020, J MATER SCI TECHNOL, V37, P96, DOI 10.1016/j.jmst.2019.06.018
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hahm JB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01785-19
   Han HQ, 2020, LANCET INFECT DIS, V20, P655, DOI 10.1016/S1473-3099(20)30174-2
   Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240
   Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899
   Huang L, 2020, ANALYST, V145, P2828, DOI 10.1039/c9an02485a
   Huang XW, 2018, ANALYST, V143, P5339, DOI 10.1039/c8an01269e
   Jiang H- w, 2020, GLOBAL PROFILING SAR
   Kaya S.I., 2020, NANOSENSORS SMART CI, P303
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Kim S., 2020, INSUFFICIENT SENSITI
   Ku K, 2020, BIORXIV
   Layqah LA, 2019, MICROCHIM ACTA, V186, DOI 10.1007/s00604-019-3345-5
   Lee HK, 2010, J VET SCI, V11, P165, DOI 10.4142/jvs.2010.11.2.165
   Li L., 2020, RADIOLOGY, DOI [10.1148/radiol.20202, DOI 10.1148/RADIOL.20202]
   Li Y, 2020, ACROSS LANG CULT, V21, P1, DOI [10.1556/084.2020.00001, 10.2214/AJR.20.22954]
   Li YX, 2019, BIOTECHNIQUES, V66, P225, DOI 10.2144/btn-2018-0184
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Lin C., 2020, COMP THROAT SWABS SP
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Lu R., 2020, VIROL SIN, P1
   Lu R, 2020, SARS COV 2 DETECTION
   Lu RF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082826
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo ZH, 2017, MICROCHIM ACTA, V184, P3505, DOI 10.1007/s00604-017-2369-y
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Nieto-Torres J.L., 2014, PLOS PATHOG, V10
   Oh MD, 2016, NEW ENGL J MED, V375, P1303, DOI 10.1056/NEJMc1511695
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Pan Y, 2020, SEROLOGICAL IMMUNOCH
   Park G.-S., 2020, J MOL DIAGN, pS1525
   Parkash O., 2019, DENGUE FEVER RESILIE, P131
   Patra P.P., 2016, PLASMOFLUIDIC SINGLE
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Peng M., 2020, ARTIFICIAL INTELLIGE
   Qiu GG, 2020, ACS NANO, V14, P5268, DOI 10.1021/acsnano.0c02439
   Ramphul K, 2020, CUREUS, V12, DOI 10.7759/cureus.7276
   Ranjan R, 2017, BIOSENS BIOELECTRON, V87, P918, DOI 10.1016/j.bios.2016.09.061
   Seo G, 2020, ACS NANO, V14, P5135, DOI 10.1021/acsnano.0c02823
   Tanner NA, 2015, BIOTECHNIQUES, V58, P59, DOI 10.2144/000114253
   Teoh BT, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-387
   To KKW, 2019, CLIN MICROBIOL INFEC, V25, P372, DOI 10.1016/j.cmi.2018.06.009
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wan ZY, 2003, S CHINA J PREV MED, V29, P36
   Wang CW, 2019, ACS APPL MATER INTER, V11, P19495, DOI 10.1021/acsami.9b03920
   Wang HH, 2020, EUR J CLIN MICROBIOL, V39, P1629, DOI 10.1007/s10096-020-03899-4
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang YS, 2020, J MED VIROL, V92, P538, DOI 10.1002/jmv.25721
   Won J, 2020, EXP NEUROBIOL, V29, P107, DOI [10.5607/en20009, 10.5607/en2009]
   Woo PCY, 2005, J CLIN MICROBIOL, V43, P3054, DOI 10.1128/JCM.43.7.3054-3058.2005
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xia N.-S., 2020, SEROLOGICAL TEST IS, DOI [10.20944/preprints202003.0184.v1, DOI 10.20944/PREPRINTS202003.0184.V1]
   Xiang J, 2020, EVALUATION ENZYME LI, DOI [10.1101/2020.02.27.20028787, DOI 10.1101/2020.02.27.20028787, 10.1101/2020.02.27. 20028787]
   Xu DD, 2018, BIOSENS BIOELECTRON, V110, P78, DOI 10.1016/j.bios.2018.03.018
   Yan C, 2020, CLIN MICROBIOL INFEC, V26, P773, DOI 10.1016/j.cmi.2020.04.001
   Yen CW, 2015, LAB CHIP, V15, P1638, DOI 10.1039/c5lc00055f
   Yip CCY, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.02127-19
   Yu L, 2020, RAPID COLORIMETRIC D, DOI [10.1101/2020.02.20.20025874, DOI 10.1101/2020.02.20.20025874]
   Yu L, 2020, CLIN CHEM, V66, P975, DOI 10.1093/clinchem/hvaa102
   Yu P, 2020, J INFECT DIS, V221, P1757, DOI 10.1093/infdis/jiaa077
   Zanoli LM, 2013, BIOSENSORS-BASEL, V3, P18, DOI 10.3390/bios3010018
   Zhang JC, 2020, J MED VIROL, V92, P680, DOI 10.1002/jmv.25742
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao Z, 2020, SIMPLE MAGNETIC NANO, DOI [10.1101/2020.02.22.961268, DOI 10.1101/2020.02.22.961268]
   Zhou J., 2020, HIGHLY ACCURATE SENS, DOI [10.1101/2020.02.22.961268, DOI 10.1101/2020.02.22.961268]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou SC, 2020, AM J ROENTGENOL, V214, P1287, DOI 10.2214/AJR.20.22975
   Zhou Y, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01056
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 95
TC 10
Z9 10
U1 85
U2 91
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD OCT 1
PY 2020
VL 165
AR 112349
DI 10.1016/j.bios.2020.112349
PG 9
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA NK5RG
UT WOS:000566789400015
PM 32510340
OA Green Published
DA 2021-01-01
ER

PT J
AU Avelino, PR
   Menezes, KKP
   Nascimento, LR
   Tenorio, RA
   Candido, GN
   Christovao, IS
   Teixeira-Salmela, LF
AF Avelino, Patrick R.
   Menezes, Kenia K. P.
   Nascimento, Lucas R.
   Tenorio, Ruani A.
   Candido, Gabriela N.
   Christovao, Isabela S.
   Teixeira-Salmela, Luci F.
TI Validation of the Telephone-Based Application of the ABILHAND for
   Assessment of Manual Ability After Stroke
SO JOURNAL OF NEUROLOGIC PHYSICAL THERAPY
LA English
DT Article
DE activities of daily living; Covid-19; rehabilitation; telephone; upper
   limb
ID CLINIMETRIC PROPERTIES; COGNITIVE STATUS; QUESTIONNAIRE; INTERVIEW;
   RELIABILITY; POPULATION; VALIDITY; THERAPY; INDEX
AB Background and Purpose: Telephone-based assessment may be a valuable and cost-effective approach to improve monitoring and follow-up assessments in patients and research participants. Telephone-based assessment may be of particular value during times when it is important to reduce in-person contract, such as during the Covid-19 pandemic. The purpose of this study was to investigate concurrent validity of the telephone-based administration of the ABILHAND for the assessment of manual ability in individuals with stroke.
   Methods: Using a cross-sectional study design, participants with stroke were invited to answer the ABILHAND questionnaire on 2 randomized occasions, face to face and by telephone, 5 to 7 days apart. The mean difference (MD) between the interviews was calculated (95% confidence interval [95% CI]) to investigate the concurrent validity. Intraclass correlation (ICC) and weighted kappa coefficients were used to investigate the agreement between face-to-face and telephone-based administration.
   Results: One hundred two participants (50 men; mean age = 65 years, SD = 13 years) were included. No significant differences were observed between the mean scores obtained with face-to-face and telephone-based administration of the ABILHAND (MD = -0.06; 95% CI, -0.72 to 0.60). Very high agreement was found between face-to-face and telephone-based administration (ICC = 0.90; 95% CI, 0.85 to 0.93) on the ABILHAND total scores. Most of the individual items had moderate or substantial kappa agreement.
   Discussion and Conclusions: Telephone-based administration of the ABILHAND is valid for the assessment of manual ability after stroke. Clinicians and researchers may use the ABILHAND for monitoring manual ability in persons with stroke and/or screening potential research participants. Video Abstract availablefor more insights from the authors (see the Video, Supplemental Digital Content 1,).
C1 [Avelino, Patrick R.; Menezes, Kenia K. P.; Nascimento, Lucas R.; Tenorio, Ruani A.; Candido, Gabriela N.; Christovao, Isabela S.; Teixeira-Salmela, Luci F.] Univ Fed Minas Gerais, Dept Phys Therapy, Ave Antonio Carlos 6627,Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
   [Menezes, Kenia K. P.] Fundacao Comunitaria Ensino Super Itabira, Dept Phys Therapy, Itabira, Brazil.
   [Nascimento, Lucas R.] Univ Fed Espirito Santo, Discipline Phys Therapy, Ctr Hlth Sci, Vitoria, ES, Brazil.
RP Avelino, PR (corresponding author), Univ Fed Minas Gerais, Dept Phys Therapy, Ave Antonio Carlos 6627,Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
EM patrickpk4@yahoo.com.br
OI Reis, AlessanRSS/0000-0001-8486-7469
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [304434/2014-0]; Fundacao de Amparo a Pesquisa de Minas Gerais
   (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG) [PPM
   00082-16]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES [001]
FX This work was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq; grant number 304434/2014-0), Fundacao de
   Amparo a Pesquisa de Minas Gerais (FAPEMIG; PPM 00082-16), and
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES; code
   001).
CR Ahn Sinae, 2018, Physical therapy rehabilitation science, V7, P67, DOI 10.14474/ptrs.2018.7.2.67
   Baggio JAO, 2014, CEREBROVASC DIS, V38, P297, DOI 10.1159/000367646
   Barber M, 2004, INT J GERIATR PSYCH, V19, P75, DOI 10.1002/gps.1041
   Barreca Susan, 2004, Top Stroke Rehabil, V11, P31
   Basilio ML, 2016, J REHABIL MED, V48, P6, DOI 10.2340/16501977-2044
   Basilio ML, 2017, REV TER OCUP U SAO P, V28, P19
   BERTOLUCCI PHF, 1994, ARQ NEURO-PSIQUIAT, V52, P1, DOI 10.1590/S0004-282X1994000100001
   Broeks JG, 1999, DISABIL REHABIL, V21, P357
   Burridge JH, 2017, J NEUROL PHYS THER, V41, pS32, DOI 10.1097/NPT.0000000000000183
   Camozzato AL, 2011, AGING NEUROPSYCHOL C, V18, P180, DOI 10.1080/13825585.2010.521814
   Connell LA, 2012, ARCH PHYS MED REHAB, V93, P221, DOI 10.1016/j.apmr.2011.09.015
   Dawson J, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c186
   Ekstrand E, 2020, DISABIL REHABIL, V42, P2279, DOI 10.1080/09638288.2018.1557265
   Ekstrand E, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0733-x
   Ekstrand E, 2014, PM&R, V6, P324, DOI 10.1016/j.pmrj.2013.09.015
   Faria-Fortini I, 2011, J HAND THER, V24, P257, DOI 10.1016/j.jht.2011.01.002
   Feys H, 2000, Physiother Res Int, V5, P1, DOI 10.1002/pri.180
   Franceschini M, 2010, EUR J PHYS REHAB MED, V46, P389
   Grimby G, 2012, J REHABIL MED, V44, P97, DOI 10.2340/16501977-0938
   Harris JE, 2007, PHYS THER, V87, P88, DOI 10.2522/ptj.20060065
   Kitago T, 2013, NEUROREHAB NEURAL RE, V27, P99, DOI 10.1177/1545968312452631
   Kyte DG, 2015, PHYSIOTHERAPY, V101, P119, DOI 10.1016/j.physio.2014.11.003
   Lima RCM, 2014, BRAZ J PHYS THER, V18, P435, DOI 10.1590/bjpt-rbf.2014.0050
   Merino JG, 2005, STROKE, V36, P232, DOI 10.1161/01.STR.0000153055.43138.2f
   Meschia JF, 2000, STROKE, V31, P1076, DOI 10.1161/01.STR.31.5.1076
   Minelli C, 2007, STROKE, V38, P2906, DOI 10.1161/STROKEAHA.107.484139
   Munro BH, 2005, STAT METHODS HLTH CA
   Pendlebury ST, 2013, STROKE, V44, P227, DOI 10.1161/STROKEAHA.112.673384
   Penta M, 2001, STROKE, V32, P1627, DOI 10.1161/01.STR.32.7.1627
   Pinto-Carral A, 2016, ARCH PHYS MED REHAB, V97, P1182, DOI 10.1016/j.apmr.2016.01.025
   Portney L.G., 2009, FDN CLIN RES APPL PR
   SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173
   Scianni A, 2012, BRAZ J PHYS THER, V16, P40, DOI 10.1590/S1413-35552012000100008
   Sezer N, 2007, ARCH PHYS MED REHAB, V88, P309, DOI 10.1016/j.apmr.2006.12.019
   Sim J, 2005, PHYS THER, V85, P257
   Universite catholique de Louvain, EV SCAL REH
   van der Lee JH, 2004, STROKE, V35, P1410, DOI 10.1161/01.STR.0000126900.24964.7e
   World Health Organization and others, 2001, INT CLASS FUNCT DIS
   Yozbatiran N, 2008, NEUROREHAB NEURAL RE, V22, P78, DOI 10.1177/1545968307305353
NR 39
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1557-0576
EI 1557-0584
J9 J NEUROL PHYS THER
JI J. Neurol. Phys. Ther.
PD OCT
PY 2020
VL 44
IS 4
BP 256
EP 260
DI 10.1097/NPT.0000000000000326
PG 5
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA OC5JQ
UT WOS:000579192900005
PM 32815891
DA 2021-01-01
ER

PT J
AU Chakraborti, S
   Bheemireddy, S
   Srinivasan, N
AF Chakraborti, Sohini
   Bheemireddy, Sneha
   Srinivasan, Narayanaswamy
TI Repurposing drugs against the main protease of SARS-CoV-2:
   mechanism-based insights supported by available laboratory and clinical
   data
SO MOLECULAR OMICS
LA English
DT Article
ID CORONAVIRUS 3C-LIKE PROTEASE; ALPHA PRODUCTION; DIMER INTERFACE; VIRUS;
   INHIBITORS; IDENTIFICATION; DOXYCYCLINE; NAFAMOSTAT; EVOLUTION; MESILATE
AB The ongoing global pandemic of COVID-19 has brought life to almost a standstill with the implementation of lockdowns and social distancing as some of the preventive measures in the absence of any approved specific therapeutic interventions. To combat this crisis, research communities worldwide are falling back on the existing repertoire of approved/investigational drugs to probe into their anti-coronavirus properties. In this report, we describe our unique efforts in identifying potential drugs that could be repurposed against the main protease of SARS-CoV-2 (SARS-CoV-2 M-pro). To achieve this goal, we have primarily exploited the principles of 'neighbourhood behaviour' in the protein 3D (workflow-I) and chemical 2D structural space (workflow-II) coupled with docking simulations and insights into the possible modes of action of the selected candidates from the available literature. This integrative approach culminated in prioritizing 29 potential repurpose-able agents (20 approved drugs and 9 investigational molecules) against SARS-CoV-2 M-pro. Apart from the approved/investigational anti-viral drugs, other notable hits include anti-bacterial, anti-inflammatory, anti-cancer and anti-coagulant drugs. Our analysis suggests that some of these drugs have the potential to simultaneously modulate the functions of viral proteins and the host response system. Interestingly, many of these identified candidates (12 molecules from workflow-I and several molecules, belonging to the chemical classes of alkaloids, tetracyclines, peptidomimetics, from workflow-II) are suggested to possess anti-viral properties, which is supported by laboratory and clinical data. Furthermore, this work opens a new avenue of research to probe into the molecular mechanism of action of many drugs, which are known to demonstrate anti-viral activity but are so far not known to target viral proteases.
C1 [Chakraborti, Sohini; Bheemireddy, Sneha; Srinivasan, Narayanaswamy] Indian Inst Sci, Mol Biophys Unit, Bengaluru 560012, India.
RP Srinivasan, N (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bengaluru 560012, India.
EM ns@iisc.ac.in
FU Mathematical Biology program; FIST program - Department of Science and
   Technology (DST)Department of Science & Technology (DOST), Philippines;
   Department of Biotechnology (DBT), Government of IndiaDepartment of
   Biotechnology (DBT) India; UGC, India-Centre for Advanced Studies;
   Ministry of Human Resource Development, IndiaMinistry of Higher
   Education & Scientific Research (MHESR); DST-INSPIREDepartment of
   Science & Technology (India); CSIR, Government of IndiaCouncil of
   Scientific & Industrial Research (CSIR) - India
FX Research in our group is generally supported by the Mathematical Biology
   program and FIST program sponsored by the Department of Science and
   Technology (DST) and the Department of Biotechnology (DBT), Government
   of India in the form of IISc-DBT partnership programme. Support from
   UGC, India-Centre for Advanced Studies and Ministry of Human Resource
   Development, India is gratefully acknowledged. SC acknowledges the
   financial support by DST-INSPIRE towards her research fellowship. SB
   acknowledges the financial support by CSIR, Government of India towards
   her research fellowship. NS is a J. C. Bose National Fellow. The authors
   are thankful to Ms Yazhini Arangasamy for providing remote technical
   assistance. All the group members, Dr. TJ Narwani and Prof. R.
   Sowdhamini are acknowledged for useful discussions. The authors are also
   grateful to Mr. Koustav Purkait for assistance in data compilation and
   proof reading.
CR Abdul V., 2019, J PHARM SCI RES, V11, P1156
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Amirian ES, 2020, ONE HEALTH-AMSTERDAM, V9, DOI 10.1016/j.onehlt.2020.100128
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anighoro A, 2014, J MED CHEM, V57, P7874, DOI 10.1021/jm5006463
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Asakura H, 2020, J THROMB HAEMOST, V18, P1521, DOI 10.1111/jth.14858
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Bajusz D, 2015, J CHEMINFORMATICS, V7, DOI 10.1186/s13321-015-0069-3
   Barrila J, 2010, BIOCHEMISTRY-US, V49, P4308, DOI 10.1021/bi1002585
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Chakraborti S., 2019, SILICO DRUG DESIGN, P463
   Chang KO, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020197
   Chen H., 2020, MEDRXIV, DOI [10.1101/2020.03.22.20034041, DOI 10.1101/2020.03.22.20034041]
   Chen QY, 2020, NATURE, V579, P193, DOI 10.1038/d41586-020-00694-1
   Chen S, 2008, J BIOL CHEM, V283, P554, DOI 10.1074/jbc.M705240200
   Choi JY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002392
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13437
   Csaba G, 2009, BMC STRUCT BIOL, V9, DOI 10.1186/1472-6807-9-23
   Cure E, 2020, J MED VIROL, V92, P1423, DOI 10.1002/jmv.25848
   Dawson NL, 2017, NUCLEIC ACIDS RES, V45, pD289, DOI 10.1093/nar/gkw1098
   Dolinsky TJ, 2007, NUCLEIC ACIDS RES, V35, pW522, DOI 10.1093/nar/gkm276
   Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005
   Dutta K, 2011, INDIAN J MED RES, V133, P467
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Farouk A, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109768
   FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034
   Fox NK, 2014, NUCLEIC ACIDS RES, V42, pD304, DOI 10.1093/nar/gkt1240
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Hakmi M, 2020, BIOINFORMATION, V16, P301, DOI 10.6026/97320630016301
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Henehan M, 2017, J EUR ACAD DERMATOL, V31, P1800, DOI 10.1111/jdv.14345
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holm L, 2019, BIOINFORMATICS, V35, P5326, DOI 10.1093/bioinformatics/btz536
   Hu TC, 2009, VIROLOGY, V388, P324, DOI 10.1016/j.virol.2009.03.034
   Hutterer C, 2017, ANTIVIR RES, V143, P113, DOI 10.1016/j.antiviral.2017.04.003
   Illergard K, 2009, PROTEINS, V77, P499, DOI 10.1002/prot.22458
   IWAKI M, 1986, JPN J PHARMACOL, V41, P155, DOI 10.1254/jjp.41.155
   Ji HL, 2020, PHYSIOL REV, V100, P1065, DOI 10.1152/physrev.00013.2020
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Konaklieva MI, 2019, SLAS DISCOV, V24, P419, DOI 10.1177/2472555218812657
   Konc J, 2012, J CHEM INF MODEL, V52, P604, DOI 10.1021/ci2005687
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Lands L. C., 2010, P CAN SALM ENT S WOR, P3
   LEWIS EL, 1992, J GEN VIROL, V73, P3285, DOI 10.1099/0022-1317-73-12-3285
   Lin K, 2013, ANTIVIR RES, V99, P68, DOI 10.1016/j.antiviral.2013.03.020
   Maggiora G, 2014, J MED CHEM, V57, P3186, DOI 10.1021/jm401411z
   Maitra A, 2020, J BIOSCIENCES, V45, DOI 10.1007/s12038-020-00046-1
   Martin TD, 2017, CELL REP, V20, P427, DOI 10.1016/j.celrep.2017.06.061
   Martin YC, 2002, J MED CHEM, V45, P4350, DOI 10.1021/jm020155c
   Mesecar A. D., X77 STRUCTURE COVID
   Meyder A, 2017, J CHEM INF MODEL, V57, P2437, DOI 10.1021/acs.jcim.7b00391
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Mushtaq S, 2018, EXCLI J, V17, P420, DOI 10.17179/excli2018-1174
   Needle D, 2015, ACTA CRYSTALLOGR D, V71, P1102, DOI 10.1107/S1399004715003521
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Pandey A, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117883
   Patterson DE, 1996, J MED CHEM, V39, P3049, DOI 10.1021/jm960290n
   Pei JM, 2008, NUCLEIC ACIDS RES, V36, P2295, DOI 10.1093/nar/gkn072
   Pence HE, 2010, J CHEM EDUC, V87, P1123, DOI 10.1021/ed100697w
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Potdar Varsha, 2020, Indian J Med Res, V151, P255, DOI 10.4103/ijmr.IJMR_1058_20
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Ramakrishnan G, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1937-2
   Ramakrishnan G, 2015, MOL BIOSYST, V11, P3316, DOI 10.1039/c5mb00476d
   RASTOGI RP, 1990, DRUG DEVELOP RES, V19, P1, DOI 10.1002/ddr.430190102
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   RISMANBAF A, 2020, ARCH ACAD EMERG MED, V8
   RL N., 1990, BIOCH CELL BIOL, V68, P1344
   Rothan HA, 2014, ARCH VIROL, V159, P711, DOI 10.1007/s00705-013-1880-7
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sandler C, 2005, INFLAMM RES, V54, P304, DOI 10.1007/s00011-005-1358-5
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Sardar R, 2020, COMP ANAL SAR COV2 G, DOI [10.1101/2020.03.21.001586, DOI 10.1101/2020.03.21.001586]
   Seley-Radtke KL, 2018, ANTIVIR RES, V154, P66, DOI 10.1016/j.antiviral.2018.04.004
   Sodhi M, 2020, PHARMACOTHERAPY, V40, P487, DOI 10.1002/phar.2395
   Song JC, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00247-7
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   STELLA VJ, 1985, DRUGS, V29, P455, DOI 10.2165/00003495-198529050-00002
   Sturtz FG, 1998, METHOD FIND EXP CLIN, V20, P643, DOI 10.1358/mf.1998.20.8.487489
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Te Helen S, 2007, Gastroenterol Hepatol (N Y), V3, P218
   Testa S, 2020, J THROMB HAEMOST, V18, P1320, DOI 10.1111/jth.14871
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Venditto VJ, 2010, MOL PHARMACEUT, V7, P307, DOI 10.1021/mp900243b
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   WEININGER D, 1988, J CHEM INF COMP SCI, V28, P31, DOI 10.1021/ci00057a005
   Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wolf AM, 2005, P NATL ACAD SCI USA, V102, P13622, DOI 10.1073/pnas.0501758102
   Wood TC, 1999, J MOL BIOL, V291, P977, DOI 10.1006/jmbi.1999.2972
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Yuksel M, 2003, J PHARMACOL EXP THER, V305, P298, DOI 10.1124/jpet.102.041988
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 113
TC 1
Z9 1
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2515-4184
J9 MOL OMICS
JI Mol. Omics
PD OCT 1
PY 2020
VL 16
IS 5
BP 474
EP 491
DI 10.1039/d0mo00057d
PG 18
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OB7CI
UT WOS:000578624800006
PM 32696772
DA 2021-01-01
ER

PT J
AU Heister, PM
   Poston, RN
AF Heister, Paula M.
   Poston, Robin N.
TI Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential
   therapeutic agent for COVID-19
SO PHARMACOLOGY RESEARCH & PERSPECTIVES
LA English
DT Article
DE calcium channel blocker; drug repurposing; endolysosomal pathway;
   SARS-CoV-2; traditional Chinese medicine; two-pore channel 2 (TPC2)
ID DEPENDENT CA2+; CALCIUM; NAADP; TOXICITY; CHANNELS; ALKALOIDS; SYSTEM;
   ENTRY
AB More than ten million patients worldwide have been diagnosed with coronavirus disease 19 (COVID-19) to date (WHO situation report, 1st July 2020). There is no vaccine to prevent infection with the causative organism, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), nor a cure. In the struggle to devise potentially useful therapeutics in record time, the repurposing of existing compounds is a key route of action. In this hypothesis paper, we argue that the bisbenzylisoquinoline and calcium channel blocker tetrandrine, originally extracted from the plant Stephania tetrandra and utilized in traditional Chinese medicine, may have potential in the treatment of COVID-19 and should be further investigated. We collate and review evidence for tetrandrine's putative mechanism of action in viral infection, specifically its recently discovered antagonism of the two-pore channel 2 (TPC2). While tetrandrine's particular history of use provides a very limited pharmacological dataset, there is a suggestion from the available evidence that it could be effective at doses used in clinical practice. We suggest that further research to investigate this possibility should be conducted.
C1 [Heister, Paula M.] Univ Cambridge, Cambridge, England.
   [Poston, Robin N.] Queen Mary Univ London, London, England.
RP Heister, PM (corresponding author), Univ Cambridge, Cambridge, England.; Poston, RN (corresponding author), Queen Mary Univ London, London, England.
EM ph535@cam.ac.uk; r.poston@qmul.ac.uk
OI Reis, AlessanRSS/0000-0001-8486-7469
CR [Anonymous], 2020, HUMAN PROTEIN ATLAS
   Bhagya N, 2018, BIOMED PHARMACOTHER, V97, P624, DOI 10.1016/j.biopha.2017.10.116
   Calcraft PJ, 2009, NATURE, V459, P596, DOI 10.1038/nature08030
   Catret M, 1998, J PHARM PHARMACOL, V50, P1267, DOI 10.1111/j.2042-7158.1998.tb03344.x
   Chen KK, 1935, J BIOL CHEM, V109, P681
   Chen XJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010094
   Chen Y, 2011, MOLECULES, V16, P8020, DOI 10.3390/molecules16098020
   Cockrell AS, 2018, MAMM GENOME, V29, P367, DOI 10.1007/s00335-018-9760-9
   Cohen J, 2020, SCIENCE, DOI [10.1126/science.abc2335, DOI 10.1126/SCIENCE.ABC2335]
   D'Elia JA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092465
   Dai CL, 2007, CANCER CHEMOTH PHARM, V60, P741, DOI 10.1007/s00280-007-0420-0
   DAI GZ, 1990, CHINESE MED J-PEKING, V103, P460
   Davis LC, 2020, EMBO J, DOI 10.15252/embj.2019104058
   Dial S, 2014, BRIT J CLIN PHARMACO, V78, P1151, DOI 10.1111/bcp.12419
   Dobson SJ, 2019, REQUIREMENT POTASSIU
   Dong Q.-k., 2011, J CLIN MED PRACT, V15, P83
   Falzarano D, 2015, SCIENCE, V347, P947, DOI 10.1126/science.aaa8121
   FERRANTE A, 1990, CLIN EXP IMMUNOL, V80, P232
   Galione A, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a035071
   Gao LN, 2016, J ORTHOP RES, V34, P1557, DOI 10.1002/jor.23155
   Genazzani AA, 1997, BRIT J PHARMACOL, V121, P1489, DOI 10.1038/sj.bjp.0701295
   Gerndt S, 2020, ELIFE, V9, DOI 10.7554/eLife.54712
   Glesby MJ, 2005, CLIN PHARMACOL THER, V78, P143, DOI 10.1016/j.clpt.2005.04.005
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Government UK, 2001, MED AR MU TONG ETC E
   Grimm C, 2020, CELL CALCIUM, V88, DOI 10.1016/j.ceca.2020.102212
   Grimm C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5699
   Guan SM, 2001, CHINESE MED J-PEKING, V114, P1046
   Gunaratne GS, 2018, CELL CALCIUM, V75, P30, DOI 10.1016/j.ceca.2018.08.003
   Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang YT, 1998, CARDIOVASC DRUG REV, V16, P1, DOI 10.1111/j.1527-3466.1998.tb00341.x
   Jiang YP, 2020, PHYTOCHEM REV, V19, P449, DOI 10.1007/s11101-020-09673-w
   Jin H, 2011, CHEM RES TOXICOL, V24, P2142, DOI 10.1021/tx200290s
   Jonsdottir HR, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0479-5
   Kannan S, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011452, DOI 10.1002/14651858.CD011452]
   Kim DE, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110696
   KING VF, 1988, J BIOL CHEM, V263, P2238
   Kwan CY, 1996, LIFE SCI, V59, pPL359, DOI 10.1016/S0024-3205(96)00552-8
   Lee CC, 2017, CRIT CARE MED, V45, P1500, DOI [10.1097/ccm.0000000000002550, 10.1097/CCM.0000000000002550]
   Li H, 2019, CELL RES, V29, P739, DOI 10.1038/s41422-019-0214-z
   LI SY, 1989, INT ARCH ALLER A IMM, V90, P169
   LI TL, 1982, ECOTOX ENVIRON SAFE, V6, P528, DOI 10.1016/0147-6513(82)90034-3
   Liu CX, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6763057
   LIU QY, 1992, J CARDIOVASC PHARM, V20, P513, DOI 10.1097/00005344-199210000-00001
   Morgan AJ, 2007, BIOCHEM J, V402, P301, DOI 10.1042/BJ20060759
   Mouton JW, 2008, J ANTIMICROB CHEMOTH, V61, P235, DOI 10.1093/jac/dkm476
   Naylor E, 2009, NAT CHEM BIOL, V5, P220, DOI 10.1038/nchembio.150
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Patel S, 2018, BBA-MOL CELL RES, V1865, P1678, DOI 10.1016/j.bbamcr.2018.05.004
   QIAN JQ, 1983, PHARMACOLOGY, V26, P187, DOI 10.1159/000137801
   Rahman T, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005450
   Remy KE, 2020, LANCET RESP MED, V8, P946, DOI 10.1016/S2213-2600(20)30217-4
   Robison GA, 1971, CYCLIC AMP
   Ruas M, 2014, MOL CELL BIOL, V34, P3981, DOI 10.1128/MCB.00113-14
   Sakurai Y, 2015, SCIENCE, V347, P995, DOI 10.1126/science.1258758
   Schutz R, 2020, ORG BIOMOL CHEM, V18, P3047, DOI 10.1039/d0ob00078g
   SEOW WK, 1989, CLIN EXP IMMUNOL, V75, P47
   Shangbin Q, 1986, HARMACOLOGY APPL CHI, VI, P400
   Shi JP, 2016, CHIN J INTEGR MED, V22, P925, DOI 10.1007/s11655-015-2303-2
   Su WQ, 2020, MOL PHARMACEUT, V17, P1596, DOI 10.1021/acs.molpharmaceut.0c00026
   Sun JL, 2019, EXP THER MED, V18, P3383, DOI 10.3892/etm.2019.7966
   Tang WW, 2019, THERANOSTICS, V9, P932, DOI 10.7150/thno.30408
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Trufanov SK, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101144
   TSAI JJ, 1995, INT ARCH ALLERGY IMM, V108, P183, DOI 10.1159/000237137
   U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2005, GUID IND EST MAX SAF
   WANG G, 1994, LIFE SCI, V56, P295, DOI 10.1016/0024-3205(94)00952-X
   Wang X, 2012, CELL, V151, P372, DOI 10.1016/j.cell.2012.08.036
   Xie QM, 2002, ACTA PHARMACOL SIN, V23, P1107
   XU B, 2020, J INFECTION, V81, pE51, DOI 10.1016/j.jinf.2020.04.012
   Xu M, 2010, TUMORI, V96, P460
   Yang GY, 2017, J CHROMATOGR B, V1070, P92, DOI 10.1016/j.jchromb.2017.10.048
   Yu Pin, 2020, Animal Model Exp Med, V3, P93, DOI 10.1002/ame2.12108
   ZENG FD, 1985, J CARDIOVASC PHARM, V7, P1034, DOI 10.1097/00005344-198511000-00004
   Zhang J, 2020, EXP THER MED, V19, P2195, DOI 10.3892/etm.2020.8431
NR 76
TC 0
Z9 0
U1 3
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2052-1707
J9 PHARMACOL RES PERSPE
JI Pharmacol. Res. Perspect.
PD OCT
PY 2020
VL 8
IS 5
AR e00653
DI 10.1002/prp2.653
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OB7PJ
UT WOS:000578658700007
PM 32930523
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Laurell, AC
AF Laurell, Asa Cristina
TI Dimensions of the COVID-19 pandemic
SO TRIMESTRE ECONOMICO
LA Spanish
DT Article
DE COVID-19; medical and epidemiological approach; social inequality of
   disease and death between groups; impact on economy; politicization of
   COVID-19
AB This paper provides a multidimensional reflection on the COVID-19 pandemic. It states that the dominant analytical approach to the pandemic is medical and epidemiological, which leads to an underestimation of its social, economic and political causes and impacts. It also calls attention to the fact that scientific knowledge on COVID-19 is still scarce and contradictory. The essay starts with a review and analysis of the magnitude of the problem compared to other causes of death in Mexico, and a review of how different social and economic conditions seem crucial for the frequency and severity of the disease. It examines the behavior of the medical industrial complex relative to the production of vaccines, drugs and other medical devices, and detects divergent conducts: one highly speculative, including financial speculation, and another that, for the time being, has promised not to take a profit. Finally, there are some considerations concerning how the virus is changing political processes.
EM laurell9998@gmail.com
CR Aburto JM, 2019, AM J PUBLIC HEALTH, V109, P483, DOI 10.2105/AJPH.2018.304878
   [Anonymous], 2020, FINANCIAL TIMES
   [Anonymous], 2020, EL UNIVERSAL
   Boltvinik J., 2020, JORNADA
   Brown E., 2020, NEW AGE
   cepal, 2020, PAN FISC AM LAT CAR
   cepal y Organizacion Panamericana de la Salud, 2020, SAL EC CONV NEC ENFR
   Esposito R., 2020, BIOPOLITCA CORONAVIR
   Frente Pela Vida, 2020, PLAN NAC ENFR PAND C
   Guimaraes R., 2020, NOTA VACUNAS SARS CO
   Infobae, 2020, MEX REB 80000 MUERT
   Medicos sin Fronteras, 2020, PHARM CORP GET MON G
   Navas M. E., 2020, BBC NEWS
   oms, 2020, DRAFT LANDSC COV 19
   pnud, 2020, DES HUM COV 19 MEX D
   Roelfs DJ, 2011, SOC SCI MED, V72, P840, DOI 10.1016/j.socscimed.2011.01.005
   Secretaria de Relaciones Exteriores, 2020, COOP INT AS VAC EQ M
   Secretaria de Salud, 2019, AT 1 SAL INT INT PRO
   Siddique C. M., 2013, INT J HLTH SERVICES, V15, P609
   Subsecretaria de Integracion y Desarrollo del Sector Salud-Secretaria de Salud, 2020, INT APS 1 MX DISTR S
   Subsecretaria de Integracion y Desarrollo del Sector Salud-Secretaria de Salud, 2020, ADM ORG DISTR SAL AP
   Universidad de los Andes, 2020, 23 U AND
   Urbanos-Garrido R. M., 2013, ESTUDIOS EC APLICADA, V31, P303
NR 23
TC 0
Z9 0
U1 2
U2 2
PU FONDO CULTURA ECONOMICA
PI TLALPAN
PA AVE PICACHO AJUSCO, NO 227, TLALPAN CP 14200, MEXICO
SN 0041-3011
J9 TRIMEST ECON
JI Trimest. Econ.
PD OCT-DEC
PY 2020
VL 87
IS 348
BP 963
EP 984
DI 10.20430/ete.v87i348.1153
PG 22
WC Economics
SC Business & Economics
GA OC2SI
UT WOS:000579009600003
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Hofer, RP
AF Hofer, Roberto Pizarro
TI One step further from COVID-19
SO TRIMESTRE ECONOMICO
LA Spanish
DT Article
DE COVID-19; globalization; industrialization; crisis; economic growth;
   subsidiary state; Keynes
AB COVID-19 has caused a humanitarian crisis of devastating proportions and an economic disaster without parallel. We live under a worrying uncertainty, because it is unknown how long the lockdown will last, the lack of income, unemployment, and even when will an effective vaccine or a medicine be discovered. Everyone suffers from uncertainty. Those who have assets, but much more those who have run out of income. The painful experience of coronavirus must be a lesson, and not only on the field of health, but an opportunity to change the existing unjust and irrational economic and social system. The coronavirus challenges the political class that has shrunk the state, with radical social cuts, which have seriously affected people's lives. This crisis provides an opportunity for changes; however, they will not be automatic, but rather they will depend on the will and struggle of men and women, who have been affected by the lack of protection of the subsidiary state for decades. If no rectifications are made, there will be not only sanitary dangers but also social ones ahead.
C1 [Hofer, Roberto Pizarro] Univ Chile, Fac Econ Polit, Santiago, Chile.
   [Hofer, Roberto Pizarro] Comis Econ Amer Latina & Caribe, Santiago, Chile.
   [Hofer, Roberto Pizarro] Asociac Latinoamer Integrac, Montevideo, Uruguay.
EM pizroberto@gmail.com
CR [Anonymous], 2020, FINANCIAL TIMES
   Aristoteles, 1937, LA POLITICA
   cepal, 2020, DIM EF COV 19 PENS R
   Chacon R., 2020, FOREIGN AFFAIRS LATI
   Chang H. J., 2003, GLOBALIZATION EC DEV
   Climent M., 2015, EL MUNDO
   Cordova M., 2020, LA TERCERA
   Europa Press, 2019, EUROPA PRESS
   Gray J., 2020, NEW STATEMENT
   Gray J., 2020, PAIS
   Hernandez Gonzalez G., 2016, ANALISIS, P6
   Keay D., 1987, WOMANS OWN
   Kemp J., 2020, REUTERS
   Patino D., 2014, FINANCIERO
   Peirano M., 2020, PAIS
   Quammen D, 2020, NY TIMES
   Rauchway E., 2020, GUARDIAN
   Redaccion Internacional, 2020, BYUNG CHUL HAN VIV C
   Rosales O., 2020, MIRADA SEMANAL
   Roubini N., 2020, PROJECT SYNDICATE
   Valenzuela Feijoo J., 2020, POSIBLE
   Valenzuela Feijoo J., 2020, EC MEXICANA AN UNPUB
   Vidal J., 2020, EL DIARIO
   Virgili A., 2020, NATL GEOGRAPHIC
   Zizek Slavoj, 2020, PANDEMIC COVID 19 SH
NR 25
TC 0
Z9 0
U1 1
U2 1
PU FONDO CULTURA ECONOMICA
PI TLALPAN
PA AVE PICACHO AJUSCO, NO 227, TLALPAN CP 14200, MEXICO
SN 0041-3011
J9 TRIMEST ECON
JI Trimest. Econ.
PD OCT-DEC
PY 2020
VL 87
IS 348
BP 1033
EP 1057
DI 10.20430/ete.v87i348.1174
PG 25
WC Economics
SC Business & Economics
GA OC2SI
UT WOS:000579009600005
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Prasanth, KR
   Hirano, M
   Fagg, WS
   McAnarney, ET
   Shan, C
   Xie, XP
   Hage, A
   Pietzsch, CA
   Bukreyev, A
   Rajsbaum, R
   Shi, PY
   Bedford, MT
   Bradrick, SS
   Menachery, V
   Garcia-Blanco, MA
AF Prasanth, K. Reddisiva
   Hirano, Minato
   Fagg, W. Samuel
   McAnarney, Eileen T.
   Shan, Chao
   Xie, Xuping
   Hage, Adam
   Pietzsch, Colette A.
   Bukreyev, Alexander
   Rajsbaum, Ricardo
   Shi, Pei-Yong
   Bedford, Mark T.
   Bradrick, Shelton S.
   Menachery, Vineet
   Garcia-Blanco, Mariano A.
TI Topoisomerase III-beta is required for efficient replication of
   positive-sense RNA viruses
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Topoisomerase III-beta (TOP3B); Positive stranded RNA viruses; Host
   factor; Dengue; SARS-CoV-2
ID TOP3-BETA; DOMAINS; LIFE
AB Based on genome-scale loss-of-function screens we discovered that Topoisomerase III-beta (TOP3B), a human topoisomerase that acts on DNA and RNA, is required for yellow fever virus and dengue virus-2 replication. Remarkably, we found that TOP3B is required for efficient replication of all positive-sense-single stranded RNA viruses tested, including SARS-CoV-2. While there are no drugs that specifically inhibit this topoisomerase, we posit that TOP3B is an attractive anti-viral target.
C1 [Prasanth, K. Reddisiva; Hirano, Minato; Fagg, W. Samuel; Shan, Chao; Xie, Xuping; Shi, Pei-Yong; Bradrick, Shelton S.; Garcia-Blanco, Mariano A.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
   [Fagg, W. Samuel] Univ Texas Med Branch, Dept Surg, Transplant Div, Galveston, TX 77555 USA.
   [McAnarney, Eileen T.; Hage, Adam; Rajsbaum, Ricardo; Menachery, Vineet] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   [Pietzsch, Colette A.; Bukreyev, Alexander] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Pietzsch, Colette A.; Bukreyev, Alexander] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA.
   [Rajsbaum, Ricardo; Shi, Pei-Yong; Bradrick, Shelton S.; Garcia-Blanco, Mariano A.] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.
   [Bedford, Mark T.] MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Smithville, TX USA.
   [Garcia-Blanco, Mariano A.] Duke NUS Med Sch, Programme Emerging Infect Dis, Singapore, Singapore.
   [Bradrick, Shelton S.] MRIGlobal, Global Hlth Surveillance & Diagnost Div, 425 Volker Blvd, Kansas City, MO 64110 USA.
RP Garcia-Blanco, MA (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
EM maragarc@utmb.edu
OI McAnarney, Eileen/0000-0003-2337-2889; Hage, Adam/0000-0001-7668-892X;
   Fagg, William/0000-0003-2909-1666
FU Uehara Foundation Fellowship; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [AI142759, R01
   CA204806, R01 GM126412]; Vacek Chair; UTMB; Sealy & Smith Foundation;
   Kleberg Foundation; John S. Dunn Foundation; Amon G. Carter Foundation;
   Gilson Longenbaugh Foundation; Summerfield Robert Foundation;
   NIH/NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [T32 AI007526, R21 AI26012, R01 AI134907]
FX We thank members of our laboratories at the University of Texas Medical
   Branch for comments and suggestions. We also thank Dr. YukChing Tse Dinh
   (Florida International University), Dr. Yves Pommier (National Cancer
   Institute), Dr. Weidong Wang (National Institute on Aging), and Dr.
   Phillip A. Sharp (MIT) for important discussions and comments. We
   acknowledge support from the Uehara Foundation Fellowship (MH), NIH R01
   CA204806, Vacek Chair, and UTMB startup package (MGB), NIH R01 GM126412
   (MTB), NIH AI142759, and the Sealy & Smith, Kleberg, John S. Dunn, Amon
   G. Carter, Gilson Longenbaugh, and Summerfield Robert Foundations (PYS),
   NIH/NIAID T32 AI007526 (AH), R21 AI26012 and R01 AI134907 (RR), UTMB
   start up funds (VM).
CR Ahmad M, 2016, NUCLEIC ACIDS RES, V44, P6335, DOI 10.1093/nar/gkw508
   Anderson DE, 2019, MBIO, V10, DOI 10.1128/mBio.00826-19
   Barrows NJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45910-9
   Cote J, 2005, J BIOL CHEM, V280, P28476, DOI 10.1074/jbc.M414328200
   Kwan KY, 2001, P NATL ACAD SCI USA, V98, P5717, DOI 10.1073/pnas.101132498
   Le Sommer C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001820
   Pommier Y, 2016, NAT REV MOL CELL BIO, V17, P703, DOI 10.1038/nrm.2016.111
   Rialdi A, 2016, SCIENCE, V352, DOI 10.1126/science.aad7993
   Sessions OM, 2009, NATURE, V458, P1047, DOI 10.1038/nature07967
   Siaw GEL, 2016, P NATL ACAD SCI USA, V113, pE5544, DOI 10.1073/pnas.1605517113
   Stoll G, 2013, NAT NEUROSCI, V16, P1228, DOI 10.1038/nn.3484
   Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Xu DY, 2013, NAT NEUROSCI, V16, P1238, DOI 10.1038/nn.3479
   Yang YZ, 2014, MOL CELL, V53, P484, DOI 10.1016/j.molcel.2014.01.011
   Zhanel George G, 2006, Treat Respir Med, V5, P437, DOI 10.2165/00151829-200605060-00009
NR 16
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD OCT
PY 2020
VL 182
AR 104874
DI 10.1016/j.antiviral.2020.104874
PG 5
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA OA6JQ
UT WOS:000577889300001
PM 32735900
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Kossoff, EH
   Turner, Z
   Adams, J
   Bessone, SK
   Avallone, J
   McDonald, TJW
   Diaz-Arias, L
   Barron, BJ
   Vizthum, D
   Cervenka, MC
AF Kossoff, Eric H.
   Turner, Zahava
   Adams, Jamie
   Bessone, Stacey K.
   Avallone, Jennifer
   McDonald, Tanya J. W.
   Diaz-Arias, Luisa
   Barron, Bobbie J.
   Vizthum, Diane
   Cervenka, Mackenzie C.
TI Ketogenic diet therapy provision in the COVID-19 pandemic: Dual-center
   experience and recommendations
SO EPILEPSY & BEHAVIOR
LA English
DT Article
DE Ketogenic; Diet; Pandemic; Telemedicine; Telehealth; Atkins
ID EPILEPSY; TELEMEDICINE
AB The current coronavirus-19 pandemic has changed dramatically how neurologists care for children and adults with epilepsy. Stay-at-home orders and resistance to hospitalizations by patients have led epileptologists to engage in telemedicine and reevaluate how to provide elective services. Ketogenic diet therapy is often started in the hospital, with families educated in hospital-based classes, but this is difficult to do in this current pandemic. At our two academic centers, both our pediatric and adult epilepsy diet centers have had to quickly consider alternative methods to both start and maintain ketogenic diet therapy. This paper provides several examples of how ketogenic diet therapy can be provided to patients in unique ways, along with recommendations from other experts and patients, learned over the past few months. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Kossoff, Eric H.] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA.
   [Turner, Zahava; Adams, Jamie] Johns Hopkins Univ Hosp, Dept Pediat, Div Nutr, Baltimore, MD 21287 USA.
   [Bessone, Stacey K.] Johns Hopkins Univ, Sch Med, Dept Nutr Serv, Baltimore, MD 21218 USA.
   [Avallone, Jennifer] Johns Hopkins Univ, Sch Med, Johns Hopkins All Childrens Hosp, Inst Brain Protect Sci, St Petersburg, FL USA.
   [Kossoff, Eric H.; McDonald, Tanya J. W.; Diaz-Arias, Luisa; Cervenka, Mackenzie C.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA.
   [Barron, Bobbie J.; Vizthum, Diane] Johns Hopkins Univ, Sch Med, Inst Clin & Translat Res, Baltimore, MD USA.
RP Kossoff, EH (corresponding author), Suite 2158,200 North Wolfe St, Baltimore, MD 21287 USA.
EM ekossoff@jhmi.edu
FU NCATS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1 TR001079] Funding Source: Medline;
   NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R01 NS075020] Funding Source: Medline
CR Ahmed SN, 2008, EPILEPSIA, V49, P573, DOI 10.1111/j.1528-1167.2007.01464.x
   Cervenka MC, 2016, EPILEPSY BEHAV, V58, P61, DOI 10.1016/j.yebeh.2016.02.038
   Cervenka MC, 2012, EPILEPSIA, V53, P728, DOI 10.1111/j.1528-1167.2012.03406.x
   French JA, 2020, NEUROLOGY, V94, P1032, DOI 10.1212/WNL.0000000000009632
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hatcher-Martin JM, 2020, NEUROLOGY, V94, P30, DOI 10.1212/WNL.0000000000008708
   Kissani N, 2020, EPILEPSY BEHAV, V103, DOI 10.1016/j.yebeh.2019.106854
   Kossoff Eric H, 2018, Epilepsia Open, V3, P175, DOI 10.1002/epi4.12225
   Kossoff EH, 2015, EPILEPSIA, V56, P1337, DOI 10.1111/epi.13039
   Leenen LAM, 2016, EPILEPSY BEHAV, V64, P268, DOI 10.1016/j.yebeh.2016.08.007
   Santos-Peyret A, 2020, REV NEUROLOGIA, V70, P323, DOI 10.33588/rn.7009.2020173
NR 11
TC 3
Z9 3
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD OCT
PY 2020
VL 111
AR 107181
DI 10.1016/j.yebeh.2020.107181
PG 6
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA NZ8BU
UT WOS:000577327900018
PM 32512472
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Abeygunasekera, A
   Jayasinghe, S
AF Abeygunasekera, Anuruddha
   Jayasinghe, Saroj
TI Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?
SO MEDICAL HYPOTHESES
LA English
DT Article
DE SARS-CoV-2; Corona; COVID-19; Diethyl carbamazine DEC
AB SARS-CoV-2 virus has resulted in a devastating pandemic of COVID-19. Exploring compounds that could offer a breakthrough in treatment is the need of the hour. Re-positioning cheap, freely available and safe drugs is a priority. The paper proposes evidence for the potential use of diethylcarbamazine (DEC) in the treatment of COVID-19. DEC has inhibitory effects on arachidonic acid metabolism to prostaglandins, little known anti-viral effects on animal retroviruses and demonstrated anti-inflammatory actions in animal models of lung inflammation indicating the need to explore this hypothesis further. We believe this is the first time DEC is being proposed to treat COVID-19.
C1 [Abeygunasekera, Anuruddha] Colombo South Teaching Hosp, Dehiwala 10350, Sri Lanka.
   [Jayasinghe, Saroj] Univ Colombo, Fac Med, Kynsey Rd, Colombo 00800, Sri Lanka.
RP Jayasinghe, S (corresponding author), Univ Colombo, Fac Med, Kynsey Rd, Colombo 00800, Sri Lanka.
EM amabey@sltnet.lk; saroj@clinmed.cmb.ac.lk
CR Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Fang CH, 2020, ADV 21ST CENT HUMAN, P39, DOI 10.1007/978-981-13-6709-0_2
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   KITCHEN LW, 1990, J CLIN LAB IMMUNOL, V33, P97
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Maduwa Kumara, ASIAN J UROL, DOI [10.1016/j.ajur.2020.03.003, DOI 10.1016/J.AJUR.2020.03.003]
   Medina-De la Garza CE, 2012, IMMUNOPHARM IMMUNOT, V34, P477, DOI 10.3109/08923973.2011.630008
   Peixoto CA, 2014, EUR J PHARMACOL, V734, P35, DOI 10.1016/j.ejphar.2014.03.046
   Ribeiro EL, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/105120
   Sakaguchi Y, 2006, LIFE SCI, V79, P442, DOI 10.1016/j.lfs.2006.01.022
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Vijay R, 2015, J EXP MED, V212, P1851, DOI 10.1084/jem.20150632
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhao JC, 2011, J CLIN INVEST, V121, P4921, DOI 10.1172/JCI59777
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 19
TC 3
Z9 3
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109843
DI 10.1016/j.mehy.2020.109843
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800016
OA Green Published
DA 2021-01-01
ER

PT J
AU Acharya, R
AF Acharya, Rituparna
TI Prospective vaccination of COVID-19 using shRNA-plasmid-LDH
   nanoconjugate
SO MEDICAL HYPOTHESES
LA English
DT Letter
DE COVID-19; SARS-CoV-2; shRNA; LDH; Plasmid; Gel mobility assay; XRD
ID RNAS
AB COVID-19 is the pandemic outbreak that is caused by SARS-CoV-2 virus from December, 2019. Human race do not know the curative measure of this devastating disease. In today's era of nanotechnology, it may use its knowledge to develop molecular vaccine to combat this disease. In this article we are intended to propose a hypothesis on the development of a vaccine that is molecular in nature to work against COVID-19. The nanoconjugate may comprise with the inorganic nanoparticle layered double hydroxide intercalated with shRNAplasmid that have a sequence targeting towards the viral genome or viral mRNA. This nanoconjugate may be used as a nasal spray to deliver the shRNA-plasmid to the target site. The nanoconjugate will have several advantages such as they are biocompatible, they forms as stable knockdown to the target cells and they are stable in the nasal mucosa.
C1 [Acharya, Rituparna] Jadavpur Univ, Sch Biosci & Engn, Kolkata 700032, India.
RP Acharya, R (corresponding author), Jadavpur Univ, Sch Biosci & Engn, Kolkata 700032, India.
EM rituparnaacharya@rediffmail.com
CR Acharya R, 2020, B MATER SCI, V43, DOI 10.1007/s12034-019-1976-0
   Acharya R, 2019, MAT SCI ENG C-MATER, V104, DOI 10.1016/j.msec.2019.109928
   Acharya R, 2019, J DRUG DELIV SCI TEC, V52, P500, DOI 10.1016/j.jddst.2019.05.008
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Moore CB, 2010, METHODS MOL BIOL, V629, P139, DOI 10.1007/978-1-60761-657-3_10
   Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002
   Peiris J. S. M., 2012, Medical microbiology: a guide to microbial infections: pathogenesis, immunity, laboratory investigation and control, P587
NR 8
TC 1
Z9 1
U1 2
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110084
DI 10.1016/j.mehy.2020.110084
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800129
PM 32663741
OA Green Published
DA 2021-01-01
ER

PT J
AU Almerie, MQ
   Kerrigan, DD
AF Almerie, Muhammad Qutayba
   Kerrigan, David Daniel
TI The association between obesity and poor outcome after COVID-19
   indicates a potential therapeutic role for montelukast
SO MEDICAL HYPOTHESES
LA English
DT Article
ID CYSTEINYL LEUKOTRIENES; CYTOKINE STORM; CORONAVIRUS
AB It is widely believed that infection with the SARS-CoV-2 virus triggers a disproportionate immune response which causes a devastating systemic injury, particularly in individuals with obesity, itself a chronic, multi-organ inflammatory disease. Immune cells accumulate in visceral adipose tissue and together with paracrine adipocytes release a wide range of biologically active cytokines (including IL-1 ss, IL5, IL6 and IL8) that can result in both local, pulmonary and systemic inflammation. A more intense `cytokine storm' is postulated as the mechanism behind the extreme immune response seen in severe COVID-19.
   It is striking how dangerous the combination of obesity and COVID-19 is, resulting in a greater risk of ICU admission and a higher mortality. Furthermore, patients from a BAME background appear to have increased mortality after SARS-CoV-2 infection; they also have a higher prevalence of central obesity and its metabolic complications.
   In the absence of an effective vaccine, the therapeutic potential of immune-modulating drugs is a priority, but the development of new drugs is expensive and time-consuming. A more pragmatic solution would be to seek to repurpose existing drugs, particularly those that might suppress the heightened cytokine activity seen in obesity, the major risk factor for a poor prognosis in COVID-19.
   Montelukast is a cysteinyl leukotriene receptor antagonist licensed to treat asthma and allergic rhinitis. It has been shown to diminish pulmonary response to antigen, tissue eosinophilia and IL-5 expression in inflammatory cells. It has also been shown to decrease elevated levels of IL-1 ss and IL8 in humans with viral upper respiratory tract infections compared with placebo-treated patients. In addition, in silico studies have demonstrated a high binding affinity of the montelukast molecule to the terminal site of the virus's main protease enzyme which is needed for virus RNA synthesis and replication.
   Montelukast, which is cheap, safe and widely available would appear to have the potential to be an ideal candidate drug for clinical trials, particularly in early stage disease before irreparable tissue damage has already occurred. Hypothesis: Through a direct anti-viral effect, or by suppression of heightened cytokine release in response to SARS-CoV-2, montelukast will reduce the severity of immune-mediated multiorgan damage resulting from COVID-19, particularly in patients with central obesity and metabolic syndrome.
C1 [Almerie, Muhammad Qutayba] Phoenix Hlth, Chester CH1 6LT, Cheshire, England.
   [Kerrigan, David Daniel] British Obes & Metab Surg Soc, Belfast, Antrim, North Ireland.
   [Kerrigan, David Daniel] Univ Chester, Chester, Cheshire, England.
   [Kerrigan, David Daniel] Phoenix Hlth, Swanley, England.
RP Kerrigan, DD (corresponding author), British Obes & Metab Surg Soc, Belfast, Antrim, North Ireland.; Kerrigan, DD (corresponding author), Univ Chester, Chester, Cheshire, England.; Kerrigan, DD (corresponding author), Phoenix Hlth, Swanley, England.
EM david.kerrigan@phoenix-health.co.uk
CR Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Docherty A.B., 2020, FEATURES 16749 HOSP, DOI [10.1101/2020.04.23.20076042thisversion, DOI 10.1101/2020.04.23.20076042]
   Farag A, 2020, IDENTIFICATION FDA A
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Georghiou T, ARE MORE BLACK ASIAN
   Han MS, 2020, P NATL ACAD SCI USA, V117, P2751, DOI 10.1073/pnas.1920004117
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ihaku D, 1999, J ALLERGY CLIN IMMUN, V104, P1147, DOI 10.1016/S0091-6749(99)70006-0
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503
   Khunti K, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1548
   Kim CS, 2006, INT J OBESITY, V30, P1347, DOI 10.1038/sj.ijo.0803259
   LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Peters-Golden M, 2006, CLIN EXP ALLERGY, V36, P689, DOI 10.1111/j.1365-2222.2006.02498.x
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Schad C, 2008, J ALLERGY CLIN IMMUN, V121, pS74, DOI 10.1016/j.jaci.2007.12.294
   Schmidt FM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121971
   Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8
   Tillin T, 2012, INT J EPIDEMIOL, V41, P33, DOI 10.1093/ije/dyq175
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wu C, 2020, ACTA PHARM SIN B, DOI [10.1016/j.apsb/2020.02.008, DOI 10.1016/J.APSB/2020.02.008]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 29
TC 4
Z9 4
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109883
DI 10.1016/j.mehy.2020.109883
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800063
PM 32492562
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Beyazit, F
   Beyazit, Y
   Tanoglu, A
   Haznedaroglu, IC
AF Beyazit, Fatma
   Beyazit, Yavuz
   Tanoglu, Alpaslan
   Haznedaroglu, Ibrahim C.
TI Ankaferd hemostat (ABS) as a potential mucosal topical agent for the
   management of COVID-19 syndrome based on its PAR-1 inhibitory effect and
   oestrogen content
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Ankaferd hemostat; Oestrogen; PAR-1; SARS-CoV-2; COVID-19
ID BREAST-CANCER; BLOOD STOPPER; IN-VIVO; ACTIVATED RECEPTORS;
   ENDOTHELIAL-CELLS; EFFICACY; PATIENT; VITRO
AB COVID-19 due to the SARS-CoV-2 infection is a multi-systemic immune syndrome affecting mainly the lungs, oropharyngeal region, and other vascular endothelial beds. There are tremendous ongoing efforts for the aim of developing drugs against the COVID-19 syndrome-associated inflammation. However, currently no specific medicine is present for the absolute pharmacological cure of COVID-19 mucositis. The re-purposing/re-positioning of already existing drugs is a very important strategy for the management of ongoing pandemy since the development of a new drug needs decades. Apart from altering angiotensin signaling pathways, novel drug candidates for re-purposing comprise medications shall target COVID-19 pathobiology, including pharmaceutical formulations that antagonize proteinase-activated receptors (PARs), mainly PAR-1. Activation of the PAR-1, mediators and hormones impact on the hemostasis, endothelial activation, alveolar epithelial cells and mucosal inflammatory responses which are the essentials of the COVID-19 pathophysiology. In this context, Ankaferd hemostat (Ankaferd Blood Stopper, ABS) which is an already approved hemostatic agent affecting via vital erythroid aggregation and fibrinogen gamma could be a potential topical remedy for the mucosal management of COVID-19. ABS is a clinically safe and effective topical hemostatic agent of plant origin capable of exerting pleiotropic effects on the endothelial cells, angiogenesis, cell proliferation and vascular dynamics. ABS had been approved as a topically applied hemostatic agent for the management of post-surgical/dental bleedings and healing of infected inflammatory mucosal wounds. The anti-inflammatory and proteinase-activated receptor axis properties of ABS with a considerable amount of oestrogenic hormone presence highlight this unique topical hemostatic drug regarding the clinical re-positioning for COVID-19-associated mucositis. Topical ABS as a biological response modifier may lessen SARS-CoV-2 associated microthrombosis, endothelial dysfunction, oropharyngeal inflammation and mucosal lung damage. Moreover, PAR-1 inhibition ability of ABS might be helpful for reducing the initial virus propagation and mocasal spread of COVID-19.
C1 [Beyazit, Fatma] Canakkale Onsekiz Mart Univ, Dept Obstet & Gynecol, Canakkale, Turkey.
   [Beyazit, Yavuz] Canakkale Onsekiz Mart Univ, Dept Gastroenterol, Canakkale, Turkey.
   [Tanoglu, Alpaslan] Sultan Abdulhamid Han Training & Res Hosp, Dept Gastroenterol, Istanbul, Turkey.
   [Haznedaroglu, Ibrahim C.] Hacettepe Univ, Dept Hematol, Fac Med, Ankara, Turkey.
RP Beyazit, Y (corresponding author), Canakkale Onsekiz Mart Univ, Dept Gastroenterol, Canakkale, Turkey.
EM yavuzbeyazit@comu.edu.tr
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Ardicoglu Y, 2016, TURK J HEMATOL, V33, P261, DOI 10.4274/tjh.2015.0143
   Atay MH, 2015, UHOD-ULUSLAR HEMATOL, V25, P166, DOI 10.4999/uhod.15811
   Balcik O, 2012, INT J LAB HEMATOL, V32, P126
   Berghofer B, 2006, J IMMUNOL, V177, P2088, DOI 10.4049/jimmunol.177.4.2088
   Beyazit F, 1992, REV ASSOC MED BRAS, V2019, P183
   Beyazit Y, 2011, WORLD J GASTROENTERO, V17, P3962, DOI 10.3748/wjg.v17.i35.3962
   Beyazit Y, 2010, ALTERN MED REV, V15, P329
   Buyuk B, 2019, TURK J OBSTET GYNECO, V16, P7, DOI 10.4274/tjod.galenos.2018.21298
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Che SPY, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00261
   Chu HW, 2014, HUM MOL GENET, V23, P355, DOI 10.1093/hmg/ddt426
   Ciftciler R, 2020, UHOD-ULUSLAR HEMATOL, V30, P113, DOI 10.4999/uhod.204171
   Ciftciler Rafiye, 2020, Turk J Med Sci, V50, P1739, DOI 10.3906/sag-1908-161
   Ciftciler R, 2020, SAGE OPEN MED, V8, DOI 10.1177/2050312120907811
   Ciftciler R, 2019, TURK J MED SCI, V49, P347, DOI 10.3906/sag-1807-206
   Ciftciler R, 2019, TURK J MED SCI, V49, P356, DOI 10.3906/sag-1808-60
   Ciftciler R, 2018, TURK J HEMATOL, V35, P302, DOI 10.4274/tjh.2018.0254
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Demiralp DO, 2010, TURK J HEMATOL, V27, P70, DOI 10.5152/tjh.2010.03
   Deveci A, 2013, MIKROBIYOL BUL, V47, P71
   Eroglu A, 2012, ANN SURG ONCOL, V19, P1365, DOI 10.1245/s10434-011-1969-8
   Fan SY, 2020, FUTURE MED CHEM, V12, P1565, DOI 10.4155/fmc-2020-0158
   Feng XD, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00301
   Goker Hakan, 2020, Turk J Med Sci, DOI 10.3906/sag-2005-395
   Gulec A, 2018, CLIN APPL THROMB-HEM, V24, P960, DOI 10.1177/1076029617737838
   Haggag Yusuf A, 2020, Med Hypotheses, V144, P109957, DOI 10.1016/j.mehy.2020.109957
   Haznedaroglu BZ, 2012, CRIT REV ONCOL HEMAT, V83, P21, DOI 10.1016/j.critrevonc.2011.10.006
   Haznedaroglu BZ, 2010, CLIN APPL THROMB-HEM, V16, P446, DOI 10.1177/1076029609343706
   Haznedaroglu IC, 2020, TURK J MED SCI, V50, P1434, DOI 10.3906/sag-2004-94
   Jin Z, 2020, EUR J PHARMACOL, V883, DOI 10.1016/j.ejphar.2020.173326
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Jose RJ, 2014, THORAX, V69, P190, DOI 10.1136/thoraxjnl-2013-204367
   Karabiyik A, 2012, TURK J HEMATOL, V29, P361, DOI [10.5152/tjh.2011.41, 10.5505/tjh.2012.90277]
   Karabiyik A, 2011, CLIN APPL THROMB-HEM, V17, pE165, DOI 10.1177/1076029610394437
   Khan D, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00635
   Kim S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33222-3
   Kocak E, 2013, SAUDI J GASTROENTERO, V19, P126, DOI 10.4103/1319-3767.111955
   Koluman A, 2017, TURK J HEMATOL, V34, P93, DOI 10.4274/tjh.2015.0073
   Kumaki Y, 2011, ANTIVIR RES, V90, P22, DOI 10.1016/j.antiviral.2011.02.003
   Liu Jun, 2010, Biol Sex Differ, V1, P6, DOI 10.1186/2042-6410-1-6
   McEachron TA, 2010, BLOOD, V116, P5037, DOI 10.1182/blood-2010-06-293126
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mihm S, 2020, J INNATE IMMUN, V12, P273, DOI 10.1159/000508076
   Nag JK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113451
   Ozturk O, 2015, GASTROINTEST ENDOSC, V81, P1048, DOI 10.1016/j.gie.2014.10.007
   Patiroglu T, 2018, TURK J HEMATOL, V35, P85, DOI 10.4274/tjh.2017.0320
   Pontecorvi P, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1657-3
   Posma JJ, 2019, ARTERIOSCL THROM VAS, V39, P13, DOI 10.1161/ATVBAHA.118.311655
   Salah Z, 2012, FASEB J, V26, P2031, DOI 10.1096/fj.11-194704
   Saribas Z, 2010, CENT EUR J MED, V5, P198, DOI 10.2478/s11536-009-0140-4
   Scully EP, 2020, NAT REV IMMUNOL, V20, P442, DOI 10.1038/s41577-020-0348-8
   Seillet C, 2012, BLOOD, V119, P454, DOI 10.1182/blood-2011-08-371831
   Simsek C, 2017, SAGE OPEN MED, V5, DOI 10.1177/2050312117722569
   Sriram K, 2020, BRIT J PHARMACOL, V177, P4971, DOI 10.1111/bph.15194
   Tas A, 2011, CLIN RES HEPATOL GAS, V35, P549, DOI 10.1016/j.clinre.2011.02.013
   Teker AM, 2009, INT J PEDIATR OTORHI, V73, P1742, DOI 10.1016/j.ijporl.2009.09.029
   Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265
   Turk C, 2020, J RENIN-ANGIO-ALDO S, V21, DOI 10.1177/1470320320928872
   Uzun O, 2014, ARCH BRONCONEUMOL, V50, P407, DOI 10.1016/j.arbres.2013.12.007
   Yang E, 2016, ONCOGENE, V35, P1529, DOI 10.1038/onc.2015.217
   Yilmaz E, 2011, TURK J HEMATOL, V28, P276, DOI 10.5152/tjh.2011.39
   Yururer D, 2009, CLIN APPL THROMB-HEM, V15, P545, DOI 10.1177/1076029608319880
   Zhu CH, 2014, INT J MOL SCI, V15, P10116, DOI 10.3390/ijms150610116
NR 64
TC 0
Z9 0
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110150
DI 10.1016/j.mehy.2020.110150
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800147
PM 32763660
OA Green Published
DA 2021-01-01
ER

PT J
AU Cure, E
   Cure, MC
AF Cure, Erkan
   Cure, Medine Cumhur
TI Alpha-lipoic acid may protect patients with diabetes against COVID-19
   infection
SO MEDICAL HYPOTHESES
LA English
DT Letter
ID GLUCOSE; ATPASE; NA+
AB COVID-19 pandemic is spreading rapidly worldwide, and drug selection can affect the morbidity and mortality of the disease positively or negatively. Alpha-lipoic acid (ALA) is a potent antioxidant and reduces oxidative stress and inhibits activation of nuclear factor-kappa B (NF-kappa B). ALA reduces ADAM17 activity and ACE2 upregulation. ALA is known to have antiviral effects against some viruses. ALA may show antiviral effect by reducing NF-kappa B activation and alleviating redox reactions. ALA increases the intracellular glutathione strengthens the human host defense. ALA activates ATP dependent K+ channels (Na+, K+-ATPase). Increased K+ in the cell raises the intracellular pH. As the intracellular pH increases, the entry of the virus into the cell decreases. ALA can increase human host defense against SARS-CoV-2 by increasing intracellular pH. ALA treatment increases antioxidant levels and reduces oxidative stress. Thus, ALA may strengthen the human host defense against SARS-CoV-2 and can play a vital role in the treatment of patients with critically ill COVID-19. It can prevent cell damage by decreasing lactate production in patients with COVID-19. Using ALA with insulin in patients with diabetes can show a synergistic effect against SARS-CoV-2. We think ALA treatment will be beneficial against COVID-19 in patients with diabetes.
C1 [Cure, Erkan] Ota & Jinemed Hosp, Dept Internal Med, Muradiye Mahallesi,Nuzhetiye Cad, TR-34357 Istanbul, Turkey.
   [Cure, Medine Cumhur] Dept Biochem, Istanbul, Turkey.
RP Cure, E (corresponding author), Ota & Jinemed Hosp, Dept Internal Med, Muradiye Mahallesi,Nuzhetiye Cad, TR-34357 Istanbul, Turkey.
EM erkancure@yahoo.com; medinecure@yahoo.com
CR Ansar H, 2011, SAUDI MED J, V32, P584
   Cure E, 2020, J NEUROIMMUNE PHARM, V15, P345, DOI 10.1007/s11481-020-09938-3
   Cure E, 2020, AM J CARDIOL, V125, P1602, DOI 10.1016/j.amjcard.2020.03.001
   Cure E, 2020, DIABETES METAB SYND, V14, P405, DOI 10.1016/j.dsx.2020.04.024
   Cure E, 2020, DIABETES METAB SYND, V14, P349, DOI 10.1016/j.dsx.2020.04.019
   Cure E, 2020, J MED VIROL, V92, P1423, DOI 10.1002/jmv.25848
   de Queiroz TM, 2015, AM J PHYSIOL-HEART C, V309, pH926, DOI 10.1152/ajpheart.00259.2015
   Dudek M, 2016, ANATOL J CARDIOL, V16, P306, DOI 10.5152/AnatolJCardiol.2015.6217
   Farhat D, 2020, BRIT J CANCER, DOI 10.1038/s41416-020-0729-6
   Golbidi S, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00069
   Hsu JL, 2015, ONCOTARGET, V6, P24032, DOI 10.18632/oncotarget.4429
   James JH, 1999, AM J PHYSIOL-ENDOC M, V277, pE176
   Konrad T, 1999, DIABETES CARE, V22, P280, DOI 10.2337/diacare.22.2.280
   Kucuk A, 2020, CLIN RHEUMATOL, V39, P2103, DOI 10.1007/s10067-020-05178-1
   NAKASHIMA RA, 1982, J BIOL CHEM, V257, P9252
   Pal R, 2020, DIABETES RES CLIN PR, V163, DOI 10.1016/j.diabres.2020.108146
   Palau V, 2020, NEPHROL DIAL TRANSPL, V35, P1071, DOI 10.1093/ndt/gfaa093
   Spisakova M, 2009, ANTIVIR RES, V81, P156, DOI 10.1016/j.antiviral.2008.11.001
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhong M, 2020, SINGLE BLIND GROUP S, DOI [10.1101/2020.04.15.20066266., DOI 10.1101/2020.04.15.20066266]
NR 20
TC 0
Z9 0
U1 3
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110185
DI 10.1016/j.mehy.2020.110185
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800052
PM 33017914
OA Green Published
DA 2021-01-01
ER

PT J
AU DiNicolantonio, JJ
   Barroso-Aranda, J
AF DiNicolantonio, James J.
   Barroso-Aranda, Jorge
TI Harnessing adenosine A2A receptors as a strategy for suppressing the
   lung inflammation and thrombotic complications of COVID-19: Potential of
   pentoxifylline and dipyridamole
SO MEDICAL HYPOTHESES
LA English
DT Article
ID SIMPLEX-VIRUS REACTIVATION; BETA-GLUCAN; IN-VIVO; PULMONARY
   INFLAMMATION; MAGNESIUM-DEFICIENCY; NEUTROPHIL ADHESION; PLUS
   PENTOXIFYLLINE; IMMUNE-RESPONSES; INHIBITION; INJURY
AB Counterproductive lung inflammation and dysregulated thrombosis contribute importantly to the lethality of advanced COVID-19. Adenosine A2A receptors (A2AR), expressed by a wide range of immune cells, as well as endothelial cells and platelets, exert cAMP-mediated anti-inflammatory and anti-thrombotic effects that potentially could be highly protective in this regard. The venerable drug pentoxifylline (PTX) exerts both anti-inflammatory and antithrombotic effects that reflect its ability to boost the responsiveness of A2AR to extracellular adenosine. The platelet-stabilizing drug dipyridamole (DIP) blocks intracellular uptake of extracellularly-generated adenosine, thereby up-regulating A2AR signaling in a way that should be functionally complementary to the impact of PTX in that regard. Moreover, DIP has recently been reported to slow the cellular replication of SARS-CoV-2 in clinically feasible concentrations. Both PTX and DIP are reasonably safe, well-tolerated, widely available, and inexpensive drugs. When COVID-19 patients can be treated within several days of symptom onset, using PTX + DIP in conjunction with hydroxychloroquine (HCQ) and an antibiotic - azithromycin (AZM) or doxycycline - might be warranted. HCQ and AZM can suppress SARS-CoV-2 proliferation in vitro and may slow the cell-to-cell spread of the virus; a large case series evaluating this combination in early-stage patients reported an impressively low mortality rate. However, whereas HCQ and AZM can promote QT interval lengthening and may be contraindicated in more advanced COVID-19 entailing cardiac damage, doxycycline has no such effect and exerts a potentially beneficial anti-inflammatory action. In contrast to HCQ, we propose that the combination of PTX+ DIP can be used in both early and advanced stages of COVID-19. Concurrent use of certain nutraceuticals - yeast beta-glucan, zinc, vitamin D, spirulina, phase 2 inducers, N-acetylcysteine, glucosamine, quercetin, and magnesium - might also improve therapeutic outcomes in COVID-19.
C1 [DiNicolantonio, James J.] Mid Amer Heart Inst, Kansas City, MO 64111 USA.
   [Barroso-Aranda, Jorge] Clin Libre Adicc, Tijuana, BC, Mexico.
RP DiNicolantonio, JJ (corresponding author), Mid Amer Heart Inst, Kansas City, MO 64111 USA.
EM jjdinicol@gmail.com
CR Aggarwal NR, 2013, AM J RESP CELL MOL, V48, P635, DOI 10.1165/rcmb.2012-0351OC
   Ali RA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09801-x
   Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005
   ARDIZZOIA A, 1993, SUPPORT CARE CANCER, V1, P331, DOI 10.1007/BF00364972
   ARMSTRONG M, 1990, ANGIOLOGY, V41, P253, DOI 10.1177/000331979004100401
   Babayigit H, 2005, INTENS CARE MED, V31, P865, DOI 10.1007/s00134-005-2629-x
   Balakumar P, 2014, PHARMACOL RES, V87, P144, DOI 10.1016/j.phrs.2014.05.008
   BARROSOARANDA J, 1990, PENTOXIFYLLINE AND ANALOGUES : EFFECTS ON LEUKOCYTE FUNCTION, P97
   BARROSOARANDA J, 1990, BIORHEOLOGY, V27, P401
   Beard JA, 2011, J CLIN VIROL, V50, P194, DOI 10.1016/j.jcv.2010.12.006
   Bedirli A, 2007, SHOCK, V27, P397, DOI 10.1097/01.shk.0000245030.24235.f1
   Bermejo Martin Jesus Fco, 2003, Med Sci Monit, V9, pSR29
   Brice DC, 2020, CURR MED CHEM, V27, P1420, DOI 10.2174/0929867326666190805151654
   Brie D, 2016, J HYPERTENS, V34, P2318, DOI 10.1097/HJH.0000000000001086
   BROZNA JP, 1990, THROMB RES, V60, P141, DOI 10.1016/0049-3848(90)90293-L
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Charles B Sheba, 2016, J Assoc Physicians India, V64, P15
   Chello M, 1999, ANN THORAC SURG, V67, P1277, DOI 10.1016/S0003-4975(99)00173-3
   Chorin E, 2020, HEART RHYTHM
   Chuang KH, 2013, AM J RESP CELL MOL, V49, P1110, DOI 10.1165/rcmb.2013-0022OC
   Cicek G, 2016, CORONARY ARTERY DIS, V27, P47, DOI 10.1097/MCA.0000000000000318
   Conforti C, 2020, DERMATOL THER, V20
   CRONSTEIN BN, 1983, J EXP MED, V158, P1160, DOI 10.1084/jem.158.4.1160
   Damle B, 2020, CLIN PHARMACOL THER, V108, P201, DOI 10.1002/cpt.1857
   Deree J, 2007, J SURG RES, V143, P99, DOI 10.1016/j.jss.2007.03.083
   DiNicolantonio JJ, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109800
   DiNicolantonio JJ, 2020, IVERMECTIN MAY BE CL
   DUFOUR E, 1988, BIOCHIM BIOPHYS ACTA, V955, P58, DOI 10.1016/0167-4838(88)90179-3
   Escher R, 2020, THROMB RES, V190, P62, DOI 10.1016/j.thromres.2020.04.014
   Fata-Hartley CL, 2005, J VIROL, V79, P11062, DOI 10.1128/JVI.79.17.11062-11070.2005
   Folkesson HG, 2012, AM J PHYSIOL-LUNG C, V303, pL259, DOI 10.1152/ajplung.00395.2011
   FOX RI, 1993, SEMIN ARTHRITIS RHEU, V23, P82, DOI 10.1016/S0049-0172(10)80012-5
   Fredholm BB, 1996, NAUNYN SCHMIEDEBERGS
   Gonzales JN, 2014, AM J PHYSIOL-LUNG C, V306, pL497, DOI 10.1152/ajplung.00086.2013
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Gromova OA, 2018, KARDIOLOGIYA, V58, P22, DOI 10.18087/cardio.2018.4.10106
   Guerrero A, 2018, CURR MED CHEM, V25, P3597, DOI 10.2174/0929867325666180313110254
   Hallevi H, 2007, EUR J NEUROL, V14, P1002, DOI 10.1111/j.1468-1331.2007.01847.x
   Hasko G, 2009, TRENDS IMMUNOL, V30, P263, DOI 10.1016/j.it.2009.04.001
   Hassanian SM, 2014, J CELL PHYSIOL, V229, P1292, DOI 10.1002/jcp.24568
   Hay KA, 1996, J MED VIROL, V50, P198
   Helms J, 2020, INTENSIVE CARE MED, DOI 10.1007/s00134-020-06062-x
   Hwang JS, 2019, J BIOL CHEM, V294, P608, DOI 10.1074/jbc.RA118.004638
   IWAMOTO T, 1994, BIOCHEM BIOPH RES CO, V199, P905, DOI 10.1006/bbrc.1994.1314
   Jiang P, 2017, SHOCK, V47, P288, DOI 10.1097/SHK.0000000000000769
   Konrad FM, 2013, FASEB J, V27, P3524, DOI 10.1096/fj.13-228122
   Korbecki M, 1985, Mol Gen Mikrobiol Virusol, P29
   Krakauer T, 2000, IMMUNOPHARMACOLOGY, V46, P253, DOI 10.1016/S0162-3109(99)00186-1
   Kreth S, 2010, SHOCK, V34, P10, DOI 10.1097/SHK.0b013e3181cdc3e2
   KUZMOV K, 1985, ZH MIKROB EPID IMMUN, P26
   LEVI M, 1994, J CLIN INVEST, V93, P114, DOI 10.1172/JCI116934
   LEVRAUX V, 1993, LIFE SCI, V52, P1917, DOI 10.1016/0024-3205(93)90632-D
   Li HL, 2016, AM J TRANSL RES, V8, P2210
   Li L, 2012, J CLIN INVEST, V122, P3931, DOI 10.1172/JCI63170
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu X, 2020, ACTA PHARM SIN B
   Liu ZH, 2013, J SURG RES, V180, P310, DOI 10.1016/j.jss.2012.04.045
   Marik PE, 2020, MED DRUG DISCOV, V29
   McCarty M. F., 2016, OPEN HEART, V3, P1
   McCarty MF, 2020, PROG CARDIOVASC DIS
   MCDONALD RJ, 1991, AM REV RESPIR DIS, V144, P1347, DOI 10.1164/ajrccm/144.6.1347
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Mercuro NJ, 2020, JAMA CARDIOL
   Milne GR, 2011, THESCIENTIFICWORLDJO, V11, P320, DOI 10.1100/tsw.2011.22
   Muller-Calleja N, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-210012
   Naksuk N, 2020, EUR HEART J-ACUTE CA, V9, P215, DOI 10.1177/2048872620922784
   Nielsen FH, 2018, J INFLAMM RES, V11, P25, DOI 10.2147/JIR.S136742
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Peng DH, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109984
   Prasad AS, 2007, AM J CLIN NUTR, V85, P837
   PRYKE AM, 1990, J CELL PHYSIOL, V142, P652, DOI 10.1002/jcp.1041420327
   Ramireddy A, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017144
   Rhodes JM, 2020, ALIMENT PHARM THER
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   SANTOS MT, 1985, PROSTAGLANDINS, V29, P113, DOI 10.1016/0090-6980(85)90156-X
   SANTOS MT, 1993, THROMB RES, V72, P219, DOI 10.1016/0049-3848(93)90189-U
   Schepp CP, 2008, CRIT CARE, V12, DOI 10.1186/cc6990
   Schmith VD, 2020, CLIN PHARM THER, DOI 10.1002/cpt.1889
   Shechter M, 2000, AM HEART J, V140, P212, DOI 10.1067/mhj.2000.107553
   Sheu JR, 2003, INT J HEMATOL, V77, P414
   Shi S, 2020, J ETHNOPHARMACOL, V256, DOI 10.1016/j.jep.2020.112780
   Silva JF, 2020, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01614
   Sobczak AIS, 2020, THROMB HAEMOSTASIS, V120, P243, DOI 10.1055/s-0039-3402808
   Song N, 2019, CELL REP, V28, P2386, DOI 10.1016/j.celrep.2019.07.085
   Sullivan GW, 1999, J INFECT DIS
   SUMMERS A, 1977, THROMB RES, V11, P611, DOI 10.1016/0049-3848(77)90019-6
   Suresh R, 2002, J IMMUNOL, V169, P4262, DOI 10.4049/jimmunol.169.8.4262
   SUZUKI S, 1992, EUR J PHARM-MOLEC PH, V227, P395, DOI 10.1016/0922-4106(92)90157-Q
   Talbott SM, 2012, J AM COLL NUTR, V31, P295, DOI 10.1080/07315724.2012.10720441
   Telcian AG, 2017, ANTIVIR RES, V137, P93, DOI 10.1016/j.antiviral.2016.11.004
   Tenser RB, 2001, ANTIMICROB AGENTS CH, V45, P3657, DOI 10.1128/AAC.45.12.3657-3659.2001
   Tripathi S, 2013, J GEN VIROL, V94, P40, DOI 10.1099/vir.0.045013-0
   Umapathy NS, 2010, VASC PHARMACOL, V52, P199, DOI 10.1016/j.vph.2009.12.008
   Varga Z, 2020, LANCET
   Vetvicka V, 2019, MOLECULES, V24, DOI 10.3390/molecules24071251
   Wang M, 2016, INT J BIOL MACROMOL, V93, P203, DOI 10.1016/j.ijbiomac.2016.06.057
   Wiedemann HP, 2002, CRIT CARE MED, V30, P1
   Wu YL, 2014, FREE RADICAL BIO MED, V69, P208, DOI 10.1016/j.freeradbiomed.2014.01.026
   Yang TZ, 2020, GENET EPIDEMIOL, V44, P880, DOI 10.1002/gepi.22348
   Yang ZD, 2005, BIOCHEM PHARMACOL, V69, P1, DOI 10.1016/j.bcp.2004.08.012
   Yao D, 2018, ARTERIOSCL THROM VAS, V38, P1309, DOI 10.1161/ATVBAHA.117.310468
   Yao X, 2020, CLIN INFECT DIS
   YAYA R, 1985, THROMB HAEMOSTASIS, V54, P896
   Ye LB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03314-9
   Zhang X, 2008, INFLAMM RES, V57, P524, DOI 10.1007/s00011-008-8007-8
NR 105
TC 1
Z9 1
U1 4
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110051
DI 10.1016/j.mehy.2020.110051
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800112
PM 32650197
OA Green Published
DA 2021-01-01
ER

PT J
AU Dixit, S
AF Dixit (Snehil), Snehil
TI Can moderate intensity aerobic exercise be an effective and valuable
   therapy in preventing and controlling the pandemic of COVID-19?
SO MEDICAL HYPOTHESES
LA English
DT Letter
C1 [Dixit (Snehil), Snehil] King Khalid Univ, Dept Med Rehabil Sci, Coll Appl Med Sci, Abha, Saudi Arabia.
RP Dixit, S (corresponding author), King Khalid Univ, Dept Med Rehabil Sci, Coll Appl Med Sci, Abha, Saudi Arabia.
EM snehildixit83@gmail.com
CR Barrett B, 2012, ANN FAM MED, V10, P337, DOI 10.1370/afm.1376
   Barrett J, 2018, J AUSTRALAS TAX TEAC, V13, P1
   Brill P, 2012, ACT ADAPT AGING, V36, P182, DOI 10.1080/01924788.2012.677794
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chubak J, 2006, AM J MED, V119, P937, DOI 10.1016/j.amjmed.2006.06.033
   Guan WJ, 2020, N ENGL J MED
   Jin YH, 2020, MILITARY MED RES, V7
   Nieman DC, 2019, J SPORT HEALTH SCI, V8, P201, DOI 10.1016/j.jshs.2018.09.009
   Nieman DC, PHYS ACTIVITY IMMUNE
   Nieman DC, 1999, CURRENT OPINION SPOR, V27
   Nieman DC, EFFECTS MODERATE EXE
   Scherr J, 2013, EUR J APPL PHYSIOL, V113, P147, DOI 10.1007/s00421-012-2421-x
   Sloan CA, 2013, INT J SPORTS MED, V34, P81, DOI 10.1055/s-0032-1314817
   Woods JA, 2009, J AM GERIATR SOC, V57, P2183, DOI 10.1111/j.1532-5415.2009.02563.x
   Zbinden-Foncea H, 2020, OBESITY, V28, P1378, DOI 10.1002/oby.22849
NR 15
TC 7
Z9 7
U1 1
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109854
DI 10.1016/j.mehy.2020.109854
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800020
PM 32464492
OA Green Published
DA 2021-01-01
ER

PT J
AU Fisher, HK
AF Fisher, H. K.
TI Hypoxemia in COVID-19 patients: An hypothesis
SO MEDICAL HYPOTHESES
LA English
DT Article
ID PATENT FORAMEN OVALE; BINDING; ACE2
AB The current SARS-Cov-2 virus pandemic challenges critical care physicians and other caregivers to find effective treatment for desperately ill patients - especially those with sudden and extreme hypoxemia. Unlike patients with other forms of Acute Respiratory Distress Syndrome, these patients do not exhibit increased lung stiffness or dramatic dyspnea., even in the presence of arterial blood oxygen levels lower than that seen normally in mixed venous blood. Urgent intubation and mechanical ventilation with high inflation pressures and raised inhaled oxygen concentration have proved unhelpful or worse, but why? Our Hypothesis is that sudden opening of a previously undetected probe-patent foramen ovale (PPFO) may explain this mystery. As hypoxemia without acidosis is a rather weak stimulus of dyspnea or increased ventilation, and opening of such an intracardiac shunt would not worsen lung mechanical properties, the absence of dramatic symptom changes would not be surprising. We point out the high frequency of PFO both in life and at autopsy, and the physiological evidence of large shunt fractions found in Covid-19 patients. Published evidence of hypercoagulability and abundant evidence of pulmonary emboli found at autopsy are in accord with our hypothesis, as they would contribute to raised pressure in the pulmonary arteries and right heart chambers, potentially causing a shunt to open. We review the interaction between viral corona spike protein and ACE-2 receptors present on the surface of alveolar lining cells, and contribution to hypercoagulabilty caused by the spike protein. Search for an open PFO after a large drop in arterial oxygen saturation can be performed at the bedside with a variety of well-established techniques including bedside echocardiography, nitrogen washout test, and imaging studies. Potential treatments might include balloon or patch closure of the shunt, and various drug treatments to lower pulmonary vascular resistance.
C1 [Fisher, H. K.] 910 S Gretna Green Way, Los Angeles, CA 90049 USA.
RP Fisher, HK (corresponding author), 910 S Gretna Green Way, Los Angeles, CA 90049 USA.
EM stlouisboy@icloud.com
CR [Anonymous], 2020, COVID 19 DASHBOARD C
   Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Braun MU, 2002, J AM COLL CARDIOL, V39, P2019, DOI 10.1016/S0735-1097(02)01904-6
   Carsana L, 2020, PULMONARY POSTMORTEM, DOI [10.1101/2020.04.19.2005462, DOI 10.1101/2020.04.19.2005462]
   Cha AE, 2020, WASHINGTON POST
   CLEMENTS JA, 1970, NEW ENGL J MED, V282, P976, DOI 10.1056/NEJM197004232821713
   Corno AF, 2004, ANN THORAC SURG, V78, P956, DOI 10.1016/j.athoracsur.2004.03.104
   Dondorp AM, 2020, AM J TROP MED HYG, V102, P1191, DOI 10.4269/ajtmh.20-0283
   Fox SE., PULMONARY CARDIAC PA, DOI [10.1101/2020.04.06.20050575, DOI 10.1101/2020.04.06.20050575]
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Gralinski LE, 2013, MBIO, V4, DOI 10.1128/mBio.00271-13
   Graves MW, 2003, RESP MED, V97, P549, DOI 10.1053/rmed.2003.1481
   Grillet F, 2020, RADIOLOGY, V296, pE186, DOI 10.1148/radiol.2020201544
   HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Kim H, 2020, RADIOLOGY, V296, pE145, DOI 10.1148/radiol.2020201343
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Levitan R., 2020, NY TIMES
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Liew Jean, 2018, Perm J, V22, P17, DOI 10.7812/TPP/17-061
   Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026
   MAEDA S, 1991, BRIT HEART J, V65, P132
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Poissy J, PULMONARY EMBOLISM C, DOI [10.1161/CirculationAHA.120.047430, DOI 10.1161/CIRCULATIONAHA.120.047430]
   Rawnsley A., 2020, CORONAVIRUS SNEAKS Y
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rotzinger D, 2020, THROMB RES, DOI [10.1016/j.thrombres.2020.04.011, DOI 10.1016/J.THROMBRES.2020.04.011]
   Spears JR, 2019, HYPOXIA, V7, P65, DOI 10.2147/HP.S217955
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tian S, 2020, J THORAC ONCOL, DOI [10.1016/jtho.2020.02.010, DOI 10.1016/JTHO.2020.02.010]
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Turner AJ, ACE2 CELL BIOL REGUL, DOI [10.1016/8978-0-12-801364-9.00025-0, DOI 10.1016/8978-0-12-801364-9.00025-0]
   Wadman M, BIOL CORONAVIRUS, DOI [10.1126/Science.abc3208, DOI 10.1126/SCIENCE.ABC3208]
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang YQ, 2020, EMERG MICROBES INFEC, V9, P246, DOI 10.1080/22221751.2020.1717999
   Wichmann D, 2020, ANNALS
   WILMSHURST PT, 1994, BRIT HEART J, V71, P209
   Zhang TT, 2015, J GERIATR CARDIOL, V12, P323, DOI 10.11909/j.issn.1671-5411.2015.03.005
NR 43
TC 1
Z9 1
U1 2
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110022
DI 10.1016/j.mehy.2020.110022
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800090
PM 32634734
OA Green Published
DA 2021-01-01
ER

PT J
AU Hoang, BX
   Hoang, HQ
   Han, B
AF Hoang, Ba X.
   Hoang, Huy Q.
   Han, Bo
TI Zinc Iodide in combination with Dimethyl Sulfoxide for treatment of
   SARS-CoV-2 and other viral infections
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Zinc Iodide; Dimethyl Sulfoxide; Viral Infection; COVID-19
ID SODIUM-BICARBONATE; GENE-EXPRESSION; KAPPA-B; REPLICATION; ACTIVATION;
   IMMUNITY; IONS
AB Zinc Iodide and Dimethyl Sulfoxide compositions are proposed as therapeutic agents to treat and prevent chronic and acute viral infections including SARS-CoV-2 infected patients. The therapeutic combinations have a wide range of virucidal effects on DNA and RNA containing viruses. The combinations also exhibit anti-inflammatory, immunomodulating, antifibrotic, antibacterial, antifungal and antioxidative effects. Given the fact that Zinc Iodide has been used as an oral antiseptic agent and DMSO has been already proven as a safe pharmaceutical solvent and therapeutic agent, we hypothesize that the combination of these two agents can be applied as an effective, safe and inexpensive treatment for SARS-CoV-2 and other viral infection. The therapeutic compound can be applied as both etiological and pathogenesis therapy and used as an effective and safe antiseptic (disinfectant) for human and animals as well.
C1 [Hoang, Ba X.; Han, Bo] Univ Southern Calif, Keck Sch Med, Dept Surg, Nimni Cordoba Tissue Engn & Drug Discovery Lab,Di, 1333 San Pablo St,BMT 302, Los Angeles, CA 90033 USA.
   [Hoang, Huy Q.] Nat Hlth Med Ctr, 4469 Redondo Beach Blvd, Lawndale, CA 90260 USA.
RP Hoang, BX (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Surg, Nimni Cordoba Tissue Engn & Drug Discovery Lab,Di, 1333 San Pablo St,BMT 302, Los Angeles, CA 90033 USA.
EM baxuanho@usc.edu
CR Bilal MY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01573
   Black R., 2003, PUBLIC HLTH
   Chang CK, 1999, J SURG RES, V82, P294, DOI 10.1006/jsre.1998.5527
   Chang CK, 2001, J SURG RES, V95, P181, DOI 10.1006/jsre.2000.6033
   Dardenne M, 2002, EUR J CLIN NUTR, V56, pS20, DOI 10.1038/sj.ejcn.1601479
   Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999
   Fischer AJ, 2011, AM J RESP CELL MOL, V45, P874, DOI 10.1165/rcmb.2010-0329OC
   Guo Q, 2016, ANTIMICROB AGENTS CH, V60, P7159, DOI 10.1128/AAC.01357-16
   Hoang Ba X, 2011, J Pain Palliat Care Pharmacother, V25, P350, DOI 10.3109/15360288.2011.606294
   Hoang Ba X, 2011, J Pain Palliat Care Pharmacother, V25, P19, DOI 10.3109/15360288.2010.536306
   Hoang Ba X., 2010, Inflammation & Allergy Drug Targets, V9, P306
   Hung M, 2002, ANTIVIR RES, V56, P99, DOI 10.1016/S0166-3542(02)00101-8
   Jernigan DB, 2020, MMWR-MORBID MORTAL W, P69
   Kaushik N, 2018, DNA CELL BIOL, V37, P593, DOI 10.1089/dna.2018.4175
   Kelly FC, 1961, IODINE MED PHARM ITS
   Klebanoff SJ, 2013, J LEUKOCYTE BIOL, V93, P185, DOI 10.1189/jlb.0712349
   Klossner BL, 1997, DERMATOLOGY, V195, P10
   Konig B, 1997, DERMATOLOGY, V195, P42, DOI 10.1159/000246029
   KORANT BD, 1974, NATURE, V248, P588, DOI 10.1038/248588a0
   Krenn BM, 2009, J VIROL, V83, P58, DOI 10.1128/JVI.01543-08
   Lanke K, 2007, J GEN VIROL, V88, P1206, DOI 10.1099/vir.0.82634-0
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Lio CWJ, 2020, IMMUNOLOGY, V161, P165, DOI 10.1111/imm.13207
   Luttikhuizen DT, 2006, TISSUE ENG, V12, P1955, DOI 10.1089/ten.2006.12.1955
   Maares M, 2016, ARCH BIOCHEM BIOPHYS, V611, P58, DOI 10.1016/j.abb.2016.03.022
   McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S
   OXFORD JS, 1974, J GEN VIROL, V23, P59, DOI 10.1099/0022-1317-23-1-59
   Paulson JA, 2014, PEDIATRICS, V133, P1163, DOI 10.1542/peds.2014-0900
   Prasad AS, 2008, EXP GERONTOL, V43, P370, DOI 10.1016/j.exger.2007.10.013
   Prasad AS, 2007, AM J CLIN NUTR, V85, P837
   Prasad AS, 2009, CURR OPIN CLIN NUTR, V12, P646, DOI 10.1097/MCO.0b013e3283312956
   Rerksuppaphol S, 2019, PEDIAT REPORTS, V11
   SINGH M, 2013, COCHRANE DATABASE SY
   Te Velthuis A.J., 2010, PLOS PATHOG, V6
   Yazar AS, 2016, TURK J GASTROENTEROL, V27, P537, DOI 10.5152/tjg.2016.16396
NR 35
TC 1
Z9 1
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109866
DI 10.1016/j.mehy.2020.109866
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800012
PM 32473509
OA Green Published
DA 2021-01-01
ER

PT J
AU Horowitz, RI
   Freeman, PR
AF Horowitz, Richard, I
   Freeman, Phyllis R.
TI Three novel prevention, diagnostic, and treatment options for COVID-19
   urgently necessitating controlled randomized trials
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Cytokine storm syndrome; Macrophage activation syndrome;
   Pneumonia; ARDS; DIC; N-Acetyl-cysteine; Glutathione; NF-kappa B; Nrf2
ID NF-KAPPA-B; ALPHA-LIPOIC ACID; OXIDATIVE STRESS; HEMOPHAGOCYTIC
   LYMPHOHISTIOCYTOSIS; VITAMIN-C; GLUTATHIONE; CYTOKINES; ZINC;
   IDENTIFICATION; PATHOGENESIS
AB Purpose: Asymptomatic or minimally symptomatic infection with COVID-19 can result in silent transmission to large numbers of individuals, resulting in expansion of the pandemic with a global increase in morbidity and mortality. New ways of screening the general population for COVID-19 are urgently needed along with novel effective prevention and treatment strategies.
   Hypothesis: A hypothetical three-part prevention, diagnostic, and treatment approach based on an up-to-date scientific literature review for COVID-19 is proposed. Regarding diagnosis, a validated screening questionnaire and digital app for COVID-19 could help identify individuals who are at risk of transmitting the disease, as well as those at highest risk for poor clinical outcomes. Global implementation and online tracking of vital signs and scored questionnaires that are statistically validated would help health authorities properly allocate essential health care resources to test and isolate those at highest risk for transmission and poor outcomes.
   Second, regarding prevention, no validated protocols except for physical distancing, hand washing, and isolation exist, and recently ivermectin has been published to have anti-viral properties against COVID-19. A randomized trial of ivermectin, and/or nutraceuticals that have been published to support immune function including glutathione, vitamin C, zinc, and immunomodulatory supplements (3,6 Beta glucan) could be beneficial in preventing transmission or lessening symptomatology but requires statistical validation.
   Third, concerning treatment, COVID-19 induced inflammation and "cytokine storm syndrome" with hemophagocytic lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS) have resulted in extreme morbidity and mortality in those with certain comorbidities, secondary to "acute respiratory distress syndrome" (ARDS) and multiorgan dysfunction with disseminated intravascular coagulation (DIC). Deficiency in red blood cell, serum and alveolar glutathione has been published in the medical literature for ARDS, as well as viral and bacterial pneumonias, resulting from increased levels of free radical/oxidative stress. A randomized controlled trial of blocking NF-?B and cytokine formation using glutathione precursors (N-acetyl-cysteine [NAC] and alpha lipoic acid) and PO/IV glutathione with associated anti-viral effects should be performed, along with an evaluation of Nrf2 activators (curcumin, sulforaphane glucosinolate) which have been scientifically proven to lower inflammation. Since high mortality rates from sepsis induced DIC due to COVID-19 infection has also been associated with thrombotic events and elevated levels of D-dimer, randomized controlled trials of using anticoagulant therapy with heparin is urgently required. This is especially important in patients on ventilators who have met certain sepsis induced coagulopathy (SIC) criteria. The use of acetazolamide with or without sildenafil also needs to be explored with or without heparin, since increased oxygen delivery to vital organs through prevention of thrombosis/pulmonary emboli along with carbonic anhydrase inhibition may help increase oxygenation and prevent adverse clinical outcomes.
   Conclusion and Implications: A three-part prevention, diagnostic, and treatment plan is proposed for addressing the severe complications of COVID-19. Digital monitoring of symptoms to clinically diagnose early exposure and response to treatment; prevention with ivermectin as well as nutritional therapies that support a healthy immune response; treatment with anti-inflammatory therapies that block NF-?B and activate Nrf2 pathways, as well as novel therapies that address COVID-19 pneumonia and ARDS with DIC including anticoagulation and/or novel respiratory therapies with or without acetazolamide and sildenafil. These three broad-based interventions urgently need to be subjected to randomized, controlled trials.
C1 [Horowitz, Richard, I] HHS Babesia & Tickborne Pathogen Subcomm, Washington, DC 20201 USA.
   [Horowitz, Richard, I; Freeman, Phyllis R.] Hudson Valley Healing Arts Ctr, 4232 Albany Post Rd, Hyde Pk, NY 12538 USA.
RP Horowitz, RI (corresponding author), Hudson Valley Healing Arts Ctr, 4232 Albany Post Rd, Hyde Pk, NY 12538 USA.
EM medical@hvhac.com
FU MSIDS Research Foundation (MRF)
FX We would like to thank the MSIDS Research Foundation (MRF) for providing
   a research grant for the publication of this study. Dr. Richard Horowitz
   is the guarantor of the contents of this manuscript.
CR Ahmed SMU, 2017, BBA-MOL BASIS DIS, V1863, P585, DOI 10.1016/j.bbadis.2016.11.005
   Allis TJ, 2012, FACIAL PLAST SURG CL, V20, P93, DOI [10.1016/j.fsc.2011.10.011, 10.3205/cto000077]
   Amatore Donatella, 2019, FASEB Bioadv, V1, P296, DOI 10.1096/fba.2018-00066
   American Academy of Otolaryngology Head and Neck Surgery, COR DIS 2019 RES
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Atallah B, 2020, EUR HEART J-CARD PHA, V6, P260, DOI 10.1093/ehjcvp/pvaa036
   Basu S, 2018, INDIAN J CLIN BIOCHE, V33, P108, DOI 10.1007/s12291-017-0655-4
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cascella M, 2020, FEATURES EVALUATION
   CDC, COR DIS 2019 COVID 1
   Chakravarthi S, 2006, EMBO REP, V7, P271, DOI 10.1038/sj.embor.7400645
   Chen XY, 2020, J MED VIROL, V92, P1572, DOI 10.1002/jmv.25810
   Christian LM, 2011, PSYCHONEUROENDOCRINO, V36, P1495, DOI 10.1016/j.psyneuen.2011.04.003
   Citera M, 2017, INT J GEN MED, V10, P249, DOI 10.2147/IJGM.S140224
   Cohoon KP, 2018, J THROMB HAEMOST, V16, P1278, DOI 10.1111/jth.14146
   Damian NV, 2020, CUREUS, V12
   Dey SK, 2020, J MED VIROL, V92, P632, DOI 10.1002/jmv.25743
   Dharsono T, 2019, J AM COLL NUTR, V38, P40, DOI 10.1080/07315724.2018.1478339
   Dietz W, 2020, OBESITY, V28, P1005, DOI 10.1002/oby.22818
   Diotallevi M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01239
   DOTY RL, 1984, SCIENCE, V226, P1441, DOI 10.1126/science.6505700
   Fraternale A, 2009, MOL ASPECTS MED, V30, P99, DOI 10.1016/j.mam.2008.09.001
   Fuller R, 2012, NUTRITION, V28, P665, DOI 10.1016/j.nut.2011.11.012
   Gadek JE, 1996, CHEST, V110, pS273, DOI 10.1378/chest.110.6_Supplement.273S
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gasparini C, 2012, CURR PHARM DESIGN, V18, P5735, DOI 10.2174/138161212803530763
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ghezzi P, 2011, INT J GEN MED, V4, P105, DOI 10.2147/IJGM.S15618
   Gomez-Escudero Octavio, 2004, Rev Gastroenterol Mex, V69, P16
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guo Li, 2017, Zhongguo Dang Dai Er Ke Za Zhi, V19, P188
   Hemila H, 2007, J ROY SOC MED, V100, P495, DOI 10.1258/jrsm.100.11.495
   Hemila H, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-0432-y
   Hemila H, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040339
   Hemila H, 2011, AM J RESP CRIT CARE, V184, P621, DOI 10.1164/ajrccm.184.5.621a
   Horowitz RI, 2020, RESPIR MED CASE REP, V30, DOI 10.1016/j.rmcr.2020.101063
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huttenbrink KB, 2013, DTSCH ARZTEBL INT, V110, P1, DOI 10.3238/arztebl.2013.0001
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Huppert LA, 2019, SEMIN RESP CRIT CARE, V40, P31, DOI 10.1055/s-0039-1683996
   Husain S, 2018, Malays Fam Physician, V13, P28
   Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60
   Karakike E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00055
   Khafaie Morteza Abdullatif, 2020, Osong Public Health Res Perspect, V11, P74, DOI 10.24171/j.phrp.2020.11.2.03
   Kotfis K, 2020, ANAESTH INTENSIVE TH, V52, P171, DOI 10.5114/ait.2020.93867
   Kwant A, 2004, BEHAV BRAIN RES, V151, P73, DOI 10.1016/j.bbr.2003.08.008
   Lalande S, 2009, EUR J APPL PHYSIOL, V106, P509, DOI 10.1007/s00421-009-1042-5
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Liao BC, 2010, TOXICOL SCI, V116, P151, DOI 10.1093/toxsci/kfq098
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Looney MR, 2009, J CLIN INVEST, V119, P3450, DOI 10.1172/JCI38432
   Mackie BK, 2020, REDMONDMAG      0320
   Martin TR, 1999, CHEST, V116, p2S, DOI 10.1378/chest.116.suppl_1.2S
   Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158
   Mehra Mandeep R, 2020, HYDROXYCHLOROQUINE C, DOI [10.1016/S0140-6736(20)31180-6, DOI 10.1016/S0140-6736(20)31180-6]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Morris D, 2013, BBA-GEN SUBJECTS, V1830, P3329, DOI 10.1016/j.bbagen.2012.10.012
   Murphy C, 2002, JAMA-J AM MED ASSOC, V288, P2307, DOI 10.1001/jama.288.18.2307
   Murphy KM, 2010, JANEWAYS IMMUNOBIOLO
   Obi AT, 2019, J VASC SURG-VENOUS L, V7, P317, DOI 10.1016/j.jvsv.2018.08.010
   PACHT ER, 1991, CHEST, V100, P1397, DOI 10.1378/chest.100.5.1397
   PALAMARA AT, 1995, ANTIVIR RES, V27, P237, DOI 10.1016/0166-3542(95)00008-A
   Paranjpe A, 2009, TOXICOL SCI, V108, P356, DOI 10.1093/toxsci/kfp010
   Patel A, 2020, USEFULNESS IVERMECTI
   Prasad AS, 2007, AM J CLIN NUTR, V85, P837
   Prasad AS, 2004, FREE RADICAL BIO MED, V37, P1182, DOI 10.1016/j.freeradbiomed.2004.07.007
   Raoult D, 2020, CELL STRESS, V4, P66, DOI 10.15698/cst2020.04.216
   Rosado FGN, 2013, AM J CLIN PATHOL, V139, P713, DOI 10.1309/AJCP4ZDKJ4ICOUAT
   Rosario C, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-185
   Rose M, 2014, DIALOGUES CLIN NEURO, V16, P197
   Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sakic B, 1997, BRAIN RES BULL, V44, P155, DOI 10.1016/S0361-9230(97)00107-X
   Schmitt B, 2015, REDOX BIOL, V6, P198, DOI 10.1016/j.redox.2015.07.012
   Seguin A, 2016, CHEST, V149, P1294, DOI 10.1016/j.chest.2015.11.004
   Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S
   Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7
   Short S, 1996, EUR J IMMUNOL, V26, P3015, DOI 10.1002/eji.1830261229
   Spyropoulos AC, 2020, LANCET, V395, pE75, DOI 10.1016/S0140-6736(20)30926-0
   Stover AM, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0571-z
   Subedi L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020194
   SUZUKI YJ, 1992, BIOCHEM BIOPH RES CO, V189, P1709, DOI 10.1016/0006-291X(92)90275-P
   Tang N, 2020, J THROMB HAEMOST, V18, P1094, DOI 10.1111/jth.14817
   Trefler S, 2014, MED INTENSIVA, V38, P73, DOI 10.1016/j.medin.2013.01.004
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Vetvicka V, 2019, MOLECULES, V24, DOI 10.3390/molecules24071251
   Wang H, 2009, ANN NY ACAD SCI, V1170, P596, DOI 10.1111/j.1749-6632.2009.04480.x
   Wang K, 2015, J APPL PHYSIOL, V119, P1494, DOI 10.1152/japplphysiol.00117.2015
   Wang W, 2020, DEFINITION RISKS CYT, DOI [10.1101/2020.02.26.20026989, DOI 10.1101/2020.02.26.20026989]
   Weiss ES, 2018, BLOOD, V131, P1442, DOI 10.1182/blood-2017-12-820852
   Wilson RS, 2011, CHEM SENSES, V36, P63, DOI 10.1093/chemse/bjq098
   Xu Y, 2015, TOXICOL MECH METHOD, V25, P596, DOI 10.3109/15376516.2015.1044150
   Yadav VS, 2005, IMMUNOPHARM IMMUNOT, V27, P485, DOI 10.1080/08923970500242244
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhang JJ, 2020, ALLERGY, V75, P1809, DOI 10.1111/all.14316
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 104
TC 8
Z9 8
U1 8
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109851
DI 10.1016/j.mehy.2020.109851
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800025
PM 32534175
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Jacobs, JJL
AF Jacobs, J. J. L.
TI Neutralizing antibodies mediate virus-immune pathology of COVID-19
SO MEDICAL HYPOTHESES
LA English
DT Article
ID CORONAVIRUS; INFECTION
AB SARS-CoV-2 is a novel beta-coronavirus causing over 200.000 lethal cases within six months of first infecting humans. SARS-CoV-2 causes COVID-19, a form of severe acute respiratory syndrome (SARS). COVID-19 is characterized by two phases: the first resembles the flu with pneumonia, but after about seven or eight days the disease suddenly worsens to a sepsis-like syndrome. It is difficult to explain this virus-immune-pathology sequence from virology or immunology only. This paper hypothesizes that host-produced anti-spike protein antibodies are responsible for immune-induced viral dissemination. Subsequently, systemic distribution of virus-antibodies complexes activates the immune pathology observed in severe COVID-19.
   This hypothesis may be counterintuitive to immunologist that consider many anti-spike antibodies to be virus-neutralizing antibodies. Although anti-spike antibodies may hinder infection of epithelial cells, antibody binding to the spike protein may facilitate virus infection of myeloid leukocytes. If myeloid leukocytes reenter the circulation, they could spread the virus from a locoregional infection to a systemic disease. Disseminated virus in combination with antibodies results in dispersed virus-antibody complexes that overstimulate the immune system.
   The hypothesis aligns with the sequences of virus, immune and pathological events in COVID-19. The delay in onset from both syndromes results from an immune system still naive to the non-cross-reactive spike protein. Details of this hypothesis are in concordance with many clinical characteristics of COVID-19, including its predominant lethality for the elderly, and the mostly asymptomatic course of disease in children. It predicts putative detrimental effects of vaccines that induce virusneutralizing antibodies against the spike protein, as has been shown for other coronaviruses.
   This hypothesis has consequences for treatment of patients, evaluation of personal and herd immunity and vaccine development. In patients, cellular immunity should be stimulated. Neutralizing antibodies might not be indicative for immunity. Vaccines should aim to stimulate cellular immunity COVID-19 and/or stimulate humoral immunity against viral proteins except for the immunodominant spike protein.
C1 [Jacobs, J. J. L.] ORTEC BV, Dept Hlth, Houtsingel 5, NL-2719 EA Zoetermeer, Netherlands.
RP Jacobs, JJL (corresponding author), ORTEC BV, Dept Hlth, Middenmolenlaan 86, NL-2807 EC Gouda, Netherlands.
EM John.Jacobs@ortec.com
OI Jacobs, John J. L./0000-0003-2249-5668
CR Jimenez-Sousa MA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00458
   [Anonymous], 2020, IMMUNITY PASSPORTS C
   Bergman P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065835
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guo L, 2020, CLIN INF DIS
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kohyama S, 2009, ANTIVIR RES, V84, P168, DOI 10.1016/j.antiviral.2009.09.004
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Monto AS, 2020, J INFECT DIS
   Quinti I, 2020, J ALLERGY CLIN IMMUN
   Sanche S, 2020, NOVEL CORONAVIRUS 20, DOI DOI 10.1101/2020.02.07.20021154V1
   Scott FW, 1999, ADV VETER MED AP, V41, P347
   Shang B, 2005, BIOCHEM BIOPH RES CO, V336, P110, DOI 10.1016/j.bbrc.2005.08.032
   Sharmin R, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-161
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tan CC, 2020, J MED VIROL, V92, P856, DOI 10.1002/jmv.25871
   Temesgen Z, 2006, DRUGS TODAY, V42, P791, DOI 10.1358/dot.2006.42.12.1025703
   Tomova R, 2009, ANTICANCER RES, V29, P5241
   Ventura Maria Teresa, 2017, Clin Mol Allergy, V15, P21, DOI 10.1186/s12948-017-0077-0
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Watkins RR, 2015, CAN J PHYSIOL PHARM, V93, P363, DOI 10.1139/cjpp-2014-0352
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365v2, DOI 10.1101/2020.03.30.20047365V2]
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu MS, 2004, CELL MOL IMMUNOL, V1, P193
NR 33
TC 0
Z9 0
U1 3
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109884
DI 10.1016/j.mehy.2020.109884
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800060
PM 32512289
DA 2021-01-01
ER

PT J
AU Kavanagh, O
   Healy, AM
   Dayton, F
   Robinson, S
   O'Reilly, NJ
   Mahoney, B
   Arthur, A
   Walker, G
   Farragher, JP
AF Kavanagh, Oisin
   Healy, Anne Marie
   Dayton, Francis
   Robinson, Shane
   O'Reilly, Niall J.
   Mahoney, Brian
   Arthur, Aisling
   Walker, Gavin
   Farragher, John P.
TI Inhaled hydroxychloroquine to improve efficacy and reduce harm in the
   treatment of COVID-19
SO MEDICAL HYPOTHESES
LA English
DT Letter
ID OLD DRUG; CHLOROQUINE; TASTE
AB Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials registered do not consider dosage adjustment in the elderly, a patient population most likely to require HCQ treatment. Here we describe an inhaled formulation of HCQ which has passed safety studies in clinical trials for the treatment of asthma and discuss how this approach may reduce side-effects and improve efficacy. As this simple formulation progressed to phase II studies, safety data can be used to immediately enable phase II trials in COVID-19.
C1 [Kavanagh, Oisin; Healy, Anne Marie; Dayton, Francis; Robinson, Shane; O'Reilly, Niall J.; Mahoney, Brian; Arthur, Aisling; Walker, Gavin; Farragher, John P.] SSPC, Limerick, Ireland.
   [Kavanagh, Oisin; Walker, Gavin] Univ Limerick, Bernal Inst, Limerick, Ireland.
   [Healy, Anne Marie] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland.
   [Robinson, Shane] Janssen Sci Ireland, Cork, Ireland.
   [O'Reilly, Niall J.] Waterford Inst Technol, Pharmaceut & Mol Biotechnol Res Ctr, Waterford, Ireland.
RP Kavanagh, O (corresponding author), SSPC, Limerick, Ireland.
EM Oisin.Kavanagh@ul.ie
OI O'Reilly, Niall/0000-0002-4308-027X
FU Science Foundation Ireland (SFI)Science Foundation Ireland
   [12/RC/2275/P2]; European Regional Development FundEuropean Union (EU)
FX The authors would like to acknowledge funding from Science Foundation
   Ireland (SFI), grant number 12/RC/2275/P2, which is cofunded under the
   European Regional Development Fund. J.F, S.R and B.M would also like to
   acknowledge Chris Masterson from PeakProsperity for simulating their
   first discussions on this topic.
CR Arnold SLM, 2020, CTS-CLIN TRANSL SCI, V13, P642, DOI 10.1111/cts.12797
   BELITZ H-D, 1985, Food Reviews International, V1, P271, DOI 10.1080/87559128509540773
   Bonow RO, 2020, JAMA CARDIOL
   Dayton F, 2006, RESP DRUG DELIV
   Dayton F., 2020, COMMUNICATION   0511
   Dayton F, 2005, SPONSOR PROTOCOL PYX
   Dayton F, 2007, SPONSOR PROTOCOL ARD
   Dorner T, 2010, NAT REV RHEUMATOL, V6, P10, DOI 10.1038/nrrheum.2009.235
   European Centre for Disease Prevention and Control, 2020, COVID 19 SITUATION U
   European Medicines Agency, 2020, COVID 19 REMINDER RI
   Food and Drug Administration, 2020, FDA DRUG SAFETY COMM
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hoffmann M, 2020, BIORXIV
   Klimke A, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109783
   Morice A, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2016-000137
   Morris JN, 2019, J AM MED DIR ASSOC, V20, P1001, DOI 10.1016/j.jamda.2018.12.014
   Pauli E, 2020, J PHARM SCI-US, V109, P1493, DOI 10.1016/j.xphs.2019.12.014
   Rabkin SW, 2016, J GERIATR CARDIOL, V13, P740, DOI 10.11909/j.issn.1671-5411.2016.09.013
   Rabkin SW, 2014, J GERIATR CARDIOL, V11, P20, DOI 10.3969/j.issn.1671-5411.2014.01.005
   Sanders JM, 2020, JAMA J AM MED ASS
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weinstein JR, 2010, ADV CHRONIC KIDNEY D, V17, P302, DOI 10.1053/j.ackd.2010.05.002
   Williamson EJ, 2020, NATURE, DOI [10.1038/s41586-020-2521-2524, DOI 10.1038/S41586-020-2521-2524]
   Wise PM, 2014, LUNG, V192, P9, DOI 10.1007/s00408-013-9515-z
   Wise PM, 2012, PULM PHARMACOL THER, V25, P236, DOI 10.1016/j.pupt.2012.03.005
   Yao X, 2020, CLIN INFECT DIS
NR 29
TC 2
Z9 2
U1 3
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110110
DI 10.1016/j.mehy.2020.110110
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800097
PM 33017904
OA Green Published
DA 2021-01-01
ER

PT J
AU Khani, MA
   SalehiRad, M
   Darbeheshti, S
   Motaghinejad, M
AF Khani, M. Allahverdi
   SalehiRad, M.
   Darbeheshti, S.
   Motaghinejad, M.
TI Survival of COVID-19 patients requires precise immune regulation: The
   hypothetical immunoprotective role of nicotinic agonists
SO MEDICAL HYPOTHESES
LA English
DT Letter
DE COVID-19; Nicotinic agonist; Immunotherapy
AB A Summary recent studies have provided novel evidence regarding the effect of nicotine agonists on the prevention or modulation of cytokines storm and reduction of infection. In this study we tried to attempt to address these issues from a therapeutic perspective of nicotine agonists in this manner and we describe one of the most challenging theories of immunotherapy in coronavirus-19 (COVID-19). The analysis of the proposed mechanism goes beyond the physiological consequences of a way to design new strategies to provide anti-inflammatory drugs.
C1 [Khani, M. Allahverdi] Islamic Azad Univ, Najafabad Branch, Clin Res Dev Ctr, Najafabad, Iran.
   [SalehiRad, M.] Islamic Azad Univ, Tehran Med Sci, Fac Pharmaceut Chem, Dept Pharmaceut Chem, Tehran, Iran.
   [Darbeheshti, S.] Shahid Beheshti Univ Med Sci, Dept Clin Biochem, Fac Med, Tehran, Iran.
   [Motaghinejad, M.] Iran Univ Med Sci, Razi Drug Res Ctr, Tehran, Iran.
RP Khani, MA (corresponding author), Shariati Hosp, Esfahan, Iran.
EM Allahverdy.maryam@yahoo.com
CR D'Elia RV, 2013, CLIN VACCINE IMMUNOL, V20, P319, DOI 10.1128/CVI.00636-12
   de Jonge WJ, 2007, BRIT J PHARMACOL, V151, P915, DOI 10.1038/sj.bjp.0707264
   Galle-Treger L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13202
   Kox M, 2009, BIOCHEM PHARMACOL, V78, P863, DOI 10.1016/j.bcp.2009.06.096
   Ulloa L, 2006, CYTOKINE GROWTH F R, V17, P189, DOI 10.1016/j.cytogfr.2006.01.003
NR 5
TC 1
Z9 1
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109871
DI 10.1016/j.mehy.2020.109871
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800010
PM 32470789
OA Green Published
DA 2021-01-01
ER

PT J
AU Lyu, JL
   Miao, TY
   Dong, JJ
   Cao, RR
   Li, Y
   Chen, QM
AF Lyu, Jinglu
   Miao, Tianyu
   Dong, Jiajia
   Cao, Ranran
   Li, Yan
   Chen, Qianming
TI Reflection on lower rates of COVID-19 in children: Does childhood
   immunizations offer unexpected protection?
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Mild symptom in children; Childhood immunization; Trained
   immunity; Immune fitness
ID ACUTE RESPIRATORY SYNDROME; T-CELLS; SARS; MEMORY
AB The incidence of COVID-19 in children and teenagers is only about 2% in China. Children had mild symptoms and hardly infected other children or adults. It is worth considering that children are the most vulnerable to respiratory pathogens, but fatal SARS-like virus had not caused severe cases among them. According to the pathological studies of COVID-19 and SARS, a sharp decrease in T lymphocytes leads to the breakdown of the immune system. The cellular immune system of children differs from that of adults may be the keystone of atypical clinical manifestations or even covert infection. The frequent childhood vaccinations and repeated pathogens infections might be resulting in trained immunity of innate immune cells, immune fitness of adaptive immune cells or cross-protection of antibodies in the children. Therefore, due to lack of specific vaccine, some vaccines for tuberculosis, influenza and pneumonia may have certain application potential for the front-line health workers in the prevention and control of COVID-19. However, for high-risk susceptible populations, such as the elderly with basic diseases such as hypertension and diabetes, it is necessary to explore the remedial effect of the planned immune process on their immunity to achieve the trained immunity or immune fitness, so as to improve their own antiviral ability.
C1 [Lyu, Jinglu; Li, Yan; Chen, Qianming] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
   [Miao, Tianyu; Dong, Jiajia] Sichuan Univ, Dept Pulm & Crit Care Med, Vasc Surg, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
   [Cao, Ranran] Sichuan Prov Ctr Dis Control & Prevent, Chengdu 610041, Sichuan, Peoples R China.
   [Lyu, Jinglu] Nanjing Univ, Nanjing Stomatol Hosp, Med Sch, Nanjing 210008, Peoples R China.
RP Li, Y (corresponding author), Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu 610041, Peoples R China.
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81771085, 81991502, 81700036, 81991500]; Key
   Projects of Sichuan Provincial Department of Science and Technology
   [20SYSX0286]; Special Funds for Prevention and Control of COVID-19 of
   Sichuan University [2020scunCoV10009]
FX This study was supported by National Natural Science Foundation of China
   (grant No.: 81771085, 81991502, 81700036 and 81991500), Key Projects of
   Sichuan Provincial Department of Science and Technology (20SYSX0286),
   Special Funds for Prevention and Control of COVID-19 of Sichuan
   University (2020scunCoV10009).
CR [Anonymous], 2016, PROCEDURES INSTRUCTI
   BANGHAM CRM, 1986, J IMMUNOL, V137, P3973
   Berg RE, 2003, J EXP MED, V198, P1583, DOI 10.1084/jem.20031051
   Cao Li, 2004, Zhonghua Er Ke Za Zhi, V42, P840
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen X, 2020, 20030437 MEDRXIV
   Chen Z-M, 2020, WORLD J PEDIATR, DOI [10.1007/s12519-12020-00345-12515., DOI 10.1007/S12519-12020-00345-12515]
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo X, 2020, 20021386 MEDRXIV
   Hu Z, 2020, 20025619 MEDRXIV
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Lan L, 2020, JAMA
   Li AM, 2005, ARCH DIS CHILD-FETAL, V90, pF461, DOI 10.1136/adc.2005.075309
   Li Lin-hai, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P1085
   Li M, CHINESE J CLIN PHARM
   Li Y, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368-019-0045-2
   Liao M, 2020, 20026690 MEDRXIV
   Liu Jing-Han, 2004, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V12, P217
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   MACKANESS GB, 1969, J EXP MED, V129, P973, DOI 10.1084/jem.129.5.973
   Miller A, 2020, 20042937 MEDRXIV
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006
   Ng PC, 2004, BIOL NEONATE, V85, P293, DOI 10.1159/000078174
   Patil VS, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aan8664
   Raiden S, 2017, J INFECT DIS, V215, P1049, DOI 10.1093/infdis/jix070
   Rato S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006678
   Schmidt ME, 2018, CYTOKINE
   Si Jian-hua, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P220
   Stockman LJ, 2007, PEDIATR INFECT DIS J, V26, P68, DOI 10.1097/01.inf.0000247136.28950.41
   Sun C, EXPLORING PREVENTIVE
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tang A., 2020, 20029710 MEDRXIV
   Varga SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00690
   Walls A.C., 2020, CELL
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan S., 2020, CHARACTERISTICS LYMP, DOI [10.20021832, DOI 10.1101/2020.02.10.20021832, 10.1101/2020.02. 10.20021832, 10.1101/2020.02.10.20021832]
   Wang Hui-juan, 2010, Chinese Journal of Virology, V26, P295
   Welsh RM, 2002, NAT REV IMMUNOL, V2, P417, DOI 10.1038/nri820
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xin G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07492-4
   Xu Hui-Fang, 2006, Zhonghua Liu Xing Bing Xue Za Zhi, V27, P950
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Xu Z, 2020, LANCET RESP MED, V18, pS2213
   Yang PH, 2014, SCI REP-UK, V4, DOI 10.1038/srep07027
   Yang X, 2020, J PEDIAT PHARM
   Yin Cheng-hong, 2005, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V17, P740
   Yu H., 2020, 20032219 MEDRXIV
   Yu J, 2020, INT J COMPUT ASS RAD, V15, P1001, DOI 10.1007/s11548-020-02196-x
   Yuan J, 2020, 20031377 MEDRXIV, P2020
   Zhao Lin-qing, 2006, Zhonghua Er Ke Za Zhi, V44, P262
   Zhu HP, 2020, TRANSL PEDIATR, V9, P51, DOI 10.21037/tp.2020.02.06
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou L, 2020, N ENGL J MED
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 59
TC 3
Z9 3
U1 4
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109842
DI 10.1016/j.mehy.2020.109842
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800014
OA Green Published
DA 2021-01-01
ER

PT J
AU Mariajoseph-Antony, LF
   Kannan, A
   Panneerselvam, A
   Loganathan, C
   Anbarasu, K
   Prahalathan, C
AF Mariajoseph-Antony, Lezy Flora
   Kannan, Arun
   Panneerselvam, Antojenifer
   Loganathan, Chithra
   Anbarasu, Kumarasamy
   Prahalathan, Chidambaram
TI Could aquaporin modulators be employed as prospective drugs for COVID-19
   related pulmonary comorbidity?
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Cytokine storm; Inflammation; Pulmonary edema; Aquaporin;
   Aquaporin modulators
ID LUNG FLUID TRANSPORT; UP-REGULATING AQP1; DECREASED EXPRESSION; WATER
   TRANSPORT; DOWN-REGULATION; MOUSE LUNG; INJURY; EDEMA; CLEARANCE; RATS
AB COVID-19 initially an epidemic caused by SARS-CoV-2 has turned out to be a life- threatening global pandemic with increased morbidity and mortality. The presence of cytokine storm has been linked with the pathogenesis of severe lung injury as evinced in COVID-19. Aquaporins (AQPs) are molecular water channels, facilitating water transport across the cell membrane in response to osmotic gradients. Impairment in alveolar fluid clearance due to altered functional expression of respiratory AQPs highlight their pathophysiological significance in pulmonary edema associated respiratory illness. Therefore, we hypothesize that targeted modulation of AQPs in lungs in the intervening period of time, could diminish the dreadful effects of inflammation- induced comorbidity in COVID-19.
C1 [Mariajoseph-Antony, Lezy Flora; Kannan, Arun; Panneerselvam, Antojenifer; Loganathan, Chithra; Prahalathan, Chidambaram] Bharathidasan Univ, Ctr Excellence Life Sci, Dept Biochem, Mol Endocrinol Lab, Tiruchirappalli 620024, Tamil Nadu, India.
   [Anbarasu, Kumarasamy] Bharathidasan Univ, Dept Marine Biotechnol, Microbial Biotechnol Lab, Tiruchirappalli 620024, Tamil Nadu, India.
RP Prahalathan, C (corresponding author), Bharathidasan Univ, Ctr Excellence Life Sci, Dept Biochem, Mol Endocrinol Lab, Tiruchirappalli 620024, Tamil Nadu, India.
EM prahalath@gmail.com
OI Chidambaram, Prahalathan/0000-0001-6947-9732
FU Department of Science and Technology (DST) - Innovation in Science
   Pursuit for Inspired Research (INSPIRE)Department of Science &
   Technology (DOST), PhilippinesDepartment of Science & Technology (India)
   [IF180563]; Department of Science and Technology (DST) - Science and
   Engineering Research Board (SERB)Department of Science & Technology
   (India)Department of Science & Technology (DOST), Philippines
   [EMR/2017/003670]; Indian Council for Medical Research (ICMR), New
   DelhiIndian Council of Medical Research (ICMR) [RBMH/FW/2018/13]
FX LFMA gratefully acknowledge financial assistance as Junior Research
   Fellowship (IF180563) from Department of Science and Technology (DST) -
   Innovation in Science Pursuit for Inspired Research (INSPIRE). CP
   acknowledges Department of Science and Technology (DST) - Science and
   Engineering Research Board (SERB) for the financial assistance
   (EMR/2017/003670) and DST-FIST for the infrastructure provided to the
   Department of Biochemistry, Bharathidasan University. AK acknowledges
   the financial assistance as Senior Research Fellowship (RBMH/FW/2018/13)
   from Indian Council for Medical Research (ICMR), New Delhi.
CR AGRE P, 1993, AM J PHYSIOL, V265, pF463
   Ba F, 2019, J THORAC DIS, V11, P3599, DOI 10.21037/jtd.2019.08.86
   Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138
   Borok Z, 2002, J APPL PHYSIOL, V93, P2199, DOI 10.1152/japplphysiol.01171.2001
   Dong CL, 2012, RESP PHYSIOL NEUROBI, V181, P21, DOI 10.1016/j.resp.2011.12.008
   FOLKESSON HG, 1994, P NATL ACAD SCI USA, V91, P4970, DOI 10.1073/pnas.91.11.4970
   Gabazza EC, 2004, PATHOL INT, V54, P774, DOI 10.1111/j.1440-1827.2004.01754.x
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Guo C, 2019, INFLAMMATION, V42, P1401, DOI 10.1007/s10753-019-01002-4
   Herrero R, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2017.12.18
   Hong-Min Fu, 2016, J Physiol Biochem, V73, P381, DOI 10.1007/s13105-017-0563-3
   Jiang YX, 2015, J HUAZHONG U SCI-MED, V35, P684, DOI 10.1007/s11596-015-1490-6
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li YH, 2018, INFLAMMATION, V41, P2196, DOI 10.1007/s10753-018-0862-z
   Liu LH, 2014, EXP LUNG RES, V40, P145, DOI 10.3109/01902148.2013.859333
   Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Meli R, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00101
   PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385
   PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110
   Quinton LJ, 2018, PHYSIOL REV, V98, P1417, DOI 10.1152/physrev.00032.2017
   Ragab D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01446
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Song LL, 2000, J GEN PHYSIOL, V115, P17, DOI 10.1085/jgp.115.1.17
   Thompson BT, 2017, NEW ENGL J MED, V377, P562, DOI 10.1056/NEJMra1608077
   Towne JE, 2000, AM J RESP CELL MOL, V22, P34, DOI 10.1165/ajrcmb.22.1.3818
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang JJ, 2019, J BIOMED RES, V33, P156, DOI 10.7555/JBR.31.20170024
   Wittekindt OH, 2019, PFLUG ARCH EUR J PHY, V471, P519, DOI 10.1007/s00424-018-2232-y
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu XM, 2009, LUNG, V187, P225, DOI 10.1007/s00408-009-9155-5
   Xiong LL, 2016, INT IMMUNOPHARMACOL, V38, P54, DOI 10.1016/j.intimp.2016.03.036
   Xu JF, 2018, ONCOL LETT, V16, P3290, DOI 10.3892/ol.2018.9026
   Zhang QY, 2014, EXP THER MED, V8, P493, DOI 10.3892/etm.2014.1739
   Zhang QY, 2016, MOL MED REP, V13, P281, DOI 10.3892/mmr.2015.4519
   Zhang YW, 2009, CLIN EXP PHARMACOL P, V36, P734, DOI 10.1111/j.1440-1681.2009.05156.x
   Zhang YW, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071183
   Zhang ZQ, 2011, J TRAUMA, V71, P1305, DOI 10.1097/TA.0b013e3182128528
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 40
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110201
DI 10.1016/j.mehy.2020.110201
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800154
PM 33017909
OA Green Published
DA 2021-01-01
ER

PT J
AU Meenakshisundaram, R
   Senthilkumaran, S
   Thirumalaikolundusubramanian, P
AF Meenakshisundaram, Ramachandran
   Senthilkumaran, Subramanian
   Thirumalaikolundusubramanian, Ponniah
TI Protective effects of vaccinations and endemic infections on COVID-19: A
   hypothesis
SO MEDICAL HYPOTHESES
LA English
DT Letter
DE Covid-19; Coronavirus; SARS; Vaccines; BCG; Measles
ID CORONAVIRUS; ANTIBODIES
C1 [Meenakshisundaram, Ramachandran; Senthilkumaran, Subramanian] Manian Med Ctr, Dept Emergency & Crit Care, Erode, India.
   [Thirumalaikolundusubramanian, Ponniah] Trichy SRM Med Coll Hosp & Res Ctr, Tiruchirapalli 621105, India.
RP Meenakshisundaram, R (corresponding author), 47 Hurrell Dr, Harrow HA2 6DY, Middx, England.
EM rmsundarchandran@gmail.com
CR Arts RJW, 2015, J LEUKOCYTE BIOL, V98, P995, DOI 10.1189/jlb.4MA0215-059R
   Chan KF, 2018, J INFECT DIS, V218, P406, DOI 10.1093/infdis/jiy184
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   Dayal D, 2020, CONNECTING BCG VACCI, DOI [10.1101/2020.04.07.20053272., DOI 10.1101/2020.04.07.20053272, 10.1101/2020.04.07.20053272]
   Hegarty PK, 2020, BCG VACCINATION MAY, DOI [10.13140/RG.2.2.35948.10880, DOI 10.13140/RG.2.2.35948.10880]
   Jenner Edward, 1804, Med Phys J, V12, P97
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435
   Laurie KL, 2018, J INFECT DIS, V217, P548, DOI 10.1093/infdis/jix509
   Liniger M, 2008, VACCINE, V26, P2164, DOI 10.1016/j.vaccine.2008.01.057
   Miller D, 2020, MODELLING NATURE-BASED SOLUTIONS: INTEGRATING COMPUTATIONAL AND PARTICIPATORY SCENARIO MODELLING FOR ENVIRONMENTAL MANAGEMENT AND PLANNING, P19
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Patrick David M, 2006, Can J Infect Dis Med Microbiol, V17, P330
   Pigliucci Massimo, 2010, P3
   Salas-Benito JS, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/873404
NR 17
TC 1
Z9 1
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109849
DI 10.1016/j.mehy.2020.109849
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800033
PM 32480250
OA Green Published
DA 2021-01-01
ER

PT J
AU Mozafari, N
   Azadi, S
   Mehdi-Alamdarlou, S
   Ashrafi, H
   Azadi, A
AF Mozafari, Negin
   Azadi, Soha
   Mehdi-Alamdarlou, Sanaz
   Ashrafi, Hajar
   Azadi, Amir
TI Inflammation: A bridge between diabetes and COVID-19, and possible
   management with sitagliptin
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Sitagliptin; COVID-19; Inflammation; Diabetes
ID NF-KAPPA-B; INSULIN; MECHANISMS; MELLITUS; EXERTS
AB Patients with SARS-CoV-2 infections experience lymphopenia and inflammatory cytokine storms in the severe stage of the disease, leading to multi-organ damage. The exact pattern of immune system changes and their condition during the disease process is unclear. The available knowledge has indicated that the NF-kappa-B pathway, which is induced by several mediators, has a significant role in cytokine storm through the various mechanisms. Therefore, identifying the state of the immune cells and the dominant mechanisms for the production of cytokines incorporated in the cytokine storm can be a critical step in the therapeutic approach. On the other hand, some studies identified a higher risk for diabetic patients. Diabetes mellitus exhibits a close association with inflammation and increases the chance of developing COVID-19. Patients with diabetes mellitus have shown to have more virus entry, impaired immunity response, less viral elimination, and dysregulated inflammatory cytokines. The parallel analysis of COVID-19 and diabetes mellitus pathogenesis has proposed that the control of the inflammation through the interfering with the critical points of major signaling pathways may provide the new therapeutic approaches. In recent years, the role of Dipeptidyl Peptidase 4 (DPP4) in chronic inflammation has been proved. Numerous immune cells express the DPP4 protein. DPP4 regulates antibody production, cytokine secretion, and immunoglobulin class switching. DPP4 inhibitors like sitagliptin reduce inflammation intensity in different states.
   Following the accumulating data, we hypothesize that sitagliptin might reduce COVID-19 severity. Sitagliptin, an available DPP4 inhibitor drug, showed multidimensional anti-inflammatory effects among diabetic patients. It reduces the inflammation mostly by affecting on NF-kappa-B signaling pathway. Under the fact that inflammatory mediators are active in individuals with COVID-19, blocking the predominant pathway could be helpful.
C1 [Mozafari, Negin; Mehdi-Alamdarlou, Sanaz; Ashrafi, Hajar; Azadi, Amir] Shiraz Univ Med Sci, Sch Pharm, Dept Pharmaceut, Shiraz, Iran.
   [Azadi, Soha] Shiraz Univ Med Sci, Sch Pharm, Dept Clin Pharm, Shiraz, Iran.
   [Azadi, Amir] Shiraz Univ Med Sci, Pharmaceut Sci Res Ctr, Shiraz, Iran.
RP Azadi, A (corresponding author), Shiraz Univ Med Sci, Sch Pharm, Dept Pharmaceut, Shiraz, Iran.
EM aazadi@sums.ac.ir
CR Aguilera ER, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00105
   Alexaki VI, 2009, J IMMUNOL, V183, P5948, DOI 10.4049/jimmunol.0901186
   American Diabetes Association, 2015, Diabetes Care, V38 Suppl, pS8, DOI 10.2337/dc15-S005
   Asferg C, 2009, AM J HYPERTENS, V22, P451, DOI 10.1038/ajh.2009.1
   Asif AH, 2018, APPL SCI-BASEL, V8, DOI 10.3390/app8060861
   Baker RG, 2011, CELL METAB, V13, P11, DOI 10.1016/j.cmet.2010.12.008
   Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166
   de Luca C, 2008, FEBS LETT, V582, P97, DOI 10.1016/j.febslet.2007.11.057
   Dorrington MG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00705
   Evans P, 2015, DIABETES PRIMARY CAR, V17, P36
   Fang L., 2020, LANCET RESP MED
   Fung TS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00296
   Gomez DI, 2013, TUBERCULOSIS, V93, P192, DOI 10.1016/j.tube.2012.10.003
   Hodgson K, 2015, IMMUNOLOGY, V144, P171, DOI 10.1111/imm.12394
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665
   Hu XY, 2017, ENDOCRINE, V55, P754, DOI 10.1007/s12020-016-1073-8
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin Y, 2020, VIROLOGY EPIDEMIOLOG
   Kim B, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.3
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li X, 2020, J PHARM ANAL
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Liu C, 2020, ROBOTICS: SCIENCE AND SYSTEMS XVI
   Lontchi-Yimagou E, 2013, CURR DIABETES REP, V13, P435, DOI 10.1007/s11892-013-0375-y
   Lumeng CN, 2009, NAT MED, V15, P846, DOI 10.1038/nm0809-846
   Makdissi A, 2012, J CLIN ENDOCR METAB, V97, P3333, DOI 10.1210/jc.2012-1544
   Marette A, 2003, INT J OBESITY, V27, pS46, DOI 10.1038/sj.ijo.0802500
   Matteucci E, 2009, CURR MED CHEM, V16, P2943, DOI 10.2174/092986709788803114
   McGonaglea D, 2020, AUTOIMMUN REV
   Muniyappa R, AM J PHYSL ENDOC M
   Nally FK, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060543
   Oh H, 2013, IMMUNOL REV, V252, P41, DOI 10.1111/imr.12033
   Onder G, 2020, JAMA
   Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200
   Schenk S, 2008, J CLIN INVEST, V118, P2992, DOI 10.1172/JCI34260
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Sun Q, 2017, BIO-MED MATER ENG, V28, pS139, DOI 10.3233/BME-171635
   Ta NN, 2010, ATHEROSCLEROSIS, V213, P429, DOI 10.1016/j.atherosclerosis.2010.08.064
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   Thondawada M, 2018, DRUG DEV IND PHARM, V44, P1120, DOI 10.1080/03639045.2018.1438460
   Ujhelyi J, 2014, REGUL PEPTIDES, V194, P23, DOI 10.1016/j.regpep.2014.09.006
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Watanabe K, 2020, SOC SCI COMPUT REV, DOI 10.1177/0894439320907027
   Wicinski M, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6091014
   Wu D, 2020, J MICROBIOL IMMUNOL
   Yazbeck R, 2009, TRENDS PHARMACOL SCI, V30, P600, DOI 10.1016/j.tips.2009.08.003
   Zhang B, 2020, IMMUNE PHENOTYPING B
   Zhang CP, 2014, HUM IMMUNOL, V75, P289, DOI 10.1016/j.humimm.2014.02.007
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zick Yehiel, 2005, Sci STKE, V2005, ppe4, DOI 10.1126/stke.2682005pe4
NR 53
TC 2
Z9 2
U1 2
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110111
DI 10.1016/j.mehy.2020.110111
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800079
PM 32721805
OA Green Published
DA 2021-01-01
ER

PT J
AU Pindiprolu, SKSS
   Kumar, CSP
   Golla, VSK
   Likitha, P
   Chandra, KS
   Basha, SKE
   Ramachandra, RK
AF Pindiprolu, Sai Kiran S. S.
   Kumar, Chirravuri S. Phani
   Golla, Venu Sampath Kumar
   Likitha, P.
   Chandra, Shreyas K.
   Basha, Esub S. K.
   Ramachandra, R. K.
TI Pulmonary delivery of nanostructured lipid carriers for effective
   repurposing of salinomycin as an antiviral agent
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Salinomycin; ACE-2; Endocytosis
ID NLC
AB Coronavirus disease outbreak caused a severe public health burden all over the world. Salinomycin (SAL) is a broad-spectrum antibiotic that had drawn attention in selective targeting of cancer and viral infections. Recent drug screen identified SAL as a potent antiviral agent against SARS-CoV-2. In this hypothesis, we discuss the potential of pulmonary delivery of SAL using nanostructured lipid carriers (NLCs) against SARS-CoV-2.
C1 [Pindiprolu, Sai Kiran S. S.; Kumar, Chirravuri S. Phani] Adarsa Coll Pharm, East Godavari, Andhra Pradesh, India.
   [Golla, Venu Sampath Kumar; Likitha, P.] Andhra Univ, AU Coll Pharmaceut Sci, Visakhapatnam, Andhra Pradesh, India.
   [Basha, Esub S. K.; Ramachandra, R. K.] Govt Coll A, Crystal Growth & Nanosci Res Ctr, Rajahmundry, Andhra Pradesh, India.
   [Chandra, Shreyas K.] Adhra Med Coll, Visakhapatnam, Andhra Pradesh, India.
RP Ramachandra, RK (corresponding author), Govt Coll A, Crystal Growth & Nanosci Res Ctr, Rajahmundry, Andhra Pradesh, India.
EM shreyaschandrak@gmail.com; esubinanu2005@gmail.com; ramc@gcrjy.ac.in
RI R K, Ramachandra/F-6545-2017
OI R K, Ramachandra/0000-0002-5400-4926; Pindiprolu, Sai
   Kiran/0000-0002-5400-4491
CR Beloqui A, 2016, NANOMED-NANOTECHNOL, V12, P143, DOI 10.1016/j.nano.2015.09.004
   Cai Q, 2020, ENGINEERING
   Cao B, 2020, NEW ENGL J MED, V382
   Colson P, 2020, INT J ANTIMICROB AG
   De Clercq Erik, 2006, Expert Rev Anti Infect Ther, V4, P291, DOI 10.1586/14787210.4.2.291
   Deng L, 2020, J INFECT
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Favalli EG, 2020, LANCET INFECT DIS
   Greener M., 2017, PRESCRIBER, V28, P34
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Jain K, 2015, DRUG DELIV, V22, P940, DOI 10.3109/10717544.2014.885999
   Jang Y, 2018, J VIROL, V92, DOI 10.1128/JVI.01441-18
   Ko M, 2020, BIORXIV
   Ko W-C, 2020, INT J ANTIMICROB AGE
   McIntosh K., 1974, Current Topics in Microbiology and Immunology, V63, P85
   Patlolla RR, 2010, J CONTROL RELEASE, V144, P233, DOI 10.1016/j.jconrel.2010.02.006
   Pindiprolu SKSS, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109765
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Shao ZY, 2015, INT J NANOMED, V10, DOI 10.2147/IJN.S77837
   Thomson G, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13503
   Weber S, 2014, EUR J PHARM BIOPHARM, V86, P7, DOI 10.1016/j.ejpb.2013.08.013
   Xu Z, 2020, LANCET RESP MED
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang Y, 2012, BIOMATERIALS, V33, P679, DOI 10.1016/j.biomaterials.2011.09.072
NR 25
TC 1
Z9 1
U1 2
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109858
DI 10.1016/j.mehy.2020.109858
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800054
PM 32516655
OA Green Published
DA 2021-01-01
ER

PT J
AU Pramod, K
   Kotta, S
   Jijith, US
   Aravind, A
   Abu Tahir, M
   Manju, CS
   Gangadharappa, HV
AF Pramod, K.
   Kotta, Sabna
   Jijith, U. S.
   Aravind, A.
   Abu Tahir, M.
   Manju, C. S.
   Gangadharappa, H., V
TI Surfactant-based prophylaxis and therapy against COVID-19: A possibility
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Peplomer; SARS-CoV-2; Spike glycoprotein; Surfactants
ID CORONAVIRUS; VIRUS; PHOSPHOLIPIDS; GLYCOPROTEIN
AB Hand hygiene by washing with soap and water is recommended for the prevention of COVID-19 spread. Soaps and detergents are explained to act by damaging viral spike glycoproteins (peplomers) or by washing out the virus through entrapment in the micelles. Technically, soaps come under a functional category of molecules known as surfactants. Surfactants are widely used in pharmaceutical formulations as excipients. We wonder why surfactants are still not tried for prophylaxis or therapy against COVID-19? That too when many of them have proven antiviral properties. Moreover, lung surfactants have already shown benefits in respiratory viral infections. Therefore, we postulate that surfactant-based prophylaxis and therapy would be promising. We believe that our hypothesis would stimulate debate or new research exploring the possibility of surfactant-based prophylaxis and therapy against COVID-19. The success of a surfactant-based technique would save the world from any such pandemic in the future too.
C1 [Pramod, K.; Jijith, U. S.; Manju, C. S.] Coll Pharmaceut Sci, Govt Med Coll, Kozhikode, Kerala, India.
   [Kotta, Sabna] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah, Saudi Arabia.
   [Aravind, A.] Govt Med Coll, Coll Pharmaceut Sci, Thiruvananthapuram, Kerala, India.
   [Abu Tahir, M.] Steril Gene Life Sci, Formulat & Dev, Pondicherry, India.
   [Gangadharappa, H., V] JSS Acad Higher Educ & Res, JSS Coll Pharm, Dept Pharmaceut, Mysuru 570015, Karnataka, India.
RP Pramod, K (corresponding author), Coll Pharmaceut Sci, Govt Med Coll, Kozhikode, Kerala, India.
EM pramodkphd@yahoo.com
RI Kotta, Sabna/AAK-2965-2020; S, U/AAU-7851-2020; Pramod,
   Kannissery/H-3912-2015; V, Gangadharappa H/AAN-8230-2020
OI Kotta, Sabna/0000-0001-6350-5733; Pramod,
   Kannissery/0000-0002-8689-3369; V, Gangadharappa H/0000-0002-2961-4108
CR [Anonymous], 2013, USP36 NF31 US PHARM
   [Anonymous], 2018, INDIAN PHARMACOPOEIA
   Bitko V, 2007, J VIROL, V81, P783, DOI 10.1128/JVI.01437-06
   Chepurnov AA, 2003, ACTA TROP, V87, P315, DOI 10.1016/S0001-706X(03)00120-7
   FDA, 2020, IN INGR DAT 2020
   Fobar R., 2020, NATL GEOGR MAG
   Fukushi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042419
   Glasser JR, 2012, MICROBES INFECT, V14, P17, DOI 10.1016/j.micinf.2011.08.019
   Guttentag S, 2011, NEOREVIEWS, DOI [10.1542/neo.12-11-e625., DOI 10.1542/NEO.12-11-E625]
   Hammad MA, 1998, EUR J PHARM BIOPHARM, V46, P361, DOI 10.1016/S0939-6411(98)00037-X
   Hashemi MM, 2018, MOLECULES, V23, DOI 10.3390/molecules23030596
   HOFMANN AF, 1988, COLLOID SURFACE, V30, P145
   Hsieh IN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01368
   Ibrahim M, 2015, MED DEVICES-EVID RES, V8, P131, DOI 10.2147/MDER.S48888
   Jeon Ga Won, 2019, Korean J Pediatr, V62, P155, DOI 10.3345/kjp.2018.07185
   Leth-Larsen R, 2007, IMMUNOBIOLOGY, V212, P201, DOI 10.1016/j.imbio.2006.12.001
   Li J, 2015, ASIAN J PHARM SCI, V10, P81, DOI 10.1016/j.ajps.2014.09.004
   Lin HR, 2016, COLLOID POLYM SCI, V294, P1209, DOI 10.1007/s00396-016-3879-6
   Numata M, 2020, J BIOL CHEM, V295, P1704, DOI 10.1074/jbc.RA119.012053
   Numata M, 2010, P NATL ACAD SCI USA, V107, P320, DOI 10.1073/pnas.0909361107
   Pellosi DS, 2018, EUR J PHARM BIOPHARM, V130, P30, DOI 10.1016/j.ejpb.2018.06.006
   Perino J, 2011, ANTIVIR RES, V89, P89, DOI 10.1016/j.antiviral.2010.11.009
   Rowe R.C., 2006, HDB PHARM EXCIPIENTS
   STURMAN LS, 1990, J VIROL, V64, P3042, DOI 10.1128/JVI.64.6.3042-3050.1990
   van Eijk M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02476
   van Hoogevest P, 2014, EUR J LIPID SCI TECH, V116, P1088, DOI 10.1002/ejlt.201400219
   Walther FJ, 2019, EXPERT REV RESP MED, V13, P499, DOI 10.1080/17476348.2019.1589372
   Wang WK, 2004, EMERG INFECT DIS, V10, P1213, DOI 10.3201/eid1007.031113
   WHO, 2019, INT PHARM 2019
   Yang CL, 2018, THERANOSTICS, V8, P464, DOI 10.7150/thno.22711
NR 30
TC 1
Z9 1
U1 4
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110081
DI 10.1016/j.mehy.2020.110081
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800023
PM 32653736
OA Green Published
DA 2021-01-01
ER

PT J
AU Rofeal, M
   Abd El-Malek, F
AF Rofeal, Marian
   Abd El-Malek, Fady
TI Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus
   replication for a potential prospective treatment
SO MEDICAL HYPOTHESES
LA English
DT Article
DE SARS-COV 2; Antiviral; Coronavirus; Ribosomal proteins; Viral
   translation
ID CORONAVIRUS; DRUGS; L9
AB Coronavirus disease (COVID-19) is caused by SARS-COV2 and has resulted in more than four million cases globally and the death cases exceeded 300,000. Normally, a range of surviving and propagating host factors must be employed for the completion of the infectious process including RPs. Viral protein biosynthesis involves the interaction of numerous RPs with viral mRNA, proteins which are necessary for viruses replication regulation and infection inside the host cells. Most of these interactions are crucial for virus activation and accumulation. However, only small percentage of these proteins is specifically responsible for host cells protection by triggering the immune pathway against virus. This research proposes RPs extracted from bacillus sp. and yeast as new forum for the advancement of antiviral therapy. Hitherto, antiviral therapy with RPs-involving viral infection has not been widely investigated as critical targets. Also, exploring antiviral strategy based on RPs could be a promising guide for more potential therapeutics.
C1 [Rofeal, Marian; Abd El-Malek, Fady] Alexandria Univ, Fac Sci, Dept Bot & Microbiol, Alexandria, Egypt.
RP Abd El-Malek, F (corresponding author), Alexandria Univ, Fac Sci, Dept Bot & Microbiol, Alexandria, Egypt.
EM fadymicro@yahoo.com
OI Abd el-malek, Fady/0000-0001-9030-403X; Rofeal,
   Marian/0000-0003-1515-8620
CR Abbas W, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-103
   Ban N, 2014, CURR OPIN STRUC BIOL, V24, P165, DOI 10.1016/j.sbi.2014.01.002
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa008
   Carvalho CM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000247
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Cui C, 2020, ACTA PHARM SIN B
   de la Cruz J, 2015, ANNU REV BIOCHEM, V84, P93, DOI 10.1146/annurev-biochem-060614-033917
   Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4
   Elfiky AA, 2018, SAR QSAR ENVIRON RES, V29, P409, DOI 10.1080/1062936X.2018.1454981
   Elfiky AA, 2017, J MED VIROL, V89, P1040, DOI 10.1002/jmv.24736
   Elfiky AA, 2016, J MED VIROL, V88, P2044, DOI 10.1002/jmv.24678
   Ganesan A, 2017, EXPERT OPIN DRUG DIS, V12, P407, DOI 10.1080/17460441.2017.1291628
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Konikkat S., 2016, DYNAMIC REMODELING E
   Li YW, 2016, VIROLOGY, V488, P216, DOI 10.1016/j.virol.2015.11.018
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lv HF, 2017, J GEN VIROL, V98, P1679, DOI 10.1099/jgv.0.000867
   Maki Y, 2000, PLANT CELL PHYSIOL, V41, P289, DOI 10.1093/pcp/41.3.289
   Mazumder B, 2014, J VIROL, V88, P9100, DOI 10.1128/JVI.01129-14
   Middle East WHO, 2016, RESP SYNDR COR MERS
   Organization WH SCDfHIWN, 2020, COR NCOV INT GUID V1
   Rocha CS, 2008, VIROLOGY, V380, P165, DOI 10.1016/j.virol.2008.08.005
   Rodnina MV, 2009, CURR OPIN CELL BIOL, V21, P435, DOI 10.1016/j.ceb.2009.01.023
   Rodnina MV, 2011, RIBOSOME MOL MACHINE
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0
   VORGIAS CE, 1991, FEBS LETT, V286, P204, DOI 10.1016/0014-5793(91)80974-8
   Wan FY, 2007, CELL, V131, P927, DOI 10.1016/j.cell.2007.10.009
   Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006
   Wild T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000522
NR 30
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109904
DI 10.1016/j.mehy.2020.109904
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800028
PM 32502901
DA 2021-01-01
ER

PT J
AU Shahzad, S
   Willcox, M
AF Shahzad, Shakeel
   Willcox, Mark
TI Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy
   including anti-inflammatory and anti-viral prostaglandin (PG J(2)) for
   effective treatment and reduction in the death toll
SO MEDICAL HYPOTHESES
LA English
DT Article
DE SARS-CoV-2; Immuno-pathology; Anti-inflammatory and anti-viral
   prostaglandin
ID ACUTE RESPIRATORY SYNDROME; ACTIVATED RECEPTOR-GAMMA; SLEEP-WAKE
   REGULATION; HERPES-SIMPLEX VIRUS; SARS-CORONAVIRUS; KAPPA-B;
   CYCLOPENTENONE PROSTAGLANDINS; CLINICAL CHARACTERISTICS; INFLAMMATORY
   CYTOKINES; LUNG PATHOLOGY
AB Coronaviruses including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2, also known as 2019nCoV especially in China) replicate and divide in host cells. During this they are partly hidden from the innate immune responses although inflammatory consequences of viral replication still occur. We propose that antiinflammatory antiviral prostaglandins may not only restrict viral replication but also prevent inflammatory responses in the lungs and other vital organs that are known to be part of the immuno-pathogenesis of coronavirus disease-19 (COVID-19). The combination of anti-inflammatory antiviral prostaglandins with interferons may lead to the clearance of viruses inside growth-restricted infected cells. However, further experimental studies and clinical trials should be conducted to evaluate the safety and efficacy of these possible therapies.
C1 [Shahzad, Shakeel] Univ Agr Faisalabad, Inst Microbiol, Faisalabad 38040, Pakistan.
   [Willcox, Mark] Univ New South Wales Sydney, Sch Optometry & Vis Sci, Sydney, NSW 2052, Australia.
RP Shahzad, S (corresponding author), Univ Agr Faisalabad, Inst Microbiol, Faisalabad 38040, Pakistan.
EM Shakeel25shahzad@gmail.com; m.willcox@unsw.edu.au
OI Shahzad, Shakeel/0000-0002-2689-2129
CR Akahoshi T, 2003, ARTHRITIS RHEUM, V48, P231, DOI 10.1002/art.10709
   Amici C, 2006, ANTIVIR THER, V11, P1021
   Arabi YM, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3846-x
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Azuma Y, 2001, BIOCHEM BIOPH RES CO, V283, P344, DOI 10.1006/bbrc.2001.4783
   Batawi S, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1165-2
   Beigel JH, 2019, ANTIVIR RES, V167, P45, DOI 10.1016/j.antiviral.2019.04.006
   Chan KH, 2004, EMERG INFECT DIS, V10, P294, DOI 10.3201/eid1002.030610
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheung CY, 2005, J VIROL, V79, P7819, DOI 10.1128/JVI.79.12.7819-7826.2005
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cloutier A, 2012, J INFECT DIS, V205, P621, DOI 10.1093/infdis/jir804
   Farcas GA, 2005, J INFECT DIS, V191, P193, DOI 10.1086/426870
   FITZPATRICK FA, 1983, J BIOL CHEM, V258, P1713
   Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Guo Y, 2008, VIRUS RES, V133, P4, DOI 10.1016/j.virusres.2007.01.022
   Hayaishi O, 2002, NEUROSCIENTIST, V8, P12, DOI 10.1177/107385840200800105
   Hayaishi O, 2002, J APPL PHYSIOL, V92, P863, DOI 10.1152/japplphysiol.00766.2001
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   HUGHESFULFORD M, 1992, ANTIMICROB AGENTS CH, V36, P2253, DOI 10.1128/AAC.36.10.2253
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Jeffers SA, 2004, P NATL ACAD SCI USA, V101, P15748, DOI 10.1073/pnas.0403812101
   Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   LAMONTAGNE L, 1989, J IMMUNOL, V142, P4458
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   Law HKW, 2005, BLOOD, V106, P2366, DOI 10.1182/blood-2004-10-4166
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Mazzulli T, 2004, EMERG INFECT DIS, V10, P20, DOI 10.3201/eid1001.030404
   Ngai JC, 2010, RESPIROLOGY, V15, P543, DOI 10.1111/j.1440-1843.2010.01720.x
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   PENTREATH VW, 1990, T ROY SOC TROP MED H, V84, P795, DOI 10.1016/0035-9203(90)90085-S
   PICA F, 1993, ANTIVIR RES, V20, P193, DOI 10.1016/0166-3542(93)90020-J
   Pica F, 2000, ANTIMICROB AGENTS CH, V44, P200, DOI 10.1128/AAC.44.1.200-204.2000
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520
   Rossi A, 1996, J BIOL CHEM, V271, P32192, DOI 10.1074/jbc.271.50.32192
   Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746
   Rozera C, 1996, J CLIN INVEST, V97, P1795, DOI 10.1172/JCI118609
   Ruan KH, 2006, CURR PHARM DESIGN, V12, P925, DOI 10.2174/138161206776055994
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   SANTORO MG, 1987, J GEN VIROL, V68, P1153, DOI 10.1099/0022-1317-68-4-1153
   Scher JU, 2005, CLIN IMMUNOL, V114, P100, DOI 10.1016/j.clim.2004.09.008
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844
   Tseng CTK, 2005, J IMMUNOL, V174, P7977, DOI 10.4049/jimmunol.174.12.7977
   Tsui PT, 2003, EMERG INFECT DIS, V9, P1064
   Valledor AF, 2004, BIOCHEM PHARMACOL, V67, P201, DOI 10.1016/j.bcp.2003.10.016
   Wang WK, 2004, CLIN INFECT DIS, V39, P1071, DOI 10.1086/423808
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Wright DH, 1998, BRIT J PHARMACOL, V123, P1317
   YAMAMOTO N, 1987, BIOCHEM BIOPH RES CO, V146, P1425, DOI 10.1016/0006-291X(87)90809-6
   Yilla M, 2005, VIRUS RES, V107, P93, DOI 10.1016/j.virusres.2004.09.004
   Zhang QF, 2004, J MED VIROL, V73, P332, DOI 10.1002/jmv.20095
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
   Zumla A, 2015, INT J INFECT DIS, V40, P71, DOI 10.1016/j.ijid.2015.09.005
NR 73
TC 0
Z9 0
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110080
DI 10.1016/j.mehy.2020.110080
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800128
PM 32683221
OA Green Published
DA 2021-01-01
ER

PT J
AU Sposato, B
   Scalese, M
AF Sposato, Bruno
   Scalese, Marco
TI Why do children seem to be more protected against COVID-19? A hypothesis
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; Infection; Children; Coronavirus
ID CORONAVIRUS; RECEPTOR; ACE2; PROTEIN
AB Today it remains unclear why children seem to be less likely to get infected by COVID-19 or why they appear to be less symptomatic after infections. All individuals, especially children, are exposed to various viruses including human coronavirus (CoVs) that can generally lead to respiratory infections. We hypothesize that recurrent CoVs exposure may induce an effective antiviral B and T-cell-mediated adaptive immune response, which could also be protective against COVID-19. Based on the high-homology between the Spike protein epitopes of taxonomically-related coronaviruses, we theorize that past/recurrent contact with CoVs might shield children also against the circulating COVID-19 through a possible neutralizing antibody response previously CoVs-induced. This would open up possible lines of research for the development of live-attenuated virus vaccines from CoVs. Future research is desirable to confirm or disprove such hypothesis.
C1 [Sposato, Bruno] Misericordia Hosp, Pneumol Dept, Azienda USL Toscana Sud Est, Grosseto, Italy.
   [Sposato, Bruno] Univ Roma Tor Vergata, Expt Med & Syst, PhD Program Dept Syst Med, Rome, Italy.
   [Scalese, Marco] CNR, Inst Clin Physiol, Pisa, Italy.
RP Sposato, B (corresponding author), Azienda Osped Misericordia, UO Pneumol, Via Senese 161, I-58100 Grosseto, Italy.
EM bru.sposato@gmail.com
CR Arvia R, 2015, MOL CELL PROBE, V29, P408, DOI 10.1016/j.mcp.2015.08.006
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cruz AT, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0834
   Day CW, 2009, VIROLOGY, V395, P210, DOI 10.1016/j.virol.2009.09.023
   Devulapalli CS, 2020, ACTA PAEDIATR, V109, P2422, DOI 10.1111/apa.15407
   Devulapalli CS, 2020, INT J PEDIAT NEONATA, V6, P165, DOI [10.15344/2455-2364/2020/165, DOI 10.15344/2455-2364/2020/165]
   Enjuanes L, 2016, ADV VIRUS RES, V96, P245, DOI 10.1016/bs.aivir.2016.08.003
   Fang F, 2020, Zhonghua Er Ke Za Zhi, V58, P81, DOI 10.3760/cma.j.issn.0578-1310.2020.02.001
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Killerby ME, 2018, J CLIN VIROL, V101, P52, DOI 10.1016/j.jcv.2018.01.019
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li WH, 2007, VIROLOGY, V367, P367, DOI 10.1016/j.virol.2007.04.035
   Ploton MC, 2020, ARCH DIS CHILD, V105, P891, DOI 10.1136/archdischild-2019-317315
   Rawat M, 2020, AM J PERINAT, V37, P845, DOI 10.1055/s-0040-1710512
   Tilocca B, 2020, MICROBES INFECT, V22, P188, DOI 10.1016/j.micinf.2020.04.002
   Tilocca B, 2020, MICROBES INFECT, V22, P218, DOI 10.1016/j.micinf.2020.03.002
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu LQ, 2020, PEDIATR RES, V88, P342, DOI 10.1038/s41390-020-0892-8
NR 23
TC 1
Z9 1
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110151
DI 10.1016/j.mehy.2020.110151
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800053
PM 32763661
OA Green Published
DA 2021-01-01
ER

PT J
AU Tastemur, S
   Ataseven, H
AF Tastemur, Seyma
   Ataseven, Hilmi
TI Is it possible to use Proton Pump Inhibitors in COVID-19 treatment and
   prophylaxis?
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID-19; SARS-CoV2; Proton Pump Inhibitors; Treatment
ID RESPIRATORY SYNDROME CORONAVIRUS; HEME OXYGENASE-1; OMEPRAZOLE;
   GLYCOPROTEIN; CHLOROQUINE; EXPRESSION; ENTRY; MERS
AB Coronaviruses (CoV), discovered after 1960, caused human life-threatening outbreaks. SARS-CoV2, which appeared in Wuhan, China in December 2019, causing Severe Acute Respiratory Syndrome and has different features than other coronaviruses, has been determined and the disease caused by the virus has been called "Coronavirus Disease-2019" (COVID-19). This disease activates both the natural and acquired immune system. The cytokin storm, in which blood levels of proinflammatory cytokines are detected excessively high is developing and the uncontrolled inflammatory response causes local and systemic tissue damages. Although a spesific drug has not been found yet, the medications currently in use for other indications, whose pharmacokineticpharmacodynamic properties and toxic doses are already known; are included in the treatment practice of COVID-19. These drugs affect the entry of the virus into the cell and its intracellular distribution. They also have anti-inflammatory and immunomodulating effects too. Therefore, we think that Proton Pump Inhibitors (PPI's) with similar mechanisms of action may also be involved in COVID-19 treatment and prophylaxis.
C1 [Tastemur, Seyma] Sivas Numune Hosp, Dept Internal Med, Sivas, Turkey.
   [Ataseven, Hilmi] Sivas Cumhuriyet Univ, Fac Med, Discipline Gastroenterol, Dept Internal Med, Sivas, Turkey.
RP Tastemur, S (corresponding author), Sivas Numune Hosp, Dept Internal Med, Sivas, Turkey.
EM yaman_seyma@yahoo.com; hilmiataseven@yahoo.com
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Becker JC, 2006, BIOCHEM BIOPH RES CO, V345, P1014, DOI 10.1016/j.bbrc.2006.04.170
   Bicakci U, 2005, PEDIATR SURG INT, V21, P800, DOI 10.1007/s00383-005-1538-y
   Bojkova D, 2020, BIORXIV, DOI [10.1101/2020.04.03.024257, DOI 10.1101/2020.04.03.024257.]
   Brocks DR, 2012, EXPERT OPIN DRUG MET, V8, P1505, DOI 10.1517/17425255.2012.722757
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Cunha CB, 2014, VIRULENCE, V5, P650, DOI 10.4161/viru.32077
   Damle B, 2020, CLIN PHARMACOL THER, V108, P201, DOI 10.1002/cpt.1857
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   GALLAGHER TM, 1991, J VIROL, V65, P1916, DOI 10.1128/JVI.65.4.1916-1928.1991
   Ghebre YT, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00499
   Hammond CL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222779
   Homolak J, 2020, WIDELY AVAILABLE LYS
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jallouli M, 2015, ARTHRITIS RHEUMATOL, V67, P2176, DOI 10.1002/art.39194
   Kochar D. K., 2006, Journal of Vector Borne Diseases, V43, P161
   Kondapuram S.K, 2019, J CANC METASTASIS TR, V5, P32, DOI [10.20517/2394-4722.2018.105, DOI 10.20517/2394-4722.2018.105]
   MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7
   Michaelis M, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02790
   Nabirotchkin S, 2020, FOCUSING UNFOLDED PR, DOI [10.20944/preprints202003, DOI 10.20944/PREPRINTS202003.]
   Namazi MR, 2009, LUPUS, V18, P104, DOI 10.1177/0961203308097574
   Nelson C, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00016
   Pagat AM, 2007, APPL BIOSAFETY, V12, P100, DOI [10.1177/153567600701200206, DOI 10.1177/153567600701200206]
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Serafin MB, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105969
   Shi Y., 2020, IMMUNOLOGY, DOI [10.1101/2020.03.12.20034736., DOI 10.1101/2020.03.12.20034736.]
   Sinha N, 2002, POSTGRAD MED J, DOI [10.1136/postgradmedj-2020-, DOI 10.1136/POSTGRADMEDJ-2020-]
   Skinner-Adams T, 1999, ANTIMICROB AGENTS CH, V43, P1304, DOI 10.1128/AAC.43.5.1304
   STURMAN LS, 1990, J VIROL, V64, P3042, DOI 10.1128/JVI.64.6.3042-3050.1990
   Tastemur S, 2020, HER YONUYLE PROTON P, P171
   Thomas DE, 2019, LUPUS SCI MED, V6, DOI 10.1136/lupus-2019-000335
   Tyteca D, 2002, EXP CELL RES, V281, P86, DOI 10.1006/excr.2002.5613
   Ubagai T, 2009, J INFECT CHEMOTHER, V15, P374, DOI 10.1007/s10156-009-0728-2
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   WANDALL JH, 1992, GUT, V33, P617, DOI 10.1136/gut.33.5.617
   Wang HL, 2009, SCI CHINA SER C, V52, P464, DOI 10.1007/s11427-009-0061-0
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yang ZY, 2004, J VIROL, V78, P5642, DOI 10.1128/JVI.78.11.5642-5650.2004
   Ye Q, 2008, EUR RESPIR J, V31, P1030, DOI 10.1183/09031936.00125407
   Zhang B, 2020, IMMUNE PHENOTYPING B, DOI [10.1101/2020.03.12.20035048, DOI 10.1101/2020.03.12.20035048.]
   Zuo W, 2010, MOLECULAR BIOLOGY OF THE SARS-CORONAVIRUS, P247, DOI 10.1007/978-3-642-03683-5_15
NR 41
TC 2
Z9 2
U1 4
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110018
DI 10.1016/j.mehy.2020.110018
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800067
PM 32679422
DA 2021-01-01
ER

PT J
AU Vatansev, H
   Kadiyoran, C
   Cure, MC
   Cure, E
AF Vatansev, Hulya
   Kadiyoran, Cengiz
   Cure, Medine Cumhur
   Cure, Erkan
TI COVID-19 infection can cause chemotherapy resistance development in
   patients with breast cancer and tamoxifen may cause susceptibility to
   COVID-19 infection
SO MEDICAL HYPOTHESES
LA English
DT Article
ID PREVENTION
AB Breast cancer is the most common cancer in women and is the second most common cause of death in women. Estrogen plays an important role in breast tumor etiopathogenesis. Tamoxifen and other anti-estrogen drugs are used in breast cancer patients who have a positive estrogen receptor (ER). While angiotensin II plays a key role in breast cancer etiology and causes tamoxifen resistance, angiotensin 1-7 has been reported to may reduce the spread and invasion of breast cancer. During the COVID-19 infection, the virus blocks ACE2, and angiotensin 1-7 production discontinued. Angiotensin III production may increase as angiotensin II destruction is reduced. Thus, aminopeptidase upregulation may occur. Increased aminopeptidase may develop resistance to chemotherapy in breast cancer patients receiving chemotherapy. Estrogen can have a protective effect against COVID-19. Estrogen increase causes ER-a upregulation in T lymphocytes. Thus, estrogen increases the release of interferon I and III from T lymphocytes. Increasing interferon I and III alleviates COVID-19 infection. Tamoxifen treatment causes down-regulation, mutation, or loss in estrogen receptors. In the long-term use of tamoxifen, its effects on estrogen receptors can be permanent. Thus, since estrogen receptors are damaged or downregulated, estrogen may not act by binding to these receptors. Tamoxifen is a P-glycoprotein inhibitor, independent of its effect on estrogen receptors. It suppresses T cell functions and interferon release. We think tamoxifen may increase the COVID-19 risk due to its antiestrogen and P-glycoprotein inhibitory effects.
C1 [Vatansev, Hulya] Necmettin Erbakan Univ, Dept Chest Dis, Konya, Turkey.
   [Kadiyoran, Cengiz] Necmettin Erbakan Univ, Dept Radiol, Konya, Turkey.
   [Cure, Medine Cumhur] Dept Biochem, Istanbul, Turkey.
   [Cure, Erkan] Ota & Jinemed Hosp, Dept Internal Med, Deryadil Sokagi 1, TR-34357 Istanbul, Turkey.
RP Cure, E (corresponding author), Ota & Jinemed Hosp, Dept Internal Med, Deryadil Sokagi 1, TR-34357 Istanbul, Turkey.
EM erkancure@yahoo.com
CR Akcay S, 2020, TURK J MED SCI, V50, P604, DOI 10.3906/sag-2004-160
   Behjati S, 2009, CURR MED CHEM, V16, P3076, DOI 10.2174/092986709788803042
   Bujak-Gizycka B, 2019, J PHYSIOL PHARMACOL, V70, P503, DOI 10.26402/jpp.2019.4.02
   Cure E, 2020, DIABETES METAB SYND, V14, P349, DOI 10.1016/j.dsx.2020.04.019
   Cure E, 2020, J MED VIROL, V92, P1423, DOI 10.1002/jmv.25848
   Ruiz-Sanjuan MD, 2015, INTEGR CANCER THER, V14, P149, DOI 10.1177/1534735414562956
   Kalidhindi RSR, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01499
   LIU CM, 2015, BIOMED RES INT, V2015, DOI DOI 10.1155/2015/64204125692143
   Namazi S, 2015, TUMOR BIOL, V36, P893, DOI 10.1007/s13277-014-2713-3
   Suba Z, 2020, J PHARM PHARM SCI, V23, P75, DOI 10.18433/jpps31069
NR 10
TC 2
Z9 2
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110091
DI 10.1016/j.mehy.2020.110091
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800081
PM 32663742
OA Green Published
DA 2021-01-01
ER

PT J
AU Wiltshire, E
   Pena, AS
   MacKenzie, K
   Shaw, G
   Couper, J
AF Wiltshire, Esko
   Pena, Alexia Sophie
   MacKenzie, Karen
   Shaw, Geoffrey
   Couper, Jennifer
TI High dose folic acid is a potential treatment for pulmonary
   hypertension, including when associated with COVID-19 pneumonia
SO MEDICAL HYPOTHESES
LA English
DT Article
ID NITRIC-OXIDE; ENDOTHELIAL FUNCTION; DYSFUNCTION; CHILDREN; DISEASE;
   FOLATE
AB Background: Pulmonary hypertension is a significant complication for some patients with COVID-19 pneumonia, especially those requiring intensive care. Tachyphylaxis to the current therapy, inhaled nitric oxide (iNO), is also common. In vitro, folic acid directly increases nitric oxide (NO) production and extends its duration of action; effects which could be of benefit in reversing pulmonary hypertension and severe hypoxaemia. Our work has shown that, in the systemic circulation, folic acid in high dose rapidly improves nitric oxide mediated vasodilation, by activating endothelial nitric oxide synthase (eNOS).
   Hypothesis: A similar effect of high dose folic acid on pulmonary endothelial function would be expected from the same mechanism and would lead to improvement in pulmonary perfusion. We therefore hypothesise that folic acid, 5 mg or greater, is a useful therapeutic option for pulmonary hypertension and/or refractory severe hypoxaemia, in patients with severe COVID-19 associated pneumonia in whom NO therapy is considered, with a very low risk of adverse effects.
C1 [Wiltshire, Esko] Univ Otago Wellington, Paediat & Child Hlth, POB 7343, Wellington 6242, New Zealand.
   [Wiltshire, Esko] Capital & Coast Dist Hlth Board, Dept Paediat & Child Hlth, Wellington 7902, New Zealand.
   [Pena, Alexia Sophie; Couper, Jennifer] Univ Adelaide, Robinson Res Inst, Adelaide, SA 5006, Australia.
   [Pena, Alexia Sophie; Couper, Jennifer] Univ Adelaide, Discipline Paediat, Adelaide, SA 5006, Australia.
   [Pena, Alexia Sophie; Couper, Jennifer] Womens & Childrens Hosp, Endocrinol & Diabet Ctr, Adelaide, SA 5006, Australia.
   [MacKenzie, Karen] Univ Otago Christchurch, Dept Paediat, Christchurch, New Zealand.
   [MacKenzie, Karen] Canterbury Dist Hlth Board, Dept Paediat, Christchurch, New Zealand.
   [Shaw, Geoffrey] Univ Otago Christchurch, Dept Anaesthesia, Christchurch, New Zealand.
   [Shaw, Geoffrey] Canterbury Dist Hlth Board, Dept Intens Care, Christchurch, New Zealand.
RP Wiltshire, E (corresponding author), Univ Otago Wellington, Dept Paediat & Child Hlth, POB 7343, Wellington, New Zealand.
EM esko.wiltshire@otago.ac.nz
FU National Health and Medical Research Council AustraliaNational Health
   and Medical Research Council of Australia [519245]
FX This work in the systemic circulation, on which this hypothesis is
   based, was supported by the National Health and Medical Research Council
   Australia - Research Grant 519245.
CR Arroliga AC, 2003, RESP MED, V97, P825, DOI 10.1016/S0954-6111(03)00038-6
   Chalupsky K, 2015, ANTIOXID REDOX SIGN, V23, P1076, DOI 10.1089/ars.2015.6329
   Chen LN, 2004, CLIN INFECT DIS, V39, P1531, DOI 10.1086/425357
   Doshi SN, 2002, CIRCULATION, V105, P22, DOI 10.1161/hc0102.101388
   Dunlap B, 2016, AM FAM PHYSICIAN, V94, P463
   Gori T, 2001, CIRCULATION, V104, P1119, DOI 10.1161/hc3501.095358
   Gunduz M, 2014, EUR J PEDIATR, V173, P1707, DOI 10.1007/s00431-014-2330-6
   Iodice FG, 2013, PEDIATRICS, V132, pE248, DOI 10.1542/peds.2012-1945
   Itelman E, 2020, ISR MED ASSOC J, V22, P269
   JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314
   MacKenzie KE, 2006, PEDIATRICS, V118, P242, DOI 10.1542/peds.2005-2143
   Rosenzweig EB, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01916-2018
   Stanhewicz AE, 2017, NUTR REV, V75, P61, DOI 10.1093/nutrit/nuw053
   Stroes ESG, 2000, CIRC RES, V86, P1129
   Verhaar MC, 1998, CIRCULATION, V97, P237, DOI 10.1161/01.CIR.97.3.237
   Wiltshire EJ, 2015, J PEDIATR-US, V166, P319, DOI 10.1016/j.jpeds.2014.10.050
NR 16
TC 0
Z9 0
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 110142
DI 10.1016/j.mehy.2020.110142
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800148
PM 32759013
OA Green Published
DA 2021-01-01
ER

PT J
AU Yaqinuddin, A
   Kashir, J
AF Yaqinuddin, Ahmed
   Kashir, Junaid
TI Novel therapeutic targets for SARS-CoV-2-induced acute lung injury:
   Targeting a potential IL-1 beta/neutrophil extracellular traps feedback
   loop
SO MEDICAL HYPOTHESES
LA English
DT Article
DE COVID19; Coronavirus; Inflammasomes; Neutrophil extracellular traps
   (NETs); SARS
ID RESPIRATORY SYNDROME CORONAVIRUS; NLRP3 INFLAMMASOME; INHIBITION
AB Most COVID-19 infected individuals present with mild flu-like symptoms; however, 5-10% of cases suffer from life-threatening pneumonia and respiratory failure. The pathogenesis of SARS-CoV-2 and its pathology of associated acute lung injury (ALI), acute respiratory distress syndrome (ARDS), sepsis, coagulopathy and multiorgan failure is not known. SARS-CoV-2 is an envelope virus with S (spike), M (membrane), N (nucleocapsid) and E (envelop) proteins. In a closely related coronavirus (SARS-CoV), the transmembrane E protein exerts an important role in membrane-ionic transport through viroporins, deletion of which reduced levels of IL-1 beta and a remarkably reduced lung edema compared to wild type. IL-1 beta is generated by macrophages upon activation of intracellular NLRP3 (NOD-like, leucine rich repeat domains, and pyrin domain-containing protein 3), part of the functional NLRP3 inflammasome complex that detects pathogenic microorganisms and stressors, while neutrophils are enhanced by increasing levels of IL-1 beta. Expiring neutrophils undergo "NETosis", producing threadlike extracellular structures termed neutrophil extracellular traps (NETs), which protect against mild infections and microbes. However, uncontrolled NET production can cause acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), coagulopathy, multiple organ failure, and autoimmune disease. Herein, we present arguments underlying our hypothesis that IL-1 beta and NETs, mediated via NLRP3 inflammasomes, form a feedforward loop leading to the excessive alveolar and endothelial damage observed in severe cases of COVID-19. Considering such assertions, we propose potential drug candidates that could be used to alleviate such pathologies. Considering that recent efforts to ascertain effective treatments of COVID-19 in severe patients has been less than successful, investigating novel avenues of treating this virus are essential.
C1 [Yaqinuddin, Ahmed; Kashir, Junaid] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia.
   [Kashir, Junaid] King Faisal Specialist Hosp & Res Ctr, Dept Comparat Med, Riyadh, Saudi Arabia.
RP Yaqinuddin, A (corresponding author), Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia.
EM ayaqinuddin@alfaisal.edu
RI Yaqinuddin, Ahmed/ABE-3689-2020
OI Yaqinuddin, Ahmed/0000-0001-7536-910X
CR Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Boeltz S, 2019, CELL DEATH DIFFER, V26, P395, DOI 10.1038/s41418-018-0261-x
   Brill A, 2011, BLOOD, V117, P1400, DOI 10.1182/blood-2010-05-287623
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   DeDiego ML, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002315
   Denning NL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02536
   Dey D, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007548
   FDA Drug Safety Communication, DRUG SAFETY COMMUNIC
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gupta AK, 2010, FEBS LETT, V584, P3193, DOI 10.1016/j.febslet.2010.06.006
   Hamam HJ, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080369
   Jing XH, 2008, P NATL ACAD SCI USA, V105, P10967, DOI 10.1073/pnas.0804958105
   Jo EK, 2016, CELL MOL IMMUNOL, V13, P148, DOI 10.1038/cmi.2015.95
   Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
   Kumar V, 2018, J INFLAMM RES, V11, P477, DOI 10.2147/JIR.S178084
   Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124
   Leung YY, 2015, SEMIN ARTHRITIS RHEU, V45, P341, DOI 10.1016/j.semarthrit.2015.06.013
   Marchetti C, 2015, J CARDIOVASC PHARM, V66, P1, DOI 10.1097/FJC.0000000000000247
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Place DE, 2018, CURR OPIN IMMUNOL, V50, P32, DOI 10.1016/j.coi.2017.10.011
   Raamsman MJB, 2000, J VIROL, V74, P2333, DOI 10.1128/JVI.74.5.2333-2342.2000
   Rossol M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2339
   Schonrich G, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00366
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0
   Tagami T, 2014, J INTENSIVE CARE, V2, DOI 10.1186/s40560-014-0067-y
   Zahid A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02538
   Zawrotniak M, 2013, ACTA BIOCHIM POL, V60, P277
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 35
TC 1
Z9 2
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD OCT
PY 2020
VL 143
AR 109906
DI 10.1016/j.mehy.2020.109906
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OA0UL
UT WOS:000577511800045
PM 32505910
DA 2021-01-01
ER

PT J
AU Andrade, G
   do Couto, FS
   Pestana, LC
AF Andrade, Gabriela
   do Couto, Frederico Simoes
   Pestana, Luis Camara
TI Recommendations about the Use of Psychotropic Medications during the
   COVID-19 Pandemic
SO ACTA MEDICA PORTUGUESA
LA Portuguese
DT Article
DE COVID-19; Pandemics; Psychiatry; Psychotropic Drugs
AB Introduction: The COVID-19 pandemic is a particularly relevant threat to mentally ill patients, and it constitutes a new challenge for health care providers. To the best of our knowledge, there is not any embracing published review about the use of psychotropic drugs during the COVID-19 pandemic.
   Material and Methods: Non-systematic literature review. A search in the PubMed database was performed, with the terms 'psychotropic drugs', 'COVID-19', 'psychiatry' and 'pandemic'. Consensus and clinical guidelines about psychotropic drugs and COVID-19 approach, published by scientific societies, governmental entities and drug regulatory agencies were included.
   Results and Discussion: We present the recommendations about the use of psychotropic drugs during the COVID-19 pandemic, in the outpatient and inpatient settings. The treatment of affective bipolar disorder and schizophrenia have now added increased difficulties. Some psychotropic drugs interfere with the pathophysiology of the novel coronavirus infection and they could interact with the drugs used in the treatment of COVID-19. Some patients will need pharmacological interventions due to the presence of delirium. Smoking cessation changes the serum levels of some psychotropic drugs and may influence their use.
   Conclusion: The COVID-19 pandemic has created new challenges in clinical practice. Psychiatric patients are a vulnerable population and often a careful clinical, laboratorial and electrocardiographic evaluation may be needed, particularly in those diagnosed with COVID-19. The regular treatment of mentally ill patients with COVID-19 presents increased complexity.
C1 [Andrade, Gabriela; do Couto, Frederico Simoes; Pestana, Luis Camara] Ctr Hosp Univ Lisboa Norte, Serv Psiquiatria & Saude Mental, Lisbon, Portugal.
   [Andrade, Gabriela; Pestana, Luis Camara] Univ Lisbon, Fac Med, Clin Univ Psiquiatria & Psicol Med, Lisbon, Portugal.
   [do Couto, Frederico Simoes] Univ Lisbon, Fac Med, Inst Farmacol & Neurociencias, Lisbon, Portugal.
RP Andrade, G (corresponding author), Ctr Hosp Univ Lisboa Norte, Serv Psiquiatria & Saude Mental, Lisbon, Portugal.; Andrade, G (corresponding author), Univ Lisbon, Fac Med, Clin Univ Psiquiatria & Psicol Med, Lisbon, Portugal.
EM gabriela.andrade@chln.min-saude.pt
OI Andrade, Gabriela/0000-0003-3049-4390
CR Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72
   Becker Daniel E, 2012, Anesth Prog, V59, P28, DOI 10.2344/0003-3006-59.1.28
   Berkshire West National Health Service, 2020, GUID MAN LONG ACT IN
   Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089
   Bruce RD, 2010, JAIDS-J ACQ IMM DEF, V54, P511, DOI 10.1097/QAI.0b013e3181d3cad3
   Electronic medicines compendium (emc), 2020, HYDR
   Ely EW, 2012, CHEST, V142, P281, DOI 10.1378/chest.12-1189
   Ferrell BA, 2014, AM J RESP CRIT CARE, V189, P1295, DOI 10.1164/rccm.201404-0788ED
   Francis J, 2020, DIAGNOSIS DELIRIUM C
   Freudenreich O, 2020, GUIDELINES PRESCRIBI
   Hirschfeld R, 2005, PRACTICE GUIDELINE T
   Infarmed, 2020, INF DGS REC SUSP US
   Jenkinson J., 2020, RCPSYCH
   Lee CP, 2015, ACTA NEUROPSYCHIATR, V27, P380, DOI 10.1017/neu.2015.29
   Levenson J., 2019, LIAISON PSYCHIAT
   Marcantonio ER, 2017, NEW ENGL J MED, V377, P1456, DOI 10.1056/NEJMcp1605501
   McCance-Katz EF, 2006, CLIN INFECT DIS, V43, pS235, DOI 10.1086/508188
   McIntosh K., 2020, CORONAVIRUS DIS
   Pandarakalam J, 2020, BMJ-BRIT MED J, V368, pm1071
   Procyshyn R, 2017, CLIN HDB PSYCHOTROPI
   Riker RR, 2017, PHARMACOTHERAPY, V37, P500, DOI 10.1002/phar.1912
   Royal College of Psychiatrists, 2020, COVID 19 MED
   Royal College of Psychiatrists, 2020, CLOZ BLOOD DYSCR PAT
   SAFFER D, 1983, J AFFECT DISORDERS, V5, P289, DOI 10.1016/0165-0327(83)90017-4
   Silbernagl S, 2016, COLOR ATLAS PATHOPHY
   Siskind D, 2020, J PSYCHIATR NEUROSCI, V45, P1
   South London and Maudsley National Health Service, 2020, COVID 19 PSYCH MED
   Sun YJ, 2020, ANIM BIOTECHNOL, DOI 10.1080/10495398.2020.1769117
   Taylor D., 2020, CLOZAPINE EMERGENCY
   Taylor J, 2018, PICTURING THE PACIFIC: JOSEPH BANKS AND THE SHIPBOARD ARTISTS OF COOK AND FLINDERS, P13
   Walter Edward, 2015, J Intensive Care Soc, V16, P306, DOI 10.1177/1751143715583502
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu Y, 2020, BRAIN BEHAV IMMUN HL, DOI [10.1016/j.bbi.2020.03031., DOI 10.1016/J.BBI.2020.03031]
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ORDEM MEDICOS
PI LISBON
PA AV ALMIRANTE GAGO COUTINHO, 151, LISBON, 1749-084, PORTUGAL
SN 1646-0758
J9 ACTA MEDICA PORT
JI Acta Medica Port.
PD OCT
PY 2020
VL 33
IS 10
BP 693
EP 702
DI 10.20344/amp.13976
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ7TK
UT WOS:000577306100012
PM 32705981
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Siniscalchi, M
   Zingone, F
   Savarino, EV
   D'Odorico, A
   Ciacci, C
AF Siniscalchi, Monica
   Zingone, Fabiana
   Savarino, Edoardo Vincenzo
   D'Odorico, Anna
   Ciacci, Carolina
TI COVID-19 pandemic perception in adults with celiac disease: an impulse
   to implement the use of telemedicine
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Article
DE Celiac disease; COVID-19; Gluten-free diet; Anxiety; depression
ID RISK; SOCIETY
AB Background: Coronavirus Disease 2019 (COVID-19) causes severe complications and deaths all over the world. COVID-19 also has indirect effects from the lockdown and the possible lack of food. We aimed to evaluate the perception of this in Celiac Disease (CeD) patients who require a lifelong gluten-free diet as a therapy.
   Methods: We invited by e-mail CeD adult patients from the University of Salerno (Campania, South Italy) and the University of Padua (Veneto, North Italy) to answer an ad hoc COVID-19 survey.
   Results: We sent the web survey to 651 email addresses and we received 276 answers (42,4%). CeD patients did not feel more vulnerable because they had CeD (not at all 56.6%) and they did not worry much about the possible shortness of gluten-free food during the epidemic (not at all 48.5%). The most worried were the elderly patients, patients with other comorbidities and females. Finally, CeD patients were happy with remote consultations and explicitly asked to have them.
   Discussion: The COVID-19 pandemic has impacted a proportion of patients with CeD; in particular, women, elderly patients, patients with other comorbidities. COVID-19, although a challenging experience from the medical and the psychological point of view, has offered an opportunity to practice, on a largescale, a remote consultation approach for CeD healthcare. (C) 2020 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
C1 [Siniscalchi, Monica; Ciacci, Carolina] Univ Salerno, Scuola Med Salernitana, Celiac Ctr, Dept Med,Surg,Dent, Salerno, Italy.
   [Zingone, Fabiana; Savarino, Edoardo Vincenzo; D'Odorico, Anna] Univ Padua, Dept Surg Oncol & Gastroenterol, Gastroenterol Unit, Padua, Italy.
RP Ciacci, C (corresponding author), Univ Salerno, Univ Hosp San Giovanni di Dio & Ruggi dAragona, Via San Leonardo, I-84125 Salerno, SA, Italy.
EM cciacci@unisa.it
RI Zingone, Fabiana/O-5361-2018
OI Zingone, Fabiana/0000-0003-1133-1502; Monica,
   Siniscalchi/0000-0001-9744-9872
CR Al-Toma A, 2019, UNITED EUR GASTROENT, V7, P583, DOI 10.1177/2050640619844125
   Chen Q, 2020, CLIN CHARACTERISTICS
   Ciacci C, 2002, DIGEST DIS SCI, V47, P2082, DOI 10.1023/A:1019637315763
   Ciacci Carolina, 2015, Diseases, V3, P102, DOI 10.3390/diseases3020102
   Corazza GR, 1999, AM J GASTROENTEROL, V94, P391
   Di Sabatino A, 2013, WORLD J GASTROENTERO, V19, P2313, DOI 10.3748/wjg.v19.i15.2313
   Dorn SD, 2010, ALIMENT PHARM THER, V31, P666, DOI 10.1111/j.1365-2036.2009.04220.x
   Hardigan PC, 2016, RES SOC ADMIN PHARM, V12, P141, DOI 10.1016/j.sapharm.2015.07.003
   Lebwohl B, 2017, AM J GASTROENTEROL, V112, P1878, DOI 10.1038/ajg.2017.400
   Lindfors K, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-018-0054-z
   Ludvigsson JF, 2008, GUT, V57, P1074, DOI 10.1136/gut.2007.133868
   Ludvigsson JF, 2011, ALIMENT PHARM THER, V33, P689, DOI 10.1111/j.1365-2036.2010.04572.x
   Ludvigsson JF, 2014, GUT, V63, P1210, DOI 10.1136/gutjnl-2013-306578
   Marild K, 2010, AM J GASTROENTEROL, V105, P2465, DOI 10.1038/ajg.2010.352
   Meng YF, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008520
   Moccia L, 2020, BRAIN BEHAV IMMUN
   Wang C, 2020, INT J ENV RES PUBLIC, V17
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zingone F, 2015, UNITED EUR GASTROENT, V3, P136, DOI 10.1177/2050640614560786
   Zingone F, 2013, DIGEST LIVER DIS, V45, P115, DOI 10.1016/j.dld.2012.10.018
NR 21
TC 6
Z9 6
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD OCT
PY 2020
VL 52
IS 10
BP 1071
EP 1075
DI 10.1016/j.dld.2020.05.014
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OA0WN
UT WOS:000577517200002
PM 32425731
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ong, CWM
   Migliori, GB
   Raviglione, M
   MacGregor-Skinner, G
   Sotgiu, G
   Alffenaar, JW
   Tiberi, S
   Adlhoch, C
   Alonzi, T
   Archuleta, S
   Brusin, S
   Cambau, E
   Capobianchi, MR
   Castilletti, C
   Centis, R
   Cirillo, DM
   D'Ambrosio, L
   Delogu, G
   Esposito, SMR
   Figueroa, J
   Friedland, JS
   Ho, BCH
   Ippolito, G
   Jankovic, M
   Kim, HY
   Klintz, SR
   Kodmon, C
   Lalle, E
   Leo, YS
   Leung, CC
   Martson, AG
   Melazzini, MG
   Fard, SN
   Penttinen, P
   Petrone, L
   Petruccioli, E
   Pontali, E
   Saderi, L
   Santin, M
   Spanevello, A
   van Crevel, R
   van der Werf, MJ
   Visca, D
   Viveiros, M
   Zellweger, JP
   Zumla, A
   Goletti, D
AF Ong, Catherine Wei Min
   Migliori, Giovanni Battista
   Raviglione, Mario
   MacGregor-Skinner, Gavin
   Sotgiu, Giovanni
   Alffenaar, Jan-Willem
   Tiberi, Simon
   Adlhoch, Cornelia
   Alonzi, Tonino
   Archuleta, Sophia
   Brusin, Sergio
   Cambau, Emmanuelle
   Capobianchi, Maria Rosaria
   Castilletti, Concetta
   Centis, Rosella
   Cirillo, Daniela M.
   D'Ambrosio, Lia
   Delogu, Giovanni
   Esposito, Susanna M. R.
   Figueroa, Jose
   Friedland, Jon S.
   Ho, Benjamin Choon Heng
   Ippolito, Giuseppe
   Jankovic, Mateja
   Kim, Hannah Yejin
   Klintz, Senia Rosales
   Kodmon, Csaba
   Lalle, Eleonora
   Leo, Yee Sin
   Leung, Chi-Chiu
   Martson, Anne-Grete
   Melazzini, Mario Giovanni
   Fard, Saeid Najafi
   Penttinen, Pasi
   Petrone, Linda
   Petruccioli, Elisa
   Pontali, Emanuele
   Saderi, Laura
   Santin, Miguel
   Spanevello, Antonio
   van Crevel, Reinout
   van der Werf, Marieke J.
   Visca, Dina
   Viveiros, Miguel
   Zellweger, Jean-Pierre
   Zumla, Alimuddin
   Goletti, Delia
TI Epidemic and pandemic viral infections: impact on tuberculosis and the
   lung
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
ID EAST RESPIRATORY SYNDROME; PNEUMONIA REQUIRING HOSPITALIZATION;
   INFLUENZA-VIRUS INFECTION; EFFECTOR MEMORY PHENOTYPE; CRITICALLY-ILL
   PATIENTS; ANTIVIRAL DRUG ARBIDOL; T-CELL RESPONSES;
   MYCOBACTERIUM-TUBERCULOSIS; SYNDROME CORONAVIRUS; BACTERIAL PNEUMONIA
AB Major epidemics, including some that qualify as pandemics, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), HIV, influenza A (H1N1)pdm/09 and most recently COVID-19, affect the lung. Tuberculosis (TB) remains the top infectious disease killer, but apart from syndemic TB/HIV little is known regarding the interaction of viral epidemics and pandemics with TB. The aim of this consensus-based document is to describe the effects of viral infections resulting in epidemics and pandemics that affect the lung (MERS, SARS, HIV, influenza A (H1N1)pdm/09 and COVID-19) and their interactions with TB. A search of the scientific literature was performed. A writing committee of international experts including the European Centre for Disease Prevention and Control Public Health Emergency (ECDC PHE) team, the World Association for Infectious Diseases and Immunological Disorders (WAidid), the Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycobacterial Infections (ESGMYC) was established. Consensus was achieved after multiple rounds of revisions between the writing committee and a larger expert group. A Delphi process involving the core group of authors (excluding the ECDC PHE team) identified the areas requiring review/consensus, followed by a second round to refine the definitive consensus elements. The epidemiology and immunology of these viral infections and their interactions with TB are discussed with implications for diagnosis, treatment and prevention of airborne infections (infection control, viral containment and workplace safety). This consensus document represents a rapid and comprehensive summary on what is known on the topic.
C1 [Ong, Catherine Wei Min; Archuleta, Sophia] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.
   [Ong, Catherine Wei Min] Natl Univ Singapore, Inst Hlth Innovat & Technol, iHealthtech, Singapore, Singapore.
   [Migliori, Giovanni Battista; Centis, Rosella] Ist Clin Sci Maugeri IRCCS, Serv Epidemiol Clin Malattie Resp, Via Roncaccio 16, I-21049 Tradate, Italy.
   [Raviglione, Mario] Univ Milan, Ctr Multidisciplinary Res Hlth Sci, Milan, Italy.
   [Raviglione, Mario] Univ Geneva, Global Studies Inst, Geneva, Switzerland.
   [MacGregor-Skinner, Gavin] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA USA.
   [Sotgiu, Giovanni; Saderi, Laura] Univ Sassari, Dept Med Surg & Expt Sci, Clin Epidemiol & Med Stat Unit, Sassari, Italy.
   [Alffenaar, Jan-Willem; Kim, Hannah Yejin] Univ Sydney, Sydney Pharm Sch, Sydney, NSW, Australia.
   [Alffenaar, Jan-Willem; Kim, Hannah Yejin] Westmead Hosp, Sydney, NSW, Australia.
   [Alffenaar, Jan-Willem; Kim, Hannah Yejin] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia.
   [Tiberi, Simon] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England.
   [Tiberi, Simon] Barts Hlth NHS Trust, Royal London Hosp, Div Infect, London, England.
   [Adlhoch, Cornelia; Brusin, Sergio; Klintz, Senia Rosales; Kodmon, Csaba; Penttinen, Pasi; van der Werf, Marieke J.] European Ctr Dis Prevent & Control, Publ Hlth Emergency Team, Stockholm, Sweden.
   [Alonzi, Tonino; Fard, Saeid Najafi; Petrone, Linda; Petruccioli, Elisa; Goletti, Delia] IRCCS, L Spallanzani Natl Inst Infect Dis INMI, Epidemiol & Preclin Res Dept, Translat Res Unit, Via Portuense 292, I-00149 Rome, Italy.
   [Cambau, Emmanuelle] Univ Paris, AP HP Lariboisiere, Natl Reference Ctr Mycobacteria, Bacteriol,Lab Associated,IAME UMR1137,INSERM, Paris, France.
   [Capobianchi, Maria Rosaria; Castilletti, Concetta; Lalle, Eleonora] IRCCS, L Spallanzani Natl Inst Infect Dis INMI, Epidemiol & Preclin Res Dept, Lab Virol, Rome, Italy.
   [Cirillo, Daniela M.] IRCCS San Raffaele Sci Inst, Emerging Bacterial Pathogens Unit, Milan, Italy.
   [D'Ambrosio, Lia] Publ Hlth Consulting Grp, Lugano, Switzerland.
   [Delogu, Giovanni] Univ Cattol Sacro Cuore, Rome, Italy.
   [Delogu, Giovanni] Mater Olbia Hosp, Olbia, Italy.
   [Esposito, Susanna M. R.] Univ Parma, Pietro Barilla Childrens Hosp, Pediat Clin, Parma, Italy.
   [Figueroa, Jose] Natl Hlth Serv, London, England.
   [Friedland, Jon S.] St Georges Univ London, London, England.
   [Ho, Benjamin Choon Heng] Tan Tock Seng Hosp, Dept Resp & Crit Care Med, TB Control Unit, Singapore, Singapore.
   [Ippolito, Giuseppe] IRCCS, L Spallanzani Natl Inst Infect Dis INMI, Sci Direct L Spallanzani, Rome, Italy.
   [Jankovic, Mateja] Univ Zagreb, Sch Med, Zagreb, Croatia.
   [Jankovic, Mateja] Univ Hosp Ctr Zagreb, Clin Resp Dis, Zagreb, Croatia.
   [Leo, Yee Sin] Natl Ctr Infect Dis, Singapore, Singapore.
   [Leung, Chi-Chiu] Chest & Heart Dis Assoc, Hong Kong TB, Wanchai, Hong Kong, Peoples R China.
   [Martson, Anne-Grete] Univ Med Ctr Groningen, Univ Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.
   [Melazzini, Mario Giovanni] Ist Clin Sci Maugeri IRCCS, Sci Direct, Pavia, Italy.
   [Pontali, Emanuele] Galliera Hosp, Dept Infect Dis, Genoa, Italy.
   [Santin, Miguel] Bellvitge Biomed Res Inst IDIBELL, Bellvitge Univ Hosp, Dept Infect Dis, Barcelona, Spain.
   [Santin, Miguel] Univ Barcelona, Dept Clin Sci, Barcelona, Spain.
   [Spanevello, Antonio; Visca, Dina] IRCCS, Ist Clin Sci Maugeri, Div Pulm Rehabil, Tradate, Italy.
   [Spanevello, Antonio; Visca, Dina] Univ Insubria, Dept Med & Surg, Resp Dis, Varese Como, Italy.
   [van Crevel, Reinout] Radboud Inst Hlth Sci, Radboudumc Ctr Infect Dis, Nijmegen, Netherlands.
   [van Crevel, Reinout] Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England.
   [Viveiros, Miguel] NOVA Univ Lisbon, Inst Hyg & Trop Med, Global Hlth & Trop Med, Lisbon, Portugal.
   [Zellweger, Jean-Pierre] Swiss Lung Assoc, TB Competence Ctr, Bern, Switzerland.
   [Zumla, Alimuddin] UCL, Div Infect & Immun, Dept Infect, London, England.
   [Zumla, Alimuddin] UCL Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Goletti, Delia] St Camillus Int Univ Hlth & Med Sci, Rome, Italy.
   [Ong, Catherine Wei Min; Migliori, Giovanni Battista] ESGMYC, Rome, Italy.
   [Ong, Catherine Wei Min; Alffenaar, Jan-Willem; Tiberi, Simon; Cambau, Emmanuelle; Cirillo, Daniela M.; Delogu, Giovanni; Friedland, Jon S.; Jankovic, Mateja; Santin, Miguel; van Crevel, Reinout; Viveiros, Miguel; Goletti, Delia] European Ctr Dis Prevent & Control Publ Hlth Emer, Stockholm, Sweden.
RP Migliori, GB (corresponding author), Ist Clin Sci Maugeri IRCCS, Serv Epidemiol Clin Malattie Resp, Via Roncaccio 16, I-21049 Tradate, Italy.; Goletti, D (corresponding author), IRCCS, L Spallanzani Natl Inst Infect Dis INMI, Epidemiol & Preclin Res Dept, Translat Res Unit, Via Portuense 292, I-00149 Rome, Italy.
EM giovannibattista.migliori@icsmaugeri.it; delia.goletti@inmi.it
RI Viveiros, Miguel/A-7326-2008; ZUMLA, Alimuddin/ABA-8208-2020
OI Viveiros, Miguel/0000-0001-9676-6251; 
FU European and Developing Countries Clinical Trials Partnership the EU
   Horizon 2020 Framework Programme for Research and Innovation; National
   Institutes of Health Research senior investigator awardUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; Singapore National Medical Research CouncilNational Medical
   Research Council, Singapore [NMRC/TA/0042/2015, CSAINV17nov014];
   National University Health System, Singapore [NUHS/RO/2017/092/SU/01,
   CFGFY18P11, NUHS/RO/2020/042/RO5+5/ad-hoc/1]; National Centre for
   Infectious Diseases, Singapore [STPRG-FY19-003]; Young Investigator
   Award, Institut Merieux, Lyon, France; Marie Sklodowska-Curie Actions
   [713660-PRONKJEWAIL-H2020-MSCACOFUND-2015]; Italian Ministry of Health,
   Ricerca CorrenteMinistry of Health, Italy; Crossref Funder Registry
FX A. Zumla is a co-Principal Investigator of the Pan-African Network on
   Emerging and Re-Emerging Infections (PANDORA-IDNET) funded by the
   European and Developing Countries Clinical Trials Partnership the EU
   Horizon 2020 Framework Programme for Research and Innovation; and is
   also in receipt of a National Institutes of Health Research senior
   investigator award. C.W.M. Ong is funded by Singapore National Medical
   Research Council (NMRC/TA/0042/2015, CSAINV17nov014); National
   University Health System, Singapore (NUHS/RO/2017/092/SU/01, CFGFY18P11,
   NUHS/RO/2020/042/RO5+5/ad-hoc/1); National Centre for Infectious
   Diseases, Singapore (STPRG-FY19-003); and is recipient of the Young
   Investigator Award, Institut Merieux, Lyon, France. A-G. Martson was
   funded by Marie Sklodowska-Curie Actions, grant agreement number
   713660-PRONKJEWAIL-H2020-MSCACOFUND-2015. The article is part of the
   activities of the Global Tuberculosis Network (GTN) and of the WHO
   Collaborating Centre for Tuberculosis and Lung Diseases, Tradate
   (ITA-80, 2017-2020-GBM/RC/LDA). Part of the work was supported by the
   Italian Ministry of Health, Ricerca Corrente (Linea 1 and Linea 4).
   Funding information for this article has been deposited with the
   Crossref Funder Registry.
CR Abraham GM, 2020, CLIN INFECT DIS, DOI 10.1093/cid/ciaa107
   Abril-Rodriguez G, 2017, CANCER CELL, V31, DOI 10.1016/j.ccell.2017.05.010
   Akiyama MJ, 2020, NEW ENGL J MED, V382, P2075, DOI 10.1056/NEJMp2005687
   Al-Tawfiq JA, 2014, CLIN INFECT DIS, V59, P160, DOI 10.1093/cid/ciu226
   Alfaraj SH, 2017, INTERVIROLOGY, V60, P53, DOI 10.1159/000477908
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Almekhlafi GA, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1303-8
   Alonso C, 2017, J VET DIAGN INVEST, V29, P298, DOI 10.1177/1040638717700221
   [Anonymous], 1919, Cal State J Med, V17, P85
   [Anonymous], 2019, WHO GUID TUB INF PRE
   [Anonymous], 2020, WHO CONS GUID TUB MO
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Arlehamn CSL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005760
   Arnold FW, 2020, CURR OPIN PULM MED, V26, P208, DOI 10.1097/MCP.0000000000000666
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Ault R, 2018, EXP GERONTOL, V111, P35, DOI 10.1016/j.exger.2018.06.029
   Azoulay E, 2020, CHEST, V157, P293, DOI 10.1016/j.chest.2019.08.002
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Ballinger MN, 2010, J INTERF CYTOK RES, V30, P643, DOI 10.1089/jir.2010.0049
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Berger A, 2004, J CLIN VIROL, V29, P13, DOI 10.1016/j.jcv.2003.09.011
   Biering-Sorensen S, 2018, J INFECT DIS, V217, P759, DOI 10.1093/infdis/jix612
   Blachere FM, 2018, INFLUENZA OTHER RESP, V12, P613, DOI 10.1111/irv.12572
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Bonny TS, 2018, AM J INFECT CONTROL, V46, P105, DOI 10.1016/j.ajic.2017.07.014
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Bortoli R, 2007, CLIN RHEUMATOL, V26, P1809, DOI 10.1007/s10067-007-0662-6
   Busti AJ, 2004, PHARMACOTHERAPY, V24, P1732, DOI 10.1592/phco.24.17.1732.52347
   Bystrom J, 2013, VIRUSES-BASEL, V5, P777, DOI 10.3390/v5030777
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carter DJ, 2018, LANCET GLOB HEALTH, V6, pE514, DOI 10.1016/S2214-109X(18)30195-5
   Centers for Disease Control and Prevention, 2020, EST INFL ILLN MED VI
   Centers for Disease Control and Prevention, 2003, GUIDELINES ENV INFEC
   Chackerian AA, 2002, INFECT IMMUN, V70, P4501, DOI 10.1128/IAI.70.8.4501-4509.2002
   Chadha MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124122
   Chan J, 2014, SEMIN IMMUNOL, V26, P588, DOI 10.1016/j.smim.2014.10.005
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen YC, 2004, EMERG INFECT DIS, V10, P782, DOI 10.3201/eid1005.030579
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   CHIACCHIO RG, 2014, J WILDLIFE DIS, V50, P496, DOI DOI 10.7589/2013-05-109
   Chiacchio T, 2018, IMMUNOL LETT, V198, P33, DOI 10.1016/j.imlet.2018.04.001
   Chiacchio T, 2014, J INFECTION, V69, P533, DOI 10.1016/j.jinf.2014.06.009
   Chiu C, 2015, NAT IMMUNOL, V16, P18, DOI 10.1038/ni.3056
   Cordero E, 2012, EUR J CLIN MICROBIOL, V31, P547, DOI 10.1007/s10096-011-1346-3
   Cui W, 2003, CLIN INFECT DIS, V37, P857, DOI 10.1086/378587
   Cui YX, 2020, J INFECT DIS, V221, P1775, DOI 10.1093/infdis/jiaa113
   Daoud A, 2019, POSTGRAD MED, V131, P299, DOI 10.1080/00325481.2019.1592400
   Dara M, 2020, INT J TUBERC LUNG D, V24, P544, DOI 10.5588/ijtld.20.0151
   Day CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094949
   Day CL, 2011, J IMMUNOL, V187, P2222, DOI 10.4049/jimmunol.1101122
   de Paus RA, 2013, TUBERCULOSIS, V93, P338, DOI 10.1016/j.tube.2013.02.006
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Deng P, 2013, ANTIMICROB AGENTS CH, V57, P1743, DOI 10.1128/AAC.02282-12
   Dharmadhikari AS, 2012, AM J RESP CRIT CARE, V185, P1104, DOI 10.1164/rccm.201107-1190OC
   Dorward J., 2020, LOPINAVIR RITONAVIR
   Duan SM, 2003, BIOMED ENVIRON SCI, V16, P246
   Dubayova T, 2010, INT J PUBLIC HEALTH, V55, P459, DOI 10.1007/s00038-010-0149-0
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Dwivedi VP, 2012, J BIOL CHEM, V287, P33656, DOI 10.1074/jbc.M112.375154
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Esposito S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01260-2020
   Esposito S, 2011, J INFECTION, V63, P300, DOI 10.1016/j.jinf.2011.07.015
   European Centre for Disease Prevention and Control, 2020, US FAC MASKS COMM RE
   European Centre for Disease Prevention and Control, 2020, COR DIS 2019 COVID 1
   European Centre for Disease Prevention and Control, 2020, DIS ENV HEALTHC NONH
   European Centre for Disease Prevention and Control, 2020, GUID US NONPH MEAS D
   European Centre for Disease Prevention and Control, 2020, CLOTH MASKS MASK STE
   Evans D, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3762-x
   Food and Drug Administration, 2020, FDA CAUT US HYDR CHL
   Fox SE., PULMONARY CARDIAC PA, DOI [10.1101/2020.04.06.20050575, DOI 10.1101/2020.04.06.20050575]
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Genovese MC, 2013, J RHEUMATOL, V40, P768, DOI 10.3899/jrheum.120687
   Gillim-Ross L, 2006, CLIN MICROBIOL REV, V19, P614, DOI 10.1128/CMR.00005-06
   Goletti D, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01089-2018
   Goletti D, 2018, RESPIROLOGY, V23, P455, DOI 10.1111/resp.13272
   Goletti D, 2014, J RHEUMATOL, V41, P24, DOI 10.3899/jrheum.140099
   Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069390
   Hagan G, 2013, CRIT CARE, V17, DOI 10.1186/cc12760
   Hatchett RJ, 2007, P NATL ACAD SCI USA, V104, P7582, DOI 10.1073/pnas.0610941104
   Hensel J, 2020, EXERCISING CAUTION C, DOI [10.1101/2020.04.08.20056051, DOI 10.1101/2020.04.08.20056051]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   International Severe Acute Respiratory and Emerging Infections Consortium, 2020, COVID 19 REP
   Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245
   Jain S, 2017, CLIN CHEST MED, V38, P1, DOI 10.1016/j.ccm.2016.11.012
   Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870
   Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0
   Jang CH, 2006, RHEUMATOLOGY, V45, P703, DOI 10.1093/rheumatology/kei282
   Jegaskanda S, 2014, J IMMUNOL, V193, P469, DOI 10.4049/jimmunol.1400432
   Jones AK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175816
   Joosten SA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005687
   Jordan Paul C., 2018, Antiviral Chemistry & Chemotherapy, V26, p2040206618764483, DOI 10.1177/2040206618764483
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Kinner SA, 2020, LANCET PUBLIC HEALTH, V5, pE188, DOI 10.1016/S2468-2667(20)30058-X
   Kirov S., 2020, ASS BCG POLICY IS SI, DOI [10.1101/2020.04.06.20055616, DOI 10.1101/2020.04.06.20055616]
   Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896
   Krzeminski P, 2018, POSTEP DERM ALERGOL, V35, P429, DOI 10.5114/ada.2018.77675
   Kufner V, 2019, GENES-BASEL, V10, DOI 10.3390/genes10090661
   Kumar A, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002079
   Kuo SC, 2020, EMERG INFECT DIS, V26, P1928, DOI 10.3201/eid2608.201192
   Lai MYY, 2005, CLIN INFECT DIS, V41, pE67, DOI 10.1086/433186
   Lancioni C, 2012, AM J RESP CRIT CARE, V185, P206, DOI 10.1164/rccm.201107-1355OC
   Lawn SD, 2011, INT J TUBERC LUNG D, V15, P571, DOI 10.5588/ijtld.10.0483
   Leung C C, 2020, Int J Tuberc Lung Dis, V24, P556, DOI 10.5588/ijtld.20.0244
   Leung CC, 2020, INT J TUBERC LUNG D, V24, P364, DOI 10.5588/ijtld.20.0124
   Leung CC, 2020, LANCET, V395, P945, DOI 10.1016/S0140-6736(20)30520-1
   Leung NHL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148669
   Lewis D, 2020, NATURE, V580, P175, DOI 10.1038/d41586-020-00974-w
   Li CX, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60992-6
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Li H, 2018, NAT REV IMMUNOL, V18, P591, DOI 10.1038/s41577-018-0028-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lin PL, 2015, SEMIN IMMUNOPATHOL, V37, P239, DOI 10.1007/s00281-015-0490-8
   Liu Q, 2020, Fa Yi Xue Za Zhi, V36, P21, DOI 10.12116/j.issn.1004-5619.2020.01.005
   Liu W, 2006, EMERG INFECT DIS, V12, P707, DOI 10.3201/eid1204.050264
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Liu Y, 2020, ACTIVE LATENT TUBERC, DOI [10.1101/2020.03.10.20033795, DOI 10.1101/2020.03.10.20033795]
   Liverpool Drug Interaction Group, 2020, INT EXP COVID 19 THE
   Louthrenoo W, 2015, JCR-J CLIN RHEUMATOL, V21, P346, DOI 10.1097/RHU.0000000000000297
   Low JGH, 2004, CLIN INFECT DIS, V38, pE123, DOI 10.1086/421396
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Lu ZK, 2015, EXPERT OPIN DRUG SAF, V14, P295, DOI 10.1517/14740338.2015.989210
   Luo T, 2014, EPIDEMIOL INFECT, V142, P2036, DOI 10.1017/S0950268813003142
   Machado D, 2019, INFECT GENET EVOL, V72, P93, DOI 10.1016/j.meegid.2018.11.021
   MacIntyre CR, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006577
   Madelain V, 2016, CLIN PHARMACOKINET, V55, P907, DOI 10.1007/s40262-015-0364-1
   Madhi SA, 2013, PEDIATR INFECT DIS J, V32, pE119, DOI 10.1097/INF.0b013e3182784b26
   Malcangi G, 2000, RHEUMATOL INT, V20, P31, DOI 10.1007/s002960000066
   Marais BJ, 2020, LANCET INFECT DIS, V20, P641, DOI 10.1016/S1473-3099(20)30167-5
   Marchisio P, 2012, HUM VACC IMMUNOTHER, V8, P17, DOI 10.4161/hv.8.1.18145
   Mathad JS, 2012, CLIN INFECT DIS, V55, P1532, DOI 10.1093/cid/cis732
   McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz538
   Mckee M, 2020, NAT MED, V26, P640, DOI 10.1038/s41591-020-0863-y
   McShane H, 2005, INT J STD AIDS, V16, P95, DOI 10.1258/0956462053057576
   Metersky ML, 2012, INT J INFECT DIS, V16, pE321, DOI 10.1016/j.ijid.2012.01.003
   Mhimbira F, 2019, CLIN MICROBIOL INFEC, V25, DOI 10.1016/j.cmi.2018.03.019
   Midgley Claire M, 2014, MMWR Morb Mortal Wkly Rep, V63, P798
   Migliori GB, 2020, INT J INFECT DIS, V92, pS15, DOI 10.1016/j.ijid.2020.01.042
   Migliori GB, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00391-2019
   Migliori GB, 2018, LANCET GLOB HEALTH, V6, pE475, DOI 10.1016/S2214-109X(18)30189-X
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.1101/2020.03.24.20042937, DOI 10.1101/2020.03.24.20042937, 10. 1101/2020.03.24.20042937]
   Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   Morens DM, 2007, J INFECT DIS, V195, P1018, DOI 10.1086/511989
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Motta I, 2020, PULMONOLOGY, V26, P233, DOI 10.1016/j.pulmoe.2020.05.002
   Mukherjee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180143
   Negin J, 2015, INT J INFECT DIS, V32, P135, DOI 10.1016/j.ijid.2014.11.018
   Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Lan NTN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084866
   Nicholls J, 2003, RESPIROLOGY, V8, pS6, DOI 10.1046/j.1440-1843.2003.00517.x
   Nikolova M, 2013, DIAGN MICR INFEC DIS, V75, P277, DOI 10.1016/j.diagmicrobio.2012.11.023
   Olin A, 2018, CELL, V174, P1277, DOI 10.1016/j.cell.2018.06.045
   Ong CWM, 2020, INT J TUBERC LUNG D, V24, P547, DOI 10.5588/ijtld.20.0140
   Ong CWM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29659-1
   Ong CWM, 2014, AM J RESP CRIT CARE, V190, P9, DOI 10.1164/rccm.201311-2106PP
   Openshaw PJ, 2013, CURR OPIN VIROL, V3, P468, DOI 10.1016/j.coviro.2013.05.005
   Pandie M, 2016, J ANTIMICROB CHEMOTH, V71, P1037, DOI 10.1093/jac/dkv447
   Park Y, 2014, TUBERC RESPIR DIS, V76, P84, DOI 10.4046/trd.2014.76.2.84
   Pasipanodya JG, 2007, CHEST, V131, P1817, DOI 10.1378/chest.06-2949
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Petruccioli E, 2020, J INFECTION, V80, P536, DOI 10.1016/j.jinf.2020.02.009
   Petruccioli E, 2016, EUR RESPIR J, V48, P1751, DOI 10.1183/13993003.01012-2016
   Petruccioli E, 2013, J INFECTION, V66, P475, DOI 10.1016/j.jinf.2013.02.004
   Pinsky BA, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.00373-19
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Protezione Civile, 2020, COR EM
   Qian XW, 2020, TRANSL PEDIATR, V9, P34, DOI 10.21037/tp.2020.01.06
   Rabenau HF, 2005, MED MICROBIOL IMMUN, V194, P1, DOI 10.1007/s00430-004-0219-0
   Rabie H, 2019, LANCET HIV, V6, pE32, DOI 10.1016/S2352-3018(18)30293-5
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reed C, 2014, CLIN INFECT DIS, V59, P166, DOI 10.1093/cid/ciu285
   Reiley WW, 2008, P NATL ACAD SCI USA, V105, P10961, DOI 10.1073/pnas.0801496105
   Rello J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01028-2020
   Rice TW, 2012, CRIT CARE MED, V40, P1487, DOI 10.1097/CCM.0b013e3182416f23
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Roth S, 2013, INFLUENZA OTHER RESP, V7, P244, DOI 10.1111/j.1750-2659.2012.00413.x
   Rozot V, 2013, EUR J IMMUNOL, V43, P1568, DOI 10.1002/eji.201243262
   Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003
   Saha S, 2014, B WORLD HEALTH ORGAN, V92, P318, DOI 10.2471/BLT.13.124412
   Saunders MJ, 2016, LANCET INFECT DIS, V16, P395, DOI 10.1016/S1473-3099(15)00434-X
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Segal Leopoldo N, 2011, Proc Am Thorac Soc, V8, P282, DOI 10.1513/pats.201006-044WR
   Shakil AO, 1996, J HEPATOL, V24, P48, DOI 10.1016/S0168-8278(96)80185-1
   Sharifian MR, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/295327
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   Shionogi & Co. Ltd, 2018, REV REP XOFL BAL
   Shiraki K, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107512
   Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085
   Siqueira PC, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.5123/s1679-49742020000300014, 10.5123/S1679-49742020000300014]
   Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567
   Song JH, 2013, J PHARM PHARMACOL, V65, P521, DOI 10.1111/jphp.12014
   Song JY, 2011, INFLUENZA OTHER RESP, V5, pR535, DOI 10.1111/j.1750-2659.2011.00269.x
   Soo RJJ, 2020, EMERG INFECT DIS, V26, P1933, DOI 10.3201/eid2608.201229
   SPENCER JC, 1977, J INFECT DIS, V136, P171, DOI 10.1093/infdis/136.2.171
   Tadolini M, 2020, EUR RESPIR J, V56
   Thorne CD, 2004, J OCCUP ENVIRON MED, V46, P613, DOI 10.1097/01.jom.0000134191.92225.f2
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tokman S, 2013, CLIN CHEST MED, V34, P191, DOI 10.1016/j.ccm.2013.02.005
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   van den Brand JMA, 2014, J COMP PATHOL, V151, P83, DOI 10.1016/j.jcpa.2014.01.004
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Vareille M, 2011, CLIN MICROBIOL REV, V24, P210, DOI 10.1128/CMR.00014-10
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vitacca M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00632-2020
   Walaza S, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz020
   Walaza S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129173
   Wang JT, 2004, EMERG INFECT DIS, V10, P818, DOI 10.3201/eid1005.030640
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang RR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105617
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wang YH, 2020, RADIOLOGY, V296, pE55, DOI 10.1148/radiol.2020200843
   Weng D, 2019, BIOMED PHARMACOTHER, V110, P440, DOI 10.1016/j.biopha.2018.11.090
   WHO, 2019, GLOB TUB REP 2019
   WHO, 2020, COVID 19 STRAT PREP
   WHO, 2020, MOD TRANSM VIR CAUS
   WHO, 2020, REP WHO CHIN JOINT M
   WHO, 2020, WHO INF NOT TUB COVI
   WHO, 2020, BAC CALM GUER BCG VA
   WHO, 2020, CLIN MAN SEV AC RESP
   Wolf AJ, 2008, J EXP MED, V205, P105, DOI 10.1084/jem.20071367
   Wong Chak-Yen, 2004, J Chin Med Assoc, V67, P579
   World Health Organisation, 2020, CRIT PREP READ RESP
   World Health Organization, 2012, WHO POL COLL TB HIV
   World Health Organization, 2013, SYST SCREEN ACT TUB
   World Health Organization, 2012, WHO INT PROT RAP OP
   World Health Organization, 2020, WHO OP HDB TUB MOD 1
   World Health Organization, 2003, EM PREP RESP PREL CL
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wumkes ML, 2017, VACCINE, V35, P1299, DOI 10.1016/j.vaccine.2017.01.039
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yan J, 2018, P NATL ACAD SCI USA, V115, P1081, DOI 10.1073/pnas.1716561115
   Yen YF, 2018, EMERG INFECT DIS, V24, P498, DOI 10.3201/eid2403.152071
   Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI 10.1093/eurheartj/ehw211
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
   Zurcher K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162575
NR 254
TC 0
Z9 0
U1 1
U2 1
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD OCT 1
PY 2020
VL 56
IS 4
PG 26
WC Respiratory System
SC Respiratory System
GA NZ4OR
UT WOS:000577075200010
DA 2021-01-01
ER

PT J
AU Ong, CWM
   Migliori, GB
   Raviglione, M
   MacGregor-Skinner, G
   Sotgiu, G
   Alffenaar, JW
   Tiberi, S
   Adlhoch, C
   Alonzi, T
   Archuleta, S
   Brusin, S
   Cambau, E
   Capobianchi, MR
   Castilletti, C
   Castilletti, C
   Centis, R
   Cirillo, DM
   Ambrosio, LD
   Delogu, G
   Esposito, SMR
   Figueroa, J
   Friedland, JS
   Ho, BCH
   Ippolito, G
   Jankovic, M
   Kim, HY
   Klintz, SR
   Kodmon, C
   Lalle, E
   Leo, YS
   Leung, CC
   Martson, AG
   Melazzini, MG
   Fard, SN
   Penttinen, P
   Petrone, L
   Petruccioli, E
   Pontali, E
   Saderi, L
   Santin, M
   Spanevello, A
   van Crevel, R
   van der Werf, MJ
   Visca, D
   Viveiros, M
   Zellweger, JP
   Zumla, A
   Goletti, D
AF Ong, Catherine Wei Min
   Migliori, Giovanni Battista
   Raviglione, Mario
   MacGregor-Skinner, Gavin
   Sotgiu, Giovanni
   Alffenaar, Jan-Willem
   Tiberi, Simon
   Adlhoch, Cornelia
   Alonzi, Tonino
   Archuleta, Sophia
   Brusin, Sergio
   Cambau, Emmanuelle
   Capobianchi, Maria Rosaria
   Castilletti, Concetta
   Castilletti, Concetta
   Centis, Rosella
   Cirillo, Daniela M.
   Ambrosio, Lia D.
   Delogu, Giovanni
   Esposito, Susanna M. R.
   Figueroa, Jose
   Friedland, Jon S.
   Ho, Benjamin Choon Heng
   Ippolito, Giuseppe
   Jankovic, Mateja
   Kim, Hannah Yejin
   Klintz, Senia Rosales
   Kodmon, Csaba
   Lalle, Eleonora
   Leo, Yee Sin
   Leung, Chi-Chiu
   Martson, Anne-Grete
   Melazzini, Mario Giovanni
   Fard, Saeid Najafi
   Penttinen, Pasi
   Petrone, Linda
   Petruccioli, Elisa
   Pontali, Emanuele
   Saderi, Laura
   Santin, Miguel
   Spanevello, Antonio
   van Crevel, Reinout
   van der Werf, Warieke J.
   Visca, Dina
   Viveiros, Miguel
   Zellweger, Jean-Pierre
   Zumla, Alimuddin
   Goletti, Delia
TI Epidemic and pandemic viral infections: impact on tuberculosis and the
   lung
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Article
ID EAST RESPIRATORY SYNDROME; PNEUMONIA REQUIRING HOSPITALIZATION;
   INFLUENZA-VIRUS INFECTION; EFFECTOR MEMORY PHENOTYPE; CRITICALLY-ILL
   PATIENTS; ANTIVIRAL DRUG ARBIDOL; T-CELL RESPONSES;
   MYCOBACTERIUM-TUBERCULOSIS; SYNDROME CORONAVIRUS; BACTERIAL PNEUMONIA
AB Major epidemics, including some that qualify as pandemics, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), HIV, influenza A (H1N1)pdm/09 and most recently COVID-19, affect the lung. Tuberculosis (TB) remains the top infectious disease killer, but apart from syndemic TB/HIV little is known regarding the interaction of viral epidemics and pandemics with TB. The aim of this consensus-based document is to describe the effects of viral infections resulting in epidemics and pandemics that affect the lung (MERS, SARS, HIV, influenza A (H1N1)pdm/09 and COVID-19) and their interactions with TB. A search of the scientific literature was performed. A writing committee of international experts including the European Centre for Disease Prevention and Control Public Health Emergency (ECDC PHE) team, the World Association for Infectious Diseases and Immunological Disorders (WAidid), the Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Mycobacterial Infections (ESGMYC) was established. Consensus was achieved after multiple rounds of revisions between the writing committee and a larger expert group. A Delphi process involving the core group of authors (excluding the ECDC PHE team) identified the areas requiring review/consensus, followed by a second round to refine the definitive consensus elements. The epidemiology and immunology of these viral infections and their interactions with TB are discussed with implications for diagnosis, treatment and prevention of airborne infections (infection control, viral containment and workplace safety). This consensus document represents a rapid and comprehensive summary on what is known on the topic.
C1 Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.
   Penn State Coll Med, Dept Publ Hlth Sciences, Hershey, PA USA.
   [Jankovic, Mateja] IRCCS San Raffaele Sci Inst, Emerging Bacterial Pathogens Unit, Milan, Italy.
EM giovannibattista.migliori@icsmaugeri.it; delia.goletti@inmi.it
RI ZUMLA, Alimuddin/ABA-8208-2020; Viveiros, Miguel/A-7326-2008; Sotgiu,
   Giovanni/N-1032-2017
OI Viveiros, Miguel/0000-0001-9676-6251; Pontali,
   Emanuele/0000-0002-1085-0442; Adlhoch, Cornelia/0000-0002-8842-0469;
   Sotgiu, Giovanni/0000-0002-1600-4474
FU European and Developing Countries Clinical Trials Partnership the EU
   Horizon 2020 Framework Programme for Research and Innovation; National
   Institutes of Health ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Singapore National
   Medical Research CouncilNational Medical Research Council, Singapore
   [NMRC/TA/0042/2015, CSAINV17nov014]; National University Health System,
   Singapore [NUHS/RO/2017/092/SU/01, CFGFY18P11,
   NUHS/RO/2020/042/RO5+5/ad-hoc/1]; National Centre for Infectious
   Diseases, Singapore [STPRG-FY19-003]; Young Investigator Award, Institut
   Merieux, Lyon, France; Marie Sklodowska-Curie Actions
   [713660-PRONKJEWAIL-H2020-MSCACOFUND-2015]; Italian Ministry of Health,
   Ricerca CorrenteMinistry of Health, Italy; Crossref Funder Registry
FX A. Zumla is a co-Principal Investigator of the Pan-African Network on
   Emerging and Re-Emerging Infections (PANDORA-IDNET) funded by the
   European and Developing Countries Clinical Trials Partnership the EU
   Horizon 2020 Framework Programme for Research and Innovation; and is
   also in receipt of a National Institutes of Health Research senior
   investigator award. C.W.M. Ong is funded by Singapore National Medical
   Research Council (NMRC/TA/0042/2015, CSAINV17nov014); National
   University Health System, Singapore (NUHS/RO/2017/092/SU/01, CFGFY18P11,
   NUHS/RO/2020/042/RO5+5/ad-hoc/1); National Centre for Infectious
   Diseases, Singapore (STPRG-FY19-003); and is recipient of the Young
   Investigator Award, Institut Merieux, Lyon, France. A-G. Martson was
   funded by Marie Sklodowska-Curie Actions, grant agreement number
   713660-PRONKJEWAIL-H2020-MSCACOFUND-2015. The article is part of the
   activities of the Global Tuberculosis Network (GTN) and of the WHO
   Collaborating Centre for Tuberculosis and Lung Diseases, Tradate
   (ITA-80, 2017-2020-GBM/RC/LDA). Part of the work was supported by the
   Italian Ministry of Health, Ricerca Corrente (Linea 1 and Linea 4).
   Funding information for this article has been deposited with the
   Crossref Funder Registry.
CR Abraham George M, 2020, Clin Infect Dis, V71, P1790, DOI 10.1093/cid/ciaa107
   Abril-Rodriguez G, 2017, CANCER CELL, V31, DOI 10.1016/j.ccell.2017.05.010
   Akiyama MJ, 2020, NEW ENGL J MED, V382, P2075, DOI 10.1056/NEJMp2005687
   Al-Tawfiq JA, 2014, CLIN INFECT DIS, V59, P160, DOI 10.1093/cid/ciu226
   Alfaraj SH, 2017, INTERVIROLOGY, V60, P53, DOI 10.1159/000477908
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Almekhlafi GA, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1303-8
   Alonso C, 2017, J VET DIAGN INVEST, V29, P298, DOI 10.1177/1040638717700221
   [Anonymous], 1919, Cal State J Med, V17, P85
   [Anonymous], 2019, WHO GUID TUB INF PRE
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Arlehamn CSL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005760
   Arnold FW, 2020, CURR OPIN PULM MED, V26, P208, DOI 10.1097/MCP.0000000000000666
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Ault R, 2018, EXP GERONTOL, V111, P35, DOI 10.1016/j.exger.2018.06.029
   Azoulay E, 2020, CHEST, V157, P293, DOI 10.1016/j.chest.2019.08.002
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Ballinger MN, 2010, J INTERF CYTOK RES, V30, P643, DOI 10.1089/jir.2010.0049
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Berger A, 2004, J CLIN VIROL, V29, P13, DOI 10.1016/j.jcv.2003.09.011
   Biering-Sorensen S, 2018, J INFECT DIS, V217, P759, DOI 10.1093/infdis/jix612
   Blachere FM, 2018, INFLUENZA OTHER RESP, V12, P613, DOI 10.1111/irv.12572
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Bonny TS, 2018, AM J INFECT CONTROL, V46, P105, DOI 10.1016/j.ajic.2017.07.014
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Bortoli R, 2007, CLIN RHEUMATOL, V26, P1809, DOI 10.1007/s10067-007-0662-6
   Busti AJ, 2004, PHARMACOTHERAPY, V24, P1732, DOI 10.1592/phco.24.17.1732.52347
   Bystrom J, 2013, VIRUSES-BASEL, V5, P777, DOI 10.3390/v5030777
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carter DJ, 2018, LANCET GLOB HEALTH, V6, pE514, DOI 10.1016/S2214-109X(18)30195-5
   Center for disease control and prevention, 2003, GUIDELINES ENV INFEC
   Centers for Disease Control and Prevention, 2020, EST INFL ILLN MED VI
   Chackerian AA, 2002, INFECT IMMUN, V70, P4501, DOI 10.1128/IAI.70.8.4501-4509.2002
   Chadha MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124122
   Chan J, 2014, SEMIN IMMUNOL, V26, P588, DOI 10.1016/j.smim.2014.10.005
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen YC, 2004, EMERG INFECT DIS, V10, P782, DOI 10.3201/eid1005.030579
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   CHIACCHIO RG, 2014, J WILDLIFE DIS, V50, P496, DOI DOI 10.7589/2013-05-109
   Chiacchio T, 2018, IMMUNOL LETT, V198, P33, DOI 10.1016/j.imlet.2018.04.001
   Chiacchio T, 2014, J INFECTION, V69, P533, DOI 10.1016/j.jinf.2014.06.009
   Chiu C, 2015, NAT IMMUNOL, V16, P18, DOI 10.1038/ni.3056
   Cordero E, 2012, EUR J CLIN MICROBIOL, V31, P547, DOI 10.1007/s10096-011-1346-3
   Cui W, 2003, CLIN INFECT DIS, V37, P857, DOI 10.1086/378587
   Cui YX, 2020, J INFECT DIS, V221, P1775, DOI 10.1093/infdis/jiaa113
   Daoud A, 2019, POSTGRAD MED, V131, P299, DOI 10.1080/00325481.2019.1592400
   Dara M, 2020, INT J TUBERC LUNG D, V24, P544, DOI 10.5588/ijtld.20.0151
   Day CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094949
   Day CL, 2011, J IMMUNOL, V187, P2222, DOI 10.4049/jimmunol.1101122
   de Paus RA, 2013, TUBERCULOSIS, V93, P338, DOI 10.1016/j.tube.2013.02.006
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Deng P, 2013, ANTIMICROB AGENTS CH, V57, P1743, DOI 10.1128/AAC.02282-12
   Dharmadhikari AS, 2012, AM J RESP CRIT CARE, V185, P1104, DOI 10.1164/rccm.201107-1190OC
   Dorward J., 2020, LOPINAVIR RITONAVIR
   Duan SM, 2003, BIOMED ENVIRON SCI, V16, P246
   Dubayova T, 2010, INT J PUBLIC HEALTH, V55, P459, DOI 10.1007/s00038-010-0149-0
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Dwivedi VP, 2012, J BIOL CHEM, V287, P33656, DOI 10.1074/jbc.M112.375154
   Esposito S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01260-2020
   Esposito S, 2011, J INFECTION, V63, P300, DOI 10.1016/j.jinf.2011.07.015
   European Centre for Disease Prevention and Control, 2020, US FAC MASKS COMM RE
   European Centre for Disease Prevention and Control, 2020, COR DIS 2019 COVID 1
   European Centre for Disease Prevention and Control, 2020, DIS ENV HEALTHC NONH
   European Centre for Disease Prevention and Control, 2020, GUID US NONPH MEAS D
   European Centre for Disease Prevention and Control, 2020, CLOTH MASKS MASK STE
   Evans D, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3762-x
   Food and Drug Administration, 2020, FDA CAUT US HYDR CHL
   Fox SE., PULMONARY CARDIAC PA, DOI [10.1101/2020.04.06.20050575, DOI 10.1101/2020.04.06.20050575]
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Genovese MC, 2013, J RHEUMATOL, V40, P768, DOI 10.3899/jrheum.120687
   Gillim-Ross L, 2006, CLIN MICROBIOL REV, V19, P614, DOI 10.1128/CMR.00005-06
   Goletti D, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01089-2018
   Goletti D, 2018, RESPIROLOGY, V23, P455, DOI 10.1111/resp.13272
   Goletti D, 2014, J RHEUMATOL, V41, P24, DOI 10.3899/jrheum.140099
   Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069390
   Hagan G, 2013, CRIT CARE, V17, DOI 10.1186/cc12760
   Hatchett RJ, 2007, P NATL ACAD SCI USA, V104, P7582, DOI 10.1073/pnas.0610941104
   Hensel J, 2020, EXERCISING CAUTION C, DOI [10.1101/2020.04.08.20056051, DOI 10.1101/2020.04.08.20056051]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   International Severe Acute Respiratory and Emerging Infections Consortium, COVID 19 REP 27 APR
   Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245
   Jain S, 2017, CLIN CHEST MED, V38, P1, DOI 10.1016/j.ccm.2016.11.012
   Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870
   Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0
   Jang CH, 2006, RHEUMATOLOGY, V45, P703, DOI 10.1093/rheumatology/kei282
   Jegaskanda S, 2014, J IMMUNOL, V193, P469, DOI 10.4049/jimmunol.1400432
   Jones AK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175816
   Joosten SA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005687
   Jordan Paul C., 2018, Antiviral Chemistry & Chemotherapy, V26, p2040206618764483, DOI 10.1177/2040206618764483
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Kinner SA, 2020, LANCET PUBLIC HEALTH, V5, pE188, DOI 10.1016/S2468-2667(20)30058-X
   Kirov S., 2020, ASS BCG POLICY IS SI, DOI [10.1101/2020.04.06.20055616, DOI 10.1101/2020.04.06.20055616]
   Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896
   Krzeminski P, 2018, POSTEP DERM ALERGOL, V35, P429, DOI 10.5114/ada.2018.77675
   Kufner V, 2019, GENES-BASEL, V10, DOI 10.3390/genes10090661
   Kumar A, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411002079
   Kuo SC, 2020, EMERG INFECT DIS, V26, P1928, DOI 10.3201/eid2608.201192
   Lai MYY, 2005, CLIN INFECT DIS, V41, pE67, DOI 10.1086/433186
   Lancioni C, 2012, AM J RESP CRIT CARE, V185, P206, DOI 10.1164/rccm.201107-1355OC
   Lawn SD, 2011, INT J TUBERC LUNG D, V15, P571, DOI 10.5588/ijtld.10.0483
   Leung C C, 2020, Int J Tuberc Lung Dis, V24, P556, DOI 10.5588/ijtld.20.0244
   Leung CC, 2020, INT J TUBERC LUNG D, V24, P364, DOI 10.5588/ijtld.20.0124
   Leung CC, 2020, LANCET, V395, P945, DOI 10.1016/S0140-6736(20)30520-1
   Leung NHL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148669
   Lewis D, 2020, NATURE, V580, P175, DOI 10.1038/d41586-020-00974-w
   Li CX, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60992-6
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Li H, 2018, NAT REV IMMUNOL, V18, P591, DOI 10.1038/s41577-018-0028-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lin PL, 2015, SEMIN IMMUNOPATHOL, V37, P239, DOI 10.1007/s00281-015-0490-8
   Liu Q, 2020, Fa Yi Xue Za Zhi, V36, P21, DOI 10.12116/j.issn.1004-5619.2020.01.005
   Liu W, 2006, EMERG INFECT DIS, V12, P707, DOI 10.3201/eid1204.050264
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Liu Y, 2020, ACTIVE LATENT TUBERC, DOI [10.1101/2020.03.10.20033795, DOI 10.1101/2020.03.10.20033795]
   Liverpul drug interactions group, 2020, INT EXP COVID 19 THE
   Louthrenoo W, 2015, JCR-J CLIN RHEUMATOL, V21, P346, DOI 10.1097/RHU.0000000000000297
   Low JGH, 2004, CLIN INFECT DIS, V38, pE123, DOI 10.1086/421396
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Lu ZK, 2015, EXPERT OPIN DRUG SAF, V14, P295, DOI 10.1517/14740338.2015.989210
   Luo T, 2014, EPIDEMIOL INFECT, V142, P2036, DOI 10.1017/S0950268813003142
   Machado D, 2019, INFECT GENET EVOL, V72, P93, DOI 10.1016/j.meegid.2018.11.021
   MacIntyre CR, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006577
   Madelain V, 2016, CLIN PHARMACOKINET, V55, P907, DOI 10.1007/s40262-015-0364-1
   Madhi SA, 2013, PEDIATR INFECT DIS J, V32, pE119, DOI 10.1097/INF.0b013e3182784b26
   Malcangi G, 2000, RHEUMATOL INT, V20, P31, DOI 10.1007/s002960000066
   Marais BJ, 2020, LANCET INFECT DIS, V20, P641, DOI 10.1016/S1473-3099(20)30167-5
   Marchisio P, 2012, HUM VACC IMMUNOTHER, V8, P17, DOI 10.4161/hv.8.1.18145
   Mathad JS, 2012, CLIN INFECT DIS, V55, P1532, DOI 10.1093/cid/cis732
   McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz538
   Mckee M, 2020, NAT MED, V26, P640, DOI 10.1038/s41591-020-0863-y
   McShane H, 2005, INT J STD AIDS, V16, P95, DOI 10.1258/0956462053057576
   Metersky ML, 2012, INT J INFECT DIS, V16, pE321, DOI 10.1016/j.ijid.2012.01.003
   Mhimbira F, 2019, CLIN MICROBIOL INFEC, V25, DOI 10.1016/j.cmi.2018.03.019
   Midgley Claire M, 2014, MMWR Morb Mortal Wkly Rep, V63, P798
   Migliori GB, 2020, INT J INFECT DIS, V92, pS15, DOI 10.1016/j.ijid.2020.01.042
   Migliori GB, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00391-2019
   Migliori GB, 2018, LANCET GLOB HEALTH, V6, pE475, DOI 10.1016/S2214-109X(18)30189-X
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.1101/2020.03.24.20042937, DOI 10.1101/2020.03.24.20042937, 10. 1101/2020.03.24.20042937]
   Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   Morens DM, 2007, J INFECT DIS, V195, P1018, DOI 10.1086/511989
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Motta I, 2020, PULMONOLOGY, V26, P233, DOI 10.1016/j.pulmoe.2020.05.002
   Mukherjee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180143
   Negin J, 2015, INT J INFECT DIS, V32, P135, DOI 10.1016/j.ijid.2014.11.018
   Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Lan NTN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084866
   Nicholls J, 2003, RESPIROLOGY, V8, pS6, DOI 10.1046/j.1440-1843.2003.00517.x
   Nikolova M, 2013, DIAGN MICR INFEC DIS, V75, P277, DOI 10.1016/j.diagmicrobio.2012.11.023
   Olin A, 2018, CELL, V174, P1277, DOI 10.1016/j.cell.2018.06.045
   Ong CWM, 2020, INT J TUBERC LUNG D, V24, P547, DOI 10.5588/ijtld.20.0140
   Ong CWM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29659-1
   Ong CWM, 2014, AM J RESP CRIT CARE, V190, P9, DOI 10.1164/rccm.201311-2106PP
   Openshaw PJ, 2013, CURR OPIN VIROL, V3, P468, DOI 10.1016/j.coviro.2013.05.005
   Pandie M, 2016, J ANTIMICROB CHEMOTH, V71, P1037, DOI 10.1093/jac/dkv447
   Park Y, 2014, TUBERC RESPIR DIS, V76, P84, DOI 10.4046/trd.2014.76.2.84
   Pasipanodya JG, 2007, CHEST, V131, P1817, DOI 10.1378/chest.06-2949
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Petruccioli E, 2020, J INFECTION, V80, P536, DOI 10.1016/j.jinf.2020.02.009
   Petruccioli E, 2016, EUR RESPIR J, V48, P1751, DOI 10.1183/13993003.01012-2016
   Petruccioli E, 2013, J INFECTION, V66, P475, DOI 10.1016/j.jinf.2013.02.004
   Pinsky BA, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.00373-19
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Principi N, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30296-6
   Protezione Civile, 2020, COR EM
   Qian XW, 2020, TRANSL PEDIATR, V9, P34, DOI 10.21037/tp.2020.01.06
   Rabenau HF, 2005, MED MICROBIOL IMMUN, V194, P1, DOI 10.1007/s00430-004-0219-0
   Rabie H, 2019, LANCET HIV, V6, pE32, DOI 10.1016/S2352-3018(18)30293-5
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Reed C, 2014, CLIN INFECT DIS, V59, P166, DOI 10.1093/cid/ciu285
   Reiley WW, 2008, P NATL ACAD SCI USA, V105, P10961, DOI 10.1073/pnas.0801496105
   Rello J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01028-2020
   Rice TW, 2012, CRIT CARE MED, V40, P1487, DOI 10.1097/CCM.0b013e3182416f23
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Roth S, 2013, INFLUENZA OTHER RESP, V7, P244, DOI 10.1111/j.1750-2659.2012.00413.x
   Rozot V, 2013, EUR J IMMUNOL, V43, P1568, DOI 10.1002/eji.201243262
   Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003
   Saha S, 2014, B WORLD HEALTH ORGAN, V92, P318, DOI 10.2471/BLT.13.124412
   Saunders MJ, 2016, LANCET INFECT DIS, V16, P395, DOI 10.1016/S1473-3099(15)00434-X
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Segal Leopoldo N, 2011, Proc Am Thorac Soc, V8, P282, DOI 10.1513/pats.201006-044WR
   Shakil AO, 1996, J HEPATOL, V24, P48, DOI 10.1016/S0168-8278(96)80185-1
   Sharifian MR, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/295327
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   Shionogi & Co. Ltd, 2018, REV REP XOFL BAL
   Shiraki K, 2020, PHARMACOL THERAPEUT, V209, DOI 10.1016/j.pharmthera.2020.107512
   Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085
   Siqueira PC, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.5123/s1679-49742020000300014, 10.5123/S1679-49742020000300014]
   Smith AC, 2020, J TELEMED TELECARE, V26, P309, DOI 10.1177/1357633X20916567
   Song JH, 2013, J PHARM PHARMACOL, V65, P521, DOI 10.1111/jphp.12014
   Song JY, 2011, INFLUENZA OTHER RESP, V5, pR535, DOI 10.1111/j.1750-2659.2011.00269.x
   Soo RJJ, 2020, EMERG INFECT DIS, V26, P1933, DOI 10.3201/eid2608.201229
   SPENCER JC, 1977, J INFECT DIS, V136, P171, DOI 10.1093/infdis/136.2.171
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tadolini M, 2020, EUR RESPIR J, V56
   Thorne CD, 2004, J OCCUP ENVIRON MED, V46, P613, DOI 10.1097/01.jom.0000134191.92225.f2
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   Tokman S, 2013, CLIN CHEST MED, V34, P191, DOI 10.1016/j.ccm.2013.02.005
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   van den Brand JMA, 2014, J COMP PATHOL, V151, P83, DOI 10.1016/j.jcpa.2014.01.004
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Vareille M, 2011, CLIN MICROBIOL REV, V24, P210, DOI 10.1128/CMR.00014-10
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vitacca M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00632-2020
   Walaza S, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz020
   Walaza S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129173
   Wang JT, 2004, EMERG INFECT DIS, V10, P818, DOI 10.3201/eid1005.030640
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang RR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105617
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wang YH, 2020, RADIOLOGY, V296, pE55, DOI 10.1148/radiol.2020200843
   Weng D, 2019, BIOMED PHARMACOTHER, V110, P440, DOI 10.1016/j.biopha.2018.11.090
   WHO, 2019, GLOB TUB REP 2019
   WHO, 2020, COVID 19 STRAT PREP
   WHO, 2020, MOD TRANSM VIR CAUS
   WHO, 2020, REP WHO CHIN JOINT M
   WHO, 2020, WHO INF NOT TUB COVI
   WHO, 2020, BAC CALM GUER BCG VA
   WHO, 2020, CLIN MAN SEV AC RESP
   Wolf AJ, 2008, J EXP MED, V205, P105, DOI 10.1084/jem.20071367
   Wong Chak-Yen, 2004, J Chin Med Assoc, V67, P579
   World Health Organisation, 2020, CRIT PREP READ RESP
   World Health Organization, 2020, WHO CONS GUID TUB MO
   World Health Organization, 2012, WHO POL COLL TB HIV
   World Health Organization, 2013, SYST SCREEN ACT TUB
   World Health Organization, 2012, WHO INT PROT RAP OP
   World Health Organization, 2003, EM PREP RESP PREL CL
   World Health Organization, 2020, WHO OP HDB TUB MOD 1
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wumkes ML, 2017, VACCINE, V35, P1299, DOI 10.1016/j.vaccine.2017.01.039
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yan J, 2018, P NATL ACAD SCI USA, V115, P1081, DOI 10.1073/pnas.1716561115
   Yen YF, 2018, EMERG INFECT DIS, V24, P498, DOI 10.3201/eid2403.152071
   Zamorano JL, 2016, EUR HEART J, V37, P2768, DOI 10.1093/eurheartj/ehw211
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
   Zurcher K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162575
NR 254
TC 2
Z9 2
U1 0
U2 0
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD OCT 1
PY 2020
VL 56
IS 4
AR 2001727
DI 10.1183/13993003.01727-2020
PG 26
WC Respiratory System
SC Respiratory System
GA NZ4OR
UT WOS:000577075200008
OA Other Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Gomez-Carballa, A
   Bello, X
   Pardo-Seco, J
   Martinon-Torres, F
   Salas, A
AF Gomez-Carballa, Alberto
   Bello, Xabier
   Pardo-Seco, Jacobo
   Martinon-Torres, Federico
   Salas, Antonio
TI Mapping genome variation of SARS-CoV-2 worldwide highlights the impact
   of COVID-19 super-spreaders
SO GENOME RESEARCH
LA English
DT Article
ID MULTIPLE SEQUENCE ALIGNMENT; PHYLOGENETIC ANALYSIS; TREE; SARS
AB The human pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the major pandemic of the twenty-first century. We analyzed more than 4700 SARS-CoV-2 genomes and associated metadata retrieved from public repositories. SARS-CoV-2 sequences have a high sequence identity (>99.9%), which drops to >96% when compared to bat coronavirus genome. We built a mutation-annotated reference SARS-CoV-2 phylogeny with two main macro-haplogroups, A and B, both of Asian origin, and more than 160 sub-branches representing virus strains of variable geographical origins worldwide, revealing a rather uniform mutation occurrence along branches that could have implications for diagnostics and the design of future vaccines. Identification of the root of SARS-CoV-2 genomes is not without problems, owing to conflicting interpretations derived from either using the bat coronavirus genomes as an outgroup or relying on the sampling chronology of the SARS-CoV-2 genomes and TMRCA estimates; however, the overall scenario favors haplogroup A as the ancestral node. Phylogenetic analysis indicates a TMRCA for SARS-CoV-2 genomes dating to November 12, 2019, thus matching epidemiological records. Sub-haplogroup A2 most likely originated in Europe from an Asian ancestor and gave rise to subclade A2a, which represents the major non-Asian outbreak, especially in Africa and Europe. Multiple founder effect episodes, most likely associated with super-spreader hosts, might explain COVID-19 pandemic to a large extent.
C1 [Gomez-Carballa, Alberto; Bello, Xabier; Pardo-Seco, Jacobo; Salas, Antonio] Univ Santiago de Compostela, Unidade Xenet, Inst Ciencias Forenses INCIFOR, Fac Med, Galicia 15706, Spain.
   [Gomez-Carballa, Alberto; Bello, Xabier; Pardo-Seco, Jacobo; Salas, Antonio] Hosp Clin Univ Santiago SERGAS, GenPoB Res Grp, Inst Invest Sanitaria IDIS, Galicia 15706, Spain.
   [Gomez-Carballa, Alberto; Bello, Xabier; Pardo-Seco, Jacobo; Martinon-Torres, Federico; Salas, Antonio] Inst Invest Sanitaria Santiago IDIS, Genet Vaccines & Pediat Infect Dis Res Grp GENVIP, Galicia 15706, Spain.
   [Gomez-Carballa, Alberto; Bello, Xabier; Pardo-Seco, Jacobo; Martinon-Torres, Federico; Salas, Antonio] Univ Santiago de Compostela USC, Galicia 15706, Spain.
   [Gomez-Carballa, Alberto; Bello, Xabier; Pardo-Seco, Jacobo; Martinon-Torres, Federico; Salas, Antonio] Hosp Clin Univ Santiago de Compostela SERGAS, Translat Pediat & Infect Dis, Dept Pediat, Galicia 15706, Spain.
RP Salas, A (corresponding author), Univ Santiago de Compostela, Unidade Xenet, Inst Ciencias Forenses INCIFOR, Fac Med, Galicia 15706, Spain.; Salas, A (corresponding author), Hosp Clin Univ Santiago SERGAS, GenPoB Res Grp, Inst Invest Sanitaria IDIS, Galicia 15706, Spain.; Salas, A (corresponding author), Inst Invest Sanitaria Santiago IDIS, Genet Vaccines & Pediat Infect Dis Res Grp GENVIP, Galicia 15706, Spain.; Salas, A (corresponding author), Univ Santiago de Compostela USC, Galicia 15706, Spain.; Salas, A (corresponding author), Hosp Clin Univ Santiago de Compostela SERGAS, Translat Pediat & Infect Dis, Dept Pediat, Galicia 15706, Spain.
EM antonio.salas@usc.es
RI Salas, Antonio/E-3977-2012
OI Salas, Antonio/0000-0002-2336-702X; Bello, Xabier/0000-0002-4990-8496
FU Instituto de Salud Carlos IIIInstituto de Salud Carlos III [PI16/01478];
   DIAVIR (Instituto de Salud Carlos III(ISCIII)) [DTS19/00049];
   Resvi-Omics (Instituto de Salud Carlos III(ISCIII)) [PI19/01039];
   project BI-BACVIR (PRIS-3; Agencia de Conocimiento en Salud
   (ACIS)-Servicio Gallego de Salud (SERGAS)-Xunta de Galicia; Spain);
   projects ReSVinext (Instituto de Salud Carlos III(ISCIII)) [PI16/01569];
   Enterogen (Instituto de Salud Carlos III(ISCIII)) [PI19/01090]
FX This study received support from the Instituto de Salud Carlos III:
   project GePEM (Instituto de Salud Carlos
   III(ISCIII)/PI16/01478/Cofinanciado FEDER), DIAVIR (Instituto de Salud
   Carlos III(ISCIII)/DTS19/00049/Cofinanciado FEDER; Proyecto de
   Desarrollo Tecnologico en Salud) and Resvi-Omics (Instituto de Salud
   Carlos III(ISCIII)/PI19/01039/Cofinanciado FEDER) and project BI-BACVIR
   (PRIS-3; Agencia de Conocimiento en Salud (ACIS)-Servicio Gallego de
   Salud (SERGAS)-Xunta de Galicia; Spain) given to A.S.; and projects
   ReSVinext (Instituto de Salud Carlos III(ISCIII)/PI16/01569/Cofinanciado
   FEDER), and Enterogen (Instituto de Salud Carlos
   III(ISCIII)/PI19/01090/Cofinanciado FEDER) given to F.M.-T. We thank
   GISAID and the contributing laboratories for giving us access to the
   SARS-CoV-2 genomes used in the present study (Supplemental Table S10).
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Patino-Galindo JA, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex029
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Artesi M, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01598-20
   Bandelt HJ, 2012, FORENSIC SCI INT-GEN, V6, P143, DOI 10.1016/j.fsigen.2011.04.004
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Colijn Caroline, 2014, Evolution Medicine and Public Health, P96, DOI 10.1093/emph/eou018
   Conrad O, 2015, GEOSCI MODEL DEV, V8, P1991, DOI 10.5194/gmd-8-1991-2015
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Endo Akira, 2020, Wellcome Open Res, V5, P67, DOI 10.12688/wellcomeopenres.15842.1
   Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Heled J, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-289
   Holland LaRinda A, 2020, J Virol, V94, DOI 10.1128/JVI.00711-20
   Hu B, 2017, BLOOD, V130
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
   Kim SJ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020220
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kupferschmidt K., 2020, SCIENCE, DOI [10.1126/ence.abc8931, DOI 10.1126/ENCE.ABC8931]
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300
   Lau SY, 2020, EMERG MICROBES INFEC, V9, P837, DOI 10.1080/22221751.2020.1756700
   Leigh JW, 2015, METHODS ECOL EVOL, V6, P1110, DOI 10.1111/2041-210X.12410
   Lemey P, 2006, AIDS REV, V8, P125
   Leventhal GE, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002413
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Metzig C, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006761
   NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269
   Norstrom MM, 2012, EVOL BIOINFORM, V8, P261, DOI 10.4137/EBO.S9738
   R Core Team, 2019, R LANG ENV STAT COMP
   Ramirez-Soriano A, 2008, GENETICS, V179, P555, DOI 10.1534/genetics.107.083006
   Rehman SU, 2020, PATHOGENS, V9, DOI [10.3390/pathogens9030240, 10.19045/bspab.2020.90001]
   Salas A, 2005, BIOCHEM BIOPH RES CO, V335, P891, DOI 10.1016/j.bbrc.2005.07.161
   Sekizuka T, 2020, P NATL ACAD SCI USA, V117, P20198, DOI 10.1073/pnas.2006824117
   Shen ZJ, 2020, CLIN INFECT DIS, V71, P713, DOI 10.1093/cid/ciaa203
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Stein RA, 2011, INT J INFECT DIS, V15, pE510, DOI 10.1016/j.ijid.2010.06.020
   TAJIMA F, 1989, GENETICS, V123, P585
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   Villabona-Arenas CJ, 2020, NAT MICROBIOL, V5, P876, DOI 10.1038/s41564-020-0738-5
   Volz EM, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex025
   Weissensteiner H, 2016, NUCLEIC ACIDS RES, V44, pW58, DOI 10.1093/nar/gkw233
   Wong G, 2015, CELL HOST MICROBE, V18, P398, DOI 10.1016/j.chom.2015.09.013
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088
   Zanini F, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex003
   Zhao Wenming, 2020, Yichuan, V42, P212, DOI 10.16288/j.yczz.20-030
NR 58
TC 2
Z9 2
U1 7
U2 7
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD OCT
PY 2020
VL 30
IS 10
BP 1434
EP 1448
DI 10.1101/gr.266221.120
PG 15
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA NZ5EI
UT WOS:000577121300005
PM 32878977
OA Other Gold
DA 2021-01-01
ER

PT J
AU Lewis, J
   LeBan, K
   Solomon, R
   Bisrat, F
   Usman, S
   Arale, A
AF Lewis, Judy
   LeBan, Karen
   Solomon, Roma
   Bisrat, Filimona
   Usman, Samuel
   Arale, Ahmed
TI The Critical Role and Evaluation of Community Mobilizers in Polio
   Eradication in Remote Settings in Africa and Asia
SO GLOBAL HEALTH-SCIENCE AND PRACTICE
LA English
DT Article
ID UTTAR-PRADESH; PROJECT; IMMUNIZATION; KNOWLEDGE; VACCINE; NIGERIA
AB This article assesses the CORE Group Polio Project (CGPP) experience over a 20-year period in 5 countries. It examines how a program designed to provide social mobilization to eradicate one disease, and which did so effectively, functioned within the general framework of community health workers (CHWs). Vertical health programs often have limited impact on broader community health. CGPP has a 20-year history of social mobilization and effective program interventions. This history provided an opportunity to assess how CGPP community mobilizers (CMs) functioned in polio and maternal and child health. The Updated Program Functionality Matrix for Optimizing Community Health Programs tool of the CHW Assessment and Improvement Matrix (AIM) was used to examine CGPP CM roles across different contexts. The analysis determined that CGPP CMs met the basic level of functioning (level 3) for 6 of the 10 components of the AIM tool. This cross-country descriptive analysis of the CGPP demonstrates the importance of embracing the full range of CHW AIM components, even in a vertical program. Use of data, community involvement, local adaptation, and linkage with the health system are especially critical for success. This general lesson could be applied to other community mobilization and disease/epidemic control initiatives, especially as we face the issues of the COVID-19 pandemic.
C1 [Lewis, Judy] Univ Connecticut, Sch Med, Farmington, CT 06032 USA.
   [LeBan, Karen] Global Hlth Consultant, Washington, DC USA.
   [Solomon, Roma] CORE Grp Polio Project India, Gurgaon, India.
   [Bisrat, Filimona] CORE Grp Polio Project Ethiopia, Addis Ababa, Ethiopia.
   [Usman, Samuel] CORE Grp Polio Project Nigeria, Abuja, Nigeria.
   [Arale, Ahmed] CORE Grp Polio Project Horn Africa, Nairobi, Kenya.
RP Lewis, J (corresponding author), Univ Connecticut, Sch Med, Farmington, CT 06032 USA.
EM lewisj@uchc.edu
CR Asegedew B, 2019, AM J TROP MED HYG, V101, P45, DOI 10.4269/ajtmh.18-1000
   Babughirana G, 2016, SCI J PUB HLTH, V4, P117
   Choudhary M, 2019, AM J TROP MED HYG, V101, P33, DOI 10.4269/ajtmh.18-0935
   Choudhary M, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3129-2
   Coates E., 2008, FINAL REV CORE GROUP
   Coates EA, 2013, CORE GROUP POLIO PRO
   Coates EA, 2013, GLOB HEALTH-SCI PRAC, V1, P68, DOI 10.9745/GHSP-D-12-00018
   Crigler L, 2011, COMMUNITY HLTH WORKE
   Curry DW, 2014, J HEALTH POPUL NUTR, V32, P356
   Duru JI, 2019, AM J TROP MED HYG, V101, P74, DOI 10.4269/ajtmh.19-0068
   Global Polio Eradication Initiative, 2013, POL ER END GAM STRAT
   Hodgins S, 2014, DEV STRENGTHENING CO
   Jaskiewicz W, 2012, HUM RESOUR HEALTH, V10, DOI 10.1186/1478-4491-10-38
   Lahiriya C., 2007, GLOBAL ERADICATION P
   Losey L, 2019, PEER REV J PUBLI OCT
   Losey L, 2019, AM J TROP MED HYG, V101, P4, DOI 10.4269/ajtmh.18-0916
   Ludwick T, 2018, HUM RESOUR HEALTH, V16, DOI 10.1186/s12960-018-0272-1
   Manoncourt E, 2019, COMPREHENSIVE ASSESS
   Perry H., 2019, American Journal of Tropical Medicine and Hygiene, V101, P1
   Perry HB, 2019, AM J TROP MED HYG, V101, P107, DOI 10.4269/ajtmh.19-0036
   Sadat R, 2016, GLOBAL HLTH COMMUNIC, V1, P48
   Scott K, 2018, HUM RESOUR HEALTH, V16, DOI 10.1186/s12960-018-0304-x
   Shuaibu FM, 2016, J PUBLIC HEALTH POL, V37, P36, DOI 10.1057/jphp.2015.34
   Stamidis K, 2018, CORE GROUP POLIO PRO
   Tessema F, 2019, AM J TROP MED HYG, V101, P52, DOI 10.4269/ajtmh.19-0022
   UNICEF, 2018, COMM HLTH WORK ASS I
   Usman S, 2019, AM J TROP MED HYG, V101, P68, DOI 10.4269/ajtmh.19-0143
NR 27
TC 0
Z9 0
U1 0
U2 0
PU JOHNS HOPKINS CENTER COMMUNICATION PROGRAMS-CCP
PI BALTIMORE
PA KNOWLEDGE SUCCESS PROJECT, 111 MARKET PLACE, STE 310, BALTIMORE, MD,
   UNITED STATES
SN 2169-575X
J9 GLOB HEALTH-SCI PRAC
JI Glob. Health
PD OCT
PY 2020
VL 8
IS 3
BP 396
EP 412
DI 10.9745/GHSP-D-20-00024
PG 17
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NZ9LK
UT WOS:000577420600009
PM 33008854
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Richez, C
   Flipo, RM
   Berenbaum, F
   Cantagrel, A
   Claudepierre, P
   Debiais, F
   Dieude, P
   Goupille, P
   Roux, C
   Schaeverbeke, T
   Wendling, D
   Pham, T
   Thomas, T
AF Richez, Christophe
   Flipo, Rene-Marc
   Berenbaum, Francis
   Cantagrel, Alain
   Claudepierre, Pascal
   Debiais, Francoise
   Dieude, Philippe
   Goupille, Philippe
   Roux, Christian
   Schaeverbeke, Thierry
   Wendling, Daniel
   Pham, Thao
   Thomas, Thierry
TI Managing patients with rheumatic diseases during the COVID-19 pandemic:
   The French Society of Rheumatology answers to most frequently asked
   questions up to May 2020
SO JOINT BONE SPINE
LA English
DT Article
DE COVID-19; Inflammatory rheumatic diseases; Treatment; Health system
ID INFLAMMATION
AB Background: Rheumatologists must contend with COVID-19 pandemic in the management of their patients and many questions have been raised on the use of both anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (DMARD). The French Society of Rheumatology (SFR) selected the most critical ones to the daily practice of a rheumatologist and a group of 10 experts from SFR and Club Rheumatism and Inflammation (CRI) boards proposed responses based on the current knowledge of May 2020.
   Methods: Following the availability of the first 18 questions and statements, 1400 individuals consulted the frequently asked questions between the March 31, 2020 and April 12, 2020. As a result, 16 additional questions were forwarded to the SFR, and answered by the board. An additional round of review by email and video conference was organized, which included updates of the previous statements. The scientific relevance of 5 of the questions led to their inclusion in this document. Each response received a final assessment on a scale of 0-10 with 0 meaning no agreement whatsoever and 10 being in complete agreement. The mean values of these votes for each question are presented as the levels of agreement (LoA) at the end of each response. This document was last updated on April 17, 2020.
   Results: Based on current scientific literature already published, in most circumstances, there is no contraindication to the initiation or continuation of anti-inflammatory drugs as well as DMARDs. If signs suggestive of infection (coronavirus or other) occur, treatments should be discontinued and resumed, if necessary, after 2 weeks without any symptoms. Only, some signals suggest that people taking an immunosuppressive dose of corticosteroid therapy are at greater risk of developing severe COVID-19. Intra-articular injections of glucocorticoids are allowed when there is no reasonable therapeutic alternative, and providing that precautions to protect the patient and the practitioner from viral contamination are adopted, included appropriate information to the patient.
   conclusions: Currently available data on managing patients with rheumatic diseases during the COVID-19 pandemic are reassuring and support continuing or initiating symptomatic as well as specific treatments of these diseases, the main target of their management remaining their appropriate control, even during this pandemic. (C) 2020 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.
C1 [Richez, Christophe; Schaeverbeke, Thierry] CHU Bordeaux, FHU ACRONIM, Pl Amelie Raba Leon, F-33076 Bordeaux, France.
   [Flipo, Rene-Marc] CHRU Lille, Hop Roger Salengro, Serv Rhumatol, Rue Prof Emile Laine, F-59037 Lille, France.
   [Berenbaum, Francis] Ctr Hosp Univ St Antoine, Serv Rhumatol, 184 Rue Faubourg St Antoine, F-755571 Paris 12, France.
   [Cantagrel, Alain] CHU Toulouse, Hop Purpan, Serv Rhumatol, Pl Docteur Baylac,TSA 40031, F-31059 Toulouse 9, France.
   [Claudepierre, Pascal] CHU Henri Mondor, Serv Rhumatol, 51 Ave Marechal Lattre Tassigny, F-94010 Creteil, France.
   [Debiais, Francoise] Ctr Hosp Univ, Serv Rhumatol, 2 Rue Miletrie,BP 577, F-86021 Poitiers, France.
   [Dieude, Philippe] Grp Hosp Univ Bichat Claude Bernard, Serv Rhumatol, 46 Rue Henri Huchard, F-75018 Paris, France.
   [Goupille, Philippe] CHRU Tours, Hop Trousseau, Serv Rhumatol, F-37044 Tours 9, France.
   [Roux, Christian] Ctr Hosp Univ Cochin, Serv Rhumatol, 27 Rue Faubourg St Jacques, F-75679 Paris 14, France.
   [Wendling, Daniel] Ctr Hosp Univ Jean Minjoz, Serv Rhumatol, 1 Blvd Fleming, F-25030 Besancon, France.
   [Pham, Thao] Ctr Hosp Univ St Marguerite, Serv Rhumatol, 270 Blvd St Marguerite, F-13274 Marseille 9, France.
   [Thomas, Thierry] Univ Lyon Univ Jean Monnet, Inserm U1059, CHU St Etienne, Dept Rheumatol,Hop Nord, St Etienne, France.
RP Thomas, T (corresponding author), Univ Lyon Univ Jean Monnet, Inserm U1059, CHU St Etienne, Dept Rheumatol,Hop Nord, St Etienne, France.
EM thieriy.thomas@chuse.fr
OI Dieude, Philippe/0000-0002-4814-0307
CR Abbasi J, 2020, JAMA-J AM MED ASSOC, V323, P1881, DOI 10.1001/jama.2020.6170
   Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706
   Benucci M, 2020, JOINT BONE SPINE, V87, P195, DOI 10.1016/j.jbspin.2020.03.013
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Costedoat-Chalumeau N, 2007, RHEUMATOLOGY, V46, P808, DOI 10.1093/rheumatology/kel402
   Eastell R, 2009, J BONE MINER RES, V24, P726, DOI [10.1359/jbmr.081215, 10.1359/JBMR.081215]
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grey A, 2012, BONE, V50, P1389, DOI 10.1016/j.bone.2012.03.016
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Kim AHJ, 2020, ANN INTERN MED, V172, P819, DOI 10.7326/M20-1223
   Lazzerini PE, 2020, CIRCULATION, V142, P7, DOI 10.1161/CIRCULATIONAHA.120.047293
   Lazzerini PE, 2017, HEART, V103, P1821, DOI 10.1136/heartjnl-2016-311079
   Little P, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6041
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   McClung MR, 2017, OSTEOPOROSIS INT, V28, P1723, DOI 10.1007/s00198-017-3919-1
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Quartuccio L, 2020, JOINT BONE SPINE, V87, P191, DOI 10.1016/j.jbspin.2020.03.011
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Richez C, 2020, JOINT BONE SPINE, V87, P187, DOI 10.1016/j.jbspin.2020.03.010
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   South AM, 2020, NAT REV NEPHROL, V16, P305, DOI 10.1038/s41581-020-0279-4
   Spinelli FR, 2020, ANN RHEUM DIS, V79, P666, DOI [10.1136/annrheumdis-2020-217367, 10.1136/annrheumdis-2020-217557]
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 35
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 1297-319X
EI 1778-7254
J9 JOINT BONE SPINE
JI Joint Bone Spine
PD OCT
PY 2020
VL 87
IS 5
BP 431
EP 437
DI 10.1016/j.jbspin.2020.05.006
PG 7
WC Rheumatology
SC Rheumatology
GA OA1KG
UT WOS:000577552900011
PM 32473418
OA Green Published
DA 2021-01-01
ER

PT J
AU Helleberg, M
   Niemann, CU
   Moestrup, KS
   Kirk, O
   Lebech, AM
   Lane, C
   Lundgren, J
AF Helleberg, Marie
   Niemann, Carsten Utoft
   Moestrup, Kasper Sommerlund
   Kirk, Ole
   Lebech, Anne-Mette
   Lane, Clifford
   Lundgren, Jens
TI Persistent COVID-19 in an Immunocompromised Patient Temporarily
   Responsive to Two Courses of Remdesivir Therapy
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; SARS-CoV-2; remdesivir; immunocompromised; case report
ID INFECTION
AB The antiviral drug remdesivir has been shown clinically effective for treatment of COVID-19. We here demonstrate suppressive but not curative effect of remdesivir in an immunocompromised patient. A man in his fifties treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia. During two 10-day courses of remdesivir starting 24 and 45 days after fever onset, pneumonia and spiking fevers remitted, but relapsed after discontinuation. Kinetics of temperature, C-reactive protein, and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection. Combination therapy or longer treatment duration may be needed in immunocompromised patients.
C1 [Helleberg, Marie; Moestrup, Kasper Sommerlund; Kirk, Ole; Lebech, Anne-Mette; Lundgren, Jens] Copenhagen Univ Hosp, Rigshosp, Dept Infect Dis, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.
   [Niemann, Carsten Utoft] Copenhagen Univ Hosp, Rigshosp, Dept Hematol, Copenhagen, Denmark.
   [Lane, Clifford] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Helleberg, M (corresponding author), Copenhagen Univ Hosp, Rigshosp, Dept Infect Dis, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.
EM marie.helleberg@regionh.dk
RI Helleberg, Marie/ABC-8199-2020; Lundgren, Jens/AAE-6876-2019; Niemann,
   Carsten/P-3497-2015
OI Helleberg, Marie/0000-0002-2370-1657; Lundgren,
   Jens/0000-0001-8901-7850; Niemann, Carsten/0000-0001-9880-5242
FU Danish National Research FoundationDanmarks Grundforskningsfond [126]
FX This work was supported by the Danish National Research Foundation
   (grant number 126).
CR Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Beigel JH, 2020, NEW ENGL J MED, V383, P994, DOI 10.1056/NEJMc2022236
   Kato H, 2020, J INFECT CHEMOTHER, V26, P865, DOI 10.1016/j.jiac.2020.05.005
   La Scola B, 2020, EUR J CLIN MICROBIOL, V39, P1059, DOI 10.1007/s10096-020-03913-9
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Mahony JB, 2011, CRIT REV CL LAB SCI, V48, P217, DOI 10.3109/10408363.2011.640976
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Morrison VA, 2009, CLIN LYMPHOMA MYELOM, V9, P365, DOI 10.3816/CLM.2009.n.071
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
NR 15
TC 3
Z9 3
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD OCT 1
PY 2020
VL 222
IS 7
BP 1103
EP 1107
DI 10.1093/infdis/jiaa446
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5WI
UT WOS:000577175500009
PM 32702095
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Fatima, U
   Rizvi, SSA
   Fatima, S
   Hassan, MI
AF Fatima, Urooj
   Rizvi, Syed Saif Abbas
   Fatima, Saher
   Hassan, Md. Imtaiyaz
TI Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides
   of the Coin
SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
LA English
DT Article
DE COVID-19; hydroxychloroquine; chloroquine; emergency use authorization;
   cytokine storm; SARS-CoV-2
ID ANTIMALARIAL-DRUGS
AB Coronavirus disease 2019 (COVID-19), which is caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has recently emerged as a global health threat. To address this health emergency, various therapeutic approaches are currently under investigation. There is limited evidence on the effectiveness of hydroxychloroquine (HCQ) and chloroquine (CQ) as COVID-19 therapies, and thus World Health Organization (WHO) mentioned that "Current data shows that this drug does not reduce deaths among hospitalized COVID-19 patients, nor help people with mild or moderate disease." CQ and HCQ are typically used for the treatment of malaria but have been recognized for certain beneficial effects in COVID-19 patients based on some clinical outcomes from the clinical treatment of COVID-19. A standard dose of HCQ has been proven effective and less toxic than CQ in COVID-19 patients; however, a comprehensive understanding of a patient's clinical condition is necessary. Based on several hospital findings, the Food and Drug Administration (FDA) has officially cancelled the emergency use authorization for HCQ and CQ for treating hospitalized COVID-19 patients on June 15, 2020. In this review, we highlight both pros and cons of the clinical use of CQ and HCQ in COVID-19 patients.
C1 [Fatima, Urooj] Aligarh Muslim Univ, Dept Bot, Aligarh, Uttar Pradesh, India.
   [Rizvi, Syed Saif Abbas] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.
   [Fatima, Saher] Aligarh Muslim Univ, Dept Agr Microbiol, Aligarh, Uttar Pradesh, India.
   [Hassan, Md. Imtaiyaz] Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, Jamia Nagar New Delhi 110025, India.
RP Hassan, MI (corresponding author), Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, Jamia Nagar New Delhi 110025, India.
EM mihassan@jmi.ac.in
RI HASSAN, Imtaiyaz/G-7072-2017
OI HASSAN, Imtaiyaz/0000-0002-3663-4940
FU Indian Council of Medical ResearchIndian Council of Medical Research
   (ICMR) [BIC/12(01)/2015]
FX This work was funded by the Indian Council of Medical Research (Grant
   No. BIC/12(01)/2015).
CR Alanagreh L, 2020, INT J RISK SAF MED, V31, P111, DOI 10.3233/JRS-200024
   Avina-Zubieta JA, 1998, ANN RHEUM DIS, V57, P582, DOI 10.1136/ard.57.10.582
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Fox R, 1996, LUPUS, V5, pS4, DOI 10.1177/096120339600500103
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gies V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01409
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Nanni O, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04527-4
   Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Retraction, 2020, 2 ELITE MED J RETRAC
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207
   Voisin O, 2020, MAYO CLIN PROC, V95, P1696, DOI 10.1016/j.mayocp.2020.05.005
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 22
TC 2
Z9 2
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1079-9907
EI 1557-7465
J9 J INTERF CYTOK RES
JI J. Interferon Cytokine Res.
PD OCT 1
PY 2020
VL 40
IS 10
BP 469
EP 471
DI 10.1089/jir.2020.0105
PG 3
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA OA6YE
UT WOS:000577927100001
PM 32881593
OA Bronze
DA 2021-01-01
ER

PT J
AU Major, R
   Selvaskandan, H
   Makkeyah, YM
   Hull, K
   Kuverji, A
   Graham-Brown, M
AF Major, Rupert
   Selvaskandan, Haresh
   Makkeyah, Yahya Mostafa
   Hull, Katherine
   Kuverji, Apexa
   Graham-Brown, Matthew
TI The Exclusion of Patients with CKD in Prospectively Registered
   Interventional Trials for COVID-19-a Rapid Review of International
   Registry Data
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Letter
DE clinical trial; chronic kidney disease; COVID-19
C1 [Major, Rupert] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England.
   [Major, Rupert; Selvaskandan, Haresh; Makkeyah, Yahya Mostafa; Hull, Katherine; Kuverji, Apexa; Graham-Brown, Matthew] Univ Hosp Leicester, Leicester Gen Hosp, John Walls Renal Unit, Leicester, Leics, England.
   [Selvaskandan, Haresh; Hull, Katherine; Graham-Brown, Matthew] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England.
   [Makkeyah, Yahya Mostafa] Ain Shams Univ, Internal Med & Nephrol Dept, Fac Med, Cairo, Egypt.
RP Major, R (corresponding author), Univ Leicester, Dept Hlth Sci, George Davies Ctr, 15 Lancaster Rd, Leicester LE1 7HA, Leics, England.
EM rwlm2@le.ac.uk
RI Makkeyah, Yahya Mostafa/A-8630-2010
OI Makkeyah, Yahya Mostafa/0000-0002-0776-9547; Hull, Katherine
   Leigh/0000-0003-0028-5408; Selvaskandan, Haresh/0000-0002-2874-7005
FU National Institute for Health Research Academic Clinical Lectureship
   award; Kidney Research UKKidney Research UK (KRUK) [TF_009_20181123];
   National Institute for Health Research Academic Clinical Fellow award
FX M. Graham-Brown is funded by a National Institute for Health Research
   Academic Clinical Lectureship award. K. Hull is funded by a National
   Institute for Health Research Academic Clinical Fellow award. H.
   Sekvaskandan is funded by Kidney Research UK grant TF_009_20181123.
CR Baigent C, 2017, KIDNEY INT, V92, P297, DOI 10.1016/j.kint.2017.04.019
   Lee SJ, 2011, NAT REV NEPHROL, V7, P718, DOI 10.1038/nrneph.2011.150
   MedicinesComplete, 2020, DEF ONL RES DRUG HEA
   National Institute of Health Research, 2020, PROSPERO INT PROSPEC
   Strippoli GFM, 2004, J AM SOC NEPHROL, V15, P411, DOI 10.1097/01.ASN.0000100125.21491.46
   The Renal Drug Database, 2020, ULT PRESCR GUID REN
   WHO, 2020, INT CLIN TRIALS REG
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
NR 8
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD OCT
PY 2020
VL 31
IS 10
BP 2250
EP 2252
DI 10.1681/ASN.2020060877
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA NZ4UI
UT WOS:000577091000007
PM 32900842
OA Bronze
DA 2021-01-01
ER

PT J
AU Elias, M
   Pievani, D
   Randoux, C
   Louis, K
   Denis, B
   Delion, A
   Le Goff, O
   Antoine, C
   Greze, C
   Pillebout, E
   Abboud, I
   Glotz, D
   Daugas, E
   Lefaucheur, C
AF Elias, Michelle
   Pievani, Daniele
   Randoux, Christine
   Louis, Kevin
   Denis, Blandine
   Delion, Alexandra
   Le Goff, Oceane
   Antoine, Corinne
   Greze, Clarisse
   Pillebout, Evangeline
   Abboud, Imad
   Glotz, Denis
   Daugas, Eric
   Lefaucheur, Carmen
TI COVID-19 Infection in Kidney Transplant Recipients: Disease Incidence
   and Clinical Outcomes
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
DE COVID-19; coronavirus; pandemic; kidney transplantation; SARS-CoV-2
ID ETHNICITY
AB Background COVID-19 has been associated with high morbidity and mortality in kidney transplant recipients. However, risk factors for COVID-19 disease in patients with kidney transplants remain poorly defined.
   Methods We enrolled patients who underwent kidney transplantation and were actively followed up in two hospitals in Paris on March 1st, 2020. Patients were screened for baseline and transplant characteristics, functional parameters, comorbidities, and immunosuppressive therapies. COVID-19 disease was assessed. Patients were followed up during the pandemic until April 30th, 2020 by the COVID-19 SLS KT survey program, including teleconsulting, at-home monitoring for patients with COVID-19, and a dedicated phone hotline platform.
   Results Among 1216 patients with kidney transplants enrolled, 66 (5%) patients were identified with COVID-19 disease, which is higher than the incidence observed in the general population in France (0.3%). Their mean age was 56.4 +/- 12.5 years, and 37 (56%) patients were men. The following factors were independently associated with COVID-19 disease: non-White ethnicity (adjusted odds ratio [OR], 2.17; 95% confidence interval [95% CI], 1.23 to 3.78; P=0.007), obesity ( OR, 2.19; 95% CI, 1.19 to 4.05; P=0.01), asthma and chronic pulmonary disease (OR, 3.09; 95% CI, 1.49 to 6.41; P=0.002), and diabetes (OR, 3.33; 95% CI, 1.92 to 5.77; P<0.001). The mortality rate related to COVID-19 disease was 1% in the overall study population and 24% in COVID-19-positive patients.
   Conclusions Patients with kidney transplants display a high risk of mortality. Non-White ethnicity and comorbidities such as obesity, diabetes, asthma, and chronic pulmonary disease were associated with higher risk of developing COVID-19 disease. It is imperative that policy makers urgently ensure the integration of such risk factors on response operations against COVID-19.
C1 [Elias, Michelle; Pievani, Daniele; Delion, Alexandra; Le Goff, Oceane; Antoine, Corinne; Pillebout, Evangeline; Abboud, Imad; Glotz, Denis; Lefaucheur, Carmen] St Louis Hosp, AP HP, Kidney Transplant Dept, 1 Ave Claude Vellefaux, F-75010 Paris, Ile De France, France.
   [Randoux, Christine; Greze, Clarisse; Daugas, Eric] Hop Xavier Bichat, AP HP, Nephrol Dept, Paris, France.
   [Louis, Kevin; Glotz, Denis; Lefaucheur, Carmen] INSERM, Paris Translat Res Ctr Organ Transplantat, UMR S970, Paris, France.
   [Denis, Blandine] St Louis Hosp, AP HP, Infect Dis Dept, Paris, France.
RP Elias, M (corresponding author), St Louis Hosp, AP HP, Kidney Transplant Dept, 1 Ave Claude Vellefaux, F-75010 Paris, Ile De France, France.
EM michelle.elias@aphp.fr
OI Louis, Kevin/0000-0003-1766-2548
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   [Anonymous], 2020, MONDE
   [Anonymous], 2020, INF NOUV COR SARS CO
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Coates PT, 2020, KIDNEY INT, V97, P1074, DOI 10.1016/j.kint.2020.04.001
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Government of France, 2020, CART DONN COV 19 FRA
   Haug C, 2020, NEW ENGL J MED, V382, pE51, DOI 10.1056/NEJMc2010122
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Institut national de la statistique et des etudes economiques, 2020, HOUS IND ACT ED PROF
   Johns Hopkins University of Medicine Coronavirus Resource Center, 2020, COVID 19 DASHB CTR S
   L'Institut Paris Region, 2020, EXC MORT COV 19 EP P
   Ministere des Solidarites et de la Sante, 2020, COVID 19 COR SIT POI
   Mohan S, 2020, J AM SOC NEPHROL, V31, P1150, DOI 10.1681/ASN.2020030375
   O'Sullivan JM, 2020, BRIT J HAEMATOL, V190, P27, DOI 10.1111/bjh.16845
   Pareek M, 2020, LANCET, V395, P1421, DOI 10.1016/S0140-6736(20)30922-3
   Pratt G, 2020, CHICAGO TRIBUNE
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   The Francophone Society of Transplantation, 2020, COVID 19
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   World Health Organization, 2020, COR DIS COVID 19 EV
   World Health Organization, 2020, COR DIS COVID 19 ADV
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Zhao H, 2015, EPIDEMIOL INFECT, V143, P3375, DOI 10.1017/S0950268815000576
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD OCT
PY 2020
VL 31
IS 10
BP 2413
EP 2423
DI 10.1681/ASN.2020050639
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA NZ4UI
UT WOS:000577091000019
PM 32847984
OA Bronze
DA 2021-01-01
ER

PT J
AU Speaker, SL
   Moffatt, C
AF Speaker, Susan L.
   Moffatt, Christie
TI The National Library of Medicine Global Health Events web archive,
   coronavirus disease (COVID-19) pandemic collecting
SO JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION
LA English
DT Article
AB Since January 30, 2020, when the World Health Organization declared the SARS CoV-2 disease (COVID-19) to be a public health emergency of international concern, the National Library of Medicine's (NLM's) Web Collecting and Archiving Working Group has been collecting a broad range of web-based content about the emerging pandemic for preservation in an Internet archive. Like NLM's other Global Health Events web collections, this content will have enduring value as a multifaceted historical record for future study and understanding of this event. This article describes the scope of the COVID-19 project; some of the content captured from websites, blogs, and social media; collecting criteria and methods; and related COVID-19 collecting efforts by other groups. The growing collection-2,500 items as of June 30, 2020-chronicles the many facets of the pandemic: epidemiology; vaccine and drug research; disease control measures and resistance to them; effects of the pandemic on health care institutions and workers, education, commerce, and many aspects of social life; effects for especially vulnerable groups; role of health disparities in infection and mortality; and recognition of racism as a public health emergency.
C1 [Speaker, Susan L.] Natl Lib Med, Digital Manuscripts Program, Hist Med Div, Bethesda, MD 20894 USA.
   [Moffatt, Christie] Natl Lib Med, Archiving Working Grp, Bethesda, MD USA.
RP Speaker, SL (corresponding author), Natl Lib Med, Digital Manuscripts Program, Hist Med Div, Bethesda, MD 20894 USA.
EM speakes1@nih.gov; christie.moffatt@nih.gov
FU NLMUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)
FX This work was carried out by staff of NLM, NIH, with support from NLM.
   The authors acknowledge and thank Delia Golden and Kristina Womack, NLM
   Technical Services Division; Sarah Eilers, John Rees, Ginny Roth, and
   Deshaun Williams, NLM History of Medicine Division; and Marielle Gage,
   Elizabeth Livesey, Brandon Wertz, and Erica Williams, History Associates
   Incorporated; Siobhan Champ-Blackwell, NLM Public Services Division; and
   Gabrielle Barr and Michele Lyons, Office of NIH History; and Ken Koyle,
   Jennifer Marill, Beth Mullen, Jeffrey S. Reznick, and Rebecca Warlow at
   NLM for leadership and support. The working group is also grateful for
   the many recommendations of content to include from within and outside
   of the NLM.
CR Adhanom Ghebreyesus T., 2020, WE NOW HAVE NAME DIS
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Brennan P., 2020, EMERGENCY FUNDING AL
   Collins F., 2020, COVID 19 BRINGS HLTH
   Documenting the Now, DOC COVID 19
   Edelman S, 2020, NY POST         0402
   Hughes T., 2020, US TODAY
   International Internet Preservation Consortium, NOV COR COVID 19
   Law T., 2020, TIME
   Moffatt C., 2020, ARCHIVING WEB CONTEN
   Moffatt C., 2016, WEB COLLECTING ZIKA
   Moffatt C., 2014, FUTURE HIST COLLECTI
   National Institutes of Health, OFF NIH HIST STETT M
   National Library of Medicine, GLOB HLTH EV WEB ARC
   National Library of Medicine, COLL DEV GUID NAT LI
   ParkerPope Tara, 2020, NY TIMES
   Parshley L., 2020, VOX             0617
   Schneider E., 2020, MY CORONAVIRUS STORY
   Snopes Staff, 2020, COR COLL FACT CHECK
   Speaker SL, 2018, OPIOID EPIDEMIC COLL
   Thomas A, 2020, ANN INTERN MED, V172, pW119, DOI 10.7326/G20-0022
   US Centers for Disease Control and Prevention, 2020, US CLOTH FAC COV HEL
   US Centers for Disease Control and Prevention, 2020, MAK MASKS CDC HOM CL
   US Centers for Disease Control and Prevention, 2020, OPT SUPPL PPE OTH EQ
   Wenc C., 2017, ARCH HIV AIDS WEB CI
   WHO. Statement on the second meeting of the International Health Regulations, 2005, 2 M INT HLTH REG 200
NR 26
TC 0
Z9 0
U1 4
U2 4
PU MEDICAL LIBRARY ASSOC
PI CHICAGO
PA 65 EAST WACKER PLACE, STE 1900, CHICAGO, IL 60601-7298 USA
SN 1536-5050
J9 J MED LIBR ASSOC
JI J. Med. Libr. Assoc.
PD OCT
PY 2020
VL 108
IS 4
BP 656
EP 662
DI 10.5195/jmla.2020.1090
PG 7
WC Information Science & Library Science
SC Information Science & Library Science
GA NZ5UE
UT WOS:000577169900021
PM 33013228
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Collado, S
   Arenas, MD
   Barbosa, F
   Cao, H
   Montero, MM
   Villar-Garcia, J
   Barrios, C
   Rodriguez, E
   Sans, L
   Sierra, A
   Perez-Saez, MJ
   Redondo-Pachon, D
   Coca, A
   Maiques, JM
   Guerri-Fernandez, R
   Horcajada, JP
   Crespo, M
   Pascual, J
AF Collado, Silvia
   Arenas, Maria Dolores
   Barbosa, Francesc
   Cao, Higini
   Montero, Maria Milagro
   Villar-Garcia, Judit
   Barrios, Clara
   Rodriguez, Eva
   Sans, Laia
   Sierra, Adriana
   Perez-Saez, Maria Jose
   Redondo-Pachon, Dolores
   Coca, Armando
   Maiques, Jose Maria
   Gueerri-Fernandez, Roberto
   Horcajada, Juan Pablo
   Crespo, Marta
   Pascual, Julio
TI COVID-19 in Grade 4-5 Chronic Kidney Disease Patients
SO KIDNEY & BLOOD PRESSURE RESEARCH
LA English
DT Article
DE SARS-CoV-2; COVID-19; Chronic kidney disease; Pneumonia
AB Introduction:Chronic kidney disease (CKD) increases the risk of mortality during coronavirus disease 2019 (COVID-19) episodes, and some reports have underlined the high incidence and severity of this infection in dialysis patients. Information on COVID-19 in nondialysis CKD patients is not available yet.Case Reports:Here we present 7 patients with grade 4-5 CKD who developed symptomatic COVID-19; they comprise 2.6% of our 267 advanced CKD patients. The estimated GFR was between 12 and 20 mL/min during the month prior to COVID-19. The 3 major symptoms were fever, cough, and dyspnea, and 5 patients showed bilateral pneumonia. Hydroxychloroquine, azithromycin, ceftriaxone, and steroids were the most frequently prescribed drugs. Two patients needed noninvasive mechanical ventilation. All patients showed minimal to moderate kidney function deterioration during admission, with an eGFR decline below 5 mL/min in 6 cases. No patient required acute dialysis. Six patients were discharged alive and remained dialysis free athe t the time of reporting, and one 76-year-old patient died.Conclusions:COVID-19 affects grade 4-5 CKD patients, but prognosis may be acceptable if prompt supportive measures are applied. These findings should be confirmed in larger cohorts, and further observations will be needed to understand the full spectrum of clinical features and the optimal approach to COVID-19 in patients with advanced CKD.
C1 [Collado, Silvia; Arenas, Maria Dolores; Barbosa, Francesc; Cao, Higini; Villar-Garcia, Judit; Barrios, Clara; Rodriguez, Eva; Sans, Laia; Sierra, Adriana; Perez-Saez, Maria Jose; Redondo-Pachon, Dolores; Crespo, Marta; Pascual, Julio] Hosp del Mar, Dept Nephrol, Passeig Maritim 25-29, ES-08003 Barcelona, Spain.
   [Montero, Maria Milagro; Gueerri-Fernandez, Roberto; Horcajada, Juan Pablo] Hosp del Mar, Dept Infect Dis, Barcelona, Spain.
   [Coca, Armando] Univ Valladolid, Hosp Clin, Dept Nephrol, Valladolid, Spain.
   [Maiques, Jose Maria] Hosp del Mar, Dept Radiol, Barcelona, Spain.
RP Pascual, J (corresponding author), Hosp del Mar, Dept Nephrol, Passeig Maritim 25-29, ES-08003 Barcelona, Spain.
EM jpascual@psmar.cat
CR Albalate M, 2020, NEFROLOGIA, V40, P279, DOI 10.1016/j.nefro.2020.04.005
   Borobia AM, 2020, COHORT PATIENTS COVI, DOI [10.1101/2020.04.29.20080853doi, DOI 10.1101/2020.04.29.20080853DOI]
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Arenas MD, 2020, NEFROLOGIA, V40, P258, DOI 10.1016/j.nefro.2020.04.001
   Goicoechea M, 2020, KIDNEY INT, V98, P27, DOI 10.1016/j.kint.2020.04.031
   Henry BM, 2020, INT UROL NEPHROL, V52, P1193, DOI 10.1007/s11255-020-02451-9
   Syed-Ahmed M, 2019, ADV CHRONIC KIDNEY D, V26, P8, DOI 10.1053/j.ackd.2019.01.004
   Tian WJ, 2020, J MED VIROL, V92, P1875, DOI 10.1002/jmv.26050
   Vivanco-Hidalgo RM, 2020, INFORME CARACTERISTI
   Wang R, 2020, AM J KIDNEY DIS, V76, P141, DOI 10.1053/j.ajkd.2020.03.009
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 11
TC 1
Z9 1
U1 2
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1420-4096
EI 1423-0143
J9 KIDNEY BLOOD PRESS R
JI Kidney Blood Pressure Res.
PD OCT
PY 2020
VL 45
IS 5
BP 768
EP 774
DI 10.1159/000511082
PG 7
WC Physiology; Urology & Nephrology; Peripheral Vascular Disease
SC Physiology; Urology & Nephrology; Cardiovascular System & Cardiology
GA OA2FO
UT WOS:000577608300012
PM 32898845
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fedotov, IV
   Yi, ZH
   Voronin, AA
   Svidzinsky, AA
   Sower, K
   Liu, XH
   Vlasova, E
   Peng, T
   Liu, XP
   Moiseev, SA
   Belousov, VV
   Sokolov, AV
   Scully, MO
   Zheltikov, AM
AF Fedotov, Ilya, V
   Yi, Zhenhuan
   Voronin, Aleksandr A.
   Svidzinsky, Anatoly A.
   Sower, Kyle
   Liu, Xinghua
   Vlasova, Ekaterina
   Peng, Tao
   Liu, Xiangpei
   Moiseev, Sergey A.
   Belousov, Vsevolod V.
   Sokolov, Alexei, V
   Scully, Marlan O.
   Zheltikov, Aleksei M.
TI Light and corona: guided-wave readout for coronavirus spike
   protein-host-receptor binding
SO OPTICS LETTERS
LA English
DT Article
ID SINGLE VIRUSES; LASER-PULSES; NANOPARTICLES; GENERATION
AB We show that waveguide sensors can enable a quantitative characterization of coronavirus spike glycoprotein-host-receptor binding-the process whereby coronaviruses enter human cells, causing disease. We demonstrate that such sensors can help quantify and eventually understand kinetic and thermodynamic properties of viruses that control their affinity to targeted cells, which is known to significantly vary in the course of virus evolution, e.g., from SARS-CoV to SARS-CoV-2, making the development of virus-specific drugs and vaccine difficult. With the binding rate constants and thermodynamic parameters as suggested by the latest SARS-CoV-2 research, optical sensors of SARS-CoV-2 spike protein-receptor binding may be within sight. (C) 2020 Optical Society of America
C1 [Fedotov, Ilya, V; Yi, Zhenhuan; Svidzinsky, Anatoly A.; Sower, Kyle; Liu, Xinghua; Peng, Tao; Liu, Xiangpei; Sokolov, Alexei, V; Scully, Marlan O.; Zheltikov, Aleksei M.] Texas A&M Univ, Inst Quantum Sci & Engn, Dept Phys & Astron, College Stn, TX 77843 USA.
   [Fedotov, Ilya, V; Voronin, Aleksandr A.; Zheltikov, Aleksei M.] Moscow MV Lomonosov State Univ, Int Laser Ctr, Phys Dept, Moscow 119992, Russia.
   [Fedotov, Ilya, V; Voronin, Aleksandr A.; Vlasova, Ekaterina; Zheltikov, Aleksei M.] Russian Quantum Ctr, Skolkovo 143025, Moscow Region, Russia.
   [Fedotov, Ilya, V; Voronin, Aleksandr A.; Moiseev, Sergey A.; Zheltikov, Aleksei M.] AN Tupolev Kazan Natl Res Tech Univ, Kazan Quantum Ctr, Kazan 420126, Russia.
   [Liu, Xiangpei] Univ Sci & Technol China, Hefei 230026, Peoples R China.
   [Belousov, Vsevolod V.] Russian Acad Sci, MM Shemyakin & Yu A Ovchinnikov Inst Bioorgan Che, Moscow 117997, Russia.
   [Belousov, Vsevolod V.] Fed Med Biol Agcy, Fed Ctr Brain Res & Neurotechnol, Moscow 117997, Russia.
   [Sokolov, Alexei, V; Scully, Marlan O.] Baylor Univ, Waco, TX 76798 USA.
   [Scully, Marlan O.] Princeton Univ, Princeton, NJ 08544 USA.
RP Zheltikov, AM (corresponding author), Texas A&M Univ, Inst Quantum Sci & Engn, Dept Phys & Astron, College Stn, TX 77843 USA.; Zheltikov, AM (corresponding author), Moscow MV Lomonosov State Univ, Int Laser Ctr, Phys Dept, Moscow 119992, Russia.; Zheltikov, AM (corresponding author), Russian Quantum Ctr, Skolkovo 143025, Moscow Region, Russia.; Zheltikov, AM (corresponding author), AN Tupolev Kazan Natl Res Tech Univ, Kazan Quantum Ctr, Kazan 420126, Russia.
EM zheltikov@physics.msu.ru
RI Fedotov, Ilya/M-3005-2014; Peng, Tao/F-7927-2019
OI Peng, Tao/0000-0002-5296-240X
FU Ministry of Education and Science of the Russian FederationMinistry of
   Education and Science, Russian Federation [Z50.31.0040/17.02.2017];
   Russian Science FoundationRussian Science Foundation (RSF)
   [20-12-00088]; Russian Foundation for Basic ResearchRussian Foundation
   for Basic Research (RFBR) [17-00-00212, 18-29-20031, 19-02-00473]; Welch
   FoundationThe Welch Foundation [A-1801-20180324, A-1547]
FX Ministry of Education and Science of the Russian Federation
   (14.Z50.31.0040/17.02.2017); Russian Science Foundation (20-12-00088);
   Russian Foundation for Basic Research (17-00-00212, 18-29-20031,
   19-02-00473); Welch Foundation (A-1801-20180324, A-1547).
CR Akimov DA, 2003, APPL PHYS B-LASERS O, V76, P515, DOI 10.1007/s00340-002-1080-8
   Akimov DA, 2002, APPL PHYS B-LASERS O, V74, P307, DOI 10.1007/s003400200811
   Balciunas T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7117
   Cohn E. J, 1943, PROTEINS AMINO ACIDS
   Dale T. P., 1858, PHILOS T R SOC LOND, V148, P887, DOI DOI 10.1098/RSTL1858.0036
   de Andrade J., 2020, DOES NOVEL CORONAVIR, V2
   Dudley JM, 2006, REV MOD PHYS, V78, P1135, DOI 10.1103/RevModPhys.78.1135
   Faez S, 2015, ACS NANO, V9, P12349, DOI 10.1021/acsnano.5b05646
   He LN, 2011, NAT NANOTECHNOL, V6, P428, DOI [10.1038/nnano.2011.99, 10.1038/NNANO.2011.99]
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Russell P, 2003, SCIENCE, V299, P358, DOI 10.1126/science.1079280
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Snyder A. W., 1983, OPTICAL WAVEGUIDE TH
   Udem T, 2002, NATURE, V416, P233, DOI 10.1038/416233a
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wiener O., 1910, BERICHTE VERHANDL MP, V62, P256
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Ymeti A, 2007, NANO LETT, V7, P394, DOI 10.1021/nl062595n
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhao HY, 2011, BIOPHYS J, V100, P2309, DOI 10.1016/j.bpj.2011.03.004
   Zheltikov AM, 2020, PHYS-USP+, V63, P698, DOI 10.3367/UFNe.2020.03.038743
   Zheltikov A. M., 2000, Physics-Uspekhi, V43, P1125, DOI 10.1070/PU2000v043n11ABEH000839
   Zhou T., 2020, PH DEPENDENT SWITCH
NR 23
TC 0
Z9 0
U1 5
U2 5
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0146-9592
EI 1539-4794
J9 OPT LETT
JI Opt. Lett.
PD OCT 1
PY 2020
VL 45
IS 19
BP 5428
EP 5431
DI 10.1364/OL.402897
PG 4
WC Optics
SC Optics
GA NZ5EB
UT WOS:000577120500035
PM 33001920
DA 2021-01-01
ER

PT J
AU Cho, J
   Lee, YJ
   Kim, JH
   Kim, SI
   Kim, SS
   Choi, BS
   Choi, JH
AF Cho, Junhyung
   Lee, Young Jae
   Kim, Je Hyoung
   Kim, Sang Il
   Kim, Sung Soon
   Choi, Byeong-Sun
   Choi, Jang-Hoon
TI Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection
   and its implication for COVID-19
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INHIBITORS; WUHAN
AB The current coronavirus (COVID-19) pandemic is exacerbated by the absence of effective therapeutic agents. Notably, patients with COVID-19 and comorbidities such as hypertension and cardiac diseases have a higher mortality rate. An efficient strategy in response to this issue is repurposing drugs with antiviral activity for therapeutic effect. Digoxin (DIG) and ouabain (OUA) are FDA drugs for heart diseases that have antiviral activity against several coronaviruses. Thus, we aimed to assess antiviral activity of DIG and OUA against SARS-CoV-2 infection. The half-maximal inhibitory concentrations (IC50) of DIG and OUA were determined at a nanomolar concentration. Progeny virus titers of single-dose treatment of DIG, OUA and remdesivir were approximately 10(3)-, 10(4)- and 10(3)-fold lower (> 99% inhibition), respectively, than that of non-treated control or chloroquine at 48 h post-infection (hpi). Furthermore, therapeutic treatment with DIG and OUA inhibited over 99% of SARS-CoV-2 replication, leading to viral inhibition at the post entry stage of the viral life cycle. Collectively, these results suggest that DIG and OUA may be an alternative treatment for COVID-19, with potential additional therapeutic effects for patients with cardiovascular disease.
C1 [Cho, Junhyung; Lee, Young Jae; Kim, Je Hyoung; Choi, Byeong-Sun; Choi, Jang-Hoon] Korea Ctr Dis Control & Prevent, Korea Natl Inst Hlth, Ctr Infect Dis Res, Div Viral Dis Res, 187 Osongsaengmyeong 2 Ro, Cheongju 28159, Chungcheongbuk, South Korea.
   [Kim, Sung Soon] Korea Ctr Dis Control & Prevent, Korea Natl Inst Hlth, Ctr Infect Dis Res, Cheongju, South Korea.
   [Kim, Sang Il] Catholic Univ, Coll Med, Seoul St Marys Hosp, Div Infect Dis, Seoul, South Korea.
RP Choi, BS; Choi, JH (corresponding author), Korea Ctr Dis Control & Prevent, Korea Natl Inst Hlth, Ctr Infect Dis Res, Div Viral Dis Res, 187 Osongsaengmyeong 2 Ro, Cheongju 28159, Chungcheongbuk, South Korea.
EM byeongsun@Korea.kr; jhchoi@nih.go.kr
FU Korea National Institute of Health fund [2019-NI-070-01]
FX This research was supported by the Korea National Institute of Health
   fund (2019-NI-070-01).
CR Akhmerov A, 2020, CIRC RES, V126, P1443, DOI 10.1161/CIRCRESAHA.120.317055
   Amarelle L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082154
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Burkard C, 2015, J VIROL, V89, P4434, DOI 10.1128/JVI.03274-14
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   (CDC) C for DC and P, 2020, RES US ONL 2019 NOV
   Centers for Disease Control and Prevention (CDC), 2020, U SYMPT COR
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Day M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1375
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Dodson AW, 2007, VIROLOGY, V366, P340, DOI 10.1016/j.virol.2007.05.001
   Dvela Moran, 2007, Pathophysiology, V14, P159, DOI 10.1016/j.pathophys.2007.09.011
   Furstenwerth H, 2010, INT J CLIN PRACT, V64, P1591, DOI 10.1111/j.1742-1241.2010.02395.x
   Ganesan VK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120368
   Goldberger ZD, 2012, AM J CARDIOL, V109, P1818, DOI 10.1016/j.amjcard.2012.02.028
   Harcourt Jennifer, 2020, bioRxiv, DOI 10.1101/2020.03.02.972935
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   ICTV, 2020, NAM 2019 COR
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Kang YJ, 2020, DISASTER MED PUBLIC, V14, P384, DOI [10.1017/dmp.2020.60, 10.1017/dmp.2020.141]
   Kapoor A, 2012, ANTIMICROB AGENTS CH, V56, P4891, DOI 10.1128/AAC.00898-12
   Kim JH, 2015, J CLIN VIROL, V65, P11, DOI 10.1016/j.jcv.2015.01.018
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Laird GM, 2014, J ANTIMICROB CHEMOTH, V69, P988, DOI 10.1093/jac/dkt471
   Lopez-Ladzaro M, 2005, J NAT PROD, V68, P1642, DOI 10.1021/np050226l
   Madjid M, 2020, JAMA CARDIOL, V10, P1
   Norris MJ, 2018, AM J RESP CELL MOL, V59, P733, DOI 10.1165/rcmb.2017-0345OC
   Ong EZY, 2020, CELL HOST MICROBE, V27, P879, DOI 10.1016/j.chom.2020.03.021
   Pollard H. B., 2020, BIORXIV
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Rahimtoola SH, 1996, CURR PROB CARDIOLOGY, V21, P787
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shi S., 2020, JAMA CARDIOL, pE1
   Shi Y, 2020, IMMUNOPATHOLOGICAL C, V160, P261, DOI [10.1101/2020.03.12.20034736, 10.1111/imm.13223, DOI 10.1101/2020.03.12.20034736]
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   The Food and Drug Administration (FDA), 2011, PRESCR INF LAN DIG
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang CW, 2018, TOXICOL APPL PHARM, V356, P90, DOI 10.1016/j.taap.2018.07.028
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 46
TC 1
Z9 1
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 1
PY 2020
VL 10
IS 1
AR 16200
DI 10.1038/s41598-020-72879-7
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ5KZ
UT WOS:000577142600012
PM 33004837
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Singh, A
   Thakur, M
   Sharma, LK
   Chandra, K
AF Singh, Abhishek
   Thakur, Mukesh
   Sharma, Lalit Kumar
   Chandra, Kailash
TI Designing a multi-epitope peptide based vaccine against SARS-CoV-2
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; STRUCTURE PREDICTION; CODON USAGE; WEB
   SERVER; SARS; GENE; EPIDEMIOLOGY; PATHOGENESIS; RECOGNITION; REFINEMENT
AB COVID-19 pandemic has resulted in 16,114,449 cases with 646,641 deaths from the 217 countries, or territories as on July 27th 2020. Due to multifaceted issues and challenges in the implementation of the safety and preventive measures, inconsistent coordination between societies-governments and most importantly lack of specific vaccine to SARS-CoV-2, the spread of the virus that initially emerged at Wuhan is still uprising after taking a heavy toll on human life. In the present study, we mapped immunogenic epitopes present on the four structural proteins of SARS-CoV-2 and we designed a multi-epitope peptide based vaccine that, demonstrated a high immunogenic response with a vast application on world's human population. On codon optimization and in-silico cloning, we found that candidate vaccine showed high expression in E. coli and immune simulation resulted in inducing a high level of both B-cell and T-cell mediated immunity. The results predicted that exposure of vaccine by administrating three injections significantly subsidized the antigen growth in the system. The proposed candidate vaccine found promising by yielding desired results and hence, should be validated by practical experimentations for its functioning and efficacy to neutralize SARS-CoV-2.
C1 [Singh, Abhishek; Thakur, Mukesh; Sharma, Lalit Kumar; Chandra, Kailash] Zool Survey India, Kolkata 700053, W Bengal, India.
   [Singh, Abhishek] Gujarat Forens Sci Univ, Gandhinagar 382007, Gujarat, India.
RP Thakur, M (corresponding author), Zool Survey India, Kolkata 700053, W Bengal, India.
EM thamukesh@gmail.com
CR Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w
   [Anonymous], 2020, WORLD CORONAVIRUS DI
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Bojin F., 2020, PREPRINT
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Castiglione F., 2012, COMPUT MATH METHOD M, V2012, P1, DOI DOI 10.1016/J.2556463
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Chauhan V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39299-8
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   El-Manzalawy Y, 2008, J MOL RECOGNIT, V21, P243, DOI 10.1002/jmr.893
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Forni D, 2017, TRENDS MICROBIOL, V25, P35, DOI 10.1016/j.tim.2016.09.001
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681
   Kozlova EEG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33298-x
   Gralinski LE, 2017, G3-GENES GENOM GENET, V7, P1653, DOI 10.1534/g3.117.041434
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458
   Hyun-Jung Lee Chloe, 2020, F1000Res, V9, P145, DOI 10.12688/f1000research.22507.1
   Ithete NL, 2013, EMERG INFECT DIS, V19, P1697, DOI 10.3201/eid1910.130946
   Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889
   Jia Y., 2020, ANAL MUTATION DYNAMI, DOI [10.1101/2020.04.09.034942V1, DOI 10.1101/2020.04.09.034942V1]
   Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102
   Li L., 2020, PREPRINT, DOI [10.1101/2020.02.25.965434V2, DOI 10.1101/2020.02.25.965434V2]
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186
   Masters PS, 2013, FIELDS VIROLOGY, V6, P825
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   Morla S, 2016, GENE, V584, P1, DOI 10.1016/j.gene.2016.02.047
   Mubarak A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6491738
   Pandey RK, 2018, J CELL BIOCHEM, V119, P7631, DOI 10.1002/jcb.27110
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wilkins MR, 1999, METH MOL B, V112, P531
   Wlodawer Alexander, 2017, Methods Mol Biol, V1607, P595, DOI 10.1007/978-1-4939-7000-1_24
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Yang YD, 2011, BIOINFORMATICS, V27, P2076, DOI 10.1093/bioinformatics/btr350
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 67
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 1
PY 2020
VL 10
IS 1
AR 16219
DI 10.1038/s41598-020-73371-y
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ5KZ
UT WOS:000577142600031
PM 33004978
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pinto, J
   van Zeller, M
   Amorim, P
   Pimentel, A
   Dantas, P
   Eusebio, E
   Neves, A
   Pipa, J
   Clara, ES
   Santiago, T
   Viana, P
   Drummond, M
AF Pinto, Josue
   van Zeller, Mafalda
   Amorim, Pedro
   Pimentel, Ana
   Dantas, Patricia
   Eusebio, Ermelinda
   Neves, Andreia
   Pipa, Joana
   Clara, Elisabete Santa
   Santiago, Teresa
   Viana, Paulo
   Drummond, Marta
TI Sleep quality in times of Covid-19 pandemic
SO SLEEP MEDICINE
LA English
DT Article
DE Sleep quality; Sleep difficulties; Covid-19 pandemic; Jenkins sleep
   scale
ID GENDER-DIFFERENCES; HEALTH; PREVALENCE
AB Background: Due to the 2019 novel coronavirus (COVID-19) disease outbreak, social distancing measures were imposed to control the spread of the pandemic. However, isolation may affect negatively the psychological well-being and impair sleep quality. Our aim was to evaluate the sleep quality of respiratory patients during the COVID-19 pandemic lockdown.
   Methods: All patients who underwent a telemedicine appointment from March 30 to April 30 of 2020 were asked to participate in the survey. Sleep difficulties were measured using Jenkins Sleep Scale.
   Results: The study population consisted of 365 patients (mean age 63.9 years, 55.6% male, 50.1% with sleep-disordered breathing [SDB]). During the lockdown, 78.9% of participants were confined at home without working. Most patients (69.6%) reported at least one sleep difficulty and frequent awakenings was the most prevalent problem. Reporting at least one sleep difficulty was associated with home confinement without working, female gender and diagnosed or suspected SDB, after adjustment for cohabitation status and use of anxiolytics. Home confinement without working was associated with difficulties falling asleep and waking up too early in the morning. Older age was a protective factor for difficulties falling asleep, waking up too early and non-restorative sleep. Notably, SDB patients with good compliance to positive airway pressure therapy were less likely to report sleep difficulties.
   Conclusions: Home confinement without working, female gender and SDB may predict a higher risk of reporting sleep difficulties. Medical support during major disasters should be strengthened and potentially delivered through telemedicine, as this comprehensive approach could reduce psychological distress and improve sleep quality. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Pinto, Josue; van Zeller, Mafalda; Amorim, Pedro; Pimentel, Ana; Dantas, Patricia; Eusebio, Ermelinda; Neves, Andreia; Pipa, Joana; Clara, Elisabete Santa; Santiago, Teresa; Viana, Paulo; Drummond, Marta] Ctr Hosp Univ Sao Joao, Dept Pulmonol, Porto, Portugal.
   [van Zeller, Mafalda; Amorim, Pedro; Pimentel, Ana; Drummond, Marta] Univ Porto, Fac Med, Porto, Portugal.
   [Pinto, Josue] Ctr Hosp Univ Sao Joao, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal.
RP Pinto, J (corresponding author), Ctr Hosp Univ Sao Joao, Dept Pulmonol, Porto, Portugal.; Pinto, J (corresponding author), Ctr Hosp Univ Sao Joao, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal.
EM josue.mpinto@gmail.com
OI Amorim, Pedro/0000-0003-0408-4881
CR American Psychiatric Association, 2000, DIAGN STAT MAN MENT
   [Anonymous], 2020, GLOBAL STRATEGY DIAG
   Arber S, 2009, SOC SCI MED, V68, P281, DOI 10.1016/j.socscimed.2008.10.016
   Bonsignore MR, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0030-2019
   Garcia R, 2017, LEARN MEMORY, V24, P462, DOI 10.1101/lm.044115.116
   Global Initiative for Asthma, 2020, GLOB STRAT ASTHM MAN
   Grandner MA, 2010, SLEEP MED, V11, P470, DOI 10.1016/j.sleep.2009.10.006
   JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2
   Krakow B, 2001, CHEST, V120, P1923, DOI 10.1378/chest.120.6.1923
   Lallukka T, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-565
   Lallukka T, 2011, J EPIDEMIOL, V21, P474, DOI 10.2188/jea.JE20110023
   Lallukka T, 2010, J SLEEP RES, V19, P466, DOI 10.1111/j.1365-2869.2010.00821.x
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Maeda M, 2019, IND HEALTH, V57, P701, DOI 10.2486/indhealth.2018-0031
   Mallampalli MP, 2014, J WOMENS HEALTH, V23, P553, DOI 10.1089/jwh.2014.4816
   McLean CP, 2011, J PSYCHIATR RES, V45, P1027, DOI 10.1016/j.jpsychires.2011.03.006
   Nutt David, 2008, Dialogues Clin Neurosci, V10, P329
   Reardon S, 2015, NATURE, V519, P13, DOI 10.1038/519013a
   Reis C, 2014, LAB PSICOLOGIA, V12, P89, DOI DOI 10.14417/1P.894
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Salk RH, 2017, PSYCHOL BULL, V143, P783, DOI 10.1037/bul0000102
   Shigemura J, 2020, PSYCHIAT CLIN NEUROS, V74, P281, DOI 10.1111/pcn.12988
   Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83
   Tang JS, 2017, SCI REP-UK, V7, DOI 10.1038/srep43690
   Teras T, 2020, SLEEP MED, V68, P42, DOI 10.1016/j.sleep.2019.08.024
   WHO Collaborating Centre for Drug Statistics Methodology, 2019, GUID ATC CLASS DDD A
   Xie M, 2020, RESP RES, V21, DOI 10.1186/s12931-020-1291-8
NR 27
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1389-9457
EI 1878-5506
J9 SLEEP MED
JI Sleep Med.
PD OCT
PY 2020
VL 74
BP 81
EP 85
DI 10.1016/j.sleep.2020.07.012
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA NZ5GD
UT WOS:000577126500014
PM 32841849
OA Green Published
DA 2021-01-01
ER

PT J
AU Nuovo, G
   Tili, E
   Suster, D
   Matys, E
   Hupp, L
   Magro, C
AF Nuovo, Gerard
   Tili, Esmerina
   Suster, David
   Matys, Eva
   Hupp, Lance
   Magro, Cynthia
TI Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium
   sp. antigen allows rapid diagnosis of Mycobacterial infections and may
   provide specific anti-SARS-CoV-2 immunity via the BCG vaccine
SO ANNALS OF DIAGNOSTIC PATHOLOGY
LA English
DT Article
DE BCG; COVID-19; Envelope protein; AFB; SARS-CoV-2
AB The vaccine BCG has been reported to offer protection against SARS-CoV-2 infection. It has been hypothesized this is based on nonspecific enhancement of innate immunity. This study addressed whether there is strong homology between a SARS-CoV-2 capsid protein and a Mycobacterium bovis protein that would allow for stronger, more specific immune protection. The study also showed the utility of immunohistochemistry in the diagnostic pathology laboratory for elucidating this information. Immunohistochemistry documented that an antibody directed against the SARS-CoV-2 envelope, but not the spike or membrane proteins, strongly cross hybridized to 11/11 Mycobacterial species tested, including M. bovis. BlastP analysis showed high homology of the SARS-CoV-2 envelope protein with 12 consecutive amino acids of the protein LytR C, which is a consensus protein unique to Mycobacteria. Six additional cases of human tuberculosis with few organisms showed that the viral envelope specific antibody (5/6) was more accurate than the AFB stain (2/6) for diagnostic purposes. These data indicate BCG vaccination induces a specific immunity against SARS CoV-2 that targets the viral envelope protein that is essential for infectivity. Thus, a concurrent booster or first use of the BCG vaccine may reduce the severity of the current COVID-19 pandemic. The data also suggests the value of using the SARS-CoV-2 envelope antibody in the diagnosis of Mycobacterial infections in formalin fixed, paraffin embedded tissues by the diagnostic pathologist.
C1 [Nuovo, Gerard; Matys, Eva; Hupp, Lance] Discovery Life Sci, Powell, OH 43065 USA.
   [Tili, Esmerina] Ohio State Univ, Med Ctr, Dept Anesthesiol, Columbus, OH 43210 USA.
   [Tili, Esmerina] Ohio State Univ, Med Ctr, Dept Canc Biol & Genet, Columbus, OH 43210 USA.
   [Suster, David] Mt Sinai Hosp, Dept Pathol Mol & Cell Based Med, New York, NY 10029 USA.
   [Suster, David] Icahn Sch Med, New York, NY USA.
   [Magro, Cynthia] Dept Pathol & Lab Med, New York, NY 10022 USA.
RP Nuovo, G (corresponding author), 1476 Manning Pkwy, Powell, OH 43065 USA.
EM nuovo.1@osu.edu; cym2003@med.cornell.edu
CR Agarwal B, 2019, CELLS, V8
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   El-Gebali S, 2019, NUCLEIC ACIDS RES, V47, pD427, DOI 10.1093/nar/gky995
   Kashyap Rajpal S, 2010, J Immune Based Ther Vaccines, V8, P3, DOI 10.1186/1476-8518-8-3
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.1101/2020.03.24.20042937, DOI 10.1101/2020.03.24.20042937, 10. 1101/2020.03.24.20042937]
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Nuovo G, 2016, ANN DIAGN PATHOL, V25, P54, DOI 10.1016/j.anndiagpath.2016.09.010
   Nuovo GJ, 2020, SITU MOLECULAR PATHO
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Redelman-Sidi G, 2020, NAT REV UROL, V17, P316, DOI 10.1038/s41585-020-0325-9
   Riello FN, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1474-6
NR 16
TC 2
Z9 2
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1092-9134
EI 1532-8198
J9 ANN DIAGN PATHOL
JI Ann. Diagn. Pathol.
PD OCT
PY 2020
VL 48
AR 151600
DI 10.1016/j.anndiagpath.2020.151600
PG 5
WC Pathology
SC Pathology
GA NZ1LH
UT WOS:000576852400008
PM 32805515
OA Green Published
DA 2021-01-01
ER

PT J
AU Danchin, M
   Biezen, R
   Manski-Nankervis, JA
   Kaufman, J
   Leask, J
AF Danchin, Margie
   Biezen, Ruby
   Manski-Nankervis, Jo-Anne
   Kaufman, Jessica
   Leask, Julie
TI Preparing the public for COVID-19 vaccines How can general practitioners
   build vaccine confidence and optimise uptake for themselves and their
   patients?
SO AUSTRALIAN JOURNAL OF GENERAL PRACTICE
LA English
DT Article
AB Background
   The availability of a COVID-19 vaccine is being heralded as the solution to control the current COVID-19 pandemic, reduce the number of infections and deaths and facilitate resumption of our previous way of life.
   Objective
   The aim of this article is to provide a framework for primary care of what will be needed to optimise COVID-19 vaccine confidence and uptake in Australia once the vaccine prioritisation schedule and key target groups are known.
   Discussion
   While a number of vaccines are currently under development, with at least seven undergoing phase III trials (28 August 2020), it is hoped that an effective COVID-19 vaccine will become available to the public in 2021. Ensuring public confidence in vaccine safety and effectiveness will be crucial to facilitate uptake. General practitioners are at the forefront of public health, and one of the most trusted sources for patients. In this article, the authors discuss the expedited vaccine development process for COVID-19 vaccines; the likely vaccine prioritisation schedule and anticipated key target groups; the behavioural and social drivers of vaccination acceptance, including the work required to facilitate this; and the implications for general practice.
C1 [Danchin, Margie; Kaufman, Jessica] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   [Danchin, Margie; Kaufman, Jessica] Murdoch Childrens Res Inst, Vaccine Uptake Grp, Parkville, Vic, Australia.
   [Danchin, Margie] Royal Childrens Hosp, Dept Gen Med, Parkville, Vic, Australia.
   [Biezen, Ruby] Univ Melbourne, Dept Gen Practice, Melbourne, Vic, Australia.
   [Manski-Nankervis, Jo-Anne] Univ Melbourne, Dept Gen Practice, Data Driven Qual Improvement Theme, Melbourne, Vic, Australia.
   [Leask, Julie] Univ Sydney, Fac Med & Hlth, Susan Wakil Sch Nursing & Midwifery, Sydney, NSW, Australia.
RP Danchin, M (corresponding author), Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.; Danchin, M (corresponding author), Murdoch Childrens Res Inst, Vaccine Uptake Grp, Parkville, Vic, Australia.; Danchin, M (corresponding author), Royal Childrens Hosp, Dept Gen Med, Parkville, Vic, Australia.
RI Danchin, Margie/ABE-3391-2020; Leask, Julie/ABE-2077-2020
OI Leask, Julie/0000-0001-5095-1443
CR Australian Partnership for Preparedness Research on Infectious Disease Emergences (APPRISE), 2020, SHOULD WE DISTR IN L
   Deming ME, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2020076
   Dept . of Health, 2020, AUSTR HLTH SECT EM R
   Dodd Rachael H, 2020, Lancet Infect Dis, DOI 10.1016/S1473-3099(20)30559-4
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Graham T, 2019, NATURE, V574
   Grayson ML, 2009, MED J AUSTRALIA, V191, P150, DOI 10.5694/j.1326-5377.2009.tb02724.x
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Knight M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2107
   Kunin Marina, 2013, Aust Fam Physician, V42, P811
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mbaeyi S, 2020, M ADV COMM IMM PRACT
   NORC at The University of Chicago, 2020, EXP COVID 19 VACC
   Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711
   WHO, 2020, R D BLUEPR COVID 19
   World Health Organization, 2020, IMM VACC BIOL IMPR V
   World Health Organization, 2020, WHO COR DIS COVID 19
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7
NR 21
TC 1
Z9 1
U1 5
U2 5
PU ROYAL AUSTRALIAN COLLEGE GENERAL PRACTITIONERS
PI SOUTH MELBOURNE
PA 1 PALMERSTON CRESCENT, SOUTH MELBOURNE, VICTORIA 3205, AUSTRALIA
SN 2208-794X
EI 2208-7958
J9 AUST J GEN PRACT
JI Aust. J. Gen. Pract.
PD OCT
PY 2020
VL 49
IS 10
BP 625
EP 629
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ1CC
UT WOS:000576828500007
PM 33015676
OA Bronze
DA 2021-01-01
ER

PT J
AU Pinato, DJ
   Zambelli, A
   Aguilar-Company, J
   Bower, M
   Sng, CCT
   Salazar, R
   Bertuzzi, A
   Brunet, J
   Mesia, R
   Segui, E
   Biello, F
   Generali, D
   Grisanti, S
   Rizzo, G
   Libertini, M
   Maconi, A
   Harbeck, N
   Vincenzi, B
   Bertulli, R
   Ottaviani, D
   Carbo, A
   Bruna, R
   Benafif, S
   Marrari, A
   Wuerstlein, R
   Carmona-Garcia, MC
   Chopra, N
   Tondini, C
   Mirallas, O
   Tovazzi, V
   Betti, M
   Provenzano, S
   Fotia, V
   Cruz, CA
   Dalla Pria, A
   D'Avanzo, F
   Evans, JS
   Saoudi-Gonzalez, N
   Felip, E
   Galazi, M
   Garcia-Fructuoso, I
   Lee, AJX
   Newsom-Davis, T
   Patriarca, A
   Garcia-Illescas, D
   Reyes, R
   Dileo, P
   Sharkey, R
   Wong, YNS
   Ferrante, D
   Marco-Hernandez, J
   Sureda, A
   Maluquer, C
   Ruiz-Camps, I
   Gaidano, G
   Rimassa, L
   Chiudinelli, L
   Izuzquiza, M
   Cabirta, A
   Franchi, M
   Santoro, A
   Prat, A
   Tabernero, J
   Gennari, A
AF Pinato, David J.
   Zambelli, Alberto
   Aguilar-Company, Juan
   Bower, Mark
   Sng, Christopher C. T.
   Salazar, Ramon
   Bertuzzi, Alexia
   Brunet, Joan
   Mesia, Ricard
   Segui, Elia
   Biello, Federica
   Generali, Daniele
   Grisanti, Salvatore
   Rizzo, Gianpiero
   Libertini, Michela
   Maconi, Antonio
   Harbeck, Nadia
   Vincenzi, Bruno
   Bertulli, Rossella
   Ottaviani, Diego
   Carbo, Anna
   Bruna, Riccardo
   Benafif, Sarah
   Marrari, Andrea
   Wuerstlein, Rachel
   Carmona-Garcia, M. Carmen
   Chopra, Neha
   Tondini, Carlo
   Mirallas, Oriol
   Tovazzi, Valeria
   Betti, Marta
   Provenzano, Salvatore
   Fotia, Vittoria
   Cruz, Claudia Andrea
   Dalla Pria, Alessia
   D'Avanzo, Francesca
   Evans, Joanne S.
   Saoudi-Gonzalez, Nadia
   Felip, Eudald
   Galazi, Myria
   Garcia-Fructuoso, Isabel
   Lee, Alvin J. X.
   Newsom-Davis, Thomas
   Patriarca, Andrea
   Garcia-Illescas, David
   Reyes, Roxana
   Dileo, Palma
   Sharkey, Rachel
   Wong, Yien Ning Sophia
   Ferrante, Daniela
   Marco-Hernandez, Javier
   Sureda, Anna
   Maluquer, Clara
   Ruiz-Camps, Isabel
   Gaidano, Gianluca
   Rimassa, Lorenza
   Chiudinelli, Lorenzo
   Izuzquiza, Macarena
   Cabirta, Alba
   Franchi, Michela
   Santoro, Armando
   Prat, Aleix
   Tabernero, Josep
   Gennari, Alessandra
TI Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with
   Cancer
SO CANCER DISCOVERY
LA English
DT Article
AB The SARS-CoV-2 pandemic significantly affected oncology practice across the globe. There is uncertainty as to the contribution of patients' demographics and oncologic features to severity and mortality from COVID-19 and little guidance as to the role of anti-cancer and anti-COVID-19 therapy in this population. In a multicenter study of 890 patients with cancer with confirmed COVID-19, we demonstrated a worsening gradient of mortality from breast cancer to hematologic malignancies and showed that male gender, older age, and number of comorbidities identify a subset of patients with significantly worse mortality rates from COVID-19. Provision of chemotherapy, targeted therapy, or immunotherapy did not worsen mortality. Exposure to antimalarials was associated with improved mortality rates independent of baseline prognostic factors. This study highlights the clinical utility of demographic factors for individualized risk stratification of patients and supports further research into emerging anti-COVID-19 therapeutics in SARS-CoV-2-infected patients with cancer.
   SIGNIFICANCE: In this observational study of 890 patients with cancer diagnosed with SARS-CoV-2, mortality was 33.6% and predicted by male gender, age >= 65, and comorbidity burden. Delivery of cancer therapy was not detrimental to severity or mortality from COVID-19. These patients should be the focus of shielding efforts during the SARS-CoV-2 pandemic.
C1 [Pinato, David J.; Evans, Joanne S.] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, London, England.
   [Zambelli, Alberto; Tondini, Carlo; Fotia, Vittoria; Chiudinelli, Lorenzo; Franchi, Michela] ASST Papa Giovanni XXIII, Oncol Unit, Bergamo, Italy.
   [Aguilar-Company, Juan; Mirallas, Oriol; Saoudi-Gonzalez, Nadia; Garcia-Illescas, David; Tabernero, Josep] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain.
   [Aguilar-Company, Juan; Mirallas, Oriol; Saoudi-Gonzalez, Nadia; Garcia-Illescas, David; Izuzquiza, Macarena; Cabirta, Alba; Tabernero, Josep] Inst Oncol VHIO, Barcelona, Spain.
   [Aguilar-Company, Juan; Ruiz-Camps, Isabel] Vall dHebron Univ Hosp, Infect Dis, Barcelona, Spain.
   [Bower, Mark; Dalla Pria, Alessia; Newsom-Davis, Thomas; Sharkey, Rachel] Chelsea & Westminster Hosp, Dept Oncol, London, England.
   [Bower, Mark; Dalla Pria, Alessia; Newsom-Davis, Thomas; Sharkey, Rachel] Chelsea & Westminster Hosp, Natl Ctr HIV Malignancy, London, England.
   [Sng, Christopher C. T.; Ottaviani, Diego; Benafif, Sarah; Chopra, Neha; Galazi, Myria; Lee, Alvin J. X.; Dileo, Palma; Wong, Yien Ning Sophia] Univ Coll London Hosp, Canc Div, London, England.
   [Salazar, Ramon] CIBERONC, Oncobell Program IDIBELL, Dept Med Oncol, ICO Hosp, Barcelona, Spain.
   [Bertuzzi, Alexia; Marrari, Andrea; Rimassa, Lorenza; Santoro, Armando] Humanitas Clin & Res Ctr IRCCS, Med Oncol & Hematol Unit, Humanitas Canc Ctr, Milan, Italy.
   [Brunet, Joan; Carbo, Anna; Carmona-Garcia, M. Carmen; Garcia-Fructuoso, Isabel] Univ Hosp Josep Trueta, Catalan Inst Oncol, Dept Med Oncol, Girona, Spain.
   [Mesia, Ricard; Felip, Eudald] Catalan Inst Oncol, Dept Med Oncol, Badalona, Spain.
   [Segui, Elia; Cruz, Claudia Andrea; Reyes, Roxana; Prat, Aleix] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain.
   [Biello, Federica; D'Avanzo, Francesca; Gennari, Alessandra] Univ Piemonte Orientale, Dept Translat Med, Div Oncol, Novara, Italy.
   [Biello, Federica; Bruna, Riccardo; D'Avanzo, Francesca; Patriarca, Andrea; Gaidano, Gianluca; Gennari, Alessandra] Maggiore Carita Hosp, Novara, Italy.
   [Generali, Daniele] ASST Cremona, Multidisciplinary Breast Pathol & Translat Res Un, Cremona, Italy.
   [Generali, Daniele] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy.
   [Grisanti, Salvatore; Tovazzi, Valeria] Spedali Civil Brescia, Med Oncol Unit, Brescia, Italy.
   [Rizzo, Gianpiero] Fdn IRCCS Policlin San Matteo, Med Oncol Unit, Pavia, Italy.
   [Libertini, Michela] Fdn Poliambulanza Ist Osped, Med Oncol Unit, Brescia, Italy.
   [Maconi, Antonio; Betti, Marta] Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Infrastruttura Ric Formaz Innovaz, Alessandria, Italy.
   [Harbeck, Nadia; Wuerstlein, Rachel] Univ Hosp Munich, Dept Gynecol & Obstet, Breast Ctr, Munich, Germany.
   [Harbeck, Nadia; Wuerstlein, Rachel] Univ Hosp Munich, Gynecol Canc Ctr, Munich, Germany.
   [Harbeck, Nadia; Wuerstlein, Rachel] Univ Hosp Munich, CCC Munich, Munich, Germany.
   [Vincenzi, Bruno] Policlin Univ Campus Biomed, Rome, Italy.
   [Bertulli, Rossella; Provenzano, Salvatore] Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
   [Bruna, Riccardo; Patriarca, Andrea; Gaidano, Gianluca] Univ Piemonte Orientale, Div Haematol, Dept Translat Med, Novara, Italy.
   [Ferrante, Daniela] Univ Piemonte Orientale, Dept Translat Med, Unit Med Stat, Novara, Italy.
   [Ferrante, Daniela] CPO Piemonte, Canc Epidemiol, Novara, Italy.
   [Marco-Hernandez, Javier] Hosp Clin Barcelona, Dept Internal Med, Barcelona, Spain.
   [Sureda, Anna; Maluquer, Clara] Univ Barcelona, Haematol Dept, ICO Hosp, IDIBELL, Barcelona, Spain.
   [Rimassa, Lorenza; Santoro, Armando] Humanitas Univ, Dept Biomed Sci, Milan, Italy.
   [Izuzquiza, Macarena; Cabirta, Alba] Vall dHebron Univ Hosp, Dept Haematol, Barcelona, Spain.
   [Prat, Aleix] IDIBAPS, Translat Genom & Targeted Therapies Solid Tumors, Barcelona, Spain.
RP Pinato, DJ (corresponding author), Imperial Coll London, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.
EM david.pinato@imperial.ac.uk
RI Aguilar-Company, Juan/U-1890-2019; Mirallas, Oriol/M-1228-2019; Rimassa,
   Lorenza/N-4884-2016; Santoro, Armando/J-9594-2018; Lee, Alvin Jun
   Xing/A-1047-2017; Brunet, Joan/C-5292-2018
OI Aguilar-Company, Juan/0000-0002-9838-1950; Mirallas,
   Oriol/0000-0002-8492-5195; Rimassa, Lorenza/0000-0001-9957-3615;
   Santoro, Armando/0000-0003-1709-9492; Lee, Alvin Jun
   Xing/0000-0002-7427-9142; Chiudinelli, Lorenzo/0000-0002-5903-1843;
   Bower, Mark/0000-0002-4077-6351; Marco-Hernandez,
   Javier/0000-0001-8486-5404; Brunet, Joan/0000-0003-1945-3512; GAIDANO,
   Gianluca/0000-0002-4681-0151
FU Wellcome Trust Strategic Fund [PS3416]; Cancer Treatment and Research
   Trust (CTRT); AIRC 5 x 1000 Grant, Associazione Italiana per la Ricerca
   sul Cancro Foundation, Milan, ItalyAssociazione Italiana per la Ricerca
   sul Cancro (AIRC) [21198]; AIRC IG Grant, Associazione Italiana per la
   Ricerca sul Cancro Foundation, Milan, ItalyAssociazione Italiana per la
   Ricerca sul Cancro (AIRC) [14230]; UPO Aging Project
FX D.J. Pinato is supported by grant funding from the Wellcome Trust
   Strategic Fund (PS3416) and acknowledges grant support from the Cancer
   Treatment and Research Trust (CTRT) and infrastructural support by the
   Cancer Research UK Imperial Centre and the NIHR Imperial Biomedical
   Research Centre. G. Gaidano is supported by the AIRC 5 x 1000 Grant, No.
   21198, Associazione Italiana per la Ricerca sul Cancro Foundation,
   Milan, Italy. A. Gennari is supported by the AIRC IG Grant, No. 14230,
   Associazione Italiana per la Ricerca sul Cancro Foundation, Milan,
   Italy. A. Gennari and G. Gaidano from the University of Piemonte
   Orientale (Novara, Italy) acknowledge support from the UPO Aging
   Project. The authors would like to acknowledge the following study
   collaborators: Dr. Lorenza Scotti, PhD (Unit of Cancer Epidemiology,
   CPO-Piemonte, University of Eastern Piedmont, Novara, Italy), Professor
   Gian Carlo Avanzi, MD, Dr. Mattia Bellan, MD, PhD, Dr. Luigi Mario
   Castello, MD, PhD, Professor Mario Pirisi, MD (Divisions of Internal and
   Emergency Medicine, Department of Translational Medicine, University of
   Piemonte Orientale and Maggiore della Carita' Hospital, Novara, Italy),
   Dr. Meritxell Molla, MD, PhD (Department of Radiation Oncology, Hospital
   Clinic, Barcelona, Spain), Judith Swallow and Maria Martinez (Imperial
   College London, Division of Surgery and Cancer). We would like to
   acknowledge Sara Wendy Oliva for her administrative support.
CR Beigel J. H., 2020, N ENGL J MED
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Ferrari D, 2020, CLIN CHEM LAB MED, V58, P1095, DOI 10.1515/cclm-2020-0398
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Lewis MA, 2020, NEW ENGL J MED, V382, P2285, DOI 10.1056/NEJMp2006588
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   Mehra M, 2020, LANCET
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Rome BN, 2020, NEW ENGL J MED, V382, P2282, DOI 10.1056/NEJMp2009457
   Safdar A, 2011, CLIN INFECT DIS, V53, P798, DOI 10.1093/cid/cir492
   Salvi R, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110267
   Sehatzadeh S, 2014, Ont Health Technol Assess Ser, V14, P1
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 25
TC 9
Z9 9
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD OCT
PY 2020
VL 10
IS 10
BP 1465
EP 1474
DI 10.1158/2159-8290.CD-20-0773
PG 10
WC Oncology
SC Oncology
GA NZ0OZ
UT WOS:000576792800022
PM 32737082
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rivera, DR
   Peters, S
   Panagiotou, OA
   Shah, DP
   Kuderer, NM
   Hsu, CY
   Rubinstein, SM
   Lee, BJ
   Choueiri, TK
   Lopes, GD
   Grivas, P
   Painter, CA
   Rini, BI
   Thompson, MA
   Arcobello, J
   Bakouny, Z
   Doroshow, DB
   Egan, PC
   Farmakiotis, D
   Fecher, LA
   Friese, CR
   Galsky, MD
   Goel, S
   Gupta, S
   Halfdanarson, TR
   Halmos, B
   Hawley, JE
   Khaki, AR
   Lemmon, CA
   Mishra, S
   Olszewski, AJ
   Pennell, NA
   Puc, MM
   Revankar, SG
   Schapira, L
   Schmidt, A
   Schwartz, GK
   Shah, SA
   Wu, JT
   Xie, ZE
   Yeh, AC
   Zhu, HL
   Shyr, Y
   Lyman, GH
   Warner, JL
AF Rivera, Donna R.
   Peters, Solange
   Panagiotou, Orestis A.
   Shah, Dimpy P.
   Kuderer, Nicole M.
   Hsu, Chih-Yuan
   Rubinstein, Samuel M.
   Lee, Brendan J.
   Choueiri, Toni K.
   Lopes, Gilberto de Lima, Jr.
   Grivas, Petros
   Painter, Corrie A.
   Rini, Brian, I
   Thompson, Michael A.
   Arcobello, Jonathan
   Bakouny, Ziad
   Doroshow, Deborah B.
   Egan, Pamela C.
   Farmakiotis, Dimitrios
   Fecher, Leslie A.
   Friese, Christopher R.
   Galsky, Matthew D.
   Goel, Sanjay
   Gupta, Shilpa
   Halfdanarson, Thorvardur R.
   Halmos, Balazs
   Hawley, Jessica E.
   Khaki, Ali Raza
   Lemmon, Christopher A.
   Mishra, Sanjay
   Olszewski, Adam J.
   Pennell, Nathan A.
   Puc, Matthew M.
   Revankar, Sanjay G.
   Schapira, Lidia
   Schmidt, Andrew
   Schwartz, Gary K.
   Shah, Sumit A.
   Wu, Julie T.
   Xie, Zhuoer
   Yeh, Albert C.
   Zhu, Huili
   Shyr, Yu
   Lyman, Gary H.
   Warner, Jeremy L.
CA COVID-19 Canc Consortium
TI Utilization of COVID-19 Treatments and Clinical Outcomes among Patients
   with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
SO CANCER DISCOVERY
LA English
DT Article
ID RISK-FACTORS; MULTICENTER; MORTALITY; DISEASE; MODELS; CHINA
AB Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials.
   SIGNIFICANCE: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access.
C1 [Rivera, Donna R.] NCI, Div Canc Control & Populat Sci, Rockville, MD USA.
   [Peters, Solange] Univ Lausanne, Dept Oncol, Lausanne, Switzerland.
   [Panagiotou, Orestis A.] Brown Univ, Dept Hlth Serv Policy & Practice, Providence, RI 02912 USA.
   [Shah, Dimpy P.] UT Hlth San Antonio MD Anderson, Dept Populat Hlth Sci, Mays Canc Ctr, San Antonio, TX USA.
   [Kuderer, Nicole M.] Adv Canc Res Grp LLC, Kirkland, WA USA.
   [Hsu, Chih-Yuan; Bakouny, Ziad; Shyr, Yu] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA.
   [Rubinstein, Samuel M.; Lee, Brendan J.; Rini, Brian, I; Warner, Jeremy L.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Nashville, TN USA.
   [Choueiri, Toni K.; Schmidt, Andrew] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Lopes, Gilberto de Lima, Jr.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA.
   [Grivas, Petros; Khaki, Ali Raza; Yeh, Albert C.] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA.
   [Grivas, Petros; Lyman, Gary H.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Painter, Corrie A.] Count Me In, Cambridge, MA USA.
   [Thompson, Michael A.] Advocate Aurora Hlth, Milwaukee, WI USA.
   [Arcobello, Jonathan; Revankar, Sanjay G.] Karmanos Canc Inst, Detroit, MI USA.
   [Doroshow, Deborah B.; Galsky, Matthew D.; Zhu, Huili] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Doroshow, Deborah B.; Galsky, Matthew D.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
   [Egan, Pamela C.; Olszewski, Adam J.] Brown Univ, Dept Med, Div Hematol Oncol, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Farmakiotis, Dimitrios] Brown Univ, Dept Med, Div Infect Dis, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Fecher, Leslie A.] Univ Michigan, Dept Internal Med, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.
   [Friese, Christopher R.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA.
   [Goel, Sanjay; Halmos, Balazs] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Gupta, Shilpa; Lemmon, Christopher A.; Pennell, Nathan A.] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA.
   [Halfdanarson, Thorvardur R.; Xie, Zhuoer] Mayo Clin, Dept Med Oncol, Rochester, MN USA.
   [Hawley, Jessica E.; Schwartz, Gary K.] Columbia Univ, Dept Med, Herbert Irving Comprehens Canc Ctr, Irving Med Ctr, New York, NY USA.
   [Mishra, Sanjay] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
   [Puc, Matthew M.] Virtua Hlth, Sect Thorac Surg, Dept Surg, Marlton, NJ USA.
   [Schapira, Lidia; Shah, Sumit A.; Wu, Julie T.] Stanford Univ, Dept Med, Div Oncol, Palo Alto, CA USA.
   [Warner, Jeremy L.] Vanderbilt Univ, Dept Biomed Informat, Med Ctr, Nashville, TN 37232 USA.
RP Warner, JL (corresponding author), Vanderbilt Univ, Med Ctr, 2220 Pierce Ave,PRB 777, Nashville, TN 37232 USA.
EM jeremy.warner@vumc.org
RI peters, solange/ABF-2187-2020; choueiri, Toni/ABE-7070-2020;
   Halfdanarson, Thorvardur/AAO-8706-2020; Bakouny, Ziad/A-1149-2018;
   Schmidt, Andrew/F-8446-2016; Khaki, Ali Raza/AAO-2437-2020; Friese,
   Christopher R./ABG-9052-2020
OI choueiri, Toni/0000-0002-9201-3217; Halfdanarson,
   Thorvardur/0000-0001-8460-1257; Bakouny, Ziad/0000-0003-1906-5704;
   Schmidt, Andrew/0000-0003-4930-4155; Khaki, Ali
   Raza/0000-0002-4655-4426; Friese, Christopher R./0000-0002-2281-2056;
   Mishra, Sanjay/0000-0002-7775-9600; Yeh, Albert/0000-0003-3455-7360;
   Xie, Zhuoer/0000-0003-1266-9804
FU American Cancer SocietyAmerican Cancer Society; Hope Foundation for
   Cancer Research [MRSG-16-152-01-CCE]; Jim and Carol O'Hare Fund;
   NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30
   CA013696, P30 CA054174, P30 CA068485, P30 CA196521, T32 CA009515, T32
   CA203703, UG1 CA189828, UG1 CA189974, U01 CA231840]; National Human
   Genome Research InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Human
   Genome Research Institute (NHGRI) [T32 HG008341]; Vanderbilt Institute
   for Clinical and Translational Research (NCATS/NIH) [UL1 TR000445]
FX This study was partly supported by grants from the American Cancer
   Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE; to
   D.P. Shah); the Jim and Carol O'Hare Fund (to S.M. Rubinstein); the NCI
   (P30 CA013696, to J.E. Hawley; P30 CA054174, to D.P. Shah; P30 CA068485,
   to C.-Y. Hsu, B.I. Rini, J.L. Warner, S. Mishra, and Y. Shyr; P30
   CA196521, to D.B. Doroshow and M.D. Galsky; T32 CA009515, to A.R. Khaki;
   T32 CA203703, to J.E. Hawley; UG1 CA189828, to O.A. Panagiotou; UG1
   CA189974, to G.H. Lyman; and U01 CA231840, to J.L. Warner); and the
   National Human Genome Research Institute (T32 HG008341, to S.M.
   Rubinstein). REDCap is developed and supported by Vanderbilt Institute
   for Clinical and Translational Research grant support (UL1 TR000445 from
   NCATS/NIH). The funding sources had no role in the writing of the
   manuscript or the decision to submit it for publication.
CR Adamsick ML, 2020, J AM SOC NEPHROL, V31, P1384, DOI 10.1681/ASN.2020050589
   Beigel J. H., 2020, N ENGL J MED
   Center for Drug Evaluation and Research, 2019, FDA DRUG SAF COMM AZ
   Center for Drug Evaluation & Research, 2020, FDA CAUT US HYDR CHL
   Chowkwanyun M, 2020, NEW ENGL J MED, V383, P201, DOI 10.1056/NEJMp2012910
   Collins R, 2020, NEW ENGL J MED, V382, P674, DOI 10.1056/NEJMsb1901642
   Desai AP, 2021, INT J CANCER, V148, P429, DOI 10.1002/ijc.33215
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gehlenborg N., 2019, UPSETR MORE SCALABLE
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Griffith G, 2020, COLLIDER BIAS UNDERM
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   Harrell Jr. F. E., 2020, HMISC HARRELL MISCEL
   Harrell Jr FE, 2020, RMS REGRESSION MODEL
   Ho D, 2011, J STAT SOFTW, V42, P28, DOI DOI 10.18637/JSS.V042.I08
   Horby P, 2020, N ENGL J MED
   Khalatbari-Soltani S, 2020, J EPIDEMIOL COMMUN H, V74, P620, DOI 10.1136/jech-2020-214297
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Lex A, 2014, IEEE T VIS COMPUT GR, V20, P1983, DOI 10.1109/TVCG.2014.2346248
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Nipp Ryan D, 2019, Am Soc Clin Oncol Educ Book, V39, P105, DOI 10.1200/EDBK_243729
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   R Core Team, 2020, R LANG ENV STAT COMP
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Rubinstein SM, 2020, CANCER CELL, V37, P738, DOI 10.1016/j.ccell.2020.04.018
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Salas M, 1999, AM J EPIDEMIOL, V149, P981
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Skipper CP, 2020, ANN INT MED
   Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0
   Tingley D, 2014, J STAT SOFTW, V59
   van der Pas S, 2020, HORSESHOE IMPLEMENTA
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zimmermann P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00302
NR 49
TC 8
Z9 8
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD OCT
PY 2020
VL 10
IS 10
BP 1514
EP 1527
DI 10.1158/2159-8290.CD-20-0941
PG 14
WC Oncology
SC Oncology
GA NZ0OZ
UT WOS:000576792800026
PM 32699031
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hassan, AO
   Kafai, NM
   Dmitriev, IP
   Fox, JM
   Smith, BK
   Harvey, IB
   Chen, RE
   Winkler, ES
   Wessel, AW
   Case, JB
   Kashentseva, E
   McCune, BT
   Bailey, AL
   Zhao, HY
   VanBlargan, LA
   Dai, YN
   Ma, MS
   Adams, LJ
   Shrihari, S
   Danis, JE
   Gralinski, LE
   Hou, YJ
   Schafer, A
   Kim, AS
   Keeler, SP
   Weiskopf, D
   Baric, RS
   Holtzman, MJ
   Fremont, DH
   Curiel, DT
   Diamond, MS
AF Hassan, Ahmed O.
   Kafai, Natasha M.
   Dmitriev, Igor P.
   Fox, Julie M.
   Smith, Brittany K.
   Harvey, Ian B.
   Chen, Rita E.
   Winkler, Emma S.
   Wessel, Alex W.
   Case, James Brett
   Kashentseva, Elena
   McCune, Broc T.
   Bailey, Adam L.
   Zhao, Haiyan
   VanBlargan, Laura A.
   Dai, Ya-Nan
   Ma, Meisheng
   Adams, Lucas J.
   Shrihari, Swathi
   Danis, Jonathan E.
   Gralinski, Lisa E.
   Hou, Yixuan J.
   Schaefer, Alexandra
   Kim, Arthur S.
   Keeler, Shamus P.
   Weiskopf, Daniela
   Baric, Ralph S.
   Holtzman, Michael J.
   Fremont, Daved H.
   Curiel, David T.
   Diamond, Michael S.
TI A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower
   Respiratory Tracts against SARS-CoV-2
SO CELL
LA English
DT Article
ID ADENOVIRUS-BASED VACCINE; MONOCLONAL-ANTIBODIES; VIRUS; CORONAVIRUS;
   INFECTION; MICE; IMMUNOGENICITY; CHALLENGES; PNEUMONIA; HEPATITIS
AB The coronavirus disease 2019 pandemic has made deployment of an effective vaccine a global health priority. We evaluated the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a prefusion stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor. Intramuscular dosing of ChAd-SARS-CoV-2-S induces robust systemic humoral and cell-mediated immune responses and protects against lung infection, inflammation, and pathology but does not confer sterilizing immunity, as evidenced by detection of viral RNA and induction of anti-nucleoprotein antibodies after SARS-CoV-2 challenge. In contrast, a single intranasal dose of ChAd-SARS-CoV-2-S induces high levels of neutralizing antibodies, promotes systemic and mucosal immunoglobulin A (IgA) and T cell responses, and almost entirely prevents SARS-CoV-2 infection in both the upper and lower respiratory tracts. Intranasal administration of ChAd-SARS-CoV-2-S is a candidate for preventing SARS-CoV-2 infection and transmission and curtailing pandemic spread.
C1 [Hassan, Ahmed O.; Kafai, Natasha M.; Fox, Julie M.; Chen, Rita E.; Winkler, Emma S.; Wessel, Alex W.; Case, James Brett; McCune, Broc T.; VanBlargan, Laura A.; Shrihari, Swathi; Kim, Arthur S.; Holtzman, Michael J.; Diamond, Michael S.] Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA.
   [Dmitriev, Igor P.; Kashentseva, Elena; Curiel, David T.] Washington Univ, Dept Radiat Oncol, Sch Med, St Louis, MO 63110 USA.
   [Kafai, Natasha M.; Harvey, Ian B.; Chen, Rita E.; Winkler, Emma S.; Wessel, Alex W.; Bailey, Adam L.; Zhao, Haiyan; Dai, Ya-Nan; Ma, Meisheng; Adams, Lucas J.; Danis, Jonathan E.; Kim, Arthur S.; Fremont, Daved H.; Diamond, Michael S.] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA.
   [Fremont, Daved H.; Diamond, Michael S.] Washington Univ, Dept Mol Microbiol, Sch Med, St Louis, MO 63110 USA.
   [Smith, Brittany K.; Fremont, Daved H.] Washington Univ, Dept Biochem & Mol Biophys, Sch Med, St Louis, MO 63110 USA.
   [Keeler, Shamus P.; Holtzman, Michael J.] Washington Univ, Div Pulm & Crit Care Med, Sch Med, St Louis, MO 63110 USA.
   [Fremont, Daved H.; Curiel, David T.; Diamond, Michael S.] Washington Univ, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, Sch Med, St Louis, MO 63110 USA.
   [Weiskopf, Daniela] La Jolla Inst Immunol, Ctr Infect Dis & Vaccine Res, La Jolla, CA 92037 USA.
   [Gralinski, Lisa E.; Hou, Yixuan J.; Schaefer, Alexandra; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27514 USA.
   [Gralinski, Lisa E.; Hou, Yixuan J.; Schaefer, Alexandra; Baric, Ralph S.] Washington Univ Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Baric, Ralph S.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27514 USA.
RP Diamond, MS (corresponding author), Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA.; Curiel, DT (corresponding author), Washington Univ, Dept Radiat Oncol, Sch Med, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Dept Mol Microbiol, Sch Med, St Louis, MO 63110 USA.; Curiel, DT; Diamond, MS (corresponding author), Washington Univ, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, Sch Med, St Louis, MO 63110 USA.
EM dcuriel@wustl.edu; diamond@wusm.wustl.edu
RI Hou, Yixuan/P-6443-2019
OI Hou, Yixuan/0000-0002-8323-7243; Adams, Lucas/0000-0002-1724-8120; Kim,
   Arthur/0000-0003-4101-6642; Keeler, Shamus/0000-0002-1301-0852; Kafai,
   Natasha/0000-0002-3115-3400; Harvey, Ian/0000-0002-5444-8287
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [75N93019C00062, 75N9301900065, R01
   AI127828, R01 AI130591, R01 AI149644, R35 HL145242]; Center for
   Structural Genomics of Infectious Diseases [HHSN272201400018C,
   HHSN272201200026C]; Defense Advanced Research Projects AgencyUnited
   States Department of DefenseDefense Advanced Research Projects Agency
   (DARPA) [HR001117S0019]; Helen Hay Whitney Foundation postdoctoral
   fellowship;  [F32 AI138392];  [T32 AI007163]
FX This study was supported by NIH contracts and grants (75N93019C00062,
   75N9301900065, R01 AI127828, R01 AI130591, R01 AI149644, and R35
   HL145242), Center for Structural Genomics of Infectious Diseases
   (HHSN272201400018C, and HHSN272201200026C), and the Defense Advanced
   Research Projects Agency (HR001117S0019). B.T.M. is supported by F32
   AI138392, E.S.W. is supported by T32 AI007163, and J.B.C. is supported
   by a Helen Hay Whitney Foundation postdoctoral fellowship. We thank Sean
   Whelan, Susan Cook, and Jennifer Philips for facilitating studies with
   SARS-CoV-2; James Earnest for performing cell culture; and the Pulmonary
   Morphology Core at Washington University School of Medicine for tissue
   sectioning. Some figures were created with BioRender software.
CR Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   Alharbi NK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52730-4
   Alsoussi WB, 2020, J IMMUNOL, V205, P915, DOI 10.4049/jimmunol.2000583
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Burton DR, 2020, CELL HOST MICROBE, V27, P695, DOI 10.1016/j.chom.2020.04.022
   Calzas C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01605
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Case J.B., 2020, CELL HOST MICROBE
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Cheung EW, 2020, JAMA-J AM MED ASSOC, V324, P294, DOI 10.1001/jama.2020.10374
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Davis CW, 2019, CELL, V177, P1566, DOI 10.1016/j.cell.2019.04.036
   de Alwis R, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102768
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Diamond MS, 2020, CELL HOST MICROBE, V27, P699, DOI 10.1016/j.chom.2020.04.021
   Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385
   Douglas AD, 2010, VACCINE, V28, P7167, DOI 10.1016/j.vaccine.2010.08.068
   Dutta A, 2016, SCI REP-UK, V6, DOI 10.1038/srep32973
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Folegatti PM, 2020, LANCET INFECT DIS, V20, P816, DOI 10.1016/S1473-3099(20)30160-2
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hashem AM, 2019, J INFECT DIS, V220, P1558, DOI 10.1093/infdis/jiz137
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Hassan AO, 2019, CELL REP, V28, P2634, DOI 10.1016/j.celrep.2019.08.005
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021
   Hodgson SH, 2015, J INFECT DIS, V211, P1076, DOI 10.1093/infdis/jiu579
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kobinger GP, 2007, VACCINE, V25, P5220, DOI 10.1016/j.vaccine.2007.04.065
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Laurie KL, 2010, J INFECT DIS, V202, P1011, DOI 10.1086/656188
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lopez-Camacho C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04859-5
   MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Munster VJ, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0029-1
   Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Penaloza-MacMaster P, 2013, J VIROL, V87, P1373, DOI 10.1128/JVI.02058-12
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Rathnasinghe Raveen, 2020, bioRxiv, DOI 10.1101/2020.07.06.190066
   Reyes-Sandoval A, 2010, INFECT IMMUN, V78, P145, DOI 10.1128/IAI.00740-09
   Roy S, 2011, J GENE MED, V13, P17, DOI 10.1002/jgm.1530
   Sabo MC, 2011, J VIROL, V85, P7005, DOI 10.1128/JVI.00586-11
   Sheehan KCF, 2006, J INTERF CYTOK RES, V26, P804, DOI 10.1089/jir.2006.26.804
   Slifka MK, 2014, VACCINE, V32, P2948, DOI 10.1016/j.vaccine.2014.03.078
   Takamura S, 2017, VIRAL IMMUNOL, V30, P438, DOI 10.1089/vim.2017.0016
   vanDoremalen N., 2020, NATURE, V30, DOI [10.1038/s41586-020-2608, DOI 10.1038/S41586-020-2608]
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Winkler Emma S, 2020, bioRxiv, DOI 10.1101/2020.07.09.196188
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yusuf H, 2017, HUM VACC IMMUNOTHER, V13, P34, DOI 10.1080/21645515.2016.1239668
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zost SJ, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0998-x
NR 67
TC 9
Z9 9
U1 4
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD OCT 1
PY 2020
VL 183
IS 1
BP 169
EP +
DI 10.1016/j.cell.2020.08.026
PG 29
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NZ0HP
UT WOS:000576772900015
PM 32931734
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Balli, N
   Kara, E
   Demirkan, K
AF Balli, Nisa
   Kara, Emre
   Demirkan, Kutay
TI The another side of COVID-19 in Alzheimer's disease patients: Drug-drug
   interactions
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Letter
C1 [Balli, Nisa; Kara, Emre; Demirkan, Kutay] Hacettepe Univ, Fac Pharm, Dept Clin Pharm, Ankara, Turkey.
RP Balli, N (corresponding author), Hacettepe Univ, Fac Pharm, Dept Clin Pharm, Ankara, Turkey.
EM nisaballi16@gmail.com
CR Caraci F, 2017, CNS NEUROL DISORD-DR, V16, P501, DOI 10.2174/1871527316666170303144817
   Pasqualetti G, 2015, CLIN INTERV AGING, V10, P1457, DOI 10.2147/CIA.S87466
   Pytliak M, 2011, DRUGS HYPOGLYCEMIA H, P131
   University of Liverpool, 2020, COVID 19 DRUG INT
   Wang HL, 2020, LANCET, V395, P1190, DOI 10.1016/S0140-6736(20)30755-8
NR 5
TC 3
Z9 3
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
EI 1742-1241
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
PD OCT
PY 2020
VL 74
IS 10
AR e13596
DI 10.1111/ijcp.13596
PG 1
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA NY8JI
UT WOS:000576628900012
PM 32593196
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hansrivijit, P
   Qian, CC
   Boonpheng, B
   Thongprayoon, C
   Vallabhajosyula, S
   Cheungpasitporn, W
   Ghahramani, N
AF Hansrivijit, Panupong
   Qian, Chenchen
   Boonpheng, Boonphiphop
   Thongprayoon, Charat
   Vallabhajosyula, Saraschandra
   Cheungpasitporn, Wisit
   Ghahramani, Nasrollah
TI Incidence of acute kidney injury and its association with mortality in
   patients with COVID-19: a meta-analysis
SO JOURNAL OF INVESTIGATIVE MEDICINE
LA English
DT Article
DE acute kidney injury; death; kidney diseases; kidney
ID RISK-FACTORS; CORONAVIRUS; 2019-NCOV; WUHAN
AB Acute kidney injury (AKI) is a complication of COVID-19. However, the incidence of AKI in COVID-19 varies among studies. Thus, we aimed to evaluate the pooled incidence of AKI and its association with mortality in patients with COVID-19 using a meta-analysis. We search Ovid MEDLINE, EMBASE, and the Cochrane Library for eligible publications reporting the clinical characteristics of patients with COVID-19 without language restriction. Incidence of AKI and mortality were reported. Meta-regression was used to describe the association between outcomes. From 26 studies (n=5497), the pooled incidence of AKI in patients with COVID-19 was 8.4% (95% CI 6.0% to 11.7%) with a pooled incidence of renal replacement therapy of 3.6% (95% CI 1.8% to 7.1%). The incidence of AKI was higher in critically ill patients (19.9%) compared with hospitalized patients (7.3%). The pooled estimated odds ratio for mortality from AKI was 13.33 (95% CI 4.05 to 43.91). No potential publication bias was detected. By using meta-regression analyses, the incidence of AKI was positively associated with mortality after adjusted for age and sex (Q=26.18; p=0.02). Moreover, age (p<0.01), diabetes (p=0.02), hypertension (p<0.01) and baseline serum creatinine levels (p=0.04) were positively associated with AKI incidence in adjusted models. In conclusion, AKI is present in 8.3% of overall patients with COVID-19 and in 19.9% of critically ill patients with COVID-19. Presence of AKI is associated with 13-fold increased risk of mortality. Age, diabetes, hypertension, and baseline serum creatinine levels are associated with increased AKI incidence.
C1 [Hansrivijit, Panupong; Qian, Chenchen] UPMC Pinnacle Harrisburg, Dept Internal Med, Harrisburg, PA 17101 USA.
   [Boonpheng, Boonphiphop] Univ Calif Los Angeles, David Geffen Sch Med, Div Nephrol, Los Angeles, CA 90095 USA.
   [Thongprayoon, Charat] Mayo Clin, Nephrol & Hypertens, Rochester, MN USA.
   [Vallabhajosyula, Saraschandra] Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA.
   [Cheungpasitporn, Wisit] Univ Mississippi, Med Ctr, Div Nephrol, Jackson, MS 39216 USA.
   [Ghahramani, Nasrollah] Penn State Univ, Coll Med, Div Nephrol, Hershey, PA USA.
RP Hansrivijit, P (corresponding author), UPMC Pinnacle Harrisburg, Dept Internal Med, Harrisburg, PA 17101 USA.
EM hansrivijitp@upmc.edu
OI Hansrivijit, Panupong/0000-0002-5041-4290; Ghahramani,
   Nasrollah/0000-0002-0299-9394; Thongprayoon, Charat/0000-0002-8313-3604
CR Alkindi F., 2020, KIDNEY INT REP, V5, pS13, DOI [10.1016/j.ekir.2020.02.033, DOI 10.1016/J.EKIR.2020.02.033]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Barrasa H, 2020, ANAESTH CRIT CARE PA, V39, P553, DOI 10.1016/j.accpm.2020.04.001
   Calza L, 2013, SCAND J INFECT DIS, V45, P147, DOI 10.3109/00365548.2012.712213
   Cao JL, 2020, CLIN INFECT DIS, V71, P748, DOI 10.1093/cid/ciaa243
   Case J, 2013, CRIT CARE RES PRACT, DOI 10.1155/2013/479730
   Cha RH, 2015, J KOREAN MED SCI, V30, P1807, DOI 10.3346/jkms.2015.30.12.1807
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Czempik P, 2016, ANAESTH INTENSIVE TH, V48, P185, DOI 10.5603/AIT.a2016.0033
   Deng Y, 2020, CHINESE MED J-PEKING, V133, P1261, DOI 10.1097/CM9.0000000000000824
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Du RH, 2020, ANN AM THORAC SOC, V17, P839, DOI 10.1513/AnnalsATS.202003-225OC
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Karie S, 2006, NEPHROL DIAL TRANSPL, V21, P3606, DOI 10.1093/ndt/gfl345
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Leblanc M, 2005, CURR OPIN CRIT CARE, V11, P533, DOI 10.1097/01.ccx.0000183666.54717.3d
   Lei ZY, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101664
   Lian JS, 2020, INFLUENZA OTHER RESP, V14, P564, DOI 10.1111/irv.12758
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Lombardi R, 2017, SHOCK, V48, P411, DOI 10.1097/SHK.0000000000000871
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1036
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Pan XW, 2020, INTENS CARE MED, V46, P1114, DOI 10.1007/s00134-020-06026-1
   Peng L, 2020, J MED VIROL, V92, P1676, DOI 10.1002/jmv.25936
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Sawhney S, 2017, AM J KIDNEY DIS, V69, P18, DOI 10.1053/j.ajkd.2016.05.018
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Sterne JA, 1756, ROBINS I TOOL ASSESS, P1756
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tang X, 2020, CHEST
   Tu WJ, 2020, INTENS CARE MED, V46, P1117, DOI 10.1007/s00134-020-06023-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HE, 2012, AM J NEPHROL, V35, P349, DOI 10.1159/000337487
   Wang L, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3541116, DOI 10.2139/SSRN.3541116]
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   WHO, 2012, MIDDL E RESP SYNDR C
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Ying LY, 2020, NURS CRIT CARE, DOI 10.1111/nicc.12551
   Zhang GQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104364
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 51
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1081-5589
EI 1708-8267
J9 J INVEST MED
JI J. Invest. Med.
PD OCT
PY 2020
VL 68
IS 7
BP 1261
EP 1270
DI 10.1136/jim-2020-001407
PG 10
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA NZ4WP
UT WOS:000577097400011
PM 32655013
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Klann, K
   Bojkova, D
   Tascher, G
   Ciesek, S
   Munch, C
   Cinatl, J
AF Klann, Kevin
   Bojkova, Denisa
   Tascher, Georg
   Ciesek, Sandra
   Muench, Christian
   Cinatl, Jindrich
TI Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2
   Replication
SO MOLECULAR CELL
LA English
DT Article
ID 1ST-IN-HUMAN PHASE-I; PI3K INHIBITOR; PHOSPHORYLATION; EGFR; ACTIVATION;
   EXPRESSION; PREDICTION; RNA
AB SARS-CoV-2 infections are rapidly spreading around the globe. The rapid development of therapies is of major importance. However, our lack of understanding of the molecular processes and host cell signaling events underlying SARS-CoV-2 infection hinders therapy development. We use a SARS-CoV-2 infection system in permissible human cells to study signaling changes by phosphoproteomics. We identify viral protein phosphorylation and define phosphorylation-driven host cell signaling changes upon infection. Growth factor receptor (GFR) signaling and downstream pathways are activated. Drug-protein network analyses revealed GFR signaling as key pathways targetable by approved drugs. The inhibition of GFR downstream signaling by five compounds prevents SARS-CoV-2 replication in cells, assessed by cytopathic effect, viral dsRNA production, and viral RNA release into the supernatant. This study describes host cell signaling events upon SARS-CoV-2 infection and reveals GFR signaling as a central pathway essential for SARS-CoV-2 replication. It provides novel strategies for COVID-19 treatment.
C1 [Klann, Kevin; Tascher, Georg; Muench, Christian] Goethe Univ, Inst Biochem 2, Fac Med, Frankfurt, Germany.
   [Bojkova, Denisa; Ciesek, Sandra; Cinatl, Jindrich] Univ Hosp Frankfurt, Inst Med Virol, Frankfurt, Germany.
   [Ciesek, Sandra] German Ctr Infect Res DZIF, External Partner Site, Frankfurt, Germany.
   [Muench, Christian] Frankfurt Canc Inst, Frankfurt, Germany.
   [Muench, Christian] Cardiopulm Inst, Frankfurt, Germany.
   [Ciesek, Sandra] Fraunhofer Inst Mol Biol & Appl Ecol IME, Branch Translat Med & Pharmacol, Frankfurt, Germany.
RP Munch, C (corresponding author), Goethe Univ, Inst Biochem 2, Fac Med, Frankfurt, Germany.; Cinatl, J (corresponding author), Univ Hosp Frankfurt, Inst Med Virol, Frankfurt, Germany.; Munch, C (corresponding author), Frankfurt Canc Inst, Frankfurt, Germany.; Munch, C (corresponding author), Cardiopulm Inst, Frankfurt, Germany.
EM ch.muench@em.uni-frankfurt.de; cinatl@em.uni-frankfurt.de
OI Klann, Kevin/0000-0003-2276-8128; Munch, Christian/0000-0003-3832-090X
FU Quantitative Proteomics Unit (IBC2, Goethe University Frankfurt);
   European Research Council under the European UnionEuropean Research
   Council (ERC) [ERC StG 803565]; Collaborative Research Center
   (CRC)Australian GovernmentDepartment of Industry, Innovation and
   ScienceCooperative Research Centres (CRC) Programme [1177]; Emmy Noether
   Programme of the Deutsche Forschungsgemeinschaft (DFG)German Research
   Foundation (DFG) [MU 4216/1-1]; Johanna Quandt Young Academy at Goethe;
   Aventis Foundation Bridge Award; Goethe Corona Fonds; Hilfe fur
   krebskranke Kinder Frankfurt e.V.; Frankfurter Stiftung fur krebskranke
   Kinder
FX We thank the Quantitative Proteomics Unit (IBC2, Goethe University
   Frankfurt) for support and expertise on LC-MS instrumentation and data
   analysis and Christiane Pallas and Lena Stegmann for assistance with the
   experimental work. C.M. was supported by the European Research Council
   under the European Union's Seventh Framework Programme (ERC StG 803565),
   Collaborative Research Center (CRC) 1177 and the Emmy Noether Programme
   of the Deutsche Forschungsgemeinschaft (DFG; MU 4216/1-1), the Johanna
   Quandt Young Academy at Goethe, the Aventis Foundation Bridge Award, and
   the Goethe Corona Fonds. J.C. was funded by the Hilfe fur krebskranke
   Kinder Frankfurt e.V. and the Frankfurter Stiftung fur krebskranke
   Kinder.
CR Baturcam E, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0378-7
   Beerli C, 2019, NAT MICROBIOL, V4, P216, DOI 10.1038/s41564-018-0288-2
   Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310
   Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Eierhoff T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001099
   Eskens FALM, 2001, J CLIN ONCOL, V19, P1167, DOI 10.1200/JCO.2001.19.4.1167
   Fucile C, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0335-7
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grimmler M, 2005, EMBO REP, V6, P70, DOI 10.1038/sj.embor.7400301
   Herzog P, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-138
   Ilan L, 2017, CELL RES, V27, P688, DOI 10.1038/cr.2017.39
   IPPOLITO T, 2016, BLOOD, V128
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Klann K, 2020, MOL CELL, V77, P913, DOI 10.1016/j.molcel.2019.11.010
   Kung CP, 2011, J VIROL, V85, P4399, DOI 10.1128/JVI.01703-10
   Li X., 2020, 2020030286 PREPR
   Luo W., 2020, 2020020407 PREPR
   Lupberger J, 2011, NAT MED, V17, P589, DOI 10.1038/nm.2341
   Martinez-Garcia M, 2012, CLIN CANCER RES, V18, P4806, DOI 10.1158/1078-0432.CCR-12-0742
   Mathew R, 2008, NAT STRUCT MOL BIOL, V15, P435, DOI 10.1038/nsmb.1415
   McAlister GC, 2014, ANAL CHEM, V86, P7150, DOI 10.1021/ac502040v
   MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x
   Munster P, 2016, CLIN CANCER RES, V22, P1932, DOI 10.1158/1078-0432.CCR-15-1665
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098
   Ren XF, 2006, J GEN VIROL, V87, P1691, DOI 10.1099/vir.0.81749-0
   Sarker D, 2015, CLIN CANCER RES, V21, P77, DOI 10.1158/1078-0432.CCR-14-0947
   Schmid P, 2016, J CLIN ONCOL, V34, P1987, DOI 10.1200/JCO.2015.63.9179
   Smith M., 2020, PREPRINT, DOI [10.26434/chemrxiv.11871402., DOI 10.26434/CHEMRXIV.11871402]
   Tangudu C, 2007, J VIROL, V81, P1220, DOI 10.1128/JVI.01515-06
   Ueki IF, 2013, J EXP MED, V210, P1929, DOI 10.1084/jem.20121401
   Venkataraman T, 2017, J VIROL, V91, DOI 10.1128/JVI.00182-17
   Venkataraman T, 2017, ANTIVIR RES, V143, P142, DOI 10.1016/j.antiviral.2017.03.022
   Wang CW, 2020, GENOM PROTEOM BIOINF, V18, P72, DOI 10.1016/j.gpb.2020.01.001
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006
   Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130
   Wu CH, 2009, J BIOL CHEM, V284, P5229, DOI 10.1074/jbc.M805747200
   Wu YQ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006281
   Yarden Y, 2001, EUR J CANCER, V37, pS3
   Zhu L, 2009, AM J RESP CELL MOL, V40, P610, DOI 10.1165/rcmb.2008-0223OC
NR 44
TC 2
Z9 2
U1 1
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1097-2765
EI 1097-4164
J9 MOL CELL
JI Mol. Cell
PD OCT 1
PY 2020
VL 80
IS 1
BP 164
EP +
DI 10.1016/j.molcel.2020.08.006
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NZ2VM
UT WOS:000576955400004
PM 32877642
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bhumbra, S
   Malin, S
   Kirkpatrick, L
   Khaitan, A
   John, CC
   Rowan, CM
   Enane, LA
AF Bhumbra, Samina
   Malin, Stefan
   Kirkpatrick, Lindsey
   Khaitan, Alka
   John, Chandy C.
   Rowan, Courtney M.
   Enane, Leslie A.
TI Clinical Features of Critical Coronavirus Disease 2019 in Children
SO PEDIATRIC CRITICAL CARE MEDICINE
LA English
DT Article
DE adolescents; coronavirus disease 2019; critical care; health
   disparities; pediatrics; severe acute respiratory syndrome coronavirus 2
AB Objectives: We sought to describe the presentation, course, and outcomes of hospitalized pediatric coronavirus disease 2019 patients, with detailed description of those requiring mechanical ventilation, and comparisons between critically ill and noncritical hospitalized pediatric patients.
   Design: Observational cohort study.
   Setting: Riley Hospital for Children at Indiana University Health in Indianapolis in the early weeks of the coronavirus disease 2019 pandemic.
   Patients: All hospitalized pediatric patients with confirmed coronavirus disease 2019 as of May 4, 2020, were included.
   Interventions: Patients received therapies including hydroxychloroquine, remdesivir, tocilizumab, and convalescent serum and were managed according to an institutional algorithm based on evidence available at the time of presentation.
   Measurements and Main Results: Of 407 children tested for severe acute respiratory syndrome-coronavirus 2 at our hospital, 24 were positive, and 19 required hospitalization. Seven (36.8%) were critically ill in ICU, and four (21%) required mechanical ventilation. Hospitalized children were predominantly male (14, 74%) and African-American or Hispanic (14, 74%), with a bimodal distribution of ages among young children less than or equal to 2 years old (8, 42%) and older adolescents ages 15-18 (6, 32%). Five of seven (71.4%) of critically ill patients were African-American (n = 3) or Hispanic (n = 2). Critical illness was associated with older age (p = 0.017), longer duration of symptoms (p = 0.036), and lower oxygen saturation on presentation (p = 0.016); with more thrombocytopenia (p = 0.015); higher C-reactive protein (p = 0.031); and lower WBC count (p = 0.039). Duration of mechanical ventilation averaged 14.1 days. One patient died.
   Conclusions: Severe, protracted coronavirus disease 2019 is seen in pediatric patients, including those without significant comorbidities. We observed a greater proportion of hospitalized children requiring mechanical ventilation than has been reported to date. Older children, African-American or Hispanic children, and males may be at risk for severe coronavirus disease 2019 requiring hospitalization. Hypoxia, thrombocytopenia, and elevated C-reactive protein may be useful markers of critical illness. Data regarding optimal management and therapies for pediatric coronavirus disease 2019 are urgently needed.
C1 [Bhumbra, Samina; Kirkpatrick, Lindsey; Khaitan, Alka; John, Chandy C.; Enane, Leslie A.] Indiana Univ Sch Med, Dept Pediat, Ryan White Ctr Pediat Infect Dis & Global Hlth, Indianapolis, IN 46202 USA.
   [Malin, Stefan; Rowan, Courtney M.] Indiana Univ Sch Med, Dept Pediat, Pediat Crit Care, Indianapolis, IN 46202 USA.
RP Enane, LA (corresponding author), Indiana Univ Sch Med, Dept Pediat, Ryan White Ctr Pediat Infect Dis & Global Hlth, Indianapolis, IN 46202 USA.
EM lenane@iu.edu
OI Malin, Stefan/0000-0001-8860-7883
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development at the National Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   Eunice Kennedy Shriver National Institute of Child Health & Human
   Development (NICHD) [K23 HD095778, T32 HD069047]; National Institute of
   Allergy and Infectious at the National Institutes of Health Diseases
   [T32 AI07637]
FX This work was supported by the Eunice Kennedy Shriver National Institute
   of Child Health and Human Development at the National Institutes of
   Health (grant numbers K23 HD095778, T32 HD069047); and by the National
   Institute of Allergy and Infectious at the National Institutes of Health
   Diseases (grant number T32 AI07637).
CR Ahmed MZ, 2020, BRIT J HAEMATOL, V189, P1057, DOI 10.1111/bjh.16769
   Bailey ZD, 2017, LANCET, V389, P1453, DOI 10.1016/S0140-6736(17)30569-X
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Bozzella MJ, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-2399
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Indiana State Department of Health, 2020, 2019 NOV COR COVID 1
   Muniraman HK, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.1179
   Parri N, 2020, N ENGL J MED
   Pathak EB, 2020, J PUBLIC HEALTH MAN, V26, P325, DOI 10.1097/PHH.0000000000001190
   Prusakowski MK, 2017, EMERG MED CLIN N AM, V35, P123, DOI 10.1016/j.emc.2016.08.008
   Shekerdemian LS, 2020, JAMA PEDIAT
   United States Census Bureau, 2020, QUICKFACTS IND
   Wei M, 2020, JAMA-J AM MED ASSOC, V323, P1313, DOI 10.1001/jama.2020.2131
   Xu PY, 2020, ANN HEMATOL, V99, P1205, DOI 10.1007/s00277-020-04019-0
NR 18
TC 2
Z9 2
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1529-7535
EI 1947-3893
J9 PEDIATR CRIT CARE ME
JI Pediatr. Crit. Care Med.
PD OCT
PY 2020
VL 21
IS 10
BP E948
EP E953
DI 10.1097/PCC.0000000000002511
PG 6
WC Critical Care Medicine; Pediatrics
SC General & Internal Medicine; Pediatrics
GA NZ4VG
UT WOS:000577093500041
PM 32639466
OA Green Published
DA 2021-01-01
ER

PT J
AU Bell, S
   Campbell, J
   McDonald, J
   O'Neill, M
   Watters, C
   Buck, K
   Cousland, Z
   Findlay, M
   Lone, NI
   Metcalfe, W
   Methven, S
   Peel, R
   Almond, A
   Sanu, V
   Spalding, E
   Thomson, PC
   Mark, PB
   Traynor, JP
AF Bell, Samira
   Campbell, Jacqueline
   McDonald, Jackie
   O'Neill, Martin
   Watters, Chrissie
   Buck, Katharine
   Cousland, Zoe
   Findlay, Mark
   Lone, Nazir I.
   Metcalfe, Wendy
   Methven, Shona
   Peel, Robert
   Almond, Alison
   Sanu, Vinod
   Spalding, Elaine
   Thomson, Peter C.
   Mark, Patrick B.
   Traynor, Jamie P.
CA Scottish Renal Registry
TI COVID-19 in patients undergoing chronic kidney replacement therapy and
   kidney transplant recipients in Scotland: findings and experience from
   the Scottish renal registry
SO BMC NEPHROLOGY
LA English
DT Article
DE COVID-19; Kidney replacement therapy; Epidemiology; Registry
ID HEMODIALYSIS-PATIENTS; OUTCOMES; CHECK
AB Background Infection with the severe acute respiratory coronavirus 2 (SARS-CoV-2) has led to a worldwide pandemic with coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2, overwhelming healthcare systems globally. Preliminary reports suggest a high incidence of infection and mortality with SARS-CoV-2 in patients receiving kidney replacement therapy (KRT). The aims of this study are to report characteristics, rates and outcomes of all patients affected by infection with SARS-CoV-2 undergoing KRT in Scotland. Methods Study design was an observational cohort study. Data were linked between the Scottish Renal Registry, Health Protection Scotland and the Scottish Intensive Care Society Audit Group national data sets using a unique patient identifier (Community Health Index (CHI)) for each individual by the Public Health and Intelligence unit of Public Health, Scotland. Descriptive statistics and survival analyses were performed. Results During the period 1st March 2020 to 31st May 2020, 110 patients receiving KRT tested positive for SARS-CoV-2 amounting to 2% of the prevalent KRT population. Of those affected, 86 were receiving haemodialysis or peritoneal dialysis and 24 had a renal transplant. Patients who tested positive were older and more likely to reside in more deprived postcodes. Mortality was high at 26.7% in the dialysis patients and 29.2% in the transplant patients. Conclusion The rate of detected SARS-CoV-2 in people receiving KRT in Scotland was relatively low but with a high mortality for those demonstrating infection. Although impossible to confirm, it appears that the measures taken within dialysis units coupled with the national shielding policy, have been effective in protecting this population from infection.
C1 [Bell, Samira] Univ Dundee, Sch Med, Div Populat Hlth & Genom, Dundee DD1 9SY, Scotland.
   [Bell, Samira; Campbell, Jacqueline; McDonald, Jackie; O'Neill, Martin; Watters, Chrissie; Traynor, Jamie P.] Scottish Hlth Audits Publ Hlth & Intelligence, Scottish Renal Registry, Informat Serv, 5 Cadogan St, Glasgow G2 6QE, Lanark, Scotland.
   [Buck, Katharine] Victoria Hosp, Renal Unit, Kirkcaldy KY2 5AH, Scotland.
   [Cousland, Zoe] Monklands Hosp, Renal Unit, Monkscourt Ave, Airdrie ML6 0JS, Scotland.
   [Findlay, Mark; Thomson, Peter C.; Mark, Patrick B.; Traynor, Jamie P.] Queen Elizabeth Univ Hosp, Glasgow Renal & Transplant Unit, Glasgow G51 4TF, Lanark, Scotland.
   [Lone, Nazir I.] Univ Edinburgh, Usher Inst, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.
   [Metcalfe, Wendy] Royal Infirm Edinburgh NHS Trust, Dept Renal Med, Edinburgh EH16 4SA, Midlothian, Scotland.
   [Methven, Shona] Aberdeen Royal Infirm, Dept Renal Med, Foresterhill Hlth Campus,Foresterhill Rd, Aberdeen AB25 2ZN, Scotland.
   [Peel, Robert] Raigmore Hosp, Renal Unit, Old Perth Rd, Inverness IV2 3UJ, Scotland.
   [Almond, Alison] Mountainhall Treatment Ctr, Renal Unit, Dumfries DG1 4AP, Scotland.
   [Sanu, Vinod] Ninewells Hosp, Renal Unit, Dundee DD1 9SY, Scotland.
   [Spalding, Elaine] Univ Hosp Crosshouse, Renal Unit, Crosshouse KA2 0BE, Scotland.
RP Bell, S (corresponding author), Univ Dundee, Sch Med, Div Populat Hlth & Genom, Dundee DD1 9SY, Scotland.; Bell, S (corresponding author), Scottish Hlth Audits Publ Hlth & Intelligence, Scottish Renal Registry, Informat Serv, 5 Cadogan St, Glasgow G2 6QE, Lanark, Scotland.
EM s.t.bell@dundee.ac.uk
RI Mark, Patrick/N-5536-2014
OI Mark, Patrick/0000-0003-3387-2123; Bell, Samira/0000-0001-9100-1575
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alberici F, 2020, KIDNEY INT, V98, P20, DOI 10.1016/j.kint.2020.04.030
   Basile C, 2020, NEPHROL DIAL TRANSPL, V35, P737, DOI 10.1093/ndt/gfaa069
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Cho JH, 2020, J AM SOC NEPHROL, V31, P1398, DOI 10.1681/ASN.2020040461
   Corbett RW, 2020, J AM SOC NEPHROL, V31, P1815, DOI 10.1681/ASN.2020040534
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Sanchez-Alvarez JE, 2020, NEFROLOGIA, V40, P272, DOI 10.1016/j.nefro.2020.04.002
   Filipe ADS, 2020, GENOMIC EPIDEMIOLOGY, V2020, p060820124834
   Goicoechea M, 2020, KIDNEY INT, V98, P27, DOI 10.1016/j.kint.2020.04.031
   Ikizler TA, 2020, NAT REV NEPHROL, V16, P311, DOI 10.1038/s41581-020-0280-y
   Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208
   Kliger AS, 2020, KIDNEY INT, V98, P12, DOI 10.1016/j.kint.2020.04.007
   Meijers B, 2020, BLOOD PURIFICAT, V49, P259, DOI 10.1159/000507537
   Public Health Scotland, SCOTTISH INDEX MULTI
   R Core Team, 2008, R LANG ENV STAT COMP
   Scottish Government, 2020, CORONAVIRUS COVID 19
   Scottish Renal Registry, ERA EDTA PRIMARY REN
   UK Renal Association, 2020, PPE USE MASKS DIALYS
   Valeri AM, 2020, J AM SOC NEPHROL, V31, P1409, DOI 10.1681/ASN.2020040470
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang R, 2020, AM J KIDNEY DIS, V76, P141, DOI 10.1053/j.ajkd.2020.03.009
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Wu J, 2020, CLIN J AM SOC NEPHRO, V15, P1139, DOI 10.2215/CJN.04160320
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD OCT 1
PY 2020
VL 21
IS 1
AR 419
DI 10.1186/s12882-020-02061-8
PG 12
WC Urology & Nephrology
SC Urology & Nephrology
GA NZ1LI
UT WOS:000576852500001
PM 33004002
OA DOAJ Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Singh, N
   Decroly, E
   Khatib, AM
   Villoutreix, BO
AF Singh, Natesh
   Decroly, Etienne
   Khatib, Abdel-Majid
   Villoutreix, Bruno O.
TI Structure-based drug repositioning over the human TMPRSS2 protease
   domain: search for chemical probes able to repress SARS-CoV-2 Spike
   protein cleavages
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Virtual screening; Drug repurposing; Drug repositioning; Homology
   modeling; SARS-CoV2; COVID-19; Structural bioinformatics
ID HIGH-THROUGHPUT; DISCOVERY; DOCKING; IDENTIFICATION; INHIBITORS;
   ACCURACY; VISUALIZATION; OPTIMIZATION; CHALLENGES; SELECTION
AB In December 2019, a new coronavirus was identified in the Hubei province of central china and named SARSCoV-2. This new virus induces COVID-19, a severe respiratory disease with high death rate. A putative target to interfere with the virus is the host transmembrane serine protease family member II (TMPRSS2). This enzyme is critical for the entry of coronaviruses into human cells by cleaving and activating the spike protein (S) of SARSCoV-2. Repositioning approved, investigational and experimental drugs on the serine protease domain of TMPRSS2 could thus be valuable. There is no experimental structure for TMPRSS2 but it is possible to develop quality structural models for the serine protease domain using comparative modeling strategies as such domains are highly structurally conserved. Beside the TMPRSS2 catalytic site, we predicted on our structural models a main exosite that could be important for the binding of protein partners and/or substrates. To block the catalytic site or the exosite of TMPRSS2 we used structure-based virtual screening computations and two different collections of approved, investigational and experimental drugs. We propose a list of 156 molecules that could bind to the catalytic site and 100 compounds that may interact with the exosite. These small molecules should now be tested in vitro to gain novel insights over the roles of TMPRSS2 or as starting point for the development of second generation analogs.
C1 [Singh, Natesh; Villoutreix, Bruno O.] Univ Lille, Inst Pasteur Lille, U1177, INSERM, F-59000 Lille, France.
   [Decroly, Etienne] Aix Marseille Univ, CNRS, AFMB UMR 7257, Marseille, France.
   [Khatib, Abdel-Majid] Univ Bordeaux, Allee Geoffroy St Hilaire, F-33615 Pessac, France.
   [Khatib, Abdel-Majid] INSERM, UMR 1029, LAMC, Allee Geoffroy St Hilaire, F-33615 Pessac, France.
RP Villoutreix, BO (corresponding author), Univ Lille, Inst Pasteur Lille, U1177, INSERM, F-59000 Lille, France.; Khatib, AM (corresponding author), Univ Bordeaux, Allee Geoffroy St Hilaire, F-33615 Pessac, France.; Khatib, AM (corresponding author), INSERM, UMR 1029, LAMC, Allee Geoffroy St Hilaire, F-33615 Pessac, France.
EM bruno.villoutreix@inserm.fr
CR Ain Q. U., 2015, REV COMPUT MOL SCI, V5, P405, DOI [10.1002/wcms.1225, DOI 10.1002/WCMS.1225]
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Bhattacharya A, 2008, PROTEINS, V70, P105, DOI 10.1002/prot.21466
   Bienstock RJ, 2012, CURR PHARM DESIGN, V18, P1240
   Bottcher T, 2016, J CHEM INF MODEL, V56, P462, DOI 10.1021/acs.jcim.5b00723
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Carter WJ, 2005, J BIOL CHEM, V280, P2745, DOI 10.1074/jbc.M411606200
   Cavasotto CN, 2011, CURR TOP MED CHEM, V11, P1528
   Cereto-Massague A, 2015, METHODS, V71, P98, DOI 10.1016/j.ymeth.2014.09.006
   Currow DC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113471
   Douguet D, 2018, ACS MED CHEM LETT, V9, P204, DOI 10.1021/acsmedchemlett.7b00462
   Ekins S, 2019, NAT MATER, V18, P435, DOI 10.1038/s41563-019-0338-z
   Eramian D, 2008, PROTEIN SCI, V17, P1881, DOI 10.1110/ps.036061.108
   Farha MA, 2019, NAT MICROBIOL, V4, P565, DOI 10.1038/s41564-019-0357-1
   Feher M, 2006, DRUG DISCOV TODAY, V11, P421, DOI 10.1016/j.drudis.2006.03.009
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL
   Huntington JA, 2014, THROMB HAEMOSTASIS, V111, P583, DOI 10.1160/TH13-10-0811
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jain AN, 2019, J COMPUT AID MOL DES, V33, P531, DOI 10.1007/s10822-019-00203-1
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Klimenko K, 2016, J CHEM INF MODEL, V56, P1438, DOI 10.1021/acs.jcim.6b00192
   Koes DR, 2013, J CHEM INF MODEL, V53, P1893, DOI 10.1021/ci300604z
   Krivak R, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0285-8
   Kruger DM, 2012, J CHEM INF MODEL, V52, P2807, DOI 10.1021/ci3003599
   Lagarde N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184648
   Lagarde Nathalie, 2018, Oncotarget, V9, P32346, DOI 10.18632/oncotarget.25966
   Lagorce D, 2017, BIOINFORMATICS, V33, P3658, DOI 10.1093/bioinformatics/btx491
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Liu ZH, 2015, BIOINFORMATICS, V31, P405, DOI 10.1093/bioinformatics/btu626
   Masters L, 2020, J MOL GRAPH MODEL, V96, DOI 10.1016/j.jmgm.2020.107532
   MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075
   Mendez-Lucio O, 2017, DRUG DISCOV TODAY, V22, P120, DOI 10.1016/j.drudis.2016.08.009
   Miteva MA, 2005, NUCLEIC ACIDS RES, V33, pW372, DOI 10.1093/nar/gki365
   Nero TL, 2014, NAT REV CANCER, V14, P248, DOI 10.1038/nrc3690
   Nicola G, 2020, J COMPUT AID MOL DES, V34, P219, DOI 10.1007/s10822-019-00276-y
   Novick PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079568
   Oprea TI, 2015, ASSAY DRUG DEV TECHN, V13, P299, DOI 10.1089/adt.2015.29011.tiodrrr
   Pan YP, 2003, J CHEM INF COMP SCI, V43, P267, DOI 10.1021/ci020055f
   Partridge JR, 2019, J STRUCT BIOL, V206, P170, DOI 10.1016/j.jsb.2019.03.001
   Patel S, 2017, ALLERGOL IMMUNOPATH, V45, P579, DOI 10.1016/j.aller.2016.10.011
   Perot S, 2010, DRUG DISCOV TODAY, V15, P656, DOI 10.1016/j.drudis.2010.05.015
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Phatak SS, 2009, EXPERT OPIN DRUG DIS, V4, P947, DOI 10.1517/17460440903190961
   Quiroga R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155183
   Rognan D, 2017, PHARMACOL THERAPEUT, V175, P47, DOI 10.1016/j.pharmthera.2017.02.034
   Rozewicki J, 2019, NUCLEIC ACIDS RES, V47, pW5, DOI 10.1093/nar/gkz342
   Rueda M, 2010, J CHEM INF MODEL, V50, P186, DOI 10.1021/ci9003943
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Sam E, 2019, BRIEF BIOINFORM, V20, P299, DOI 10.1093/bib/bbx125
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Singh N., 2020, BRIEF BIOINFORM
   Siramshetty VB, 2018, NUCLEIC ACIDS RES, V46, pD1137, DOI 10.1093/nar/gkx1088
   Sperandio O, 2014, THROMB RES, V133, P1105, DOI 10.1016/j.thromres.2014.01.026
   Sperandio Olivier, 2008, Open Biochem J, V2, P29, DOI 10.2174/1874091X00802010029
   Stumpfe D., 2020, J CHEM INF MODEL
   Trisciuzzi D, 2019, DRUG DISCOV TODAY, V24, P551, DOI 10.1016/j.drudis.2018.11.013
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Ursu O, 2019, NUCLEIC ACIDS RES, V47, pD963, DOI 10.1093/nar/gky963
   van der Worp HB, 2002, NEUROLOGY, V58, P133, DOI 10.1212/WNL.58.1.133
   Villoutreix BO, 2016, TRENDS PHARMACOL SCI, V37, P641, DOI 10.1016/j.tips.2016.06.003
   Villoutreix BO, 2014, MOL INFORM, V33, P414, DOI 10.1002/minf.201400040
   Villoutreix BO, 2013, DRUG DISCOV TODAY, V18, P1081, DOI 10.1016/j.drudis.2013.06.013
   Wang RX, 2001, J CHEM INF COMP SCI, V41, P1422, DOI 10.1021/ci010025x
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Willems H., 2020, J MED CHEM
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wojcikowski M, 2017, SCI REP-UK, V7, DOI 10.1038/srep46710
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yap JL, 2017, J MED CHEM, V60, P821, DOI 10.1021/acs.jmedchem.5b01888
   Zhou P., 2020, EUROPEAN J PHARM SCI, V153
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu T, 2013, J MED CHEM, V56, P6560, DOI 10.1021/jm301916b
NR 82
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD OCT 1
PY 2020
VL 153
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY8LF
UT WOS:000576633800014
DA 2021-01-01
ER

PT J
AU Singh, N
   Decroly, E
   Khatib, AM
   Villoutreix, BO
AF Singh, Natesh
   Decroly, Etienne
   Khatib, Abdel-Majid
   Villoutreix, Bruno O.
TI Structure-based drug repositioning over the human TMPRSS2 protease
   domain: search for chemical probes able to repress SARS-CoV-2 Spike
   protein cleavages
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Virtual screening; Drug repurposing; Drug repositioning; Homology
   modeling; SARS-CoV2; COVID-19; Structural bioinformatics
ID HIGH-THROUGHPUT; CORONAVIRUS; DISCOVERY; DOCKING; IDENTIFICATION;
   VISUALIZATION; INHIBITORS; ACCURACY; OPTIMIZATION; CHALLENGES
AB In December 2019, a new coronavirus was identified in the Hubei province of central china and named SARSCoV-2. This new virus induces COVID-19, a severe respiratory disease with high death rate. A putative target to interfere with the virus is the host transmembrane serine protease family member II (TMPRSS2). This enzyme is critical for the entry of coronaviruses into human cells by cleaving and activating the spike protein (S) of SARSCoV-2. Repositioning approved, investigational and experimental drugs on the serine protease domain of TMPRSS2 could thus be valuable. There is no experimental structure for TMPRSS2 but it is possible to develop quality structural models for the serine protease domain using comparative modeling strategies as such domains are highly structurally conserved. Beside the TMPRSS2 catalytic site, we predicted on our structural models a main exosite that could be important for the binding of protein partners and/or substrates. To block the catalytic site or the exosite of TMPRSS2 we used structure-based virtual screening computations and two different collections of approved, investigational and experimental drugs. We propose a list of 156 molecules that could bind to the catalytic site and 100 compounds that may interact with the exosite. These small molecules should now be tested in vitro to gain novel insights over the roles of TMPRSS2 or as starting point for the development of second generation analogs.
C1 [Singh, Natesh; Villoutreix, Bruno O.] Univ Lille, Inst Pasteur Lille, U1177, INSERM, F-59000 Lille, France.
   [Decroly, Etienne] Aix Marseille Univ, CNRS, AFMB UMR 7257, Marseille, France.
   [Khatib, Abdel-Majid] Univ Bordeaux, Allee Geoffroy St Hilaire, F-33615 Pessac, France.
   [Khatib, Abdel-Majid] INSERM, LAMC, UMR 1029, Allee Geoffroy St Hilaire, F-33615 Pessac, France.
RP Villoutreix, BO (corresponding author), Univ Lille, Inst Pasteur Lille, U1177, INSERM, F-59000 Lille, France.; Khatib, AM (corresponding author), Univ Bordeaux, Allee Geoffroy St Hilaire, F-33615 Pessac, France.; Khatib, AM (corresponding author), INSERM, LAMC, UMR 1029, Allee Geoffroy St Hilaire, F-33615 Pessac, France.
EM bruno.villoutreix@inserm.fr
OI Villoutreix, Bruno/0000-0002-6456-7730
CR Ain Q. U., 2015, REV COMPUT MOL SCI, V5, P405, DOI [10.1002/wcms.1225, DOI 10.1002/WCMS.1225]
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Bhattacharya A, 2008, PROTEINS, V70, P105, DOI 10.1002/prot.21466
   Bienstock RJ, 2012, CURR PHARM DESIGN, V18, P1240
   Bottcher T, 2016, J CHEM INF MODEL, V56, P462, DOI 10.1021/acs.jcim.5b00723
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Carter WJ, 2005, J BIOL CHEM, V280, P2745, DOI 10.1074/jbc.M411606200
   Cavasotto CN, 2011, CURR TOP MED CHEM, V11, P1528
   Cereto-Massague A, 2015, METHODS, V71, P98, DOI 10.1016/j.ymeth.2014.09.006
   Currow DC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113471
   Douguet D, 2018, ACS MED CHEM LETT, V9, P204, DOI 10.1021/acsmedchemlett.7b00462
   Ekins S, 2019, NAT MATER, V18, P435, DOI 10.1038/s41563-019-0338-z
   Eramian D, 2008, PROTEIN SCI, V17, P1881, DOI 10.1110/ps.036061.108
   Farha MA, 2019, NAT MICROBIOL, V4, P565, DOI 10.1038/s41564-019-0357-1
   Feher M, 2006, DRUG DISCOV TODAY, V11, P421, DOI 10.1016/j.drudis.2006.03.009
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Heurich A, 2014, J VIROL, V88, P1293, DOI 10.1128/JVI.02202-13
   Hoffmann M, 2020, CELL
   Huntington JA, 2014, THROMB HAEMOSTASIS, V111, P583, DOI 10.1160/TH13-10-0811
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jain AN, 2019, J COMPUT AID MOL DES, V33, P531, DOI 10.1007/s10822-019-00203-1
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Klimenko K, 2016, J CHEM INF MODEL, V56, P1438, DOI 10.1021/acs.jcim.6b00192
   Koes DR, 2013, J CHEM INF MODEL, V53, P1893, DOI 10.1021/ci300604z
   Krivak R, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0285-8
   Kruger DM, 2012, J CHEM INF MODEL, V52, P2807, DOI 10.1021/ci3003599
   Lagarde N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184648
   Lagarde Nathalie, 2018, Oncotarget, V9, P32346, DOI 10.18632/oncotarget.25966
   Lagorce D, 2017, BIOINFORMATICS, V33, P3658, DOI 10.1093/bioinformatics/btx491
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   Liu ZH, 2015, BIOINFORMATICS, V31, P405, DOI 10.1093/bioinformatics/btu626
   Masters L, 2020, J MOL GRAPH MODEL, V96, DOI 10.1016/j.jmgm.2020.107532
   MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075
   Mendez-Lucio O, 2017, DRUG DISCOV TODAY, V22, P120, DOI 10.1016/j.drudis.2016.08.009
   Miteva MA, 2005, NUCLEIC ACIDS RES, V33, pW372, DOI 10.1093/nar/gki365
   Nero TL, 2014, NAT REV CANCER, V14, P248, DOI 10.1038/nrc3690
   Nicola G, 2020, J COMPUT AID MOL DES, V34, P219, DOI 10.1007/s10822-019-00276-y
   Novick PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079568
   Oprea TI, 2015, ASSAY DRUG DEV TECHN, V13, P299, DOI 10.1089/adt.2015.29011.tiodrrr
   Pan YP, 2003, J CHEM INF COMP SCI, V43, P267, DOI 10.1021/ci020055f
   Partridge JR, 2019, J STRUCT BIOL, V206, P170, DOI 10.1016/j.jsb.2019.03.001
   Patel S, 2017, ALLERGOL IMMUNOPATH, V45, P579, DOI 10.1016/j.aller.2016.10.011
   Perot S, 2010, DRUG DISCOV TODAY, V15, P656, DOI 10.1016/j.drudis.2010.05.015
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Phatak SS, 2009, EXPERT OPIN DRUG DIS, V4, P947, DOI 10.1517/17460440903190961
   Quiroga R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155183
   Rognan D, 2017, PHARMACOL THERAPEUT, V175, P47, DOI 10.1016/j.pharmthera.2017.02.034
   Rozewicki J, 2019, NUCLEIC ACIDS RES, V47, pW5, DOI 10.1093/nar/gkz342
   Rueda M, 2010, J CHEM INF MODEL, V50, P186, DOI 10.1021/ci9003943
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Sam E, 2019, BRIEF BIOINFORM, V20, P299, DOI 10.1093/bib/bbx125
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101
   Singh N., 2020, BRIEF BIOINFORM
   Siramshetty VB, 2018, NUCLEIC ACIDS RES, V46, pD1137, DOI 10.1093/nar/gkx1088
   Sperandio O, 2014, THROMB RES, V133, P1105, DOI 10.1016/j.thromres.2014.01.026
   Sperandio Olivier, 2008, Open Biochem J, V2, P29, DOI 10.2174/1874091X00802010029
   Stumpfe D., 2020, J CHEM INF MODEL
   Trisciuzzi D, 2019, DRUG DISCOV TODAY, V24, P551, DOI 10.1016/j.drudis.2018.11.013
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Ursu O, 2019, NUCLEIC ACIDS RES, V47, pD963, DOI 10.1093/nar/gky963
   van der Worp HB, 2002, NEUROLOGY, V58, P133, DOI 10.1212/WNL.58.1.133
   Villoutreix BO, 2016, TRENDS PHARMACOL SCI, V37, P641, DOI 10.1016/j.tips.2016.06.003
   Villoutreix BO, 2014, MOL INFORM, V33, P414, DOI 10.1002/minf.201400040
   Villoutreix BO, 2013, DRUG DISCOV TODAY, V18, P1081, DOI 10.1016/j.drudis.2013.06.013
   Wang RX, 2001, J CHEM INF COMP SCI, V41, P1422, DOI 10.1021/ci010025x
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Willems H., 2020, J MED CHEM
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wojcikowski M, 2017, SCI REP-UK, V7, DOI 10.1038/srep46710
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yap JL, 2017, J MED CHEM, V60, P821, DOI 10.1021/acs.jmedchem.5b01888
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu T, 2013, J MED CHEM, V56, P6560, DOI 10.1021/jm301916b
NR 81
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD OCT 1
PY 2020
VL 153
AR 105495
DI 10.1016/j.ejps.2020.105495
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY8LF
UT WOS:000576633800010
PM 32730844
OA Green Published
DA 2021-01-01
ER

PT J
AU Gioia, LC
   Poppe, AY
   Laroche, R
   Dacier-Falque, T
   Sevigny, I
   Daneault, N
   Deschaintre, Y
   Jacquin, G
   Stapf, C
   Odier, C
AF Gioia, Laura C.
   Poppe, Alexandre Y.
   Laroche, Roxanne
   Dacier-Falque, Tristan
   Sevigny, Isabelle
   Daneault, Nicole
   Deschaintre, Yan
   Jacquin, Gregory
   Stapf, Christian
   Odier, Celine
TI Streamlined Poststroke Treatment Order Sets During the SARS-CoV-2
   Pandemic Simplifying While Not Compromising Care
SO STROKE
LA English
DT Article
AB Background and Purpose: Standard poststroke treatment monitoring protocols are made problematic during the coronavirus disease 2019 (COVID-19) pandemic by the frequency of patient assessments, requiring repeated donning and doffing procedures in a short interval of time.
   Methods: A streamlined poststroke treatment protocol was developed to limit frequency of patient encounters while maximizing the yield of each encounter by grouping together different components of poststroke care into single bedside visits.
   Results: Streamlined order sets were developed late March 2020. During the first 6 weeks following implementation, 70 patients were admitted to a geographically defined designated warm COVID-19 unit with modified poststroke care order sets. Of these, 33 (47.1%) patients received acute reperfusion therapy. All but 3 patients evolved favorably with either stable or improving National Institutes of Health Stroke Scale at 24 hours. In the 3 patients who experienced early neurological deterioration, none were found to be attributable to insufficient patient monitoring.
   Conclusions: Adapting preexisting poststroke care protocols may be necessary while the risk of COVID-19 infection remains high. We propose a streamlined approach to facilitate poststroke monitoring in patients with stroke with unknown COVID status.
C1 [Gioia, Laura C.; Poppe, Alexandre Y.; Daneault, Nicole; Deschaintre, Yan; Jacquin, Gregory; Stapf, Christian; Odier, Celine] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada.
   [Gioia, Laura C.; Poppe, Alexandre Y.; Daneault, Nicole; Deschaintre, Yan; Jacquin, Gregory; Stapf, Christian; Odier, Celine] Ctr Rech Univ Montreal CRCHUM, Neurovascular Hlth Grp, Neurosci Axis, Montreal, PQ, Canada.
   [Gioia, Laura C.; Poppe, Alexandre Y.; Daneault, Nicole; Deschaintre, Yan; Jacquin, Gregory; Stapf, Christian; Odier, Celine] Ctr Hosp Univ Montreal CHUM, Dept Neurol, Neurovascular Hlth Program, Montreal, PQ, Canada.
   [Laroche, Roxanne; Dacier-Falque, Tristan; Sevigny, Isabelle] Ctr Hosp Univ Montreal CHUM, Dept Nursing Sci, Montreal, PQ, Canada.
RP Gioia, LC (corresponding author), Univ Montreal, CHU Montreal, 1051 Sanguinet, Montreal, PQ H2X 3E4, Canada.
EM laura.gioia@umontreal.ca
CR [Anonymous], 2020, STROKE, V51, P1910, DOI [DOI 10.1161/STROKEAHA.120.030023, 10.1161/STROKEAHA.120.030023]
   Faigle R, 2020, NEUROHOSPITALIST, V10, P11, DOI 10.1177/1941874419845229
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Smith EE, 2020, CAN J NEUROL SCI, V47, P474, DOI 10.1017/cjn.2020.74
   Yaghi S, 2017, STROKE, V48, pE343, DOI 10.1161/STR.0000000000000152
NR 5
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD OCT
PY 2020
VL 51
IS 10
BP 3115
EP 3118
DI 10.1161/STROKEAHA.120.031008
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA NY6XP
UT WOS:000576529900041
PM 32790493
OA Green Published
DA 2021-01-01
ER

PT J
AU Stallmach, A
   Sturm, A
   Blumenstein, I
   Helwig, U
   Koletzko, S
   Lynen, P
   Schmidt, C
   Dignass, A
   Kucharzik, T
AF Stallmach, Andreas
   Sturm, Andreas
   Blumenstein, Irina
   Helwig, Ulf
   Koletzko, Sibylle
   Lynen, Petra
   Schmidt, Carsten
   Dignass, Axel
   Kucharzik, Torsten
TI Addendum to S3-Guidelines Crohn's disease and ulcerative colitis:
   Management of Patients with Inflammatory Bowel Disease in the COVID-19
   Pandemic - open questions and answers
SO ZEITSCHRIFT FUR GASTROENTEROLOGIE
LA English
DT Article
ID FECAL CALPROTECTIN; OPPORTUNISTIC INFECTIONS; INFLIXIMAB MAINTENANCE;
   CLINICAL-ASSESSMENT; RISK-FACTORS; OPEN-LABEL; MULTICENTER; IBD;
   GASTROENTEROLOGY; CORONAVIRUS
AB The COVID-19 pandemic is a global outbreak of new onset infections with the SARS-CoV-2 virus. To date, more than 3.4 million people have been infected throughout the world. In Germany, approximately 450,000 patients suffer from inflammatory bowel disease; these patients generally require continuous expert care and support. Against the background of a rapidly accumulating knowledge base on SARS-CoV-2, 68 expert authors of the current DGVS guidelines for Crohn's disease and ulcerative colitis took part in a virtual meeting to compile up-to-date, practice-orientated recommendations aimed at improving the care of patients with IBD. These recommendations address the risk of infection, including the risk for specific patient groups, the possible course of the disease, and consequences for pharmacological and surgical therapies of the underlying disease, as well as general measures for infection prevention and adjuvant prophylactic and therapeutic options.
C1 [Stallmach, Andreas] Univ Klinikum Jena, Klin Innere Med Gastroenterol Infektiol & Hepatol, Jena, Germany.
   [Sturm, Andreas] DRK Kliniken Berlin Westend, Innere Med Klin, Schwerpunkt Gastroenterol, Berlin, Germany.
   [Blumenstein, Irina] Goethe Univ Frankfurt, Univ Klinikum Frankfurt, Med Klin Gastroenterol & Hepatol Pneumol & Allerg, Endokrinol & Diabetol Ernahrungsmed, Frankfurt, Germany.
   [Helwig, Ulf] Internist Praxengemeinschaft Oldenburg, Oldenburg, Germany.
   [Koletzko, Sibylle] Univ Munich, LMU Klinikum, Kinderklin & Kinderpoliklin Dr von Hauner Kinders, Munich, Germany.
   [Lynen, Petra] Deutsch Gesell Gastroenterol Verdauungs & Stoffwe, Berlin, Germany.
   [Schmidt, Carsten] Univ Med Marburg, Med Klin Gastroenterol Hepatol Endokrinol Diabeto, Klinikum Fulda, Campus Fulda, Fulda, Germany.
   [Dignass, Axel] Agaples Markus Krankenhaus, Med Klin 1, Frankfurt, Germany.
   [Kucharzik, Torsten] Klinikum Luneburg, Klin Innere Med, Gastroenterol, Luneburg, Germany.
RP Stallmach, A (corresponding author), Univ Klinikum Jena, Klin Innere Med 4, Klinikum 1, D-07743 Jena, Germany.
EM Andreas.stallmach@med.uni-jena.de
OI Dabritz, Jan/0000-0003-4219-5283
CR Allocca M, 2020, CLIN GASTROENTEROL H, V18, P2134, DOI 10.1016/j.cgh.2020.04.071
   An P, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3543590, DOI 10.2139/SSRN.3543590]
   Armann JP, 2020, DTSCH ARZTEBL INT, V117, P373, DOI 10.3238/arztebl.2020.0373
   Balestrieri P, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020372
   Beck MA, 2004, TRENDS MICROBIOL, V12, P417, DOI 10.1016/j.tim.2004.07.007
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Bin Abdulrahman AK, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7726-9
   Boor PPC, 2017, TRANSL RES, V188, P67, DOI 10.1016/j.trsl.2016.11.006
   Boyapati RK, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012540.pub2
   Burisch J, 2019, J CROHNS COLITIS, V13, P198, DOI 10.1093/ecco-jcc/jjy154
   Burisch J, 2019, GUT, V68, P423, DOI 10.1136/gutjnl-2017-315568
   Calder PC, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041181
   Carvalho A, 2020, AM J GASTROENTEROL, V115, P942, DOI 10.14309/ajg.0000000000000667
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Chen LJ, 2020, AM J GASTROENTEROL, V115, P790, DOI 10.14309/ajg.0000000000000610
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng HY, 2020, JAMA INTERN MED, V180, P1156, DOI 10.1001/jamainternmed.2020.2020
   Chiu PWY, 2020, GUT, V69, P991, DOI 10.1136/gutjnl-2020-321185
   Colombel JF, 2020, J CROHNS COLITIS, V14, P254, DOI 10.1093/ecco-jcc/jjz131
   Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475
   de Jong MJ, 2020, CLIN GASTROENTEROL H, V18, P1744, DOI 10.1016/j.cgh.2020.04.038
   de Jong MJ, 2017, LANCET, V390, P959, DOI 10.1016/S0140-6736(17)31327-2
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Dorrington AM, 2020, J CROHNS COLITIS, V14, P1316, DOI 10.1093/ecco-jcc/jjaa053
   Dreher M, 2020, DTSCH ARZTEBL INT, V117, P271, DOI 10.3238/arztebl.2020.0271
   ECDC, 2020, COR DIS 2019 COVID 1
   El-Matary W, 2017, INFLAMM BOWEL DIS, V23, P2104, DOI 10.1097/MIB.0000000000001259
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Favalli EG, 2020, LANCET INFECT DIS, V20, P1012, DOI 10.1016/S1473-3099(20)30262-0
   Feagan BG, 2018, J CROHNS COLITIS, V12, P905, DOI 10.1093/ecco-jcc/jjy047
   Fleming SB, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4030023
   Fukuyo S, 2014, MOD RHEUMATOL, V24, P275, DOI 10.3109/14397595.2013.843747
   Gasmi A, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108409
   Ghebreyesus T, 2020, WHO DIRECTOR GEN OPE
   Giwa Al, 2020, Emerg Med Pract, V22, P1
   Grainge MJ, 2010, LANCET, V375, P657, DOI 10.1016/S0140-6736(09)61963-2
   Gralnek IM, 2020, ENDOSCOPY, V52, P483, DOI 10.1055/a-1155-6229
   Grunert P C, 2020, J Crohns Colitis, DOI 10.1093/ecco-jcc/jjaa126
   Gu JY, 2020, GASTROENTEROLOGY, V158, P1518, DOI 10.1053/j.gastro.2020.02.054
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Haisma SM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214751
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Han J, 2020, GASTROINTEST ENDOSC, V92, P445, DOI 10.1016/j.gie.2020.03.3855
   Hea Streeck, 2020, VORLAUFIGES ERGEBNIS, pS4
   Heida A, 2017, INFLAMM BOWEL DIS, V23, P894, DOI 10.1097/MIB.0000000000001082
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iacucci M, 2020, LANCET GASTROENTEROL, V5, P598, DOI 10.1016/S2468-1253(20)30119-9
   (ISS) ISdS, 2020, SORV INT COVID 19 IT
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Johnston ER, 2019, GASTROINTEST ENDOSC, V89, P818, DOI 10.1016/j.gie.2018.10.034
   Kelesidis Theodoros, 2014, BMC Infect Dis, V14, P321, DOI 10.1186/1471-2334-14-321
   Kirchgesner J, 2018, GASTROENTEROLOGY, V155, P337, DOI 10.1053/j.gastro.2018.04.012
   Ko MKL, 2016, J DIGEST DIS, V17, P610, DOI 10.1111/1751-2980.12397
   Kochar B, 2020, GASTROENTEROLOGY, V158, P2104, DOI 10.1053/j.gastro.2020.02.032
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Kucharzik T, 2019, Z GASTROENTEROL, V57, P162, DOI 10.1055/a-0824-0861
   Kucharzik T, 2017, CLIN GASTROENTEROL H, V15, P535, DOI 10.1016/j.cgh.2016.10.040
   Lavezzo E, 2020, SUPPRESSION COVID 19, DOI [10.1101/2020.04.17.20053157, DOI 10.1101/2020.04.17.20053157]
   Liang-Ru Zhu RM, 2020, THOMAS SCHNEIDER BEH
   Lichtenstein GR, 2012, AM J GASTROENTEROL, V107, P1409, DOI 10.1038/ajg.2012.218
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Long MD, 2013, AM J GASTROENTEROL, V108, P240, DOI 10.1038/ajg.2012.406
   Maaser C, 2020, GUT, V69, P1629, DOI 10.1136/gutjnl-2019-319451
   Magro F, 2020, J CROHNS COLITIS, V14, pS798, DOI 10.1093/ecco-jcc/jjaa160
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Massironi S, 2013, CLIN NUTR, V32, P904, DOI 10.1016/j.clnu.2013.03.020
   Mehta AK, 2018, CYTOKINE, V101, P14, DOI 10.1016/j.cyto.2016.08.003
   Neumann H, 2020, DIGEST ENDOSC, V32, P658, DOI 10.1111/den.13712
   Neurath MF, 2020, GUT, V69, P1335, DOI 10.1136/gutjnl-2020-321269
   Ng K, 2020, ANN INTERN MED, V172, P766, DOI 10.7326/L20-0175
   Ng SC, 2018, INFLAMM BOWEL DIS, V24, P2431, DOI 10.1093/ibd/izy153
   Nguyen GC, 2008, INFLAMM BOWEL DIS, V14, P1105, DOI 10.1002/ibd.20429
   Nguyen GC, 2014, GASTROENTEROLOGY, V146, P835, DOI 10.1053/j.gastro.2014.01.042
   Norsa L, 2020, GASTROENTEROLOGY, V159, P371, DOI [10.1053/j.gastro.2020.03.062, 10.1053/j.gastro.2020.03.06]
   Occhipinti V, 2020, INFLAMM BOWEL DIS, V26, P793, DOI 10.1093/ibd/izaa084
   Orlicka K, 2013, THER ADV CHRONIC DIS, V4, P167, DOI 10.1177/2040622313485275
   Papamichael K, 2016, J CROHNS COLITIS, V10, P371, DOI 10.1093/ecco-jcc/jjv206
   Ponsioen CY, 2017, LANCET GASTROENTEROL, V2, P785, DOI 10.1016/S2468-1253(17)30248-0
   Preiss JC, 2014, Z GASTROENTEROL, V52, P1431, DOI 10.1055/s-0034-1385199
   Repici A, 2020, GASTROENTEROLOGY, V159, P363, DOI 10.1053/j.gastro.2020.04.003
   Repici A, 2020, GASTROINTEST ENDOSC, V92, P192, DOI 10.1016/j.gie.2020.03.019
   RKI, 2020, EPIDEMIOLOGISCHES B, V18
   Robert-Koch-Institut (RKI), 2020, TAGL LAG RKI COR KRA
   Roblin X, 2017, ALIMENT PHARM THER, V46, P142, DOI 10.1111/apt.14106
   Rodriguez-Lago I, 2020, GASTROENTEROLOGY, V159, P781, DOI 10.1053/j.gastro.2020.04.043
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P6, DOI 10.1053/j.gastro.2020.04.002
   Ruemmele FM, 2014, J CROHNS COLITIS, V8, P1179, DOI 10.1016/j.crohns.2014.04.005
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   SACHAR DB, 1984, AM J GASTROENTEROL, V79, P913
   Sandborn WJ, 2020, GASTROENTEROLOGY, V158, P562, DOI 10.1053/j.gastro.2019.08.027
   Schreiner P, 2020, DIGESTION, V101, P120, DOI 10.1159/000505368
   Seksik P, 2009, ALIMENT PHARM THER, V29, P1106, DOI 10.1111/j.1365-2036.2009.03973.x
   Sipponen T, 2015, SCAND J GASTROENTERO, V50, P74, DOI 10.3109/00365521.2014.987809
   Song Y, 2020, GUT, V69, P1143, DOI 10.1136/gutjnl-2020-320891
   Spinelli FR, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc5367
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Stevens T, 2020, J CROHNS COLITIS, V14
   Strohl M, 2018, WORLD J GASTROENTERO, V24, P2363, DOI 10.3748/wjg.v24.i22.2363
   Sultan S, 2020, GASTROENTEROLOGY, V159, P739, DOI 10.1053/j.gastro.2020.03.072
   Taxonera C, 2020, ALIMENT PHARM THER, V52, P276, DOI 10.1111/apt.15804
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Tinsley A, 2019, INFLAMM BOWEL DIS, V25, P369, DOI 10.1093/ibd/izy243
   Torres J, 2020, J CROHNS COLITIS, V14, P4, DOI 10.1093/ecco-jcc/jjz180
   Toruner M, 2008, GASTROENTEROLOGY, V134, P929, DOI 10.1053/j.gastro.2008.01.012
   Tosca J, 2020, INT J COLORECTAL DIS, V35, P491, DOI 10.1007/s00384-019-03501-0
   Turner D, 2020, J PEDIATR GASTR NUTR, V70, P727, DOI 10.1097/MPG.0000000000002729
   Van Assche G, 2008, GASTROENTEROLOGY, V134, P1861, DOI 10.1053/j.gastro.2008.03.004
   Van Assche G, 2010, J CROHNS COLITIS, V4, P329, DOI 10.1016/j.crohns.2009.12.012
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Vavricka SR, 2010, ENDOSCOPY, V42, P736, DOI 10.1055/s-0030-1255615
   WHO, 2020, REP WHO CHIN JOINT M
   Winthrop KL, 2018, INFLAMM BOWEL DIS, V24, P2258, DOI 10.1093/ibd/izy131
   Wisniewski A, 2020, UNITED EUR GASTROENT, V8, P303, DOI 10.1177/2050640619889763
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Xiao F, 2020, GASTROENTEROLOGY, DOI [10.1053/j.gas-tro.2020.02.055, DOI 10.1053/J.GAS-TRO.2020.02.055]
   Zabana Y, 2019, J CROHNS COLITIS, V13, P828, DOI 10.1093/ecco-jcc/jjz013
   Zabotti A, 2020, EXPERT OPIN DRUG SAF, V19, P69, DOI 10.1080/14740338.2020.1703946
NR 124
TC 0
Z9 0
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0044-2771
EI 1439-7803
J9 Z GASTROENTEROL
JI Z. Gastroent.
PD OCT
PY 2020
VL 58
IS 10
BP 982
EP 1002
DI 10.1055/a-1234-8079
PG 21
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NY5PS
UT WOS:000576441800020
PM 33036052
DA 2021-01-01
ER

PT J
AU Abo-zeid, Y
   Ismail, NSM
   McLean, GR
   Hamdy, NM
AF Abo-zeid, Yasmin
   Ismail, Nasser S. M.
   McLean, Gary R.
   Hamdy, Nadia M.
TI A molecular docking study repurposes FDA approved iron oxide
   nanoparticles to treat and control COVID-19 infection
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Iron oxide nanoparticles (IONPs); Covid-19; Repurposing medication;
   Molecular docking; Sars-CoV-2; Hcv glycoproteins E1 and E2; Reactive
   oxygen species (ROS)
ID HEPATITIS-C VIRUS; INFLUENZA-VIRUS; CORONAVIRUSES; INACTIVATION;
   INHIBITION
AB COVID-19, is a disease resulting from the SARS-CoV-2 global pandemic. Due to the current global emergency and the length of time required to develop specific antiviral agent(s) and a vaccine for SARS-CoV-2, the world health organization (WHO) adopted the strategy of repurposing existing medications to treat COVID-19. Iron oxide nanoparticles (IONPs) were previously approved by the US food and drug administration (FDA) for anemia treatment and studies have also demonstrated its antiviral activity in vitro. Therefore, we performed a docking study to explore the interaction of IONPs (Fe2O3 and Fe3O4) with the spike protein receptor binding domain (S1-RBD) of SARS-CoV-2 that is required for virus attachment to the host cell receptors. A similar docking analysis was also performed with hepatitis C virus (HCV) glycoproteins E1 and E2. These studies revealed that both Fe2O3 and Fe3O4 interacted efficiently with the SARS-CoV-2 Sl-RBD and to HCV glycoproteins, E1 and E2. Fe3O4 formed a more stable complex with Sl-RBD whereas Fe2O3 favored HCV E1 and E2. These interactions of IONPs are expected to be associated with viral proteins conformational changes and hence, viral inactivation. Therefore, we recommend FDA-approved-IONPs to proceed for COVID-19 treatment clinical trials.
C1 [Abo-zeid, Yasmin] Helwan Univ, Fac Pharm, Pharmaceut Dept, Cairo, Egypt.
   [Ismail, Nasser S. M.] Future Univ Egypt, Fac Pharmaceut Sci & Pharmaceut Ind, Pharmaceut Chem Dept, Cairo 12311, Egypt.
   [McLean, Gary R.] London Metropolitan Univ, Cellular & Mol Immunol Res Ctr, 166-220 Holloway Rd, London N7 8DB, England.
   [McLean, Gary R.] Imperial Coll London, Natl Heart & Lung Inst, Norfolk Pl, London W2 1PG, England.
   [Hamdy, Nadia M.] Ain Shams Univ, Fac Pharm, Biochem Dept, Cairo 11566, Egypt.
RP Abo-zeid, Y (corresponding author), Helwan Univ, Fac Pharm, Pharmaceut Dept, Cairo, Egypt.
EM yasmin.abozeid@pharm.helwan.edu.eg; nasser.saad@fue.edu.eg;
   g.mclean@londonmet.ac.uk; nadia_hamdy@pharma.asu.edu.eg
OI ismail, nasser/0000-0002-5119-9318
CR Abo-zeid Y, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1592
   Abo-zeid Y, 2018, INT J PHARMACEUT, V547, P572, DOI 10.1016/j.ijpharm.2018.06.027
   Aderibigbe BA, 2017, MOLECULES, V22, DOI 10.3390/molecules22081370
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Arias LS, 2018, ANTIBIOTICS-BASEL, V7, DOI 10.3390/antibiotics7020046
   Baram-Pinto D, 2010, SMALL, V6, P1044, DOI 10.1002/smll.200902384
   Bobo D, 2016, PHARM RES-DORDR, V33, P2373, DOI 10.1007/s11095-016-1958-5
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chang CC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177383
   Choudhary S., 2020, IDENTIFICATION SARS, P1, DOI DOI 10.26434/CHEMRXIV.12005988
   Coyne DW, 2009, EXPERT OPIN PHARMACO, V10, P2563, DOI 10.1517/14656560903224998
   Ditta IB, 2008, APPL MICROBIOL BIOT, V79, P127, DOI 10.1007/s00253-008-1411-8
   Dowell SF, 2004, CLIN INFECT DIS, V39, P652, DOI 10.1086/422652
   Engineering G, 2020, STAT KEY LAB GEN ENG, DOI DOI 10.1101/2020.02.01.930537
   Fujimori Y, 2012, APPL ENVIRON MICROB, V78, P951, DOI 10.1128/AEM.06284-11
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ghaffari H., 2019, J BIOMEDICAL SCI, V26, P1
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Gutierrez L, 2009, WATER RES, V43, P5198, DOI 10.1016/j.watres.2009.08.031
   Hang XF, 2015, J VIROL METHODS, V222, P150, DOI 10.1016/j.jviromet.2015.06.010
   Imai K, 2012, ANTIVIR RES, V93, P225, DOI 10.1016/j.antiviral.2011.11.017
   Issa M.El Nahhal, 2016, SYNTHESIS NANOMETAL, DOI [10.5772/63505, DOI 10.5772/63505]
   Jeong GN, 2010, ARCH TOXICOL, V84, P63, DOI 10.1007/s00204-009-0469-0
   Kai K., 2014, SCIENCE, V367, P1412
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kong L, 2013, SCIENCE, V342, P1090, DOI 10.1126/science.1243876
   Kumar R, 2019, J INFECT CHEMOTHER, V25, P325, DOI 10.1016/j.jiac.2018.12.006
   Lai T.H.T., 2020, STEPPING INFECT CONT
   Murugan K, 2017, PARASITOL RES, V116, P495, DOI 10.1007/s00436-016-5310-0
   Otter JA, 2016, J HOSP INFECT, V92, P235, DOI 10.1016/j.jhin.2015.08.027
   Papp I, 2010, SMALL, V6, P2900, DOI 10.1002/smll.201001349
   Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938
   Pink R, 2005, NAT REV DRUG DISCOV, V4, P727, DOI 10.1038/nrd1824
   Raghunath A, 2017, INT J ANTIMICROB AG, V49, P137, DOI 10.1016/j.ijantimicag.2016.11.011
   Rai M, 2014, CRIT REV MICROBIOL, P1
   Shionoiri N, 2012, J BIOSCI BIOENG, V113, P580, DOI 10.1016/j.jbiosc.2011.12.006
   Ventola C Lee, 2017, P T, V42, P742
   Wang J, 2020, J HOSP INFECT, V105, P188, DOI 10.1016/j.jhin.2020.03.029
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Xu HF, 2017, AM MINERAL, V102, P711, DOI 10.2138/am-2017-5849
   Zhang ZR, 2020, FRONT MED-PRC, V14, P229, DOI 10.1007/s11684-020-0765-x
NR 41
TC 2
Z9 2
U1 18
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD OCT 1
PY 2020
VL 153
AR 105465
DI 10.1016/j.ejps.2020.105465
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY8LP
UT WOS:000576634800008
PM 32668312
OA Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Meo, SA
   Zaidi, SZA
   Shang, T
   Zhang, JY
   Al-Khlaiwi, T
   Bukhari, IA
   Akram, J
   Klonoff, DC
AF Meo, Sultan Ayoub
   Zaidi, Syed Ziauddin A.
   Shang, Trisha
   Zhang, Jennifer Y.
   Al-Khlaiwi, Thamir
   Bukhari, Ishfaq A.
   Akram, Javed
   Klonoff, David C.
TI Biological, molecular and pharmacological characteristics of
   chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for
   COVID-19 pandemic: A comparative analysis
SO JOURNAL OF KING SAUD UNIVERSITY SCIENCE
LA English
DT Article
DE COVID-19; Hydroxychloroquine; Chloroquine; Remdesivir; Convalescent
   Plasma
ID METABOLISM
AB Objectives: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, also known as COVID-19 pandemic has caused an alarming situation worldwide. Since the first detection, in December 2019, there have been no effective drug therapy options for treating the SARS-CoV-2 pandemic. However, healthcare professionals are using chloroquine, hydroxychloroquine, remdesivir, convalescent plasma and some other options of treatments. This study aims to compare the biological, molecular, pharmacological, and clinical characteristics of these three treatment modalities for SARS-COV-2 infections, Chloroquine and Hydroxychloroquine, Convalescent Plasma, and Remdesivir.
   Methods: A search was conducted in the "Institute of Science Information (ISI)-Web of Science, PubMed, EMBASE, ClinicalTrials.gov , Cochrane Library databases, Scopus, and Google Scholar" for peer reviewed, published studies and clinical trials through July 30, 2020. The search was based on keywords "COVID-19" SARS-COV-2, chloroquine, hydroxychloroquine, convalescent plasma, remdesivir and treatment modalities.
   Results: As of July 30, 2020, a total of 36,640 relevant documents were published. From them 672 peer reviewed, published articles, and clinical trials were screened. We selected 17 relevant published original articles and clinical trials: 05 for chloroquine and/or hydroxychloroquine with total sample size (n = 220), 05 for Remdesivir (n = 1,781), and 07 for Convalescent Plasma therapy (n = 398), with a combined total sample size (n = 2,399). Based on the available data, convalescent plasma therapy showed clinical advantages in SARS-COV-2 patients.
   Conclusions: All three treatment modalities have both favorable and unfavorable characteristics, but none showed clear evidence of benefit for early outpatient disease or prophylaxis. Based on the current available data, convalescent plasma therapy appears to show clinical advantages for inpatient use. In the future, ongoing large sample size randomized controlled clinical trials may further clarify the comparative efficacy and safety of these three treatment classes, to conclusively determine whom to treat with which drug and when to treat them. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.
C1 [Meo, Sultan Ayoub; Al-Khlaiwi, Thamir] King Saud Univ, Coll Med, Dept Physiol, Riyadh, Saudi Arabia.
   [Zaidi, Syed Ziauddin A.] Univ Hlth Sci, Dept Pathol Hematol, Lahore, Pakistan.
   [Shang, Trisha; Zhang, Jennifer Y.] Diabet Technol Soc, Burlingame, CA USA.
   [Bukhari, Ishfaq A.] King Saud Univ, Coll Med, Dept Pharmacol, Riyadh, Saudi Arabia.
   [Akram, Javed] Univ Hlth Sci, Lahore, Pakistan.
   [Klonoff, David C.] Mills Peninsula Med Ctr San Mateo, Diabet Res Inst, San Mateo, CA USA.
RP Meo, SA (corresponding author), King Saud Univ, Coll Med, Riyadh 11461, Saudi Arabia.
EM smeo@ksu.edu.sa; trishashang@diabetestechnology.org;
   jenniferzhang@diabetestechnology.org; talkhlaiwi@ksu.edu.sa;
   dklonoff@diabetestechnology.org
OI Shang, Trisha/0000-0001-9687-9336; Zhang, Jennifer
   Y./0000-0002-3374-9777
FU King Saud University, Riyadh, Saudi ArabiaKing Saud University
   [RSP-2019/47]
FX Thankful to the "Researchers Supporting Project Number (RSP-2019/47),
   King Saud University, Riyadh, Saudi Arabia".
CR Abolghasemi H, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102875
   Antinori S, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104899
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Blignaut M, 2019, CARDIOVASC DRUG THER, V33, P1, DOI 10.1007/s10557-018-06847-9
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Braga Cassio Braga E, 2015, Interdiscip Perspect Infect Dis, V2015, P346853, DOI 10.1155/2015/346853
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Browning DJ, 2014, CHLOROQUINE RETINOPA, V4, p35 63, DOI [10.1007/978-1-4939-0597-3_2, DOI 10.1007/978-1-4939-0597-3_2]
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Devine A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005602
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Gajic O, 2007, AM J RESP CRIT CARE, V176, P886, DOI 10.1164/rccm.200702-271OC
   Gasparyan AY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e176
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Maraj I, 2020, J CARDIOVASC ELECTR, V31, P1904, DOI 10.1111/jce.14594
   Mazzanti A, CIRCULATION, DOI [10.1161/CIRCULATIONAHA.120.048476., DOI 10.1161/CIRCULATIONAHA.120.048476.]
   McCarthy J.S., 2015, MANDELL DOUGLAS BENN, V1, P495, DOI [10.1016/B978-1-4557-4801-3.00040-0e5., DOI 10.1016/B978-1-4557-4801-3.00040-0E5]
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   MEO SA, 2020, J KING SAUD UNIV SCI, V32, P2495, DOI DOI 10.1016/J.JKSUS.2020.04.004
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Olivares-Gazca Juan C, 2020, Rev Invest Clin, V72, P159, DOI 10.24875/RIC.20000237
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Permin Henrik, 2016, Dan Medicinhist Arbog, V44, P9
   Perotti Cesare, 2020, Haematologica, DOI 10.3324/haematol.2020.261784
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   ROBERTS S, 1956, J BIOL CHEM, V222, P555
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Rosado J., 2020, SEROLOGICAL SIGNATUR, DOI [10.1101/2020.05.07.20093963., DOI 10.1101/2020.05.07.20093963]
   Salazar E, 2020, AM J PATHOL
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Singh AK, 2020, DIABETES METAB SYND, V14, P641, DOI 10.1016/j.dsx.2020.05.018
   Skalny AV, 2020, INT J MOL MED, V46, P17, DOI 10.3892/ijmm.2020.4575
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   World Health Organization, 2020, COR
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 45
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1018-3647
EI 2213-686X
J9 J KING SAUD UNIV SCI
JI J. King Saud Univ. Sci.
PD OCT
PY 2020
VL 32
IS 7
BP 3159
EP 3166
DI 10.1016/j.jksus.2020.09.002
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NY8NZ
UT WOS:000576641300009
PM 32921965
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Martin, TA
   Wan, DW
   Hajifathalian, K
   Tewani, S
   Shah, SL
   Mehta, A
   Kaplan, A
   Ghosh, G
   Choi, AJ
   Krisko, TI
   Fortune, BE
   Crawford, CV
   Sharaiha, RZ
AF Martin, Tracey A.
   Wan, David W.
   Hajifathalian, Kaveh
   Tewani, Sunena
   Shah, Shawn L.
   Mehta, Amit
   Kaplan, Alyson
   Ghosh, Gaurav
   Choi, Anthony J.
   Krisko, Tibor, I
   Fortune, Brett E.
   Crawford, Carl, V
   Sharaiha, Reem Z.
TI Gastrointestinal Bleeding in Patients With Coronavirus Disease 2019: A
   Matched Case-Control Study
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID FECAL MANAGEMENT-SYSTEM
AB INTRODUCTION: Although current literature has addressed gastrointestinal presentations including nausea, vomiting, diarrhea, abnormal liver chemistries, and hyperlipasemia as possible coronavirus disease 2019 (COVID-19) manifestations, the risk and type of gastrointestinal bleeding (GIB) in this population is not well characterized.
   METHODS: This is a matched case-control (1:2) study with 41 cases of GIB (31 upper and 10 lower) in patients with COVID-19 and 82 matched controls of patients with COVID-19 without GIB. The primary objective was to characterize bleeding etiologies, and our secondary aim was to discuss outcomes and therapeutic approaches.
   RESULTS: There was no difference in the presenting symptoms of the cases and controls, and no difference in severity of COVID-19 manifestations (P> 0.05) was observed. Ten (32%) patients with upper GIB underwent esophagogastroduodenoscopy and 5 (50%) patients with lower GIBs underwent flexible sigmoidoscopy or colonoscopy. The most common upper and lower GIB etiologies were gastric or duodenal ulcers (80%) and rectal ulcers related to rectal tubes (60%), respectively. Four of the esophagogastroduodenoscopies resulted in therapeutic interventions, and the 3 patients with rectal ulcers were referred to colorectal surgery for rectal packing. Successful hemostasis was achieved in all 7 cases that required interventions. Transfusion requirements between patients who underwent endoscopic therapy and those who were conservatively managed were not significantly different. Anticoagulation and rectal tube usage trended toward being a risk factor for GIB, although it did not reach statistical significance.
   DISCUSSION: In COVID-19 patients with GIB, compared with matched controls of COVID-19 patients without GIB, there seemed to be no difference in initial presenting symptoms. Of those with upper and lower GIB, the most common etiology was peptic ulcer disease and rectal ulcers from rectal tubes, respectively. Conservative management seems to be a reasonable initial approach in managing these complex cases, but larger studies are needed to guide management.
C1 [Martin, Tracey A.; Wan, David W.; Hajifathalian, Kaveh; Shah, Shawn L.; Mehta, Amit; Kaplan, Alyson; Ghosh, Gaurav; Choi, Anthony J.; Krisko, Tibor, I; Fortune, Brett E.; Crawford, Carl, V; Sharaiha, Reem Z.] New York Presbyterian Hosp, Div Gastroenterol & Hepatol, Weill Cornell Med, New York, NY 10032 USA.
   [Tewani, Sunena] New York Presbyterian Hosp, Div Hosp Med, Weill Cornell Med, New York, NY USA.
RP Wan, DW (corresponding author), New York Presbyterian Hosp, Div Gastroenterol & Hepatol, Weill Cornell Med, New York, NY 10032 USA.
EM daw9044@med.cornell.edu
RI Krisko, Tibor/AAG-7595-2020
OI Krisko, Tibor/0000-0002-9414-5846; Ghosh, Gaurav/0000-0002-8558-8098
CR Abu-Ssaydeh DA, 2018, ANAESTH INTENS CARE, V46, P139
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bang CS, 2020, GUT LIVER, V14, P57, DOI 10.5009/gnl19009
   Cavaliere K, 2020, GASTROINTEST ENDOSC
   Centers for Disease Control and Prevention CDC COVID Data Tracker, 2020, CDC COVID DAT TRACK
   Deeb L, 2011, AM J GASTROENTEROL, V106, pS334, DOI 10.14309/00000434-201110002-00891
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Lau JYW, 2020, NEW ENGL J MED, V382, P1299, DOI 10.1056/NEJMoa1912484
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Padmanabhan A, 2007, AM J CRIT CARE, V16, P384
   Ray WA, 2018, JAMA-J AM MED ASSOC, V320, P2221, DOI 10.1001/jama.2018.17242
   Sparks D, 2010, DIS COLON RECTUM, V53, P346, DOI 10.1007/DCR.0b013e3181c38351
   Strate LL, 2016, AM J GASTROENTEROL, V111, P755, DOI 10.1038/ajg.2016.155
   Tiwari A, 2017, CASE REP GASTROINTES, DOI 10.1155/2017/5278971
   Whiteley I, 2014, OSTOMY WOUND MANAG, V60, P37
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 19
TC 0
Z9 0
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2020
VL 115
IS 10
BP 1609
EP 1616
DI 10.14309/ajg.0000000000000805
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NX9JQ
UT WOS:000576018400016
PM 32796176
OA Green Published
DA 2021-01-01
ER

PT J
AU Mather, JF
   Seip, RL
   McKay, RG
AF Mather, Jeffrey F.
   Seip, Richard L.
   McKay, Raymond G.
TI Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients
   With COVID-19
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID HUMAN-NEUTROPHILS; MAST-CELLS; HISTAMINE; INHIBITION
AB INTRODUCTION: To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine therapy with those not receiving famotidine.
   METHODS: Retrospective, propensity-matched observational study of consecutive COVID-19-positive patients between February 24, 2020, and May 13, 2020.
   RESULTS: Of 878 patients in the analysis, 83 (9.5%) received famotidine. In comparison to patients not treated with famotidine, patients treated with famotidine were younger (63.5 +/- 15.0 vs 67.5 +/- 15.8 years,P= 0.021), but did not differ with respect to baseline demographics or preexisting comorbidities. Use of famotidine was associated with a decreased risk of in-hospital mortality (odds ratio 0.37, 95% confidence interval 0.16-0.86,P= 0.021) and combined death or intubation (odds ratio 0.47, 95% confidence interval 0.23-0.96,P= 0.040). Propensity score matching to adjust for age difference between groups did not alter the effect on either outcome. In addition, patients receiving famotidine displayed lower levels of serum markers for severe disease including lower median peak C-reactive protein levels (9.4 vs 12.7 mg/dL,P= 0.002), lower median procalcitonin levels (0.16 vs 0.30 ng/mL,P= 0.004), and a nonsignificant trend to lower median mean ferritin levels (797.5 vs 964.0 ng/mL,P= 0.076). Logistic regression analysis demonstrated that famotidine was an independent predictor of both lower mortality and combined death/intubation, whereas older age, body mass index >30 kg/m(2), chronic kidney disease, National Early Warning Score, and higher neutrophil-lymphocyte ratio were all predictors of both adverse outcomes.
   DISCUSSION: Famotidine use in hospitalized patients with COVID-19 is associated with a lower risk of mortality, lower risk of combined outcome of mortality and intubation, and lower levels of serum markers for severe disease in hospitalized patients with COVID-19.
   [GRAPHICS]
   .
C1 [Mather, Jeffrey F.; Seip, Richard L.; McKay, Raymond G.] Hartford Hosp, Div Res Adm & Intervent Cardiol, Hartford, CT 06106 USA.
RP Mather, JF (corresponding author), Hartford Hosp, Div Res Adm & Intervent Cardiol, Hartford, CT 06106 USA.
EM jeffrey.mather@hhchealth.org
RI Zixuan, Huang/ABI-3557-2020
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Borrell B., 2020, SCIENCE
   Bourinbaiar AS, 1996, LIFE SCI, V59, pPL365, DOI 10.1016/S0024-3205(96)00553-X
   BURDE R, 1989, N-S ARCH PHARMACOL, V340, P671, DOI 10.1007/BF00717743
   Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5
   Eliezer M, 2020, JAMA OTOLARYNGOL, V146, P674, DOI 10.1001/jamaoto.2020.0832
   Ezeamuzie CI, 2000, BRIT J PHARMACOL, V131, P482, DOI 10.1038/sj.bjp.0703556
   Flamand N, 2004, BRIT J PHARMACOL, V141, P552, DOI 10.1038/sj.bjp.0705654
   Freedberg DE, 2020, GASTROENTEROLOGY, V159, P1129, DOI 10.1053/j.gastro.2020.05.053
   Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330
   Janowitz T, 2020, GUT, V0, P1
   Kritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritas
   Malone Robert W, 2020, Res Sq, DOI 10.21203/rs.3.rs-30934/v2
   Marshall JS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174241
   Metcalfe DD, 1997, PHYSIOL REV, V77, P1033
   Mukai K, 2018, IMMUNOL REV, V282, P121, DOI 10.1111/imr.12634
   RABIER M, 1989, INT ARCH ALLER A IMM, V89, P314, DOI 10.1159/000234967
   Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   WADEE AA, 1980, INT ARCH ALLER A IMM, V63, P322, DOI 10.1159/000232643
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
NR 21
TC 1
Z9 1
U1 6
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2020
VL 115
IS 10
BP 1617
EP 1623
DI 10.14309/ajg.0000000000000832
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NX9JQ
UT WOS:000576018400017
PM 32852338
OA Green Published
DA 2021-01-01
ER

PT J
AU Papa, A
   Gasbarrini, A
   Tursi, A
AF Papa, Alfredo
   Gasbarrini, Antonio
   Tursi, Antonio
TI Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in
   Patients With Inflammatory Bowel Disease
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
AB INTRODUCTION: It has been hypothesized that people suffering from inflammatory bowel disease (IBD) have an increased risk of coronavirus disease (COVID-19). However, it is not known whether immunosuppressive therapies exacerbate the COVID-19 outcome.
   METHODS: We reviewed data on the prevalence and clinical outcomes of COVID-19 in patients with IBD.
   RESULTS: COVID-19 prevalence in patients with IBD was comparable with that in the general population. Therapies using antitumor necrosis factor-alpha agents have been associated with better clinical outcomes.
   DISCUSSION: Management and treatments provided by gastroenterologists were effective in reducing COVID-19 risk. Antitumor necrosis factor-alpha agents seem to mitigate the course of COVID-19.
C1 [Papa, Alfredo; Gasbarrini, Antonio] Fdn Policlin A Gemelli, Dept Internal Med & Gastroenterol, IRCCS, Rome, Italy.
   [Papa, Alfredo; Gasbarrini, Antonio] Univ Cattolica S Cuore, Rome, Italy.
   [Tursi, Antonio] Terr Gastroenterol Serv, ASL Bat, Andria, Italy.
RP Tursi, A (corresponding author), Terr Gastroenterol Serv, ASL Bat, Andria, Italy.
EM antotursi@tiscali.it
CR Allocca M, 2020, CLIN GASTROENTEROL H, V18, P2134, DOI 10.1016/j.cgh.2020.04.071
   An P, 2020, LANCET GASTROENTEROL, V5, P525, DOI 10.1016/S2468-1253(20)30121-7
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Brenner EJ, SECURE IBD DATABASE
   Burgueno JF, 2020, INFLAMM BOWEL DIS, V26, P797, DOI 10.1093/ibd/izaa085
   Gubatan J, 2020, GASTROENTEROLOGY
   Jacobs J, 2020, INFLAMM BOWEL DIS, V26, pE64, DOI 10.1093/ibd/izaa093
   Khan N, 2020, GASTROENTEROLOGY
   Mazza S, 2020, GUT, V69, P1148, DOI 10.1136/gutjnl-2020-321183
   Norsa L, 2020, GASTROENTEROLOGY, V159, P371, DOI [10.1053/j.gastro.2020.03.062, 10.1053/j.gastro.2020.03.06]
   Rodriguez-Lago I, 2020, UNITED EUR GASTROENT, V8, P1056, DOI 10.1177/2050640620947579
   Taxonera C, 2020, ALIMENT PHARM THER, V52, P276, DOI 10.1111/apt.15804
   Tursi A, 2020, GUT, V69, P1364, DOI 10.1136/gutjnl-2020-321240
   Wang W, 2007, VIRUS RES, V128, P1, DOI 10.1016/j.virusres.2007.02.007
NR 14
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2020
VL 115
IS 10
BP 1722
EP 1724
DI 10.14309/ajg.0000000000000830
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NX9JQ
UT WOS:000576018400030
PM 32826572
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tan, MC
   Thrift, AP
AF Tan, Mimi C.
   Thrift, Aaron P.
TI Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in
   Patients With Inflammatory Bowel Disease Response
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
ID GASTRIC-CANCER
C1 [Tan, Mimi C.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
   [Thrift, Aaron P.] Baylor Coll Med, Dept Med, Sect Epidemiol & Populat Sci, Houston, TX 77030 USA.
   [Thrift, Aaron P.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA.
RP Tan, MC (corresponding author), Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA.
EM mc2@bcm.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P30 DK056338]; VA
   HSR&D Center for Innovations in Quality, Effectiveness and Safety at
   theMichael E. DeBakey VA Medical Center, Houston, TX [CIN 13-413]
FX This work was supported in part by National Institutes of Health grant
   P30 DK056338 (Study Design and Clinical Research Core), which supports
   the Texas Medical Center Digestive Diseases Center. This research was
   supported in part with resources at the VA HSR&D Center for Innovations
   in Quality, Effectiveness and Safety (#CIN 13-413), at theMichael E.
   DeBakey VA Medical Center, Houston, TX. The opinions expressed reflect
   those of the authors and not necessarily those of the Department of
   Veterans Affairs, the U.S. government or Baylor College of Medicine.
CR Choi YJ, 2016, KOREAN J INTERN MED, V31, P1042, DOI 10.3904/kjim.2016.147
   Da B, 2019, HELICOBACTER, V24, DOI 10.1111/hel.12548
   Locke GR, 1997, GASTROENTEROLOGY, V112, P1448, DOI 10.1016/S0016-5085(97)70025-8
   Oliveira C, 2015, LANCET ONCOL, V16, pE60, DOI 10.1016/S1470-2045(14)71016-2
   Queiroz DMM, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-107
   Tan MC, 2020, AM J GASTROENTEROL, V115, P381, DOI 10.14309/ajg.0000000000000498
   Thrift AP, 2013, AM J GASTROENTEROL, V108, P915, DOI 10.1038/ajg.2013.72
NR 7
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2020
VL 115
IS 10
BP 1725
EP 1725
DI 10.14309/ajg.0000000000000721
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NX9JQ
UT WOS:000576018400031
PM 33017119
DA 2021-01-01
ER

PT J
AU Desai, TK
   Chey, WD
AF Desai, Tusar K.
   Chey, William D.
TI Epidemiology and the Impact of Therapies on the Outcome of COVID-19 in
   Patients With Inflammatory Bowel Disease Response
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
C1 [Desai, Tusar K.] William Beaumont Hosp, Royal Oak, MI 48072 USA.
   [Chey, William D.] Univ Michigan, Med Ctr, Ann Arbor, MI USA.
RP Desai, TK (corresponding author), William Beaumont Hosp, Royal Oak, MI 48072 USA.
EM tusardesai@aol.com
CR Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Gerberding JL, 2020, ANTIBIOTIC RESISTANC
   Howlader N, 1975, SEER CANC STAT REV 1
   Kumar S, 2020, AM J GASTROENTEROL, V115, P716, DOI 10.14309/ajg.0000000000000626
   Rogers MAM, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-121
   Rogers MAM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042091
   Schroder W, 2016, J ANTIMICROB CHEMOTH, V71, P1800, DOI 10.1093/jac/dkw054
   Skole Kevin S, 2020, Am J Gastroenterol, V115, P1301, DOI 10.14309/ajg.0000000000000618
   Surawicz CM, 2013, AM J GASTROENTEROL, V108, P478, DOI 10.1038/ajg.2013.4
NR 9
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD OCT
PY 2020
VL 115
IS 10
BP 1726
EP 1726
DI 10.14309/ajg.0000000000000758
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NX9JQ
UT WOS:000576018400032
PM 32769425
DA 2021-01-01
ER

PT J
AU Gurard-Levin, ZA
   Liu, C
   Jekle, A
   Jaisinghani, R
   Ren, SP
   Vandyck, K
   Jochmans, D
   Leyssen, P
   Neyts, J
   Blatt, LM
   Beigelman, L
   Symons, JA
   Raboisson, P
   Scholle, MD
   Deval, J
AF Gurard-Levin, Zachary A.
   Liu, Cheng
   Jekle, Andreas
   Jaisinghani, Ruchika
   Ren, Suping
   Vandyck, Koen
   Jochmans, Dirk
   Leyssen, Pieter
   Neyts, Johan
   Blatt, Lawrence M.
   Beigelman, Leonid
   Symons, Julian A.
   Raboisson, Pierre
   Scholle, Michael D.
   Deval, Jerome
TI Evaluation of SARS-CoV-2 3C-like protease inhibitors using
   self-assembled monolayer desorption ionization mass spectrometry
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE COVID-19; Coronavirus; 3CLpro; Protease inhibitor; SAMDI-MS; Mass
   spectrometry
ID SARS-CORONAVIRUS; IDENTIFIES INHIBITORS; FLUORESCENCE; ASSAY
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic that began in 2019. The coronavirus 3-chymotrypsin-like cysteine protease (3CLpro) controls replication and is therefore considered a major target for antiviral discovery. This study describes the evaluation of SARS-CoV-2 3CLpro inhibitors in a novel self-assembled monolayer desorption ionization mass spectrometry (SAMDI-MS) enzymatic assay. Compared with a traditional FRET readout, the label-free SAMDI-MS assay offers greater sensitivity and eliminates false positive inhibition from compound interference with the optical signal. The SAMDI-MS assay was optimized and validated with known inhibitors of coronavirus 3CLpro such as GC376 (IC50 = 0.060 mu M), calpain inhibitors II and XII (IC50 similar to 20-25 mu M). The FDA-approved drugs shikonin, disulfiram, and ebselen did not inhibit SARS-CoV-2 3CLpro activity in the SAMDI-MS assay under physiologically relevant reducing conditions. The three drugs did not directly inhibit human beta-coronavirus OC-43 or SARS-CoV-2 in vitro, but instead induced cell death. In conclusion, the SAMDI-MS 3CLpro assay, combined with antiviral and cytotoxic assessment, provides a robust platform to evaluate antiviral agents directed against SARS-CoV-2.
C1 [Gurard-Levin, Zachary A.; Scholle, Michael D.] SAMDI Tech Inc, Chicago, IL USA.
   [Liu, Cheng; Jekle, Andreas; Jaisinghani, Ruchika; Ren, Suping; Blatt, Lawrence M.; Beigelman, Leonid; Symons, Julian A.; Deval, Jerome] Aligos Therapeut Inc, San Francisco, CA 94080 USA.
   [Vandyck, Koen; Raboisson, Pierre] Aligos Belgium BV, Leuven, Belgium.
   [Jochmans, Dirk; Leyssen, Pieter; Neyts, Johan] Katholieke Univ Leuven, Rega Inst, Leuven, Belgium.
RP Deval, J (corresponding author), Aligos Therapeut Inc, San Francisco, CA 94080 USA.
EM jdeval@aligos.com
RI NEYTS, Johan/U-8267-2017; JOCHMANS, DIRK/T-6223-2017
OI NEYTS, Johan/0000-0002-0033-7514; Vandyck, Koen/0000-0002-0923-8301;
   JOCHMANS, DIRK/0000-0002-9265-6028
FU Aligos Therapeutics
FX Aligos Therapeutics provided funding for this study but did not have any
   additional role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101608
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Beilhartz GL, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8926
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Buker SM, 2020, SLAS DISCOV, V25, P361, DOI 10.1177/2472555219878408
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Fan KQ, 2005, BIOCHEM BIOPH RES CO, V329, P934, DOI 10.1016/j.bbrc.2005.02.061
   Gao D, 2002, BIOL PHARM BULL, V25, P827, DOI 10.1248/bpb.25.827
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grum-Tokars V, 2008, VIRUS RES, V133, P63, DOI 10.1016/j.virusres.2007.02.015
   Gurard-Levin ZA, 2011, ACS COMB SCI, V13, P347, DOI 10.1021/co2000373
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Ison MG, 2020, JAMA-J AM MED ASSOC, V323, P2365, DOI 10.1001/jama.2020.8863
   Ivens T, 2005, J VIROL METHODS, V129, P56, DOI 10.1016/j.jviromet.2005.05.010
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jochmans D, 2012, J VIROL METHODS, V183, P176, DOI 10.1016/j.jviromet.2012.04.011
   Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   Kuang WF, 2005, BIOCHEM BIOPH RES CO, V331, P1554, DOI 10.1016/j.bbrc.2005.04.072
   Lee H, 2012, ANAL BIOCHEM, V423, P46, DOI 10.1016/j.ab.2012.01.006
   Liu YC, 2005, BIOCHEM BIOPH RES CO, V333, P194, DOI 10.1016/j.bbrc.2005.05.095
   Liu YY, 1999, ANAL BIOCHEM, V267, P331, DOI 10.1006/abio.1998.3014
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Min DH, 2004, NAT BIOTECHNOL, V22, P717, DOI 10.1038/nbt973
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Mrksich M, 2008, ACS NANO, V2, P7, DOI 10.1021/nn7004156
   O'Kane PT, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw9180
   Palmier MO, 2007, ANAL BIOCHEM, V371, P43, DOI 10.1016/j.ab.2007.07.008
   Patel K, 2015, J BIOMOL SCREEN, V20, P842, DOI 10.1177/1087057115588512
   Pedersen NC, 2018, J FELINE MED SURG, V20, P378, DOI 10.1177/1098612X17729626
   Rodriguez CE, 2005, CHEM-BIOL INTERACT, V155, P97, DOI 10.1016/j.cbi.2005.05.002
   Shen ML, 2000, BIOCHEM PHARMACOL, V60, P947, DOI 10.1016/S0006-2952(00)00435-4
   Swalm BM, 2014, ACS CHEM BIOL, V9, P2459, DOI 10.1021/cb500548b
   Szymczak LC, 2018, METHOD ENZYMOL, V607, P389, DOI 10.1016/bs.mie.2018.04.021
   Takahashi D, 2013, VIRUS RES, V178, P437, DOI 10.1016/j.virusres.2013.09.008
   Valente C, 2007, BIOORGAN MED CHEM, V15, P5340, DOI 10.1016/j.bmc.2007.04.068
   Wiench B, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/726025
   Wigle TJ, 2015, J BIOMOL SCREEN, V20, P810, DOI 10.1177/1087057115575689
   Zauner T, 2011, ANAL CHEM, V83, P7356, DOI 10.1021/ac201274f
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou H, 2020, BRIT J PHARMACOL, V177, P3147, DOI 10.1111/bph.15092
   Zorman J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159826
NR 43
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD OCT
PY 2020
VL 182
AR 104924
DI 10.1016/j.antiviral.2020.104924
PG 11
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA NY0FH
UT WOS:000576075400002
PM 32896566
OA Other Gold
DA 2021-01-01
ER

PT J
AU Theerawatanasirikul, S
   Kuo, CJ
   Phecharat, N
   Chootip, J
   Lekcharoensuk, C
   Lekcharoensuk, P
AF Theerawatanasirikul, Sirin
   Kuo, Chih Jung
   Phecharat, Nanthawan
   Chootip, Jullada
   Lekcharoensuk, Chalermpol
   Lekcharoensuk, Porntippa
TI Structural-based virtual screening and in vitro assays for small
   molecules inhibiting the feline coronavirus 3CL protease as a surrogate
   platform for coronaviruses
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Small molecules; Virtual screening; Feline infectious peritonitis virus
   (FIP); Antiviral activity; CoVs surrogate
ID MAIN PROTEASE; VIRUS; PHARMACOKINETICS; COMBINATION; RITONAVIR;
   MECHANISM; RIBAVIRIN; UPDATE; RNA
AB Feline infectious peritonitis (FIP) which is caused by feline infectious peritonitis virus (FIPV), a variant of feline coronavirus (FCoV), is a member of family Coronaviridae, together with severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2. So far, neither effective vaccines nor approved antiviral therapeutics are currently available for the treatment of FIPV infection. Both human and animal CoVs shares similar functional proteins, particularly the 3CL protease (3CL(pro)), which plays the pivotal role on viral replication. We investigated the potential drug-liked compounds and their inhibitory interaction on the 3CL(pro) active sites of CoVs by the structural-bases virtual screening. Fluorescence resonance energy transfer (FRET) assay revealed that three out of twenty-eight compounds could hamper FIPV 3CL(pro) activities with IC50 of 3.57 +/- 0.36 mu M to 25.90 +/- 1.40 mu M, and Ki values of 2.04 +/- 0.08 to 15.21 +/- 1.76 mu M, respectively. Evaluation of antiviral activity using cell-based assay showed that NSC629301 and NSC71097 could strongly inhibit the cytopathic effect and also reduced replication of FIPV in CRFK cells in all examined conditions with the low range of EC50 (6.11 +/- 1.90 to 7.75 +/- 0.48 mu M and 1.99 +/- 0.30 to 4.03 +/- 0.60 mu M, respectively), less than those of ribavirin and lopinavir. Analysis of FIPV 3CL(pro)-ligand interaction demonstrated that the selected compounds reacted to the crucial residues (His41 and Cys144) of catalytic dyad. Our investigations provide a fundamental knowledge for the further development of antiviral agents and increase the number of anti-CoV agent pools for feline coronavirus and other related CoVs.
C1 [Theerawatanasirikul, Sirin] Kasetsart Univ, Fac Vet Med, Dept Anat, Bangkok 10900, Thailand.
   [Kuo, Chih Jung] Natl Chung Hsing Univ, Dept Vet Med, Taichung 40227, Taiwan.
   [Phecharat, Nanthawan; Chootip, Jullada; Lekcharoensuk, Porntippa] Kasetsart Univ, Fac Vet Med, Dept Microbiol & Immunol, Bangkok 10900, Thailand.
   [Lekcharoensuk, Chalermpol] Kasetsart Univ, Fac Vet Med, Dept Compan Anim Clin Sci, Bangkok 10900, Thailand.
   [Lekcharoensuk, Porntippa] KU Inst, Ctr Adv Studies Agr & Food, Bangkok, Thailand.
RP Kuo, CJ (corresponding author), Natl Chung Hsing Univ, Dept Vet Med, Taichung 40227, Taiwan.; Lekcharoensuk, P (corresponding author), Kasetsart Univ, Fac Vet Med, Dept Microbiol & Immunol, Bangkok 10900, Thailand.
EM ck476@nchu.edu.tw; fvetptn@ku.ac.th
RI Theerawatanasirikul, Sirin/J-1063-2019
OI Lekcharoensuk, Porntippa/0000-0001-5595-3296; Kuo,
   Chih-Jung/0000-0002-4988-5124
FU Thailand Science Research and Innovation [RTA6280011]; Agricultural
   Research Development Agency [CRP6305032230]; New Southbound Policy and
   the Featured Areas Research Center Program
FX This work was supported by Thailand Science Research and Innovation
   (grant number RTA6280011); Agricultural Research Development Agency
   (grant number CRP6305032230) and The New Southbound Policy and the
   Featured Areas Research Center Program within the framework of the
   Higher Education Sprout Project by the Ministry of Education in Taiwan.
CR Arvieux C, 2005, DRUGS, V65, P633, DOI 10.2165/00003495-200565050-00005
   Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419
   BARLOUGH JE, 1994, VET REC, V135, P177, DOI 10.1136/vr.135.8.177
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Cameron CE, 2001, CURR OPIN INFECT DIS, V14, P757, DOI 10.1097/00001432-200112000-00015
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CDC-Centers for Disease Control and Prevention, 2020, INT LAB BIOS GUID HA
   Centers for Disease Control and Prevention (CDCP), 2009, BIOS MICR BIOM LAB B
   Crommentuyn KML, 2005, BRIT J CLIN PHARMACO, V60, P378, DOI 10.1111/j.1365-2125.2005.02455.x
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004
   Fatkenheuer G, 2020, NEW ENGL J MED, V382
   Garavito MF, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01479
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   HERREWEGH AAPM, 1995, J CLIN MICROBIOL, V33, P684, DOI 10.1128/JCM.33.3.684-689.1995
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kankanamalage ACG, 2018, EUR J MED CHEM, V150, P334, DOI 10.1016/j.ejmech.2018.03.004
   Kim Y., 2016, REVERSAL PROGR FATAL, P1, DOI [10.1371/journal.ppat.1005531, DOI 10.1371/JOURNAL.PPAT.1005531]
   Kim Y, 2013, ANTIVIR RES, V97, P161, DOI 10.1016/j.antiviral.2012.11.005
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   Kuo CJ, 2004, BIOCHEM BIOPH RES CO, V318, P862, DOI 10.1016/j.bbrc.2004.04.098
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lekcharoensuk P, 2012, VACCINE, V30, P1453, DOI 10.1016/j.vaccine.2011.12.109
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Manasateinkij W., 2009, Kasetsart Journal, Natural Sciences, V43, P720
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Murphy BG, 2018, VET MICROBIOL, V219, P226, DOI 10.1016/j.vetmic.2018.04.026
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Pedersen NC, 2014, VET J, V201, P133, DOI 10.1016/j.tvjl.2014.04.016
   Rokas KEE, 2012, ANN PHARMACOTHER, V46, P578, DOI 10.1345/aph.1Q616
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sykes J.E., 2013, ANTIVIRAL IMMUNOMODU, DOI [10.1016/B978-1-4377-0795-3.00007-7, DOI 10.1016/B978-1-4377-0795-3.00007-7]
   Tamble CM, 2011, MOL BIOSYST, V7, P2019, DOI 10.1039/c0mb00298d
   Theerawatanasirikul S, 2020, ANTIVIR RES, V174, DOI 10.1016/j.antiviral.2019.104697
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   van Heeswijk RPG, 2001, ANTIVIR THER, V6, P201
   Wang FH, 2017, J MED CHEM, V60, P3212, DOI 10.1021/acs.jmedchem.7b00103
   Wang FH, 2016, J VIROL, V90, P1910, DOI 10.1128/JVI.02685-15
   WEISS RC, 1989, VET MICROBIOL, V20, P255, DOI 10.1016/0378-1135(89)90049-7
   WHO, 2020, WHO DISC HYDR LOP RI
   Wilkes R.P., 2016, AUGUSTS CONSULT FELI, V7, P84, DOI [10.1016/B978-0-323-22652-3.00007-4., DOI 10.1016/B978-0-323-22652-3.00007-4]
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
NR 43
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD OCT
PY 2020
VL 182
AR 104927
DI 10.1016/j.antiviral.2020.104927
PG 9
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA NY0DV
UT WOS:000576071600004
PM 32910955
OA Green Published
DA 2021-01-01
ER

PT J
AU Thalappillil, R
   White, RS
   Tam, CW
AF Thalappillil, Richard
   White, Robert S.
   Tam, Christopher W.
TI POCUS to Guide Fluid Therapy in COVID-19
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Letter
C1 [Thalappillil, Richard; White, Robert S.] Weill Cornell Med Ctr, Div Cardiac Anesthesiol, Dept Anesthesiol, New York, NY 10065 USA.
   [Tam, Christopher W.] Weill Cornell Med Ctr, Dept Anesthesiol, Div Cardiac Anesthesiol & Crit Care, New York, NY USA.
RP Thalappillil, R (corresponding author), Weill Cornell Med Ctr, Div Cardiac Anesthesiol, Dept Anesthesiol, New York, NY 10065 USA.
CR Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Sanjan A, 2019, J EMERG TRAUMA SHOCK, V12, P248, DOI 10.4103/JETS.JETS_47_19
   Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564
NR 5
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
EI 1532-8422
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD OCT
PY 2020
VL 34
IS 10
BP 2854
EP 2856
DI 10.1053/j.jvca.2020.04.049
PG 3
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
   Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA NM0VP
UT WOS:000567823200052
PM 32493663
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Jannelli, E
   Castelli, A
   Calderoni, EF
   Annunziata, S
   Maccario, G
   Ivone, A
   Pasta, G
   Mosconi, M
AF Jannelli, Eugenio
   Castelli, Alberto
   Calderoni, Enrico Ferranti
   Annunziata, Salvatore
   Maccario, Gaia
   Ivone, Alessandro
   Pasta, Gianluigi
   Mosconi, Mario
TI Fractures in Patients With COVID-19 Infection: Early Prognosis and
   Management. A Case Series of 20 Patients in a Single Institution in
   Lombardy, Northern Italy
SO JOURNAL OF ORTHOPAEDIC TRAUMA
LA English
DT Article
DE Covid-19; fractures; SF-36; management; early prognosis
ID QUALITY-OF-LIFE; ELDERLY-PATIENTS; HIP FRACTURE
AB Fifty-eight percent of the total infections in Italy of COVID-19 were found in northern Italy, in particular, Lombardy. From February 21, 2020, to March 23, 2020, 20 patients with a fracture and a diagnosis of COVID-19 were hospitalized. Demographic data, COVID-19 symptoms, laboratory and radiographic examinations, and treatment methods were recorded. At 1-month follow-up, patients were assessed with the SF-36 score. This case series includes 20 patients (16 women and 4 men), with an average age of 82.35 years (range 59-95). Eleven patients (55%) had a femur fracture. Fourteen patients (70%) had 3 or more comorbidities or previous pathologies. Three patients with severe comorbidities died during the hospitalization. Thirteen patients (65%) had fever, 18 patients (90%) asthenia, and 17 patients (85%) dyspnea. All patients (100%) were given antibiotic therapy, whereas 16 patients (80%) underwent hydroxychloroquine therapy and 8 (40%) were treated with corticosteroids. Eighteen patients (90%) underwent antithromboembolic prophylaxis. Eighteen patients (90%) had lymphopenia. All 20 patients (100%) required noninvasive mechanical ventilation. High D-dimer and polymerase chain reaction values were found in all patients (100%), whereas lactate dehydrogenase was increased in 18 patients (90%). Patients with fractures, especially in the lower limbs, frequently require hospitalization, making these patients more subjected to the risk of COVID-19 infection. COVID-19 infection therefore does not seem to influence the fracture pattern in the elderly population but can lead to health deterioration with increased mortality. The typical symptoms of COVID-19 disease have not changed when associated with a fracture or trauma. Laboratory data are in line with what is reported in recent studies, whereas a more invasive assisted ventilation is associated with a poor prognosis. Finally, analyzing the data obtained from the SF-36 score, significantly lower values emerged when compared with those reported in the literature.
C1 [Jannelli, Eugenio; Castelli, Alberto; Calderoni, Enrico Ferranti; Annunziata, Salvatore; Maccario, Gaia; Ivone, Alessandro; Pasta, Gianluigi; Mosconi, Mario] Fdn IRCCS Policlin San Matteo, Clin Ortopedia & Traumatol, Viale Camillo Golgi 19, I-27100 Pavia, PV, Italy.
RP Calderoni, EF (corresponding author), Fdn IRCCS Policlin San Matteo, Clin Ortopedia & Traumatol, Viale Camillo Golgi 19, I-27100 Pavia, PV, Italy.
EM e_ferranti@libero.it
RI Pasta, Gianluigi/ABH-1649-2020
OI Pasta, Gianluigi/0000-0002-1919-5130; Reis,
   AlessanRSS/0000-0001-8486-7469; Annunziata,
   Salvatore/0000-0003-3850-2156
CR Agrawal S, 2020, MONALDI ARCH CHEST D, V90, DOI 10.4081/monaldi.2020.1289
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Baidwan NK, 2017, PUBLIC HEALTH, V142, P64, DOI 10.1016/j.puhe.2016.10.018
   Borges FK, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-033150
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Fang Y., 2020, RADIOLOGY, DOI DOI 10.1148/RADI0L.2020200432
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gregory JJ, 2010, INJURY, V41, P1273, DOI 10.1016/j.injury.2010.06.009
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   Kastanis G, 2016, SCIENTIFICA, V2016, DOI 10.1155/2016/7096245
   Kokkinakis Ioannis, 2020, Rev Med Suisse, V16, P699
   Laucis NC, 2015, J BONE JOINT SURG AM, V97A, P1628, DOI 10.2106/JBJS.O.00030
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Mi BB, 2020, J BONE JOINT SURG AM, V102, P750, DOI 10.2106/JBJS.20.00390
   Peng J, 2020, J HOSP INFECT, V105, P106, DOI 10.1016/j.jhin.2020.02.020
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Randell AG, 2000, OSTEOPOROSIS INT, V11, P460, DOI 10.1007/s001980070115
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Salute MD, COV 19 SIT IT
   Shyu YIL, 2004, OSTEOPOROSIS INT, V15, P95, DOI 10.1007/s00198-003-1533-x
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
NR 24
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0890-5339
EI 1531-2291
J9 J ORTHOP TRAUMA
JI J. Orthop. Trauma
PD OCT
PY 2020
VL 34
IS 10
BP E389
EP E397
DI 10.1097/BOT.0000000000001905
PG 9
WC Orthopedics; Sport Sciences
SC Orthopedics; Sport Sciences
GA NX8XJ
UT WOS:000575986500007
PM 32947590
DA 2021-01-01
ER

PT J
AU Hosseini, FS
   Amanlou, M
AF Hosseini, Faezeh Sadat
   Amanlou, Massoud
TI Anti-HCV and anti-malaria agent, potential candidates to repurpose for
   coronavirus infection: Virtual screening, molecular docking, and
   molecular dynamics simulation study
SO LIFE SCIENCES
LA English
DT Article
DE COVID-19; Simeprevir; Repurpose; Virtual screening; Docking; Molecular
   dynamics simulation
ID HEPATITIS-C; DISCOVERY; INHIBITOR; CHINA
AB Aims: Coronavirus disease 2019 (COVID-19) has appeared in Wuhan, China but the fast transmission has led to its widespread prevalence in various countries, which has made it a global concern. Another concern is the lack of definitive treatment for this disease. The researchers tried different treatment options which are not specific. The current study aims to identify potential small molecule inhibitors against the main protease protein of SARSCoV-2 by the computational approach.
   Main methods: In this study, a virtual screening procedure employing docking of the two different datasets from the ZINC database, including 1615 FDA approved drugs and 4266 world approved drugs were used to identify new potential small molecule inhibitors for the newly released crystal structure of main protease protein of SARS-CoV-2. In the following to validate the docking result, molecular dynamics simulations were applied on selected ligands to identify the behavior and stability of them in the binding pocket of the main protease in 150 nanoseconds (ns). Furthermore, binding energy using the MMPBSA approach was also calculated.
   Key findings: The result indicates that simeprevir (Hepatitis C virus NS3/4A protease inhibitor) and pyronaridine (antimalarial agent) could fit well to the binding pocket of the main protease and because of some other beneficial features including broad-spectrum antiviral properties and ADME profile, they might be a promising drug candidate for repurposing to the treatment of COVID-19.
   Significance: Simeprevir and pyronaridine were selected by the combination of virtual screening and molecular dynamics simulation approaches as a potential candidate for treatment of COVID-19.
C1 [Hosseini, Faezeh Sadat; Amanlou, Massoud] Univ Tehran Med Sci, Fac Pharm, Dept Med Chem, Tehran, Iran.
   [Amanlou, Massoud] Univ Tehran Med Sci, Expt Med Res Ctr, Tehran, Iran.
RP Amanlou, M (corresponding author), Univ Tehran Med Sci, Expt Med Res Ctr, Tehran, Iran.
EM amanlou@tums.ac.ir
FU Research Council of Tehran University of Medical Sciences and Health
   Services, Tehran, IranTehran University of Medical Sciences; Iran
   National Science FoundationIran National Science Foundation (INSF)
   [INSF-99008187]
FX This study was financially supported by the Research Council of Tehran
   University of Medical Sciences and Health Services, Tehran, Iran, and
   Iran National Science Foundation (INSF-99008187).
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Alamri M.A., 2020, PHARMACOINFORMATICS
   [Anonymous], 2020, GILEAD SCI INITIATES
   Bagherzadeh K, 2015, J BIOMOL STRUCT DYN, V33, P487, DOI 10.1080/07391102.2014.893203
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   Contini A., 2020, VIRTUAL SCREENING FD, DOI [10.26434/chemrxiv., DOI 10.26434/CHEMRXIV.]
   Dassault Systemes BIOVIA, 2016, DASSAULT SYSTEMES BI
   de Oliveira L., 2020, COMPARATIVE COMPUTAT, DOI [10.26434/chemrxiv.12044538.v3., DOI 10.26434/CHEMRXIV.12044538.V3.]
   Ekins S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003878
   Flanagan S, 2014, EXPERT REV CLIN PHAR, V7, P691, DOI 10.1586/17512433.2014.956091
   Francis D., 2020, REPURPOSING SIMEPREV
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gentile I, 2014, REV RECENT CLIN TRIA, V9, P115, DOI 10.2174/1574887109666140529222602
   Goetz DH, 2007, BIOCHEMISTRY-US, V46, P8744, DOI 10.1021/bi0621415
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lane TR, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007890
   Lavecchia A, 2013, CURR MED CHEM, V20, P2839, DOI 10.2174/09298673113209990001
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Li Z, 2019, ANTIVIR RES, V172, DOI 10.1016/j.antiviral.2019.104607
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Lin S., 2020, BIORXIV, pE014, DOI [10.3760/cma.j.issn.1001-0939.2020.0014., DOI 10.3760/CMA.J.ISSN.1001-0939.2020.0014.]
   Lo H.S., 2020, BIORXIV
   Lombardo FC, 2019, EUR J PHARM BIOPHARM, V142, P240, DOI 10.1016/j.ejpb.2019.06.029
   Love MS, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005373
   Mirza M.U., 2020, J PHARM ANAL, DOI [10. 1016/j.jpha.2020.04.008., DOI 10.1016/J.JPHA.2020.04.008.]
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Naisbitt DJ, 1998, CHEM RES TOXICOL, V11, P1586, DOI 10.1021/tx980148k
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   OBoyle N.M., 2011, J CHEMINFORMATICS, V33
   Okoth WA, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00394-18, 10.1128/aac.00394-18]
   Polamreddy P, 2019, DRUG DISCOV TODAY, V24, P789, DOI 10.1016/j.drudis.2018.11.022
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Sun ML, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201910043
   Taherizadeh M, 2020, IRAN J PUBLIC HEALTH, V49, P30
   Wang CH, 2018, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00087
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, 2019, CORONAVIRUS DIS 2019
   World Health Organization, 2020, CLIN MANAGEMENT SEVE
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yu WB, 2012, J COMPUT CHEM, V33, P2451, DOI 10.1002/jcc.23067
NR 45
TC 1
Z9 1
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD OCT 1
PY 2020
VL 258
AR 118205
DI 10.1016/j.lfs.2020.118205
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NW7BG
UT WOS:000575171200002
PM 32777300
OA Green Published
DA 2021-01-01
ER

PT J
AU Henderson, R
   Edwards, RJ
   Mansouri, K
   Janowska, K
   Stalls, V
   Gobeil, SMC
   Kopp, M
   Li, DP
   Parks, R
   Hsu, AL
   Borgnia, MJ
   Haynes, BF
   Acharya, P
AF Henderson, Rory
   Edwards, Robert J.
   Mansouri, Katayoun
   Janowska, Katarzyna
   Stalls, Victoria
   Gobeil, Sophie M. C.
   Kopp, Megan
   Li, Dapeng
   Parks, Rob
   Hsu, Allen L.
   Borgnia, Mario J.
   Haynes, Barton F.
   Acharya, Priyamvada
TI Controlling the SARS-CoV-2 spike glycoprotein conformation
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
ID HIV-1 ENVELOPE TRIMERS; CRYO-EM STRUCTURE; IMMUNOGENICITY; CORONAVIRUS;
   VISUALIZATION; MICROSCOPY; FEATURES; DESIGN; ENV
AB The coronavirus (CoV) spike (S) protein, involved in viral-host cell fusion, is the primary immunogenic target for virus neutralization and the current focus of many vaccine design efforts. The highly flexible S-protein, with its mobile domains, presents a moving target to the immune system. Here, to better understand S-protein mobility, we implemented a structure-based vector analysis of available beta-CoV S-protein structures. Despite an overall similarity in domain organization, we found that S-proteins from different beta-CoVs display distinct configurations. Based on this analysis, we developed two soluble ectodomain constructs for the SARS-CoV-2 S-protein, in which the highly immunogenic and mobile receptor binding domain (RBD) is either locked in the all-RBDs 'down' position or adopts 'up' state conformations more readily than the wild-type S-protein. These results demonstrate that the conformation of the S-protein can be controlled via rational design and can provide a framework for the development of engineered CoV S-proteins for vaccine applications.
C1 [Henderson, Rory; Edwards, Robert J.; Mansouri, Katayoun; Janowska, Katarzyna; Stalls, Victoria; Gobeil, Sophie M. C.; Kopp, Megan; Li, Dapeng; Parks, Rob; Haynes, Barton F.; Acharya, Priyamvada] Duke Human Vaccine Inst, Durham, NC 27710 USA.
   [Henderson, Rory; Edwards, Robert J.; Haynes, Barton F.] Duke Univ, Dept Med, Durham, NC 27708 USA.
   [Hsu, Allen L.; Borgnia, Mario J.] NIEHS, Genome Integr & Struct Biol Lab, NIH, Dept Hlth & Human Serv, Durham, NC USA.
   [Haynes, Barton F.] Duke Univ, Dept Immunol, Durham, NC USA.
   [Acharya, Priyamvada] Duke Univ, Dept Surg, Durham, NC 27708 USA.
RP Henderson, R; Acharya, P (corresponding author), Duke Human Vaccine Inst, Durham, NC 27710 USA.; Henderson, R (corresponding author), Duke Univ, Dept Med, Durham, NC 27708 USA.; Acharya, P (corresponding author), Duke Univ, Dept Surg, Durham, NC 27708 USA.
EM rory.henderson@duke.edu; priyamvada.acharya@duke.edu
OI Hsu, Allen/0000-0003-2065-3802; Henderson, Rory/0000-0002-4301-6382;
   Edwards, Robert/0000-0003-4446-1194; gobeil, sophie/0000-0002-0057-2477;
   Mansouri, Katayoun/0000-0001-6232-7330
FU NIH Common Fund Transformative High Resolution Cryo-Electron Microscopy
   programUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [U24 GM129539]; Simons Foundation
   [SF349247]; Integrated Preclinical/Clinical AIDS Vaccine Development
   Program, NIAID, NIH [U19 AI142596]; Duke University Center for AIDS
   Research (CFAR); Intramural Research Program of the NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; National Institute of Environmental Health SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Environmental Health Sciences (NIEHS)
   [ZIC ES103326]; State of North Carolina Pandemic Recovery Office through
   funds from the Coronavirus Aid, Relief and Economic Security (CARES)
   Act; NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1S10OD018164-01];  [R01 AI145687]
FX Initial cryo-EM data were collected on the Titan Krios system at the
   Shared Materials and Instrumentation Facility in Duke University. Data
   collection for high-resolution structure determination was performed at
   the National Center for Cryo-EM Access and Training (NCCAT) and the
   Simons Electron Microscopy Center located at the New York Structural
   Biology Center, supported by the NIH Common Fund Transformative High
   Resolution Cryo-Electron Microscopy program (U24 GM129539) and by grants
   from the Simons Foundation (SF349247) and NY State. We thank E. Eng, D.
   Bobe, M. Walters and H. Leddy for microscope alignments and assistance
   with cryo-EM data collection as well as J. McLellan for providing the
   plasmid for the unmutated construct and K. Manne for preparing the
   CR3022 Fab. This work was supported by U19 AI142596 (B.F.H.), Integrated
   Preclinical/Clinical AIDS Vaccine Development Program, NIAID, NIH; Duke
   University Center for AIDS Research (CFAR); an administrative supplement
   to NIH R01 AI145687 for coronavirus research and Translating Duke Health
   Initiative (P.A. and R.C.H.), the Intramural Research Program of the
   NIH; National Institute of Environmental Health Sciences (ZIC ES103326
   to M.J.B.), and a contract from the State of North Carolina Pandemic
   Recovery Office through funds from the Coronavirus Aid, Relief and
   Economic Security (CARES) Act. This study utilized the computational
   resources offered by Duke Research Computing (http://rc.duke.edu; NIH
   1S10OD018164-01) at Duke University. We thank M. DeLong, C. Kneifel, M.
   Newton, V. Orlikowski, T. Milledge and D. Lane from the Duke Office of
   Information Technology and Research Computing for providing assistance
   with setting up and maintaining the computing environment.
CR Afonine PV, 2018, ACTA CRYSTALLOGR D, V74, P531, DOI 10.1107/S2059798318006551
   [Anonymous], 2020, MAESTR
   Barnes CO, 2020, CELL, V182, P828, DOI 10.1016/j.cell.2020.06.025
   Beard H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082849
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Cai Yongfei, 2020, bioRxiv, DOI 10.1101/2020.05.16.099317
   Chen CP, 2017, J VIROL, V91, DOI 10.1128/JVI.02491-16
   de la Pena AT, 2017, CELL REP, V20, P1805, DOI 10.1016/j.celrep.2017.07.077
   de Taeye SW, 2015, CELL, V163, P1702, DOI 10.1016/j.cell.2015.11.056
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Guenaga J, 2016, J VIROL, V90, P2806, DOI 10.1128/JVI.02652-15
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   He LL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau6769
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsieh Ching-Lin, 2020, bioRxiv, DOI 10.1101/2020.05.30.125484
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kulp DW, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01549-6
   Medina-Ramirez M, 2017, J EXP MED, V214, P2573, DOI 10.1084/jem.20161160
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   R Core Team, 2017, R LANG ENV STAT COMP
   Rey FA, 2018, CELL, V172, P1319, DOI 10.1016/j.cell.2018.02.054
   Salam NK, 2014, PROTEIN ENG DES SEL, V27, P365, DOI 10.1093/protein/gzu017
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Scheres SHW, 2016, METHOD ENZYMOL, V579, P125, DOI 10.1016/bs.mie.2016.04.012
   Schrodinger LLC, 2015, PYMOL MOL GRAPHICS S
   Sharma SK, 2015, CELL REP, V11, P539, DOI 10.1016/j.celrep.2015.03.047
   Sliepen K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10262-5
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Steichen JM, 2016, IMMUNITY, V45, P483, DOI 10.1016/j.immuni.2016.08.016
   Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Turoova B., 2020, BIORXIV, DOI [10.1101/2020.06.26.173476, DOI 10.1101/2020.06.26.173476]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang L, 2018, J VIROL, V92, DOI 10.1128/JVI.01060-18
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang LF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01631
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang P, 2018, CELL HOST MICROBE, V23, P832, DOI 10.1016/j.chom.2018.05.002
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zost SJ, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0998-x
NR 52
TC 17
Z9 16
U1 10
U2 10
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD OCT
PY 2020
VL 27
IS 10
BP 925
EP +
DI 10.1038/s41594-020-0479-4
PG 22
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA NX9KU
UT WOS:000576021400008
PM 32699321
OA Bronze
DA 2021-01-01
ER

PT J
AU Xiong, XL
   Qu, K
   Ciazynska, KA
   Hosmillo, M
   Carter, AP
   Ebrahimi, S
   Ke, ZL
   Scheres, SHW
   Bergamaschi, L
   Grice, GL
   Zhang, Y
   Nathan, JA
   Baker, S
   James, LC
   Baxendale, HE
   Goodfellow, I
   Doffinger, R
   Briggs, JAG
AF Xiong, Xiaoli
   Qu, Kun
   Ciazynska, Katarzyna A.
   Hosmillo, Myra
   Carter, Andrew P.
   Ebrahimi, Soraya
   Ke, Zunlong
   Scheres, Sjors H. W.
   Bergamaschi, Laura
   Grice, Guinevere L.
   Zhang, Ying
   Nathan, James A.
   Baker, Stephen
   James, Leo C.
   Baxendale, Helen E.
   Goodfellow, Ian
   Doffinger, Rainer
   Briggs, John A. G.
CA CITIID-NIHR COVID-19 Bioresource
TI A thermostable, closed SARS-CoV-2 spike protein trimer
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
ID BEAM-INDUCED MOTION; CRYO-EM; CORONAVIRUS; VACCINE
AB The spike (S) protein of SARS-CoV-2 mediates receptor binding and cell entry and is the dominant target of the immune system. It exhibits substantial conformational flexibility. It transitions from closed to open conformations to expose its receptor-binding site and, subsequently, from prefusion to postfusion conformations to mediate fusion of viral and cellular membranes. S-protein derivatives are components of vaccine candidates and diagnostic assays, as well as tools for research into the biology and immunology of SARS-CoV-2. Here we have designed mutations in S that allow the production of thermostable, disulfide-bonded S-protein trimers that are trapped in the closed, prefusion state. Structures of the disulfide-stabilized and non-disulfide-stabilized proteins reveal distinct closed and locked conformations of the S trimer. We demonstrate that the designed, thermostable, closed S trimer can be used in serological assays. This protein has potential applications as a reagent for serology, virology and as an immunogen.
C1 [Xiong, Xiaoli; Qu, Kun; Ciazynska, Katarzyna A.; Carter, Andrew P.; Ke, Zunlong; Scheres, Sjors H. W.; Briggs, John A. G.] MRC, Lab Mol Biol, Struct Studies Div, Cambridge, England.
   [Hosmillo, Myra; Goodfellow, Ian] Univ Cambridge, Dept Pathol, Div Virol, Cambridge, England.
   [Ebrahimi, Soraya; Doffinger, Rainer] Addenbrookes Hosp, Dept Clin Biochem & Immunol, Cambridge, England.
   [Bergamaschi, Laura; Grice, Guinevere L.; Nathan, James A.; Baker, Stephen] Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis CIT, Cambridge, England.
   [Zhang, Ying] Sun Yat Sen Univ, Affiliated Hosp 7, Precis Med Ctr, Shenzhen, Guangdong, Peoples R China.
   [Zhang, Ying] Francis Crick Inst, London, England.
   [James, Leo C.] MRC, Prot & Nucle Acid Chem Div, Lab Mol Biol, Cambridge, England.
   [Baxendale, Helen E.] Royal Papworth Hosp NHS Fdn Trust, Cambridge, England.
RP Xiong, XL; Briggs, JAG (corresponding author), MRC, Lab Mol Biol, Struct Studies Div, Cambridge, England.
EM xiong@mrc-lmb.cam.ac.uk; jbriggs@mrc-lmb.cam.ac.uk
RI Mescia, Federica/ABE-1176-2020; Bergamaschi, Laura/ABE-1175-2020
OI Mescia, Federica/0000-0002-2759-4027; Ciazynska, Katarzyna
   A./0000-0002-9899-2428; Scheres, Sjors/0000-0002-0462-6540
FU European Research Council (ERC) under the European UnionEuropean
   Research Council (ERC) [648432]; Medical Research Council as part of
   United Kingdom Research and Innovation [MC_UP_A025_1011,
   MC_UP_A025_1013, MC_U105181010, MC_UP_1201/16]; 100 Top Talents Program
   of Sun Yat-sen University; Wellcome Trust Senior FellowshipWellcome
   Trust [207498/Z/17/Z]
FX We thank the staff of the MRC-LMB for generous support during the
   COVID-19 pandemic lockdown. We thank the staff of the MRC-LMB EM
   Facility, in particular G. Sharov and G. Cannone, for supporting EM; J.
   Grimmett and T. Darling for supporting scientific computing; and P.
   Edwards for supporting cell culture. We thank T. Nakane for advice on
   image processing, K. Dent for assistance with sample screening, A.
   Fountain for assistance with primer design, C. Lu for assistance with
   bioinformatics, F. Coscia for assistance with EM grid preparation and R.
   Aricescu for advice on protein expression. We thank D. Mallery and D.
   Paul for performing exploratory experiments. We thank the Royal Papworth
   Hospital Clinical Staff and R&D team in supporting patient and staff
   recruitment, J. Gronlund for support with sample collection and Royal
   Papworth Hospital healthy staff donors for their participation in this
   research. This study was supported by funding from the European Research
   Council (ERC) under the European Union's Horizon 2020 research and
   innovation program (ERC-CoG-648432 MEMBRANEFUSION to J.A.G.B.), the
   Medical Research Council as part of United Kingdom Research and
   Innovation (MC_UP_A025_1011 to A.P.C., MC_UP_A025_1013 to S.H.W.S.,
   MC_U105181010 to L.C.J. and MC_UP_1201/16 to J.A.G.B.), 100 Top Talents
   Program of Sun Yat-sen University (to Y.Z.) and a Wellcome Trust Senior
   Fellowship (207498/Z/17/Z to I.G.).
CR Afonine PV, 2018, ACTA CRYSTALLOGR D, V74, P531, DOI 10.1107/S2059798318006551
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Graham BS, 2019, ANNU REV MED, V70, P91, DOI 10.1146/annurev-med-121217-094234
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Henderson R, 2020, NAT STRUCT MOL BIOL, V27, P925, DOI 10.1038/s41594-020-0479-4
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kidmose RT, 2019, IUCRJ, V6, P526, DOI 10.1107/S2052252519007619
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Liu C., 2020, VIRAL ARCHITECTURE S, DOI [10.1101/2020.03.02.972927v1, DOI 10.1101/2020.03.02.972927V1]
   Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007
   McCallum M., 2020, CLOSING CORONAVIRUS, DOI [10.1101/2020.06.03.129817v1, DOI 10.1101/2020.06.03.129817V1]
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pancera M, 2017, CURR OPIN HIV AIDS, V12, P229, DOI 10.1097/COH.0000000000000360
   Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Shang J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007009
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Toelzer C., 2020, UNEXPECTED FREE FATT, DOI [10.1101/2020.06.18.158584v1, DOI 10.1101/2020.06.18.158584V1]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xiong XL, 2018, J VIROL, V92
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang L., 2020, BIORXIV, DOI [10.1101/2020.06.12.148726v1, DOI 10.1101/2020.06.12.148726V1]
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zivanov J, 2020, IUCRJ, V7, P253, DOI 10.1107/S2052252520000081
   Zivanov J, 2019, IUCRJ, V6, P5, DOI 10.1107/S205225251801463X
NR 46
TC 10
Z9 10
U1 11
U2 11
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD OCT
PY 2020
VL 27
IS 10
BP 934
EP +
DI 10.1038/s41594-020-0478-5
PG 16
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA NX9KU
UT WOS:000576021400009
PM 32737467
OA Bronze
DA 2021-01-01
ER

PT J
AU McCallum, M
   Walls, AC
   Bowen, JE
   Corti, D
   Veesler, D
AF McCallum, Matthew
   Walls, Alexandra C.
   Bowen, John E.
   Corti, Davide
   Veesler, David
TI Structure-guided covalent stabilization of coronavirus spike
   glycoprotein trimers in the closed conformation
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
ID CRYO-EM STRUCTURE; RESPIRATORY SYNDROME CORONAVIRUS; STOMATITIS-VIRUS
   GLYCOPROTEIN; MERS-COV; INFLUENZA HEMAGGLUTININ; FUNCTIONAL RECEPTOR;
   CRYSTAL-STRUCTURE; CELL ENTRY; PROTEIN; MICROSCOPY
AB SARS-CoV-2 is the causative agent of the COVID-19 pandemic, with 10 million infections and more than 500,000 fatalities by June 2020. To initiate infection, the SARS-CoV-2 spike (S) glycoprotein promotes attachment to the host cell surface and fusion of the viral and host membranes. Prefusion SARS-CoV-2 S is the main target of neutralizing antibodies and the focus of vaccine design. However, its limited stability and conformational dynamics are limiting factors for developing countermeasures against this virus. We report here the design of a construct corresponding to the prefusion SARS-CoV-2 S ectodomain trimer, covalently stabilized by a disulfide bond in the closed conformation. Structural and antigenicity analyses show we successfully shut S in the closed state without otherwise altering its architecture. We demonstrate that this strategy is applicable to other beta-coronaviruses, such as SARS-CoV and MERS-CoV, and might become an important tool for structural biology, serology, vaccine design and immunology studies.
C1 [McCallum, Matthew; Walls, Alexandra C.; Bowen, John E.; Veesler, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   [Corti, Davide] Humabs Biomed SA, Bellinzona, Switzerland.
RP Veesler, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
EM dveesler@uw.edu
OI Bowen, John/0000-0003-3590-9727
FU National Institute of General Medical SciencesUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM120553];
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201700059C]; Pew Biomedical Scholars Award; Investigators in the
   Pathogenesis of Infectious Disease Award from the Burroughs Wellcome
   Fund; Bill & Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1156262]; University of Washington Arnold and Mabel Beckman Cryo-EM
   Center; Fast Grants
FX This study was supported by the National Institute of General Medical
   Sciences (grant no. R01GM120553 to D.V.), the National Institute of
   Allergy and Infectious Diseases (grant no. HHSN272201700059C to D.V.), a
   Pew Biomedical Scholars Award (D.V.), an Investigators in the
   Pathogenesis of Infectious Disease Award from the Burroughs Wellcome
   Fund (D.V.), the Bill & Melinda Gates Foundation (grant no. OPP1156262
   to D.V.), Fast Grants (to D.V.) and the University of Washington Arnold
   and Mabel Beckman Cryo-EM Center. We thank J. Bloom, A. Dingens and H.
   Chu for providing the COVID-19 convalescent serum sample and the study
   participant who contributed this serum.
CR Barad BA, 2015, NAT METHODS, V12, P943, DOI [10.1038/nmeth.3541, 10.1038/NMETH.3541]
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   Dang HV, 2019, NAT STRUCT MOL BIOL, V26, P980, DOI 10.1038/s41594-019-0308-9
   DiMaio F, 2015, NAT METHODS, V12, P361, DOI [10.1038/NMETH.3286, 10.1038/nmeth.3286]
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Ferlin A, 2014, J VIROL, V88, P13396, DOI 10.1128/JVI.01962-14
   Frenz B, 2019, STRUCTURE, V27, P134, DOI 10.1016/j.str.2018.09.006
   Goddard TD, 2007, J STRUCT BIOL, V157, P281, DOI 10.1016/j.jsb.2006.06.010
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Joyce M Gordon, 2020, bioRxiv, DOI 10.1101/2020.03.15.992883
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Ke Z., 2020, BIORXIV, DOI [10.1101/2020.06.27.174979, DOI 10.1101/2020.06.27.174979]
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Liu C, 2020, VIRAL ARCHITECTURE S, DOI [10.1101/2020.03.02.972927, DOI 10.1101/2020.03.02.972927]
   Liu Q, 2015, J VIROL, V89, P1838, DOI 10.1128/JVI.02277-14
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lyumkis D, 2013, SCIENCE, V342, P1484, DOI 10.1126/science.1245627
   Madu IG, 2009, J VIROL, V83, P7411, DOI 10.1128/JVI.00079-09
   Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Miroshnikov KA, 1998, PROTEIN ENG, V11, P329, DOI 10.1093/protein/11.4.329
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pancera M, 2014, NATURE, V514, P455, DOI 10.1038/nature13808
   Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Pruijssers AJ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107940
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Qiao H, 1998, J CELL BIOL, V141, P1335, DOI 10.1083/jcb.141.6.1335
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Roche S, 2007, SCIENCE, V315, P843, DOI 10.1126/science.1135710
   Roche S, 2006, SCIENCE, V313, P187, DOI 10.1126/science.1127683
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Scheres SHW, 2012, NAT METHODS, V9, P853, DOI 10.1038/nmeth.2115
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stewart-Jones GBE, 2018, P NATL ACAD SCI USA, V115, P12265, DOI 10.1073/pnas.1811980115
   Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010
   Tegunov D, 2019, NAT METHODS, V16, P1146, DOI 10.1038/s41592-019-0580-y
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Turoova B., 2020, BIORXIV, DOI [10.1101/2020.06.26.173476, DOI 10.1101/2020.06.26.173476]
   Walls A, 2017, PROTEIN SCI, V26, P113, DOI 10.1002/pro.3048
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang RYR, 2016, ELIFE, V5, DOI 10.7554/eLife.17219
   Wong JJW, 2016, P NATL ACAD SCI USA, V113, P1056, DOI 10.1073/pnas.1523303113
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiong XL, 2018, J VIROL, V92
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zivanov J, 2019, IUCRJ, V6, P5, DOI 10.1107/S205225251801463X
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 83
TC 5
Z9 5
U1 7
U2 7
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD OCT
PY 2020
VL 27
IS 10
BP 942
EP +
DI 10.1038/s41594-020-0483-8
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA NX9KU
UT WOS:000576021400010
PM 32753755
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Zhou, DRN
   Duyvesteyn, HME
   Chen, CP
   Huang, CG
   Chen, TH
   Shih, SR
   Lin, YC
   Cheng, CY
   Cheng, SH
   Huang, YC
   Linz, TY
   Ma, C
   Huo, JD
   Carrique, L
   Malinauskas, T
   Ruza, RR
   Shah, PNM
   Tan, TK
   Rijal, P
   Donat, RF
   Godwin, K
   Buttigieg, KR
   Tree, JA
   Radecke, J
   Paterson, NG
   Supasa, P
   Mongkolsapaya, J
   Screaton, GR
   Carroll, MW
   Gilbert-Jaramillo, J
   Knight, ML
   James, W
   Owens, RJ
   Naismith, JH
   Townsend, AR
   Fry, EE
   Zhao, YG
   Ren, JS
   Stuart, DI
   Huang, KYA
AF Zhou, Darning
   Duyvesteyn, Helen M. E.
   Chen, Cheng-Pin
   Huang, Chung-Guei
   Chen, Ting-Hua
   Shih, Shin-Ru
   Lin, Yi-Chun
   Cheng, Chien-Yu
   Cheng, Shu-Hsing
   Huang, Yhu-Chering
   Linz, Tzou-Yien
   Ma, Che
   Huo, Jiandong
   Carrique, Loic
   Malinauskas, Tomas
   Ruza, Reinis R.
   Shah, Pranav N. M.
   Tan, Tiong Kit
   Rijal, Pramila
   Donat, Robert F.
   Godwin, Kerry
   Buttigieg, Karen R.
   Tree, Julia A.
   Radecke, Julika
   Paterson, Neil G.
   Supasa, Piyada
   Mongkolsapaya, Juthathip
   Screaton, Gavin R.
   Carroll, Miles W.
   Gilbert-Jaramillo, Javier
   Knight, Michael L.
   James, William
   Owens, Raymond J.
   Naismith, James H.
   Townsend, Alain R.
   Fry, Elizabeth E.
   Zhao, Yuguang
   Ren, Jingshan
   Stuart, David, I
   Huang, Kuan-Ying A.
TI Structural basis for the neutralization of SARS-CoV-2 by an antibody
   from a convalescent patient
SO NATURE STRUCTURAL & MOLECULAR BIOLOGY
LA English
DT Article
ID NANOLITRE CRYSTALLIZATION EXPERIMENTS; CRYO-EM STRUCTURE; SARS
   CORONAVIRUS; POTENT NEUTRALIZATION; PROTEIN; SPIKE
AB The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently no approved therapies. We have isolated an antibody, EY6A, from an individual convalescing from COVID-19 and have shown that it neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds the receptor binding domain (RBD) of the viral spike glycoprotein tightly (K-D of 2 nM), and a 2.6-angstrom-resolution crystal structure of an RBD-EY6A Fab complex identifies the highly conserved epitope, away from the ACE2 receptor binding site. Residues within this footprint are key to stabilizing the pre-fusion spike. Cryo-EM analyses of the pre-fusion spike incubated with EY6A Fab reveal a complex of the intact spike trimer with three Fabs bound and two further multimeric forms comprising the destabilized spike attached to Fab. EY6A binds what is probably a major neutralizing epitope, making it a candidate therapeutic for COVID-19.
C1 [Zhou, Darning; Duyvesteyn, Helen M. E.; Huo, Jiandong; Carrique, Loic; Malinauskas, Tomas; Ruza, Reinis R.; Shah, Pranav N. M.; Owens, Raymond J.; Naismith, James H.; Fry, Elizabeth E.; Zhao, Yuguang; Ren, Jingshan; Stuart, David, I] Univ Oxford, Nuffield Dept Med, Div Struct Biol, Wellcome Ctr Human Genet, Oxford, England.
   [Chen, Cheng-Pin; Lin, Yi-Chun; Cheng, Chien-Yu; Cheng, Shu-Hsing] Minist Hlth & Welf, Taoyuan Gen Hosp, Dept Infect Dis, Taoyuan, Taiwan.
   [Chen, Cheng-Pin; Cheng, Chien-Yu] Natl Yang Ming Univ, Taipei, Taiwan.
   [Huang, Chung-Guei; Shih, Shin-Ru; Huang, Kuan-Ying A.] Chang Gung Univ, Coll Med, Res Ctr Emerging Viral Infect, Taoyuan, Taiwan.
   [Huang, Chung-Guei; Shih, Shin-Ru] Chang Gung Mem Hosp, Dept Lab Med, Taoyuan, Taiwan.
   [Chen, Ting-Hua; Ma, Che] Acad Sinica, Genom Res Ctr, Taipei, Taiwan.
   [Lin, Yi-Chun; Cheng, Shu-Hsing] Taipei Med Univ, Taipei, Taiwan.
   [Huang, Yhu-Chering; Linz, Tzou-Yien; Huang, Kuan-Ying A.] Chang Gung Mem Hosp, Dept Pediat, Div Pediat Infect Dis, Taoyuan, Taiwan.
   [Huo, Jiandong; Owens, Raymond J.; Naismith, James H.] Rosalind Franklin Inst, Harwell Campus, Didcot, Oxon, England.
   [Huo, Jiandong; Owens, Raymond J.; Naismith, James H.] Res Complex Harwell, Prot Prod UK, Harwell Sci & Innovat Campus, Didcot, Oxon, England.
   [Tan, Tiong Kit; Rijal, Pramila; Donat, Robert F.; Townsend, Alain R.] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England.
   [Rijal, Pramila; Townsend, Alain R.; Stuart, David, I] Univ Oxford, Chinese Acad Med Sci, Ctr Translat Immunol, Oxford Inst, Oxford, England.
   [Godwin, Kerry; Buttigieg, Karen R.; Tree, Julia A.; Carroll, Miles W.] Publ Hlth England, Natl Infect Serv, Salisbury, Wilts, England.
   [Radecke, Julika; Paterson, Neil G.; Stuart, David, I] Diamond Light Source Ltd, Harwell Sci & Innovat Campus, Didcot, Oxon, England.
   [Supasa, Piyada; Mongkolsapaya, Juthathip; Screaton, Gavin R.; Carroll, Miles W.] Univ Oxford, Wellcome Ctr Human Genet, Nuffield Dept Med, Oxford, England.
   [Mongkolsapaya, Juthathip] Mahidol Univ, Siriraj Hosp, Fac Med, Off Res & Dev,Dengue Hemorrhag Fever Res Unit, Bangkok, Thailand.
   [Gilbert-Jaramillo, Javier; Knight, Michael L.; James, William] Univ Oxford, William Dunn Sch Pathol, Oxford, England.
RP Stuart, DI (corresponding author), Univ Oxford, Nuffield Dept Med, Div Struct Biol, Wellcome Ctr Human Genet, Oxford, England.; Huang, KYA (corresponding author), Chang Gung Univ, Coll Med, Res Ctr Emerging Viral Infect, Taoyuan, Taiwan.; Huang, KYA (corresponding author), Chang Gung Mem Hosp, Dept Pediat, Div Pediat Infect Dis, Taoyuan, Taiwan.; Stuart, DI (corresponding author), Univ Oxford, Chinese Acad Med Sci, Ctr Translat Immunol, Oxford Inst, Oxford, England.; Stuart, DI (corresponding author), Diamond Light Source Ltd, Harwell Sci & Innovat Campus, Didcot, Oxon, England.
EM dave@strubi.ox.ac.uk; arthur1726@cgmh.org.tw
RI Malinauskas, Tomas/H-3133-2012; Naismith, James Henderson/AAB-8614-2020;
   Alex, Che/AAF-3280-2019; james, william/H-4289-2013
OI Malinauskas, Tomas/0000-0002-4847-5529; Naismith, James
   Henderson/0000-0001-6744-5061; Alex, Che/0000-0002-4741-2307; Chen,
   Cheng-Pin/0000-0002-0629-9790; Chen, Ting-Hua/0000-0001-8104-0562;
   Gilbert, Javier/0000-0003-1268-2304; Carrique, Loic/0000-0001-5332-8593;
   Shah, Pranav NM/0000-0003-1212-904X; james, william/0000-0002-2506-1198;
   Ren, Jingshan/0000-0003-4015-1404; Rijal, Pramila/0000-0002-9214-9851
FU Chang Gung Memorial HospitalChang Gung Memorial Hospital [BMRPE22];
   Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical
   Science (CIFMS), China [2018-I2M-2-002]; Wellcome TrustWellcome Trust
   [101122/Z/13/Z, 095541/A/11/Z, 090532/Z/09/Z]; Cancer Research UKCancer
   Research UK [C375/A17721, C20724/A14414, C20724/A26752]; UK Medical
   Research CouncilMedical Research Council UK (MRC) [MR/N00065X/1]; EPA
   Cephalosporin Fund; Rosalind Franklin Institute EPSRC grant
   [EP/S025243/1]; National Institute for Health Research Biomedical
   Research CentreNational Institute for Health Research (NIHR); Fast
   Grants (Mercatus Center); EPA Cephalosporin Early Career Teaching and
   Research Fellowship; Townsend-Jeantet Charitable Trust [1011770]
FX We acknowledge the BD FACSAria cell sorter service provided by the Core
   Instrument Center of Chang Gung University. The sorting of plasmablasts
   and production and characterization of human mAbs were supported by the
   Chang Gung Memorial Hospital (BMRPE22). This work was supported by the
   Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical
   Science (CIFMS), China (grant no. 2018-I2M-2-002) to D.I.S., G.R.S. and
   A.R.T., which supported P.R.; E.E.F., H.M.E.D. and J. Ren are supported
   by the Wellcome Trust (101122/Z/13/Z); Y.Z. by Cancer Research UK
   (C375/A17721); and D.I.S. and E.E.F. by the UK Medical Research Council
   (MR/N00065X/1); J.H. is supported by a grant from the EPA Cephalosporin
   Fund; and PPUK is funded by the Rosalind Franklin Institute EPSRC grant
   no. EP/S025243/1 (J.H.N. and R.J.O.). The National Institute for Health
   Research Biomedical Research Centre Funding Scheme supports G.R.S. We
   are also grateful for a Fast Grant from Fast Grants (Mercatus Center) to
   support the isolation of human monoclonal antibodies to SARS-2. G.R.S.
   is also supported as a Wellcome Trust Senior Investigator (grant no.
   095541/A/11/Z). T.K.T. is funded by an EPA Cephalosporin Early Career
   Teaching and Research Fellowship and the Townsend-Jeantet Charitable
   Trust (charity no. 1011770). T.M. is supported by Cancer Research UK
   grants C20724/A14414 and C20724/A26752 to C. Siebold. This is a
   contribution from the UK Instruct-ERIC Centre. The Wellcome Centre for
   Human Genetics is supported by the Wellcome Trust (grant no.
   090532/Z/09/Z). Virus used for the neutralization assays was a gift from
   J. Druce at the Doherty Centre, Melbourne, Australia. We acknowledge the
   Diamond Light Source for time on Beamline I03 under proposal mx19946 and
   for electron microscope time at the UK National Electron Bio-Imaging
   Centre (eBIC), proposal BI26983, both COVID-19 Rapid Access. D.I.S. is a
   Jenner Investigator. We thank the teams, especially at the Diamond Light
   Source and Department of Structural Biology, Oxford University, that
   have enabled work to continue during the pandemic.
CR [Anonymous], 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gong YQ, 2020, EPIDEMIOL INFECT, V148, DOI [10.1017/S0950268820000771, 10.1080/22221751.2020.1782271]
   Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556
   Grist N. R., 1966, DIAGNOSTIC METHODS C
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang KYA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00736-9
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI 10.1038/s41594-020-0469-6
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Lv Z, 2020, SCIENCE, V369, P1505, DOI 10.1126/science.abc5881
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Neffleship Joanne E., 2009, V498, P245, DOI 10.1007/978-1-59745-196-3_16
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Roy S., 2020, PREPRINT, DOI [10.1101/2020.04.20.052290V1, DOI 10.1101/2020.04.20.052290V1]
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Sievers F, 2018, PROTEIN SCI, V27, P135, DOI 10.1002/pro.3290
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808
   Walter TS, 2003, J APPL CRYSTALLOGR, V36, P308, DOI 10.1107/S0021889803001997
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Winter G, 2010, J APPL CRYSTALLOGR, V43, P186, DOI 10.1107/S0021889809045701
   Winter G, 2018, ACTA CRYSTALLOGR D, V74, P85, DOI 10.1107/S2059798317017235
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 50
TC 12
Z9 12
U1 9
U2 9
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1545-9993
EI 1545-9985
J9 NAT STRUCT MOL BIOL
JI Nat. Struct. Mol. Biol.
PD OCT
PY 2020
VL 27
IS 10
BP 950
EP +
DI 10.1038/s41594-020-0480-y
PG 22
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA NX9KU
UT WOS:000576021400011
PM 32737466
OA Bronze
DA 2021-01-01
ER

PT J
AU Di Lorenzo, G
   Buonerba, L
   Ingenito, C
   Crocetto, F
   Buonerba, C
   Libroia, A
   Sciarra, A
   Ragone, G
   Sanseverino, R
   Iaccarino, S
   Napodano, G
   Imbimbo, C
   Leo, E
   Kozlakidis, Z
   De Placido, S
AF Di Lorenzo, Giuseppe
   Buonerba, Luciana
   Ingenito, Concetta
   Crocetto, Felice
   Buonerba, Carlo
   Libroia, Annamaria
   Sciarra, Antonella
   Ragone, Gianluca
   Sanseverino, Roberto
   Iaccarino, Simona
   Napodano, Giorgio
   Imbimbo, Ciro
   Leo, Emilio
   Kozlakidis, Zisis
   De Placido, Sabino
TI Clinical Characteristics of Metastatic Prostate Cancer Patients Infected
   with COVID-19 in South Italy
SO ONCOLOGY
LA English
DT Article
DE Comorbidities; Coronavirus disease SARS-CoV-2; Drug interaction;
   Hormonal therapy; Prostate cancer
ID RISK
AB Background:To date, the clinical characteristics of coronavirus disease 19 (COVID-19)-infected urologic cancer patients are unknown.Methods:We have analyzed all patients with prostate cancer undergoing hormonal or chemotherapy treatment and receiving telephone and in person pre-triage between March 1 and 27, 2020, at the Tortora Hospital, Pagani, Italy.Results:Among 72 patients, 48 and 24 were hormone-sensitive (HS) and castration-resistant prostate cancer (CRPC), respectively; 0 HS and 2 (8.3%) CRPC (p< 0.05) were positive for COVID-19. Both patients were receiving LHRH agonist therapy, and 1 patient was receiving enzalutamide. Urgent intensive care unit admission was required due to clinical worsening. Blood tests showed severe lymphopenia, anemia, and an increase in platelets. Retroviral therapy, antibiotics, heparin, and chloroquine were prescribed at the beginning. One patient also received tocilizumab as a salvage treatment. After 3 weeks of hospitalization, the patients were discharged from the hospital. Both patients suffered from an aggressive COVID-19 course due to concomitant comorbidities.Conclusions:Investigating whether hormonal therapy, especially in advanced disease, acts as a protective factor or a risk factor during COVID-19 could be useful.
C1 [Di Lorenzo, Giuseppe; Buonerba, Luciana; Ingenito, Concetta; Libroia, Annamaria; Sciarra, Antonella; Ragone, Gianluca; Iaccarino, Simona; Leo, Emilio] ASL Salerno, Andrea Tortora Hosp, Oncol Unit, IT-84016 Pagani, Italy.
   [Di Lorenzo, Giuseppe] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, Campobasso, Italy.
   [Crocetto, Felice; Imbimbo, Ciro] Univ Naples Federico II, Dept Neurosci Sci Reprod & Odontostomatol, Naples, Italy.
   [Buonerba, Carlo; De Placido, Sabino] Univ Federico II Naples, Dept Clin Med & Surg, Naples, Italy.
   [Sanseverino, Roberto; Napodano, Giorgio] Umberto I Hosp, Urol Div, Nocera Inferiore, Italy.
   [Kozlakidis, Zisis] WHO, Int Agcy Res Canc, Lyon, France.
RP Di Lorenzo, G (corresponding author), ASL Salerno, Andrea Tortora Hosp, Oncol Unit, IT-84016 Pagani, Italy.
EM direttoreuocpagani@gmail.com
OI Crocetto, Felice/0000-0002-4315-7660; Kozlakidis,
   Zisis/0000-0002-3836-7209
CR Alyamani M, 2020, ANN ONCOL, V31, P369, DOI 10.1016/j.annonc.2019.12.002
   Association of Italian Medical Oncology (AIOM), GUID PROST CANC
   Colomba E, 2020, EUR J CANCER, V129, P117, DOI 10.1016/j.ejca.2020.01.017
   Del Pinto R, 2019, HIGH BLOOD PRESS CAR, V26, P27, DOI 10.1007/s40292-018-0290-z
   Di Lorenzo G, 2020, EUR UROL
   Di Lorenzo G, 2020, CRIT REV ONCOL HEMAT, V152, DOI [10.1016/j.critrevonc.2020.102901, 10.1016/j.critrevonc.2020.102991]
   Di Lorenzo G, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00140
   Gillessen S, 2020, EUR UROL, V77, P667, DOI 10.1016/j.eururo.2020.03.026
   Ingenito C, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00189
   LUYAO GL, 2018, J CLIN ONCOL S, V36
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Nhean S, 2018, AIDS, V32, P2640, DOI 10.1097/QAD.0000000000002019
   Rupp MRG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00794
   Small EJ, 2019, ANN ONCOL, V30, P1813, DOI 10.1093/annonc/mdz397
   Tatsi C, 2018, PEDIATR RES, V83, P431, DOI 10.1038/pr.2017.278
   Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0
NR 16
TC 1
Z9 1
U1 2
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-2414
EI 1423-0232
J9 ONCOLOGY-BASEL
JI Oncology
PD OCT
PY 2020
VL 98
IS 10
BP 743
EP 747
DI 10.1159/000509434
PG 5
WC Oncology
SC Oncology
GA NX9SW
UT WOS:000576042400010
PM 32570240
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Singleton, MN
   Soffin, EM
AF Singleton, Michael N.
   Soffin, Ellen M.
TI Daring discourse: are we ready to recommend neuraxial anesthesia and
   peripheral nerve blocks during the COVID-19 pandemic? A pro-con
SO REGIONAL ANESTHESIA AND PAIN MEDICINE
LA English
DT Article
ID REGIONAL ANESTHESIA; ANALGESIA; SOCIETY; PATIENT
AB The recent joint statement from the American Society of Regional Anesthesia and Pain Medicine (ASRA) and the European Society of Regional Anesthesia and Pain Therapy (ESRA) recommends neuraxial and peripheral nerve blocks for patients with coronavirus disease 2019 (COVID-2019) illness. The benefits of regional anesthetic and analgesic techniques on patient outcomes and healthcare systems are evident. Regional techniques are now additionally promoted as a mechanism to reduce aerosolizing procedures. However, caring for patients with COVID-19 illness requires rapid redefinition of risks and benefits-both for patients and practitioners. These should be fully considered within the context of available evidence and expert opinion. In this Daring Discourse, we present two opposing perspectives on adopting the ASRA/ESRA recommendation. Areas of controversy in the literature and opportunities for research to address knowledge gaps are highlighted. We hope this will stimulate dialogue and research into the optimal techniques to improve patient outcomes and ensure practitioner safety during the pandemic.
C1 [Singleton, Michael N.; Soffin, Ellen M.] Hosp Special Surg, Dept Anesthesiol Crit Care & Pain Management, New York, NY 10021 USA.
RP Soffin, EM (corresponding author), Hosp Special Surg, Dept Anesthesiol Crit Care & Pain Management, New York, NY 10021 USA.
EM soffine@hss.edu
CR Ahn EJ, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029245
   Altiparmak Basak, 2021, Reg Anesth Pain Med, V46, P91, DOI 10.1136/rapm-2020-101477
   Amer Soc Anesthesiologists Task Fo, 2016, ANESTHESIOLOGY, V124, P270, DOI 10.1097/ALN.0000000000000935
   Bikdeli B., 2020, J AM COLL CARDIOL
   Centers for Disease Control and Prevention, 2020, CHAR HLTH CAR PERS C
   Chen R, 2020, CAN J ANESTH, V67, P655, DOI 10.1007/s12630-020-01630-7
   Fanaroff AC, 2019, JAMA-J AM MED ASSOC, V321, P1069, DOI 10.1001/jama.2019.1122
   Feng GZ, 2020, CASE STUD THERM ENG, V21, DOI 10.1016/j.csite.2020.100685
   Heinzerling A, 2020, MMWR-MORBID MORTAL W, V69, P472, DOI 10.15585/mmwr.mm6915e5
   Henry BM, CLIN CHEM LAB MED
   Hui DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050845
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Lie SA, 2020, CAN J ANESTH, V67, P885, DOI 10.1007/s12630-020-01637-0
   Memtsoudis SG, 2019, BRIT J ANAESTH, V123, P269, DOI 10.1016/j.bja.2019.05.042
   Neal JM, 2012, REGION ANESTH PAIN M, V37, P16, DOI 10.1097/AAP.0b013e31822e0d8a
   Nicas M, 2005, J OCCUP ENVIRON HYG, V2, P143, DOI 10.1080/15459620590918466
   Raboud J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010717
   Rosenberg PH, 2004, REGION ANESTH PAIN M, V29, P564, DOI 10.1016/j.rapm.2004.08.003
   Schulz-Stubner S, 2005, CRIT CARE MED, V33, P1400, DOI 10.1097/01.CCM.0000165843.39713.Ae
   Schulz-Stubner S, 2006, CURR OPIN ANESTHESIO, V19, P538, DOI 10.1097/01.aco.0000245281.07411.f7
   Smith LM, 2017, ANESTH ANALG, V125, P1931, DOI 10.1213/ANE.0000000000002069
   Stundner O, 2012, REGION ANESTH PAIN M, V37, P537, DOI 10.1097/AAP.0b013e3182625f1a
   Uppal V, 2020, PRACTICE RECOMMENDAT
   Wedel DJ, 2006, REGION ANESTH PAIN M, V31, P324, DOI 10.1016/j.rapm.2006.04.003
   Yao W, 2020, BRIT J ANAESTH, V12, P30203
   Zhong Q, 2020, BRIT J ANAESTH, V124, P670, DOI 10.1016/j.bja.2020.03.007
NR 26
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1098-7339
EI 1532-8651
J9 REGION ANESTH PAIN M
JI Region. Anesth. Pain Med.
PD OCT
PY 2020
VL 45
IS 10
BP 831
EP 834
DI 10.1136/rapm-2020-101653
PG 4
WC Anesthesiology
SC Anesthesiology
GA NY3LZ
UT WOS:000576296800016
PM 32447292
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gudipati, S
   Brar, I
   Murray, S
   McKinnon, JE
   Yared, N
   Markowitz, N
AF Gudipati, Smitha
   Brar, Indira
   Murray, Shannon
   McKinnon, John E.
   Yared, Nicholas
   Markowitz, Norman
TI Descriptive Analysis of Patients Living With HIV Affected by COVID-19
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; COVID-19; SARS-CoV-2; cART; tenofovir
AB Background: COVID-19 disease has spread globally and was declared a pandemic on March 11, 2020, by the World Health Organization. On March 10, the State of Michigan confirmed its first 2 cases of COVID-19, and the number of confirmed cases has reached 47,182 as of May 11, 2020, with 4555 deaths. Setting: Currently, little is known if patients living with HIV (PLWH) are at a higher risk of severe COVID-19 or if their antiretrovirals are protective. This study presents epidemiologic and clinical features of COVID-19 infected PLWH in Detroit, Michigan. Methods: This is a case series that included 14 PLWH with laboratory-confirmed COVID-19 infection who were evaluated at Henry Ford Hospital in Detroit, Michigan, between March 20, 2020, and April 30, 2020. Results: Fourteen PLWH were diagnosed with COVID-19. Twelve patients were men and 2 were women; 13 patients were virally suppressed. Eight patients were hospitalized, and 6 patients were told to self-quarantine at home after their diagnoses. Three patients who were admitted expired during their hospital stay. No patient required bilevel positive airway pressure or nebulizer use in the emergency department, and none developed acute respiratory distress syndrome, pulmonary embolism, deep venous thrombosis, or a cytokine storm while on therapy for COVID-19. Conclusion: Although the clinical spectrum of COVID-19 among PLWH cannot be fully ascertained by this report, it adds to the data that suggest that HIV-positive patients with SARS-CoV-2 infection are not at a greater risk of severe disease or death as compared to HIV-negative patients.
C1 [Gudipati, Smitha; Brar, Indira; Murray, Shannon; McKinnon, John E.; Yared, Nicholas; Markowitz, Norman] Henry Ford Hosp, Dept Infect Dis, Detroit, MI 48202 USA.
RP Gudipati, S (corresponding author), 2799 W Grand Blvd, Detroit, MI 48202 USA.
EM Sgudipa2@hfhs.org
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   del Amo J, 2020, ANN INTERN MED, V173, P536, DOI 10.7326/M20-3689
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   GISAID Initiative, 2020, GEN EP HCOV 19 GISAI
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z
   Hladik F, 2015, ELIFE, V4, DOI 10.7554/eLife.04525
   Jones R, 2020, LANCET HIV, V7, pE383, DOI 10.1016/S2352-3018(20)30139-9
   KWON H, 2020, MBIO, V11, DOI DOI 10.3389/FPSYG.2020.01114
   Melchjorsen J, 2011, JAIDS-J ACQ IMM DEF, V57, P265, DOI 10.1097/QAI.0b013e3182185276
   Muema DM, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01529-6
   Suleyman G, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.12270
   Vizcarra P, 2020, LANCET HIV, P30163
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 16
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2020
VL 85
IS 2
BP 123
EP 126
DI 10.1097/QAI.0000000000002450
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA NX8XS
UT WOS:000575987400005
PM 32675771
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Gao, GJ
   Wang, AB
   Wang, S
   Qian, F
   Chen, ML
   Yu, FT
   Zhang, J
   Wang, XD
   Ma, XY
   Zhao, TW
   Zhang, FJ
   Chen, ZH
AF Gao, Guiju
   Wang, Aibin
   Wang, Sa
   Qian, Fang
   Chen, Meiling
   Yu, Fengting
   Zhang, Ju
   Wang, Xudong
   Ma, Xiaoyang
   Zhao, Tianwei
   Zhang, Fujie
   Chen, Zhihai
TI Brief Report: Retrospective Evaluation on the Efficacy of
   Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE COVID-19; efficacy; lopinavir; ritonavir; chloroquine
ID CORONAVIRUS; SARS
AB Background: The effectiveness of lopinavir/ritonavir (LPV/r) and chloroquine treatment for COVID-19 has not been verified. Methods: We conducted a retrospective study to summarize the clinical practices of nonsevere patients with COVID-19 receiving the standard care, LPV/r or chloroquine in Beijing Ditan Hospital from January 20 to March 26, 2020. The main outcome measurements include the changes of cycle threshold values of open reading frame 1 ab (ORF1ab) and nucleocapsid (N) genes by reverse transcriptase-polymerase chain reaction assay from day 1 to 7 after admission for patients receiving standard care or after treatment being initiated for patients receiving either LPV/r or chloroquine. The proportion of developing severe illness, fever duration and the time from symptom onset to chest computer tomography improvement, and negative conversion of nucleic acid were compared. Results: Of the 129 patients included in the study, 59 received the standard care, 51 received LPV/r, and 19 received chloroquine. The demographics and baseline characteristics were comparable among the 3 groups. The median duration of fever, median time from symptom onset to chest computer tomography improvement, and negative conversion of the nucleic acid were similar among the 3 groups. The median increase in cycle threshold values of N and ORF1ab gene for patients receiving LPV/r or chloroquine or the standard care during the treatment course was 7.0 and 8.5, 8.0, and 7.6, 5.0, and 4.0, respectively. These figures were not found significantly different among the 3 groups. Conclusions: Antiviral therapy using LPV/r or chloroquine seemed not to improve the prognosis or shorten the clinical course of COVID-19.
C1 [Gao, Guiju; Wang, Aibin; Wang, Sa; Qian, Fang; Yu, Fengting; Zhao, Tianwei; Zhang, Fujie; Chen, Zhihai] Capital Med Univ, Beijing Ditan Hosp, Clin & Res Ctr Infect Dis, 8 Jingshun Dongjie, Beijing 100015, Peoples R China.
   [Chen, Meiling] Capital Med Univ, Beijing Ditan Hosp, Med Record Stat Dept, Beijing, Peoples R China.
   [Zhang, Ju] Capital Med Univ, Beijing Ditan Hosp, Inst Infect Dis, Beijing Key Lab Emerging Infect Dis, Beijing, Peoples R China.
   [Wang, Xudong] Capital Med Univ, Beijing Ditan Hosp, Surg Dept, Beijing, Peoples R China.
   [Ma, Xiaoyang] Capital Med Univ, Beijing Ditan Hosp, Neurol Dept, Beijing, Peoples R China.
RP Zhang, FJ (corresponding author), Capital Med Univ, Beijing Ditan Hosp, Clin & Res Ctr Infect Dis, 8 Jingshun Dongjie, Beijing 100015, Peoples R China.
EM treatment@chinaaids.cn
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   [陈军 Chen Jun], 2020, [中华传染病杂志, Chinese Journal of Infections Diseases], V38, P86
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI DOI 10.1101/2020.03.22.20040758V3
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   National Health Commission of the People's Republic of China, 2020, TREATM PROT PAT NOV
   Toumi M, 2020, J MARK ACCESS HLTH P, V8
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 2020, COR DIS COVID 19 SIT
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 18
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2020
VL 85
IS 2
BP 239
EP 243
DI 10.1097/QAI.0000000000002452
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA NX8XS
UT WOS:000575987400020
PM 32740371
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Kumar, V
   Singh, SB
   Singh, S
AF Kumar, Vijay
   Singh, Shyam Babu
   Singh, Simranjeet
TI COVID-19: Environment concern and impact of Indian medicinal system
SO JOURNAL OF ENVIRONMENTAL CHEMICAL ENGINEERING
LA English
DT Article
DE Coronavirus; Environment concern of COVID-19; Traditional medicines;
   Immunomodulatory herbs; Ayurveda
ID TOXICITY; BIODEGRADATION; INFECTION; AYURVEDA; PLANTS
AB The COVID-19 outbreak has came in existence in late December 2019 at Wuhan, China. It is declared as an epidemic by WHO. The rationale of this study is to provide the details regarding prevention, environment concern, social economic consequences, and medicines for COVID-19. Social distancing, screening, lockdown, use of mask and application of sanitizer or soap at regular time interval is the best prevention against COVID-19. The "oral-feces" transmission of COVID-19 is threat to environment. Improper disposal of medical/biomedical and human waste may harm the total environment. Nitrifying-enriched activated sludge i.e. NAS approach can play important role to clean the environment compartments like sludge and waste. COVID-19 has shown impact on social and economic life, but there is no alternate until the drug discovery. In medicine or treatment of COVID-19 point of views, an integrated approach between modern and traditional medicine system may ensure an early prevention of further viral spread. Based on the symptoms of COVID-19, list of herbs and drugs of Indian Medicine System has been searched and reported. To develop the potential drug against COVID-19, the detailed experimentation and clinical trials to be performed for future prospective.
C1 [Kumar, Vijay] Reg Ayurveda Res Inst Drug Dev, Dept Chem, Gwalior 474009, Madhya Pradesh, India.
   [Singh, Shyam Babu] Reg Ayurveda Res Inst Drug Dev, Dept Ayurveda, Gwalior 474009, Madhya Pradesh, India.
   [Singh, Simranjeet] Lovely Profess Univ, Dept Biotechnol, Phagwara 144002, Punjab, India.
   [Singh, Simranjeet] Punjab Biotechnol Incubators, Mohali 160059, Punjab, India.
   [Singh, Simranjeet] Reg Adv Water Testing Lab, Mohali 160059, Punjab, India.
RP Kumar, V (corresponding author), Reg Ayurveda Res Inst Drug Dev, Dept Chem, Gwalior 474009, Madhya Pradesh, India.
EM vijaychem99@gmail.com
RI Kumar, Vijay/I-3983-2013
OI Kumar, Vijay/0000-0002-5413-2856; Singh, Simranjeet/0000-0003-0486-4802
CR Aggarwal BB, 2011, CURR DRUG TARGETS, V12, P1595
   Akoachere J F T K, 2002, East Afr Med J, V79, P588
   Alam G, 2002, PLANTA MED, V68, P1047, DOI 10.1055/s-2002-35650
   Ali I, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138861
   Azami H, 2012, IRAN J ENVIRON HEALT, V9, DOI 10.1186/1735-2746-9-30
   BECK BR, 2020, BIORXIV, DOI DOI 10.1101/2020.01.31.929547
   Blanchard JE, 2004, CHEM BIOL, V11, P1445, DOI 10.1016/j.chembiol.2004.08.011
   Chang JS, 2013, J ETHNOPHARMACOL, V145, P146, DOI 10.1016/j.jep.2012.10.043
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Contini A., 2020, VIRTUAL SCREENING FD, DOI [10.26434/chemrxiv., DOI 10.26434/CHEMRXIV]
   Coon JT, 2004, PLANTA MED, V70, P293, DOI 10.1055/s-2004-818938
   Diao B., 2020, REDUCTION FUNCTIONAL, DOI [10.1101/2020.02.18.20024364, DOI 10.1101/2020.02.18.20024364]
   El Din AMS, 1998, DESALINATION, V115, P145
   Fan W, 2020, RESEARCHGATE, DOI [10.13140/RG.2.2.31786.98248, DOI 10.13140/RG.2.2.31786.98248]
   Feketea G, 2017, FOOD CHEM, V230, P578, DOI 10.1016/j.foodchem.2017.03.043
   Fiore C, 2008, PHYTOTHER RES, V22, P141, DOI 10.1002/ptr.2295
   Galani Varsha J, 2010, Int J Ayurveda Res, V1, P247, DOI 10.4103/0974-7788.76790
   Gostic Katelyn M, 2020, medRxiv, DOI 10.1101/2020.01.28.20019224
   Guivarc'h M, 2017, J ENDODONT, V43, P16, DOI 10.1016/j.joen.2016.09.023
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Heller L, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.138919
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jahangiri M, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138872
   Jaiswal Y, 2016, J ETHNOPHARMACOL, V194, P245, DOI 10.1016/j.jep.2016.06.052
   John KMM, 2015, SAUDI J BIOL SCI, V22, P191, DOI 10.1016/j.sjbs.2014.09.009
   Joshi VK, 2017, J ETHNOPHARMACOL, V197, P32, DOI 10.1016/j.jep.2016.07.030
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Kampf G., 2020, INFECT PREV PRACT, V2, DOI [10.1016/j.infpip.2020.100044, DOI 10.1016/J.INFPIP.2020.100044]
   Kaur S, 2017, FRONT CHEM, V5, DOI 10.3389/fchem.2017.00043
   Kim SW, 2020, BRAIN BEHAV IMMUN, V87, P4, DOI 10.1016/j.bbi.2020.03.025
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Kumar D, 2012, J MICROBIOL IMMUNOL, V45, P165, DOI 10.1016/j.jmii.2011.09.030
   Kumar V, 2018, INDIAN J PHARM SCI, V80, P1151, DOI 10.4172/pharmaceutical-sciences.1000467
   Kumar V, 2020, MINI-REV ORG CHEM, V17, P277, DOI 10.2174/1570193X166661901219161757
   Kumar V, 2019, BIOCATAL AGR BIOTECH, V22, DOI 10.1016/j.bcab.2019.101405
   Kumar V, 2019, BIOCATAL AGR BIOTECH, V21, DOI 10.1016/j.bcab.2019.101359
   Kumar V, 2019, BIOCATAL AGR BIOTECH, V20, DOI 10.1016/j.bcab.2019.101222
   Kumar V, 2019, CURR TRADIT MED, V5, P270, DOI 10.2174/2215083805666190521103308
   Kumar V, 2019, J ENVIRON CHEM ENG, V7, DOI 10.1016/j.jece.2019.103094
   Kumar V, 2019, BIOCATAL AGR BIOTECH, V18, DOI 10.1016/j.bcab.2019.01.056
   Kumar Vijay, 2017, Journal of Chemical Biology, V10, P179, DOI 10.1007/s12154-017-0174-z
   Kumar V, 2015, 3 BIOTECH, V6, DOI 10.1007/s13205-015-0313-6
   Kumar V, 2015, 3 BIOTECH, V5, P791, DOI 10.1007/s13205-015-0281-x
   Kumar V, 2015, ARAB J CHEM, V8, P624, DOI 10.1016/j.arabjc.2014.12.007
   Kumar V, 2015, B ENVIRON CONTAM TOX, V94, P807, DOI 10.1007/s00128-015-1523-7
   Liou CJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00635
   Liu JT, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138513
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Ma YL, 2020, SCI TOTAL ENVIRON, V724, DOI 10.1016/j.scitotenv.2020.138226
   Madhuri D., 2017, INT J CURR RES, V9, P58472, DOI [10.4103/Int.J. Curr.Res_208_14., DOI 10.4103/INT.J.CURR.RES_208_14]
   Nikhat S, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138859
   Nunez-Delgado A, 2020, SCI TOTAL ENVIRON, V727, DOI 10.1016/j.scitotenv.2020.138647
   Ochwoto M, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-017-0174-3
   Olivieri F, 1996, FEBS LETT, V396, P132, DOI 10.1016/0014-5793(96)01089-7
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Panda A.K., 2020, J AYURVEDA INTEGR ME, V5, P98
   Parasuraman Subramani, 2014, Pharmacogn Rev, V8, P73, DOI 10.4103/0973-7847.134229
   Pedersen A, 2010, PSYCHOSOM MED, V72, P823, DOI 10.1097/PSY.0b013e3181f1d003
   Premila M.S., 2006, AYURVEDIC HERBS CLIN
   Rabenau HF, 2005, J HOSP INFECT, V61, P107, DOI 10.1016/j.jhin.2004.12.023
   Rajkumar RP, 2020, BRAIN BEHAV IMMUN, V87, P8, DOI 10.1016/j.bbi.2020.04.056
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Rutala WA, 2008, GUIDELINE DISINFECTI
   Saadat S, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138870
   Sadeghi F, 2017, PETROL SCI TECHNOL, V35, P222, DOI 10.1080/10916466.2011.572108
   Sepehri A, 2018, CHEM ENG PROCESS, V128, P10, DOI 10.1016/j.cep.2018.04.006
   Shariati FP, 2013, BIORESOURCE TECHNOL, V140, P357, DOI 10.1016/j.biortech.2013.04.099
   Sharma S, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138878
   Sidhu GK, 2019, CRIT REV ENV SCI TEC, V49, P1135, DOI 10.1080/10643389.2019.1565554
   Singh S, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030433
   Singh S, 2019, BIOCATAL AGR BIOTECH, V20, DOI 10.1016/j.bcab.2019.101196
   Singh S, 2019, J ENVIRON CHEM ENG, V7, DOI 10.1016/j.jece.2019.103098
   Singh S, 2019, BIOCATAL AGRIC BIOTE, V17, P665, DOI 10.1016/j.bcab.2019.01.035
   Singh S, 2018, ENVIRON CHEM LETT, V16, P211, DOI 10.1007/s10311-017-0665-8
   Singh S, 2017, 3 BIOTECH, V7, DOI 10.1007/s13205-017-0900-9
   Singh S, 2016, ENVIRON CHEM LETT, V14, P317, DOI 10.1007/s10311-016-0566-2
   Srivastava RAK, 2015, NUTR METAB, V12, DOI 10.1186/s12986-015-0018-1
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Tkaczyk A, 2020, SCI TOTAL ENVIRON, V717, DOI 10.1016/j.scitotenv.2020.137222
   Tobias A, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138539
   Tosepu R, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138436
   Tripathi J S, 1999, Anc Sci Life, V19, P59
   Tsai YC, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030366
   Tyan K, 2018, AM J INFECT CONTROL, V46, P1254, DOI 10.1016/j.ajic.2018.04.223
   Vaghasiya Y, 2009, J HERB MED TOXICOL, V3, P161
   Vellingiri B., 2020, COVID 19 PROMISING C, DOI [10.1016/j.scitotenv.2020.138277, DOI 10.1016/J.SCITOTENV.2020.138277]
   Vijay Kumar, 2014, Journal of Biodiversity and Environmental Sciences (JBES), V5, P149
   Vimalanathan S, 2009, PHARM BIOL, V47, P422, DOI 10.1080/13880200902800196
   Welton T, 2015, P ROY SOC A-MATH PHY, V471, DOI 10.1098/rspa.2015.0502
   World Health Organization, 2020, 40 WHO
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xie JG, 2020, SCI TOTAL ENVIRON, V724, DOI 10.1016/j.scitotenv.2020.138201
   Zambrano-Monserrate MA, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138813
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
NR 96
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
EI 2213-3437
J9 J ENVIRON CHEM ENG
JI J. Environ. Chem. Eng.
PD OCT
PY 2020
VL 8
IS 5
AR 104144
DI 10.1016/j.jece.2020.104144
PG 8
WC Engineering, Environmental; Engineering, Chemical
SC Engineering
GA NX2MS
UT WOS:000575549400004
DA 2021-01-01
ER

PT J
AU Sut, BB
AF Sut, Burcu Biterge
TI Molecular profiling of immune cell-enriched Severe Acute Respiratory
   Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13
SO LIFE SCIENCES
LA English
DT Article
DE COVID-19; Coronavirus; SARS-CoV-2 interacting proteins; Ubiquitin
   Specific Peptidase 13; USP13
ID CANCER; PATHWAY; TARGETS; LIGASES
AB Aims: Coronavirus disease 2019 (COVID-19), which is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is a major health concern worldwide. Due to the lack of specific medication and vaccination, drug-repurposing attempts has emerged as a promising approach and identified several human proteins interacting with the virus. This study aims to provide a comprehensive molecular profiling of the immune cell-enriched SARS-CoV-2 interacting protein USP13.
   Materials and methods: The list of immune cell-enriched proteins interacting with SARS-CoV-2 was retrieved from The Human Protein Atlas. Genomic alterations were identified using cBioPortal. Survival analysis was performed via Kaplan-Meier Plotter. Analyses of protein expression and tumor infiltration levels were carried out by TIMER.
   Key findings: 14 human proteins that interact with SARS-CoV-2 were enriched in immune cells. Among these proteins, USP13 had the highest frequency of genomic alterations. Higher USP13 levels were correlated with improved survival in breast and lung cancers, while resulting in poor prognosis in ovarian and gastric cancers. Furthermore, copy number variations of USP13 significantly affected the infiltration levels of distinct subtypes of immune cells in head & neck, lung, ovarian and stomach cancers. Although our results suggested a tumor suppressor role for USP13 in lung cancer, in other cancers, its role seemed to be context-dependent.
   Significance: It is critical to identify and characterize human proteins that interact with SARS-CoV-2 in order to have a better understanding of the disease and to develop better therapies/vaccines. Here, we provided a comprehensive molecular profiling the immune cell-enriched SARS-CoV-2 interacting protein USP13, which will be useful for future studies.
C1 [Sut, Burcu Biterge] Nigde Omer Halisdemir Univ, Fac Med, Dept Med Biol, Nigde, Turkey.
RP Sut, BB (corresponding author), Nigde Omer Halisdemir Univ, Main Campus, TR-51240 Nigde, Turkey.
EM bbitergesut@ohu.edu.tr
CR Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   D'Arcy P, 2012, INT J BIOCHEM CELL B, V44, P1729, DOI 10.1016/j.biocel.2012.07.011
   Fang XG, 2017, J EXP MED, V214, P245, DOI 10.1084/jem.20151673
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hendry S, 2017, ADV ANAT PATHOL, V24, P311, DOI 10.1097/PAP.0000000000000161
   Holm CK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10680
   Hwang WT, 2012, GYNECOL ONCOL, V124, P192, DOI 10.1016/j.ygyno.2011.09.039
   Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581
   Kaushal K, 2018, DRUG DISCOV TODAY, V23, P1974, DOI 10.1016/j.drudis.2018.05.035
   Kondo T, 2012, BIOCHEM BIOPH RES CO, V422, P501, DOI 10.1016/j.bbrc.2012.05.028
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li ST, 2011, IMMUNITY, V35, P426, DOI 10.1016/j.immuni.2011.06.014
   Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Mahon C, 2014, BIOMOLECULES, V4, P897, DOI 10.3390/biom4040897
   Man XJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1262-4
   Milne K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006412
   Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y
   Paul S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01124
   Pollara G, 2005, INT J EXP PATHOL, V86, P187, DOI 10.1111/j.0959-9673.2005.00440.x
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Qu Z, 2019, CANCER MANAG RES, V11, P9175, DOI 10.2147/CMAR.S186829
   Remark R, 2015, AM J RESP CRIT CARE, V191, P377, DOI 10.1164/rccm.201409-1671PP
   Russell Sm, 2013, Head Neck Oncol, V5, P24
   Sun H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15534
   Tan AHM, 2008, J BIOL CHEM, V283, P128, DOI 10.1074/jbc.M707693200
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Wan S., 2020, CHARACTERISTICS LYMP, DOI [10.20021832, DOI 10.1101/2020.02.10.20021832, 10.1101/2020.02. 10.20021832, 10.1101/2020.02.10.20021832]
   World Health Organization, 2020, 151 WHO
   World Health Organization, 2020, NAM COR DIS COVID 19
   Wu Y, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108831
   Yang Y., 2020, EXUBERANT ELEVATION, DOI [10.1101/2020.03.02.20029975, DOI 10.1101/2020.03.02.20029975]
   Yeh HM, 2013, J IMMUNOL, V191, P3328, DOI 10.4049/jimmunol.1300225
   Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874
   Zhang SZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02693-9
   Zhao XS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1421
   Zheng N, 2017, ANNU REV BIOCHEM, V86, P129, DOI 10.1146/annurev-biochem-060815-014922
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845
NR 41
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD OCT 1
PY 2020
VL 258
AR 118170
DI 10.1016/j.lfs.2020.118170
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NW7AV
UT WOS:000575169900011
PM 32735883
OA Green Published
DA 2021-01-01
ER

PT J
AU Dubbke-Laule, A
   Gnauck, M
   Straub, R
   Berthold, F
   Jenssen, C
AF Dubbke-Laule, Alexandra
   Gnauck, Manuela
   Straub, Ralf
   Berthold, Frank
   Jenssen, Christian
TI Quadruple negative SARS-CoV-2-PCR: still COVID-19 pneumonia!
SO DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
LA German
DT Article
DE COVID-19; SARS-CoV-2; computed tomography; PCR; seroconversion
AB Medical history and clinical findings A 78-year-old man fell ill with weakness, coughing and fever 19 days after a cruise in early April 2020 and was admitted 4 days later with increasing shortness of breath.
   Examination and diagnosis On admission, the patient had subfebrile temperatures, exercise dyspnea, and right-basal rales. CRP was moderately elevated and oxygen saturation was slightly reduced. Thoracic CT showed bilateral ground-glass infiltrates. Immediately after the cruise a nasopharyngeal swab was negative for SARS-CoV-2.
   Therapy and course Due to the fact that the patient's asymptomatic wife had been tested positive for SARS-CoV-2 immediately after returning from the cruise, we suspected COVID-19 disease and admitted the patient to our isolation ward. Two nasopharyngeal swabs and bronchial lavage yielded negative results for SARS-CoV-2. Finally, suspected COVID-19 diagnosis was verified serologically.
   Conclusion In case of a high degree of clinical suspicion in combination with typical findings of thoracic imaging, the suspected diagnosis COVID-19 disease should be maintained even in case of multiple negative SARS-CoV-2-PCR. Seroconversion occurs a few days to 2 weeks after the onset of symptoms and can be used to confirm the diagnosis.
C1 [Dubbke-Laule, Alexandra; Gnauck, Manuela; Jenssen, Christian] Krankenhaus Mark Oderland, Klin Innere Med, Protzeler Chaussee 5, D-15344 Strausberg, Germany.
   [Straub, Ralf] Praxis Radiol, Strausberg, Germany.
   [Berthold, Frank] IMD Lab Oderland, Frankfurt, Germany.
RP Jenssen, C (corresponding author), Krankenhaus Mark Oderland, Klin Innere Med, Protzeler Chaussee 5, D-15344 Strausberg, Germany.
EM c.jenssen@khmol.de
CR Ai T., 2020, RADIOLOGY
   ander Heiden M, 2020, EPID B, V17, P10, DOI [10.25646/6692.2, DOI 10.25646/6692.2]
   Hao WD, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101627
   Hornuss D, 2020, DTSCH MED WSCHR
   Kim H, 2020, RADIOLOGY
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lechien JR, 2020, J INTERN MED, V288, P335, DOI 10.1111/joim.13089
   Li Q, 2020, INFECT DIS THER, V9, P823, DOI 10.1007/s40121-020-00332-3
   Lippi G., 2020, CLIN CHEM LAB MED
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Long CQ, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108961
   Mallapaty Smriti, 2020, Nature, V580, P18, DOI 10.1038/d41586-020-00885-w
   Mizumoto K, 2020, INFECT DIS MODEL, V5, P264, DOI 10.1016/j.idm.2020.02.003
   Padoan A, 2020, CLIN CHIM ACTA, V507, P164, DOI 10.1016/j.cca.2020.04.026
   Stadnytskyi V, 2020, P NATL ACAD SCI USA, V117, P11875, DOI 10.1073/pnas.2006874117
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu J, 2020, CLIN INFECT DIS
   Wu Z, 2020, JAMA
   Zhang XY, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018-020-01698-3
NR 19
TC 0
Z9 0
U1 4
U2 4
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0012-0472
EI 1439-4413
J9 DEUT MED WOCHENSCHR
JI Dtsch. Med. Wochenschr.
PD OCT
PY 2020
VL 145
IS 20
BP 1498
EP 1502
DI 10.1055/a-1202-3936
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NX0SE
UT WOS:000575428400015
PM 32869227
DA 2021-01-01
ER

PT J
AU Zoumpourlis, V
   Goulielmaki, M
   Rizos, E
   Baliou, S
   Spandidos, DA
AF Zoumpourlis, Vassilios
   Goulielmaki, Maria
   Rizos, Emmanouil
   Baliou, Stella
   Spandidos, Demetrios A.
TI The COVID-19 pandemic as a scientific and social challenge in the 21st
   century
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE COVID-19; SARS-CoV-2; pandemic; socio-political; economic
AB The coronavirus disease-2019 (COVID-19) pandemic, caused by the new coronavirus SARS-CoV-2, has spread around the globe with unprecedented consequences for the health of millions of people. While the pandemic is still in progress, with new incidents being reported every day, the resilience of the global society is constantly being challenged. Under these circumstances, the future seems uncertain. SARS-CoV-2 coronavirus has spread panic among civilians and insecurity at all socio-political and economic levels, dramatically disrupting everyday life, global economy, international travel and trade. The disease has also been linked to the onset of depression in many individuals due to the extreme restriction measures that have been taken for the prevention of the rapid spreading of COVID-19. First, the socio-economic, political and psychological implications of the COVID-19 pandemic were explored. Substantial evidence is provided for the consequences of the pandemic on all aspects of everyday life, while at the same time we unravel the role and the pursuits of national regimes during this unforeseen situation. The second goal of this review is related to the scientific aspect of the pandemic. Hence, we explain why SARS-CoV-2 is not a so-called 'invisible enemy', and also attempt to give insight regarding the origin of the virus, in an effort to reject the conspiracy theories that have arisen during the pandemic. Finally, rational strategies were investigated for successful vaccine development. We are optimistic that this review will complement the knowledge of specialized scientists and inform non-specialized readers on basic scientific questions, and also on the social and economic implications of the COVID-19 pandemic.
C1 [Zoumpourlis, Vassilios; Goulielmaki, Maria; Baliou, Stella] Natl Hellen Res Fdn NHRF, Inst Chem Biol, Biomed Applicat Unit, Athens 11635, Greece.
   [Rizos, Emmanouil] Natl & Kapodistrian Univ Athens, Univ ATTIKON Gen Hosp, Med Sch, Dept Psychiat 2, Athens 12462, Greece.
   [Spandidos, Demetrios A.] Univ Crete, Med Sch, Lab Clin Virol, Iraklion 71003, Greece.
RP Zoumpourlis, V (corresponding author), Natl Hellen Res Fdn NHRF, Inst Chem Biol, Biomed Applicat Unit, Athens 11635, Greece.
EM vzub@eie.gr
CR Aiken V, 2020, DISCOVER SOC
   Allington Daniel, 2020, Psychol Med, P1, DOI 10.1017/S003329172000224X
   [Anonymous], 2020, DEATHS INV COR COVID
   [Anonymous], 2020, CNEWS           0404
   [Anonymous], 2020, NDTV
   [Anonymous], 2020, 7 ANT VACC PROT DEV
   [Anonymous], 2020, MOSCOWS QUARANTINED
   [Anonymous], 2020, PM MITS MEETS ONL NE
   Ansermet F, 2004, PLASTICITE NEURONALE
   Antonarakis S, 2020, COMMUNICATION
   Baker S, 2020, BUSINESS INSIDE 0202
   Birnbaum R, 2020, DER TAGESSPIEGEL
   Brecht B, 1988, GROSSE KOMMENTIERTE, V11
   Brun J, 1968, PRESOCRATIQUES
   Carrington D., 2020, GUARDIAN
   Cellan-Jones R., 2020, BBC NEWS
   Cimons M, 2019, RISING TEMPERATURES
   Docea AO, 2020, INT J MOL MED, V45, P1631, DOI 10.3892/ijmm.2020.4555
   European Commission, 2019, REFL PAP SUST EUR 20
   Greger M, 2020, COVID 19
   Gross JA, 2020, TIMES ISRAEL
   Guevara E, 1960, REVOLUTIONARY MED OB
   Guiness P, 2012, ENV SYSTEMS SOC IB D, P59
   Hawksworth John., 2017, LONG VIEW WILL GLOBA
   Jawad R, 2020, BBC NEWS
   Ji YP, 2020, LANCET GLOB HEALTH, V8, pE480, DOI 10.1016/S2214-109X(20)30068-1
   Keaten J, 2020, AP NEWS         0506
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Kupferschmidt K, 2020, SCI NEWS
   Langreth R, 2020, BLOOMBERG       0319
   Marx K, 1976, GERMAN IDEOLOGY PROG
   Marx21, 2020, COR AGR WOULD RISK M
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Mikulic M, 2019, GLOBAL PHARM INDUSTR
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Nitulescu GM, 2020, INT J MOL MED, V46, P467, DOI 10.3892/ijmm.2020.4608
   Pollack Andrew, 2015, NY TIMES
   Popovich Nadja, 2020, NY TIMES
   Rabin R. C., 2020, NY TIMES
   Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8
   Schwab N, 2020, DAILY MAIL
   Scott D, 2020, VOX             0318
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Tsitoura E, 2020, EXP THER MED, V20, P147, DOI 10.3892/etm.2020.8692
   United Nations (UN) Environment Programme, 2020, 6 NAT FACTS REL COR
   Vagena E, 2020, CORONA NEWS     0323, V24
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   Velicu I, 2020, WHOEVER DOES NOT HAV
   World Health Organization (WHO), 2020, WHO ANN COVID 19 OUT
   Xiao KP, 2020, NATURE, V583, P286, DOI 10.1038/s41586-020-2313-x
   Zaninoni R, 2020, CORONAVIRUS DIARIES
NR 52
TC 1
Z9 1
U1 2
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD OCT
PY 2020
VL 22
IS 4
BP 3035
EP 3048
DI 10.3892/mmr.2020.11393
PG 14
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA NW4US
UT WOS:000575004300048
PM 32945405
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Luo, J
   Rizvi, H
   Preeshagul, IR
   Egger, JV
   Hoyos, D
   Bandlamudi, C
   McCarthy, CG
   Falcon, CJ
   Schoenfeld, AJ
   Arbour, KC
   Chaft, JE
   Daly, RM
   Drilon, A
   Eng, J
   Iqbal, A
   Lai, WV
   Li, BT
   Lito, P
   Namakydoust, A
   Ng, K
   Offin, M
   Paik, PK
   Riely, GJ
   Rudin, CM
   Yu, HA
   Zauderer, MG
   Donoghue, MTA
   Luksza, M
   Greenbaum, BD
   Kris, MG
   Hellmann, MD
AF Luo, J.
   Rizvi, H.
   Preeshagul, I. R.
   Egger, J., V
   Hoyos, D.
   Bandlamudi, C.
   McCarthy, C. G.
   Falcon, C. J.
   Schoenfeld, A. J.
   Arbour, K. C.
   Chaft, J. E.
   Daly, R. M.
   Drilon, A.
   Eng, J.
   Iqbal, A.
   Lai, W., V
   Li, B. T.
   Lito, P.
   Namakydoust, A.
   Ng, K.
   Offin, M.
   Paik, P. K.
   Riely, G. J.
   Rudin, C. M.
   Yu, H. A.
   Zauderer, M. G.
   Donoghue, M. T. A.
   Luksza, M.
   Greenbaum, B. D.
   Kris, M. G.
   Hellmann, M. D.
TI COVID-19 in patients with lung cancer
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE chemotherapy; COVID-19; immunotherapy/checkpoint blockade; lung cancer;
   small molecule agents
AB Background: Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic.
   Patients and methods: We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n = 102) at a single center from 12 March 2020 to 6 May 2020. Thresholds of severity were defined a priori as hospitalization, intensive care unit/intubation/do not intubate ([ICU/intubation/DNI] a composite metric of severe disease), or death. Recovery was defined as >14 days from COVID-19 test and >3 days since symptom resolution. Human leukocyte antigen (HLA) alleles were inferred from MSK-IMPACT (n = 46) and compared with controls with lung cancer and no known non-COVID-19 (n = 5166).
   Results: COVID-19 was severe in patients with lung cancer (62% hospitalized, 25% died). Although severe, COVID-19 accounted for a minority of overall lung cancer deaths during the pandemic (11% overall). Determinants of COVID-19 severity were largely patient-specific features, including smoking status and chronic obstructive pulmonary disease [odds ratio for severe COVID-19 2.9, 95% confidence interval 1.07-9.44 comparing the median (23.5 pack-years) to never-smoker and 3.87, 95% confidence interval 1.35-9.68, respectively]. Cancer-specific features, including prior thoracic surgery/radiation and recent systemic therapies did not impact severity. Human leukocyte antigen supertypes were generally similar in mild or severe cases of COVID-19 compared with non-COVID-19 controls. Most patients recovered from COVID-19, including 25% patients initially requiring intubation. Among hospitalized patients, hydroxychloroquine did not improve COVID-19 outcomes.
   Conclusion: COVID-19 is associated with high burden of severity in patients with lung cancer. Patient-specific features, rather than cancer-specific features or treatments, are the greatest determinants of severity.
C1 [Luo, J.; Preeshagul, I. R.; Schoenfeld, A. J.; Arbour, K. C.; Chaft, J. E.; Daly, R. M.; Drilon, A.; Eng, J.; Iqbal, A.; Lai, W., V; Li, B. T.; Lito, P.; Namakydoust, A.; Ng, K.; Offin, M.; Paik, P. K.; Riely, G. J.; Rudin, C. M.; Yu, H. A.; Zauderer, M. G.; Kris, M. G.; Hellmann, M. D.] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, 1275 York Ave, New York, NY 10065 USA.
   [Rizvi, H.; Egger, J., V; McCarthy, C. G.; Falcon, C. J.; Rudin, C. M.] Mem Sloan Kettering Canc Ctr, Druckenmiller Ctr Lung Canc Res, New York, NY 10065 USA.
   [Hoyos, D.; Greenbaum, B. D.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Computat Oncol, New York, NY 10065 USA.
   [Bandlamudi, C.] Mem Sloan Kettering Canc Ctr, Marie Josee & Henry R Kravis Ctr Mol Oncol, New York, NY 10065 USA.
   [Schoenfeld, A. J.; Arbour, K. C.; Chaft, J. E.; Daly, R. M.; Drilon, A.; Lai, W., V; Li, B. T.; Lito, P.; Offin, M.; Paik, P. K.; Riely, G. J.; Rudin, C. M.; Yu, H. A.; Zauderer, M. G.; Donoghue, M. T. A.; Kris, M. G.; Hellmann, M. D.] Weill Cornell Med Ctr, Dept Med, New York, NY USA.
   [Luksza, M.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.
   [Hellmann, M. D.] Mem Sloan Kettering Canc Ctr, Parker Inst Canc Immunotherapy, 1275 York Ave, New York, NY 10065 USA.
RP Hellmann, MD (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.
EM hellmann@mskcc.org
OI McCarthy, Caroline/0000-0002-5521-3869; Falcon,
   Christina/0000-0001-9143-1639
FU Memorial Sloan Kettering Cancer Center Support Grant/Core [P30CA008748];
   Druckenmiller Center for Lung Cancer Research at Memorial Sloan
   Kettering Cancer Center; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [T32-CA009207, K30-UL1TR00457, HHSN272201400008C, 7R01AI081848-04,
   1R01CA240924-01]; Damon Runyon Cancer Research Foundation [CI-98-18];
   Stand Up To Cancer, a program of the Entertainment Industry Foundation;
   Society for Immunotherapy of Cancer; Lustgarten Foundation; Mark
   Foundation for Cancer Research
FX This work was supported by Memorial Sloan Kettering Cancer Center
   Support Grant/Core [grant number P30CA008748] and the Druckenmiller
   Center for Lung Cancer Research at Memorial Sloan Kettering Cancer
   Center; the National Institutes of Health [grant numbers T32-CA009207 to
   JL, K30-UL1TR00457 to JL, HHSN272201400008C to ML, 7R01AI081848-04 to
   BDG, 1R01CA240924-01 to BDG]; Damon Runyon Cancer Research Foundation
   [grant number CI-98-18 to MDH]. BDG and DH are supported under a
   collaboration by Stand Up To Cancer, a program of the Entertainment
   Industry Foundation, the Society for Immunotherapy of Cancer, and the
   Lustgarten Foundation. BDG is a The Pershing Square Sohn PrizedMark
   Foundation Fellow supported by funding from The Mark Foundation for
   Cancer Research. MDH is a member of the Parker Institute for Cancer
   Immunotherapy.
CR Barlesi F, 2020, AACR VIRT ANN M
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Docherty AB, 2020, BMJ, V369, pm1985
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lewnard JA, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1923
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   WHISENANT JG, 2020, J CLIN ONCOL S, V38, pNIL9, DOI DOI 10.1200/JCO.2020.38.18_suppl.LBA111
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 25
TC 12
Z9 13
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2020
VL 31
IS 10
BP 1386
EP 1396
DI 10.1016/j.annonc.2020.06.007
PG 11
WC Oncology
SC Oncology
GA NW0DL
UT WOS:000574680100002
PM 32561401
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Caffo, O
   Zagonel, V
   Baldessari, C
   Berruti, A
   Bortolus, R
   Buti, S
   Ceresoli, GL
   Donini, M
   Ermacora, P
   Fornarini, G
   Fratino, L
   Masini, C
   Massari, F
   Mosca, A
   Mucciarini, C
   Procopio, G
   Tucci, M
   Verri, E
   Zucali, P
   Buttigliero, C
AF Caffo, O.
   Zagonel, V.
   Baldessari, C.
   Berruti, A.
   Bortolus, R.
   Buti, S.
   Ceresoli, G. L.
   Donini, M.
   Ermacora, P.
   Fornarini, G.
   Fratino, L.
   Masini, C.
   Massari, F.
   Mosca, A.
   Mucciarini, C.
   Procopio, G.
   Tucci, M.
   Verri, E.
   Zucali, P.
   Buttigliero, C.
TI On the relationship between androgen-deprivation therapy for prostate
   cancer and risk of infection by SARS-CoV-2
SO ANNALS OF ONCOLOGY
LA English
DT Letter
C1 [Caffo, O.] Santa Chiara Hosp, Dept Med Oncol, Trento, Italy.
   [Zagonel, V.] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Oncol 1, Padua, Italy.
   [Baldessari, C.] Univ Hosp Modena, Med Oncol Unit, Modena, Italy.
   [Berruti, A.] Univ Brescia, ASST Spedali Civili, Med Oncol Unit, Brescia, Italy.
   [Bortolus, R.] Ctr Riferimento Oncol Aviano CRO IRCCS, Dept Radiat Oncol, Aviano, Italy.
   [Buti, S.] Univ Hosp Parma, Med Oncol Unit, Parma, Italy.
   [Ceresoli, G. L.] Humanitas Gavazzeni, Thorac & Urol Oncol Unit, Bergamo, Italy.
   [Donini, M.] ASST Cremona, Dept Med Oncol, Cremona, Italy.
   [Ermacora, P.] Univ Hosp Udine, Dept Oncol, Udine, Italy.
   [Fornarini, G.] IRCCS Azienda Osped Univ San Martino IST Ist Nazl, Med Oncol Dept, Genoa, Italy.
   [Fratino, L.] Ctr Riferimento Oncol Aviano CRO IRCCS, Dept Med Oncol, Aviano, Italy.
   [Masini, C.] IRCCS Reggio Emilia, Med Oncol Unit, AUSL, Reggio Emilia, Italy.
   [Massari, F.] St Orsola Marcello Malpighi Hosp, Div Oncol, Bologna, Italy.
   [Mosca, A.] FPO IRCCS, Candiolo Canc Inst, Multidisciplinary Oncol Outpatient Clin, Candiolo, Italy.
   [Mucciarini, C.] Ramazzini Hosp, Dept Med Oncol, Carpi, Italy.
   [Procopio, G.] Fdn IRCCS Ist Nazl Tumori Milan, Genitourinary Oncol Unit, Milan, Italy.
   [Tucci, M.] Cardinal Massaia Hosp, Dept Med Oncol, Asti, Italy.
   [Verri, E.] European Inst Oncol IRCCS, Med Oncol Div Urogenital & Head & Neck Tumours, IEO, Milan, Italy.
   [Zucali, P.] IRCCS, Humanitas Clin & Res Ctr, Dept Oncol, Milan, Italy.
   [Buttigliero, C.] Univ Torino, San Luigi Hosp, Med Oncol Dept, Orbassano, Italy.
RP Caffo, O (corresponding author), Santa Chiara Hosp, Dept Med Oncol, Trento, Italy.
EM orazio.caffo@apss.tn.it
RI Mosca, Alessandra/O-7975-2016; zagonel, vittorina/F-4226-2014
OI Mosca, Alessandra/0000-0003-2538-8411; zagonel,
   vittorina/0000-0002-0829-2525
CR [Anonymous], 2020, COR COVID 19 DIS PAN
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
NR 2
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2020
VL 31
IS 10
BP 1415
EP 1416
DI 10.1016/j.annonc.2020.06.005
PG 2
WC Oncology
SC Oncology
GA NW0DL
UT WOS:000574680100020
PM 32562741
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Patel, VG
   Zhong, X
   Liaw, B
   Tremblay, D
   Tsao, CK
   Galsky, MD
   Oh, WK
AF Patel, V. G.
   Zhong, X.
   Liaw, B.
   Tremblay, D.
   Tsao, C. -K.
   Galsky, M. D.
   Oh, W. K.
TI Does androgen deprivation therapy protect against severe complications
   from COVID-19?
SO ANNALS OF ONCOLOGY
LA English
DT Letter
C1 [Patel, V. G.; Liaw, B.; Tremblay, D.; Tsao, C. -K.; Galsky, M. D.; Oh, W. K.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA.
   [Zhong, X.] Icahn Sch Med Mt Sinai, Dept Populat Hlth & Policy, New York, NY 10029 USA.
RP Oh, WK (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA.
EM william.oh@mssm.edu
CR Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Lin BY, 1999, CANCER RES, V59, P4180
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Sharifi N, 2020, ENDOCR-RELAT CANCER, V27, pE1, DOI 10.1530/ERC-20-0133
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 6
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2020
VL 31
IS 10
BP 1419
EP 1420
DI 10.1016/j.annonc.2020.06.023
PG 2
WC Oncology
SC Oncology
GA NW0DL
UT WOS:000574680100023
PM 32653425
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Husky, MM
   Kovess-Masfety, V
   Swendsen, JD
AF Husky, Mathilde M.
   Kovess-Masfety, Viviane
   Swendsen, Joel D.
TI Stress and anxiety among university students in France during Covid-19
   mandatory confinement
SO COMPREHENSIVE PSYCHIATRY
LA English
DT Article
DE Covid-19; Confinement; Stress
AB While necessary from a public health standpoint, Covid-19 confinement strategies are often contrary to evidence-based therapies used to treat mental disorders. University students may be particularly vulnerable to mental health problems, but recent studies have indicated only a negligible impact of confinement strategies. French respondents to a World Mental Health survey of university students completed questions concerning Covid-19 confinement. The sample experienced increased anxiety as well as moderate to severe stress during confinement. Respondents who did not relocate to live with parents were disproportionately affected. Knowledge of confinement effects may be used to reduce its negative impact in vulnerable populations. (C) 2020 The Author(s). Published by Elsevier Inc.
C1 [Husky, Mathilde M.] Univ Bordeaux, Lab Psychol EA4139, 3 Ter,Pl Victoire, F-33076 Bordeaux, France.
   [Kovess-Masfety, Viviane] Univ Paris, EA 4057, Sorbonne Paris Cite, Paris, France.
   [Swendsen, Joel D.] Univ Bordeaux, EPHE PSL Res Univ, CNRS UMR 5287, Inst Univ France, Bordeaux, France.
RP Husky, MM (corresponding author), Univ Bordeaux, Lab Psychol EA4139, 3 Ter,Pl Victoire, F-33076 Bordeaux, France.
EM mathilde.husky@u-bordeaux.fr
FU Institut Universitaire de France
FX Support from the Institut Universitaire de France (M. Husky) was used to
   fund the study.
CR Auerbach RP, 2018, J ABNORM PSYCHOL, V127, P623, DOI 10.1037/abn0000362
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Chau SWH, 2019, INT REV PSYCHIATR, V31, P626, DOI 10.1080/09540261.2019.1679976
   FISHER S, 1987, BRIT J PSYCHOL, V78, P425, DOI 10.1111/j.2044-8295.1987.tb02260.x
   Hao F., 2020, BRAIN BEHAV IMMUN
   Ho CSH, 2020, ANN ACAD MED SINGAP, V49, P155
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Kivimaki M, 2020, LANCET PUBLIC HEALTH, V5, pE140, DOI 10.1016/S2468-2667(19)30248-8
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Lee AM, 2007, CAN J PSYCHIAT, V52, P233, DOI 10.1177/070674370705200405
   Mao Y, 2019, BMC MED EDUC, V19, DOI 10.1186/s12909-019-1744-2
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Rubley JN, 2017, CHRON HIGHER EDUC, P3
   Wang CY, 2020, BRAIN BEHAV IMMUN, V87, P40, DOI 10.1016/j.bbi.2020.04.028
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
NR 15
TC 5
Z9 5
U1 12
U2 12
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0010-440X
EI 1532-8384
J9 COMPR PSYCHIAT
JI Compr. Psychiat.
PD OCT
PY 2020
VL 102
AR 152191
DI 10.1016/j.comppsych.2020.152191
PG 3
WC Psychiatry
SC Psychiatry
GA NW2FG
UT WOS:000574825000012
PM 32688023
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kinoshita, M
   Tanaka, M
AF Kinoshita, Masako
   Tanaka, Masami
TI Impact of Routine Infant BCG Vaccination on COVID-19
SO JOURNAL OF INFECTION
LA English
DT Article
DE Coronavirus disease 2019; COVID-19; Bacillus Calmette-Guerin
   vaccination; BCG; Prevention
ID NONSPECIFIC PROTECTION; TUBERCULOSIS
AB Objectives: In Japan, the first case of coronavirus disease 2019 (COVID-19) was diagnosed on January 15, 2020 and subsequent infections rapidly increased. The Bacillus Calmette-Guerin (BCG) vaccination program is the principal element of tuberculosis control in Japan. We investigated the impact of routine infant BCG vaccination on prevention of local COVID-19 spread.
   Methods: Data on the prevalence of SARS-CoV-2 infection, annual routine infant BCG vaccine coverage (represented by the number of BCG vaccinations per live births), and other candidate factors in each prefecture were obtained from the official notifications database in Japan. We analysed the association of vaccine coverage with the prevalence of SARS-CoV-2 infection.
   Results: The BCG vaccine coverage in 1999-2002, 2004, and 2012 in five prefectures with no COVID-19 infections was significantly higher than that in five prefectures with a high prevalence of infections (Mann-Whitney U test, p<0.05). The prevalence of SARS-CoV-2 infection was significantly negatively correlated with BCG vaccine coverage in 2004 and was significantly positively correlated with age groups 20-34 and 40-54 years (Spearman's rank correlation, p<0.01).
   Conclusions: Our findings suggest that routine infant BCG vaccination coverage in young generation had a significant impact on prevention of local COVID-19 spread in Japan. (C) 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
C1 [Kinoshita, Masako] Natl Hosp Org, Utano Natl Hosp, Dept Neurol, Ukyo Ku, 8 Ondoyama Cho, Kyoto 6168255, Japan.
   [Tanaka, Masami] Kyoto Min Iren Chuo Hosp, Kyoto MS Ctr, Nakagyo Ku, 16-1 Kasuga Cho Nishinokyo, Kyoto 6048453, Japan.
   [Tanaka, Masami] Kaikoukai Josai Hosp, Dept Neurol, Nakamura Ku, 4-1 Kitahata Cho, Nagoya, Aichi 4530815, Japan.
RP Kinoshita, M (corresponding author), Natl Hosp Org, Utano Natl Hosp, Dept Neurol, Ukyo Ku, 8 Ondoyama Cho, Kyoto 6168255, Japan.
EM machak@kuhp.kyoto-u.ac.jp; nra17777@nifty.com
CR [Anonymous], 2020, SCIENCE
   [Anonymous], 2018, CURR STAT COUNT DE 1
   [Anonymous], 1999, DECLARATION STATE EM
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Bluhm R, 2020, COVID EC, V19, P87
   Ferrucci L, 2005, BLOOD, V105, P2294, DOI 10.1182/blood-2004-07-2599
   Freyne B, 2018, J INFECT DIS, V217, P1798, DOI 10.1093/infdis/jiy069
   Guan WJ, 2020, RESPIROLOGY, V25, P898, DOI 10.1111/resp.13885
   Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Katsuda N, 2015, NAGOYA J MED SCI, V77, P19
   Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Klinger D., 2020, VACCINES, V8, P378, DOI [10.3390/vaccines803037832664505, DOI 10.3390/VACCINES803037832664505]
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Ministry of Health Labour and Welfare of Japan, 2020, COR DIS 2019 COVID 1
   Obayashi Y, 1964, KEKKAKU, V39, P369
   Obayashi Y, 1955, SERIES, V28
   Rahman M, 2003, J EPIDEMIOL, V13, P127, DOI 10.2188/jea.13.127
   Redelman-Sidi G, 2020, NAT REV UROL, V17, P316, DOI 10.1038/s41585-020-0325-9
   Sharma A, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2720-9
   Toida I, 2004, I NFORMATION REV TUB, V48, P15
   Weng CH, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820001569
   Yamamoto S, 2007, JPN J INFECT DIS, V60, P331
NR 24
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD OCT
PY 2020
VL 81
IS 4
BP 625
EP 633
DI 10.1016/j.jinf.2020.08.013
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA NV5WZ
UT WOS:000574392800019
PM 32795481
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Chen, X
   Shan, YH
   Wen, YY
   Sun, J
   Du, HK
AF Chen, Xian
   Shan, Yuheng
   Wen, Yingyu
   Sun, Jia
   Du, Haike
TI Mesenchymal stem cell therapy in severe COVID-19: A retrospective study
   of short-term treatment efficacy and side effects
SO JOURNAL OF INFECTION
LA English
DT Letter
ID CYTOKINE STORM
C1 [Chen, Xian; Du, Haike] Peoples Armed Police Force, Dept Emergency, Characterist Med Ctr, Tianjin 300162, Peoples R China.
   [Shan, Yuheng] Chinese Peoples Liberat Army Gen Hosp, Dept Neurol, Beijing 100853, Peoples R China.
   [Shan, Yuheng; Sun, Jia] Peoples Armed Police Force, Dept Neurol, Characterist Med Ctr, Tianjin 300162, Peoples R China.
   [Shan, Yuheng] Med Sch Chinese PLA, Beijing 100853, Peoples R China.
   [Wen, Yingyu] Peoples Armed Police Force, Dept Renal Med, Characterist Med Ctr, Tianjin 300162, Peoples R China.
RP Shan, YH (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Neurol, Beijing 100853, Peoples R China.
EM 964668032@qq.com
CR Armitage J, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.02369-2017
   CANTINI L, 2020, J INFECTION, V10, DOI DOI 10.3389/FONC.2020.00343
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Lin L, 2020, Zhonghua Yi Xue Za Zhi, V100, P805, DOI 10.3760/cma.j.cn112137-20200205-00199
   Sun XJ, 2020, CYTOKINE GROWTH F R, V53, P38, DOI 10.1016/j.cytogfr.2020.04.002
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhai P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105955
NR 9
TC 4
Z9 4
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD OCT
PY 2020
VL 81
IS 4
BP 652
EP 654
DI 10.1016/j.jinf.2020.05.020
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA NV5WZ
UT WOS:000574392800025
PM 32422152
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rossotti, R
   Travi, G
   Ughi, N
   Corradin, M
   Baiguera, C
   Fumagalli, R
   Bottiroli, M
   Mondino, M
   Merli, M
   Bellone, A
   Basile, A
   Ruggeri, R
   Colombo, F
   Moreno, M
   Pastori, S
   Perno, CF
   Tarsia, P
   Epis, OM
   Puoti, M
AF Rossotti, Roberto
   Travi, Giovanna
   Ughi, Nicola
   Corradin, Matteo
   Baiguera, Chiara
   Fumagalli, Roberto
   Bottiroli, Maurizio
   Mondino, Michele
   Merli, Marco
   Bellone, Andrea
   Basile, Andriano
   Ruggeri, Ruggero
   Colombo, Fabrizio
   Moreno, Mauro
   Pastori, Stefano
   Perno, Carlo Federico
   Tarsia, Paolo
   Epis, Oscar Massimiliano
   Puoti, Massimo
TI Safety and efficacy of anti-i16-receptor tocilizumab use in severe and
   critical patients affected by coronavirus disease 2019: A comparative
   analysis
SO JOURNAL OF INFECTION
LA English
DT Article
DE Tocilizumab; COVID-19; SARS-CoV2; IL-6; Orotracheal tube
ID INTERLEUKIN-6 RECEPTOR INHIBITION; MODIFYING ANTIRHEUMATIC DRUGS;
   RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; COVID-19; PLACEBO; COMBINATION
AB Background: As the novel SARS-CoV-2 pandemic occurred, no specific treatment was yet available. Inflammatory response secondary to viral infection might be the driver of severe diseases. We report the safety and efficacy (in terms of overall survival and hospital discharge) of the anti-IL6 tocilizumab (TCZ) in subjects with COVID-19.
   Methods: This retrospective, single-center analysis included all the patients consecutively admitted to our Hospital with severe or critical COVID-19 who started TCZ treatment from March 13th to April 03rd, 2020. A 1:2 matching to patients not treated with TCZ was performed according to age, sex, severity of disease, P/F, Charlson Comorbidity Index and length of time between symptoms onset and hospital admittance. Descriptive statistics and non-parametric tests to compare the groups were applied. Kaplan Meier probability curves and Cox regression models for survival, hospital discharge and orotracheal intubation were used.
   Results: Seventy-four patients treated with TCZ were matched with 148 matched controls. They were mainly males (81.5%), Caucasian (82.0%) and with a median age of 59 years. The majority (69.8%) showed critical stage COVID-19 disease. TCZ use was associated with a better overall survival (HR 0.499 [95% CI 0.262-0.952], p =0.035) compared to controls but with a longer hospital stay (HR 1.658 [95% CI 1.0882.524], p = 0.019) mainly due to biochemical, respiratory and infectious adverse events.
   Discussion: TCZ use resulted potentially effective on COVID-19 in terms of overall survival. Caution is warranted given the potential occurrence of adverse events. (C) 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
C1 [Rossotti, Roberto; Travi, Giovanna; Baiguera, Chiara; Merli, Marco; Puoti, Massimo] ASST Grande Osped Metropolitano Niguarda, Infect Dis Unit, Piazza Osped Maggiore 3, I-20162 Milan, Italy.
   [Ughi, Nicola; Epis, Oscar Massimiliano] ASST Grande Osped Metropolitano Niguarda, Rheumatol Unit, Milan, Italy.
   [Corradin, Matteo; Moreno, Mauro] ASST Grande Osped Metropolitano Niguarda, Healthcare Management Dept, Milan, Italy.
   [Fumagalli, Roberto; Bottiroli, Maurizio; Mondino, Michele] ASST Grande Osped Metropolitano Niguarda, Dept Anaesthesia & Crit Care, Milan, Italy.
   [Fumagalli, Roberto] Univ Milano Bicocca, Sch Med & Surg, Monza, Italy.
   [Bellone, Andrea; Basile, Andriano] ASST Grande Osped Metropolitano Niguarda, Emergency Dept, Milan, Italy.
   [Ruggeri, Ruggero; Colombo, Fabrizio] ASST Grande Osped Metropolitano Niguarda, Internal Med Dept, Milan, Italy.
   [Pastori, Stefano; Perno, Carlo Federico] ASST Grande Osped Metropolitano Niguarda, Chem Clin & Microbiol Anal, Milan, Italy.
   [Perno, Carlo Federico] Univ Milan, Dept Oncol & Oncohematol, Milan, Italy.
   [Tarsia, Paolo] ASST Grande Osped Metropolitano Niguarda, Pneumol Unit, Milan, Italy.
RP Rossotti, R (corresponding author), ASST Grande Osped Metropolitano Niguarda, Infect Dis Unit, Piazza Osped Maggiore 3, I-20162 Milan, Italy.
EM roberto.rossotti@ospedaleniguarda.it
RI Bottiroli, Maurizio/L-4801-2019
OI Bottiroli, Maurizio/0000-0002-1579-7767; Merli,
   Marco/0000-0001-5081-8669; Puoti, Massimo/0000-0003-3278-7138
CR [Anonymous], 2016, ECDC ANN EPIDEMIOL R
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Cellina M, 2020, DIAGN INTERV IMAG, V101, P323, DOI 10.1016/j.diii.2020.03.010
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Dimopoulos G, 2020, CELL HOST MICROBE, V28, P117, DOI 10.1016/j.chom.2020.05.007
   Dougados M, 2014, ANN RHEUM DIS, V73, P803, DOI 10.1136/annrheumdis-2013-204761
   Emery P, 2008, ANN RHEUM DIS, V67, P1516, DOI 10.1136/ard.2008.092932
   Gabay C, 2013, LANCET, V381, P1541, DOI 10.1016/S0140-6736(13)60250-0
   Genovese MC, 2008, ARTHRITIS RHEUM-US, V58, P2968, DOI 10.1002/art.23940
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jones G, 2010, ANN RHEUM DIS, V69, P88, DOI 10.1136/ard.2008.105197
   Katano H, 2018, ADV EXP MED BIOL, V1045, P357, DOI 10.1007/978-981-10-7230-7_16
   Kivitz A, 2014, ARTHRIT CARE RES, V66, P1653, DOI 10.1002/acr.22384
   Kremer JM, 2011, ARTHRITIS RHEUM-US, V63, P609, DOI 10.1002/art.30158
   Lin L, 2020, Zhonghua Yi Xue Za Zhi, V100, P805, DOI 10.3760/cma.j.cn112137-20200205-00199
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Lu CC, 2020, J CHIN MED ASSOC, V83, P534, DOI 10.1097/JCMA.0000000000000318
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Rubini Alessandro, 2013, Inflammation & Allergy Drug Targets, V12, P315
   Shieh JM, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/7947596
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140-6736(08)60453-5
   Stebbing J, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012697
   Uciechowski P, 2020, ONCOLOGY-BASEL, V98, P131, DOI 10.1159/000505099
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 35
TC 5
Z9 6
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
EI 1532-2742
J9 J INFECTION
JI J. Infect.
PD OCT
PY 2020
VL 81
IS 4
BP E11
EP E17
DI 10.1016/j.jinf.2020.07.008
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA NV5WZ
UT WOS:000574392800002
PM 32652164
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Meyer, B
   Torriani, G
   Yerly, S
   Mazza, L
   Calame, A
   Arm-Vernez, I
   Zimmer, G
   Agoritsas, T
   Stirnemann, J
   Spechbach, H
   Guessous, I
   Stringhini, S
   Pugin, J
   Roux-Lombard, P
   Fontao, L
   Siegrist, CA
   Eckerle, I
   Vuilleumier, N
   Kaiser, L
AF Meyer, B.
   Torriani, G.
   Yerly, S.
   Mazza, L.
   Calame, A.
   Arm-Vernez, I
   Zimmer, G.
   Agoritsas, T.
   Stirnemann, J.
   Spechbach, H.
   Guessous, I
   Stringhini, S.
   Pugin, J.
   Roux-Lombard, P.
   Fontao, L.
   Siegrist, C-A
   Eckerle, I
   Vuilleumier, N.
   Kaiser, L.
CA Geneva Ctr Emerging Viral Dis
TI Validation of a commercially available SARS-CoV-2 serological
   immunoassay
SO CLINICAL MICROBIOLOGY AND INFECTION
LA English
DT Article
DE COVID-19; ELISA; Pseudovirus neutralisation assay; Recombinant
   immunofluorescence assay; SARS-CoV-2; Serological assays; Serological
   testing strategy
ID ANTIBODIES; CORONAVIRUSES; VACCINES; PROTEIN
AB Objectives: To validate the diagnostic accuracy of a Euroimmun SARS-CoV-2 IgG and IgA immunoassay for COVID-19.
   Methods: In this unmatched (1:2) case-control validation study, we used sera of 181 laboratory-confirmed SARS-CoV-2 cases and 326 controls collected before SARS-CoV-2 emergence. Diagnostic accuracy of the immunoassay was assessed against a whole spike protein-based recombinant immunofluorescence assay (rIFA) by receiver operating characteristic (ROC) analyses. Discrepant cases between ELISA and rIFA were further tested by pseudo-neutralization assay.
   Results: COVID-19 patients were more likely to be male and older than controls, and 50.3% were hospitalized. ROC curve analyses indicated that IgG and IgA had high diagnostic accuracies with AUCs of 0.990 (95% Confidence Interval [95%CI]: 0.983-0.996) and 0.978 (95%CI: 0.967-0.989), respectively. IgG assays outperformed IgA assays (p=0.01). Taking an assessed 15% inter-assay imprecision into account, an optimized IgG ratio cut-off > 2.5 displayed a 100% specificity (95%CI: 99-100) and a 100% positive predictive value (95%CI: 96-100). A 0.8 cut-off displayed a 94% sensitivity (95%CI: 88-97) and a 97% negative predictive value (95%CI: 95-99). Substituting the upper threshold for the manufacturer's, improved assay performance, leaving 8.9% of IgG ratios indeterminate between 0.8-2.5.
   Conclusions: The Euroimmun assay displays a nearly optimal diagnostic accuracy using IgG against SARS-CoV-2 in patient samples, with no obvious gains from IgA serology. The optimized cut-offs are fit for rulein and rule-out purposes, allowing determination of whether individuals in our study population have been exposed to SARS-CoV-2 or not. IgG serology should however not be considered as a surrogate of protection at this stage. (C) 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Meyer, B.; Fontao, L.; Siegrist, C-A] Univ Geneva, Ctr Vaccinol, Dept Pathol & Immunol, Geneva, Switzerland.
   [Torriani, G.; Eckerle, I] Univ Geneva, Dept Microbiol & Mol Med, Geneva, Switzerland.
   [Yerly, S.; Mazza, L.; Arm-Vernez, I; Kaiser, L.] Geneva Univ Hosp, Lab Virol, Geneva, Switzerland.
   [Calame, A.; Eckerle, I; Kaiser, L.] Geneva Univ Hosp, Div Infect Dis, Geneva, Switzerland.
   [Zimmer, G.] Inst Virol & Immunol IVI, Mittelhausern, Switzerland.
   [Zimmer, G.] Univ Bern, Vetsuisse Fac, Dept Infect Dis & Pathobiol DIP, Bern, Switzerland.
   [Agoritsas, T.; Stirnemann, J.] Geneva Univ Hosp, Dept Med, Div Gen Internal Med, Geneva, Switzerland.
   [Agoritsas, T.] Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
   [Spechbach, H.; Guessous, I] Geneva Univ Hosp, Div & Dept Primary Care Med, Geneva, Switzerland.
   [Guessous, I] Geneva Univ Hosp, Div Primary Care, Unit Populat Epidemiol, Geneva, Switzerland.
   [Stringhini, S.] Geneva Univ Hosp, Div Intens Care, Geneva, Switzerland.
   [Pugin, J.; Vuilleumier, N.] Geneva Univ Hosp, Dept Diagnost, Div Lab Med, Geneva, Switzerland.
   [Pugin, J.; Vuilleumier, N.] Univ Geneva, Geneva, Switzerland.
   [Roux-Lombard, P.] Geneva Univ Hosp, Div Dermatol & Lab Med, Geneva, Switzerland.
   [Eckerle, I; Kaiser, L.] Geneva Univ Hosp, Geneva Ctr Emerging Viral Dis, Geneva, Switzerland.
   [Vuilleumier, N.] Fac Med, Dept Med, Div Lab Med, Geneva, Switzerland.
RP Kaiser, L (corresponding author), Geneva Univ Hosp, Lab Virol, Geneva, Switzerland.
EM Laurent.kaiser@hcuge.ch
RI ; Agoritsas, Thomas/F-4321-2014
OI Zimmer, Gert/0000-0002-2708-2507; Agoritsas, Thomas/0000-0002-6182-9969
FU Center for Emerging Viral Diseases; Private Foundation of the Geneva
   University Hospitals; Pictet Charitable Foundation; Ancrage Foundation;
   Center of Vaccinology
FX We would like to thank Markus Hoffmann and Stefan Pohlmann (DPZ,
   University of Gottingen) for providing a SARS-CoV-2 spike protein
   expression vector. We thank Erik Boehm for help with writing and editing
   the manuscript. We are also thankful to Romain Burquier, Krystel
   Tommasini, Karine Derrac, Lydia Massa-Rouffineau, Myriam
   Florey-Thevenoz, Katia, Marjan Mohitzadeh and Liliane Marchand for
   technical assistance and help with the serological assays. Last, we
   would like to thank patients for providing samples and participating in
   this study. This work was entirely supported by the Center for Emerging
   Viral Diseases, a grant from the Private Foundation of the Geneva
   University Hospitals, the Pictet Charitable Foundation, the Ancrage
   Foundation and by research funds from the Center of Vaccinology.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 1998, REV SCI TECH OIE, V17, P600
   Corman V. M., 2012, EUROSURVEILLANCE, V17, P49, DOI DOI 10.2807/ESE.17.49.20334-EN
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Duan JZ, 2005, BIOCHEM BIOPH RES CO, V333, P186, DOI 10.1016/j.bbrc.2005.05.089
   Fukushi S, 2005, J GEN VIROL, V86, P2269, DOI 10.1099/vir.0.80955-0
   Geurtsvan Kessel CH, 2020, NEXT PHASE EVALUATIO, DOI [10.1101/2020.04.23.20077156, 10.1101/2020.04 .23.20077156, DOI 10.1101/2020.04.23.20077156]
   Gluer CC, 1999, J BONE MINER RES, V14, P1952, DOI 10.1359/jbmr.1999.14.11.1952
   Gorse GJ, 2010, CLIN VACCINE IMMUNOL, V17, P1875, DOI 10.1128/CVI.00278-10
   Keng CT, 2005, J VIROL, V79, P3289, DOI 10.1128/JVI.79.6.3289-3296.2005
   Lassauniere R, 2020, EVALUATION 9 COMMERC, DOI [10.1101/2020.04.09.20056325, DOI 10.1101/2020.04.09.20056325]
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Muller MA, 2015, LANCET INFECT DIS, V15, P629, DOI 10.1016/S1473-3099(15)00029-8
   Ohst C, 2018, ADV EXP MED BIOL, V1062, P19, DOI 10.1007/978-981-10-8727-1_3
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Omar F, 2008, J CLIN PATHOL, V61, P426, DOI 10.1136/jcp.2007.054833
   Seibel M J, 2002, Clin Lab, V48, P579
   Sim J, 2005, PHYS THER, V85, P257
   Spertini V, 2011, GMS HYG INFECT CONTR, V6
   Torriani G, 2019, J VIROL, V93, DOI 10.1128/JVI.01744-18
   Zeng FY, 2006, FEBS LETT, V580, P5612, DOI 10.1016/j.febslet.2006.08.085
   Zhong XF, 2005, J VIROL, V79, P3401, DOI 10.1128/JVI.79.6.3401-3408.2005
NR 23
TC 15
Z9 15
U1 7
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1198-743X
EI 1469-0691
J9 CLIN MICROBIOL INFEC
JI Clin. Microbiol. Infect.
PD OCT
PY 2020
VL 26
IS 10
BP 1386
EP 1394
DI 10.1016/j.cmi.2020.06.024
PG 9
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA NU2DS
UT WOS:000573452600019
PM 32603801
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kopelovich, SL
   Turkington, D
AF Kopelovich, Sarah L.
   Turkington, Doug
TI Remote CBT for Psychosis During the COVID-19 Pandemic: Challenges and
   Opportunities
SO COMMUNITY MENTAL HEALTH JOURNAL
LA English
DT Article; Early Access
DE Cognitive behavioral therapy for psychosis; Serious mental illness;
   Telehealth; COVID-19
ID COGNITIVE-BEHAVIORAL THERAPY; MOBILE HEALTH; INTERVENTION; DISORDERS;
   RECOVERY; PEOPLE
AB The COVID pandemic is now leading to the emergence of a secondary mental health pandemic. Clients with psychosis are at increased risk of poorer medium- and long-term psychosocial and clinical outcomes. In response to the pressing need to flexibly deliver high-quality care to individuals with psychosis, this brief report proposes high yield cognitive behavioral techniques for psychosis (HY-CBt-p) facilitated by task sharing and digital enhancements. HY-CBt-p is delivered over fewer sessions than formulation-based Cognitive Behavioral Therapy for psychosis (CBTp), can be learned by a range of providers, and includes techniques such as developing a normalizing explanation; techniques to reduce anxiety, depression, and insomnia, which perpetuate psychotic symptoms; self-monitoring; reality testing; and wellness planning. Previous research suggests that effect sizes will be lower than that of 16-session formulation-driven CBTp, but additional research is needed to test the feasibility, acceptability, efficacy, and comparative effectiveness of different forms of remote-delivered CBTp.
C1 [Kopelovich, Sarah L.] Univ Washington, Harborview Med Ctr, Dept Psychiat & Behav Sci, 325 Ninth Ave,POB 359911, Seattle, WA 98104 USA.
   [Turkington, Doug] Monkwearmouth Hosp, Cumbria Northumberland Tyne & Wear NHS Fdn Trust, Newcastle Rd, Sunderland, Tyne & Wear, England.
RP Kopelovich, SL (corresponding author), Univ Washington, Harborview Med Ctr, Dept Psychiat & Behav Sci, 325 Ninth Ave,POB 359911, Seattle, WA 98104 USA.
EM skopelov@uw.edu
CR American Psychiatric Association, 2004, PRACT GUID TREATM PA
   [Anonymous], 2019, LANCET PSYCHIAT, V6, P81, DOI 10.1016/S2215-0366(19)30006-9
   Aschbrenner KA, 2018, PSYCHIATRY, V4, P1
   Backhaus A, 2012, PSYCHOL SERV, V9, P111, DOI 10.1037/a0027924
   Bee PE, 2010, SOC SCI MED, V71, P1308, DOI 10.1016/j.socscimed.2010.06.031
   Bell IH, 2017, PSYCHIAT SERV, V68, P1172, DOI 10.1176/appi.ps.201600523
   Ben-Zeev D, 2019, NPJ SCHIZOPHR, V5, DOI 10.1038/s41537-019-0083-y
   Ben-Zeev D, 2018, PSYCHIAT SERV, V69, P978, DOI 10.1176/appi.ps.201800063
   Ben-Zeev D, 2014, J DUAL DIAGN, V10, P197, DOI 10.1080/15504263.2014.962336
   Ben-Zeev D, 2014, SCHIZOPHRENIA BULL, V40, P1244, DOI 10.1093/schbul/sbu033
   Brown E, 2020, SCHIZOPHR RES, V222, P79, DOI 10.1016/j.schres.2020.05.005
   Daker-White G, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-279
   Druss BG, 2020, JAMA PSYCHIAT, V77, P891, DOI 10.1001/jamapsychiatry.2020.0894
   Freeman D, 2016, BRIT J PSYCHIAT, V209, P62, DOI 10.1192/bjp.bp.115.176438
   Garety PA, 2018, PSYCHIAT SERV, V69, P9, DOI 10.1176/appi.ps.201700268
   Gottlieb JD, 2013, SCHIZOPHR RES, V145, P82, DOI 10.1016/j.schres.2013.01.002
   Hartley S, 2014, BEHAV COGN PSYCHOTH, V42, P435, DOI 10.1017/S135246581300026X
   Hays R, 2019, PSYCHIAT CLIN N AM, V42, P611, DOI 10.1016/j.psc.2019.08.003
   Kola L, 2020, LANCET PSYCHIAT, DOI [10.24869/psyd.2020.6, DOI 10.24869/PSYD.2020.6]
   Kopelovich S., 2019, S ASS BEH COGN THER
   Malik N, 2009, J CLIN PSYCHIAT, V70, P201, DOI 10.4088/JCP.07m03990
   Meadows Mental Health Policy Institute, 2020, COVID 19 RESP BRIEF
   Naeem F, 2016, SCHIZOPHR RES, V173, P69, DOI 10.1016/j.schres.2016.03.003
   Naeem F, 2016, INT J COGN THER, V9, P73
   Naslund JA, 2016, MENT HEALTH PHYS ACT, V10, P10, DOI 10.1016/j.mhpa.2016.02.001
   National Institute for Clinical Excellence, 2014, PSYCH SCHIZ AD PREV
   Reeve S, 2018, PSYCHIAT RES, V269, P673, DOI 10.1016/j.psychres.2018.08.090
   Rotondi A, 2014, USING TECHNOLOGY SUP, P69
   Santesteban-Echarri O, 2020, J TELEMED TELECARE, V26, P14, DOI 10.1177/1357633X18794100
   Torous J, 2020, SCHIZOPHR RES, V218, P36, DOI 10.1016/j.schres.2020.04.013
   Turkington D, 2002, BRIT J PSYCHIAT, V180, P523, DOI 10.1192/bjp.180.6.523
   Turkington D, 2018, COGENT PSYCHOL, V5, DOI 10.1080/23311908.2018.1497749
   Turkington D, 2014, J NERV MENT DIS, V202, P30, DOI 10.1097/NMD.0000000000000070
   Varshney U, 2014, DECIS SUPPORT SYST, V66, P20, DOI 10.1016/j.dss.2014.06.001
   Waller G, 2020, INT J EAT DISORDER, V53, P1132, DOI 10.1002/eat.23289
   Waller H, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-255
   Wilhelm S, 2020, BEHAV THER, V51, P1, DOI 10.1016/j.beth.2019.08.001
   Wright JH, 2010, HIGH YIELD COGNITIVE
NR 38
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0010-3853
EI 1573-2789
J9 COMMUNITY MENT HLT J
JI Community Ment. Health J.
DI 10.1007/s10597-020-00718-0
EA OCT 2020
PG 5
WC Health Policy & Services; Public, Environmental & Occupational Health;
   Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health; Psychiatry
GA NV4XC
UT WOS:000574325500001
PM 33001323
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tucker, JS
   Amico, EJ
   Pedersen, ER
   Garvey, R
   Rodriguez, A
   Klein, DJ
AF Tucker, Joan S.
   Amico, Elizabeth J.
   Pedersen, Eric R.
   Garvey, Rick
   Rodriguez, Anthony
   Klein, David J.
TI Behavioral Health and Service Usage During the COVID-19 Pandemic Among
   Emerging Adults Currently or Recently Experiencing Homelessness
SO JOURNAL OF ADOLESCENT HEALTH
LA English
DT Article
DE COVID-19; Young people; Homelessness; Mental health; Substance use;
   Services
ID YOUTH
AB Purpose: This study provides information on how the coronavirus disease 2019 (COVID-19) outbreak is affecting emerging adults currently or recently homeless in terms of engagement in protective behaviors, mental health, substance use, and access to services.
   Methods: Ninety participants in an ongoing clinical trial of a risk reduction program for homeless, aged 18-25 years, were administered items about COVID-19 between April 10 and July 9, 2020.
   Results: Most participants reported engaging in COVID-19 protective behaviors. Past week mental health symptoms were reported by 38%-48% of participants, depending on symptoms. Among those who used substances before the outbreak, 16%-28% reported increased use of alcohol, tobacco, and marijuana. More than half of the participants reported increased difficulty meeting basic needs (e.g., food), and approximately 32%-44% reported more difficulty getting behavioral health services since the outbreak.
   Conclusions: Innovative strategies are needed to address the increased behavioral health needs of young people experiencing homelessness during events such as the COVID-19 outbreak. (C) 2020 Society for Adolescent Health and Medicine. All rights reserved.
C1 [Tucker, Joan S.; Amico, Elizabeth J.; Pedersen, Eric R.; Garvey, Rick; Klein, David J.] RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA.
   [Pedersen, Eric R.] Univ Southern Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90007 USA.
   [Rodriguez, Anthony] RAND Corp, Boston, MA USA.
RP Tucker, JS (corresponding author), RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA.
EM jtucker@rand.org
FU National Institute on Alcohol Abuse and AlcoholismUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)
   [R01AA025641]
FX This work was supported by grant R01AA025641 from the National Institute
   on Alcohol Abuse and Alcoholism (principal investigator: J.S.T.).
CR Centers for Disease Control and Prevention, 2020, INT GUID HOM SERV PL
   Edidin JP, 2012, CHILD PSYCHIAT HUM D, V43, P354, DOI 10.1007/s10578-011-0270-1
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Henry M, 2020, 2019 ANN HOMELESS AS
   Johns Hopkins Bloomberg School of Public Health (JHSPH), 2020, COVID 19 MENT HLTH M
   Kulik DM, 2011, PAED CHILD HEALT-CAN, V16, pE43, DOI 10.1093/pch/16.6.e43
   Pedersen ER, 2018, HEALTH SERV RES, V53, P4609, DOI 10.1111/1475-6773.12990
   Pedersen ER, 2016, J ADOLESCENT HEALTH, V59, P144, DOI 10.1016/j.jadohealth.2016.03.035
   Quimby EG, 2012, BEHAV SCI-BASEL, V2, DOI 10.3390/bs2030186
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Tucker JS, 2020, ADDICT SCI CLIN PRAC, V15, DOI 10.1186/s13722-020-00201-x
   Tucker JS, 2018, CHILD YOUTH SERV REV, V91, P347, DOI 10.1016/j.childyouth.2018.06.027
   Tucker JS, 2017, J SUBST ABUSE TREAT, V76, P20, DOI 10.1016/j.jsat.2017.02.008
   Whitbeck LB, 2004, J ADOLESCENT HEALTH, V35, P132, DOI 10.1016/j.jadohealth.2003.08.011
NR 14
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1054-139X
EI 1879-1972
J9 J ADOLESCENT HEALTH
JI J. Adolesc. Health
PD OCT
PY 2020
VL 67
IS 4
BP 603
EP 605
DI 10.1016/j.jadohealth.2020.07.013
PG 3
WC Psychology, Developmental; Public, Environmental & Occupational Health;
   Pediatrics
SC Psychology; Public, Environmental & Occupational Health; Pediatrics
GA NT5ZH
UT WOS:000573018200025
PM 32792255
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Feng, ZC
   Li, ENE
   Yao, SH
   Yu, QZ
   Zhou, WM
   Mao, XW
   Li, HL
   Kang, WD
   Ouyang, X
   Mei, J
   Zeng, QH
   Liu, JC
   Ma, XQ
   Rong, PF
   Wang, W
AF Feng, Zhichao
   Li, Jennifer
   Yao, Shanhu
   Yu, Qizhi
   Zhou, Wenming
   Mao, Xiaowen
   Li, Huiling
   Kang, Wendi
   Ouyang, Xin
   Mei, Ji
   Zeng, Qiuhua
   Liu, Jincai
   Ma, Xiaoqian
   Rong, Pengfei
   Wang, Wei
TI Clinical Factors Associated with Progression and Prolonged Viral
   Shedding in COVID-19 Patients: A Multicenter Study
SO AGING AND DISEASE
LA English
DT Article
DE Viral pneumonia; coronavirus disease 2019; disease progression; viral
   shedding; risk factors
ID ANGIOTENSIN-CONVERTING ENZYME-2; ACE2; CORONAVIRUS; PNEUMONIA; SARS
AB Coronavirus disease 2019 (COVID-19) is a global pandemic associated with a high mortality. Our study aimed to determine the clinical risk factors associated with disease progression and prolonged viral shedding in patients with COVID-19. Consecutive 564 hospitalized patients with confirmed COVID-19 between January 17, 2020 and February 28, 2020 were included in this multicenter, retrospective study. The effects of clinical factors on disease progression and prolonged viral shedding were analyzed using logistic regression and Cox regression analyses. 69 patients (12.2%) developed severe or critical pneumonia, with a higher incidence in the elderly and in individuals with underlying comorbidities, fever, dyspnea, and laboratory and imaging abnormalities at admission. Multivariate logistic regression analysis indicated that older age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02-1.06), hypertension without receiving angiotensinogen converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) therapy (OR, 2.29; 95% CI, 1.14-4.59), and chronic obstructive pulmonary disease (OR, 7.55; 95% CI, 2.44-23.39) were independent risk factors for progression to severe or critical pneumonia. Hypertensive patients without receiving ACEI/ARB therapy showed higher lactate dehydrogenase levels and computed tomography (CT) lung scores at about 3 days after admission than those on ACEI/ARB therapy. Multivariate Cox regression analysis revealed that male gender (hazard ratio [HR], 1.22; 95% CI, 1.02-1.46), receiving lopinavir/ritonavir treatment within 7 days from illness onset (HR, 0.75; 95% CI, 0.63-0.90), and receiving systemic glucocorticoid therapy (HR, 1.79; 95% CI, 1.46-2.21) were independent factors associated with prolonged viral shedding. Our findings presented several potential clinical factors associated with developing severe or critical pneumonia and prolonged viral shedding, which may provide a rationale for clinicians in medical resource allocation and early intervention.
C1 [Feng, Zhichao; Yao, Shanhu; Li, Huiling; Kang, Wendi; Ma, Xiaoqian; Rong, Pengfei; Wang, Wei] Cent South Univ, Xiangya Hosp 3, Dept Radiol, Changsha, Hunan, Peoples R China.
   [Feng, Zhichao; Yao, Shanhu; Ma, Xiaoqian; Rong, Pengfei; Wang, Wei] Cent South Univ, Mol Imaging Res Ctr, Changsha, Hunan, Peoples R China.
   [Li, Jennifer] Univ Sydney, Fac Med & Hlth, Westmead Clin Sch, Sydney, NSW, Australia.
   [Yu, Qizhi] First Hosp Changsha, Dept Radiol, Changsha, Hunan, Peoples R China.
   [Zhou, Wenming] First Hosp Yueyang, Dept Med Imaging, Yueyang, Hunan, Peoples R China.
   [Mao, Xiaowen] Cent Hosp Shaoyang, Dept Med Imaging, Shaoyang, Hunan, Peoples R China.
   [Ouyang, Xin] Cent Hosp Xiangtan, Dept Radiol, Xiangtan, Hunan, Peoples R China.
   [Mei, Ji] Second Hosp Changde, Dept Radiol, Changde, Hunan, Peoples R China.
   [Zeng, Qiuhua] Cent Hosp Loudi, Dept Radiol, Loudi, Hunan, Peoples R China.
   [Liu, Jincai] Univ South China, Affiliated Hosp 1, Dept Radiol, Hengyang, Hunan, Peoples R China.
RP Rong, PF; Wang, W (corresponding author), Cent South Univ, Xiangya Hosp 3, Changsha, Hunan, Peoples R China.
EM rongpengfei66@163.com; cjr.wangwei@vip.163.com
OI yao, shanhu/0000-0002-9782-4692
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81771827, 81471715]
FX We thank Hongzhuan Tan, from the Department of Epidemiology, Xiangya
   School of Public Health, Central South University for his kind support
   and advice in statistical analysis. We also thank Wei Nie, Qin Liu, Jing
   Zhao, Junhong Duan, Zhimin Yan, and Min Yang, from Department of
   Radiology, Ying Li, from Health Management Center, Sujie Jia, from
   Department of Pharmacy, Third Xiangya Hospital, Central South
   University, for their help in data collection and analysis. They were
   not compensated for their contributions. This study was supported by
   National Natural Science Foundation of China (81771827, 81471715).
CR Agata J, 2006, HYPERTENS RES, V29, P865, DOI 10.1291/hypres.29.865
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Barba C, 2004, LANCET, V363, P157, DOI 10.1016/s0140-6736(03)15268-3
   Burrell LM, 2005, EUR HEART J, V26, P369, DOI 10.1093/eurheartj/ehi114
   Cai QX, 2020, DIABETES CARE, V43, P1392, DOI 10.2337/dc20-0576
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cook TM, 2020, ANAESTHESIA, V75, P976, DOI 10.1111/anae.15103
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Fu Y, 2020, EUROPEAN RESP J, DOI [10.1183/13993003.01190- 2020:2001190., DOI 10.1183/13993003.01190-2020:2001190]
   Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan Wei-jie, 2020, EUR RESP J, V55
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Koka V, 2008, AM J PATHOL, V172, P1174, DOI 10.2353/ajpath.2008.070762
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Mendoza-Torres Evelyn, 2015, Ther Adv Cardiovasc Dis, V9, P217, DOI 10.1177/1753944715597623
   Mortensen EM, 2008, EUR RESPIR J, V31, P611, DOI 10.1183/09031936.00162006
   Muchtar E, 2017, BRIT J HAEMATOL, V178, P888, DOI 10.1111/bjh.14830
   Ocaranza MP, 2006, HYPERTENSION, V48, P572, DOI 10.1161/01.HYP.0000237862.94083.45
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
   Yan D, 2020, EUR RESPIR J, DOI [10.1183/13993003.00799-2020:2000799., DOI 10.1183/13993003.00799-2020:2000799]
   Yang Y, 2020, EPIDEMIOLOGICAL CLIN, DOI [10.1101/2020.02.10.20021675 %J medRxiv:2020.2002.2010.20021675., DOI 10.1101/2020.02.10.20021675%JMEDRXIV:2020.2002.2010.20021675]
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zu ZY, 2020, RADIOLOGY, DOI [10.1148/radiol.2020200490:200490, DOI 10.1148/RADIOL.2020200490:200490]
NR 45
TC 0
Z9 0
U1 5
U2 5
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD OCT
PY 2020
VL 11
IS 5
BP 1069
EP 1081
DI 10.14336/AD.2020.0630
PG 13
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA NV6KQ
UT WOS:000574428300005
PM 33014523
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Guzman-Prado, Y
AF Guzman-Prado, Yuli
TI Retraction of Studies on Potential Drug Therapies for COVID-19: A Call
   for Reliability and Scientific Integrity
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Letter
C1 [Guzman-Prado, Yuli] Int Ctr Med Res, Poole, Dorset, England.
RP Guzman-Prado, Y (corresponding author), Int Ctr Med Res, Poole, Dorset, England.
OI Guzman-Prado, Yuli/0000-0002-0433-1371
CR Guzman-Prado Y., 2020, AM J CARDIOL, DOI [10.1016/j.amj-card.2020.06.003., DOI 10.1016/J.AMJ-CARD.2020.06.003]
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
NR 3
TC 0
Z9 0
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD OCT 1
PY 2020
VL 132
BP 173
EP 173
DI 10.1016/j.amjcard.2020.06.061
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NU6QN
UT WOS:000573767100001
PM 32713654
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Saeki, T
   Ogawa, F
   Chiba, R
   Nonogaki, M
   Uesugi, J
   Takeuchi, I
   Nakamura, T
AF Saeki, Takuya
   Ogawa, Fumihiro
   Chiba, Ryosuke
   Nonogaki, Manabu
   Uesugi, Jo
   Takeuchi, Ichiro
   Nakamura, Takeshi
TI Rehabilitation Therapy for a COVID-19 Patient Who Received Mechanical
   Ventilation in Japan
SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION
LA English
DT Article
DE Novel Coronavirus Infection; Mobilization in the Acute Phase; Acute
   Phase; Physical Function; Case Report
AB A 65-yr-old man visited a primary care hospital with a continued fever of 38 degrees C for 3 days. As his fever did not improve until 8 days after, he was admitted into another acute care hospital, where his respiratory condition rapidly worsened. Therefore, the patient was transferred to our hospital. On the day of transfer (day 1), he was started on mechanical ventilation. COVID-19 was diagnosed using a polymerase chain reaction assay 6 days after admission (day 6). The rehabilitation therapy was begun on day 6. The initial rehabilitation programs focused on positioning and postural drainage. The patient was extubated on day 19, and he began standing and stepping on the same day. Gait exercises began on day 22, and endurance training was initiated on day 28. The patient was discharged from our hospital on day 34 as he met the physical function milestones. One month after discharge, the Medical Research Council sum score and Barthel Index had each improved; therefore, muscle strength and daily activities had returned to normal. It was assumed that mobilization should be performed as soon as possible after the end of sedation during the acute phase of severe COVID-19 infection in patients receiving mechanical ventilation.
C1 [Saeki, Takuya; Nonogaki, Manabu; Nakamura, Takeshi] Yokohama City Univ, Grad Sch Med, Dept Rehabil Med, Yokohama, Kanagawa, Japan.
   [Saeki, Takuya; Chiba, Ryosuke; Uesugi, Jo] Yokohama City Univ Med, Dept Rehabil Med, Yokohama, Kanagawa, Japan.
   [Ogawa, Fumihiro; Takeuchi, Ichiro] Yokohama City Univ, Grad Sch Med, Dept Emergency Med, Yokohama, Kanagawa, Japan.
RP Nakamura, T (corresponding author), Yokohama City Univ, Grad Sch Med, Dept Rehabil Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guerin C, 2013, NEW ENGL J MED, V368, P2159, DOI 10.1056/NEJMoa1214103
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9
   Thomas P, 2020, J PHYSIOTHER, V66, P73, DOI 10.1016/j.jphys.2020.03.011
   World Health Organization, 2020, 46 WHO
NR 7
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0894-9115
EI 1537-7385
J9 AM J PHYS MED REHAB
JI Am. J. Phys. Med. Rehabil.
PD OCT
PY 2020
VL 99
IS 10
BP 873
EP 875
DI 10.1097/PHM.0000000000001545
PG 3
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA NV9SP
UT WOS:000574651900008
PM 32732744
OA Green Published
DA 2021-01-01
ER

PT J
AU Scarsi, M
   Piantoni, S
   Colombo, E
   Airo, P
   Richini, D
   Miclini, M
   Bertasi, V
   Bianchi, M
   Bottone, D
   Civelli, P
   Cotelli, MS
   Damiolini, E
   Galbassini, G
   Gatta, D
   Ghirardelli, ML
   Magri, R
   Malamani, P
   Mendeni, M
   Molinari, S
   Morotti, A
   Salada, L
   Turla, M
   Vender, A
   Tincani, A
   Brucato, A
   Franceschini, F
   Furloni, R
   Andreoli, L
AF Scarsi, Mirko
   Piantoni, Silvia
   Colombo, Enrico
   Airo, Paolo
   Richini, Donata
   Miclini, Marco
   Bertasi, Valeria
   Bianchi, Marta
   Bottone, Damiano
   Civelli, Patrizia
   Cotelli, Maria-Sofia
   Damiolini, Ezio
   Galbassini, Gloria
   Gatta, Diego
   Ghirardelli, Maria-Laura
   Magri, Roberto
   Malamani, Paola
   Mendeni, Monia
   Molinari, Stefano
   Morotti, Andrea
   Salada, Luisa
   Turla, Marinella
   Vender, Angiola
   Tincani, Angela
   Brucato, Antonio
   Franceschini, Franco
   Furloni, Roberto
   Andreoli, Laura
TI Association between treatment with colchicine and improved survival in a
   single-centre cohort of adult hospitalised patients with COVID-19
   pneumonia and acute respiratory distress syndrome
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
DE therapeutics; anti-inflammatory agents; non-steroidal; antirheumatic
   agents; communicable diseases; imported; inflammation
AB Objectives The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC). Methods In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction). Results Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%)vs63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk. Conclusion This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials.
C1 [Scarsi, Mirko; Colombo, Enrico; Richini, Donata; Miclini, Marco; Galbassini, Gloria; Ghirardelli, Maria-Laura; Malamani, Paola; Mendeni, Monia; Molinari, Stefano; Furloni, Roberto] ASST Valcamonica, Dept Internal Med, Hosp Esine, I-25050 Esine, Lombardia, Italy.
   [Scarsi, Mirko; Colombo, Enrico; Richini, Donata; Miclini, Marco; Bertasi, Valeria; Bianchi, Marta; Bottone, Damiano; Civelli, Patrizia; Cotelli, Maria-Sofia; Damiolini, Ezio; Galbassini, Gloria; Gatta, Diego; Ghirardelli, Maria-Laura; Magri, Roberto; Malamani, Paola; Mendeni, Monia; Molinari, Stefano; Morotti, Andrea; Salada, Luisa; Turla, Marinella; Furloni, Roberto] ASST Valcamonica, COVID Unit, Hosp Esine, Esine, Lombardia, Italy.
   [Piantoni, Silvia; Tincani, Angela; Franceschini, Franco; Andreoli, Laura] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy.
   [Piantoni, Silvia; Airo, Paolo; Tincani, Angela; Franceschini, Franco; Andreoli, Laura] ASST Spedali Civili Brescia, Rheumatol & Clin Immunol Unit, Brescia, Lombardia, Italy.
   [Bertasi, Valeria; Bianchi, Marta; Civelli, Patrizia; Cotelli, Maria-Sofia; Morotti, Andrea; Turla, Marinella] ASST Valcamonica, Neurol Unit, Hosp Esine, Esine, Lombardia, Italy.
   [Bottone, Damiano; Damiolini, Ezio; Gatta, Diego; Magri, Roberto; Salada, Luisa] ASST Valcamonica, Pneumol Unit, Hosp Esine, Esine, Lombardia, Italy.
   [Vender, Angiola] ASST Valcamonica, Hosp Pharm, Hosp Esine, Esine, Lombardia, Italy.
   [Brucato, Antonio] Univ Milan, Dept Biomed & Clin Sci Sacco, Osped Fatebenefratelli, Milan, Italy.
RP Scarsi, M (corresponding author), ASST Valcamonica, Dept Internal Med, Hosp Esine, I-25050 Esine, Lombardia, Italy.
EM m.scarsi@asst-valcamonica.it
RI Cotelli, Maria Sofia/K-4534-2017; brucato, antonio/C-5983-2019
OI Cotelli, Maria Sofia/0000-0002-7010-2809; brucato,
   antonio/0000-0002-7566-5600
CR AIFA, SPER CLIN COVID 19
   Angelidis C, 2018, CURR PHARM DESIGN, V24, P659, DOI 10.2174/1381612824666180123110042
   [Anonymous], 2020, INFEZ MED, V28, P143
   ColCorona, TRIAL REQ
   Deftereos SG, 2020, HELL J CARDIOL, V61, P42, DOI 10.1016/j.hjc.2020.03.002
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Gultekin N, 2014, J PAK MED ASSOC, V64, P1420
   Ishizuka T, 2005, RESPIROLOGY, V10, P541, DOI 10.1111/j.1440-1843.2005.00733.x
   Karamanou M, 2018, CURR PHARM DESIGN, V24, P654, DOI 10.2174/1381612824666180115105850
   Lazaros G, 2018, CURR PHARM DESIGN, V24, P702, DOI 10.2174/1381612824666180116101823
   Maestroni S, 2017, INT J CARDIOL, V229, P42, DOI 10.1016/j.ijcard.2016.10.031
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Milewska A, 2018, J VIROL, V92, DOI 10.1128/JVI.01933-17
   Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010
   Pereira EG, 2016, AN BRAS DERMATOL, V91, P231, DOI 10.1590/abd1806-4841.20164029
   Spoto S, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-018-3606-7
   Stewart S, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-2120-7
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 20
TC 8
Z9 9
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD OCT
PY 2020
VL 79
IS 10
BP 1286
EP 1289
DI 10.1136/annrheumdis-2020-217712
PG 4
WC Rheumatology
SC Rheumatology
GA NU8YZ
UT WOS:000573924600024
PM 32732245
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Aouba, A
   Baldolli, A
   Geffray, L
   Verdon, R
   Bergot, E
   Martin-Silva, N
   Justet, A
AF Aouba, Achille
   Baldolli, Aurelie
   Geffray, Loik
   Verdon, Renaud
   Bergot, Emmanuel
   Martin-Silva, Nicolas
   Justet, Aurelien
TI Targeting the inflammatory cascade with anakinra in moderate to severe
   COVID-19 pneumonia: case series
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Letter
DE antirheumatic agents; biological therapy; cytokines; interleukin 1
   receptor antagonist protein; therapeutics
C1 [Aouba, Achille; Martin-Silva, Nicolas] CHU Caen, Dept Internal Med & Clin Immunol, Caen, France.
   [Baldolli, Aurelie; Verdon, Renaud] CHU Caen, Dept Infect Dis, Caen, France.
   [Geffray, Loik] CH Lisieux, Dept Internal Med & Clin Immunol, Lisieux, France.
   [Bergot, Emmanuel; Justet, Aurelien] CHU Caen, Dept Pulmonol, Caen, France.
RP Aouba, A (corresponding author), CHU Caen, Serv Med Interne, F-14000 Caen, France.
EM achille.aouba@gmail.com
CR Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Xu X, 2020, EFFECTIVE TREATMENT
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
NR 5
TC 41
Z9 43
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD OCT
PY 2020
VL 79
IS 10
BP 1381
EP 1381
DI 10.1136/annrheumdis-2020-217706
PG 1
WC Rheumatology
SC Rheumatology
GA NU8YZ
UT WOS:000573924600036
PM 32376597
OA Bronze
DA 2021-01-01
ER

PT J
AU Politi, I
   McParland, E
   Smith, R
   Crummey, S
   Fan, K
AF Politi, I
   McParland, E.
   Smith, R.
   Crummey, S.
   Fan, K.
TI The impact of COVID-19 on cervicofacial infection of dental aetiology
SO BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY
LA English
DT Article
DE COVID-19; pandemic; lockdown; dental infection; cervico-facial
   infection; dental facial infection; post dental extraction infection;
   incision and drainage; urgent dental care centres; UDCC; dental
   emergency
AB Cervicofacial infections of dental aetiology can be life-threatening and with the closure of dental practices following the onset of the COVID19, it would be anticipated that their prevalence presenting to maxillofacial surgery would increase and services may be overwhelmed, with patients presenting later with a potential subsequent increase in morbidity. A retrospective analysis of patients with cervicofacial infection of dental aetiology referred to maxillofacial surgery during the initial six weeks of COVID-19 lockdown in 2020 was carried out and compared with the equivalent period in the two preceding years. Unexpectedly, during COVID-19 lockdown, there was a reduction in patients seen with cervicofacial infection of dental aetiology. This may have resulted from patient adherence to government guidelines "Stay at home", successful triaging of patients in primary care and emergency treatment provided by urgent dental care centres. Proportionally more patients who presented to hospital had received prior antibiotic therapy and required in-patient admission. All patients admitted received incision and drainage, with an increase extraoral drainage and an associated reduction in length of stay. During COVID-19 lockdown, maxillofacial managed a reduced number of patients with cervicofacial infection, likely resulting from primary and secondary dental care working together. The rate of incision and drainage of patients not admitted increased under local anaesthesia with increase of extraoral drainage and reduced length of stay for those admitted. Crown Copyright (C) 2020 Published by Elsevier Ltd on behalf of The British Association of Oral and Maxillofacial Surgeons. All rights reserved.
C1 [Politi, I; McParland, E.; Smith, R.; Crummey, S.] Kings Coll Hosp London, Dept Oral & Maxillofacial Surg, London SE5 9RS, England.
   [Fan, K.] Kings Coll London, Fac Dent Oral & Craniofacial Sci, London, England.
RP Fan, K (corresponding author), Kings Coll London, Fac Dent Oral & Craniofacial Sci, London, England.
EM kfan@nhs.net
CR Bali Rishi Kumar, 2015, Natl J Maxillofac Surg, V6, P136, DOI 10.4103/0975-5950.183867
   Dave M, 2020, LANCET, V395, P1257, DOI 10.1016/S0140-6736(20)30806-0
   GOV.UK, 2020, COR COVID 19 UK
   Hammond D, 2020, BRIT J ORAL MAX SURG, V58, P834, DOI 10.1016/j.bjoms.2020.05.008
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Long L, 2020, BRIT J ORAL MAX SURG, V58, P713, DOI 10.1016/j.bjoms.2020.04.030
   NHS England and NHS Improvement, 2020, PREP NESS LETT PRIM
   Obisesan O, 2020, BRIT J ORAL MAX SURG, V58, P727, DOI 10.1016/j.bjoms.2020.04.031
   Razai MS, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m800
NR 9
TC 0
Z9 0
U1 1
U2 1
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0266-4356
EI 1532-1940
J9 BRIT J ORAL MAX SURG
JI Br. J. Oral Maxillofac. Surg.
PD OCT
PY 2020
VL 58
IS 8
BP 1029
EP 1033
DI 10.1016/j.bjoms.2020.07.017
PG 5
WC Dentistry, Oral Surgery & Medicine; Surgery
SC Dentistry, Oral Surgery & Medicine; Surgery
GA NU1TC
UT WOS:000573422900027
PM 32811723
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Parzy, G
   Daviet, F
   Puech, B
   Sylvestre, A
   Guervilly, C
   Porto, A
   Hraiech, S
   Chaumoitre, K
   Papazian, L
   Forel, JM
AF Parzy, Gabriel
   Daviet, Florence
   Puech, Basile
   Sylvestre, Aude
   Guervilly, Christophe
   Porto, Alizee
   Hraiech, Sami
   Chaumoitre, Kathia
   Papazian, Laurent
   Forel, Jean-Marie
TI Venous Thromboembolism Events Following Venovenous Extracorporeal
   Membrane Oxygenation for Severe Acute Respiratory Syndrome Coronavirus 2
   Based on CT Scans
SO CRITICAL CARE MEDICINE
LA English
DT Article
DE acute respiratory distress syndrome; cannula; deep vein thrombosis;
   extracorporeal membrane oxygenation; severe acute respiratory syndrome
   coronavirus 2
ID THROMBOSIS
AB Objectives: The main objective of the study was to determine the prevalence of venous thromboembolism events in patients infected with severe acute respiratory syndrome coronavirus 2 requiring venovenous extracorporeal membrane oxygenation. The secondary objective was to compare venous thromboembolism events and coagulation variables in patients requiring venovenous extracorporeal membrane oxygenation according to the pathogen. Design: Retrospective observational analysis at a single center. Setting: Tertiary referral university teaching hospital. Patients: Patients with severe acute respiratory syndrome coronavirus 2-related severe acute respiratory distress syndrome requiring venovenous extracorporeal membrane oxygenation therapy with an injected CT scan performed after extracorporeal membrane oxygenation retrieval. Interventions: None. Measurements and Main Results: We included 13 severe acute respiratory syndrome coronavirus 2 patients requiring venovenous extracorporeal membrane oxygenation. All of these patients experienced venous thromboembolism: 10 patients (76.9%) had isolated cannula-associated deep vein thrombosis, two patients (15.4%) had isolated pulmonary embolism, and one patient (7.7%) had both cannula-associated deep vein thrombosis and pulmonary embolism. Eleven patients (84.6%) had cannula-associated deep vein thrombosis. A jugular associated cannula-associated deep vein thrombosis was identified in seven patients (53.8%), a femoral associated cannula-associated deep vein thrombosis was identified in 10 patients (76.9%), and six patients (46.2%) had both femoral and jugular cannula-associated deep vein thrombosis. A pulmonary embolism was found in three patients (23.1%). No patient had central venous catheter-related deep vein thrombosis. One patient had thrombotic occlusion of the centrifugal pump, and one had oxygenator thrombosis requiring circuit replacement. Three patients (23.1%) had significant bleeding. Three patients (23.1%) had laboratory-confirmed heparin-induced thrombocytopenia, and all of them developed cannula-associated deep vein thrombosis. These three patients had femoral cannula-associated deep vein thrombosis, and two had an oxygenator or pump thrombosis. The mean activated partial thromboplastin time ratio was higher in the severe acute respiratory syndrome coronavirus 2 group than in the influenza group and the community-acquired pneumonia group (1.91 vs 1.48 vs 1.53;p= 0.001), which was also found in regard to the percentage of patients with an activated partial thromboplastin time ratio greater than 1.8 (47.8% vs 20% vs 20.9%;p= 0.003) and the mean prothrombin ratio (86.3 vs 61.6 vs 67.1;p= 0.003). There was no difference in baseline characteristics or venous thromboembolism events. Conclusions: We report a 100% occurrence of venous thromboembolism in critically ill patients supported by venovenous extracorporeal membrane oxygenation for severe acute respiratory syndrome coronavirus 2-related acute respiratory distress syndrome using CT scan imaging despite a high target and close monitoring of anticoagulation.
C1 [Parzy, Gabriel; Daviet, Florence; Sylvestre, Aude; Guervilly, Christophe; Hraiech, Sami; Papazian, Laurent; Forel, Jean-Marie] CHU Nord, AP HM, Med Intens Reanimat Detresses Resp & Infect Sever, Marseille, France.
   [Parzy, Gabriel; Daviet, Florence; Sylvestre, Aude; Guervilly, Christophe; Hraiech, Sami; Papazian, Laurent; Forel, Jean-Marie] Aix Marseille Univ, CEReSS Ctr Studies & Res Hlth Serv & Qual Life, EA3279, Marseille, France.
   [Puech, Basile; Chaumoitre, Kathia] CHU Nord, AP HM, Serv Imagerie Med, Marseille, France.
   [Porto, Alizee] CHU Timone, AP HM, Dept Chirurg Cardiaque, Marseille, France.
RP Parzy, G (corresponding author), CHU Nord, AP HM, Med Intens Reanimat Detresses Resp & Infect Sever, Marseille, France.; Parzy, G (corresponding author), Aix Marseille Univ, CEReSS Ctr Studies & Res Hlth Serv & Qual Life, EA3279, Marseille, France.
EM gabriel.parzy@ap-hm.fr
FU Xenios Fresenius Medical Care; Sedana
FX Dr. Guervilly received funding from Xenios Fresenius Medical Care. Dr.
   Papazian's institution received funding from Sedana (grant for a study),
   and he received funding from Lowenstein and Hamilton. The remaining
   authors have disclosed that they do not have any potential conflicts of
   interest.
CR Abrams D, 2019, LANCET RESP MED, V7, P108, DOI 10.1016/S2213-2600(18)30506-X
   Beyls C, 2020, BR J ANAESTH
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bowles L, 2020, N ENGL J MED
   Cooper E, 2015, CRIT CARE MED, V43, pE581, DOI 10.1097/CCM.0000000000001277
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   McGonagle D, 2020, LANCET RHEUMATOL
   Menaker J, 2017, ASAIO J, V63, P588, DOI 10.1097/MAT.0000000000000539
   Parzy G, 2020, CRIT CARE MED, V48, P192, DOI 10.1097/CCM.0000000000004129
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
NR 11
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0090-3493
EI 1530-0293
J9 CRIT CARE MED
JI Crit. Care Med.
PD OCT
PY 2020
VL 48
IS 10
BP E971
EP E975
DI 10.1097/CCM.0000000000004504
PG 5
WC Critical Care Medicine
SC General & Internal Medicine
GA NU4MF
UT WOS:000573616600016
PM 32618700
OA Green Published
DA 2021-01-01
ER

PT J
AU Ino, H
AF Ino, Hiroyasu
TI Vaccine mandate in long-term care facilities
SO GERIATRICS & GERONTOLOGY INTERNATIONAL
LA English
DT Letter
DE COVID-19; geriatrics; long-term care facilities; medical ethics; vaccine
   policy
C1 [Ino, Hiroyasu] Univ Tokyo Hosp, Tokyo, Japan.
RP Ino, H (corresponding author), Univ Tokyo Hosp, Tokyo, Japan.
EM i-no@umin.ac.jp
RI Ino, Hiroyasu/AAH-2719-2020
OI Ino, Hiroyasu/0000-0001-5561-0111
CR Attwell K, 2018, VACCINE, V36, P7377, DOI 10.1016/j.vaccine.2018.10.019
   Brown JG, 2000, NURSING HOME VACCINA
   Caplan A, 2011, LANCET, V378, P310, DOI 10.1016/S0140-6736(11)61156-2
   Clark S, 2018, FLU VACCINE NURSING
   Comas-Herrera A., 2020, MORTALITY ASS COVID
   Field RI, 2008, KENNEDY INST ETHIC J, V18, P111
   Kluge HHP, 2020, STATEMENT PRESS 0423
   Malm H, 2015, KENNEDY INST ETHIC J, V25, P133, DOI 10.1353/ken.2015.0013
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042
   Pawelec G, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00180-2
   Stockman F, 2020, NY TIMES
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1444-1586
EI 1447-0594
J9 GERIATR GERONTOL INT
JI Geriatr. Gerontol. Int.
PD OCT
PY 2020
VL 20
IS 10
BP 995
EP 996
DI 10.1111/ggi.14023
PG 2
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA NV0TA
UT WOS:000574044500027
PM 33003254
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hippisley-Cox, J
   Young, D
   Coupland, C
   Channon, KM
   Tan, PS
   Harrison, DA
   Rowan, K
   Aveyard, P
   Pavord, ID
   Watkinson, PJ
AF Hippisley-Cox, Julia
   Young, Duncan
   Coupland, Carol
   Channon, Keith M.
   Tan, Pui San
   Harrison, David A.
   Rowan, Kathryn
   Aveyard, Paul
   Pavord, Ian D.
   Watkinson, Peter J.
TI Risk of severe COVID-19 disease with ACE inhibitors and angiotensin
   receptor blockers: cohort study including 8.3 million people
SO HEART
LA English
DT Article
AB Background There is uncertainty about the associations of angiotensive enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) drugs with COVID-19 disease. We studied whether patients prescribed these drugs had altered risks of contracting severe COVID-19 disease and receiving associated intensive care unit (ICU) admission.
   Methods This was a prospective cohort study using routinely collected data from 1205 general practices in England with 8.28 million participants aged 20-99 years. We used Cox proportional hazards models to derive adjusted HRs for exposure to ACE inhibitor and ARB drugs adjusted for sociodemographic factors, concurrent medications and geographical region. The primary outcomes were: (a) COVID-19 RT-PCR diagnosed disease and (b) COVID-19 disease resulting in ICU care.
   Findings Of 19 486 patients who had COVID-19 disease, 1286 received ICU care. ACE inhibitors were associated with a significantly reduced risk of COVID-19 disease (adjusted HR 0.71, 95% CI 0.67 to 0.74) but no increased risk of ICU care (adjusted HR 0.89, 95% CI 0.75 to 1.06) after adjusting for a wide range of confounders. Adjusted HRs for ARBs were 0.63 (95% CI 0.59 to 0.67) for COVID-19 disease and 1.02 (95% CI 0.83 to 1.25) for ICU care.
   There were significant interactions between ethnicity and ACE inhibitors and ARBs for COVID-19 disease. The risk of COVID-19 disease associated with ACE inhibitors was higher in Caribbean (adjusted HR 1.05, 95% CI 0.87 to 1.28) and Black African (adjusted HR 1.31, 95% CI 1.08 to 1.59) groups than the white group (adjusted HR 0.66, 95% CI 0.63 to 0.70). A higher risk of COVID-19 with ARBs was seen for Black African (adjusted HR 1.24, 95% CI 0.99 to 1.58) than the white (adjusted HR 0.56, 95% CI 0.52 to 0.62) group.
   Interpretation ACE inhibitors and ARBs are associated with reduced risks of COVID-19 disease after adjusting for a wide range of variables. Neither ACE inhibitors nor ARBs are associated with significantly increased risks of receiving ICU care. Variations between different ethnic groups raise the possibility of ethnic-specific effects of ACE inhibitors/ARBs on COVID-19 disease susceptibility and severity which deserves further study.
C1 [Hippisley-Cox, Julia] Univ Oxford, Primary Care Hlth Sci, Oxford OX1 2JD, England.
   [Young, Duncan] John Radcliffe Hosp, Adult Intens Care Unit, Oxford, England.
   [Young, Duncan] Univ Oxford, Kadoorie Ctr, Oxford, England.
   [Coupland, Carol] Univ Nottingham, Sch Med, Div Primary Care, Nottingham, England.
   [Channon, Keith M.; Watkinson, Peter J.] Univ Oxford, John Radcliffe Hosp, Div Cardiovasc Med, British Heart Fdn,Ctr Res Excellence, Oxford, England.
   [Tan, Pui San; Aveyard, Paul] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England.
   [Harrison, David A.] ICNARC, Clin Trials Unit, London, England.
   [Rowan, Kathryn] Intens Care Natl Audit & Res Ctr ICNARC, London, England.
   [Pavord, Ian D.] Univ Oxford, Resp Med Unit, Res Bldg,Old Rd Campus, Oxford, England.
   [Pavord, Ian D.] Univ Oxford, Oxford Resp NIHR BRC Nuffield Dept Med NDM, Res Bldg,Old Rd Campus, Oxford, England.
   [Watkinson, Peter J.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford NIHR BRC, Oxford, England.
RP Hippisley-Cox, J (corresponding author), Univ Oxford, Primary Care Hlth Sci, Oxford OX1 2JD, England.
EM Julia.Hippisley-Cox@phc.ox.ac.uk
RI Hippisley-Cox, Julia/AAY-2788-2020; Harrison, David/O-4355-2018
OI Hippisley-Cox, Julia/0000-0002-2479-7283; channon,
   keith/0000-0002-1043-4342; Watkinson, Peter/0000-0003-1023-3927;
   Harrison, David/0000-0002-9002-9098
FU NIHR Oxford Biomedical Research CentreNational Institute for Health
   Research (NIHR); Medical Sciences Division of the University of Oxford;
   John Fell Oxford University Press Research Fund; Oxford Wellcome
   Institutional Strategic Support Fund [204826/Z/16/Z]; Cancer Research UK
   (CR-UK) through the Cancer Research UK Oxford Centre [C5255/A18085];
   Wellcome TrustWellcome Trust [221514/Z/20/Z]; British Heart
   FoundationBritish Heart Foundation [CH/16/1/32013]; NIHR Oxford
   Biomedical Research Centre and Applied Research Centre
FX This study was supported by funds from the NIHR Oxford Biomedical
   Research Centre and the Medical Sciences Division of the University of
   Oxford. QResearch is funded by the John Fell Oxford University Press
   Research Fund, the Oxford Wellcome Institutional Strategic Support Fund
   (204826/Z/16/Z), Cancer Research UK (CR-UK) grant number C5255/A18085,
   through the Cancer Research UK Oxford Centre and the Wellcome Trust
   (grant number is 221514/Z/20/Z). It also receives contributions in kind
   from EMIS Health (commercial supplier of NHS health computer systems).
   KC is supported by the British Heart Foundation (CH/16/1/32013). PA is
   an NIHR senior investigator and funded by NIHR Oxford Biomedical
   Research Centre and Applied Research Centre. JH is the guarantor of the
   study and had full access to all the data in the study and had final
   responsibility for the decision to submit for publication.
CR Berlin I, 2020, NICOTINE TOB RES, V22, P1650, DOI 10.1093/ntr/ntaa059
   Cai GS, 2020, AM J RESP CRIT CARE, V201, P1557, DOI 10.1164/rccm.202003-0693LE
   CHANGEUX jean-pierre, 2020, QEIOS
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Coupland CAC, 2019, JAMA INTERN MED, V179, P1084, DOI 10.1001/jamainternmed.2019.0677
   Damian MS, 2020, EUR J NEUROL, V27, P557, DOI 10.1111/ene.14106
   European Society of Cardiology, 2020, POS STAT ESC COUNC H
   Ferrando-Vivas P, 2017, J CRIT CARE, V38, P335, DOI 10.1016/j.jcrc.2016.11.031
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guslandi M, 1999, BRIT J CLIN PHARMACO, V48, P481
   Hippisley-Cox JYD, 2020, CORONAVIRUS RECORD L
   Kontopantelis E, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020738
   Ledford Heidi, 2020, Nature, DOI 10.1038/d41586-020-01295-8
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Maier LA, 2004, AM J RESP CRIT CARE, V169, P893, DOI 10.1164/rccm.2402023
   Majeed Azeem, 2004, Health Stat Q, P5
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta N, 2020, JAMA CARDIOL
   Miyara MTF, 2020, QEIOS
   National Institute for Clinical Excellence, 2019, HYP AD DIAGN MAN NIC
   Pareek M, 2020, LANCET, V395, P1421, DOI 10.1016/S0140-6736(20)30922-3
   Piva S, 2020, J CRIT CARE, V58, P29, DOI 10.1016/j.jcrc.2020.04.004
   Public Health England, 2020, DISP RISK OUTC COVID
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Steyerberg EW, 2007, J CLIN EPIDEMIOL, V60, P979, DOI 10.1016/j.jclinepi.2007.03.003
   Trials C, 2020, LOS PAT COVID 19 NOT
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
NR 30
TC 11
Z9 11
U1 4
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1355-6037
EI 1468-201X
J9 HEART
JI Heart
PD OCT
PY 2020
VL 106
IS 19
BP 1503
EP 1511
DI 10.1136/heartjnl-2020-317393
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NU8WM
UT WOS:000573918100013
PM 33153994
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Flacco, ME
   Martellucci, CA
   Bravi, F
   Parruti, G
   Cappadona, R
   Mascitelli, A
   Manfredini, R
   Mantovani, LG
   Manzoli, L
AF Flacco, Maria Elena
   Martellucci, Cecilia Acuti
   Bravi, Francesca
   Parruti, Giustino
   Cappadona, Rosaria
   Mascitelli, Alfonso
   Manfredini, Roberto
   Mantovani, Lorenzo G.
   Manzoli, Lamberto
TI Treatment with ACE inhibitors or ARBs and risk of severe/lethal
   COVID-19: a meta-analysis
SO HEART
LA English
DT Article
AB Objective It has been hypothesised that the use of ACE inhibitors and angiotensin receptor blockers (ARBs) might either increase or reduce the risk of severe or lethal COVID-19. The findings from the available observational studies varied, and summary estimates are urgently needed to elucidate whether these drugs should be suspended during the pandemic, or patients and physicians should be definitely reassured. This meta-analysis of adjusted observational data aimed to summarise the existing evidence on the association between these medications and severe/lethal COVID-19.
   Methods We searched MedLine, Scopus and preprint repositories up to 8 June 2020 to retrieve cohort or case-control studies comparing the risk of severe/fatal COVID-19 (either mechanical ventilation, intensive care unit admission or death), among hypertensive subjects treated with: (1) ACE inhibitors, (2) ARBs and (3) both, versus untreated subjects. Data were combined using a random-effect generic inverse variance approach.
   Results Ten studies, enrolling 9890 hypertensive subjects were included in the analyses. Compared with untreated subjects, those using either ACE inhibitors or ARBs showed a similar risk of severe or lethal COVID-19 (summary OR: 0.90; 95% CI 0.65 to 1.26 for ACE inhibitors; 0.92; 95% CI 0.75 to 1.12 for ARBs). The results did not change when both drugs were considered together, when death was the outcome and excluding the studies with significant, divergent results.
   Conclusion The present meta-analysis strongly supports the recommendation of several scientific societies to continue ARBs or ACE inhibitors for all patients, unless otherwise advised by their physicians who should thus be reassured.
C1 [Flacco, Maria Elena; Cappadona, Rosaria; Manzoli, Lamberto] Univ Ferrara, Dept Med Sci, Ferrara, Emilia Romagna, Italy.
   [Martellucci, Cecilia Acuti] Polytech Univ Marche, Sch Med & Surg, Ancona, Marche, Italy.
   [Bravi, Francesca] Univ Hosp Ferrara, Arcispedale St Anna Med Dept, Cona, Emilia Romagna, Italy.
   [Parruti, Giustino] Local Hlth Unit Pescara, Infect Dis Unit, Pescara, Italy.
   [Mascitelli, Alfonso] Reg Healthcare Agcy Abruzzo, Pescara, Italy.
   [Manfredini, Roberto] Univ Ferrara, Dipartimento Sci Med, Ferrara, Italy.
   [Mantovani, Lorenzo G.] Univ Milano Bicocca, Ctr Publ Hlth Res, Milan, Lombardia, Italy.
   [Mantovani, Lorenzo G.] IRCCS MultiMed, Sesto San Giovanni, Lombardia, Italy.
RP Manzoli, L (corresponding author), Univ Ferrara, Med Sci, I-44121 Ferrara, Italy.
EM lmanzoli@post.harvard.edu
RI Manzoli, Lamberto/K-1895-2018; Flacco, Maria Elena/E-3306-2017
OI Manzoli, Lamberto/0000-0002-8129-9344; Flacco, Maria
   Elena/0000-0003-1404-4314; CAPPADONA, Rosaria/0000-0003-3254-6043
CR American Hearth Association, 2020, PAT TAK ACE I ARBS W
   [Anonymous], 2020, CLIN INFECT DIS, V71, P899, DOI 10.1093/cid/ciaa492
   Bavishi C, 2020, JAMA CARDIOL, V5, P745, DOI 10.1001/jamacardio.2020.1282
   Bean D, 2020, TREATMENT ACE UNPUB
   Bravi F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235248
   Carr D., 2020, SHARING RES DATA FIN
   de Abajo FJ, 2020, LANCET, V395, P1705, DOI 10.1016/S0140-6736(20)31030-8
   European Medicines Agency, 2020, EM ADV CONT US MED H
   European Society of Cardiology, 2020, POS STAT ESC COUNC H
   Giorgi Rossi P, 2020, CHARACTERISTICS OUTC
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo T, 2020, JAMA CARDIOL
   Karakiulakis G, 2020, LANCET RESP MED
   Kuster GM, 2020, EUR HEART J, V41, P1857, DOI 10.1093/eurheartj/ehaa335
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Manfredini R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030404
   Manzoli L, 2016, EUR J EPIDEMIOL, V31, P351, DOI 10.1007/s10654-015-0104-8
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Mehta N, 2020, JAMA CARDIOL
   Page MJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011863
   Reynolds HR, 2020, N ENGL J MED
   Thomas LE, 2020, JAMA CARDIOL
   Vaduganathan M, 2020, NEW ENGL J MED, V382
   Wang BY, 2020, J HUM HYPERTENS, DOI 10.1038/s41371-020-0314-8
   Wells G, 2005, NEWCASTLE OTTAWA SCA
   World Health Organization, 2020, COVID 19 US ANG CONV
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang P, 2020, CIRC RES
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 32
TC 6
Z9 6
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1355-6037
EI 1468-201X
J9 HEART
JI Heart
PD OCT
PY 2020
VL 106
IS 19
BP 1519
EP +
DI 10.1136/heartjnl-2020-317336
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NU8WM
UT WOS:000573918100015
PM 32611676
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Strickland, E
   Zorpette, G
AF Strickland, Eliza
   Zorpette, Glenn
TI COVID-19 HAS TAUGHT US THAT FORESIGHT AND TECH ARE A WINNING COMBINATION
   PREPPING FOR THE NEXT BIG ONE
SO IEEE SPECTRUM
LA English
DT Article
AB When the Spanish flu pandemic swept across the globe in 1918, it ravaged a population with essentially no technological countermeasures. There were no diagnostic tests, no mechanical ventilators, and no antiviral or widely available anti-inflammatory medications other than aspirin. The first inactivated-virus vaccines would not become available until 1936. An estimated 50 million people died. Today, a best-case scenario predicts 1.3 million fatalities from COVID-19 in 2020, according to projections by Imperial College London, and rapidly declining numbers after that. That in a world with 7.8 billion people-more than four times as many as in 1918. Many factors have lessened mortality this time, including better implementation of social-distancing measures. But technology is also a primary bulwark. Since January of this year, roughly US $50 billion has been spent in the United States alone to ramp up testing, diagnosis, modeling, treatment, vaccine creation, and other tech-based responses,
NR 0
TC 0
Z9 0
U1 2
U2 2
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9235
EI 1939-9340
J9 IEEE SPECTRUM
JI IEEE Spectr.
PD OCT
PY 2020
VL 57
IS 10
BP 21
EP 23
PG 3
WC Engineering, Electrical & Electronic
SC Engineering
GA NU6UR
UT WOS:000573777900013
DA 2021-01-01
ER

PT J
AU Jakob, CEM
   Borgmann, S
   Duygu, F
   Behrends, U
   Hower, M
   Merle, U
   Friedrichs, A
   Tometten, L
   Hanses, F
   Jung, N
   Rieg, S
   Wille, K
   Gruner, B
   Klinker, H
   Gersbacher-Runge, N
   Hellwig, K
   Eberwein, L
   Dolff, S
   Rauschning, D
   von Bergwelt-Baildon, M
   Lanznaster, J
   Strauss, R
   Trauth, J
   de With, K
   Ruethrich, M
   Lueck, C
   Nattermann, J
   Tscharntke, L
   Pilgram, L
   Fuhrmann, S
   Classen, A
   Stecher, M
   Schons, M
   Spinner, C
   Vehreschild, JJ
AF Jakob, Carolin E. M.
   Borgmann, Stefan
   Duygu, Fazilet
   Behrends, Uta
   Hower, Martin
   Merle, Uta
   Friedrichs, Anette
   Tometten, Lukas
   Hanses, Frank
   Jung, Norma
   Rieg, Siegbert
   Wille, Kai
   Gruener, Beate
   Klinker, Hartwig
   Gersbacher-Runge, Nicole
   Hellwig, Kerstin
   Eberwein, Lukas
   Dolff, Sebastian
   Rauschning, Dominic
   von Bergwelt-Baildon, Michael
   Lanznaster, Julia
   Strauss, Richard
   Trauth, Janina
   de With, Katja
   Ruethrich, Maria
   Lueck, Catherina
   Nattermann, Jacob
   Tscharntke, Lene
   Pilgram, Lisa
   Fuhrmann, Sandra
   Classen, Annika
   Stecher, Melanie
   Schons, Maximilian
   Spinner, Christoph
   Vehreschild, Joerg Janne
TI First results of the "Lean European Open Survey on SARS-CoV-2-Infected
   Patients (LEOSS)"
SO INFECTION
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; LEOSS; Cohort study
AB Purpose Knowledge regarding patients' clinical condition at severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection is sparse. Data in the international, multicenter Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS) cohort study may enhance the understanding of COVID-19. Methods Sociodemographic and clinical characteristics of SARS-CoV-2-infected patients, enrolled in the LEOSS cohort study between March 16, 2020, and May 14, 2020, were analyzed. Associations between baseline characteristics and clinical stages at diagnosis (uncomplicated vs. complicated) were assessed using logistic regression models. Results We included 2155 patients, 59.7% (1,287/2,155) were male; the most common age category was 66-85 years (39.6%; 500/2,155). The primary COVID-19 diagnosis was made in 35.0% (755/2,155) during complicated clinical stages. A significant univariate association between age; sex; body mass index; smoking; diabetes; cardiovascular, pulmonary, neurological, and kidney diseases; ACE inhibitor therapy; statin intake and an increased risk for complicated clinical stages of COVID-19 at diagnosis was found. Multivariable analysis revealed that advanced age [46-65 years: adjusted odds ratio (aOR): 1.73, 95% CI 1.25-2.42,p = 0.001; 66-85 years: aOR 1.93, 95% CI 1.36-2.74,p < 0.001; > 85 years: aOR 2.38, 95% CI 1.49-3.81,p < 0.001 vs. individuals aged 26-45 years], male sex (aOR 1.23, 95% CI 1.01-1.50,p = 0.040), cardiovascular disease (aOR 1.37, 95% CI 1.09-1.72,p = 0.007), and diabetes (aOR 1.33, 95% CI 1.04-1.69,p = 0.023) were associated with complicated stages of COVID-19 at diagnosis. Conclusion The LEOSS cohort identified age, cardiovascular disease, diabetes and male sex as risk factors for complicated disease stages at SARS-CoV-2 diagnosis, thus confirming previous data. Further data regarding outcomes of the natural course of COVID-19 and the influence of treatment are required.
C1 [Jakob, Carolin E. M.; Jung, Norma; Tscharntke, Lene; Fuhrmann, Sandra; Classen, Annika; Stecher, Melanie; Schons, Maximilian; Vehreschild, Joerg Janne] Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany.
   [Jakob, Carolin E. M.; Behrends, Uta; Nattermann, Jacob; Classen, Annika; Stecher, Melanie; Spinner, Christoph; Vehreschild, Joerg Janne] German Ctr Infect Res DZIF, Braunschweig, Germany.
   [Borgmann, Stefan] Ingolstadt Hosp, Dept Infect Dis & Infect Control, Ingolstadt, Germany.
   [Duygu, Fazilet] Goethe Univ Frankfurt, Dept Internal Med, Infect Dis, Frankfurt, Germany.
   [Behrends, Uta] Tech Univ Munich, Childrens Hosp, Munich, Germany.
   [Behrends, Uta] Helmholtz Zentrum Muenchen, Res Unit Gene Vectors, Munich, Germany.
   [Hower, Martin] Hosp Dortmund gGmbH, Clin Pneumol Infectiol Internal Med & Intens Care, Dortmund, Germany.
   [Merle, Uta] Heidelberg Univ Hosp, Dept Gastroenterol & Infectiol, Heidelberg, Germany.
   [Friedrichs, Anette] Univ Hosp Schleswig Holstein, Dept Internal Med, Kiel, Germany.
   [Tometten, Lukas] Klinikum Ernst von Bergmann, Dept Gastroenterol & Infectiol, Potsdam, Germany.
   [Hanses, Frank] Univ Hosp Regensburg, Emergency Dept, Regensburg, Germany.
   [Rieg, Siegbert] Univ Freiburg, Dept Med 2, Freiburg, Germany.
   [Wille, Kai] Univ Bochum, Univ Clin Haematol Oncol Haemostaseol & Palliat C, Minden, Germany.
   [Gruener, Beate] Univ Hosp Ulm, Dept Internal Med 3, Div Infect Dis, Ulm, Germany.
   [Klinker, Hartwig] Univ Wurzburg, Dept Med 2, Div Infect Dis, Med Ctr, Wurzburg, Germany.
   [Gersbacher-Runge, Nicole] Ctr Infectiol Berlin Prenzlauer Berg, Berlin, Germany.
   [Hellwig, Kerstin] Ruhr Univ Bochum, Dept Neurol, Katholisches Klinikum Bochum, Bochum, Germany.
   [Eberwein, Lukas] Klinikum Leverkusen gGmbH, Dept Internal Med 4, Leverkusen, Germany.
   [Dolff, Sebastian] Univ Duisburg Essen, Univ Hosp Essen, Dept Infect Dis, Essen, Germany.
   [Rauschning, Dominic] Bundeswehr Cent Hosp, Koblenz, Germany.
   [von Bergwelt-Baildon, Michael] Ludwig Maximilians Univ Munchen, Dept Internal Med 3, Munich, Germany.
   [von Bergwelt-Baildon, Michael] German Canc Consortium DKTK, Partner Site Munich, Munich, Germany.
   [von Bergwelt-Baildon, Michael] Bavarian Ctr Canc Res BZKF, Munich, Germany.
   [Lanznaster, Julia] Hosp Passau, Med Clin 2, Passau, Germany.
   [Strauss, Richard] Univ Hosp Erlangen, Dept Med 1, Erlangen, Germany.
   [Trauth, Janina] Univ Hosp Giessen, Med Clin 2, Giessen, Germany.
   [de With, Katja] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Div Infect Dis, Dresden, Germany.
   [Ruethrich, Maria] Univ Hosp Jena, Dept Internal Med 2, Jena, Germany.
   [Lueck, Catherina] Hannover Med Sch, Dept Haematol Haemostasis Oncol & Stem Cell Trans, Hannover, Germany.
   [Nattermann, Jacob] UKB Univ Hosp Bonn, Dept Internal Med 1, Bonn, Germany.
   [Spinner, Christoph] Tech Univ Munich, Univ Hosp Rechts Isar, Sch Med, Dept Internal Med 2, Munich, Germany.
   [Pilgram, Lisa; Vehreschild, Joerg Janne] Goethe Univ Frankfurt, Dept Internal Med Hematol & Oncol, Frankfurt, Germany.
RP Vehreschild, JJ (corresponding author), Univ Cologne, Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany.; Vehreschild, JJ (corresponding author), German Ctr Infect Res DZIF, Braunschweig, Germany.; Vehreschild, JJ (corresponding author), Goethe Univ Frankfurt, Dept Internal Med Hematol & Oncol, Frankfurt, Germany.
EM joerg.vehreschild@uk-koeln.de
RI Rieg, Siegbert/ABB-7954-2020; Spinner, Christoph/H-7039-2019
OI Rieg, Siegbert/0000-0001-7493-7080; Spinner,
   Christoph/0000-0002-3875-5367
FU Projekt DEAL
FX No funding was received for this study. Open Access funding provided by
   Projekt DEAL.
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen QQ, 2020, INFECTION, V48, P543, DOI 10.1007/s15010-020-01432-5
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   COVID-19 National Emergency Response Center Epidemiology and Case Management Team Korea Centers for Disease Control and Prevention, 2020, Osong Public Health Res Perspect, V11, P85, DOI 10.24171/j.phrp.2020.11.2.05
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Dreher M, 2020, DTSCH ARZTEBL INT, V117, P271, DOI 10.3238/arztebl.2020.0271
   Gotzinger F, 2020, LANCET CHILD ADOLESC, V4, P653, DOI 10.1016/S2352-4642(20)30177-2
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Henry BM, 2020, INT UROL NEPHROL, V52, P1193, DOI 10.1007/s11255-020-02451-9
   International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC), 2020, COVID 19 REP 19 MAY
   Lewnard JA, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1923
   Mackey K, 2020, ANN INTERN MED, V173, P195, DOI 10.7326/M20-1515
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Moon AM, 2020, J HEPATOL, V73, P705, DOI 10.1016/j.jhep.2020.05.013
   Petrilli CM, 2010, FACTORS ASS HOSPITAL, DOI 10.1101/2020.04.08.20057794
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang L, 2020, MED MALADIES INFECT, V50, P332, DOI 10.1016/j.medmal.2020.03.007
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 2
Z9 2
U1 3
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
DI 10.1007/s15010-020-01499-0
EA OCT 2020
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA NV4SE
UT WOS:000574312700001
PM 33001409
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Catteau, L
   Dauby, N
   Montourcy, M
   Bottieau, E
   Hautekiet, J
   Goetghebeur, E
   van Ierssel, S
   Duysburgh, E
   Van Oyen, H
   Wyndham-Thomas, C
   Van Beckhoven, D
   Bafort, K
   Belkhir, L
   Bossuyt, N
   Caprasse, P
   Colombie, V
   De Munter, P
   Deblonde, J
   Delmarcelle, D
   Delvallee, M
   Demeester, R
   Dugernier, T
   Holemans, X
   Kerzmann, B
   Machurot, PY
   Minette, P
   Minon, JM
   Mokrane, S
   Nachtergal, C
   Noirhomme, S
   Pierard, D
   Rossi, C
   Schirvel, C
   Sermijn, E
   Staelens, F
   Triest, F
   Van Goethem, N
   Van Praet, J
   Vanhoenacker, A
   Verstraete, R
   Willems, E
AF Catteau, Lucy
   Dauby, Nicolas
   Montourcy, Marion
   Bottieau, Emmanuel
   Hautekiet, Joris
   Goetghebeur, Els
   van Ierssel, Sabrina
   Duysburgh, Els
   Van Oyen, Herman
   Wyndham-Thomas, Chloe
   Van Beckhoven, Dominique
   Bafort, Kristof
   Belkhir, Leila
   Bossuyt, Nathalie
   Caprasse, Philippe
   Colombie, Vincent
   De Munter, Paul
   Deblonde, Jessika
   Delmarcelle, Didier
   Delvallee, Melanie
   Demeester, Remy
   Dugernier, Thierry
   Holemans, Xavier
   Kerzmann, Benjamin
   Machurot, Pierre Yves
   Minette, Philippe
   Minon, Jean-Marc
   Mokrane, Saphia
   Nachtergal, Catherine
   Noirhomme, Severine
   Pierard, Denis
   Rossi, Camelia
   Schirvel, Carole
   Sermijn, Erica
   Staelens, Frank
   Triest, Filip
   Van Goethem, Nina
   Van Praet, Jens
   Vanhoenacker, Anke
   Verstraete, Roeland
   Willems, Elise
CA Belgian Collaborative Grp COVID-19
TI Low-dose hydroxychloroquine therapy and mortality in hospitalised
   patients with COVID-19: a nationwide observational study of 8075
   participants
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Hydroxychloroquine; COVID-19; SARS-CoV-2; Mortality; Observational study
ID AZITHROMYCIN; CORONAVIRUS
AB Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg. In Belgium, off-label use of low-dose HCQ (total 2400 mg over 5 days) was recommended for hospitalised patients with COVID-19. We conducted a retrospective analysis of in-hospital mortality in the Belgian national COVID-19 hospital surveillance data. Patients treated either with HCQ monotherapy and supportive care (HCQ group) were compared with patients treated with supportive care only (no-HCQ group) using a competing risks proportional hazards regression with discharge alive as competing risk, adjusted for demographic and clinical features with robust standard errors. Of 8075 patients with complete discharge data on 24 May 2020 and diagnosed before 1 May 2020, 4542 received HCQ in monotherapy and 3533 were in the no-HCQ group. Death was reported in 804/4542 (17.7%) and 957/3533 (27.1%), respectively. In the multivariable analysis, mortality was lower in the HCQ group compared with the no-HCQ group [adjusted hazard ratio (aHR) = 0.684, 95% confidence interval (CI) 0.617-0.758]. Compared with the no-HCQ group, mortality in the HCQ group was reduced both in patients diagnosed <= 5 days (n = 3975) and >5 days (n = 3487) after symptom onset [aHR = 0.701 (95% CI 0.617-0.796) and aHR = 0.647 (95% CI 0.525-0.797), respectively]. Compared with supportive care only, low-dose HCQ monotherapy was independently associated with lower mortality in hospitalised patients with COVID-19 diagnosed and treated early or later after symptom onset. (C) 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
C1 [Catteau, Lucy; Montourcy, Marion; Hautekiet, Joris; Duysburgh, Els; Van Oyen, Herman; Wyndham-Thomas, Chloe] Sciensano, Dept Epidemiol & Publ Hlth, Brussels, Belgium.
   [Dauby, Nicolas] CHU St Pierre, Dept Infect Dis, Brussels, Belgium.
   [Dauby, Nicolas] Univ Libre Bruxelles ULB, Inst Med Immunol, Brussels, Belgium.
   [Dauby, Nicolas] Univ Libre Bruxelles ULB, Publ Hlth Sch, Environm Hlth Res Ctr, Brussels, Belgium.
   [Bottieau, Emmanuel] Inst Trop Med, Dept Clin Sci, Antwerp, Belgium.
   [Hautekiet, Joris; Goetghebeur, Els] Univ Ghent, Dept Appl Math Comp Sci & Stat, Ghent, Belgium.
   [van Ierssel, Sabrina] Univ Hosp Antwerp UZA, Dept Gen Internal Med Infect Dis & Trop Med, Edegem, Belgium.
   [Van Oyen, Herman] Univ Ghent, Publ Hlth & Primary Care, Ghent, Belgium.
   [Dauby, Nicolas] Univ Libre Bruxelles ULB, Sch Publ Hlth, Dept Infect Dis, CHU St Pierre, Brussels, Belgium.
RP Dauby, N (corresponding author), CHU St Pierre, Dept Infect Dis, Brussels, Belgium.; Dauby, N (corresponding author), Univ Libre Bruxelles ULB, Inst Med Immunol, Brussels, Belgium.; Dauby, N (corresponding author), Univ Libre Bruxelles ULB, Publ Hlth Sch, Environm Hlth Res Ctr, Brussels, Belgium.; Dauby, N (corresponding author), Univ Libre Bruxelles ULB, Sch Publ Hlth, Dept Infect Dis, CHU St Pierre, Brussels, Belgium.
EM Nicolas.dauby@ulb.ac.be
RI Dauby, Nicolas/F-1235-2011
OI Dauby, Nicolas/0000-0002-7697-6849; van Ierssel, Sabrina
   H./0000-0003-2955-4130; Van Praet, Jens Tomas/0000-0002-7125-7001;
   catteau, lucy/0000-0003-4695-4275
CR [Anonymous], 2020, SCIENSANO INTERIM CL
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   da Silva JC, 2013, CLINICS, V68, P766, DOI 10.6061/clinics/2013(06)07
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Federal Agency for Medicines and Health Products (FAMHP), 2020, SUMM ADV DRUG REACT
   Feng YL, 2020, J MACH LEARN RES, V21
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grassin-Delyle Stanislas, 2020, Clin Infect Dis, V71, P2265, DOI 10.1093/cid/ciaa546
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]
   Jang CH, 2006, RHEUMATOLOGY, V45, P703, DOI 10.1093/rheumatology/kei282
   Kaptein SJ, 2020, BIORXIV, DOI [10.1101/2020.06.19.159053., DOI 10.1101/2020.06.19.159053]
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Lagier JC, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101791
   Lane J.C., 2020, SAFETY HYDROXYCHLORO, DOI [10.1101/2020.04.08.20054551, DOI 10.1101/2020.04.08.20054551]
   Le Borgne F, 2016, STAT MED, V35, P1103, DOI 10.1002/sim.6777
   Ledford H, 2020, NATURE, V582, P160, DOI 10.1038/d41586-020-01695-w
   Lee TC, 2020, INT J INFECT DIS, V98, P216, DOI 10.1016/j.ijid.2020.06.095
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   Martin-Blondel G, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa558
   Mertens P, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00225
   Mikami T, 2020, J GEN INTERN MED, DOI 10.1007/s11606-020-05983-z
   Oscanoa TJ, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106078
   Paccoud Olivier, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa791
   Perinel Sophie, 2020, Clin Infect Dis, V71, P2227, DOI 10.1093/cid/ciaa394
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Sbidian E, 2020, HYDROXYCHLOROQUINE A, DOI [10.1101/2020.06.16.20132597, DOI 10.1101/2020.06.16.20132597]
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Sciensano, 2020, COVID 19 B EP 25 MAI
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   van der Wal WM, 2011, J STAT SOFTW, V43, P1
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 45
TC 7
Z9 7
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD OCT
PY 2020
VL 56
IS 4
AR 106144
DI 10.1016/j.ijantimicag.2020.106144
PG 8
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NT9OZ
UT WOS:000573271200008
PM 32853673
OA Green Published
DA 2021-01-01
ER

PT J
AU Davido, B
   Boussaid, G
   Vaugier, I
   Lansaman, T
   Bouchand, F
   Lawrence, C
   Alvarez, JC
   Moine, P
   Perronne, V
   Barbot, F
   Saleh-Mghir, A
   Perronne, C
   Annane, D
   De Truchis, P
AF Davido, Benjamin
   Boussaid, Ghilas
   Vaugier, Isabelle
   Lansaman, Thibaud
   Bouchand, Frederique
   Lawrence, Christine
   Alvarez, Jean-Claude
   Moine, Pierre
   Perronne, Veronique
   Barbot, Frederic
   Saleh-Mghir, Azzam
   Perronne, Christian
   Annane, Djillali
   De Truchis, Pierre
CA COVID-19 RPC Team
TI Impact of medical care, including use of anti-infective agents, on
   prognosis of COVID-19 hospitalized patients over time
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE azithromycin; hydroxychloroquine; Covid-19; pneumonia
ID AZITHROMYCIN
AB Introduction: The effect of anti-infective agents in COVID-19 is unclear. The impact of changes in practice on prognosis over time has not been evaluated.
   Methods: Single center, retrospective study in adults hospitalized in a medicine ward for COVID-19 from March 5th to April 25th 2020. Patient characteristics were compared between two periods (before/after March 19th) considering French guidelines. The aim of the study was to evaluate how medical care impacted unfavorable outcome, namely admission to intensive care unit (ICU) and/or death.
   Results: A total of 132 patients were admitted: mean age 59.0 +/- 16.3 years; mean C-reactive protein (CRP) level 84.0 +/- 71.1 mg/L; 46% had a lymphocyte count <1000/mm(3). Prescribed anti-infective agents were lopinavir-ritonavir (n=12), azithromycin (AZI) (n=28) and AZI combined with hydroxychloroquine (HCQ) (n=52). There was a significant decrease in ICU admission, from 43% to 12%, between the two periods (P<0.0001). Delays until transfer to ICU were similar between periods (P=0.86). Pulmonary computerized tomography (CT)-scans were performed significantly more often with time (from 50% to 90%, P<0.0001), and oxygen-dependency (53% vs 80%, P=0.001) and prescription of AZI +/- HCQ (from 25% to 76%, P<0.0001) were also greater over time. Multivariate analyses showed a reduction of unfavorable outcome in patients receiving AZI +/- HCQ (hazard ratio [HR]=0.45, 95% confidence interval [CI: 0.21-0.97], P=0.04), particularly among an identified category of individuals (lymphocyte >= 1000/mm(3) or CRP >= 100 mg/L).
   Conclusion: The present study showed a significant decrease in admission to ICU over time, which was probably related to multiple factors, including a better indication of pulmonary CT-scan, oxygen therapy, and a suitable prescription of anti-infective agents. (C) 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
C1 [Davido, Benjamin; Perronne, Veronique; Saleh-Mghir, Azzam; Perronne, Christian; De Truchis, Pierre] Univ Paris Saclay, Hop Raymond Poincare, AP HP, Malad Infect, Garches, France.
   [Boussaid, Ghilas] Univ Paris Saclay, UVSQ, F-78000 Versailles, France.
   [Vaugier, Isabelle; Barbot, Frederic] Univ Paris Saclay, Hop Raymond Poincare, AP HP, Ctr Invest Clin,Inserm CIC 1429, Garches, France.
   [Lansaman, Thibaud] Univ Paris Saclay, Hop Raymond Poincare, AP HP, Reeduc Fonct, Garches, France.
   [Bouchand, Frederique] Univ Paris Saclay, Hop Raymond Poincare, AP HP, Pharm Hosp, Garches, France.
   [Lawrence, Christine] Univ Paris Saclay, Hop Raymond Poincare, AP HP, EOH, Garches, France.
   [Alvarez, Jean-Claude] Univ Paris Saclay, Hop Raymond Poincare, AP HP, Pharmaco Toxicol, Garches, France.
   [Moine, Pierre; Annane, Djillali] Univ Paris Saclay, Hop Raymond Poincare, AP HP, Reanimat Med, Garches, France.
RP Davido, B (corresponding author), Hop Raymond Poincare, Serv Malad Infect & Trop, F-92380 Garches, France.
EM benjamin.davido@aphp.fr
OI Davido, Benjamin/0000-0002-2859-8417
CR Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Bacharier LB, 2015, JAMA-J AM MED ASSOC, V314, P2034, DOI 10.1001/jama.2015.13896
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   COVID19 APHP Grp, 2020, LANCET, V395, P1760, DOI 10.1016/S0140-6736(20)31210-1
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Kumar A, 2011, J ANTIMICROB CHEMOTH, V66, P959, DOI 10.1093/jac/dkr090
   Lagier JC, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101791
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   SRLF-SFAR-SFMU-GFRUP-SPILF-SPLF, 2020, REC DEXP PORT PRIC C, P29
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Touret F., 2020, IN VITRO SCREENING F, DOI [10.1101/2020.04.03.023846., DOI 10.1101/2020.04.03.023846]
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD OCT
PY 2020
VL 56
IS 4
AR 106129
DI 10.1016/j.ijantimicag.2020.106129
PG 9
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NT9OZ
UT WOS:000573271200022
PM 32755653
OA Green Published
DA 2021-01-01
ER

PT J
AU Padilla, S
   Telenti, G
   Guillen, L
   Garcia, JA
   Garcia-Abellan, J
   Ding, C
   Mora, A
   Garcia-Pachon, E
   Gutierrez, F
   Masia, M
AF Padilla, Sergio
   Telenti, Guillermo
   Guillen, Lucia
   Garcia, Jose A.
   Garcia-Abellan, Javier
   Ding, Carolina
   Mora, Antonia
   Garcia-Pachon, Eduardo
   Gutierrez, Felix
   Masia, Mar
CA COVID19-Elx Grp
TI Predictive factors for cardiac conduction abnormalities with
   hydroxychloroquine-containing combinations for COVID-19
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; QT interval; Hydroxychloroquine; Azithromycin;
   Lopinaviri/ritonavir; Troponin
ID QT-INTERVAL
AB This longitudinal, prospective cohort study aimed to assess risk of QTc interval prolongation and its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19. Moderate-to-severe QTc prolongation during therapy was defined as a QTc interval >470 ms in men or >480 ms in women. Patients were treated under strict cardiac supervision. A total of 105 adults were included [56% male; median (IQR) age 69 (57-79) years]. All patients received therapy with HCQ in combination with azithromycin (AZM), and 95 (90%) also with lopinavir/ritonavir (LPV/r). Concomitant medications classified as having risk of developing torsades de pointes (TdP) were simultaneously used in 81 patients (77%). Moderate-to-severe QTc prolongation was observed in 14 patients (13%), mostly at Days 3-5 from baseline, with 6 (6%) developing severe prolongation (>500 ms). There was no evidence of TdP arrhythmia or TdP-associated death. Adding LPV/r to HCQ+AZM did not significantly prolong the QTc interval. Multivariable Cox regression revealed that comedications with known risk of TdP (HR = 11.28, 95% CI 1.08-117.41), higher neutrophil-to-lymphocyte (NLR) ratio (HR = 1.10, 95% CI 1.03-1.18 per unit increase) and higher serum hs-cardiac troponin I (HR = 4.09, 95% CI 1.36-12.2 per unit increase) were major contributors to moderate-to-severe QTc prolongation. In this closely screened and monitored cohort, no complications derived from QTc prolongation were observed during pharmacological therapy containing HCQ for COVID-19. Evidence of myocardial injury with elevated troponin and strong inflammatory response, specifically higher NLR, are conditions requiring careful QTc interval monitoring. (C) 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
C1 [Padilla, Sergio; Telenti, Guillermo; Guillen, Lucia; Garcia-Abellan, Javier; Ding, Carolina; Mora, Antonia; Gutierrez, Felix; Masia, Mar] Hosp Gen Univ Elche, Internal Med & Infect Dis Unit, Alicante, Spain.
   [Padilla, Sergio; Gutierrez, Felix; Masia, Mar] Univ Miguel Hernandez Elche, Alicante, Spain.
   [Garcia, Jose A.] Univ Miguel Hernandez, Operat Res Ctr, Stat, Alicante, Spain.
   [Garcia-Pachon, Eduardo] Hosp Gen Univ Elche, Sect Resp Med, Alicante, Spain.
RP Padilla, S; Gutierrez, F (corresponding author), Hosp Gen Univ Elche, Cami Almazara 11, Alicante 03203, Spain.
EM sergiopadurr@gmail.com; gutierrezfel@gmail.com
RI Fernandez-Gonzalez, Marta/U-7492-2017; Gutierrez, Felix/Q-7880-2018
OI Fernandez-Gonzalez, Marta/0000-0001-9949-8504; Gutierrez,
   Felix/0000-0002-9485-6867; Garcia-Pachon, Eduardo/0000-0002-7144-3197;
   Telenti, Guillermo/0000-0002-1571-6090; GARCIA GOMEZ, JOSE
   ALBERTO/0000-0002-1203-7260
FU Proyectos de Investigacion sobre el SARS-CoV-2 y enfermedad COVID-19 of
   the ISCIII [COV20/00005]
FX This work was partially supported by Proyectos de Investigacion sobre el
   SARS-CoV-2 y enfermedad COVID-19 of the ISCIII [COV20/00005].
CR Baden LR, 2020, NEW ENGL J MED, V382, P1851, DOI 10.1056/NEJMe2005477
   Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Blaschke D, 2007, PHARMACOPSYCHIATRY, V40, P294, DOI 10.1055/s-2007-992147
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Chen YT, 2018, BMC CARDIOVASC DISOR, V18, DOI 10.1186/s12872-018-0906-1
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   CredibleMeds, 2020, TDP RISK CAT
   Elliott A, 2018, CNS SPECTRUMS, V23, P278, DOI 10.1017/S1092852917000402
   European Medicine Agency (EMA), 2020, EMA1705902020
   Freeman BD, 2008, PHARMACOEPIDEM DR S, V17, P971, DOI 10.1002/pds.1637
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Goldenberg I, 2006, J CARDIOVASC ELECTR, V17, P333, DOI 10.1111/j.1540-8167.2006.00408.x
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hu H, 2020, EUR HEART J
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002
   Ohara H, 2015, CARDIOVASC TOXICOL, V15, P232, DOI 10.1007/s12012-014-9289-4
   Stella F, 2018, CURR DRUG METAB, V19, P641, DOI 10.2174/1389200219666171227203225
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   US Food and Drug Administration (FDA), 2020, FDA DRUG SAF COMM SA
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, COR DIS COVID 19 SIT
   Xiong TY, 2020, EUR HEART J, V41, P1798, DOI 10.1093/eurheartj/ehaa231
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yu CM, 2006, POSTGRAD MED J, V82, P140, DOI 10.1136/pgmj.2005.037515
NR 30
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD OCT
PY 2020
VL 56
IS 4
AR 106142
DI 10.1016/j.ijantimicag.2020.106142
PG 7
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NT9OZ
UT WOS:000573271200014
PM 32853675
OA Green Published
DA 2021-01-01
ER

PT J
AU Sims, OT
   Jackson, A
   Guo, YQ
   Truong, DN
   Odame, EA
   Mamudu, HM
AF Sims, Omar T.
   Jackson, Asti
   Guo, Yuqi
   Truong, Duong N.
   Odame, Emmanuel A.
   Mamudu, Hadii M.
TI A Cross-Sectional Analysis of Tobacco Use and Concurrent Alcohol and
   Substance Use Among Patients Living with HIV/HCV Co-infection: Findings
   from a Large Urban Tertiary Center
SO JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS
LA English
DT Article; Early Access
DE HIV; HCV; Tobacco; Smoking; Alcohol use; Substance use
ID ACTIVE ANTIRETROVIRAL THERAPY; SMOKING-CESSATION; CIGARETTE-SMOKING;
   CONSUMPTION QUESTIONS; VIRUS-INFECTION; SCREENING-TEST; HEPATITIS-B;
   HIV; SMOKERS; MORTALITY
AB This study aimed to assess the prevalence of and factors associated with tobacco use among patients living with HIV/HCV co-infection. Patient reported outcomes (PROs) were analyzed of patients living with HIV/HCV co-infection (n = 313) who presented for clinical evaluation and treatment of HCV between 2013 and 2017 at a university-affiliated HIV/HCV Co-infection Clinic. The prevalence of tobacco use in patients living with HIV/HCV co-infection was 48%. Compared to non-smokers, a higher proportion of tobacco smokers had substance use disorders and concurrent alcohol and substance use. In the multivariate analysis, concurrent alcohol and substance use was positively associated with tobacco use. The findings suggest clinical interventions are urgently needed to reduce tobacco use among patients living with HIV/HCV co-infection-a doubly-vulnerable immunocompromised population. Otherwise, failed efforts to dedicate resources and targeted behavioral interventions for this respective population will inhibit survival-especially considering the recent and evolving COVID-19 pandemic.
C1 [Sims, Omar T.] Univ Alabama Birmingham, Coll Arts & Sci, Dept Social Work, 3137 Univ Hall,1720 2nd Ave South, Birmingham, AL 35294 USA.
   [Sims, Omar T.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL 35294 USA.
   [Sims, Omar T.] Univ Alabama Birmingham, Sch Med, Ctr AIDS Res, Birmingham, AL 35294 USA.
   [Sims, Omar T.] Univ Alabama Birmingham, Sch Med, Integrat Ctr Aging Res, Birmingham, AL 35294 USA.
   [Sims, Omar T.] Univ Calif San Francisco, Dept Med, Div Prevent Sci, Ctr AIDS Prevent Studies, San Francisco, CA 94158 USA.
   [Jackson, Asti] Yale Univ, Sch Med, Dept Psychiat, 300 George St, New Haven, CT 06511 USA.
   [Guo, Yuqi] Univ N Carolina, Coll Hlth & Human Serv, Dept Social Work, 9201 Univ City Blvd, Charlotte, NC 28223 USA.
   [Truong, Duong N.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Care Org & Policy, 1665 Univ Blvd, Birmingham, AL 35233 USA.
   [Truong, Duong N.] Univ Alabama Birmingham, Collat Sch Business, 1665 Univ Blvd, Birmingham, AL 35233 USA.
   [Odame, Emmanuel A.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Environm Hlth Sci, RPHB 530B,1665 Univ Blvd, Birmingham, AL 35233 USA.
   [Mamudu, Hadii M.] East Tennessee State Univ, Coll Publ Hlth, Dept Hlth Serv Management & Policy, POB 70623, Johnson City, TN 37614 USA.
RP Sims, OT (corresponding author), Univ Alabama Birmingham, Coll Arts & Sci, Dept Social Work, 3137 Univ Hall,1720 2nd Ave South, Birmingham, AL 35294 USA.; Sims, OT (corresponding author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL 35294 USA.; Sims, OT (corresponding author), Univ Alabama Birmingham, Sch Med, Ctr AIDS Res, Birmingham, AL 35294 USA.; Sims, OT (corresponding author), Univ Alabama Birmingham, Sch Med, Integrat Ctr Aging Res, Birmingham, AL 35294 USA.; Sims, OT (corresponding author), Univ Calif San Francisco, Dept Med, Div Prevent Sci, Ctr AIDS Prevent Studies, San Francisco, CA 94158 USA.
EM sims.omar@gmail.com
OI sims, omar/0000-0002-3207-2231
FU National Institute on Drug AbuseUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [R25DA028567, R25DA035163, T32DA007238]
FX This work was supported by the National Institute on Drug Abuse under
   Grant R25DA028567 to Omar T. Sims and under Grants R25DA035163 and
   T32DA007238 to Asti Jackson. The study sponsor had no role in study
   design; collection, analysis, and interpretation of data; writing the
   report; and the decision to submit the paper for publication.
CR Arnson Y, 2010, J AUTOIMMUN, V34, pJ258, DOI 10.1016/j.jaut.2009.12.003
   Barrett SP, 2006, HUM PSYCHOPHARM CLIN, V21, P255, DOI 10.1002/hup.766
   Bean MC, 2016, SOUTH MED J, V109, P305, DOI 10.14423/SMJ.0000000000000460
   Berlin I, 2020, NICOTINE TOB RES, V22, P1650, DOI 10.1093/ntr/ntaa059
   Bhatta DN, 2018, TOB INDUC DIS, V16, DOI [10.18332/tid/83946, 10.18332/tid/86716]
   Bosh KA, 2018, EPIDEMIOL INFECT, V146, P920, DOI [10.1017/s0950268818000766, 10.1017/S0950268818000766]
   Bradley KA, 1998, ALCOHOL CLIN EXP RES, V22, P1842, DOI 10.1097/00000374-199811000-00034
   Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789
   Calvo M, 2015, AIDS REV, V17, P47
   Calvo-Sanchez M, 2015, HIV MED, V16, P201, DOI 10.1111/hiv.12193
   Cohn AM, 2018, AM J ADDICTION, V27, P491, DOI 10.1111/ajad.12766
   Creamer MR, 2019, MMWR-MORBID MORTAL W, V68, P1013, DOI 10.15585/mmwr.mm6845a2
   Cropsey KL, 2016, J ADDICT MED, V10, P13, DOI 10.1097/ADM.0000000000000172
   Easterbrook P, 2012, SEMIN LIVER DIS, V32, P147, DOI 10.1055/s-0032-1316476
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Feldman C, 2013, J INFECTION, V67, P169, DOI 10.1016/j.jinf.2013.05.004
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Gartner C, 2017, LANCET, V390, P2033, DOI 10.1016/S0140-6736(17)32460-1
   Gritz ER, 2013, CLIN INFECT DIS, V57, P608, DOI 10.1093/cid/cit349
   Helleberg M, 2013, CLIN INFECT DIS, V56, P727, DOI 10.1093/cid/cis933
   Hezode C, 2003, GUT, V52, P126, DOI 10.1136/gut.52.1.126
   Huang XY, 2020, ARCH IRAN MED, V23, P268, DOI 10.34172/aim.2020.09
   Humfleet GL, 2009, AIDS EDUC PREV, V21, P54, DOI 10.1521/aeap.2009.21.3_supp.54
   Jha P, 2013, NEW ENGL J MED, V368, P341, DOI 10.1056/NEJMsa1211128
   Jiang HB, 2020, LANCET HIV, V7, pE308, DOI 10.1016/S2352-3018(20)30105-3
   Keith A, 2016, JAIDS-J ACQ IMM DEF, V72, P527, DOI 10.1097/QAI.0000000000001007
   Kim RS, 2018, AM J MED, V131, P669, DOI 10.1016/j.amjmed.2018.01.011
   Konopnicki D, 2005, AIDS, V19, P593, DOI 10.1097/01.aids.0000163936.99401.fe
   Koziel MJ, 2007, NEW ENGL J MED, V356, P1445, DOI 10.1056/NEJMra065142
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lim JK, 2014, CLIN INFECT DIS, V58, P1449, DOI 10.1093/cid/ciu097
   Lo Re V, 2014, ANN INTERN MED, V160, P369, DOI 10.7326/M13-1829
   Massa A, 2012, J ADDICTION RES THER, DOI [10.4172/2155-6105.1000129, DOI 10.4172/2155-6105.1000129]
   Mercie P, 2018, LANCET HIV, V5, pE126, DOI 10.1016/S2352-3018(18)30002-X
   Nahvi S, 2009, AIDS EDUC PREV, V21, P14, DOI 10.1521/aeap.2009.21.3_supp.14
   National Center for Chronic Disease Prevention and Health Promotion (US), 2010, TOB SMOK CAUS DIS BI
   National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health, 2014, HLTH CONSMOK 50 YE
   National Institutes of Health, 2019, PAT REP OUTC MEAS IN
   Newcombe DAL, 2005, DRUG ALCOHOL REV, V24, P217, DOI 10.1080/09595230500170266
   Pessione F, 2001, HEPATOLOGY, V34, P121, DOI 10.1053/jhep.2001.25385
   Petrosillo N, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-16
   Pool ERM, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011120.pub2
   Promotion O. of D. P. and H, 2020, HLTH PEOPL
   Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087
   Rahmanian Shiva, 2011, Proc Am Thorac Soc, V8, P313, DOI 10.1513/pats.201009-058WR
   Shuter J, 2020, NICOTINE TOB RES, V22, P398, DOI 10.1093/ntr/nty208
   Shuter J, 2017, NICOTINE TOB RES, V19, P836, DOI 10.1093/ntr/ntw212
   Sims OT, 2020, J RACIAL ETHN HEALTH, V7, P28, DOI 10.1007/s40615-019-00630-8
   Sims OT, 2018, J COMMUN HEALTH, V43, P725, DOI 10.1007/s10900-018-0476-2
   Steel HC, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/8357109
   Strzelak A, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15051033
   Szabo G, 2010, ALCOHOL CLIN EXP RES, V34, P1675, DOI 10.1111/j.1530-0277.2010.01255.x
   Taylor LE, 2012, CLIN INFECT DIS, V55, pS33, DOI 10.1093/cid/cis367
   Teira R, 2013, AIDS, V27, P845, DOI 10.1097/QAD.0b013e32835ecaf7
   Tesoriero JM, 2010, AIDS BEHAV, V14, P824, DOI 10.1007/s10461-008-9449-2
   Thein HH, 2008, AIDS, V22, P1979, DOI 10.1097/QAD.0b013e32830e6d51
   Triant VA, 2020, NICOTINE TOB RES, V22, P1170, DOI 10.1093/ntr/ntz168
   U.S. Department of Health & Human Services, 2015, CALC US POP BAS RQ 5
   Vidrine DJ, 2012, NICOTINE TOB RES, V14, P106, DOI 10.1093/ntr/ntr121
   Zhao LJ, 2013, MED HYPOTHESES, V80, P131, DOI 10.1016/j.mehy.2012.11.009
   Zhao QW, 2020, J MED VIROL, V92, P1915, DOI 10.1002/jmv.25889
NR 61
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9583
EI 1573-3572
J9 J CLIN PSYCHOL MED S
JI J. Clin. Psychol. Med. Settings
DI 10.1007/s10880-020-09744-2
EA OCT 2020
PG 9
WC Psychology, Clinical
SC Psychology
GA NV5MX
UT WOS:000574366600001
PM 33001329
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Udrea, AM
   Avram, S
   Nistorescu, S
   Pascu, ML
   Romanitan, MO
AF Udrea, Ana-Maria
   Avram, Speranta
   Nistorescu, Simona
   Pascu, Mihail-Lucian
   Romanitan, Mihaela Oana
TI Laser irradiated phenothiazines: New potential treatment for COVID-19
   explored by molecular docking
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; Laser irradiated phenothiazines; Molecular docking
AB The worldwide infection with the new Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) demands urgently new potent treatment(s). In this study we predict, using molecular docking, the binding affinity of 15 phenothiazines (antihistaminic and antipsychotic drugs) when interacting with the main protease (M-pro) of SARS-CoV-2. Additionally, we tested the binding affinity of photoproducts identified after irradiation of phenothiazines with Nd:YAG laser beam at 266 nm respectively 355 nm. Our results reveal that thioridazine and its identified photoproducts (mesoridazine and sulforidazine) have high biological activity on the virus M-pro. This shows that thioridazine and its two photoproducts might represent new potent medicines to be used for treatment in this outbreak. Such results recommend these medicines for further tests on cell cultures infected with SARS-CoV-2 or animal model. The transition to human subjects of the suggested treatment will be smooth due to the fact that the drugs are already available on the market.
C1 [Udrea, Ana-Maria; Nistorescu, Simona; Pascu, Mihail-Lucian] Natl Inst Laser Plasma & Radiat Phys, Laser Dept, Magurele, Ilfov, Romania.
   [Udrea, Ana-Maria; Avram, Speranta] Univ Bucharest, Fac Biol, Dept Anat Anim Biol Anim Physiol & Biophys, Bucharest, Romania.
   [Nistorescu, Simona] Univ Bucharest, Fac Biol, Dept Bot & Microbiol, Bucharest, Romania.
   [Pascu, Mihail-Lucian] Univ Bucharest, Fac Phys, Magurele, Romania.
   [Romanitan, Mihaela Oana] Stockholm South Gen Hosp, Karolinska Inst, Dept Emergency Internal Med & Neurol, Stroke Res Network Sodersjukhuset, S-11883 Stockholm, Sweden.
RP Pascu, ML (corresponding author), Natl Inst Laser Plasma & Radiat Phys, Laser Dept, Magurele, Ilfov, Romania.
EM mihai.pascu@inflpr.ro
OI Udrea, Ana-Maria/0000-0002-7659-7435
FU Romanian National Authority for Scientific Research and Innovation,
   CNCS/CCCDI-UEFISCDI [PN-III-P1-1.1-PCCDI-2017-0728]
FX This work was supported by Romanian National Authority for Scientific
   Research and Innovation, CNCS/CCCDI-UEFISCDI, project
   PN-III-P1-1.1-PCCDI-2017-0728.
CR Abdel-Rahman LH, 2017, J PHOTOCH PHOTOBIO B, V170, P271, DOI 10.1016/j.jphotobiol.2017.04.003
   ALEXANDRU T, 2013, BIOCHEM PHARMACOL, V2, P1
   Alexandru T, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.5.051002
   Amaral L, 2004, IN VIVO, V18, P725
   Chang Y.C., 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2, DOI 10.20944/PREPRINTS202002.0242.V2]
   Dassault Systemes BIOVIA, 2019, BIOVIA DISC STUD
   Deng X, 2014, J VIROL, V88, P11886, DOI 10.1128/JVI.01528-14
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Forterre P, 2010, ORIGINS LIFE EVOL B, V40, P151, DOI 10.1007/s11084-010-9194-1
   Hou XB, 2013, J CHEM INF MODEL, V53, P188, DOI [10.1021/ci300117y, 10.1021/ci300417y]
   Kalkanidis M, 2002, BIOCHEM PHARMACOL, V63, P833, DOI 10.1016/S0006-2952(01)00840-1
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Khan S, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.01297-20, 10.1128/JCM.00187-20]
   Kujawski S.A., 2020, PUBLIC GLOBAL HLTH, DOI [10.1101/2020.03.09, DOI 10.1101/2020.03.09]
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Pinzi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184331
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Raha K, 2005, ANN REP COMPUT CHEM, V1, P113
   Smarandache A, 2012, PROC SPIE, V8411, DOI 10.1117/12.966414
   Takahashi D, 2013, PROTEIN SCI, V22, P347, DOI 10.1002/pro.2215
   Tozar T, 2019, MICROB PATHOGENESIS, V129, P250, DOI 10.1016/j.micpath.2019.02.012
   Tripathi SK, 2013, J THEOR BIOL, V334, P87, DOI 10.1016/j.jtbi.2013.05.014
   Udrea AM, 2018, FARMACIA, V66, P680, DOI 10.31925/farmacia.2018.4.18
   Vlad IM, 2020, MOLECULES, V25, DOI 10.3390/molecules25020321
   WHO, COR DIS 2019 COVID 1
   WHO, COR DIS 2019 COVID 1
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 28
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD OCT
PY 2020
VL 211
AR 111997
DI 10.1016/j.jphotobiol.2020.111997
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NU1YN
UT WOS:000573437900007
PM 32829256
OA Green Published
DA 2021-01-01
ER

PT J
AU Glober, N
   Mohler, G
   Huynh, P
   Arkins, T
   O'Donnell, D
   Carter, J
   Ray, B
AF Glober, Nancy
   Mohler, George
   Huynh, Philip
   Arkins, Tom
   O'Donnell, Dan
   Carter, Jeremy
   Ray, Brad
TI Impact of COVID-19 Pandemic on Drug Overdoses in Indianapolis
SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE
LA English
DT Article
DE Overdose; Opioid; COVID-19; Pandemic; EMS
ID DEATHS; STATES
AB We described the change in drug overdoses during the COVID-19 pandemic in one urban emergency medical services (EMS) system. Data was collected from Marion County, Indiana (Indianapolis), including EMS calls for service (CFS) for suspected overdose, CFS in which naloxone was administered, and fatal overdose data from the County Coroner's Office. With two sample t tests and ARIMA time series forecasting, we showed changes in the daily rates of calls (all EMS CFS, overdose CFS, and CFS in which naloxone was administered) before and after the stay-at-home order in Indianapolis. We further showed differences in the weekly rate of overdose deaths. Overdose CFS and EMS naloxone administration showed an increase with the social isolation of the Indiana stay-at-home order, but a continued increase after the stay-at-home order was terminated. Despite a mild 4% increase in all EMS CFS, overdose CFS increased 43% and CFS with naloxone administration increased 61% after the stay-at-home order. Deaths from drug overdoses increased by 47%. There was no change in distribution of age, race/ethnicity, or zip code of those who overdosed after the stay-at-home order was issued. We hope this data informs policy-makers preparing for future COVID-19 responses and other disaster responses.
C1 [Glober, Nancy; Mohler, George; Arkins, Tom; O'Donnell, Dan; Carter, Jeremy] Indiana Univ, Indianapolis, IN 46204 USA.
   [Huynh, Philip; Ray, Brad] Wayne State Univ, Detroit, MI USA.
RP Glober, N (corresponding author), Indiana Univ, Indianapolis, IN 46204 USA.
EM nglober@iu.edu
OI Glober, Nancy/0000-0001-5769-3651
FU NSFNational Science Foundation (NSF) [ATD-1737996, SCC-1737585]; Centers
   for Disease Control and Prevention Overdose Data to Action (CDC)
   [NU17CE924990]
FX This work was supported in part by NSF grants ATD-1737996 and
   SCC-1737585 and, in part, by the Centers for Disease Control and
   Prevention Overdose Data to Action (CDC; Grant#NU17CE924990).
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P667, DOI 10.1109/TAC.1974.1100707
   Alter A, 2020, CONSEQUENCES COVID 1, P5
   [Anonymous], 2020, ISS BRIEF REP INCR O
   Bellrichard C. B.C., 2020, CBC NEWS
   Centers for Disease Control and Prevention, 2020, OP OV UND EP
   Ciccarone D, 2019, INT J DRUG POLICY, V71, P183, DOI 10.1016/j.drugpo.2019.01.010
   Feder S, 2020, BUSINESS INSIDER
   Fisher R, 2016, PREHOSP EMERG CARE, V20, P675, DOI 10.1080/10903127.2016.1182605
   Gladden RM, 2019, MMWR-MORBID MORTAL W, V68, P737, DOI 10.15585/mmwr.mm6834a2
   Hainer R., 2019, POLYSUBSTANCE USE DA
   Hedegaard H., 2020, DRUG OVERDOSE DEATHS, V356, P8
   Hoots B, 2020, ADDICTION, V115, P946, DOI 10.1111/add.14878
   Huechtker S., 2020, COVID 19 PANDEMIC GR
   Hyndman RJ, 2007, AUTOMATIC TIME SERIE, V6/07
   Indianapolis Emergency Medical Services, 2014, IND METR AR EMS PROT
   Kirkland T., 2020, OVERDOSE DEATHS SKYR
   Local 24, 2020, SPIK DRUG OV SHELB C
   mycitizensnews, 2020, CITIZENS NEWS
   Ray B, 2020, DRUG ALCOHOL DEPEN, V206, DOI 10.1016/j.drugalcdep.2019.107658
   Roth AN, 2020, ROCHESTER DEMOCRAT C
   Schladebeck J., 2020, DAILY NEWS
   Slavova S, 2020, DRUG ALCOHOL DEPEN, V214, DOI 10.1016/j.drugalcdep.2020.108176
   Struett D., 2020, CHICAGO SUN TIMES
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Wilson CG, 2020, J RURAL HEALTH, DOI 10.1111/jrh.12438
   Wilson N, 2020, MMWR-MORBID MORTAL W, V69, P290, DOI 10.15585/mmwr.mm6911a4
NR 26
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1099-3460
EI 1468-2869
J9 J URBAN HEALTH
JI J. Urban Health
PD DEC
PY 2020
VL 97
IS 6
BP 802
EP 807
DI 10.1007/s11524-020-00484-0
EA OCT 2020
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA PE5TW
UT WOS:000574358400001
PM 33005988
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mittal, S
   Madan, K
   Mohan, A
AF Mittal, Saurabh
   Madan, Karan
   Mohan, Anant
TI COVID-19 and steroid therapy: Impact on diabetes
SO PRIMARY CARE DIABETES
LA English
DT Letter
C1 [Mittal, Saurabh; Madan, Karan; Mohan, Anant] All India Inst Med Sci AIIMS, Dept Pulm Crit Care & Sleep Med, New Delhi 110029, India.
RP Mittal, S (corresponding author), All India Inst Med Sci AIIMS, Dept Pulm Crit Care & Sleep Med, New Delhi 110029, India.
EM Saurabh_kgmu@yahoo.co.in
CR Horby P, 2020, N ENGL J MED
   Papadokostaki E., 2020, PRIM CARE DIABETES
   Qi D, 2004, DIABETES, V53, P1790, DOI 10.2337/diabetes.53.7.1790
   Rubino F, 2020, N ENGL J MED
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1751-9918
EI 1878-0210
J9 PRIM CARE DIABETES
JI Prim. Care Diabetes
PD OCT
PY 2020
VL 14
IS 5
BP 568
EP 568
PG 1
WC Endocrinology & Metabolism; Primary Health Care
SC Endocrinology & Metabolism; General & Internal Medicine
GA NU4TG
UT WOS:000573635200030
PM 32778507
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Omidi, N
   Forouzannia, SK
   Poorhosseini, H
   Tafti, SHA
   Salehbeigi, S
   Lotfi-Tokaldany, M
AF Omidi, Negar
   Forouzannia, Seyed Khalil
   Poorhosseini, Hamidreza
   Tafti, Seyed Hossein Ahmadi
   Salehbeigi, Shahrzad
   Lotfi-Tokaldany, Masoumeh
TI Prosthetic heart valves and the COVID-19 pandemic era: What should we be
   concerned about?
SO JOURNAL OF CARDIAC SURGERY
LA English
DT Article
DE coronavirus; COVID-19; international normalized ratio; lopinavir;
   ritonavir; prosthetic heart valve; warfarin
ID WARFARIN; CHINA
AB Background The disturbance in the international normalized ratio (INR) in patients receiving warfarin therapy is of concern. We aimed to evaluate coagulation features in hospitalized patients under warfarin treatment for prosthetic heart valves during the novel coronavirus disease 2019 (COVID-19) pneumonia pandemic. Methods Between 20 February and 28 March 2020, 10 patients (7 males) who were under warfarin therapy for prosthetic heart valves were hospitalized after a diagnosis of COVID-19 in Tehran Heart Center, Tehran, Iran. The clinical, paraclinical, and in-hospital outcomes were described. The patients were followed for 4 weeks. Results The median age was 62 years. All the patients received antiviral treatment, either lopinavir/ritonavir or oseltamivir. The serum level of high-sensitivity C-reactive protein ranged between 0.24 and 15.24 mg/dL. Alanine aminotransaminase was normal in all the patients except for two, with levels 1.6 and 4.2 times above normal values. The INR increased in all the patients. One (10%) patient died in the hospital. No bleeding, ischemic, or thrombotic events occurred during the hospital stay and within the 4-week follow-up. Conclusions Antiviral therapy in patients with COVID-19 with prosthetic heart valves might be an issue responsible for an uncontrolled INR. Liver injury may happen in a minority of patients. Bridging in these patients during the antiviral treatment might be required and because of significant INR fluctuations, it might be safer to prescribe antiviral treatment in an inpatient setting.
C1 [Omidi, Negar] Univ Tehran Med Sci, Dept Cardiol, Tehran Heart Ctr, Tehran, Iran.
   [Forouzannia, Seyed Khalil; Tafti, Seyed Hossein Ahmadi] Univ Tehran Med Sci, Dept Cardiac Surg, Tehran Heart Ctr & Res Dev, Tehran, Iran.
   [Poorhosseini, Hamidreza] Univ Tehran Med Sci, Intervent Dept, Tehran Heart Ctr & Res Dev, Tehran, Iran.
   [Salehbeigi, Shahrzad; Lotfi-Tokaldany, Masoumeh] Univ Tehran Med Sci, Res Dept, Tehran Heart Ctr & Res Dev, Tehran, Iran.
RP Lotfi-Tokaldany, M (corresponding author), Tehran Heart Ctr, North Kargar St, Tehran 1411713138, Iran.
EM lotfi21366@yahoo.co.uk
FU Tehran University of Medical Sciences and Health Services, IranTehran
   University of Medical Sciences [99-1-138 to 47358] Funding Source:
   Medline
CR Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Fan ZY, 2020, CLIN GASTROENTEROL H, V18, P1561, DOI 10.1016/j.cgh.2020.04.002
   Han Y, 2020, LACTATE DEHYDROGENAS
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hughes CA, 2007, CAN MED ASSOC J, V177, P357, DOI 10.1503/cmaj.061284
   Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Mosholder AD, 2013, ANN PHARMACOTHER, V47, P1420, DOI 10.1177/1060028013500940
   Newshan G, 1999, AIDS, V13, P1788, DOI 10.1097/00002030-199909100-00028
   Obe BH, 2020, PRACTICAL GUIDANCE P
   Poorhosseini H, 2018, EUR HEART J, V39, P2695, DOI 10.1093/eurheartj/ehy369
   Ren ZN, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4609-8
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Uthman IW, 2002, SEMIN ARTHRITIS RHEU, V31, P256, DOI 10.1053/sarh.2002.28303
   Wada H, 2013, J THROMB HAEMOST, V11, P2078, DOI 10.1111/jth.12366
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 22
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0886-0440
EI 1540-8191
J9 J CARDIAC SURG
JI J. Card. Surg.
PD OCT
PY 2020
VL 35
IS 10
BP 2500
EP 2505
DI 10.1111/jocs.14707
PG 6
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA NT5YX
UT WOS:000573017200011
PM 33043651
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Minami, CA
   Kantor, O
   Weiss, A
   Nakhlis, F
   King, TA
   Mittendorf, EA
AF Minami, Christina A.
   Kantor, Olga
   Weiss, Anna
   Nakhlis, Faina
   King, Tari A.
   Mittendorf, Elizabeth A.
TI Association Between Time to Operation and Pathologic Stage in Ductal
   Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast
   Cancer
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID ACTIVE SURVEILLANCE; SURGICAL-TREATMENT; PHASE-III; FOLLOW-UP; LOW-RISK;
   SURGERY; WOMEN; MULTICENTER; TAMOXIFEN; SURVIVAL
AB BACKGROUND: During the COVID-19 pandemic, surgical delays have been common for patients with ductal carcinoma in situ (DCIS) and early-stage estrogen receptor-positive (ER+) breast cancer, often in favor of neoadjuvant endocrine therapy (NET). To understand possible ramifications of these delays, we examined the association between time to operation and pathologic staging and overall survival (OS).
   STUDY DESIGN: Patients with DCIS or ER+ cT1-2N0 breast cancer treated from 2010 through 2016 were identified in the National Cancer Database. Time to operation was recorded. Factors associated with pathologic upstaging were examined using logistic regression analyses. Cox proportional hazard models were used to analyze OS. Analyses were stratified by disease stage and initial treatment strategy.
   RESULTS: There were 378,839 patients identified. Among those undergoing primary surgical procedure, time to operation was within 120 days in > 98% in all groups. Among cT1-2N0 patients selected for NET, operations were performed within 120 days in 59.6% of cT1NO and 30.9% of cT2NO patients. Increased time to operation was associated with increased odds of pathologic upstaging in DCIS patients (ER+: 60 to 120 days: odds ratio 1.15; 95% CI, 1.08 to 1.22; more than 120 days: odds ratio 1.44; 95% CI, 1.24 to 1.68; ER-: 60 to 120 days: NS; more than 120 days: odds ratio 1.36; 95% CI, 1.01 to 1.82; 60 days or less: reference), but not in patients with invasive cancer, irrespective of initial treatment strategy. No difference in OS was seen by time to operation in DCIS or NET patients.
   CONCLUSIONS: Increased time to operation was associated with a small increase in pathologic upstaging in DCIS patients, but did not impact OS. In patients with cT1-2N0 disease, NET use did not impact stage or OS, supporting the safety of delay strategies in ER+ breast cancer patients during the pandemic. (C) 2020 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.
C1 [Mittendorf, Elizabeth A.] Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 450 Brookline Ave,Yawkey 1220, Boston, MA 02215 USA.
   [Mittendorf, Elizabeth A.] Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, 450 Brookline Ave,Yawkey 1220, Boston, MA 02215 USA.
RP Mittendorf, EA (corresponding author), Brigham & Womens Hosp, Dept Surg, Div Breast Surg, 450 Brookline Ave,Yawkey 1220, Boston, MA 02215 USA.; Mittendorf, EA (corresponding author), Dana Farber Brigham & Womens Canc Ctr, Breast Oncol Program, 450 Brookline Ave,Yawkey 1220, Boston, MA 02215 USA.
EM emittendorf@bwh.harvard.edu
FU Conquer Cancer Foundation; American College of Surgeons [2020-2022]
FX Dr Minami's institution receives research support from Conquer Cancer
   Foundation (Young Investigator Award, 2020-2021) and the American
   College of Surgeons (Faculty Research Fellowship, 2020-2022).
CR Bear HD, 2017, J SURG ONCOL, V115, P917, DOI 10.1002/jso.24610
   Bleicher RJ, 2016, JAMA ONCOL, V2, P330, DOI 10.1001/jamaoncol.2015.4508
   Brazda A, 2010, ANN SURG ONCOL, V17, pS291, DOI 10.1245/s10434-010-1250-6
   Brennan ME, 2011, RADIOLOGY, V260, P119, DOI 10.1148/radiol.11102368
   Chiba A, 2017, ANN SURG ONCOL, V24, P418, DOI 10.1245/s10434-016-5585-5
   Colleoni M, 2016, J CLIN ONCOL, V34, P927, DOI 10.1200/JCO.2015.62.3504
   Comber H, 2005, Ir Med J, V98, P238
   Dicks E, 2019, CURR ONCOL, V26, pE216, DOI 10.3747/co.26.4305
   Dietz JR, RECOMMENDATIONS PRIO
   Ellis MJ, 2011, J CLIN ONCOL, V29, P2342, DOI 10.1200/JCO.2010.31.6950
   Elshof LE, 2015, EUR J CANCER, V51, P1497, DOI 10.1016/j.ejca.2015.05.008
   Eteshola E, 2020, J CLIN ONCOL, V38
   Fennessy M, 2004, BRIT J SURG, V91, P699, DOI 10.1002/bjs.4603
   Francis A, 2015, EUR J CANCER, V51, P2296, DOI 10.1016/j.ejca.2015.07.017
   Giuliano AE, 2017, CA-CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393
   Grimm LJ, 2017, ANN SURG ONCOL, V24, P3534, DOI 10.1245/s10434-017-6018-9
   Hamelinck VC, 2018, J GERIATR ONCOL, V9, P170, DOI 10.1016/j.jgo.2017.08.011
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Hind D, 2007, BRIT J CANCER, V96, P1025, DOI 10.1038/sj.bjc.6603600
   Hwang ES, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026797
   McLaughlin JM, 2012, J CLIN ONCOL, V30, P4493, DOI 10.1200/JCO.2012.39.7695
   Mustacchi G, 2003, ANN ONCOL, V14, P414, DOI 10.1093/annonc/mdg117
   Narod SA, 2015, JAMA ONCOL, V1, P888, DOI 10.1001/jamaoncol.2015.2510
   Nettleton J, 1996, OBSTET GYNECOL, V87, P414, DOI 10.1016/0029-7844(95)00470-X
   Pilewskie M, 2016, ANN SURG ONCOL, V23, P3487, DOI 10.1245/s10434-016-5268-2
   Polverini AC, 2016, ANN SURG ONCOL, V23, P3392, DOI 10.1245/s10434-016-5486-7
   Sainsbury R, 1999, LANCET, V353, P1132
   Sivell S, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-92
   Spring LM, 2016, JAMA ONCOL, V2, P1477, DOI 10.1001/jamaoncol.2016.1897
   Wagner JL, 2011, ANN SURG, V254, P119, DOI 10.1097/SLA.0b013e318217e97f
   Ward WH, 2020, ANN SURG ONCOL, V27, P386, DOI 10.1245/s10434-019-07844-4
   Weiss A, 2019, ANN SURG ONCOL, V26, P4326, DOI 10.1245/s10434-019-07785-y
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1072-7515
EI 1879-1190
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD OCT
PY 2020
VL 231
IS 4
BP 434
EP +
DI 10.1016/j.jamcollsurg.2020.06.021
PG 16
WC Surgery
SC Surgery
GA NT9AZ
UT WOS:000573231600003
PM 32771654
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Vanderheiden, A
   Ralfs, P
   Chirkova, T
   Upadhyay, AA
   Zimmerman, MG
   Bedoya, S
   Aoued, H
   Tharp, GM
   Pellegrini, KL
   Manfredi, C
   Sorscher, E
   Mainou, B
   Lobby, JL
   Kohlmeier, JE
   Lowen, AC
   Shi, PY
   Menachery, VD
   Anderson, LJ
   Grakoui, A
   Bosinger, SE
   Suthar, MS
AF Vanderheiden, Abigail
   Ralfs, Philipp
   Chirkova, Tatiana
   Upadhyay, Amit A.
   Zimmerman, Matthew G.
   Bedoya, Shamika
   Aoued, Hadj
   Tharp, Gregory M.
   Pellegrini, Kathryn L.
   Manfredi, Candela
   Sorscher, Eric
   Mainou, Bernardo
   Lobby, Jenna L.
   Kohlmeier, Jacob E.
   Lowen, Anice C.
   Shi, Pei-Yong
   Menachery, Vineet D.
   Anderson, Larry J.
   Grakoui, Arash
   Bosinger, Steven E.
   Suthar, Mehul S.
TI Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human
   Airway Epithelial Cultures
SO JOURNAL OF VIROLOGY
LA English
DT Article
DE COVID-19; lung; SARS-CoV-2; cytokines; innate immunity; type I
   interferon
ID ACUTE RESPIRATORY SYNDROME; SYNDROME CORONAVIRUS INFECTION;
   ENDOPLASMIC-RETICULUM STRESS; MESENCHYMAL TRANSITION; PNEUMONIA;
   INDUCTION; PATHWAY; PROTEIN; ACE2
AB The newly emerged human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a pandemic of respiratory illness. Current evidence suggests that severe cases of SARS-CoV-2 are associated with a dys-regulated immune response. However, little is known about how the innate immune system responds to SARS-CoV-2. In this study, we modeled SARS-CoV-2 infection using primary human airway epithelial (pHAE) cultures, which are maintained in an air-liquid interface. We found that SARS-CoV-2 infects and replicates in pHAE cultures and is directionally released on the apical, but not basolateral, surface. Transcriptional profiling studies found that infected pHAE cultures had a molecular signature dominated by proinflammatory cytokines and chemokine induction, including interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and CXCL8, and identified NF-kappa B and ATF-4 as key drivers of this proinflammatory cytokine response. Surprisingly, we observed a complete lack of a type I or III interferon (IFN) response to SARS-CoV-2 infection. However, pretreatment and posttreatment with type I and III IFNs significantly reduced virus replication in pHAE cultures that correlated with upregulation of antiviral effector genes. Combined, our findings demonstrate that SARS-CoV-2 does not trigger an IFN response but is sensitive to the effects of type I and III IFNs. Our studies demonstrate the utility of pHAE cultures to model SARS-CoV-2 infection and that both type I and III IFNs can serve as therapeutic options to treat COVID-19 patients.
   IMPORTANCE The current pandemic of respiratory illness, COVID-19, is caused by a recently emerged coronavirus named SARS-CoV-2. This virus infects airway and lung cells causing fever, dry cough, and shortness of breath. Severe cases of COVID-19 can result in lung damage, low blood oxygen levels, and even death. As there are currently no vaccines approved for use in humans, studies of the mechanisms of SARS-CoV-2 infection are urgently needed. Our research identifies an excellent system to model SARS-CoV-2 infection of the human airways that can be used to test various treatments. Analysis of infection in this model system found that human air-way epithelial cell cultures induce a strong proinflammatory cytokine response yet block the production of type I and III IFNs to SARS-CoV-2. However, treatment of airway cultures with the immune molecules type I or type III interferon (IFN) was able to inhibit SARS-CoV-2 infection. Thus, our model system identified type I or type III IFN as potential antiviral treatments for COVID-19 patients.
C1 [Vanderheiden, Abigail; Chirkova, Tatiana; Zimmerman, Matthew G.; Mainou, Bernardo; Anderson, Larry J.; Grakoui, Arash; Suthar, Mehul S.] Ctr Childhood Infect & Vaccines CCIV, Atlanta, GA 30329 USA.
   [Vanderheiden, Abigail; Chirkova, Tatiana; Zimmerman, Matthew G.; Mainou, Bernardo; Anderson, Larry J.; Grakoui, Arash; Suthar, Mehul S.] Childrens Healthcare Atlanta, Atlanta, GA 30329 USA.
   [Vanderheiden, Abigail; Chirkova, Tatiana; Zimmerman, Matthew G.; Mainou, Bernardo; Anderson, Larry J.; Grakoui, Arash; Suthar, Mehul S.] Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA 30322 USA.
   [Vanderheiden, Abigail; Ralfs, Philipp; Chirkova, Tatiana; Upadhyay, Amit A.; Zimmerman, Matthew G.; Aoued, Hadj; Tharp, Gregory M.; Pellegrini, Kathryn L.; Anderson, Larry J.; Grakoui, Arash; Bosinger, Steven E.; Suthar, Mehul S.] Emory Univ, Emory Vaccine Ctr, Sch Med, Atlanta, GA 30322 USA.
   [Vanderheiden, Abigail; Ralfs, Philipp; Upadhyay, Amit A.; Zimmerman, Matthew G.; Aoued, Hadj; Tharp, Gregory M.; Pellegrini, Kathryn L.; Bosinger, Steven E.; Suthar, Mehul S.] Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.
   [Ralfs, Philipp; Bedoya, Shamika; Lobby, Jenna L.; Kohlmeier, Jacob E.; Lowen, Anice C.; Grakoui, Arash] Emory Univ, Sch Med, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.
   [Upadhyay, Amit A.; Aoued, Hadj; Tharp, Gregory M.; Pellegrini, Kathryn L.; Bosinger, Steven E.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
   [Manfredi, Candela; Sorscher, Eric] Emory Univ, Dept Pediat, Div Pulm Med, Sch Med, Atlanta, GA USA.
   [Bedoya, Shamika; Kohlmeier, Jacob E.; Lowen, Anice C.; Suthar, Mehul S.] Emory UGA Ctr Excellence Influenza Res & Surveill, Atlanta, GA 30322 USA.
   [Shi, Pei-Yong] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
   [Menachery, Vineet D.] Univ Texas Med Branch, World Reference Ctr Emerging Viruses & Arboviruse, Inst Human Infect & Immun, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
RP Suthar, MS (corresponding author), Ctr Childhood Infect & Vaccines CCIV, Atlanta, GA 30329 USA.; Suthar, MS (corresponding author), Childrens Healthcare Atlanta, Atlanta, GA 30329 USA.; Suthar, MS (corresponding author), Emory Univ, Sch Med, Dept Pediat, Div Infect Dis, Atlanta, GA 30322 USA.; Suthar, MS (corresponding author), Emory Univ, Emory Vaccine Ctr, Sch Med, Atlanta, GA 30322 USA.; Suthar, MS (corresponding author), Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.; Suthar, MS (corresponding author), Emory UGA Ctr Excellence Influenza Res & Surveill, Atlanta, GA 30322 USA.
EM mehul.s.suthar@emory.edu
FU Emory EVPHA Synergy Fund award; Woodruff Health Sciences Center; Emory
   School of Medicine; Emory University; MP3 Initiative; National
   Institutes of Health ORIP/OD (NIAID Centers of Excellence for Influenza
   Research and Surveillance, CEIRS) [P51OD011132, HHSN272201400004C, R00
   AG049092]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P51 OD011132, S10
   OD026799]; Center for Childhood Infections and Vaccines, Children's
   Healthcare of Atlanta; World Reference Center for Emerging Viruses and
   Arboviruses [R24 AI120942]
FX The research reported in this publication was supported in part by an
   Emory EVPHA Synergy Fund award (M.S.S.), COVID-Catalyst-I3 Funds from
   the Woodruff Health Sciences Center and Emory School of Medicine
   (M.S.S.), by Emory University and the MP3 Initiative (M.S.S. and
   A.C.L.), Center for Childhood Infections and Vaccines, Children's
   Healthcare of Atlanta, and National Institutes of Health ORIP/OD
   P51OD011132 (M.S.S.), HHSN272201400004C (NIAID Centers of Excellence for
   Influenza Research and Surveillance, CEIRS; M.S.S., J.E.K.), R00
   AG049092 (V.D.M.), and World Reference Center for Emerging Viruses and
   Arboviruses R24 AI120942 (V.D.M.). The Yerkes NHP Genomics Core is
   supported in part by NIH P51 OD011132 and an equipment grant, NIH S10
   OD026799 (S.E.B.).
CR Bettigole SE, 2015, ANNU REV IMMUNOL, V33, P107, DOI 10.1146/annurev-immunol-032414-112116
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen J, 2007, ANNU REV IMMUNOL, V25, P443, DOI 10.1146/annurev.immunol.25.022106.141706
   Chirkova T, 2015, J GEN VIROL, V96, P2543, DOI 10.1099/vir.0.000218
   Crotta S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003773
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Forero A, 2019, IMMUNITY, V51, P451, DOI 10.1016/j.immuni.2019.07.007
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Hu Y, 2017, J VIROL, V91, DOI 10.1128/JVI.02143-16
   Huang SH, 2017, J MICROBIOL IMMUNOL, V50, P277, DOI 10.1016/j.jmii.2015.07.002
   Jauregui AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062416
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Jilg N, 2014, HEPATOLOGY, V59, P1250, DOI 10.1002/hep.26653
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103
   Klinkhammer J, 2018, ELIFE, V7, DOI 10.7554/eLife.33354
   Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025
   Le TTT, 2014, J IMMUNOL, V193, P3755, DOI 10.4049/jimmunol.1302470
   LIN LJ, 2017, SCI REP-UK, V7, DOI DOI 10.1038/S41598
   Lourenco AR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14556-x
   Menachery VD, 2014, MBIO, V5, DOI 10.1128/mBio.01174-14
   Minakshi R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008342
   Sims AC, 2005, J VIROL, V79, P15511, DOI 10.1128/JVI.79.24.15511-15524.2005
   Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303
   Spiegel M, 2005, J VIROL, V79, P2079, DOI 10.1128/JVI.79.4.2079-2086.2005
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tang BM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11249-y
   Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Weaver CT, 2013, ANNU REV PATHOL-MECH, V8, P477, DOI 10.1146/annurev-pathol-011110-130318
   WHO, 2020, COVID 19 DASHB
   Wong HH, 2018, VIROLOGY, V515, P165, DOI 10.1016/j.virol.2017.12.028
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zimmerman MG, 2019, J VIROL, V93, DOI 10.1128/JVI.00665-19
NR 44
TC 6
Z9 6
U1 14
U2 14
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD OCT
PY 2020
VL 94
IS 19
AR e00985-20
DI 10.1128/JVI.00985-20
PG 16
WC Virology
SC Virology
GA NT5XG
UT WOS:000573012900006
PM 32699094
OA Bronze
DA 2021-01-01
ER

PT J
AU Aguila, EJT
   Lontok, MAD
   Francisco, CPD
AF Aguila, Enrik John T.
   Lontok, Marie Antoinette Dc.
   Francisco, Carlos Paolo D.
TI Follow Your Gut: Challenges in Nutritional Therapy During the COVID-19
   Pandemic
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Letter
ID ENTERAL NUTRITION
C1 [Aguila, Enrik John T.; Lontok, Marie Antoinette Dc.; Francisco, Carlos Paolo D.] St Lukes Med Ctr Global City, Inst Digest & Liver Dis, Manila, Philippines.
RP Aguila, EJT (corresponding author), St Lukes Med Ctr Global City, Inst Digest & Liver Dis, Manila, Philippines.
RI Aguila, Enrik John/AAU-7411-2020
CR Jabbar Abdul, 2003, Nutr Clin Pract, V18, P461, DOI 10.1177/0115426503018006461
   Martindale A, AM SOC PARENTERAL EN, DOI [10.1002/jpen.1930, DOI 10.1002/JPEN.1930]
   Mentec H, 2001, CRIT CARE MED, V29, P1955, DOI 10.1097/00003246-200110000-00018
   Pash E, 2018, NUTR CLIN PRACT, V33, P170, DOI 10.1002/ncp.10007
   de la Fuente IS, 2016, JPEN-PARENTER ENTER, V40, P250, DOI 10.1177/0148607114553232
   Sethi A, 2020, CLIN GASTROENTEROL H, V18, P1673, DOI 10.1016/j.cgh.2020.04.032
   Soetikno R, 2020, GASTROINTEST ENDOSC
   Terragni PP, 2010, JAMA-J AM MED ASSOC, V303, P1483, DOI 10.1001/jama.2010.447
NR 8
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD OCT
PY 2020
VL 18
IS 11
BP 2638
EP 2639
DI 10.1016/j.cgh.2020.05.046
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NT2ZY
UT WOS:000572816500043
PM 32480010
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Bhowmik, D
   Nandi, R
   Jagadeesan, R
   Kumar, N
   Prakash, A
   Kumar, D
AF Bhowmik, Deep
   Nandi, Rajat
   Jagadeesan, Rahul
   Kumar, Niranjan
   Prakash, Amresh
   Kumar, Diwakar
TI Identification of potential inhibitors against SARS-CoV-2 by targeting
   proteins responsible for envelope formation and virion assembly using
   docking based virtual screening, and pharmacokinetics approaches
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE SARS-CoV-2; Structural proteins; Molecular docking; Simulation; Virion;
   Envelope
ID RESPIRATORY SYNDROME CORONAVIRUS; INFECTIOUS-BRONCHITIS VIRUS;
   NUCLEOCAPSID PROTEIN; IN-VITRO; HEPATITIS-C; FERULIC ACID;
   MOLECULAR-PROPERTIES; MURINE CORONAVIRUS; MEMBRANE-PROTEIN; CLEAVAGE
   SITE
AB WHO has declared the outbreak of COVID-19 as a public health emergency of international concern. The evergrowing new cases have called for an urgent emergency for specific anti-COVID-19 drugs. Three structural proteins (Membrane, Envelope and Nucleocapsid protein) play an essential role in the assembly and formation of the infectious virion particles. Thus, the present study was designed to identify potential drug candidates from the unique collection of 548 anti-viral compounds (natural and synthetic anti-viral), which target SARS-CoV-2 structural proteins. High-end molecular docking analysis was performed to characterize the binding affinity of the selected drugs-the ligand, with the SARS-CoV-2 structural proteins, while high-level Simulation studies analyzed the stability of drug-protein interactions. The present study identified rutin, a bioflavonoid and the antibiotic, doxycycline, as the most potent inhibitor of SARS-CoV-2 envelope protein. Caffeic acid and ferulic acid were found to inhibit SARS-CoV-2 membrane protein while the anti-viral agent's simeprevir and grazoprevir showed a high binding affinity for nucleocapsid protein. All these compounds not only showed excellent pharmacokinetic properties, absorption, metabolism, minimal toxicity and bioavailability but were also remain stabilized at the active site of proteins during the MD simulation. Thus, the identified lead compounds may act as potential molecules for the development of effective drugs against SARS-CoV-2 by inhibiting the envelope formation, virion assembly and viral pathogenesis.
C1 [Bhowmik, Deep; Nandi, Rajat; Kumar, Diwakar] Assam Univ, Dept Microbiol, Silchar 788011, Assam, India.
   [Jagadeesan, Rahul] Univ Madras, CAS Crystallog & Biophys, Guindy Campus, Chennai 600025, Tamil Nadu, India.
   [Kumar, Niranjan] Jawaharlal Nehru Univ, Sch Computat & Integrat Sci, New Delhi 110067, India.
   [Prakash, Amresh] Amity Univ Haryana, Amity Inst Integrat Sci & Hlth, Gurgaon 122413, India.
RP Kumar, D (corresponding author), Assam Univ, Dept Microbiol, Silchar 788011, Assam, India.
EM diwakar11@gmail.com
OI Kumar, Diwakar/0000-0002-3050-5179
FU Science and Engineering Research Board, India [ECR/2015//000155];
   Department of Biotechnology (India)Department of Biotechnology (DBT)
   India [BT/PR16224/NER/95/176/2015, BT/PR24504/NER/95/746/2017];
   SERBDepartment of Science & Technology (India)Science Engineering
   Research Board (SERB), India [ECR/2015//000155]; DBTDepartment of
   Biotechnology (DBT) India [BT/PR24504/NER/95/746/2017]
FX Lab is supported by Science and Engineering Research Board, India (FILE
   NO. ECR/2015//000155) and Department of Biotechnology (India) (order no:
   BT/PR16224/NER/95/176/2015 & BT/PR24504/NER/95/746/2017) to Dr. Diwakar
   Kumar. Deep Bhowmik received funding from the SERB grant (FILE NO.
   ECR/2015//000155). Rajat Nandi received funding from the DBT grant
   (order no: BT/PR24504/NER/95/746/2017).
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Bae EA, 2000, BIOL PHARM BULL, V23, P1122, DOI 10.1248/bpb.23.1122
   Bekhit A. E. D., 2014, STUDIES NATURAL PROD, V42, DOI [DOI 10.1016/B978-0-444-63281-4.00007-0, 10.1016/b978-0-444-63281-4.00007-0]
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   Bhowmik D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1739557
   Bos ECW, 1996, VIROLOGY, V218, P52, DOI 10.1006/viro.1996.0165
   Bruning A. H. L., 2018, New Microbes and New Infections, V24, P52, DOI 10.1016/j.nmni.2018.04.007
   Chandrasekaran K., 2016, Journal of Chemical and Pharmaceutical Research, V8, P849
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Cong YY, 2014, REV MED VIROL, V24, P308, DOI 10.1002/rmv.1792
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   Dent SD, 2015, J GEN VIROL, V96, P3499, DOI 10.1099/jgv.0.000304
   DYALL J, 2017, DRUGS, V77, P1935, DOI [10.1007/s40265-017-0830-1, DOI 10.1007/S40265-017-0830-1]
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   El Sayed K. A., 2000, STUDIES NATURAL PROD, V24, P473, DOI DOI 10.1016/S1572-5995(00)80051-4
   Escors D, 2001, J VIROL, V75, P1312, DOI 10.1128/JVI.75.3.1312-1324.2001
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fried MW, 2013, HEPATOLOGY, V58, P1918, DOI 10.1002/hep.26641
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ghose AK, 1999, J COMB CHEM, V1, P55, DOI 10.1021/cc9800071
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gretebeck LM, 2015, CURR OPIN VIROL, V13, P123, DOI 10.1016/j.coviro.2015.06.009
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hariono M, 2016, SCI REP-UK, V6, DOI 10.1038/srep38692
   Hayashi N, 2014, J GASTROENTEROL, V49, P138, DOI 10.1007/s00535-013-0875-1
   He RT, 2004, VIRUS RES, V105, P121, DOI 10.1016/j.virusres.2004.05.002
   Hebert MF, 2013, CLINICAL PHARMACOLOGY DURING PREGNANCY, P17
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Hsin WC, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0449-x
   Hurst KR, 2010, J VIROL, V84, P10276, DOI 10.1128/JVI.01287-10
   Husain A, 2016, SAUDI PHARM J, V24, P104, DOI 10.1016/j.jsps.2015.02.008
   Jeyaram RA, 2019, J BIOMOL STRUCT DYN, V37, P4813, DOI [10.1080/07391102.2019.1677500, 10.1080/07391102.2019.1568304]
   Joung IS, 2008, J PHYS CHEM B, V112, P9020, DOI 10.1021/jp8001614
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994
   Krieger E, 2009, PROTEINS, V77, P114, DOI 10.1002/prot.22570
   Kumar N, 2020, J BIOMOL STRUCT DYN, V38, P3396, DOI 10.1080/07391102.2019.1657499
   Kumar V, 2018, BIOCHEM J, V475, P1701, DOI 10.1042/BCJ20180085
   Kuo LL, 2016, VIROLOGY, V494, P100, DOI 10.1016/j.virol.2016.04.009
   Lahiri M., 2019, WORLD SCI NEWS, V127, P177
   LAI PK, 1992, J GEN APPL MICROBIOL, V38, P303, DOI 10.2323/jgam.38.303
   Langland J, 2018, ANTIVIR RES, V160, P143, DOI 10.1016/j.antiviral.2018.10.021
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Le Rouzic E, 2002, J BIOL CHEM, V277, P45091, DOI 10.1074/jbc.M207439200
   Li W.-Y., 2019, J BIOMOL STRUCT DYN, P1, DOI 10.1080/07391102.2019.1567392
   Lill MA, 2011, J COMPUT AID MOL DES, V25, P13, DOI 10.1007/s10822-010-9395-8
   Lim KP, 2001, J BIOL CHEM, V276, P17515, DOI 10.1074/jbc.M009731200
   Lim SV, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S13-S24
   Lin YJ, 2012, J VIROL METHODS, V182, P93, DOI 10.1016/j.jviromet.2012.03.020
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Luo HB, 2006, INT J BIOCHEM CELL B, V38, P589, DOI 10.1016/j.biocel.2005.10.022
   Luthra PM, 2009, NEUROSCI LETT, V463, P215, DOI 10.1016/j.neulet.2009.07.085
   Ma YL, 2010, PROTEIN CELL, V1, P688, DOI 10.1007/s13238-010-0079-x
   Malathi K, 2019, J BIOMOL STRUCT DYN, V37, P4601, DOI 10.1080/07391102.2018.1556737
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   Mishra CB, 2018, EUR J MED CHEM, V151, P520, DOI 10.1016/j.ejmech.2018.04.007
   Mokhnache K., 2019, SCHOLARS J APPL MED, V7, P167, DOI [10.21276/sjams.2019.7.1.31, DOI 10.21276/SJAMS.2019.7.1.31]
   Narayanan K, 2000, J VIROL, V74, P8127, DOI 10.1128/JVI.74.17.8127-8134.2000
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Nieto-Torres JL, 2011, VIROLOGY, V415, P69, DOI 10.1016/j.virol.2011.03.029
   OPSTELTEN DJE, 1995, J CELL BIOL, V131, P339, DOI 10.1083/jcb.131.2.339
   Ortego J, 2007, VIROLOGY, V368, P296, DOI 10.1016/j.virol.2007.05.032
   Pal Sourav, 2020, COMPILATION POTENTIA, DOI [10.26434/chemrxiv.12084468.v1, DOI 10.26434/CHEMRXIV.12084468.V1]
   PARRINELLO M, 1980, PHYS REV LETT, V45, P1196, DOI 10.1103/PhysRevLett.45.1196
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Prakash A, 2018, J BIOMOL STRUCT DYN, V36, P2391, DOI 10.1080/07391102.2017.1355847
   Rocco AG, 2008, BIOPHYS J, V94, P2241, DOI 10.1529/biophysj.107.115535
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101578
   Rothan HA, 2014, ARCH VIROL, V159, P711, DOI 10.1007/s00705-013-1880-7
   Ruch TR, 2011, J VIROL, V85, P675, DOI 10.1128/JVI.01570-10
   Sakai S, 1999, MEDIAT INFLAMM, V8, P173, DOI 10.1080/09629359990513
   Sayers EW, 2019, NUCLEIC ACIDS RES, V47, pD23, DOI 10.1093/nar/gky1069
   Sharma S, 2013, EXPERT OPIN INV DRUG, V22, P1063, DOI 10.1517/13543784.2013.805744
   Shirasago Y, 2019, BIOL PHARM BULL, V42, P770, DOI 10.1248/bpb.b18-00970
   Singh R, 2020, J BIOMOL STRUCT DYN, V38, P5027, DOI 10.1080/07391102.2019.1695669
   Srimai V, 2013, MED CHEM RES, V22, P5314, DOI 10.1007/s00044-013-0532-5
   Srinivasan M, 2007, J CLIN BIOCHEM NUTR, V40, P92, DOI 10.3164/jcbn.40.92
   Summa V, 2012, ANTIMICROB AGENTS CH, V56, P4161, DOI 10.1128/AAC.00324-12
   Talwani R, 2013, DRUG TODAY, V49, P769, DOI 10.1358/dot.2013.49.12.2067249
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   TOOZE J, 1984, EUR J CELL BIOL, V33, P281
   Ungell AL, 1997, DRUG DEV IND PHARM, V23, P879, DOI 10.3109/03639049709148694
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Venkatagopalan P, 2015, VIROLOGY, V478, P75, DOI 10.1016/j.virol.2015.02.005
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   Verheije MH, 2010, J VIROL, V84, P11575, DOI 10.1128/JVI.00569-10
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wang GF, 2009, ANTIVIR RES, V83, P186, DOI 10.1016/j.antiviral.2009.05.002
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wong ACP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020174
   Wu ST, 2007, NUCLEIC ACIDS RES, V35, P3375, DOI 10.1093/nar/gkm251
   Wu ZC, 2015, FEMS MICROBIOL LETT, V362, DOI 10.1093/femsle/fnv195
   Yan YM, 2020, NAT PROTOC, V15, P1829, DOI 10.1038/s41596-020-0312-x
   Yang JY, 2015, NUCLEIC ACIDS RES, V43, pW174, DOI 10.1093/nar/gkv342
   Ye Y, 2007, J VIROL, V81, P3597, DOI 10.1128/JVI.01472-06
   Yeh WW, 2018, CLIN THER, V40, P704, DOI 10.1016/j.clinthera.2018.03.002
   Zeng WH, 2020, BIOCHEM BIOPH RES CO, V527, P618, DOI 10.1016/j.bbrc.2020.04.136
   Zhang XY, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1726819
   Zhao YH, 2002, PHARM RES-DORDR, V19, P1446, DOI 10.1023/A:1020444330011
   Zhou H, 2020, CURR BIOL, V30, P2196, DOI 10.1016/j.cub.2020.05.023
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 109
TC 0
Z9 0
U1 18
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD OCT
PY 2020
VL 84
AR 104451
DI 10.1016/j.meegid.2020.104451
PG 14
WC Infectious Diseases
SC Infectious Diseases
GA NT3UQ
UT WOS:000572870600005
PM 32640381
OA Green Published
DA 2021-01-01
ER

PT J
AU Vashi, Y
   Jagrit, V
   Kumar, S
AF Vashi, Yoya
   Jagrit, Vipin
   Kumar, Sachin
TI Understanding the B and T cell epitopes of spike protein of severe acute
   respiratory syndrome coronavirus-2: A computational way to predict the
   immunogens
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE SARS-CoV-2; Spike protein; Epitopes; Diagnostics
ID PEPTIDE VACCINE; NEURAL-NETWORKS; SEQUENCE
AB The 2019 novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak has caused a large number of deaths, with thousands of confirmed cases worldwide. The present study followed computational approaches to identify Band T-cell epitopes for the spike (S) glycoprotein of SARS-CoV-2 by its interactions with the human leukocyte antigen alleles. We identified 24 peptide stretches on the SARS-CoV-2 S protein that are well conserved among the reported strains. The S protein structure further validated the presence of predicted peptides on the surface, of which 20 are surface exposed and predicted to have reasonable epitope binding efficiency. The work could be useful for understanding the immunodominant regions in the surface protein of SARS-CoV-2 and could potentially help in designing some peptide-based diagnostics. Also, identified T-cell epitopes might be considered for incorporation in vaccine designs.
C1 [Vashi, Yoya; Jagrit, Vipin; Kumar, Sachin] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Viral Immunol Grp, Gauhati 781039, Assam, India.
RP Kumar, S (corresponding author), Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Viral Immunol Grp, Gauhati 781039, Assam, India.
EM sachinku@iitg.ac.in
OI Vashi, Yoya/0000-0003-2262-5477; Jagrit, Vipin/0000-0002-5925-1205
CR Adamczak R, 2004, PROTEINS, V56, P753, DOI 10.1002/prot.20176
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Andersen PH, 2006, PROTEIN SCI, V15, P2558, DOI 10.1110/ps.062405906
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Dey S, 2017, COMPUT BIOL CHEM, V68, P143, DOI 10.1016/j.compbiolchem.2017.03.002
   Garcia-Boronat M, 2008, NUCLEIC ACIDS RES, V36, pW35, DOI 10.1093/nar/gkn211
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171
   Ichihashi T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024626
   Karosiene E, 2012, IMMUNOGENETICS, V64, P177, DOI 10.1007/s00251-011-0579-8
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Mohanraj U, 2017, CURR PROTEIN PEPT SC, V18, P939, DOI 10.2174/1389203717666160724205226
   Navalkar KA, 2015, J IMMUNOL METHODS, V417, P10, DOI 10.1016/j.jim.2014.12.002
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Oany AR, 2014, DRUG DES DEV THER, V8, P1139, DOI [10.2147/DDDT.567861, 10.2147/DDDT.S67861]
   Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113
   Peters B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-132
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Ponomarenko JV, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-64
   Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   World Health Organization, 2020, 71 WHO
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiong XL, 2018, J VIROL, V92
   Yi HG, 2020, CLIN INFECT DIS, V71, P884, DOI 10.1093/cid/ciaa219
   Zhao K, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-186
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 46
TC 3
Z9 3
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD OCT
PY 2020
VL 84
AR 104382
DI 10.1016/j.meegid.2020.104382
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA NT3WG
UT WOS:000572874800009
PM 32473352
OA Green Published
DA 2021-01-01
ER

PT J
AU Altamura, C
   Cevoli, S
   Aurilia, C
   Egeo, G
   Fofi, L
   Torelli, P
   Brunelli, N
   Pierangeli, G
   Favoni, V
   Fallacara, A
   Pensato, U
   Barbanti, P
   Vernieri, F
AF Altamura, Claudia
   Cevoli, Sabina
   Aurilia, Cinzia
   Egeo, Gabriella
   Fofi, Luisa
   Torelli, Paola
   Brunelli, Nicoletta
   Pierangeli, Giulia
   Favoni, Valentina
   Fallacara, Adriana
   Pensato, Umberto
   Barbanti, Piero
   Vernieri, Fabrizio
TI Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the
   PandeMig study
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE Migraine; CGRP; COVID-19; Erenumab; Galcanezumab
ID MIGRAINE; STRESS; PAIN
AB Objectives The COVID-19 pandemic and the consequent lockdown came as a storm disrupting people's everyday life. This study aimed at observing whether the COVID-19 related lockdown influenced migraine frequency and disability in migraine patients on therapy with monoclonal antibodies inhibiting the CGRP pathway. Methods In this longitudinal observational cohort study, 147 consecutive patients receiving monthly administration of erenumab or galcanezumab were enrolled in four Italian headache centers. All patients filled a questionnaire concerning working and household settings, recent flu symptoms or COVID-19 diagnosis, and family loss due to COVID-19 infection. Monthly migraine days (MMDs), monthly painkiller intake (MPI), and HIT-6 disability relative to the first month of lockdown imposition (T-lock) and the month before (T-free) were also collected. Results From T-free to T-lock, the cohort displayed a reduction in MMDs (from 10.5 +/- 7.6 to 9.8 +/- 7.6,p= .024) and HIT-6 scores (from 59.3 +/- 8.3 men reduced MPI more frequently than women (p= .005). Conclusions Our study observed that the lockdown impact to 57.8 +/- 8.8,p = .009), while MPI resulted unchanged (from 11.6 +/- 11.5 to 11.1 +/- 11.7;p= .114). MMDs, MPI, and HIT-6 variations from T-free to T-lock did not differ according to work settings or household. Patients beyond the first 3 months of therapy presented less often a reduction in MMDs (p= .006) and on everyday life did not affect the migraine load in patients receiving monoclonal antibodies inhibiting the CGRP pathway. Patients in the first months of therapy experienced a greater improvement according to drug pharmacokinetics, while women more frequently needed rescue medications, possibly indicating presenteeism or cephalalgophobia.
C1 [Altamura, Claudia; Brunelli, Nicoletta; Fallacara, Adriana; Vernieri, Fabrizio] Campus Biomed Univ Hosp, Headache & Neurosonol Unit, Neurol, Via Alvaro Portillo 200, I-00128 Rome, Italy.
   [Cevoli, Sabina; Pierangeli, Giulia; Favoni, Valentina; Pensato, Umberto] IRCCS Ist Sci Neurol Bologna, Bologna, Italy.
   [Aurilia, Cinzia; Egeo, Gabriella; Fofi, Luisa; Barbanti, Piero] IRCCS San Raffaele Pisana, Headache & Pain Unit, Rome, Italy.
   [Torelli, Paola] Univ Parma, Dept Med & Surg, Headache Ctr, Parma, Italy.
   [Pierangeli, Giulia; Pensato, Umberto] Univ Bologna, Dept Biomed & NeuroMotor Sci DIBINEM, Bologna, Italy.
RP Altamura, C (corresponding author), Campus Biomed Univ Hosp, Headache & Neurosonol Unit, Neurol, Via Alvaro Portillo 200, I-00128 Rome, Italy.
EM c.altamura@unicampus.it
RI Brunelli, Nicoletta/ABE-1864-2020; Pensato, Umberto/AAT-3058-2020
OI Pensato, Umberto/0000-0002-4042-4735; Altamura,
   Claudia/0000-0002-5934-5535
CR Avona A, 2020, PAIN, V161, P2539, DOI 10.1097/j.pain.0000000000001953
   Barbanti P, 2020, HEADACHE, V60, P2103, DOI 10.1111/head.13935
   Black AK, 2015, HEADACHE, V55, P669, DOI 10.1111/head.12561
   Buse DC, 2019, HEADACHE, V59, P306, DOI 10.1111/head.13459
   Detke HC, 2020, HEADACHE, V60, P348, DOI 10.1111/head.13691
   Goadsby PJ, 2017, NEW ENGL J MED, V377, P2123, DOI 10.1056/NEJMoa1705848
   Goadsby PJ, 2014, NEUROLOGY, V82, P1388, DOI 10.1212/WNL.0000000000000349
   Houts CR, 2020, HEADACHE, V60, P28, DOI 10.1111/head.13701
   Istituto Superiore di Sanita, MAL GEN IMP SOC IT
   Iyengar S, 2017, PAIN, V158, P543, DOI 10.1097/j.pain.0000000000000831
   Kelman L, 2007, CEPHALALGIA, V27, P394, DOI 10.1111/j.1468-2982.2007.01303.x
   Lipton RB, 2014, NEUROLOGY, V82, P1395, DOI 10.1212/WNL.0000000000000332
   Lo Buono V, 2019, INT J NEUROSCI, V129, P588, DOI 10.1080/00207454.2018.1554658
   Parodi IC, 2020, NEUROL SCI, V41, P2025, DOI 10.1007/s10072-020-04543-x
   Santangelo G, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0667-0
   Sauro KM, 2009, HEADACHE, V49, P1378, DOI 10.1111/j.1526-4610.2009.01476.x
   Vernieri F, 2020, NEUROL SCI, V41, P487, DOI 10.1007/s10072-020-04669-y
   Vo P, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0907-6
NR 18
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
PD DEC
PY 2020
VL 41
IS 12
BP 3385
EP 3389
DI 10.1007/s10072-020-04767-x
EA OCT 2020
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OP9VA
UT WOS:000574349100006
PM 33001407
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bramstedt, KA
AF Bramstedt, Katrina A.
TI Unicorn Poo and Blessed Waters: COVID-19 Quackery and FDA Warning
   Letters
SO THERAPEUTIC INNOVATION & REGULATORY SCIENCE
LA English
DT Article; Early Access
DE COVID-19; Severe acute respiratory syndrome coronavirus 2; Quackery;
   Bioethics; Standards
AB Background The COVID-19 pandemic has created a global setting of clinical crisis and human anxiety. Without available safe and effective vaccines and cures, an unscrupulous marketplace has emerged selling COVID-19 quackery (fraudulent misrepresentation of preventions and treatments). Methods US Food and Drug Administration (FDA) Warning Letters issued from March 2020 to July 2020 were analyzed for themes pertaining to unapproved, adulterated, and misbranded COVID-19 products. Results During this period, the FDA issued 3,139 Warning Letters of which 98 (3.14%) of these were focused on COVID-19-related drugs, devices, biologics, and dietary supplements (products and ingredients). Specifically, these Warning Letters revealed regulatory nonconformities involving 40 identified herbs, 22 minerals/compounds, 6 devices and biologicals, and 3 vitamins. Products included hand sanitizers; COVID-19 antibody test kits; herbal teas and tinctures; nasal gel; toothpaste; and 1 vaccine. Nine Warning Letters were issued for products being sold via the Amazon online shopping platform. Conclusion A small percentage of FDA Warning Letters recently have been focused on COVID-19. These Letters expose the blatant and potentially harmful quackery of vendors across the world who prioritize financial gain over clinical beneficence. Patient history-taking should include queries about non-traditional and unapproved products to identify, document, and report potentially harmful quackery. FDA Warning Letters are a component of meaningful corrective action; however, greater effort in spreading awareness of such misrepresented, unapproved, and adulterated products is needed to deter purchases of such products.
C1 [Bramstedt, Katrina A.] Luxembourg Agcy Res Integr, 6 Ave Hauts Fourneaux, L-4362 Esch Sur Alzette, Luxembourg.
   [Bramstedt, Katrina A.] Bond Univ, Fac Hlth Sci & Med, Program Med, Gold Coast, Qld, Australia.
RP Bramstedt, KA (corresponding author), Luxembourg Agcy Res Integr, 6 Ave Hauts Fourneaux, L-4362 Esch Sur Alzette, Luxembourg.; Bramstedt, KA (corresponding author), Bond Univ, Fac Hlth Sci & Med, Program Med, Gold Coast, Qld, Australia.
EM txbioethics@yahoo.com
OI Bramstedt, Katrina Andrea/0000-0001-5446-0123
CR Almurayshid A, 2020, J COSMET DERMATOL-US, V19, P1877, DOI 10.1111/jocd.13549
   [Anonymous], 2020, ECONOMIST
   Ashely DD, 2020, WARNING LETT BUTTERF
   Ashley DD, 2020, WARNING LETT
   Bramstedt Katrina A, 2020, J Med Ethics, V46, P803, DOI 10.1136/medethics-2020-106494
   Correll WA, 2020, WARNING LETT JB SHOW
   Correll WA, 2020, WARNING LETT 21 CENT
   Correll WA, 2020, WARNING LETT
   Freckelton I, 2020, INT J LAW PSYCHIAT, DOI [10.1016/j.ijlp.2020.101611, DOI 10.1016/J.IJLP.2020.1016117351412]
   Gilbert B, 2020, J PHARM PRACT, V33, P705, DOI 10.1177/0897190019850706
   Jiang RL, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03170-4
   Lee BJ, 2020, INTEGR MED RES, V9, DOI 10.1016/j.imr.2020.100470
   McGuffin M, 2020, IND COALITION REMIND
   National Institutes of Health, 2020, NIH LAUNCH PUBL PREV
   National Library of Medicine, MESH MED SUBJ HEAD T
   Papin JF, 2005, ANTIVIR RES, V68, P84, DOI 10.1016/j.antiviral.2005.07.001
   Stenzel TT, 2020, WARNING LETT SONRISA
   Therapeutic Goods Administration, 2020, AUSTR 1 COVID TREATM
   US Food and Drug Administration, 2020, COR COVID 19 UPD FDA
   US Food and Drug Administration, COR TREATM ACC PROGR
   US Food and Drug Administration, 2020, WARN LETT
   WHO, 2020, IMM PUBL MIS
   World Health Organization, 2020, 2 M INT HLTH REG 200
NR 23
TC 0
Z9 0
U1 6
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2168-4790
EI 2168-4804
J9 THER INNOV REGUL SCI
JI Ther. Innov. Regul. Sci.
DI 10.1007/s43441-020-00224-1
EA OCT 2020
PG 6
WC Medical Informatics; Pharmacology & Pharmacy
SC Medical Informatics; Pharmacology & Pharmacy
GA NV5NM
UT WOS:000574368100001
PM 33001378
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bartsch, SM
   O'Shea, KJ
   Ferguson, MC
   Bottazzi, ME
   Wedlock, PT
   Strych, U
   McKinnell, JA
   Siegmund, SS
   Cox, SN
   Hotez, PJ
   Lee, BY
AF Bartsch, Sarah M.
   O'Shea, Kelly J.
   Ferguson, Marie C.
   Bottazzi, Maria Elena
   Wedlock, Patrick T.
   Strych, Ulrich
   McKinnell, James A.
   Siegmund, Sheryl S.
   Cox, Sarah N.
   Hotez, Peter J.
   Lee, Bruce Y.
TI Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or
   Stop an Epidemic as the Sole Intervention
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
AB Introduction: Given the continuing COVID-19 pandemic and much of the U.S. implementing social distancing owing to the lack of alternatives, there has been a push to develop a vaccine to eliminate the need for social distancing.
   Methods: In 2020, the team developed a computational model of the U.S. simulating the spread of COVID-19 coronavirus and vaccination.
   Results: Simulation experiments revealed that to prevent an epidemic (reduce the peak by >99%), the vaccine efficacy has to be at least 60% when vaccination coverage is 100% (reproduction number=2.5-3.5). This vaccine efficacy threshold rises to 70% when coverage drops to 75% and up to 80% when coverage drops to 60% when reproduction number is 2.5, rising to 80% when coverage drops to 75% when the reproduction number is 3.5. To extinguish an ongoing epidemic, the vaccine efficacy has to be at least 60% when coverage is 100% and at least 80% when coverage drops to 75% to reduce the peak by 85%-86%, 61%-62%, and 32% when vaccination occurs after 5%, 15%, and 30% of the population, respectively, have already been exposed to COVID-19 coronavirus. A vaccine with an efficacy between 60% and 80% could still obviate the need for other measures under certain circumstances such as much higher, and in some cases, potentially unachievable, vaccination coverages.
   Conclusions: This study found that the vaccine has to have an efficacy of at least 70% to prevent an epidemic and of at least 80% to largely extinguish an epidemic without any other measures (e.g., social distancing). (C) 2020 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Bartsch, Sarah M.; O'Shea, Kelly J.; Ferguson, Marie C.; Wedlock, Patrick T.; Siegmund, Sheryl S.; Cox, Sarah N.; Lee, Bruce Y.] CUNY, Grad Sch Publ Hlth & Hlth Policy, Publ Hlth Informat Computat & Operat Res, New York, NY 10027 USA.
   [Bottazzi, Maria Elena; Strych, Ulrich; Hotez, Peter J.] Baylor Coll Med, Natl Sch Trop Med, Houston, TX 77030 USA.
   [Bottazzi, Maria Elena; Strych, Ulrich; Hotez, Peter J.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   [Bottazzi, Maria Elena; Strych, Ulrich; Hotez, Peter J.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
   [McKinnell, James A.] Harbor UCLA Med Ctr, Lundquist Inst, Infect Dis Clin Outcomes Res Unit ID CORE, Torrance, CA 90509 USA.
   [McKinnell, James A.] Torrance Mem Med Ctr, Torrance, CA USA.
RP Lee, BY (corresponding author), CUNY, Hlth Policy & Management, PHICOR, Grad Sch Publ Hlth & Hlth Policy, 55 West 125th St, New York, NY 10027 USA.
EM bruceleemdmba@gmail.com
FU City University of New York's Graduate School of Public Health and
   Health Policy, Agency for Healthcare Research and Quality [R01HS023317];
   U.S. Agency for International DevelopmentUnited States Agency for
   International Development (USAID) [AID-OAA-A-15-00064]; Eunice Kennedy
   Shriver National Institute of Child Health and Human DevelopmentUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [U01HD086861, 5R01HD086013-02];
   National Institute of General Medical Sciences through the Models of
   Infectious Disease Agent Study network [R01 GM127512]
FX This work was supported in part by the City University of New York's
   Graduate School of Public Health and Health Policy, Agency for
   Healthcare Research and Quality (through grant number R01HS023317), U.S.
   Agency for International Development (under agreement number
   AID-OAA-A-15-00064), the Eunice Kennedy Shriver National Institute of
   Child Health and Human Development (grant numbers U01HD086861 and
   5R01HD086013-02), and National Institute of General Medical Sciences
   through the Models of Infectious Disease Agent Study network under grant
   R01 GM127512.
CR [Anonymous], 2019, OCC EMPL STAT MAY 20
   [Anonymous], 2020, DRAFT LANDSC COVID 1
   [Anonymous], 2020, COR DIS 2019 COVID 1
   Bartsch SM, 2020, HEALTH AFFAIR, V39, P927, DOI 10.1377/hlthaff.2020.00426
   Bernstein S., 2020, REUTERS
   Ewing P, 2020, NPR
   Gallagher J., 2020, BBC NEWS
   Kakaes K., 2020, MIT TECHNOLOGY REV
   Lee BY, 2008, CLIN INFECT DIS, V46, P1139, DOI 10.1086/529441
   Lee BY, 2017, VACCINE, V35, pA36, DOI 10.1016/j.vaccine.2016.11.033
   Lee BY, 2010, VACCINE, V28, P2806, DOI 10.1016/j.vaccine.2009.09.047
   Lee BY, 2020, REUTERS
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Simmons-Duffin S, 2020, NPR
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhou Tao, 2020, J Evid Based Med, V13, P3, DOI 10.1111/jebm.12376
NR 18
TC 3
Z9 3
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD OCT
PY 2020
VL 59
IS 4
BP 493
EP 503
DI 10.1016/j.amepre.2020.06.011
PG 11
WC Public, Environmental & Occupational Health; Medicine, General &
   Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA NT1BO
UT WOS:000572685500007
PM 32778354
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Coppola, S
   Ciabattoni, A
   Pozzi, T
   Castagna, V
   Bassi, GL
   Chiumello, D
AF Coppola, Silvia
   Ciabattoni, Arianna
   Pozzi, Tommaso
   Castagna, Valentina
   Bassi, Gianluigi L.
   Chiumello, Davide
TI Hazardous mismatch between pulmonary pathogens and antibiotic treatments
   in COVID-19 patients
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Letter
DE antibiotic therapy; bacterial pneumonia; coinfection; COVID-19;
   mechanical ventilation
ID PNEUMONIA; ADULTS; WUHAN; CHINA
C1 [Coppola, Silvia; Chiumello, Davide] San Paolo Univ Hosp, ASST Santi Paolo & Carlo, Dept Anesthesia & Intens Care, Milan, Italy.
   [Ciabattoni, Arianna; Pozzi, Tommaso; Castagna, Valentina; Chiumello, Davide] Univ Milan, Dept Hlth Sci, Milan, Italy.
   [Chiumello, Davide] Univ Milan, Coordinated Res Ctr Resp Failure, Milan, Italy.
   [Bassi, Gianluigi L.] Prince Charles Hosp, Crit Care Res Grp, Chermside, Australia.
RP Chiumello, D (corresponding author), San Paolo Univ Hosp, ASST Santi Paolo & Carlo, Dept Anesthesia & Intens Care, Milan, Italy.; Chiumello, D (corresponding author), Univ Milan, Dept Hlth Sci, Milan, Italy.; Chiumello, D (corresponding author), Univ Milan, Coordinated Res Ctr Resp Failure, Milan, Italy.
EM davide.chiumello@unimi.it
OI Coppola, Silvia/0000-0001-9290-5090
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 9
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD OCT
PY 2020
VL 125
IS 4
BP E380
EP E382
DI 10.1016/j.bja.2020.07.019
PG 3
WC Anesthesiology
SC Anesthesiology
GA NT0WX
UT WOS:000572673400022
PM 32792137
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Xu, JS
   Wang, J
   Zhong, ZC
   Su, XS
   Yang, KY
   Chen, ZF
   Zhang, DX
   Li, TD
   Wang, YB
   Zhang, SY
   Ge, SX
   Zhang, J
   Xia, NS
AF Xu, Jiasu
   Wang, Jin
   Zhong, Zecheng
   Su, Xiaosong
   Yang, Kunyu
   Chen, Zhongfu
   Zhang, Dongxu
   Li, Tingdong
   Wang, Yingbin
   Zhang, Shiyin
   Ge, Shengxiang
   Zhang, Jun
   Xia, Ningshao
TI Room-temperature-storable PCR mixes for SARS-CoV-2 detection
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Freeze-drying; PCR
ID VIRUS REVERSE-TRANSCRIPTASE; THERMOSTABILITY; VACCINES; INCREASE
AB Objectives: A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) emerged in late 2019, causing an outbreak of pneumonia [coronavirus disease 2019 (COVID-19)] globally. Although the use of ready-made reaction mixes can enable more rapid PCR-based diagnosis of COVID-19, the need to transport and store these mixes at low temperatures presents challenges to already overburdened logistics networks.
   Methods: Here, we present an optimized freeze-drying procedure that allows SARS-CoV-2 PCR mixes to be transported and stored at ambient temperatures, without loss of activity. Additive-supplemented PCR mixes were freeze-dried. The residual moisture of the freeze-dried PCR mixes was measured by Karl-Fischer titration.
   Results: We found that the freeze-dried PCR mixes with-1.2% residual moisture are optimal for storage, transport, and reconstitution. The sensitivity, specificity, and repeatability of the freeze-dried reagents were similar to those of freshly prepared, wet reagents. The freeze-dried mixes retained activity at room temperature (18 25 degrees C) for 28 days, and for 14 and 10 days when stored at 37 degrees C and 56 degrees C, respectively.
   Conclusion: The uptake of this approach will ease logistical challenges faced by transport networks and make more cold storage space available at diagnosis and hospital laboratories.
C1 [Xu, Jiasu; Wang, Jin; Zhong, Zecheng; Su, Xiaosong; Chen, Zhongfu; Zhang, Dongxu; Li, Tingdong; Wang, Yingbin; Zhang, Shiyin; Ge, Shengxiang; Zhang, Jun; Xia, Ningshao] Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China.
   [Yang, Kunyu] Xiamen Int Travel Healthcare Ctr, Xiamen 361013, Peoples R China.
RP Zhang, SY; Ge, SX (corresponding author), Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China.
EM zhangshiyin@xmu.edu.cn; sxge@xmu.edu.cn
FU Xiamen Science and Technology Major Project [3502Z2020YJ01]; National
   Science and Technology Major Project of China [2018ZX10732101-001-002];
   National Key Research and Development Program, China [2018YFC1200100]
FX This work was supported by the Xiamen Science and Technology Major
   Project [grant numbers 3502Z2020YJ01]; the National Science and
   Technology Major Project of China [grant number 2018ZX10732101-001-002];
   and the National Key Research and Development Program, China [grant
   number 2018YFC1200100].
CR Ahlford A, 2010, ANALYST, V135, P2377, DOI 10.1039/c0an00321b
   Arezi B, 2009, NUCLEIC ACIDS RES, V37, P473, DOI 10.1093/nar/gkn952
   Assegehegn G, 2019, J PHARM SCI-US, V108, P1378, DOI 10.1016/j.xphs.2018.11.039
   Baba M, 2017, PROTEIN ENG DES SEL, V30, P551, DOI 10.1093/protein/gzx046
   Brulls M., 2007, J PHARM BIOMED ANAL, V44
   Chen WL, 2020, EMERG MICROBES INFEC, V9, P469, DOI 10.1080/22221751.2020.1732837
   Fissore D, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00622
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hansen LJJ, 2015, VACCINE, V33, P5507, DOI 10.1016/j.vaccine.2015.08.085
   Klatser PR, 1998, J CLIN MICROBIOL, V36, P1798, DOI 10.1128/JCM.36.6.1798-1800.1998
   Liang L., 2020, MICROORGANISMS, V8
   Lippi G., 2020, CLIN CHEM LAB MED
   Liu R, 2020, CLIN CHIM ACTA, V505, P172, DOI 10.1016/j.cca.2020.03.009
   Siow CRS, 2018, AAPS PHARMSCITECH, V19, P845, DOI 10.1208/s12249-017-0899-6
   Takekawa J.Y., 2011, J VIS EXP, V54
   Takekawa JY, 2010, J VIROL METHODS, V166, P92, DOI 10.1016/j.jviromet.2010.02.029
   Tomiie A, 2016, J OLEO SCI, V65, P681, DOI 10.5650/jos.ess15253
   Tomlinson JA, 2005, APPL ENVIRON MICROB, V71, P6702, DOI 10.1128/AEM.71.11.6702-6710.2005
   Wang Y, 2020, J INFECT DIS
   World Health Organization, COR DIS 2019 COVID 1
   Yao Bai Y, 2020, JAMA
   Zheng Y, 2008, J PHARMACEUT BIOMED, V46, P592, DOI 10.1016/j.jpba.2007.11.011
   Zhi XT, 2019, ANAL SCI, V35, P777, DOI 10.2116/analsci.18P575
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 24
TC 1
Z9 1
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD OCT
PY 2020
VL 84
BP 73
EP 78
DI 10.1016/j.clinbiochem.2020.06.013
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA NT2QH
UT WOS:000572791400010
PM 32592724
OA Green Published
DA 2021-01-01
ER

PT J
AU Georgakopoulos, JR
   Mufti, A
   Vender, R
   Yeung, J
AF Georgakopoulos, Jorge R.
   Mufti, Asfandyar
   Vender, Ron
   Yeung, Jensen
TI Treatment discontinuation and rate of disease transmission in psoriasis
   patients receiving biologic therapy during the COVID-19 pandemic: A
   Canadian multicenter retrospective study
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Letter
C1 [Georgakopoulos, Jorge R.; Mufti, Asfandyar; Yeung, Jensen] Univ Toronto, Div Dermatol, Dept Med, Toronto, ON, Canada.
   [Vender, Ron] McMaster Univ, Dept Dermatol, Hamilton, ON, Canada.
   [Vender, Ron] Dermatrials Res Inc, Hamilton, ON, Canada.
   [Vender, Ron] Venderm Innovat Psoriasis, Hamilton, ON, Canada.
   [Yeung, Jensen] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
   [Yeung, Jensen] Womens Coll Hosp, Toronto, ON, Canada.
   [Yeung, Jensen] Prob Med Res Inc, Waterloo, ON, Canada.
RP Yeung, J (corresponding author), Womens Coll Hosp, Dept Dermatol, 76 Grenville St,Fifth Floor, Toronto, ON M5S 1B2, Canada.
EM jensen.yeung@utoronto.ca
CR JHCRC, 2020, COVID 19 CAS TRACK
   Kim HJ, 2019, DERMATOL CLIN, V37, P29, DOI 10.1016/j.det.2018.07.004
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Shah P, 2020, J AM ACAD DERMATOL, V82, pE203, DOI 10.1016/j.jaad.2020.03.056
   Warren RB, 2019, J AM ACAD DERMATOL, V81, pAB113
NR 5
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
EI 1097-6787
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD OCT
PY 2020
VL 83
IS 4
BP 1212
EP 1214
DI 10.1016/j.jaad.2020.07.021
PG 3
WC Dermatology
SC Dermatology
GA NT0WZ
UT WOS:000572673600029
PM 32679279
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Holcomb, ZE
   Santillan, MR
   Morss-Walton, PC
   Salian, P
   Her, MJ
   Giannotti, NM
   Kimball, AB
   Porter, ML
AF Holcomb, Zachary E.
   Santillan, Monica Rosales
   Morss-Walton, Peyton C.
   Salian, Prerna
   Her, Min Ji
   Giannotti, Nicole M.
   Kimball, Alexa B.
   Porter, Martina L.
TI Risk of COVID-19 in dermatologic patients receiving long-term
   immunomodulatory therapy
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Letter
ID PSORIASIS
C1 [Holcomb, Zachary E.] Massachusetts Gen Hosp, Dept Dermatol, Harvard Combined Dermatol Residency Program, Boston, MA 02114 USA.
   [Santillan, Monica Rosales; Morss-Walton, Peyton C.; Salian, Prerna; Giannotti, Nicole M.; Kimball, Alexa B.; Porter, Martina L.] Beth Israel Deaconess Med Ctr, Dept Dermatol, Clin Lab Epidemiol & Appl Res Skin, Boston, MA 02215 USA.
   [Her, Min Ji] Beth Israel Deaconess Med Ctr, Dept Pharm, Boston, MA 02215 USA.
   [Morss-Walton, Peyton C.] Univ Massachusetts, Sch Med, Worcester, MA USA.
   [Giannotti, Nicole M.] Northeastern Univ, Boston, MA 02115 USA.
   [Kimball, Alexa B.; Porter, Martina L.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.
RP Porter, ML (corresponding author), Beth Israel Deaconess Med Ctr, Clin Lab Epidemiol & Appl Res Skin, 330 Brookline Ave, Boston, MA 02215 USA.
EM clears@bidmc.harvard.edu
CR Gisondi P, 2020, J AM ACAD DERMATOL, V83, P285, DOI 10.1016/j.jaad.2020.04.085
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Massachusetts Department of Public Health, 2020, INF OUTBR COR DIS 20
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
NR 5
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
EI 1097-6787
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD OCT
PY 2020
VL 83
IS 4
BP 1215
EP 1218
DI 10.1016/j.jaad.2020.06.999
PG 2
WC Dermatology
SC Dermatology
GA NT0WZ
UT WOS:000572673600031
PM 32622141
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Din, S
   Kent, A
   Pollok, RC
   Meade, S
   Kennedy, NA
   Arnott, I
   Beattie, RM
   Chua, F
   Cooney, R
   Dart, RJ
   Galloway, J
   Gaya, DR
   Ghosh, S
   Griffiths, M
   Hancock, L
   Hansen, R
   Hart, A
   Lamb, CA
   Lees, CW
   Limdi, JK
   Lindsay, JO
   Patel, K
   Powell, N
   Murray, CD
   Probert, C
   Raine, T
   Selinger, C
   Sebastian, S
   Smith, PJ
   Tozer, P
   Ustianowski, A
   Younge, L
   Samaan, MA
   Irving, PM
AF Din, Shahida
   Kent, Alexandra
   Pollok, Richard C.
   Meade, Susanna
   Kennedy, Nicholas A.
   Arnott, Ian
   Beattie, R. Mark
   Chua, Felix
   Cooney, Rachel
   Dart, Robin J.
   Galloway, James
   Gaya, Daniel R.
   Ghosh, Subrata
   Griffiths, Mark
   Hancock, Laura
   Hansen, Richard
   Hart, Ailsa
   Lamb, Christopher Andrew
   Lees, Charlie W.
   Limdi, Jimmy K.
   Lindsay, James O.
   Patel, Kamal
   Powell, Nick
   Murray, Charles D.
   Probert, Chris
   Raine, Tim
   Selinger, Christian
   Sebastian, Shaji
   Smith, Philip J.
   Tozer, Phil
   Ustianowski, Andrew
   Younge, Lisa
   Samaan, Mark A.
   Irving, Peter M.
TI Adaptations to the British Society of Gastroenterology guidelines on the
   management of acute severe UC in the context of the COVID-19 pandemic: a
   RAND appropriateness panel
SO GUT
LA English
DT Article
DE ulcerative colitis; clinical decision making; IBD clinical
ID CORTICOSTEROID TREATMENT; ULCERATIVE-COLITIS; THERAPY
AB Objective Management of acute severe UC (ASUC) during the novel COVID-19 pandemic presents significant dilemmas. We aimed to provide COVID-19-specific guidance using current British Society of Gastroenterology (BSG) guidelines as a reference point. Design We convened a RAND appropriateness panel comprising 14 gastroenterologists and an IBD nurse consultant supplemented by surgical and COVID-19 experts. Panellists rated the appropriateness of interventions for ASUC in the context of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Median scores and disagreement index (DI) were calculated. Results were discussed at a moderated meeting prior to a second survey. Results Panellists recommended that patients with ASUC should be isolated throughout their hospital stay and should have a SARS-CoV-2 swab performed on admission. Patients with a positive swab should be discussed with COVID-19 specialists. As per BSG guidance, intravenous hydrocortisone was considered appropriate as initial management; only in patients with COVID-19 pneumonia was its use deemed uncertain. In patients requiring rescue therapy, infliximab with continuing steroids was recommended. Delaying colectomy because of COVID-19 was deemed inappropriate. Steroid tapering as per BSG guidance was deemed appropriate for all patients apart from those with COVID-19 pneumonia in whom a 4-6 week taper was preferred. Post-ASUC maintenance therapy was dependent on SARS-CoV-2 status but, in general, biologics were more likely to be deemed appropriate than azathioprine or tofacitinib. Panellists deemed prophylactic anticoagulation postdischarge to be appropriate in patients with a positive SARS-CoV-2 swab. Conclusion We have suggested COVID-19-specific adaptations to the BSG ASUC guideline using a RAND panel.
C1 [Din, Shahida; Arnott, Ian; Lees, Charlie W.] Western Gen Hosp, Dept Gastroenterol, Edinburgh, Midlothian, Scotland.
   [Din, Shahida] Univ Edinburgh, Gastroenterol & Hepatol Unit, Edinburgh, Midlothian, Scotland.
   [Kent, Alexandra] Kings Coll Hosp NHS Fdn Trust, Dept Gastroenterol, London, England.
   [Kent, Alexandra] Kings Coll London, Fac Life Sci & Med, London, England.
   [Pollok, Richard C.; Patel, Kamal] St Georges Healthcare NHS Trust, Dept Gastroenterol, London, England.
   [Pollok, Richard C.] St Georges Univ Hosp NHS Fdn Trust, Inst Infect & Immun, London, England.
   [Meade, Susanna; Samaan, Mark A.; Irving, Peter M.] Guys & St Thomas Hosp NHS Trust, Dept Gastroenterol, London SE1 7EH, England.
   [Kennedy, Nicholas A.] Royal Devon & Exeter NHS Fdn Trust, Dept Gastroenterol, Exeter, Devon, England.
   [Kennedy, Nicholas A.] Univ Exeter, Exeter IBD Res Grp, Exeter, Devon, England.
   [Beattie, R. Mark] Southampton Childrens Hosp, Dept Paediat Gastroenterol, Southampton, Hants, England.
   [Chua, Felix] Royal Brompton Hosp, Dept Resp Med, Interstitial Lung Dis Unit, London, England.
   [Cooney, Rachel; Ghosh, Subrata] Queen Elizabeth Hosp Birmingham, Dept Gastroenterol, Birmingham, W Midlands, England.
   [Dart, Robin J.; Murray, Charles D.] Royal Free Hosp, Dept Gastroenterol, London, England.
   [Galloway, James] Kings Coll Hosp London, Dept Rheumatol, London, England.
   [Gaya, Daniel R.] Glasgow Royal Infirm, Gastroenterol Unit, Glasgow, Lanark, Scotland.
   [Griffiths, Mark] Barts Hlth NHS Trust, Perioperat Med, London, England.
   [Griffiths, Mark] Natl Heart & Lung Inst, Fac Med, London, England.
   [Hancock, Laura] Manchester Univ NHS Fdn Trust, Dept Gen Surg, Manchester, Lancs, England.
   [Hansen, Richard] Royal Hosp Children, Paediat Gastroenterol & Nutr, Glasgow, Lanark, Scotland.
   [Hart, Ailsa; Tozer, Phil; Younge, Lisa] St Marks Hosp, IBD Unit, London, England.
   [Hart, Ailsa] Imperial Coll London, Antigen Presentat Res Grp, London, England.
   [Lamb, Christopher Andrew] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.
   [Lamb, Christopher Andrew] Newcastle Upon Tyne Hosp NHS Fdn Trust, Dept Gastroenterol, Newcastle Upon Tyne, Tyne & Wear, England.
   [Lees, Charlie W.] Univ Edinburgh, Ctr Genom & Expt Med, Edinburgh, Midlothian, Scotland.
   [Limdi, Jimmy K.] Pennine Acute Hosp NHS Trust, Dept Gastroenterol, Manchester, Lancs, England.
   [Limdi, Jimmy K.] Manchester Acad, Hlth Sci Ctr, Manchester, Lancs, England.
   [Lindsay, James O.] Barts Hlth NHS Trust, Dept Gastroenterol, London, England.
   [Powell, Nick] Imperial Coll London, Div Digest Dis, London, England.
   [Probert, Chris] Univ Liverpool, Dept Cellular & Mol Physiol, Gastroenterol Res Unit, Inst Translat Med, Liverpool, Merseyside, England.
   [Raine, Tim] Cambridge Univ Hosp NHS Fdn Trust, Dept Gastroenterol, Cambridge, England.
   [Selinger, Christian] Leeds Teaching Hosp NHS Trust, Leeds Gastroenterol Inst, Leeds, W Yorkshire, England.
   [Sebastian, Shaji] Hull Univ Teaching Hosp NHS Trust, Dept Gastroenterol, Kingston Upon Hull, N Humberside, England.
   [Sebastian, Shaji] Hull York Med Sch, Dept Immunuol & Inflammat, Kingston Upon Hull, N Humberside, England.
   [Smith, Philip J.] Royal Liverpool Univ Hosp, Dept Gastroenterol, Liverpool, Merseyside, England.
   [Ustianowski, Andrew] North Manchester Gen Hosp, Dept Infect Dis, Manchester, Lancs, England.
   [Younge, Lisa] Crohns & Colitis UK, St Albans, England.
   [Irving, Peter M.] Kings Coll London, Sch Immunol & Microbial Sci, Peter Gorer Dept Immunobiol, London, England.
RP Irving, PM (corresponding author), Guys & St Thomas Hosp NHS Trust, Dept Gastroenterol, London SE1 7EH, England.
EM peter.irving@gstt.nhs.uk
RI Murray, Charles/K-5327-2013
OI Murray, Charles/0000-0001-6736-1546; Raine, Tim/0000-0002-5855-9873;
   Griffiths, Mark/0000-0002-1615-1896; Pollok,
   Richard/0000-0001-6452-6763; Hancock, Laura/0000-0002-8399-8632; Hansen,
   Richard/0000-0002-3944-6646
FU Medical Research CouncilMedical Research Council UK (MRC) [MR/T005564/1]
FX PMI is supported by a grant from the Medical Research Council
   [MR/T005564/1]
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Al-Ani AH, 2020, ALIMENT PHARM THER, V52, P54, DOI 10.1111/apt.15779
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   British Thoracic Society, 2020, BTS GUID VEN THROMB
   Carvalho A, 2020, AM J GASTROENTEROL, V1
   Chaparro M, 2013, INFLAMM BOWEL DIS, V19, P1404, DOI 10.1097/MIB.0b013e318281f28f
   Coulter Ian, 2016, BMC Res Notes, V9, P16, DOI 10.1186/s13104-015-1802-8
   Ding SY, 2020, GASTROENTEROLOGY, V159, P53, DOI 10.1053/j.gastro.2020.04.052
   Fanelli V, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02872-z
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Fitch K, 2001, RAND UCLA APPROPRIAT
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johns Hopkins University, 2020, J HOPK COR RES CTR
   Kirchgesner J, 2018, GASTROENTEROLOGY, V155, P337, DOI 10.1053/j.gastro.2018.04.012
   Kotwani P, 2020, J CROHNS COLITIS, V14, P1026, DOI 10.1093/ecco-jcc/jjaa018
   Lamb CA, 2019, GUT, V68, pS1, DOI 10.1136/gutjnl-2019-318484
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Lei S, 2020, ECLINICALMEDICINE, V21, DOI [10.1016/j.eclinm.2020.100331.9., DOI 10.1016/JECLINM.2020.200331]
   Lewis SR, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004477.pub3
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Norsa L, 2020, GASTROENTEROLOGY, V159, P371, DOI [10.1053/j.gastro.2020.03.062, 10.1053/j.gastro.2020.03.06]
   Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620
   Rodriguez-Lago I, 2020, GASTROENTEROLOGY, V159, P781, DOI 10.1053/j.gastro.2020.04.043
   Royal College of Surgeons of England, 2020, UPD INT GEN SURG GUI
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P6, DOI 10.1053/j.gastro.2020.04.002
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sandborn WJ, 2017, NEW ENGL J MED, V376, P1723, DOI 10.1056/NEJMoa1606910
   Seah D, 2016, ALIMENT PHARM THER, V43, P482, DOI 10.1111/apt.13491
   SECURE-IBD, 2020, SEC IBD REG SURV EP
   Shah ED, 2017, INFLAMM BOWEL DIS, V23, P570, DOI 10.1097/MIB.0000000000001049
   Singh S, 2020, CLIN GASTROENTEROL H, V18, P69, DOI 10.1016/j.cgh.2019.02.044
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   The Royal College of Radiologists, 2020, STAT US CT CHEST SCR
   Travis SPL, 1996, GUT, V38, P905, DOI 10.1136/gut.38.6.905
   TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041
   Turner D, 2007, CLIN GASTROENTEROL H, V5, P103, DOI 10.1016/j.cgh.2006.09.033
   Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053
   Walker AN, 2020, AM GOV POLIT POL, P17
   WHO, 2020, CLIN MAN SEV AC RESP
   Wisniewski A, 2020, UNITED EUR GASTROENT, V8, P303, DOI 10.1177/2050640619889763
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zhou L, 2020, CHINESE CLIN TRIAL R
NR 47
TC 1
Z9 1
U1 3
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD OCT
PY 2020
VL 69
IS 10
BP 1769
EP 1777
DI 10.1136/gutjnl-2020-321927
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NS5ZF
UT WOS:000572338600012
PM 32513653
OA Green Published, Green Accepted, Other Gold
DA 2021-01-01
ER

PT J
AU Becchetti, C
   Zambelli, MF
   Pasulo, L
   Donato, MF
   Invernizzi, F
   Detry, O
   Dahlqvist, G
   Ciccarelli, O
   Morelli, MC
   Fraga, M
   Svegliati-Baroni, G
   van Vlierberghe, H
   Coenraad, MJ
   Romero, MC
   de Gottardi, A
   Toniutto, P
   Del Prete, L
   Abbati, C
   Samuel, D
   Pirenne, J
   Nevens, F
   Dufour, JF
AF Becchetti, Chiara
   Zambelli, Marco Fabrizio
   Pasulo, Luisa
   Donato, Maria Francesca
   Invernizzi, Federica
   Detry, Olivier
   Dahlqvist, Geraldine
   Ciccarelli, Olga
   Morelli, Maria Cristina
   Fraga, Montserrat
   Svegliati-Baroni, Gianluca
   van Vlierberghe, Hans
   Coenraad, Minneke J.
   Romero, Mario Cristobal
   de Gottardi, Andrea
   Toniutto, Pierluigi
   Del Prete, Luca
   Abbati, Claudia
   Samuel, Didier
   Pirenne, Jacques
   Nevens, Frederik
   Dufour, Jean-Francois
CA COVID LT Grp
TI COVID-19 in an international European liver transplant recipient cohort
SO GUT
LA English
DT Article
DE orthotopic liver transplantation; chronic liver disease; infectious
   disease
ID INFECTION; MORTALITY
AB Objective Knowledge on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in liver transplant recipients is lacking, particularly in terms of severity of the disease. The aim of this study was to describe the demographic, baseline clinical characteristics and early outcomes of a European cohort of liver transplant recipients with SARS-CoV-2 infection. Design We conducted an international prospective study across Europe on liver transplant recipients with SARS-CoV-2 infection confirmed by microbiological assay during the first outbreak of COVID-19 pandemic. Baseline characteristics, clinical presentation, management of immunosuppressive therapy and outcomes were collected. Results 57 patients were included (70% male, median (IQR) age at diagnosis 65 (57-70) years). 21 (37%), 32 (56%) and 21 (37%) patients had one cardiovascular disease, arterial hypertension and diabetes mellitus, respectively. The most common symptoms were fever (79%), cough (55%), dyspnoea (46%), fatigue or myalgia (56%) and GI symptoms (33%). Immunosuppression was reduced in 22 recipients (37%) and discontinued in 4 (7%). With this regard, no impact on outcome was observed. Forty-one (72%) subjects were hospitalised and 11 (19%) developed acute respiratory distress syndrome. Overall, we estimated a case fatality rate of 12% (95% CI 5% to 24%), which increased to 17% (95% CI 7% to 32%) among hospitalised patients. Five out of the seven patients who died had a history of cancer. Conclusion In this European multicentre prospective study of liver transplant recipients, COVID-19 was associated with an overall and in-hospital fatality rate of 12% (95% CI 5% to 24%) and 17% (95% CI 7% to 32%), respectively. A history of cancer was more frequent in patients with poorer outcome.
C1 [Becchetti, Chiara; Dufour, Jean-Francois] Univ Bern, Univ Clin Visceral Surg & Med, Inselspital, Bern, Switzerland.
   [Zambelli, Marco Fabrizio; Del Prete, Luca; Abbati, Claudia] Papa Giovanni XXIII Hosp, Dept Surg, Gen Surg & Abdominal Transplant Unit, Bergamo, Lombardia, Italy.
   [Pasulo, Luisa] Papa Giovanni XXIII Hosp, Gastroenterol & Transplant Hepatol, Bergamo, Lombardia, Italy.
   [Donato, Maria Francesca; Invernizzi, Federica] Maggiore Hosp Policlin, IRCSS Fdn Ca Granda, CRC AM & A Migliavacca Ctr Liver Dis, Transplant Hepatol Unit,Div Gastroenterol & Hepat, Milan, Italy.
   [Detry, Olivier] Cent Univ Hosp Liege, Dept Abdominal Surg & Transplantat, Liege, Belgium.
   [Dahlqvist, Geraldine] Clin Univ St Luc, Hepatogastroenterol Unit, Brussels, Belgium.
   [Ciccarelli, Olga] Clin Univ St Luc, Dept Abdominal Surg & Transplantat, Brussels, Belgium.
   [Morelli, Maria Cristina] Univ Bologna, Dept Organ Failures & Transplantat, Azienda Osped Bologna Policlin St Orsola Malpighi, Bologna, Emilia Romagna, Italy.
   [Fraga, Montserrat] Univ Lausanne, CHU Vaudois, Div Gastroenterol & Hepatol, Lausanne, Switzerland.
   [Svegliati-Baroni, Gianluca] AOU Osped Riuniti Ancona, Liver Injury & Transplant Unit, Ancona, Marche, Italy.
   [Svegliati-Baroni, Gianluca] Polytech Univ Marche, Dept Clin & Mol Sci, Ancona, Marche, Italy.
   [Svegliati-Baroni, Gianluca] Polytech Univ Marche, Obes Ctr, Ancona, Marche, Italy.
   [van Vlierberghe, Hans] Ghent Univ Hosp, Gastroenterol & Hepatol, Ghent, Belgium.
   [Coenraad, Minneke J.] Leiden Univ, Med Ctr, Gastroenterol & Hepatol, Leiden, Netherlands.
   [Romero, Mario Cristobal] Gen Univ Hosp Gregorio Maranon, Dept Hepatol, Madrid, Spain.
   [de Gottardi, Andrea] Univ Svizzera Italiana, Ente Osped Cantonale, Gastroenterol & Hepatol, Lugano, Switzerland.
   [Toniutto, Pierluigi] Azienda Sanit Univ Integrata Udine, Hepatol & Liver Transplant Unit, Udine, Friuli Venezia, Italy.
   [Samuel, Didier] Paris Saclay Univ, Inserm Res Unit, Ctr Hepatobiliaire, Hop Paul Brousse, Villejuif, France.
   [Pirenne, Jacques] KU Leuven Hosp, Abdominal Transplant Surg, Leuven, Flanders, Belgium.
   [Nevens, Frederik] KU Leuven Hosp, Hepatol, Leuven, Flanders, Belgium.
   [Dufour, Jean-Francois] Univ Bern, Hepatol, Dept Biomed Res, Bern, Switzerland.
RP Dufour, JF (corresponding author), Univ Hosp Bern, Inselspital, Dept Visceral Surg & Med, Hepatol, CH-3010 Bern, Switzerland.
EM jean-francois.dufour@dbmr.unibe.ch
RI PETRIDIS, IOANNIS/S-2031-2017; Vitale, Giovanni/K-6322-2016
OI PETRIDIS, IOANNIS/0000-0002-8668-5674; Burra,
   Patrizia/0000-0002-8791-191X; Del Prete, Luca/0000-0003-0268-3266;
   Coenraad, Minneke/0000-0002-3434-4421; Vitale,
   Giovanni/0000-0003-2603-8245; Pascual, Manuel A./0000-0001-7747-1693
FU Stiftung fur die Leberkrankheiten (Switzerland)
FX This study was funded by Stiftung fur die Leberkrankheiten
   (Switzerland).
CR AlGhamdi M, 2015, AM J TRANSPLANT, V15, P1101, DOI 10.1111/ajt.13085
   American Association for the Study of Liver Diseases, 2020, CLIN INS HEP LIV TRA
   [Anonymous], 2020, GLOBAL SURVEILLANCE
   Bhoori S, 2020, LANCET GASTROENTEROL, V5, P532, DOI 10.1016/S2468-1253(20)30116-3
   Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Deng Xiaowei, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa578
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Fan ZY, 2020, CLIN GASTROENTEROL H, V18, P1561, DOI 10.1016/j.cgh.2020.04.002
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fishman JA, 2007, NEW ENGL J MED, V357, P2601, DOI 10.1056/NEJMra064928
   Fishman JA, 2020, AM J TRANSPLANT, V20, P1765, DOI 10.1111/ajt.15890
   Fix OK, 2020, HEPATOLOGY, V72, P287, DOI 10.1002/hep.31281
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kumar D, 2003, AM J TRANSPLANT, V3, P977, DOI 10.1034/j.1600-6143.2003.00197.x
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Rabkin JM, 2001, AM J SURG, V181, P475, DOI 10.1016/S0002-9610(01)00595-5
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Webb GJ, 2020, LANCET GASTROENTEROL, V5, P643, DOI 10.1016/S2468-1253(20)30125-4
   WHO, COR DIS COVID 19 PAN
   Wong HYF, 2020, RADIOLOGY, V296, pE72, DOI 10.1148/radiol.2020201160
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang J, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104392
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 33
TC 4
Z9 4
U1 2
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD OCT
PY 2020
VL 69
IS 10
BP 1832
EP 1840
DI 10.1136/gutjnl-2020-321923
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NS5ZF
UT WOS:000572338600018
PM 32571972
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Leiva, O
   Bhatt, AS
   Vaduganathan, M
AF Leiva, Orly
   Bhatt, Ankeet S.
   Vaduganathan, Muthiah
TI Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus
   Disease 2019
SO HEART FAILURE CLINICS
LA English
DT Article
DE Ambulatory; Care optimization; COVID-19; Guideline-directed medical
   therapy; Heart failure
ID OBSTRUCTIVE PULMONARY-DISEASE; REDUCED EJECTION FRACTION; INITIATE
   LIFESAVING TREATMENT; CLINICAL-OUTCOMES; CARDIOVASCULAR OUTCOMES;
   INFLUENZA VACCINATION; HOSPITALIZED-PATIENTS; ORGANIZED PROGRAM; MEDICAL
   THERAPY; OPTIMIZE-HF
C1 [Leiva, Orly] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [Bhatt, Ankeet S.; Vaduganathan, Muthiah] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA.
RP Vaduganathan, M (corresponding author), 75 Francis St, Boston, MA 02215 USA.
EM mvaduganathan@bwh.harvard.edu
FU KL2/Catalyst Medical Research Investigator Training award from Harvard
   Catalyst (NIH/NCATS Award) [UL 1TR002541]; NovartisNovartis; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA
FX O. Leiva and A.S. Bhatt have no relevant disclosures. M. Vaduganathan is
   supported by the KL2/Catalyst Medical Research Investigator Training
   award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541); serves on
   advisory boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG,
   Boehringer Ingelheim, Cytokinetics, and Relypsa; and participates on
   clinical endpoint committees for studies sponsored by Novartis and the
   National Institutes of Health.
CR Abraham WT, 2011, LANCET, V377, P658, DOI 10.1016/S0140-6736(11)60101-3
   Adams KF, 2005, AM HEART J, V149, P209, DOI 10.1016/j.ahj.2004.08.005
   Allen LA, 2015, CIRCULATION, V132, P1347, DOI 10.1161/CIRCULATIONAHA.115.014281
   Andersson B, 2005, INT J CARDIOL, V104, P257, DOI 10.1016/j.ijcard.2004.10.028
   Balakumaran K, 2019, IJC HEART VASC, V22, P1, DOI 10.1016/j.ijcha.2018.10.003
   Bergethon KE, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.115.002594
   Bhatt AS, 2018, JACC-HEART FAIL, V6, P844, DOI 10.1016/j.jchf.2018.04.012
   Bhatt AS, 2017, JACC-HEART FAIL, V5, P194, DOI 10.1016/j.jchf.2016.12.007
   Blizzard S, 2019, ANN PHARMACOTHER, V53, P905, DOI 10.1177/1060028019842656
   Bress AP, 2019, J AM COLL CARDIOL, V73, P945, DOI 10.1016/j.jacc.2018.12.027
   Brunner-La Rocca HP, 2019, JACC-HEART FAIL, V7, P13, DOI 10.1016/j.jchf.2018.10.010
   Butler T, 2016, BRIT J NUTR, V115, P1202, DOI 10.1017/S000711451500553X
   Canepa M, 2017, CARDIOLOGY, V136, P128, DOI 10.1159/000448166
   Chaudhry SI, 2010, NEW ENGL J MED, V363, P2301, DOI 10.1056/NEJMoa1010029
   Chen S, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1452-4
   Curtis LH, 2009, CIRC-CARDIOVASC QUAL, V2, P377, DOI 10.1161/CIRCOUTCOMES.108.822692
   DeVore AD, 2017, AM HEART J, V189, P177, DOI 10.1016/j.ahj.2017.04.010
   Eurlings CGMJ, 2019, NETH HEART J, V27, P5, DOI 10.1007/s12471-018-1202-5
   Fonarow GC, 2004, AM HEART J, V148, P43, DOI 10.1016/j.ahj.2004.03.004
   Gattis WA, 2004, J AM COLL CARDIOL, V43, P1534, DOI 10.1016/j.jacc.2003.12.040
   Givertz MM, 2017, J AM COLL CARDIOL, V70, P1875, DOI 10.1016/j.jacc.2017.08.010
   Greene SJ, 2019, J AM COLL CARDIOL, V73, P2365, DOI 10.1016/j.jacc.2019.02.015
   Guder G, 2014, EUR J HEART FAIL, V16, P1273, DOI 10.1002/ejhf.183
   Hawkins NM, 2013, EUR HEART J, V34, P2795, DOI 10.1093/eurheartj/eht192
   Heidenreich PA, 2012, CIRC-CARDIOVASC QUAL, V5, P37, DOI 10.1161/CIRCOUTCOMES.110.959122
   Hong Yuling, 2006, Crit Pathw Cardiol, V5, P179, DOI 10.1097/01.hpc.0000243588.00012.79
   Inglis SC, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007228.pub2
   Ingram A, 2019, J PHARM PRACT
   Jeyanantham K, 2017, HEART FAIL REV, V22, P731, DOI 10.1007/s10741-017-9640-5
   Koehler F, 2018, LANCET, V392, P1047, DOI 10.1016/S0140-6736(18)31880-4
   Komajda M, 2017, EUR J HEART FAIL, V19, P1495, DOI 10.1002/ejhf.876
   Komajda M, 2016, EUR J HEART FAIL, V18, P514, DOI 10.1002/ejhf.510
   Lawson CA, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002540
   McKelvie RS, 2008, HEART FAIL REV, V13, P3, DOI 10.1007/s10741-007-9052-z
   McKinley D, 2018, AM J MENS HEALTH, V13, DOI 10.1177/1557988318814295
   McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303
   Mediano MFF, 2018, JACC-HEART FAIL, V6, P1011, DOI 10.1016/j.jchf.2018.09.012
   Mentz RJ, 2019, CIRC-CARDIOVASC QUAL, V12, pA252
   Mentz RJ, 2018, J AM COLL CARDIOL, V72, P41, DOI 10.1016/j.jacc.2018.04.038
   Modin D, 2019, CIRCULATION, V139, P575, DOI 10.1161/CIRCULATIONAHA.118.036788
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152]
   Myhre PL, 2019, EUR J HEART FAIL, V21, P1245, DOI 10.1002/ejhf.1586
   Neal B, 2017, NEW ENGL J MED, V377, P644, DOI 10.1056/NEJMoa1611925
   Newhouse A, 2014, HEART FAIL CLIN, V10, P295, DOI 10.1016/j.hfc.2013.10.004
   O'Connor CM, 2008, AM HEART J, V156, P662, DOI 10.1016/j.ahj.2008.04.030
   O'Connor CM, 2019, JACC-HEART FAIL, V7, P442, DOI 10.1016/j.jchf.2019.04.001
   O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454
   Pasternak B, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4772
   Peri-Okonny PA, 2019, JACC-HEART FAIL, V7, P350, DOI 10.1016/j.jchf.2018.11.011
   Rahman A, 2016, JPEN-PARENTER ENTER, V40, P475, DOI 10.1177/0148607114566854
   Rutledge T, 2006, J AM COLL CARDIOL, V48, P1527, DOI 10.1016/j.jacc.2006.06.055
   Sharma A, 2018, CIRC-HEART FAIL, V11, DOI 10.1161/CIRCHEARTFAILURE.117.004646
   Udell JA, 2013, JAMA-J AM MED ASSOC, V310, P1711, DOI 10.1001/jama.2013.279206
   Van Spall HGC, 2019, JAMA-J AM MED ASSOC, V321, P753, DOI 10.1001/jama.2019.0710
   Vardeny O, 2016, JACC-HEART FAIL, V4, P152, DOI 10.1016/j.jchf.2015.10.012
   Velazquez EJ, 2019, NEW ENGL J MED, V380, P539, DOI 10.1056/NEJMoa1812851
   Wagner EH, 2000, BMJ-BRIT MED J, V320, P569, DOI 10.1136/bmj.320.7234.569
   Werhahn SM, 2019, ESC HEART FAIL, V6, P516, DOI 10.1002/ehf2.12425
   Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI 10.1056/NEJMoa1812389
   Yancy CW, 2018, J AM COLL CARDIOL, V71, P201, DOI 10.1016/j.jacc.2017.11.025
   Zelniker TA, 2018, J AM COLL CARDIOL, V72, P1845, DOI 10.1016/j.jacc.2018.06.040
   Zinman B, 2015, NEW ENGL J MED, V373, P2117, DOI 10.1056/NEJMoa1504720
NR 62
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1551-7136
J9 HEART FAIL CLIN
JI Heart Fail. Clin.
PD OCT
PY 2020
VL 16
IS 4
BP 433
EP 440
DI 10.1016/j.hfc.2020.06.004
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NS6GG
UT WOS:000572356900009
PM 32888638
OA Green Published
DA 2021-01-01
ER

PT J
AU Ibrahim, H
   Perl, A
   Smith, D
   Lewis, T
   Kon, Z
   Goldenberg, R
   Yarta, K
   Staniloae, C
   Williams, M
AF Ibrahim, Homam
   Perl, Andras
   Smith, Deane
   Lewis, Tyler
   Kon, Zachary
   Goldenberg, Ronald
   Yarta, Kinan
   Staniloae, Cezar
   Williams, Mathew
TI Therapeutic blockade of inflammation in severe COVID-19 infection with
   intravenous N-acetylcysteine
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE Coronavirus 19; COVID-19; N-acetylcysteine; Glutathione; Glucose
   6-phosphate dehydrogenase; Mechanistic target of rapamycin; C-reactive
   protein; Ferritin; Respirator; Extracorporeal membrane oxygenation
ID ACUTE LUNG INJURY; OXIDATIVE STRESS; DOUBLE-BLIND; CELLS; GLUTATHIONE;
   DEFICIENCY; PRIMAQUINE; RAPAMYCIN; FIBROSIS; RECOVERY
AB Glucose 6-phosphate dehydrogenase (G6PD) deficiency facilitates human coronavirus infection due to glutathione depletion. G6PD deficiency may especially predispose to hemolysis upon coronavirus disease-2019 (COVID-19) infection when employing pro-oxidant therapy. However, glutathione depletion is reversible by N-acetylcysteine (NAC) administration. We describe a severe case of COVID-19 infection in a G6PD-deficient patient treated with hydroxychloroquine who benefited from intravenous (IV) NAC beyond reversal of hemolysis. NAC blocked hemolysis and elevation of liver enzymes, C-reactive protein (CRP), and ferritin and allowed removal from respirator and veno-venous extracorporeal membrane oxygenator and full recovery of the G6PD-deficient patient. NAC was also administered to 9 additional respirator-dependent COVID-19-infected patients without G6PD deficiency. NAC elicited clinical improvement and markedly reduced CRP in all patients and ferritin in 9/10 patients. NAC mechanism of action may involve the blockade of viral infection and the ensuing cytokine storm that warrant follow-up confirmatory studies in the setting of controlled clinical trials.
C1 [Ibrahim, Homam; Smith, Deane; Lewis, Tyler; Kon, Zachary; Goldenberg, Ronald; Yarta, Kinan; Staniloae, Cezar; Williams, Mathew] NYU, Grossman Sch Med, New York, NY 10016 USA.
   [Perl, Andras] Upstate Med Univ Hosp, Syracuse, NY 13210 USA.
RP Ibrahim, H (corresponding author), NYU, Grossman Sch Med, New York, NY 10016 USA.; Perl, A (corresponding author), Upstate Med Univ Hosp, Syracuse, NY 13210 USA.
EM Homam.ibrahim@NYUlangone.org; perla@upstate.edu
OI goldenberg, ron/0000-0002-0717-7250; Williams,
   Mathew/0000-0003-2055-8741
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI 072648, AI 122176,
   AI141304, AR068052, AR076092]
FX This work was supported in part by grants AI 072648, AI 122176,
   AI141304, AR068052, and AR076092 from the National Institutes of Health.
CR Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994
   Cao X., 2016, ANGIOTENSIN CONVERTI
   Cao X, 2019, DIABETES-METAB RES, V35, DOI 10.1002/dmrr.3123
   CARSON PE, 1956, SCIENCE, V124, P484, DOI 10.1126/science.124.3220.484-a
   Chai PW, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00883-5
   Chen G., 2020, J CLIN INVEST, V130
   Chen JF, 2018, INT J MOL MED, V41, P2865, DOI 10.3892/ijmm.2018.3507
   Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198
   Du T., 2018, ACS APPL MAT INTERFA, V10, P4369
   Fajgenbaum DC, 2019, J CLIN INVEST, V129, P4451, DOI 10.1172/JCI126091
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Geiler J, 2010, BIOCHEM PHARMACOL, V79, P413, DOI 10.1016/j.bcp.2009.08.025
   Giovanella F, 2015, AN ACAD BRAS CIENC, V87, P1487, DOI 10.1590/0001-3765201520140637
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guo T, 2020, CARDIOVASCULAR IMPLI
   He F, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9171905
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   Hou W, 2020, INFECT DIS NOR 0505, V2020, P1, DOI DOI 10.1080/237442435.2020.1759817
   Huang N, 2018, TRENDS IMMUNOL, V39, P562, DOI 10.1016/j.it.2018.04.006
   Ioannou Y, 2010, BLOOD, V116, P1961, DOI 10.1182/blood-2009-04-215335
   Keidar S., 2007, ACE2 ACTIVITY IS INC
   La-Torre E., 2020, CLIN IMMUNOL, V217
   Lai KY, 2010, ANN INTERN MED, V152, P687, DOI 10.7326/0003-4819-152-10-201005180-00017
   Lai ZW, 2018, LANCET, V391, P1186, DOI 10.1016/S0140-6736(18)30485-9
   Lai ZW, 2012, ARTHRITIS RHEUM-US, V64, P2937, DOI 10.1002/art.34502
   Lee R, 2012, CURR MED CHEM, V19, P2504, DOI 10.2174/092986712800493057
   Lin CI, 2018, INT J BIOL SCI, V14, P253, DOI 10.7150/ijbs.23489
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Madu IG, 2009, VIROLOGY, V393, P265, DOI 10.1016/j.virol.2009.07.038
   MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2512
   Mastaglio S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108450
   Morales-Ortega A, 2020, CLIN IMMUNOL, V218, DOI 10.1016/j.clim.2020.108518
   Oaks Z, 2016, ARTHRITIS RHEUMATOL, V68, P2728, DOI 10.1002/art.39791
   Omarjee L, 2020, CLIN IMMUNOL, V216, DOI 10.1016/j.clim.2020.108464
   Ortolani O, 2000, SHOCK, V13, P14, DOI 10.1097/00024382-200013010-00003
   Paizis G, 2005, GUT, V54, P1790, DOI 10.1136/gut.2004.062398
   Perl A, 2016, NAT REV RHEUMATOL, V12, P169, DOI 10.1038/nrrheum.2015.172
   Perl A, 2015, ANN NY ACAD SCI, V1346, P33, DOI 10.1111/nyas.12756
   Perl A, 2011, TRENDS MOL MED, V17, P395, DOI 10.1016/j.molmed.2011.01.014
   Porcu M, 2018, PSYCHIAT RES, V263, P268, DOI 10.1016/j.psychres.2018.02.056
   Pruimboom L, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00290
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Qiao WL, 2015, CARDIOLOGY, V131, P97, DOI 10.1159/000375362
   Qiu YC, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501764
   Rushworth GF, 2014, PHARMACOL THERAPEUT, V141, P150, DOI 10.1016/j.pharmthera.2013.09.006
   Sawalha AH, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108410
   SMILKSTEIN MJ, 1991, ANN EMERG MED, V20, P1058, DOI 10.1016/S0196-0644(05)81352-6
   Sodhi C.P., 2018, ATTENUATION PULMONAR
   Sodhi CP, 2019, J IMMUNOL, V203, P3000, DOI 10.4049/jimmunol.1900579
   Song B, 2013, REGUL PEPTIDES, V185, P44, DOI 10.1016/j.regpep.2013.06.007
   SU YK, 2020, NEW ENGL J MED, DOI DOI 10.1002/ADMT.201901153
   SUTER PM, 1994, CHEST, V105, P190, DOI 10.1378/chest.105.1.190
   Wang QX, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01396-y
   Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551
   Wong A, 2019, HEPATOLOGY, V69, P774, DOI 10.1002/hep.30224
   Wu YH, 2008, J INFECT DIS, V197, P812, DOI 10.1086/528377
   Yisireyili M, 2018, BRAIN BEHAV IMMUN, V69, P167, DOI 10.1016/j.bbi.2017.11.010
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang J, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104392
   Zhang XM, 2019, ARCH BIOCHEM BIOPHYS, V672, DOI 10.1016/j.abb.2019.07.026
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhong JC, 2010, CIRCULATION, V122, P717, DOI 10.1161/CIRCULATIONAHA.110.955369
   Zuin R, 2005, CLIN DRUG INVEST, V25, P401, DOI 10.2165/00044011-200525060-00005
NR 64
TC 6
Z9 6
U1 6
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD OCT
PY 2020
VL 219
AR 108544
DI 10.1016/j.clim.2020.108544
PG 6
WC Immunology
SC Immunology
GA NR3AR
UT WOS:000571435100010
PM 32707089
OA Green Published
DA 2021-01-01
ER

PT J
AU Laurence, J
   Mulvey, JJ
   Seshadri, M
   Racanelli, A
   Harp, J
   Schenck, EJ
   Zappetti, D
   Horn, EM
   Magro, CM
AF Laurence, Jeffrey
   Mulvey, J. Justin
   Seshadri, Madhav
   Racanelli, Alexandra
   Harp, Joanna
   Schenck, Edward J.
   Zappetti, Dana
   Horn, Evelyn M.
   Magro, Cynthia M.
TI Anti-complement C5 therapy with eculizumab in three cases of critical
   COVID-19
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE Complement; Lectin pathway; MASP2; Coronavirus; COVID-19; Eculizumab
AB Respiratory failure and acute kidney injury (AKI) are associated with high mortality in SARS-CoV-2-associated Coronavirus disease 2019 (COVID-19). These manifestations are linked to a hypercoaguable, pro-inflammatory state with persistent, systemic complement activation. Three critical COVID-19 patients recalcitrant to multiple interventions had skin biopsies documenting deposition of the terminal complement component C5b-9, the lectin complement pathway enzyme MASP2, and C4d in microvascular endothelium. Administration of anti-05 monoclonal antibody eculizumab led to a marked decline in D-dimers and neutrophil counts in all three cases, and normalization of liver functions and creatinine in two. One patient with severe heart failure and AKI had a complete remission. The other two individuals had partial remissions, one with resolution of his AKI but ultimately succumbing to respiratory failure, and another with a significant decline in FiO(2) requirements, but persistent renal failure. In conclusion, anti-complement therapy may be beneficial in at least some patients with critical COVID-19.
C1 [Laurence, Jeffrey; Seshadri, Madhav] Weill Cornell Med, Div Hematol & Med Oncol, Dept Med, New York, NY 10065 USA.
   [Mulvey, J. Justin] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA.
   [Racanelli, Alexandra; Schenck, Edward J.; Zappetti, Dana] Weill Cornell Med, Div Pulm & Crit Care Med, Dept Med, New York, NY USA.
   [Harp, Joanna] Weill Cornell Med, Dept Dermatol, New York, NY USA.
   [Horn, Evelyn M.] Weill Cornell Med, Div Cardiol, Dept Med, New York, NY USA.
   [Magro, Cynthia M.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA.
RP Laurence, J (corresponding author), Weill Cornell Med, Div Hematol & Med Oncol, Dept Med, New York, NY 10065 USA.
EM jlaurenc@med.cornell.edu
FU Angelo Donghia Foundation
FX Dr. Laurence is a Senior Scientist for Programs at amfAR, The Foundation
   for AIDS Research, and received funding from the Angelo Donghia
   Foundation in support of this study.
CR Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cugno M., 2020, J ALLERGY CLIN IMMUN, DOI [10.1016/jaci.2020.05.006., DOI 10.1016/JACI.2020.05.006]
   Diao B, 2020, HUMAN KIDNEY IS TARG, DOI [10.1101/2020.03.04.20031120, DOI 10.1101/2020.03.04.20031120]
   Diurno F, 2020, EUR REV MED PHARMACO, V24, P4040, DOI 10.26355/eurrev_202004_20875
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Elhadad S, 2021, CLIN EXP IMMUNOL, V203, P96, DOI 10.1111/cei.13497
   Fan BE, 2020, AM J HEMATOL, V95, P723, DOI 10.1002/ajh.25785
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Giudice V, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00857
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Grover SP, 2018, ARTERIOSCL THROM VAS, V38, P709, DOI 10.1161/ATVBAHA.117.309846
   Jiang YT, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0063-8
   Jones SA, 1999, J EXP MED, V189, P599, DOI 10.1084/jem.189.3.599
   Laurence J, 2020, CLIN ADV HEMATOL ONC, V18, P221
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Mastaglio S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108450
   Orrem HL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02035
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Risitano AM, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0320-7
   Sandhu V., 2017, OPEN RHEUM J, DOI [10.2174/187431290171101011311113-122, DOI 10.2174/]
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Yago T, 2018, BLOOD, V132, P1426, DOI 10.1182/blood-2018-05-850859
NR 27
TC 6
Z9 6
U1 4
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD OCT
PY 2020
VL 219
AR 108555
DI 10.1016/j.clim.2020.108555
PG 7
WC Immunology
SC Immunology
GA NR3AR
UT WOS:000571435100002
PM 32771488
OA Green Published
DA 2021-01-01
ER

PT J
AU Montesu, MA
   Biondi, G
   Sotgiu, G
   Sucato, F
   Satta, R
AF Montesu, Maria A.
   Biondi, Gabriele
   Sotgiu, Giovanni
   Sucato, Federica
   Satta, Rosanna
TI Biologic drugs during COVID-19 outbreak
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Letter
C1 [Montesu, Maria A.; Biondi, Gabriele; Sucato, Federica; Satta, Rosanna] Univ Sassari, Dept Clin & Expt Med, Sassari, Italy.
   [Sotgiu, Giovanni] Dept Biomed Sci, Clin Epidemiol & Med Stat Unit, Sassari, Italy.
RP Biondi, G (corresponding author), Univ Sassari, Dept Clin & Expt Med, Sassari, Italy.
EM babilon22@hotmail.com
CR Atzori L, 2020, J EUR ACAD DERMATOL, V34, pE247, DOI 10.1111/jdv.16473
   Burlando M, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1770165
   Facheris P, 2020, INT J DERMATOL, V59, pE267, DOI 10.1111/ijd.15008
   Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158
   Gisondi P, 2020, J EUR ACAD DERMATOL, V34, P1196, DOI 10.1111/jdv.16515
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
EI 1365-4632
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD OCT
PY 2020
VL 59
IS 10
BP 1293
EP 1293
DI 10.1111/ijd.15088
PG 1
WC Dermatology
SC Dermatology
GA NS4BP
UT WOS:000572209300043
PM 32767379
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Taylor, S
   Landry, CA
   Rachor, GS
   Paluszek, MM
   Asmundson, GJG
AF Taylor, Steven
   Landry, Caeleigh A.
   Rachor, Geoffrey S.
   Paluszek, Michelle M.
   Asmundson, Gordon J. G.
TI Fear and avoidance of healthcare workers: An important, under-recognized
   form of stigmatization during the COVID-19 pandemic
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Healthcare workers; Pandemic; COVID-19; Stigma; Fear; Avoidance
AB Background: During past disease outbreaks, healthcare workers (HCWs) have been stigmatized (e.g., shunned, ostracized) by members in their community, for fear that HCWs are sources of infection. There has been no systematic evaluation of HCW stigmatization during the COVID-19 pandemic.
   Methods: Non-HCW adults from the United States and Canada (N = 3551) completed an online survey, including measures of HCW stigmatization, COVID Stress Syndrome, and avoidance.
   Results: Over a quarter of respondents believed that HCWs should have severe restrictions placed on their freedoms, such as being kept in isolation from their communities and their families. Over a third of respondents avoided HCWs for fear of infection. Participation in altruistic support of HCWs (i.e., evening clapping and cheering) was unrelated to stigmatizing attitudes. Demographic variables had small or trivial correlations with HCW stigmatization. People who stigmatized HCWs also tended to avoid other people, avoid drug stores and supermarkets, and avoid leaving their homes. Factor analysis suggested that HCW stigmatization is linked to the COVID Stress Syndrome.
   Conclusion: Fear and avoidance of HCWs is a widespread, under-recognized problem during the COVID-19 pandemic. It is associated with the COVID Stress Syndrome and might be reduced by interventions targeting this syndrome.
C1 [Taylor, Steven] Univ British Columbia, Dept Psychiat, Vancouver, BC V6E 2A1, Canada.
   [Landry, Caeleigh A.; Rachor, Geoffrey S.; Paluszek, Michelle M.; Asmundson, Gordon J. G.] Univ Regina, Dept Psychol, Regina, SK, Canada.
RP Taylor, S (corresponding author), Univ British Columbia, Dept Psychiat, Vancouver, BC V6E 2A1, Canada.
EM steven.taylor@ubc.ca
OI Landry, Caeleigh/0000-0001-5709-5053
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [439751]; University of Regina
FX This research was funded by the Canadian Institutes of Health Research
   (#439751) and the University of Regina. Dr. Taylor receives financial
   support through royalties from various book publishers and from
   editorial duties as Associate Editor of the Journal of
   Obsessive-Compulsive and Related Disorders. Dr. Asmundson is the
   Editor-inChief of the Journal of Anxiety Disorders and Development
   Editor of Clinical Psychology Review. He receives financial support
   through payments for his editorial work on the aforementioned journals
   and royalties from various book publishers. Dr. Peter McEvoy served as
   action editor on this manuscript submission.
CR Bagcchi S, 2020, LANCET INFECT DIS, V20, P782, DOI 10.1016/S1473-3099(20)30498-9
   Bhaumik S., 2020, BMJ GLOB HEALTH, V5, DOI [10.1136/bmjgh-2020-002769.e002769., DOI 10.1136/BMJGH-2020-002769.E002769]
   CDC COVID-19 Response Team, 2020, MMWR Morb Mortal Wkly Rep, V69, P477, DOI 10.15585/mmwr.mm6915e6
   Centers for Disease Control and Prevention, 2020, RED STIGM
   Cheng VCC, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.9687
   COHEN J, 1988, NEW YORK TIMES BK R, P26
   COVID-19 Scientific Advisory Group, 2020, COVID 19 SCI ADV GRO
   Crosby AW, 2003, AM FORGOTTEN PANDEMI
   Goffman E, 1963, STIGMA NOTES MANAGEM
   Kluytmans-van Den Bergh MFQ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.9673
   Koh D, 2005, MED CARE, V43, P676, DOI 10.1097/01.mlr.0000167181.36730.cc
   Koh D, 2020, OCCUP MED-OXFORD, V70, P3, DOI 10.1093/occmed/kqaa036
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Liu M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2195
   McNeish D, 2018, PSYCHOL METHODS, V23, P412, DOI 10.1037/met0000144
   Ramaci T, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12093834
   Schaller M, 2011, CURR DIR PSYCHOL SCI, V20, P99, DOI 10.1177/0963721411402596
   Taylor S, 2020, FEM PSYCHOL, V30, P63, DOI 10.1177/0959353519864390
   Taylor S, 2020, DEPRESS ANXIETY, V37, P706, DOI 10.1002/da.23071
   Taylor S, 2020, J ANXIETY DISORD, V72, DOI 10.1016/j.janxdis.2020.102232
   Teo AR, 2018, PSYCHIAT CLIN NEUROS, V72, P780, DOI 10.1111/pcn.12691
   World Health Organization (WHO), 2020, SOC STIGM ASS COVID
NR 22
TC 3
Z9 3
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD OCT
PY 2020
VL 75
AR 102289
DI 10.1016/j.janxdis.2020.102289
PG 5
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA NR8RI
UT WOS:000571828000009
PM 32853884
OA Green Published
DA 2021-01-01
ER

PT J
AU Karamitros, T
   Papadopoulou, G
   Bousali, M
   Mexias, A
   Tsiodras, S
   Mentis, A
AF Karamitros, Timokratis
   Papadopoulou, Gethsimani
   Bousali, Maria
   Mexias, Anastasios
   Tsiodras, Sotirios
   Mentis, Andreas
TI SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency
   polymorphic quasispecies
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19 epidemic; Intra-host variability; Quasispecies;
   Genomic rearrangements; Molecular diagnostics
ID ACUTE RESPIRATORY SYNDROME; HUMAN CORONAVIRUS; EVOLUTIONARY
   EPIDEMIOLOGY; SARS; RECOMBINATION; COVID-19; PNEUMONIA; DIVERSITY;
   EMERGENCE; ALIGNMENT
AB In December 2019, an outbreak of atypical pneumonia (Coronavirus disease 2019 -COVID-19) associated with a novel coronavirus (SARS-CoV-2) was reported in Wuhan city, Hubei province, China. The outbreak was traced to a seafood wholesale market and human to human transmission was confirmed. The rapid spread and the death toll of the new epidemic warrants immediate intervention. The intra-host genomic variability of SARS-CoV-2 plays a pivotal role in the development of effective antiviral agents and vaccines, as well as in the design of accurate diagnostics.
   We analyzed NGS data derived from clinical samples of three Chinese patients infected with SARS-CoV-2, in order to identify small- and large-scale intra-host variations in the viral genome. We identified tens of low- or higher- frequency single nucleotide variations (SNVs) with variable density across the viral genome, affecting 7 out of 10 protein-coding viral genes. The majority of these SNVs (72/104) corresponded to missense changes. The annotation of the identified SNVs but also of all currently circulating strain variations revealed colocalization of intra-host as well as strain specific SNVs with primers and probes currently used in molecular diagnostics assays. Moreover, we de-novo assembled the viral genome, in order to isolate and validate intra-host structural variations and recombination breakpoints. The bioinformatics analysis disclosed genomic rearrangements over poly-A / poly-U regions located in ORF lab and spike (S) gene, including a potential recombination hot-spot within S gene.
   Our results highlight the intra-host genomic diversity and plasticity of SARS-CoV-2, pointing out genomic regions that are prone to alterations. The isolated SNVs and genomic rearrangements reflect the intra-patient capacity of the polymorphic quasispecies, which may arise rapidly during the outbreak, allowing immunological escape of the virus, offering resistance to anti-viral drugs and affecting the sensitivity of the molecular diagnostics assays.
C1 [Karamitros, Timokratis; Papadopoulou, Gethsimani; Bousali, Maria; Mexias, Anastasios] Hellenic Pasteur Inst, Dept Microbiol, Bioinformat & Appl Genom Unit, 127 Vas Sophias Ave, Athens 11521, Greece.
   [Tsiodras, Sotirios] Natl & Kapodistrian Univ Athens, Acad Dept Internal Med 4, Med Sch, Athens, Greece.
   [Mentis, Andreas] Hellenic Pasteur Inst, Dept Microbiol, Publ Hlth Labs, Athens, Greece.
RP Karamitros, T (corresponding author), Hellenic Pasteur Inst, Dept Microbiol, Bioinformat & Appl Genom Unit, 127 Vas Sophias Ave, Athens 11521, Greece.
EM tkaram@pasteur.gr
OI Karamitros, Timokratis/0000-0003-0841-9159
CR Aaskov J, 2006, SCIENCE, V311, P236, DOI 10.1126/science.1115030
   Aleanizy FS, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2137-3
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Andrews S, FASTQC QUALITY CONTR
   Antia R, 2003, NATURE, V426, P658, DOI 10.1038/nature02104
   Bal A, 2020, CLIN MICROBIOL INFEC, V26, P960, DOI 10.1016/j.cmi.2020.03.020
   Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021
   BARIC RS, 1990, VIROLOGY, V177, P646, DOI 10.1016/0042-6822(90)90530-5
   Beloukas A, 2012, VIRUS RES, V166, P54, DOI 10.1016/j.virusres.2012.03.002
   BONHOEFFER S, 1994, P NATL ACAD SCI USA, V91, P8062, DOI 10.1073/pnas.91.17.8062
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Cingolani Pablo, 2012, Frontiers in Genetics, V3, P35, DOI 10.3389/fgene.2012.00035
   Cooper D.N., 2003, NATURE ENCY HUMAN GE
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Day T, 2020, CURR BIOL, V30, pR849, DOI 10.1016/j.cub.2020.06.031
   Destras G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010058
   Enjuanes L, 2008, VIRUS RES, V133, P45, DOI 10.1016/j.virusres.2007.01.021
   Fehr A.R., 2016, HHS PUBLIC ACCESS, P1, DOI [10.1007/978-1-4939-2438-7, DOI 10.1007/978-1-4939-2438-7]
   Gruber AR, 2008, NUCLEIC ACIDS RES, V36, pW70, DOI 10.1093/nar/gkn188
   Holmes E.C., 2009, EVOLUTION EMERGENCE
   Holmes EC, 2010, P NATL ACAD SCI USA, V107, P1742, DOI 10.1073/pnas.0906193106
   Hon CC, 2008, J VIROL, V82, P1819, DOI 10.1128/JVI.01926-07
   Kalendar R, 2017, GENOMICS, V109, P312, DOI 10.1016/j.ygeno.2017.05.005
   Karamichali E, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02942
   Karamitros T, 2016, SCI REP-UK, V6, DOI 10.1038/srep33598
   Karamitros T, 2015, LIVER INT, V35, P2506, DOI 10.1111/liv.12859
   Kostaki EG, 2018, AIDS RES HUM RETROV, V34, P415, DOI [10.1089/aid.2017.0233, 10.1089/AID.2017.0233]
   Kumar S, 2019, CORONAVIRUS DIS 2019, V2020, P43, DOI DOI 10.1007/978-981-15-4814-7_5
   LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992
   Lan JM, 2017, VACCINE, V35, P10, DOI 10.1016/j.vaccine.2016.11.064
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lau SKP, 2011, J VIROL, V85, P11325, DOI 10.1128/JVI.05512-11
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Lipsitch M, 2007, J R SOC INTERFACE, V4, P787, DOI 10.1098/rsif.2007.0229
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Magiorkinis G, 2018, AM J EPIDEMIOL, V187, P2615, DOI 10.1093/aje/kwy160
   Magiorkinis G, 2014, LANCET, V383, P71
   Malley R, 2005, P NATL ACAD SCI USA, V102, P4848, DOI 10.1073/pnas.0501254102
   Markham NR, 2005, NUCLEIC ACIDS RES, V33, pW577, DOI 10.1093/nar/gki591
   Memish ZA, 2020, LANCET, V395, P1063, DOI 10.1016/S0140-6736(19)33221-0
   Nicolas R.J., 2017, PHYSIOL BEHAV, V176, P139, DOI [10.1016/j.physbeh.2017.03.040, DOI 10.1016/J.PHYSBEH.2017.03.040]
   Noh JY, 2017, ARCH VIROL, V162, P1617, DOI 10.1007/s00705-017-3281-9
   Paraskevis D, 2018, INFECT GENET EVOL, V62, P11, DOI 10.1016/j.meegid.2018.04.010
   Paules C.I., 2020, JAMA-J AM MED ASSOC, V2520, P3, DOI [10.1007/82, DOI 10.1007/82]
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Pyrc K, 2006, J MOL BIOL, V364, P964, DOI 10.1016/j.jmb.2006.09.074
   Rabaan Ali A, 2020, Infez Med, V28, P174
   Robinson JT, 2017, CANCER RES, V77, pE31, DOI 10.1158/0008-5472.CAN-17-0337
   Sabir JSM, 2016, SCIENCE, V351, P81, DOI 10.1126/science.aac8608
   Simon B, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020108
   Sutton TDS, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0626-5
   Tastan C, 2020, TURK J BIOL, V44, P192, DOI 10.3906/biy-2004-113
   Toyoshima Y, 2020, J HUM GENET, V65, P1075, DOI 10.1038/s10038-020-0808-9
   Vignuzzi M, 2006, NATURE, V439, P344, DOI 10.1038/nature04388
   Vijaykrishna D, 2007, J VIROL, V81, P4012, DOI 10.1128/JVI.02605-06
   WHO, 2020, PNEUM UNK CAUS
   Wilm A, 2012, NUCLEIC ACIDS RES, V40, P11189, DOI 10.1093/nar/gks918
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue KS, 2018, TRENDS MICROBIOL, V26, P781, DOI 10.1016/j.tim.2018.02.007
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
NR 67
TC 1
Z9 1
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD OCT
PY 2020
VL 131
AR 104585
DI 10.1016/j.jcv.2020.104585
PG 9
WC Virology
SC Virology
GA NR9PH
UT WOS:000571894100012
PM 32818852
OA Green Published
DA 2021-01-01
ER

PT J
AU Zucker, A
   Noyce, P
AF Zucker, Andrew
   Noyce, Pendred
TI Lessons from the pandemic about science education
SO PHI DELTA KAPPAN
LA English
DT Article
DE science; education; standards; pandemic; COVID-19; Next Generation
   Science Standards; NGSS; policy
AB The coronavirus pandemic vividly illuminates deficiencies of the Next Generation Science Standards (NGSS). The NGSS does not mention immunization, antibodies, vaccines, or the Centers for Disease Control and Prevention, nor do they ask students to investigate a topic outside the standards or read a science-related book or article. The stated goal of the standards is to prepare students for college and careers, which means that they do not prioritize how science connects to societal or personal concerns of every adult, even those who do not pursue science in higher education or their careers. Andrew Zucker and Pendred Noyce suggest several approaches to improve the NGSS.
C1 [Zucker, Andrew] Concord Consortium, Concord, MA USA.
   [Noyce, Pendred] Tumblehome Inc, Boston, MA 02116 USA.
RP Noyce, P (corresponding author), Tumblehome Inc, Boston, MA 02116 USA.
EM andyzucker@gmail.com; pnoyce@tumblehomebooks.org
CR Anderson M, 2018, TEENS SOCIAL MEDIA H
   [Anonymous], 1989, SCI ALL AM
   Clotfelter CT, 2015, J HUM RESOUR, V50, P159, DOI 10.3368/jhr.50.1.159
   Domina T, 2015, EDUC EVAL POLICY AN, V37, P275, DOI 10.3102/0162373714543685
   Hacker A., 2012, NY TIMES
   Hockfield S, 2018, SCIENCE, V359, P499, DOI 10.1126/science.aat0957
   Holt R., 2017, APS AM PHYS SOC NEWS, V26
   Kafai Y.B., 2020, PHI DELTA KAPPAN
   Massachusetts Dept. of Elementary & Secondary Education, 2016, 2016 MASS SCI TECHN
   National Research Council, 2012, FRAM K 12 SCI ED PRA
   National Science Teaching Association, 2016, POS STAT TEACH SCI C
   National Science Teaching Association, 2020, NSTA POS STAT NAT SC
   NGSS Lead States, 2013, NEXT GENERATION SCIE, DOI 10.17226/18290
   NRC, 1996, NAT SCI ED STAND
   Ryan C. L., 2016, ED ATTAINMENT US 201
NR 15
TC 0
Z9 0
U1 11
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0031-7217
EI 1940-6487
J9 PHI DELTA KAPPAN
JI Phi Delta Kappan
PD OCT
PY 2020
VL 102
IS 2
BP 44
EP 49
DI 10.1177/0031721720963231
PG 6
WC Education & Educational Research
SC Education & Educational Research
GA NS2SU
UT WOS:000572118100010
DA 2021-01-01
ER

PT J
AU Shahinshavali, S
   Hossain, KA
   Kumar, AVDN
   Reddy, AG
   Kolli, D
   Nakhi, A
   Rao, MVB
   Pal, M
AF Shahinshavali, Shaik
   Hossain, Kazi Amirul
   Kumar, Abbaraju Venkata Durga Nagendra
   Reddy, Alugubelli Gopi
   Kolli, Deepti
   Nakhi, Ali
   Rao, Mandava Venkata Basaveswara
   Pal, Manojit
TI Ultrasound assisted synthesis of 3-alkynyl substituted
   2-chloroquinoxaline derivatives: Their in silico assessment as potential
   ligands for N-protein of SARS-CoV-2
SO TETRAHEDRON LETTERS
LA English
DT Article
DE Chloroquinoxaline; Alkyne; Ultrasound; In silico study; COVID-19
ID COUPLING REACTION; TERMINAL ALKYNES; ARYL IODIDES; SONOGASHIRA;
   QUINOXALINES; CORONAVIRUS; INHIBITORS; SYSTEM; DRUG
AB In view of recent global pandemic the 3-alkynyl substituted 2-chloroquinoxaline framework has been explored as a potential template for the design of molecules targeting COVID-19. Initial in silico studies of representative compounds to assess their binding affinities via docking into the N-terminal RNA-binding domain (NTD) of N-protein of SARS-CoV-2 prompted further study of these molecules. Thus building of a small library of molecules based on the said template became essential for this purpose. Accordingly, a convenient and environmentally safer method has been developed for the rapid synthesis of 3-alkynyl substituted 2-chloroquinoxaline derivatives under Cu-catalysis assisted by ultrasound. This simple and straightforward method involved the coupling of 2,3-dichloroquinoxaline with commercially available terminal alkynes in the presence of CuI, PPh3 and K2CO3 in PEG-400. Further in silico studies revealed some remarkable observations and established a virtual SAR (Structure Activity Relationship) within the series. Three compounds appeared as potential agents for further studies. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Shahinshavali, Shaik; Rao, Mandava Venkata Basaveswara] Krishna Univ, Dept Chem, Machilipatnam 521001, Andhra Pradesh, India.
   [Hossain, Kazi Amirul] Gdansk Univ Technol, Dept Phys Chem, Gdansk, Poland.
   [Kumar, Abbaraju Venkata Durga Nagendra] GITAM Deemed Be Univ, Dept Chem, GIS, Visakhapatnam 530045, Andhra Pradesh, India.
   [Reddy, Alugubelli Gopi] Sana Coll Pharm, Dept Pharm, Kodad 508206, Telangana, India.
   [Kolli, Deepti] Koneru Lakshmaiah Educ Fdn, Dept Chem, Vaddeswaram 522502, Andhra Pradesh, India.
   [Nakhi, Ali; Pal, Manojit] Univ Hyderabad Campus, Dr Reddys Inst Life Sci, Hyderabad 500046, India.
RP Rao, MVB (corresponding author), Krishna Univ, Dept Chem, Machilipatnam 521001, Andhra Pradesh, India.; Pal, M (corresponding author), Univ Hyderabad Campus, Dr Reddys Inst Life Sci, Hyderabad 500046, India.
EM vbrmandava@yahoo.com; manojitpal@rediffmail.com
RI Nakhi, Ali/ABG-1823-2020
OI Nakhi, Ali/0000-0002-4366-9770; Hossain, Kazi Amirul/0000-0002-1149-964X
CR AMES DE, 1980, J CHEM SOC PERK T 1, P1384, DOI 10.1039/p19800001384
   Arcadi A, 2004, TETRAHEDRON LETT, V45, P2431, DOI 10.1016/j.tetlet.2004.01.058
   Armengol M, 2001, J CHEM SOC PERK T 1, P978, DOI 10.1039/b101458g
   Armengol M, 2001, J CHEM SOC PERK T 1, P154, DOI 10.1039/b008459j
   Brimble MA, 2002, TETRAHEDRON LETT, V43, P1735, DOI 10.1016/S0040-4039(02)00065-5
   Cella R., 2012, GREEN TECHNIQUES ORG, P343, DOI [0.1002/9780470711828.ch13, DOI 10.1002/9780470711828.CH13]
   Chang CK, 2016, MOL BIOSYST, V12, P59, DOI 10.1039/c5mb00582e
   Chen G, 2011, SYNTHETIC COMMUN, V41, P3123, DOI 10.1080/00397911.2010.517363
   Chen J, 2005, GREEN CHEM, V7, P64, DOI 10.1039/b413546f
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   DECLERCQ E, 1991, ANTIMICROB AGENTS CH, V35, P679, DOI 10.1128/AAC.35.4.679
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Guan JT, 2009, APPL ORGANOMET CHEM, V23, P75, DOI 10.1002/aoc.1474
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Liu YJ, 2017, CHEMISTRYSELECT, V2, P11599, DOI 10.1002/slct.201702854
   Mason TJ, 1997, CHEM SOC REV, V26, P443, DOI 10.1039/cs9972600443
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nakhi A, 2013, ORG BIOMOL CHEM, V11, P4930, DOI 10.1039/c3ob41069b
   Nakhi A, 2012, BIOORG MED CHEM LETT, V22, P6433, DOI 10.1016/j.bmcl.2012.08.056
   Neudert G, 2011, BIOINFORMATICS, V27, P1021, DOI 10.1093/bioinformatics/btr055
   Nxumalo W, 2013, HETEROCYCLES, V87, P79, DOI 10.3987/COM-12-12610
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pizzuti L., 2012, GREEN CHEM ENV BENIG, DOI [10.5772/35171, DOI 10.5772/35171]
   Puri S, 2013, CURR ORG CHEM, V17, P1790, DOI 10.2174/13852728113179990018
   Reddy DNK, 2016, RSC ADV, V6, P67212, DOI 10.1039/c6ra14228a
   Rosenblum SB, 2000, TETRAHEDRON, V56, P5735, DOI 10.1016/S0040-4020(00)00429-4
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   SHEALY YF, 1986, J MED CHEM, V29, P79, DOI 10.1021/jm00151a013
   Simossis VA, 2005, NUCLEIC ACIDS RES, V33, pW289, DOI 10.1093/nar/gki390
   SUSLICK KS, 1986, J AM CHEM SOC, V108, P5641, DOI 10.1021/ja00278a055
   Thorand S, 1998, J ORG CHEM, V63, P8551, DOI 10.1021/jo9808021
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   World Health Organization, COR COVID 19
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 36
TC 4
Z9 4
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0040-4039
J9 TETRAHEDRON LETT
JI Tetrahedron Lett.
PD OCT 1
PY 2020
VL 61
IS 40
AR 152336
DI 10.1016/j.tetlet.2020.152336
PG 8
WC Chemistry, Organic
SC Chemistry
GA NR3QS
UT WOS:000571478800006
PM 32868957
OA Green Published
DA 2021-01-01
ER

PT J
AU Konstantinou, GN
   Downar, J
   Daskalakis, ZJ
   Blumberger, DM
AF Konstantinou, Gerasimos N.
   Downar, Jonathan
   Daskalakis, Zafiris J.
   Blumberger, Daniel M.
TI Accelerated Intermittent Theta Burst Stimulation in Late-Life
   Depression: A Possible Option for Older Depressed Adults in Need of ECT
   During the COVID-19 Pandemic
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Article
DE Accelerated intermittent theta burst; stimulation; COVID-19; depression;
   elder
ID TRANSCRANIAL MAGNETIC STIMULATION
AB Objective: Electroconvulsive therapy (ECT) is an essential psychiatric service with an important role in treating older adults with severe or treatment-resistant depression. During the COVID-19 pandemic, ECT services have be constrained by infection control measures. We report a case of a 66-year-old female patient with a severe major depressive episode who had previously responded to right unilateral ECT and was treated with two modified accelerated intermittent theta-burst stimulation (aiTBS) protocols. Methods: The two aiTBS courses consisted of eight daily sessions over five consecutive days, followed by gradual tapering, using 1,800 pulses per session pre-COVID-19 (first course), and 600 pulses per session during the pandemic (second course). Results: Moderate to severe baseline depressive symptoms reached remission levels after both courses. Conclusion: The 600-pulses aiTBS treatment protocol reported here warrants further study and evaluation, but may be a potential option in cases where older adults with severe depressive symptoms cannot access ECT during the COVID-19 pandemic.
C1 [Blumberger, Daniel M.] Univ Toronto, Dept Psychiat, 1001 Queen St W Unit 4,Room 115, Toronto, ON M6J 1H4, Canada.
   [Blumberger, Daniel M.] Ctr Addict & Mental Hlth, Temerty Ctr Therapeut Brain Intervent, 1001 Queen St W Unit 4,Room 115, Toronto, ON M6J 1H4, Canada.
   Ctr Addict & Mental Hlth, Campbell Family Res Inst, Toronto, ON, Canada.
   Univ Hlth Network, Toronto Western Hosp, Poul Hansen Depress Ctr, Dept Psychiat, Toronto, ON, Canada.
RP Blumberger, DM (corresponding author), Univ Toronto, Dept Psychiat, 1001 Queen St W Unit 4,Room 115, Toronto, ON M6J 1H4, Canada.; Blumberger, DM (corresponding author), Ctr Addict & Mental Hlth, Temerty Ctr Therapeut Brain Intervent, 1001 Queen St W Unit 4,Room 115, Toronto, ON M6J 1H4, Canada.
EM daniel.blumberger@camh.ca
OI Konstantinou, Gerasimos/0000-0002-0303-1633
FU Brainsway Inc; Magventure Inc; Canadian Institutes of Health Research
   (CIHR)Canadian Institutes of Health Research (CIHR); National Institutes
   of Mental Health (NIMH)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH); Brain Canada; Temerty Family; Campbell
   Institute; CIHRCanadian Institutes of Health Research (CIHR); NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA; Temerty Family through the CAMH Foundation; Campbell
   Research Institute; Brainsway Ltd.; Grant Family; Centre for Addiction
   and Mental Health (CAMH) Foundation
FX ZJD has received research and equipment in-kind support for an
   investigator-initiated study through Brainsway Inc and Magventure Inc,
   in the last 5 years. His work is supported by the Canadian Institutes of
   Health Research (CIHR), the National Institutes of Mental Health (NIMH),
   Brain Canada and the Temerty Family and Grant Family and through the
   Centre for Addiction and Mental Health (CAMH) Foundation and the
   Campbell Institute.; DMB has received research support from the CIHR,
   NIH, Brain Canada and the Temerty Family through the CAMH Foundation and
   the Campbell Research Institute. He received research support and
   in-kind equipment support for an investigator-initiated study from
   Brainsway Ltd., and he is the principal site investigator for three
   sponsor-initiated studies for Brainsway Ltd. He receives in-kind
   equipment support from Magventure for investigator-initiated research.
   He received medication supplies for an investigator-initiated trial from
   Indivior.
CR Blumberger DM, 2018, LANCET, V391, P1683, DOI 10.1016/S0140-6736(18)30295-2
   Blumberger Daniel M, 2015, Curr Treat Options Psychiatry, V2, P413
   Caulfield KA, 2020, J NEUROPHYSIOL, V123, P1, DOI 10.1152/jn.00537.2019
   Cole EJ, 2020, AM J PSYCHIAT
   Flexman AM, 2020, J NEUROSURG ANESTH, V32, P202, DOI 10.1097/ANA.0000000000000691
   Furukawa Nathan W, 2020, Emerg Infect Dis, V26, DOI 10.3201/eid2607.201595
   Mir-Moghtadaei A, 2015, BRAIN STIMUL, V8, P965, DOI 10.1016/j.brs.2015.05.008
   Nettekoven C, 2014, J NEUROSCI, V34, P6849, DOI 10.1523/JNEUROSCI.4993-13.2014
   Sienaert P, 2020, AM J GERIATR PSYCHIA
   Tor PC, 2020, J ECT, V36, P80, DOI 10.1097/YCT.0000000000000690
   World Health Organization (WHO), 66 WHO
NR 11
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD OCT
PY 2020
VL 28
IS 10
BP 1025
EP 1029
DI 10.1016/j.jagp.2020.07.007
PG 5
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA NR1XE
UT WOS:000571355300003
PM 32753340
OA Green Published
DA 2021-01-01
ER

PT J
AU Jakovac, H
AF Jakovac, Hrvoje
TI COVID-19 and hypertension: is the HSP60 culprit for the severe course
   and worse outcome?
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Article
DE COVID-19; HSP60; hypertension; mizoribine; SARS-CoV-2; severity
ID HEAT-SHOCK-PROTEIN; SYSTEM
AB The 60-kDa heat shock protein (HSP60) is a chaperone essential for mitochondrial proteostasis ensuring thus sufficient aerobic energy production. In pathological conditions, HSP60 can be translocated from the mitochondria and excreted from the cell. In turn, the extracellular HSP60 has a strong ability to trigger and enhance inflammatory response with marked proinflammatory cytokine induction, which is mainly mediated by Toll-like receptor binding. Previous studies have found increased circulating levels of HSP60 in hypertensive patients, as well as enhanced HSP60 expression and membrane translocation in the hypertrophic myocardium. These observations are of particular interest, since they could provide a possible pathophysiological explanation of the severe course and worse outcome of severe acute respiratory syndrome coronavirus 2 infection in hypertensive patients, repeatedly reported during the recent coronavirus disease 2019 (COVID-19) pandemic and related to hyperinflammatory response and cytokine storm development during the third phase of the disease. In this regard, pharmacological inhibition of HSP60 could attract attention to potentially ameliorate inappropriate inflammatory reaction in severe COVID-19 patients. Among HSP60 antagonizing drugs, mizoribine is the most intriguing, since it is clinically approved and exerts antiviral activity. However, this topic requires to be further scrutinized.
C1 [Jakovac, Hrvoje] Univ Rijeka, Med Fac, Dept Physiol & Immunol, Rijeka, Croatia.
RP Jakovac, H (corresponding author), Univ Rijeka, Med Fac, Dept Physiol & Immunol, Rijeka, Croatia.
EM hrvoje.jakovac@medri.uniri.hr
RI Jakovac, Hrvoje/P-6514-2018
OI Jakovac, Hrvoje/0000-0001-8174-5124
FU NA Funding Source: Medline
CR Belancic Andrej, 2020, Obes Med, V19, P100259, DOI 10.1016/j.obmed.2020.100259
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferencic A, 2020, SCAND J CLIN LAB INV, V80, P236, DOI 10.1080/00365513.2020.1725977
   Gies V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01409
   Goshua G, 2020, LANCET HAEMATOL, V7, pE575, DOI 10.1016/S2352-3026(20)30216-7
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Jakovac H, 2020, AM J PHYSIOL-LUNG C, V318, pL1025, DOI 10.1152/ajplung.00119.2020
   Knowlton AA, 2017, ADV EXP MED BIOL, V1003, P17, DOI 10.1007/978-3-319-57613-8_2
   Kreutz R, 2020, CARDIOVASC RES, V116, P1688, DOI 10.1093/cvr/cvaa097
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Meng QL, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00035
   Mitchell JA, 2007, BIOCHEM SOC T, V35, P1449, DOI 10.1042/BST0351449
   Monnerat-Cahli G, 2014, J MOL CELL CARDIOL, V76, P116, DOI 10.1016/j.yjmcc.2014.08.012
   Pespeni M, 2005, J SURG RES, V126, P41, DOI 10.1016/j.jss.2005.01.012
   Pirola CJ, 2020, J INFECTION, V81, P276, DOI 10.1016/j.jinf.2020.05.052
   Pockley AG, 2002, J HYPERTENS, V20, P1815, DOI 10.1097/00004872-200209000-00027
   Pockley AG, 2000, HYPERTENSION, V36, P303, DOI 10.1161/01.HYP.36.2.303
   Pons S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03062-7
   Rodriguez-Iturbe B, 2018, PHYSIOL INT, V105, P19, DOI 10.1556/2060.105.2018.1.4
   Romagnoli S, 2020, PHYSIOL REV, V100, P1455, DOI 10.1152/physrev.00020.2020
   Saijo M, 2005, ANTIVIR RES, V66, P159, DOI 10.1016/j.antiviral.2005.01.003
   Tignanelli CJ, 2020, LANCET RESP MED, V8, pE30, DOI 10.1016/S2213-2600(20)30153-3
   Toga W, 2007, BIOL PHARM BULL, V30, P105, DOI 10.1248/bpb.30.105
   Wan Qianya, 2020, Signal Transduct Target Ther, V5, P125, DOI 10.1038/s41392-020-00233-4
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou J, 2005, J CEREBR BLOOD F MET, V25, P878, DOI 10.1038/sj.jcbfm.9600082
NR 28
TC 2
Z9 2
U1 2
U2 2
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
EI 1522-1539
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD OCT
PY 2020
VL 319
IS 4
BP H793
EP H796
DI 10.1152/ajpheart.00506.2020
PG 4
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Physiology
GA NR2TA
UT WOS:000571414100008
PM 32886002
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gurung, AB
   Ali, MA
   Lee, J
   Abul Farah, M
   Al-Anazi, KM
AF Gurung, Arun Bahadur
   Ali, Mohammad Ajmal
   Lee, Joongku
   Abul Farah, Mohammad
   Al-Anazi, Khalid Mashay
TI In silico screening of FDA approved drugs reveals ergotamine and
   dihydroergotamine as potential coronavirus main protease enzyme
   inhibitors
SO SAUDI JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Coronaviruses; Coronaviral main protease; FDA approved drugs;
   Ergotamine; Dihydroergotamine; COVID-19; SARS-CoV-2; SARS-CoV; MERS-CoV;
   2019-nCoV
ID SARS
AB Coronaviruses with the largest viral genomes are positive-sense RNA viruses associated with a history of global epidemics such as the severe respiratory syndrome (SARS), the Middle East respiratory syndrome (MERS) and recently the coronavirus disease 2019 (COVID-19). There has been no vaccines or drugs available for the treatment of human coronavirus infections to date. In the present study, we have explored the possibilities of FDA approved drugs as potential inhibitors of the coronavirus main protease, a therapeutically important drug target playing a salient role in the maturation and processing of the viral polyproteins and are vital for viral replication and transcription. We have used molecular docking approach and have successfully identified the best lead molecules for each enzyme target. Interestingly, the anti-migraine drugs such as ergotamine and its derivative, dihydroergotamine were found to bind to all the three target enzymes within the Cys-His catalytic dyad cleft with lower binding energies as compared to the control inhibitors (alpha-ketoamide 13b, SG85 and GC813) and the molecules are held within the pocket through a good number of hydrogen bonds and hydrophobic interactions. Hence both these lead molecules can be further taken for wet-lab experimentation studies before repurposing them as anti-coronaviral drug candidates. (C) 2020 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.
C1 [Gurung, Arun Bahadur] North Eastern Hill Univ, Dept Basic Sci & Social Sci, Shillong 793022, Meghalaya, India.
   [Ali, Mohammad Ajmal] King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh 11451, Saudi Arabia.
   [Lee, Joongku] Chungnam Natl Univ, Dept Environm & Forest Resources, 99 Daehak Ro, Daejeon 34134, South Korea.
   [Abul Farah, Mohammad; Al-Anazi, Khalid Mashay] King Saud Univ, Coll Sci, Dept Zool, Genet Lab, Riyadh 11451, Saudi Arabia.
RP Gurung, AB (corresponding author), North Eastern Hill Univ, Dept Basic Sci & Social Sci, Shillong 793022, Meghalaya, India.; Lee, J (corresponding author), Chungnam Natl Univ, Dept Environm & Forest Resources, 99 Daehak Ro, Daejeon 34134, South Korea.
EM arunbgurung@gmail.com; joongku@cnu.ac.kr
FU Deanship of Scientific Research at King Saud UniversityKing Saud
   University [RG1438-015]; Chungnam National University, Daejeon, Republic
   of Korea
FX The authors would like to extend their sincere appreciation to the
   Deanship of Scientific Research at King Saud University for its funding
   of the research through the research group project #RG1438-015. J. Lee
   thanks to Chungnam National University, Daejeon, Republic of Korea for
   the funding support. The authors thank the Deanship of Scientific
   Research and RSSU at King Saud University for their technical support.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Bigal Marcelo E, 2003, Curr Pain Headache Rep, V7, P55, DOI 10.1007/s11916-003-0011-7
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gurung Arun Bahadur, 2016, Informatics in Medicine Unlocked, V5, P1, DOI 10.1016/j.imu.2016.09.004
   Gurung AB, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117831
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI 10.1002/(SICI)1096-987X(199604)17:6<490::AID-JCC1>3.3.CO;2-V
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Lai M., 2001, FIELDS VIROLOGY, P1163
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   LEE HJ, 1991, VIROLOGY, V180, P567, DOI 10.1016/0042-6822(91)90071-I
   Lobo-Galo N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764393
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Richman D.D., 2016, CLIN VIROLOGY
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Snijder E. J., 1995, The coronaviridae., P239
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Tfelt-Hansen P, 2000, BRAIN, V123, P9, DOI 10.1093/brain/123.1.9
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 26
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319-562X
EI 2213-7106
J9 SAUDI J BIOL SCI
JI Saudi J. Biol. Sci.
PD OCT
PY 2020
VL 27
IS 10
BP 2674
EP 2682
DI 10.1016/j.sjbs.2020.06.005
PG 9
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA NQ4UB
UT WOS:000570858800025
PM 32837219
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Niaki, OZ
   Anadkat, MJ
   Chen, ST
   Fox, LP
   Harp, J
   Micheletti, RG
   Nambudiri, VE
   Pasieka, HB
   Shinohara, MM
   Rosenbach, M
   Merola, JF
AF Niaki, Omid Zahedi
   Anadkat, Milan J.
   Chen, Steven T.
   Fox, Lindy P.
   Harp, Joanna
   Micheletti, Robert G.
   Nambudiri, Vinod E.
   Pasieka, Helena B.
   Shinohara, Michi M.
   Rosenbach, Misha
   Merola, Joseph F.
TI Navigating immunosuppression in a pandemic: A guide for the
   dermatologist from the COVID Task Force of the Medical Dermatology
   Society and Society of Dermatology Hospitalists
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Article
DE autoimmune disease; COVID-19; dermatology-rheumatology;
   immunosuppression; immunosuppressive therapy; medical dermatology;
   SARS-CoV-2
ID ACTIVE RHEUMATOID-ARTHRITIS; LONG-TERM SAFETY; SERIOUS INFECTIONS;
   HERPES-ZOSTER; INADEQUATE RESPONSE; VIRAL-INFECTIONS; CLINICAL-TRIAL;
   MERS-COV; RITUXIMAB; RISK
AB Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in coronavirus disease 2019 (COVID-19) are scarce. This article reviews and offers guidance based on currently available safety data and the most recent COVID-19 outcome data in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasizes a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic.
C1 [Niaki, Omid Zahedi; Nambudiri, Vinod E.; Merola, Joseph F.] Brigham & Womens Hosp, Harvard Med Sch, Dept Dermatol, Boston, MA USA.
   [Anadkat, Milan J.] Washington Univ, Div Dermatol, St Louis Sch Med, St Louis, MO USA.
   [Chen, Steven T.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Internal Med, Boston, MA USA.
   [Chen, Steven T.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Dermatol, Boston, MA USA.
   [Fox, Lindy P.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA USA.
   [Harp, Joanna] Weill Cornell Med, Dept Dermatol, New York, NY USA.
   [Micheletti, Robert G.; Rosenbach, Misha] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA USA.
   [Micheletti, Robert G.; Rosenbach, Misha] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA USA.
   [Pasieka, Helena B.] Georgetown Univ, Dept Dermatol, Medstar Washington Hosp Ctr, Sch Med, Washington, DC USA.
   [Shinohara, Michi M.] Univ Washington, Div Dermatol, Dept Med, Seattle, WA USA.
   [Merola, Joseph F.] Brigham & Womens Hosp, Div Rheumatol, Dept Med, Harvard Med Sch, Boston, MA USA.
RP Niaki, OZ (corresponding author), 41 Ave Louis Pasteur 319, Boston, MA 02115 USA.
EM OmidZahediMD@gmail.com
CR Aksoy S, 2007, LEUKEMIA LYMPHOMA, V48, P1307, DOI 10.1080/10428190701411441
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bernatsky S, 2007, RHEUMATOLOGY, V46, P1157, DOI 10.1093/rheumatology/kem076
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   Brownstone ND, 2020, DERMATOL THER, V10, P339
   Casulo C, 2013, CL LYMPH MYELOM LEUK, V13, P106, DOI 10.1016/j.clml.2012.11.011
   Cooper N, 2009, BRIT J HAEMATOL, V146, P120, DOI 10.1111/j.1365-2141.2009.07715.x
   Cour M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03014-1
   Crowley J, 2017, J AM ACAD DERMATOL, V77, P310, DOI 10.1016/j.jaad.2017.01.052
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475
   Davila-Seijo P, 2017, J INVEST DERMATOL, V137, P313, DOI 10.1016/j.jid.2016.08.034
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Eichenfield LF, 2019, AM J CLIN DERMATOL, V20, P443, DOI 10.1007/s40257-019-00445-7
   Emery P, 2010, ANN RHEUM DIS, V69, P1629, DOI 10.1136/ard.2009.119933
   Feldman CH, 2017, ARTHRITIS RHEUMATOL, V69, P387, DOI 10.1002/art.39849
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Greenberg JD, 2010, ANN RHEUM DIS, V69, P380, DOI 10.1136/ard.2008.089276
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Herrinton LJ, 2016, J RHEUMATOL, V43, P1503, DOI 10.3899/jrheum.150671
   Horby P, 2020, EFFECT DEXAMETHASONE
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Ibrahim A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010015
   Joly P, 2017, LANCET, V389, P2031, DOI 10.1016/S0140-6736(17)30070-3
   Kalb RE, 2015, JAMA DERMATOL, V151, P961, DOI 10.1001/jamadermatol.2015.0718
   Kavanaugh A, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1901-3
   Keown P, 1996, TRANSPLANTATION, V61, P1029
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Kim SH, 2017, J INFECT CHEMOTHER, V23, P769, DOI 10.1016/j.jiac.2017.04.004
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lam MF, 2004, AM J RESP CRIT CARE, V169, P125, DOI 10.1164/rccm.200306-754CR
   Lansbury L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010406.pub3
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Makatsori M, 2014, QJM-INT J MED, V107, P821, DOI 10.1093/qjmed/hcu094
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mease PJ, 2010, J RHEUMATOL, V37, P917, DOI 10.3899/jrheum.090442
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Migita K, 2013, MEDICINE, V92, P285, DOI 10.1097/MD.0b013e3182a72299
   Nash P, 2020, ANN RHEUM DIS, V79, P679, DOI 10.1136/annrheumdis-2019-216821
   Nazi I, 2013, BLOOD, V122, P1946, DOI 10.1182/blood-2013-04-494096
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Olivera PA, 2020, GASTROENTEROLOGY, V158, P1554, DOI 10.1053/j.gastro.2020.01.001
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Perez-Chada LM, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108397
   Prescott J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00205
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Schneeweiss Maria C, 2019, J Am Acad Dermatol, DOI 10.1016/j.jaad.2019.05.073
   Smolen JS, 2019, J RHEUMATOL, V46, P7, DOI 10.3899/jrheum.171361
   Solomon DH, 2020, ANN INTERN MED, V172, P369, DOI 10.7326/M19-3369
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Strand V, 2017, ANN RHEUM DIS, V76, P284, DOI 10.1136/annrheumdis-2017-eular.2439
   STUCK AE, 1989, REV INFECT DIS, V11, P954
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   US Food & Drug Administration, 2020, FDA CAUT US HYDR CHL
   van Assen S, 2010, ARTHRITIS RHEUM-US, V62, P75, DOI 10.1002/art.25033
   van Vollenhoven RF, 2015, J RHEUMATOL, V42, P1761, DOI 10.3899/jrheum.150051
   Vieira MC, 2016, CLIN THER, V38, P2628, DOI 10.1016/j.clinthera.2016.11.004
   Wakkee M, 2011, J AM ACAD DERMATOL, V65, P1135, DOI 10.1016/j.jaad.2010.08.036
   Wan MT, 2020, J AM ACAD DERMATOL, V83, P677, DOI 10.1016/j.jaad.2020.05.035
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Winthrop KL, 2019, ARTHRIT CARE RES, V71, P993, DOI 10.1002/acr.23781
   Winthrop KL, 2017, ARTHRITIS RHEUMATOL, V69, P1960, DOI 10.1002/art.40189
   Winthrop KL, 2017, J AM ACAD DERMATOL, V77, P302, DOI 10.1016/j.jaad.2017.03.023
   Wisniewski A, 2020, UNITED EUR GASTROENT, V8, P303, DOI 10.1177/2050640619889763
   Wolfe F, 2006, RHEUMATOLOGY, V45, P1370, DOI 10.1093/rheumatology/kel328
   Wollenhaupt J, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1866-2
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 74
TC 3
Z9 3
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
EI 1097-6787
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD OCT
PY 2020
VL 83
IS 4
BP 1150
EP 1159
DI 10.1016/j.jaad.2020.06.051
PG 10
WC Dermatology
SC Dermatology
GA NO2HX
UT WOS:000569306800023
PM 32569797
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wang, SP
   Pan, Y
   Wang, QY
   Miao, HY
   Brown, AN
   Rong, LB
AF Wang, Sunpeng
   Pan, Yang
   Wang, Quanyi
   Miao, Hongyu
   Brown, Ashley N.
   Rong, Libin
TI Modeling the viral dynamics of SARS-CoV-2 infection
SO MATHEMATICAL BIOSCIENCES
LA English
DT Article
ID SARS CORONAVIRUS; FUNCTIONAL RECEPTOR; T-CELLS; MERS; TRANSMISSION;
   PATHOGENESIS; PNEUMONIA; OUTBREAK; INSIGHTS; IMMUNITY
AB Coronavirus disease 2019 (COVID-19), an infectious disease caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading and causing the global coronavirus pandemic. The viral dynamics of SARS-CoV-2 infection have not been quantitatively investigated. In this paper, we use mathematical models to study the pathogenic features of SARS-CoV-2 infection by examining the interaction between the virus, cells and immune responses. Models are fit to the data of SARS-CoV-2 infection in patients and non-human primates. Data fitting and numerical simulation show that viral dynamics of SARS-CoV-2 infection have a few distinct stages. In the initial stage, viral load increases rapidly and reaches the peak, followed by a plateau phase possibly generated by lymphocytes as a secondary target of infection. In the last stage, viral load declines due to the emergence of adaptive immune responses. When the initiation of seroconversion is late or slow, the model predicts viral rebound and prolonged viral persistence, consistent with the observation in non-human primates. Using the model we also evaluate the effect of several potential therapeutic interventions for SARS-CoV-2 infection. Model simulation shows that anti-inflammatory treatments or antiviral drugs combined with interferon are effective in reducing the duration of the viral plateau phase and diminishing the time to recovery. These results provide insights for understanding the infection dynamics and might help develop treatment strategies against COVID-19.
C1 [Wang, Sunpeng] NYU, Dept Biol, New York, NY 10012 USA.
   [Pan, Yang; Wang, Quanyi] Beijing Ctr Dis Prevent & Control, Beijing 100013, Peoples R China.
   [Pan, Yang; Wang, Quanyi] Beijing Res Ctr Prevent Med, Beijing, Peoples R China.
   [Pan, Yang] Capital Med Univ, Sch Publ Hlth, Beijing, Peoples R China.
   [Miao, Hongyu] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Dept Biostat & Data Sci, Houston, TX 77030 USA.
   [Brown, Ashley N.] Univ Florida, Coll Med, Inst Therapeut Innovat, Dept Med, Orlando, FL 32827 USA.
   [Rong, Libin] Univ Florida, Dept Math, Gainesville, FL 32611 USA.
RP Rong, LB (corresponding author), Univ Florida, Dept Math, Gainesville, FL 32611 USA.
EM libinrong@ufl.edu
OI Miao, Hongyu/0000-0002-4131-3164
FU NSFNational Science Foundation (NSF) [DMS-1758290, DMS-1620957];
   University of Florida Clinical and Translational Science Institute; NIH
   National Center for Advancing Translational Sciences [UL1TR001427]
FX HM is supported by the NSF grant DMS-1620957. ANB is supported by the
   University of Florida Clinical and Translational Science Institute,
   which is supported in part by the NIH National Center for Advancing
   Translational Sciences under award number UL1TR001427. LR is supported
   by the NSF grant DMS-1758290. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the National Institutes of Health.
CR Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Berg RE, 2006, CURR OPIN IMMUNOL, V18, P338, DOI 10.1016/j.coi.2006.03.010
   Best K, 2017, P NATL ACAD SCI USA, V114, P8847, DOI 10.1073/pnas.1704011114
   Bohmer MM, 2020, LANCET INFECT DIS, V20, P920, DOI 10.1016/S1473-3099(20)30314-5
   Boulos MKN, 2020, INT J HEALTH GEOGR, V19, DOI 10.1186/s12942-020-00202-8
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   CASTRANOVA V, 1988, TOXICOL APPL PHARM, V93, P472, DOI 10.1016/0041-008X(88)90051-8
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Chen TM, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00640-3
   Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Fang YQ, 2020, J MED VIROL, V92, P645, DOI 10.1002/jmv.25750
   Frieman M, 2007, J VIROL, V81, P9812, DOI 10.1128/JVI.01012-07
   Gao Zhiru, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.05.001
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gutcher I, 2007, J CLIN INVEST, V117, P1119, DOI 10.1172/JCI31720
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   HAN SW, 2020, LANCET RESP MED, DOI DOI 10.1016/S2213-2600(20)30079-5
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Janeway C. A., 2001, IMMUNOBIOLOGY IMMUNE
   Jaume M, 2011, J VIROL, V85, P10582, DOI 10.1128/JVI.00671-11
   Jian-ya G., 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.02.20.20025536, DOI 10.1101/2020.02.20.20025536]
   Kaur A, 2008, J VIROL, V82, P1084, DOI 10.1128/JVI.02197-07
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e86
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5
   Kumari G, 2020, BIORXIV, DOI [10.1101/2020.03.07.982264, DOI 10.1101/2020.03.07.982264]
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Leung Nancy H L, 2020, Nat Med, V26, P676, DOI 10.1038/s41591-020-0843-2
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu T., 2020, BIORXIV, DOI [10.1101/2020.01.2.919787., DOI 10.1101/2020.01.2.919787]
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mac Sweeney R, 2016, LANCET, V388, P2416, DOI 10.1016/S0140-6736(16)00578-X
   Manicone AM, 2009, EXPERT REV CLIN IMMU, V5, P63, DOI 10.1586/1744666X.5.1.63
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   McElreath R., 2018, STAT RETHINKING BAYE
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Ochs M, 2004, AM J RESP CRIT CARE, V169, P120, DOI 10.1164/rccm.200308-1107OC
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Pawelek KA, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002588
   Perelson AS, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-96
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Qian ZH, 2013, AM J RESP CELL MOL, V48, P742, DOI 10.1165/rcmb.2012-0339OC
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218, DOI 10.1128/AAC.42.12.3218
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shen M, 2020, MODELLING EPIDEMIC T, DOI [10.1101/2020.01.23.916726, DOI 10.1101/2020.01.23.916726, 10.1101/2020.01.23.916726.]
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shim E, 2020, INT J INFECT DIS, V93, P339, DOI 10.1016/j.ijid.2020.03.031
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Taddy M., 2019, BUSINESS DATA SCI CO
   Tan L, 2020, SPECIAL CASE COVID 1, DOI [10.1101/2020.03.22.20040071, DOI 10.1101/2020.03.22.20040071]
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941
   Wang HB, 2004, CLIN CHEM, V50, P1237, DOI 10.1373/clinchem.2004.031237
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang SP, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004665
   Wang XL, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0424-9
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Yuan J, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.03.06.20031377, DOI 10.1101/2020.03.06.20031377]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 93
TC 1
Z9 1
U1 12
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-5564
EI 1879-3134
J9 MATH BIOSCI
JI Math. Biosci.
PD OCT
PY 2020
VL 328
AR 108438
DI 10.1016/j.mbs.2020.108438
PG 12
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA NO3MV
UT WOS:000569390500006
PM 32771304
OA Green Published
DA 2021-01-01
ER

PT J
AU Wasserman, D
   Iosue, M
   Wuestefeld, A
   Carli, V
AF Wasserman, Danuta
   Iosue, Miriam
   Wuestefeld, Anika
   Carli, Vladimir
TI Adaptation of evidence-based suicide prevention strategies during and
   after theCOVID-19 pandemic
SO WORLD PSYCHIATRY
LA English
DT Article
DE Suicide; suicidal behaviour; mental health; COVID-19; socio-ecological
   model; universal prevention; selective prevention; indicated prevention
ID COGNITIVE-BEHAVIORAL THERAPY; HEALTH-CARE WORKERS; FACE-TO-FACE;
   MENTAL-HEALTH; PSYCHOLOGICAL IMPACT; GENERAL-POPULATION; BRIEF
   INTERVENTION; COMPLICATED GRIEF; SOCIAL-ISOLATION; GREAT RECESSION
AB Suicide is preventable. Nevertheless, each year 800,000 people die of suicide in the world. While there is evidence indicating that suicide rates de-crease during times of crises, they are expected to increase once the immediate crisis has passed. The COVID-19 pandemic affects risk and pro-tective factors for suicide at each level of the socio-ecological model. Economic downturn, augmented barriers to accessing health care, increased access to suicidal means, inappropriate media reporting at the societal level; deprioritization of mental health and preventive activities at the community level; interpersonal conflicts, neglect and violence at the relationship level; unemployment, poverty, loneliness and hopelessness at the individual level: all these variables contribute to an increase of depression, anxiety, post-traumatic stress disorder, harmful use of alcohol, substance abuse, and ultimately suicide risk. Suicide should be prevented by strengthening universal strategies directed to the entire population, including mitigation of unemployment, poverty and inequalities; prioritization of access to mental health care; responsible media reporting, with information about available support; prevention of increased alcohol intake; and restriction of access to lethal means of suicide. Selective interventions should continue to target known vulnerable groups who are socio-economically disadvantaged, but also new ones such as first responders and health care staff, and the bereaved by COVID-19 who have been deprived of the final contact with loved ones and funerals. Indicated preventive strategies targeting individuals who display suicidal behaviour should focus on available pharmacological and psychological treatments of mental disorders, ensuring proper follow-up and chain of care by increased use of telemedicine and other digital means. The scientific community, health care professionals, politicians and decision-makers will find in this paper a systematic description of the effects of the pandemic on suicide risk at the society, community, family and individual levels, and an overview of how evidence-based suicide preventive interventions should be adapted. Research is needed to investigate which adaptations are effective and in which con-texts.
C1 [Wasserman, Danuta; Iosue, Miriam; Wuestefeld, Anika; Carli, Vladimir] Karolinska Inst, Natl Ctr Suicide Res & Prevent Mental Ill Hlth, Stockholm, Sweden.
RP Wasserman, D (corresponding author), Karolinska Inst, Natl Ctr Suicide Res & Prevent Mental Ill Hlth, Stockholm, Sweden.
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Ghebreyesus TA, 2020, WORLD PSYCHIATRY, V19, P129, DOI 10.1002/wps.20768
   Aguilar EJ, 2007, PSYCHOPHARMACOL BULL, V40, P128
   Ahgren Bengt, 2003, Int J Integr Care, V3, pe01
   Ajdacic-Gross V, 2008, B WORLD HEALTH ORGAN, V86, P726, DOI 10.2471/BLT.07.043489
   Al Jurdi RK, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0614-9
   Andersson G, 2019, WORLD PSYCHIATRY, V18, P20, DOI 10.1002/wps.20610
   [Anonymous], 2020, LANCET CHILD ADOLESC, V4, P341, DOI 10.1016/S2352-4642(20)30105-X
   [Anonymous], 2020, ALC COVID 19 WHAT YO
   [Anonymous], RIS LEV HAT SPEECH O
   Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Azar KMJ, 2020, HEALTH AFFAIR, V39, P1253, DOI 10.1377/hlthaff.2020.00598
   Bach Trevor, 2020, US NEWS
   Balazs J, 2013, J CHILD PSYCHOL PSYC, V54, P670, DOI 10.1111/jcpp.12016
   Baldessarini RJ, 2006, ARCH GEN PSYCHIAT, V63, P246, DOI 10.1001/archpsyc.63.3.246
   Barak Y, 2004, PSYCHOPHARMACOLOGY, V175, P215, DOI 10.1007/s00213-004-1801-2
   Barbui C, 2009, CAN MED ASSOC J, V180, P291, DOI 10.1503/cmaj.081514
   Barnett ML, 2020, PSYCHIAT SERV, V71, P197, DOI 10.1176/appi.ps.201900555
   Barney A, J ADOLESC HLTH
   Bashshur R, 2020, TELEMED E-HEALTH, V26, P571, DOI 10.1089/tmj.2020.29040.rb
   Bateman K, 2007, SUICIDE LIFE-THREAT, V37, P284, DOI 10.1521/suli.2007.37.3.284
   Ben-Zeev D, 2013, ADM POLICY MENT HLTH, V40, P340, DOI 10.1007/s10488-012-0424-x
   Berman AL, 2020, SUICIDE LIFE-THREAT, V50, P643, DOI 10.1111/sltb.12610
   Berrouiguet S, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.7780
   Bo H-X, PSYCHOL MED
   Bohanna I, 2012, CRISIS, V33, P190, DOI 10.1027/0227-5910/a000137
   Borges G, 2010, CURR OPIN PSYCHIATR, V23, P195, DOI 10.1097/YCO.0b013e3283386322
   Bouziri H, 2020, OCCUP ENVIRON MED, V77, P509, DOI 10.1136/oemed-2020-106599
   Brent DA, 2016, PSYCHIAT CLIN N AM, V39, P503, DOI 10.1016/j.psc.2016.04.002
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Brooks SK, 2018, J OCCUP ENVIRON MED, V60, P248, DOI 10.1097/JOM.0000000000001235
   Brown GK, 2014, AM J PREV MED, V47, pS209, DOI 10.1016/j.amepre.2014.06.006
   Bruffaerts R, 2011, BRIT J PSYCHIAT, V199, P64, DOI 10.1192/bjp.bp.110.084129
   Bryan CJ, 2017, J AFFECT DISORDERS, V212, P64, DOI 10.1016/j.jad.2017.01.028
   Burke L.A, 2013, COMPLICATED GRIEF SC, P145
   Calati R, 2019, J AFFECT DISORDERS, V245, P653, DOI 10.1016/j.jad.2018.11.022
   Cano-Montalban I, 2018, EUR J PSYCHOL APPL L, V10, P15, DOI 10.5093/ejpalc2018a2
   Carli V, 2014, WORLD PSYCHIATRY, V13, P78, DOI 10.1002/wps.20088
   Carr D, 2020, J AGING SOC POLICY, V32, P425, DOI 10.1080/08959420.2020.1764320
   Centers for Disease Control and Prevention, 2020, MENT HLTH COP COVID
   Centers for Disease Control and Prevention, LEAD CAUS DEATH REP
   Centers for Medicare & Medicaid Services, TEL
   Chandan JS, 2020, LANCET PUBLIC HEALTH, V5, pE309, DOI 10.1016/S2468-2667(20)30112-2
   Chen PJ, 2020, J SPORT HEALTH SCI, V9, P103, DOI 10.1016/j.jshs.2020.02.001
   Chevance A, 2020, ENCEPHALE, V46, P193, DOI 10.1016/j.encep.2020.04.005
   Chia BH, 2011, SUICIDE LIFE-THREAT, V41, P574, DOI 10.1111/j.1943-278X.2011.00055.x
   Cho Jaelim, 2013, J Prev Med Public Health, V46, P147, DOI 10.3961/jpmph.2013.46.3.147
   Christian C, 2019, REV ECON STAT, V101, P905, DOI 10.1162/rest_a_00777
   Cipriani A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3646
   Collins K., 2020, NY TIMES
   Cusimano MD, 2011, INJURY PREV, V17, P43, DOI 10.1136/ip.2009.025502
   Cylus J, 2014, AM J EPIDEMIOL, V180, P45, DOI 10.1093/aje/kwu106
   Dale B, 2020, BBC NEWS, V18
   Dalton TR, 2019, EMERG MED J, V36, P407, DOI 10.1136/emermed-2018-207561
   Darvishi N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126870
   Davydow DS, 2008, GEN HOSP PSYCHIAT, V30, P421, DOI 10.1016/j.genhosppsych.2008.05.006
   De Jaegere E, 2019, BEHAV RES THER, V119, DOI 10.1016/j.brat.2019.05.003
   DeCou CR, 2019, BEHAV THER, V50, P60, DOI 10.1016/j.beth.2018.03.009
   Del Matto L, 2020, NEUROSCI BIOBEHAV R, V116, P142, DOI 10.1016/j.neubiorev.2020.06.017
   Devries KM, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001439
   Di Renzo L, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02399-5
   Druss BG, JAMA PSYCHIAT
   Durkee T, 2012, ADDICTION, V107, P2210, DOI 10.1111/j.1360-0443.2012.03946.x
   Eckhardt CI, 2013, PARTN ABUSE, V4, P196, DOI 10.1891/1946-6560.4.2.196
   European Commission, 2020, EUR EC FOR
   Fairchild RM, TELEMED E HLTH
   Fiorillo A, 2020, EUR PSYCHIAT, V63, DOI 10.1192/j.eurpsy.2020.35
   Fleischmann A, 2008, B WORLD HEALTH ORGAN, V86, P703, DOI 10.2471/BLT.07.046995
   Fowler KA, 2015, AM J PUBLIC HEALTH, V105, P311, DOI 10.2105/AJPH.2014.301945
   Franco-Martin MA, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-0926-5
   Franklin JC, 2016, J CONSULT CLIN PSYCH, V84, P544, DOI 10.1037/ccp0000093
   Garfin DR, 2020, HEALTH PSYCHOL, V39, P355, DOI 10.1037/hea0000875
   Gesi C, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00489
   Giansanti D, TELEMED E HLTH
   Gibbons RD, 2012, ARCH GEN PSYCHIAT, V69, P580, DOI 10.1001/archgenpsychiatry.2011.2048
   Gibson M, UNIVERSAL BASIC INCO
   Gilmore AK, 2019, J TELEMED TELECARE, V25, P59, DOI 10.1177/1357633X17735559
   Goldsmith S. K., 2002, REDUCING SUICIDE NAT
   Gonzalez-Sanguino C, 2020, BRAIN BEHAV IMMUN, V87, P172, DOI 10.1016/j.bbi.2020.05.040
   Greenberg N, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1211
   Gunnell D, 2020, LANCET PSYCHIAT, V7, P468, DOI 10.1016/S2215-0366(20)30171-1
   Gunnell D, 2017, LANCET GLOB HEALTH, V5, pE1026, DOI 10.1016/S2214-109X(17)30299-1
   Hadlaczky G, 2014, INT REV PSYCHIATR, V26, P467, DOI 10.3109/09540261.2014.924910
   Hao FY, 2020, BRAIN BEHAV IMMUN, V87, P100, DOI 10.1016/j.bbi.2020.04.069
   Hetrick SE, 2017, EVID-BASED MENT HEAL, V20, P76, DOI 10.1136/eb-2017-102719
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Houle JN, 2014, AM J PUBLIC HEALTH, V104, P1073, DOI 10.2105/AJPH.2013.301774
   Huang J, CLIN INFECT DIS
   Hubley S, 2016, WORLD J PSYCHIATR, V6, P269, DOI 10.5498/wjp.v6.i2.269
   International Association for Suicide Prevention, BRIEF STAT COR DIS C
   International Association for Suicide Prevention, REP SUIC COVID 19 PA
   International Monetary Fund, IMFS GEORG COVID 19
   Isaac M, 2009, CAN J PSYCHIAT, V54, P260, DOI 10.1177/070674370905400407
   Kaess M, 2014, EUR CHILD ADOLES PSY, V23, P611, DOI 10.1007/s00787-013-0490-y
   Kang LJ, 2020, BRAIN BEHAV IMMUN, V87, P11, DOI 10.1016/j.bbi.2020.03.028
   Kannampallil T, TELEMED E HLTH
   Karolinska Institutet National Centre for Suicide Research and Prevention, COR RISK INCR SUIC S
   Katz C, 2013, DEPRESS ANXIETY, V30, P1030, DOI 10.1002/da.22114
   Kawohl W, 2020, LANCET PSYCHIAT, V7, P389, DOI 10.1016/S2215-0366(20)30141-3
   Kim C, 2018, INT J HEALTH SERV, V48, P512, DOI 10.1177/0020731418767548
   Klomek AB, 2020, LANCET PSYCHIAT, V7, P390, DOI 10.1016/S2215-0366(20)30142-5
   Kokou-Kpolou CK, 2020, PSYCHOL TRAUMA-US, V12, pS94, DOI 10.1037/tra0000798
   Kolves K, 2013, J AFFECT DISORDERS, V146, P1, DOI 10.1016/j.jad.2012.07.037
   Kreuze E, 2017, J TELEMED TELECARE, V23, P605, DOI 10.1177/1357633X16657928
   Latham AE, 2004, SUICIDE LIFE-THREAT, V34, P350, DOI 10.1521/suli.34.4.350.53737
   Latifi R, TELEMED E HLTH
   Leavey K, 2017, COGN BEHAV THERAPY, V46, P353, DOI 10.1080/16506073.2017.1332095
   Lee J, 2020, LANCET CHILD ADOLESC, V4, P421, DOI 10.1016/S2352-4642(20)30109-7
   Lee SM, 2018, COMPR PSYCHIAT, V87, P123, DOI 10.1016/j.comppsych.2018.10.003
   Leigh-Hunt N, 2017, PUBLIC HEALTH, V152, P157, DOI 10.1016/j.puhe.2017.07.035
   Lester D., 2009, OXFORD TXB SUICIDOLO, P215
   Li JF, 2020, WORLD PSYCHIATRY, V19, P249, DOI 10.1002/wps.20758
   Lizardi D, 2010, PSYCHIAT SERV, V61, P1183, DOI 10.1176/ps.2010.61.12.1183
   Lobb EA, 2010, DEATH STUD, V34, P673, DOI 10.1080/07481187.2010.496686
   Lu W, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112936
   Luxton DD, 2013, CRISIS, V34, P32, DOI 10.1027/0227-5910/a000158
   Luxton DD, 2011, TELEMED E-HEALTH, V17, P50, DOI 10.1089/tmj.2010.0091
   Mamun MA, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102073
   Mannix R, ANN INTERN MED
   Matsubayashi T, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8264-1
   Mattioli AV, 2020, EUR J CLIN NUTR, V74, P852, DOI 10.1038/s41430-020-0646-z
   Mayland CR, 2020, J PAIN SYMPTOM MANAG, V60, pE33, DOI 10.1016/j.jpainsymman.2020.05.012
   McIntyre M, 2020, AM J PHYS MED REHAB, V99, P464, DOI 10.1097/PHM.0000000000001453
   McIntyre RS, 2020, WORLD PSYCHIATRY, V19, P250, DOI 10.1002/wps.20767
   Mew EJ, 2017, J AFFECT DISORDERS, V219, P93, DOI 10.1016/j.jad.2017.05.002
   Meyer B, OXFORD TXB SUICIDOLO
   Miller JN, 2020, CURR PSYCHIAT REP, V22, DOI 10.1007/s11920-020-1130-0
   Mississippi State University, 2020, DMH MSU OFF ALL PROJ
   Modi C, 2020, DEADLY IS COVID 19 R, DOI [10.1101/2020.04.15.20067074, DOI 10.1101/2020.04.15.20067074]
   Mogensen H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164274
   Naohiro Y, 2019, J AFFECT DISORDERS, V246, P506, DOI 10.1016/j.jad.2018.12.052
   National Action Alliance for Suicide Prevention, 2019, BEST PRACT CAR TRANS
   Newby J, ACUTE MENTAL HLTH RE, DOI [10.1101/2020.05.03.20089961v1, DOI 10.1101/2020.05.03.20089961V1]
   Niederkrotenthaler T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m575
   Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113
   Norstrom T, 2016, ARCH SUICIDE RES, V20, P489, DOI 10.1080/13811118.2016.1158678
   Norstrom T, 2015, J EPIDEMIOL COMMUN H, V69, P110, DOI 10.1136/jech-2014-204602
   Oyesanya M, 2015, WORLD J PSYCHIATR, V5, P243, DOI 10.5498/wjp.v5.i2.243
   Painter A, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i6473
   Pappot N, 2020, TELEMED E-HEALTH, V26, P847, DOI 10.1089/tmj.2020.0099
   Parmar D, 2016, BMJ-BRIT MED J, V354, pi4588, DOI DOI 10.1136/BMJ.I4588
   Peng XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079476
   Polizzi C, 2020, CLIN NEUROPSYCHIATR, V17, P59, DOI 10.36131/CN20200204
   Puig-Barrachina V, 2020, EUR J PUBLIC HEALTH, V30, P36, DOI 10.1093/eurpub/ckz026
   Reeves A, 2015, EUR J PUBLIC HEALTH, V25, P404, DOI 10.1093/eurpub/cku168
   Reger MA, JAMA PSYCHIAT
   Reinhardt I, 2019, CURR PSYCHIAT REP, V21, DOI 10.1007/s11920-019-1054-8
   Robinson J, 2018, AUSTRALAS PSYCHIATRY, V26, P132, DOI 10.1177/1039856218759406
   Robinson J, 2013, CRISIS, V34, P164, DOI 10.1027/0227-5910/a000168
   Romano S, RES SOCIAL ADM PHARM
   Rushe Dominic, 2020, GUARDIAN
   Sarchiapone M, 2011, INT J ENV RES PUB HE, V8, P4550, DOI 10.3390/ijerph8124550
   Schomerus G, 2012, ACTA PSYCHIAT SCAND, V125, P440, DOI 10.1111/j.1600-0447.2012.01826.x
   Scott BK, TELEMED E HLTH
   Seidel RW, 2014, J TELEMED TELECARE, V20, P59, DOI 10.1177/1357633X13519902
   Selman LE, 2020, J PAIN SYMPTOM MANAG, V60, pE81, DOI 10.1016/j.jpainsymman.2020.04.024
   Shanafelt T, JAMA
   Sher L, 2020, SLEEP MED, V70, P124, DOI 10.1016/j.sleep.2020.04.019
   Shibata H., 2014, JPN SOCIOL REV, V65, P116
   Simpson SA, PSYCHOSOMATICS
   Sisask M, 2012, INT J ENV RES PUB HE, V9, P123, DOI 10.3390/ijerph9010123
   Smith KA, 2017, BIPOLAR DISORD, V19, P575, DOI 10.1111/bdi.12543
   Soole R, 2015, ARCH SUICIDE RES, V19, P285, DOI 10.1080/13811118.2014.996694
   Spicer RS, 2000, AM J PUBLIC HEALTH, V90, P1885, DOI 10.2105/AJPH.90.12.1885
   Stanley B, 2012, COGN BEHAV PRACT, V19, P256, DOI 10.1016/j.cbpra.2011.01.001
   Stuckler D, 2009, LANCET, V374, P315, DOI 10.1016/S0140-6736(09)61124-7
   Suicide Prevention Resource Center, 2011, UND RISK PROT FACT S
   Tarrier N, 2008, BEHAV MODIF, V32, P77, DOI 10.1177/0145445507304728
   The World Bank, E AS PAC TIM COVID 1
   Thornicroft G, 2016, LANCET, V387, P1123, DOI 10.1016/S0140-6736(15)00298-6
   Too LS, 2019, J AFFECT DISORDERS, V259, P302, DOI 10.1016/j.jad.2019.08.054
   Torous J, 2019, WORLD PSYCHIATRY, V18, P97, DOI 10.1002/wps.20592
   Torry M., 2020, BIEN CONVERSATI 0609, V9
   Triana AJ, TELEMED E HLTH
   Trivedi MH, 2018, AM J PSYCHIAT, V175, P97, DOI 10.1176/appi.ajp.2017.17111261
   United Nations, EV INCL SOC IMP COVI
   United Nations, 2020, POL BRIEF COVID 19 N
   United Nations Economic Commission for Africa, COVID 19 AFR PROT LI
   United Nations Economic Commission for Latin America and the Carribean, MEAS IMP COVID 19 VI
   Usher K, 2020, INT J MENT HEALTH NU, V29, P549, DOI 10.1111/inm.12735
   Valentino-DeVries J., 2020, NY TIMES
   van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X
   van Gelder N, 2020, EClinicalMedicine, V21, P100348, DOI 10.1016/j.eclinm.2020.100348
   Van Lancker W, 2020, LANCET PUBLIC HEALTH, V5, pE243, DOI 10.1016/S2468-2667(20)30084-0
   Wahlbeck K, 2017, SOC PSYCH PSYCH EPID, V52, P505, DOI 10.1007/s00127-017-1370-4
   Wang ZC, 2020, NAT MED, P19, DOI 10.1038/s41591-020-0823-6
   Ward-Ciesielski EF, 2018, GEN HOSP PSYCHIAT, V55, P100, DOI 10.1016/j.genhosppsych.2018.09.002
   Wasserman D, 2020, EUR PSYCHIAT, V63, DOI [10.1192/j.eurpsy.2020.60, 10.1192/j.eurpsy.2020.79]
   Wasserman D, 1998, ACTA PSYCHIAT SCAND, V98, P1, DOI 10.1111/j.1600-0447.1998.tb10758.x
   Wasserman D., 2020, SCIENCE, V367, P1282
   Wasserman D., 2016, SUICIDE UNNECESSARY
   Wasserman D, 2009, OXFORD TXB SUICIDOLO, P381
   Wasserman D, 2015, LANCET, V385, P1536, DOI 10.1016/S0140-6736(14)61213-7
   Watson AR, TELEMED E HLTH
   Weinberg I, 2006, J PERS DISORD, V20, P482, DOI 10.1521/pedi.2006.20.5.482
   Weitoft GR, 2014, PHARMACOEPIDEM DR S, V23, P290, DOI 10.1002/pds.3567
   Welton Randon S, 2007, Psychiatry (Edgmont), V4, P24
   WHO, 2017, PREV SUIC RES MED PR
   Wilcock AD, 2019, JAMA INTERN MED, V179, P1580, DOI 10.1001/jamainternmed.2019.2234
   Wilcox HC, 2004, DRUG ALCOHOL DEPEN, V76, pS11, DOI 10.1016/j.drugalcdep.2004.08.003
   Wilkinson ST, 2018, AM J PSYCHIAT, V175, P150, DOI 10.1176/appi.ajp.2017.17040472
   Witt K, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1458-0
   Wong PWC, 2014, SOC PSYCH PSYCH EPID, V49, P211, DOI 10.1007/s00127-013-0743-6
   Wong TW, 2005, EUR J EMERG MED, V12, P13, DOI 10.1097/00063110-200502000-00005
   World Health Oraganization, 2014, PREV SUIC GLOB IMP
   World Health Organization, 2010, GLOB STRAT RED HARMF
   World Health Organization, SUICIDE
   World Health Organization, 2019, SUIC WORLD GLOB HLTH
   World Health Organization, 2020, MENT HLTH PSYCH CONS
   World Health Organization, WHO COR DIS COVID 19
   World Health Organization, 2015, MHGAP EV BAS REC MAN
   World Health Organization, 2018, NAT SUIC PREV STRAT
   World Health Organization Europe, 2020, MENT HLTH COVID 19
   World Health Organization (WHO), 2016, TEL
   Wu J, 2020, NY TIMES
   Xuan ZM, 2016, ALCOHOL CLIN EXP RES, V40, P2043, DOI 10.1111/acer.13203
   Yip PSF, 2012, LANCET, V379, P2393, DOI 10.1016/S0140-6736(12)60521-2
   Zalsman G, 2016, LANCET PSYCHIAT, V3, P646, DOI 10.1016/S2215-0366(16)30030-X
   Zarghami A, TELEMED E HLTH
   Zatti C, 2017, PSYCHIAT RES, V256, P353, DOI 10.1016/j.psychres.2017.06.082
   Zero Suicide Alliance, ZER SUIC ALL TRAIN
   Zero Suicide Institute, TEL SUIC CAR COVID 1
   Zhang SX, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112958
   Zhou JY, 2020, AM J PSYCHIAT, V177, P574, DOI 10.1176/appi.ajp.2020.20030304
NR 223
TC 2
Z9 2
U1 23
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1723-8617
EI 2051-5545
J9 WORLD PSYCHIATRY
JI World Psychiatry
PD OCT
PY 2020
VL 19
IS 3
BP 294
EP 306
DI 10.1002/wps.20801
PG 13
WC Psychiatry
SC Psychiatry
GA NO1BM
UT WOS:000569220400004
PM 32931107
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Naik, B
   Gupta, N
   Ojha, R
   Singh, S
   Prajapati, VK
   Prusty, D
AF Naik, Biswajit
   Gupta, Nidhi
   Ojha, Rupal
   Singh, Satyendra
   Prajapati, Vijay Kumar
   Prusty, Dhaneswar
TI High throughput virtual screening reveals SARS-CoV-2 multi-target
   binding natural compounds to lead instant therapy for COVID-19 treatment
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE COVID-19; Natural compounds; Muti-target; Molecular docking; Molecular
   dynamics
ID MOLECULAR DOCKING; SARS CORONAVIRUS; STRUCTURE VALIDATION; ANTIOXIDANT
   ACTIVITY; POTENT INHIBITORS; CRYSTAL-STRUCTURE; VIRUS ACTIVITY; DRUG
   TARGETS; EBOLA-VIRUS; RNA VIRUS
AB The present-day world is severely suffering from the recently emerged SARS-CoV-2. The lack of prescribed drugs for the deadly virus has stressed the likely need to identify novel inhibitors to alleviate and stop the pandemic. In the present high throughput virtual screening study, we used in silico techniques like receptor-ligand docking, Molecular dynamic (MD), and ADME properties to screen natural compounds. It has been documented that many natural compounds display antiviral activities, including anti-SARS-CoV effect. The present study deals with compounds of Natural Product Activity and Species Source (NPASS) database with known biological activity that probably impedes the activity of six essential enzymes of the virus. Promising drug-like compounds were identified, demonstrating better docking score and binding energy for each druggable targets. After an extensive screening analysis, three novel multi-target natural compounds were predicted to subdue the activity of three/more major drug targets simultaneously. Concerning the utility of natural compounds in the formulation of many therapies, we propose these compounds as excellent lead candidates for the development of therapeutic drugs against SARS-CoV-2. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Naik, Biswajit; Gupta, Nidhi; Ojha, Rupal; Singh, Satyendra; Prajapati, Vijay Kumar; Prusty, Dhaneswar] Cent Univ Rajasthan, Sch Life Sci, Dept Biochem, NH-8, Ajmer 305817, Rajasthan, India.
RP Prusty, D (corresponding author), Cent Univ Rajasthan, Sch Life Sci, Dept Biochem, NH-8, Ajmer 305817, Rajasthan, India.
EM dhaneswarprusty@curaj.ac.in
OI Naik, Biswajit/0000-0003-3732-5063; Prajapati, Vijay/0000-0001-6510-0596
FU UGCUniversity Grants Commission, India
FX DP is thankful to UGC for providing a start-up grant.
CR Adedeji AO, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00235-16
   Adedeji AO, 2012, ANTIMICROB AGENTS CH, V56, P4718, DOI 10.1128/AAC.00957-12
   Adedeji AO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036521
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Ak T, 2008, CHEM-BIOL INTERACT, V174, P27, DOI 10.1016/j.cbi.2008.05.003
   Alame MM, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00450
   Alhammad YMO, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040384
   Anderson AC, 2003, CHEM BIOL, V10, P787, DOI 10.1016/j.chembiol.2003.09.002
   Annan A, 2013, EMERG INFECT DIS, V19, P456, DOI 10.3201/eid1903.121503
   Babu YS, 2000, J MED CHEM, V43, P3482, DOI 10.1021/jm0002679
   Beavers MP, 2008, J CHEM INF MODEL, V48, P1464, DOI 10.1021/ci800085c
   Benkert P, 2009, NUCLEIC ACIDS RES, V37, pW510, DOI 10.1093/nar/gkp322
   Bhardwaj K, 2004, J VIROL, V78, P12218, DOI 10.1128/JVI.78.22.12218-12224.2004
   Bhattacharya A, 2016, NUCLEIC ACIDS RES, V44, pD1005, DOI 10.1093/nar/gkv1220
   Bhattacharya D., 2013, PLOS ONE, V8
   Birnkrant D, 2009, NEW ENGL J MED, V361, P2204, DOI 10.1056/NEJMp0910479
   Bitencourt-Ferreira G, 2019, METHODS MOL BIOL, V2053, P231, DOI 10.1007/978-1-4939-9752-7_15
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Braden CR, 2013, EMERG INFECT DIS, V19, P864, DOI 10.3201/eid1906.130192
   Canduri F, 2005, BIOCHEM BIOPH RES CO, V327, P646, DOI 10.1016/j.bbrc.2004.12.052
   Canduri F, 2008, CURR DRUG TARGETS, V9, P1048, DOI 10.2174/138945008786949423
   Cape W., CLOSE RELATIVE HUMAN, DOI [10.1038/s41564-020-0695-z, DOI 10.1038/S41564-020-0695-Z]
   Cardoso JMS, 2018, COMPUT BIOL CHEM, V77, P291, DOI 10.1016/j.compbiolchem.2018.10.011
   Case JB, 2016, J VIROL, V90, P7248, DOI 10.1128/JVI.00542-16
   Chang CK, 2016, DRUG DISCOV TODAY, V21, P562, DOI 10.1016/j.drudis.2015.11.015
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chen ZM, 2015, APPL BIOCHEM BIOTECH, V176, P2267, DOI 10.1007/s12010-015-1716-x
   Cheng JL, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-18
   Cheng PW, 2006, CLIN EXP PHARMACOL P, V33, P612, DOI 10.1111/j.1440-1681.2006.04415.x
   Cherry James D, 2004, Paediatr Respir Rev, V5, P262, DOI 10.1016/j.prrv.2004.07.009
   Clark DE, 2006, EXPERT OPIN DRUG DIS, V1, P103, DOI 10.1517/17460441.1.2.103
   Coleman CM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003595
   Csermely P, 2005, TRENDS PHARMACOL SCI, V26, P178, DOI 10.1016/j.tips.2005.02.007
   da Silveira NJF, 2005, BMC STRUCT BIOL, V5, DOI 10.1186/1472-6807-5-1
   de Azevedo WF, 2008, CURR DRUG TARGETS, V9, P1071, DOI 10.2174/138945008786949441
   de Azevedo WF, 2002, BIOCHEM BIOPH RES CO, V295, P142, DOI 10.1016/S0006-291X(02)00632-0
   de Paulis T, 2007, CURR OPIN INVEST DR, V8, P78
   Dinesh DC, 2020, CURR DRUG TARGETS, V21, P105, DOI 10.2174/1389450119666190920153247
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Eryanni-Levin S, 2015, BBA-MOL CELL BIOL L, V1851, P1118, DOI 10.1016/j.bbalip.2015.04.008
   Fawcett T, 2006, PATTERN RECOGN LETT, V27, P882, DOI 10.1016/j.patrec.2005.10.012
   Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010
   Food and Drug Administration, 2015, RAPIVABTM PER INJ IN
   Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Ganesan A, 2008, CURR OPIN CHEM BIOL, V12, P306, DOI 10.1016/j.cbpa.2008.03.016
   Ghosh AK, 2005, J MED CHEM, V48, P6767, DOI 10.1021/JM050548m
   Gleason LJ, 2013, CLIN INTERV AGING, V8, P749, DOI 10.2147/CIA.S37738
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Gulcin I, 2020, ARCH TOXICOL, V94, P651, DOI 10.1007/s00204-020-02689-3
   Gulcin I, 2012, ARCH TOXICOL, V86, P345, DOI 10.1007/s00204-011-0774-2
   Gulcin I, 2011, J MED FOOD, V14, P975, DOI 10.1089/jmf.2010.0197
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   He RT, 2004, BIOCHEM BIOPH RES CO, V320, P1199, DOI 10.1016/j.bbrc.2004.06.076
   Heo L, 2018, P NATL ACAD SCI USA, V115, P13276, DOI 10.1073/pnas.1811364115
   Heo L, 2018, PROTEINS, V86, P177, DOI 10.1002/prot.25393
   Holmes EC, 2009, ANNU REV ECOL EVOL S, V40, P353, DOI 10.1146/annurev.ecolsys.110308.120248
   Huang KW, 2016, J MED CHEM, V59, P8019, DOI 10.1021/acs.jmedchem.6b00794
   Ivanov KA, 2004, P NATL ACAD SCI USA, V101, P12694, DOI 10.1073/pnas.0403127101
   Jain RP, 2004, J MED CHEM, V47, P6113, DOI 10.1021/jm0494873
   Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201
   Jones JC, 2016, ANTIMICROB AGENTS CH, V60, P5504, DOI 10.1128/AAC.00888-16
   Kim Y, 2015, J VIROL, V89, P4942, DOI 10.1128/JVI.03688-14
   Kitazato K, 2007, DRUG DISCOV THER, V1, P14
   Kranich R, 2007, J MED CHEM, V50, P1101, DOI 10.1021/jm060536g
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078
   Lau KM, 2008, J ETHNOPHARMACOL, V118, P79, DOI 10.1016/j.jep.2008.03.018
   Li BW, 2014, BIOORGAN MED CHEM, V22, P3146, DOI 10.1016/j.bmc.2014.04.016
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Li Z, 2007, CHEMOTHERAPY, V53, P320, DOI 10.1159/000107690
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Lin XQ, 2020, MOLECULES, V25, DOI 10.3390/molecules25061375
   Liu AL, 2008, BIOORGAN MED CHEM, V16, P7141, DOI 10.1016/j.bmc.2008.06.049
   Liu MM, 2012, EUR J MED CHEM, V52, P33, DOI 10.1016/j.ejmech.2012.03.002
   Lo MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep43395
   Loke WM, 2009, J NUTR, V139, P2309, DOI 10.3945/jn.109.113613
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Lu SH, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-8
   LU YQ, 1995, J VIROL, V69, P3554, DOI 10.1128/JVI.69.6.3554-3559.1995
   Luo SQ, 2019, CURR DRUG TARGETS, V20, P399, DOI 10.2174/1389450119666180830125958
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   Ma L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30153-x
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Marrakchi H, 2000, MICROBIOL-UK, V146, P289, DOI 10.1099/00221287-146-2-289
   Mass T, 2013, CURR BIOL, V23, P1126, DOI 10.1016/j.cub.2013.05.007
   McNitt DH, 2019, CURR MED CHEM, V26, P1933, DOI 10.2174/0929867325666180831165704
   Melo CC, 2019, EUR J MED CHEM, V163, P649, DOI 10.1016/j.ejmech.2018.11.062
   Mercader AG, 2010, EUR J MED CHEM, V45, P1724, DOI 10.1016/j.ejmech.2010.01.005
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Mitsuhashi S, 2008, BIOORGAN MED CHEM, V16, P2645, DOI 10.1016/j.bmc.2007.11.041
   Modi V, 2016, PROTEINS, V84, P260, DOI 10.1002/prot.25048
   Murgueitio Manuela S, 2012, Drug Discov Today Technol, V9, pe219, DOI 10.1016/j.ddtec.2012.07.009
   Nair SB, 2012, COMPUT BIOL MED, V42, P697, DOI 10.1016/j.compbiomed.2012.04.001
   Nirwan S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1712258
   odinger S., 2019, RELEASE
   Owens J, 2003, DRUG DISCOV TODAY, V8, P12, DOI 10.1016/S1359-6446(02)02556-4
   Panda SS, 2020, CURR MED CHEM, V27, P5887, DOI 10.2174/0929867326666190618113613
   Pandey RK, 2015, J BIOMOL STRUCT DYN, V33, P2541, DOI 10.1080/07391102.2015.1085904
   Park H, 2016, PROTEINS, V84, P314, DOI 10.1002/prot.24862
   Patel B., 2019, STRUCTURAL BIOINFORM, VI, P169
   Pereira C.A., 2020, PARASITOLOGY, P1
   Pereira JH, 2003, BIOCHEM BIOPH RES CO, V312, P608, DOI 10.1016/j.bbrc.2003.10.175
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Pillay D, 1998, BMJ-BRIT MED J, V317, P660, DOI 10.1136/bmj.317.7159.660
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952
   Rutenber EE, 1996, STRUCTURE, V4, P1317, DOI 10.1016/S0969-2126(96)00139-6
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Santos F., 2019, J CHEM INF MODEL, DOI DOI 10.1021/ACS
   Sarwar MS, 2018, CURR MED CHEM, V25, P5057, DOI 10.2174/0929867324666170918123413
   Setlur AS, 2017, INTERDISCIP SCI, V9, P254, DOI 10.1007/s12539-016-0149-8
   Sidwell RW, 2002, EXPERT OPIN INV DRUG, V11, P859
   Siegel D, 2017, DISCOVERY SYNTHESIS
   Sun Y, 2014, ANTIVIR RES, V104, P156, DOI 10.1016/j.antiviral.2014.02.002
   Tanner JA, 2005, CHEM BIOL, V12, P303, DOI 10.1016/j.chembiol.2005.01.006
   Tatum NJ, 2017, ORG BIOMOL CHEM, V15, P10245, DOI 10.1039/c7ob00910k
   Te Velthuis A.J., 2010, PLOS PATHOG, V6
   Truchon JF, 2007, J CHEM INF MODEL, V47, P488, DOI 10.1021/ci600426e
   TYRRELL DAJ, 1965, BMJ-BRIT MED J, V1, P1467, DOI 10.1136/bmj.1.5448.1467
   Vabret A, 2009, PATHOL BIOL, V57, P149, DOI 10.1016/j.patbio.2008.02.018
   VANGELDER CWG, 1994, PROTEINS, V18, P174, DOI 10.1002/prot.340180209
   Vyas VK, 2013, J MOL GRAPH MODEL, V42, P17, DOI 10.1016/j.jmgm.2013.01.010
   W.H. Organization, 2019, COUNTR AGR NEXT STEP
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249
   Yang S, 2006, J MED CHEM, V49, P4971, DOI 10.1021/jm0603926
   Yarlagadda S.B., 2019, GOOGLE PATENTS
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zeng X, 2018, NUCLEIC ACIDS RES, V46, pD1217, DOI 10.1093/nar/gkx1026
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang Y, 2009, CURR OPIN STRUC BIOL, V19, P145, DOI 10.1016/j.sbi.2009.02.005
   Zheng XF, 2018, J MED CHEM, V61, P10228, DOI 10.1021/acs.jmedchem.8b01394
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 141
TC 1
Z9 1
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD OCT 1
PY 2020
VL 160
BP 1
EP 17
DI 10.1016/j.ijbiomac.2020.05.184
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA NN4KL
UT WOS:000568758200001
PM 32470577
OA Green Published
DA 2021-01-01
ER

PT J
AU Stessel, B
   Vancuchelen, C
   Bruckers, L
   Geebelen, L
   Callebaut, I
   Vandenbrande, J
   Pallens, B
   Van Tornout, M
   Ory, JP
   van Halem, K
   Messiaen, P
   Herbots, L
   Ramaekers, D
   Dubois, J
AF Stessel, Bjorn
   Vancuchelen, Charlotte
   Bruckers, Liesbeth
   Geebelen, Laurien
   Callebaut, Ina
   Vandenbrande, Jeroen
   Pallens, Ben
   Van Tornout, Michiel
   Ory, Jean-Paul
   van Halem, Karlijn
   Messiaen, Peter
   Herbots, Lieven
   Ramaekers, Dirk
   Dubois, Jasperina
TI Impact of implementation of an individualised thromboprophylaxis
   protocol in critically ill ICU patients with COVID-19: A longitudinal
   controlled before-after study
SO THROMBOSIS RESEARCH
LA English
DT Article
DE COVID-19; Thromboprophylaxis; Venous thromboembolism; Mortality;
   Continuous renal replacement therapy
AB Introduction: An individualised thromboprophylaxis was implemented in critically ill patients suffering from coronavirus disease 2019 (COVID-19) pneumonia to reduce mortality and improve clinical outcome. The aim of this study was to evaluate the effect of this intervention on clinical outcome.
   Methods: In this mono-centric, controlled, before-after study, all consecutive adult patients with confirmed COVID-19 pneumonia admitted to ICU from March 13th to April 20th 2020 were included. A thromboprophylaxis protocol, including augmented LMWH dosing, individually tailored with anti-Xa measurements and twice-weekly ultrasonography screening for DVT, was implemented on March 31th 2020. Primary endpoint is one-month mortality. Secondary outcomes include two-week and three-week mortality, the incidence of VTE, acute kidney injury and continuous renal replacement therapy (CRRT). Multiple regression modelling was used to correct for differences between the two groups.
   Results: 46 patients were included in the before group, 26 patients in the after group. One month mortality decreased from 39.13% to 3.85% (p < 0.001). After correction for confounding variables, one-month mortality was significantly higher in the before group (p = 0.02, OR 8.86 (1.46, 53.75)). The cumulative incidence of VTE and CRRT was respectively 41% and 30.4% in the before group and dropped to 15% (p = 0.03) and 3.8% (p = 0.01), respectively. After correction for confounding variables, risk of VTE (p = 0.03, 6.01 (1.13, 32.12)) and CRRT (p = 0.02, OR 19.21 (1.44, 255.86)) remained significantly higher in the before group.
   Conclusion: Mortality, cumulative risk of VTE and need for CRRT may be significantly reduced in COVID-19 patients by implementation of a more aggressive thromboprophylaxis protocol. Future research should focus on confirmation of these results in a randomized design and on uncovering the mechanisms underlying these observations. .
C1 [Stessel, Bjorn; Vancuchelen, Charlotte; Geebelen, Laurien; Callebaut, Ina; Vandenbrande, Jeroen; Pallens, Ben; Van Tornout, Michiel; Ory, Jean-Paul; Dubois, Jasperina] Jessa Hosp, Dept Intens Care & Anesthesiol, Hasselt, Belgium.
   [Stessel, Bjorn; Callebaut, Ina; Messiaen, Peter] UHasselt, Fac Med & Life Sci, LCRC, B-3590 Diepenbeek, Belgium.
   [Geebelen, Laurien] Hasselt Univ, Data Sci Inst, I BioStat, Martelarenlaan 42, B-3500 Hasselt, Belgium.
   [van Halem, Karlijn; Messiaen, Peter] Jessa Hosp, Dept Infect Dis & Immun, Hasselt, Belgium.
   [Herbots, Lieven] Jessa Hosp, Dept Cardiol, Hasselt, Belgium.
   [Herbots, Lieven] Jessa Hosp, Coronary Care Unit, Hasselt, Belgium.
   [Ramaekers, Dirk] Jessa Hosp, Hasselt, Belgium.
   [Ramaekers, Dirk] Univ Leuven, Leuven Inst Healthcare Policy LIHP, Leuven, Belgium.
RP Stessel, B (corresponding author), Jessa Hosp Hasselt, Dept Intens Care & Anesthesiol, Virga Jesse Campus,Stadsomvaart 11, B-3500 Hasselt, Belgium.
EM bjorn.stessel@jessazh.be
OI Callebaut, Ina/0000-0002-6666-6783
FU foundation Limburg Sterk Merk; province of Limburg; Flemish government;
   Hasselt University; Ziekenhuis Oost-Limburg; Jessa Hospital
FX This study is part of the Limburg Clinical Research Program (LCRP)
   UHasselt-ZOL-Jessa, supported by the foundation Limburg Sterk Merk,
   province of Limburg, Flemish government, Hasselt University, Ziekenhuis
   Oost-Limburg and Jessa Hospital.
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   [Anonymous], 2013, ANTIFACTOR XA ANTIXA, V992
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Cemeroglu AP, 2020, AM J CASE REP, V21, DOI 10.12659/AJCR.925273
   Chan JFW, LANCES, V395, P514
   Chang CH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005822
   Ciavarella A, 2020, THROMB RES, V191, P29, DOI 10.1016/j.thromres.2020.04.023
   Creel-Bulos C, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010459
   Du LY, 2007, BIOCHEM BIOPH RES CO, V359, P174, DOI 10.1016/j.bbrc.2007.05.092
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Hirsh J, 2004, CHEST, V126, p188S, DOI 10.1378/chest.126.3_suppl.188S
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Mousavi S, 2015, ADV PHARMACOL SCI, V2015, DOI 10.1155/2015/507151
   Pellens B.R.M., 2020, JECCM
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Schunemann HJ, 2018, BLOOD ADV, V2, P3198, DOI 10.1182/bloodadvances.2018022954
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   van Halem K, 2020, NETH J MED, V78, P111
   Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153
   West JR, 2015, ANN EMERG MED, V65, P699, DOI 10.1016/j.annemergmed.2014.06.025
   WHO, LAB TEST COR DIS 201, P1
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 36
TC 3
Z9 3
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
EI 1879-2472
J9 THROMB RES
JI Thromb. Res.
PD OCT
PY 2020
VL 194
BP 209
EP 215
DI 10.1016/j.thromres.2020.07.038
PG 7
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NN0PF
UT WOS:000568490100037
PM 32788120
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Poduri, R
   Joshi, G
   Jagadeesh, G
AF Poduri, Ramarao
   Joshi, Gaurav
   Jagadeesh, Gowraganahalli
TI Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring
   promising drugs for the treatment of Covid-19
SO CELLULAR SIGNALLING
LA English
DT Article
DE Covid-19; SARS-CoV-2; ACE2; Ang (1-7); Remdesivir; Immunomodulators
ID RESPIRATORY SYNDROME CORONAVIRUS; ANGIOTENSIN-CONVERTING ENZYME-2; II
   RECEPTOR BLOCKERS; SPIKE PROTEIN; LOPINAVIR-RITONAVIR; SYSTEM
   INHIBITORS; SARS; ACE2; DISEASE; ACTIVATION
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single-stranded RNA virus that causes the potentially lethal Covid-19 respiratory tract infection. It does so by binding to host cell angiotensin converting enzyme 2 (ACE2) receptors, leading to endocytosis with the receptor, and subsequently using the host cell's machinery to replicate copies of itself and invade new cells. The extent of the spread of infection in the body is dependent on the pattern of ACE2 expression and overreaction of the immune system. Additionally, by inducing an imbalance in the renin-angiotensin-aldosterone system (RAAS) and the loss of ACE2 would favour the progression of inflammatory and thrombotic processes in the lungs. No drug or vaccine has yet been approved to treat human coronaviruses. Hundreds of clinical trials on existing approved drugs from different classes acting on a multitude of targets in the virus life cycle are ongoing to examine potential effectiveness for the prevention and treatment of the infection. This review summarizes the SARS-CoV-2 virus life cycle in the host cell and provides a biological and pathological point of view for repurposed and experimental drugs for this novel coronavirus. The viral life cycle provides potential targets for drug therapy.
C1 [Poduri, Ramarao; Joshi, Gaurav] Cent Univ Punjab, Dept Pharmaceut Sci & Nat Prod, Bathinda 151001, India.
   [Jagadeesh, Gowraganahalli] US FDA, Off Cardiol Hematol Endocrinol & Nephrol, CDER, Silver Spring, MD USA.
RP Jagadeesh, G (corresponding author), US FDA, Div Pharmacol & Toxicol, Off Cardiol Hematol Endocrinol & Nephrol, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA.
EM ramaraop@yahoo.com; garvpharma29@gmail.com; Gowra.Jagadeesh@fda.hhs.gov
RI Joshi, Gaurav/ABI-2044-2020; Stefanadis, Christodoulos/ABH-2232-2020
OI Joshi, Gaurav/0000-0002-7812-2871; Stefanadis,
   Christodoulos/0000-0001-5974-6454
CR Alhenc-Gelas F, 2020, KIDNEY INT, V97, P1091, DOI 10.1016/j.kint.2020.04.009
   Alvarez RA, 2020, AM J RESP CRIT CARE, V202, P16, DOI 10.1164/rccm.202005-1906ED
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Andreania J, 2020, LUNG, V21, P22
   Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Arias-Reyes C, 2020, RESP PHYSIOL NEUROBI, V277, DOI 10.1016/j.resp.2020.103443
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Aube J, 2012, ACS MED CHEM LETT, V3, P442, DOI 10.1021/ml300114c
   Baker NC, 2018, DRUG DISCOV TODAY, V23, P661, DOI 10.1016/j.drudis.2018.01.018
   Balakumar P, 2017, PHARMACOL RES, V125, P1, DOI 10.1016/j.phrs.2017.07.003
   Balakumar P, 2016, PHARMACOL RES, V113, P600, DOI 10.1016/j.phrs.2016.09.040
   Balakumar P, 2014, CELL SIGNAL, V26, P2147, DOI 10.1016/j.cellsig.2014.06.011
   Balakumar Pitchai, 2012, Curr Mol Pharmacol, V5, P219
   Baldelli S, 2020, J ANTIMICROB CHEMOTH, V75, P2704, DOI 10.1093/jac/dkaa190
   Bar-On YM, 2020, ELIFE, V9, DOI 10.7554/eLife.57309
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Ben Salah A, 2013, NEW ENGL J MED, V368, P524, DOI 10.1056/NEJMoa1202657
   Bifulco M, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104803
   Bittmann S., 2020, J REGEN BIOL MED, V2, P1, DOI [10.37191/Mapsci-2582-385X-2(2)-022, DOI 10.37191/MAPSCI-2582-385X-2(2)-022]
   Boretti A, 2020, PHARMANUTRITION, V12, DOI 10.1016/j.phanu.2020.100190
   Breckenridge A, 2019, NAT REV DRUG DISCOV, V18, P1, DOI 10.1038/nrd.2018.92
   Brielle ES, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050497
   Brown JD, 2020, LANCET RESP MED, V8, pE28, DOI 10.1016/S2213-2600(20)30158-2
   Brufsky A, 2020, J MED VIROL, V92, P1386, DOI 10.1002/jmv.25902
   Buratta S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072576
   C.N.H. Commission, 2020, CHINESE CLIN GUIDANC
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Carr AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02851-4
   Castiglione V, 2020, EUR HEART J-CARD PHA, V6, P258, DOI 10.1093/ehjcvp/pvaa042
   Cavalla D, 2013, DRUG DISCOV TODAY, V18, P523, DOI 10.1016/j.drudis.2012.12.009
   Chappell MC, 2016, AM J PHYSIOL-HEART C, V310, pH137, DOI 10.1152/ajpheart.00618.2015
   Chen R, 2020, CAN J ANESTH, V67, P655, DOI 10.1007/s12630-020-01630-7
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chong EA, 2020, CLIN CANCER RES, V26, P3514, DOI 10.1158/1078-0432.CCR-20-1427
   Cohen S, 2019, DRUG DES DEV THER, V13, P491, DOI 10.2147/DDDT.S195294
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   D'Alessandro S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8010085
   Dang ZC, 2020, J ETHNOPHARMACOL, V250, DOI 10.1016/j.jep.2019.112470
   Dastan F, 2020, IRAN J PHARM RES, V19, P1, DOI [10.22037/ijpr.2020.113369.14259, 10.22037/IJPR.2020.113369.14259]
   Davis DA, 2012, ANTIMICROB AGENTS CH, V56, P3620, DOI 10.1128/AAC.00055-12
   Deftereos SG, 2020, HELL J CARDIOL, V61, P42, DOI 10.1016/j.hjc.2020.03.002
   Deng X, 2020, ARXIV200300751
   Devaux CA, 2020, J MICROBIOL IMMUNOL, V53, P425, DOI 10.1016/j.jmii.2020.04.015
   Dilucca M., 2020, ANAL CODON USAGE EVO, DOI [10.1101/2020.03.25.006569, DOI 10.1101/2020.03.25.006569]
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Dorlo TPC, 2012, J ANTIMICROB CHEMOTH, V67, P2576, DOI 10.1093/jac/dks275
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Eckerle I, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-359
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Farag A., 2020, IDENTIFICATION FDA A, DOI [10.26434/ chemrxiv.12003930.v1, DOI 10.26434/CHEMRXIV.12003930.V1]
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Ferreira BI, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00625
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Fragoulis GE, 2019, RHEUMATOLOGY, V58, P43, DOI 10.1093/rheumatology/key276
   Furuhashi M, 2015, AM J HYPERTENS, V28, P15, DOI 10.1093/ajh/hpu086
   Galandrin S, 2016, HYPERTENSION, V68, P1365, DOI 10.1161/HYPERTENSIONAHA.116.08118
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gao Y., 2020, STRUCTURE RNA DEPEND, DOI [10.1101/2020.03.16, DOI 10.1101/2020.03.16]
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   Glebov O., 2020, UNDERSTANDING CELL B, DOI [10.31219/osf.io/xhz29., DOI 10.31219/OSF.IO/XHZ29]
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gritti G, 2020, USE SILTUXIMAB PATIE, V04, P1912, DOI [10. 1101/2020.04.01.20048561., DOI 10.1101/2020.04.01.20048561, 10.1101/2020.04.01.20048561]
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Guo T., 2020, JAMA CARDIOL, DOI [10.1001/jamacardio.18 2020.1017., DOI 10.1001/JAMACARDIO.182020.1017]
   Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   He F, 2020, J MED VIROL, V92, P719, DOI [10.1002/jmv.25766, 10.3171/2020.3.JNS193202]
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hilgenfeld R, 2013, ANTIVIR RES, V100, P286, DOI 10.1016/j.antiviral.2013.08.015
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2004, TRENDS MICROBIOL, V12, P466, DOI 10.1016/j.tim.2004.08.008
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hubers A, 2020, J NEUROL NEUROSUR PS, V91, P1124, DOI 10.1136/jnnp-2020-323565
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Hussain M., 2020, STRUCTURAL BASIS SAR, DOI [10.1101/2020.04.21.052639, DOI 10.1101/2020.04.21.052639]
   Ibrahim O.O., 2020, EC PULMONOL RESP MED, V9, P65
   Jia HP, 2009, AM J PHYSIOL-LUNG C, V297, pL84, DOI 10.1152/ajplung.00071.2009
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jockusch S, 2020, BIORXIV, DOI [10.1101/2020.04.03.022939, DOI 10.1101/2020.04.03.022939]
   Joshi G., 2020, VIRTUAL SCREENING EN, DOI [10.26434/chemrxiv.12198966, DOI 10.26434/CHEMRXIV.12198966]
   Kachaev ZM, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20192825
   Kai H, 2020, HYPERTENS RES, V43, P648, DOI 10.1038/s41440-020-0455-8
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Katsiki N, 2020, ARCH MED SCI, V16, P485, DOI 10.5114/aoms.2020.94503
   Keidar S, 2005, CIRC RES, V97, P946, DOI 10.1161/01.RES.0000187500.24964.7A
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Kong R, 2020, COVID 19 DOCKING SER
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lang Y., 2020, CORONAVIRUS HEMAGGLU, DOI [10.1101/2020.04.03.003699, DOI 10.1101/2020.04.03.003699]
   Li GP, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102463
   Li JY, 2020, JAMA CARDIOL, V5, P825, DOI 10.1001/jamacardio.2020.1624
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI 10.1515/cclm-2020-0198
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Liu J, 2010, J INFECT DIS, V202, P1171, DOI 10.1086/656315
   Liu S, 2020, BIOINFORMATICS, V36, P3295, DOI 10.1093/bioinformatics/btaa224
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Lovren F, 2008, AM J PHYSIOL-HEART C, V295, pH1377, DOI 10.1152/ajpheart.00331.2008
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Mahnam K., 2020, INHIBITION VIRAL MAC
   Malik YA, 2020, MALAYS J PATHOL, V42, P3
   Mani D, 2019, J YOUNG PHARM, V11, P117, DOI 10.5530/jyp.2019.11.26
   Matsuyama S., 2020, INHALED CORTICOSTERO, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]
   McGonagle D, 2020, LANCET RHEUMATOL, V2, pE437, DOI 10.1016/S2665-9913(20)30121-1
   Medina D, 2019, AM J HYPERTENS, V32, P1133, DOI 10.1093/ajh/hpz146
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Misra D.P., 2020, CLIN RHEUMATOL, P1, DOI DOI 10.1007/S10067-020-05073-9
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Mu JF, 2020, SCI CHINA LIFE SCI, DOI 10.1007/s11427-020-1692-1
   Nakajima K, 2020, MAYO CLIN PROC, V95, P1297
   Oberfeld B, 2020, CELL, V181, P954, DOI 10.1016/j.cell.2020.04.013
   Ogen Y, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138605
   Osman A.H., 2020, INT J CLIN VIROL, V4, DOI [10.29328/journal.ijcv.1001014, DOI 10.29328/JOURNAL.IJCV.1001014]
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113
   Peiro C, 2020, CIRCULATION, V141, P1665, DOI 10.1161/CIRCULATIONAHA.120.047297
   Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Riva Laura, 2020, bioRxiv, DOI 10.1101/2020.04.16.044016
   Robertson CE, 2020, HEADACHE, V60, P1450, DOI 10.1111/head.13853
   Robson B, 2020, COMPUT BIOL MED, V121, DOI 10.1016/j.compbiomed.2020.103749
   Romano M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051267
   Rossi JJ, 2020, NUCLEIC ACID THER, V30, P129, DOI 10.1089/nat.2020.0868
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Rothlin RP, 2020, DRUG DEVELOP RES, V81, P768, DOI 10.1002/ddr.21679
   Roumier M, 2020, INTERLEUKIN 6 BLOCKA, DOI [10.1101/2020.04.20.20061861, 10.1101/2020.04.20.20061861., DOI 10.1101/2020.04.20.20061861]
   Rouviere CP, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104815
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Shaughnessy AF, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d741
   Sheikh H. Khadim, 2020, REPURPOSED SINGLE IN, DOI [10.26434/chemrxiv.12192660.v1, DOI 10.26434/CHEMRXIV.12192660.V1]
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Shu T., 2020, SARS CORONAVIRUS 2 N
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Siddamreddy S, 2020, CUREUS, V12, DOI 10.7759/cureus.7782
   Santos SHS, 2014, PEPTIDES, V59, P34, DOI 10.1016/j.peptides.2014.07.002
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Talreja H, 2020, NEW ZEAL MED J, V133, P85
   Tan KR, 2011, AM J TROP MED HYG, V84, P517, DOI 10.4269/ajtmh.2011.10-0285
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Teixeira L.B., 2017, SCI REP, V7, P1
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Tersalvi G, 2020, J CARD FAIL, V26, P470, DOI 10.1016/j.cardfail.2020.04.009
   Tikoo K, 2015, BIOCHEM PHARMACOL, V93, P343, DOI 10.1016/j.bcp.2014.11.013
   Uciechowski P, 2020, ONCOLOGY-BASEL, V98, P131, DOI 10.1159/000505099
   Uhlen M, 2020, PROTEIN EXPRES PURIF, DOI [10.1101/2020.03.31.016048., DOI 10.1101/2020.03.31.016048]
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Venkatakrishnan A., 2020, BIORXIV, DOI [10.1101/2020.03.24.005702, DOI 10.1101/2020.03.24.005702]
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Verdecchia P, 2020, J HYPERTENS, V38, P1190, DOI 10.1097/HJH.0000000000002469
   Villapol S, 2015, AM J HYPERTENS, V28, P289, DOI 10.1093/ajh/hpu197
   Virtanen AT, 2019, BIODRUGS, V33, P15, DOI 10.1007/s40259-019-00333-w
   Viswanathan Thiruselvam, 2020, bioRxiv, DOI 10.1101/2020.04.26.061705
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wadman M, 2020, SCIENCE, V368, P356, DOI 10.1126/science.368.6489.356
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang FZ, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.924700
   Wang XW, 2012, EXP BIOL MED, V237, P1394, DOI 10.1258/ebm.2012.012212
   Wang Y., 2020, EARLY LOW DOSE SHORT, DOI [10.1101/2020.03.06.20032342., DOI 10.1101/2020.03.06.20032342, 10.1101/2020.03.06. 20032342.]
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wehkamp J, 2006, FEBS LETT, V580, P5344, DOI 10.1016/j.febslet.2006.08.083
   Willis MD, 2020, J NEUROL, V267, P1567, DOI 10.1007/s00415-020-09822-3
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wysocki J, 2010, HYPERTENSION, V55, P90, DOI 10.1161/HYPERTENSIONAHA.109.138420
   Xie P, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00189
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yan R-H, 2020, BIORXIV, DOI [10.1101/2020.02.19.956946., DOI 10.1101/2020.02.19.956946]
   Yang G, 2020, HYPERTENSION, V76, P51, DOI 10.1161/HYPERTENSIONAHA.120.15143
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zeinalian M, 2020, INFECT CONT HOSP EP, V41, P752, DOI 10.1017/ice.2020.80
   Zeng QH, 2008, P NATL ACAD SCI USA, V105, P9065, DOI 10.1073/pnas.0800502105
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang YH, 2015, J RENIN-ANGIO-ALDO S, V16, P292, DOI 10.1177/1470320314542829
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zheng YF, 2020, J MED VIROL, V92, P1495, DOI 10.1002/jmv.26009
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2020, BIORXIV, DOI [10.1101/2020.02.12.945576, DOI 10.1101/2020.02.12.945576]
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 214
TC 3
Z9 3
U1 24
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD OCT
PY 2020
VL 74
AR 109721
DI 10.1016/j.cellsig.2020.109721
PG 20
WC Cell Biology
SC Cell Biology
GA NL9XK
UT WOS:000567760100002
PM 32711111
OA Green Published
DA 2021-01-01
ER

PT J
AU Li, X
   Li, YL
   Guo, S
   Liu, WJ
AF Li, Xiang
   Li, Yanli
   Guo, Shuai
   Liu, Wenjun
TI Drug evaluation and pharmaceutical care in a critically ill COVID-19
   patient
SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE COVID-19; critically ill; respiratory failure; diabetes mellitus; drug
   evaluation; pharmaceutical care
AB Background: Currently, the novel coronavirus pneumonia is rampaging around the world. 13.2 - 21.3% of patients with COVID-19 infection developed severe or critical illness. Treatment of these critically ill patients is becoming one of the major challenges we are facing. Frequently, more than 10 types of drugs are used simultaneously in the treatment of these critically ill patients, and the combination of many different drugs may easily lead to drug interactions and adverse reactions. Therefore, clinical pharmacist should participate in the optimization of drug treatment programs. Materials and methods: A case of a critically ill COVID-19 patient with respiratory failure and diabetes mellitus is used as an example of an analysis of the treatment plan, utilization of combined medications, and the delivery of pharmaceutical care. Results: There were some drug use unreasonable phenomena, including the extended continuation of aroidol treatment, the use of broad-spectrum antibacterial drugs, the use of drugs with unproven anti-coronavirus effects. Conclusion: Clinical pharmacists should participate in the optimization of drug treatment programs and provide pharmaceutical care for critically ill COVID-19 patients; this can promote the rational use of drugs.
C1 [Li, Xiang] Shandong Univ, Dept Pharm, Shandong Prov Chest Hosp, Jinan, Shandong, Peoples R China.
   [Li, Yanli] Shandong Univ, Dept Nursing, Shandong Prov Chest Hosp, Jinan, Shandong, Peoples R China.
   [Guo, Shuai; Liu, Wenjun] Shandong Univ, Dept Hosp, Shandong Prov Chest Hosp, Jinan 250013, Shandong, Peoples R China.
RP Liu, WJ (corresponding author), Shandong Univ, Dept Hosp, Shandong Prov Chest Hosp, Jinan 250013, Shandong, Peoples R China.
EM 18560069051@163.com
OI Reis, AlessanRSS/0000-0001-8486-7469
FU Shandong Province Special Research Project for Prevention and Control of
   Novel Coronavirus Pneumonia [2020SFXGFY07]; special fund of clinical
   pharmacy application research project of Shandong Medical Association
   [YXH2019ZX026]; Medical and Health Science and Technology Development
   Project of Shandong Province in China [2014WS0112]
FX This work was supported by a grant from the Shandong Province Special
   Research Project for Prevention and Control of Novel Coronavirus
   Pneumonia (No. 2020SFXGFY07) and the special fund of clinical pharmacy
   application research project of Shandong Medical Association
   (YXH2019ZX026) and the Medical and Health Science and Technology
   Development Project of Shandong Province in China (No.2014WS0112).
CR [Anonymous], NTR, P1
   [Anonymous], NTR
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Tamez-Perez HE, 2015, WORLD J DIABETES, V6, P1073, DOI 10.4239/wjd.v6.i8.1073
   He F, 2018, BIOMED PHARMACOTHER, V106, P1404, DOI 10.1016/j.biopha.2018.07.111
   Jia P, 2013, TALANTA, V107, P103, DOI 10.1016/j.talanta.2012.12.031
   Qin YY, 2020, CHINESE MED J-PEKING, V133, P1080, DOI 10.1097/CM9.0000000000000791
   Vanderbeke L, 2018, CURR OPIN INFECT DIS, V31, P471, DOI [10.1097/QCO.0000000000000504, 10.1097/qco.0000000000000504]
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang YT, 2017, BIOMED PHARMACOTHER, V91, P393, DOI 10.1016/j.biopha.2017.04.091
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 15
TC 0
Z9 0
U1 6
U2 6
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0946-1965
J9 INT J CLIN PHARM TH
JI Int. J. Clin. Pharmacol. Ther.
PD OCT
PY 2020
VL 58
IS 10
BP 568
EP 574
DI 10.5414/CP203772
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NM5SQ
UT WOS:000568157100008
PM 32729823
DA 2021-01-01
ER

PT J
AU Gatfield, ER
   Mukesh, MB
   Loo, SW
AF Gatfield, E. R.
   Mukesh, M. B.
   Loo, S. W.
TI Adjuvant Systemic Anti-cancer Therapy in Early Breast Cancer During the
   COVID-19 Pandemic: Differences between Clinicians and Patients in
   Perception of Treatment Risks and Benefits
SO CLINICAL ONCOLOGY
LA English
DT Letter
C1 [Gatfield, E. R.; Mukesh, M. B.; Loo, S. W.] Colchester Hosp, Dept Oncol, Colchester, Essex, England.
RP Gatfield, ER (corresponding author), Colchester Hosp, Dept Oncol, Colchester, Essex, England.
CR Earl HM, 2019, LANCET, V393, P2599, DOI 10.1016/S0140-6736(19)30650-6
   National Institute for Health and Care Excellence, 2020, INT TREATM CHANG OPT
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0936-6555
EI 1433-2981
J9 CLIN ONCOL-UK
JI Clin. Oncol.
PD OCT
PY 2020
VL 32
IS 10
BP E218
EP E218
DI 10.1016/j.clon.2020.06.001
PG 1
WC Oncology
SC Oncology
GA NL7OY
UT WOS:000567601400013
PM 32536560
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Martinez, D
   Sarria, GJ
   Wakefield, D
   Flores, C
   Malhotra, S
   Li, B
   Ehmann, M
   Schwartz, DL
   Sarria, GR
AF Martinez, David
   Sarria, Gustavo J.
   Wakefield, Daniel
   Flores, Claudio
   Malhotra, Sameeksha
   Li, Benjamin
   Ehmann, Michael
   Schwartz, David L.
   Sarria, Gustavo R.
TI COVID's Impact on Radiation Oncology: A Latin American Survey Study
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
AB Purpose: The impact of the COVID-19 pandemic on Latin American radiation therapy services has not yet been widely assessed. In comparison to centers in Europe or the United States, the scarcity of data on these terms might impair design of adequate measures to ameliorate the pandemic's potential damage. The first survey-based analysis revealing regional information is herein presented.
   Methods and Materials: From May 6 to May 30, 2020, the American Society for Radiation Oncology's COVID-19 Survey was distributed across Latin America with support of the local national radiation therapy societies. Twenty-six items, including facility demographic and financial characteristics, personnel and patient features, current and expected impact of the pandemic, and research perspectives, were included in the questionnaire.
   Results: Complete responses were obtained from 115 (50%) of 229 practices across 15 countries. Only 2.6% of centers closed during the pandemic. A median of 4 radiation oncologists (1-27) and 9 (1-100) radiation therapists were reported per center. The median number of new patients treated in 2019 was 600 (24-6200). A median 8% (1%-90%) decrease in patient volume was reported, with a median of 53 patients (1-490) remaining under treatment. Estimated revenue reduction was 20% or more in 53% of cases. Shortage of personal protective equipment was reported in 51.3% of centers, and 27% reported personnel shortage due to COVID-19. Reported delays in treatment for low-risk entities included early stage breast cancer (42.6%), low-risk status prostate cancer (67%), and nonmalignant conditions (42.6%). Treatment of COVID-19 patients at designated treatment times and differentiated bunkers were reported in 22.6% and 10.4% of centers, respectively. Telehealth initiatives have been started in 64.3% of facilities to date for on-treatment (29.6%) and posttreatment (34.8%) patients.
   Conclusions: Regional information regarding COVID-19 pandemic in Latin America may help elucidate suitable intervention strategies for personnel and patients. Follow-up surveys will be performed to provide dynamic monitoring the pandemic's impact on radiation therapy services and adoption of ameliorating measures. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Martinez, David; Sarria, Gustavo J.] Oncosalud AUNA, Dept Radiat Oncol, Lima, Peru.
   [Martinez, David; Wakefield, Daniel; Malhotra, Sameeksha; Li, Benjamin; Sarria, Gustavo R.] Rayos Canc Inc, Nashville, TN 37203 USA.
   [Sarria, Gustavo J.] Inst Nacl Enfermedades Neoplas, Dept Radiotherapy, Lima, Peru.
   [Wakefield, Daniel; Schwartz, David L.] Univ Tennessee, Hlth Sci Ctr, Dept Radiat Oncol, Memphis, TN USA.
   [Wakefield, Daniel] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
   [Flores, Claudio] Oncosalud AUNA, Dept Stat & Translat Invest, Lima, Peru.
   [Malhotra, Sameeksha] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Li, Benjamin] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA.
   [Ehmann, Michael; Sarria, Gustavo R.] Univ Bonn, Univ Hosp Bonn, Dept Radiat Oncol, Bonn, Germany.
RP Sarria, GR (corresponding author), Rayos Canc Inc, Nashville, TN 37203 USA.; Sarria, GR (corresponding author), Univ Bonn, Univ Hosp Bonn, Dept Radiat Oncol, Bonn, Germany.
EM gustavo.sarria-vargas@umm.de
RI Flores, Claudio J./AAZ-5919-2020
OI Flores, Claudio J./0000-0002-3659-4993; Sarria Vargas,
   Gustavo/0000-0002-5929-7270; Reis, AlessanRSS/0000-0001-8486-7469
CR Al-Quteimat OM, 2020, AM J CLIN ONCOL-CANC, V43, P452, DOI 10.1097/COC.0000000000000712
   ASTRO, COVID 19S IMP RAD ON
   Bishr MK, 2018, INT J RADIAT ONCOL, V102, P490, DOI 10.1016/j.ijrobp.2018.06.046
   Burki T, 2020, LANCET INFECT DIS, V20, P547, DOI 10.1016/S1473-3099(20)30303-0
   Combs SE, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01527-1
   Ferrinho P., 2004, HUMAN RESOURCES HLTH, V2, P14, DOI DOI 10.1186/1478-4491-2-14
   Grover S, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00380
   Ho PJ, 2020, CANCER MED-US, V9, P2435, DOI 10.1002/cam4.2830
   Malta M, 2020, ECLINICALMEDICINE, V23
   Mayor S, 2020, LANCET ONCOL, V21, P633, DOI 10.1016/S1470-2045(20)30240-0
   Pinillos L, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.784
   Rivera A, ADV RAD ONCOL, DOI [10.1016/j.adro.2020.03., DOI 10.1016/J.ADRO.2020.03]
   Sierra MS, 2016, CANCER EPIDEMIOL, V44, pS23, DOI 10.1016/j.canep.2016.07.013
   Wei W, 2020, RADIOTHER ONCOL, V148, P203, DOI 10.1016/j.radonc.2020.03.029
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD OCT 1
PY 2020
VL 108
IS 2
BP 374
EP 378
DI 10.1016/j.ijrobp.2020.06.058
PG 5
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA NK7HN
UT WOS:000566904000017
PM 32890516
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Orazem, M
   Oblak, I
   Spanic, T
   Ratosa, I
AF Orazem, Miha
   Oblak, Irena
   Spanic, Tanja
   Ratosa, Ivica
TI Telemedicine in Radiation Oncology Post-COVID-19 Pandemic: There Is No
   Turning Back
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
AB Purpose: We aimed to assess patients' and physicians' perspectives on wider implementation of telemedicine in radiation oncology practice, disrupted by the novel coronavirus disease 2019 (COVID-19).
   Methods: Quantitative questionnaires were prepared and distributed between May 27 and June 11, 2020. A 29-question survey targeting patients with cancer was distributed electronically via cancer support organizations. Cross-sectional data from a selected weekday at a radiation oncology department were also analyzed. In addition, a 25-question survey was distributed to 168 physicians employed by a comprehensive cancer center.
   Results: In total, we have analyzed 468 patients' and 101 physicians' responses. Among responding patients, 310 were undergoing active treatment and 158 were in follow-up care. Both patients and physicians reported no experiences with video consultations during the COVID-19 pandemic, but 15% of patients stated that they missed telemedicine services that would include a video call. Overall, 30.6% of patients expressed interest in more frequent usage of telemedicine and 23.3% would start using it. Sixty-seven percent of radiation oncologists expressed interest in more frequent usage of telemedicine, and 14% would use it similarly as in the past. For patients treated with radiation therapy (RT), 59.9% and 63.4% of the responding patients acknowledged that video consultations would be an important addition to medical care during RT course or after the completion of RT, respectively. Comparably, 61.1% and 63.9% of radiation oncologists believed video consultations would be useful or extremely useful for patients undergoing RT or for patients in the follow-up setting, respectively.
   Conclusions: The post-COVID-19 era represents a unique chance to improve and guarantee continuity of cancer care via telemedicine solutions, when appropriate. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Orazem, Miha; Oblak, Irena; Ratosa, Ivica] Univ Ljubljana, Inst Oncol Ljubljana, Div Radiat Oncol, Ljubljana, Slovenia.
   [Orazem, Miha; Oblak, Irena; Ratosa, Ivica] Univ Ljubljana, Fac Med, Ljubljana, Slovenia.
   [Spanic, Tanja] Europa Donna European Breast Canc Coalit, Milan, Italy.
RP Ratosa, I (corresponding author), Univ Ljubljana, Inst Oncol Ljubljana, Div Radiat Oncol, Ljubljana, Slovenia.; Ratosa, I (corresponding author), Univ Ljubljana, Fac Med, Ljubljana, Slovenia.
EM iratosa@onko-i.si
RI Ratosa, Ivica/ABI-3977-2020
OI Ratosa, Ivica/0000-0002-5551-6616; Reis, AlessanRSS/0000-0001-8486-7469
CR American Society for Radiation Oncology, COVID 19S IMP RAD ON
   Hamilton E, 2019, CLIN TRANSL RAD ONCO, V15, P20, DOI 10.1016/j.ctro.2018.11.005
   Khan R, 2020, RADIOTHER ONCOL, V148, P274, DOI 10.1016/j.radonc.2020.05.034
   Kitamura C, 2010, CURR ONCOL, V17, P105
   Krengli M, ADV RAD ONCOL, DOI [10.1016/j.adro.2020.03, DOI 10.1016/J.ADRO.2020.03]
   Lewis GD, 2020, ADV RADIAT ONCOL, V5, P780, DOI 10.1016/j.adro.2020.04.018
   Orazem M, 2020, CLIN ONCOL-UK, V32, pE175, DOI 10.1016/j.clon.2020.05.006
   Pennic F., UPMC LAUNCHES NEW TE
   Shachar C, 2020, JAMA-J AM MED ASSOC, V323, P2375, DOI 10.1001/jama.2020.7943
   Zaorsky NG, 2020, ADV RADIAT ONCOL, V5, P659, DOI 10.1016/j.adro.2020.03.010
NR 10
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0360-3016
EI 1879-355X
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD OCT 1
PY 2020
VL 108
IS 2
BP 411
EP 415
DI 10.1016/j.ijrobp.2020.06.052
PG 5
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA NK7HN
UT WOS:000566904000025
PM 32890523
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bataille, P
   Amiot, A
   Claudepierre, P
   Paris, N
   Neuraz, A
   Lerner, I
   Garcelon, N
   Rance, B
   Grisel, O
   Moreau, T
   Bernaux, M
   Audureau, E
   Sbidian, E
AF Bataille, Pauline
   Amiot, Aurelien
   Claudepierre, Pascal
   Paris, Nicolas
   Neuraz, Antoine
   Lerner, Ivan
   Garcelon, Nicolas
   Rance, Bastien
   Grisel, Olivier
   Moreau, Thomas
   Bernaux, Melodie
   Audureau, Etienne
   Sbidian, Emilie
CA AP-HP Universities Inserm COVID-19
   Entrepot Donnees Sante AP-HP Conso
TI Letter: severe COVID-19 infection and biologic therapies-a cohort study
   of 7 808 patients in France
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Letter
C1 [Bataille, Pauline; Claudepierre, Pascal; Sbidian, Emilie] Univ Paris Est Creteil, EA 7379 EpiDermE, Creteil, France.
   [Amiot, Aurelien] Hop Henri Mondor, AP HP, Dept Gastroenterol, Creteil, France.
   [Claudepierre, Pascal] Hop Henri Mondor, AP HP, Dept Rheumatol, Creteil, France.
   [Paris, Nicolas] Greater Paris Univ Hosp, AP HP, WIND Dept, Paris, France.
   [Neuraz, Antoine; Lerner, Ivan; Garcelon, Nicolas; Rance, Bastien] Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, INSERM,UMRS 1138, Paris, France.
   [Neuraz, Antoine; Lerner, Ivan] Hop Necker Enfants Malad, AP HP, Dept Informat Med, Paris, France.
   [Garcelon, Nicolas] Univ Paris, Univ Paris Descartes, Inst Imagine, Paris, France.
   [Rance, Bastien] Hop Europeen Georges Pompidou, AP HP, Dept Informat Med, Paris, France.
   [Grisel, Olivier; Moreau, Thomas] Univ Paris Saclay, CEA, INRIA, St Aubin, France.
   [Bernaux, Melodie] AP HP, Direct Strategie & Transformat, Paris, France.
   [Audureau, Etienne] Univ Paris Est Creteil UPEC, Inst Mondor Rech Biomed IMRB, Equipe CEpiA Clin Epidemiol & Ageing, INSERM,U955, Creteil, France.
   [Sbidian, Emilie] Hop Henri Mondor, AP HP, Dept Dermatol, Creteil, France.
   [Sbidian, Emilie] INSERM, Ctr Invest Clin 1430, Creteil, France.
RP Sbidian, E (corresponding author), Univ Paris Est Creteil, EA 7379 EpiDermE, Creteil, France.; Sbidian, E (corresponding author), Hop Henri Mondor, AP HP, Dept Dermatol, Creteil, France.; Sbidian, E (corresponding author), INSERM, Ctr Invest Clin 1430, Creteil, France.
EM emilie.sbidian@aphp.fr
RI Neuraz, Antoine/ABI-6442-2020; Sbidian, Emilie/ABH-5714-2020
OI Neuraz, Antoine/0000-0001-7142-6728; Garcelon,
   Nicolas/0000-0002-3326-2811
FU Commission Nationale de l'Informatique et des Libertes [MR004]
FX The authors declare no funding sources. The authors thank all
   contributing APHP institutions and all patients for their efforts in
   collecting these data. The study was authorised by the EDS ethical and
   scientific committee (cse190005, cse200011). It was supported by the
   Commission Nationale de l'Informatique et des Libertes, MR004 reference
   methodology.
CR Brat GA, 2020, INFECT DIS, DOI [10.1101/2020.04.13.20059691, DOI 10.1101/2020.04.13.20059691]
   Cheng MP, 2020, ANN INTERN MED, V172, P726, DOI 10.7326/M20-1301
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Kirchgesner J, 2018, GASTROENTEROLOGY, V155, P337, DOI 10.1053/j.gastro.2018.04.012
   Li XT, 2020, ANN RHEUM DIS, V79, P285, DOI 10.1136/annrheumdis-2019-216102
   Taxonera C, 2020, ALIMENT PHARM THER, V52, P276, DOI 10.1111/apt.15804
NR 7
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD OCT
PY 2020
VL 52
IS 7
BP 1245
EP 1248
DI 10.1111/apt.16040
PG 4
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA NL0SK
UT WOS:000567135700027
PM 33016546
DA 2021-01-01
ER

PT J
AU Taxonera, C
   Alba, C
AF Taxonera, Carlos
   Alba, Cristina
TI Letter: severe COVID-19 infection and biologic therapies-a cohort study
   of 7808 patients in France. Authors' reply
SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS
LA English
DT Letter
C1 [Taxonera, Carlos] Hosp Clin San Carlos, Dept Gastroenterol, Inflammatory Bowel Dis Unit, Madrid, Spain.
   Inst Invest Hosp Clin San Carlos IdISSC, Madrid, Spain.
RP Taxonera, C (corresponding author), Hosp Clin San Carlos, Dept Gastroenterol, Inflammatory Bowel Dis Unit, Madrid, Spain.
EM carlos.taxonera@salud.madrid.org
CR Bataille P, 2020, ALIMENT PHARM THER, V52, P1245, DOI 10.1111/apt.16040
   Brenner EJ, IBD DATABASE PUBLIC
   Brenner RJ, 2020, GASTROENTEROLOGY, DOI 10.1053/j.gastro.2020.05.032
   Ford AC, 2013, AM J GASTROENTEROL, V108, P1268, DOI 10.1038/ajg.2013.138
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Stallmach A, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03158-0
   Taxonera C, 2020, ALIMENT PHARM THER, V52, P276, DOI 10.1111/apt.15804
NR 8
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-2813
EI 1365-2036
J9 ALIMENT PHARM THER
JI Aliment. Pharmacol. Ther.
PD OCT
PY 2020
VL 52
IS 7
BP 1249
EP 1250
DI 10.1111/apt.16055
PG 2
WC Gastroenterology & Hepatology; Pharmacology & Pharmacy
SC Gastroenterology & Hepatology; Pharmacology & Pharmacy
GA NL0SK
UT WOS:000567135700028
PM 33016549
DA 2021-01-01
ER

PT J
AU Ognibene, A
   Lorubbio, M
   Magliocca, P
   Tripodo, E
   Vaggelli, G
   Iannelli, G
   Feri, M
   Scala, R
   Tartaglia, AP
   Galano, A
   Pancrazzi, A
   Tacconi, D
AF Ognibene, Agostino
   Lorubbio, Maria
   Magliocca, Pasqualino
   Tripodo, Emanuela
   Vaggelli, Guendalina
   Iannelli, Giovanni
   Feri, Marco
   Scala, Raffaele
   Tartaglia, Alessandro Polcini
   Galano, Angelo
   Pancrazzi, Alessandro
   Tacconi, Danilo
TI Elevated monocyte distribution width in COVID-19 patients: The
   contribution of the novel sepsis indicator
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Monocyte distribution width; COVID-19; SARS-CoV-2
ID CYTOKINE STORM
AB Introduction: Interesting results regarding the contribution of MDW (Monocyte Distribution Width) in the Infectious Disease Unit have been reported. An observational study is ongoing at San Donato Hospital with the aim to evaluate the contribution of MDW in the diagnostic pathway in adult patients entering in the ED setting and tested for SARS-CoV-2.
   Material and method: COVID-19 symptomatic and paucisymptomatic patients presenting to ED (Emergency Department), have been enrolled consecutively. Whole blood venous samples have been collected on K2 EDTA for MDW determination, at the same time a nasopharyngeal swab for SARS-CoV-2 RNA detection have been collected.
   Results: One hundred six patients were negative for SARS-CoV-2 with MDW mean value of 20.3 +/- 3.3, while forty-one were positive for SARS-CoV-2 with higher MDW mean value of 27.3 +/- 4.9 (P < 0.005). The ROC curve analysis has been evaluated showing MDW AUC of 0.91. Finally twenty-three patients hospitalized in high-intensity care unit showed an MDW value higher than the eighteen patients presenting few symptoms [28.8 +/- 5.3 vs 25.4 +/- 3.6 respectively, P < 0.05].
   Discussion: Monocytic population, in Covid19 disease, are the first elements of innate immunity to be involved, these changes are the basis of the modification of the MDW, with evident efficacy in term of sensitivity, particularly in the studied Covid19 patients. Moreover the patients hospitalized in high-intensity care unit showed significantly elevated MDW respects to middle or low symptomatic one, suggest including this parameter as prognostic marker or of therapy efficacy, integrated with other laboratory findings.
C1 [Ognibene, Agostino; Lorubbio, Maria; Magliocca, Pasqualino; Tripodo, Emanuela; Vaggelli, Guendalina; Tartaglia, Alessandro Polcini; Galano, Angelo; Pancrazzi, Alessandro] Azienda USL Toscana Sudest, Lab Med Dept, Osped San Donato, Via Pietro Nenni 20, I-52100 Arezzo, Italy.
   [Iannelli, Giovanni; Feri, Marco] Azienda USL Toscana Sudest, Emergency Dept, Osped San Donato, Arezzo, Italy.
   [Scala, Raffaele] Azienda USL Toscana Sudest, Internal Med Dept, Pneumol Dis Sect, Osped San Donato, Arezzo, Italy.
   [Tacconi, Danilo] Azienda USL Toscana Sudest, Infect Dis Sect, Internal Med Dept, Osped San Donato, Arezzo, Italy.
RP Ognibene, A (corresponding author), Azienda USL Toscana Sudest, Lab Med Dept, Osped San Donato, Via Pietro Nenni 20, I-52100 Arezzo, Italy.
EM agostino.ognibene@uslsudest.toscana.it
CR Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   Crouser ED, 2019, CRIT CARE MED, V47, P1018, DOI 10.1097/CCM.0000000000003799
   Crouser ED, 2017, CHEST, V152, P518, DOI 10.1016/j.chest.2017.05.039
   Devi Ramnath Raina, 2006, J ORGAN DYSFUNCT, P80
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527
   Polilli E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227300
   QIN CX, 2020, CLIN INFECT DIS, V12, DOI DOI 10.3390/SYM12020248
   van Kasterena Puck B., 2020, J CLIN VIROL, V128
   Yoshikawa T, 2009, J VIROL, V83, P3039, DOI 10.1128/JVI.01792-08
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
NR 12
TC 4
Z9 4
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD OCT
PY 2020
VL 509
BP 22
EP 24
DI 10.1016/j.cca.2020.06.002
PG 3
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA NK4YF
UT WOS:000566737800004
PM 32504637
DA 2021-01-01
ER

PT J
AU Poggiali, E
   Zaino, D
   Immovilli, P
   Rovero, L
   Losi, G
   Dacrema, A
   Nuccetelli, M
   Vadacca, GB
   Guidetti, D
   Vercelli, A
   Magnacavallo, A
   Bernardini, S
   Terracciano, C
AF Poggiali, Erika
   Zaino, Domenica
   Immovilli, Paolo
   Rovero, Luca
   Losi, Giulia
   Dacrema, Alessandro
   Nuccetelli, Marzia
   Vadacca, Giovanni Battista
   Guidetti, Donata
   Vercelli, Andrea
   Magnacavallo, Andrea
   Bernardini, Sergio
   Terracciano, Chiara
TI Lactate dehydrogenase and C-reactive protein as predictors of
   respiratory failure in CoVID-19 patients
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE CoVID-19; LDH; CRP; Italian epidemic; CoVID-19 pneumonia; Acute
   respiratory failure
ID LUNG
AB Objective: The dramatic worldwide CoVID-19 infection requires the identification of a reliable and inexpensive tool to quickly discriminate patients with a more unfavorable outcome.
   Methods: We performed routine laboratory tests suitable to identify tissue damage and inflammatory status in 123 consecutive CoVID-19 patients admitted to the Emergency Department of the hospital of Piacenza (EmiliaRomagna, Northern Italy). The results were correlated with patients' respiratory function evaluated by the partial pressure of arterial oxygen to fraction of inspired oxygen ratio (PaO2/FiO2).
   Results: The most common laboratory abnormalities were lyrnphocytopenia and elevated values of C-reactive protein (CRP) and lactate dehydrogenase (LDH). Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and creatine kinase (CK) were also increased. The respiratory performance (PaO2/FiO2) showed a strong inverse correlation with LDH (r = 0.62, r(2) 0.38, p value < 0.0001) and CRP (r = 0.55, r(2) 0.31, p value < 0.0001). PaO2/FiO2 values also showed a significant inverse correlation with age (r = -0.37, p < 0.0001), AST (r = -0.31, p < 0.01), WBC (r = -0.49, p < 0.0001), neutrophils count (r = -0.5, p < 0.001). ROC curves showed a sensitivity of 75% and specificity of 70% for the LDH cut-off value of 450 U/L and a sensitivity of 72% and specificity of 71% for the CRP cut-off value of 11 mg/dl in identifying CoVID-19 with moderate-severe ARDS.
   Conclusions: LDH and CRP may be related to respiratory function (PaO2/FiO2) and be a predictor of respiratory failure in CoVID-19 patients. LDH and CRP should be considered a useful test for the early identification of patients who require closer respiratory monitoring and more aggressive supportive therapies to avoid poor prognosis.
C1 [Poggiali, Erika; Rovero, Luca; Losi, Giulia; Dacrema, Alessandro; Vercelli, Andrea; Magnacavallo, Andrea] Guglielmo da Saliceto Hosp, Emergency Dept, Piacenza, Italy.
   [Zaino, Domenica; Immovilli, Paolo; Guidetti, Donata; Terracciano, Chiara] Guglielmo da Saliceto Hosp, Neurol Unit, Via Taverna 49, Piacenza, Italy.
   [Nuccetelli, Marzia; Bernardini, Sergio] Tor Vergata Univ Hosp, Dept Expt Med & Surg, Lab Med, Rome, Italy.
   [Vadacca, Giovanni Battista] Guglielmo da Saliceto Hosp, Clin Pathol Dept, Biochem Unit, Piacenza, Italy.
RP Terracciano, C (corresponding author), Guglielmo da Saliceto Hosp, Neurol Unit, Via Taverna 49, Piacenza, Italy.
EM c.terracciano@ausl.pc.it
RI terracciano, chiara/C-2955-2018; TERRACCIANO, CHIARA/ABA-5492-2020
OI terracciano, chiara/0000-0002-1853-5578; TERRACCIANO,
   CHIARA/0000-0002-1853-5578; immovilli, paolo/0000-0001-9417-3903
CR [Anonymous], 2020, WORDOMETERS
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Colombi D, 2020, RADIOLOGY, V296, pE86, DOI 10.1148/radiol.2020201433
   Harenberg J, 2020, CLIN CHEM LAB MED, V58, P1029, DOI 10.1515/cclm-2020-0502
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369
   Huang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30252-X
   Lapic I, 2020, CLIN CHEM LAB MED, V58, P1146, DOI 10.1515/cclm-2020-0620
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI 10.1515/cclm-2020-0198
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   MCFADDEN RG, 1991, CHEST, V100, P1182, DOI 10.1378/chest.100.4.1182-b
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Poggiali Erika, 2020, Eur J Case Rep Intern Med, V7, P001632, DOI 10.12890/2020_001632
   Poggiali E, 2020, RADIOLOGY, V295, pE6, DOI 10.1148/radiol.2020200847
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Sepulveda J, 2013, ACCURATE RESULTS IN THE CLINICAL LABORATORY: A GUIDE TO ERROR DETECTION AND CORRECTION, P131, DOI 10.1016/B978-0-12-415783-5.00009-8
   Tan CC, 2020, J MED VIROL, V92, P856, DOI 10.1002/jmv.25871
   WHO, 2020, NOV COR 2019 NCOV TE
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 21
TC 7
Z9 7
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD OCT
PY 2020
VL 509
BP 135
EP 138
DI 10.1016/j.cca.2020.06.012
PG 4
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA NK4YF
UT WOS:000566737800021
PM 32531257
OA Green Published
DA 2021-01-01
ER

PT J
AU Cerofolini, L
   Fragai, M
   Luchinat, C
   Ravera, E
AF Cerofolini, Linda
   Fragai, Marco
   Luchinat, Claudio
   Ravera, Enrico
TI Orientation of immobilized antigens on common surfaces by a simple
   computational model: Exposition of SARS-CoV-2 Spike protein RBD epitopes
SO BIOPHYSICAL CHEMISTRY
LA English
DT Article
DE Immunosensing; Bioconjugation; United residue model; Protein-surface
   interaction
ID SOLID-STATE NMR; MOLECULAR ALIGNMENT; SIMULATION; PREDICTION;
   NANOPARTICLES; ADSORPTION; RATIONALIZATION; CONFORMATION; ANTIBODIES;
   MONOLAYERS
AB The possibility of immobilizing a protein with antigenic properties on a solid support offers significant possibilities in the development of immunosensors and vaccine formulations. For both applications, the orientation of the antigen should ensure ready accessibility of the antibodies to the epitope. However, an experimental assessment of the orientational preferences necessarily proceeds through the preparation/isolation of the antigen, the immobilization on different surfaces and one or more biophysical characterization steps. To predict a priori whether favorable orientations can be achieved or not would allow one to select the most promising experimental routes, partly mitigating the time cost towards the final product. In this manuscript, we apply a simple computational model, based on united-residue modelling, to the prediction of the orientation of the receptor binding domain of the SARS-CoV-2 spike protein on surfaces commonly used in lateral-flow devices. These calculations can account for the experimental observation that direct immobilization on gold gives sufficient exposure of the epitope to obtain a response in immunochemical assays.
C1 [Cerofolini, Linda; Fragai, Marco; Luchinat, Claudio; Ravera, Enrico] Magnet Resonance Ctr CERM, Via L Sacconi 6, I-50019 Sesto Fiorentino, Italy.
   [Cerofolini, Linda; Fragai, Marco; Luchinat, Claudio; Ravera, Enrico] Interuniv Consortium Magnet Resonance Met Prot CI, Via L Sacconi 6, I-50019 Sesto Fiorentino, Italy.
   [Fragai, Marco; Luchinat, Claudio; Ravera, Enrico] Univ Florence, Dept Chem Ugo Schiff, Via Lastruccia 3, I-50019 Sesto Fiorentino, Italy.
RP Ravera, E (corresponding author), Magnet Resonance Ctr CERM, Via L Sacconi 6, I-50019 Sesto Fiorentino, Italy.; Ravera, E (corresponding author), Interuniv Consortium Magnet Resonance Met Prot CI, Via L Sacconi 6, I-50019 Sesto Fiorentino, Italy.
EM ravera@cerm.unifi.it
FU Fondazione Cassa di Risparmio di FirenzeFondazione Cassa Risparmio
   Firenze; Italian Ministero della SaluteMinistry of Health, Italy
   [GR-2016-02361586]; Italian Ministero dell'Istruzione, dell'Universita e
   della Ricerca through the "Progetto Dipartimenti di Eccellenza
   2018-2022"; University of Florence through the "Progetti Competitivi per
   Ricercatori"
FX Discussion with Luca Sgheri (National Research Council of Italy) and
   Cesare Bracco (Department of Mathematics and Informatics "Ulisse Dini",
   University of Florence) is acknowledged. This work has been supported by
   the Fondazione Cassa di Risparmio di Firenze, the Italian Ministero
   della Salute through the grant GR-2016-02361586, the Italian Ministero
   dell'Istruzione, dell'Universita e della Ricerca through the "Progetto
   Dipartimenti di Eccellenza 2018-2022" to the Department of Chemistry
   "Ugo Schiff" of the University of Florence, and the University of
   Florence through the "Progetti Competitivi per Ricercatori". The authors
   acknowledge the support and the use of resources of Instruct-ERIC, a
   landmark ESFRI project, and specifically the CERM/CIRMMP Italy center.
   This work is part of the COVID19-NMR project (https://covid19-nmr.de/).
CR Adiram-Filiba N, 2017, BIOINTERPHASES, V12, DOI 10.1116/1.4983273
   ALDURI B, 1995, J AM OIL CHEM SOC, V72, P1351, DOI 10.1007/BF02546211
   [Anonymous], EU EA MEASURES MITIG, P24
   Aouidate A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779130
   Atkins P., 2018, ATKINS PHYS CHEM
   Aubin-Tam ME, 2013, METHODS MOL BIOL, V1025, P19, DOI 10.1007/978-1-62703-462-3_3
   Bak M, 1997, J MAGN RESON, V125, P132, DOI 10.1006/jmre.1996.1087
   Bak M, 2000, J MAGN RESON, V147, P296, DOI 10.1006/jmre.2000.2179
   Bereau T, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3152842
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bolivar JM, 2020, BBA-PROTEINS PROTEOM, V1868, DOI 10.1016/j.bbapap.2019.140333
   Bolivar JM, 2016, CATAL TODAY, V259, P66, DOI 10.1016/j.cattod.2015.05.004
   Brancolini G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163866
   Carletti T., 2020, ARXIV200511085PHYSQB
   Cerofolini L, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0115-7
   COLLARD DM, 1991, LANGMUIR, V7, P1192, DOI 10.1021/la00054a029
   Cutiño-Avila Bessy, 2014, Rev. colomb. biotecnol, V16, P19, DOI 10.15446/rev.colomb.biote.v16n1.44184
   de Vries SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017695
   del Monte-Martinez A, 2018, METHODS MOL BIOL, V1835, P243, DOI 10.1007/978-1-4939-8672-9_14
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Edridge A.W., 2020, 20086439 MEDRXIV, DOI DOI 10.1101/2020.05.11.200864392020.05.11.20086439
   Eliaz Y., 2020, 20079343 MEDRXIV, DOI [10.1101/2020.04.25.20079343, DOI 10.1101/2020.04.25.20079343, 10.1101/2020.04.25.20079343 2020.04.25.20079343.]
   Fanelli D, 2020, CHAOS SOLITON FRACT, V134, DOI 10.1016/j.chaos.2020.109761
   Giuntini S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18109-z
   Gronbeck H, 2000, J AM CHEM SOC, V122, P3839, DOI 10.1021/ja993622x
   Hakkinen H, 2012, NAT CHEM, V4, P443, DOI [10.1038/NCHEM.1352, 10.1038/nchem.1352]
   Harris LJ, 1998, J MOL BIOL, V275, P861, DOI 10.1006/jmbi.1997.1508
   Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+
   Huang R, 2014, BIOPHYS J, V106, P2126, DOI 10.1016/j.bpj.2014.03.051
   Kellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439
   Kim YC, 2008, J MOL BIOL, V375, P1416, DOI 10.1016/j.jmb.2007.11.063
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Kumal RR, 2015, J PHYS CHEM C, V119, P16200, DOI 10.1021/acs.jpcc.5b00568
   Lavezzo E., 2020, SUPPRESSION COVID 19, DOI [10.1101/2020.04.17.20053157 2020.04.17., DOI 10.1101/2020.04.17.200531572020.04.17]
   Li H, 2005, PROTEINS, V61, P704, DOI 10.1002/prot.20660
   Li W, 2020, BIOPHYS CHEM, V264, DOI 10.1016/j.bpc.2020.106420
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Liao CY, 2014, RSC ADV, V4, P15759, DOI 10.1039/c3ra47381c
   Liu J, 2015, CHEM ENG SCI, V121, P331, DOI 10.1016/j.ces.2014.07.021
   Liu J, 2013, LANGMUIR, V29, P11366, DOI 10.1021/la401171v
   Lopez-Gallego F, 2013, METHODS MOL BIOL, V1051, P59, DOI 10.1007/978-1-62703-550-7_5
   Louka A, 2018, PHYS CHEM CHEM PHYS, V20, P12719, DOI 10.1039/c8cp00419f
   Macchiagodena M., 2020, ARXIV200209937QBIO
   Macchiagodena M, 2020, CHEM PHYS LETT, V750, DOI 10.1016/j.cplett.2020.137489
   Martos-Maldonado MC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05695-3
   Matlahov I, 2014, PHYS CHEM CHEM PHYS, V16, P9031, DOI 10.1039/c3cp55520h
   Miyazawa S, 1996, J MOL BIOL, V256, P623, DOI 10.1006/jmbi.1996.0114
   Mroue KH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11991
   Oliver C, 2010, METHODS MOL BIOL, V588, P375, DOI 10.1007/978-1-59745-324-0_40
   Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097
   Procacci P, 2020, CHEM COMMUN, V56, P8854, DOI 10.1039/d0cc03558k
   Rao P, 2020, BIOPHYS CHEM, V264, DOI 10.1016/j.bpc.2020.106425
   Ravera E, 2016, SCI REP-UK, V6, DOI 10.1038/srep27851
   Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692
   Scapin G, 2015, NAT STRUCT MOL BIOL, V22, P953, DOI 10.1038/nsmb.3129
   Selo I, 1996, J IMMUNOL METHODS, V199, P127, DOI 10.1016/S0022-1759(96)00173-1
   Shajahan Asif, 2020, Glycobiology, V30, P981, DOI 10.1093/glycob/cwaa042
   Sondergaard CR, 2011, J CHEM THEORY COMPUT, V7, P2284, DOI 10.1021/ct200133y
   Tian DL, 2017, J PHYS CHEM B, V121, P6108, DOI 10.1021/acs.jpcb.7b02838
   Tosner Z, 2014, J MAGN RESON, V246, P79, DOI 10.1016/j.jmr.2014.07.002
   Tsao HK, 1998, J COLLOID INTERF SCI, V202, P527, DOI 10.1006/jcis.1998.5471
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   Varghese S, 2016, J PHYS CHEM C, V120, P28717, DOI 10.1021/acs.jpcc.6b11575
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   WHO, 2020, STAT REG CLUST PNEUM
   Winter AK, 2020, LANCET INFECT DIS, V20, P758, DOI 10.1016/S1473-3099(20)30322-4
   Xie Y, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3305244
   Xue Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4766
   Yu GB, 2016, PHYS CHEM CHEM PHYS, V18, P23500, DOI 10.1039/c6cp01478j
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhao DH, 2015, PHYS CHEM CHEM PHYS, V17, P840, DOI 10.1039/c4cp04696j
   Zhou J, 2004, J PHYS CHEM B, V108, P17418, DOI 10.1021/jp038048x
   Zhou J, 2003, LANGMUIR, V19, P3472, DOI 10.1021/la026871z
   Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908
   Zweckstetter M, 2004, BIOPHYS J, V86, P3444, DOI 10.1529/biophysj.103.035790
   Zweckstetter M, 2008, NAT PROTOC, V3, P679, DOI 10.1038/nprot.2008.36
NR 76
TC 1
Z9 1
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0301-4622
EI 1873-4200
J9 BIOPHYS CHEM
JI Biophys. Chem.
PD OCT
PY 2020
VL 265
AR 106441
DI 10.1016/j.bpc.2020.106441
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA NK1AQ
UT WOS:000566472600008
PM 32745829
OA Green Published
DA 2021-01-01
ER

PT J
AU Giavoli, C
   Profka, E
   Giancola, N
   Rodari, G
   Giacchetti, F
   Ferrante, E
   Arosio, M
   Mantovani, G
AF Giavoli, Claudia
   Profka, Eriselda
   Giancola, Noemi
   Rodari, Giulia
   Giacchetti, Federico
   Ferrante, Emanuele
   Arosio, Maura
   Mantovani, Giovanna
TI Growth hormone therapy at the time of Covid-19 pandemic: adherence and
   drug supply issues
SO EUROPEAN JOURNAL OF ENDOCRINOLOGY
LA English
DT Letter
ID ENDOCRINOLOGY; CHILDREN
C1 [Giavoli, Claudia; Rodari, Giulia; Ferrante, Emanuele; Arosio, Maura; Mantovani, Giovanna] Osped Maggiore Policlin, Endocrinol Unit, Fdn IRCCS Ca Granda, Milan, Italy.
   [Giavoli, Claudia; Profka, Eriselda; Giancola, Noemi; Rodari, Giulia; Giacchetti, Federico; Arosio, Maura; Mantovani, Giovanna] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
RP Giavoli, C (corresponding author), Osped Maggiore Policlin, Endocrinol Unit, Fdn IRCCS Ca Granda, Milan, Italy.; Giavoli, C (corresponding author), Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
EM claudia.giavoli@unimi.it
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Arlt W, 2020, EUR J ENDOCRINOL, V183, pE1, DOI 10.1530/EJE-20-0386
   Bagnasco F, 2017, ENDOCR PRACT, V23, P929, DOI 10.4158/EP171786.OR
   Cutfield WS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016223
   Fleseriu M, 2020, EUR J ENDOCRINOL, V183, pG17, DOI 10.1530/EJE-20-0473
   Giavoli C, 2004, J CLIN ENDOCR METAB, V89, P5397, DOI 10.1210/jc.2004-1114
   Giavoli C, 2017, BEST PRACT RES CL EN, V31, P71, DOI 10.1016/j.beem.2017.02.003
   HAYNES RB, 1976, LANCET, V1, P1265
   Kreitschmann-Andermahr I, 2020, PITUITARY, V23, P479, DOI 10.1007/s11102-020-01046-y
   Mohseni S, 2018, J PEDIATR ENDOCR MET, V31, P13, DOI 10.1515/jpem-2017-0157
   Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x
   Yuen KCJ, 2019, EXPERT REV ENDOCRINO, DOI 10.1080/17446651.2019.1689119
NR 11
TC 0
Z9 0
U1 3
U2 3
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0804-4643
EI 1479-683X
J9 EUR J ENDOCRINOL
JI Eur. J. Endocrinol.
PD OCT
PY 2020
VL 183
IS 4
BP L13
EP L15
DI 10.1530/EJE-20-0481
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NI7QK
UT WOS:000565543400006
PM 32688337
OA Bronze
DA 2021-01-01
ER

PT J
AU Antunes, AEC
   Vinderola, G
   Xavier-Santos, D
   Sivieri, K
AF Antunes, Adriane E. C.
   Vinderola, Gabriel
   Xavier-Santos, Douglas
   Sivieri, Katia
TI Potential contribution of beneficial microbes to face the COVID-19
   pandemic
SO FOOD RESEARCH INTERNATIONAL
LA English
DT Article
DE SARS-CoV-2; Coronavirus disease; Microbiota; Fermented foods;
   Probiotics; Prebiotics
ID INTERNATIONAL SCIENTIFIC ASSOCIATION; FUNCTIONAL-CHARACTERIZATION;
   CONSENSUS STATEMENT; GUT MICROBIOTA; PROBIOTICS; INFECTIONS;
   SUPPLEMENTATION; PREBIOTICS; CHILDREN; INFANTS
AB The year 2020 will be remembered by a never before seen, at least by our generation, global pandemic of COVID19. While a desperate search for effective vaccines or drug therapies is on the run, nutritional strategies to promote immunity against SARS-CoV-2, are being discussed. Certain fermented foods and probiotics may deliver viable microbes with the potential to promote gut immunity. Prebiotics, on their side, may enhance gut immunity by selectively stimulating certain resident microbes in the gut. Different levels of evidence support the use of fermented foods, probiotics and prebiotics to promote gut and lungs immunity. Without being a promise of efficacy against COVID-19, incorporating them into the diet may help to low down gut inflammation and to enhance mucosal immunity, to possibly better face the infection by contributing to diminishing the severity or the duration of infection episodes.
C1 [Antunes, Adriane E. C.; Xavier-Santos, Douglas] Univ Estadual Campinas, Sch Appl Sci FCA, 1300 Pedro Zaccaria St, BR-13484350 Limeira, SP, Brazil.
   [Vinderola, Gabriel] Univ Nacl Litoral, Fac Ingn Quim, Inst Lactol Ind INLAIN, CONICET, Santiago Estero 2829, BR-3000 Santa Fe, Brazil.
   [Sivieri, Katia] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Dept Food & Nutr, Rodovia Araraquara Jau Km 1, BR-14800903 Araraquara, SP, Brazil.
RP Sivieri, K (corresponding author), Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Dept Food & Nutr, Rodovia Araraquara Jau Km 1, BR-14800903 Araraquara, SP, Brazil.
EM katia.sivieri@unesp.br
CR Anand S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02147
   Anderson JL, 2017, J CYST FIBROS, V16, P186, DOI 10.1016/j.jcf.2016.09.004
   Ashraf R, 2014, CRIT REV FOOD SCI, V54, P938, DOI 10.1080/10408398.2011.619671
   Bassis CM, 2015, MBIO, V6, DOI 10.1128/mBio.00037-15
   Baud D, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00186
   Belizario Jose E, 2018, Exp Suppl, V109, P459, DOI 10.1007/978-3-319-74932-7_13
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Brown RL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01803-x
   Budding AE, 2020, AGE DEPENDENT PHARYN, DOI [10.2139/ssrn.3582780, DOI 10.2139/SSRN.3582780]
   Cai XF, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00258
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cryan JF, 2019, PHYSIOL REV, V99, P1877, DOI 10.1152/physrev.00018.2018
   de Vrese M, 2005, CLIN NUTR, V24, P481, DOI 10.1016/j.clnu.2005.02.006
   Enaud R, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00009
   Fanos V, 2020, J PEDIATR NEONATAL I, V9, DOI 10.7363/090139
   Gao W, 2015, INT J FOOD SCI TECH, V50, P1468, DOI 10.1111/ijfs.12801
   Gao X., 2016, COGENT FOOD AGR, V2, P127
   Gibson GR, 2017, NAT REV GASTRO HEPAT, V14, P491, DOI 10.1038/nrgastro.2017.75
   Gill HS, 2004, POSTGRAD MED J, V80, P516, DOI 10.1136/pgmj.2003.008664
   Gill HS, 2001, AM J CLIN NUTR, V74, P833
   Gou W., 2020, GUT MICROBIOTA MAY U, DOI [10.1101/2020.04.22.20076091, DOI 10.1101/2020.04.22.20076091]
   Guillemard E, 2010, J AM COLL NUTR, V29, P455, DOI 10.1080/07315724.2010.10719882
   Hao QK, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006895.pub3
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Hill C, 2014, NAT REV GASTRO HEPAT, V11, P506, DOI 10.1038/nrgastro.2014.66
   Holscher HD, 2017, GUT MICROBES, V8, P172, DOI 10.1080/19490976.2017.1290756
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Infusino F, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061718
   Jia X, 2020, 2 THINGS COVID 19 MI, DOI [10.20944/preprints202002.0315.v1, DOI 10.20944/PREPRINTS202002.0315.V1]
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   King DE, 2007, ARCH INTERN MED, V167, P502, DOI 10.1001/archinte.167.5.502
   King S, 2014, BRIT J NUTR, V112, P41, DOI 10.1017/S0007114514000075
   Larsen JM, 2015, IMMUNOLOGY, V144, P333, DOI 10.1111/imm.12376
   Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200
   Lehtoranta L, 2014, J CLIN VIROL, V60, P276, DOI 10.1016/j.jcv.2014.03.021
   Lenoir-Wijnkoop I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166232
   Lenoir-Wijnkoop I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122765
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu S, 2013, INDIAN PEDIATR, V50, P377, DOI 10.1007/s13312-013-0123-z
   Liu Y, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009413.pub2
   Luoto R, 2014, J ALLERGY CLIN IMMUN, V133, P405, DOI 10.1016/j.jaci.2013.08.020
   Mak JWY, 2020, LANCET GASTROENTEROL, V5, P644, DOI 10.1016/S2468-1253(20)30122-9
   Marco ML, 2017, CURR OPIN BIOTECH, V44, P94, DOI 10.1016/j.copbio.2016.11.010
   Milani C, 2017, MICROBIOL MOL BIOL R, V81, DOI 10.1128/MMBR.00036-17
   Moeller AH, 2017, CURR OPIN MICROBIOL, V38, P30, DOI 10.1016/j.mib.2017.04.002
   Molin G, 2001, AM J CLIN NUTR, V73, p380S, DOI 10.1093/ajcn/73.2.380s
   Namba K, 2010, BIOSCI BIOTECH BIOCH, V74, P939, DOI 10.1271/bbb.90749
   National Institutes of Health, COVID 19 TREATM GUID
   Panigrahi P, 2017, NATURE, V548, P407, DOI 10.1038/nature23480
   Rautava S, 2009, BRIT J NUTR, V101, P1722, DOI 10.1017/S0007114508116282
   Reid G, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00424
   Rivellese F, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102536
   Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42
   Rosa DD, 2017, NUTR RES REV, V30, P82, DOI 10.1017/S0954422416000275
   Sanchez B, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600240
   Saterdal Ingvil, 2012, Glob Adv Health Med, V1, P124, DOI 10.7453/gahmj.2012.1.2.014
   Schuijt TJ, 2016, GUT, V65, P575, DOI 10.1136/gutjnl-2015-309728
   Shimizu K, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2167-x
   Sonnenburg JL, 2019, SCIENCE, V366, P444, DOI 10.1126/science.aaw9255
   Su MM, 2020, RESP CARE, V65, P673, DOI 10.4187/respcare.07097
   Syngai GG, 2016, J FOOD SCI TECH MYS, V53, P921, DOI 10.1007/s13197-015-2011-0
   Tamang JP, 2020, COMPR REV FOOD SCI F, V19, P184, DOI 10.1111/1541-4337.12520
   Tamburini S, 2016, NAT MED, V22, P713, DOI 10.1038/nm.4142
   Taylor BC, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00901-19
   Thursby E, 2017, BIOCHEM J, V474, P1823, DOI 10.1042/BCJ20160510
   Vouloumanou EK, 2009, INT J ANTIMICROB AG, V34, DOI 10.1016/j.ijantimicag.2008.11.005
   Waki N, 2014, LETT APPL MICROBIOL, V59, P565, DOI 10.1111/lam.12340
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wang YZ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004509
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu Kaijin, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P147, DOI 10.3785/j.issn.1008-9292.2020.02.02
   Yang Y., 2020, EXUBERANT ELEVATION, DOI [10.1101/2020.03.02.20029975, DOI 10.1101/2020.03.02.20029975]
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zhang H, 2020, DIGESTIVE SYSTEM IS, DOI [10.1101/2020.01.30.927806, DOI 10.1101/2020.01.30.927806]
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zheng JS, 2020, INT J SYST EVOL MICR, V70, P2782, DOI 10.1099/ijsem.0.004107
   Zmora N, 2019, NAT REV GASTRO HEPAT, V16, P35, DOI 10.1038/s41575-018-0061-2
NR 80
TC 2
Z9 2
U1 47
U2 47
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0963-9969
EI 1873-7145
J9 FOOD RES INT
JI Food Res. Int.
PD OCT
PY 2020
VL 136
AR 109577
DI 10.1016/j.foodres.2020.109577
PG 10
WC Food Science & Technology
SC Food Science & Technology
GA NH3CK
UT WOS:000564551500014
PM 32846611
OA Green Published
DA 2021-01-01
ER

PT J
AU Wang, MP
   Fu, TT
   Hao, JY
   Li, LT
   Tian, MY
   Jin, NY
   Ren, LZ
   Li, C
AF Wang, Maopeng
   Fu, Tingting
   Hao, Jiayi
   Li, Letian
   Tian, Mingyao
   Jin, Ningyi
   Ren, Linzhu
   Li, Chang
TI A recombinant Lactobacillus plantarum strain expressing the spike
   protein of SARS-CoV-2
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Lactobacillus plantarum (L. plantarum); Coronavirus disease 2019
   (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
ID ORAL IMMUNIZATION; CORONAVIRUS; FOOD; MICE
AB Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic in the past four months and causes respiratory disease in humans of almost all ages. Although several drugs have been announced to be partially effective treatments for this disease, no approved vaccine is available. Here, we described the construction of a recombinant Lactobacillus plantarum strain expressing the SARS-CoV-2 spike protein. The results showed that the spike gene with optimized codons could be efficiently expressed on the surface of recombinant L. plantarum and exhibited high antigenicity. The highest protein yield was obtained under the following conditions: cells were induced with 50 ng/mL SppIP at 37 degrees C for 6-10 h. The recombinant spike (S) protein was stable under normal conditions and at 50 degrees C, pH = 1.5, or a high salt concentration. Recombinant L. plantarum may provide a promising food-grade oral vaccine candidate against SARS-CoV-2 infection. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Wang, Maopeng] Wenzhou Univ, Inst Virol, Wenzhou 325035, Peoples R China.
   [Wang, Maopeng; Fu, Tingting; Hao, Jiayi; Li, Letian; Tian, Mingyao; Jin, Ningyi; Li, Chang] Chinese Acad Med Sci, Acad Mil Med Sci, Res Unit Key Technol Prevent & Control Virus Zoon, Mil Vet Inst, Changchun 130122, Peoples R China.
   [Ren, Linzhu] Jilin Univ, Coll Anim Sci, Jilin Prov Key Lab Anim Embryo Engn, Key Lab Zoonoses Res,Minist Educ, Changchun 130062, Peoples R China.
RP Li, C (corresponding author), Chinese Acad Med Sci, Acad Mil Med Sci, Res Unit Key Technol Prevent & Control Virus Zoon, Mil Vet Inst, Changchun 130122, Peoples R China.; Ren, LZ (corresponding author), Jilin Univ, Coll Anim Sci, Jilin Prov Key Lab Anim Embryo Engn, Key Lab Zoonoses Res,Minist Educ, Changchun 130062, Peoples R China.
EM renlz@jlu.edu.cn; lichang78@163.com
FU Changchun Science and Technology Bureau emergency project [2020RW002];
   National Key Research and Development Program of China [2017YFD0501002];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31772747, 31802224]; Jilin University
   Science and Technology Innovative Research Team [JLU-STIRT] [2017TD-05]
FX This work was supported by the Changchun Science and Technology Bureau
   emergency project [No. 2020RW002], the National Key Research and
   Development Program of China [No. 2017YFD0501002], the National Natural
   Science Foundation of China [No. 31772747, 31802224], and the Jilin
   University Science and Technology Innovative Research Team [JLU-STIRT,
   2017TD-05]. The funders had no role in the study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], 2000, Nat Biotechnol, V18, P367
   Cui Q., 2020, AGTR2 ONE POSIBLE NO
   del Rio B, 2008, CLIN VACCINE IMMUNOL, V15, P1429, DOI 10.1128/CVI.00169-08
   Gustafsson C, 2004, TRENDS BIOTECHNOL, V22, P346, DOI 10.1016/j.tibtech.2004.04.006
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Lal P, 2007, Indian J Med Microbiol, V25, P93
   Li C, 2020, INFECT GENET EVOL, V82, DOI 10.1016/j.meegid.2020.104285
   Liu MY, 2020, VACCINE, V38, P3031, DOI 10.1016/j.vaccine.2020.02.036
   Liu YW, 2018, J MICROBIOL, V56, P601, DOI 10.1007/s12275-018-8079-2
   Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2
   Mustafa AD, 2018, BMC BIOTECHNOL, V18, DOI 10.1186/s12896-018-0461-y
   Negro F, 2020, SWISS MED WEEKLY, V150
   Park D, 2019, J MICROBIOL BIOTECHN, V29, P1729, DOI 10.4014/jmb.1907.07039
   Peeples L, 2020, P NATL ACAD SCI USA, V117, P8218, DOI 10.1073/pnas.2005456117
   Ren DY, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/925219
   Ren DY, 2015, ANAEROBE, V35, P22, DOI 10.1016/j.anaerobe.2015.06.008
   Ren DY, 2014, ANAEROBE, V30, P1, DOI 10.1016/j.anaerobe.2014.07.004
   Ren DY, 2012, ANAEROBE, V18, P508, DOI 10.1016/j.anaerobe.2012.08.001
   Ruane D, 2016, MUCOSAL IMMUNOL, V9, P1340, DOI 10.1038/mi.2015.133
   Scheppler L, 2002, VACCINE, V20, P2913, DOI 10.1016/S0264-410X(02)00229-3
   Seddik HA, 2017, PROBIOTICS ANTIMICRO, V9, P111, DOI 10.1007/s12602-017-9264-z
   Shakoor S, 2019, ACTA VIROL, V63, P245, DOI 10.4149/av_2019_301
   Shi SH, 2016, VIRUS RES, V211, P46, DOI 10.1016/j.virusres.2015.09.005
   Sun YX, 2018, VET MICROBIOL, V223, P9, DOI 10.1016/j.vetmic.2018.07.009
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang FZ, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.924700
   Wang K, 2020, SARS COV 2 INVADES H
   Wang MP, 2020, INT J BIOL MACROMOL, V143, P112, DOI 10.1016/j.ijbiomac.2019.12.006
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wang SH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02299
   XU ZJ, 2020, GEROSCIENCE 0611, DOI DOI 10.1126/SCIENCE.ABC1932
   Yip M S, 2016, Hong Kong Med J, V22, P25
   Zha L., 2020, DEV COVID 19 VACCINE
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 35
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD OCT 1
PY 2020
VL 160
BP 736
EP 740
DI 10.1016/j.ijbiomac.2020.05.239
PG 5
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA NH6BL
UT WOS:000564753300006
PM 32485251
OA Green Published
DA 2021-01-01
ER

PT J
AU Hedenstierna, G
   Chen, LN
   Hedenstierna, M
   Lieberman, R
   Fine, DH
AF Hedenstierna, Goran
   Chen, Luni
   Hedenstierna, Magnus
   Lieberman, Robert
   Fine, David H.
TI Nitric oxide dosed in short bursts at high concentrations may protect
   against Covid 19
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Article
DE Nitric oxide; Smoking; Viral suppression; Covid-19
ID ACUTE RESPIRATORY SYNDROME; MAINSTREAM; INHALATION; SMOKING; TOBACCO
AB It has long been suggested that NO may inhibit an early stage in viral replication. Furthermore, in vitro tests have shown that NO inhibits the replication cycle of severe acute respiratory syndrome coronavirus. Despite smoking being listed as a risk factor to contract Covid-19, only a low proportion of the smokers suffered from SARS-corona infection in China 2003, and from Covid-19 in China, Europe and the US. We hypothesize, that the intermittent bursts of high NO concentration in cigarette smoke may be a mechanism in protecting against the virus. Mainstream smoke from cigarettes contains NO at peak concentrations of between about 250 ppm and 1350 ppm in each puff as compared to medicinal use of no more than 80 to a maximum of 160 ppm. The diffusion of NO through the cell wall to reach the virus should be significantly more effective at the very high NO concentration in the smoke, according to classic laws of physics. The only oxide of nitrogen in the mainstream smoke is NO, and the NO2 concentration that is inhaled is very low or undetectable, and methemoglobin levels are lower in smokers than non-smokers, reasonably explained by the breaths of air in between the puffs that wash out the NO. Specialized iNO machines can now be developed to provide the drug intermittently in short bursts at high concentration dose, which would then provide both a preventative drug for those at high risk, as well as an effective treatment, without the health hazards associated with smoking.
C1 [Hedenstierna, Goran] Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
   [Chen, Luni] Karolinska Inst, Dept MTC, Solna, Sweden.
   [Hedenstierna, Magnus] Danderyd Hosp, Dept Infect Dis, Danderyd, Sweden.
   [Lieberman, Robert] Contello Consulting LLC, Mendham, NJ USA.
   [Fine, David H.] Pieto LLC, Melbourne, FL USA.
RP Hedenstierna, G (corresponding author), Univ Hosp, Clin Physiol, S-75185 Uppsala, Sweden.
EM goran.hedenstierna@medsci.uu.se
CR Adam T, 2006, CHEM RES TOXICOL, V19, P511, DOI 10.1021/tx050220w
   Akerstrom S, 2005, J VIROL, V79, P1966, DOI 10.1128/JVI.79.3.1966-1969.2005
   Berlin I, 2020, NICOTINE TOB RES, V22, P1650, DOI 10.1093/ntr/ntaa059
   BORLAND C, 1985, ARCH ENVIRON HEALTH, V40, P330, DOI 10.1080/00039896.1985.10545943
   Chen LN, 2004, CLIN INFECT DIS, V39, P1531, DOI 10.1086/425357
   Gaibazzi N., 2020, SMOKING PREVALENCE L, DOI [10.1101/2020.05.05.20092015., DOI 10.1101/2020.05.05.20092015]
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Ignarro LJ, 2020, BRIT J PHARMACOL, V177, P3848, DOI 10.1111/bph.15085
   Keyaerts E, 2004, INT J INFECT DIS, V8, P223, DOI 10.1016/j.ijid.2004.04.012
   Leung JM, 2020, EUR RESP J, V55
   Lundin S, 1999, INTENS CARE MED, V25, P911, DOI 10.1007/s001340050982
   Malinovschi A, 2006, EUR RESPIR J, V28, P339, DOI 10.1183/09031936.06.00113705
   Miyara M., 2020, AMOURA Z LOW RATE DA
   NORMAN V, 1983, BEITR TABAKFORSCH, V12, P55
   Oakes JM, 2018, AM J PHYSIOL-REG I, V315, pR895, DOI 10.1152/ajpregu.00099.2018
   Parascandola M, 2019, TRANSL LUNG CANCER R, V8, pS21, DOI 10.21037/tlcr.2019.03.12
   Patanavanich R, 2020, NICOTINE TOB RES, V22, P1653, DOI 10.1093/ntr/ntaa082
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Pezone MJ, 2016, NITRIC OXIDE-BIOL CH, V58, P42, DOI 10.1016/j.niox.2016.06.001
   Reiss CS, 1998, J VIROL, V72, P4547, DOI 10.1128/JVI.72.6.4547-4551.1998
   Taylor DR, 2006, THORAX, V61, P817, DOI 10.1136/thx.2005.056093
   Tsui PT, 2003, EMERG INFECT DIS, V9, P1064
   Uk Department of Health, 1998, NITR OX YIELDS CIG R
   van Zyl-Smit RN, 2020, LANCET RESP MED, V8, P664, DOI 10.1016/S2213-2600(20)30239-3
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 26
TC 3
Z9 3
U1 4
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
EI 1089-8611
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD OCT 1
PY 2020
VL 103
BP 1
EP 3
DI 10.1016/j.niox.2020.06.005
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NG9QZ
UT WOS:000564317800001
PM 32590117
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Baba, H
   Kanamori, H
   Oshima, K
   Seike, I
   Niitsuma-Sugaya, I
   Takei, K
   Sato, Y
   Tokuda, K
   Aoyagi, T
AF Baba, Hiroaki
   Kanamori, Hajime
   Oshima, Kengo
   Seike, Issei
   Niitsuma-Sugaya, Ikumi
   Takei, Kentaro
   Sato, Yukio
   Tokuda, Koichi
   Aoyagi, Tetsuji
TI Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid
   arthritis taking iguratimod treated with ciclesonide
SO JOURNAL OF INFECTION AND CHEMOTHERAPY
LA English
DT Article
DE Coronavirus disease 2019; Iguratimod; Ciclesonide; Viral shedding
AB We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation. (C) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Baba, Hiroaki; Kanamori, Hajime; Oshima, Kengo; Seike, Issei; Niitsuma-Sugaya, Ikumi; Takei, Kentaro; Sato, Yukio; Tokuda, Koichi; Aoyagi, Tetsuji] Tohoku Univ, Dept Infect Dis, Grad Sch Med, Internal Med,Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.
   [Baba, Hiroaki; Kanamori, Hajime; Oshima, Kengo; Tokuda, Koichi; Aoyagi, Tetsuji] Tohoku Univ, Dept Intelligent Network Infect Control, Grad Sch Med, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
   [Kanamori, Hajime; Tokuda, Koichi] Tohoku Univ Hosp, Div Infect Control, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.
   [Sato, Yukio] Sendai Med Imaging Clin, Aoba Ku, 2-1-25 Itsutsubashi, Sendai, Miyagi 9800022, Japan.
RP Baba, H (corresponding author), 1-1 Seiryo Machi,Aoba Ku, Sendai, Miyagi 9808574, Japan.
EM hbaba48@med.tohoku.ac.jp
CR Aikawa Y, 2002, INFLAMM RES, V51, P188, DOI 10.1007/PL00000291
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Hashimoto Atsushi, 2015, Nihon Rinsho Meneki Gakkai Kaishi, V38, P109, DOI 10.2177/jsci.38.109
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Iwabuchi K, 2020, J INFECT CHEMOTHER, V26, P625, DOI 10.1016/j.jiac.2020.04.007
   Japan College of Pheumatology, REG NOV COR INF COVI
   Lacaille D, 2008, ARTHRIT RHEUM-ARTHR, V59, P1074, DOI 10.1002/art.23913
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu J, 2020, LONGITUDINAL CHARACT, DOI [10.1101/ 2020.02.16.20023671, DOI 10.1101/2020.02.16.20023671, 10.1101/2020.02.16.20023671]
   Matsuyama S., 2020, INHALED CORTICOSTERO, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]
   Monti S, 2020, ANN RHEUM DIS, DOI [10.1036/annrheumdis-2020-217424., DOI 10.1036/ANNRHEUMDIS-2020-217424]
   Nishiura H, 2020, INT J INFECT DIS, V93, P284, DOI 10.1016/j.ijid.2020.02.060
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Robinson PC, 2020, NAT REV RHEUMATOL, V16, P293, DOI 10.1038/s41584-020-0418-0
   Shirato Kazuya, 2020, Jpn J Infect Dis, V73, P304, DOI 10.7883/yoken.JJID.2020.061
   Watanabe T, 2014, JPN J MED INSTRUM, V84, P7
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Xu KJ, 2020, CLIN INFECT DIS, V71, P799, DOI 10.1093/cid/ciaa351
NR 18
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1341-321X
EI 1437-7780
J9 J INFECT CHEMOTHER
JI J. Infect. Chemother.
PD OCT
PY 2020
VL 26
IS 10
BP 1100
EP 1103
DI 10.1016/j.jiac.2020.06.022
PG 4
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA NC2WG
UT WOS:000561076200018
PM 32631736
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kumar, A
   Kumar, A
   Kumar, N
   Kumar, A
   Singh, PK
AF Kumar, Amarjeet
   Kumar, Abhyuday
   Kumar, Neeraj
   Kumar, Ajeet
   Singh, Prabhat Kumar
TI Modified oxygen therapy device for prevention of aerosol dispersion in
   COVID-19 patients
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Letter
C1 [Kumar, Amarjeet; Kumar, Neeraj] AIIMS, Dept Trauma & Emergency, Patna, Bihar, India.
   [Kumar, Abhyuday; Kumar, Ajeet] AIIMS, Dept Anaesthesia, Patna, Bihar, India.
   [Singh, Prabhat Kumar] AIIMS, Room 503,OT Complex, Patna 801507, Bihar, India.
RP Kumar, A (corresponding author), AIIMS, Room 503,OT Complex, Patna 801507, Bihar, India.
EM drabhyudaykumar@aiimspatna.org
CR [Anonymous], NEW IND CLAR
   Hui D S C, 2014, Hong Kong Med J, V20 Suppl 4, P9
   Hui DS, 2006, CHEST, V130, P822, DOI 10.1378/chest.130.3.822
   Hui DS, 2011, RESPIROLOGY, V16, P1005, DOI 10.1111/j.1440-1843.2011.01995.x
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
NR 5
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0952-8180
EI 1873-4529
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD OCT
PY 2020
VL 65
AR 109884
DI 10.1016/j.jclinane.2020.109884
PG 2
WC Anesthesiology
SC Anesthesiology
GA MP3SX
UT WOS:000552127600048
PM 32447167
OA Green Published
DA 2021-01-01
ER

PT J
AU Gopalsamuthiram, V
   Williams, C
   Noble, J
   Jamison, TF
   Gupton, BF
   Snead, DR
AF Gopalsamuthiram, Vijayagopal
   Williams, Corshai
   Noble, Jeffrey
   Jamison, Timothy F.
   Gupton, B. Frank
   Snead, David R.
TI A Concise Route to MK-4482 (EIDD-2801) from Cytidine: Part 2
SO SYNLETT
LA English
DT Article; Early Access
DE antiviral; nucleoside; COVID-19
AB A new route to MK-4482 was developed. The route replaces uridine with the more available and less expensive cytidine. Low-cost, simple reagents are used for the chemical transformations, and the yield is improved from 17% to 44%. A step is removed from the longest linear sequence, and these advancements are expected to expand access to MK-4482 should it become a viable drug substance.
C1 [Gopalsamuthiram, Vijayagopal; Noble, Jeffrey; Gupton, B. Frank; Snead, David R.] Virginia Commonwealth Univ, Med All Inst, 737 N 5th St,Box 980100, Richmond, VA 23298 USA.
   [Williams, Corshai; Jamison, Timothy F.] MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
RP Snead, DR (corresponding author), Virginia Commonwealth Univ, Med All Inst, 737 N 5th St,Box 980100, Richmond, VA 23298 USA.
EM drsnead@vcu.edu
OI Jamison, Timothy/0000-0002-8601-7799
FU Bill and Melinda Gates FoundationBill & Melinda Gates Foundation
   [OPP1176590]
FX We thank the Bill and Melinda Gates Foundation (OPP1176590) for their
   longstanding support of our research.
CR Camacho-Garcia J, 2015, ORG BIOMOL CHEM, V13, P4506, DOI 10.1039/c5ob00098j
   Cross R., 2020, CHEM ENG NEWS, V98, P12
   Halford B, 2020, CHEM ENG NEWS, V98, P25
   Painter G. R., 2019, [No title captured], Patent No. [WO2019173602, 2019173602]
   Painter G. R., 2018, [No title captured], Patent No. [WO2019113462, 2019113462]
   Painter G. R., 2016, [No title captured], Patent No. [WO2016106050A1, 2016106050]
   Vasudevan N, 2020, CHEMRXIV, DOI [10.26434/chemrxiv.12818327.v1, DOI 10.26434/CHEMRXIV.12818327.V1]
NR 7
TC 1
Z9 1
U1 4
U2 4
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0936-5214
EI 1437-2096
J9 SYNLETT
JI Synlett
DI 10.1055/a-1275-2848
EA SEP 2020
PG 3
WC Chemistry, Organic
SC Chemistry
GA OI1HR
UT WOS:000583038900001
DA 2021-01-01
ER

PT J
AU Barbieri, A
   Robinson, N
   Palma, G
   Maurea, N
   Desiderio, V
   Botti, G
AF Barbieri, Antonio
   Robinson, Nirmal
   Palma, Giuseppe
   Maurea, Nicola
   Desiderio, Vincenzo
   Botti, Gerardo
TI Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2
   Hyperinflammatory Syndrome?-Lessons Learned From Cancer
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV2; Beta adrenergic receptors; beta-blockers; Cytokine
   storm; immune response; hyperinflammation
ID RESPIRATORY SYNDROME CORONAVIRUS; BETA-BLOCKERS; SARS-COV; PROPRANOLOL;
   STRESS; INTERFERON; RECEPTOR; NOREPINEPHRINE; CELLS; DISCOVERY
AB SARS-CoV-2 infection is a new threat to global public health in the 21(st)century (2020), which has now rapidly spread around the globe causing severe pneumonia often linked to Acute Respiratory Distress Syndrome (ARDS) and hyperinflammatory syndrome. SARS-CoV-2 is highly contagious through saliva droplets. The structural analysis suggests that the virus enters human cells through the ligation of the spike protein to angiotensin-converting enzyme 2 (ACE(2)). The progression of Covid-19 has been divided into three main stages: stage I-viral response, stage II-pulmonary phase, and stage III-hyperinflammation phase. Once the patients enter stage III, it will likely need ventilation and it becomes difficult to manage. Thus, it will be of paramount importance to find therapies to prevent or slow down the progression of the disease toward stage III. The key event leading to hyperinflammation seems to be the activation of Th-17 immunity response and Cytokine storm. B-2-adrenergic receptors (B(2)ARs) are expressed on airways and on all the immune cells such as macrophages, dendritic cells, B and T lymphocytes. Blocking (B(2)AR) has been proven, also in clinical settings, to reduce Th-17 response and negatively modulate inflammatory cytokines including IL-6 while increasing IFN gamma. Non-selective beta-blockers are currently used to treat several diseases and have been proven to reduce stress-induced inflammation and reduce anxiety. For these reasons, we speculate that targeting B(2)AR in the early phase of Covid-19 might be beneficial to prevent hyperinflammation.
C1 [Barbieri, Antonio; Palma, Giuseppe] Ist Ricovero & Cura Carattere Sci Fdn G Pascale, Anim Facil, Ist Nazl Tumori, Naples, Italy.
   [Robinson, Nirmal] Univ South Australia, Ctr Canc Biol, Adelaide, SA, Australia.
   [Robinson, Nirmal] SA Pathol, Adelaide, SA, Australia.
   [Maurea, Nicola] Ist Ricovero & Cura Carattere Sci Fdn G Pascale, Div Cardiol, Ist Nazl Tumori, Naples, Italy.
   [Desiderio, Vincenzo] Univ Campania Luigi Vanvitelli, Sect Histol, Dept Expt Med, Naples, Italy.
   [Botti, Gerardo] IRCCS Fdn G Pascale, Sci Directorate, Ist Nazl Tumori, Naples, Italy.
RP Barbieri, A (corresponding author), Ist Ricovero & Cura Carattere Sci Fdn G Pascale, Anim Facil, Ist Nazl Tumori, Naples, Italy.
EM a.barbieri@istitutotumori.na.it
OI Robinson, Nirmal/0000-0002-7361-9491
FU Italian Ministry of HealthMinistry of Health, Italy
FX This work was funded by an "Ricerca Corrente" grant from the Italian
   Ministry of Health.
CR Ali A, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0913-x
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arboe B, 2013, INT J GEN MED, V6, P549, DOI 10.2147/IJGM.S46592
   Barbieri A, 2015, INT J ONCOL, V47, P527, DOI 10.3892/ijo.2015.3038
   Barbieri A, 2012, J CELL MOL MED, V16, P920, DOI 10.1111/j.1582-4934.2011.01375.x
   Bonten TN, 2014, BRIT J CLIN PHARMACO, V78, P940, DOI 10.1111/bcp.12404
   Buonaguro FM, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02333-9
   CARSTAIRS JR, 1985, AM REV RESPIR DIS, V132, P541
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chan JFW, 2013, J FORMOS MED ASSOC, V112, P372, DOI 10.1016/j.jfma.2013.05.010
   Changotra H, 2009, J VIROL, V83, P5683, DOI 10.1128/JVI.00231-09
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716
   GREENDYKE RM, 1986, J NERV MENT DIS, V174, P290, DOI 10.1097/00005053-198605000-00005
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Haldar R, 2018, BRAIN BEHAV IMMUN, V73, P294, DOI 10.1016/j.bbi.2018.05.014
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   He F, 2020, J MED VIROL, V92, P719, DOI [10.1002/jmv.25766, 10.3171/2020.3.JNS193202]
   Hoppener MR, 2004, J THROMB HAEMOST, V2, P1316, DOI 10.1111/j.1538-7836.2004.00851.x
   Huang HW, 2015, NEUROIMMUNOMODULAT, V22, P138, DOI 10.1159/000360579
   Huang HW, 2013, NEUROIMMUNOMODULAT, V20, P1, DOI 10.1159/000343099
   Hwang S, 2012, CELL HOST MICROBE, V11, P397, DOI 10.1016/j.chom.2012.03.002
   Johnson M, 2006, J ALLERGY CLIN IMMUN, V117, P18, DOI 10.1016/j.jaci.2005.11.012
   Josset L, 2013, MBIO, V4, DOI 10.1128/mBio.00165-13
   KAPLAN R, 1980, ARTHRITIS RHEUM, V23, P253, DOI 10.1002/art.1780230220
   Khalili A, 2013, IRAN J IMMUNOL, V10, P70, DOI IJIv10i2A2
   Lavine JA, 2017, INVEST OPHTH VIS SCI, V58, P299, DOI 10.1167/iovs.16-20204
   Lee CK, 2000, J IMMUNOL, V165, P3571, DOI 10.4049/jimmunol.165.7.3571
   Li CG, 2012, CELL RES, V22, P528, DOI 10.1038/cr.2011.165
   Madden KS, 2011, BREAST CANCER RES TR, V130, P747, DOI 10.1007/s10549-011-1348-y
   Manni M, 2011, CYTOKINE, V55, P380, DOI 10.1016/j.cyto.2011.05.013
   Mosaddeghi P., 2020, THERAPEUTIC APPROACH, DOI [10.20944/preprints202003.0206.v1., DOI 10.20944/PREPRINTS202003.0206.V1]
   NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670
   Nielsen Anne Orholm, 2019, EClinicalMedicine, V7, P21, DOI 10.1016/j.eclinm.2019.01.004
   Peskind ER, 2005, ALZ DIS ASSOC DIS, V19, P23, DOI 10.1097/01.wad.0000155067.16313.5e
   Senik A, ANN IMMUNOL PARIS C, V131C, P349
   Shaashua L, 2017, CLIN CANCER RES, V23, P4651, DOI 10.1158/1078-0432.CCR-17-0152
   SIDMAN CL, 1984, NATURE, V309, P801, DOI 10.1038/309801a0
   SONNENFELD G, 1992, BRAIN BEHAV IMMUN, V6, P170, DOI 10.1016/0889-1591(92)90016-H
   Stohl LL, 2013, CYTOKINE, V64, P605, DOI 10.1016/j.cyto.2013.08.005
   von Kanel R, 2008, J CARDIOVASC PHARM, V51, P231, DOI 10.1097/FJC.0b013e318161ea63
   Wachter SB, 2012, CARDIOLOGY, V122, P104, DOI 10.1159/000339271
   Wang J, 2020, J LEUKOCYTE BIOL, V108, P17, DOI 10.1002/JLB.3COVR0520-272R
   Weizman OE, 2017, CELL, V171, P795, DOI 10.1016/j.cell.2017.09.052
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu L, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01313
   Yang EV, 2009, BRAIN BEHAV IMMUN, V23, P267, DOI 10.1016/j.bbi.2008.10.005
   Zhou L, 2016, J IMMUNOL, V196, P3460, DOI 10.4049/jimmunol.1501677
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 54
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 30
PY 2020
VL 11
AR 588724
DI 10.3389/fimmu.2020.588724
PG 6
WC Immunology
SC Immunology
GA OB3HO
UT WOS:000578363700001
PM 33117402
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Niu, XF
   Li, S
   Li, PC
   Pan, WJ
   Wang, Q
   Feng, Y
   Mo, XN
   Yan, QH
   Ye, XM
   Luo, J
   Qu, LB
   Weber, D
   Byrne-Steele, ML
   Wang, Z
   Yu, FJ
   Li, F
   Myers, RM
   Lotze, MT
   Zhong, NS
   Han, J
   Chen, L
AF Niu, Xuefeng
   Li, Song
   Li, Pingchao
   Pan, Wenjing
   Wang, Qian
   Feng, Ying
   Mo, Xiaoneng
   Yan, Qihong
   Ye, Xianmiao
   Luo, Jia
   Qu, Linbing
   Weber, Daniel
   Byrne-Steele, Miranda L.
   Wang, Zhe
   Yu, Fengjia
   Li, Fang
   Myers, Richard M.
   Lotze, Michael T.
   Zhong, Nanshan
   Han, Jian
   Chen, Ling
TI Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts
   Reveal Dynamic Immune Response in COVID-19 Patients
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; T cell receptor; B cell receptor; immune
   repertoire; biomarker
ID CORONAVIRUS; ANTIBODIES; ANTIGEN; IGA
AB Severe COVID-19 is associated with profound lymphopenia and an elevated neutrophil to lymphocyte ratio. We applied a novel dimer avoidance multiplexed polymerase chain reaction next-generation sequencing assay to analyze T (TCR) and B cell receptor (BCR) repertoires. Surprisingly, TCR repertoires were markedly diminished during the early onset of severe disease but recovered during the convalescent stage. Monitoring TCR repertoires could serve as an indicative biomarker to predict disease progression and recovery. Panoramic concurrent assessment of BCR repertoires demonstrated isotype switching and a transient but dramatic early IgA expansion. Dominant B cell clonal expansion with decreased diversity occurred following recovery from infection. Profound changes in T cell homeostasis raise critical questions about the early events in COVID-19 infection and demonstrate that immune repertoire analysis is a promising method for evaluating emergent host immunity to SARS-CoV-2 viral infection, with great implications for assessing vaccination and other immunological therapies.
C1 [Niu, Xuefeng; Feng, Ying; Zhong, Nanshan; Chen, Ling] Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Affiliated Hosp 1, Guangzhou, Peoples R China.
   [Li, Song; Wang, Zhe; Yu, Fengjia; Han, Jian] Appl Adaptome Immunol Inst, Jiangsu Ind Technol Res Inst JITRI, Nanjing, Peoples R China.
   [Li, Song; Pan, Wenjing; Weber, Daniel; Byrne-Steele, Miranda L.; Han, Jian] IRepertoire Inc, Huntsville, AL 35806 USA.
   [Li, Song; Wang, Qian; Yan, Qihong; Ye, Xianmiao; Luo, Jia; Qu, Linbing; Chen, Ling] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangdong Lab Computat Biomed, Guangzhou Regenerat Med & Hlth Guangdong Lab GRMH, Guangzhou, Peoples R China.
   [Pan, Wenjing; Myers, Richard M.; Han, Jian] HudsonAlpha Inst Biotechnol, Huntsville, AL 35806 USA.
   [Mo, Xiaoneng; Chen, Ling] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China.
   [Lotze, Michael T.] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA USA.
RP Chen, L (corresponding author), Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Affiliated Hosp 1, Guangzhou, Peoples R China.; Han, J (corresponding author), Appl Adaptome Immunol Inst, Jiangsu Ind Technol Res Inst JITRI, Nanjing, Peoples R China.; Han, J (corresponding author), IRepertoire Inc, Huntsville, AL 35806 USA.; Chen, L (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangdong Lab Computat Biomed, Guangzhou Regenerat Med & Hlth Guangdong Lab GRMH, Guangzhou, Peoples R China.; Han, J (corresponding author), HudsonAlpha Inst Biotechnol, Huntsville, AL 35806 USA.; Chen, L (corresponding author), Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China.
EM jhan@hudsonalpha.org; chen_ling@gibh.ac.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82041014, 81661148056]; special program for
   SARS-COV-2 research of Guangzhou Institute of Respiratory Health (GIRH);
   China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2020T130115ZX]
FX This work was supported by the National Natural Science Foundation of
   China (82041014 and 81661148056) and the special program for SARS-COV-2
   research of Guangzhou Institute of Respiratory Health (GIRH) for LC and
   XN. China Postdoctoral Science Foundation (Grant No. 2020T130115ZX) for
   PL.
CR Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Cai YX, 2020, J THORAC ONCOL, V15, P1065, DOI 10.1016/j.jtho.2020.04.003
   Davey MS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04076-0
   Davey MS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14760
   Davis CW, 2019, CELL, V177, P1566, DOI 10.1016/j.cell.2019.04.036
   Davis MM, 2017, NAT IMMUNOL, V18, P725, DOI 10.1038/ni.3768
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Drake LY, 2016, J IMMUNOL, V197, P1335, DOI 10.4049/jimmunol.1502669
   GLEESON M, 1995, IMMUNOL CELL BIOL, V73, P397, DOI 10.1038/icb.1995.62
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han J, 2020, METHODS MOL BIOL, V2055, P369, DOI 10.1007/978-1-4939-9773-2_17
   Hopkins AC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122092
   Horns F, 2020, CELL REP, V30, P905, DOI 10.1016/j.celrep.2019.12.063
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lefranc MP, 2003, NUCLEIC ACIDS RES, V31, P307, DOI 10.1093/nar/gkg085
   Lombardo KA, 2017, BLOOD ADV, V1, P535, DOI 10.1182/bloodadvances.2016000794
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6
   Mo HY, 2006, RESPIROLOGY, V11, P49, DOI 10.1111/j.1440-1843.2006.00783.x
   Niu XF, 2020, EMERG MICROBES INFEC, V9, P111, DOI 10.1080/22221751.2019.1701953
   O'Donnell R, 2003, BRIT MED J, V327, P620, DOI 10.1136/bmj.327.7415.620-b
   Paulson KG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06300-3
   Renegar KB, 2004, J IMMUNOL, V173, P1978, DOI 10.4049/jimmunol.173.3.1978
   Russell CD, 2017, CLIN MICROBIOL REV, V30, P481, DOI 10.1128/CMR.00090-16
   Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678
   Setliff I, 2019, CELL, V179, P1636, DOI 10.1016/j.cell.2019.11.003
   Sheridan C, 2020, NAT BIOTECHNOL, V38, P515, DOI 10.1038/d41587-020-00010-2
   Sterlin D, 2020, IGA DOMINATES EARLY, DOI [10.1101/2020.06.10.20126532, DOI 10.1101/2020.06.10.20126532]
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Wang CL, 2010, P NATL ACAD SCI USA, V107, P1518, DOI 10.1073/pnas.0913939107
   Wec AZ, 2020, P NATL ACAD SCI USA, V117, P6675, DOI 10.1073/pnas.1921388117
   Wendel BS, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aan8884
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu J, 2018, MUCOSAL IMMUNOL, V11, P1487, DOI 10.1038/s41385-018-0046-z
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yager EJ, 2008, J EXP MED, V205, P711, DOI 10.1084/jem.20071140
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Y, 2015, ELIFE, V4, DOI 10.7554/eLife.09083
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 44
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 30
PY 2020
VL 11
AR 582010
DI 10.3389/fimmu.2020.582010
PG 9
WC Immunology
SC Immunology
GA OB1RM
UT WOS:000578252100001
PM 33117392
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Faasse, K
   Newby, JM
AF Faasse, Kate
   Newby, Jill M.
TI Public Perceptions of COVID-19 in Australia: Perceived Risk, Knowledge,
   Health-Protective Behaviors, and Vaccine Intentions
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE COVID-19; emerging infectious disease; health behaviors; perceived risk;
   worry; knowledge; uncertainty; misinformation
ID HONG-KONG; RESPONSES; MODEL
AB Widespread and sustained engagement with health-protective behaviors (i.e., hygiene and distancing) is critical to successfully managing the COVID-19 pandemic. Evidence from previous emerging infectious disease outbreaks points to the role of perceived risk, worry, media coverage, and knowledge in shaping engagement with health-protective behaviors and vaccination intentions. The aim of the current study was to examine the role of these factors in predicting recommended health-protective behaviors early in the pandemic. A secondary aim was to assess uncertainty and misconceptions about COVID-19. An online survey of 2,174 Australian residents was completed between March 2 and 9, 2020, at an early stage of the COVID-19 outbreak in Australia. Results revealed that two-thirds of respondents were at least moderately worried about a widespread COVID-19 outbreak. Worry about the outbreak and closely following media coverage were consistent predictors of greater engagement with health-protective behaviors and higher vaccination intentions. Uncertainty and misconceptions about COVID-19 were common, including uncertainty about whether people are likely to have natural or existing immunity to the virus. There was also uncertainty around whether specific home remedies (e.g., vitamins and saline rinses) would offer protection and whether the virus was human-made and deliberately released. Such misconceptions are likely to cause concern for members of the public. The findings also highlight psychological and demographic factors associated with lower engagement with health-protective behaviors, including male gender, younger age, and low levels of worry about the outbreak. These findings offer potential pathways and targets for interventions to encourage health-protective behaviors. The results relating to uncertainty and misconceptions about COVID-19 point to areas that could be usefully targeted by public information campaigns.
C1 [Faasse, Kate; Newby, Jill M.] UNSW Sydney, Sch Psychol, Sydney, NSW, Australia.
   [Newby, Jill M.] UNSW Sydney, Black Dog Inst, Sydney, NSW, Australia.
RP Faasse, K (corresponding author), UNSW Sydney, Sch Psychol, Sydney, NSW, Australia.
EM k.faasse@unsw.edu.au
FU UNSW Science Goldstar (2020); Australian Research Council Discovery
   Early Career Research Award (DECRA)Australian Research Council
   [DE180100471]
FX This research was funded by a UNSW Science Goldstar (2020) awarded to
   KF. KF was supported by an Australian Research Council Discovery Early
   Career Research Award (DECRA; DE180100471).
CR Asmundson GJG, 2020, J ANXIETY DISORD, V70, DOI 10.1016/j.janxdis.2020.102196
   Australian Government Department of Health, 2020, COR COVID 19 CURR SI
   Australian Government Department of Health, 2020, COR COVID 19 HLTH AL
   Australian Government Department of Health, 2020, WHAT YOU NEED KNOW C
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826
   Bonell C, 2020, J EPIDEMIOL COMMUN H, V74, P617, DOI 10.1136/jech-2020-214290
   Bults M, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-2
   Bults M, 2015, DISASTER MED PUBLIC, V9, P207, DOI 10.1017/dmp.2014.160
   Centers for Disease Control and Prevention (CDC), 2020, WAT COVID 19 FAQS
   Collinson S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141423
   Day M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1375
   Diefenbach MA, 1996, J SOC DISTRESS HOMEL, V5, P11, DOI 10.1007/BF02090456
   Garfin DR, 2020, HEALTH PSYCHOL, V39, P355, DOI 10.1037/hea0000875
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han PKJ, 2006, J HEALTH COMMUN, V11, P51, DOI 10.1080/10810730600637541
   Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359
   Klemm C, 2016, J RISK RES, V19, P1, DOI 10.1080/13669877.2014.923029
   Lau JTF, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-18
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Michie S, 2020, BMJ OPINION
   Minister for Health, 2020, 1 CONF CAS NOV COR A
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Paek H.-J., 2017, RISK PERCEPTIONS RIS, DOI [10.1093/acrefore/9780190228613.013.283, DOI 10.1093/ACREFORE/9780190228613.013.283, 10.1093/acrefore/97801 90228613.013.283]
   Petrie KJ, 2016, DISASTER MED PUBLIC, V10, P674, DOI 10.1017/dmp.2016.67
   Rubin GJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2651
   Simpson CR, 2019, LANCET INFECT DIS, V19, pE295, DOI 10.1016/S1473-3099(18)30786-2
   Slovic P, 2007, EUR J OPER RES, V177, P1333, DOI 10.1016/j.ejor.2005.04.006
   Tang CSK, 2003, AM J PUBLIC HEALTH, V93, P1887, DOI 10.2105/AJPH.93.11.1887
   Vosoughi S, 2018, SCIENCE, V359, P1146, DOI 10.1126/science.aap9559
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   WEINSTEIN ND, 1988, HEALTH PSYCHOL, V7, P355, DOI 10.1037/0278-6133.7.4.355
   Weinstein ND, 2007, HEALTH PSYCHOL, V26, P146, DOI 10.1037/0278-6133.26.2.146
   Wheaton MG, 2012, COGNITIVE THER RES, V36, P210, DOI 10.1007/s10608-011-9353-3
   WHO, 2020, MOD TRANSM VIR CAUS
   Wikipedia, 2020, MIS REL 2019 20 COR
   World Health Organization, 2020, COR DIS COVID 19 ADV
   World Health Organization, 2020, ROLL UPD COR DIS COV
   Worldometer, 2020, WORLD COR AUSTR
   Zimet GD, 2013, PREV MED, V57, P414, DOI 10.1016/j.ypmed.2013.05.013
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 42
TC 1
Z9 1
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD SEP 30
PY 2020
VL 11
AR 551004
DI 10.3389/fpsyg.2020.551004
PG 11
WC Psychology, Multidisciplinary
SC Psychology
GA OB2JQ
UT WOS:000578300100001
PM 33117223
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alag, S
AF Alag, Shray
TI Analysis of COVID-19 clinical trials: A data-driven, ontology-based, and
   natural language processing approach
SO PLOS ONE
LA English
DT Article
AB With the novel COVID-19 pandemic disrupting and threatening the lives of millions, researchers and clinicians have been recently conducting clinical trials at an unprecedented rate to learn more about the virus and potential drugs/treatments/vaccines to treat its infection. As a result of the influx of clinical trials, researchers, clinicians, and the lay public, now more than ever, face a significant challenge in keeping up-to-date with the rapid rate of discoveries and advances. To remedy this problem, this research mined the ClinicalTrials.gov corpus to extract COVID-19 related clinical trials, produce unique reports to summarize findings and make the meta-data available via Application Programming Interfaces (APIs). Unique reports were created for each drug/intervention, Medical Subject Heading (MeSH) term, and Human Phenotype Ontology (HPO) term. These reports, which have been run over multiple time points, along with APIs to access meta-data, are freely available at. The pipeline, reports, association of COVID-19 clinical trials with MeSH and HPO terms, insights, public repository, APIs, and correlations produced are all novel in this work. The freely available, novel resources present up-to-date relevant biological information and insights in a robust, accessible manner, illustrating their invaluable potential to aid researchers overcome COVID-19 and save hundreds of thousands of lives.
C1 [Alag, Shray] Harker Sch, San Jose, CA 95117 USA.
RP Alag, S (corresponding author), Harker Sch, San Jose, CA 95117 USA.
EM 21shraya@students.harker.org
CR Alag S., 2008, COLLECTIVE INTELLIGE
   Alag S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233438
   [Anonymous], 2020, LANCET EDITORIAL, V2, pE268, DOI 10.1016/S2589-7500(20)30113-8
   [Anonymous], 2006, DRUGS LACT DAT LACTM
   Das S, 2020, CLIN DRUG INVEST, V40, P591, DOI 10.1007/s40261-020-00927-1
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Ferreira JC, 2017, J BRAS PNEUMOL, V43, P5, DOI [10.1590/S1806-37562017000000021, 10.1590/s1806-37562017000000021]
   Heidary F, 2020, J ANTIBIOT, V73, P593, DOI 10.1038/s41429-020-0336-z
   Ingersoll G. S., 2013, TAMING TEXT FIND ORG
   Kelleni MT, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104874
   Li ZY, 2020, DRUG DISCOV THER, V14, P73, DOI 10.5582/ddt.2020.01015
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
NR 12
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 30
PY 2020
VL 15
IS 9
AR e0239694
DI 10.1371/journal.pone.0239694
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ4YT
UT WOS:000577103100022
PM 32997699
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lombardo, FL
   Salvi, E
   Lacorte, E
   Piscopo, P
   Mayer, F
   Ancidoni, A
   Remoli, G
   Bellomo, G
   Losito, G
   D'Ancona, F
   Canevelli, M
   Onder, G
   Vanacore, N
AF Lombardo, Flavia L.
   Salvi, Emanuela
   Lacorte, Eleonora
   Piscopo, Paola
   Mayer, Flavia
   Ancidoni, Antonio
   Remoli, Giulia
   Bellomo, Guido
   Losito, Gilda
   D'Ancona, Fortunato
   Canevelli, Marco
   Onder, Graziano
   Vanacore, Nicola
CA Italian Natl Inst Hlth Nursing
TI Adverse Events in Italian Nursing Homes During the COVID-19 Epidemic: A
   National Survey
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE dementia; adverse events; nursing homes; Long-Term Care Facilities;
   COVID-19; public health
ID CARE; RESIDENTS
AB Older people living in nursing homes (NHs) are particularly vulnerable in the ongoing COVID-19 pandemic, due to the high prevalence of chronic diseases and disabilities (e.g., dementia). The phenomenon of adverse events (AEs), intended as any harm or injury resulting from medical care or to the failure to provide care, has not yet been investigated in NHs during the pandemic. We performed a national survey on 3,292 NHs, either public or providing services both privately and within the national health system, out of the 3,417 NHs covering the whole Italian territory. An online questionnaire was addressed to the directors of each facility between March 24 and April 27, 2020. The list of NHs was provided by the Dementia Observatory, an online map of Italian services for people with dementia, which was one of the objectives of the implementation of the Italian National Dementia Plan. About 26% of residents in the Italian NHs for older people listed within the Dementia Observatory site had dementia. The objective of our study was to report the frequency of AEs that occurred during the months when SARS-CoV-2 spreading rate was at its highest in the Italian NHs and to identify which conditions and attributes were most associated with the occurrence of AEs by means of multivariate regression logistic analysis. Data are referred to 1,356 NHs that participated in the survey. The overall response rate was 41.2% over a time-period of six weeks (from March 24 to May 5). About one third of the facilities (444 out of 1,334) (33.3%) reported at least 1 adverse event, with a total of 2,000 events. Among the included NHs, having a bed capacity higher than the median of 60 beds (OR=1.57, CI95% 1.17-2.09; p=0.002), an observed increased in the use of psychiatric drugs (OR=1.80, CI95% 1.05-3.07; p=0.032), adopting physical restraint measures (OR=1.97, CI95% 1.47-2.64; p<0.001), residents hospitalized due to flu-like symptoms (OR =1.73, CI95% 1.28-2.32; p<0.001), and being located in specific geographic areas (OR=3.59, CI95% 1.81-7.08; OR = 2.90, CI95% 1.45-5.81 and OR = 4.02, CI05% 2.01-8.04 for, respectively, North-West, North-East and Centre vs South, p<0.001) were all factors positively associated to the occurrence of adverse events in the facility. Future recommendations for the management and care of residents in NHs during the COVID-19 pandemic should include specific statements for the most vulnerable populations, such as people with dementia.
C1 [Lombardo, Flavia L.; Lacorte, Eleonora; Mayer, Flavia; Ancidoni, Antonio; Bellomo, Guido; Canevelli, Marco; Vanacore, Nicola] Italian Natl Inst Hlth, Natl Ctr Dis Prevent & Hlth Promot, Rome, Italy.
   [Salvi, Emanuela] Italian Natl Inst Hlth, Natl Ctr Drug Res & Evaluat, Rome, Italy.
   [Piscopo, Paola] Italian Natl Inst Hlth, Dept Neurosci, Rome, Italy.
   [Remoli, Giulia; Canevelli, Marco] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy.
   [Losito, Gilda] Unit Hlth Care & Deprivat Liberty, Rome, Italy.
   [D'Ancona, Fortunato] Italian Natl Inst Hlth, Dept Infect Dis, Rome, Italy.
   [Onder, Graziano] Italian Natl Inst Hlth, Dept Cardiovasc Endocrine Metab Dis & Aging, Rome, Italy.
RP Vanacore, N (corresponding author), Italian Natl Inst Hlth, Natl Ctr Dis Prevent & Hlth Promot, Rome, Italy.
EM nicola.vanacore@iss.it
CR Abrams HR, 2020, J AM GERIATR SOC, V68, P1653, DOI 10.1111/jgs.16661
   Amer Geriatrics Soc, 2020, J AM GERIATR SOC, V68, P1131, DOI 10.1111/jgs.16510
   Ancidoni A, SURVEY NAZL CONTAGIO
   Andersson A, 2018, J CLIN NURS, V27, pE354, DOI 10.1111/jocn.13914
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Bleijlevens MHC, 2016, J AM GERIATR SOC, V64, P2307, DOI 10.1111/jgs.14435
   British Geriatrics Society, 2020, MAN COVID 19 PAND CA
   Burki T, 2020, LANCET, V395, P1602, DOI 10.1016/S0140-6736(20)31199-5
   Centers for Disease Control, 2020, PREP COVID 19 LONG T
   Cherubini A, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2011.04.001
   Di Fiandra T, 2015, ANN I SUPER SANITA, V51, P261, DOI 10.4415/ANN_15_04_02
   Di Pucchio A, 2017, ANN I SUPER SANITA, V53, P246, DOI 10.4415/ANN_17_03_11
   Edelman Linda S, 2020, JMIR Aging, V3, pe20110, DOI 10.2196/20110
   ELJEN Technology Corporation, 2020, TECHNICAL REPORT
   Gardner W, 2020, J AGING SOC POLICY, V32, P310, DOI 10.1080/08959420.2020.1750543
   Gaur S, 2020, INFECT CONT HOSP EP, V41, P729, DOI 10.1017/ice.2020.98
   Graham NSN, 2020, J INFECTION, V81, P411, DOI 10.1016/j.jinf.2020.05.073
   Husebo BS, 2020, AM J GERIAT PSYCHIAT, V28, P792, DOI 10.1016/j.jagp.2020.04.016
   Interim indications for the prevention and control of SARS-COV-2 infection in residential social and health facilities, 2020, 42020 I SUP SAN, pii
   Kapoor A, 2019, JAMA INTERN MED, V179, P1254, DOI 10.1001/jamainternmed.2019.2005
   Landi F, 2014, J AM MED DIR ASSOC, V15, P825, DOI 10.1016/j.jamda.2014.08.002
   McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412
   Padala SP, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.113028
   Recio-Saucedo A, 2018, J CLIN NURS, V27, P2248, DOI 10.1111/jocn.14058
   Riccardo F, 2020, EPIDEMIOLOGICAL CHAR, DOI [10.1101/2020.04.08.20056861, DOI 10.1101/2020.04.08.20056861, 10.1101/2020.04.08.2005686115.]
   Ruggiero C, 2009, DRUG AGING, V26, P15, DOI 10.2165/11534630-000000000-00000
   Seitz D, 2010, INT PSYCHOGERIATR, V22, P1025, DOI 10.1017/S1041610210000608
   Shmueli T, 2014, INT J HEALTH CARE Q, V27, P91, DOI 10.1108/IJHCQA-05-2012-0051
   Stall NM, PROFIT NURSING HOMES, DOI [10.1101/2020.05.25.20112664, DOI 10.1101/2020.05.25.20112664]
   TAN LF, 2020, J AM GERIATR SO 0402, DOI DOI 10.1016/j.jmii.2020.04.018
   Trabucchi M, 2020, LANCET PSYCHIAT, V7, P387, DOI 10.1016/S2215-0366(20)30149-8
   Tsai HH, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1678
   Vanacore N, 2019, 13 C IMP CTR COGN DI, P97
   Wang HL, 2020, LANCET, V395, P1190, DOI 10.1016/S0140-6736(20)30755-8
   World Health Organization, 2020, INF PREV CONTR GUID
   Zimmermann J, 2019, EUR J AGEING, V16, P503, DOI 10.1007/s10433-019-00511-3
NR 36
TC 1
Z9 1
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD SEP 30
PY 2020
VL 11
AR 578465
DI 10.3389/fpsyt.2020.578465
PG 9
WC Psychiatry
SC Psychiatry
GA OA1AI
UT WOS:000577527100001
PM 33132938
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Zhou, T
   Nguyen, TVT
   Zhong, JY
   Liu, JS
AF Zhou, Tong
   Thuy-vy Thi Nguyen
   Zhong, Jiayi
   Liu, Junsheng
TI A COVID-19 descriptive study of life after lockdown in Wuhan, China
SO ROYAL SOCIETY OPEN SCIENCE
LA English
DT Article
DE loneliness; depression; well-being; COVID-19
ID LATENT GROWTH; SELF-DETERMINATION; FAMILY ROUTINES; CURVE MODELS;
   MISSING DATA; SET-POINT; POWER; UNEMPLOYMENT; HAPPINESS; EVENTS
AB On 8 April 2020, the Chinese government lifted the lockdown and opened up public transportation in Wuhan, China, the epicentre of the COVID-19 pandemic. After 76 days in lockdown, Wuhan residents were allowed to travel outside of the city and go back to work. Yet, given that there is still no vaccine for the virus, this leaves many doubting whether life will indeed go back to normal. The aim of this research was to track longitudinal changes in motivation for self-isolating, life-structured, indicators of well-being and mental health after lockdown was lifted. We have recruited 462 participants in Wuhan, China, prior to lockdown lift between 3 and 7 April 2020 (Time 1), and have followed up with 292 returning participants between 18 and 22 April 2020 (Time 2), 284 between 6 and 10 May 2020 (Time 3), and 279 between 25 and 29 May 2020 (Time 4). This four-wave study used latent growth models to examine how Wuhan residents' psychological experiences change (if at all) within the first two months after lockdown was lifted. The Stage 1 manuscript associated with this submission received in-principle acceptance (IPA) on 2 June 2020. Following IPA, the accepted Stage 1 version of the manuscript was preregistered on the OSF at https://osf.io/g2t3b. This preregistration was performed prior to data analysis. Generally, our study found that: (i) a majority of people still continue to value self-isolation after lockdown was lifted; (ii) by the end of lockdown, people perceived gradual return to normality and restored structure of everyday life; (iii) the psychological well-being slightly improved after lockdown was lifted; (iv) people who used problem solving and help-seeking as coping strategies during lockdown had better well-being and mental health by the end of the lockdown; (v) those who experienced more disruptions in daily life during lockdown would display more indicators of psychological ill-being by the end of the lockdown.
C1 [Zhou, Tong; Zhong, Jiayi; Liu, Junsheng] East China Normal Univ, Sch Psychol & Cognit Sdence, Dept Psychol, Shanghai, Peoples R China.
   [Thuy-vy Thi Nguyen] Univ Durham, Durham, England.
RP Nguyen, TVT (corresponding author), Univ Durham, Durham, England.
EM thuy-vy.nguyen@durham.ac.uk
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2017ECNUHLYT013,
   2018ECNU-QKT015]
FX This work was supported by the Fundamental Research Funds for the
   Central Universities (2017ECNUHLYT013, 2018ECNU-QKT015) to J.L.
CR Allison PD, 2003, J ABNORM PSYCHOL, V112, P545, DOI 10.1037/0021-843X.112.4.545
   Andresen EM, 2013, SAGE OPEN MED, V1, DOI 10.1177/2050312113514576
   Asmundson GJG, 2020, J ANXIETY DISORD, V71, DOI 10.1016/j.janxdis.2020.102211
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Brandmaier AM, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00272
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Chen BW, 2015, MOTIV EMOTION, V39, P216, DOI 10.1007/s11031-014-9450-1
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Chen SM, 2020, LANCET, V395, P1305, DOI 10.1016/S0140-6736(20)30744-3
   Chen SM, 2020, LANCET, V395, P764, DOI 10.1016/S0140-6736(20)30421-9
   Cristadoro R, 2012, J CHIN ECON BUS STUD, V10, P275, DOI 10.1080/14765284.2012.699702
   Curran PJ, 2010, J COGN DEV, V11, P121, DOI 10.1080/15248371003699969
   Diallo TMO, 2014, BEHAV RES METHODS, V46, P357, DOI 10.3758/s13428-013-0395-1
   Diener E, 2009, SOC INDIC RES SER, V39, P213, DOI 10.1007/978-90-481-2354-4_10
   Fan XT, 2005, J EXP EDUC, V73, P121
   Ferro MA, 2014, ANN EPIDEMIOL, V24, P75, DOI 10.1016/j.annepidem.2013.10.007
   Fiese BH, 2002, J FAM PSYCHOL, V16, P381, DOI 10.1037//0893-3200.16.4.381
   Frederick SY, 1999, STUD INT R, P306
   Gao JL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231924
   Ghosh R, 2020, MINERVA PEDIATR, V72, P226, DOI 10.23736/S0026-4946.20.05887-9
   Hall NW, 1997, PARENTS MAGAZINE MAR, V72, P90
   Harrist A. W., 2019, APA HDB CONT FAMILY, P223, DOI [10.1037/0000099-013, DOI 10.1037/0000099-013]
   He H, 2018, J MONETARY ECON, V94, P94, DOI 10.1016/j.jmoneco.2017.12.002
   He LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084164
   Hersey F., 2018, TECHNODE        0327
   Hertzog C, 2008, STRUCT EQU MODELING, V15, P541, DOI 10.1080/10705510802338983
   Hu YY, 2020, BRAIN BEHAV IMMUN, V89, P587, DOI 10.1016/j.bbi.2020.07.016
   Huang P, 2020, LIFE LOCKDOWN SHOCK
   Infurna FJ, 2019, CURR DIR PSYCHOL SCI, V28, P152, DOI 10.1177/0963721419827017
   JENSEN EW, 1983, SOC SCI MED, V17, P201, DOI 10.1016/0277-9536(83)90117-X
   Jeong H, 2016, EPIDEMIOL HEALTH, V38, DOI 10.4178/epih.e2016048
   Kase LM, 1999, PARENTS MAGAZINE OCT, V74, P114
   Kessler RC, 1997, ANNU REV PSYCHOL, V48, P191, DOI 10.1146/annurev.psych.48.1.191
   Kuo Lily, 2020, GUARDIAN
   La Guardia JG, 2000, J PERS SOC PSYCHOL, V79, P367, DOI 10.1037//0022-3514.79.3.367
   Li CX, 2018, INT J SPORT EXERC PS, V16, P465, DOI [10.1080/1612197X.2016.1256342, 10.1080/1612197x.2016.1256342]
   Lucas RE, 2004, PSYCHOL SCI, V15, P8, DOI 10.1111/j.0963-7214.2004.01501002.x
   Lucas RE, 2007, CURR DIR PSYCHOL SCI, V16, P75, DOI 10.1111/j.1467-8721.2007.00479.x
   Luchetti M, 2020, AM PSYCHOL, V75, P897, DOI 10.1037/amp0000690
   Meng X, 2003, J COMP ECON, V31, P465, DOI 10.1016/S0147-5967(03)00069-6
   Ryan RM, 2006, J PERS, V74, P1557, DOI 10.1111/j.1467-6494.2006.00420.x
   RYAN RM, 1989, J PERS SOC PSYCHOL, V57, P749, DOI 10.1037/0022-3514.57.5.749
   SCALISE JJ, 1984, J PERS ASSESS, V48, P525, DOI 10.1207/s15327752jpa4805_12
   Shin T, 2017, PSYCHOL METHODS, V22, P426, DOI 10.1037/met0000094
   Song XB, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093120
   Sytsma SE, 2001, J PSYCHOPATHOL BEHAV, V23, P241, DOI 10.1023/A:1012727419873
   Tang WJ, 2018, PSYCHIAT RES, V270, P89, DOI 10.1016/j.psychres.2018.09.027
   Tuncay T, 2015, J SOC SERV RES, V41, P466, DOI 10.1080/01488376.2015.1033584
   Weinstein N, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.200458
   World Bank, 2020, 2020 WORLD BANK E AS
   Xiao J., 1996, J CHINESE MENTAL HLT, V10, P164
   Yu XX, 2020, INFLUENZA OTHER RESP, V14, P474, DOI 10.1111/irv.12743
   Zhang ML, 2018, WP18277 IMF
   ZHENG YP, 1994, PSYCHOSOM MED, V56, P296, DOI 10.1097/00006842-199407000-00004
NR 54
TC 0
Z9 0
U1 3
U2 3
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 2054-5703
J9 ROY SOC OPEN SCI
JI R. Soc. Open Sci.
PD SEP 30
PY 2020
VL 7
IS 9
AR 200705
DI 10.1098/rsos.200705
PG 41
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ2UO
UT WOS:000576952800001
PM 33047032
OA DOAJ Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Sahin, U
   Muik, A
   Derhovanessian, E
   Vogler, I
   Kranz, LM
   Vormehr, M
   Baum, A
   Pascal, K
   Quandt, J
   Maurus, D
   Brachtendorf, S
   Lorks, V
   Sikorski, J
   Hilker, R
   Becker, D
   Eller, AK
   Grutzner, J
   Boesler, C
   Rosenbaum, C
   Kuhnle, MC
   Luxemburger, U
   Kemmer-Bruck, A
   Langer, D
   Bexon, M
   Bolte, S
   Kariko, K
   Palanche, T
   Fischer, B
   Schultz, A
   Shi, PY
   Fontes-Garfias, C
   Perez, JL
   Swanson, KA
   Loschko, J
   Scully, IL
   Cutler, M
   Kalina, W
   Kyratsous, CA
   Cooper, D
   Dormitzer, PR
   Jansen, KU
   Tureci, O
AF Sahin, Ugur
   Muik, Alexander
   Derhovanessian, Evelyna
   Vogler, Isabel
   Kranz, Lena M.
   Vormehr, Mathias
   Baum, Alina
   Pascal, Kristen
   Quandt, Jasmin
   Maurus, Daniel
   Brachtendorf, Sebastian
   Loerks, Verena
   Sikorski, Julian
   Hilker, Rolf
   Becker, Dirk
   Eller, Ann-Kathrin
   Gruetzner, Jan
   Boesler, Carsten
   Rosenbaum, Corinna
   Kuehnle, Marie-Cristine
   Luxemburger, Ulrich
   Kemmer-Brueck, Alexandra
   Langer, David
   Bexon, Martin
   Bolte, Stefanie
   Kariko, Katalin
   Palanche, Tania
   Fischer, Boris
   Schultz, Armin
   Shi, Pei-Yong
   Fontes-Garfias, Camila
   Perez, John L.
   Swanson, Kena A.
   Loschko, Jakob
   Scully, Ingrid L.
   Cutler, Mark
   Kalina, Warren
   Kyratsous, Christos A.
   Cooper, David
   Dormitzer, Philip R.
   Jansen, Kathrin U.
   Tuereci, Oezlem
TI COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell
   responses
SO NATURE
LA English
DT Article; Early Access
ID RNA; CORONAVIRUS; CAPACITY; MICE
AB In a phase I/II dose-escalation clinical trial, the mRNA COVID-19 vaccine BNT162b1 elicits specific T cell and antibody responses that suggest it has protective potential.
   An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein(1). Here we present antibody and T cell responses after vaccination with BNT162b1 from a second, non-randomized open-label phase I/II trial in healthy adults, 18-55 years of age. Two doses of 1-50 mu g of BNT162b1 elicited robust CD4(+)and CD8(+)T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those seen in serum from a cohort of individuals who had recovered from COVID-19. Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-mu g dose) to 3.5-fold (50-mu g dose) those of the recovered individuals. Immune sera broadly neutralized pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (T(H)1)-skewed T cell immune responses with RBD-specific CD8(+)and CD4(+)T cell expansion. Interferon-gamma was produced by a large fraction of RBD-specific CD8(+)and CD4(+)T cells. The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
C1 [Sahin, Ugur; Muik, Alexander; Derhovanessian, Evelyna; Vogler, Isabel; Kranz, Lena M.; Vormehr, Mathias; Quandt, Jasmin; Maurus, Daniel; Brachtendorf, Sebastian; Loerks, Verena; Sikorski, Julian; Hilker, Rolf; Becker, Dirk; Eller, Ann-Kathrin; Gruetzner, Jan; Boesler, Carsten; Rosenbaum, Corinna; Kuehnle, Marie-Cristine; Luxemburger, Ulrich; Kemmer-Brueck, Alexandra; Langer, David; Bolte, Stefanie; Kariko, Katalin; Palanche, Tania; Fischer, Boris; Tuereci, Oezlem] BioNTech, Mainz, Germany.
   [Sahin, Ugur] Univ Med Ctr Johannes Gutenberg, TRON gGmbH Translat Oncol, Mainz, Germany.
   [Baum, Alina; Pascal, Kristen; Kyratsous, Christos A.] Regeneron Pharmaceut, Tarrytown, NY USA.
   [Bexon, Martin] Bexon Clin Consulting, Montclair, NJ USA.
   [Schultz, Armin] CRS Clin Res Serv Mannheim GmbH, Mannheim, Germany.
   [Shi, Pei-Yong; Fontes-Garfias, Camila] Univ Texas Med Branch, Galveston, TX 77555 USA.
   [Perez, John L.; Swanson, Kena A.; Loschko, Jakob; Scully, Ingrid L.; Cutler, Mark; Kalina, Warren; Cooper, David; Dormitzer, Philip R.; Jansen, Kathrin U.] Pfizer, Pearl River, NY USA.
RP Sahin, U (corresponding author), BioNTech, Mainz, Germany.; Sahin, U (corresponding author), Univ Med Ctr Johannes Gutenberg, TRON gGmbH Translat Oncol, Mainz, Germany.
EM ugur.sahin@biontech.de
OI Hilker, Rolf/0000-0002-8576-7731; Vormehr, Mathias/0000-0001-7788-3380
CR Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074
   [Anonymous], COR DIS COVID 19 DAS
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Chong WP, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-82
   Destexhe E, 2013, J PHARMACOL TOX MET, V68, P367, DOI 10.1016/j.vascn.2013.04.003
   Doener F, 2019, VACCINE, V37, P1819, DOI 10.1016/j.vaccine.2019.02.024
   Gallais F., 2020, INTRAFAMILIAL EXPOSU, DOI [10.1101/2020.06.21.20132449v1, DOI 10.1101/2020.06.21.20132449V1]
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024
   Kamphuis E, 2006, BLOOD, V108, P3253, DOI 10.1182/blood-2006-06-027599
   Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200
   Moodie Z, 2010, CANCER IMMUNOL IMMUN, V59, P1489, DOI 10.1007/s00262-010-0875-4
   Moodie Z, 2006, J IMMUNOL METHODS, V315, P121, DOI 10.1016/j.jim.2006.07.015
   Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4
   Muruato AE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17892-0
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Pardi N, 2019, MOL THER-NUCL ACIDS, V15, P36, DOI 10.1016/j.omtn.2019.03.003
   Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0
   Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450
   Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428
   Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9
   Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278
   Sainz B, 2004, VIROLOGY, V329, P11, DOI 10.1016/j.virol.2004.08.011
   Sette A, 2008, IMMUNITY, V28, P847, DOI 10.1016/j.immuni.2008.04.018
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Taylor DN, 2012, VACCINE, V30, P5761, DOI 10.1016/j.vaccine.2012.06.086
   Tsai MY, 2005, J LAB CLIN MED, V145, P323, DOI 10.1016/j.lab.2005.03.009
   U.S. Department of Health and Human Services, 2007, TOX GRAD SCAL HLTH A
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   von Niessen AGO, 2019, MOL THER, V27, P824, DOI 10.1016/j.ymthe.2018.12.011
   Walsh E. E., 2020, RNA BASED COVID 19 V, DOI [10.1101/2020.08.17.20176651v2, DOI 10.1101/2020.08.17.20176651V2]
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Zhang L., 2020, BIORXIV, DOI [10.1101/2020.06.12.148726v1, DOI 10.1101/2020.06.12.148726V1]
NR 37
TC 5
Z9 5
U1 37
U2 37
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
DI 10.1038/s41586-020-2814-7
EA SEP 2020
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ7QQ
UT WOS:000577298900001
PM 32998157
OA Other Gold
DA 2021-01-01
ER

PT J
AU Abella, BS
   Jolkovsky, EL
   Biney, BT
   Uspal, JE
   Hyman, MC
   Frank, I
   Hensley, SE
   Gill, S
   Vogl, DT
   Maillard, I
   Babushok, DV
   Huang, AC
   Nasta, SD
   Walsh, JC
   Wiletyo, EP
   Gimotty, PA
   Milone, MC
   Amaravadi, RK
AF Abella, Benjamin S.
   Jolkovsky, Eliana L.
   Biney, Barbara T.
   Uspal, Julie E.
   Hyman, Matthew C.
   Frank, Ian
   Hensley, Scott E.
   Gill, Saar
   Vogl, Dan T.
   Maillard, Ivan
   Babushok, Daria, V
   Huang, Alexander C.
   Nasta, Sunita D.
   Walsh, Jennifer C.
   Wiletyo, E. Paul
   Gimotty, Phyllis A.
   Milone, Michael C.
   Amaravadi, Ravi K.
CA Prevention Treatment COVID-19 Hydr
TI Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure
   SARS-CoV-2 Prophylaxis Among Health Care Workers A Randomized Clinical
   Trial
SO JAMA INTERNAL MEDICINE
LA English
DT Article; Early Access
ID AZITHROMYCIN; COVID-19
AB IMPORTANCE Health care workers (HCWs) caring for patients with coronavirus disease 2019 (COVID-19) are at risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, to our knowledge, there is no effective pharmacologic prophylaxis for individuals at risk.
   OBJECTIVE To evaluate the efficacy of hydroxychloroquine to prevent transmission of SARS-CoV-2 in hospital-based HCWs with exposure to patients with COVID-19 using a pre-exposure prophylaxis strategy.
   DESIGN, SETTING, AND PARTICIPANTS This randomized, double-blind, placebo-controlled clinical trial (the Prevention and Treatment of COVID-19 With Hydroxychloroquine Study) was conducted at 2 tertiary urban hospitals, with enrollment from April 9, 2020, to July 14, 2020; follow-up ended August 4, 2020. The trial randomized 132 full-time, hospital-based HCWs (physicians, nurses, certified nursing assistants, emergency technicians, and respiratory therapists), of whom 125 were initially asymptomatic and had negative results for SARS-CoV-2 by nasopharyngeal swab. The trial was terminated early for futility before reaching a planned enrollment of 200 participants.
   INTERVENTIONS Hydroxychloroquine, 600 mg, daily, or size-matched placebo taken orally for 8 weeks.
   MAIN OUTCOMES AND MEASURES The primary outcome was the incidence of SARS-CoV-2 infection as determined by a nasopharyngeal swab during the 8 weeks of treatment. Secondary outcomes included adverse effects, treatment discontinuation, presence of SARS-CoV-2 antibodies, frequency of QTc prolongation, and clinical outcomes for SARS-CoV-2-positive participants.
   RESULTS Of the 132 randomized participants (median age, 33 years [range, 20-66 years]; 91 women [69%]), 125 (94.7%) were evaluable for the primary outcome. There was no significant difference in infection rates in participants randomized to receive hydroxychloroquine compared with placebo (4 of 64 [6.3%] vs 4 of 61 [6.6%];P > .99). Mild adverse events were more common in participants taking hydroxychloroquine compared with placebo (45% vs 26%; P = .04); rates of treatment discontinuation were similar in both arms (19% vs 16%; P = .81). The median change in QTc (baseline to 4-week evaluation) did not differ between arms (hydroxychloroquine: 4 milliseconds; 95% CI, -9 to 17; vs placebo: 3 milliseconds; 95% CI, -5 to 11; P = .98). Of the 8 participants with positive results for SARS-CoV-2 (6.4%), 6 developed viral symptoms; none required hospitalization, and all clinically recovered.
   CONCLUSIONS AND RELEVANCE In this randomized clinical trial, although limited by early termination, there was no clinical benefit of hydroxychloroquine administered daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19.
C1 [Abella, Benjamin S.; Jolkovsky, Eliana L.; Biney, Barbara T.; Uspal, Julie E.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA.
   [Hyman, Matthew C.] Univ Penn, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA.
   [Frank, Ian] Univ Penn, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA.
   [Hensley, Scott E.] Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA.
   [Gill, Saar; Vogl, Dan T.; Maillard, Ivan; Babushok, Daria, V; Huang, Alexander C.; Nasta, Sunita D.; Walsh, Jennifer C.; Amaravadi, Ravi K.] Univ Penn, Dept Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Gill, Saar; Vogl, Dan T.; Maillard, Ivan; Babushok, Daria, V; Huang, Alexander C.; Nasta, Sunita D.; Walsh, Jennifer C.; Amaravadi, Ravi K.] Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.
   [Wiletyo, E. Paul; Gimotty, Phyllis A.] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA.
   [Milone, Michael C.] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA.
RP Amaravadi, RK (corresponding author), Div Hematol Oncol, 852 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.
EM ravi.amaravadi@pennmedidne.upenn.edu
CR BAMPOE S, 2020, ANAESTHESIA 0810, DOI DOI 10.1111/ANAE.15229
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Cohen MS, 2020, NEW ENGL J MED, V383, P585, DOI 10.1056/NEJMe2020388
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Google, PUBLICLY AVAILABLE C
   Grau-Pujol B, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04621-7
   Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   Nanni O, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04527-4
   National Cancer Institute, COMMON TERMINOLOGY C
   Olender Susan A, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1041
   Puntmann Valentina O, 2020, JAMA Cardiol, V5, P1265, DOI 10.1001/jamacardio.2020.3557
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Shippey EA, 2018, CLEV CLIN J MED, V85, P459, DOI 10.3949/ccjm.85a.17034
   Tai Don Bambino Geno, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa815
   US Centers for Disease Control and Prevention , CDC COVID DATA TRACK
   Voisin O, 2020, MAYO CLIN PROC, V95, P1696, DOI 10.1016/j.mayocp.2020.05.005
   Weinberger DM, 2020, JAMA INTERN MED, V180, P1336, DOI 10.1001/jamainternmed.2020.3391
   Wright JK, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04577-8
   Ye CY, 2020, J MED VIROL, V92, P2821, DOI 10.1002/jmv.26183
   Zhang CH, 2020, J RURAL HEALTH, V36, P433, DOI 10.1111/jrh.12476
NR 23
TC 6
Z9 6
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
DI 10.1001/jamainternmed.2020.6319
EA SEP 2020
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA NY4LR
UT WOS:000576363600001
PM 33001138
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Jiang, YY
   Liu, LX
   Manning, M
   Bonahoom, M
   Lotvola, A
   Yang, Z
   Yang, ZQ
AF Jiang, Yuanyuan
   Liu, Lanxin
   Manning, Morenci
   Bonahoom, Madison
   Lotvola, Aaron
   Yang, Zhe
   Yang, Zeng-Quan
TI Structural analysis, virtual screening and molecular simulation to
   identify potential inhibitors targeting 2'-O-ribose methyltransferase of
   SARS-CoV-2 coronavirus
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; nsp16; methyltransferase; KDKE motif; virtual screening;
   molecular dynamics simulation; inhibitor
ID RNA METHYLATION; RIBOSOMAL-RNA; PROTEIN; DOCKING; ATTENUATION;
   2'-O-METHYLATION; VISUALIZATION; RIMEGEPANT; MUTATIONS; DISCOVERY
AB SARS-CoV-2, an emerging coronavirus, has spread rapidly around the world, resulting in over ten million cases and more than half a million deaths as of July 1, 2020. Effective treatments and vaccines for SARS-CoV-2 infection do not currently exist. Previous studies demonstrated that nonstructural protein 16 (nsp16) of coronavirus is an S-adenosyl methionine (SAM)-dependent 2'-O-methyltransferase (2'-O-MTase) that has an important role in viral replication and prevents recognition by the host innate immune system. In the present study, we employed structural analysis, virtual screening, and molecular simulation approaches to identify clinically investigated and approved drugs which can act as promising inhibitors against nsp16 2 '-O-MTase of SARS-CoV-2. Comparative analysis of primary amino acid sequences and crystal structures of seven human CoVs defined the key residues for nsp16 2-O'-MTase functions. Virtual screening and docking analysis ranked the potential inhibitors of nsp16 from more than 4,500 clinically investigated and approved drugs. Furthermore, molecular dynamics simulations were carried out on eight top candidates, including Hesperidin, Rimegepant, Gs-9667, and Sonedenoson, to calculate various structural parameters and understand the dynamic behavior of the drug-protein complexes. Our studies provided the foundation to further test and repurpose these candidate drugs experimentally and/or clinically for COVID-19 treatment. Communicated by Ramaswamy H. Sarma
EM yangz@karmanos.org
FU Department of Defense (DoD) Breast Cancer Program [BC161536]; Elsa U.
   Pardee Foundation; DMC Foundation; Molecular Therapeutics Program of
   Karmanos Cancer Institute; Susan G. KomenSusan G. Komen Breast Cancer
   Foundation [GTDR14299438]; Wayne State University Graduate School
FX This work was partially supported by grants from the Department of
   Defense (DoD) Breast Cancer Program BC161536, Elsa U. Pardee Foundation,
   DMC Foundation and Molecular Therapeutics Program of Karmanos Cancer
   Institute to Dr. Zeng-Quan Yang; and by funding from Susan G. Komen
   GTDR14299438 and Wayne State University Graduate School Dean Mathur
   Fellowship to Morenci Manning.
CR Aggarwal V, 2020, EXP BIOL MED, V245, P486, DOI 10.1177/1535370220903671
   Aouadi W, 2017, J VIROL, V91, DOI 10.1128/JVI.02217-16
   Ayadi L, 2019, BBA-GENE REGUL MECH, V1862, P253, DOI 10.1016/j.bbagrm.2018.11.009
   Bai L, 2019, AM J CHINESE MED, V47, P933, DOI 10.1142/S0192415X19500496
   Belanger F, 2010, J BIOL CHEM, V285, P33037, DOI 10.1074/jbc.M110.155283
   Bell IM, 2014, J MED CHEM, V57, P7838, DOI 10.1021/jm500364u
   Berman H. M., 2000, NUCL ACIDS RES, V28, pD235, DOI DOI HTTPS://DOI.ORG/10.1093/NAR/28.1.235
   Bhardwaj VK, 2020, INT J BIOL MACROMOL, V148, P999, DOI 10.1016/j.ijbiomac.2020.01.212
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   Boccaletto P, 2018, NUCLEIC ACIDS RES, V46, pD303, DOI 10.1093/nar/gkx1030
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Bugl H, 2000, MOL CELL, V6, P349, DOI 10.1016/S1097-2765(00)00035-6
   Byszewska M, 2014, RNA BIOL, V11, P1597, DOI 10.1080/15476286.2015.1004955
   Chang CK, 2016, MOL BIOSYST, V12, P59, DOI 10.1039/c5mb00582e
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Chiu SW, 2009, J PHYS CHEM B, V113, P2748, DOI 10.1021/jp807056c
   Davis IW, 2009, J MOL BIOL, V385, P381, DOI 10.1016/j.jmb.2008.11.010
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Ding Z, 2018, ANTIVIR THER, V23, P611, DOI 10.3851/IMP3235
   Drilon A, 2019, ANN ONCOL, V30, pVIII23, DOI 10.1093/annonc/mdz282
   ENCINAR JA, 2020, VIRUSES BASEL, V12, DOI DOI https://doi.org/10.3390/v12050525
   Freude K, 2004, AM J HUM GENET, V75, P305, DOI 10.1086/422507
   Gao ZG, 2011, EXPERT OPIN EMERG DR, V16, P597, DOI 10.1517/14728214.2011.644786
   Geiss GK, 2003, J VIROL, V77, P6367, DOI 10.1128/JVI.77.11.6367-6375.2003
   GIOIA D, 2017, MOLECULES, V22, DOI DOI https://doi.org/10.3390/molecules22112029
   Gonzales-van Horn SR, 2017, CELL HOST MICROBE, V21, P661, DOI 10.1016/j.chom.2017.05.008
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guy MP, 2015, HUM MUTAT, V36, P1176, DOI 10.1002/humu.22897
   Hager J, 2002, J BIOL CHEM, V277, P41978, DOI 10.1074/jbc.M205423200
   Haggag Yusuf A, 2020, Med Hypotheses, V144, P109957, DOI 10.1016/j.mehy.2020.109957
   Hijikata A, 2020, FEBS LETT, V594, P1960, DOI 10.1002/1873-3468.13806
   Holm Liisa, 2020, Methods Mol Biol, V2112, P29, DOI 10.1007/978-1-0716-0270-6_3
   Hyde JL, 2015, VIROLOGY, V479, P66, DOI 10.1016/j.virol.2015.01.019
   INESTAVAQUERA F, 2017, WIRES RNA, V8, DOI DOI https://doi.org/10.1002/wrna.1450
   JACOBSON KA, 2019, FRONT CELL NEUROSCI, V13, DOI DOI https://doi.org/10.3389/fncel.2019.00124
   Kadumuri RV, 2018, TRENDS MOL MED, V24, P886, DOI 10.1016/j.molmed.2018.07.010
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI https://doi.org/10.1080/07391102.2020.1753577
   Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   LAGARDE N, 2019, INT J MOL SCI, V20, DOI DOI https://doi.org/10.3390/ijms20184648
   Lagarde Nathalie, 2018, Oncotarget, V9, P32346, DOI 10.18632/oncotarget.25966
   Lasko LM, 2017, NATURE, V550, P128, DOI 10.1038/nature24028
   Lee KW, 2014, J BIOL CHEM, V289, P24936, DOI 10.1074/jbc.C114.581868
   Lee KW, 2013, J BIOL CHEM, V288, P31386, DOI 10.1074/jbc.M113.515692
   Lemmon G, 2012, METHODS MOL BIOL, V819, P143, DOI 10.1007/978-1-61779-465-0_10
   LI B, 2020, NAT COMMUN, V11, DOI DOI https://doi.org/10.1038/s41467-019-13965-x
   Li J, 2020, EMBO REP, V21, DOI 10.15252/embr.202050095
   Li S, 2014, ANNU REV GENOM HUM G, V15, P127, DOI 10.1146/annurev-genom-090413-025405
   Lipton RB, 2019, NEW ENGL J MED, V381, P142, DOI 10.1056/NEJMoa1811090
   MAIA EHB, 2020, FRONT CHEM, V8, DOI DOI https://doi.org/10.3389/fchem.2020.00343
   Manning M, 2020, RNA BIOL, V17, P474, DOI 10.1080/15476286.2019.1708549
   Mateo J, 2016, BRIT J CANCER, V114, P889, DOI 10.1038/bjc.2016.59
   Menachery VD, 2014, VIRUS RES, V194, P191, DOI 10.1016/j.virusres.2014.09.009
   Menachery VD, 2014, J VIROL, V88, P4251, DOI 10.1128/JVI.03571-13
   NETZBAND R, 2020, WIRES RNA, V11, DOI DOI https://doi.org/10.1002/wrna.1576
   Paissoni C., 2015, COMPUT PHYS COMMUN, V186, P105, DOI DOI 10.1016/j.cpc.2014.09.010
   Panda PK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8097
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   PINZI L, 2019, INT J MOL SCI, V20, DOI DOI https://doi.org/10.3390/ijms20184331
   POLI G, 2020, MOLECULES, V25, DOI DOI https://doi.org/10.3390/molecules25081971
   Rajendran V, 2018, J CELL BIOCHEM, V119, P918, DOI 10.1002/jcb.26257
   Ringeard M, 2019, NATURE, V565, P500, DOI 10.1038/s41586-018-0841-4
   Roundtree IA, 2017, CELL, V169, P1187, DOI 10.1016/j.cell.2017.05.045
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Salvatore CA, 2010, J PHARMACOL EXP THER, V333, P152, DOI 10.1124/jpet.109.163816
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Sartore-Bianchi A, 2020, EXPERT REV ANTICANC, V20, P333, DOI 10.1080/14737140.2020.1747439
   Schneidman-Duhovny D, 2008, NUCLEIC ACIDS RES, V36, pW223, DOI 10.1093/nar/gkn187
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Scott LJ, 2020, DRUGS, V80, P741, DOI 10.1007/s40265-020-01301-3
   Sevajol M, 2014, VIRUS RES, V194, P90, DOI 10.1016/j.virusres.2014.10.008
   Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025
   Skuta C, 2017, NAT METHODS, V14, P758, DOI 10.1038/nmeth.4365
   Slater O, 2019, EXPERT OPIN DRUG DIS, V14, P619, DOI 10.1080/17460441.2019.1604677
   Sledz P, 2018, CURR OPIN STRUC BIOL, V48, P93, DOI 10.1016/j.sbi.2017.10.010
   Smietanski M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4004
   Staehr PM, 2013, J CLIN PHARMACOL, V53, P385, DOI 10.1002/jcph.9
   Su AI, 2002, P NATL ACAD SCI USA, V99, P15669, DOI 10.1073/pnas.202608199
   Subissi L, 2014, ANTIVIR RES, V101, P122, DOI 10.1016/j.antiviral.2013.11.006
   TAZIKEHLEMESKI E, 2020, J BIOMOL STRUCT 0619, DOI DOI https://doi.org/10.1080/07391102.2020.1779133
   Tejada S, 2018, CURR MED CHEM, V25, P4929, DOI 10.2174/0929867324666170718104412
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   VIJAYAN V, 2020, J BIOMOL STRUCT 0731, DOI DOI https://doi.org/10.1080/07391102.2020.1802349
   VISWANATHAN T, 2020, NAT COMMUN, V11, DOI DOI https://doi.org/10.1038/s41467-020-17496-8
   Volkamer A, 2012, BIOINFORMATICS, V28, P2074, DOI 10.1093/bioinformatics/bts310
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang Y, 2005, NUCLEIC ACIDS RES, V33, P2302, DOI 10.1093/nar/gki524
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zust R, 2011, NAT IMMUNOL, V12, P137, DOI 10.1038/ni.1979
NR 93
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1828172
EA SEP 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NW4PZ
UT WOS:000574991800001
PM 33016237
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ayerbe, L
   Risco-Risco, C
   Ayis, S
AF Ayerbe, Luis
   Risco-Risco, Carlos
   Ayis, Salma
TI The association of treatment with hydroxychloroquine and hospital
   mortality in COVID-19 patients
SO INTERNAL AND EMERGENCY MEDICINE
LA English
DT Article
DE Coronavirus infections; COVID-19; Hydroxychloroquine; Mortality
AB This study investigates the association between the treatment with hydroxychloroquine and mortality in patients admitted with COVID-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with COVID-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with hydroxychloroquine, azithromycin, heparin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality. Multivariable logistic regression models were used to investigate the associations. At the time of collecting the data, 301 patients had died, 1449 had been discharged home from the hospitals, 240 were still admitted, and 85 had been transferred to hospitals not included in the study. Median follow-up time was 8 (IQR 5-12) days. Hydroxychloroquine had been used in 1857 patients. Hydroxychloroquine was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI): 0.44 (0.29-0.67). This association remained significant when saturation of oxygen < 90% and temperature > 37 degrees C were added to de model with OR 0.45 (0.30-0.68)p < 0.001, and also when all the other drugs, and time of admission, were included as covariates. The association between hydroxychloroquine and lower mortality observed in this study can be acknowledged by clinicians in hospitals and in the community. Randomized-controlled trials to assess the causal effects of hydroxychloroquine in different therapeutic regimes are required.
C1 [Ayerbe, Luis] Queen Mary Univ London, Ctr Primary Care & Publ Hlth, 58 Turner St, London E1 2AB, England.
   [Ayerbe, Luis] Carnarvon Med Ctr, Southend On Sea, England.
   [Risco-Risco, Carlos] Univ HM Sanchinarro, Serv Internal Med, Madrid, Spain.
   [Ayis, Salma] Kings Coll London, Sch Populat Hlth & Environm Sci, London, England.
   [Ayis, Salma] Guys & St Thomas NHS Fdn Trust, Natl Inst Hlth Res, Biomed Res Ctr, London, England.
RP Ayerbe, L (corresponding author), Queen Mary Univ London, Ctr Primary Care & Publ Hlth, 58 Turner St, London E1 2AB, England.; Ayerbe, L (corresponding author), Carnarvon Med Ctr, Southend On Sea, England.
EM l.garcia-morzon@qmul.ac.uk
OI Ayerbe Garcia-Monzon, Luis/0000-0001-7177-0262; Ayis,
   Salma/0000-0002-0449-869X
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Guy's and St Thomas' NHS Foundation Trust and King's College
   London
FX Salma Ayis was funded by the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS
   Foundation Trust and King's College London. The views expressed are
   those of the authors and not necessarily those of the NHS, the NIHR, or
   the Department of Health.
CR [Anonymous], 2020, LANCET, V395, P1011, DOI DOI 10.1016/S0140-6736(20)30686-3
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Chen L, 2020, EFFICACY SAFETY CHLO, DOI DOI 10.1101/2020.06.19.20136093V1
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gbinigie Kome, 2020, BJGP Open, V4, DOI 10.3399/bjgpopen20X101069
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Guastalegname M, 2020, CLIN INFECT DIS, V71, P888, DOI 10.1093/cid/ciaa321
   Guerin V, 2020, ASIAN J MED HLTH, V18, P45, DOI [10.9734/ajmah/2020/v18i730224, DOI 10.9734/AJMAH/2020/V18I730224]
   Ip A, 2020, HYDROXYCHLOROQUINE T, DOI DOI 10.1101/2020.05.21.20109207V1
   Lagier JC, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101791
   Leung K, 2020, LANCET, V395, P1382, DOI 10.1016/S0140-6736(20)30746-7
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Membrillo FJ, 2020, EARLY HYDROXYCHLOROQ
   Mikami T, 2020, J GEN INTERN MED, DOI 10.1007/s11606-020-05983-z
   Million M, 2020, New Microbes New Infect, V38, P100709, DOI 10.1016/j.nmni.2020.100709
   NICE-BNF, 2020, HYDR SULF
   Patel AP, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01227-y
   Raoult D, 2020, COMMUNICATION
   Recovery, 2020, NO CLIN BEN US HYDR
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Sbidian E, 2020, HYDROXYCHLOROQUINE A, DOI DOI 10.1101/2020.06.16.20132597V1
   Scholz M, 2020, COVID 19 OUTPATIENTS
   Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Walker PGT, 2020, GLOBAL IMPACT COVID
   WHO, 2020, COR DIS COVID 19 PAN
   WHO, 2020, WHO DISC HYDR LOP RI
   WISE J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2294
   World Health Organization, 2020, SOL CLIN TRIAL COVID
   World Health Organization, 2020, NAM COR DIS COVID 19
   Worldometer, 2020, COVID 19 COR PAND
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Yu B, 2020, SCI CHINA LIFE SCI, V63, P1515, DOI 10.1007/s11427-020-1732-2
NR 40
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1828-0447
EI 1970-9366
J9 INTERN EMERG MED
JI Intern. Emerg. Med.
PD NOV
PY 2020
VL 15
IS 8
SI SI
BP 1501
EP 1506
DI 10.1007/s11739-020-02505-x
EA SEP 2020
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA OM3BZ
UT WOS:000574051500001
PM 32997237
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Ziade, N
   Hmamouchi, I
   el Kibbi, L
   Abdulateef, N
   Halabi, H
   Abutiban, F
   Hamdi, W
   el Rakawi, M
   Eissa, M
   Masri, B
AF Ziade, Nelly
   Hmamouchi, Ihsane
   el Kibbi, Lina
   Abdulateef, Nizar
   Halabi, Hussein
   Abutiban, Fatemah
   Hamdi, Wafa
   el Rakawi, Manal
   Eissa, Mervat
   Masri, Basel
TI The impact of COVID-19 pandemic on rheumatology practice: a
   cross-sectional multinational study
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Access to care; COVID-19; Rheumatologist; Rheumatology practice
ID RECOMMENDATIONS; ARTHRITIS
AB Objective To evaluate the impact of the coronavirus disease 2019 (COVID-19) pandemic on rheumatology practice.
   Method A cross-sectional web survey was designed by the members of the Arab League of Associations for Rheumatology (ArLAR), validated by its scientific committee and disseminated through e-mail and social media. It included close-ended questions about the impact of the pandemic on the rheumatology activities, including outpatient visits and hospitalizations (in percentage, 100% corresponds to complete suspension) and open-ended questions about unmet needs. Univariate and multivariable logistic regression analyses were used to evaluate the predictors of impact. Suggestions were developed to improve the practice.
   Results A total of 858 rheumatologists were included in the analysis (27.3% of registered in ArLAR), 37% were 35-44 years old, 60% were females, and 48% worked in the private sector. The impact of COVID-19 was a decrease of 69% in hospitalizations, 65% in outpatient clinic, 56% in infusion centers, and 43% in income. It was associated with the region (highest in the Gulf), use of telemedicine, impact on income and practice sector (lowest in private). There was a hydroxychloroquine shortage in 47%. Telemedicine was mostly based on traditional telephone contacts and e-mails and reimbursed in 12%. Fifteen rheumatologists (1.8%) were infected and 156 cases of COVID-19 were reported among patients. The top-cited unmet needs in rheumatology practice were access to drugs and a telemedicine platform.
   Conclusions The negative impact of the COVID-19 pandemic on rheumatology practice may compromise rheumatic diseases control. Better access to drugs and providing telemedicine platforms are recommended to improve the practice.
C1 [Ziade, Nelly] St Joseph Univ, Hotel Dieu France Hosp, Tour Consultat Externes, 6th Floor,Alfred Naccache Blvd Achrafieh, Beirut, Lebanon.
   [Hmamouchi, Ihsane] Mohammed V Univ, Temara Hosp, Lab Biostat Clin Res & Epidemiol LBRCE, Fac Med & Pharm, Rabat, Morocco.
   [el Kibbi, Lina] Specialized Med Ctr, Riyadh, Saudi Arabia.
   [Abdulateef, Nizar] Univ Baghdad, Rheumatol Unit, Dept Med, Coll Med, Baghdad, Iraq.
   [Halabi, Hussein] King Faisal Specialist Hosp & Res Ctr, Jeddah, Saudi Arabia.
   [Abutiban, Fatemah] Jaber Alahmed Alsabah Hosp, Rheumatol Unit, Dept Med, Kuwait, State Of Kuwait, Kuwait.
   [Hamdi, Wafa] Tunis El Manar Univ, Dept Rheumatol, Kassab Inst Orthoped, UR17SP04,Fac Med Tunis, Tunis, Tunisia.
   [el Rakawi, Manal] Douera Hosp, Dept Rheumatol, Fac Med, Saad Dahlab, Blida, Algeria.
   [Eissa, Mervat] Cairo Univ, Dept Rheumatol, Cairo, Egypt.
   [Masri, Basel] Jordan Hosp, Amman, Jordan.
RP Ziade, N (corresponding author), St Joseph Univ, Hotel Dieu France Hosp, Tour Consultat Externes, 6th Floor,Alfred Naccache Blvd Achrafieh, Beirut, Lebanon.
EM nellziade@yahoo.fr
OI Eissa, Mervat/0000-0001-7999-3401
CR Benucci Maurizio, 2020, Rev Rhum Ed Fr, V87, P150, DOI 10.1016/j.rhum.2020.03.010
   Caricchio R, 2020, J RHEUMATOL, V47, DOI 10.3899/jrheum.200740
   Cron RQ, 2020, J RHEUMATOL, V47, P1723, DOI [10.3899/jrheum.200744, 10.3899/jrheum.200334]
   D'Silva KM, 2020, ANN RHEUM DIS, V79, P1156, DOI [10.1136/annrheumdis-2020-217888, 10.1136/annrheumdis-2020-218196, 10.1136/annrheumdis-2020-218179, 10.1136/annrheumdis-2020-218431]
   England NHS, 2020, CLIN GUID MAN RHEUM, P1
   Eurosurveillance Editorial Team, 2020, EUROSURVEILLANCE, V25, P2019, DOI DOI 10.2807/1560-7917.ES.2020.25.5.200131E
   Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34
   Favalli EG, 2020, J RHEUMATOL, V47, P1296, DOI 10.3899/jrheum.200507
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Freites D., 2020, RISK FACTORS HOSP AD, DOI [10.1101/2020.05.14.20101584, DOI 10.1101/2020.05.14.20101584]
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Government MBRS, 2017, AR SOC MED REP SOC M
   Graef ER, 2020, ANN RHEUM DIS, V79, P734, DOI 10.1136/annrheumdis-2020-217480
   Michaud Kaleb, 2020, ACR Open Rheumatol, V2, P335, DOI 10.1002/acr2.11148
   Mikuls TR, 2020, ARTHRITIS RHEUMATOL, V72, P1241, DOI 10.1002/art.41301
   Misra DP, 2020, CLIN RHEUMATOL, V39, P2055, DOI 10.1007/s10067-020-05073-9
   Mohn N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01059
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Prevention C for DC, 2020, CDC HLTH ALERT NETW, P1
   Putman MS, 2020, J RHEUMATOL, V47, P791, DOI 10.3899/jrheum.200411
   Rose C, 2020, NEW ENGL J MED, V382, P1684, DOI 10.1056/NEJMp2004768
   Schulze-Koops H, 2020, ANN RHEUM DIS, V79, P840, DOI 10.1136/annrheumdis-2020-217628
   Shanthanna H, 2020, ANAESTHESIA, V75, P935, DOI 10.1111/anae.15076
   Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919
   Tang DL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008536
   Wendy E, 2020, NEW ENGL J MED, V28, P1, DOI DOI 10.1056/NEJMP2002125
   World Health Organization, 2020, WORLD HEAL ORGAN, V119, P2633, DOI [10.1001/jama.2020.2633, DOI 10.1001/JAMA.2020.2633]
   World Health Organization (WHO), 2020, WHO ANN COVID 19 OUT
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Ye C, 2020, ANN RHEUM DIS, V79, P1007, DOI 10.1136/annrheumdis-2020-217627
NR 31
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770-3198
EI 1434-9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD NOV
PY 2020
VL 39
IS 11
BP 3205
EP 3213
DI 10.1007/s10067-020-05428-2
EA SEP 2020
PG 9
WC Rheumatology
SC Rheumatology
GA OA8ZQ
UT WOS:000573793000002
PM 32996071
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Aazh, H
   Swanepoel, D
   Moore, BCJ
AF Aazh, Hashir
   Swanepoel, De Wet
   Moore, Brian C. J.
TI Telehealth tinnitus therapy during the COVID-19 outbreak in the UK:
   uptake and related factors
SO INTERNATIONAL JOURNAL OF AUDIOLOGY
LA English
DT Article; Early Access
DE Tinnitus; audiology; covid-19; video; telehealth
AB Objective The Audiology Department at the Royal Surrey County Hospital usually offers face-to-face audiologist-delivered cognitive behavioural therapy (CBT) for tinnitus rehabilitation. During COVID-19 lockdown, patients were offered telehealth CBT via video using a web-based platform. This study evaluated the proportion of patients who took up the offer of telehealth sessions and factors related to this. Design Retrospective service evaluation. Study sample 113 consecutive patients whose care was interrupted by the lockdown. Results 80% of patients accepted telehealth. The main reasons for declining were not having access to a suitable device and the belief that telehealth appointments would not be useful. Compared to having no hearing loss in the better ear, having a mild or moderate hearing loss increased the chance of declining telehealth by factors of 3.5 (p = 0.04) and 14.9 (p = 0.038), respectively. High tinnitus annoyance as measured via the visual analogue scale increased the chance of declining telehealth appointments by a factor of 1.4 (p = 0.019). Conclusions Although CBT via telehealth was acceptable to most patients, alternatives may be necessary for the 20% who declined. These tended to have worse hearing in their better ear and more annoying tinnitus.
C1 [Aazh, Hashir] Royal Surrey Cty Hosp NHS Fdn Trust, Dept Audiol, Guildford, Surrey, England.
   [Swanepoel, De Wet] Univ Pretoria, Dept Speech Language Pathol & Audiol, Gauteng, South Africa.
   [Swanepoel, De Wet] Ear Sci Inst Australia, Subiaco, WA, Australia.
   [Moore, Brian C. J.] Univ Cambridge, Dept Expt Psychol, Cambridge, England.
RP Aazh, H (corresponding author), Royal Surrey Cty Hosp, Dept Audiol, Tinnitus & Hyperacusis Therapy Specialist Clin, Egerton Rd, Guildford GU2 7XX, Surrey, England.
EM hashir.aazh@nhs.net
OI Aazh, Hashir/0000-0002-6839-5649; Moore, Brian/0000-0001-7071-0671
CR Aazh Hashir, 2019, Am J Audiol, V28, P973, DOI 10.1044/2019_AJA-19-0045
   Aazh H, 2019, PSYCHOL RES BEHAV MA, V12, P991, DOI 10.2147/PRBM.S179138
   Aazh H, 2019, J AM ACAD AUDIOL, V30, P712, DOI 10.3766/jaaa.17144
   Aazh H, 2018, AM J AUDIOL, V27, P547, DOI 10.1044/2018_AJA-17-0096
   Aazh H, 2018, INT J AUDIOL, V57, P415, DOI 10.1080/14992027.2018.1431405
   Aazh H, 2017, AM J AUDIOL, V26, P226, DOI 10.1044/2017_AJA-17-0011
   Aazh H, 2017, INT J AUDIOL, V56, P489, DOI 10.1080/14992027.2017.1298850
   Aazh H, 2016, INT J AUDIOL, V55, P149, DOI 10.3109/14992027.2015.1074733
   Aazh H, 2009, AM J AUDIOL, V18, P7, DOI 10.1044/1059-0889(2009/08-0037)
   Adamchic I, 2012, AM J AUDIOL, V21, P215, DOI 10.1044/1059-0889(2012/12-0010)
   Almufarrij I, 2020, INT J AUDIOL, V59, P487, DOI 10.1080/14992027.2020.1776406
   Bennett-Levy J., 2004, OXFORD GUIDE BEHAV E
   Beukes EW, 2019, TRENDS HEAR, V23, P1, DOI 10.1177/2331216519851749
   Beukes EW, 2018, AM J AUDIOL, V27, P431, DOI 10.1044/2018_AJA-IMIA3-18-0004
   Beukes EW, 2018, EAR HEARING, V39, P423, DOI 10.1097/AUD.0000000000000505
   Bogoch II, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa011
   Bolot J. C., 1995, LECT NOTES COMPUTER, P154
   BSA, 2011, PUR TON AIR COND BON
   Dang S, 2018, TELEMED E-HEALTH, V24, P203, DOI 10.1089/tmj.2017.0089
   De Sousa KC, 2020, INT J AUDIOL, V59, P801, DOI 10.1080/14992027.2020.1783585
   DiGiovanni G, 2020, J GERIATR ONCOL, V11, P761, DOI 10.1016/j.jgo.2020.04.007
   Donaghy E, 2019, BRIT J GEN PRACT, V69, pE586, DOI 10.3399/bjgp19X704141
   Eby TL, 2020, OTOLARYNG HEAD NECK, V163, P110, DOI 10.1177/0194599820928989
   Ericsson, 2020, ERICSSON MOBILITY RE
   Figueiredo Ricardo Rodrigues, 2009, Braz J Otorhinolaryngol, V75, P76
   Fletcher H., 1953, SPEECH HEARING COMMU
   Henry JA, 2019, EAR HEARING, V40, P227, DOI 10.1097/AUD.0000000000000609
   HLAA, 2020, FREE ACC AUT CAPT PE
   Huang VW, 2020, HEAD NECK-J SCI SPEC, V42, P1664, DOI 10.1002/hed.26235
   Iacobucci G, 2020, BMJ, V368, pm39, DOI 10.1136/bmj.m39
   Iacobucci G, 2018, BMJ, V362, pk2946, DOI 10.1136/bmj.k294629973394
   Keesara S, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005835
   Kilic O, 2020, INT J INFECT DIS, V97, P208, DOI 10.1016/j.ijid.2020.06.023
   Kowalski LP, 2020, HEAD NECK-J SCI SPEC, V42, P1259, DOI 10.1002/hed.26164
   Mahafza N, 2020, INT J AUDIOL, DOI 10.1080/14992027.2020.1804081
   MAXWELL C, 1978, BRIT J CLIN PHARMACO, V6, P15, DOI 10.1111/j.1365-2125.1978.tb01676.x
   McManus F, 2012, J BEHAV THER EXP PSY, V43, P540, DOI 10.1016/j.jbtep.2011.07.003
   Molini-Avejonas DR, 2015, J TELEMED TELECARE, V21, P367, DOI 10.1177/1357633X15583215
   Moore B. C. J., 2007, COCHLEAR HEARING LOS
   Moss P, 2020, LANCET, V395, pE46, DOI 10.1016/S0140-6736(20)30463-3
   NHS, 2019, NHS LONG TERM PLAN
   ODowd A., 2018, BMJ, V362, pk3934, DOI 10.1136/bmj.k393430217932
   Peto J, 2020, LANCET, V395, P1420, DOI 10.1016/S0140-6736(20)30936-3
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Ratanjee-Vanmali H, 2020, J MED INTERNET RES, V22, DOI 10.2196/15875
   Rix AW, 2001, INT CONF ACOUST SPEE, P749, DOI 10.1109/ICASSP.2001.941023
   Rogers C., 1965, CLIENT CTR THERAPY
   StataCorp, 2013, STATA STAT SOFTW REL
   Swanepoel DW, 2010, TELEMED J E-HEALTH, V16, P182, DOI 10.1089/tmj.2009.0111
   Swanepoel DW, 2020, HEAR J, V73, P20, DOI DOI 10.1097/01.HJ.0000669852.90548.75
   Tao KFM, 2018, J SPEECH LANG HEAR R, V61, P1831, DOI 10.1044/2018_JSLHR-H-16-0397
   Wosik J, 2020, J AM MED INFORM ASSN, V27, P957, DOI 10.1093/jamia/ocaa067
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
NR 53
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1499-2027
EI 1708-8186
J9 INT J AUDIOL
JI Int. J. Audiol.
DI 10.1080/14992027.2020.1822553
EA SEP 2020
PG 6
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA NV2XX
UT WOS:000574192400001
PM 33000663
OA Bronze
DA 2021-01-01
ER

PT J
AU Dadras, MS
   Ahmadzadeh, Z
   Younespour, S
   Abdollahimajd, F
AF Shahidi Dadras, Mohammad
   Ahmadzadeh, Zohreh
   Younespour, Shima
   Abdollahimajd, Fahimeh
TI Evaluation of anxiety and depression in patients with morphea taking
   immunosuppressive drugs during the COVID-19 pandemic
SO JOURNAL OF DERMATOLOGICAL TREATMENT
LA English
DT Article; Early Access
DE Anxiety; coronavirus disease 2019; COVID-19; depression;
   immunosuppressive treatment; SARS-CoV-2
ID QUALITY-OF-LIFE
AB Background During the coronavirus disease 2019 (COVID-19) pandemic, individuals especially those with chronic diseases face various problems like psychological distress. Aim To evaluate anxiety and depression among morphea patients taking immunosuppressants compared with controls during the COVID-19 pandemic. Methods In this case-control study, electronic data of 42 eligible morphea patients and 42 age- and sex-matched healthy subjects were extracted. All participants were asked about adherence to the health protocols and the symptoms of COVID-19. To investigate anxiety and depression, we provided the participants with an online version of the Hospital Anxiety and Depression Scale (HADS) Questionnaire. In this standard questionnaire, a score >= 11 represents a significant psychological disorder. Results The two groups did not differ significantly in the mean HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) scores (p= .08 andp= .79, respectively). HADS-A and HADS-D scores were >= 11 in 16.67% and 11.90% of the patients, respectively. Among the morphea patients, those with sleeping problems during COVID-19 had a significantly higher mean HADS-D score (p= .048). Notably, 21.43% of patients discontinued their treatment due to fear of COVID-19 and experienced disease recurrence. Adherence to health protocols was higher in patients compared with controls. The rate of COVID-19 occurrence was not significantly different between the groups. Conclusions Although there was no significant difference in anxiety and depression between the groups, it is recommended to provide psychiatric counseling opportunities to morphea patients to improve treatment outcomes during this pandemic.
C1 [Shahidi Dadras, Mohammad; Ahmadzadeh, Zohreh; Abdollahimajd, Fahimeh] Shahid Beheshti Univ Med Sci, Skin Res Ctr, Tehran, Iran.
   [Younespour, Shima] Univ Tehran Med Sci, Dent Res Inst, Tehran, Iran.
   [Abdollahimajd, Fahimeh] Shahid Beheshti Univ Med Sci, Shohada E Tajrish Hosp, Clin Res Dev Unit, Tehran, Iran.
RP Abdollahimajd, F (corresponding author), Shahid Beheshti Univ Med Sci, Shohada E Tajrish Hosp, Skin Res Ctr, Tehran, Iran.
EM fabdollahimajd@sbmu.ac.ir
CR Albuquerque JVD, 2019, COCHRANE DB SYST REV, V7
   Alipour A, 2020, J HEALTH PSYCHOL, V8, P163, DOI DOI 10.30473/HPJ.2020.52023.4756
   [Anonymous], 2020, CLIN GUIDE MANAGEMEN
   Bali G, 2018, QUAL LIFE RES, V27, P2525, DOI 10.1007/s11136-018-1897-1
   Bocran C, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0354-0
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13298
   Das S, 2014, J AM ACAD DERMATOL, V70, P904, DOI 10.1016/j.jaad.2013.11.037
   Kaviani H, 2009, TEHRAN U MED J, V67, P379
   Klimas NK, 2015, BRIT J DERMATOL, V172, P1329, DOI 10.1111/bjd.13572
   Kroft EBM, 2009, ARCH DERMATOL, V145, P1017, DOI 10.1001/archdermatol.2009.202
   Rocken M, 2018, TXB DERMATOLOGY, P707
   Salari M, 2020, MOVEMENT DISORD, V35, P1095, DOI 10.1002/mds.28116
   Dadras MS, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1775771
   Shahidi-Dadras M, 2018, DERMAT RES PRACT, DOI 10.1155/2018/8391218
   Szramka-Pawlak B, 2014, APPL RES QUAL LIFE, V9, P863, DOI 10.1007/s11482-013-9273-3
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 16
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-6634
EI 1471-1753
J9 J DERMATOL TREAT
JI J. Dermatol. Treat.
DI 10.1080/09546634.2020.1819528
EA SEP 2020
PG 7
WC Dermatology
SC Dermatology
GA NV0AF
UT WOS:000573995600001
PM 32893725
OA Other Gold
DA 2021-01-01
ER

PT J
AU Abdelrheem, DA
   Ahmed, SA
   Abd El-Mageed, HR
   Mohamed, HS
   Rahman, AA
   Elsayed, KNM
   Ahmed, SA
AF Abdelrheem, Doaa A.
   Ahmed, Shimaa A.
   Abd El-Mageed, H. R.
   Mohamed, Hussein S.
   Rahman, Aziz A.
   Elsayed, Khaled N. M.
   Ahmed, Sayed A.
TI The inhibitory effect of some natural bioactive compounds against
   SARS-CoV-2 main protease: insights from molecular docking analysis and
   molecular dynamic simulation
SO JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART A-TOXIC/HAZARDOUS
   SUBSTANCES & ENVIRONMENTAL ENGINEERING
LA English
DT Article
DE COVID-19 virus protease; natural products; caulerpin; molecular docking;
   MD simulation
ID ANTIVIRAL DRUG; ACID; GLYCOGLYCEROLIPIDS; CONSTITUENTS; EXTRACT; LEAVES;
   ALGAE; RED
AB This work aimed at evaluating the inhibitory effect of ten natural bioactive compounds (1-10) as potential inhibitors of SARS-CoV-2-3CL main protease (PDB ID: 6LU7) and SARS-CoV main proteases (PDB IDs: 2GTB and 3TNT) by molecular docking analysis. The inhibitory effect of all studied compounds was studied with compared to some proposed antiviral drugs which currently used in COVID-19 treatment such as chloroquine, hydroxychloroquine, azithromycin, remdesivir, baloxvir, lopinavir, and favipiravir. Homology modeling and sequence alignment was computed to evaluate the similarity between the SARS-CoV-2-3CL main protease and other SARS-CoV receptors. ADMET properties of all studied compounds were computed and reported. Also, molecular dynamic (MD) simulation was performed on the compound which has the highest binding affinity inside 6LU7 obtained from molecular docking analysis to study it is stability inside receptor in explicit water solvent. Based on molecular docking analysis, we found that caulerpin has the highest binding affinity inside all studied receptors compared to other bioactive compounds and studied drugs. Our homology modeling and sequence alignment showed that SARS-CoV main protease (PDB ID: 3TNT) shares high similarity with 3CLpro (96.00%). Also, ADMET properties confirmed that caulerpin obeys Lipinski's rule and passes ADMET property, which make it a promising compound to act as a new safe natural drug against SARS-CoV-2-3CL main protease. Finally, MD simulation confirmed that the complex formed between caulerpin and 3CLpro is stable in water explicit and had no major effect on the flexibility of the protein throughout the simulations and provided a suitable basis for our study. Also, binding free energy between caulerpin and 6LU7 confirmed the efficacy of the caulerpin molecule against SARS-CoV-2 main protease. So, this study suggested that caulerpin could be used as a potential candidate in COVID-19 treatment.
C1 [Abdelrheem, Doaa A.; Ahmed, Shimaa A.; Ahmed, Sayed A.] Beni Suef Univ, Fac Sci, Dept Chem, Bani Suwayf 62511, Egypt.
   [Abd El-Mageed, H. R.] Beni Suef Univ, Fac Sci, Microanal & Environm Res & Community Serv Ctr, Bani Suwayf, Egypt.
   [Mohamed, Hussein S.] Beni Suef Univ, Res Inst Med & Aromat Plants RIMAP, Bani Suwayf, Egypt.
   [Rahman, Aziz A.] Univ Rajshahi, Dept Pharm, Rajshahi, Bangladesh.
   [Elsayed, Khaled N. M.] Beni Suef Univ, Fac Sci, Dept Bot, Bani Suwayf, Egypt.
RP Ahmed, SA (corresponding author), Beni Suef Univ, Fac Sci, Dept Chem, Bani Suwayf 62511, Egypt.
EM sayed.hassan@science.bsu.edu.eg
CR Abdelrheem DA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1784285
   Abubakar Mustapha N, 2016, Medicines (Basel), V3, DOI 10.3390/medicines3010003
   Ahmed SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1774418
   Angiola L., 2018, COMPLEM ALTERN MED, V2018
   Baell JB, 2016, J NAT PROD, V79, P616, DOI 10.1021/acs.jnatprod.5b00947
   Baidya M, 2012, J AM CHEM SOC, V134, P18566, DOI 10.1021/ja309311z
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Boxall ABA, 2004, EMBO REP, V5, P1110, DOI 10.1038/sj.embor.7400307
   Chen XR, 2017, FRONT CHEM, V5, DOI 10.3389/fchem.2017.00098
   Chen Z, 2014, J AGR FOOD CHEM, V62, P6130, DOI 10.1021/jf500083r
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   El-Sherif M. F., 2004, EGYPT J PHYCOL, V5
   Esteves PO, 2019, NAT PROD COMMUN, V14, DOI 10.1177/1934578X19878295
   Fasya AG, 2019, AIP CONF PROC, V2120, DOI 10.1063/1.5115629
   Fithriani D, 2019, IOP C SER EARTH ENV, V404, DOI 10.1088/1755-1315/404/1/012064
   GHOSAL S, 1976, J PHARM SCI, V65, P1549, DOI 10.1002/jps.2600651038
   Govenkar MB, 2000, PHYTOCHEMISTRY, V54, P979, DOI 10.1016/S0031-9422(00)00078-9
   Grabarczyk M., 2015, FOLIA BIOL OECOL, V11, P1, DOI [10.1515/fobio-2015-0001, DOI 10.1515/FOBIO-2015-0001]
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hoet S, 2007, J NAT PROD, V70, P1360, DOI 10.1021/np070038q
   Horincar VB, 2014, J APPL PHYCOL, V26, P551, DOI 10.1007/s10811-013-0053-0
   Huang XP, 2007, MOLECULES, V12, P582, DOI 10.3390/12030582
   Illijas MI, 2009, J OLEO SCI, V58, P103, DOI 10.5650/jos.58.103
   Krishnan K. R., 2016, Journal of Chemical and Pharmaceutical Research, V8, P614
   Lee JA, 2017, PHYTOTHER RES, V31, P1694, DOI 10.1002/ptr.5892
   Li Y, 2020, BIORXIV
   Libran-Perez M, 2019, FISH SHELLFISH IMMUN, V95, P595, DOI 10.1016/j.fsi.2019.10.055
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Liu X., 2020, CRYSTAL STRUCTURE CO
   Lorenzo VP, 2015, REV BRAS FARMACOGN, V25, P690, DOI 10.1016/j.bjp.2015.08.005
   Lu IL, 2006, J MED CHEM, V49, P5154, DOI 10.1021/jm060207o
   Lunagariya J, 2019, MINI-REV MED CHEM, V19, P751, DOI 10.2174/1389557517666170927154231
   Mahmoud Eman A., 2015, Egyptian Journal of Petroleum, V24, P97, DOI 10.1016/j.ejpe.2015.02.010
   Malarvizhi D., 2016, ADV CHEM, V6, P669, DOI DOI 10.1080/22297928.2016.1238319
   Marcolongo G, 2006, NAT PROD RES, V20, P766, DOI 10.1080/14786410500176393
   Mericli Filiz, 2017, Pharm Biol, V55, P1239, DOI 10.1080/13880209.2017.1296003
   Nagappan T, 2014, J APPL PHYCOL, V26, P1019, DOI 10.1007/s10811-013-0147-8
   Nyigo V.A., 2016, J PHYTOPHARM, V5, P100
   Ododo MM, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2894-x
   Otero P, 2018, MAR DRUGS, V16, DOI 10.3390/md16050156
   ozen o., 2015, INT C APPL BIOL SCI
   Parvez MK, 2018, SAUDI PHARM J, V26, P685, DOI 10.1016/j.jsps.2018.02.022
   Payghami N, 2015, PHARMACOGN RES, V7, P314, DOI 10.4103/0974-8490.167893
   Peng Y, 2018, MOLECULES, V23, DOI 10.3390/molecules23020348
   Plouguerne E, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00174
   Macedo NRPV, 2012, REV BRAS FARMACOGN, V22, P861, DOI 10.1590/S0102-695X2012005000072
   SANDS JA, 1977, ANTIMICROB AGENTS CH, V12, P523, DOI 10.1128/AAC.12.4.523
   Sang P., 2020, PREPRINT
   Shahat AA, 2019, ACTA TROP, V191, P243, DOI 10.1016/j.actatropica.2019.01.013
   Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606
   Shi DY, 2011, CHIN J OCEANOL LIMN, V29, P674, DOI 10.1007/s00343-011-0183-7
   Shiota A, 2010, J MED INVESTIG, V57, P314, DOI 10.2152/jmi.57.314
   Wang XY, 2020, KNOWL MANAG AQUAT EC, DOI 10.1051/kmae/2020011
   Xia B, 2011, PROTEIN CELL, V2, P282, DOI 10.1007/s13238-011-1034-1
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang Xiudong, 2011, Algae, V26, P201, DOI 10.4490/algae.2011.26.2.201
   Yang Y, 2015, MICROBIOLOGY+, V84, P710, DOI 10.1134/S0026261715050173
   Zhang HP, 2020, INTERDISCIP SCI, V12, P368, DOI 10.1007/s12539-020-00376-6
   Zhang J, 2014, MAR DRUGS, V12, P3634, DOI 10.3390/md12063634
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 60
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1093-4529
EI 1532-4117
J9 J ENVIRON SCI HEAL A
JI J. Environ. Sci. Health Part A-Toxic/Hazard. Subst. Environ. Eng.
PD SEP 30
PY 2020
VL 55
IS 11
BP 1373
EP 1386
DI 10.1080/10934529.2020.1826192
EA SEP 2020
PG 14
WC Engineering, Environmental; Environmental Sciences
SC Engineering; Environmental Sciences & Ecology
GA OD5GU
UT WOS:000574022100001
PM 32998618
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Cohen, A
   Harari, E
   Cipok, M
   Laish-Farkash, A
   Bryk, G
   Yahud, E
   Sela, Y
   Lador, NK
   Mann, T
   Mayo, A
   Lev, EI
AF Cohen, Amir
   Harari, Emanuel
   Cipok, Michal
   Laish-Farkash, Avishag
   Bryk, Gabriel
   Yahud, Ella
   Sela, Yaron
   Lador, Nili Karp
   Mann, Tal
   Mayo, Ami
   Lev, Eli I.
TI Immature platelets in patients hospitalized with Covid-19
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article; Early Access
DE Coronavirus disease 2019; SARS-CoV-2 infection; Thrombosis; Platelet
   aggregation inhibitors; Reticulated platelets; Immature platelets
ID ACUTE CORONARY SYNDROME; RETICULATED PLATELETS
AB Coronavirus disease 2019 (Covid-19) is associated with high incidence of venous and arterial thromboembolic events. Currently, there are no markers to guide antithrombotic therapy in Covid-19. Immature platelets represent a population of hyper-reactive platelets associated with arterial events. This prospective study compared consecutive Covid-19 patients (n = 47, median age = 56 years) to patients with acute myocardial infarction (AMI, n = 100, median age = 59 years) and a group of stable patients with cardiovascular risk factors (n = 64, median age = 68 years). Immature platelet fraction (IPF) and immature platelet count (IPC) were determined by the Sysmex XN-3000 auto-analyzer on admission and at subsequent time-points. IPF% on admission was higher in Covid-19 than the stable group and similar to the AMI group (4.8% [IQR 3.4-6.9], 3.5% [2.7-5.1], 4.55% [3.0-6.75], respectively, p = 0.0053). IPC on admission was also higher in Covid-19 than the stable group and similar to the AMI group (10.8 x 10(9)/L [8.3-18.1], 7.35 x 10(9)/L [5.3-10.5], 10.7 x 10(9)/L [7.7-16.8], respectively, P < 0.0001). The maximal IPF% among the Covid-19 group was higher than the stable group and similar to the AMI group. The maximal IPC in Covid-19 was higher than the maximal IPC in both the stable and AMI groups (COVID-19: 14.4 x 10(9)/L [9.4-20.9], AMI: 10.9 x 10(9)/L [7.6-15.2], P = 0.0035, Stable: 7.55 x 10(9)/L [5.55-10.5], P < 0.0001). Patients with Covid-19 have increased immature platelets indices compared to stable patients with cardiovascular risk factors, and as the disease progresses also compared to AMI patients. The enhanced platelet turnover and reactivity may have a role in the development of thrombotic events in Covid-19 patients.
C1 [Cohen, Amir; Harari, Emanuel; Laish-Farkash, Avishag; Yahud, Ella; Lev, Eli I.] Ben Gurion Univ Negev, Assuta Ashdod Med Ctr, Dept Cardiol, Fac Hlth Sci, 7 Harefua St, Ashdod, Israel.
   [Cipok, Michal; Bryk, Gabriel] Ben Gurion Univ Negev, Assuta Ashdod Med Ctr, Lab Div, Fac Hlth Sci, Ashdod, Israel.
   [Sela, Yaron] Tel Aviv Univ, Sch Psychol Sci, Tel Aviv, Israel.
   [Lador, Nili Karp; Mann, Tal; Mayo, Ami] Ben Gurion Univ Negev, Assuta Ashdod Med Ctr, Dept Intens Care, Fac Hlth Sci, Ashdod, Israel.
RP Lev, EI (corresponding author), Ben Gurion Univ Negev, Assuta Ashdod Med Ctr, Dept Cardiol, Fac Hlth Sci, 7 Harefua St, Ashdod, Israel.
EM elil@assuta.co.il
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Assinger A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00649
   Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Bernlochner I, 2015, EUR HEART J, V36, P3202, DOI 10.1093/eurheartj/ehv326
   Cesari F, 2013, THROMB HAEMOSTASIS, V109, P846, DOI 10.1160/TH12-09-0709
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Connolly-Andersen AM, 2015, J INFECT DIS, V212, P1061, DOI 10.1093/infdis/jiv161
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Freynhofer MK, 2015, THROMB HAEMOSTASIS, V114, P459, DOI 10.1160/TH15-02-0179
   Hottz ED, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00121
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ibrahim H, 2014, J AM COLL CARDIOL, V64, P2122, DOI 10.1016/j.jacc.2014.06.1210
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Lakkis N, 2004, J AM COLL CARDIOL, V44, P2091, DOI 10.1016/j.jacc.2004.05.033
   Lev EI, 2016, CIRCULATION, V134, P987, DOI 10.1161/CIRCULATIONAHA.116.022538
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   McCabe DJH, 2004, BRIT J HAEMATOL, V126, P861, DOI 10.1111/j.1365-2141.2004.05137.x
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Pons I, 2010, EUR J HAEMATOL, V85, P158, DOI 10.1111/j.1600-0609.2010.01468.x
   Seyoum M, 2018, THROMB J, V16, DOI 10.1186/s12959-018-0170-8
   Stefanini GG, 2020, CIRCULATION, V141, P2113, DOI 10.1161/CIRCULATIONAHA.120.047525
   Stratz C, 2016, J AM COLL CARDIOL, V68, P286, DOI 10.1016/j.jacc.2016.04.056
   Subbe CP, 2001, QJM-MON J ASSOC PHYS, V94, P521, DOI 10.1093/qjmed/94.10.521
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 27
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
DI 10.1007/s11239-020-02290-6
EA SEP 2020
PG 9
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA NV2GO
UT WOS:000574147300003
PM 32997333
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Zhao, HL
   Mendenhall, M
   Deininger, MW
AF Zhao, Helong
   Mendenhall, Michelle
   Deininger, Michael W.
TI Imatinib is not a potent anti-SARS-CoV-2 drug
SO LEUKEMIA
LA English
DT Letter
ID RESPIRATORY SYNDROME CORONAVIRUS
C1 [Zhao, Helong; Deininger, Michael W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
   [Mendenhall, Michelle] Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA.
   [Deininger, Michael W.] Univ Utah, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA.
RP Deininger, MW (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
EM Michael.Deininger@hci.utah.edu
FU NCI CCSG [P30CA42014-31]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01CA178397]
FX The author would like to thank Thomas O'Hare for valuable feedback on
   the manuscript. This work was supported in part by NCI CCSG grant
   P30CA42014-31 to the Huntsman Cancer Institute and NIH grant R01CA178397
   to Thomas O'Hare and MWD.
CR Breccia M, 2020, LEUKEMIA, V34, P2260, DOI 10.1038/s41375-020-0904-z
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Ector GICG, 2020, LEUKEMIA, V34, P2533, DOI 10.1038/s41375-020-0964-0
   Grimminger F, 2010, NAT REV DRUG DISCOV, V9, P956, DOI 10.1038/nrd3297
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Janes J, 2018, P NATL ACAD SCI USA, V115, P10750, DOI 10.1073/pnas.1810137115
   Li WM, 2020, LEUKEMIA, V34, P1799, DOI 10.1038/s41375-020-0853-6
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mohty M, 2005, TRENDS MOL MED, V11, P397, DOI 10.1016/j.molmed.2005.07.007
   Morales-Ortega A, 2020, CLIN IMMUNOL, V218, DOI 10.1016/j.clim.2020.108518
   Rizzo AN, 2015, ARTERIOSCL THROM VAS, V35, P1071, DOI 10.1161/ATVBAHA.115.305085
   Schoepfer J, 2018, J MED CHEM, V61, P8120, DOI 10.1021/acs.jmedchem.8b01040
   Sisk JM, 2018, J GEN VIROL, V99, P619, DOI 10.1099/jgv.0.001047
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 15
TC 1
Z9 1
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD NOV
PY 2020
VL 34
IS 11
BP 3085
EP 3087
DI 10.1038/s41375-020-01045-9
EA SEP 2020
PG 3
WC Oncology; Hematology
SC Oncology; Hematology
GA OG4TG
UT WOS:000574125600001
PM 32999432
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hooshmand, SA
   Ghobadi, MZ
   Hooshmand, SE
   Jamalkandi, SA
   Alavi, SM
   Masoudi-Nejad, A
AF Hooshmand, Seyed Aghil
   Zarei Ghobadi, Mohadeseh
   Hooshmand, Seyyed Emad
   Azimzadeh Jamalkandi, Sadegh
   Alavi, Seyed Mehdi
   Masoudi-Nejad, Ali
TI A multimodal deep learning-based drug repurposing approach for treatment
   of COVID-19
SO MOLECULAR DIVERSITY
LA English
DT Article; Early Access
DE Drug repurposing; Deep learning; Multimodal data fusion; Restricted
   Boltzmann machine; COVID-19
ID IN-VITRO; REPLICATION; SIMILARITY
AB Recently, various computational methods have been proposed to find new therapeutic applications of the existing drugs. The Multimodal Restricted Boltzmann Machine approach (MM-RBM), which has the capability to connect the information about the multiple modalities, can be applied to the problem of drug repurposing. The present study utilized MM-RBM to combine two types of data, including the chemical structures data of small molecules and differentially expressed genes as well as small molecules perturbations. In the proposed method, two separate RBMs were applied to find out the features and the specific probability distribution of each datum (modality). Besides, RBM was used to integrate the discovered features, resulting in the identification of the probability distribution of the combined data. The results demonstrated the significance of the clusters acquired by our model. These clusters were used to discover the medicines which were remarkably similar to the proposed medications to treat COVID-19. Moreover, the chemical structures of some small molecules as well as dysregulated genes' effect led us to suggest using these molecules to treat COVID-19. The results also showed that the proposed method might prove useful in detecting the highly promising remedies for COVID-19 with minimum side effects. All the source codes are accessible using https ://github.com/LBBSoft/Multimodal-Drug-Repurposing.git
   [GRAPHICS]
   .
C1 [Hooshmand, Seyed Aghil; Masoudi-Nejad, Ali] Univ Tehran, Dept Bioinformat, Lab Syst Biol & Bioinformat LBB, Kish Int Campus, Kish Island, Iran.
   [Hooshmand, Seyed Aghil; Zarei Ghobadi, Mohadeseh; Masoudi-Nejad, Ali] Univ Tehran, Inst Biochem & Biophys, Lab Syst Biol & Bioinformat LBB, Tehran, Iran.
   [Hooshmand, Seyyed Emad] Iran Univ Med Sci, Fac Adv Technol Med, Dept Med Nanotechnol, Tehran, Iran.
   [Azimzadeh Jamalkandi, Sadegh] Syst Biol & Poisonings Inst, Chem Injuries Res Ctr, Tehran, Iran.
   [Alavi, Seyed Mehdi] Natl Inst Genet Engn & Biotechnol, Dept Plant Biotechnol, Tehran, Iran.
RP Masoudi-Nejad, A (corresponding author), Univ Tehran, Dept Bioinformat, Lab Syst Biol & Bioinformat LBB, Kish Int Campus, Kish Island, Iran.; Masoudi-Nejad, A (corresponding author), Univ Tehran, Inst Biochem & Biophys, Lab Syst Biol & Bioinformat LBB, Tehran, Iran.
EM amasoudin@ut.ac.ir
RI hooshmand, seyyed emad/ABC-1595-2020
OI hooshmand, seyyed emad/0000-0001-5573-5539
CR Abadi M, 2016, PROCEEDINGS OF OSDI'16: 12TH USENIX SYMPOSIUM ON OPERATING SYSTEMS DESIGN AND IMPLEMENTATION, P265
   Al-Tawfiq JA, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101615
   ANDREWS PR, 1982, ANESTHESIOLOGY, V57, P314, DOI 10.1097/00000542-198210000-00014
   Athauda D, 2018, CNS DRUGS, V32, P747, DOI 10.1007/s40263-018-0548-y
   Barlow A, 2020, PHARMACOTHERAPY, V40, P416, DOI 10.1002/phar.2398
   Bowers Jennifer Muir, 2004, Nutr Clin Pract, V19, P375, DOI 10.1177/0115426504019004375
   Brown AS, 2017, J AM MED INFORM ASSN, V24, P614, DOI 10.1093/jamia/ocw142
   Chen L, 2017, J AGR FOOD CHEM, V65, P745, DOI 10.1021/acs.jafc.6b05128
   Chollet F., 2015, KERAS
   Davis AP, 2019, NUCLEIC ACIDS RES, V47, pD948, DOI 10.1093/nar/gky868
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Dudley JT, 2011, BRIEF BIOINFORM, V12, P303, DOI 10.1093/bib/bbr013
   Egan TJ, 1996, S AFR J SCI, V92, P11
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hooshmand SA, 2020, MOL DIVERS, DOI 10.1007/s11030-020-10065-7
   Iorio F, 2013, DRUG DISCOV TODAY, V18, P350, DOI 10.1016/j.drudis.2012.07.014
   Jain S, 2019, ARAB J CHEM, V12, P4920, DOI 10.1016/j.arabjc.2016.10.009
   Koleti A, 2018, NUCLEIC ACIDS RES, V46, pD558, DOI 10.1093/nar/gkx1063
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liang MX, 2015, IEEE ACM T COMPUT BI, V12, P928, DOI 10.1109/TCBB.2014.2377729
   Liu JZ, 2010, EUR J MED CHEM, V45, P5108, DOI 10.1016/j.ejmech.2010.08.021
   Marlin B., 2010, P 13 INT C ART INT S, P509
   Masoudi-Sobhanzadeh Y, 2020, BIOIMPACTS, V10, P205, DOI 10.34172/bi.2020.25
   Masoudi-Sobhanzadeh Y, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-03644-w
   Masoudi-Sobhanzadeh Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45814-8
   Masoudi-Sobhanzadeh Y, 2020, GENOMICS, V112, P1087, DOI 10.1016/j.ygeno.2019.06.021
   Masoudi-Sobhanzadeh Y, 2019, COMPUT BIOL MED, V109, P254, DOI 10.1016/j.compbiomed.2019.05.006
   Masoudi-Sobhanzadeh Y, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2754-0
   Napolitano F, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-30
   Ngiam J., 2011, MULTIMODAL DEEP LEAR
   Ngiam Jiquan, 2011, P 28 INT C MACH LEAR
   Obach RS, 2008, CHEM RES TOXICOL, V21, P1890, DOI 10.1021/tx800185b
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Ramachandram D, 2017, IEEE SIGNAL PROC MAG, V34, P96, DOI 10.1109/MSP.2017.2738401
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Rouillard AD, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw100
   Shang XF, 2018, MED RES REV, V38, P775, DOI 10.1002/med.21466
   Sienczyk M, 2011, BIOORGAN MED CHEM, V19, P1277, DOI 10.1016/j.bmc.2010.12.008
   Srivatsan Padmanabhan M., 2020, POTENTIAL DUAL THERA, DOI [10.13140/RG.2.2.28124.74882, DOI 10.13140/RG.2.2.28124.74882]
   Suk HI, 2014, NEUROIMAGE, V101, P569, DOI 10.1016/j.neuroimage.2014.06.077
   Tan FJ, 2014, MOL BIOSYST, V10, P1126, DOI 10.1039/c3mb70554d
   Toma S, 2009, J VIRAL HEPATITIS, V16, P506, DOI 10.1111/j.1365-2893.2009.01102.x
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wen M, 2017, J PROTEOME RES, V16, P1401, DOI 10.1021/acs.jproteome.6b00618
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Xu YJ, 2015, J CHEM INF MODEL, V55, P2085, DOI 10.1021/acs.jcim.5b00238
   Zeng H, 2015, DATABASE-OXFORD, DOI 10.1093/database/bav061
   Zeng XX, 2019, BIOINFORMATICS, V35, P5191, DOI 10.1093/bioinformatics/btz418
NR 51
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1381-1991
EI 1573-501X
J9 MOL DIVERS
JI Mol. Divers.
DI 10.1007/s11030-020-10144-9
EA SEP 2020
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Applied; Chemistry,
   Medicinal; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA NV1MC
UT WOS:000574094100001
PM 32997257
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Nelde, A
   Bilich, T
   Heitmann, JS
   Maringer, Y
   Salih, HR
   Roerden, M
   Lubke, M
   Bauer, J
   Rieth, J
   Wacker, M
   Peter, A
   Horber, S
   Traenkle, B
   Kaiser, PD
   Rothbauer, U
   Becker, M
   Junker, D
   Krause, G
   Strengert, M
   Schneiderhan-Marra, N
   Templin, MF
   Joos, TO
   Kowalewski, DJ
   Stos-Zweifel, V
   Fehr, M
   Rabsteyn, A
   Mirakaj, V
   Karbach, J
   Jager, E
   Graf, M
   Gruber, LC
   Rachfalski, D
   Preuss, B
   Hagelstein, I
   Marklin, M
   Bakchoul, T
   Gouttefangeas, C
   Kohlbacher, O
   Klein, R
   Stevanovic, S
   Rammensee, HG
   Walz, JS
AF Nelde, Annika
   Bilich, Tatjana
   Heitmann, Jonas S.
   Maringer, Yacine
   Salih, Helmut R.
   Roerden, Malte
   Luebke, Maren
   Bauer, Jens
   Rieth, Jonas
   Wacker, Marcel
   Peter, Andreas
   Hoerber, Sebastian
   Traenkle, Bjoern
   Kaiser, Philipp D.
   Rothbauer, Ulrich
   Becker, Matthias
   Junker, Daniel
   Krause, Gerard
   Strengert, Monika
   Schneiderhan-Marra, Nicole
   Templin, Markus F.
   Joos, Thomas O.
   Kowalewski, Daniel J.
   Stos-Zweifel, Vlatka
   Fehr, Michael
   Rabsteyn, Armin
   Mirakaj, Valbona
   Karbach, Julia
   Jaeger, Elke
   Graf, Michael
   Gruber, Lena-Christin
   Rachfalski, David
   Preuss, Beate
   Hagelstein, Ilona
   Maerklin, Melanie
   Bakchoul, Tamam
   Gouttefangeas, Cecile
   Kohlbacher, Oliver
   Klein, Reinhild
   Stevanovic, Stefan
   Rammensee, Hans-Georg
   Walz, Juliane S.
TI SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T
   cell recognition
SO NATURE IMMUNOLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; CROSS-REACTIVITY; MEMORY; PROTECTION;
   RESPONSES; INFECTION; IMMUNITY; DATABASE; DISEASE
AB SARS-CoV-2-specific CD4(+)and CD8(+)T cell epitopes are found in both convalescent patients and virus-naive volunteers and are indicative of heterologous recognition shared with seasonal cold viruses.
   T cell immunity is central for the control of viral infections. To characterize T cell immunity, but also for the development of vaccines, identification of exact viral T cell epitopes is fundamental. Here we identify and characterize multiple dominant and subdominant SARS-CoV-2 HLA class I and HLA-DR peptides as potential T cell epitopes in COVID-19 convalescent and unexposed individuals. SARS-CoV-2-specific peptides enabled detection of post-infectious T cell immunity, even in seronegative convalescent individuals. Cross-reactive SARS-CoV-2 peptides revealed pre-existing T cell responses in 81% of unexposed individuals and validated similarity with common cold coronaviruses, providing a functional basis for heterologous immunity in SARS-CoV-2 infection. Diversity of SARS-CoV-2 T cell responses was associated with mild symptoms of COVID-19, providing evidence that immunity requires recognition of multiple epitopes. Together, the proposed SARS-CoV-2 T cell epitopes enable identification of heterologous and post-infectious T cell immunity and facilitate development of diagnostic, preventive and therapeutic measures for COVID-19.
C1 [Nelde, Annika; Bilich, Tatjana; Heitmann, Jonas S.; Maringer, Yacine; Salih, Helmut R.; Bauer, Jens; Rieth, Jonas; Wacker, Marcel; Gruber, Lena-Christin; Rachfalski, David; Hagelstein, Ilona; Maerklin, Melanie; Walz, Juliane S.] Univ Hosp Tubingen, Dept Internal Med, Clin Collaborat Unit Translat Immunol, German Canc Consortium DKTK, Tubingen, Germany.
   [Nelde, Annika; Bilich, Tatjana; Maringer, Yacine; Roerden, Malte; Luebke, Maren; Bauer, Jens; Rieth, Jonas; Wacker, Marcel; Fehr, Michael; Rabsteyn, Armin; Gouttefangeas, Cecile; Stevanovic, Stefan; Rammensee, Hans-Georg; Walz, Juliane S.] Univ Tubingen, Inst Cell Biol, Dept Immunol, Tubingen, Germany.
   [Nelde, Annika; Bilich, Tatjana; Heitmann, Jonas S.; Maringer, Yacine; Salih, Helmut R.; Roerden, Malte; Maerklin, Melanie; Gouttefangeas, Cecile; Rammensee, Hans-Georg; Walz, Juliane S.] Univ Tubingen, Cluster Excellence iFIT EXC2180 Image Guided & Fu, Tubingen, Germany.
   [Salih, Helmut R.; Gouttefangeas, Cecile; Stevanovic, Stefan; Rammensee, Hans-Georg] German Canc Consortium DKTK, Partner Site Tubingen, Tubingen, Germany.
   [Salih, Helmut R.; Gouttefangeas, Cecile; Stevanovic, Stefan; Rammensee, Hans-Georg] German Canc Res Ctr, Partner Site Tubingen, Tubingen, Germany.
   [Roerden, Malte; Klein, Reinhild] Univ Hosp Tubingen, Dept Hematol Oncol Clin Immunol & Rheumatol, Tubingen, Germany.
   [Peter, Andreas; Hoerber, Sebastian] Univ Hosp Tubingen, Inst Clin Chem & Pathobiochem, Dept Diagnost Lab Med, Tubingen, Germany.
   [Traenkle, Bjoern; Kaiser, Philipp D.; Rothbauer, Ulrich; Becker, Matthias; Junker, Daniel; Schneiderhan-Marra, Nicole; Templin, Markus F.; Joos, Thomas O.] Univ Tubingen, Nat & Med Sci Inst, NMI, Reutlingen, Germany.
   [Rothbauer, Ulrich] Univ Tubingen, Pharmaceut Biotechnol, Tubingen, Germany.
   [Krause, Gerard; Strengert, Monika] Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, Germany.
   [Krause, Gerard; Strengert, Monika] TWINCORE GmbH, Ctr Expt & Clin Infect Res, Hannover, Germany.
   [Krause, Gerard] German Ctr Infect Res, Braunschweig, Germany.
   [Kowalewski, Daniel J.; Stos-Zweifel, Vlatka] Immat Biotechnol GmbH, Tubingen, Germany.
   [Rabsteyn, Armin] Univ Childrens Hosp Tubingen, Dept Gen Pediat, Oncol Hematol, Tubingen, Germany.
   [Mirakaj, Valbona] Univ Hosp Tubingen, Dept Anesthesia & Intens Care Med, Tubingen, Germany.
   [Karbach, Julia; Jaeger, Elke] Krankenhaus NW Frankfurt, Dept Oncol & Hematol, Frankfurt, Germany.
   [Graf, Michael; Kohlbacher, Oliver] Univ Tubingen, Ctr Bioinformat, Appl Bioinformat, Tubingen, Germany.
   [Graf, Michael; Kohlbacher, Oliver] Univ Tubingen, Dept Comp Sci, Tubingen, Germany.
   [Bakchoul, Tamam] Univ Hosp Tubingen, Inst Clin & Expt Transfus Med, Tubingen, Germany.
   [Kohlbacher, Oliver] Univ Tubingen, Inst Bioinformat & Med Informat, Tubingen, Germany.
   [Kohlbacher, Oliver] Max Planck Inst Dev Biol, Biomol Interact, Tubingen, Germany.
   [Kohlbacher, Oliver] Univ Hosp Tubingen, Inst Translat Bioinformat, Tubingen, Germany.
RP Walz, JS (corresponding author), Univ Hosp Tubingen, Dept Internal Med, Clin Collaborat Unit Translat Immunol, German Canc Consortium DKTK, Tubingen, Germany.; Walz, JS (corresponding author), Univ Tubingen, Inst Cell Biol, Dept Immunol, Tubingen, Germany.; Walz, JS (corresponding author), Univ Tubingen, Cluster Excellence iFIT EXC2180 Image Guided & Fu, Tubingen, Germany.
EM juliane.walz@med.uni-tuebingen.de
RI Bilich, Tatjana/ABH-2314-2020
OI Bilich, Tatjana/0000-0002-8107-0419; Roerden, Malte/0000-0001-7283-9778;
   Bauer, Jens/0000-0003-3731-2385; Nelde, Annika/0000-0001-8504-8481
FU Bundesministerium fur Bildung und ForschungFederal Ministry of Education
   & Research (BMBF) [FKZ:01KI20130]; Deutsche Forschungsgemeinschaft
   (German Research Foundation)German Research Foundation (DFG) [WA
   4608/1-2]; Deutsche Forschungsgemeinschaft under Germany's Excellence
   StrategyGerman Research Foundation (DFG) [EXC2180-390900677]; Wilhelm
   Sander Stiftung [2016.177.2]; Jose Carreras Leukamie-Stiftung [DJCLS
   05R/2017]; Fortune Program of the University of Tubingen [2451-0-0,
   2581-0-0]; European Union's Horizon 2020 Research and Innovation Program
   [101003480]; German Cancer Consortium
FX We thank all SARS and PRE donors for their support of our research. We
   thank U. Schmidt, C. Bauer, A. Petz, M. Storz, I. Riedlinger, S. Sauter,
   S. Augstein, C. Rei beta, V. Agrusa, S. Dethling, M. Beller and C.
   Falkenburger for technical support and project coordination. This work
   was supported by the Bundesministerium fur Bildung und Forschung
   (FKZ:01KI20130; J.W.), the Deutsche Forschungsgemeinschaft (German
   Research Foundation, grant WA 4608/1-2; J.W.), the Deutsche
   Forschungsgemeinschaft under Germany's Excellence Strategy (grant
   EXC2180-390900677; J.W., S.S., H.-G.R., C.G. and H.R.S.), the German
   Cancer Consortium (S.S., H.-G.R., C.G. and H.R.S.), the Wilhelm Sander
   Stiftung (grant 2016.177.2; J.W.), the Jose Carreras Leukamie-Stiftung
   (grant DJCLS 05R/2017; J.W.) and the Fortune Program of the University
   of Tubingen (Fortune nos. 2451-0-0 and 2581-0-0; J.W. and M.R.).
   Multiplex antibody detection against common cold coronaviruses is part
   of a project that has received funding from the European Union's Horizon
   2020 Research and Innovation Program under grant agreement no. 101003480
   - CORESMA (G.K. and M.S.).
CR Acierno PM, 2003, J TRANSL MED, V1, P3, DOI DOI 10.1186/1479-5876-1-3
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Aslan N, 2017, MBIO, V8, DOI 10.1128/mBio.01841-17
   Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004
   Borbulevych OY, 2009, IMMUNITY, V31, P885, DOI 10.1016/j.immuni.2009.11.003
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Einsele H, 2002, BLOOD, V99, P3916, DOI 10.1182/blood.V99.11.3916
   FALK K, 1994, IMMUNOLOGY, V82, P337
   Friberg H, 2011, IMMUNOL CELL BIOL, V89, P122, DOI 10.1038/icb.2010.61
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z
   Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171
   Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Khan N, 2007, J IMMUNOL, V178, P4455, DOI 10.4049/jimmunol.178.7.4455
   Khan S, 2020, J CLIN MICROBIOL, V58, DOI [10.1128/JCM.01297-20, 10.1128/JCM.00187-20]
   Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520
   Kruttgen A, 2020, J CLIN VIROL, V128
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lubke M, 2020, J EXP MED, V217, DOI 10.1084/jem.20191164
   Messaoudi I, 2002, SCIENCE, V298, P1797, DOI 10.1126/science.1076064
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Mudd PA, 2012, NATURE, V491, P129, DOI 10.1038/nature11443
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Nielsen M, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0288-x
   Petrova G, 2012, CRIT REV IMMUNOL, V32, P349
   Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595
   Robert Koch Institute, 2020, COR DIS 2019 COVID 1
   Schlott F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193554
   Schmidt AH, 2009, HUM IMMUNOL, V70, P895, DOI 10.1016/j.humimm.2009.08.006
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Sidhom J.-W., 2020, ANAL SARS COV 2 SPEC, DOI [10.1101/2020.06.20.160499, DOI 10.1101/2020.06.20.160499]
   Soghoian DZ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003165
   Su LF, 2013, IMMUNITY, V38, P373, DOI 10.1016/j.immuni.2012.10.021
   Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152
   Tan ACL, 2013, IMMUNOL CELL BIOL, V91, P96, DOI 10.1038/icb.2012.54
   Tan ACL, 2011, J IMMUNOL, V187, P1895, DOI 10.4049/jimmunol.1100664
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Vali B, 2011, J VIROL, V85, P254, DOI 10.1128/JVI.01743-10
   Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Watkin LB, 2017, J ALLERGY CLIN IMMUN, V140, P1206, DOI 10.1016/j.jaci.2017.05.037
   Welsh RM, 2010, IMMUNOL REV, V235, P244, DOI 10.1111/j.0105-2896.2010.00897.x
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yin YY, 2009, IMMUNITY, V31, P849, DOI 10.1016/j.immuni.2009.12.002
   Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
NR 54
TC 3
Z9 3
U1 11
U2 11
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1529-2908
EI 1529-2916
J9 NAT IMMUNOL
JI Nat. Immunol.
PD JAN
PY 2021
VL 22
IS 1
DI 10.1038/s41590-020-00808-x
EA SEP 2020
PG 25
WC Immunology
SC Immunology
GA PG2HK
UT WOS:000574099400001
PM 32999467
OA Bronze
DA 2021-01-01
ER

PT J
AU Aktokmakyan, TV
   Tokocin, M
   Meric, S
   Celebi, F
AF Vartanoglu Aktokmakyan, Talar
   Tokocin, Merve
   Meric, Serhat
   Celebi, Fatih
TI Is Mesenteric Ischemia In COVID-19 Patients A Surprise?
SO SURGICAL INNOVATION
LA English
DT Article; Early Access
DE COVID-19; hypercoagulability; mesenteric ischemia
AB Aim.The disease caused by the 2019 novel coronavirus is known predominantly for its respiratory outcomes; a subset of critically ill patients demonstrates clinically remarkable hypercoagulability in which thrombotic events range from acute pulmonary embolism in patients with COVID-19 pneumonia to extremity ischemia. Our observational study aimed to describe the incidence and characteristics, as well as clinical outcomes, of patients presenting and treated for mesenteric ischemia during the COVID-19 pandemic.Material and Methods.Between March 13 and May 13, 2020, 60 patients operated for emergency reasons were analyzed, and it was noticed that 5 of the 6 COVID-positive patients were operated due to mesenteric ischemia.Results.Five of sixty patients (83.3%) applied to our emergency clinic with COVID-19 positive and acute abdomen. Two of them (40%) did not have any comorbidities. All of them (%100) were male. There were no complications and only 1 death (20%). Mean leukocyte, neutrophil, and platelet levels were within the normal range, while the lymphocyte level was near the lower limit. C-Reactive Protein was above the limit in all patients. The mean levels of International Normalized Ratio, Platelet, and Activated Partial Thromboplastin Time were above the limits. While D-dimer levels were close to the upper limit; fibrinogen levels were above the normal limit for each patient.Conclusion.The presence of hypercoagulation status in critical COVID-19 patients should be observed closely, and anticoagulation therapy can be considered in selected patients. More clinical data are needed to examine the role of anticoagulation in COVID-19 treatment.
C1 [Vartanoglu Aktokmakyan, Talar; Tokocin, Merve; Meric, Serhat; Celebi, Fatih] Istanbul Bagcilar Training & Res Hosp, Dept Gen Surg, TR-34200 Istanbul, Turkey.
RP Aktokmakyan, TV (corresponding author), Istanbul Bagcilar Training & Res Hosp, Dept Gen Surg, TR-34200 Istanbul, Turkey.
EM talarim@gmail.com
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Mei H, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, P185, DOI 10.3760/cma.j.issn.0253-2727.2020.0002
   Zhang Y, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, pE006, DOI [10.3760/cma.j.issn.0253-2727.2020.008, 10.3760/cma.j.issn.0253-2727.2020.0006]
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 7
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1553-3506
EI 1553-3514
J9 SURG INNOV
JI Surg. Innov.
AR 1553350620962892
DI 10.1177/1553350620962892
EA SEP 2020
PG 3
WC Surgery
SC Surgery
GA NX1HA
UT WOS:000575467000001
PM 32996834
OA Bronze
DA 2021-01-01
ER

PT J
AU Ciotti, JR
   Grebenciucova, E
   Moss, BP
   Newsome, SD
AF Ciotti, John R.
   Grebenciucova, Elena
   Moss, Brandon P.
   Newsome, Scott D.
TI Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era
SO ANNALS OF NEUROLOGY
LA English
DT Article
C1 [Ciotti, John R.] Washington Univ, Sch Med, Campus Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.
   [Grebenciucova, Elena] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Moss, Brandon P.] Cleveland Clin, Mellen Ctr MS, Cleveland, OH 44106 USA.
   [Newsome, Scott D.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RP Ciotti, JR (corresponding author), Washington Univ, Sch Med, Campus Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.
EM ciottij@wustl.edu
OI Ciotti, John/0000-0002-5696-8841
CR Bar-Or Amit, 2020, Neurology, V95, pe1999, DOI 10.1212/WNL.0000000000010380
   COViMS Registry, COVIMS DAT PUBL DAT
   Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581
   Maarouf A, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000825
   Moss BP, 2020, MULT SCLER J, V26, P1163, DOI 10.1177/1352458520948231
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
NR 6
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD DEC
PY 2020
VL 88
IS 6
BP 1062
EP 1064
DI 10.1002/ana.25907
EA SEP 2020
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OR5IQ
UT WOS:000573675200001
PM 32951235
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Petousis-Harris, H
AF Petousis-Harris, Helen
TI Assessing the Safety of COVID-19 Vaccines: A Primer
SO DRUG SAFETY
LA English
DT Article
ID COLLABORATION STANDARDIZED TEMPLATE; BENEFIT-RISK ASSESSMENT; BRIGHTON
   COLLABORATION; KEY INFORMATION; IMMUNIZATION; COLLECTION; EPIDEMIC;
   DISEASE
AB Vaccines against COVID-19 are being developed at speeds not previously achieved. With this unprecedented effort comes challenges for post-marketing safety monitoring and challenges for vaccine safety communication. To deploy these new vaccines fast across diverse populations, it is vital that robust pharmacovigilance and active surveillance systems are in place. Not all countries have the capability or resources to undertake adequate surveillance and will rely on data from those who can. The tools exist to assess COVID-19 vaccines as they are deployed such as surveillance systems, administrative data and case definitions for adverse events of special interest. However, stitching these all together and using them effectively requires investment and collaboration. This paper provides a high-level overview of some of the facets of modern vaccine safety assessment and how they are, or can be, applied to COVID-19 vaccines.
C1 [Petousis-Harris, Helen] Univ Auckland, Dept Gen Practice & Primary Hlth Care, Fac Med & Hlth Sci, Auckland, New Zealand.
RP Petousis-Harris, H (corresponding author), Univ Auckland, Dept Gen Practice & Primary Hlth Care, Fac Med & Hlth Sci, Auckland, New Zealand.
EM h.petousis-harris@auckland.ac.nz
CR [Anonymous], 2006, DEV SAF UPD REP DSUR
   [Anonymous], 2018, REACT WKLY, V1700, P1, DOI [10.1007/s40278-018-45575-x, DOI 10.1007/S40278-018-45575-X]
   Black S, 2009, LANCET, V374, P2115, DOI 10.1016/S0140-6736(09)61877-8
   Bollaerts K, 2019, VACCINE
   Bonhoeffer J, 2002, VACCINE, V21, P298, DOI 10.1016/S0264-410X(02)00449-8
   Brende B, 2017, LANCET, V389, P233, DOI 10.1016/S0140-6736(17)30131-9
   Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765
   Clarke DK, 2016, VACCINE, V34, P6597, DOI 10.1016/j.vaccine.2016.06.071
   Donahue JG, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-1808
   EBERS GC, 1993, NEUROEPIDEMIOLOGY, V12, P1, DOI 10.1159/000110293
   Ebers GC, 2008, LANCET NEUROL, V7, P268, DOI 10.1016/S1474-4422(08)70042-5
   European Medicines Agency, 2020, GUID MED DEV CO COVI
   Federal Drug Administration, 2020, DEV LIC VACC PREV CO
   Guillard-Maure C, 2018, VACCINE, V36, P355, DOI 10.1016/j.vaccine.2017.07.085
   Henao-Restrepo AM, 2016, CURR OPIN VIROL, V17, P138, DOI 10.1016/j.coviro.2016.03.008
   Henao-Restrepo AM, 2015, LANCET, V386, P857, DOI 10.1016/S0140-6736(15)61117-5
   Kim D, 2020, VACCINE, V38, P5556, DOI 10.1016/j.vaccine.2020.06.017
   Kochhar S, 2020, VACCINE, V38, P5734, DOI 10.1016/j.vaccine.2020.06.044
   Lakdawala SS, 2020, SCIENCE, V368, P942, DOI 10.1126/science.abc6141
   Lambert PH, 2020, VACCINE, V38, P4783, DOI 10.1016/j.vaccine.2020.05.064
   Law B, D2 3 PRIORITY LIST A
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   McNeil MM, 2014, VACCINE, V32, P5390, DOI 10.1016/j.vaccine.2014.07.073
   McNicholas A, 2007, HUM VACCINES, V3, P196, DOI 10.4161/hv.3.5.4458
   Perez-Vilar S, 2018, VACCINE, V36, P347, DOI 10.1016/j.vaccine.2017.05.012
   Petkova E, 2020, JAMA-J AM MED ASSOC, V324, P543, DOI 10.1001/jama.2020.13042
   Petousis-Harris H, 2020, PEDIATR INFECT DIS J, V39, P1023, DOI 10.1097/INF.0000000000002785
   Siegrist CA, 2007, PEDIATR INFECT DIS J, V26, P979, DOI 10.1097/INF.0b013e318149dfea
   Tate JE, 2018, NEW ENGL J MED, V378, P1521, DOI [10.1056/NEJMoa1713909, 10.1056/nejmoa1713909]
   Tatley MV, 2008, VACCINE, V26, P2746, DOI 10.1016/j.vaccine.2008.03.017
   Weibel D, 2018, VACCINE, V36, P6202, DOI 10.1016/j.vaccine.2018.08.008
   Wolf J, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0204-7
   World Health Organization, 2012, GLOB VACC SAF BLUEPR
   World Health Organization, 2018, GLOB VACC ACT PLAN M
   World Health Organization Global Advisory Committee on Vaccine Safety, 2020, WKLY EPIDEMIOL REC, V28, P325
NR 35
TC 0
Z9 0
U1 2
U2 2
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD DEC
PY 2020
VL 43
IS 12
BP 1205
EP 1210
DI 10.1007/s40264-020-01002-6
EA SEP 2020
PG 6
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA OW1DX
UT WOS:000574068900002
PM 32997318
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Cui, YL
   Xin, HW
   Tao, YD
   Mei, LJ
   Wang, Z
AF Cui, Yulei
   Xin, Huawei
   Tao, Yanduo
   Mei, Lijuan
   Wang, Zhen
TI Arenaria kansuensis attenuates pulmonary fibrosis in mice via the
   activation of Nrf2 pathway and the inhibition ofNF-kB/TGF-beta1/Smad2/3
   pathway
SO PHYTOTHERAPY RESEARCH
LA English
DT Article; Early Access
DE Arenaria kansuensis; COVID-19; inflammation; oxidative stress; pulmonary
   fibrosis
ID NF-KAPPA-B; SIGNALING DRIVES; GENE-EXPRESSION; BLEOMYCIN; INFLAMMATION;
   EXTRACT; TARGETS; MODELS; CELL
AB Pulmonary fibrosis is a key feature of COVID-19, Chinese herbal medicineArenaria kansuensishas been used for curing pulmonary disease and antivirus for a long time and it has the potential against COVID-19. In this work, protective effect ofA. kansuensisethanol extract (AE) on pulmonary fibrosis was evaluated through paraquat (PQ)-induced pulmonary fibrosis animal model. Results showed that AE could significantly improve the survival rate, increase the body weight and reduce the lung index of mice at the raw drug doses of 700 and 350 mg/kg. Histopathological observation results showed that the destruction degree of lung tissue structure in mice was significantly improved with the increase of AE dosage. Collagen deposition in lung interstitium was significantly reduced. The marker protein alpha-SMA involved in PF were significantly inhibited through repressing TGF-beta1/Smads pathway. The degree of inflammatory infiltration was significantly reduced and inflammatory cytokines were significantly inhibited in mice through inhibiting the NF-kB-p65. Besides, oxidant stress level including upregulated ROS and down-regulated SOD and GSH was efficiently improved by AE through upregulation of Nrf2 and downregulation of NOX4. In summary, this study firstly showed that the protective effect of AE on pulmonary fibrosis was partly due to activation of Nrf2 pathway and the inhibition of NF-kB/TGF-beta1/Smad2/3 pathway.
C1 [Cui, Yulei; Xin, Huawei; Wang, Zhen] Linyi Univ, Coll Pharm, Linyi, Shandong, Peoples R China.
   [Xin, Huawei] Linyi Univ, Linyi Key Lab Targeted Therapeut & Drug Delivery, Linyi, Shandong, Peoples R China.
   [Tao, Yanduo; Mei, Lijuan] Chinese Acad Sci, Northwest Inst Plateau Biol, Xining 810008, Qinghai, Peoples R China.
   [Tao, Yanduo; Mei, Lijuan] Chinese Acad Sci, Key Lab Tibetan Med Res, Xining, Peoples R China.
   [Tao, Yanduo; Mei, Lijuan] Key Lab Tibetan Med Res Qinghai Prov, Xining, Peoples R China.
RP Wang, Z (corresponding author), Linyi Univ, Coll Pharm, Linyi, Shandong, Peoples R China.; Mei, LJ (corresponding author), Chinese Acad Sci, Northwest Inst Plateau Biol, Xining 810008, Qinghai, Peoples R China.
EM meilijuan11@163.com; wangzhen@lyu.edu.cn
FU Science and Technology Major Project of Qinghai Province [2014-GX-A3A];
   National Key R & D Program of China [2018YFC1200400]; Key Research and
   Development Project of Shandong Province [2017YYSP027]; Key Laboratory
   of Tibetan Medicine Research of Qinghai Province [2017-ZJ-Y11]; Linyi
   University [40620002]; Key project at central government level: The
   ability establishment of sustainable use for valuable Chinese medicine
   resources [2060302]
FX Science and Technology Major Project of Qinghai Province, Grant/Award
   Number: 2014-GX-A3A; National Key R & D Program of China, Grant/Award
   Number: 2018YFC1200400; Key Research and Development Project of Shandong
   Province, Grant/Award Number: 2017YYSP027; Key Laboratory of Tibetan
   Medicine Research of Qinghai Province, Grant/Award Number: 2017-ZJ-Y11;
   Linyi University, Grant/Award Number: 40620002; Key project at central
   government level: The ability establishment of sustainable use for
   valuable Chinese medicine resources, Grant/Award Number: 2060302
CR Bahri S, 2017, BIOMED PHARMACOTHER, V93, P666, DOI 10.1016/j.biopha.2017.06.052
   Bardou O, 2016, AM J RESP CRIT CARE, V193, P847, DOI 10.1164/rccm.201502-0299OC
   Bian C, 2018, FREE RADICAL BIO MED, V129, P446, DOI 10.1016/j.freeradbiomed.2018.10.423
   Cheng HS, 2013, EMBO MOL MED, V5, P1017, DOI 10.1002/emmm.201202318
   Collard Harold R, 2012, J Med Econ, V15, P829, DOI 10.3111/13696998.2012.680553
   Cui YL, 2019, J CHROMATOGR SCI, V57, P418, DOI 10.1093/chromsci/bmz010
   Cui YL, 2017, J SEP SCI, V40, P2895, DOI 10.1002/jssc.201700144
   Dobaczewski M, 2012, J CARDIOVASC TRANSL, V5, P837, DOI 10.1007/s12265-012-9406-3
   Eser PO, 2018, PHARMACOL THERAPEUT, V184, P112, DOI 10.1016/j.pharmthera.2017.11.004
   Fielding CA, 2014, IMMUNITY, V40, P40, DOI 10.1016/j.immuni.2013.10.022
   GharaeeKermani M, 1996, J BIOL CHEM, V271, P17779, DOI 10.1074/jbc.271.30.17779
   Ghisletti S, 2005, MOL CELL BIOL, V25, P2957, DOI 10.1128/MCB.25.8.2957-2968.2005
   Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423
   Gieling RG, 2009, AM J PHYSIOL-GASTR L, V296, pG1324, DOI 10.1152/ajpgi.90564.2008
   Gong LK, 2005, J ETHNOPHARMACOL, V96, P537, DOI 10.1016/j.jep.2004.09.046
   Guo JL, 2013, ARCH TOXICOL, V87, P1963, DOI 10.1007/s00204-013-1063-z
   Jiang CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041411
   Jones LK, 2009, NEPHROL DIAL TRANSPL, V24, P3024, DOI 10.1093/ndt/gfp214
   Kolb M, 2017, RESP MED, V131, P49, DOI 10.1016/j.rmed.2017.07.062
   Kulkarni AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015909
   Li M., 2007, CHINESE TRADITIONAL, V11, P1
   Luo W., 2020, CLIN PATHOLOGY CRITI
   Mack M, 2018, MATRIX BIOL, V68-69, P106, DOI 10.1016/j.matbio.2017.11.010
   Martin G. E. M., 2007, DRUG DISCOV TODAY DI, V3, P99, DOI DOI 10.1016/j.ddmec.2006.03.006
   Mojiri-Forushani H, 2017, J INTEGR MED-JIM, V15, P433, DOI 10.1016/S2095-4964(17)60363-7
   Mora AL, 2017, NAT REV DRUG DISCOV, V16, DOI [10.1038/nrd.2017.225, 10.1038/nrd.2017.170]
   Morry J, 2017, REDOX BIOL, V11, P240, DOI 10.1016/j.redox.2016.12.011
   Nickel J, 2018, ACTA BIOCH BIOPH SIN, V50, P12, DOI 10.1093/abbs/gmx126
   O'Reilly S, 2014, J BIOL CHEM, V289, P9952, DOI 10.1074/jbc.M113.545822
   Peng XY, 2018, MOLECULES, V23, DOI 10.3390/molecules23010215
   Raghu G, 2016, EUR RESPIR J, V48, P179, DOI 10.1183/13993003.01653-2015
   Ramos C, 2001, AM J RESP CELL MOL, V24, P591, DOI 10.1165/ajrcmb.24.5.4333
   Reynolds HY, 2013, MATRIX BIOL, V58, p281A
   Ricard-Blum S, 2018, MATRIX BIOL, V68-69, P122, DOI 10.1016/j.matbio.2018.02.004
   Saravanan S, 2014, INFLAMM RES, V63, P451, DOI 10.1007/s00011-014-0717-5
   Scotton CJ, 2007, CHEST, V132, P1311, DOI 10.1378/chest.06-2568
   Selman M, 2001, ANN INTERN MED, V134, P136, DOI 10.7326/0003-4819-134-2-200101160-00015
   Sundarakrishnan A, 2018, ADV DRUG DELIVER REV, V129, P78, DOI 10.1016/j.addr.2017.12.013
   SZAPIEL SV, 1979, AM REV RESPIR DIS, V120, P893
   Szondy Z, 2017, PHARMACOL RES, V115, P124, DOI 10.1016/j.phrs.2016.11.025
   Wen SL, 2016, SCI REP-UK, V6, DOI 10.1038/srep35426
   Wilson MS, 2010, J EXP MED, V207, P535, DOI 10.1084/jem.20092121
   You XY, 2015, J ETHNOPHARMACOL, V175, P172, DOI 10.1016/j.jep.2015.08.034
   Zhang WR, 2012, HYPERTENSION, V59, P136, DOI 10.1161/HYPERTENSIONAHA.111.173328
NR 44
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
DI 10.1002/ptr.6857
EA SEP 2020
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NU4JO
UT WOS:000573609300001
PM 32996197
DA 2021-01-01
ER

PT J
AU Uygun-Can, B
   Acar-Bolat, B
AF Uygun-Can, Banu
   Acar-Bolat, Bilge
TI Clinical Properties and Diagnostic Methods of COVID-19 Infection in
   Pregnancies: Meta-Analysis
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS; PNEUMONIA; OUTBREAK; WUHAN;
   CHINA; WOMEN
AB We aimed to summarize reliable medical evidence by the meta-analysis of all published retrospective studies that examined data based on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by clinical symptoms, molecular (RT-PCR) diagnosis, and characteristic CT imaging features in pregnant women. The MEDLINE, PubMed, Scopus, ISI Web of Science, ClinicalKey, and CINAHL databases were used to select the studies. Then, 384 articles were received, including the studies until 01/May/2020. As a result of the full-text evaluation, 12 retrospective articles covering all the data related were selected. A total of 181 pregnant cases with SARS-CoV-2 infections were included in the meta-analysis within the scope of these articles. According to the results, the incidence of fever was 38.1% (95% CI: 14.2-65%) and cough was 22% (95% CI: 10.8-35.2%) among all clinical features of pregnant cases with SARS-CoV-2 infection. So, fever and cough are the most common symptoms in pregnant cases with SARS-CoV-2 infection, and 91.8% (95% CI: 76.7-99.9%) of RT-PCR results are positive. Moreover, abnormal CT incidence is 97.9% (95% CI: 94.2-99.9%) positive. No case was death. However, as this virus spreads globally, it should not be overlooked that the incidence will increase in pregnant women and maybe in the risky group. RT-PCR and CT can be used together in an accurate and safe diagnosis. In conclusion, these findings will provide important guidance for current studies regarding the clinical features and correct detection of SARS-CoV-2 infection in pregnant women, as well as whether it will create emergency tables that will require the use of a viral drug.
C1 [Uygun-Can, Banu] Marmara Univ, Fac Dent, Dept Microbiol, Istanbul, Turkey.
   [Acar-Bolat, Bilge] Istanbul Univ, Sch Business, Dept Quantitat Methods, Istanbul, Turkey.
RP Uygun-Can, B (corresponding author), Marmara Univ, Fac Dent, Dept Microbiol, Istanbul, Turkey.
EM drbanucan@gmail.com; bacar@istanbul.edu.tr
RI bolat, bilge acar/T-2056-2019
OI bolat, bilge acar/0000-0001-9815-4371; Uygun-Can,
   Banu/0000-0002-9577-0352
CR Alfaraj SH, 2019, J MICROBIOL IMMUNOL, V52, P501, DOI 10.1016/j.jmii.2018.04.005
   [Anonymous], 2020, LANCET, V395, P311, DOI 10.1016/S0140-6736(20)30186-0
   Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104
   Biscayart C, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101567
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen S, 2020, Zhonghua Bing Li Xue Za Zhi, V49, P418, DOI 10.3760/cma.j.cn112151-20200225-00138
   Chen SY, 2020, J MED VIROL, V92, P1556, DOI 10.1002/jmv.25789
   Dashraath P, 2020, AM J OBSTET GYNECOL, V222, P521, DOI 10.1016/j.ajog.2020.03.021
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2017, CLIN CHEST MED, V38, P71, DOI 10.1016/j.ccm.2016.11.007
   Lam CM, 2004, BJOG-INT J OBSTET GY, V111, P771, DOI 10.1111/j.1471-0528.2004.00199.x
   Li Na, 2020, Clin Infect Dis, V71, P2035, DOI 10.1093/cid/ciaa352
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu DH, 2020, AM J ROENTGENOL, V215, P127, DOI [10.2214/AJR.20.23072, 10.1080/13813455.2020.1799018]
   Liu HH, 2020, J INFECTION, V80, pE7, DOI 10.1016/j.jinf.2020.03.007
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Moher D, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0087-2
   Pringle KG, 2011, PLACENTA, V32, P956, DOI 10.1016/j.placenta.2011.09.020
   Qiao J, 2020, LANCET, V395, P760, DOI 10.1016/S0140-6736(20)30365-2
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Rousseau MJ, 2017, COGENT MED, V4, P1, DOI DOI 10.1080/2331205X.2017.1334318
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sun PF, 2020, J MED VIROL, V92, P612, DOI 10.1002/jmv.25735
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wu CC, 2020, VIROL SIN, V35, P305, DOI 10.1007/s12250-020-00227-0
   Wu XQ, 2020, INT J GYNECOL OBSTET, V150, P58, DOI 10.1002/ijgo.13165
   Xie LX, 2005, CHEST, V127, P2119, DOI 10.1378/chest.127.6.2119
   Yang H, 2020, J INFECTION, V81, pE40, DOI 10.1016/j.jinf.2020.04.003
   Yu N, 2020, LANCET INFECT DIS, V20, P559, DOI 10.1016/S1473-3099(20)30176-6
   Zhang L, 2020, Zhonghua Fu Chan Ke Za Zhi, V55, P166, DOI 10.3760/cma.j.cn112141-20200218-00111
   Zhao XX, 2020, EUR J CLIN MICROBIOL, V39, P1209, DOI 10.1007/s10096-020-03897-6
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu HP, 2020, TRANSL PEDIATR, V9, P51, DOI 10.21037/tp.2020.02.06
NR 41
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD SEP 29
PY 2020
VL 2020
AR 1708267
DI 10.1155/2020/1708267
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA OG9WH
UT WOS:000582224700007
PM 33029489
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xu, ZR
   Yang, LX
   Zhang, XH
   Zhang, QL
   Yang, ZB
   Liu, YH
   Wei, S
   Liu, WK
AF Xu, Zhongren
   Yang, Lixiang
   Zhang, Xinghao
   Zhang, Qiling
   Yang, Zhibin
   Liu, Yuanhao
   Wei, Shuang
   Liu, Wukun
TI Discovery of Potential Flavonoid Inhibitors Against COVID-19 3CL
   Proteinase Based on Virtual Screening Strategy
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE COVID-19 3CL proteinase; flavonoids; rutin; virtual screening; machine
   learning; molecular docking
ID RESPIRATORY SYNDROME CORONAVIRUS; PROTEASE INHIBITOR; SARS; REPLICATION;
   DERIVATIVES; GENERATION; 3CL(PRO); PATIENT
AB The outbreak of 2019 novel coronavirus (COVID-19) has caused serious threat to public health. Discovery of new anti-COVID-19 drugs is urgently needed. Fortunately, the crystal structure of COVID-19 3CL proteinase was recently resolved. The proteinase has been identified as a promising target for drug discovery in this crisis. Here, a dataset including 2030 natural compounds was screened and refined based on the machine learning and molecular docking. The performance of six machine learning (ML) methods of predicting active coronavirus inhibitors had achieved satisfactory accuracy, especially, the AUC (Area Under ROC Curve) scores with fivefold cross-validation of Logistic Regression (LR) reached up to 0.976. Comprehensive ML prediction and molecular docking results accounted for the compound Rutin, which was approved by NMPA (National Medical Products Administration), exhibited the best AUC and the most promising binding affinity compared to other compounds. Therefore, Rutin might be a promising agent in anti-COVID-19 drugs development.
C1 [Xu, Zhongren; Zhang, Xinghao; Zhang, Qiling; Yang, Zhibin; Liu, Yuanhao; Liu, Wukun] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Sch Med & Holist Integrat Med, Sch Pharm, Nanjing, Peoples R China.
   [Yang, Lixiang] Shenzhen Bay Lab, Shenzhen, Peoples R China.
   [Wei, Shuang] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Resp & Crit Care Med, Tongji Med Coll, Wuhan, Peoples R China.
RP Liu, WK (corresponding author), Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Sch Med & Holist Integrat Med, Sch Pharm, Nanjing, Peoples R China.
EM liuwukun0000@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81703337, 81772477, 81201848]; Jiangsu
   Province Graduate Practice Innovation Program [KYCX20_1489]; Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (Integration of Chinese and Western Medicine); Jiangsu
   Specially-Appointed Professors program; Six Talent Peaks Project in
   Jiangsu Province of China [SWYY-069]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81703337, WL; Nos. 81772477 and 81201848, SW),
   the Jiangsu Province Graduate Practice Innovation Program (KYCX20_1489).
   The Priority Academic Program Development of Jiangsu Higher Education
   Institutions (Integration of Chinese and Western Medicine) and the
   Jiangsu Specially-Appointed Professors program and the Six Talent Peaks
   Project in Jiangsu Province of China (No. SWYY-069).
CR Adedeji AO, 2014, CURR OPIN VIROL, V8, P45, DOI 10.1016/j.coviro.2014.06.002
   ALTMAN NS, 1992, AM STAT, V46, P175, DOI 10.2307/2685209
   Berry M, 2015, VIRUSES-BASEL, V7, P6642, DOI 10.3390/v7122963
   Biau G, 2008, J MACH LEARN RES, V9, P2015
   Cao P, 2020, CARBOHYD POLYM, V240, DOI 10.1016/j.carbpol.2020.116346
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Chen LL, 2006, BIOORGAN MED CHEM, V14, P8295, DOI 10.1016/j.bmc.2006.09.014
   Chen LL, 2005, J VIROL, V79, P7095, DOI 10.1128/JVI.79.11.7095-7103.2005
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Duan QN, 2020, J ETHNOPHARMACOL, V249, DOI 10.1016/j.jep.2019.112405
   Garcia-Fernandez R, 2016, PROTEIN EXPRES PURIF, V123, P42, DOI 10.1016/j.pep.2016.03.003
   Hand DJ, 2009, MACH LEARN, V77, P103, DOI 10.1007/s10994-009-5119-5
   Hu XP, 2020, FUTURE VIROL, V15, P359, DOI 10.2217/fvl-2020-0099
   Jacobs J, 2013, J MED CHEM, V56, P534, DOI 10.1021/jm301580n
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Konno H, 2017, BIOORG MED CHEM LETT, V27, P2746, DOI 10.1016/j.bmcl.2017.04.056
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Li CM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20918
   Liu X., 2020, CRYSTAL STRUCTURE CO
   Ma QH, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10030117
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   Park JY, 2016, J ENZYM INHIB MED CH, V31, P23, DOI 10.3109/14756366.2014.1003215
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   POLTON DJ, 1982, ONLINE REV, V6, P235, DOI 10.1108/eb024099
   Qiu RJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00781
   Rohini K, 2018, APPL BIOCHEM BIOTECH, V184, P1421, DOI 10.1007/s12010-017-2625-y
   SAFAVIAN SR, 1991, IEEE T SYST MAN CYB, V21, P660, DOI 10.1109/21.97458
   Shi CY, 2017, ACS OMEGA, V2, P8682, DOI 10.1021/acsomega.7b01464
   SU H, 2020, ACTA PHARMACOL 0731, DOI DOI 10.1101/2020.04.13.038687
   Tolles J, 2016, JAMA-J AM MED ASSOC, V316, P533, DOI 10.1001/jama.2016.7653
   Wang FS, 2020, LANCET, V395, P391, DOI 10.1016/S0140-6736(20)30300-7
   Wang SQ, 2007, AMINO ACIDS, V33, P129, DOI 10.1007/s00726-006-0403-1
   Watson P, 2008, J CHEM INF MODEL, V48, P166, DOI 10.1021/ci7003253
   Watts KS, 2010, J CHEM INF MODEL, V50, P534, DOI 10.1021/ci100015j
   Wilsey C, 2013, COMPUT BIOL CHEM, V47, P121, DOI 10.1016/j.compbiolchem.2013.08.006
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xue L, 2004, J CHEM INF COMP SCI, V44, P2032, DOI 10.1021/ci0400819
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Yoshizawa S, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2019.115273
   Zhang SN, 2010, PROTEIN CELL, V1, P371, DOI 10.1007/s13238-010-0044-8
   Zhao Q, 2019, J ETHNOPHARMACOL, V244, DOI 10.1016/j.jep.2019.112132
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 44
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD SEP 29
PY 2020
VL 7
AR 556481
DI 10.3389/fmolb.2020.556481
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OD4BE
UT WOS:000579797000001
PM 33134310
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sviridov, D
   Miller, YI
   Ballout, RA
   Remaley, AT
   Bukrinsky, M
AF Sviridov, Dmitri
   Miller, Yury I.
   Ballout, Rami A.
   Remaley, Alan T.
   Bukrinsky, Michael
TI Targeting Lipid Rafts-A Potential Therapy for COVID-19
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus; lipid rafts; inflammation; lipids;
   cholesterol
ID MEMBRANE MICRODOMAINS; SARS-CORONAVIRUS; ENTRY; SARS-COV-2; VIRUS;
   RECEPTOR
AB COVID-19 is a global pandemic currently in an acute phase of rapid expansion. While public health measures remain the most effective protection strategy at this stage, when the peak passes, it will leave in its wake important health problems. Historically, very few viruses have ever been eradicated. Instead, the virus may persist in communities causing recurrent local outbreaks of the acute infection as well as several chronic diseases that may arise from the presence of a "suppressed" virus or as a consequence of the initial exposure. An ideal solution would be an anti-viral medication that (i) targets multiple stages of the viral lifecycle, (ii) is insensitive to frequent changes of viral phenotype due to mutagenesis, (iii) has broad spectrum, (iv) is safe and (v) also targets co-morbidities of the infection. In this Perspective we discuss a therapeutic approach that owns these attributes, namely "lipid raft therapy." Lipid raft therapy is an approach aimed at reducing the abundance and structural modifications of host lipid rafts or at targeted delivery of therapeutics to the rafts. Lipid rafts are the sites of the initial binding, activation, internalization and cell-to-cell transmission of SARS-CoV-2. They also are key regulators of immune and inflammatory responses, dysregulation of which is characteristic to COVID-19 infection. Lipid raft therapy was successful in targeting many viral infections and inflammatory disorders, and can potentially be highly effective for treatment of COVID-19.
C1 [Sviridov, Dmitri] Baker Heart & Diabet Inst, Melbourne, Vic, Australia.
   [Sviridov, Dmitri] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia.
   [Miller, Yury I.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Ballout, Rami A.; Remaley, Alan T.] NHLBI, Lipoprot Metab Sect, Translat Vasc Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Bukrinsky, Michael] George Washington Univ, Sch Med & Hlth Sci, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
RP Sviridov, D (corresponding author), Baker Heart & Diabet Inst, Melbourne, Vic, Australia.; Sviridov, D (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia.
EM dmitri.sviridov@baker.edu.au
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [HL131473, P30
   AI117970, NS102432, HL135737, HL136275, NS104769]; NIH intramural
   research fundsUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA
FX This study was supported by grants from the National Institutes of
   Health: HL131473 (DS and MB), P30 AI117970 (MB), NS102432, HL135737,
   HL136275, NS104769 (YM) and NIH intramural research funds (RB and AR).
CR Altman MO, 2018, VIRAL IMMUNOL, V31, P142, DOI 10.1089/vim.2017.0129
   Bagam P, 2017, CELL BIOL TOXICOL, V33, P429, DOI 10.1007/s10565-017-9386-9
   Ballout RA, 2020, FASEB J, V34, P7253, DOI 10.1096/fj.202000654R
   Bukrinsky MI, 2020, J LIPID RES, V61, P601, DOI 10.1194/jlr.TR119000391
   Calkin AC, 2009, CIRCULATION, V120, P2095, DOI 10.1161/CIRCULATIONAHA.109.870709
   Carter GC, 2009, VIROLOGY, V386, P192, DOI 10.1016/j.virol.2008.12.031
   Choi SH, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120519
   Diamond MS, 2020, CELL HOST MICROBE, V27, P699, DOI 10.1016/j.chom.2020.04.021
   Dubrovsky L, 2020, MBIO, V11, DOI 10.1128/mBio.02956-19
   Fang LH, 2019, CURR OPIN LIPIDOL, V30, P218, DOI 10.1097/MOL.0000000000000596
   Fecchi K, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01821
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Glende J, 2008, VIROLOGY, V381, P215, DOI 10.1016/j.virol.2008.08.026
   He Y, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01302
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2004, TRENDS MICROBIOL, V12, P466, DOI 10.1016/j.tim.2004.08.008
   Koker O, 2020, RHEUMATOL INT, V40, P1613, DOI 10.1007/s00296-020-04663-9
   Lee SY, 2018, ACS APPL MATER INTER, V10, P36628, DOI 10.1021/acsami.8b08243
   Li GM, 2007, MICROBES INFECT, V9, P96, DOI 10.1016/j.micinf.2006.10.015
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lingwood D, 2010, SCIENCE, V327, P46, DOI 10.1126/science.1174621
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Lu YN, 2008, BIOCHEM BIOPH RES CO, V369, P344, DOI 10.1016/j.bbrc.2008.02.023
   Miesbach W, 2020, CLIN APPL THROMB-HEM, V26, DOI 10.1177/1076029620938149
   Mortensen A, 2016, EFSA J, V14, DOI 10.2903/j.efsa.2016.4597
   Musarrat F, 2020, J MED VIROL, V92, P2087, DOI 10.1002/jmv.25985
   Niyogi K, 2001, J VIROL, V75, P7351, DOI 10.1128/JVI.75.16.7351-7361.2001
   Omsland M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29391-w
   Ong EZY, 2020, CELL HOST MICROBE, V27, P879, DOI 10.1016/j.chom.2020.03.021
   Panja P, 2020, J PHYS CHEM B, V124, P5323, DOI 10.1021/acs.jpcb.0c03444
   Partlow KC, 2008, BIOMATERIALS, V29, P3367, DOI 10.1016/j.biomaterials.2008.04.030
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Rosseels MLA, 2013, REGUL TOXICOL PHARM, V67, P351, DOI 10.1016/j.yrtph.2013.08.013
   Sabnis S, 2017, INT J NANOMED, V12, P1453, DOI 10.2147/IJN.S122036
   Schneider DA, 2018, J LIPID RES, V59, P854, DOI 10.1194/jlr.M083618
   Shulla A, 2011, J VIROL, V85, P873, DOI 10.1128/JVI.02062-10
   Sorci-Thomas MG, 2016, CIRC RES, V118, P679, DOI 10.1161/CIRCRESAHA.115.306246
   Sviridov D, 2020, J LIPID RES, V61, P687, DOI 10.1194/jlr.TR120000658
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wang HL, 2008, CELL RES, V18, P290, DOI 10.1038/cr.2008.15
   Woller SA, 2018, CELL REP, V23, P2667, DOI 10.1016/j.celrep.2018.04.110
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zimmer S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6100
NR 45
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 29
PY 2020
VL 11
AR 574508
DI 10.3389/fimmu.2020.574508
PG 5
WC Immunology
SC Immunology
GA OB6ZH
UT WOS:000578616900001
PM 33133090
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pendyala, B
   Patras, A
   Pokharel, B
   D'Souza, D
AF Pendyala, Brahmaiah
   Patras, Ankit
   Pokharel, Bharat
   D'Souza, Doris
TI Genomic Modeling as an Approach to Identify Surrogates for Use in
   Experimental Validation of SARS-CoV-2 and HuNoV Inactivation by UV-C
   Treatment
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE genomic modeling; UV-C inactivation; viruses; SARS-CoV-2 (2019-nCoV);
   norovirus (NoV); surrogates
ID HEPATITIS-A VIRUS; FELINE CALICIVIRUS; MURINE NOROVIRUS; ULTRAVIOLET
   INACTIVATION; SARS CORONAVIRUS; IRRADIATION; DISINFECTION;
   GASTROENTERITIS; REPLICATION; COLIPHAGE
AB Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) is responsible for the COVID-19 pandemic that continues to pose significant public health concerns. While research to deliver vaccines and antivirals are being pursued, various effective technologies to control its environmental spread are also being targeted. Ultraviolet light (UV-C) technologies are effective against a broad spectrum of microorganisms when used even on large surface areas. In this study, we developed a pyrimidine dinucleotide frequency based genomic model to predict the sensitivity of select enveloped and non-enveloped viruses to UV-C treatments in order to identify potential SARS-CoV-2 and human norovirus surrogates. The results revealed that this model was best fitted using linear regression withr(2)= 0.90. The predicted UV-C sensitivity (D-90- dose for 90% inactivation) for SARS-CoV-2 and MERS-CoV was found to be 21.5 and 28 J/m(2), respectively (with an estimated 18 J/m(2)obtained from published experimental data for SARS-CoV-1), suggesting that coronaviruses are highly sensitive to UV-C light compared to other ssRNA viruses used in this modeling study. Murine hepatitis virus (MHV) A59 strain with aD(90)of 21 J/m(2)close to that of SARS-CoV-2 was identified as a suitable surrogate to validate SARS-CoV-2 inactivation by UV-C treatment. Furthermore, the non-enveloped human noroviruses (HuNoVs), had predictedD(90)values of 69.1, 89, and 77.6 J/m(2)for genogroups GI, GII, and GIV, respectively. Murine norovirus (MNV-1) of GV with aD(90)= 100 J/m(2)was identified as a potential conservative surrogate for UV-C inactivation of these HuNoVs. This study provides useful insights for the identification of potential non-pathogenic (to humans) surrogates to understand inactivation kinetics and their use in experimental validation of UV-C disinfection systems. This approach can be used to narrow the number of surrogates used in testing UV-C inactivation of other human and animal ssRNA viral pathogens for experimental validation that can save cost, labor and time.
C1 [Pendyala, Brahmaiah; Patras, Ankit; Pokharel, Bharat] Tennessee State Univ, Coll Agr, Dept Agr & Environm Sci, Food Sci Program, Nashville, TN 37203 USA.
   [D'Souza, Doris] Univ Tennessee, Dept Food Sci, Knoxville, TN USA.
RP Pendyala, B; Patras, A (corresponding author), Tennessee State Univ, Coll Agr, Dept Agr & Environm Sci, Food Sci Program, Nashville, TN 37203 USA.
EM bpendyal@tnstate.edu; apatras@tnstate.edu
FU Agriculture and Food Research Initiative (Food Safety Challenge Area);
   USDAUnited States Department of Agriculture (USDA) [2018-38821-27732,
   2019-69015-29233]
FX This project is funded under the Agriculture and Food Research
   Initiative (Food Safety Challenge Area), USDA, Award numbers;
   2018-38821-27732 and 2019-69015-29233.
CR Alagaili AN, 2014, MBIO, V5, DOI DOI 10.1128/MBIO.00884-14
   BATTIGELLI DA, 1993, WATER SCI TECHNOL, V27, P339
   BECKER MM, 1989, J MOL BIOL, V210, P429, DOI 10.1016/0022-2836(89)90120-4
   Bhullar MS, 2019, FOOD SCI TECHNOL INT, V25, P562, DOI 10.1177/1082013219843395
   Bolton JR, 2003, J ENVIRON ENG-ASCE, V129, P209, DOI 10.1061/(ASCE)0733-9372(2003)129:3(209)
   Darnell MER, 2004, J VIROL METHODS, V121, P85, DOI 10.1016/j.jviromet.2004.06.006
   Kumar GD, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01351
   Di Stefano R, 1976, G Batteriol Virol Immunol, V69, P3
   Douki T, 2013, PHOTOCH PHOTOBIO SCI, V12, P1286, DOI 10.1039/c3pp25451h
   Doultree JC, 1999, J HOSP INFECT, V41, P51, DOI 10.1016/S0195-6701(99)90037-3
   DUBININ NP, 1975, P NATL ACAD SCI USA, V72, P386, DOI 10.1073/pnas.72.1.386
   Estes MK, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070638
   Ettayebi K, 2016, SCIENCE, V353, P1387, DOI 10.1126/science.aaf5211
   Fankhauser RL, 2002, J INFECT DIS, V186, P1, DOI 10.1086/341085
   Gerba CP, 2002, APPL ENVIRON MICROB, V68, P5167, DOI 10.1128/AEM.68.10.5167-5169.2002
   Godoy P, 2006, REV CLIN ESP, V206, P435, DOI 10.1016/S0014-2565(06)72851-X
   Gopisetty VVS, 2019, INNOV FOOD SCI EMERG, V52, P66, DOI 10.1016/j.ifset.2018.11.002
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Haji Malayeri A, 2016, IUVA NEWS, V18, P4, DOI DOI 10.1128/AEM.01587-07
   Husman AMD, 2004, APPL ENVIRON MICROB, V70, P5089, DOI 10.1128/AEM.70.9.5089-5093.2004
   Kariwa H, 2006, DERMATOLOGY, V212, P119, DOI 10.1159/000089211
   KELLOFF G, 1970, VIROLOGY, V42, P1133, DOI 10.1016/0042-6822(70)90361-2
   Kowalski W., 2009, IUVA NEWS, V11, P15
   Lazarova V, 2004, WATER SCI TECHNOL, V50, P203
   Lee J, 2008, APPL ENVIRON MICROB, V74, P2111, DOI 10.1128/AEM.02442-07
   NOMURA S, 1972, J GEN VIROL, V14, P213, DOI 10.1099/0022-1317-14-2-213
   Park GW, 2011, LETT APPL MICROBIOL, V52, P162, DOI 10.1111/j.1472-765X.2010.02982.x
   Patras A., 2020, ULTRAVIOLET TREATMEN
   Pendyala B, 2019, FOOD BIOPROCESS TECH, DOI 10.1007/s11947-019-02363-2
   Pendyala B, 2019, FOODBORNE PATHOG DIS, V16, P704, DOI 10.1089/fpd.2019.2623
   Ronnqvist M, 2014, FOOD ENVIRON VIROL, V6, P48, DOI 10.1007/s12560-013-9128-y
   Ross T, 2000, INT J FOOD MICROBIOL, V62, P231, DOI 10.1016/S0168-1605(00)00340-8
   SAKNIMIT M, 1988, EXP ANIM TOKYO, V37, P341, DOI 10.1538/expanim1978.37.3_341
   SETLOW RB, 1966, J MOL BIOL, V17, P237, DOI 10.1016/S0022-2836(66)80105-5
   Shin GA, 2005, J ENVIRON ENG SCI, V4, pS7, DOI 10.1139/S04-036
   Simonet J, 2006, APPL ENVIRON MICROB, V72, P7671, DOI 10.1128/AEM.01106-06
   SMIRNOV YA, 1992, VIRUS RES, V22, P151, DOI 10.1016/0168-1702(92)90041-7
   Smithyman K., 1969, MOL PHOTOBIOLOGY INA
   Thompson SS, 2003, WATER ENVIRON RES, V75, P163, DOI 10.2175/106143003X140944
   Thurston-Enriquez JA, 2003, APPL ENVIRON MICROB, V69, P577, DOI 10.1128/AEM.69.1.577-582.2003
   USEPA, 2020, LIST N DIS US SARS C
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   VONBRODOROTTI HS, 1982, ZBL VET MED B, V29, P129
   Walker DI, 2019, FOOD ENVIRON VIROL, V11, P229, DOI 10.1007/s12560-019-09390-4
   Wang DP, 2014, INT J FOOD MICROBIOL, V172, P76, DOI 10.1016/j.ijfoodmicro.2013.11.027
   WEISS M, 1986, VET MICROBIOL, V11, P41, DOI 10.1016/0378-1135(86)90005-2
   WHO, 2020, REP WHO CHIN JOINT M
   Widdowson MA, 2005, EMERG INFECT DIS, V11, P95, DOI 10.3201/eid1101.040426
   WIEDENMANN A, 1993, WATER SCI TECHNOL, V27, P335
   Wilson B. R., 1992, P AWWA WAT QUAL TECH
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   World Health Organization, 2020, 143 WHO
   ZAVADOVA Z, 1975, ACTA VIROL, V19, P88
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 54
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD SEP 29
PY 2020
VL 11
AR 572331
DI 10.3389/fmicb.2020.572331
PG 9
WC Microbiology
SC Microbiology
GA OB7DK
UT WOS:000578627600001
PM 33133042
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Montiel, V
   Robert, A
   Robert, A
   Nabaoui, A
   Marie, T
   Mestre, NM
   Guillaume, M
   Laterre, PF
   Wittebole, X
AF Montiel, Virginie
   Robert, Arnaud
   Robert, Annie
   Nabaoui, Anas
   Marie, Tourneux
   Mestre, Natalia Morales
   Guillaume, Maerckx
   Laterre, Pierre-Francois
   Wittebole, Xavier
TI Surgical mask on top of high-flow nasal cannula improves oxygenation in
   critically ill COVID-19 patients with hypoxemic respiratory failure
SO ANNALS OF INTENSIVE CARE
LA English
DT Article
DE Hypoxemic failure; High-flow nasal cannula; COVID-19 patient
ID THERAPY; ADULTS
AB Objective Critically ill patients admitted in ICU because of COVID-19 infection display severe hypoxemic respiratory failure. The Surviving Sepsis Campaign recommends oxygenation through high-flow nasal cannula over non-invasive ventilation. The primary outcome of our study was to evaluate the effect of the addition of a surgical mask on a high-flow nasal cannula system on oxygenation parameters in hypoxemic COVID-19 patients admitted in ICU who do not require urgent intubation. The secondary outcomes were relevant changes in PaCO(2)associated with clinical modifications and patient's feelings. Design We prospectively assessed 21 patients admitted in our mixed Intensive Care Unit of the Cliniques Universitaires Saint Luc. Main results While FiO2 was unchanged, we demonstrate a significant increase of PaO2(from 59 (+/- 6), to 79 mmHg (+/- 16),p < 0.001), PaO2/FiO(2)from 83 (+/- 22), to 111 (+/- 38),p < 0.001) and SaO(2)(from 91% (+/- 1.5), to 94% (+/- 1.6),p < 0.001), while the patients were under the surgical mask. The SpO(2)returned to pre-treatment values when the surgical mask was removed confirming the effect of the device rather than a spontaneous positive evolution. Conclusion A surgical mask placed on patient's face already treated by a High-flow nasal cannula device improves COVID-19 patient's oxygenation admitted in Intensive Care Unit for severe hypoxemic respiratory failure without any clinically relevant side.
C1 [Montiel, Virginie; Robert, Arnaud; Nabaoui, Anas; Marie, Tourneux; Mestre, Natalia Morales; Guillaume, Maerckx; Laterre, Pierre-Francois; Wittebole, Xavier] UCLouvain, Clin Univ St Luc, Intens Care Unit, 10 Ave Hippocrate, B-1200 Brussels, Belgium.
   [Robert, Annie] UCLouvain, Pole Epidemiol & Biostat, Inst Rech Expt & Clin, Brussels, Belgium.
   [Mestre, Natalia Morales; Guillaume, Maerckx] UCLouvain, Inst Rech Expt & Clin IREC, Pole Pneumol ORL & Dermatol PNEU, Brussels, Belgium.
RP Montiel, V (corresponding author), UCLouvain, Clin Univ St Luc, Intens Care Unit, 10 Ave Hippocrate, B-1200 Brussels, Belgium.
EM virginie.montiel@uclouvain.be
RI Maerckx, Guillaume/ABC-6800-2020
OI Montiel, Virginie/0000-0002-5769-9954
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Duprez F, 2019, RESP CARE, V64, P908, DOI 10.4187/respcare.06520
   Elshof J, 2020, RESPIRATION, V99, P140, DOI 10.1159/000505583
   Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326
   Hui DS, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.02339-2018
   Ip M, 2007, AM J INFECT CONTROL, V35, P684, DOI 10.1016/j.ajic.2007.05.007
   Kotoda M, 2020, J HOSP INFECT, V104, P534, DOI 10.1016/j.jhin.2019.11.010
   Lee CC, 2016, RESP MED, V121, P100, DOI 10.1016/j.rmed.2016.11.004
   Leonard S, 2020, CHEST, VS0012-3692, P30579
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Li J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00892-2020
   Loh NHW, 2020, CAN J ANESTH, V67, P893, DOI 10.1007/s12630-020-01634-3
   Nishimura M, 2016, RESP CARE, V61, P529, DOI 10.4187/respcare.04577
   Rochwerg B, 2019, INTENS CARE MED, V45, P563, DOI 10.1007/s00134-019-05590-5
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Truog RD, 2020, NEW ENGL J MED, V382, P1973, DOI 10.1056/NEJMp2005689
   Wang K, 2020, CLIN RADIOL, V75, P341, DOI 10.1016/j.crad.2020.03.004
   Wang K, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00653-z
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 19
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2110-5820
J9 ANN INTENSIVE CARE
JI Ann. Intensive Care
PD SEP 29
PY 2020
VL 10
IS 1
AR 125
DI 10.1186/s13613-020-00744-x
PG 7
WC Critical Care Medicine
SC General & Internal Medicine
GA NZ2IM
UT WOS:000576919000001
PM 32990864
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cadegiani, FA
AF Cadegiani, Flavio A.
TI Repurposing existing drugs for COVID-19: an endocrinology perspective
SO BMC ENDOCRINE DISORDERS
LA English
DT Letter
DE COVID-19; SARS-CoV-2; ACE2; TMPRSS2; Pandemic
ID ACUTE LUNG INJURY; ANGIOTENSIN-ALDOSTERONE SYSTEM; CONVERTING ENZYME 2;
   RESPIRATORY-DISTRESS-SYNDROME; MINERALOCORTICOID RECEPTOR BLOCKADE;
   VITAMIN-D; VENOUS THROMBOEMBOLISM; N-ACETYLCYSTEINE; BLOOD-PRESSURE;
   GLUTATHIONE SYNTHESIS
AB Background: Coronavirus Disease 2019 (COVID-19) is a multi-systemic infection caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), that has become a pandemic. Although its prevailing symptoms include anosmia, ageusia, dry couch, fever, shortness of brief, arthralgia, myalgia, and fatigue, regional and methodological assessments vary, leading to heterogeneous clinical descriptions of COVID-19. Aging, uncontrolled diabetes, hypertension, obesity, and exposure to androgens have been correlated with worse prognosis in COVID-19. Abnormalities in the renin-angiotensin-aldosterone system (RAAS), angiotensin-converting enzyme-2 (ACE2) and the androgen-driven transmembrane serine protease 2 (TMPRSS2) have been elicited as key modulators of SARS-CoV-2.
   Main text: While safe and effective therapies for COVID-19 lack, the current moment of pandemic urges for therapeutic options. Existing drugs should be preferred over novel ones for clinical testing due to four inherent characteristics: 1. Well-established long-term safety profile, known risks and contraindications; 2. More accurate predictions of clinical effects; 3. Familiarity of clinical management; and 4. Affordable costs for public health systems. In the context of the key modulators of SARS-CoV-2 infectivity, endocrine targets have become central as candidates for COVID-19.
   The only endocrine or endocrine-related drug class with already existing emerging evidence for COVID-19 is the glucocorticoids, particularly for the use of dexamethasone for severely affected patients. Other drugs that are more likely to present clinical effects despite the lack of specific evidence for COVID-19 include anti-androgens (spironolactone, eplerenone, finasteride and dutasteride), statins, N-acetyl cysteine (NAC), ACE inhibitors (ACEi), angiotensin receptor blockers (ARB), and direct TMPRSS-2 inhibitors (nafamostat and camostat). Several other candidates show less consistent plausibility. In common, except for dexamethasone, all candidates have no evidence for COVID-19, and clinical trials are needed.
   Conclusion: While dexamethasone may reduce mortality in severely ill patients with COVID-19, in the absence of evidence of any specific drug for mild-to-moderate COVID-19, researchers should consider testing existing drugs due to their favorable safety, familiarity, and cost profile. However, except for dexamethasone in severe COVID-19, drug treatments for COVID-19 patients must be restricted to clinical research studies until efficacy has been extensively proven, with favorable outcomes in terms of reduction in hospitalization, mechanical ventilation, and death.
C1 [Cadegiani, Flavio A.] Univ Fed Sao Paulo, EPM UNIFESP, Div Endocrinol & Metab, Adrenal & Hypertens Unit,Dept Med,Escola Paulista, Rua Pedro Toledo 781,13th Floor, BR-04039032 Sao Paulo, SP, Brazil.
RP Cadegiani, FA (corresponding author), Univ Fed Sao Paulo, EPM UNIFESP, Div Endocrinol & Metab, Adrenal & Hypertens Unit,Dept Med,Escola Paulista, Rua Pedro Toledo 781,13th Floor, BR-04039032 Sao Paulo, SP, Brazil.
EM flavio.cadegiani@unifesp.br
CR Abdelmaksoud A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13482
   Abobaker A, 2020, WORLD J UROL, DOI 10.1007/s00345-020-03208-w
   Alijotas-Reig J, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102569
   Almohanna HM, 2018, EXPERT OPIN DRUG SAF, V17, P1115, DOI 10.1080/14740338.2018.1533549
   Andreou A, 2020, IN VIVO, V34, P1567, DOI 10.21873/invivo.11946
   Andriole GL, 2003, EUR UROL, V44, P82, DOI 10.1016/S0302-2838(03)00198-2
   Angelina A, 2020, INT J ELECTRON, P1
   Annweiler Cedric, 2020, Infectious Disorders - Drug Targets, V20, P407, DOI 10.2174/1871526520666200518073329
   [Anonymous], 2020, LANCET HAEMATOL, V7, pE425, DOI [10.1016/S2352-3026(20)30151-4, 10.1016/j.thromres.2020.04.041]
   [Anonymous], J AM ACAD DERM
   Arefi S, 2013, GYNECOL ENDOCRINOL, V29, P470, DOI 10.3109/09513590.2013.769513
   Arentz M, 2020, JAMA
   Assimakopoulos SF, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109778
   Aygun H, 2020, N-S ARCH PHARMACOL, P1
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Barnett N, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/2110-5820-4-5
   Bartley J, 2010, J LARYNGOL OTOL, V124, P465, DOI 10.1017/S0022215109992684
   Bassendine MF, 2020, J DIABETES, V12, P649, DOI 10.1111/1753-0407.13052
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Baudrand R, 2015, CIRCULATION, V132, P1825, DOI 10.1161/CIRCULATIONAHA.115.016759
   Beard JA, 2011, J CLIN VIROL, V50, P194, DOI 10.1016/j.jcv.2010.12.006
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Beckers PAJ, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.01.41
   Bedi O, 2016, N-S ARCH PHARMACOL, V389, P695, DOI 10.1007/s00210-016-1252-4
   Bem D, 2015, SYST REV-LONDON, V4, DOI 10.1186/s13643-015-0078-3
   BOESGAARD S, 1993, J PHARMACOL EXP THER, V265, P1239
   Bonkhoff H, 2009, EUR UROL, V55, P533, DOI 10.1016/j.eururo.2008.10.035
   Bonora BM, 2020, DIABET METAB SYND OB, V13, P161, DOI 10.2147/DMSO.S233538
   Borghi C, 2017, NUTR METAB CARDIOVAS, V27, P115, DOI 10.1016/j.numecd.2016.07.013
   Boyack Mark, 2002, J Am Acad Nurse Pract, V14, P150, DOI 10.1111/j.1745-7599.2002.tb00107.x
   Breithaupt-Faloppa AC, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1980
   Briand-Mesange F, 2020, OBESITY, V28, P1580, DOI 10.1002/oby.22916
   Brotons C, 2015, AM J CARDIOVASC DRUG, V15, P113, DOI 10.1007/s40256-014-0100-5
   BROULIK PD, 1976, ENDOKRINOLOGIE, V68, P35
   Burn J, 2020, LANCET, V395, P1855, DOI 10.1016/S0140-6736(20)30366-4
   Cadegiani FA., AM J PHYSL
   Carboni E, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109776
   Maya WDC, 2020, REPROD BIOMED ONLINE, V40, P763, DOI [10.1016/j.rbmo.2020.04.0091472-6483, 10.1016/j.rbmo.2020.04.009]
   Cariou B, 2020, DIABETOLOGIA, P1
   Castiglione V, 2020, EUR HEART J-CARD PHA, V6, P258, DOI 10.1093/ehjcvp/pvaa042
   Chanplakorn Niramol, 2011, Hormones & Cancer, V2, P73, DOI 10.1007/s12672-010-0062-2
   Chen Y, 2020, BIOCH BIOPHYS RES CO
   Chen Y, 2018, CHINESE MED J-PEKING, V131, P376, DOI 10.4103/0366-6999.223856
   Cheung KS, 2020, GASTROENTEROLOGY
   Chojkier M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031516
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Ciaglia E, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00206
   Ciavarella C, 2020, MOLECULES, V25, DOI 10.3390/molecules25092076
   Circu ML, 2008, FREE RADICAL RES, V42, P689, DOI 10.1080/10715760802317663
   Cardona GC, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116824
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Cure E, 2020, DIABETES METAB SYND, V14, P405, DOI 10.1016/j.dsx.2020.04.024
   Cutolo M, 2020, CLIN EXP RHEUMATOL, V38, P383
   Dalan R, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108230
   Dalan R, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108216
   Dastan F, 2020, IRAN J ALLERGY ASTHM, V19, P10, DOI 10.18502/ijaai.v19i(s1.r1).2849
   Del Fiol FD, 2015, J INFECT DEV COUNTR, V9, P355, DOI 10.3855/jidc.5711
   Di Stadio A, 2020, EUR REV MED PHARMACO, V24, P5195, DOI 10.26355/eurrev_202005_21298
   Diaz A, 2017, VACCINE, V35, P2694, DOI 10.1016/j.vaccine.2017.03.078
   Dieterich H A, 2005, Fiziol Cheloveka, V31, P97
   Dolgin E, 2020, NAT BIOTECHNOL, V38, P510, DOI [10.1038/s41587-020-0520-5, 10.1038/s41587-020-0528-x]
   Doucet D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009421
   Drapala A, 2014, J RENIN-ANGIO-ALDO S, V15, P250, DOI 10.1177/1470320314531058
   Dumanli GY, 2020, TURK J ANAESTHESIOL, V48, P254, DOI 10.5152/TJAR.2020.569
   EL-Arabey AA, 2020, J MED VIROL, V92, P2293, DOI 10.1002/jmv.25958
   Ellis AJ, 2015, EXPERT OPIN DRUG SAF, V14, P1799, DOI 10.1517/14740338.2015.1071913
   Facchiano A, 2020, AM J PHYSIOL-ENDOC M, V318, pE838, DOI 10.1152/ajpendo.00185.2020
   Fadini GP, 2020, DIABETES OBES METAB, V22, P1946, DOI 10.1111/dom.14097
   Fan E, 2018, JAMA-J AM MED ASSOC, V319, P698, DOI 10.1001/jama.2017.21907
   Fanelli V, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02872-z
   Fedson DS, 2020, MBIO, V11, DOI 10.1128/mBio.00398-20
   Feng Y, 2018, EUR REV MED PHARMACO, V22, P3190, DOI 10.26355/eurrev_201805_15080
   Feraco A, 2013, J STEROID BIOCHEM, V137, P99, DOI 10.1016/j.jsbmb.2013.02.012
   Fraccarollo D, 2008, HYPERTENSION, V51, P905, DOI 10.1161/HYPERTENSIONAHA.107.100941
   Fukano K, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03257
   Fuller PJ, 2000, KIDNEY INT, V57, P1256, DOI 10.1046/j.1523-1755.2000.00959.x
   Gawrys J, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7902081
   Georgianos PI, 2017, CURR VASC PHARMACOL, V15, P599, DOI 10.2174/1570161115666170201113817
   Ghavimi H, 2018, IRAN J BASIC MED SCI, V21, P469, DOI 10.22038/IJBMS.2018.24610.6126
   Ghazizadeh Zaniar, 2020, bioRxiv, DOI 10.1101/2020.05.12.091082
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Gil C, 2020, J MED CHEM, V63, P12359, DOI 10.1021/acs.jmedchem.0c00606
   Glebov OO, 2020, FEBS J, V287, P3664, DOI 10.1111/febs.15369
   Glinsky GV, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050129
   Gokakin AK, 2013, BURNS, V39, P1193, DOI 10.1016/j.burns.2012.12.017
   Goren A, 2020, J COSMET DERMATOL-US, V19, P1545, DOI 10.1111/jocd.13443
   Goren A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13365
   Grandi G, 2020, EUR J CONTRACEP REPR, V25, P60, DOI [10.1080/13625187.2019.1709964, 10.1080/14740338.2020.1791818]
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Grommes J, 2012, EUR RESPIR J, V40, P416, DOI 10.1183/09031936.00091011
   Grommes J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038917
   Gruber-Bzura BM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082419
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Zhou GJ, 2007, ACTA PHARMACOL SIN, V28, P1585, DOI 10.1111/j.1745-7254.2007.00637.x
   Guerra-Mora JR, 2017, TRANSPL P, V49, P1461, DOI 10.1016/j.transproceed.2017.03.089
   Guerrero CA, 2012, ANTIVIR RES, V96, P269, DOI 10.1016/j.antiviral.2012.11.001
   Guo K, 2019, J INVEST SURG, DOI 10.1080/08941939.2019.1680777
   Guo T, 2020, JAMA CARDIOL
   Hajifathalian K, 2020, OBESITY, V28, P1606, DOI 10.1002/oby.22923
   Halpin DMG, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01009-2020
   Hamidi SA, 2011, ENDOCRINOLOGY, V152, P4729, DOI 10.1210/en.2011-1631
   Hamming I, 2007, J PATHOL, V212, P1, DOI 10.1002/path.2162
   Hastie CE, 2020, DIABETES METAB SYND, V14, P561, DOI 10.1016/j.dsx.2020.04.050
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Hermidorff MM, 2015, BIOCHEM CELL BIOL, V93, P83, DOI 10.1139/bcb-2014-0110
   Hierweger AM, 2019, AM J REPROD IMMUNOL, V81, DOI 10.1111/aji.13084
   Hilliard LM, 2013, CURR HYPERTENS REP, V15, P71, DOI 10.1007/s11906-012-0319-y
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Horowitz RI, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109851
   Huang Sharon A, 2013, P T, V38, P407
   Inciardi RM, 2020, JAMA CARDIOL
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jakovac H, 2020, AM J PHYSIOL-ENDOC M, V318, pE589, DOI 10.1152/ajpendo.00138.2020
   Jean SS, 2020, EXPERT REV ANTI-INFE, V18, P843, DOI 10.1080/14787210.2020.1771181
   Ji WJ, 2016, NANOMEDICINE-UK, V11, P1393, DOI 10.2217/nnm-2016-0006
   Ji WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081090
   Jian MY, 2013, AM J PHYSIOL-LUNG C, V305, pL844, DOI 10.1152/ajplung.00173.2013
   Kalligeros M, 2020, OBESITY, V28, P1200, DOI 10.1002/oby.22859
   Kan WH, 2008, ANN SURG, V248, P294, DOI 10.1097/SLA.0b013e318180a3db
   Kao SJ, 2006, CLIN EXP PHARMACOL P, V33, P33, DOI 10.1111/j.1440-1681.2006.04320.x
   Kaplan J, 2014, INNATE IMMUN-LONDON, V20, P519, DOI 10.1177/1753425913501565
   Kaser S, 2010, INT J CLIN PRACT, V64, P968, DOI 10.1111/j.1742-1241.2009.02327.x
   Kato Y, 2014, IMMUNOPHARM IMMUNOT, V36, P237, DOI 10.3109/08923973.2014.921690
   KAVANAGH TJ, 1990, J CELL PHYSIOL, V145, P472, DOI 10.1002/jcp.1041450312
   Kawasaki T, 2012, J ANESTH, V26, P883, DOI 10.1007/s00540-012-1425-3
   Kawasaki T, 2018, AM J PHYSIOL-LUNG C, V315, pL834, DOI 10.1152/ajplung.00031.2018
   Keidar S, 2005, CIRC RES, V97, P946, DOI 10.1161/01.RES.0000187500.24964.7A
   KELLERWOOD M, 1990, AM J PHYSIOL, V259, pR350
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Khattab M, 2010, LIVER INT, V30, P447, DOI 10.1111/j.1478-3231.2009.02171.x
   Kim H, 2017, ONCOTARGET, V8, P62820, DOI 10.18632/oncotarget.11355
   Kim IC, 2020, EUR HEART J
   Kino T, 2004, ESSAYS BIOCHEM, V40, P137, DOI 10.1042/bse0400137
   Klaff LS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049076
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kniotek M, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/4541958
   Kochi AN, 2020, J CARDIOVASC ELECTR, V31, P1003, DOI 10.1111/jce.14479
   Komukai K, 2010, FUND CLIN PHARMACOL, V24, P687, DOI 10.1111/j.1472-8206.2010.00854.x
   Kong EL, 2019, J CELL COMMUN SIGNAL, V13, P17, DOI 10.1007/s12079-018-0466-2
   Kosutova P, 2018, J PHYSIOL PHARMACOL, V69, P815, DOI 10.26402/jpp.2018.5.15
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuchay Mohammad Shafi, 2021, Adv Exp Med Biol, V1307, P213, DOI 10.1007/5584_2020_479
   Kurisu S, 2013, J RENIN-ANGIO-ALDO S, V14, P51, DOI 10.1177/1470320312452028
   Kutsukake M, 2014, J SURG RES, V189, P295, DOI 10.1016/j.jss.2014.03.007
   Kvandova M, 2018, J PHYSIOL PHARMACOL, V69, DOI 10.26402/jpp.2018.2.09
   Lacombe B, 2016, J VIROL, V90, P10972, DOI 10.1128/JVI.01722-16
   Lalau JD, 2017, DIABETES OBES METAB, V19, P1502, DOI 10.1111/dom.12974
   Laliberte F, 2018, MENOPAUSE, V25, P1297, DOI 10.1097/GME.0000000000001232
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lee IC, 2020, J CHIN MED ASSOC, V83, P521, DOI 10.1097/JCMA.0000000000000319
   Jimenez DL, 2019, LANCET DIABETES ENDO, V7, P337, DOI 10.1016/S2213-8587(19)30065-8
   Letko M, 2018, CELL REP, V24, P1730, DOI 10.1016/j.celrep.2018.07.045
   Leung PS, 2019, MOLECULES, V24, DOI 10.3390/molecules24132479
   Li L, 2018, J PHARMACOL SCI, V137, P220, DOI 10.1016/j.jphs.2017.10.006
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI0215219, 10.1172/JCI200215219]
   Li Y, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101160
   Liang HY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00738
   Lieber GB, 2013, EUR J PHARMACOL, V718, P290, DOI 10.1016/j.ejphar.2013.08.019
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Liu DD, 2007, CLIN EXP PHARMACOL P, V34, P61, DOI 10.1111/j.1440-1681.2007.04526.x
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lobo-Galo N, FDA APPROVED THIOL R
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ludtke DD, SCAND J MED SCI SPOR
   Luo P, 2020, AM J TROP MED HYG, V103, P69, DOI 10.4269/ajtmh.20-0375
   Ma SQ, 2020, J MED VIROL, V92, P2396, DOI 10.1002/jmv.26086
   Magrone T, 2020, ENDOCR METAB IMMUNE, V20, P807, DOI 10.2174/1871530320666200427112902
   Manning JT, 2020, EARLY HUM DEV, V146, DOI 10.1016/j.earlhumdev.2020.105074
   Maric-Bilkan C, 2012, GENDER MED, V9, P287, DOI 10.1016/j.genm.2012.06.005
   Matsutani T, 2017, BIOL PHARM BULL, V40, P638, DOI 10.1248/bpb.b16-00883
   Mazzanti A, 2020, CIRCULATION, V142, P513, DOI 10.1161/CIRCULATIONAHA.120.048476
   McCoy J, 2020, J COSMET DERMATOL-US, V19, P1542, DOI 10.1111/jocd.13455
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   McMullan CJ, 2017, J HYPERTENS, V35, P822, DOI 10.1097/HJH.0000000000001220
   Menendez JA, 2020, AGING-US, V12, P8760, DOI 10.18632/aging.103347
   Mercorelli B, 2018, TRENDS MICROBIOL, V26, P865, DOI 10.1016/j.tim.2018.04.004
   Mestre L, 2018, BIOCHEM PHARMACOL, V157, P51, DOI 10.1016/j.bcp.2018.08.037
   Meune C, 2003, J RENIN-ANGIO-ALDO S, V4, P149, DOI 10.3317/jraas.2003.023
   Mirabelli M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103664
   Mishra JS, 2019, BIOL REPROD, V100, P139, DOI 10.1093/biolre/ioy179
   Mokhtari V, 2017, CELL J, V19, P11
   Mokra D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194765
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Morath C, 2009, J MOL MED, V87, P53, DOI 10.1007/s00109-008-0404-5
   Morgante G, 2006, GYNECOL ENDOCRINOL, V22, P376, DOI 10.1080/09513590600850300
   Mostaghel EA, 2010, CANCER RES, V70, P1286, DOI 10.1158/0008-5472.CAN-09-2509
   Mungmunpuntipantip R, 2020, J EUR ACAD DERMATOL, V34, pE246, DOI 10.1111/jdv.16483
   Murthy S, 2005, PROSTATE, V64, P362, DOI 10.1002/pros.20251
   Musa S, 2020, ARAB J GASTROENTEROL, V21, P3, DOI 10.1016/j.ajg.2020.03.002
   Muskiet MHA, 2019, LANCET DIABETES ENDO, V7, P397, DOI 10.1016/S2213-8587(18)30263-8
   Nakano S, 2005, HYPERTENS RES, V28, P925, DOI 10.1291/hypres.28.925
   Natoli S, 2020, EUR J NEUROL, V27, P1764, DOI 10.1111/ene.14277
   Nawarskas JJ, 1998, PHARMACOTHERAPY, V18, P1041
   O'Connor KA, 2005, NAT REV DRUG DISCOV, V4, P1005, DOI 10.1038/nrd1900
   O'Donnell E, 2014, AM J PHYSIOL-REG I, V307, pR498, DOI 10.1152/ajpregu.00182.2014
   Oelkers W, 2002, GYNECOL ENDOCRINOL, V16, P83
   Offringa A, 2020, EUR HEART J CARDIOVA
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Ozacmak HS, 2014, J SURG RES, V191, P350, DOI 10.1016/j.jss.2014.04.040
   Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262
   Pandey A, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117883
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Patel S, 2017, BIOMED PHARMACOTHER, V94, P317, DOI 10.1016/j.biopha.2017.07.091
   Peck KM, 2017, J VIROL, V91, DOI 10.1128/JVI.00534-17
   Penlioglou T, 2020, DIABETES THER, V11, P1195, DOI 10.1007/s13300-020-00830-0
   Petrykiv S, 2018, DIABETES OBES METAB, V20, P224, DOI 10.1111/dom.13057
   Poe FL, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109862
   Pozzilli P, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154252
   Qin YY, 2020, CHINESE MED J-PEKING, V133, P1080, DOI 10.1097/CM9.0000000000000791
   Rafatian N, 2014, AM J PHYSIOL-REG I, V307, pR879, DOI 10.1152/ajpregu.00075.2014
   Ramos PM, 2020, J EUR ACAD DERMATOL, DOI 10.1111/jdv.16645
   Rashid S, 2005, CLIN BIOCHEM, V38, P401, DOI 10.1016/j.clinbiochem.2004.11.009
   RASTRELLI G, 2020, ANDROLOGY US 0603, DOI DOI 10.1111/ANDR.12821
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Reiner Z, 2020, ARCH MED SCI, V16, P490, DOI 10.5114/aoms.2020.94655
   Rieder SA, 2010, IMMUNOBIOLOGY, V215, P598, DOI 10.1016/j.imbio.2009.04.001
   Rogosnitzky Moshe, 2020, JMIR Public Health Surveill, V6, pe19199, DOI 10.2196/19199
   Rolfe M, 2019, HEART FAIL REV, V24, P617, DOI 10.1007/s10741-019-09784-3
   Rossi F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113809
   Rotzinger DC, 2020, THROMB RES, V190, P58, DOI 10.1016/j.thromres.2020.04.011
   Rovinski D, 2018, THROMB RES, V168, P83, DOI 10.1016/j.thromres.2018.06.014
   Rowlands J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00672
   Rozner RN, 2019, BREAST CANCER RES TR, V174, P15, DOI 10.1007/s10549-018-4996-3
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Salonia A, 2020, ANDROLOGY-US, DOI 10.1111/andr.12811
   Schaich CL, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12108
   Scheen AJ, 2020, DIABETES METAB
   Scheres LJJ, 2019, J THROMB HAEMOST, V17, P1297, DOI 10.1111/jth.14474
   Schjoedt KJ, 2011, DAN MED BULL, V58
   Schork A, 2019, CARDIOVASC DIABETOL, V18, DOI 10.1186/s12933-019-0852-y
   Schuliga M, 2017, AM J PHYSIOL-LUNG C, V312, P1772, DOI 10.1152/ajplung.00553.2016
   Sekhar RV, 2011, AM J CLIN NUTR, V94, P847, DOI 10.3945/ajcn.110.003483
   Sekhar RV, 2011, DIABETES CARE, V34, P162, DOI 10.2337/dc10-1006
   Sert M, 2003, ACTA MED OKAYAMA, V57, P73
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Sharma S, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108183
   Shaughnessy AF, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d741
   Shekarforoush S, 2019, ACTA CARDIOL, V74, P109, DOI 10.1080/00015385.2018.1472840
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Shen Y, 2016, ACTA PHARMACOL SIN, V37, P637, DOI 10.1038/aps.2016.12
   Shi M, 2018, AM J TRANSL RES, V10, P2335
   Shi YY, 2016, MOL MED REP, V13, P1186, DOI 10.3892/mmr.2015.4685
   Shin SR, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2985148
   Shurrab NT, 2020, OBES MED, V17, DOI [10.1016/j.obmed.2020.10018652, DOI 10.1016/J.OBMED.2020.100186]
   Siang KC, 2020, J MED VIROL, DOI [10.1002/jmv.26090, DOI 10.1002/JMV.26090]
   Simon JA, 2016, MENOPAUSE, V23, P600, DOI 10.1097/GME.0000000000000590
   Skov J, 2016, DIABETES OBES METAB, V18, P581, DOI 10.1111/dom.12651
   Skov J, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00023
   Skov J, 2013, J CLIN ENDOCR METAB, V98, pE664, DOI 10.1210/jc.2012-3855
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Speeckaert MM, 2020, AGING CLIN EXP RES, V32, P1207, DOI 10.1007/s40520-020-01607-y
   Speyer CL, 2005, AM J PHYSIOL-CELL PH, V288, pC881, DOI 10.1152/ajpcell.00467.2004
   Springer J, 2017, ESC HEART FAIL, V4, P492, DOI 10.1002/ehf2.12237
   STEELMAN SL, 1969, STEROIDS, V14, P449, DOI 10.1016/S0039-128X(69)80007-3
   Stelzig KE, 2020, AM J PHYSIOL-LUNG C, V318, pL1280, DOI 10.1152/ajplung.00153.2020
   Strollo R, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3330
   Suba Z, 2020, J PHARM PHARM SCI, V23, P75, DOI 10.18433/jpps31069
   Sumino H, 2010, GERIATR GERONTOL INT, V10, P70, DOI 10.1111/j.1447-0594.2009.00562.x
   Suzuki T, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0660-4
   Tacconelli S, 2020, BIOCHEM PHARMACOL, V178, DOI 10.1016/j.bcp.2020.114094
   Tadic M, 2020, J CLIN HYPERTENS, V22, P943, DOI 10.1111/jch.13912
   Taira M, 2008, EUR J PHARMACOL, V589, P264, DOI 10.1016/j.ejphar.2008.06.019
   Takagi K, 2010, ENDOCR-RELAT CANCER, V17, P415, DOI 10.1677/ERC-09-0257
   Takeda Y, 2007, AM J HYPERTENS, V20, P1119, DOI 10.1016/j.amjhyper.2007.05.008
   Tang BMP, 2009, CRIT CARE MED, V37, P1594, DOI 10.1097/CCM.0b013e31819fb507
   te Riet L, 2015, CIRC RES, V116, P960, DOI 10.1161/CIRCRESAHA.116.303587
   Tentolouris A, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16162965
   Teymoori-Rad M, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2032
   Tilgner J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161218
   Tindall DJ, 2008, J UROLOGY, V179, P1235, DOI 10.1016/j.juro.2007.11.033
   Topol EJ, 2010, LANCET, V376, P517, DOI 10.1016/S0140-6736(10)60935-X
   Tsai WL, 2017, ONCOTARGET, V8, P91928, DOI 10.18632/oncotarget.20248
   Tsaknis G, 2012, CRIT CARE, V16, DOI 10.1186/cc11439
   Turin A, 2018, AM J CARDIOL, V122, P780, DOI 10.1016/j.amjcard.2018.05.013
   Uno Y, 2020, INTERN EMERG MED, V15, P1577, DOI 10.1007/s11739-020-02345-9
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Vaez H, 2016, IRAN J ALLERGY ASTHM, V15, P498
   Vecchiola A, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00223
   Vemuri VK, 2008, PHYSIOL BEHAV, V93, P671, DOI 10.1016/j.physbeh.2007.11.012
   Verma D, 2016, P NATL ACAD SCI USA, V113, P3609, DOI 10.1073/pnas.1523686113
   Vieira RF, 2018, J HEART LUNG TRANSPL, V37, P1381, DOI 10.1016/j.healun.2018.06.015
   Wang D, 2019, PULM PHARMACOL THER, V58, DOI 10.1016/j.pupt.2019.101833
   Wang GX, 2015, INT J MOL SCI, V16, P27015, DOI 10.3390/ijms161126010
   Wang NS, 2013, CELL RES, V23, P986, DOI 10.1038/cr.2013.92
   Wang YW, 2017, DRUG DES DEV THER, V11, P2421, DOI 10.2147/DDDT.S141675
   Wang Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0158-2
   Washington MN, 2010, ENDOCRINOLOGY, V151, P1409, DOI 10.1210/en.2009-0991
   Whillier S, 2009, REDOX REP, V14, P115, DOI 10.1179/135100009X392539
   Williams B, 2020, LANCET, V395, P1671, DOI 10.1016/S0140-6736(20)31131-4
   Williams EA, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104762
   Win TT, 2020, J GASTROINTEST LIVER, V29, P191, DOI 10.15403/jgld-818
   Wright TJ, 2018, J CACHEXIA SARCOPENI, V9, P482, DOI 10.1002/jcsm.12295
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu Y, 2013, PROSTATE, V73, P1470, DOI 10.1002/pros.22694
   Wyrwoll CS, 2007, HYPERTENSION, V50, P579, DOI 10.1161/HYPERTENSIONAHA.107.091603
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Xiao Y, 2020, VIRULENCE, V11, P39, DOI 10.1080/21505594.2019.1706305
   Xie S, 2007, J CLIN PHARM THER, V32, P209, DOI 10.1111/j.1365-2710.2007.00817.x
   Xiong B, 2016, RESPIROLOGY, V21, P1026, DOI 10.1111/resp.12820
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu J, 2019, LAB INVEST, V99, P577, DOI 10.1038/s41374-018-0170-0
   Xu J, 2017, MOL MED REP, V16, P7432, DOI 10.3892/mmr.2017.7546
   Xu L, 2020, LIVER INT, V40, P998, DOI 10.1111/liv.14435
   Xun YH, 2014, J VIRAL HEPATITIS, V21, P597, DOI 10.1111/jvh.12187
   Yan TT, 2020, FASEB J, V34, P6017, DOI 10.1096/fj.202000782
   Yin J, 2018, CHINESE MED J-PEKING, V131, P1138, DOI 10.4103/0366-6999.231520
   Yu H, 2018, AM J EMERG MED, V36, P1486, DOI 10.1016/j.ajem.2018.05.017
   Yu LL, 2018, EUR REV MED PHARMACO, V22, P5355, DOI 10.26355/eurrev_201808_15737
   Zdrenghea MT, 2017, REV MED VIROL, V27, DOI 10.1002/rmv.1909
   Zeng JH, 2020, INFECTION, V48, P773, DOI 10.1007/s15010-020-01424-5
   Zhang L, 2014, LAB INVEST, V94, P839, DOI 10.1038/labinvest.2014.69
   Zhang W, 2014, SCI WORLD J, V2014, P603409, DOI DOI 10.1155/2014/6034093914411
   Zhang W, 2013, ANN HEPATOL, V12, P892, DOI 10.1016/S1665-2681(19)31294-3
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang XC, 2017, SAUDI PHARM J, V25, P666, DOI 10.1016/j.jsps.2017.05.001
   Zhang YT, 2014, ENDOCRINE, V47, P598, DOI 10.1007/s12020-014-0196-z
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zheng SX, 2020, BIOCHEM PHARMACOL, V177, DOI 10.1016/j.bcp.2020.113955
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou F, 2016, EUR J PHARMACOL, V791, P735, DOI 10.1016/j.ejphar.2016.10.016
   Zhou Q, 2009, CURR PHARM DESIGN, V15, P467, DOI 10.2174/138161209787315684
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
   Zhu A, 2009, J HYPERTENS, V27, P800, DOI 10.1097/HJH.0b013e328325d861
   Zhu H, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01292-3
   Zhu T, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/3601454
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 331
TC 0
Z9 0
U1 5
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472-6823
J9 BMC ENDOCR DISORD
JI BMC Endocr. Disord.
PD SEP 29
PY 2020
VL 20
IS 1
AR 149
DI 10.1186/s12902-020-00626-0
PG 19
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NZ2NR
UT WOS:000576933300004
PM 32993622
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gollust, SE
   Saloner, B
   Hest, R
   Blewett, LA
AF Gollust, Sarah E.
   Saloner, Brendan
   Hest, Robert
   Blewett, Lynn A.
TI US Adults' Preferences for Public Allocation of a Vaccine for
   Coronavirus Disease 2019
SO JAMA NETWORK OPEN
LA English
DT Article
AB This survey study examines public perception of high priority groups for receipt of an eventual coronavirus disease 2019 vaccine in case of shortage of supply.
C1 [Gollust, Sarah E.] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, 420 Delaware St SE,MMC 729, Minneapolis, MN 55455 USA.
   [Saloner, Brendan] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
   [Hest, Robert] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, State Hlth Access Data Assistance Ctr, Minneapolis, MN USA.
   [Blewett, Lynn A.] Univ Minnesota, Sch Publ Hlth, State Hlth Access Data Assistance Ctr, Minneapolis, MN USA.
RP Gollust, SE (corresponding author), Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, 420 Delaware St SE,MMC 729, Minneapolis, MN 55455 USA.
EM sgollust@umn.edu
FU State Health Access Data Assistance Center at the University of
   Minnesota School of Public Health
FX The data set used in this study was developed with support from the
   State Health Access Data Assistance Center at the University of
   Minnesota School of Public Health.
CR Kinlaw K, 2009, DISASTER MED PUBLIC, V3, pS185, DOI 10.1097/DMP.0b013e3181ac194f
   Mello MM, 2020, NEW ENGL J MED, V383, P1296, DOI 10.1056/NEJMp2020926
   National Academies of Sciences Engineering and Medicine, 2020, DISC DRAFT PREL FRAM, DOI [10.17226/25914, DOI 10.17226/25914]
   Schmidt H, 2020, HASTINGS CENT REP, DOI 10.1002/hast.1113
   Toner E, 2020, INTERIM FRAMEWORK CO
   Vawter DE, GOOD US ALL ETHICALL
NR 6
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD SEP 29
PY 2020
VL 3
IS 9
DI 10.1001/jamanetworkopen.2020.23020
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ3BR
UT WOS:000576973100009
PM 32990736
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Eross, B
   Molnar, Z
   Szakacs, Z
   Zadori, N
   Szako, L
   Vancsa, S
   Juhasz, MF
   Ocskay, K
   Vorhendi, N
   Marta, K
   Szentesi, A
   Parniczky, A
   Hegyi, PJ
   Kiss, S
   Foldi, M
   Dembrovszky, F
   Kanjo, A
   Pazmany, P
   Varro, A
   Csatho, A
   Helyes, Z
   Peterfi, Z
   Czopf, L
   Kiss, I
   Zemplenyi, A
   Czapari, D
   Hegyi, E
   Dobszai, D
   Miklos, E
   Marta, A
   Toth, D
   Farkas, R
   Farkas, N
   Birkas, B
   Pinter, E
   Petho, G
   Zsigmond, B
   Sarkozi, A
   Nagy, A
   Hegyi, P
AF Eross, Balint
   Molnar, Zsolt
   Szakacs, Zsolt
   Zadori, Noemi
   Szako, Lajos
   Vancsa, Szilard
   Juhasz, Mark Felix
   Ocskay, Klementina
   Vorhendi, Nora
   Marta, Katalin
   Szentesi, Andrea
   Parniczky, Andrea
   Hegyi, Peter J.
   Kiss, Szabolcs
   Foldi, Maria
   Dembrovszky, Fanni
   Kanjo, Anna
   Pazmany, Piroska
   Varro, Andras
   Csatho, Arpad
   Helyes, Zsuzsanna
   Peterfi, Zoltan
   Czopf, Laszlo
   Kiss, Istvan
   Zemplenyi, Antal
   Czapari, Dora
   Hegyi, Eszter
   Dobszai, Dalma
   Miklos, Emoke
   Marta, Attila
   Toth, Dominika
   Farkas, Richard
   Farkas, Nelli
   Birkas, Bela
   Pinter, Erika
   Petho, Gabor
   Zsigmond, Borbala
   Sarkozi, Andrea
   Nagy, Aniko
   Hegyi, Peter
TI Personalised health education against health damage of COVID-19 epidemic
   in the elderly Hungarian population (PROACTIVE-19): protocol of an
   adaptive randomised controlled clinical trial
SO TRIALS
LA English
DT Article
DE COVID-19; SARS-CoV-2; nCov-2019; Public health; Randomised controlled
   trial; Prevention
ID MENTAL-HEALTH; CORONAVIRUS
AB BackgroundEarly reports indicate that COVID-19 may require intensive care unit (ICU) admission in 5-26% and overall mortality can rise to 11% of the recognised cases, particularly affecting the elderly. There is a lack of evidence-based targeted pharmacological therapy for its prevention and treatment.We aim to compare the effects of a World Health Organization recommendation-based education and a personalised complex preventive lifestyle intervention package (based on the same WHO recommendation) on the outcomes of the COVID-19.MethodsPROACTIVE-19 is a pragmatic, randomised controlled clinical trial with adaptive "sample size re-estimation" design. Hungarian population over the age of 60years without confirmed COVID-19 will be approached to participate in a telephone health assessment and lifestyle counselling voluntarily. Volunteers will be randomised into two groups: (A) general health education and (B) personalised health education. Participants will go through questioning and recommendation in 5 fields: (1) mental health, (2) smoking habits, (3) physical activity, (4) dietary habits, and (5) alcohol consumption. Both groups A and B will receive the same line of questioning to assess habits concerning these topics. Assessment will be done weekly during the first month, every second week in the second month, then monthly. The composite primary endpoint will include the rate of ICU admission, hospital admission (longer than 48h), and mortality in COVID-19-positive cases. The estimated sample size is 3788 subjects per study arm. The planned duration of the follow-up is a minimum of 1 year.DiscussionThese interventions may boost the body's cardiovascular and pulmonary reserve capacities, leading to improved resistance against the damage caused by COVID-19. Consequently, lifestyle changes can reduce the incidence of life-threatening conditions and attenuate the detrimental effects of the pandemic seriously affecting the older population.Trial registrationThe study has been approved by the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (IV/2428- 2 /2020/EKU) and has been registered at clinicaltrials.gov (NCT04321928) on 25 March 2020.
C1 [Eross, Balint; Molnar, Zsolt; Szakacs, Zsolt; Zadori, Noemi; Szako, Lajos; Vancsa, Szilard; Juhasz, Mark Felix; Ocskay, Klementina; Vorhendi, Nora; Marta, Katalin; Szentesi, Andrea; Parniczky, Andrea; Hegyi, Peter J.; Kiss, Szabolcs; Foldi, Maria; Dembrovszky, Fanni; Kanjo, Anna; Pazmany, Piroska; Czapari, Dora; Hegyi, Eszter; Dobszai, Dalma; Miklos, Emoke; Marta, Attila; Toth, Dominika; Farkas, Richard; Farkas, Nelli; Hegyi, Peter] Univ Pecs, Inst Translat Med, Sch Med, Szigeti Ut 12, H-7624 Pecs, Hungary.
   [Eross, Balint; Szentesi, Andrea; Hegyi, Peter] Translat Med Fdn, Szeged, Hungary.
   [Molnar, Zsolt] Poznan Univ Med Sci, Dept Anaesthesiol & Intens Therapy, Poznan, Poland.
   [Szakacs, Zsolt; Zadori, Noemi; Szako, Lajos; Vancsa, Szilard; Juhasz, Mark Felix; Ocskay, Klementina; Vorhendi, Nora; Marta, Katalin; Hegyi, Peter J.; Kiss, Szabolcs; Foldi, Maria; Dembrovszky, Fanni; Kanjo, Anna; Pazmany, Piroska; Helyes, Zsuzsanna; Pinter, Erika; Petho, Gabor; Hegyi, Peter] Univ Pecs, Janos Szentagothai Res Ctr, Pecs, Hungary.
   [Szentesi, Andrea; Kiss, Szabolcs; Foldi, Maria; Hegyi, Peter] Univ Szeged, Dept Med, Ctr Translat Med, Szeged, Hungary.
   [Parniczky, Andrea; Kanjo, Anna; Pazmany, Piroska; Zsigmond, Borbala; Sarkozi, Andrea; Nagy, Aniko] Heim Pal Natl Pediat Inst, Budapest, Hungary.
   [Kiss, Szabolcs; Foldi, Maria] Univ Szeged, Doctoral Sch Clin Med, Szeged, Hungary.
   [Varro, Andras] Univ Szeged, Dept Pharmacol & Pharmacotherapy, Szeged, Hungary.
   [Csatho, Arpad; Birkas, Bela] Univ Pecs, Sch Med, Dept Behav Sci, Pecs, Hungary.
   [Helyes, Zsuzsanna; Pinter, Erika; Petho, Gabor] Univ Pecs, Sch Med, Dept Pharmacol & Pharmacotherapy, Pecs, Hungary.
   [Peterfi, Zoltan] Univ Pecs, Sch Med, Dept Med 1, Div Infect Dis, Pecs, Hungary.
   [Czopf, Laszlo] Univ Pecs, Sch Med, Dept Med 1, Div Cardiol, Pecs, Hungary.
   [Kiss, Istvan] Univ Pecs, Sch Med, Dept Publ Hlth, Pecs, Hungary.
   [Zemplenyi, Antal] Univ Pecs, Hlth Technol Assessment Ctr, Pecs, Hungary.
   [Zemplenyi, Antal] Univ Pecs, Dept Pharmaceut, Div Pharmacoecon, Fac Pharm, Pecs, Hungary.
   [Hegyi, Eszter] Univ Szeged, Fac Law, Szeged, Hungary.
   [Farkas, Nelli] Univ Pecs, Sch Med, Inst Bioanal, Pecs, Hungary.
RP Hegyi, P (corresponding author), Univ Pecs, Inst Translat Med, Sch Med, Szigeti Ut 12, H-7624 Pecs, Hungary.; Hegyi, P (corresponding author), Translat Med Fdn, Szeged, Hungary.
EM p.hegyi@tm-centre.org
FU Human Resources Development Operational Programme Grant - European Union
   (European Regional Development Fund) [EFOP 3.6.2-16-2017-00006];
   Translational Medicine Foundation
FX Center costs (IT, biostatistics, trial organisation etc.) are covered by
   the University of Pecs Medical School, and other costs are funded by
   Human Resources Development Operational Programme Grant, Grant Number:
   EFOP 3.6.2-16-2017-00006 - LIVE LONGER which is co-financed by the
   European Union (European Regional Development Fund) within the framework
   of Programme Szechenyi 2020 as well as the Translational Medicine
   Foundation. The sponsor was not involved in the design of the study.
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bao YP, 2020, LANCET, V395, pE37, DOI 10.1016/S0140-6736(20)30309-3
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Chan KS, 2003, RESPIROLOGY, V8, pS36, DOI 10.1046/j.1440-1843.2003.00522.x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chow SC, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-11
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Ferguson NM, 2020, IMPACT NONPHARMACEUT, P20, DOI [10.25561/77482, DOI 10.25561/77482]
   Fischbeck S, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5401-1
   Hamer M, 2019, PREV MED, V123, P65, DOI 10.1016/j.ypmed.2019.03.002
   Leung C, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2103
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   MacIntyre CR, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3548-0
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Mutsaerts MAQ, 2016, NEW ENGL J MED, V374, P1942, DOI 10.1056/NEJMoa1505297
   Nassar MS, 2018, EUR REV MED PHARMACO, V22, P4956, DOI 10.26355/eurrev_201808_15635
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105
   Prince M, 2007, LANCET, V370, P859, DOI 10.1016/S0140-6736(07)61238-0
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   Richard Hatchett A.-M.T, 2020, CEPI WELCOMES UK GOV
   Villareal DT, 2011, NEW ENGL J MED, V364, P1218, DOI 10.1056/NEJMoa1008234
   WHO, 2016, GUID MAN ETH ISS INF
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhang H, 2020, JAMA-J AM MED ASSOC, V323, P1844, DOI 10.1001/jama.2020.4362
NR 32
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 29
PY 2020
VL 21
IS 1
AR 809
DI 10.1186/s13063-020-04733-0
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NZ2NO
UT WOS:000576933000001
PM 32993779
OA DOAJ Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Weber, AG
   Chau, AS
   Egeblad, M
   Barnes, BJ
   Janowitz, T
AF Weber, Andrew G.
   Chau, Alice S.
   Egeblad, Mikala
   Barnes, Betsy J.
   Janowitz, Tobias
TI Nebulized in-line endotracheal dornase alfa and albuterol administered
   to mechanically ventilated COVID-19 patients: a case series
SO MOLECULAR MEDICINE
LA English
DT Article
DE SARS-CoV-2; COVID-19; Coronavirus; Mucopurulent secretions; Dornase
   alfa; Neutrophil extracellular traps; ARDS; VV-ECMO
ID TRAPS
AB Background Mechanically ventilated patients with COVID-19 have a mortality of 24-53%, in part due to distal mucopurulent secretions interfering with ventilation. DNA from neutrophil extracellular traps (NETs) contribute to the viscosity of mucopurulent secretions and NETs are found in the serum of COVID-19 patients. Dornase alfa is recombinant human DNase 1 and is used to digest DNA in mucoid sputum. Here, we report a single-center case series where dornase alfa was co-administered with albuterol through an in-line nebulizer system. Methods Demographic and clinical data were collected from the electronic medical records of five mechanically ventilated patients with COVID-19-including three requiring veno-venous extracorporeal membrane oxygenation-treated with nebulized in-line endotracheal dornase alfa and albuterol, between March 31 and April 24, 2020. Data on tolerability and response were analyzed. Results The fraction of inspired oxygen requirements was reduced for all five patients after initiating dornase alfa administration. All patients were successfully extubated, discharged from hospital and remain alive. No drug-associated toxicities were identified. Conclusions Results suggest that dornase alfa will be well-tolerated by patients with severe COVID-19. Clinical trials are required to formally test the dosing, safety, and efficacy of dornase alfa in COVID-19, and several have been recently registered.
C1 [Weber, Andrew G.] Northwell Hlth, Dept Med, Div Pulm Crit Care & Sleep Med, 300 Community Dr, Manhasset, NY 11030 USA.
   [Chau, Alice S.] Univ Washington, Div Allergy & Infect Dis, Dept Med, 1900 9th Ave, Seattle, WA 98101 USA.
   [Chau, Alice S.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, 1900 9th Ave, Seattle, WA 98101 USA.
   [Egeblad, Mikala; Janowitz, Tobias] Cold Spring Harbor Lab, Canc Ctr, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.
   [Barnes, Betsy J.] Donald & Barbara Zucker Sch Med Hofstra Northwell, Ctr Autoimmune Musculoskeletal & Hematopoiet Dis, Feinstein Inst Med Res, Dept Mol Med, 350 Community Dr, Manhasset, NY 11030 USA.
   [Barnes, Betsy J.] Donald & Barbara Zucker Sch Med Hofstra Northwell, Ctr Autoimmune Musculoskeletal & Hematopoiet Dis, Feinstein Inst Med Res, Dept Pediat, 350 Community Dr, Manhasset, NY 11030 USA.
   [Janowitz, Tobias] Northwell Hlth Canc Inst, 450 Lakeville Rd, New Hyde Pk, NY 11042 USA.
RP Egeblad, M (corresponding author), Cold Spring Harbor Lab, Canc Ctr, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.; Barnes, BJ (corresponding author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Ctr Autoimmune Musculoskeletal & Hematopoiet Dis, Feinstein Inst Med Res, Dept Mol Med, 350 Community Dr, Manhasset, NY 11030 USA.; Barnes, BJ (corresponding author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Ctr Autoimmune Musculoskeletal & Hematopoiet Dis, Feinstein Inst Med Res, Dept Pediat, 350 Community Dr, Manhasset, NY 11030 USA.
EM egeblad@cshl.edu; bbarnes1@northwell.edu
OI Barnes, Betsy/0000-0001-6766-4352
FU William C. and Joyce C. O'Neil Charitable Trust; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [5P30CA045508-30, 1R01AR076242-01]; DOD LRP [W81XWH-18-1-0674];
   The Primary Immune Deficiency Treatment Consortium - National Center for
   Advancing Translational Sciences (NCATS) [U54 AI 082973]; The Primary
   Immune Deficiency Treatment Consortium - National Institute of Allergy
   and Infectious Diseases (NIAID) [U54 AI 082973]
FX This work was supported by the William C. and Joyce C. O'Neil Charitable
   Trust. In addition, M.E. and T.J. are supported by NIH grant
   5P30CA045508-30. B.J.B. is supported by NIH grant 1R01AR076242-01 and
   DOD LRP W81XWH-18-1-0674. A.S.C. was supported by The Primary Immune
   Deficiency Treatment Consortium (U54 AI 082973), funded jointly by the
   National Center for Advancing Translational Sciences (NCATS) and the
   National Institute of Allergy and Infectious Diseases (NIAID). The
   funding bodies had no role in the design of the study, in collection,
   analysis, and interpretation of data, or in writing the manuscript.
CR Adrover JM, 2020, NAT IMMUNOL, V21, P135, DOI 10.1038/s41590-019-0571-2
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Durante G, 2002, AM J RESP CRIT CARE, V165, P1271
   Earhart AP, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100689
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Greenland JR, 2020, ANESTHESIOLOGY, V132, P1346, DOI 10.1097/ALN.0000000000003303
   Lefrancais E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98178
   Leppkes M, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102925
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   Marino F, 2018, J LEUKOCYTE BIOL, V104, P603, DOI 10.1002/JLB.3A1017-398RR
   Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008
   Morris C, 2004, ANAESTHESIA, V59, P1249, DOI 10.1111/j.1365-2044.2004.04018.x
   Papayannopoulos V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028526
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Schoenrich Gunther, 2020, Advances in Biological Regulation, V77, P100741, DOI 10.1016/j.jbior.2020.100741
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Thomas GM, 2012, BLOOD, V119, P6335, DOI 10.1182/blood-2012-01-405183
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Yang CN, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001127.pub4
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 25
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1076-1551
EI 1528-3658
J9 MOL MED
JI Mol. Med.
PD SEP 29
PY 2020
VL 26
IS 1
AR 91
DI 10.1186/s10020-020-00215-w
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA NZ2BT
UT WOS:000576900900002
PM 32993479
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Min, YQ
   Mo, Q
   Wang, J
   Deng, F
   Wang, HL
   Ning, YJ
AF Min, Yuan-Qin
   Mo, Qiong
   Wang, Jun
   Deng, Fei
   Wang, Hualin
   Ning, Yun-Jia
TI SARS-CoV-2 nsp1: Bioinformatics, Potential Structural and Functional
   Features, and Implications for Drug/Vaccine Designs
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; coronavirus; nsp1; pathogenic factor;
   bioinformatics; structure and function analysis; drug and vaccine
   development
ID RESPIRATORY SYNDROME CORONAVIRUS; HOST GENE-EXPRESSION; GASTROENTERITIS
   VIRUS NSP1; NONSTRUCTURAL PROTEIN-1; SARS-COV; RATIONAL DESIGN; I
   INTERFERON; ALPHACORONAVIRUS; IDENTIFICATION; TRANSLATION
AB The emerging coronavirus disease (COVID-19) caused by SARS-CoV-2 has led to social and economic disruption globally. It is urgently needed to understand the structure and function of the viral proteins for understanding of the viral infection and pathogenesis and development of prophylaxis and treatment strategies. Coronavirus non-structural protein 1 (nsp1) is a notable virulence factor with versatile roles in virus-host interactions and exhibits unique characteristics on sequence, structure, and function mode. However, the roles and characteristics of SARS-CoV-2 nsp1 are currently unclear. Here, we analyze the nsp1 of SARS-CoV-2 from the following perspectives: (1) bioinformatics analysis reveals that the novel nsp1 is conserved among SARS-CoV-2 strains and shares significant sequence identity with SARS-CoV nsp1; (2) structure modeling shows a 3D alpha/beta-fold of SARS-CoV-2 nsp1 highly similar to that of the SARS-CoV homolog; (3) by detailed, functional review of nsp1 proteins from other coronaviruses (especially SARS-CoV) and comparison of the protein sequence and structure, we further analyzed the potential roles of SARS-CoV-2 nsp1 in manipulating host mRNA translation, antiviral innate immunity and inflammation response and thus likely promoting viral infection and pathogenesis, which are merited to be tested in the future. Finally, we discussed how understanding of the novel nsp1 may provide valuable insights into the designs of drugs and vaccines against the unprecedented coronavirus pandemic.
C1 [Min, Yuan-Qin; Mo, Qiong; Wang, Jun; Deng, Fei; Wang, Hualin; Ning, Yun-Jia] Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, State Key Lab Virol, Wuhan, Peoples R China.
   [Mo, Qiong] Univ Chinese Acad Sci, Beijing, Peoples R China.
RP Ning, YJ (corresponding author), Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, State Key Lab Virol, Wuhan, Peoples R China.
EM nyj@wh.iov.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31870162, 31700146]; National Key Research
   and Development Program of China [2018YFA0507202]; Youth Innovation
   Promotion Association of Chinese Academy of Sciences
FX This work was supported by the National Natural Science Foundation of
   China (31870162 and 31700146), the National Key Research and Development
   Program of China (2018YFA0507202), and the Youth Innovation Promotion
   Association of Chinese Academy of Sciences.
CR Acharya D, 2020, NAT REV IMMUNOL, V20, P397, DOI 10.1038/s41577-020-0346-x
   Almeida MS, 2007, J VIROL, V81, P3151, DOI 10.1128/JVI.01939-06
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen CJ, 2004, J VIROL, V78, P10410, DOI 10.1128/JVI.78.19.10410-10419.2004
   Connor RF, 2007, TRENDS MICROBIOL, V15, P51, DOI 10.1016/j.tim.2006.12.005
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Enjuanes L, 2016, ADV VIRUS RES, V96, P245, DOI 10.1016/bs.aivir.2016.08.003
   Fischer G, 2010, CURR OPIN INVEST DR, V11, P911
   Gaglia MM, 2012, J VIROL, V86, P9527, DOI 10.1128/JVI.01230-12
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gomez GN, 2019, BIOCHEM CELL BIOL, V97, P758, DOI 10.1139/bcb-2018-0394
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Huang C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002433
   Huang C, 2011, J VIROL, V85, P638, DOI 10.1128/JVI.01806-10
   Jansson AM, 2013, J VIROL, V87, P2949, DOI 10.1128/JVI.03163-12
   Jauregui AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062416
   Jimenez-Guardeno JM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005215
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Kindler E, 2016, CELL HOST MICROBE, V19, P139, DOI 10.1016/j.chom.2016.01.012
   Lambert PH, 2005, NAT MED, V11, pS54, DOI 10.1038/nm1216
   Law AHY, 2007, J VIROL, V81, P416, DOI 10.1128/JVI.02336-05
   Lin L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061166
   Lokugamage KG, 2015, J VIROL, V89, P10970, DOI 10.1128/JVI.01352-15
   Lokugamage KG, 2012, J VIROL, V86, P13598, DOI 10.1128/JVI.01958-12
   Narayanan K, 2015, VIRUS RES, V202, P89, DOI 10.1016/j.virusres.2014.11.019
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004
   SCHUBERT K, 2020, NAT STRUCT MOL 0909, DOI DOI 10.1101/2020.07.07.191676
   Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520
   Shen Z, 2018, J VIROL, V92, DOI 10.1128/JVI.01896-17
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Soy M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/s10067-020-05190-5
   Tanaka T, 2012, J VIROL, V86, P11128, DOI 10.1128/JVI.01700-12
   Thoms M, 2020, SCIENCE, V369, P1249, DOI 10.1126/science.abc8665
   Tohya Y, 2009, J VIROL, V83, P5282, DOI 10.1128/JVI.02485-08
   Wang YJ, 2010, INFECT GENET EVOL, V10, P919, DOI 10.1016/j.meegid.2010.05.014
   Wathelet MG, 2007, J VIROL, V81, P11620, DOI 10.1128/JVI.00702-07
   Wong LYR, 2016, VIROL SIN, V31, P12, DOI 10.1007/s12250-015-3683-3
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   World Health Organization, 2020, NOV COR 2019 NCOV SI
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang T, 2020, CURR BIOL, V30, P1578, DOI 10.1016/j.cub.2020.03.063
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
   Zust R, 2007, PLOS PATHOG, V3, P1062, DOI 10.1371/journal.ppat.0030109
NR 56
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD SEP 29
PY 2020
VL 11
AR 587317
DI 10.3389/fmicb.2020.587317
PG 12
WC Microbiology
SC Microbiology
GA NZ1QD
UT WOS:000576865000001
PM 33133055
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Habel, JR
   Nguyen, THO
   van de Sandt, CE
   Juno, JA
   Chaurasia, P
   Wragg, K
   Koutsakos, M
   Hensen, L
   Jia, XX
   Chua, B
   Zhang, WJ
   Tan, HX
   Flanagan, KL
   Doolan, DL
   Torresi, J
   Chen, WS
   Wakim, LM
   Cheng, AC
   Doherty, PC
   Petersen, J
   Rossjohn, J
   Wheatley, AK
   Kent, SJ
   Rowntree, LC
   Kedzierska, K
AF Habel, Jennifer R.
   Nguyen, Thi H. O.
   van de Sandt, Carolien E.
   Juno, Jennifer A.
   Chaurasia, Priyanka
   Wragg, Kathleen
   Koutsakos, Marios
   Hensen, Luca
   Jia, Xiaoxiao
   Chua, Brendon
   Zhang, Wuji
   Tan, Hyon-Xhi
   Flanagan, Katie L.
   Doolan, Denise L.
   Torresi, Joseph
   Chen, Weisan
   Wakim, Linda M.
   Cheng, Allen C.
   Doherty, Peter C.
   Petersen, Jan
   Rossjohn, Jamie
   Wheatley, Adam K.
   Kent, Stephen J.
   Rowntree, Louise C.
   Kedzierska, Katherine
TI Suboptimal SARS-CoV-2-specific CD8(+) T cell response associated with
   the prominent HLA-A*02:01 phenotype
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE CD8+T cells; COVID-19; HLA-A*02:01; SARS-CoV-2 epitopes
AB An improved understanding of human T cell-mediated immunity in COVID-19 is important for optimizing therapeutic and vaccine strategies. Experience with influenza shows that infection primes CD8(+) T cell memory to peptides presented by common HLA types like HLA-A2, which enhances recovery and diminishes clinical severity upon reinfection. Stimulating peripheral blood mononuclear cells from COVID-19 convalescent patients with overlapping peptides from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the clonal expansion of SARS-CoV-2-specific CD8(+) and CD4(+) T cells in vitro, with CD4(+) T cells being robust. We identified two HLA-A*02:01-restricted SARS-CoV-2-specfic CD8(+) T cell epitopes, A2/S-269(-2)77 and A2/Orf1ab(3183-3191). Using peptide-HLA tetramer enrichment, direct ex vivo assessment of A2/S(269)(+)CD8(+) and A2/Orf1ab(3183)(+)CD8(+) populations indicated that A2/S(269)(+)CD8(+ )T cells were detected at comparable frequencies (similar to 1.3 x 10(-5)) in acute and convalescent HLA-A*02:01(+) patients. These frequencies were higher than those found in uninfected HLA-A*02:01(+) donors (similar to 2.5 x 10(-6)), but low when compared to frequencies for influenza-specific (A2/M1(58)) and Epstein-Barr virus (EBV)-specific (A2/BMLF1280) (similar to 1.38 x 10(-4)) populations. Phenotyping A2/S(269)(+)CD8(+) T cells from COVID-19 convalescents ex vivo showed that A2/S(269)(+)CD8(+) T cells were predominantly negative for CD38, HLA-DR, PD-1, and CD71 activation markers, although the majority of total CD8(+) T cells expressed granzymes and/or perforin. Furthermore, the bias toward naive, stem cell memory and central memory A2/S(269)(+)CD8(+) T cells rather than effector memory populations suggests that SARS-CoV-2 infection may be compromising CD8(+) T cell activation. Priming with appropriate vaccines may thus be beneficial for optimizing CD8(+) T cell immunity in COVID-19.
C1 [Habel, Jennifer R.; Nguyen, Thi H. O.; van de Sandt, Carolien E.; Juno, Jennifer A.; Wragg, Kathleen; Koutsakos, Marios; Hensen, Luca; Jia, Xiaoxiao; Chua, Brendon; Zhang, Wuji; Tan, Hyon-Xhi; Torresi, Joseph; Wakim, Linda M.; Doherty, Peter C.; Wheatley, Adam K.; Kent, Stephen J.; Rowntree, Louise C.; Kedzierska, Katherine] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic 3000, Australia.
   [van de Sandt, Carolien E.] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Hematopoiesis, Sanquin Res & Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands.
   [Chaurasia, Priyanka; Petersen, Jan; Rossjohn, Jamie] Monash Univ, Biomed Discovery Inst, Infect & Immun Program, Clayton, Vic 3800, Australia.
   [Chaurasia, Priyanka; Rossjohn, Jamie] Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
   [Flanagan, Katie L.] Launceston Gen Hosp, Dept Infect Dis, Launceston, Tas 7250, Australia.
   [Flanagan, Katie L.; Petersen, Jan] Univ Tasmania, Sch Hlth Sci, Launceston, Tas 7248, Australia.
   [Flanagan, Katie L.; Petersen, Jan] Univ Tasmania, Sch Med, Launceston, Tas 7248, Australia.
   [Flanagan, Katie L.] Monash Univ, Dept Immunol & Pathol, Melbourne, Vic 3800, Australia.
   [Flanagan, Katie L.] RMIT Univ, Sch Hlth & Biomed Sci, Melbourne, Vic 3000, Australia.
   [Doolan, Denise L.] James Cook Univ, Ctr Mol Therapeut, Australian Inst Trop Hlth & Med, Cairns, Qld 4814, Australia.
   [Chen, Weisan] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Bundoora, Vic 3084, Australia.
   [Cheng, Allen C.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia.
   [Cheng, Allen C.] Alfred Hlth, Infect Prevent & Healthcare Epidemiol Unit, Melbourne, Vic 3004, Australia.
   [Doherty, Peter C.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA.
   [Petersen, Jan; Rossjohn, Jamie] Monash Univ, Australian Res Council Ctr Excellence Adv Mol Ima, Clayton, Vic 3800, Australia.
   [Rossjohn, Jamie] Cardiff Univ, Inst Infect & Immun, Sch Med, Cardiff CF14 4XN, Wales.
   [Wheatley, Adam K.; Kent, Stephen J.] Univ Melbourne, Ausralian Res Council Ctr Excellence Convergent B, Melbourne, Vic 3010, Australia.
RP Doherty, PC; Kedzierska, K (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic 3000, Australia.; Doherty, PC (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA.
EM pcd@unimelb.edu.au; kkedz@unimelb.edu.au
RI Koutsakos, Marios/AAF-4259-2019; Chua, Brendon/A-9755-2012
OI Koutsakos, Marios/0000-0001-9994-9723; Habel,
   Jennifer/0000-0003-0380-1527; Reis, AlessanRSS/0000-0001-8486-7469;
   Juno, Jennifer/0000-0002-9072-1017; Chua, Brendon/0000-0001-5654-1293;
   Hensen, Luca/0000-0001-8467-8537; van de Sandt,
   Carolien/0000-0002-4155-7433
FU Clifford Craig Foundation; National Health and Medical Research Council
   (NHMRC)National Health and Medical Research Council of Australia
   [1173871, 1132975, 1149990, 1162760, 1140509, 1102792, 1137285, 1136322,
   1123673]; Research Grants Council of the Hong Kong Special
   Administrative Region, ChinaHong Kong Research Grants Council
   [T11-712/19-N]; Victorian Government; Medical Research Future Fund
   (MRFF) Award [2002073, 1202445]; Australian Research Council Laureate
   fellowshipAustralian Research Council; Melbourne Research Scholarship
   from The University of Melbourne; European Union's Horizon 2020 research
   and innovation program under Marie Sklodowska-Curie Grant [792532];
   Melbourne International Research Scholarship from The University of
   Melbourne; Melbourne International Fee Remission Scholarship from The
   University of Melbourne
FX We thank all of the participants involved in the study, and Robyn
   Esterbauer, Hannah Kelly, Jane Batten, and Helen Kent for support with
   the cohort. We thank Jill Garlick, Janine Roney, Anne Paterson, and the
   research nurses at the Alfred Hospital. This work was supported by the
   Clifford Craig Foundation for K.L.F. and K.K.; National Health and
   Medical Research Council (NHMRC) Leadership Investigator Grant 1173871
   to K.K.; NHMRC Program Grant 1132975 to D.L.D.; Research Grants Council
   of the Hong Kong Special Administrative Region, China (Grant
   T11-712/19-N) to K.K.; the Victorian Government (S.J.K., A.K.W.);
   Medical Research Future Fund (MRFF) Award 2002073 to S.J.K. and A.K.W.;
   MRFF Award 1202445 to K.K.; NHMRC program Grant 1149990 (S.J.K.); and
   NHMRC project Grant 1162760 (A.K.W.). A.C.C. is supported by NHMRC
   Career Development Fellowship 1140509, K.K. is supported by NHMRC Senior
   Research Fellowship 1102792, D.L.D. is supported by NHMRC Principal
   Research Fellowship 1137285, and S.J.K. is supported by NHMRC Senior
   Principal Research Fellowship 1136322. J.R. is supported by an
   Australian Research Council Laureate fellowship. J.R.H. is supported by
   the Melbourne Research Scholarship from The University of Melbourne.
   C.E.v.d.S. has received funding from the European Union's Horizon 2020
   research and innovation program under Marie Sklodowska-Curie Grant
   Agreement 792532. L.H. is supported by the Melbourne International
   Research Scholarship and the Melbourne International Fee Remission
   Scholarship from The University of Melbourne. J.A.J. is supported by
   NHMRC Early Career Fellowship 1123673. W.Z. is supported by the
   Melbourne Research Scholarship from The University of Melbourne.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Grant EJ, 2016, J BIOL CHEM, V291, P24335, DOI 10.1074/jbc.M116.753988
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hu Y, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104371
   Kedzierska K, 2020, VIRAL IMMUNOL, V33, P160, DOI 10.1089/vim.2019.0184
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lucas C, 2020, NATURE, DOI 10.1038/s41586-020-2588-y
   Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871
   Meng H, 2020, J INFECTION, V81, pE33, DOI 10.1016/j.jinf.2020.04.004
   Nguyen THO, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.4
   Shomuradova A. S., 2020, SARS COV 2 EPITOPES, DOI [10.1101/2020.05.20.20107813, DOI 10.1101/2020.05.20.20107813]
   Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Valkenburg SA, 2016, P NATL ACAD SCI USA, V113, P4440, DOI 10.1073/pnas.1603106113
   Wang YQ, 2020, J CLIN INVEST, V130, P5235, DOI 10.1172/JCI138759
   Wang ZF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03243-7
   Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao JX, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5393
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zhou R., 2020, IMMUNITY
NR 28
TC 2
Z9 2
U1 1
U2 1
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 29
PY 2020
VL 117
IS 39
BP 24384
EP 24391
DI 10.1073/pnas.2015486117
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NY8ZJ
UT WOS:000576672700021
PM 32913053
OA Green Published, Other Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Rosas-Lemus, M
   Minasov, G
   Shuvalova, L
   Inniss, NL
   Kiryukhina, O
   Brunzelle, J
   Satchell, KJF
AF Rosas-Lemus, Monica
   Minasov, George
   Shuvalova, Ludmilla
   Inniss, Nicole L.
   Kiryukhina, Olga
   Brunzelle, Joseph
   Satchell, Karla J. F.
TI High-resolution structures of the SARS-CoV-2 2 '-O-methyltransferase
   reveal strategies for structure-based inhibitor design
SO SCIENCE SIGNALING
LA English
DT Article
ID RNA CAP; CORONAVIRUS NSP10; METHYLTRANSFERASE; VIRUS; RECOGNITION;
   ACTIVATION; MECHANISMS; PROTEINS; TARGET; MODEL
AB There are currently no antiviral therapies specific for SARS-CoV-2, the virus responsible for the global pandemic disease COVID-19. To facilitate structure-based drug design, we conducted an x-ray crystallographic study of the SARS-CoV-2 nsp16-nsp10 2'-O-methyltransferase complex, which methylates Cap-0 viral mRNAs to improve viral protein translation and to avoid host immune detection. We determined the structures for nsp16-nsp10 heterodimers bound to the methyl donor S-adenosylmethionine (SAM), the reaction product S-adenosylhomocysteine (SAH), or the SAH analog sinefungin (SFG). We also solved structures for nsp16-nsp10 in complex with the methylated Cap-0 analog m(7)GpppA and either SAM or SAH. Comparative analyses between these structures and published structures for nsp16 from other betacoronaviruses revealed flexible loops in open and closed conformations at the m(7)GpppA-binding pocket. Bound sulfates in several of the structures suggested the location of the ribonucleic acid backbone phosphates in the ribonucleotide-binding groove. Additional nucleotide-binding sites were found on the face of the protein opposite the active site. These various sites and the conserved dimer interface could be exploited for the development of antiviral inhibitors.
C1 [Rosas-Lemus, Monica; Minasov, George; Shuvalova, Ludmilla; Inniss, Nicole L.; Kiryukhina, Olga; Satchell, Karla J. F.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.
   [Rosas-Lemus, Monica; Minasov, George; Shuvalova, Ludmilla; Inniss, Nicole L.; Kiryukhina, Olga; Satchell, Karla J. F.] Northwestern Univ, Ctr Struct Genom Infect Dis, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Brunzelle, Joseph] Northwestern Univ, Northwestern Synchrotron Res Ctr, Life Sci Collaborat Access Team, Argonne, IL 60439 USA.
RP Satchell, KJF (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.; Satchell, KJF (corresponding author), Northwestern Univ, Ctr Struct Genom Infect Dis, Feinberg Sch Med, Chicago, IL 60611 USA.
EM k-satchell@northwestern.edu
OI Brunzelle, Joseph/0000-0001-9197-0018; Minasov,
   George/0000-0001-5460-3462; Shuvalova, Ludmilla/0000-0003-1702-6998;
   Kiryukhina, Olga/0000-0001-5962-8423; Satchell,
   Karla/0000-0003-3274-7611
FU Department of Health and Human Services, NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA;
   National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [HHSN272201700060C]; DOE Office of ScienceUnited States Department of
   Energy (DOE) [DE-AC02-06CH11357]; Michigan Economic Development
   Corporation; Michigan Technology Tri-Corridor [085P1000817]
FX This project has been funded in whole or in part with Federal funds from
   the Department of Health and Human Services, NIH, and National Institute
   of Allergy and Infectious Diseases under contract no. HHSN272201700060C.
   This research used resources of the Advanced Photon Source, a U.S.
   Department of Energy (DOE) Office of Science User Facility operated for
   the DOE Office of Science by Argonne National Laboratory under contract
   no. DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the
   Michigan Economic Development Corporation and the Michigan Technology
   Tri-Corridor (grant 085P1000817).
CR Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Aouadi W, 2017, J VIROL, V91, DOI 10.1128/JVI.02217-16
   Benoni R., 2020, PREPRINT, DOI DOI 10.1101/2020.07.30.228478
   Bollati M, 2009, J MOL BIOL, V385, P140, DOI 10.1016/j.jmb.2008.10.028
   Bouvet M, 2014, J BIOL CHEM, V289, P25783, DOI 10.1074/jbc.M114.577353
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Chen Y, 2016, VIROL SIN, V31, P3, DOI 10.1007/s12250-016-3726-4
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Chen Y, 2009, P NATL ACAD SCI USA, V106, P3484, DOI 10.1073/pnas.0808790106
   de Freitas RF, 2019, MOLECULES, V24, DOI 10.3390/molecules24244492
   Debarnot C, 2011, ACTA CRYSTALLOGR F, V67, P404, DOI 10.1107/S1744309111002867
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Eschenfeldt William H., 2013, Journal of Structural and Functional Genomics, V14, P135, DOI 10.1007/s10969-013-9163-9
   Furuichi Y, 2000, ADV VIRUS RES, V55, P135, DOI 10.1016/S0065-3527(00)55003-9
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Hrabe T, 2016, NUCLEIC ACIDS RES, V44, pD423, DOI 10.1093/nar/gkv1316
   Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Joseph JS, 2006, J VIROL, V80, P7894, DOI 10.1128/JVI.00467-06
   Keni R, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00216
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Krafcikova P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17495-9
   Kwon K, 2014, METHODS MOL BIOL, V1140, P61, DOI 10.1007/978-1-4939-0354-2_5
   Lin S, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00241-4
   Lugari A, 2010, J BIOL CHEM, V285, P33230, DOI 10.1074/jbc.M110.120014
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Matthes N, 2006, FEBS LETT, V580, P4143, DOI 10.1016/j.febslet.2006.06.061
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Millard CS, 2003, PROTEIN EXPRES PURIF, V29, P311, DOI 10.1016/S1046-5928(03)00063-9
   Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   NOLAN LL, 1987, ANTIMICROB AGENTS CH, V31, P1542, DOI 10.1128/AAC.31.10.1542
   Painter J, 2006, ACTA CRYSTALLOGR D, V62, P439, DOI 10.1107/S0907444906005270
   Pan JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003299
   Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI 10.1016/S1473-3099(20)30484-9
   Ramanathan A, 2016, NUCLEIC ACIDS RES, V44, P7511, DOI 10.1093/nar/gkw551
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2
   Sedova M., 2020, BIOINFORMATICS
   Shuvalova L, 2014, METHODS MOL BIOL, V1140, P137, DOI 10.1007/978-1-4939-0354-2_10
   Smietanski M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4004
   Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218
   Su D, 2006, J VIROL, V80, P7902, DOI 10.1128/JVI.00483-06
   Viswanathan T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17496-8
   von Grotthuss M, 2003, CELL, V113, P701, DOI 10.1016/S0092-8674(03)00424-0
   Wang Y, 2015, J VIROL, V89, P8416, DOI 10.1128/JVI.00948-15
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Ye YZ, 2004, NUCLEIC ACIDS RES, V32, pW582, DOI 10.1093/nar/gkh430
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Zhao YQ, 2015, P NATL ACAD SCI USA, V112, P14834, DOI 10.1073/pnas.1514978112
   Zheng SS, 2006, J BIOL CHEM, V281, P35904, DOI 10.1074/jbc.M607292200
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
NR 59
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD SEP 29
PY 2020
VL 13
IS 651
AR eabe1202
DI 10.1126/scisignal.abe1202
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NY4MC
UT WOS:000576364700002
PM 32994211
OA Other Gold
DA 2021-01-01
ER

PT J
AU Fida, M
   Mala, R
   Pupo, L
   Dibra, A
   Nasto, K
AF Fida, Monika
   Mala, Ritjana
   Pupo, Laerta
   Dibra, Arvin
   Nasto, Kristiana
TI Case report:SARS-CoV-2-induced urticaria or just a concomitance?
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE azithromycin; COVID-19; drug reaction; SARS-CoV-2; urticaria
AB The association between urticaria and different virus infections has been reported in many studies. Different virus infections have been reported to be comorbidities of spontaneous urticaria. In this paper, we report the case of a male patient with acute urticaria 7 days after he left the hospital where he was treated for coronavirus disease 2019 (COVID-19). This infection may act as a causative or a facilitating factor for the initiation of acute urticaria and additional cofactors such as stress may contribute for the urticaria phenotype to be expressed. Additional facts for severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) virus in future will clarify if urticarial rash is one of the COVID's multiple faces.
C1 [Fida, Monika; Mala, Ritjana] Univ Med Tirana, Dermatol Dept, UHC Mother Teresa Tirana, Tirana, Albania.
   [Pupo, Laerta] Allergol Serv, Outpatient Unit, Tirana, Albania.
   [Dibra, Arvin] Univ Med Tirana, Dept Surg, Tirana, Albania.
   [Nasto, Kristiana] Baylor Coll Med, Houston, TX 77030 USA.
RP Fida, M (corresponding author), Univ Med Tirana, Dermatol Dept, UHC Mother Teresa Tirana, Tirana, Albania.
EM monikafida@yahoo.co.uk
CR Balamurugesan Kandan, 2019, J Family Med Prim Care, V8, P2545, DOI 10.4103/jfmpc.jfmpc_413_19
   Bansal CJ, 2019, ALLERGY ASTHMA CL IM, V15, DOI 10.1186/s13223-019-0372-z
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Fujii K, 2001, J DERMATOL, V28, P248, DOI 10.1111/j.1346-8138.2001.tb00126.x
   Imbalzano E, 2016, ALLERGY ASTHMA PROC, V37, P18, DOI 10.2500/aap.2016.37.3915
   Kay AB, 2015, BRIT J DERMATOL, V172, P1294, DOI 10.1111/bjd.13621
   Kim MH, 2014, ALLERGY ASTHMA IMMUN, V6, P485, DOI 10.4168/aair.2014.6.6.485
   Otto A, 2020, MEDGE DERMATOL
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Shaeer KM, 2019, PHARMACY-BASEL, V7, DOI 10.3390/pharmacy7030135
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 13
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14250
DI 10.1111/dth.14250
EA SEP 2020
PG 3
WC Dermatology
SC Dermatology
GA NU3UA
UT WOS:000573566900001
PM 32860461
OA Bronze
DA 2021-01-01
ER

PT J
AU Kumar, N
   Sood, D
   Chandra, R
AF Kumar, Neeraj
   Sood, Damini
   Chandra, Ramesh
TI Design and optimization of a subunit vaccine targeting COVID-19
   molecular shreds using an immunoinformatics framework
SO RSC ADVANCES
LA English
DT Article
ID NORMAL-MODE ANALYSIS; B-CELL EPITOPES; CORONAVIRUS; PREDICTION;
   PATHOGENESIS; FLEXIBILITY; SERVER; SARS
AB COVID-19 has been declared as a global health emergency and exposed the world to a deadly virus, which has dramatically changed the lives of humans for an unknown period of time. In the battleground with the virus, we have employed an immunoinformatics framework to design a robust vaccine as an insurance plan for the future. The pathogenic sequence with cryptic epitope taken from patients in Wuhan, China, was harnessed to design a promiscuous cytotoxic T-lymphocyte, helper T-lymphocyte, and B-cell epitope based subunit vaccine, engineered with adjuvants and conformational linkers. The reported vaccine has high antigenicity and immunogenicity profiles with potential TAP affinity, which ensures elevated antigen processing capability. It has strong binding with major histocompatibility complex (MHC) receptors (MHC-1 and MHC-2) and virus-specific membrane receptor TLR-2, with scores of -1010.7, -1035.7, and -1076.3 kcal mol(-1), respectively. Molecular dynamics simulation analysis was used to assess the stable binding with TLR-2 with minimal atomic motions through a deformation plot, covariance matrix, and elastic network. Importantly, anin silicoimmunization assay showed the reliable elicitation of key players in terms of immune cells together with memory cells to evoke adaptive immune responses upon administration of the construct. In view of favorable outcomes, we also propose a plausible vaccine mechanism to elicit an immune response to fight coronavirus.
C1 [Kumar, Neeraj; Sood, Damini; Chandra, Ramesh] Univ Delhi, Dept Chem, Delhi 110007, India.
RP Chandra, R (corresponding author), Univ Delhi, Dept Chem, Delhi 110007, India.
EM acbrdu@hotmail.com; rameshchandradu@gmail.com
FU CSIRCouncil of Scientific & Industrial Research (CSIR) - India;
   DST-Purse; DST-SERBDepartment of Science & Technology (India)Science
   Engineering Research Board (SERB), India [EEQ/2016/000489]; CSIR, New
   Delhi, IndiaCouncil of Scientific & Industrial Research (CSIR) - India
   [09/045(1706)2019 EMR-1]; UGCUniversity Grants Commission, India
FX R. C. is grateful to CSIR, DST-Purse, and DST-SERB (EEQ/2016/000489) for
   providing financial assistance. N. K. thanks CSIR, New Delhi, India, for
   the Research Associateship (09/045(1706)2019 EMR-1) and the University
   of Delhi for Guest Assistant Professor Opportunity to conduct the
   research smoothly. D. S. thanks UGC for the SRF fellowship.
CR Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   Ahmad B, 2019, MICROB PATHOGENESIS, V132, P243, DOI 10.1016/j.micpath.2019.05.010
   Alexpandi R, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01796
   [Anonymous], 2020, CORONAVIRUS DIS 2019
   [Anonymous], 2020, COR DIS COVID 19 DAS
   [Anonymous], 2020, DRAFT LANDSCAPE COVI
   Beniac DR, 2006, NAT STRUCT MOL BIOL, V13, P751, DOI 10.1038/nsmb1123
   Bhasin M, 2004, VACCINE, V22, P3195, DOI 10.1016/j.vaccine.2004.02.005
   Bhattacharya Manojit, 2020, Inform Med Unlocked, V20, P100394, DOI 10.1016/j.imu.2020.100394
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   CHAKRABORTY C, 2020, INT J PEPT RES 0208, DOI DOI 10.1016/j.arcmed.2020.05.021
   Chakraborty C, 2020, J MED VIROL, V92, P2260, DOI 10.1002/jmv.26078
   Chakraborty C, 2020, ASIAN PAC J TROP MED, V13, P242, DOI 10.4103/1995-7645.281613
   Chakraborty C, 2020, J MED VIROL, V92, P2314, DOI 10.1002/jmv.25997
   Chen J, 2007, AMINO ACIDS, V33, P423, DOI 10.1007/s00726-006-0485-9
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Dong R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01784
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Enjuanes L, 2016, ADV VIRUS RES, V96, P245, DOI 10.1016/bs.aivir.2016.08.003
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Feng Y., 2020, BIORXIV, DOI [10.1101/2020.03.03.962332. 2020.03.03.962332, DOI 10.1101/2020.03.03.962332]
   Ferraz WR, 2020, FUTURE MED CHEM, V12, P1815, DOI 10.4155/fmc-2020-0165
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Gralinski LE, 2015, J PATHOL, V235, P185, DOI 10.1002/path.4454
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Guan PP, 2003, NUCLEIC ACIDS RES, V31, P3621, DOI 10.1093/nar/gkg510
   Hagar M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113922
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kaliamurthi S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010063
   Kaurav M, 2018, ARTIF CELL NANOMED B, V46, pS818, DOI 10.1080/21691401.2018.1513941
   Khan M I, 2019, SCI REP, V9, P1, DOI DOI 10.1038/s41598-018-37186-2
   Khan SZ, 2019, INFECT GENET EVOL, V73, P390, DOI 10.1016/j.meegid.2019.06.006
   Kovacs JA, 2004, PROTEINS, V56, P661, DOI 10.1002/prot.20151
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kumar N, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1792990, 10.1080/03601234.2020.1808416]
   Kumar N, 2020, J PROTEOME RES, V19, P4678, DOI 10.1021/acs.jproteome.0c00367
   Kumar N, 2020, J CHEM INF MODEL, V60, P421, DOI 10.1021/acs.jcim.9b01051
   Kumar N, 2019, ACS OMEGA, V4, P21370, DOI 10.1021/acsomega.9b03035
   Kumar N, 2019, J BIOMOL STRUCT DYN, V37, P2098, DOI 10.1080/07391102.2018.1477620
   Lei Y, 2019, PEERJ, V6, DOI 10.7717/peerj.6185
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li L, 2016, EXPERT REV VACCINES, V15, P313, DOI 10.1586/14760584.2016.1124762
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Mahony JB, 2011, CRIT REV CL LAB SCI, V48, P217, DOI 10.3109/10408363.2011.640976
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Mirza MU, 2016, SCI REP-UK, V6, DOI 10.1038/srep37313
   Navas-Martin S, 2003, VIRAL IMMUNOL, V16, P461, DOI 10.1089/088282403771926292
   Naz A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01663
   Ngo Son Tung, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00491
   Oliveira-Nascimento L, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00079
   Olubiyi OO, 2020, MOLECULES, V25, DOI 10.3390/molecules25143193
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224
   Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339
   Lopez-Blanco JR, 2011, BIOINFORMATICS, V27, P2843, DOI 10.1093/bioinformatics/btr497
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Saha A, 2020, ARCH MED RES, V51, P595, DOI 10.1016/j.arcmed.2020.05.009
   Saha A, 2020, ARCH MED RES, V51, P585, DOI 10.1016/j.arcmed.2020.05.001
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Sarkar B, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2020.151955
   Shahinshavali S, 2020, TETRAHEDRON LETT, V61, DOI 10.1016/j.tetlet.2020.152336
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sood D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35384-6
   Stratmann T, 2015, VACCINES-BASEL, V3, P579, DOI 10.3390/vaccines3030579
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   WHO, 2020, COR DIS COVID 19 PAN
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang NR, 2020, J MED VIROL, V92, P408, DOI 10.1002/jmv.25674
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 78
TC 0
Z9 0
U1 2
U2 2
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD SEP 29
PY 2020
VL 10
IS 59
BP 35856
EP 35872
DI 10.1039/d0ra06849g
PG 17
WC Chemistry, Multidisciplinary
SC Chemistry
GA NV8TH
UT WOS:000574586100026
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Dauby, N
   Van Praet, S
   Vanhomwegen, C
   Veliziotis, I
   Konopnicki, D
   Roman, A
AF Dauby, Nicolas
   Van Praet, Serge
   Vanhomwegen, Charlotte
   Veliziotis, Ioannis
   Konopnicki, Deborah
   Roman, Alain
TI Tolerability of favipiravir therapy in critically ill patients with
   COVID-19: A report of four cases
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Letter; Early Access
C1 [Dauby, Nicolas; Konopnicki, Deborah] Univ Libre Bruxelles, CHU St Pierre, Dept Infect Dis, Brussels, Belgium.
   [Van Praet, Serge] CHU St Pierre, Dept Pharm, Brussels, Belgium.
   [Vanhomwegen, Charlotte; Veliziotis, Ioannis; Roman, Alain] Univ Libre Bruxelles, Intens Care Unit, CHU St Pierre, Brussels, Belgium.
RP Dauby, N (corresponding author), CHU St Pierre, Dept Infect Dis, Rue Haute 322, B-1000 Brussels, Belgium.
EM Nicolas.Dauby@stpierre-bru.be
RI Dauby, Nicolas/F-1235-2011
OI Dauby, Nicolas/0000-0002-7697-6849
CR Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Chinello P, 2017, PLOS NEGLECT TROP D, V11, DOI [10.1371/journal.pntd.0006034, DOI 10.1371/JOURNAL.PNTD.0006034]
   Doi K, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03078-z
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Eloy P, 2020, CLIN PHARMACOL THER, V108, P188, DOI 10.1002/cpt.1877
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Irie K, 2020, CTS-CLIN TRANSL SCI, V13, P880, DOI 10.1111/cts.12827
   Malvy D, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008259
   Mubagwa K, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106057
   Pilkington V, 2020, J VIRUS ERAD, V6, P45
   Veliziotis I, 2020, EMERG INFECT DIS, V26, P1562, DOI 10.3201/eid2607.200275
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
NR 12
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26488
EA SEP 2020
PG 3
WC Virology
SC Virology
GA NU2WX
UT WOS:000573504900001
PM 32886358
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Anand, R
   Biswal, S
   Bhatt, R
   Tiwary, BN
AF Anand, Rajesh
   Biswal, Subham
   Bhatt, Renu
   Tiwary, Bhupendra N.
TI Computational perspectives revealed prospective vaccine candidates from
   five structural proteins of novel SARS corona virus 2019 (SARS-CoV-2)
SO PEERJ
LA English
DT Article
DE SARS-CoV-2; COVID-19; Peptide epitopes; Computational tools; Vaccine
   target
ID TAP TRANSPORT EFFICIENCY; CLASS-I; PEPTIDE VACCINE; PROTEASOMAL
   CLEAVAGE; EPITOPE PREDICTION; PEP-FOLD; RECEPTOR; BINDING; DESIGN;
   IMMUNOGENICITY
AB Background: The present pandemic COVID-19 is caused by SARS-CoV-2, a single-stranded positive-sense RNA virus from the Coronaviridae family. Due to a lack of antiviral drugs, vaccines against the virus are urgently required.
   Methods: In this study, validated computational approaches were used to identify peptide-based epitopes from six structural proteins having antigenic properties. The Net-CTL 1.2 tool was used for the prediction of CD8(+) T-cell epitopes, while the robust tools Bepi-Pred 2 and LBtope was employed for the identification of linear B-cell epitopes. Docking studies of the identified epitopes were performed using HADDOCK 2.4 and the structures were visualized by Discovery Studio and LigPlot(+). Antigenicity, immunogenicity, conservancy, population coverage and allergenicity of the predicted epitopes were determined by the bioinformatics tools like VaxiJen v2.0 server, the Immune Epitope Database tools and AllerTOP v.2.0, AllergenFP 1.0 and ElliPro.
   Results: The predicted T cell and linear B-cell epitopes were considered as prime vaccine targets in case they passed the requisite parameters like antigenicity, immunogenicity, conservancy, non-allergenicity and broad range of population coverage. Among the predicted CD8+ T cell epitopes, potential vaccine targets from surface glycoprotein were; YQPYRVVVL, PYRVVVLSF, GVYFASTEK, QLTPTWRVY, and those from ORF3a protein were LKKRWQLAL, HVTFFIYNK. Similarly, RFLYIIKLI, LTWICLLQF from membrane protein and three epitopes viz; SPRWYFYYL, TWLTYTGAI, KTFPPTEPK from nucleocapsid phosphoprotein were the superior vaccine targets observed in our study. The negative values of HADDOCK and Z scores obtained for the best cluster indicated the potential of the epitopes as suitable vaccine candidates. Analysis of the 3D and 2D interaction diagrams of best cluster produced by HADDOCK 2.4 displayed the binding interaction of leading T cell epitopes within the MHC-1 peptide binding clefts. On the other hand, among linear B cell epitopes the majority of potential vaccine targets were from nucleocapsid protein, viz; (59-)HGKEDLKFPRGQGVPINTNSS PDDQIGYYRRATRRIRGGDGKMKDLS(-105), (227-)LNQLE SKMSGKGQQQQGQT VTKKSAAEASKKPRQKRTATK(-266), (3-)DNGPQNQRNAPRITFGGP(-20), (29-)GERSG ARSKQRRPQGL(-45). Two other prime vaccine targets, (370-)NSASFSTFKCYGVSPTK LNDLCFTNV-395 and (260-)AGAAAYYVGYLQPRT(-274) were identified in the spike protein. The potential B-cell conformational epitopes were predicted on the basis of a higher protrusion index indicating greater solvent accessibility. These conformational epitopes were of various lengths and belonged to spike, ORF3a, membrane and nucleocapsid proteins.
   Conclusions: Taken together, eleven T cell epitopes, seven B cell linear epitopes and ten B cell conformational epitopes were identified from five structural proteins of SARS-CoV-2 using advanced computational tools. These potential vaccine candidates may provide important timely directives for an effective vaccine against SARS-CoV-2.
C1 [Anand, Rajesh; Biswal, Subham; Bhatt, Renu; Tiwary, Bhupendra N.] Guru Ghasidas Vishwavidyalaya, Dept Biotechnol, Bilaspur, Chhattisgarh, India.
RP Anand, R (corresponding author), Guru Ghasidas Vishwavidyalaya, Dept Biotechnol, Bilaspur, Chhattisgarh, India.
EM rajesh9in@gmail.com
CR Adhikari UK, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6718083
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266
   Chakraborty Sajib, 2010, In Silico Biology, V10, P235, DOI 10.3233/ISB-2010-0435
   Dassault Systemes, 2020, BIOBIA DISC STUD VIS
   De Groot Anne S, 2004, Expert Rev Vaccines, V3, P59
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dhanda SK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01369
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Dong N, 2020, BIORXIV, DOI [10.1101/2020.01.20.913368., DOI 10.1101/2020.01.20.913368]
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Fernandez-Recio J, 2004, J MOL BIOL, V335, P843, DOI 10.1016/j.jmb.2003.10.069
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Gras S, 2010, P NATL ACAD SCI USA, V107, P12599, DOI 10.1073/pnas.1007270107
   Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957
   Hasan MA, 2013, BIOINFORM BIOL INSIG, V7, P347, DOI 10.4137/BBI.S13402
   Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang SY, 2015, DRUG DISCOV TODAY, V20, P969, DOI 10.1016/j.drudis.2015.03.007
   Ilinskaya AN, 2016, TOXICOL APPL PHARM, V299, P70, DOI 10.1016/j.taap.2016.01.005
   Islam R, 2012, FUTURE VIROL, V7, P1029, DOI 10.2217/FVL.12.95
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Korber B, 2006, PLOS COMPUT BIOL, V2, P484, DOI 10.1371/journal.pcbi.0020071
   Lai M.M.C., 2007, FIELDS VIROLOGY, V1, P1305
   Lapelosa M, 2009, J MOL BIOL, V385, P675, DOI 10.1016/j.jmb.2008.10.089
   Larsen MV, 2005, EUR J IMMUNOL, V35, P2295, DOI 10.1002/eji.200425811
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu GW, 2013, NATURE, V500, P227, DOI 10.1038/nature12328
   Lundegaard C, 2008, NUCLEIC ACIDS RES, V36, pW509, DOI 10.1093/nar/gkn202
   Manzin A, 1998, J VIROL, V72, P6271, DOI 10.1128/JVI.72.7.6271-6276.1998
   Maria Ribas-Aparicio Rosa, 2017, VACCINES
   McKeever TM, 2004, AM J PUBLIC HEALTH, V94, P985, DOI 10.2105/AJPH.94.6.985
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Oany AR, 2014, DRUG DES DEV THER, V8, P1139, DOI [10.2147/DDDT.567861, 10.2147/DDDT.S67861]
   Patronov A, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120139
   Peters B, 2005, IMMUNOGENETICS, V57, P326, DOI 10.1007/s00251-005-0803-5
   Peters B, 2003, J IMMUNOL, V171, P1741, DOI 10.4049/jimmunol.171.4.1741
   Petsko G., 2004, PROTEIN STRUCTURE FU
   Pickett BE, 2012, NUCLEIC ACIDS RES, V40, pD593, DOI 10.1093/nar/gkr859
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224
   Rodrigues JPGLM, 2014, FEBS J, V281, P1988, DOI 10.1111/febs.12771
   Sarkander J, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.81
   Schrodinger LLC, 2019, PYMOL MOL GRAPH SYST
   Seib KL, 2012, CLIN MICROBIOL INFEC, V18, P109, DOI 10.1111/j.1469-0691.2012.03939.x
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shen YM, 2014, J CHEM THEORY COMPUT, V10, P4745, DOI 10.1021/ct500592m
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Singh H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064138
   Song ZQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010059
   STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5
   Sun PP, 2013, COMPUT MATH METHOD M, DOI 10.1155/2013/943636
   Taguchi F, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00068
   Tenzer S, 2005, CELL MOL LIFE SCI, V62, P1025, DOI 10.1007/s00018-005-4528-2
   Thevenet P, 2012, NUCLEIC ACIDS RES, V40, pW288, DOI 10.1093/nar/gks419
   Toseland Christopher P, 2005, Immunome Res, V1, P4, DOI 10.1186/1745-7580-1-4
   Twiddy SS, 2003, MOL BIOL EVOL, V20, P122, DOI 10.1093/molbev/msg010
   Van Regenmortel MHV, 2001, BIOLOGICALS, V29, P209, DOI 10.1006/biol.2001.0308
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   World Health Organization, 2020, COR DIS COVID 2019 S
   World Health Organization, 2019, COR DIS 2019
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 73
TC 0
Z9 0
U1 3
U2 3
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD SEP 29
PY 2020
VL 8
AR e9855
DI 10.7717/peerj.9855
PG 33
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NU0QD
UT WOS:000573344900008
PM 33062414
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Reiter, PL
   Pennell, ML
   Katz, ML
AF Reiter, Paul L.
   Pennell, Michael L.
   Katz, Mira L.
TI Acceptability of a COVID-19 vaccine among adults in the United States:
   How many people would get vaccinated?
SO VACCINE
LA English
DT Article
DE Coronavirus; COVID-19; Vaccine; Adults
ID HUMAN-PAPILLOMAVIRUS VACCINATION; BISEXUAL MEN; MODEL; GAY
AB Background: Coronavirus disease 2019 (COVID-19) was declared a pandemic in March 2020. Several prophylactic vaccines against COVID-19 are currently in development, yet little is known about people's acceptability of a COVID-19 vaccine.
   Methods: We conducted an online survey of adults ages 18 and older in the United States (n = 2,006) in May 2020. Multivariable relative risk regression identified correlates of participants' willingness to get a COVID-19 vaccine (i.e., vaccine acceptability).
   Results: Overall, 69% of participants were willing to get a COVID-19 vaccine. Participants were more likely to be willing to get vaccinated if they thought their healthcare provider would recommend vaccination (RR = 1.73, 95% CI: 1.49-2.02) or if they were moderate (RR = 1.09, 95% CI: 1.02-1.16) or liberal (RR = 1.14, 95% CI: 1.07-1.22) in their political leaning. Participants were also more likely to be willing to get vaccinated if they reported higher levels of perceived likelihood getting a COVID-19 infection in the future (RR = 1.05, 95% CI: 1.01-1.09), perceived severity of COVID-19 infection (RR = 1.08, 95% CI: 1.04-1.11), or perceived effectiveness of a COVID-19 vaccine (RR = 1.46, 95% CI: 1.40-1.52). Participants were less likely to be willing to get vaccinated if they were non-Latinx black (RR = 0.81, 95% CI: 0.74-0.90) or reported a higher level of perceived potential vaccine harms (RR = 0.95, 95% CI: 0.92-0.98).
   Conclusions: Many adults are willing to get a COVID-19 vaccine, though acceptability should be monitored as vaccine development continues. Our findings can help guide future efforts to increase COVID-19 vaccine acceptability (and uptake if a vaccine becomes available). (C) 2020 Elsevier Ltd. All rights reserved.
C1 Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA.
   Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA.
RP Reiter, PL (corresponding author), Ohio State Univ, Coll Publ Hlth, Div Hlth Behav & Hlth Promot, 1841 Neil Ave,Room 359B, Columbus, OH 43210 USA.
EM reiter.36@osu.edu
FU National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002733]
FX Supported by Award Number Grant UL1TR002733 from the National Center for
   Advancing Translational Sciences. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Center for Advancing Translational
   Sciences or the National Institutes of Health.
CR APM Research Lab, 2020, COL COR COVID 19 DEA
   Aris E, 2020, VACCINE, V38, P2984, DOI 10.1016/j.vaccine.2020.02.057
   Becker M, 1974, HLTH ED MONOGRAPHS, V2, P324, DOI [10.1177/109019817400200401, DOI 10.1177/109019817400200407]
   Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Gargano LM, 2014, HEALTH PROMOT PRACT, V15, P556, DOI 10.1177/1524839913518222
   Gidengil CA, 2012, AM J PUBLIC HEALTH, V102, P672, DOI 10.2105/AJPH.2011.300407
   Gross CP, 2020, RACIAL ETHNIC DISPAR, DOI [10.1101/2020.05.07.20094250v1., DOI 10.1101/2020.05.07.20094250V1]
   Horney JA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011226
   JCH Impact, 2020, NEW YORK COVID 19
   Kaiser Family Foundation, 2020, STAT DAT POL ACT ADD
   Kelly B, 2020, PREDICTING WILLINGNE
   Lanese N., 2020, WILL COVID 19 VACCIN
   Ling M, 2019, SOC SCI MED, V233, P87, DOI 10.1016/j.socscimed.2019.06.002
   Maurer J, 2009, VACCINE, V27, P5732, DOI 10.1016/j.vaccine.2009.07.080
   McRee AL, 2018, VACCINE, V36, P8158, DOI 10.1016/j.vaccine.2018.01.009
   McRee AL, 2010, SEX TRANSM DIS, V37, P234, DOI 10.1097/OLQ.0b013e3181c37e15
   Pazol K, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6620a1
   PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390
   Reiter PL, 2018, LGBT HEALTH, V5, P325, DOI 10.1089/lgbt.2018.0059
   Reiter PL, 2015, AM J PUBLIC HEALTH, V105, P96, DOI 10.2105/AJPH.2014.302095
   Reiter PL, 2013, AM J PUBLIC HEALTH, V103, P1419, DOI 10.2105/AJPH.2012.301189
   Reiter PL, 2011, HUM VACCINES, V7, P191, DOI 10.4161/hv.7.2.13847
   Reiter PL, 2011, HUM VACCINES, V7, P67, DOI 10.4161/hv.7.1.13500
   Reiter PL, 2009, SOC SCI MED, V69, P475, DOI 10.1016/j.socscimed.2009.05.024
   Rodriguez SA, 2020, PREV MED, V131, DOI 10.1016/j.ypmed.2019.105968
   Rogers R. W., 1983, SOCIAL PSYCHOPHYSIOL, P153, DOI DOI 10.1093/DEAFED/ENT031
   Sharpe HR, IMMUNOLOGY
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   U.S. Department of Agriculture, 2016, RUR URB CONT COD
   US Census Bureau, 2020, AM COMM SURV ACS
   Van Bavel JJ, 2020, PANDEMIC POLITICAL P
   Webb Hooper M, JAMA
   WEINSTEIN ND, 1992, HEALTH PSYCHOL, V11, P170, DOI 10.1037/0278-6133.11.3.170
   WHO, 2020, COR DIS COVID 19 PAN
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 37
TC 2
Z9 2
U1 12
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 29
PY 2020
VL 38
IS 42
BP 6500
EP 6507
DI 10.1016/j.vaccine.2020.08.043
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA NU1TY
UT WOS:000573425200003
PM 32863069
OA Green Published
DA 2021-01-01
ER

PT J
AU Larenas-Linnemann, DE
   Rodriguez-Monroy, F
AF Larenas-Linnemann, Desiree E.
   Rodriguez-Monroy, Fernanda
TI Thirty-six COVID-19 cases preventively vaccinated with
   mumps-measles-rubella vaccine: All mild course
SO ALLERGY
LA English
DT Letter; Early Access
DE COVID-19; measles vaccine; MMR vaccine; innate immunity; prevention
ID BCG VACCINATION; RESPONSES
C1 [Larenas-Linnemann, Desiree E.; Rodriguez-Monroy, Fernanda] Clin Fdn & Hosp, Med Sur, Mexico City, DF, Mexico.
RP Larenas-Linnemann, DE (corresponding author), Hosp Med Sur, Torre 2,Cons 602,Puente Piedra 150, Mexico City 14050, DF, Mexico.
EM Marlar1@prodigy.net.mx
OI Larenas Linnemann, Desiree/0000-0002-5713-5331
CR Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684
   Cirauqui C, 2018, EUR J IMMUNOL, V48, P180, DOI 10.1002/eji.201747024
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Hong M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7588
   Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Matricardi PM, 2020, PEDIAT ALLERG IMM-UK, V31, P454, DOI 10.1111/pai.13271
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
NR 9
TC 2
Z9 2
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
DI 10.1111/all.14584
EA SEP 2020
PG 5
WC Allergy; Immunology
SC Allergy; Immunology
GA NU1XB
UT WOS:000573433900001
PM 32894782
OA Bronze
DA 2021-01-01
ER

PT J
AU Ogawa, H
   Kakuchi, Y
   Asakura, H
AF Ogawa, Haruhiko
   Kakuchi, Yasushi
   Asakura, Hidesaku
TI Adjunctive therapies for early withdrawal from extracorporeal membrane
   oxygenation
SO JOURNAL OF CARDIAC SURGERY
LA English
DT Letter
ID PNEUMONIA; COVID-19
C1 [Ogawa, Haruhiko] Kanazawa Univ, Dept Environm & Prevent Med, Takaramachi 13-1, Kanazawa, Ishikawa 9208640, Japan.
   [Kakuchi, Yasushi] Ishikawa Ken Saiseikai Kanazawa Hosp, Div Internal Med, Kanazawa, Ishikawa, Japan.
   [Asakura, Hidesaku] Kanazawa Univ Hosp, Dept Hematol, Kanazawa, Ishikawa, Japan.
RP Ogawa, H (corresponding author), Kanazawa Univ, Dept Environm & Prevent Med, Takaramachi 13-1, Kanazawa, Ishikawa 9208640, Japan.
EM h-ogawa@jintikai.com
OI Kakuchi, Yasushi/0000-0002-6505-9586
CR Araki T, 2011, THER APHER DIAL, V15, P207, DOI 10.1111/j.1744-9987.2010.00872.x
   Haiduc AA, 2020, J CARDIAC SURG, V35, P2679, DOI 10.1111/jocs.14879
   Henry BM, 2020, LANCET RESP MED, V8, pE24, DOI 10.1016/S2213-2600(20)30119-3
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   Rilinger J, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04447-3
   Ronco C, 2014, CRIT CARE, V18, DOI 10.1186/cc13912
   Yasuda H, 2017, J DERMATOL, V44, P1164, DOI 10.1111/1346-8138.13887
NR 7
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0886-0440
EI 1540-8191
J9 J CARDIAC SURG
JI J. Card. Surg.
PD DEC
PY 2020
VL 35
IS 12
BP 3671
EP 3672
DI 10.1111/jocs.15024
EA SEP 2020
PG 2
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA OZ8XY
UT WOS:000573359700001
PM 32989829
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Islam, MZ
   Zahan, MKE
   Al-Bari, MAA
AF Islam, Md. Zahurul
   Zahan, Md. Kudrat-E
   Al-Bari, Md. Abdul Alim
TI Convergence between global BCG vaccination and COVID-19 pandemic
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE BCG vaccination; correlation data; COVID-19; severity variation; trained
   immunity
ID CORONAVIRUSES; OUTBREAK; UPDATE; INNATE; SARS
AB The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has kept the whole world in tenterhooks due to its severe life-threatening infectious disease, COVID-19. The virus is distinct from its cousins, SARS-CoV and MERS-CoV in terms of severity of the infection. The obligated killing properties of the SARS-CoV-2 virus is mediated by its unique structure. Efforts for developing vaccines for COVID-19 are ongoing, but it is unlikely to be available in the immediate future. Due to the absence of precise treatment, the investigators are discovering other effective, protective, and healing choices. However, the lower than a predictable number of SARS-CoV-2 cases in countries with fragile health systems is mystifying. Recently, there has been a buzz about the protective effect of Bacille Calmette-Guerin (BCG) vaccine in COVID-19 through long-term boosting of trained immunity. Based onepidemiological correlations, we link up that BCG vaccination adopted by different countries might influence the SARS-CoV-2 transmission patterns and/or COVID-19 associated mortality through the vaccine's capacity to confer heterologous protection. A number of clinical studies are underway to investigate this possibility but even if they prove effective-many questions will remain. Moreover, responsiblestewardship of the BCGvaccine in the context of the COVID-19 epidemic is directly needed.
C1 [Islam, Md. Zahurul] Univ Rajshahi, Dept Appl Math, Rajshahi, Bangladesh.
   [Zahan, Md. Kudrat-E] Univ Rajshahi, Dept Chem, Rajshahi, Bangladesh.
   [Al-Bari, Md. Abdul Alim] Univ Rajshahi, Dept Pharm, Rajshahi 6205, Bangladesh.
RP Al-Bari, MAA (corresponding author), Univ Rajshahi, Dept Pharm, Rajshahi 6205, Bangladesh.
EM alimalbari347@ru.ac.bd
RI ; Al-Bari, Md. Abdul Alim/C-2946-2018
OI , Dr.Md.Kudrat-E-Zahan/0000-0001-8159-5293; Al-Bari, Md. Abdul
   Alim/0000-0002-1777-3662
CR Abbott S, 2019, VACCINE, V37, P5067, DOI 10.1016/j.vaccine.2019.06.056
   [Anonymous], 2017, BCG WORLD ATLAS DATA
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041
   Covian C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02806
   de Bree CLCJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00869
   Desouky E, 2020, WORLD J UROL, DOI 10.1007/s00345-020-03251-7
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152
   Goodridge HS, 2016, NAT REV IMMUNOL, V16, P392, DOI 10.1038/nri.2016.43
   Gursel M, 2020, ALLERGY, V75, P1815, DOI 10.1111/all.14345
   Hegarty PK, 2020, EUR UROL ONCOL, V3, P259, DOI 10.1016/j.euo.2020.04.001
   Hirve S, 2012, VACCINE, V30, P7300, DOI 10.1016/j.vaccine.2012.09.035
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1036
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1252
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.1101/2020.03.24.20042937, DOI 10.1101/2020.03.24.20042937, 10. 1101/2020.03.24.20042937]
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Mulder WJM, 2019, NAT REV DRUG DISCOV, V18, P553, DOI 10.1038/s41573-019-0025-4
   Netea MG, 2019, CELL HOST MICROBE, V25, P13, DOI 10.1016/j.chom.2018.12.006
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   O'Connor E, 2020, FUTURE ONCOL, V16, P1323, DOI 10.2217/fon-2020-0381
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Redelman-Sidi G, 2014, NAT REV UROL, V11, P153, DOI 10.1038/nrurol.2014.15
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   SAGE Working Group on BCG Vaccines and WHO Secretariat, 2017, BCG VACC US PROT AG
   SCHRIER DJ, 1982, J CLIN INVEST, V69, P651, DOI 10.1172/JCI110492
   Stoecklin SB, 2020, EUROSURVEILLANCE, V25, P20, DOI 10.2807/1560-7917.ES.2020.25.6.2000094
   Phan T, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104211
   Virological.org, 2020, NOV 2019 COR GEN
   Vrieze J., 2020, SCIENCE, DOI [10.1126/science.abb8297, 10.1126/science.abb8297., DOI 10.1126/SCIENCE.ABB8297]
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   WHO, BAC CALM GUER BCG VA
   WMHC, 2020, WUH MUN HLTH HLTH CO
   World Health Organization (WHO), 2020, NOV COR JAP EX CHIN
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yamazaki-Nakashimada MA, 2020, HUM VACC IMMUNOTHER, V16, P1841, DOI 10.1080/21645515.2019.1706930
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
NR 45
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26450
EA SEP 2020
PG 10
WC Virology
SC Virology
GA NU0LS
UT WOS:000573333400001
PM 32827313
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Letaief, F
   Gharbi, I
   Hamdi, A
   Yahyaoui, Y
   Ayadi, M
   Blousa, I
   Mezlini, A
AF Letaief, Feriel
   Gharbi, Imen
   Hamdi, Adel
   Yahyaoui, Yosra
   Ayadi, Mona
   Blousa, Imen
   Mezlini, Amel
TI A practical approach to the management of colorectal cancer during the
   COVID-19 crisis in the reference cancer treatment center in Tunisia
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Article
DE COVID-19; colorectal cancer; Tunisia
AB COVID-19 is an exceptional public healthcare emergency that affected all countries. The corona virus pandemic has made the treatment of all cancers difficult. This international phenomenon represents an outbreak in medicine and this situation is a major issue for all patients, whether they are infected with the virus or not. Colorectal cancer is one of the most common malignant tumors of the digestive tract which needs special multidisciplinary care. Treatment modalities including chemotherapy and targeted therapies can weaken the immune system and then cause serious or lethal coronavirus infections. This document gives an idea about how we dealt to protect patients with colorectal cancer at Salah Azaiez Institute during COVID 19 pandemic.
C1 [Letaief, Feriel; Gharbi, Imen; Yahyaoui, Yosra; Ayadi, Mona; Mezlini, Amel] Univ Tunis El Manar, Salah Azaiez Inst, Dept Med Oncol, Tunis, Tunisia.
   [Hamdi, Adel; Blousa, Imen] Salah Azaiez Inst, Fac Pharm Monastir, Dept Pharm, Monastir, Tunisia.
RP Gharbi, I (corresponding author), Univ Tunis El Manar, Salah Azaiez Inst, Dept Med Oncol, Tunis, Tunisia.
EM imenegharbii@gmail.com
OI HAMDI, Adel/0000-0002-9223-9259
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [21R04868]; University of British Columbia
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by Canadian Institutes of Health Research (21R04868) and
   University of British Columbia.
CR [Anonymous], 2020, WHO CORONAVIRUS DIS
   Ma XT, 2020, CELL ONCOL, V43, P751, DOI 10.1007/s13402-020-00512-w
   Wang HP, 2020, LANCET ONCOL, V21, pE181, DOI 10.1016/S1470-2045(20)30149-2
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 4
TC 0
Z9 0
U1 5
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078-1552
EI 1477-092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD DEC
PY 2020
VL 26
IS 8
BP 1931
EP 1933
AR 1078155220961139
DI 10.1177/1078155220961139
EA SEP 2020
PG 3
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA PA6RQ
UT WOS:000575138700001
PM 32990193
DA 2021-01-01
ER

PT J
AU Helfand, BKI
   Webb, M
   Gartaganis, SL
   Fuller, L
   Kwon, CS
   Inouye, SK
AF Helfand, Benjamin K. I.
   Webb, Margaret
   Gartaganis, Sarah L.
   Fuller, Lily
   Kwon, Churl-Su
   Inouye, Sharon K.
TI The Exclusion of Older Persons From Vaccine and Treatment Trials for
   Coronavirus Disease 2019-Missing the Target
SO JAMA INTERNAL MEDICINE
LA English
DT Letter; Early Access
C1 [Helfand, Benjamin K. I.] Univ Massachusetts, Med Sch, Dept Emergency Med, Worcester, MA 01605 USA.
   [Helfand, Benjamin K. I.] Brown Univ, Dept Psychiat & Human Behav, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Helfand, Benjamin K. I.] Brown Univ, Dept Neurol, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Webb, Margaret; Gartaganis, Sarah L.; Fuller, Lily; Inouye, Sharon K.] Harvard Med Sch, Marcus Inst Aging Res, Aging Brain Ctr, Hebrew SeniorLife, Boston, MA 02115 USA.
   [Kwon, Churl-Su] Dept Neurol, Div Hlth Outcomes & Knowledge Translat Res, New York, NY USA.
   [Kwon, Churl-Su] Dept Neurosurg, Div Hlth Outcomes & Knowledge Translat Res, New York, NY USA.
   [Kwon, Churl-Su] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
RP Inouye, SK (corresponding author), Hebrew SeniorLife, Marcus Inst Aging Res, 1200 Ctr St, Boston, MA 02131 USA.
EM sharoninouye@hsl.harvard.edu
FU National Institute on AgingUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [R24AG054259]; University of Massachusetts Medical School
   [T32GM107000]
FX Supported in part by Grant R24AG054259 (Inouye) from the National
   Institute on Aging and T32GM107000 (Helfand) Training Program at the
   University of Massachusetts Medical School.
CR Bernard MA, 2018, JAMA-J AM MED ASSOC, V320, P1535, DOI 10.1001/jama.2018.12368
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Centers for Disease Control and Prevention, 2020, CAS DEATHS US
   Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010
   Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012
   United Nations Department of Economic and Social Affairs Population Dynamics, 2020, DAT QUER POP AG SEX
NR 6
TC 1
Z9 1
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
DI 10.1001/jamainternmed.2020.5084
EA SEP 2020
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA NY4LU
UT WOS:000576363900011
PM 32986099
OA Bronze
DA 2021-01-01
ER

PT J
AU Virdi, RS
   Bavisotto, RV
   Hopper, NC
   Vuksanovic, N
   Melkonian, TR
   Silvaggi, NR
   Frick, DN
AF Virdi, Rajdeep S.
   Bavisotto, Robert V.
   Hopper, Nicholas C.
   Vuksanovic, Nemanja
   Melkonian, Trevor R.
   Silvaggi, Nicholas R.
   Frick, David N.
TI Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3
SO SLAS DISCOVERY
LA English
DT Article
DE COVID-19; antiviral drug target; macrodomain; coronavirus; thermal shift
ID OPTIMIZATION; BINDING
AB Small molecules that bind the SARS-CoV-2 nonstructural protein 3 Mac1 domain in place of ADP-ribose could be useful as molecular probes or scaffolds for COVID-19 antiviral drug discovery because Mac1 has been linked to the ability of coronaviruses to evade cellular detection. A high-throughput assay based on differential scanning fluorimetry (DSF) was therefore optimized and used to identify possible Mac1 ligands in small libraries of drugs and drug-like compounds. Numerous promising compounds included nucleotides, steroids, beta-lactams, and benzimidazoles. The main drawback to this approach was that a high percentage of compounds in some libraries were found to influence the observed Mac1 melting temperature. To prioritize DSF screening hits, the shapes of the observed melting curves and initial assay fluorescence were examined, and the results were compared with virtual screens performed using AutoDock Vina. The molecular basis for alternate ligand binding was also examined by determining a structure of one of the hits, cyclic adenosine monophosphate, with atomic resolution.
C1 [Virdi, Rajdeep S.; Bavisotto, Robert V.; Hopper, Nicholas C.; Vuksanovic, Nemanja; Melkonian, Trevor R.; Silvaggi, Nicholas R.; Frick, David N.] Univ Wisconsin, Dept Chem & Biochem, 3210 N Cramer St, Milwaukee, WI 53211 USA.
RP Frick, DN (corresponding author), Univ Wisconsin, Dept Chem & Biochem, 3210 N Cramer St, Milwaukee, WI 53211 USA.
EM frickd@uwm.edu
FU University of Wisconsin-Milwaukee's generous F&A cost return policy
   (National Institutes of Health grant)United States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [R01
   AI088001]; National Science FoundationNational Science Foundation (NSF)
   [CHE-1855199, CHE-1903899]; DOE Office of ScienceUnited States
   Department of Energy (DOE) [DE-AC02-06CH11357]; Michigan Economic
   Development Corporation; Michigan Technology Tri-Corridor [085P1000817]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by The University of Wisconsin-Milwaukee's generous F&A cost
   return policy (National Institutes of Health grant no. R01 AI088001) and
   is based upon work supported by the National Science Foundation under
   grant nos. CHE-1855199 and CHE-1903899 (N.V. and N.R.S.). This research
   used resources of the Advanced Photon Source, a U.S. Department of
   Energy (DOE) Office of Science User Facility operated for the DOE Office
   of Science by the Argonne National Laboratory under contract no.
   DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the
   Michigan Economic Development Corporation and the Michigan Technology
   Tri-Corridor (grant no. 085P1000817).
CR Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   Bai N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37072-x
   Cho CC, 2016, J BIOL CHEM, V291, P4894, DOI 10.1074/jbc.M115.700542
   Claverie JM, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060646
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Ericsson UB, 2006, ANAL BIOCHEM, V357, P289, DOI 10.1016/j.ab.2006.07.027
   Freitas BT, 2020, ACS INFECT DIS, V6, P2099, DOI 10.1021/acsinfecdis.0c00168
   Frick DN, 2020, BIOCHEMISTRY-US, V59, P2608, DOI 10.1021/acs.biochem.0c00309
   Huynh Kathy, 2015, Curr Protoc Protein Sci, V79, DOI 10.1002/0471140864.ps2809s79
   Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460
   Layton CJ, 2010, BIOCHEMISTRY-US, V49, P10831, DOI 10.1021/bi101414z
   Lee PH, 2019, SLAS DISCOV, V24, P606, DOI 10.1177/2472555218823547
   Li KL, 2012, J MED CHEM, V55, P3319, DOI 10.1021/jm300021v
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Malet H, 2009, J VIROL, V83, P6534, DOI 10.1128/JVI.00189-09
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Michalska K, 2020, IUCRJ, V7, P814, DOI 10.1107/S2052252520009653
   Mukherjee S, 2014, ACS CHEM BIOL, V9, P2393, DOI 10.1021/cb500512z
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pantoliano MW, 2001, J BIOMOL SCREEN, V6, P429, DOI 10.1177/108705710100600609
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Shimizu JF, 2020, ACTA TROP, V207, DOI 10.1016/j.actatropica.2020.105490
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wazir S, 2021, SLAS DISCOV, V26, P67, DOI 10.1177/2472555220928911
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
NR 25
TC 1
Z9 1
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2472-5552
EI 2472-5560
J9 SLAS DISCOV
JI SLAS Discov.
PD DEC
PY 2020
VL 25
IS 10
SI SI
BP 1162
EP 1170
AR 2472555220960428
DI 10.1177/2472555220960428
EA SEP 2020
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry
GA OT8JK
UT WOS:000575439200001
PM 32981460
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Huber, W
   Lorenz, G
   Heilmaier, M
   Bottcher, K
   Sahm, P
   Middelhoff, M
   Ritzer, B
   Schulz, D
   Bekka, E
   Hesse, F
   Poszler, A
   Geisler, F
   Spinner, C
   Schmid, RM
   Lahmer, T
AF Huber, Wolfgang
   Lorenz, Georg
   Heilmaier, Markus
   Boettcher, Katrin
   Sahm, Philipp
   Middelhoff, Moritz
   Ritzer, Barbara
   Schulz, Dominik
   Bekka, Elias
   Hesse, Felix
   Poszler, Alexander
   Geisler, Fabian
   Spinner, Christoph
   Schmid, Roland M.
   Lahmer, Tobias
TI Extracorporeal multiorgan support including CO2-removal with the
   ADVanced Organ Support (ADVOS) system for COVID-19: A case report
SO INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
LA English
DT Article; Early Access
DE COVID-19; Multiple organ support; Extracorporeal CO(2)removal; ARDS;
   ADVOS; ECMO
ID RESPIRATORY-DISTRESS-SYNDROME; COAGULATION; ACIDOSIS; ECMO
AB A substantial part of COVID-19-patients suffers from multi-organ failure (MOF). We report on an 80-year old patient with pulmonary, renal, circulatory, and hepatic failure. We decided against the use of extracorporeal membrane oxygenation (ECMO) due to old age and a SOFA-score of 13. However, the patient was continuously treated with the extracorporeal multi-organ- "ADVanced Organ Support" (ADVOS) device (ADVITOS GmbH, Munich, Germany). During eight 24h-treatment-sessions blood flow (100-300 mL/min), dialysate flow (160-320 mL/min) and dialysate pH (7.6-9.0) were adapted to optimize arterial PaCO(2)and pH. Effective CO(2)removal and correction of acidosis could be demonstrated by mean arterial- versus post-dialyzer values of pCO(2)(68.7 +/- 13.8 vs. 26.9 +/- 11.6 mmHg;p < 0.001). The CO2-elimination rate was 48 +/- 23mL/min. The initial vasopressor requirement could be reduced in parallel to pH-normalization. Interruptions of ADVOS-treatment repeatedly resulted in reversible deteriorations of p(a)CO(2)and pH. After 95 h of continuous extracorporeal decarboxylating therapy the patient had markedly improved circulatory parameters compared to baseline. In the context of secondary pulmonary infection and progressive liver failure, the patient had a sudden cardiac arrest. In accordance with the presumed patient will, we decided against mechanical resuscitation. Irrespective of the outcome we conclude that extracorporeal CO(2)removal and multiorgan-support were feasible in this COVID-19-patient. Combined and less invasive approaches such as ADVOS might be considered in old-age-COVID-19 patients with MOF.
C1 [Huber, Wolfgang; Lorenz, Georg; Heilmaier, Markus; Boettcher, Katrin; Sahm, Philipp; Middelhoff, Moritz; Ritzer, Barbara; Schulz, Dominik; Bekka, Elias; Hesse, Felix; Poszler, Alexander; Geisler, Fabian; Spinner, Christoph; Schmid, Roland M.; Lahmer, Tobias] Tech Univ Munich, Med Klin & Poliklin 2, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany.
   [Lorenz, Georg] Tech Univ Munich, Abt Nephrol, Klinikum Rechts Isar, Munich, Germany.
RP Lahmer, T (corresponding author), Tech Univ Munich, Med Klin & Poliklin 2, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany.
EM tobias.lahmer@mri.tum.de
RI Spinner, Christoph/H-7039-2019
OI Spinner, Christoph/0000-0002-3875-5367; Bekka, Elias/0000-0001-9958-7769
CR Abe H, 2000, BIOCHEMISTRY-MOSCOW+, V65, P757
   Arabi YM, 2020, INTENS CARE MED, V46, P833, DOI 10.1007/s00134-020-05955-1
   Auriemma CL, 2020, INTENS CARE MED, V46, P1222, DOI 10.1007/s00134-020-06010-9
   Bartlett RH, 2020, ASAIO J, V66, P472, DOI 10.1097/MAT.0000000000001173
   Chiu LC, 2015, ANN THORAC SURG, V99, P243, DOI 10.1016/j.athoracsur.2014.07.064
   Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   de Garibay APR, 2019, INTENS CARE MED EXP, V7, DOI 10.1186/s40635-019-0269-7
   Del Sorbo L, 2011, CURR OPIN CRIT CARE, V17, P1, DOI 10.1097/MCC.0b013e3283427295
   Dizier S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144278
   Engstrom M, 2006, J TRAUMA, V61, P624, DOI 10.1097/01.ta.0000226739.30655.75
   Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Henry BM, 2020, LANCET RESP MED, V8, pE24, DOI 10.1016/S2213-2600(20)30119-3
   Huber W, 2020, MED KLIN-INTENSIVMED, V115, P28, DOI 10.1007/s00063-020-00658-3
   Huber W., 2008, Intensivmedizin und Notfallmedizin, V45, P337, DOI 10.1007/s00390-008-0894-y
   Huber W, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0569-x
   Huber W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153430
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Pierrakos C, 2012, EUR RESPIR J, V40, P589, DOI 10.1183/09031936.00130511
   Riley DS, 2017, J CLIN EPIDEMIOL, V89, P218, DOI 10.1016/j.jclinepi.2017.04.026
   Schmidt M, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2038-5
   STRINGER W, 1994, J APPL PHYSIOL, V76, P1462
   Terragni PP, 2009, ANESTHESIOLOGY, V111, P826, DOI 10.1097/ALN.0b013e3181b764d2
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Zampieri FG, 2014, CRIT CARE, V18, DOI 10.1186/cc13993
   Zhong JX, 2020, LANCET RHEUMATOL, V2, pE428, DOI 10.1016/S2665-9913(20)30120-X
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 29
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0391-3988
EI 1724-6040
J9 INT J ARTIF ORGANS
JI Int. J. Artif. Organs
AR 0391398820961781
DI 10.1177/0391398820961781
EA SEP 2020
PG 7
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA NW2ZX
UT WOS:000574879500001
PM 32985328
OA Other Gold
DA 2021-01-01
ER

PT J
AU Bos, R
   Rutten, L
   van der Lubbe, JEM
   Bakkers, MJG
   Hardenberg, G
   Wegmann, F
   Zuijdgeest, D
   de Wilde, AH
   Koornneef, A
   Verwilligen, A
   van Manen, D
   Kwaks, T
   Vogels, R
   Dalebout, TJ
   Myeni, SK
   Kikkert, M
   Snijder, EJ
   Li, ZF
   Barouch, DH
   Vellinga, J
   Langedijk, JPM
   Zahn, RC
   Custers, J
   Schuitemaker, H
AF Bos, Rinke
   Rutten, Lucy
   van der Lubbe, Joan E. M.
   Bakkers, Mark J. G.
   Hardenberg, Gijs
   Wegmann, Frank
   Zuijdgeest, David
   de Wilde, Adriaan H.
   Koornneef, Annemart
   Verwilligen, Annemiek
   van Manen, Danielle
   Kwaks, Ted
   Vogels, Ronald
   Dalebout, Tim J.
   Myeni, Sebenzile K.
   Kikkert, Marjolein
   Snijder, Eric J.
   Li, Zhenfeng
   Barouch, Dan H.
   Vellinga, Jort
   Langedijk, Johannes P. M.
   Zahn, Roland C.
   Custers, Jerome
   Schuitemaker, Hanneke
TI Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized
   SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune
   responses
SO NPJ VACCINES
LA English
DT Article
ID HIV-1 ENV VACCINE; ADENOVIRUS VECTORS; HEALTHY-ADULTS; SAFETY;
   ANTIBODIES; PROTEIN; VIRUS
AB Development of effective preventative interventions against SARS-CoV-2, the etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS-CoV-2 is a key target for prophylactic measures as it is critical for the viral replication cycle and the primary target of neutralizing antibodies. We evaluated design elements previously shown for other coronavirus S protein-based vaccines to be successful, e.g., prefusion-stabilizing substitutions and heterologous signal peptides, for selection of a S-based SARS-CoV-2 vaccine candidate. In vitro characterization demonstrated that the introduction of stabilizing substitutions (i.e., furin cleavage site mutations and two consecutive prolines in the hinge region of S2) increased the ratio of neutralizing versus non-neutralizing antibody binding, suggestive for a prefusion conformation of the S protein. Furthermore, the wild-type signal peptide was best suited for the correct cleavage needed for a natively folded protein. These observations translated into superior immunogenicity in mice where the Ad26 vector encoding for a membrane-bound stabilized S protein with a wild-type signal peptide elicited potent neutralizing humoral immunity and cellular immunity that was polarized towards Th1 IFN-gamma. This optimized Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in a phase I clinical trial (ClinicalTrials.gov Identifier: NCT04436276).
C1 [Bos, Rinke; Rutten, Lucy; van der Lubbe, Joan E. M.; Bakkers, Mark J. G.; Hardenberg, Gijs; Wegmann, Frank; Zuijdgeest, David; de Wilde, Adriaan H.; Koornneef, Annemart; Verwilligen, Annemiek; van Manen, Danielle; Kwaks, Ted; Vogels, Ronald; Vellinga, Jort; Langedijk, Johannes P. M.; Zahn, Roland C.; Custers, Jerome; Schuitemaker, Hanneke] Janssen Vaccines & Prevent BV, Leiden, Netherlands.
   [Dalebout, Tim J.; Myeni, Sebenzile K.; Kikkert, Marjolein; Snijder, Eric J.] Leiden Univ, Dept Med Microbiol, Mol Virol Lab, Med Ctr, Leiden, Netherlands.
   [Li, Zhenfeng; Barouch, Dan H.] Harvard Med Sch, Ctr Virol & Vaccine Res, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Schuitemaker, H (corresponding author), Janssen Vaccines & Prevent BV, Leiden, Netherlands.
EM HSchuite@its.jnj.com
OI Wegmann, Frank/0000-0002-9821-1492
FU Department of Health and Human Services Biomedical Advanced Research and
   Development Authority (BARDA) [HHS0100201700018C]
FX This project was funded in part by the Department of Health and Human
   Services Biomedical Advanced Research and Development Authority (BARDA)
   under contract HHS0100201700018C. We thank Isabel de los Rios Oakes,
   Esmeralda van der Helm, Dirk Spek, Iris Swart, Marina Koning, Alies
   Brandjes, Nelie van Dijk, Eleni Kourkouta, Santusha Karia, Marjon Navis,
   Rina van Schie, Janneke Verhagen, Jessica Vreugdenhil, Sanne Kroos, Ella
   van Huizen, Jeroen Tolboom, Leacky Muchene, Joke Drijver, Liz van Erp,
   Michel Mulders, Aric van Drie, Eveline Sneekes-Vriese, Sharitee
   Bouthisma, Ava Sadi, Sven Blokland, Richard Voorzaat, Lam Le, Remko van
   der Vlugt, Theo Schouten, Mandy Jongeneelen, Lisa Tostanoski, Noe
   Mercado, and Katherine McMahan for generous advice and assistance.
CR Abbink P, 2007, J VIROL, V81, P4654, DOI 10.1128/JVI.02696-06
   Algaissi Abdullah, 2020, Methods Mol Biol, V2099, P107, DOI 10.1007/978-1-0716-0211-9_9
   Alharbi NK, 2017, VACCINE, V35, P3780, DOI 10.1016/j.vaccine.2017.05.032
   Anywaine Z, 2019, J INFECT DIS, V220, P46, DOI 10.1093/infdis/jiz070
   Baden LR, 2016, ANN INTERN MED, V164, P313, DOI 10.7326/M15-0880
   Baden LR, 2013, J INFECT DIS, V207, P240, DOI 10.1093/infdis/jis670
   Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/s0140-6736(18)31364-3, 10.1016/S0140-6736(18)31364-3]
   Barouch DH, 2013, J INFECT DIS, V207, P248, DOI 10.1093/infdis/jis671
   Battles MB, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01708-9
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI 10.1038/s41586-020-2622-0
   Gilbert S. C, 2017, patent, Patent No. [WO 2018/215766 Al, 2018215766]
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hastie KM, 2017, SCIENCE, V356, P923, DOI 10.1126/science.aam7260
   Hierholzer J. C., 1996, P25, DOI 10.1016/B978-012465330-6/50003-8
   Honda-Okubo Y, 2015, J VIROL, V89, P2995, DOI 10.1128/JVI.02980-14
   Iwata-Yoshikawa N, 2014, J VIROL, V88, P8597, DOI 10.1128/JVI.00983-14
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Krarup A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9143
   Lindblad EB, 2004, IMMUNOL CELL BIOL, V82, P497, DOI 10.1111/j.0818-9641.2004.01286.x
   Liu JY, 2008, J VIROL, V82, P4844, DOI 10.1128/JVI.02616-07
   Liu P, 2018, KIDNEY INT, V94, P114, DOI 10.1016/j.kint.2018.01.029
   MAIZEL JV, 1968, VIROLOGY, V36, P115, DOI 10.1016/0042-6822(68)90121-9
   Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026
   Mercado N. B, 2020, NATURE, DOI [10.1038/s41586-020-2607-z, DOI 10.1038/S41586-020-2607-Z(]
   Millet Jean Kaoru, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.2035
   Milligan ID, 2016, JAMA-J AM MED ASSOC, V315, P1610, DOI 10.1001/jama.2016.4218
   Mutua G, 2019, J INFECT DIS, V220, P57, DOI 10.1093/infdis/jiz071
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Radosevic K, 2010, CLIN VACCINE IMMUNOL, V17, P1687, DOI 10.1128/CVI.00311-10
   Rutten L, 2020, CELL REP, V30, P4540, DOI 10.1016/j.celrep.2020.03.025
   Rutten L, 2018, CELL REP, V23, P584, DOI 10.1016/j.celrep.2018.03.061
   Sanders RW, 2002, J VIROL, V76, P8875, DOI 10.1128/JVI.76.17.8875-8889.2002
   Shukarev G, 2017, HUM VACC IMMUNOTHER, V13, P266, DOI 10.1080/21645515.2017.1264755
   Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0
   Sternberg A, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118056
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   van den Brink EN, 2005, J VIROL, V79, P1635, DOI 10.1128/JVI.79.3.1635-1644.2005
   van der Fits L, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0200-y
   vanDoremalen N, 2020, NATURE, DOI [10.1038/s41586-020-2608-y, DOI 10.1038/S41586-020-2608-Y(]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang FB, 2005, VACCINE, V23, P4500, DOI 10.1016/j.vaccine.2005.04.023
   Winslow RL, 2017, JAMA-J AM MED ASSOC, V317, P1074, DOI 10.1001/jama.2016.20644
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wunderlich K, 2018, patent, Patent No. [WO/2018/146205, 2018146205]
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zahn R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044115
NR 49
TC 0
Z9 0
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2059-0105
J9 NPJ VACCINES
JI npj Vaccines
PD SEP 28
PY 2020
VL 5
IS 1
AR 91
DI 10.1038/s41541-020-00243-x
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA NT9LK
UT WOS:000573260900001
PM 33083026
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tattan-Birch, H
   Perski, O
   Jackson, S
   Shahab, L
   West, R
   Brown, J
AF Tattan-Birch, Harry
   Perski, Olga
   Jackson, Sarah
   Shahab, Lion
   West, Robert
   Brown, Jamie
TI COVID-19, smoking, vaping and quitting: a representative population
   survey in England
SO ADDICTION
LA English
DT Article; Early Access
DE Coronavirus; COVID-19; e-cigarettes; quitting; SARS-CoV-2; smoking;
   smoking cessation; vaping
ID CIGARETTE; NICOTINE
AB Aims To estimate (1) associations between self-reported COVID-19, hand-washing, smoking status, e-cigarette use and nicotine replacement therapy (NRT) use and (2) the extent to which COVID-19 has prompted smoking and vaping quit attempts and more smoking inside the home. Design Cross-sectional household surveys. Setting and participants A representative sample of the population in England from April to May 2020. The sample included 3179 adults aged >= 18 years. Measurements Participants who reported that they definitely or thought they had coronavirus were classified as having self-reported COVID-19. Participants were asked how often they wash their hands after returning home, before preparing foods, before eating or before touching their face. They were also asked whether, due to COVID-19, they had (i) attempted to quit smoking, (ii) attempted to quit vaping and (iii) changed the amount they smoke inside the home. Findings Odds of self-reported COVID-19 were significantly greater among current smokers [20.9%, adjusted odds ratio (aOR) = 1.34, 95% confidence interval (CI) = 1.04-1.73] and long-term (> 1-year) ex-smokers (16.1%, aOR = 1.33, 95% CI = 1.05-1.68) compared with never smokers (14.5%). Recent (< 1-year) ex-smokers had non-significantly greater odds of self-reported COVID-19 (22.2%, aOR = 1.50, 95% CI = 0.85-2.53). Bayes factors indicated there was sufficient evidence to rule out large differences in self-reported COVID-19 by NRT use and medium differences by e-cigarette use. With the exception of hand-washing before face-touching, engagement in hand-washing behaviours was high (> 85%), regardless of nicotine use. A minority (12.2%) of quit attempts in the past 3 months were reportedly triggered by COVID-19, and approximately one in 10 current e-cigarette users reported attempting to quit vaping because of COVID-19. Conclusions In England, current smokers and long-term ex-smokers appear to have higher odds of self-reported COVID-19 compared with never smokers in adjusted analyses, but there were no large differences between people who used nicotine replacement therapy or e-cigarettes. Engagement in hand-washing appears to be high, regardless of nicotine or tobacco use. A minority of past-year smokers and current e-cigarette users, respectively, report attempting to quit smoking/vaping due to COVID-19.
C1 [Tattan-Birch, Harry; Perski, Olga; Jackson, Sarah; Shahab, Lion; West, Robert; Brown, Jamie] UCL, Inst Epidemiol & Hlth Care, London, England.
   [Tattan-Birch, Harry; Perski, Olga; Jackson, Sarah; Shahab, Lion; West, Robert; Brown, Jamie] SPECTRUM Consortium, London, England.
RP Tattan-Birch, H (corresponding author), Inst Epidemiol & Hlth Care, 1-19 Torrington Pl, London WC1E 7HB, England.
EM h.tattan-birch@ucl.ac.uk
RI ; Shahab, Lion/B-5835-2009; Brown, Jamie/F-4413-2011; West,
   Robert/B-5414-2009
OI Tattan-Birch, Harry/0000-0001-9410-8343; Shahab,
   Lion/0000-0003-4033-442X; Jackson, Sarah/0000-0001-5658-6168; Brown,
   Jamie/0000-0002-2797-5428; West, Robert/0000-0001-6398-0921
FU Cancer Research UK fund the Smoking Toolkit Study [C1417/A22962]; Public
   Health England [558585/180737]
FX Cancer Research UK fund the Smoking Toolkit Study and the salaries of
   O.P. and S.J. (C1417/A22962). H.T.B. holds a funded studentship from
   Public Health England (558585/180737). The funders had no role in the
   design and conduct of the study; collection, management, analysis and
   interpretation of the data; preparation, review or approval of the
   manuscript; and decision to submit the manuscript for publication.
CR Aldridge Robert W, 2020, Wellcome Open Res, V5, P88, DOI 10.12688/wellcomeopenres.15922.2
   Chalmers V., DAILY MAIL
   Denholm JT, 2010, MED J AUSTRALIA, V192, P84, DOI 10.5694/j.1326-5377.2010.tb03424.x
   Dienes Z, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00781
   Eaton DL, 2018, PUBLIC HEALTH CONSEQUENCES OF E-CIGARETTES, P55
   Farsalinos K, 2020, SMOKING VAPING HOSP, DOI [10.32388/Z69O8A.13, DOI 10.32388/Z69O8A.13]
   Farsalinos Konstantinos, 2020, Toxicol Rep, V7, P658, DOI 10.1016/j.toxrep.2020.04.012
   Feldman C, 2013, J INFECTION, V67, P169, DOI 10.1016/j.jinf.2013.05.004
   Fidler JA, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-479
   Heerfordt C, 2020, PUBLIC HEALTH, V183, P6, DOI 10.1016/j.puhe.2020.04.012
   Heneghan C, 2020, COVID 19 ADMISSIONS
   Hopkinson N. S., 2020, CURRENT TOBACCO SMOK, P44, DOI [10.1101/2020.05.18.20105288, DOI 10.1101/2020.05.18.20105288]
   Jackson SE, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.10161
   Jusot F, 2013, ADDICT BEHAV, V38, P2167, DOI 10.1016/j.addbeh.2012.12.011
   Kloc M, 2020, IMMUNOL LETT, V224, P28, DOI 10.1016/j.imlet.2020.06.002
   Kock L, 2019, ADDICTION, V114, P294, DOI 10.1111/add.14446
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Lakens D, 2020, J GERONTOL B-PSYCHOL, V75, P45, DOI 10.1093/geronb/gby065
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   McNeill A, 2020, VAPING ENGLAND 2020
   Miyara M, 2020, QEIOS, DOI [10.32388/WPP19W.4, DOI 10.32388/WPP19W.4, 10.32388/WPP19W.4.]
   Muus C, 2020, BIORXIV, DOI [10.1101/2020.04.19.049254, DOI 10.1101/2020.04.19.049254]
   Oakes JM, 2018, AM J PHYSIOL-REG I, V315, pR895, DOI 10.1152/ajpregu.00099.2018
   Perski O, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/19494
   Perski O, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01565-2
   PHE, 2020, DISP RISK OUTC COVID
   Prior R., CNN
   Public Health England, GOV UK NEWS
   R Development Core Team, 2008, R LANG ENV STAT COMP
   Rizzo A., WHAT YOU NEED KNOW S
   Samuel H., TELEGRAPH
   Shahab L, 2017, ANN INTERN MED, V166, P390, DOI 10.7326/M16-1107
   Simons D, 2020, ASS SMOKING STATUS S, DOI [10.32388/UJR2AW.3, DOI 10.32388/UJR2AW.3]
   Simons D, BMJ NEWS
   Tattan-Birch H, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.6981
   UK Government, COR COVID 19 WHAT YO
   West R, 2020, NAT HUM BEHAV, DOI 10.1038/s41562-020-0887-9
   Windsor-Shellard B, 2020, CORONAVIRUS COVID 19
NR 38
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0965-2140
EI 1360-0443
J9 ADDICTION
JI Addiction
DI 10.1111/add.15251
EA SEP 2020
PG 10
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA NT8UV
UT WOS:000573213100001
PM 32918300
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, YX
   Li, FC
   Zhang, Y
   Zhou, Y
   Tan, Y
   Chen, YZ
   Zhu, F
AF Wang, Yunxia
   Li, Fengcheng
   Zhang, Ying
   Zhou, Ying
   Tan, Ying
   Chen, Yuzong
   Zhu, Feng
TI Databases for the targeted COVID-19 therapeutics
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Letter
AB Many drugs are being developed and clinically tested for treating COVID-19. The knowledge of the targets and the properties of these drugs are highly useful for facilitating the drug repurposing, clinical evaluation, and drug and target discovery efforts. A variety of databases have provided the dedicated information sources and access facilities to support these efforts. The main features of these databases are described.
C1 [Wang, Yunxia; Li, Fengcheng; Zhang, Ying; Zhu, Feng] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China.
   [Zhou, Ying] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Peoples R China.
   [Tan, Ying] Tsinghua Univ, State Key Lab Chem Oncogen, Shenzhen, Peoples R China.
   [Chen, Yuzong] Natl Univ Singapore, Dept Pharm, Singapore 117543, Singapore.
RP Zhu, F (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China.; Chen, YZ (corresponding author), Natl Univ Singapore, Dept Pharm, Singapore 117543, Singapore.
EM phacyz@nus.edu.sg; zhufeng@zju.edu.cn
FU National Key R&D Program of China [2019YFA0905900, 2018YFC0910500];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81872798, 81973512, 91856126]; Shenzhen
   Development and Reform Committee [20151961, 2019156]; Shenzhen Science,
   Technology and Innovation Commission [2017B030314083,
   JCYJ20170413113448742]; Key R&D Program of Zhejiang Province
   [2020C03010]; Shenzhen Bay Laboratory [201901]; Singapore Academic Funds
   [R-148-000-273-114]; Leading Talent of "Ten Thousand Plan"-National
   High-Level Talents Special Support Plan
FX We acknowledge the support from the National Key R&D Program of China
   (2019YFA0905900 and 2018YFC0910500), National Natural Science Foundation
   of China (81872798, 81973512, and 91856126), Shenzhen Development and
   Reform Committee (20151961 and 2019156), Shenzhen Science, Technology
   and Innovation Commission Grant (2017B030314083 and
   JCYJ20170413113448742), Key R&D Program of Zhejiang Province
   (2020C03010), Shenzhen Bay Laboratory (no. 201901), Singapore Academic
   Funds (R-148-000-273-114), and Leading Talent of "Ten Thousand
   Plan"-National High-Level Talents Special Support Plan.
CR Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Hong JJ, 2020, BRIEF BIOINFORM, V21, P1437, DOI 10.1093/bib/bbz081
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou H, 2020, BRIT J PHARMACOL, V177, P3147, DOI 10.1111/bph.15092
NR 5
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV
PY 2020
VL 177
IS 21
BP 4999
EP 5001
DI 10.1111/bph.15234
EA SEP 2020
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OC7OD
UT WOS:000573209300001
PM 32845521
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ding, C
   Feng, XW
   Chen, YF
   Yuan, J
   Yi, P
   Li, YT
   Ni, Q
   Zou, RR
   Li, XH
   Sheng, JF
   Li, LJ
   Xu, KJ
AF Ding, Cheng
   Feng, Xuewen
   Chen, Yanfei
   Yuan, Jing
   Yi, Ping
   Li, Yongtao
   Ni, Qin
   Zou, Rongrong
   Li, Xiaohe
   Sheng, Jifang
   Li, Lanjuan
   Xu, Kaijin
TI Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance
   in Patients with Mild COVID-19: A Retrospective Cohort Study
SO INFECTIOUS DISEASES AND THERAPY
LA English
DT Article
DE Corticosteroid; COVID-19; RNA clearance; SARS-CoV-2
ID SARS; EXPOSURE
AB Introduction In December, 2019, an outbreak of the coronavirus disease 2019 (COVID-19), which was caused by a novel coronavirus, started in Wuhan, China. So far, there is limited clinical evidence on the effect of corticosteroid therapy for this disease. This study aims to investigate the association between corticosteroid therapy and the duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clearance among patients with mild COVID-19. Methods Patients with mild COVID-19 were enrolled from two medical centers in China between January 13, 2020 and February 29, 2020. Baseline characteristics and durations of RNA clearance were compared between the corticosteroid and non-corticosteroid therapy groups. The independent effects of corticosteroid therapy on the duration of RNA clearance were estimated by generalized linear models. Results Of 82 patients with a mild infection, 40 patients were male (48.8%), with a median age of 49 years (interquartile range, IQR 36-61). Among those patients, 36 patients (43.9%) received corticosteroid therapy. The adjusted multivariate models showed that the effects of corticosteroids were non-significant on the durations of onset to first RNA clearance [beta 2.48, 95% CI (95% confidence interval) - 0.42 to 5.38,P = 0.0926] and to persistent RNA clearance (beta 1.54, 95% CI - 1.41 to 4.48,P = 0.3016), and durations of therapy to first RNA clearance (beta 2.16, 95% CI - 0.56 to 4.89,P = 0.1184) and to persistent RNA clearance (beta 1.22, 95% CI - 1.52 to 3.95,P = 0.3787). Conclusions Corticosteroid therapy in patients with mild COVID-19 was not associated with the duration of SARS-CoV-2 clearance, suggesting that the use of corticosteroids may not be beneficial for patients with mild COVID-19 and should be prudently recommended in clinical practice. However, further studies are needed to verify the findings.
C1 [Ding, Cheng; Feng, Xuewen; Chen, Yanfei; Yi, Ping; Li, Yongtao; Ni, Qin; Sheng, Jifang; Li, Lanjuan; Xu, Kaijin] Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Natl Clin Res Ctr Infect Dis,Collaborat Innovat C, Natl Med Ctr Infect Dis,Coll Med,Affiliated Hosp, Hangzhou, Peoples R China.
   [Yuan, Jing; Zou, Rongrong; Li, Xiaohe] Shenzhen Third Peoples Hosp, Diag & Treatment Infect Dis Res Lab, Shenzhen, Peoples R China.
RP Li, LJ; Xu, KJ (corresponding author), Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Natl Clin Res Ctr Infect Dis,Collaborat Innovat C, Natl Med Ctr Infect Dis,Coll Med,Affiliated Hosp, Hangzhou, Peoples R China.
EM ljli@zju.edu.cn; zdyxyxkj@zju.edu.cn
FU National Science and Technology Major Project [2017ZX10105001,
   2017ZX10204401001002, 2018ZX10715014]; National Human Genetic Resources
   Sharing Service Platform [2005DKA21300]; Sanming Project of Medicine in
   Shenzhen [SZSM201512005]
FX Sponsorship for this study was funded by the National Science and
   Technology Major Project (Grant numbers 2017ZX10105001,
   2017ZX10204401001002, 2018ZX10715014); the National Human Genetic
   Resources Sharing Service Platform (Grant number 2005DKA21300); and the
   Sanming Project of Medicine in Shenzhen (Grant number SZSM201512005).
   The Rapid Service Fees were funded by the authors.
CR [Anonymous], 2020, 51 WHO
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616
   Carmo A, 2020, J MED VIROL, V92, P2227, DOI 10.1002/jmv.26103
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cohen J, 2020, CORONAVIRUS SEEMS UN
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Horby P, EFFECT DEXAMETHASONE, DOI 10.1101/2020.06.22.20137273
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kaufmann I, 2008, INTENS CARE MED, V34, P344, DOI 10.1007/s00134-007-0868-8
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Liu DR, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-30
   MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/bmj.m2422
   National Health Commission of China, 2020, DIAGN TREATM STRAT N
   National Institutes of Health, 2020, COR DIS 2019 COVID 1
   Rice JB, 2017, CLIN THER, V39, P2216, DOI 10.1016/j.clinthera.2017.09.011
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   So LKY, 2003, LANCET, V361, P1615, DOI 10.1016/S0140-6736(03)13265-5
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wan ES, 2012, AM J RESP CRIT CARE, V186, P1248, DOI 10.1164/rccm.201207-1280OC
   WHO, 2020, 22 WHO
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, 182 WHO
   World Health Organization, 2020, 39 WHO
   Wu Z, 2020, CHARACTERISTICS IMPO
   Xu K, 2020, ZHEJIANG DA XUE XUE, V49
   Zhang XJ, 2020, CELL METAB, V32, P176, DOI 10.1016/j.cmet.2020.06.015
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 35
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 2193-8229
EI 2193-6382
J9 INFECT DIS THER
JI Infect. Dis. Ther.
PD DEC
PY 2020
VL 9
IS 4
BP 943
EP 952
DI 10.1007/s40121-020-00337-y
EA SEP 2020
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA OU0TA
UT WOS:000573456700002
PM 32986226
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Balakrishnan, V
   Lakshminarayanan, K
AF Balakrishnan, Vijayakumar
   Lakshminarayanan, Karthik
TI Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease:
   Coronavirus Disease
SO INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS
LA English
DT Article; Early Access
DE Coronavirus; COVID-19; FDA approved drugs; High throughput virtual
   screening; Sincalide; Pentagastrin
ID INFECTION; OUTBREAK; CHILDREN
AB At the end of December 2019, a new strain of coronavirus was identified in the Wuhan city of Hubei province in China. Within a shorter period of time, an unprecedented outbreak of this strain was witnessed over the entire Wuhan city. This novel coronavirus strain was later officially renamed as COVID-19 (Coronavirus disease 2019) by the World Health Organization. The mode of transmission was human-to-human contact and hence resulted in a rapid surge across the globe where more than 24 million people have been infected with COVID-19. In the current scenario, finding potent drug candidates for the treatment of COVID-19 has emerged as the most challenging task for clinicians and researchers worldwide. Identification of new drugs and vaccine development may take from a few months to years based on the clinical trial processes. To overcome the several limitations involved in identifying and bringing out potent drug candidates for treating COVID-19, in the present study attempts were made to screen the FDA approved drugs using High Throughput Virtual Screening (HTVS). The COVID-19 main protease (COVID-19 Mpro) was chosen as the drug target for which the FDA approved drugs were initially screened with HTVS. The drug candidates that exhibited favorable docking score, energy, and emodel calculations were further taken for performing Induced Fit Docking (IFD) using Schrodinger's GLIDE. From the flexible docking results, the following four FDA approved drugs Sincalide, Pentagastrin, Ritonavir, and Phytonadione were identified. In particular, Sincalide and Pentagastrin can be considered potential key players for the treatment of COVID-19 disease.
C1 [Balakrishnan, Vijayakumar] Univ Sao Paulo, Sao Carlos Inst Phys IFSC, Ave Joao Dagnone,1100 Jardim Santa Angelina, BR-13563120 Sao Carlos, Brazil.
   [Lakshminarayanan, Karthik] ToxiVen Biotech, Kovaipudur 641042, Tamil Nadu, India.
RP Balakrishnan, V (corresponding author), Univ Sao Paulo, Sao Carlos Inst Phys IFSC, Ave Joao Dagnone,1100 Jardim Santa Angelina, BR-13563120 Sao Carlos, Brazil.
EM vijaybioscience@ifsc.usp.br
FU National Institute of Science and Technology-Biorational Control of
   Insects and Pests (INCT-CBIP) [FAPESP 2008/51859-5, CNPq 573742/2008-1];
   Sao Paulo State Foundation for Research (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2018/00492-4]
FX This work was supported by the National Institute of Science and
   Technology-Biorational Control of Insects and Pests (INCT-CBIP; Grant
   Numbers FAPESP 2008/51859-5 and CNPq 573742/2008-1), Sao Paulo State
   Foundation for Research (FAPESP; Grant Numbers 2018/00492-4. The authors
   would also like to thank Prof. Dr. Andre Luis Berteli Ambrosio and Prof.
   Dr. Rafael Victorio Carvalho Guido for the research support and software
   facility.
CR Chang Y.C., 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2, DOI 10.20944/PREPRINTS202002.0242.V2]
   Falsey AR, 1997, J AM GERIATR SOC, V45, P706, DOI 10.1111/j.1532-5415.1997.tb01474.x
   Graat JM, 2003, J CLIN EPIDEMIOL, V56, P1218, DOI 10.1016/S0895-4356(03)00171-9
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kim Jeong-Min, 2020, Osong Public Health Res Perspect, V11, P3, DOI 10.24171/j.phrp.2020.11.1.02
   Komarnytsky S, 2011, INT J OBESITY, V35, P236, DOI 10.1038/ijo.2010.192
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Mackay IM, 2012, VIRUSES-BASEL, V4, P637, DOI 10.3390/v4040637
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101578
   Vabret A, 2003, CLIN INFECT DIS, V36, P985, DOI 10.1086/374222
   Vabret A, 2008, J PAEDIATR CHILD H, V44, P176, DOI 10.1111/j.1440-1754.2007.01246.x
   van Elden LJR, 2004, J INFECT DIS, V189, P652, DOI 10.1086/381207
   Zhijian Xu, 2020, BIORXIV, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 17
TC 0
Z9 0
U1 6
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1573-3149
EI 1573-3904
J9 INT J PEPT RES THER
JI Int. J. Pept. Res. Ther.
DI 10.1007/s10989-020-10115-6
EA SEP 2020
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NU1PT
UT WOS:000573413700001
PM 33013255
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Caruso, A
   Caccuri, F
   Bugatti, A
   Zani, A
   Vanoni, M
   Bonfanti, P
   Cazzaniga, ME
   Perno, CF
   Messa, C
   Alberghina, L
AF Caruso, Arnaldo
   Caccuri, Francesca
   Bugatti, Antonella
   Zani, Alberto
   Vanoni, Marco
   Bonfanti, Paolo
   Cazzaniga, Marina E.
   Perno, Carlo F.
   Messa, Cristina
   Alberghina, Lilia
TI Methotrexate inhibits SARS-CoV-2 virus replication "in vitro"
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE COVID-19; drug repurposing; methotrexate; purine biosynthesis inhibition
AB In early 2020 the new respiratory syndrome COVID-19 (caused by the zoonotic SARS-CoV-2 virus) spread like a pandemic, starting from Wuhan, China, causing severe economic depression. Despite some advances in drug treatments of medical complications in the later stages of the disease, the pandemic's death toll is tragic, as no vaccine or specific antiviral treatment is currently available. By using a systems approach, we identify the host-encoded pathway, which provides ribonucleotides to viral RNA synthesis, as a possible target. We show that methotrexate, an FDA-approved inhibitor of purine biosynthesis, potently inhibits viral RNA replication, viral protein synthesis, and virus release. The effective antiviral methotrexate concentrations are similar to those used for established human therapies using the same drug. Methotrexate should be most effective in patients at the earliest appearance of symptoms to effectively prevent viral replication, diffusion of the infection, and possibly fatal complications.
C1 [Caruso, Arnaldo; Caccuri, Francesca; Bugatti, Antonella; Zani, Alberto] Univ Brescia, Sect Microbiol & Virol, Dept Mol & Translat Med, Sch Med, Brescia, Italy.
   [Vanoni, Marco; Alberghina, Lilia] Univ Milano Bicocca, Dept Biotechnol & Biosci, ISBE IT SYSBIO Ctr Syst Biol, Milan, Italy.
   [Bonfanti, Paolo; Cazzaniga, Marina E.; Messa, Cristina] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy.
   [Bonfanti, Paolo] Clin Infect Dis ASST Monza, Monza, Italy.
   [Cazzaniga, Marina E.] ASST Monza, Phase 1 Res Unit, Monza, Italy.
   [Perno, Carlo F.] Irccs Children Hosp Bambino Gesu, Rome, Italy.
   [Messa, Cristina] Tecnomed Fdn, Milan, Italy.
RP Messa, C (corresponding author), Univ Milano Bicocca, Sch Med & Surg, Tecnomed Fdn, Milan, Italy.
EM cristina.messa@unimib.it
OI VANONI, MARCO ERCOLE/0000-0002-8690-2587; Caccuri,
   Francesca/0000-0002-1923-9033
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Beck S., 2019, VIRUSES, V11, P4
   Bedoui Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205023
   Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603
   Chen J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2603-0
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Colleoni M, 2016, J CLIN ONCOL, V34, P3400, DOI 10.1200/JCO.2015.65.6595
   CRILLY A, 1995, J RHEUMATOL, V22, P224
   Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3
   Lauer S.A., 2020, ANN INTERN MED
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   SEIDEMAN P, 1993, BRIT J CLIN PHARMACO, V35, P409, DOI 10.1111/j.1365-2125.1993.tb04158.x
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Zhang RY, 2020, P NATL ACAD SCI USA, V117, P14857, DOI 10.1073/pnas.2009637117
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26512
EA SEP 2020
PG 6
WC Virology
SC Virology
GA NT6PA
UT WOS:000573059100001
PM 32926453
OA Other Gold
DA 2021-01-01
ER

PT J
AU Chen, S
   Liu, HT
   Li, T
   Huang, R
   Gui, R
   Zhang, JH
AF Chen, Sai
   Liu, Hanting
   Li, Tie
   Huang, Rong
   Gui, Rong
   Zhang, Junhua
TI Correlation analysis of coagulation dysfunction and liver damage in
   patients with novel coronavirus pneumonia: a single-center,
   retrospective, observational study
SO UPSALA JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Blood coagulation dysfunction; COVID-19; liver damage; pneumonia;
   SARS-CoV-2
AB Background The novel coronavirus disease 2019 (COVID-19) is currently breaking out worldwide. COVID-19 patients may have different degrees of coagulopathy, but the mechanism is not yet clear. We aimed to analyse the relationship between coagulation dysfunction and liver damage in patients with COVID-19. Methods A retrospective analysis of 74 patients with COVID-19 admitted to the First People's Hospital of Yueyang from 1 January to 30 March 2020 was carried out. According to the coagulation function, 27 cases entered the coagulopathy group and 47 cases entered the control group. A case control study was conducted to analyse the correlation between the occurrence of coagulation dysfunction and liver damage in COVID-19 patients. Results Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), markers of liver damage, were positively correlated with coagulopathy (p = 0.039, OR 2.960, 95% CI 1.055-8.304; andp = 0.028, OR 3.352, 95% CI 1.137-9.187). Alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (gamma-GT), and total bilirubin (TBIL) were not statistically correlated with coagulopathy. According to the diagnosis and treatment plan, the included cases were classified into mild, moderate, severe, and critical. The results showed that the occurrence of coagulation dysfunction had no statistical correlation with the severity of COVID-19. Conclusion Coagulation dysfunction in patients with COVID-19 is closely related to liver damage. A longer course of the disease may cause a vicious circle of coagulopathy and liver damage. Clinicians need to closely monitor coagulation and liver function tests and to give prophylactic or supportive therapy when needed.
C1 [Chen, Sai; Liu, Hanting; Huang, Rong; Gui, Rong; Zhang, Junhua] Cent South Univ, Xiangya Hosp 3, Dept Blood Transfus, Changsha, Peoples R China.
   [Li, Tie] First Peoples Hosp Yueyang, Dept Clin Lab, Yueyang, Peoples R China.
RP Gui, R; Zhang, JH (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Blood Transfus, Changsha, Peoples R China.
EM aguirong@163.com; xy3zhangjunhua@csu.edu.cn
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Boeckmans J, 2020, ARCH TOXICOL, V94, P1367, DOI 10.1007/s00204-020-02734-1
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Chapin JC, 2015, BLOOD REV, V29, P17, DOI 10.1016/j.blre.2014.09.003
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kazmi RS, 2015, SEMIN THROMB HEMOST, V41, P549, DOI 10.1055/s-0035-1556586
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   National Health Commission of the People's Republic of China, 2020, DIAGN TREATM COR DIS
   Pan XQ, 2020, TOXICOL LETT, V323, P48, DOI 10.1016/j.toxlet.2020.01.026
   Sonzogni A, 2020, LIVER INT, V40, P2110, DOI 10.1111/liv.14601
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 19
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300-9734
EI 2000-1967
J9 UPSALA J MED SCI
JI Ups. J. Med. Sci.
PD OCT 1
PY 2020
VL 125
IS 4
BP 293
EP 296
DI 10.1080/03009734.2020.1822960
EA SEP 2020
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA OI9HE
UT WOS:000573327400001
PM 32990149
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rahman, F
   Liu, STH
   Taimur, S
   Jacobs, S
   Sullivan, T
   Dunn, D
   Baneman, E
   Fuller, R
   Aberg, JA
   Bouvier, N
   Rana, MM
AF Rahman, Farah
   Liu, Sean T. H.
   Taimur, Sarah
   Jacobs, Samantha
   Sullivan, Timothy
   Dunn, Dallas
   Baneman, Emily
   Fuller, Risa
   Aberg, Judith A.
   Bouvier, Nicole
   Rana, Meenakshi M.
TI Treatment with convalescent plasma in solid organ transplant recipients
   with COVID-19: Experience at large transplant center in New York City
SO CLINICAL TRANSPLANTATION
LA English
DT Article; Early Access
DE infection and infectious agents; infection and infectious agents;
   transfusion; viral
ID THERAPY
AB Solid organ transplant (SOT) recipients may be at higher risk for poor outcomes with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Convalescent plasma is an investigational therapy that may benefit immunosuppressed patients by providing passive immunity. Convalescent plasma was administered to hospitalized patients with coronavirus disease-2019 (COVID-19) at an academic transplant center in New York City. Eligible patients were hospitalized and required to have positive nasopharyngeal polymerase chain reaction (PCR) diagnosis of SARS-CoV-2 infection, be at least 18 years old, and have either dyspnea, blood oxygen saturation <= 93% on ambient air, respiratory frequency >= 30 breaths/min, partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, or lung infiltrates > 50%. Thirteen SOT recipients received convalescent plasma from April 9, 2020, to May 17, 2020. The median time from symptom onset to plasma infusion was 8 days. Eight of 13 patients (62%) had de-escalating oxygenation support by day 7 post-convalescent plasma. Nine (69%) patients were discharged, 1 (7%) patients remain hospitalized, and 3 (23%) patients died. This series supports the need for additional studies on convalescent plasma use in SOT recipients with COVID-19 to better determine efficacy and identify patients who are likely to benefit.
C1 [Rahman, Farah; Liu, Sean T. H.; Taimur, Sarah; Jacobs, Samantha; Sullivan, Timothy; Dunn, Dallas; Baneman, Emily; Fuller, Risa; Aberg, Judith A.; Bouvier, Nicole; Rana, Meenakshi M.] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, One Gustave L Levy Pl, New York, NY 10029 USA.
RP Rahman, F (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, One Gustave L Levy Pl, New York, NY 10029 USA.
EM farah.rahman@mssm.edu
OI Rana, Meenakshi M./0000-0001-9366-5359; Rahman,
   Farah/0000-0001-8696-8730; Sullivan, Timothy/0000-0001-6465-3586
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   [Anonymous], 2020, REMD FACT SHEET
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Cravedi P, 2020, AM J TRANSPLANT, V20, P3140, DOI 10.1111/ajt.16185
   Hung IFN, 2013, CHEST, V144, P712, DOI 10.1378/chest.13-0571
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Kotton CN, 2018, TRANSPLANTATION, V102, P900, DOI 10.1097/TP.0000000000002191
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Rajendran K, 2020, J MED VIROL, V92, P1475, DOI 10.1002/jmv.25961
   Rosenberg ES, 2020, JAMA
   Salazar E, 2020, TREATM COVID 19 PATI
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Snydman D R, 2001, Transpl Infect Dis, V3 Suppl 2, P6, DOI 10.1034/j.1399-3062.2001.00002.x
   Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600
   World Health Organization, 2020, WHO TIM COVID 19
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 19
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
EI 1399-0012
J9 CLIN TRANSPLANT
JI Clin. Transplant.
AR e14089
DI 10.1111/ctr.14089
EA SEP 2020
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA NT6ZV
UT WOS:000573087200001
PM 32918761
OA Bronze
DA 2021-01-01
ER

PT J
AU Brussow, H
AF Brussow, Harald
TI Efforts towards aCOVID-19 vaccine
SO ENVIRONMENTAL MICROBIOLOGY
LA English
DT Article
AB To many scientists and political authorities, the development of a vaccine against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be the way to restore normality to civil life in this time of a devastating pandemic. Expectations for a vaccine are high while the case numbers continue to rise. As of mid-August 2020, more than 20 million people have been infected and more than 760 000 lives have been lost worldwide. The threat of this virus to health, the economy and to society is so great that the wish for a fast track vaccine is understandable, but how realistic is it? This survey article tries to give an overview of vaccine candidates in development, including preclinical and clinical testing, and it mentions some of the societal problems of vaccine acceptance.
C1 [Brussow, Harald] Katholieke Univ Leuven, Lab Gene Technol, Dept Biosyst, Leuven, Belgium.
RP Brussow, H (corresponding author), Katholieke Univ Leuven, Lab Gene Technol, Dept Biosyst, Leuven, Belgium.
EM haraldbruessow@yahoo.com
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 2020, ECONOMIST
   Ball P, 2020, NATURE, V581, P371, DOI 10.1038/d41586-020-01452-z
   Berg MK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc1463
   Bloom BR, 2020, NEW ENGL J MED, V383, P676, DOI 10.1056/NEJMe2024894
   Callaway E, 2020, NATURE, V584, P334, DOI 10.1038/d41586-020-02386-2
   Case J.B., 2020, CELL HOST MICROBE, DOI [10.1016/j.chom.2020.07.018, DOI 10.1016/J.CH0M.2020.07.018]
   Cohen J., 2020, SCIENCE, DOI [10.1126/science.abc0006, DOI 10.1126/SCIENCE.ABC0006]
   Cohen J, 2020, SCIENCE, V368, P456, DOI 10.1126/science.368.6490.456
   Cohen J, 2020, SCIENCE, V368, P14, DOI 10.1126/science.368.6486.14
   Corbett Kizzmekia S, 2020, bioRxiv, DOI 10.1101/2020.06.11.145920
   Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   Dagotto G, 2020, CELL HOST MICROBE, V28, P364, DOI 10.1016/j.chom.2020.08.002
   de Chaisemartin Clement, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1223
   Deming ME, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2020076
   Erasmus JH, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc9396
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Fuller DH, 2020, NEW ENGL J MED, V382, P2469, DOI 10.1056/NEJMcibr2009737
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gostin LO, 2020, LANCET, V396, P293, DOI 10.1016/S0140-6736(20)31527-0
   Hamiel U, 2020, JAMA-J AM MED ASSOC, V323, P2340, DOI 10.1001/jama.2020.8189
   Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026
   Heaton PM, 2020, NEW ENGL J MED, V383, P1986, DOI 10.1056/NEJMe2025111
   Jackson L. A, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2022483, DOI 10.1056/NEJM0A2022483, 10.1056/NEJMoa2022483.]
   Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1
   Khamsi R, 2020, NATURE, V580, P578, DOI 10.1038/d41586-020-01063-8
   Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019
   Lane R, 2020, LANCET, V395, P1247, DOI 10.1016/S0140-6736(20)30796-0
   Lurie N, 2020, JAMA-J AM MED ASSOC, V324, P439, DOI 10.1001/jama.2020.12461
   Mello MM, 2020, NEW ENGL J MED, V383, P1296, DOI 10.1056/NEJMp2020926
   Mercado NB, 2020, NATURE, DOI 10.1038/s41586-020-2607-z
   Modjarrad K, 2020, LANCET INFECT DIS, V20, P760, DOI 10.1016/S1473-3099(20)30317-0
   Moorlag Simone J C F M, 2020, Cell Rep Med, V1, P100073, DOI 10.1016/j.xcrm.2020.100073
   O'Callaghan KP, 2020, JAMA-J AM MED ASSOC, V324, P437, DOI 10.1001/jama.2020.12190
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Thorp HH, 2020, SCIENCE, V369, P885, DOI 10.1126/science.abe3147
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008
   World Health Organization, 2020, ACC SAF EFF COVID 19
   Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   ZHANG NN, 2020, THERMOSTABLE MRNA VA, V182, P1271, DOI DOI 10.1016/J.CELL.2020.07.024
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 44
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-2912
EI 1462-2920
J9 ENVIRON MICROBIOL
JI Environ. Microbiol.
PD OCT
PY 2020
VL 22
IS 10
BP 4071
EP 4084
DI 10.1111/1462-2920.15225
EA SEP 2020
PG 14
WC Microbiology
SC Microbiology
GA OD2TA
UT WOS:000573010200001
PM 32893468
OA Bronze
DA 2021-01-01
ER

PT J
AU Neto, AGM
   Lo, KB
   Wattoo, A
   Salacup, G
   Pelayo, J
   DeJoy, R
   Bhargav, R
   Gul, F
   Peterson, E
   Albano, J
   Patarroyo-Aponte, G
   Rangaswami, J
   Azmaiparashvili, Z
AF Goncalves Mendes Neto, Alvaro
   Lo, Kevin Bryan
   Wattoo, Ammaar
   Salacup, Grace
   Pelayo, Jerald
   DeJoy, Robert, III
   Bhargav, Ruchika
   Gul, Fahad
   Peterson, Eric
   Albano, Jeri
   Patarroyo-Aponte, Gabriel
   Rangaswami, Janani
   Azmaiparashvili, Zurab
TI Bacterial infections and patterns of antibiotic use in patients with
   COVID-19
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE antibiotic use; coinfections; inflammation; pandemics; SARS-CoV-2
ID INFLAMMATION; PNEUMONIA
AB Bacterial coinfection is associated with poor outcomes in patients with viral pneumonia, but data on its role in the mortality of patients with coronavirus disease 2019 (COVID-19) is limited. This is a single-center retrospective analysis of 242 patients with confirmed COVID-19 admitted to both intensive care and non-intensive care settings. Bacterial coinfection was determined by the presence of characteristic clinical features and positive culture results. Multivariable logistic regression was used to analyze the association of concomitant bacterial infection with inpatient death after adjusting for demographic factors and comorbidities. Antibiotic use pattern was also determined. Bacterial coinfection was detected in 46 (19%) patients. Genitourinary source was the most frequent, representing 57% of all coinfections. The overall mortality rate was 21%. Concomitant bacterial infections were independently associated with increased inpatient mortality (OR, 5.838; 95% CI, 2.647-12.876). Patients with bacterial coinfection were relatively older (71.35 +/- 11.20 vs 64.78 +/- 15.23;P = .006). A total of 67% of patients received antibiotic therapy, yet 72% did not have an obvious source of bacterial infection. There was a significantly higher rate of inpatient mortality in patients who received antibiotics compared to those who did not (30% vs 5%;P < .0001). Bacterial coinfection in COVID-19 is associated with increased mortality.
C1 [Goncalves Mendes Neto, Alvaro; Lo, Kevin Bryan; Wattoo, Ammaar; Salacup, Grace; Pelayo, Jerald; DeJoy, Robert, III; Bhargav, Ruchika; Gul, Fahad; Peterson, Eric; Albano, Jeri; Patarroyo-Aponte, Gabriel; Rangaswami, Janani; Azmaiparashvili, Zurab] Albert Einstein Med Ctr Philadelphia, Dept Med, Philadelphia, PA USA.
   [Patarroyo-Aponte, Gabriel; Rangaswami, Janani] Thomas Jefferson Univ, Sidney Kimmel Coll, Philadelphia, PA 19107 USA.
   [Patarroyo-Aponte, Gabriel] Albert Einstein Med Ctr Philadelphia, Div Pulm & Crit Care & Sleep Med, Philadelphia, PA USA.
RP Neto, AGM (corresponding author), Albert Einstein Med Ctr, 5501 Old York Rd, Philadelphia, PA 19141 USA.
EM GoncalvA@einstein.edu
OI Lo, Kevin Bryan/0000-0001-7088-6677; Salacup, Grace/0000-0002-0003-2040
CR Abou-Ismail MY, 2020, THROMB RES, V194, P101, DOI 10.1016/j.thromres.2020.06.029
   Ambite I, 2017, URINARY TRACT INFECT, P523
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Barrasa H, 2020, ANAESTH CRIT CARE PA, V39, P553, DOI 10.1016/j.accpm.2020.04.001
   Casqueiro Juliana, 2012, Indian J Endocrinol Metab, V16 Suppl 1, pS27, DOI 10.4103/2230-8210.94253
   Cawcutt K, 2017, CURR OPIN CRIT CARE, V23, P385, DOI 10.1097/MCC.0000000000000435
   Chamarthi B, 2011, AM J HYPERTENS, V24, P1143, DOI 10.1038/ajh.2011.113
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Colwell JA, 1999, DIABETES CARE, V22, P1927, DOI 10.2337/diacare.22.12.1927
   de Lucena TMC, 2020, DIABETES METAB SYND, V14, P597, DOI 10.1016/j.dsx.2020.05.025
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   Dharmashankar K, 2010, CURR HYPERTENS REP, V12, P448, DOI 10.1007/s11906-010-0150-2
   Diamanti AP, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093330
   Dooley KE, 2009, LANCET INFECT DIS, V9, P737, DOI 10.1016/S1473-3099(09)70282-8
   Fatkhullina AR, 2016, BIOCHEMISTRY-MOSCOW+, V81, P1358, DOI 10.1134/S0006297916110134
   Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC
   Hamdan HZ, 2015, ANN CLIN MICROB ANTI, V14, DOI 10.1186/s12941-015-0082-4
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iannelli A, 2020, OBES SURG, V30, P4615, DOI 10.1007/s11695-020-04734-7
   Lansbury L, 2020, J INFECTION, V81, P266, DOI 10.1016/j.jinf.2020.05.046
   Meftahi GH, 2020, INFLAMM RES, V69, P825, DOI 10.1007/s00011-020-01372-8
   Mo Pingzheng, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa270
   Morris DE, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01041
   Phosat C, 2017, BMC ENDOCR DISORD, V17, DOI 10.1186/s12902-017-0189-z
   Prasso JE, 2017, CLIN CHEST MED, V38, P127, DOI 10.1016/j.ccm.2016.11.006
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Siripanthong B, 2020, HEART RHYTHM, V17, P1463, DOI 10.1016/j.hrthm.2020.05.001
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Veronese N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00170
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhao DH, 2020, CLIN INFECT DIS, V71, P756, DOI 10.1093/cid/ciaa247
NR 37
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26441
EA SEP 2020
PG 7
WC Virology
SC Virology
GA NT6GH
UT WOS:000573036400001
PM 32808695
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Taghiloo, S
   Aliyali, M
   Abedi, S
   Mehravaran, H
   Sharifpour, A
   Zaboli, E
   Eslami-Jouybari, M
   Ghasemian, R
   Vahedi-Larijani, L
   Hossein-Nattaj, H
   Amjadi, O
   Rezazadeh, H
   Ajami, A
   Asgarian-Omran, H
AF Taghiloo, Saeid
   Aliyali, Masoud
   Abedi, Siavash
   Mehravaran, Hossein
   Sharifpour, Ali
   Zaboli, Ehsan
   Eslami-Jouybari, Mohammad
   Ghasemian, Roya
   Vahedi-Larijani, Laleh
   Hossein-Nattaj, Hadi
   Amjadi, Omolbanin
   Rezazadeh, Hadiseh
   Ajami, Abolghasem
   Asgarian-Omran, Hossein
TI Apoptosis and immunophenotyping of peripheral blood lymphocytes in
   Iranian COVID-19 patients: Clinical and laboratory characteristics
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE apoptosis; COVID-19; Iran; lymphocyte subpopulations; lymphopenia
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS; PNEUMONIA
AB A novel member of human coronavirus, named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been recently recognized in China and rapidly spread worldwide. Studies showed the decreasing of peripheral blood lymphocytes in a majority of patients. In this study, we have reported the clinical features, laboratory characteristics, the frequency of peripheral blood lymphocyte subpopulations, and their apoptosis pattern in Iranian coronavirus infectious disease (COVID-19) patients. Demographic and clinical data of 61 hospitalized confirmed cases with COVID-19 at Imam Khomeini Hospital were collected and analyzed. Peripheral blood mononuclear cells were isolated from all samples and the apoptosis pattern was evaluated using Annexin V/propidium iodide method. The frequency of lymphocyte subsets, including T-CD4(+), T-CD8(+), NK, B cells, and monocytes, was measured in all patients and 31 controls by flow cytometry. Our findings demonstrated that the percentage of lymphocytes, CD4(+), and CD8(+)T cells were decreased in COVID-19 patients compared with the control group. Regarding the clinical severity, the number of lymphocytes, CD4(+), CD8(+)T cells, and NK cells were also decreased in severe cases when compared with mild cases. Finally, our data have also indicated the increase in apoptosis of mononuclear cells from COVID-19 patients which was more remarkable in severe clinical cases. The frequency of immune cells is a useful indicator for prediction of severity and prognosis of COVID-19 patients. These results could help to explain the immunopathogenesis of SARS-CoV-2 and introducing novel biomarkers, therapeutic strategies, and vaccine candidates.
C1 [Taghiloo, Saeid; Hossein-Nattaj, Hadi; Ajami, Abolghasem; Asgarian-Omran, Hossein] Mazandaran Univ Med Sci, Sch Med, Dept Immunol, Sari 481751665, Iran.
   [Taghiloo, Saeid] Mazandaran Univ Med Sci, Student Res Comm, Deputy Res & Technol, Sari, Iran.
   [Aliyali, Masoud; Abedi, Siavash; Mehravaran, Hossein; Sharifpour, Ali; Asgarian-Omran, Hossein] Mazandaran Univ Med Sci, Sch Med, Pulm & Crit Care Div, Dept Internal Med, Sari, Iran.
   [Zaboli, Ehsan; Eslami-Jouybari, Mohammad; Amjadi, Omolbanin; Rezazadeh, Hadiseh] Mazandaran Univ Med Sci, Noncommunicable Dis Inst, Gastrointestinal Canc Res Ctr, Sari, Iran.
   [Ghasemian, Roya] Mazandaran Univ Med Sci, Sch Med, Dept Infect Dis & Trop Med, Sari, Iran.
   [Vahedi-Larijani, Laleh] Mazandaran Univ Med Sci, Dept Pathol, Sari, Iran.
   [Asgarian-Omran, Hossein] Mazandaran Univ Med Sci, Sch Med, Immunogenet Res Ctr, Sari, Iran.
RP Ajami, A; Asgarian-Omran, H (corresponding author), Mazandaran Univ Med Sci, Sch Med, Dept Immunol, Sari 481751665, Iran.
EM ajami36@gmail.com; asgarianhossein@yahoo.com
OI Reis, AlessanRSS/0000-0001-8486-7469
FU Mazandaran University of Medical Sciences [1398.7273]
FX Mazandaran University of Medical Sciences, Grant/Award Number: 1398.7273
CR Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Bermejo-Martin JF, 2020, J INFECTION, V80, pE23, DOI 10.1016/j.jinf.2020.02.029
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380
   Cui W, 2003, CLIN INFECT DIS, V37, P857, DOI 10.1086/378587
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Fei J, 2020, REDUCTION LYMPHOCYTE
   Ganji A, 2020, BLOOD CELL MOL DIS, V83, DOI 10.1016/j.bcmd.2020.102437
   He RY, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104361
   He ZP, 2005, INT J INFECT DIS, V9, P323, DOI 10.1016/j.ijid.2004.07.014
   Hou J., 2020, SSRN, V3550044, P1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Rokni M, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2107
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang M, 2004, INT J MOL MED, V14, P311
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zheng H, 2020, CURR EYE RES, V45, P1043, DOI [10.1080/02713683.2020.1716986, 10.1080/10408398.2020.1740645]
NR 24
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26505
EA SEP 2020
PG 10
WC Virology
SC Virology
GA NT7CN
UT WOS:000573094200001
PM 32910458
OA Bronze
DA 2021-01-01
ER

PT J
AU Zhou, W
   Xu, XM
   Chang, ZG
   Wang, H
   Zhong, XF
   Tong, XL
   Liu, TT
   Li, YM
AF Zhou, Wei
   Xu, Xiaomao
   Chang, Zhigang
   Wang, He
   Zhong, Xuefeng
   Tong, Xunliang
   Liu, Taotao
   Li, Yanming
TI The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients
   with COVID-19
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE antibody response; COVID-19; dynamic changes; recovery stage
ID ANTIBODY-RESPONSES; CORONAVIRUS
AB Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a worldwide pandemic since it emerged in December 2019. Previous studies have reported rapid antibody response to SARS-CoV-2 in the first 2 to 3 weeks after symptom onset. Here, we retrospectively described the dynamic changes of serum immunoglobulin M (IgM) and IgG specifically against SARS-CoV-2 in later weeks (mainly 4-10 weeks) in 97 hospitalized patients with COVID-19. We observed that serum IgM and IgG, especially in patients with moderate-to-high levels, declined significantly between week 4 to 10 after illness onset. Notably, IgG levels in high percentage of patients (77.5%, 31 of 40) rapidly declined by half, from 212.5 (range, 163.7-420.3) to 96.3 (range, 75.0-133.4) AU/mL, within 1 to 2 weeks in the second month and then sustained at around 100 AU/mL until discharge from hospital. Significant reduction of IgM was also observed as SARS-CoV-2 nucleic acid turned negative (P = .002). In the recovery stage, serum IgG declined significantly (early vs late recovery stage, n = 16,P = .003) with a median reduction of 50.0% (range, 3.7%-77.0%). Our results suggested that the decline of IgM may be an indicator of virus clearance and recovered patients may have a robust immunity against reinfection within at least 3 months after illness onset. Yet, the rapid reduction of IgG by half rises serious concerns on the robustness and sustainability of the humoral immune response in the period after discharge, which is crucial for immunity strategy and developing a vaccine.
C1 [Zhou, Wei; Xu, Xiaomao; Wang, He; Zhong, Xuefeng; Tong, Xunliang; Li, Yanming] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Dept Resp & Crit Care Med,Natl Ctr Gerontol, 1 Dahua Rd, Beijing 100730, Peoples R China.
   [Chang, Zhigang; Liu, Taotao] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Dept Surg Intens Care Med,Natl Ctr Gerontol, Beijing, Peoples R China.
RP Li, YM (corresponding author), Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Dept Resp & Crit Care Med,Natl Ctr Gerontol, 1 Dahua Rd, Beijing 100730, Peoples R China.
EM liyanming2632@bjhmoh.cn
FU Special Foundation for National Science and Technology Basic Research
   Program of China [2017FY101200]
FX Special Foundation for National Science and Technology Basic Research
   Program of China, Grant/Award Number: 2017FY101200
CR Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Espejo AP, 2020, AM J CLIN PATHOL, V154, P293, DOI 10.1093/ajcp/aqaa112
   Hou H, 2020, CLIN EXP IMMUNOL, V201, P76, DOI 10.1111/cei.13450
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ko JH, 2017, DIAGN MICR INFEC DIS, V89, P106, DOI 10.1016/j.diagmicrobio.2017.07.006
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lou B, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00763-2020
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Payne DC, 2016, EMERG INFECT DIS, V22, P1824, DOI 10.3201/eid2210.160706
   Shi YL, 2004, J CLIN VIROL, V31, P66, DOI 10.1016/j.jcv.2004.05.006
   Sun BQ, 2020, EMERG MICROBES INFEC, V9, P940, DOI 10.1080/22221751.2020.1762515
   Taylor A, 2015, IMMUNOL REV, V268, P340, DOI 10.1111/imr.12367
   Wang Xiaoli, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa721
   Wang YW, 2020, J CHROMATOGR A, V1623, DOI 10.1016/j.chroma.2020.461171
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 22
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26353
EA SEP 2020
PG 10
WC Virology
SC Virology
GA NT6EV
UT WOS:000573032600001
PM 32706425
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Hazan, J
   Congdon, L
   Sathanandan, S
   Grewal, P
AF Hazan, Jemma
   Congdon, Lawrence
   Sathanandan, Shivanthi
   Grewal, Pardeep
TI An analysis of initial service transformation in response to the
   COVID-19 pandemic in two inner-city substance misuse services
SO JOURNAL OF SUBSTANCE USE
LA English
DT Article; Early Access
DE COVID-19; substance misuse; services; opioid substitution therapy
AB Background The COVID-19 pandemic presents challenges to substance misuse services. Patients face a higher risk of infection and transmission to others. Services were required to reconfigure quickly in response to the government lockdown. These changes had to be completed before national guidance was published. Method To examine the strategy and operational delivery of two London boroughs and measure how convergent they were with national guidelines. Referral data were analyzed and compared to a similar time frame pre-COVID-19. Results Both services adopted similar strategies and pace of change. Longer supplies of opiate substitution therapy (OST) were prescribed, with less restrictive arrangements for collection. There was an increase in opiate assessments and a reduction in alcohol assessments. There was no overall increase in mortality. There was minor deviation from national guidance when it was initially published. Conclusions The services were well equipped to respond to the rapid changes demanded during early lockdown. Reduced restrictions in OST may not be associated with negative service or patient outcomes. The move to remote consultations and home working are likely to have value in substance misuse services after the pandemic. The long-term impact of lockdown presents uncertainties in terms of clinical safety and requires evaluation.
C1 [Hazan, Jemma; Grewal, Pardeep] Barnet & Haringey Mental Hlth Trust, Addict Psychiat, London, England.
   [Congdon, Lawrence; Sathanandan, Shivanthi] Camden & Islington Fdn Trust, Addict Psychiat, London, England.
RP Grewal, P (corresponding author), Barnet & Haringey Mental Hlth Trust, London, England.
EM pardeep.grewal@nhs.net
CR Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Department of Health & Social Care, 2020, COVID 19 GUID COMM P
   Dunn P., 2020, COVID 19 POLICY TRAC
   European Monitoring Centre for Drug Addiction, 2020, IMPL COVID 19 POPL W
   Flanagan SM, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-92
   Haringey Council, 2019, HAR GLANC
   Holmes L., 2020, DRINKING LOCKDOWN HE
   Kamara M., 2017, ISLINGTON HARINGEY J
   Karnad A., 2019, PROFILE POVERTY INEQ
   Ministry of Housing Communities & Local Government, 2019, ENGL IND DEPR 2019
   Mitchell CA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012823
   National Institute of Clinical Excellence, 2007, METH BUPR MAN OP DEP
   Royal College of Psychiatrists, 2020, COVID 19 WORK COMM M
NR 13
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1465-9891
EI 1475-9942
J9 J SUBST USE
JI J. Subst. Use
DI 10.1080/14659891.2020.1820089
EA SEP 2020
PG 5
WC Substance Abuse
SC Substance Abuse
GA NT7MG
UT WOS:000573119500001
OA Bronze
DA 2021-01-01
ER

PT J
AU Hess, CB
   Buchwald, ZS
   Stokes, W
   Nasti, TH
   Switchenko, JM
   Weinberg, BD
   Steinberg, JP
   Godette, KD
   Murphy, D
   Ahmed, R
   Curran, WJ
   Khan, MK
AF Hess, Clayton B.
   Buchwald, Zachary S.
   Stokes, William
   Nasti, Tahseen H.
   Switchenko, Jeffrey M.
   Weinberg, Brent D.
   Steinberg, James P.
   Godette, Karen D.
   Murphy, David
   Ahmed, Rafi
   Curran, Walter J., Jr.
   Khan, Mohammad K.
TI Low-dose whole-lung radiation for COVID-19 pneumonia: Planned day 7
   interim analysis of a registered clinical trial
SO CANCER
LA English
DT Article
DE coronavirus; coronavirus disease 2019 (COVID-19); immune modulation;
   pandemic; radiation
AB Background Individuals of advanced age with comorbidities face a higher risk of death from coronavirus disease 2019 (COVID-19), especially once they are ventilator-dependent. Respiratory decline in patients with COVID-19 is precipitated by a lung-mediated aberrant immune cytokine storm. Low-dose lung radiation was used to treat pneumonia in the pre-antibiotic era. Radiation immunomodulatory effects may improve outcomes for select patients with COVID-19. Methods A single-institution trial evaluating the safety and efficacy of single-fraction, low-dose whole-lung radiation for patients with COVID-19 pneumonia is being performed for the first time. This report describes outcomes of a planned day 7 interim analysis. Eligible patients were hospitalized, had radiographic consolidation, required supplemental oxygen, and were clinically deteriorating. Results Of 9 patients screened, 5 were treated with whole-lung radiation on April 24 until April 28 2020, and they were followed for a minimum of 7 days. The median age was 90 years (range, 64-94 years), and 4 were nursing home residents with multiple comorbidities. Within 24 hours of radiation, 3 patients (60%) were weaned from supplemental oxygen to ambient air, 4 (80%) exhibited radiographic improvement, and the median Glasgow Coma Scale score improved from 10 to 14. A fourth patient (80% overall recovery) was weaned from oxygen at hour 96. The mean time to clinical recovery was 35 hours. There were no acute toxicities. Conclusions In a pilot trial of 5 oxygen-dependent elderly patients with COVID-19 pneumonia, low-dose whole-lung radiation led to rapid improvements in clinical status, encephalopathy, and radiographic consolidation without acute toxicity. Low-dose whole-lung radiation appears to be safe, shows early promise of efficacy, and warrants further study. Lay Summary
   Researchers at Emory University report preliminary safety outcomes for patients treated with low-dose lung irradiation for coronavirus disease 2019 (COVID-19) pneumonia. Five residents of nursing or group homes were hospitalized after testing positive for COVID-19. Each had pneumonia visible on a chest x-ray, required supplemental oxygen, and experienced a clinical decline in mental status or in work of breathing or a prolonged or escalating supplemental oxygen requirement. A single treatment of low-dose (1.5-Gy) radiation to both lungs was delivered over the course of 10 to 15 minutes. There was no acute toxicity attributable to radiation therapy. Within 24 hours, 4 patients had rapidly improved breathing, and they recovered to room air at an average of 1.5 days (range, 3-96 hours). Three were discharged at a mean time of 12 days, and 1 was preparing for discharge. Blood tests and repeat imaging confirm that low-dose whole-lung radiation treatment appears safe for COVID-19 pneumonia. Further trials are warranted.
C1 [Hess, Clayton B.; Buchwald, Zachary S.; Stokes, William; Godette, Karen D.; Curran, Walter J., Jr.; Khan, Mohammad K.] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   [Hess, Clayton B.; Buchwald, Zachary S.; Stokes, William; Switchenko, Jeffrey M.; Godette, Karen D.; Ahmed, Rafi; Curran, Walter J., Jr.; Khan, Mohammad K.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   [Nasti, Tahseen H.; Ahmed, Rafi] Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.
   [Switchenko, Jeffrey M.] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA.
   [Weinberg, Brent D.] Emory Univ, Dept Diagnost Radiol, Atlanta, GA 30322 USA.
   [Steinberg, James P.] Emory Univ, Dept Infect Dis, Atlanta, GA 30322 USA.
   [Murphy, David] Emory Univ, Dept Pulm Crit Care, Atlanta, GA 30322 USA.
RP Khan, MK (corresponding author), Emory Univ Hosp, 1365 Clifton Rd NE, Atlanta, GA 30345 USA.
EM drkhurram2000@gmail.com
RI Weinberg, Brent D/E-8442-2010
OI Weinberg, Brent D/0000-0002-7992-1747; Switchenko,
   Jeffrey/0000-0002-5563-9325
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30
   CA138292] Funding Source: Medline
CR Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Calabrese Edward J., 2013, Yale Journal of Biology and Medicine, V86, P555
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   NAKAMURA N, 1990, RADIAT RES, V123, P224, DOI 10.2307/3577549
   Taylor E, 2015, BMC MED IMAGING, V15, DOI 10.1186/s12880-015-0103-y
   TEASDALE G, 1974, LANCET, V2, P81
NR 8
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD DEC 1
PY 2020
VL 126
IS 23
BP 5109
EP 5113
DI 10.1002/cncr.33130
EA SEP 2020
PG 5
WC Oncology
SC Oncology
GA OM5EW
UT WOS:000573065600001
PM 32986274
OA Green Accepted
DA 2021-01-01
ER

PT J
AU Sargsyan, K
   Lin, CC
   Chen, T
   Grauffel, C
   Chen, YP
   Yang, WZ
   Yuan, HS
   Lim, C
AF Sargsyan, Karen
   Lin, Chien-Chu
   Chen, Ting
   Grauffel, Cedric
   Chen, Yi-Ping
   Yang, Wei-Zen
   Yuan, Hanna S.
   Lim, Carmay
TI Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2
   domains by clinically safe Zn-ejectors
SO CHEMICAL SCIENCE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; PAPAIN-LIKE PROTEASE; DRUG; PROTEINS;
   DISULFIRAM; REACTIVITY
AB We present a near-term treatment strategy to tackle pandemic outbreaks of coronaviruses with no specific drugs/vaccines by combining evolutionary and physical principles to identify conserved viral domains containing druggable Zn-sites that can be targeted by clinically safe Zn-ejecting compounds. By applying this strategy to SARS-CoV-2 polyprotein-1ab, we predicted multiple labile Zn-sites in papain-like cysteine protease (PLpro), nsp10 transcription factor, and nsp13 helicase. These are attractive drug targets because they are highly conserved among coronaviruses and play vital structural/catalytic roles in viral proteins indispensable for virus replication. We show that five Zn-ejectors can release Zn(2+)from PL(pro)and nsp10, and clinically-safe disulfiram and ebselen can not only covalently bind to the Zn-bound cysteines in both proteins, but also inhibit PL(pro)protease. We propose combining disulfiram/ebselen with broad-spectrum antivirals/drugs to target different conserved domains acting at various stages of the virus life cycle to synergistically inhibit SARS-CoV-2 replication and reduce the emergence of drug resistance.
C1 [Sargsyan, Karen; Chen, Ting; Grauffel, Cedric; Lim, Carmay] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.
   [Lin, Chien-Chu; Chen, Yi-Ping; Yang, Wei-Zen; Yuan, Hanna S.] Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.
   [Lim, Carmay] Natl Tsing Hua Univ, Dept Chem, Hsinchu 300, Taiwan.
RP Lim, C (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.; Yuan, HS (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.; Lim, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu 300, Taiwan.
EM hanna@sinica.edu.tw; carmay@gate.sinica.edu.tw
RI Lim, Carmay/N-9648-2015
OI Lim, Carmay/0000-0001-9077-7769; Yuan, Hanna S./0000-0001-9671-6967
FU Academia SinicaAcademia Sinica - Taiwan [AS-CFII-108-102, AS-IA-107-L03,
   AS-IA-105-L04]; Ministry of Science and Technology, TaiwanMinistry of
   Science and Technology, Taiwan [MOST 109-3114-Y-001-001]; Academia
   Sinica Core Facility and Innovative Instrument Project
   [AS-CFII-108-107]; Ministry of Science Technology
   [MOST-107-2113-M-001-018]
FX The cell-based experiments were performed by Dr Jian-Jong Liang
   (jjliang1234@yahoo.com.tw) and Dr Chun-Che Liao
   (jfliao@ibms.sinica.edu.tw) in Dr Yi-Ling Lin's laboratory at the
   Institute of Biomedical Sciences (IBMS), Academia Sinica, Taipei,
   Taiwan. We thank Taiwan CDC for providing SARS-CoV-2 (TCDC#4) and
   funding support for the P3 facility in IBMS from Academia Sinica
   (AS-CFII-108-102) and the Ministry of Science and Technology, Taiwan
   (MOST 109-3114-Y-001-001). The MS/MS data analyzed by Orbitrap Fusion
   mass spectrometer were acquired at the Academia Sinica Common Mass
   Spectrometry Facilities for Proteomics and Protein Modification Analysis
   at the Institute of Biological Chemistry, Academia Sinica, supported by
   Academia Sinica Core Facility and Innovative Instrument Project
   (AS-CFII-108-107). We thank Dr Tse Wen Chang and Dr Zhu Tong for helpful
   discussion. We also thank the Biophysics Core and Genomics Core
   Facilities at the Institute of Molecular Biology, Academia Sinica for
   assistance in fluorescence and MALDI-TOF MASS assays, respectively. This
   work was supported by the Ministry of Science & Technology
   (MOST-107-2113-M-001-018 to C. L.) and Academia Sinica (AS-IA-107-L03 to
   C. L. and AS-IA-105-L04 to H. S. Y.) Taiwan.
CR Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451
   Briknarova K, 2011, J BIOL CHEM, V286, P1528, DOI 10.1074/jbc.M110.166025
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Dudev T, 2007, J AM CHEM SOC, V129, P12497, DOI 10.1021/ja073322c
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Huang MJ, 1998, J MED CHEM, V41, P1371, DOI 10.1021/jm9708543
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joseph JS, 2006, J VIROL, V80, P7894, DOI 10.1128/JVI.00467-06
   Kar M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02347
   Lee YM, 2016, J AM CHEM SOC, V138, P3856, DOI 10.1021/jacs.6b00299
   Lee YM, 2014, J CHIN CHEM SOC-TAIP, V61, P142, DOI 10.1002/jccs.201300392
   Lee YM, 2013, J AM CHEM SOC, V135, P14028, DOI 10.1021/ja406300c
   Lee YM, 2011, J AM CHEM SOC, V133, P8691, DOI 10.1021/ja202165x
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lin MH, 2018, ANTIVIR RES, V150, P155, DOI 10.1016/j.antiviral.2017.12.015
   Marchler-Bauer A, 2017, NUCLEIC ACIDS RES, V45, pD200, DOI 10.1093/nar/gkw1129
   PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Singh N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2320
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Srinivasan T N, 1996, Indian J Psychiatry, V38, P47
   Velthuis AJWT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001176
   Willis R, 2012, LUPUS, V21, P830, DOI 10.1177/0961203312437270
   Xue J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109180
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 29
TC 2
Z9 2
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2041-6520
EI 2041-6539
J9 CHEM SCI
JI Chem. Sci.
PD SEP 28
PY 2020
VL 11
IS 36
BP 9904
EP 9909
DI 10.1039/d0sc02646h
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA NS4WA
UT WOS:000572262400012
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Lotfinejad, P
   Asadzadeh, Z
   Najjary, S
   Somi, MH
   Hajiasgharzadeh, K
   Mokhtarzadeh, A
   Derakhshani, A
   Roshani, E
   Baradaran, B
AF Lotfinejad, Parisa
   Asadzadeh, Zahra
   Najjary, Shiva
   Somi, Mohammad Hossein
   Hajiasgharzadeh, Khalil
   Mokhtarzadeh, Ahad
   Derakhshani, Afshin
   Roshani, Elmira
   Baradaran, Behzad
TI COVID-19 Infection: Concise Review Based on the Immunological
   Perspective
SO IMMUNOLOGICAL INVESTIGATIONS
LA English
DT Article; Early Access
DE Coronavirus; 2019 novel coronavirus; COVID-19; host immune response;
   vaccine development
ID ACUTE RESPIRATORY SYNDROME; INNATE IMMUNE-RESPONSES; CLASS-II ALLELES;
   SARS-CORONAVIRUS; CYTOKINE STORM; FUNCTIONAL RECEPTOR; IFN-LAMBDA;
   INTERFERON; VACCINE; PNEUMONIA
AB The outbreak of coronavirus disease 2019 (COVID-19) has posed a serious threat to public health. There is an urgent need for discovery methods for the prevention and treatment of COVID-19 infection. Understanding immunogenicity together with immune responses are expected to provide further information about this virus. We hope that this narrative review article may create new insights for researchers to take great strides toward designing vaccines and novel therapies in the near future. The functional properties of the immune system in COVID-19 infection is not exactly clarified yet. This is compounded by the many gaps in our understanding of the SARS-CoV-2 immunogenicity properties. Possible immune responses according to current literature are discussed as thefirst line of defenseand acquired immunity. Here, we focus on proposed modern preventive immunotherapy methods in COVID-19 infection.
C1 [Lotfinejad, Parisa; Asadzadeh, Zahra; Najjary, Shiva; Hajiasgharzadeh, Khalil; Mokhtarzadeh, Ahad; Derakhshani, Afshin; Roshani, Elmira; Baradaran, Behzad] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran.
   [Lotfinejad, Parisa; Baradaran, Behzad] Tabriz Univ Med Sci, Dept Immunol, Tabriz, Iran.
   [Lotfinejad, Parisa] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Somi, Mohammad Hossein] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran.
   [Roshani, Elmira] Urmia Univ Med Sci, Sch Med, Dept Biochem, Orumiyeh, Iran.
RP Baradaran, B (corresponding author), Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran.
EM baradaranb@tbzmed.ac.ir
RI Hajiasgharzadeh, Khalil/V-3941-2017; Baradaran, Behzad/AAQ-5177-2020
OI Hajiasgharzadeh, Khalil/0000-0003-4593-4803; Baradaran,
   Behzad/0000-0002-8642-6795; Derakhshani, Afshin/0000-0002-3243-233X;
   mokhtarzadeh, ahad/0000-0002-4515-8675
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014
   Aquino-Jarquin G, 2019, NANOMED-NANOTECHNOL, V18, P428, DOI 10.1016/j.nano.2019.03.006
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arruvito L, 2014, J IMMUNOL, V193, P4469, DOI 10.4049/jimmunol.1401490
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Bezerra RD, 2020, J MED VIROL, V92, P2607, DOI 10.1002/jmv.26072
   Bordi L, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.8.2000170
   Cao B, 2020, NEW ENGL J MED, V382
   Carter LJ, 2020, ACS CENTRAL SCI, V6, P591, DOI 10.1021/acscentsci.0c00501
   Chafekar A, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020093
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380
   Coccia EM, 2004, EUR J IMMUNOL, V34, P796, DOI 10.1002/eji.200324610
   Cohen J, 2020, SCIENCE, V367, P492, DOI 10.1126/science.367.6477.492
   D'Elia RV, 2013, CLIN VACCINE IMMUNOL, V20, P319, DOI 10.1128/CVI.00636-12
   Dai WC, 2020, CAN ASSOC RADIOL J, V71, P195, DOI 10.1177/0846537120913033
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du LY, 2015, EXPERT OPIN BIOL TH, V15, P1647, DOI 10.1517/14712598.2015.1092518
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Dunning J, 2018, NAT IMMUNOL, V19, P625, DOI 10.1038/s41590-018-0111-5
   Frieman M, 2008, VIRUS RES, V133, P101, DOI 10.1016/j.virusres.2007.03.015
   Gabriella D, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106519
   Gousseff M, 2020, J INFECTION, V81, P821, DOI 10.1016/j.jinf.2020.06.073
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Haanen JB, 2018, CELL, V175, P1720, DOI 10.1016/j.cell.2018.11.048
   Hajeer AH, 2016, ANN THORAC MED, V11, P211, DOI 10.4103/1817-1737.185756
   Hu Y, 2017, J VIROL, V91, DOI 10.1128/JVI.02143-16
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Jauregui AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062416
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Keicho N, 2009, HUM IMMUNOL, V70, P527, DOI 10.1016/j.humimm.2009.05.006
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Kopecky-Bromberg SA, 2007, J VIROL, V81, P548, DOI 10.1128/JVI.01782-06
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   Lauterbach H, 2010, J EXP MED, V207, P2703, DOI 10.1084/jem.20092720
   Law HKW, 2005, BLOOD, V106, P2366, DOI 10.1182/blood-2004-10-4166
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li FL, 2013, GASTROENTEROLOGY, V144, P392, DOI 10.1053/j.gastro.2012.10.039
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li Q, 2020, N ENGL J MED, V382
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Liu J, 2010, J VIROL, V84, P11849, DOI 10.1128/JVI.01464-10
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318
   Mescher MF, 2006, IMMUNOL REV, V211, P81, DOI 10.1111/j.0105-2896.2006.00382.x
   Millan-Onate J, 2020, INFECTIO, V24, P3
   Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10
   Nelemans T, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100961
   Niemeyer D, 2013, J VIROL, V87, P12489, DOI 10.1128/JVI.01845-13
   Okabayashi T, 2011, VIRUS RES, V160, P360, DOI 10.1016/j.virusres.2011.07.011
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Park M, 2020, EUR J IMMUNOL, V50, P308, DOI 10.1002/eji.202070035
   Pormohammad A, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2112
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ray A, 2015, IMMUNOLOGY, V146, P359, DOI 10.1111/imm.12511
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Seguin A, 2016, CHEST, V149, P1294, DOI 10.1016/j.chest.2015.11.004
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   Song ZF, 2020, J SURV ENG, V146, DOI 10.1061/(ASCE)SU.1943-5428.0000307
   Sourav S, 2020, MED J ARMED FORCES I, DOI [10.1016/j.mjafi.2020.04.008, DOI 10.1016/J.MJAFI.2020.04.008]
   Spann KM, 2014, THORAX, V69, P918, DOI 10.1136/thoraxjnl-2013-204908
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Tian X., 2020, ELECTRONICS, V9, P1, DOI DOI 10.1080/22221751.2020.1729069
   Tiwari R, 2020, VET QUART, V40, P169, DOI 10.1080/01652176.2020.1766725
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Tseng CTK, 2005, J IMMUNOL, V174, P7977, DOI 10.4049/jimmunol.174.12.7977
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   Venkatagopalan P, 2015, VIROLOGY, V478, P75, DOI 10.1016/j.virol.2015.02.005
   Vittori A, 2020, ANESTH ANALG, V131, P117, DOI 10.1213/ANE.0000000000004914
   Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang M, 2020, CELL RES 0204, V30, P269, DOI [DOI 10.1038/S41422-020-0282-0, 10.1038/s41422-020-0282-0]
   Wang SF, 2011, VIRAL IMMUNOL, V24, P421, DOI 10.1089/vim.2011.0024
   Wang Y, 2016, MBIO, V7, DOI 10.1128/mBio.01872-15
   Wei CW, 2010, J IMMUNOL, V185, P1158, DOI 10.4049/jimmunol.0903874
   Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862
   Wiener RS, 2007, J CELL BIOCHEM, V101, P1278, DOI 10.1002/jcb.21248
   Woodland DL, 2018, VIRAL IMMUNOL, V31, P595, DOI 10.1089/vim.2018.29032.dlw
   World Health Organization, 2020, WHO2019NCOVLABORATOR
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zalinger ZB, 2015, J VIROL, V89, P12330, DOI 10.1128/JVI.01470-15
   Zhang QW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103083
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 113
TC 0
Z9 0
U1 6
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0139
EI 1532-4311
J9 IMMUNOL INVEST
JI Immunol. Invest.
DI 10.1080/08820139.2020.1825480
EA SEP 2020
PG 20
WC Immunology
SC Immunology
GA NT7RA
UT WOS:000573131900001
PM 32981399
DA 2021-01-01
ER

PT J
AU Gurnani, P
   Blakney, AK
   Yeow, J
   Bouton, CR
   Shattock, RJ
   Stevens, MM
   Alexander, C
AF Gurnani, Pratik
   Blakney, Anna K.
   Yeow, Jonathan
   Bouton, Clement R.
   Shattock, Robin J.
   Stevens, Molly M.
   Alexander, Cameron
TI An improved synthesis of poly(amidoamine)s for complexation with
   self-amplifying RNA and effective transfection
SO POLYMER CHEMISTRY
LA English
DT Article
ID MICROWAVE-ASSISTED SYNTHESIS; PARALLEL SYNTHESIS; GENE; DELIVERY;
   POLYMERIZATIONS; AMINE)S
AB Cationic polymers are widely used as materials to condense nucleic acids for gene-based therapies. These have been developed to mainly deliver DNA and RNA for cancer therapies but the ongoing COVID-19 pandemic has demonstrated an urgent need for new DNA and RNA vaccines. Given this, suitable manufacturing conditions for such cationic polymers which can protect the nucleic acid in the formulation and delivery stages but release the cargo in the correct cellular compartment effectively and safely are required. A number of polymers based on poly(amidoamine)s fit these criteria but their syntheses can be time-consuming, inefficient and poorly reproducible, precluding their adoption as manufacturable vaccine excipients. Here we report an improved synthesis of poly(cystamine bisacrylamide-co-4-amino-1-butanol), abbreviated as pABOL,viamodifications in concentration, reaction time and reaction conditions. Optimisation of monomer contents and stoichiometries, solvents, diluents and temperature, combined with the application of microwaves, enabled the preparation of vaccine candidate pABOL materials in 4 h compared to 48 h reported for previous syntheses. These procedures were highly reproducible in multiple repeat syntheses. Transfection experiments with a model RNA showed that polymers of formulation with appropriate molar masses and mass distributions were as effective in model cell lines as polymers derived from the unoptimised syntheses which have been shown to have high efficacy as RNA vaccine formulation candidates.
C1 [Gurnani, Pratik; Alexander, Cameron] Univ Nottingham, Div Mol Therapeut & Formulat, Sch Pharm, Nottingham NG7 2RD, England.
   [Blakney, Anna K.; Bouton, Clement R.; Shattock, Robin J.] St Marys Hosp, Dept Infect Dis, Sch Med, Imperial Coll London, Praed St, London W2 1NY, England.
   [Yeow, Jonathan; Stevens, Molly M.] Imperial Coll London, Dept Mat, Prince Consort Rd, London SW7 2AZ, England.
   [Yeow, Jonathan; Stevens, Molly M.] Imperial Coll London, Dept Bioengn, Prince Consort Rd, London SW7 2AZ, England.
RP Gurnani, P; Alexander, C (corresponding author), Univ Nottingham, Div Mol Therapeut & Formulat, Sch Pharm, Nottingham NG7 2RD, England.
EM pratik.gurnani@nottingham.ac.uk; cameron.alexander@nottingham.ac.uk
RI ; Alexander, Cameron/N-7729-2014
OI Bouton, Clement/0000-0001-9607-6533; Blakney, Anna/0000-0002-5812-9689;
   Alexander, Cameron/0000-0001-8337-1875; Gurnani,
   Pratik/0000-0002-6559-5514; Yeow, Jonathan/0000-0003-3709-5149
FU Department of Health and Social Care; Engineering and Physical Sciences
   Research Council (EPSRC)Engineering & Physical Sciences Research Council
   (EPSRC) [EP/R013764/1]; Royal Society through a Wolfson Research Merit
   Award [WM150086]
FX This research is funded by the Department of Health and Social Care
   using UK Aid funding and is managed by the Engineering and Physical
   Sciences Research Council (EPSRC, grant number: EP/R013764/1). The views
   expressed in this publication are those of the author(s) and not
   necessarily those of the Department of Health and Social Care. We thank
   Dr Yunqing Zhu for useful discussions on pABOL synthesis. This research
   was also funded through the Royal Society through a Wolfson Research
   Merit Award [WM150086]. We also thank Douglas Crackett and Paul Cooling
   for expert technical assistance and Carol Turrill for outstanding
   administrative support.
CR Akinc A, 2003, J AM CHEM SOC, V125, P5316, DOI 10.1021/ja034429c
   Akinc A, 2003, BIOCONJUGATE CHEM, V14, P979, DOI 10.1021/bc034067y
   Anselmo AC, 2019, NAT REV DRUG DISCOV, V18, P19, DOI 10.1038/nrd.2018.183
   Ben-Akiva E, 2019, BIOMATER SCI-UK, V7, P14, DOI 10.1039/c8bm01285g
   Blakney AK, 2020, ACS NANO, V14, P5711, DOI 10.1021/acsnano.0c00326
   Blakney AK, 2020, BIOMACROMOLECULES, V21, P2482, DOI 10.1021/acs.biomac.0c00445
   Cheng Q, 2020, NAT NANOTECHNOL, V15, P313, DOI 10.1038/s41565-020-0669-6
   Cordeiro RA, 2019, J CONTROL RELEASE, V310, P155, DOI 10.1016/j.jconrel.2019.08.024
   Duan SZ, 2020, BIOMATER SCI-UK, V8, P290, DOI 10.1039/c9bm01452g
   Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109
   Glasnov TN, 2007, MACROMOL RAPID COMM, V28, P395, DOI 10.1002/marc.200600665
   Goto A, 2004, PROG POLYM SCI, V29, P329, DOI 10.1016/j.progpolymsci.2004.01.002
   Gurnani P, 2020, BIOMACROMOLECULES, V21, P3242, DOI 10.1021/acs.biomac.0c00698
   Kaczmarek JC, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0450-0
   Kedmi R, 2018, NAT NANOTECHNOL, V13, P214, DOI 10.1038/s41565-017-0043-5
   Kempe K, 2011, MACROMOLECULES, V44, P5825, DOI 10.1021/ma2004794
   Kozielski KL, 2019, BIOMATERIALS, V209, P79, DOI 10.1016/j.biomaterials.2019.04.020
   Lin C, 2008, J CONTROL RELEASE, V126, P166, DOI 10.1016/j.jconrel.2007.11.012
   Lin C, 2006, J CONTROL RELEASE, V116, P130, DOI 10.1016/j.jconrel.2006.09.009
   Liu Y, 2003, CHEM COMMUN, P2630, DOI 10.1039/b309487a
   Lostale-Seijo I, 2018, NAT REV CHEM, V2, P258, DOI 10.1038/s41570-018-0039-1
   Lovato T, 2018, J MATER CHEM B, V6, P6550, DOI 10.1039/c8tb01215f
   Lynn DM, 2001, J AM CHEM SOC, V123, P8155, DOI 10.1021/ja016288p
   Lynn DM, 2000, J AM CHEM SOC, V122, P10761, DOI 10.1021/ja0015388
   McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9
   Meredith JC, 2009, J MATER CHEM, V19, P34, DOI 10.1039/b808649d
   Mout R, 2017, BIOCONJUGATE CHEM, V28, P880, DOI 10.1021/acs.bioconjchem.7b00057
   Muhammad K, 2020, BIOMATER SCI-UK, V8, P64, DOI 10.1039/c9bm01112a
   Nuchter M, 2004, GREEN CHEM, V6, P128, DOI 10.1039/b310502d
   Rui Y, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aay3255
   Saviano F, 2020, J MATER CHEM B, V8, P4940, DOI 10.1039/d0tb00942c
   STILLE JK, 1981, J CHEM EDUC, V58, P862, DOI 10.1021/ed058p862
   Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017
   Yeow J, 2018, CHEM SOC REV, V47, P4357, DOI 10.1039/c7cs00587c
   Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594
   Zhong ZY, 2005, J CONTROL RELEASE, V109, P317, DOI 10.1016/j.jconrel.2005.06.022
NR 36
TC 0
Z9 0
U1 4
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1759-9954
EI 1759-9962
J9 POLYM CHEM-UK
JI Polym. Chem.
PD SEP 28
PY 2020
VL 11
IS 36
BP 5861
EP 5869
DI 10.1039/d0py00912a
PG 9
WC Polymer Science
SC Polymer Science
GA NR5HR
UT WOS:000571593600013
OA Other Gold
DA 2021-01-01
ER

PT J
AU Zimmerman, RK
   Nowalk, MP
   Bear, T
   Taber, R
   Clarke, KS
   Sax, TM
   Eng, H
   Clarke, LG
   Balasubramani, GK
AF Zimmerman, Richard K.
   Nowalk, Mary Patricia
   Bear, Todd
   Taber, Rachel
   Clarke, Karen S.
   Sax, Theresa M.
   Eng, Heather
   Clarke, Lloyd G.
   Balasubramani, G. K.
TI Proposed clinical indicators for efficient screening and testing for
   COVID-19 infection using Classification and Regression Trees (CART)
   analysis
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE COVID-19; symptoms; SARS-CoV-2; screening; classification trees
AB The introduction and rapid transmission of SARS-CoV-2 in the United States resulted in methods to assess, mitigate, and contain the resulting COVID-19 disease derived from limited knowledge. Screening for testing has been based on symptoms typically observed in inpatients, yet outpatient symptoms may differ. Classification and regression trees recursive partitioning created a decision tree classifying participants into laboratory-confirmed cases and non-cases. Demographic and symptom data from patients ages 18-87 years enrolled from March 29-June 8, 2020 were included. Presence or absence of SARS-CoV-2 was the target variable. Of 832 tested, 77 (9.3%) tested positive. Cases significantly more often reported diarrhea (12 percentage points (PP)), fever (15 PP), nausea/vomiting (9 PP), loss of taste/smell (52 PP), and contact with a COVID-19 case (54 PP), but less frequently reported sore throat (-27 PP). The 4-terminal node optimal tree had sensitivity of 69%, specificity of 78%, positive predictive value of 20%, negative predictive value of 97%, and AUC of 76%. Among those referred for testing, negative responses to two questions could classify about half (49%) of tested persons with low risk for SARS-CoV-2 and would save limited testing resources. Outpatient symptoms of COVID-19 appear to be broader than the inpatient syndrome. Initial supplies of anticipated COVID-19 vaccines may be limited and administration of first such available vaccines may need to be prioritized for essential workers, the most vulnerable, or those likely to have a robust response to vaccine. Another priority group could be those not previously infected. Those who screen out of testing may be less likely to have been infected by SARS-CoV-2 virus thus may be prioritized for vaccination when supplies are limited.
C1 [Zimmerman, Richard K.; Nowalk, Mary Patricia; Clarke, Karen S.] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA 15260 USA.
   [Bear, Todd; Taber, Rachel] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA USA.
   [Sax, Theresa M.; Eng, Heather; Balasubramani, G. K.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
   [Clarke, Lloyd G.] UPMC Hlth Syst, Dept Pharm, Pittsburgh, PA USA.
RP Nowalk, MP (corresponding author), Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA 15260 USA.
EM tnowalk@pitt.edu
FU Centers for Disease Control and Prevention (CDC)United States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
   [U01 IP000467]; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [1UL1
   TR001857]; CDCUnited States Department of Health & Human ServicesCenters
   for Disease Control & Prevention - USA
FX This study was supported through a cooperative agreement with the
   Centers for Disease Control and Prevention (CDC) through grant number
   U01 IP000467 and the National Institutes of Health grant number 1UL1
   TR001857. The US Flu VE Network is supported through cooperative
   agreements funded by CDC. The findings and conclusions are those of the
   authors and do not necessarily represent the official position of the
   Centers for Disease Control and Prevention. It is subject to the CDC's
   Open Access Policy.
CR Babapour Mofrad Rosha, 2019, Alzheimers Dement (Amst), V11, P1, DOI 10.1016/j.dadm.2018.10.004
   Breiman L., 1984, WADSWORTH STAT PROBA
   Centers for Disease Control and Prevention, 2020, SYMPT COR
   Chow EJ, 2020, JAMA-J AM MED ASSOC, V323, P2087, DOI 10.1001/jama.2020.6637
   Ebell MH, 2017, ANN FAM MED, V15, P347, DOI 10.1370/afm.2060
   Ghiasi MM, 2020, COMPUT METH PROG BIO, V192, DOI 10.1016/j.cmpb.2020.105400
   Hong WD, 2011, DIGEST DIS SCI, V56, P3664, DOI 10.1007/s10620-011-1849-x
   Ihle-Hansen H, 2020, TIDSSKR NOR LAEGEFOR, DOI 10-4045/tidsskr.20.0301
   Kim GU, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.04.040
   Lu XY, 2020, EMERG INFECT DIS, V26, P1654, DOI 10.3201/eid2608.201246
   Luers JC, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa52, DOI 10.1093/CID/CIAA52]
   Pascarella G, 2020, J INTERN MED, V288, P192, DOI 10.1111/joim.13091
   Quirke M, 2018, POSTGRAD MED J, V94, P25, DOI 10.1136/postgradmedj-2017-134968
   Shi KQ, 2017, J VIRAL HEPATITIS, V24, P132, DOI 10.1111/jvh.12617
   Zimmerman RK, 2015, 37 ANN M SOC MED DEC
   Zitek T, 2020, WEST J EMERG MED, V21, P470, DOI 10.5811/westjem.2020.4.47370
NR 16
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1822135
EA SEP 2020
PG 4
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA OD5PX
UT WOS:000579906900001
PM 33079625
OA Bronze
DA 2021-01-01
ER

PT J
AU Milenkovic, DA
   Dimic, DS
   Avdovic, EH
   Markovic, ZS
AF Milenkovic, Dejan A.
   Dimic, Dusan S.
   Avdovic, Edina H.
   Markovic, Zoran S.
TI Several coumarin derivatives and their Pd(ii) complexes as potential
   inhibitors of the main protease of SARS-CoV-2, anin silicoapproach
SO RSC ADVANCES
LA English
DT Article
ID CRYSTAL-STRUCTURES; CORONAVIRUS; CINANSERIN; GROMACS
AB The global pandemic of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused many fatalities among people and significantly influenced the global economy. Since efficient treatment is not available, the computational methods in biology and chemistry are a promising starting point towards adequate medication. Three previously synthesized coumarin derivatives and their Pd(ii) complexes were examined for the binding affinity towards the M(pro)protein of SARS-CoV-2 by molecular docking and compared to two Food and Drug Administration (FDA) drugs,cinanserinandchloroquine. All of the investigated compounds bind to the active position of the mentioned protein. Coumarin-Pd(ii) complexes showed higher binding affinities compared to the approved drugs. The bindings of the bis(3-(1-((3-chlorophenyl)amino)ethylidene)-chroman-2,4-dione) palladium(ii) complex, its corresponding ligand, andcinanserinto SARS-CoV-2 M(pro)were further subjected to the molecular dynamics simulations. The binding free energies, computed by MM/PBSA approach were analyzed in detail and the importance of specific interactions outlined. These results showed that the molecules bearing structural similarity to the approved drugs and their complexes have the potential to inhibit the functional activity of SARS-CoV-2 protease and further experimental studies should be undertaken.
C1 [Milenkovic, Dejan A.; Avdovic, Edina H.; Markovic, Zoran S.] Univ Kragujevac, Inst Informat Technol, Dept Sci, Jovana Cvijica Bb, Kragujevac 34000, Serbia.
   [Dimic, Dusan S.] Univ Belgrade, Fac Phys Chem, Studentski Trg 12-16, Belgrade 11000, Serbia.
   [Avdovic, Edina H.] Univ Kragujevac, Fac Sci, Radoja Domanovica 12, Kragujevac 34000, Serbia.
RP Markovic, ZS (corresponding author), Univ Kragujevac, Inst Informat Technol, Dept Sci, Jovana Cvijica Bb, Kragujevac 34000, Serbia.
EM zmarkovic@uni.kg.ac.rs
OI Dimic, Dusan/0000-0001-8127-5396; Markovic, Zoran/0000-0003-2287-6049;
   Milenkovic, Dejan/0000-0001-7083-2257
FU Ministry of Education, Science, and Technological Development of the
   Republic of Serbia [451-03-68/2020-14/200146, 451-03-68/2020-14/200378]
FX The authors wish to acknowledge the Ministry of Education, Science, and
   Technological Development of the Republic of Serbia for the financial
   support through contracts no. 451-03-68/2020-14/200146 and
   451-03-68/2020-14/200378.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Adamu A, 2017, COMPUT BIOL CHEM, V70, P125, DOI 10.1016/j.compbiolchem.2017.08.007
   Alexpandi R, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01796
   Avdovic EH, 2020, INORG CHIM ACTA, V504, DOI 10.1016/j.ica.2020.119465
   Avdovic EH, 2019, INORG CHIM ACTA, V484, P52, DOI 10.1016/j.ica.2018.09.014
   Avdovic EH, 2018, SPECTROCHIM ACTA A, V195, P31, DOI 10.1016/j.saa.2018.01.023
   Banerjee P, 2018, NUCLEIC ACIDS RES, V46, pW257, DOI 10.1093/nar/gky318
   BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098
   Best RB, 2012, J CHEM THEORY COMPUT, V8, P3257, DOI 10.1021/ct300400x
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   BIOVIA, 2016, DISC STUD
   Chen LL, 2005, J VIROL, V79, P7095, DOI 10.1128/JVI.79.11.7095-7103.2005
   Dai W., 2020, SCIENCE, V1335, peabb4489
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Du X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020144
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Ferraz WR, 2020, FUTURE MED CHEM, V12, P1815, DOI 10.4155/fmc-2020-0165
   Fischer A., 2020, INT J MOL SCI, V21, P1
   Frisch M. J, 2013, GAUSSIAN 09 REVISION
   Gaudino EC, 2016, RSC ADV, V6, P46394, DOI 10.1039/c6ra07071j
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Guan AY, 2011, NAT PROD COMMUN, V6, P1917
   Hagar M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113922
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kalathiya U., 2019, SCI REP, V9, P1
   KANE FJ, 1970, AM J PSYCHIAT, V126, P1020, DOI 10.1176/ajp.126.7.1020
   Kokkinidis M, 2012, ADV PROTEIN CHEM STR, V87, P181, DOI 10.1016/B978-0-12-398312-1.00007-X
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935
   Lee TW, 2005, J MOL BIOL, V353, P1137, DOI 10.1016/j.jmb.2005.09.004
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Macchiagodena M, 2020, CHEM PHYS LETT, V750, DOI 10.1016/j.cplett.2020.137489
   Marmor MF, 2020, AM J OPHTHALMOL, V213, pA3, DOI 10.1016/j.ajo.2020.03.028
   Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Olubiyi OO, 2020, MOLECULES, V25, DOI 10.3390/molecules25143193
   Rambabu D, 2012, BIOORG MED CHEM LETT, V22, P6745, DOI 10.1016/j.bmcl.2012.08.082
   Rappoport D, 2010, J CHEM PHYS, V133, DOI 10.1063/1.3484283
   Ravindranath PA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004586
   Romanelli F, 2004, CURR PHARM DESIGN, V10, P2643, DOI 10.2174/1381612043383791
   Sang P, 2020, RSC ADV, V10, P15775, DOI 10.1039/d0ra01899f
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shimamoto Y, 2015, BIOORGAN MED CHEM, V23, P876, DOI 10.1016/j.bmc.2014.12.028
   Shu C., 2020, STEMEDICINE, V1, pe41, DOI [https://doi.org/10.37175/stemedicine.v1i2.41, DOI 10.37175/STEMEDICINE.V1I2.41]
   Silva A. Sanches, 2020, RECENT ADV NATURAL P
   Song W., 2020, AM J OPHTHALMIC CLIN, V2, P8
   Stefanachi A, 2018, MOLECULES, V23, DOI 10.3390/molecules23020250
   Tong TR, 2009, EXPERT OPIN THER PAT, V19, P415, DOI 10.1517/13543770802600698
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 60
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD SEP 27
PY 2020
VL 10
IS 58
BP 35099
EP 35108
DI 10.1039/d0ra07062a
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA NU7JC
UT WOS:000573815400013
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Trujillo, H
   Caravaca-Fontan, F
   Sevillano, A
   Gutierrez, E
   Fernandez-Ruiz, M
   Lopez-Medrano, F
   Hernandez, A
   Aguado, JM
   Praga, M
   Andres, A
AF Trujillo, Hernando
   Caravaca-Fontan, Fernando
   Sevillano, Angel
   Gutierrez, Eduardo
   Fernandez-Ruiz, Mario
   Lopez-Medrano, Francisco
   Hernandez, Ana
   Aguado, Jose Maria
   Praga, Manuel
   Andres, Amado
TI Tocilizumab use in Kidney Transplant Patients with COVID-19
SO CLINICAL TRANSPLANTATION
LA English
DT Article
DE coronavirus disease 2019; kidney transplantation; outcomes; severe acute
   respiratory syndrome coronavirus 2; tocilizumab
AB A potential benefit of immunomodulatory agents such as tocilizumab (TCZ) has been reported in patients with coronavirus disease 2019 (COVID-19) and severe pulmonary involvement. However, this therapy has been scarcely studied in kidney transplant (KT) recipients. Herein, we describe the clinical course and outcome of 10 KT patients with severe COVID-19 that were treated with TCZ. Mean age of the study group was 54 +/- 10 years (70% females), and 30% of the cases were within 6 months from transplant. Mycophenolate mofetil was discontinued in all cases upon admission, whereas baseline steroids were maintained and tacrolimus dose was reduced. Initial treatment included hydroxychloroquine, antibiotics, and prophylactic anticoagulation. Before treatment with TCZ, 3 patients were receiving high-flow oxygen, 4 patients low-flow oxygen and 1 case non-invasive ventilation. All patients received a single dose of intravenous TCZ within a mean time of 7 +/- 4 days since admission. During a median follow-up of 16 days (IQR: 10-29), 7 patients (70%) gradually improved and were finally discharged while three cases (30%) did not exhibited clinical improvement and ultimately died. In conclusion, although treatment with TCZ could be associated with improved clinical outcomes in a subset of KT recipients with COVID-19, further studies are warranted before drawing firm conclusions.
C1 [Trujillo, Hernando; Caravaca-Fontan, Fernando; Sevillano, Angel; Gutierrez, Eduardo; Hernandez, Ana; Praga, Manuel; Andres, Amado] Hosp Univ, Dept Nephrol, 12 Octubre Av Cordoba Km 5-400, Madrid 28041, Spain.
   [Caravaca-Fontan, Fernando; Fernandez-Ruiz, Mario; Lopez-Medrano, Francisco; Aguado, Jose Maria; Praga, Manuel; Andres, Amado] Res Inst Hosp, Madrid, Spain.
   [Fernandez-Ruiz, Mario; Lopez-Medrano, Francisco; Aguado, Jose Maria] Hosp Univ, Unit Infect Dis, Madrid, Spain.
   [Lopez-Medrano, Francisco; Aguado, Jose Maria; Praga, Manuel; Andres, Amado] Univ Complutense Madrid, Dept Med, Madrid, Spain.
RP Gutierrez, E (corresponding author), Hosp Univ, Dept Nephrol, 12 Octubre Av Cordoba Km 5-400, Madrid 28041, Spain.
EM eduardogutmat90@gmail.com
RI Andres, Amado/ABC-6482-2020
OI Andres, Amado/0000-0003-0238-1364; Caravaca-Fontan,
   Fernando/0000-0002-5830-9663; Hernandez, Ana/0000-0003-3739-4085;
   Trujillo, Hernando/0000-0002-3520-1422; Lopez-Medrano,
   Francisco/0000-0001-5333-7529
FU Instituto de Salud Carlos III, Spanish Ministry of Science and
   Innovation - European Development Regional Fund "A way to achieve
   Europe" [COV20/00181]; Instituto de Salud Carlos III, Spanish Ministry
   of Science and InnovationInstituto de Salud Carlos IIISpanish Government
   [CP 18/00073]
FX This work was supported by Instituto de Salud Carlos III, Spanish
   Ministry of Science and Innovation (COV20/00181)co-financed by European
   Development Regional Fund "A way to achieve Europe". MFR holds a
   research contract "Miguel Servet" (CP 18/00073) from the Instituto de
   Salud Carlos III, Spanish Ministry of Science and Innovation.
CR Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Choi J, 2017, AM J TRANSPLANT, V17, P2381, DOI 10.1111/ajt.14228
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Hughes S, 2020, CLIN MICROBIOL INFEC, V26, P1395, DOI 10.1016/j.cmi.2020.06.025
   Kewan Tariq, 2020, EClinicalMedicine, V24, P100418, DOI 10.1016/j.eclinm.2020.100418
   Kojima T, 2013, MOD RHEUMATOL, V23, P977, DOI [10.3109/s10165-012-0782-y, 10.1007/s10165-012-0782-y]
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Maini RN, 2006, ARTHRITIS RHEUM-US, V54, P2817, DOI 10.1002/art.22033
   Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713
   Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shin BH, 2020, TRANSPLANTATION, V104, P856, DOI 10.1097/TP.0000000000002895
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Trujillo H, 2020, KIDNEY INT REP, V5, P905, DOI 10.1016/j.ekir.2020.04.024
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
NR 17
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-0063
EI 1399-0012
J9 CLIN TRANSPLANT
JI Clin. Transplant.
PD NOV
PY 2020
VL 34
IS 11
AR e14072
DI 10.1111/ctr.14072
EA SEP 2020
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OZ9QZ
UT WOS:000572807100001
PM 32862472
OA Bronze
DA 2021-01-01
ER

PT J
AU Abosheasha, MA
   El-Gowily, AH
AF Abosheasha, Mohammed A.
   El-Gowily, Afnan H.
TI Superiority of cilostazol among antiplateletFDA-approved drugs
   againstCOVID19 M(pro)and spike protein: Drug repurposing approach
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article; Early Access
DE antiplatelet; COVID-19; molecular docking; M-pro; SARS-CoV-2; spike
   glycoprotein
ID CORONAVIRUS
AB Coronavirus disease 2019 (COVID 19) was first identified in Wuhan, China near the end of 2019. To date, COVID-19 had spread to almost 235 countries and territories due to its highly infectious nature. Moreover, there is no vaccine or Food and Drug Administration (FDA)-approved drug. More time is needed to establish one of them. Consequently, the drug repurposing approach seems to be the most attractive and quick solution to accommodate this crisis. In this regard, we performed molecular docking-based virtual screening of antiplatelet FDA-approved drugs on the key two viral target proteins: main protease (M-pro) and spike glycoprotein (S) as potential inhibitor candidates for COVID-19. In the present study, 15 antiplatelet FDA-approved drugs were investigated against the concerned targets using the Molecular Docking Server. Our study revealed that only cilostazol has the most favorable binding interaction on M-pro(PDB ID: 6LU7) and cilostazol, iloprost, epoprostenol, prasugrel, and icosapent ethyl have a higher binding affinity on spike glycoprotein (S) (PDB ID: 6VYB) compared with recent anti-CoVID-19. Therefore, cilostazol is a promising FDA drug against COVID-19 by inhibiting both M(pro)and S protein. The insights gained in this study may be useful for quick approach against COVID-19 in the future.
C1 [Abosheasha, Mohammed A.] Tokyo Metropolitan Univ, Grad Sch Sci, Cellular Genet Lab, Tokyo 1920397, Japan.
   [El-Gowily, Afnan H.] Tanta Univ, Fac Sci, Div Biochem, Dept Chem, Tanta, Egypt.
   [El-Gowily, Afnan H.] Juntendo Univ, Dept Organ & Cell Physiol, Tokyo, Japan.
RP Abosheasha, MA (corresponding author), Tokyo Metropolitan Univ, Grad Sch Sci, Cellular Genet Lab, Tokyo 1920397, Japan.; El-Gowily, AH (corresponding author), Juntendo Univ, Div Biochem, Dept Chem, Fac Sci,Organ & Cell Physiol Dept, Tokyo, Japan.
EM mohammed-abosheasha@ed.tmu.ac.jp; afnan.hamdy@science.tanta.edu.eg
OI Abosheasha, Mohammed/0000-0002-8866-0040; El-Gowily, Afnan
   Hamdy/0000-0001-5290-7278
CR Bikadi Z, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-15
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Obi AT, 2019, J VASC SURG-VENOUS L, V7, P317, DOI 10.1016/j.jvsv.2018.08.010
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Ramphul K, 2020, CUREUS, V12, DOI 10.7759/cureus.7276
   Salata C, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftaa006
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Sohag AA, 2020, DRUG DEVELOP RES, V81, P919, DOI 10.1002/ddr.21709
   SOLIS FJ, 1981, MATH OPER RES, V6, P19, DOI 10.1287/moor.6.1.19
   Stewart JJP, 2009, J MOL MODEL, V15, P765, DOI 10.1007/s00894-008-0420-y
   Tremblay D, 2020, BLOOD, V136, P144, DOI 10.1182/blood.2020006941
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   WHO, 2020, 92 WHO
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
NR 25
TC 0
Z9 0
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
DI 10.1002/ddr.21743
EA SEP 2020
PG 13
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NT6BZ
UT WOS:000573025200001
PM 32984987
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Arafkas, M
   Khosrawipour, T
   Kocbach, P
   Zielinski, K
   Schubert, J
   Mikolajczyk, A
   Celinska, M
   Khosrawipour, V
AF Arafkas, Mohamed
   Khosrawipour, Tanja
   Kocbach, Piotr
   Zielinski, Kacper
   Schubert, Justyna
   Mikolajczyk, Agata
   Celinska, Maria
   Khosrawipour, Veria
TI Current meta-analysis does not support the possibility of COVID-19
   reinfections
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article; Early Access
DE coronavirus; COVID-19; effective; measures; pandemic; spread
ID CORONAVIRUS
AB Coronavirus disease 2019 (COVID-19) reinfections could be a major aggravating factor in this current pandemic, as this would further complicate potential vaccine development and help to maintain worldwide virus pockets. To investigate this critical question, we conducted a clinical meta-analysis including all available currently reported cases of potential COVID-19 reinfections. We searched for all peer-reviewed articles in the search engine of the National Center for Biotechnology Information. While there are over 30,000 publications on COVID-19, only about 15 specifically target the subject of COVID-19 reinfections. Available patient data in these reports was analyzed for age, gender, time of reported relapse after initial infection and persistent COVID-19 positive polymerase chain reaction (PCR) results. Following the first episode of infection, cases of clinical relapse are reported at 34 (mean) +/- 10.5 days after full recovery. Patients with clinical relapse have persisting positive COVID-19 PCR testing results until 39 +/- 9 days following initial positive testing. For patients without clinical relapse, positive testing was reported up to 54 +/- 24 days. There were no reports of any clinical reinfections after a 70-day period following initial infection.
C1 [Arafkas, Mohamed] St Petrus Hosp, Dept Plast Surg, Wuppertal, Germany.
   [Khosrawipour, Tanja; Khosrawipour, Veria] Univ Calif Irvine, Dept Surg, Irvine, CA 92717 USA.
   [Khosrawipour, Tanja] Heinrich Heine Univ Duesseldorf, Univ Hosp Duesseldorf, Dept Surg A, Dusseldorf, Germany.
   [Kocbach, Piotr] Univ Warmia & Mazury, Div Infect Dis, Olszytn, Poland.
   [Zielinski, Kacper] Wroclaw Med Univ, Sch Med, Wroclaw, Poland.
   [Schubert, Justyna] Wroclaw Univ Environm & Life Sci, Dept Food Hyg & Consumer Hlth Protect, Wroclaw, Poland.
   [Mikolajczyk, Agata; Celinska, Maria] Wroclaw Univ Environm & Life Sci, Fac Vet Sci, Dept Biochem & Mol Biol, Wroclaw, Poland.
RP Khosrawipour, T (corresponding author), Univ Calif Irvine UCI, Dept Gen Surg, 333 City Blvd West,Suite 850, Orange, CA 92868 USA.
EM tkhosrawipour@gmail.com
RI Khosrawipour, Priv.- Doz. Dr. med. Tanja/AAI-2372-2019; Khosrawipour,
   Veria/ABH-8841-2020
OI Khosrawipour, Priv.- Doz. Dr. med. Tanja/0000-0003-0233-551X; 
FU Projekt DEAL
FX Open access funding enabled and organized by Projekt DEAL.
CR Atkinson B, 2020, LANCET, V395, P1339, DOI 10.1016/S0140-6736(20)30868-0
   Cao H, 2020, J MED VIROL, V92, P2159, DOI 10.1002/jmv.26017
   Chen LD, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05245-7
   Dou C, 2020, DIABETES RES CLIN PR, V166
   Duggan Nicole M, 2021, Am J Emerg Med, V39, DOI 10.1016/j.ajem.2020.06.079
   Galanti Marta, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa392
   Gousseff M, 2020, J INFECTION, V81, P821, DOI 10.1016/j.jinf.2020.06.073
   Ip DKM, 2016, CLIN INFECT DIS, V62, P431, DOI 10.1093/cid/civ909
   Jin YJ, 2020, INT J INFECT DIS, V94, P49, DOI 10.1016/j.ijid.2020.03.065
   Juckel D, 2020, M S-MED SCI, V36, P633, DOI 10.1051/medsci/2020113
   Khosrawipour V, 2020, J MED VIROL, V92, P863, DOI 10.1002/jmv.25883
   Lafaie L, 2020, J AM GERIATR SOC, V68, P2179, DOI 10.1111/jgs.16728
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Lau H, 2020, PULMONOLOGY
   Lau H, 2020, J MICROBIOL IMMUNOL, V53, P467, DOI 10.1016/j.jmii.2020.03.026
   Lau H, 2020, J MICROBIOL IMMUNOL, V53, P454, DOI 10.1016/j.jmii.2020.03.013
   Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037
   Li JY, 2020, AM J TROP MED HYG, V102, P1210, DOI 10.4269/ajtmh.20-0275
   Loconsole D, 2020, INFECTION, DOI 10.1007/s15010-020-01444-1
   Oh MD, 2016, NEW ENGL J MED, V375, P1303, DOI 10.1056/NEJMc1511695
   Okhuese VA, 2020, JMIR PUBLIC HLTH SUR, V6
   Ota Miyo, 2020, Nat Rev Immunol, V20, P351, DOI 10.1038/s41577-020-0316-3
   Paz-Bailey G, 2019, NEW ENGL J MED, V380, P198, DOI 10.1056/NEJMc1814416
   Sah R, 2020, MICROBIOL RESOUR ANN, V9, DOI 10.1128/MRA.00169-20
   Wang YM, 2018, J INFECT DIS, V217, P1708, DOI 10.1093/infdis/jiy115
   Williams DR, 2020, JAMA-J AM MED ASSOC, V323, P2478, DOI 10.1001/jama.2020.8051
   Xiao AT, 2020, J MED VIROL, V92, P1755, DOI 10.1002/jmv.25855
   York A, 2020, NAT REV MICROBIOL, V18, P1, DOI 10.1038/s41579-019-0302-6
NR 28
TC 1
Z9 1
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
DI 10.1002/jmv.26496
EA SEP 2020
PG 6
WC Virology
SC Virology
GA NT2YK
UT WOS:000572812500001
PM 32897549
OA Other Gold
DA 2021-01-01
ER

PT J
AU Wang, J
   Zhang, XL
   Omarini, AB
   Li, BL
AF Wang, Jiao
   Zhang, Xiaoli
   Omarini, Alejandra B.
   Li, Binglin
TI Virtual screening for functional foods against the main protease of
   SARS-CoV-2
SO JOURNAL OF FOOD BIOCHEMISTRY
LA English
DT Article
DE docking; functional foods; molecular dynamics; quercetrin; SARS-CoV-2
ID GUI MEMBRANE-BUILDER; DYNAMICS
AB The special attention was paid on the interaction between functional foods and the main protease of severe acute respiratory syndrome coronavirus (SARS-CoV-2). Here, 10,870 ligands were employed and screened by the molecular docking, which involved 12 kinds of functional foods (carbohydrates, fatty acids, phospholipids, vitamin, beta-sitosterol, flavonoids, nordihydroguaiaretic acid, curcumin, nootkatone, beta-pinene, tincturoid, betulinic acid, and their isomers/analogs/derivatives). Then, 60 ligands were obtained with the good docking affinity. Most of them belong to quercetrin and its isomers/analogs/derivatives, which also showed the highest affinity for the main protease of SARS-CoV-2. The dynamic simulation indicated that quercetrin-protease and quercetrin-analog-protease showed the excellent stability. Compared with reported docking results, quercetrin should be the best inhibitor for the main protease of SARS-CoV-2. Considering the green and white tea are rich in quercetrin and its isomers/analogs/derivatives, tea and relative beverages may become a good option to regulate our metabolism and help us to overcome this special time.
   Practical applications
   The docking and molecular dynamics technology were combined to screen the functional foods, which would be the potential candidate of the inhibitor for SARS-CoV-2. Many functional foods screened in this work belong to necessary nutrients for body. Thus, SARS-CoV-2 would consume some necessary nutrients, and thus, damage our body. It should be further consideration whether exogenous nutrients should be provided to slow, halt, or reverse biochemical alterations and structural deterioration in our body. On the contrary, this work also provided a new possibility to design a functional food or drug to help us overcome this special time.
C1 [Wang, Jiao] Northwest Univ, Sch Chem Engn, Xian, Peoples R China.
   [Zhang, Xiaoli; Li, Binglin] Northwest Univ, Coll Food Sci & Engn, 229 North Taibai Rd, Xian 710000, Shaanxi, Peoples R China.
   [Omarini, Alejandra B.] Univ Nacl La Pampa, Inst Earth & Environm Sci La Pampa, Santa Rosa, Argentina.
RP Zhang, XL; Li, BL (corresponding author), Northwest Univ, Coll Food Sci & Engn, 229 North Taibai Rd, Xian 710000, Shaanxi, Peoples R China.
EM xlzhang@nwu.edu.cn; libinglin@nwu.edu.cn
FU Key Research and Invention Program in Shaanxi Province of China
   [2020NY-127, 2018NY-131]
FX This work was supported by Key Research and Invention Program in Shaanxi
   Province of China (Program No. 2020NY-127 and 2018NY-131).
CR Binglin L., 2020, DRYAD DATASET, DOI [10.5061/dryad.j9kd51c8w, DOI 10.5061/DRYAD.J9KD51C8W]
   Gray R., 2020, BBC
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000880
   Jo S, 2009, BIOPHYS J, V97, P50, DOI 10.1016/j.bpj.2009.04.013
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Multum Cerner, 2020, RIBOFLAVIN
   Odhar HA, 2020, BIOINFORMATION, V16, P236, DOI 10.6026/97320630016236
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Rudkowska I, 2008, J AM COLL NUTR, V27, P588, DOI 10.1080/07315724.2008.10719742
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Wu EL, 2014, J COMPUT CHEM, V35, P1997, DOI 10.1002/jcc.23702
NR 21
TC 0
Z9 0
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-8884
EI 1745-4514
J9 J FOOD BIOCHEM
JI J. Food Biochem.
PD NOV
PY 2020
VL 44
IS 11
AR e13481
DI 10.1111/jfbc.13481
EA SEP 2020
PG 11
WC Biochemistry & Molecular Biology; Food Science & Technology
SC Biochemistry & Molecular Biology; Food Science & Technology
GA OY0PV
UT WOS:000572816700001
PM 32984999
DA 2021-01-01
ER

PT J
AU Logunov, DY
   Dolzhikova, IV
   Zubkova, OV
   Tukhvatullin, AI
   Shcheblyakov, DV
   Dzharullaeva, AS
   Grousova, DM
   Erokhova, AS
   Kovyrshina, AV
   Botikov, AG
   Izhaeva, FM
   Popova, O
   Ozharovskaya, TA
   Esmagambetov, IB
   Favorskaya, IA
   Zrelkin, DI
   Voronina, DV
   Shcherbinin, DN
   Semikhin, AS
   Simakova, YV
   Tokarskaya, EA
   Lubenets, NL
   Egorova, DA
   Shmarov, MM
   Nikitenko, NA
   Morozova, LF
   Smolyarchuk, EA
   Kryukov, EV
   Babira, VF
   Borisevich, SV
   Naroditsky, BS
   Gintsburg, AL
AF Logunov, Denis Y.
   Dolzhikova, Inna V.
   Zubkova, Olga V.
   Tukhvatullin, Amir I.
   Shcheblyakov, Dmitry V.
   Dzharullaeva, Alina S.
   Grousova, Daria M.
   Erokhova, Alina S.
   Kovyrshina, Anna V.
   Botikov, Andrei G.
   Izhaeva, Fatima M.
   Popova, Olga
   Ozharovskaya, Tatiana A.
   Esmagambetov, Ilias B.
   Favorskaya, Irina A.
   Zrelkin, Denis I.
   Voronina, Daria V.
   Shcherbinin, Dmitry N.
   Semikhin, Alexander S.
   Simakova, Yana V.
   Tokarskaya, Elizaveta A.
   Lubenets, Nadezhda L.
   Egorova, Daria A.
   Shmarov, Maksim M.
   Nikitenko, Natalia A.
   Morozova, Lola F.
   Smolyarchuk, Elena A.
   Kryukov, Evgeny V.
   Babira, Vladimir F.
   Borisevich, Sergei V.
   Naroditsky, Boris S.
   Gintsburg, Alexander L.
TI Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous
   prime-boost COVID-19 vaccine in two formulations: two open,
   non-randomised phase 1/2 studies from Russia
SO LANCET
LA English
DT Article
ID GENE-THERAPY; SARS-COV-2; STRATEGIES; RESPONSES; RECEPTOR
AB Background We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S). We aimed to assess the safety and immunogenicity of two formulations ( frozen and lyophilised) of this vaccine.
   Methods We did two open, non-randomised phase 1/2 studies at two hospitals in Russia. We enrolled healthy adult volunteers (men and women) aged 18-60 years to both studies. In phase 1 of each study, we administered intramuscularly on day 0 either one dose of rAd26-S or one dose of rAd5-S and assessed the safety of the two components for 28 days. In phase 2 of the study, which began no earlier than 5 days after phase 1 vaccination, we administered intramuscularly a prime-boost vaccination, with rAd26-S given on day 0 and rAd5-S on day 21. Primary outcome measures were antigen-specific humoral immunity (SARS-CoV-2-specific antibodies measured by ELISA on days 0, 14, 21, 28, and 42) and safety (number of participants with adverse events monitored throughout the study). Secondary outcome measures were antigen-specific cellular immunity (T-cell responses and interferon-gamma concentration) and change in neutralising antibodies (detected with a SARS-CoV-2 neutralisation assay). These trials are registered with ClinicalTrials.gov, NCT04436471 and NCT04437875.
   Findings Between June 18 and Aug 3, 2020, we enrolled 76 participants to the two studies (38 in each study). In each study, nine volunteers received rAd26-S in phase 1, nine received rAd5-S in phase 1, and 20 received rAd26-S and rAd5-S in phase 2. Both vaccine formulations were safe and well tolerated. The most common adverse events were pain at injection site (44 [58%]), hyperthermia (38 [50%]), headache (32 [42%]), asthenia (21 [28%]), and muscle and joint pain (18 [24%]). Most adverse events were mild and no serious adverse events were detected. All participants produced antibodies to SARS-CoV-2 glycoprotein. At day 42, receptor binding domain-specific IgG titres were 14 703 with the frozen formulation and 11 143 with the lyophilised formulation, and neutralising antibodies were 49.25 with the frozen formulation and 45.95 with the lyophilised formulation, with a seroconversion rate of 100%. Cell-mediated responses were detected in all participants at day 28, with median cell proliferation of 2.5% CD4(+) and 1.3% CD8(+) with the frozen formulation, and a median cell proliferation of 1.3% CD4(+) and 1.1% CD8(+) with the lyophilised formulation.
   Interpretation The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants. Further investigation is needed of the effectiveness of this vaccine for prevention of COVID-19. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Logunov, Denis Y.; Dolzhikova, Inna V.; Zubkova, Olga V.; Tukhvatullin, Amir I.; Shcheblyakov, Dmitry V.; Dzharullaeva, Alina S.; Grousova, Daria M.; Erokhova, Alina S.; Kovyrshina, Anna V.; Botikov, Andrei G.; Izhaeva, Fatima M.; Popova, Olga; Ozharovskaya, Tatiana A.; Esmagambetov, Ilias B.; Favorskaya, Irina A.; Zrelkin, Denis I.; Voronina, Daria V.; Shcherbinin, Dmitry N.; Semikhin, Alexander S.; Simakova, Yana V.; Tokarskaya, Elizaveta A.; Lubenets, Nadezhda L.; Egorova, Daria A.; Shmarov, Maksim M.; Nikitenko, Natalia A.; Naroditsky, Boris S.; Gintsburg, Alexander L.] Minist Hlth Russian Federat, Fed State Budget Inst, Natl Res Ctr Epidemiol & Microbiol, Moscow, Russia.
   [Morozova, Lola F.; Smolyarchuk, Elena A.] Sechenov Univ, Fed State Autonomous Educ Inst Higher Educ, IM Sechenov First Moscow State Med Univ, Minist Hlth Russian Federat, Moscow, Russia.
   [Kryukov, Evgeny V.] Minist Def Russian Federat, Main Mil Clin Hosp, Fed State Budgetary Inst, Moscow, Russia.
   [Babira, Vladimir F.] Minist Def Russian Federat, Branch 7, Fed State Budgetary Inst, Main Mil Clin Hosp, Moscow, Russia.
   [Borisevich, Sergei V.] Minist Def Russian Federat, Cent Res Inst 48, Moscow, Russia.
RP Logunov, DY (corresponding author), NF Gamaleya Natl Res Ctr Epidemiol & Microbiol, Moscow 123098, Russia.
EM ldenisy@gmail.com
RI Semikhin, Alexander/R-6760-2019; Logunov, Denis/E-8300-2014; Morozova,
   Lola/C-7721-2014
OI Semikhin, Alexander/0000-0003-0560-5589; Kryukov,
   Evgeniy/0000-0002-8396-1936; Logunov, Denis/0000-0003-4035-6581;
   Morozova, Lola/0000-0003-3033-1401; Zrelkin, Denis/0000-0003-0899-8357;
   Shmarov, Maxim/0000-0002-5268-1296
FU Ministry of Health of the Russian Federation [056-00034-20-02]
FX This research was supported by the Ministry of Health of the Russian
   Federation (state assignment no 056-00034-20-02, to ALG and DYL). We
   thank the study participants, site research staff, and members of the
   trial management groups, trial steering committee, and independent data
   monitoring committee.
CR Afkhami S, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.30
   Ahlers JD, 2010, BLOOD, V115, P1678, DOI 10.1182/blood-2009-06-227546
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Datta PK, 2020, THERANOSTICS, V10, P7448, DOI 10.7150/thno.48076
   Dolzhikova IV, 2017, ACTA NATURAE, V9, P4, DOI 10.32607/20758251-2017-9-3-4-11
   Dolzhikova IV, 2017, HUM VACC IMMUNOTHER, V13, P613, DOI 10.1080/21645515.2016.1238535
   Evans TG, 1998, CLIN EXP IMMUNOL, V111, P243
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   [Ковыршина А.В. Kovyrshina A.V.], 2020, [Иммунология, Immunology, Immunologiya], V41, P35, DOI 10.33029/0206-4952-2020-41-2-135-143
   Mubarak A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6491738
   Othman H, 2020, BIOCHEM BIOPH RES CO, V527, P702, DOI 10.1016/j.bbrc.2020.05.028
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Sheridan C, 2011, NAT BIOTECHNOL, V29, P121, DOI 10.1038/nbt.1769
   Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013
   US Centers for Disease Control and Prevention, 2020, HEP B VIS
   Volpers C, 2004, J GENE MED, V6, pS164, DOI 10.1002/jgm.496
   Wang DL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030355
   WHO, 2020, TRANSM SARS COV 2 IM
   Wold WSM, 2013, CURR GENE THER, V13, P421
   World Health Organization, 2019, COR DIS COVID 19 PAN
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xu XJ, 2004, CELL MOL IMMUNOL, V1, P119
   Zhang C, 2016, HUM VACC IMMUNOTHER, V12, P2064, DOI 10.1080/21645515.2016.1165908
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang WW, 2018, HUM GENE THER, V29, P160, DOI 10.1089/hum.2017.218
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 32
TC 21
Z9 20
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD SEP 26
PY 2020
VL 396
IS 10255
BP 887
EP 897
DI 10.1016/S0140-6736(20)31866-3
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ8FF
UT WOS:000577336800024
PM 32896291
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Scherrmann, JM
AF Scherrmann, Jean-Michel
TI Possible Role of ABCB1 in Lysosomal Accumulation of Azithromycin in
   COVID-19 Therapy
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Letter; Early Access
C1 [Scherrmann, Jean-Michel] Univ Paris, Inserm, UMRS 1144, Fac Pharm, Paris, France.
RP Scherrmann, JM (corresponding author), Univ Paris, Inserm, UMRS 1144, Fac Pharm, Paris, France.
EM jean-michel.scherrmann@inserm.fr
CR Damle B, 2020, CLIN PHARMACOL THER, V108, P201, DOI 10.1002/cpt.1857
   Derendorf H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.106007
   Poschet Jens F, 2020, bioRxiv, DOI 10.1101/2020.03.29.008631
   Scherrmann JM, 2020, AAPS J, V22, DOI 10.1208/s12248-020-00465-w
   Simmons G, 2011, VIROLOGY, V413, P265, DOI 10.1016/j.virol.2011.02.020
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9236
EI 1532-6535
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
DI 10.1002/cpt.2020
EA SEP 2020
PG 1
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NT1DJ
UT WOS:000572690200001
PM 32804426
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wu, L
   Yuan, Q
   Kuang, YB
   Chen, Y
   Li, J
   Feng, YH
   Luo, J
AF Wu, Liu
   Yuan, Qiang
   Kuang, Yongbing
   Chen, Yong
   Li, Jin
   Feng, Yinhao
   Luo, Jian
TI External treatment of traditional Chinese medicine for COVID-19 A
   protocol for systematic review and meta-analysis
SO MEDICINE
LA English
DT Article
DE COVID-19; systematic review; traditional Chinese medicine
AB Background: There is a worldwide outbreak of COVID-19, as the number of patients increases. External treatment of traditional Chinese medicine includes acupuncture, massage, fire needle, cupping, and other alternative therapies. Currently, there are no relevant articles for systematic review. Methods: We will search the randomized controlled trials related to the external treatment of traditional Chinese medicine (such as, acupuncture, massage, etc) and COVID-19 from inception to June 2020. The following database is our focus area: the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, EMBASE, Web of Science, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Wan-Fang Database. All published randomized controlled trials in English or Chinese related to massage for COVID-19 will be included. Primary outcomes include the influence of external treatment of traditional Chinese medicine on the patients with COVID-19. Secondary outcomes include accompanying symptoms (such as myalgia, expectoration, stuffiness, runny nose, pharyngalgia, anhelation, chest distress, dyspnea, crackles, headache, nausea, vomiting, anorexia, diarrhea) disappear rate, negative COVID-19 results rate on 2 consecutive occasions (not on the same day), average hospitalization time, Clinical curative effect, and improved quality of life. Results: The results will provide a high-quality synthesis of current evidence for researchers in this subject area. Conclusion: The conclusion of our study will provide evidence to judge whether external treatment of traditional Chinese medicine is an effective intervention on the patients with COVID-19. PROSPERO registration number: CRD42020181336
C1 [Wu, Liu; Yuan, Qiang; Kuang, Yongbing; Li, Jin; Feng, Yinhao; Luo, Jian] Hosp Chengdu Univ Tradit Chinese Med, Dept Tuina, Chengdu, Sichuan, Peoples R China.
   [Chen, Yong] Hosp Chengdu Univ Tradit Chinese Med, Emergency Dept, Chengdu, Sichuan, Peoples R China.
RP Luo, J (corresponding author), Hosp Chengdu Univ Tradit Chinese Med, 39 Shi Er Qiao Rd, Chengdu 610072, Sichuan, Peoples R China.
EM Lj6176@126.com
FU Chengdu Science and Technology Bureau [2015-HM01-00432-SF]
FX This study was supported by Chengdu Science and Technology Bureau
   (NO.2015-HM01-00432-SF).
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Chu Kuo-An, 2007, J Chin Med Assoc, V70, P265, DOI 10.1016/S1726-4901(07)70002-3
   Davis P A, 1998, Allergol Immunopathol (Madr), V26, P263
   Gansler T, 2008, CANCER-AM CANCER SOC, V113, P1048, DOI 10.1002/cncr.23659
   Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]
   Shigemura J, 2020, PSYCHIAT CLIN NEUROS, V74, P281, DOI 10.1111/pcn.12988
   Yan YX, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072323
   Yu Wen-Hua, 2020, Zool Res, P1, DOI 10.24272/j.issn.2095-8137.2020.224
   Zhao Wenming, 2020, Yichuan, V42, P212, DOI 10.16288/j.yczz.20-030
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhuang Y, 2013, INT REV NEUROBIOL, V111, P1, DOI 10.1016/B978-0-12-411545-3.00001-8
NR 17
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP 25
PY 2020
VL 99
IS 39
DI 10.1097/MD.0000000000022316
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC8ZT
UT WOS:000579445400040
PM 32991438
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alberca, RW
   Teixeira, FME
   Beserra, DR
   de Oliveira, EA
   Andrade, MMD
   Pietrobon, AJ
   Sato, MN
AF Alberca, Ricardo Wesley
   Teixeira, Franciane Mouradian Emidio
   Beserra, Danielle Rosa
   de Oliveira, Emily Araujo
   Andrade, Milena Mary de Souza
   Pietrobon, Anna Julia
   Sato, Maria Notomi
TI Perspective: The Potential Effects of Naringenin in COVID-19
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE antiviral; anti-inflammatory; naringenin; SARS-CoV-2; COVID-19; TNF;
   ACE2
ID RESPIRATORY SYNDROME-CORONAVIRUS; INDUCED AIRWAY INFLAMMATION; FLAVONOID
   NARINGENIN; IN-VITRO; GRAPEFRUIT JUICE; OXIDATIVE STRESS; CYTOKINE
   STORM; SARS-COV; HUMANS; MERS
AB Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), was declared a pandemic by the World Health Organization in March 2020. Severe COVID-19 cases develop severe acute respiratory syndrome, which can result in multiple organ failure, sepsis, and death. The higher risk group includes the elderly and subjects with pre-existing chronic illnesses such as obesity, hypertension, and diabetes. To date, no specific treatment or vaccine is available for COVID-19. Among many compounds, naringenin (NAR) a flavonoid present in citrus fruits has been investigated for antiviral and anti-inflammatory properties like reducing viral replication and cytokine production. In this perspective, we summarize NAR potential anti-inflammatory role in COVID-19 associated risk factors and SARS-CoV-2 infection.
C1 [Alberca, Ricardo Wesley; Beserra, Danielle Rosa; de Oliveira, Emily Araujo; Andrade, Milena Mary de Souza; Sato, Maria Notomi] Univ Sao Paulo, Sch Med, Dept Dermatol, Lab Dermatol & Immunodeficiencies,LIM 56, Sao Paulo, Brazil.
   [Alberca, Ricardo Wesley; Beserra, Danielle Rosa; de Oliveira, Emily Araujo; Andrade, Milena Mary de Souza; Sato, Maria Notomi] Univ Sao Paulo, Inst Trop Med Sao Paulo, Sao Paulo, Brazil.
   [Teixeira, Franciane Mouradian Emidio; Pietrobon, Anna Julia] Univ Sao Paulo, Inst Biomed Sci, Sao Paulo, Brazil.
RP Alberca, RW (corresponding author), Univ Sao Paulo, Sch Med, Dept Dermatol, Lab Dermatol & Immunodeficiencies,LIM 56, Sao Paulo, Brazil.; Alberca, RW (corresponding author), Univ Sao Paulo, Inst Trop Med Sao Paulo, Sao Paulo, Brazil.
EM ricardowesley@gmail.com
RI Custodio, Ricardo Wesley Alberca/D-9895-2016
OI Custodio, Ricardo Wesley Alberca/0000-0002-3602-3306; de Souza Andrade,
   Milena Mary/0000-0003-0226-3413
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [17/18199-9, 19/02679-7, 18/18230-6, 19/269286]
FX RA holds a post-doctorate fellowship from FAPESP (19/02679-7). FT holds
   a doctorate fellowship from FAPESP (18/18230-6). EO holds a scientific
   initiation fellowship from FAPESP (19/269286). MS have a research grant
   from FAPESP (17/18199-9).
CR Ahmadi A, 2016, RSC ADV, V6, P69421, DOI 10.1039/c6ra16640g
   Al-Rejaie SS, 2015, NEUROL RES, V37, P924, DOI 10.1179/1743132815Y.0000000079
   Alberca GGF, 2020, FRONT YOUNG MINDS, V8, DOI [10.3389/frym.2020.00074, DOI 10.3389/FRYM.2020.00074]
   Alberca RW, 2020, CRIT REV FOOD SCI, DOI 10.1080/10408398.2020.1775546
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Andreone P, 2001, ANTIVIR RES, V49, P75, DOI 10.1016/S0166-3542(00)00141-8
   Assini JM, 2015, ENDOCRINOLOGY, V156, P2087, DOI 10.1210/en.2014-2003
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Benkerrou D, 2019, BIOPHYS CHEM, V254, DOI 10.1016/j.bpc.2019.106246
   Bodet C, 2008, J PERIODONTAL RES, V43, P400, DOI 10.1111/j.1600-0765.2007.01055.x
   Bourian M, 1999, EXP TOXICOL PATHOL, V51, P289, DOI 10.1016/S0940-2993(99)80008-6
   Braz-De-Melo HA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56556-y
   Breinholt VM, 2008, BASIC CLIN PHARMACOL, V94, P30, DOI [10.1111/j.1742-7843.2004.pto_940106.x, DOI 10.1111/J.1742-7843.2004.PTO_940106.X]
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Castrillo M, 2015, AV BIOMED, V4, P69
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chen G., 2020, CLIN IMMUNOLOGIC FEA, DOI [10.1101/2020.02.16.20023903, DOI 10.1101/2020.02.16.20023903]
   Chen H., 2020, POTENTIAL NATURAL CO, DOI [10.20944/preprints202001.0358.v3, 10.20944/preprints202001., DOI 10.20944/PREPRINTS202001.0358.V3]
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen SY, 2012, FOOD CHEM TOXICOL, V50, P3025, DOI 10.1016/j.fct.2012.06.006
   Cheng L, 2020, CITRUS FRUITS ARE RI, DOI 10.20944/preprints202002.0313.v1
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Den Hartogh DJ, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9030099
   Cataneo AHD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52626-3
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Dou W, 2013, BRIT J NUTR, V110, P599, DOI 10.1017/S0007114512005594
   Du GJ, 2009, CANCER RES, V69, P3205, DOI 10.1158/0008-5472.CAN-08-3393
   Erlund I, 2001, J NUTR, V131, P235
   Fast DJ, 2019, J FOOD BIOACT, V8, P58, DOI [10.31665/jfb.2019.8207, DOI 10.31665/JFB.2019.8207]
   da Silva CCF, 2019, REV BRAS FARMACOGN, V29, P309, DOI 10.1016/j.bjp.2019.04.001
   Fouad AA, 2016, PHARMACOLOGY, V97, P224, DOI 10.1159/000444262
   Fox SE., PULMONARY CARDIAC PA, DOI [10.1101/2020.04.06.20050575, DOI 10.1101/2020.04.06.20050575]
   Frabasile S, 2017, SCI REP-UK, V7, DOI 10.1038/srep41864
   FUHR U, 1995, CLIN PHARMACOL THER, V58, P365, DOI 10.1016/0009-9236(95)90048-9
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Gembardt F, 2005, PEPTIDES, V26, P1270, DOI 10.1016/j.peptides.2005.01.009
   Gera S, 2017, AAPS PHARMSCITECH, V18, P3151, DOI 10.1208/s12249-017-0790-5
   Goldwasser J, 2011, J HEPATOL, V55, P963, DOI 10.1016/j.jhep.2011.02.011
   Goncalves D, 2017, FOOD NUTR RES, V61, DOI 10.1080/16546628.2017.1296675
   Grimm C, 2020, CELL CALCIUM, V88, DOI 10.1016/j.ceca.2020.102212
   Gunaratne GS, 2018, CELL CALCIUM, V75, P30, DOI 10.1016/j.ceca.2018.08.003
   Gupta SC, 2014, ARCH BIOCHEM BIOPHYS, V559, P91, DOI 10.1016/j.abb.2014.06.006
   Habauzit V, 2015, AM J CLIN NUTR, V102, P66, DOI 10.3945/ajcn.114.104646
   Hansdottir S, 2010, J IMMUNOL, V184, P965, DOI 10.4049/jimmunol.0902840
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Iwamura Chiaki, 2010, Allergology International, V59, P67, DOI 10.2332/allergolint.09-OA-0118
   Jain A, 2011, ECOTOX ENVIRON SAFE, V74, P607, DOI 10.1016/j.ecoenv.2010.08.002
   Jin LT, 2017, J IMMUNOL, V199, P3466, DOI 10.4049/jimmunol.1602016
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Jo S, 2019, CHEM BIOL DRUG DES, V94, P2023, DOI 10.1111/cbdd.13604
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kanaze FI, 2007, EUR J CLIN NUTR, V61, P472, DOI 10.1038/sj.ejcn.1602543
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Khan AW, 2015, DRUG DELIV, V22, P552, DOI 10.3109/10717544.2013.878003
   Kim JH, 2015, ARCH PHARM RES, V38, P2042, DOI 10.1007/s12272-015-0624-5
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kumar RP, 2016, CHEM-BIOL INTERACT, V257, P110, DOI 10.1016/j.cbi.2016.07.012
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lin Y, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/8753894
   Liu J, 2020, NEUTROPHIL TO LYMPHO, DOI [10.1101/2020.02.10.20021584, DOI 10.1101/2020.02.10.20021584]
   Liu Jinghua, 2018, J Microbiol Biotechnol, DOI 10.4014/jmb.1810.10061
   Liu X, 2016, SCI REP-UK, V6, DOI 10.1038/srep39735
   Lu WJ, 2011, CHIRALITY, V23, P891, DOI 10.1002/chir.21005
   Lyu SY, 2005, ARCH PHARM RES, V28, P1293, DOI 10.1007/BF02978215
   MAHASE E, 2020, BMJ-BRIT MED J, V368, P48071, DOI DOI 10.1136/BMJ.M641
   Manchope MF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153015
   Martinez RM, 2015, J NAT PROD, V78, P1647, DOI 10.1021/acs.jnatprod.5b00198
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Mu L, 2019, MED SCI MONITOR, V25, P5986, DOI 10.12659/MSM.916400
   Mulvihill EE, 2009, DIABETES, V58, P2198, DOI 10.2337/db09-0634
   Nahmias Y, 2008, HEPATOLOGY, V47, P1437, DOI 10.1002/hep.22197
   Nguyen-Ngo C, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201900224
   Nielsen ILF, 2006, J NUTR, V136, P404
   Palmeira P, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1947
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Pinho-Ribeiro FA, 2016, J NUTR BIOCHEM, V33, P8, DOI 10.1016/j.jnutbio.2016.03.013
   Pinho-Ribeiro FA, 2016, NEUROPHARMACOLOGY, V105, P508, DOI 10.1016/j.neuropharm.2016.02.019
   Pohjala L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028923
   Qin L, 2011, PROTEIN CELL, V2, P507, DOI 10.1007/s13238-011-1056-8
   Rabaan Ali A, 2020, Infez Med, V28, P174
   RECOURT K, 1989, J BACTERIOL, V171, P4370, DOI 10.1128/JB.171.8.4370-4377.1989
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Romaszko E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185954
   Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003
   Salehi B, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12010011
   Peron JPS, 2020, CLINICS, V75, DOI 10.6061/clinics/2020/e1912
   Shen DB, 2011, BIOESSAYS, V33, P448, DOI 10.1002/bies.201000152
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Shi Y, 2009, CAN J PHYSIOL PHARM, V87, P729, DOI [10.1139/Y09-065, 10.1139/y09-065]
   Smith AM, 2009, J EXP MED, V206, P1883, DOI 10.1084/jem.20091233
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Tamura J, 1999, CLIN EXP IMMUNOL, V116, P28
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HK, 2012, J AGR FOOD CHEM, V60, P2171, DOI 10.1021/jf204625y
   Wang K, 2020, SARS COV 2 INVADES H, V3, P14, DOI DOI 10.1101/2020.03.14.988345
   Wang YW, 2017, AAPS PHARMSCITECH, V18, P586, DOI 10.1208/s12249-016-0537-8
   Wang ZZ, 2019, INT J MED SCI, V16, P644, DOI 10.7150/ijms.31075
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Widagdo W, 2016, J VIROL, V90, P4838, DOI 10.1128/JVI.02994-15
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071
   Xiong GH, 2016, INFLAMMATION, V39, P891, DOI 10.1007/s10753-016-0321-7
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Yilma AN, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/102457
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Zandi K, 2011, J MED PLANTS RES, V5, P5534
   Zeng WF, 2018, PHARMACOL RES, V135, P122, DOI 10.1016/j.phrs.2018.08.002
   Zhang C, 2018, J PHARMACOL EXP THER, V366, P341, DOI 10.1124/jpet.118.248807
   Zhang FY, 2009, PHARM RES-DORDR, V26, P914, DOI 10.1007/s11095-008-9793-y
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang YH, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110195
   Zhao MH, 2017, EXP THER MED, V14, P2228, DOI 10.3892/etm.2017.4772
NR 121
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 25
PY 2020
VL 11
AR 570919
DI 10.3389/fimmu.2020.570919
PG 9
WC Immunology
SC Immunology
GA OA5ZF
UT WOS:000577862200001
PM 33101291
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU West, H
AF West, Howard (Jack)
TI Telemedicine in Oncology: Delivering on an Overdue Promise in the
   COVID-19 Era
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE telemedicine; tele-oncology; telehealth; coronavirus; COVID-19
AB Telemedicine has historically been underutilized in medicine broadly, and specifically in oncology, despite the general availability of the needed infrastructure to offer it as a platform for remote care. The COVID-19 pandemic posed new risks of infection exposure and potentially life-threatening complications, particularly in patients with cancer, created a new setting for cancer care ideally suited for the rapid roll-out of telemedicine for patients with cancer who need regular follow up but in whom live visits may not be critical. In the months since the upheaval of our health care system and wider society in the United States, as well as other countries, our early experience with telemedicine has demonstrated the feasibility of telemedicine for a subset of patients with cancer, facilitated by a removal of regulatory hurdles and payment parity, at least temporarily. At the same time, however, many patients still need to return to the clinic for routine infusions of anti-cancer therapy that obviate much of the value of remote clinic visits, and many patients remain limited by access to hardware, fast and reliable internet, and technical expertise. While we need to address these shortcomings and ensure training of health care professionals in "webside manner" with patients, as well as to work to develop ways to incorporate remote care in the conduct of clinical trials, telemedicine is poised to emerge not merely as an interim solution to a transient challenge but as a valuable tool ideally suited to deliver cancer care efficiently for a subset of patients well suited to adopt this platform.
C1 [West, Howard (Jack)] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA 91010 USA.
   [West, Howard (Jack)] AccessHope, Duarte, CA 91010 USA.
RP West, H (corresponding author), City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA 91010 USA.; West, H (corresponding author), AccessHope, Duarte, CA 91010 USA.
EM hwest@coh.org
CR [Anonymous], 2020, MED TEL HLTH CAR FAC
   Anthem Press, 2020, 2019 NATL HLTH BENEF
   Barrett J., 2020, CASE STUDY REVEALS R
   Centers for Medicare and Medicaid Services, 2020, TRUMP ADM ISS 2 ROUN
   Garber J., 2020, WHATS DRIVING AM RUR
   Henry TA., 2020, COVID 19 MAKES TELEM
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Mamedova S, 2020, DESCRIPTION US ADULT
   National Telehealth Policy Resource Center, 2020, COVID 19 TEL COV POL
   Rae M, 2020, COVERAGE UTILIZATION
   Rosenblatt RA, 2000, WESTERN J MED, V173, P348, DOI 10.1136/ewjm.173.5.348
   Ryan C, 2020, COMPUTER INTERNET US
NR 13
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD SEP 25
PY 2020
VL 10
AR 578888
DI 10.3389/fonc.2020.578888
PG 4
WC Oncology
SC Oncology
GA OA6EK
UT WOS:000577875700001
PM 33102236
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abbas, MZ
AF Abbas, Muhammad Zaheer
TI Strategic use of patent opposition safeguard to improve equitable access
   to innovative health technologies: A case study of CAR T-cell therapy
   Kymriah
SO GLOBAL PUBLIC HEALTH
LA English
DT Article; Early Access
DE Civil society; gene therapy; Kymriah; patent opposition; public health
AB Kymriah is an innovative cancer therapy which works by removing disease fighting T-cells from patients, genetically modifying or reprogramming the immune cells to attack cancer, and re-infusing them back into the patients. It treats childhood blood and bone marrow cancer. The cost of this new hope-giving gene therapy is CHF 450,000 per treatment. This exorbitantly high price set by Novartis, in exercise of its exclusive rights resulting from patent protection, undermines the real-world impact of this revolutionary therapy. On December 16, 2019, Novartis relinquished its European patent on Kymriah as a result of a successful patent opposition lodged by 'Public Eye' and 'Medicins du Monde'. This case study of Kymriah highlights the potential role of civil society in improving equitable and affordable access to innovative health technologies by using the procedural safeguard of patent opposition. This study finds that patent opposition is an important policy option to alleviate some of the financial burdens of health systems, especially in the wake of COVID-19.
C1 [Abbas, Muhammad Zaheer] Queensland Univ Technol QUT, Fac Law, Brisbane, Qld, Australia.
RP Abbas, MZ (corresponding author), Queensland Univ Technol, Brisbane, Qld, Australia.
EM muhammadzaheer.abbas@connect.qut.edu.au
OI Abbas, Muhammad Zaheer/0000-0002-8301-885X
CR Ali S, 2020, ONCOLOGIST, V25, pE321, DOI 10.1634/theoncologist.2019-0233
   [Anonymous], 2010, LANCET, V376, P657, DOI 10.1016/S0140-6736(10)61315-3
   [Anonymous], 2018, PROTECT PATIENTS NOT
   Bach PB, 2017, JAMA-J AM MED ASSOC, V318, P1861, DOI 10.1001/jama.2017.15218
   Bonnet CS, 2017, J ORTHOP RES, V35, pS1
   Brigand T., 2018, CAR T CELL THERAPIES
   Cavallo J., 2018, AM SOC CLIN ONCOLOGY
   Charles N., 2019, European Patent Application, Patent No. [17191702.4, 17191702]
   Charles N., 2019, Oppositions to the grant of European Parent No. 3214091/17153799.6 in the name of: The Trustees of the University of Pennsylvania, Patent No. 321409117153799
   CMS, 2017, INN TREATM CALL INN
   Correa C. M., 2007, GUIDELINES EXAMINATI
   Douglass CH, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1162-z
   Gaessler F., 2017, ACAD MANAGEMENT P, DOI 10.5465/AMBPP.2017.302
   Gil Abinader L., 2019, PATENTABILITY GENETI
   Godara A, 2019, BIOL BLOOD MARROW TR, V25
   Grupp S, 2019, HUM GENE THER, V30, pA8
   Gugliuzza PR, 2018, GEORGETOWN LAW J, V106, P619
   Herper M., 2017, FORBES
   Hollywood J., 2019, RISE PATENT WARS EUR
   Homer C., 2018, HEMONC TODAY
   Huettermann Michalski, 2017, DOUBLE WIN KYMRIAH C
   ICER Institute for Clinical and Economic Review, 2018, PHARMACOECONOMICS OU
   Kimani J, 2020, GLOB PUBLIC HEALTH, V15, P1073, DOI 10.1080/17441692.2020.1770831
   Liu J., 2017, NEW DRUG REV
   Manu T, 2017, IIC-INT REV INTELL P, V48, P813, DOI 10.1007/s40319-017-0633-7
   Medecins Du Monde, 2019, PRESS KIT OPP EUR PA
   MULLIN E, 2017, TECHNOL REV, V120, P18
   National Institute for Health and Care Excellence, 2019, PHARMACO EC OUTCOMES
   Phrmaletter  T, 2018, PHRMALETTER
   Plomer A, 2015, PATENTS, HUMAN RIGHTS AND ACCESS TO SCIENCE, P1, DOI 10.4337/9781783475933
   Robinson JC, 2018, JAMA-J AM MED ASSOC, V319, P2169, DOI 10.1001/jama.2018.5367
   Shapiro M., 2019, CTV NEWS
   Shi Q., 2003, AIPLA QJ, V31, P433
   Singhroy D., 2017, KNOWLEDGE ECOLOGY IN
   U.S. Food and Drug Association, 2017, BL 125646 0 BIOL APP
   Upton J., 2018, PHARM EXECUTIVE
   World Health Organization, 2006, PUBL HLTH INN INT PR
   World Trade Organization, 1995, AGR TRAD REL ASP INT
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1744-1692
EI 1744-1706
J9 GLOB PUBLIC HEALTH
JI Glob. Public Health
DI 10.1080/17441692.2020.1825769
EA SEP 2020
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OA5HB
UT WOS:000577815000001
PM 33031009
OA Bronze
DA 2021-01-01
ER

PT J
AU Malhotra, A
   Hepokoski, M
   McCowen, KC
   Shyy, JYJ
AF Malhotra, Atul
   Hepokoski, Mark
   McCowen, Karen C.
   Shyy, John Y-J
TI ACE2, Metformin, and COVID-19
SO ISCIENCE
LA English
DT Article
AB COVID-19 is becoming a leading cause of mortality throughout the world, and few effective therapies are currently available. Angiotensin converting enzyme 2 (ACE2) is essential to COVID-19 pathogenesis, as the binding of SARS-CoV-2 spike protein (S protein) is required for viral entry and development of COVID-19. AC72 regulates the protective arm of the renin-angiotensin-aldosterone system (RAAS) that endows anti-hypertensive and anti-inflammatory effects in the cardiovascular and pulmonary systems. Preclinical data suggest ACE2 might be downregulated after SARS-CoV-2 binding, and treatments that increase ACE2 may prevent cardiopulmonary injury. Development, testing, and mass production of novel ACE2 therapies may take years, whereas more effective treatments for COVID-19 are needed urgently. Metformin is a widely available anti-diabetic agent that has an excellent safety profile, and clinical and preclinical data suggest metformin may offer cardiopulmonary protection in COVID-19 via enhanced ACE2 expression.
C1 [Malhotra, Atul; Hepokoski, Mark; McCowen, Karen C.; Shyy, John Y-J] Univ Calif San Diego, Dept Med, La Jolla, CA 92023 USA.
   [Malhotra, Atul; Hepokoski, Mark] Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, La Jolla, CA 92023 USA.
   [McCowen, Karen C.] Univ Calif San Diego, Div Endocrinol, La Jolla, CA 92023 USA.
   [Shyy, John Y-J] Univ Calif San Diego, Div Cardiol, La Jolla, CA 92023 USA.
   [Hepokoski, Mark] VA San Diego Hlth Syst, 9500 Gilman Dr, La Jolla, CA 92023 USA.
RP Malhotra, A; Shyy, JYJ (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92023 USA.; Malhotra, A (corresponding author), Univ Calif San Diego, Div Pulm Crit Care & Sleep Med, La Jolla, CA 92023 USA.; Shyy, JYJ (corresponding author), Univ Calif San Diego, Div Cardiol, La Jolla, CA 92023 USA.
EM amalhotra@health.ucsd.edu; jshyy@health.ucsd.edu
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01 HL148436, R01 HL085188, K24 HL132105] Funding
   Source: Medline; NIA NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [R01 AG063925] Funding Source: Medline
CR Bergmark BA, 2019, CIRCULATION, V140, P1004, DOI 10.1161/CIRCULATIONAHA.119.040144
   Chen ATC, 2020, NEW ENGL J MED, V382, P1859, DOI 10.1056/NEJMc2005203
   Chen XY, 2015, AM J PHYSIOL-LUNG C, V309, pL262, DOI 10.1152/ajplung.00389.2014
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Ji MX, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015095
   Jian MY, 2013, AM J PHYSIOL-LUNG C, V305, pL844, DOI 10.1152/ajplung.00173.2013
   Jo YS, 2017, TUBERC RESPIR DIS, V80, P296, DOI 10.4046/trd.2017.80.3.296
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Luo P, 2020, AM J TROP MED HYG, V103, P69, DOI 10.4269/ajtmh.20-0375
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Ouyang J, 2020, AIDS RES THER, V17, DOI 10.1186/s12981-020-00267-2
   Prospective Diabetes Study (UKPDS) Group, LANCET, V352, P837
   Ramchand J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198144
   Reddy R., 2019, PLOS ONE, V14
   Shang FQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151845
   Soberanes S, 2019, CELL METAB, V29, P335, DOI 10.1016/j.cmet.2018.09.019
   Santos RAS, 2018, PHYSIOL REV, V98, P505, DOI 10.1152/physrev.00023.2016
   Tsaknis G, 2012, CRIT CARE, V16, DOI 10.1186/cc11439
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yu S, 2013, CRIT CARE MED, V41, P2720, DOI 10.1097/CCM.0b013e318298a2eb
   Zhang J, 2018, AM J RESP CRIT CARE, V198, P509, DOI 10.1164/rccm.201712-2570OC
NR 23
TC 1
Z9 1
U1 3
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2589-0042
J9 ISCIENCE
JI iScience
PD SEP 25
PY 2020
VL 23
IS 9
AR 101425
DI 10.1016/j.isci.2020.101425
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NZ4VI
UT WOS:000577093800003
PM 32818905
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kumar, P
AF Kumar, Pradeep
TI Co-aerosolized Pulmonary Surfactant and Ambroxol for COVID-19 ARDS
   Intervention: What Are We Waiting for?
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE ARDS; COVID-19; pulmonary surfactant; ambroxol; evidence-based
   therapeutics
ID RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; PROTEINS;
   HYDROCHLORIDE; INACTIVATION; EXPECTORANT; MEMBRANES; THERAPY; ADULTS;
   FILMS
AB After more than 225 days of the first reports of the novel coronavirus from China, COVID-19 pandemic is still on surge. The search for an effective and efficient therapeutic and pharmaceutical intervention is as important and urgent now as it was on Day 1. Majority of the efforts in this direction are toward finding small molecule interventions via repurposing or redirecting the therapeutic approaches. This hypothesis proposes a physical intervention approach directed toward rescuing the complex lung pathology observed in COVID-19 related acute respiratory distress syndrome (CARDS). The loss of content as well as the synthesis and turnover of the surfactant in ARDS has been termed as a "collateral damage." A synergistic, early stage, cost-effective, pharmaceutically viable, safe, and immediately available solution is hence required. The effectiveness of exogenous surfactant treatment in ARDS has been marred with several limitations as pointed out in various clinical trials and require revised protocols related to surfactant dose and mode of delivery. This hypothesis proposes aerosolized surfactant delivery taking the optimal dosing and coating costs into account along with co-delivery of ambroxol to provide synergistic benefits. Ambroxol is reported to have anti-inflammatory, -oxidant, -viral, and -bacterial activities and has a direct impact on the production and secretion of the surfactant from the alveolar Type 2 cells. If aerosolized, atomized, or nebulized in the form of ambroxol-loaded phospholipid nanovesicles at the early stages of ARDS, depleted surfactant levels may be reinstated and surfactant turnover can be initiated and maintained. The ability to deliver both the components in aerosolized-nebulized form may have a huge impact on alleviating the healthcare burden in low resource settings where the availability of ventilators is limited. In conclusion, the surfactant-ambroxol co-aerosolized intervention approach hypothesized here has implications reaching to clinical and pharmaceutical translation worldwide.
C1 [Kumar, Pradeep] Univ Witwatersrand, Dept Pharm & Pharmacol, Fac Hlth Sci, Sch Therapeut Sci, Johannesburg, South Africa.
RP Kumar, P (corresponding author), Univ Witwatersrand, Dept Pharm & Pharmacol, Fac Hlth Sci, Sch Therapeut Sci, Johannesburg, South Africa.
EM pradeep.kumar@wits.ac.za
CR Basabe-Burgos O., 2020, THESIS
   Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9
   Chimote G, 2010, J BIOMED MATER RES B, V94B, P1, DOI 10.1002/jbm.b.31608
   Coronavirus Resource Center, 2020, COR RES CTR COVID 19
   Davidson WJ, 2006, CRIT CARE, V10, DOI 10.1186/cc4851
   Depfenhart M, 2020, INTERN EMERG MED, V15, P801, DOI 10.1007/s11739-020-02383-3
   Dhand R, 2017, RESP CARE, V62, P1343, DOI 10.4187/respcare.05803
   Dushianthan A, 2012, CRIT CARE, V16, DOI 10.1186/cc11512
   Echaide M, 2017, BBA-BIOMEMBRANES, V1859, P1725, DOI 10.1016/j.bbamem.2017.03.015
   Fattal E, 2018, EUR J PHARM SCI, V113, P1, DOI 10.1016/j.ejps.2017.10.037
   Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Gibson PG, 2020, MED J AUSTRALIA, V213, P54, DOI 10.5694/mja2.50674
   Grotberg JB, 2017, AM J RESP CRIT CARE, V195, P538, DOI 10.1164/rccm.201607-1401LE
   Joshi N, 2014, SCI REP-UK, V4, DOI 10.1038/srep07085
   Altube MJ, 2017, J MATER CHEM B, V5, P8083, DOI 10.1039/c7tb01694h
   Kanie S, 2017, J TOXICOL PATHOL, V30, P153, DOI 10.1293/tox.2016-0050
   Kantar Ahmad, 2020, Multidiscip Respir Med, V15, P511, DOI 10.4081/mrm.2020.511
   Parra FL, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00163
   LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218
   Malerba M, 2008, EXPERT OPIN DRUG MET, V4, P1119, DOI [10.1517/17425255.4.8.1119, 10.1517/17425255.4.8.1119 ]
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   Matera MG, 2020, RESP MED, V171, DOI 10.1016/j.rmed.2020.106114
   Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2
   Meng SS, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-018-0761-y
   Mezzetti M, 1990, SURG INTENSIVE CARE, V13, P179
   Nieman GF, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00227
   Paleari D, 2011, EXPERT OPIN DRUG DIS, V6, P1203, DOI 10.1517/17460441.2011.629646
   Perez-Gil J, 2008, BBA-BIOMEMBRANES, V1778, P1676, DOI 10.1016/j.bbamem.2008.05.003
   Plomer Manuel, 2017, MMW Fortschr Med, V159, P22, DOI 10.1007/s15006-017-9805-0
   POST M, 1983, LUNG, V161, P349, DOI 10.1007/BF02713884
   Raghavendran K, 2011, CRIT CARE CLIN, V27, P525, DOI 10.1016/j.ccc.2011.04.005
   Rice TW, 2020, ANN AM THORAC SOC, V17, P787, DOI 10.1513/AnnalsATS.202004-325IP
   Rodriguez-Capote K, 2006, BIOPHYS J, V90, P2808, DOI 10.1529/biophysj.105.073106
   Rzepka-Wrona P, 2018, CAN RESPIR J, V2018, DOI 10.1155/2018/8959370
   Seifart C, 2005, TOXICOL APPL PHARM, V203, P27, DOI 10.1016/j.taap.2004.07.015
   Shah S, 2011, WORLD J PEDIATR, V7, P11, DOI 10.1007/s12519-010-0201-4
   Taeusch HW, 2005, BIOPHYS J, V89, P1769, DOI 10.1529/biophysj.105.062620
   Takeda K, 2016, IMMUNE NETW, V16, P165, DOI 10.4110/in.2016.16.3.165
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Verder H, 2009, ACTA PAEDIATR, V98, P1400, DOI 10.1111/j.1651-2227.2009.01413.x
   Willson DF, 2015, RESP CARE, V60, P774, DOI 10.4187/respcare.03579
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu XD, 2014, J CLIN PHARMACOL, V54, P1199, DOI 10.1002/jcph.389
   Xiang JJ, 2019, EXP THER MED, V18, P654, DOI 10.3892/etm.2019.7615
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan YM, 2012, J TRAUMA ACUTE CARE, V73, P1114, DOI 10.1097/TA.0b013e318265cbe9
   Zhang JM, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00915
   Zhang LN, 2013, EXP THER MED, V5, P237, DOI 10.3892/etm.2012.746
   Zhao ZQ, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02973-9
   Zhou CY, 2020, LANCET INFECT DIS, V20, P510, DOI 10.1016/S1473-3099(20)30156-0
NR 51
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD SEP 25
PY 2020
VL 8
AR 577172
DI 10.3389/fbioe.2020.577172
PG 7
WC Biotechnology & Applied Microbiology; Multidisciplinary Sciences
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA OA8LW
UT WOS:000578033300001
PM 33102461
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, J
   Chen, G
   Zhang, MM
   Tu, SH
   Chen, C
AF Li, Jing
   Chen, Gang
   Zhang, Mingmin
   Tu, Shenghao
   Chen, Chao
TI Different clinical presentations of two renal transplant recipients with
   coronavirus disease 2019: a case report
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Coronavirus disease 2019; Acute respiratory syndrome coronavirus 2;
   Renal transplant recipients; Immunosuppressive therapy; Case report
ID WUHAN; PNEUMONIA; CHINA
AB Background The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome Coronavirus-2 has spread rapidly worldwide and disease spread is currently increasing. Data on the clinical picture of transplant recipients and management of the anti-rejection immunosuppressive therapy on COVID-19 infection are lacking. Case presentation We report two cases of COVID-19 infection in renal transplant recipients with variable clinical presentations. The first patient presented with mild respiratory symptoms and a stable clinical course. The second patient had more severe clinical characteristics and presented with severe pneumonia and multi-organ failure. Both patients received a combination therapy including antiviral treatment and reduced immunosuppression therapy and finally recovered. Conclusions We report COVID-19 infection in two renal transplant recipients with a favorable outcome but different clinical courses, which may provide a reference value for treating such patients.
C1 [Li, Jing; Chen, Gang; Zhang, Mingmin; Tu, Shenghao] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Integrated Tradit Chinese & Western Med, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.
   [Chen, Chao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, 1277 Jiefang Ave, Wuhan 430022, Peoples R China.
RP Chen, C (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, 1277 Jiefang Ave, Wuhan 430022, Peoples R China.
EM chenchao027@163.com
OI chen, chao/0000-0001-6099-4527
CR Abrishami A, 2020, EUR UROL, V6
   Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Bussalino E, 2020, AM J TRANSPLANT, V20, P1922, DOI 10.1111/ajt.15920
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Centers for Disease Control and Prevention, INT GUID COLL HANDL
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Corman V, DIAGNOSTIC DETECTION
   Cunningham-Rundles C, 2005, NAT REV IMMUNOL, V5, P880, DOI 10.1038/nri1713
   Eckerle I, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-359
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fung M, 2020, AM J TRANSPLANT, V20, P3225, DOI 10.1111/ajt.16079
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gupta KK, 2020, J INTERF CYTOK RES, V40, P19, DOI 10.1089/jir.2019.0085
   Holzhauser L, 2020, AM J TRANSPLANT, V20, P2916, DOI 10.1111/ajt.15982
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Johnson KM, 2020, PHARMACOTHERAPY, V40, P517, DOI 10.1002/phar.2410
   Koczulla RA, 2020, AM J TRANSPLANT, V20, P2928, DOI 10.1111/ajt.15998
   Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093
   Latif F, 2020, JAMA CARDIOL, V5, P1165, DOI 10.1001/jamacardio.2020.2159
   Machado DJD, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13306
   Michaels MG, 2020, AM J TRANSPLANT, V20, P1768, DOI 10.1111/ajt.15832
   Mohan S, 2020, J AM SOC NEPHROL, V31, P1150, DOI 10.1681/ASN.2020030375
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Ren ZL, 2020, J HEART LUNG TRANSPL, V39, P412, DOI 10.1016/j.healun.2020.03.008
   Rose-John S, 2017, NAT REV RHEUMATOL, V13, P399, DOI 10.1038/nrrheum.2017.83
   Seminari E, 2020, AM J TRANSPLANT, V20, P1882, DOI 10.1111/ajt.15902
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Wang JP, 2020, EUR UROL, V77, P769, DOI 10.1016/j.eururo.2020.03.036
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhu L, 2020, EUR UROL, V77, P748, DOI 10.1016/j.eururo.2020.03.039
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 33
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD SEP 25
PY 2020
VL 20
IS 1
AR 707
DI 10.1186/s12879-020-05434-4
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA NY3RD
UT WOS:000576310200003
PM 32977764
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mahallawi, W
AF Mahallawi, Waleed
TI Case Report: A Recovered SARS CoV-2 Patient Protected From Reinfection
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE SARS CoV-2; reinfection; protection; herd immunity; vaccines
AB The COVID-19 pandemic caused by SARS CoV-2 is a worldwide emergency, and is taking a substantial toll on human health, lives, and the global economy. Due to the novelty of this virus, no SARS CoV-2-specific treatments or licensed vaccines are available though few vaccines are undergoing clinical trials. Therefore, continued research into an effective vaccine is an urgent necessity. The reinfection of recovered patients is one of the major concerns of healthcare providers worldwide. Health authorities are currently seeking evidence of protection from reinfection in recovered individuals. This is the first case report in Saudi Arabia on a patient who was diagnosed as COVID-19-positive; recovered; and after successful recovery was protected against reinfection.
C1 [Mahallawi, Waleed] Taibah Univ, Coll Appl Med Sci, Med Lab Technol Dept, Madinah, Saudi Arabia.
RP Mahallawi, W (corresponding author), Taibah Univ, Coll Appl Med Sci, Med Lab Technol Dept, Madinah, Saudi Arabia.
EM wmahallawi@gmail.com
OI Mahallawi, Waleed/0000-0001-6977-9006
CR Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZY, 2020, NAT REV IMMUNOL, V20, P529, DOI 10.1038/s41577-020-0402-6
   Eubank S, 2020, B MATH BIOL, V82, DOI 10.1007/s11538-020-00726-x
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Heaton PM, 2020, NEW ENGL J MED, V383, P1986, DOI 10.1056/NEJMe2025111
   Hu BY, 2020, J MED VIROL, DOI 10.1002/jmv.26232
   Hu DJ, 2020, CLIN CHIM ACTA, V510, P1, DOI 10.1016/j.cca.2020.06.040
   Juno JA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0995-0
   Li CX, 2020, CLIN CHIM ACTA, V510, P35, DOI 10.1016/j.cca.2020.06.045
   Liu AD, 2020, J MED VIROL, DOI 10.1002/jmv.26241
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1036
   Meyerowitz EA, 2020, FASEB J, V34, P6027, DOI 10.1096/fj.202000919
   Pascarella G, 2020, J INTERN MED, V288, P192, DOI 10.1111/joim.13091
   PENG Y, 2020, NAT IMMUNOL 0904, DOI DOI 10.1101/2020.06.05.134551
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Wang X, 2020, NEUTRALIZING ANTIBOD, DOI [10. 1101/2020.04.15.20065623, DOI 10.1101/2020.04.15.20065623]
   Weitz JS, 2020, NAT MED, V26, P849, DOI 10.1038/s41591-020-0895-3
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
NR 22
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD SEP 25
PY 2020
VL 7
AR 564264
DI 10.3389/fmed.2020.564264
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NY2DV
UT WOS:000576207700001
PM 33102502
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cai, YF
   Zhang, J
   Xiao, TS
   Peng, HQ
   Sterling, SM
   Walsh, RM
   Rawson, S
   Rits-Volloch, S
   Chen, B
AF Cai, Yongfei
   Zhang, Jun
   Xiao, Tianshu
   Peng, Hanqin
   Sterling, Sarah M.
   Walsh, Richard M., Jr.
   Rawson, Shaun
   Rits-Volloch, Sophia
   Chen, Bing
TI Distinct conformational states of SARS-CoV-2 spike protein
SO SCIENCE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; INFLUENZA-VIRUS HEMAGGLUTININ; CRYO-EM
   STRUCTURE; MEMBRANE-FUSION; CELL ENTRY; SARS-CORONAVIRUS;
   GENETIC-ANALYSIS; HIV-1 GP41; MECHANISMS; INSIGHTS
AB Intervention strategies are urgently needed to control the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The trimeric viral spike (S) protein catalyzes fusion between viral and target cell membranes to initiate infection. Here, we report two cryo-electron microscopy structures derived from a preparation of the full-length S protein, representing its prefusion (2.9-angstrom resolution) and postfusion (3.0-angstrom resolution) conformations, respectively. The spontaneous transition to the postfusion state is independent of target cells. The prefusion trimer has three receptor-binding domains clamped down by a segment adjacent to the fusion peptide. The postfusion structure is strategically decorated by N-linked glycans, suggesting possible protective roles against host immune responses and harsh external conditions. These findings advance our understanding of SARS-CoV-2 entry and may guide the development of vaccines and therapeutics.
C1 [Cai, Yongfei; Zhang, Jun; Xiao, Tianshu; Peng, Hanqin; Rits-Volloch, Sophia; Chen, Bing] Boston Childrens Hosp, Div Mol Med, Boston, MA 02115 USA.
   [Cai, Yongfei; Zhang, Jun; Xiao, Tianshu; Chen, Bing] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
   [Sterling, Sarah M.; Walsh, Richard M., Jr.; Rawson, Shaun] Harvard Med Sch, Harvard CryoEM Ctr Struct Biol, Boston, MA 02115 USA.
   [Sterling, Sarah M.; Walsh, Richard M., Jr.; Rawson, Shaun] Harvard Med Sch, Blavatnik Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
   [Rawson, Shaun] Harvard Med Sch, SBGrid Consortium, Boston, MA 02115 USA.
RP Chen, B (corresponding author), Boston Childrens Hosp, Div Mol Med, Boston, MA 02115 USA.; Chen, B (corresponding author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
EM bchen@crystal.harvard.edu
RI Cai, Yongfei/ABI-7748-2020
OI Cai, Yongfei/0000-0002-3628-3802; Walsh, Richard/0000-0002-8939-8988
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI147884, 3R01AI147884-01A1S1,
   AI141002, AI127193]; COVID-19 Award by Massachusetts Consortium on
   Pathogen Readiness (MassCPR)
FX This work was supported by NIH grants AI147884 (to B.C.),
   3R01AI147884-01A1S1 (to B.C), AI141002 (to B.C.), and AI127193 (to B.C.
   and James Chou), as well as a COVID-19 Award by Massachusetts Consortium
   on Pathogen Readiness (MassCPR; to B.C.).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Banerjee A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010041
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bosch BJ, 2005, VIROLOGY, V334, P306, DOI 10.1016/j.virol.2005.02.001
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Chen J, 2015, SCIENCE, V349, P191, DOI 10.1126/science.aaa9804
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559
   Daniloski Zharko, 2020, bioRxiv, DOI 10.1101/2020.06.14.151357
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fan XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17371-6
   Frey G, 2008, P NATL ACAD SCI USA, V105, P3739, DOI 10.1073/pnas.0800255105
   Frey G, 2010, NAT STRUCT MOL BIOL, V17, P1486, DOI 10.1038/nsmb.1950
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Harrison SC, 2015, VIROLOGY, V479, P498, DOI 10.1016/j.virol.2015.03.043
   Henderson Rory, 2020, bioRxiv, DOI 10.1101/2020.05.18.102087
   Hijawi B, 2013, E MEDITERR HEALTH J, V19, pS12
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117
   Kielian M, 2014, ANNU REV VIROL, V1, P171, DOI 10.1146/annurev-virology-031413-085521
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kovacs JM, 2012, P NATL ACAD SCI USA, V109, P12111, DOI 10.1073/pnas.1204533109
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Liu C, 2020, VIRAL ARCHITECTURE S, DOI [10.1101/2020.03.02.972927, DOI 10.1101/2020.03.02.972927]
   Lontok E, 2004, J VIROL, V78, P5913, DOI 10.1128/JVI.78.11.5913-5922.2004
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Mohd HA, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0544-0
   Morin A, 2013, ELIFE, V2, DOI 10.7554/eLife.01456
   PARSEGIAN VA, 1979, P NATL ACAD SCI USA, V76, P2750, DOI 10.1073/pnas.76.6.2750
   Petit CM, 2005, VIROLOGY, V341, P215, DOI 10.1016/j.virol.2005.06.046
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   RAND RP, 1984, CAN J BIOCHEM CELL B, V62, P752, DOI 10.1139/o84-097
   Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008
   Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006
   Schroth-Diez B, 2000, BIOSCIENCE REP, V20, P571, DOI 10.1023/A:1010415122234
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Wagner T, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0437-z
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Ye R, 2004, J VIROL, V78, P9904, DOI 10.1128/JVI.78.18.9904-9917.2004
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 58
TC 30
Z9 30
U1 23
U2 23
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD SEP 25
PY 2020
VL 369
IS 6511
BP 1586
EP +
DI 10.1126/science.abd4251
PG 40
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NV9TD
UT WOS:000574653300027
PM 32694201
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Gu, HJ
   Chen, Q
   Yang, G
   He, L
   Fan, H
   Deng, YQ
   Wang, YX
   Teng, Y
   Zhao, ZP
   Cui, YJ
   Li, YC
   Li, XF
   Li, JF
   Zhang, NN
   Yang, XL
   Chen, SL
   Guo, Y
   Zhao, GY
   Wang, XL
   Luo, DY
   Wang, H
   Yang, X
   Li, Y
   Han, GC
   He, YX
   Zhou, XJ
   Geng, SS
   Sheng, XL
   Jiang, SB
   Sun, SH
   Qin, CF
   Zhou, YS
AF Gu, Hongjing
   Chen, Qi
   Yang, Guan
   He, Lei
   Fan, Hang
   Deng, Yong-Qiang
   Wang, Yanxiao
   Teng, Yue
   Zhao, Zhongpeng
   Cui, Yujun
   Li, Yuchang
   Li, Xiao-Feng
   Li, Jiangfan
   Zhang, Na-Na
   Yang, Xiaolan
   Chen, Shaolong
   Guo, Yan
   Zhao, Guangyu
   Wang, Xiliang
   Luo, De-Yan
   Wang, Hui
   Yang, Xiao
   Li, Yan
   Han, Gencheng
   He, Yuxian
   Zhou, Xiaojun
   Geng, Shusheng
   Sheng, Xiaoli
   Jiang, Shibo
   Sun, Shihui
   Qin, Cheng-Feng
   Zhou, Yusen
TI Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
SO SCIENCE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; RECEPTOR-BINDING DOMAIN; SPIKE
   PROTEIN; SARS-COV; TARGET
AB The ongoing coronavirus disease 2019 (COVID-19) pandemic has prioritized the development of small-animal models for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We adapted a clinical isolate of SARS-CoV-2 by serial passaging in the respiratory tract of aged BALB/c mice. The resulting mouse-adapted strain at passage 6 (called MASCp6) showed increased infectivity in mouse lung and led to interstitial pneumonia and inflammatory responses in both young and aged mice after intranasal inoculation. Deep sequencing revealed a panel of adaptive mutations potentially associated with the increased virulence. In particular, the N501Y mutation is located at the receptor binding domain (RBD) of the spike protein. The protective efficacy of a recombinant RBD vaccine candidate was validated by using this model. Thus, this mouse-adapted strain and associated challenge model should be of value in evaluating vaccines and antivirals against SARS-CoV-2.
C1 [Gu, Hongjing; Chen, Qi; He, Lei; Fan, Hang; Deng, Yong-Qiang; Teng, Yue; Zhao, Zhongpeng; Cui, Yujun; Li, Yuchang; Li, Xiao-Feng; Li, Jiangfan; Zhang, Na-Na; Yang, Xiaolan; Chen, Shaolong; Guo, Yan; Zhao, Guangyu; Wang, Xiliang; Luo, De-Yan; Wang, Hui; Sun, Shihui; Qin, Cheng-Feng; Zhou, Yusen] Acad Mil Med Sci, Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.
   [Yang, Guan; Wang, Yanxiao; Yang, Xiao] Beijing Inst Life, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing 102206, Peoples R China.
   [Li, Yan; Han, Gencheng] Inst Mil Cognit & Brain Sci, Beijing 100850, Peoples R China.
   [He, Yuxian] Chinese Acad Med Sci & Peking Union Med Coll, Inst Pathogen Biol, Beijing 100730, Peoples R China.
   [Zhou, Xiaojun] Acad Mil Med Sci, Lab Anim Ctr, Beijing 100071, Peoples R China.
   [Geng, Shusheng; Sheng, Xiaoli] Beijing JOINN Biol Co, Beijing 100176, Peoples R China.
   [Jiang, Shibo] Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai 200032, Peoples R China.
RP Sun, SH; Qin, CF (corresponding author), Acad Mil Med Sci, Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.; Jiang, SB (corresponding author), Fudan Univ, Sch Basic Med Sci, Key Lab Med Mol Virol MOE NHC CAMS, Shanghai 200032, Peoples R China.
EM shibojiang@fudan.edu.cn; sunsh01@163.com; qincf@bml.ac.cn
RI Qin, Cheng-Feng/I-6839-2019
OI Qin, Cheng-Feng/0000-0002-0632-2807; zhongpeng,
   zhao/0000-0002-9147-6252; Cui, Yujun/0000-0001-7236-2412
FU National Key Plan for Scientific Research and Development of China
   [2016YFD0500304, 2016YFD0500306, 2020YFA0707801]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [82041006, 82041025]; National Science and Technology Major
   Project of China [2018ZX09711003, 2017ZX10304402003]; Beijing Municipal
   Science and Technology Project [Z201100001020004]; National Science Fund
   for Distinguished Young ScholarNational Natural Science Foundation of
   China (NSFC)National Science Fund for Distinguished Young Scholars
   [81925025]; Innovative Research Group from the NSFC [81621005]; CAMS
   Innovation Fund for Medical Sciences [2019-I2M-5-049]
FX This work was supported by the National Key Plan for Scientific Research
   and Development of China (2016YFD0500304, 2016YFD0500306, and
   2020YFA0707801), the National Natural Science Foundation of China
   (82041006 and 82041025), the National Science and Technology Major
   Project of China (2018ZX09711003 and 2017ZX10304402003), and Beijing
   Municipal Science and Technology Project (Z201100001020004). C.-F.Q. was
   supported by the National Science Fund for Distinguished Young Scholar
   (81925025), the Innovative Research Group (81621005) from the NSFC, and
   the CAMS Innovation Fund for Medical Sciences (2019-I2M-5-049).
CR Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Carsana L, 2020, LANCET INFECT DIS
   Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5
   Deng W., 2020, SCIENCE
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Dinnon K. H., 2020, 081497 BIORXIV, DOI DOI 10.1101/2020.05.06.081497
   Du LY, 2007, VACCINE, V25, P2832, DOI 10.1016/j.vaccine.2006.10.031
   Du LY, 2013, J VIROL, V87, P9939, DOI 10.1128/JVI.01048-13
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756
   Frieman M, 2012, J VIROL, V86, P884, DOI 10.1128/JVI.05957-11
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908
   Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Li Kun, 2020, Methods Mol Biol, V2099, P161, DOI 10.1007/978-1-0716-0211-9_13
   Moriarty LF, 2020, MMWR-MORBID MORTAL W, V69, P347, DOI 10.15585/mmwr.mm6912e3
   Petersen E., 2020, LANCET INFECT DIS, VS1473-3099, P30484
   Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI 10.1016/S1473-3099(20)30484-9
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Wang CF, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102833
   Wang YJ, 2020, P NATL ACAD SCI USA, V117, P13967, DOI 10.1073/pnas.2008209117
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Yi CY, 2020, CELL MOL IMMUNOL, V17, P621, DOI 10.1038/s41423-020-0458-z
   Yu J., 2020, SCIENCE
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 34
TC 12
Z9 11
U1 14
U2 14
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD SEP 25
PY 2020
VL 369
IS 6511
BP 1603
EP +
DI 10.1126/science.abc4730
PG 26
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NV9TD
UT WOS:000574653300030
PM 32732280
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Harapan, H
   Wagner, AL
   Yufika, A
   Winardi, W
   Anwar, S
   Gan, AK
   Setiawan, AM
   Rajamoorthy, Y
   Sofyan, H
   Vo, TQ
   Hadisoemarto, PF
   Muller, R
   Groneberg, DA
   Mudatsir, M
AF Harapan, Harapan
   Wagner, Abram L.
   Yufika, Amanda
   Winardi, Wira
   Anwar, Samsul
   Gan, Alex Kurniawan
   Setiawan, Abdul M.
   Rajamoorthy, Yogambigai
   Sofyan, Hizir
   Vo, Trung Quang
   Hadisoemarto, Panji Fortuna
   Mueller, Ruth
   Groneberg, David A.
   Mudatsir, Mudatsir
TI Willingness-to-pay for a COVID-19 vaccine and its associated
   determinants in Indonesia
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE COVID-19; SARS-CoV-2; vaccine; vaccination; willingness-to-pay;
   indonesia
ID CROSS-SECTIONAL SURVEY; DENGUE VACCINE; ACCEPTANCE; DEMAND
AB How countries, particularly low- and middle-income economies, should pay the coronavirus disease 2019 (COVID-19) vaccine is an important and understudied issue. We undertook an online survey to measure the willingness-to-pay (WTP) for a COVID-19 vaccine and its determinants in Indonesia. The WTP was assessed using a simple dichotomous contingent valuation approach and a linear regression model was used to assess its associated determinants. There were 1,359 respondents who completed the survey. In total, 78.3% (1,065) were willing to pay for the COVID-19 vaccine with a mean and median WTP of US$ 57.20 (95%CI: US$ 54.56, US$ 59.85) and US$ 30.94 (95%CI: US$ 30.94, US$ 30.94), respectively. Being a health-care worker, having a high income, and having high perceived risk were associated with higher WTP. These findings suggest that the WTP for a COVID-19 vaccine is relatively high in Indonesia. This WTP information can be used to construct a payment model for a COVID-19 vaccine in the country. Nevertheless, to attain higher vaccine coverage, it may be necessary to partially subsidize the vaccine for those who are less wealthy and to design health promotion materials to increase the perceived risk for COVID-19 in the country.
C1 [Harapan, Harapan; Gan, Alex Kurniawan; Mudatsir, Mudatsir] Univ Syiah Kuala, Sch Med, Med Res Unit, Banda Aceh 23111, Indonesia.
   [Harapan, Harapan; Mudatsir, Mudatsir] Univ Syiah Kuala, Sch Med, Trop Dis Ctr, Banda Aceh, Indonesia.
   [Harapan, Harapan; Mudatsir, Mudatsir] Univ Syiah Kuala, Sch Med, Dept Microbiol, Banda Aceh, Indonesia.
   [Wagner, Abram L.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Yufika, Amanda] Univ Syiah Kuala, Sch Med, Dept Family Med, Banda Aceh, Indonesia.
   [Winardi, Wira] Univ Syiah Kuala, Sch Med, Dept Pulmonol & Resp Med, Banda Aceh, Indonesia.
   [Anwar, Samsul; Sofyan, Hizir] Univ Syiah Kuala, Fac Math & Nat Sci, Dept Stat, Banda Aceh, Indonesia.
   [Setiawan, Abdul M.] Maulana Malik Ibrahim State Islamic Univ Malang, Fac Med & Hlth Sci, Dept Microbiol, Malang, Indonesia.
   [Rajamoorthy, Yogambigai] Univ Tunku Abdul Rahman, Fac Accountancy & Management, Dept Econ, Kajang, Malaysia.
   [Vo, Trung Quang] Pham Ngoc Thach Univ Med, Fac Pharm, Dept Econ & Adm Pharm, Ho Chi Minh City, Vietnam.
   [Hadisoemarto, Panji Fortuna] Padjadjaran State Univ, Fac Med, Dept Publ Hlth, Sumedang, Indonesia.
   [Mueller, Ruth] Inst Trop Med, Dept Biomed Sci, Antwerp, Belgium.
   [Mueller, Ruth; Groneberg, David A.] Goethe Univ, Inst Occupat Social & Environm Med, Dept Trop Med & Publ Hlth, Frankfurt, Germany.
RP Harapan, H (corresponding author), Univ Syiah Kuala, Sch Med, Med Res Unit, Banda Aceh 23111, Indonesia.
EM harapan@unsyiah.ac.id
RI Groneberg, David/A-5132-2018; Harapan, Harapan/I-8741-2016
OI Groneberg, David/0000-0001-8551-6556; Harapan,
   Harapan/0000-0001-7630-8413; Wagner, Abram/0000-0003-4691-7802
CR [Anonymous], 2020, DIG 2020 IND
   Arbiol J, 2015, HUM VACC IMMUNOTHER, V11, P1046, DOI 10.1080/21645515.2015.1010901
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Berghea F, 2020, WILLINGNESS PAY POTE, DOI [10.21203/rs.3.rs-32595/v1, DOI 10.21203/RS.3.RS-32595/V1]
   Birhane MG, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004486
   Bishai D, 2004, B WORLD HEALTH ORGAN, V82, P652
   Boissay F, 2020, MACROECONOMIC EFFECT
   Boyle J, 2017, CONTINGENT VALUATION
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Feng Changyong, 2014, Shanghai Arch Psychiatry, V26, P105, DOI 10.3969/j.issn.1002-0829.2014.02.009
   Fu C, 2020, ACCEPTANCE PREFERENC, DOI [10.1101/2020.04.09.20060103, DOI 10.1101/2020.04.09.20060103]
   Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068
   GLEJSER H, 1969, J AM STAT ASSOC, V64, P316, DOI 10.2307/2283741
   Hadisoemarto PF, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002427
   Hanney SR, 2020, HEALTH RES POLICY SY, V18, DOI 10.1186/s12961-020-00571-3
   Hansen KS, 2013, HEALTH POLICY PLANN, V28, P185, DOI 10.1093/heapol/czs048
   Harapan H., 2017, Asian Pacific Journal of Tropical Disease, V7, P193, DOI 10.12980/apjtd.7.2017D6-386
   Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Harapan H, 2020, ACTA TROP, V206, DOI 10.1016/j.actatropica.2020.105450
   Harapan H, 2020, PATHOG GLOB HEALTH, V114, P68, DOI 10.1080/20477724.2020.1743037
   Harapan H, 2019, VACCINE, V37, P1398, DOI 10.1016/j.vaccine.2019.01.062
   Harapan H, 2017, ACTA TROP, V166, P249, DOI 10.1016/j.actatropica.2016.11.035
   Harapan H, 2016, VACCINE, V34, P3670, DOI 10.1016/j.vaccine.2016.05.026
   Lee JS, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003810
   Lloyd J, 2020, CORONAVIRUS CAN HERD
   Nguyen LH, 2018, PATIENT PREFER ADHER, V12, P1917, DOI 10.2147/PPA.S178444
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Masters N, 2020, PLOS ONE
   Mudatsir Mudatsir, 2019, F1000Res, V8, P1441, DOI 10.12688/f1000research.20144.2
   Muniz RL, 2019, EXPERT REV PHARM OUT, V19, P473, DOI 10.1080/14737167.2019.1552136
   O'Brien RM, 2007, QUAL QUANT, V41, P673, DOI 10.1007/s11135-006-9018-6
   Painter JE, 2018, HUM VACC IMMUNOTHER, V14, P1665, DOI 10.1080/21645515.2018.1423928
   Palanca-Tan R, 2008, VACCINE, V26, P914, DOI 10.1016/j.vaccine.2007.12.011
   Rajamoorthy Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215125
   Rajamoorthy Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208402
   Sarmento TTR, 2019, EXPERT REV PHARM OUT, DOI 10.1080/14737167.2020.1703181
   Sauerborn R, 2005, SCAND J PUBLIC HEALT, V33, P146, DOI 10.1080/14034940510005743
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Nguyen TTM, 2020, VACCINE, V38, P2045, DOI 10.1016/j.vaccine.2019.12.047
   Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065
   Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8
   Vo TQ, 2018, PATIENT PREFER ADHER, V12, P2507, DOI 10.2147/PPA.S188581
   Ughasoro MD, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003838
   Vasilevska M, 2014, INFECT CONT HOSP EP, V35, P699, DOI 10.1086/676427
   Victoria A, 2020, RATA RATA PENDAPATAN
   Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279
   Yang J, 2019, CMES-COMP MODEL ENG, V120, P1, DOI 10.32604/cmes.2019.04727
   Yap BW, 2011, J STAT COMPUT SIM, V81, P2141, DOI 10.1080/00949655.2010.520163
   Yeo HY, 2018, COST EFFECT RESOUR A, V16, DOI 10.1186/s12962-018-0163-2
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 51
TC 0
Z9 0
U1 9
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1819741
EA SEP 2020
PG 7
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA NU5CN
UT WOS:000573659400001
PM 32991230
DA 2021-01-01
ER

PT J
AU Jiang, ZW
   Wang, XY
   Xia, JL
AF Jiang, Zhiwei
   Wang, Xuanyi
   Xia, Jielai
TI Considerations on the clinical development of COVID-19 vaccine from
   trial design perspectives
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE COVID-19 vaccine; ring vaccination trial; seamless design; vaccine
   efficacy; data safety monitoring board
ID EBOLA-VIRUS; EFFICACY; DISEASE
AB COVID-19 has become a global pandemic, and an effective vaccine is needed. During the outbreak, the urgency for developing candidate vaccines has brought distinct challenges to clinical development. An efficacy trial, which measures whether the vaccine reduces the incidence of disease, is ordinarily required to fully evaluate vaccine efficacy. However, emergency use may be possible if promising immunogenicity results are observed. A ring vaccination trial, which recruits subjects connected to a known case either socially or geographically, is a solution to evaluate vaccine efficacy and control the spread of the disease simultaneously although its conduct is challenging. Nevertheless, when COVID-19 becomes a recurrent epidemic, an 'individual-level' efficacy trial is preferred. Innovative statistical designs, including seamless design, platform trial, master protocol design, are helpful to accelerate clinical development. A seamless Phase I/II design has been applied in multiple COVID-19 vaccine studies to date. However, Phase II/III design should be done very carefully. The control of type I error, maintaining trial blinding and statistical methods leading to unbiased estimates should be pre-specified in the clinical protocol. A Data Safety Monitoring Board is especially important, given the need to assure an adequate level of safety when society want a safe and effective vaccine.
C1 [Jiang, Zhiwei] Beijing KeyTech Stat Consulting Co Ltd, Dept Biostat, Beijing, Peoples R China.
   [Wang, Xuanyi] Fudan Univ, Key Lab Med Mol Virol, MoE MoH, Shanghai Med Coll, Shanghai, Peoples R China.
   [Wang, Xuanyi] Fudan Univ, Inst Biomed Sci, Shanghai Med Coll, Shanghai, Peoples R China.
   [Xia, Jielai] Air Force Mil Med Univ, Dept Hlth Stat, Xian, Shaanxi, Peoples R China.
RP Jiang, ZW (corresponding author), Beijing KeyTech Stat Consulting Co Ltd, Beijing, Peoples R China.
EM zhi.wei.jiang@ktstat.com
CR Berry SM, 2015, JAMA-J AM MED ASSOC, V313, P1619, DOI 10.1001/jama.2015.2316
   Chen YHJ, 2015, CLIN TRIALS, V12, P84, DOI 10.1177/1740774514552110
   ClinicalTrials.gov, PHAS IB 2 TRIAL DEND
   ClinicalTrials.gov, PHAS 1 2 CLIN TRIAL
   ClinicalTrials.gov, STUD DESCR SAF TOL I
   Cummings J, 2016, J Prev Alzheimers Dis, V3, P114, DOI 10.14283/jpad.2016.93
   Ebola ca suffit ring vaccination trial con,sortium, 2015, BMJ, V315
   Food and Drug Administration, AD DES CLIN TRIALS D
   Food and Drug Administration, MAST PROT EFF CLIN T
   Hemming K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h391
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0358-6
   Hussey MA, 2007, CONTEMP CLIN TRIALS, V28, P182, DOI 10.1016/j.cct.2006.05.007
   Jamrozik E, 2020, LANCET INFECT DIS, V20, pE198, DOI 10.1016/S1473-3099(20)30438-2
   Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120
   Luczkowiak J, 2016, VIRUS RES, V213, P224, DOI 10.1016/j.virusres.2015.12.019
   Mossler C, 2013, VACCINE, V31, P6194, DOI 10.1016/j.vaccine.2013.10.061
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Saville BR, 2016, CLIN TRIALS, V13, P358, DOI 10.1177/1740774515626362
   World Health Organization, SOL CLIN TRIAL COVID
   World Health Organization, CORR VACC IND PROT M
   World Health Organization, KEY CRIT ETH ACC COV
   World Health Organization, HUM CHALL TRIALS VAC
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 24
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1815489
EA SEP 2020
PG 5
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA NU5GT
UT WOS:000573670400001
PM 32991223
OA Bronze
DA 2021-01-01
ER

PT J
AU Latour, C
   O'Byrne, L
   McCarthy, M
   Chacko, R
   Russell, E
   Price, RK
AF Latour, Chase
   O'Byrne, Lorcan
   McCarthy, Margaret
   Chacko, Ravi
   Russell, Elizabeth
   Price, Rumi Kato
TI Improving mental health in US Veterans using mHealth tools: A pilot
   study
SO HEALTH INFORMATICS JOURNAL
LA English
DT Article
DE mental health; mobile applications; post-traumatic stress disorder;
   stress monitor; U; S; Veterans
ID POSTTRAUMATIC-STRESS-DISORDER; REDUCTION; PTSD; AFGHANISTAN; DEPRESSION;
   CHECKLIST; COACH; PHQ-9; DUTY; IRAQ
AB Rates of PTSD remain elevated among U.S. Veterans, highlighting a need for innovative management tools. Previous studies have shown mobile apps to have positive effects on PTSD symptoms, but few apps have been examined systematically. This pilot study evaluated the perceived effectiveness and usability of Mindset, a novel mobile app that monitors user stress level via heart rate to encourage e-therapy use. The study sample included 30 community-residing Veterans who completed baseline assessments. They used the Mindset app and associated smartwatch until their approximate 1-month follow-up. Self-reported assessments included pre- and post-deployment experiences; experience with Mindset; and standard screeners for PTSD (PCL-M), anxiety (GAD-7), depression (PHQ-9), and alcohol use problems (AUDIT). Among the 24 participants who completed follow-up interviews, a significant decrease (p < 0.05) was found in PCL-M, PHQ-9, and modified AUDIT scores. Respondents reported moderate to high acceptance and satisfaction with Mindset features, though considerable frustration with the associated smartwatch. These findings highlight mHealth apps such as Mindset as potentially useful tools for PTSD and depression symptom management. These findings are also encouraging in the context of the current COVID-19 pandemic, which may accelerate further innovation and implementation of mHealth technologies to improve mental health self-care.
C1 [Latour, Chase; McCarthy, Margaret] Washington Univ, St Louis, MO 14263 USA.
   [Latour, Chase] Univ North Carolina Chapel Hill, Chapel Hill, NC USA.
   [O'Byrne, Lorcan] Univ Coll Dublin, Dublin, Ireland.
   [Chacko, Ravi] Univ Chicago, Chicago, IL 60637 USA.
   [Chacko, Ravi; Russell, Elizabeth] DataDog Hlth Inc, Seattle, WA USA.
RP Price, RK (corresponding author), Washington Univ, Dept Psychiat, Sch Med, 660 S Euclid Ave,Med Box 8134, St Louis, MO 63110 USA.
EM pricerk@wustl.edu
RI O'Byrne, Lorcan/ABG-8974-2020
OI O'Byrne, Lorcan/0000-0003-3700-2782; Latour, Chase/0000-0002-9362-2516
FU Washington University, Institute for Public Health, Center for
   Dissemination and Implementation Pilot Program [CDI] [2016-03];
   Washington University Institute of Clinical and Translational Sciences
   [UL1TR000448, TL1TR000449]; National Center for Advancing Translational
   Sciences (NCATS) of the National Institutes of Health (NIH)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS);
   Institute for Public Health and its Global Health Center of Washington
   University in St. Louis; Department of Medicine in Washington
   University's School of Medicine; Department of Molecular Microbiology in
   Washington University's School of Medicine; Departments of Pediatrics in
   Washington University's School of Medicine; Children's Discovery
   Institute of Washington University; St. Louis Children's Hospital;
   Mallinckrodt Pharmaceuticals Charitable Giving Program
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The study
   was in part supported by the Washington University, Institute for Public
   Health, Center for Dissemination and Implementation Pilot Program [CDI
   grant number 2016-03] (CL, MM, RP) and the Washington University
   Institute of Clinical and Translational Sciences [grant number
   UL1TR000448, sub-award number TL1TR000449], from the National Center for
   Advancing Translational Sciences (NCATS) of the National Institutes of
   Health (NIH) (RC). In addition, this work was completed as part of a
   summer program supported by the Institute for Public Health and its
   Global Health Center of Washington University in St. Louis; the
   Departments of Medicine, Molecular Microbiology, and Pediatrics in
   Washington University's School of Medicine; the Children's Discovery
   Institute of Washington University and St. Louis Children's Hospital;
   Mallinckrodt Pharmaceuticals Charitable Giving Program; Stephanie and
   Chris Doerr; and Dr. and Mrs. Mark Stephen Gold (LO).
CR Battle DE, 2013, CODAS, V25, P191
   Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272
   Burnam MA, 2008, INVISIBLE WOUNDS WAR, P245
   D'Andrea Wendy, 2011, J Am Psychiatr Nurses Assoc, V17, P378, DOI 10.1177/1078390311425187
   Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944
   Erbes CR, 2014, MIL MED, V179, P1218, DOI 10.7205/MILMED-D-14-00014
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Golinelli D, 2020, COVID 19 PANDEMIC FA, DOI [10.1101/2020.04.26.20080341, DOI 10.1101/2020.04.26.20080341]
   Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7
   Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603
   Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423
   KABATZINN J, 1992, AM J PSYCHIAT, V149, P936
   KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012
   Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593
   Kuhn E, 2014, MIL MED, V179, P12, DOI 10.7205/MILMED-D-13-00271
   Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093
   Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006
   Manea L, 2012, CAN MED ASSOC J, V184, pE191, DOI 10.1503/cmaj.110829
   Martin A, 2006, GEN HOSP PSYCHIAT, V28, P71, DOI 10.1016/j.genhosppsych.2005.07.003
   Morina N, 2014, CLIN PSYCHOL REV, V34, P249, DOI 10.1016/j.cpr.2014.03.002
   Ouimette P, 2004, J TRAUMA STRESS, V17, P1, DOI 10.1023/B:JOTS.0000014670.68240.38
   Polusny MA, 2015, JAMA-J AM MED ASSOC, V314, P456, DOI 10.1001/jama.2015.8361
   Price M, 2014, CLIN PSYCHOL PSYCHOT, V21, P427, DOI 10.1002/cpp.1855
   Reger GM, 2015, MIL PSYCHOL, V27, P287, DOI 10.1037/mil0000083
   Reinert DF, 2002, ALCOHOL CLIN EXP RES, V26, P272, DOI 10.1097/00000374-200202000-00016
   Rodriguez-Paras Carolina, 2017, Proceedings of the Human Factors and Ergonomics Society Annual Meeting, V61, P1824, DOI 10.1177/1541931213601937
   Rodriguez-Paras C, 2017, JMIR MHEALTH UHEALTH, V5, DOI 10.2196/mhealth.7318
   Schell TL, 2008, INVISIBLE WOUNDS WAR, P87
   Shiner B., 2011, PTSD RES Q, V22, P1
   Shura RD, 2020, J RURAL HEALTH, P1
   Stefanovics EA, 2018, PSYCHIAT QUART, V89, P141, DOI 10.1007/s11126-017-9522-y
   Torous J, 2020, SCHIZOPHR RES, V218, P36, DOI 10.1016/j.schres.2020.04.013
   van Walraven C, 1999, J CLIN EPIDEMIOL, V52, P717, DOI 10.1016/S0895-4356(99)00050-5
   Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837
   Wilson JAB, 2008, CYBERPSYCHOL BEHAV, V11, P767, DOI 10.1089/cpb.2008.0071
   Wolf EJ, 2016, PSYCHONEUROENDOCRINO, V63, P155, DOI 10.1016/j.psyneuen.2015.09.020
NR 36
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1460-4582
EI 1741-2811
J9 HEALTH INFORM J
JI Health Inform. J.
PD DEC
PY 2020
VL 26
IS 4
BP 3201
EP 3214
AR 1460458220954613
DI 10.1177/1460458220954613
EA SEP 2020
PG 14
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA PF7PY
UT WOS:000573545600001
PM 32972313
OA Other Gold
DA 2021-01-01
ER

PT J
AU Zekarias, A
   Watson, S
   Vidlin, SH
   Grundmark, B
AF Zekarias, Alem
   Watson, Sarah
   Vidlin, Sara Hedfors
   Grundmark, Birgitta
TI Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in
   a Global Database of Individual Case Safety Reports
SO DRUG SAFETY
LA English
DT Article
AB Introduction In late 2019, a new coronavirus-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-was discovered in Wuhan, China, and the World Health Organization later declared coronavirus disease 2019 (COVID-19) a pandemic. Numerous drugs have been repurposed and investigated for therapeutic effectiveness in the disease, including those from "Solidarity," an international clinical trial (azithromycin, chloroquine, hydroxychloroquine, the fixed combination lopinavir/ritonavir, and remdesivir). Objective Our objective was to evaluate adverse drug reaction (ADR) reporting for drugs when used in the treatment of COVID-19 compared with use for other indications, specifically focussing on sex differences. Method We extracted reports on COVID-19-specific treatments from the global ADR database, VigiBase, using an algorithm developed to identify reports that listed COVID-19 as the indication. The Solidarity trial drugs were included, as were any drugs reported >= 100 times. We performed a descriptive comparison of reports for the same drugs used in non-COVID-19 indications. The data lock point date was 7 June 2020. Results In total, 2573 reports were identified for drugs used in the treatment of COVID-19. In order of frequency, the most reported ADRs were electrocardiogram QT-prolonged, diarrhoea, nausea, hepatitis, and vomiting in males and diarrhoea, electrocardiogram QT-prolonged, nausea, vomiting, and upper abdominal pain in females. Other hepatic and kidney-related events were included in the top ten ADRs in males, whereas no hepatic or renal terms were reported for females. COVID-19-related reporting patterns differed from non-pandemic reporting for these drugs. Conclusion Review of a global database of suspected ADR reports revealed sex differences in the reporting patterns for drugs used in the treatment of COVID-19. Patterns of ADR sex differences need further elucidation.
C1 [Zekarias, Alem; Watson, Sarah; Vidlin, Sara Hedfors; Grundmark, Birgitta] Uppsala Monitoring Ctr, Uppsala, Sweden.
RP Zekarias, A (corresponding author), Uppsala Monitoring Ctr, Uppsala, Sweden.
EM alem.zekarias@who-umc.org
CR Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Gebhard C, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00304-9
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   ICH, HARM TRIP GUID POST
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Miranda DG, 2011, US PHARM, V36, pHS2
   Rozenberg S, 2020, MATURITAS, V138, P62, DOI 10.1016/j.maturitas.2020.05.009
   Watson Sarah, 2019, EClinicalMedicine, V17, P100188, DOI 10.1016/j.eclinm.2019.10.001
   Wolbrette D, 1999, CURR OPIN CARDIOL, V14, P36, DOI 10.1097/00001573-199901000-00007
   World Health Organization, 2020, COR DIS COVID 2019 S
NR 10
TC 1
Z9 1
U1 0
U2 0
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0114-5916
EI 1179-1942
J9 DRUG SAFETY
JI Drug Saf.
PD DEC
PY 2020
VL 43
IS 12
BP 1309
EP 1314
DI 10.1007/s40264-020-01000-8
EA SEP 2020
PG 6
WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy;
   Toxicology
GA OW1DX
UT WOS:000572734800002
PM 32978702
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nie, JH
   Li, QQ
   Wu, JJ
   Zhao, CY
   Hao, H
   Liu, H
   Zhang, L
   Nie, LL
   Qin, HY
   Wang, M
   Lu, Q
   Li, XY
   Sun, QY
   Liu, JK
   Fan, CF
   Huang, WJ
   Xu, M
   Wang, YC
AF Nie, Jianhui
   Li, Qianqian
   Wu, Jiajing
   Zhao, Chenyan
   Hao, Huan
   Liu, Huan
   Zhang, Li
   Nie, Lingling
   Qin, Haiyang
   Wang, Meng
   Lu, Qiong
   Li, Xiaoyu
   Sun, Qiyu
   Liu, Junkai
   Fan, Changfa
   Huang, Weijin
   Xu, Miao
   Wang, Youchun
TI Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped
   virus-based assay
SO NATURE PROTOCOLS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; VESICULAR STOMATITIS-VIRUS; SPIKE
   PROTEIN; ENTRY; PNEUMONIA; VACCINE; TARGET; COV
AB Pseudotyped viruses are useful virological tools because of their safety and versatility. On the basis of a vesicular stomatitis virus (VSV) pseudotyped virus production system, we developed a pseudotyped virus-based neutralization assay against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in biosafety level 2 facilities. Compared with the binding antibody test, the neutralization assay could discriminate the protective agents from the antibody family. This protocol includes production and titration of the SARS-CoV-2 S pseudotyped virus and the neutralization assay based on it. Various types of samples targeting virus attachment and entry could be evaluated for their potency, including serum samples derived from animals and humans, monoclonal antibodies and fusion inhibitors (peptides or small molecules). If the pseudotyped virus stock has been prepared in advance, it will take 2 days to get the potency data for the candidate samples. Experience in handling cells is needed before implementing this protocol.
   The production and titration of the SARS-CoV-2 S pseudotyped virus using a VSV-based pseudovirus production system in this protocol enable its use under biosafety level 2 conditions as well as in a neutralization assay to assess the level of neutralizing antibodies or molecular inhibitors in a sample.
C1 [Nie, Jianhui; Li, Qianqian; Wu, Jiajing; Zhao, Chenyan; Hao, Huan; Liu, Huan; Zhang, Li; Nie, Lingling; Qin, Haiyang; Wang, Meng; Lu, Qiong; Li, Xiaoyu; Sun, Qiyu; Liu, Junkai; Huang, Weijin; Wang, Youchun] Natl Inst Food & Drug Control NIFDC, Div HIV AIDS & Sex Transmitted Virus Vaccines, Inst Biol Prod Control, Beijing, Peoples R China.
   [Nie, Jianhui; Li, Qianqian; Wu, Jiajing; Zhao, Chenyan; Hao, Huan; Liu, Huan; Zhang, Li; Nie, Lingling; Qin, Haiyang; Wang, Meng; Lu, Qiong; Li, Xiaoyu; Sun, Qiyu; Liu, Junkai; Huang, Weijin; Xu, Miao; Wang, Youchun] WHO Collaborating Ctr Standardizat & Evaluat Biol, Beijing, Peoples R China.
   [Li, Qianqian] Peking Union Med Coll, Grad Sch, Beijing, Peoples R China.
   [Wu, Jiajing] Wuhan Inst Biol Prod, Wuhan, Peoples R China.
   [Fan, Changfa] Natl Inst Food & Drug Control, Inst Lab Anim Resources, Div Anim Model Res, Beijing, Peoples R China.
   [Xu, Miao] Natl Inst Food & Drug Control, Inst Biol Prod Control, Beijing, Peoples R China.
RP Huang, WJ; Wang, YC (corresponding author), Natl Inst Food & Drug Control NIFDC, Div HIV AIDS & Sex Transmitted Virus Vaccines, Inst Biol Prod Control, Beijing, Peoples R China.; Huang, WJ; Xu, M; Wang, YC (corresponding author), WHO Collaborating Ctr Standardizat & Evaluat Biol, Beijing, Peoples R China.; Xu, M (corresponding author), Natl Inst Food & Drug Control, Inst Biol Prod Control, Beijing, Peoples R China.
EM huangweijin@nifdc.org.cn; xumiaobj@126.com; wangyc@nifdc.org.cn
OI Nie, Jianhui/0000-0002-1474-0427; Huang, Weijin/0000-0002-4246-8889
FU National Science and Technology Major Projects of Drug Discovery
   [2018ZX09101001]; National Science and Technology Major Projects of
   Infectious Disease [2017ZX10304402]; Key Project of Public Safety Risk
   Prevention and Control and Emergency Technical Equipment
   [2020YFC0860500]; Bill & Melinda Gates FoundationBill & Melinda Gates
   FoundationCGIAR [INV-006379]
FX This work was supported by National Science and Technology Major
   Projects of Drug Discovery (grant number 2018ZX09101001), National
   Science and Technology Major Projects of Infectious Disease (grant
   number 2017ZX10304402), Key Project of Public Safety Risk Prevention and
   Control and Emergency Technical Equipment (grant number 2020YFC0860500)
   and the Bill & Melinda Gates Foundation (Investment ID INV-006379).
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chen YX, 2020, J INFECTION, V81, P420, DOI 10.1016/j.jinf.2020.05.067
   Cho H, 2018, HUM VACC IMMUNOTHER, V14, P304, DOI 10.1080/21645515.2017.1389362
   Conte C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020309
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Ferguson MR, 2002, CLIN LAB MED, V22, P611, DOI 10.1016/S0272-2712(02)00015-X
   Ghaebi M, 2020, J CELL PHYSIOL, V235, P9098, DOI 10.1002/jcp.29771
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holmes M, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004961
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Lee BH, 2006, VACCINE, V24, P2928, DOI 10.1016/j.vaccine.2005.12.040
   Li C, 2020, INFECT GENET EVOL, V82, DOI 10.1016/j.meegid.2020.104285
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li Q, 2020, CELL, V182, P284
   Lichty BD, 2004, TRENDS MOL MED, V10, P210, DOI 10.1016/j.molmed.2004.03.003
   Lv Z, 2020, SCIENCE
   Ma J, 2019, HUM VACC IMMUNOTHER, V15, P2286, DOI 10.1080/21645515.2019.1627820
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   MATUMOTO M., 1949, JAP JOUR EXPTL MED, V20, P175
   Moeschler S, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8090254
   Munis AM, 2020, EXPERT OPIN BIOL TH, V20, P1187, DOI 10.1080/14712598.2020.1787981
   Negrete OA, 2005, NATURE, V436, P401, DOI 10.1038/nature03838
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pinto D., 2020, PREPRINT, DOI [10.1101/2020.04.07.023903v3, DOI 10.1101/2020.04.07.023903V3]
   Quinn K, 2009, J VIROL, V83, P10176, DOI 10.1128/JVI.00422-09
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Yi L, 2004, J VIROL, V78, P11334, DOI 10.1128/JVI.78.20.11334-11339.2004
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010060
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 43
TC 0
Z9 0
U1 11
U2 11
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PD NOV
PY 2020
VL 15
IS 11
DI 10.1038/s41596-020-0394-5
EA SEP 2020
PG 19
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA OH8VJ
UT WOS:000572727200001
PM 32978602
OA Bronze
DA 2021-01-01
ER

PT J
AU Mahapatra, SR
   Sahoo, S
   Dehury, B
   Raina, V
   Patro, S
   Misra, N
   Suar, M
AF Mahapatra, Soumya Ranjan
   Sahoo, Susrita
   Dehury, Budheswar
   Raina, Vishakha
   Patro, Shubhransu
   Misra, Namrata
   Suar, Mrutyunjay
TI Designing an efficient multi-epitope vaccine displaying interactions
   with diverse HLA molecules for an efficient humoral and cellular immune
   response to prevent COVID-19 infection
SO EXPERT REVIEW OF VACCINES
LA English
DT Article
DE SARS-CoV-2; COVID-19; multi-epitopic vaccine; immunoinformatics;
   receptor-binding domain
ID RESPIRATORY SYNDROME CORONAVIRUS; RECEPTOR-BINDING DOMAIN; SARS
   CORONAVIRUS; NUCLEOCAPSID PROTEIN; SPIKE PROTEIN; COV; SARS-COV-2;
   ANTIBODIES; NEUTRALIZATION; STRATEGY
AB Background The novel SARS-CoV-2 coronavirus, the causative agent of the ongoing pandemic COVID-19 disease continues to infect people globally and has infected millions of humans worldwide. However, no effective vaccine against this virus exists. Method Using Immunoinformatics, epitopic sequences from multiple glycoproteins that play crucial role in pathogenesis were identified. Particularly, epitopes were mapped from conserved receptor-binding domain of spike protein which have been experimentally validated in SARS-CoV-1 as a promising target for vaccine development. Results A multi-epitopic vaccine construct comprising of B-cell, CTL, HTL epitopes was developed along with fusion of adjuvant and linkers. The epitopes identified herein are reported for the first time and were predicted to be highly antigenic, stable, nonallergen, nontoxic and displayed conservation across several SARS-CoV-2 isolates from different countries. Additionally, the epitopes associated with maximum HLA alleles and population coverage analysis shows the proposed epitopes would be a relevant representative of large proportion of the world population. A reliable three-dimensional structure of the vaccine construct was developed. Consequently, docking and molecular-dynamics simulation ensured the stable interaction between vaccine and innate-immune receptor.
C1 [Mahapatra, Soumya Ranjan; Sahoo, Susrita; Dehury, Budheswar; Raina, Vishakha; Misra, Namrata; Suar, Mrutyunjay] Kalinga Inst Ind Technol KIIT DU, Sch Biotechnol, Bhubaneswar 751024, India.
   [Misra, Namrata; Suar, Mrutyunjay] Kalinga Inst Ind Technol KIIT DU, KIIT Technol Business Incubator KIIT TBI, Bhubaneswar 751024, India.
   [Patro, Shubhransu] Kalinga Inst Ind Technol KIIT DU, Kalinga Inst Med Sci KIMS, Bhubaneswar 751024, India.
RP Suar, M (corresponding author), Kalinga Inst Ind Technol KIIT DU, Sch Biotechnol, Bhubaneswar 751024, India.
EM msbiotek@yahoo.com
RI Patro, Shubhransu/O-5972-2019
OI Patro, Shubhransu/0000-0002-3597-4302
CR Ali FR, 2005, EXPERT REV VACCINES, V4, P881, DOI 10.1586/14760584.4.6.881
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty C, 2020, ASIAN PAC J TROP MED, V13, P242, DOI 10.4103/1995-7645.281613
   Chakraborty C, 2020, J MED VIROL, V92, P2314, DOI 10.1002/jmv.25997
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen WH, 2020, CURR TROP MED REP
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Feng Y., 2020, BIORXIV, DOI [10.1101/2020.03.03.962332. 2020.03.03.962332, DOI 10.1101/2020.03.03.962332]
   Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278
   Foged C, 2011, THER DELIV, V2, P1057, DOI 10.4155/TDE.11.68
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   He YX, 2006, J IMMUNOL, V176, P6085, DOI 10.4049/jimmunol.176.10.6085
   He YX, 2005, VIRAL IMMUNOL, V18, P327, DOI 10.1089/vim.2005.18.327
   Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Jiang SB, 2012, EXPERT REV VACCINES, V11, P1405, DOI [10.1586/erv.12.126, 10.1586/ERV.12.126]
   Jimenez-Guardeno JM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004320
   Jin HL, 2005, BIOCHEM BIOPH RES CO, V328, P979, DOI 10.1016/j.bbrc.2005.01.048
   Karch CP, 2016, BIOCHEM PHARMACOL, V120, P1, DOI 10.1016/j.bcp.2016.05.001
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Kumar S, 2020, 20202020020071 PREPR, DOI [10.20944/preprints202002.0071.v1, DOI 10.20944/PREPRINTS202002.0071.V1]
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Lazoura E, 2006, IMMUNOLOGY, V119, P306, DOI 10.1111/j.1365-2567.2006.02434.x
   Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045
   Liu ZQ, 2003, IMMUNOBIOLOGY, V208, P423, DOI 10.1078/0171-2985-00286
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mocellin S, 2009, CURR MED CHEM, V16, P4779, DOI 10.2174/092986709789909648
   Nitin N, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh063
   Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26
   Oppenheim JJ, 2003, ANN RHEUM DIS S2, V62, pii17
   Pandey RK, 2018, VACCINE, V36, P2262, DOI 10.1016/j.vaccine.2018.03.042
   Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036
   Pietersz GA, 2006, CURR MED CHEM, V13, P1591, DOI 10.2174/092986706777441922
   Reynisson B, 2020, NUCL ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Saha A, 2020, ARCH MED RES, V51, P585, DOI 10.1016/j.arcmed.2020.05.001
   Saha S., 2006, PROTEIN-STRUCT FUNCT, V65, P1
   Sambhara S, 2009, CURR TOP MICROBIOL, V333, P413, DOI 10.1007/978-3-540-92165-3_20
   Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594
   Soria-Guerra RE, 2015, J BIOMED INFORM, V53, P405, DOI 10.1016/j.jbi.2014.11.003
   Structure LF, 2016, ANNU REV VIROL, V3
   Tani K, 2000, INT IMMUNOL, V12, P691, DOI 10.1093/intimm/12.5.691
   Tomar N, 2010, IMMUNOLOGY, V131, P153, DOI 10.1111/j.1365-2567.2010.03330.x
   Totura AL, 2015, MBIO, V6, DOI 10.1128/mBio.00638-15
   Vivona S, 2008, TRENDS BIOTECHNOL, V26, P190, DOI 10.1016/j.tibtech.2007.12.006
   Wang YD, 2004, J VIROL, V78, P5612, DOI 10.1128/JVI.78.11.5612-5618.2004
   Wei WY, 2012, ARCH VIROL, V157, P635, DOI 10.1007/s00705-011-1221-7
   Wilkins MR, 1999, METH MOL B, V112, P531
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, BIORXIV, p20200124919183, DOI [10.1101/2020.01.24.919183, DOI 10.1101/2020.01.24.919183]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Yang LT, 2007, J GEN VIROL, V88, P2740, DOI 10.1099/vir.0.82839-0
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zhao JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000636
   Zhou YS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010060
NR 75
TC 0
Z9 0
U1 4
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-0584
EI 1744-8395
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD SEP 1
PY 2020
VL 19
IS 9
BP 871
EP 885
DI 10.1080/14760584.2020.1811091
EA SEP 2020
PG 15
WC Immunology
SC Immunology
GA OU3GD
UT WOS:000572530500001
PM 32869699
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bertzbach, LD
   Vladimirova, D
   Dietert, K
   Abdelgawad, A
   Gruber, AD
   Osterrieder, N
   Trimpert, J
AF Bertzbach, Luca D.
   Vladimirova, Daria
   Dietert, Kristina
   Abdelgawad, Azza
   Gruber, Achim D.
   Osterrieder, Nikolaus
   Trimpert, Jakob
TI SARS-CoV-2 infection of Chinese hamsters (Cricetulus griseus) reproduces
   COVID-19 pneumonia in a well-established small animal model
SO TRANSBOUNDARY AND EMERGING DISEASES
LA English
DT Article; Early Access
DE coronavirus; experimental animal models; histopathology
AB The SARS-CoV-2 pandemic has caused a yet unresolved global crisis. Effective medical intervention by vaccination or therapy seems to be the only possibility to control the pandemic. In this context, animal models are an indispensable tool for basic and applied research to combat SARS-CoV-2 infection. Here, we established a SARS-CoV-2 infection model in Chinese hamsters suitable for studying pathogenesis of the disease as well as pre-clinical testing of vaccines and therapies. This species of hamster is susceptible to SARS-CoV-2 infection as demonstrated by robust virus replication in the upper and lower respiratory tract accompanied by bronchitis and pneumonia as well as significant body weight loss following infection. The Chinese hamster features advantages compared to the Syrian hamster model, including more pronounced clinical symptoms, its small size, well-characterized genome, transcriptome and translatome data and availability of molecular tools.
C1 [Bertzbach, Luca D.; Vladimirova, Daria; Abdelgawad, Azza; Osterrieder, Nikolaus; Trimpert, Jakob] Free Univ Berlin, Inst Virol, Berlin, Germany.
   [Dietert, Kristina; Gruber, Achim D.] Free Univ Berlin, Inst Tierpathol, Berlin, Germany.
   [Dietert, Kristina] Free Univ Berlin, Tiermed Zentrum Resistenzforsch, Berlin, Germany.
   [Osterrieder, Nikolaus] City Univ Hong Kong, Dept Infect Dis & Publ Hlth, Jockey Club Coll Vet Med & Life Sci, Kowloon, Hong Kong, Peoples R China.
RP Trimpert, J (corresponding author), Free Univ Berlin, Inst Virol, Berlin, Germany.
EM trimpert.jakob@fu-berlin.de
RI Bertzbach, Luca/ABB-9013-2020
OI Bertzbach, Luca/0000-0002-0698-5395; Trimpert,
   Jakob/0000-0003-1616-0810; Osterrieder, Nikolaus/0000-0002-5313-2176;
   Dietert, Kristina/0000-0002-5667-6750
FU Freie Universitat Berlin; Deutsche ForschungsgemeinschaftGerman Research
   Foundation (DFG) [SFB-TR84]
FX Freie Universitat Berlin; Deutsche Forschungsgemeinschaft, Grant/Award
   Number: SFB-TR84
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dhama K, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00028-20
   Gruber AD, 2020, AM J RESP CELL MOL, V63, P856, DOI 10.1165/rcmb.2020-0280LE
   Halfmann PJ, 2020, NEW ENGL J MED, V383, P592, DOI 10.1056/NEJMc2013400
   Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI [10.1073/pnas.2009799117/-/DCSupplemental., 10.1073/pnas.2009799117]
   Kreye J, 2020, SARS COV 2 NEUTR ANT, DOI [10.1101/2020.08.15.252320, DOI 10.1101/2020.08.15.252320]
   Lakdawala SS, 2020, SCIENCE, V368, P942, DOI 10.1126/science.abc6141
   Leroy EM, 2020, ONE HEALTH-AMSTERDAM, V10, DOI 10.1016/j.onehlt.2020.100133
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Luan JW, 2020, J MED VIROL, V92, P1649, DOI 10.1002/jmv.25817
   Luo D, 2007, VIRAL IMMUNOL, V20, P495, DOI 10.1089/vim.2007.0038
   Matasci M, 2008, DRUG DISCOV TODAY TE, V5, P37, DOI DOI 10.1016/J.DDTEC.2008.12.003
   Metersky M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01525-2019
   Nakamura T, 2017, J VET MED SCI, V79, P1230, DOI 10.1292/jvms.17-0210
   Osterrieder N, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070779
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Trimpert J., 2020, ROBOROVSKI DWARF HAM, DOI [10.2139/ssrn.3659394, DOI 10.2139/SSRN.3659394]
   Walsh G, 2018, NAT BIOTECHNOL, V36, P1136, DOI 10.1038/nbt.4305
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Yuan LZ, 2020, EMERG MICROBES INFEC, V9, P949, DOI 10.1080/22221751.2020.1764871
NR 22
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1865-1674
EI 1865-1682
J9 TRANSBOUND EMERG DIS
JI Transbound. Emerg. Dis.
DI 10.1111/tbed.13837
EA SEP 2020
PG 5
WC Infectious Diseases; Veterinary Sciences
SC Infectious Diseases; Veterinary Sciences
GA NS7DQ
UT WOS:000572418400001
PM 32946664
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vazzana, N
   Dipaola, F
   Ognibene, S
AF Vazzana, Natale
   Dipaola, Francesco
   Ognibene, Silvia
TI Procalcitonin and secondary bacterial infections in COVID-19:
   association with disease severity and outcomes
SO ACTA CLINICA BELGICA
LA English
DT Article; Early Access
DE COVID-19; procalcitonin; infections; severe disease
AB Introduction: Procalcitonin (PCT) is an emerging prognostic marker in coronavirus disease 2019 (COVID-19). Whether PCT can detect secondary bacterial infections or reflect target tissue injury in this setting is still unclear. Here we performed a meta-analysis to review the prognostic value of PCT for severe disease and adverse outcome events in COVID-19.Methods: We searched relevant publications in online databases. Studies were included if they reported categorical data according to disease severity and/or outcomes. We analysed extracted data using fixed or random-effects meta-analysis models, as appropriate, depending on the presence of significant heterogeneity.Results: Data from 14 studies (3492 patients) were included in the analysis. Overall, 163 of 256 patients with elevated PCT had severe disease (63.7%) compared with 553 of 2047 with negative PCT (27.0%) (OR: 5.92; 95% CI: 3.20 to 10.94). Elevated PCT was also associated with adverse outcomes (OR: 13.1; 95% CI: 7.37 to 23.1). PCT was increased in 22.8% and 30.6% of patients with the severe course and adverse outcome, respectively. Rates of secondary bacterial infections ranged from 4.7% to 19.5% and were associated with increased risk of severe course or fatal outcomes (OR: 20.8; 95% CI: 11.6 to 37.4).Conclusions: Elevated PCT levels could identify a subset of COVID-19 patients at increased risk of severe disease and adverse outcome. Its limitations include low sensitivity and undefined cost-utility ratio. Whether PCT may be used for detecting secondary bacterial infections and guiding antibiotic therapy in COVID-19 is still undefined.
C1 [Vazzana, Natale; Dipaola, Francesco; Ognibene, Silvia] AUSL Reggio Emilia, Dept Internal Med, C Magati Hosp, I-42019 Scandiano, Italy.
RP Vazzana, N (corresponding author), AUSL Reggio Emilia, Dept Internal Med, C Magati Hosp, I-42019 Scandiano, Italy.
EM natale.vazzana@ausl.re.it
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   AlRawahi AN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2669-1
   Bakaletz LO, 2017, CURR OPIN MICROBIOL, V35, P30, DOI 10.1016/j.mib.2016.11.003
   Barrasa H, 2020, ANAESTH CRIT CARE PA, VS2352-5568, P30064
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chen TL, 2020, J GERONTOL A-BIOL, V75, P1788, DOI 10.1093/gerona/glaa089
   Chesi G, 2016, ITAL J MED, V10, P301, DOI 10.4081/itjm.2016.795
   Fan ZY, 2020, CLIN GASTROENTEROL H, V18, P1561, DOI 10.1016/j.cgh.2020.04.002
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan WJ, 2020, NEW ENGL J MED, V382
   Huang C, 2019, LANCET, V2020, P395
   Huang DT, 2018, NEW ENGL J MED, V379, P236, DOI [10.1056/NEJMoa1802670, 10.1056/nejmoa1802670]
   Joo K, 2011, J KOREAN MED SCI, V26, P1147, DOI 10.3346/jkms.2011.26.9.1147
   Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1733, DOI 10.1002/jmv.25819
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Lippi G, 2020, CLIN CHIM ACTA, V505, P190, DOI 10.1016/j.cca.2020.03.004
   Liu F, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104370
   Maakaron J, 2018, BLOOD, V132
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Muller F, 2010, CHEST, V138, P121, DOI 10.1378/chest.09-2920
   Sakr Y, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy313
   Schuetz P, 2018, JAMA-J AM MED ASSOC, V319, P925, DOI 10.1001/jama.2018.0852
   Schuetz P, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-107
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   van Nieuwkoop C, 2010, CRIT CARE, V14, DOI 10.1186/cc9328
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wu P, 2020, JAMA OPHTHALMOL, V138, P575, DOI 10.1001/jamaophthalmol.2020.1291
   Yuan JB, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00738-19
   Zhang GQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104364
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 35
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1784-3286
EI 2295-3337
J9 ACTA CLIN BELG
JI Acta Clin. Belg.
DI 10.1080/17843286.2020.1824749
EA SEP 2020
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NS4JH
UT WOS:000572229300001
PM 32966166
OA Bronze
DA 2021-01-01
ER

PT J
AU Gupta, GP
   Shah, YD
   Pant, DK
   Lekhak, S
   Shahi, R
   Mandal, A
   Poudel, P
   Dumre, SP
   Pandey, K
   Pandey, BD
AF Gupta, Govind Prasad
   Shah, Yogendra
   Pant, Dhan Kumar
   Lekhak, Sunil
   Shahi, Ramesh
   Mandal, Ananda
   Poudel, Pramod
   Dumre, Shayam Prakash
   Pandey, Kishor
   Pandey, Basu Dev
TI Preparatory phase for clinical trials of COVID-19 vaccine in Nepal
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Letter; Early Access
DE COVID-19; vaccines; clinical manifestations; asymptomatic infections;
   molecular diagnostics; Nepal
AB Public health data suggested a rapid rise in COVID-19-confirmed cases in Nepal along with increased deaths. There has been a wide variation in clinical outcomes of this disease. Control of this pandemic depends on the availability of vaccines or drugs for SARS-CoV-2. Thus, viral and human genetics/genomics and immunology are necessary to understand whether these factors will affect clinical trials of vaccines in Nepal.
C1 [Gupta, Govind Prasad] Lovely Profess Univ, Dept Clin Microbiol, Sch Physiotherapy & Paramed Sci, Phagwara, India.
   [Shah, Yogendra; Pant, Dhan Kumar] Natl Zoonosis & Food Hyg Res Ctr, Dept Microbiol, Kathmandu, Nepal.
   [Lekhak, Sunil] Decode Genom & Res Ctr, Dept Infect Dis, Kathmandu, Nepal.
   [Shahi, Ramesh; Mandal, Ananda] Seti Prov Hosp, Dept Med Lab, Dhangadhi, Nepal.
   [Poudel, Pramod] Univ Grants Commiss, Res Div, Bhaktapur, Nepal.
   [Dumre, Shayam Prakash] Nagasaki Univ, Inst Trop Med, Nagasaki, Japan.
   [Pandey, Kishor] Nepal Acad Sci & Technol, Mol Biotechnol Unit, Lalitpur, Nepal.
   [Pandey, Basu Dev] Epidemiol & Dis Control Div, Head Div, Teku, Nepal.
RP Gupta, GP (corresponding author), Lovely Profess Univ, Phagwara, Punjab, India.
EM govind_nir@yahoo.com
OI Reis, AlessanRSS/0000-0001-8486-7469; Shah, Yogendra/0000-0002-0820-4556
CR Bastola A, 2020, LANCET INFECT DIS, V20, P279, DOI 10.1016/S1473-3099(20)30067-0
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Kim YC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0188-3
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ozkan K, 2020, J PURE APPL MICROBIO, V14, P893, DOI 10.22207/JPAM.14.SPL1.26
   The Ministry of Health and Population Government of Nepal, 2020, COVID 19
   Wang J, 2020, APPL PHYS EXPRESS, V13
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   World Health Organization (WHO), 2020, COR DIS COVID 19 SIT
NR 10
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1809267
EA SEP 2020
PG 2
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA NS3WB
UT WOS:000572194900001
PM 32966155
DA 2021-01-01
ER

PT J
AU Miao, ZC
   Tidu, A
   Eriani, G
   Martin, F
AF Miao, Zhichao
   Tidu, Antonin
   Eriani, Gilbert
   Martin, Franck
TI Secondary structure of the SARS-CoV-2 5'-UTR
SO RNA BIOLOGY
LA English
DT Article; Early Access
DE SARS-CoV-2; 5MODIFIER LETTER PRIME-UTR; secondary structure; probing
ID 5' UNTRANSLATED REGION; STEM-LOOP; 5'-UNTRANSLATED REGION; RNA;
   CONSERVATION; TRANSLATION; ALIGNMENT; HOST
AB The SARS-CoV-2, a positive-sense single-stranded RNA Coronavirus, is a global threat to human health. Thus, understanding its life cycle mechanistically would be important to facilitate the design of antiviral drugs. A key aspect of viral progression is the synthesis of viral proteins by the ribosome of the human host. In Coronaviruses, this process is regulated by the viral 5MODIFIER LETTER PRIME and 3MODIFIER LETTER PRIME untranslated regions (UTRs), but the precise regulatory mechanism has not yet been well understood. In particular, the 5MODIFIER LETTER PRIME-UTR of the viral genome is most likely involved in translation initiation of viral proteins. Here, we performed inline probing and RNase V1 probing to establish a model of the secondary structure of SARS-CoV-2 5MODIFIER LETTER PRIME-UTR. We found that the 5MODIFIER LETTER PRIME-UTR contains stable structures including a very stable four-way junction close to the AUG start codon. Sequence alignment analysis of SARS-CoV-2 variants 5MODIFIER LETTER PRIME-UTRs revealed a highly conserved structure with few co-variations that confirmed our secondary structure model based on probing experiments.
C1 [Miao, Zhichao] European Bioinformat Inst EMBLEBI, European Mol Biol Lab, Wellcome Genome Campus, Hinxton, England.
   [Miao, Zhichao] Tongji Univ, Shanghai Peoples Hosp 4, Sch Med, Translat Res Inst Brain & Brain Intelligence, Shanghai, Peoples R China.
   [Miao, Zhichao] Tongji Univ, Shanghai Peoples Hosp 4, Sch Med, Dept Anesthesiol, Shanghai, Peoples R China.
   [Miao, Zhichao] Newcastle Univ, Fac Med Sci, Inst Cellular Med, Newcastle Fibrosis Res Grp, Newcastle Upon Tyne, Tyne & Wear, England.
   [Tidu, Antonin; Eriani, Gilbert; Martin, Franck] Univ Strasbourg, Inst Biol Mol & Cellulaire, Architecture & Reactivite ARN, CNRS, Strasbourg, France.
RP Martin, F (corresponding author), Univ Strasbourg, Inst Biol Mol & Cellulaire, Architecture & Reactivite ARN, CNRS, Strasbourg, France.
EM f.martin@ibmc-cnrs.unistra.fr
RI ; MARTIN, Franck/D-9042-2015
OI Miao, Zhichao/0000-0002-5777-9815; Eriani, Gilbert/0000-0002-8518-4675;
   MARTIN, Franck/0000-0001-9724-4025
FU Agence Nationale de la Recherche (FR)French National Research Agency
   (ANR) [ANR17-CE11-0024, ANR-17-CE12-0025-01, ANR-20-COVI-0078]; Welcome
   TrustWellcome Trust [108437/Z/15/Z]; Fondation pour la Recherche
   Medicale [CoronaIRES]
FX This work was supported by the Agence Nationale de la Recherche (FR)
   [ANR-17-CE12-0025-01]; Agence Nationale de la Recherche (FR)
   [ANR17-CE11-0024]; Welcome Trust [108437/Z/15/Z]; Fondation pour la
   Recherche Medicale [CoronaIRES]; Agence Nationale de la Recherche (FR)
   [ANR-20-COVI-0078].
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Babendure JR, 2006, RNA, V12, P851, DOI 10.1261/rna.2309906
   Boussemart L, 2014, NATURE, V513, P105, DOI 10.1038/nature13572
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Chen SC, 2010, VIROLOGY, V401, P29, DOI 10.1016/j.virol.2010.02.007
   CLARK K, 2016, NUCL ACIDS RES, V44
   Escors D, 2003, J VIROL, V77, P7890, DOI 10.1128/JVI.77.14.7890-7902.2003
   Guan BJ, 2012, J VIROL, V86, P4631, DOI 10.1128/JVI.06265-11
   Guan BJ, 2011, J VIROL, V85, P5593, DOI 10.1128/JVI.00263-11
   Gutell RR, 2000, J MOL BIOL, V300, P791, DOI 10.1006/jmbi.2000.3900
   Hershey JWB, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a032607
   Huston NC, 2020, COMPREHENSIVE IN VIV, V7
   Jaeger S, 2006, NUCLEIC ACIDS RES, V34, P4987, DOI 10.1093/nar/gkl666
   Kamitani W, 2006, P NATL ACAD SCI USA, V103, P12885, DOI 10.1073/pnas.0603144103
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Kerpedjiev P, 2015, BIOINFORMATICS, V31, P3374, DOI 10.1093/bioinformatics/btv372
   Lan TCT, 2020, STRUCTURE FULL SARS, V2020, P29178343
   Leppek K, 2018, NAT REV MOL CELL BIO, V19, P158, DOI 10.1038/nrm.2017.103
   Li LC, 2008, J MOL BIOL, V377, P790, DOI 10.1016/j.jmb.2008.01.068
   Liu PH, 2007, RNA, V13, P763, DOI 10.1261/rna.261807
   Liu PH, 2009, J VIROL, V83, P12084, DOI 10.1128/JVI.00915-09
   Lokugamage KG, 2012, J VIROL, V86, P13598, DOI 10.1128/JVI.01958-12
   Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-26
   Madhugiri R, 2018, VIROLOGY, V517, P44, DOI 10.1016/j.virol.2017.11.025
   Mailliot J, 2018, WIRES RNA, V9, DOI 10.1002/wrna.1458
   Manfredonia I, 2020, GENOME WIDE MAPPING, V06
   Narayanan K, 2015, VIRUS RES, V202, P89, DOI 10.1016/j.virusres.2014.11.019
   Orr MW, 2020, NUCLEIC ACIDS RES, V48, P1029, DOI 10.1093/nar/gkz734
   PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679
   Pestova TV, 2002, GENE DEV, V16
   Plant EP, 2013, VIRUSES-BASEL, V5, P279, DOI 10.3390/v5010279
   Plant EP, 2010, J VIROL, V84, P4330, DOI 10.1128/JVI.02480-09
   Raman S, 2005, J VIROL, V79, P12434, DOI 10.1128/JVI.79.19.12434-12446.2005
   Raman S, 2003, J VIROL, V77, P6720, DOI 10.1128/JVI.77.12.6720-6730.2003
   Rangan R, 2020, RNA, V26, P937, DOI 10.1261/rna.076141.120
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Weinberg Z, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-3
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Yang D, 2015, VIROLOGY, V475, P15, DOI 10.1016/j.virol.2014.11.001
NR 42
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1547-6286
EI 1555-8584
J9 RNA BIOL
JI RNA Biol.
DI 10.1080/15476286.2020.1814556
EA SEP 2020
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NS3XX
UT WOS:000572199700001
PM 32965173
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Christensen, SR
   Pilling, EB
   Eyring, JB
   Dickerson, G
   Sloan, CD
   Magnusson, BM
AF Christensen, Sarah R.
   Pilling, Emily B.
   Eyring, J. B.
   Dickerson, Grace
   Sloan, Chantel D.
   Magnusson, Brianna M.
TI Political and personal reactions to COVID-19 during initial weeks of
   social distancing in the United States
SO PLOS ONE
LA English
DT Article
AB Objective To examine perceptions, behaviors, and impacts surrounding COVID-19 early in the pandemic response. Materials and methods A cross-sectional survey of 1,030 U.S. adults was administered on March 31st, 2020. This survey examined attitudes toward media, government, and community responses to COVID-19 by political ideology and sociodemographic factors. Knowledge, anxieties, and impacts of COVID-19 were also assessed. Results Conservatives were more likely to report that COVID-19 was receiving too much media coverage and people were generally overreacting; liberals were more likely to report the government had not done enough in response to the pandemic. Females and those with lower income experienced more COVID-19 related economic anxieties. Those working and with children at home reported higher social, home, and work disruption. Social distancing behaviors were more common among liberals and were associated with increases in depressive symptoms. General knowledge about COVID-19 was widely exhibited across the sample, however, Black and Hispanic respondents were less likely to correctly answer questions about the availability of a vaccine and modes of transmission. Conclusions Public health experts should consider the political climate in crafting messaging that appeals to the values of those across the political spectrum. Research on the COVID-19 pandemic should continue to monitor the effects of social distancing on mental health and among vulnerable populations.
C1 [Christensen, Sarah R.; Pilling, Emily B.; Eyring, J. B.; Dickerson, Grace; Sloan, Chantel D.; Magnusson, Brianna M.] Brigham Young Univ, Coll Life Sci, Dept Publ Hlth, Provo, UT 84602 USA.
RP Magnusson, BM (corresponding author), Brigham Young Univ, Coll Life Sci, Dept Publ Hlth, Provo, UT 84602 USA.
EM Brianna.Magnusson@byu.edu
OI Eyring, J. B./0000-0002-4416-6673; Magnusson,
   Brianna/0000-0001-6389-8186
CR Ad Fontes Media, 2020, MED BIAS CHART VERS
   AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T
   Bianchi SM, 2012, SOC FORCES, V91, P55, DOI 10.1093/sf/sos120
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Doherty C, 2014, POLITICAL POLARIZATI
   Edison Research, 2019, WOM EC ANX
   Fiorina MP, 2008, ANNU REV POLIT SCI, V11, P563, DOI 10.1146/annurev.polisci.11.053106.153836
   Holt-Lunstad J, 2015, PERSPECT PSYCHOL SCI, V10, P227, DOI 10.1177/1745691614568352
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Leigh-Hunt N, 2017, PUBLIC HEALTH, V152, P157, DOI 10.1016/j.puhe.2017.07.035
   Leiserowitz A.A., 2011, GLOBAL WARMINGS 6 AM
   Littlefield RS, 2007, J APPL COMMUN RES, V35, P26, DOI 10.1080/00909880601065664
   Malka A, 2010, SOC JUSTICE RES, V23, P156, DOI 10.1007/s11211-010-0114-3
   Newman Nic, 2019, REUTERS I DIGITAL NE
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Reyes C., 2020, CHICAGO TRIBUNE
   Reynolds B, 2008, HEALTH PROMOT PRACT, V9, p13S, DOI 10.1177/1524839908325267
   Rossi R, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10185
   SAGE Working Group on Vaccine Hesitancy, 2018, VACC HES SURV QUEST
   Talevi D, 2020, RIV PSICHIATR, V55, P137, DOI 10.1708/3382.33569
   U.S. Census Bureau, 2019, FAM PRES OWN CHILDR
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
NR 23
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2020
VL 15
IS 9
AR e0239693
DI 10.1371/journal.pone.0239693
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NY2ZZ
UT WOS:000576265600015
PM 32970761
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Groarke, JM
   Berry, E
   Graham-Wisener, L
   McKenna-Plumley, PE
   McGlinchey, E
   Armour, C
AF Groarke, Jenny M.
   Berry, Emma
   Graham-Wisener, Lisa
   McKenna-Plumley, Phoebe E.
   McGlinchey, Emily
   Armour, Cherie
TI Loneliness in the UK during the COVID-19 pandemic: Cross-sectional
   results from the COVID-19 Psychological Wellbeing Study
SO PLOS ONE
LA English
DT Article
ID GENERALIZED ANXIETY DISORDER; COGNITIVE-BEHAVIORAL THERAPY;
   QUESTIONNAIRE F-SOZU; SOCIAL-ISOLATION; MENTAL-HEALTH; OLDER-ADULTS;
   RISK-FACTORS; BRIEF FORM; QUARANTINE; IMPACT
AB Objectives Loneliness is a significant public health issue. The COVID-19 pandemic has resulted in lockdown measures limiting social contact. The UK public are worried about the impact of these measures on mental health outcomes. Understanding the prevalence and predictors of loneliness at this time is a priority issue for research. Method The study employed a cross-sectional online survey design. Baseline data collected between March 23rd and April 24th 2020 from UK adults in the COVID-19 Psychological Wellbeing Study were analysed (N = 1964, 18-87 years, M = 37.11, SD = 12.86, 70% female). Logistic regression analysis examined the influence of sociodemographic, social, health and COVID-19 specific factors on loneliness. Results The prevalence of loneliness was 27% (530/1964). Risk factors for loneliness were younger age group (OR: 4.67-5.31), being separated or divorced (OR: 2.29), scores meeting clinical criteria for depression (OR: 1.74), greater emotion regulation difficulties (OR: 1.04), and poor quality sleep due to the COVID-19 crisis (OR: 1.30). Higher levels of social support (OR: 0.92), being married/co-habiting (OR: 0.35) and living with a greater number of adults (OR: 0.87) were protective factors. Conclusions Rates of loneliness during the initial phase of lockdown were high. Risk factors were not specific to the COVID-19 crisis. Findings suggest that supportive interventions to reduce loneliness should prioritise younger people and those with mental health symptoms. Improving emotion regulation and sleep quality, and increasing social support may be optimal initial targets to reduce the impact of COVID-19 regulations on mental health outcomes.
C1 [Groarke, Jenny M.; Berry, Emma; Graham-Wisener, Lisa; McKenna-Plumley, Phoebe E.; Armour, Cherie] Queens Univ Belfast, Ctr Improving Hlth Related Qual Life CIHRQoL, Sch Psychol, Belfast, Antrim, North Ireland.
   [McGlinchey, Emily; Armour, Cherie] Queens Univ Belfast, Sch Psychol, Stress Trauma & Related Condit STARC Res Lab, Belfast, Antrim, North Ireland.
RP Groarke, JM (corresponding author), Queens Univ Belfast, Ctr Improving Hlth Related Qual Life CIHRQoL, Sch Psychol, Belfast, Antrim, North Ireland.
EM j.groarke@qub.ac.uk
OI Groarke, Jenny/0000-0001-6370-7116; Armour, Cherie/0000-0001-7649-3874
CR [Anonymous], 2017, LANCET HIV, V2, pe115
   [Anonymous], 1996, PEAMIM, V66, P20
   [Anonymous], 2001, NEUROLOGY S3, V56, pA351
   [Anonymous], 2019, BMJ, V365, pl1494, DOI 10.1136/bmj.l149430940623
   Armour C, 2020, PSYARXIV
   Berking M, 2013, PSYCHOTHER PSYCHOSOM, V82, P234, DOI 10.1159/000348448
   Beutel ME, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1262-x
   Blevins CA, 2015, J TRAUMA STRESS, V28, P489, DOI 10.1002/jts.22059
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Bu F, 2020, WHO IS LONELY LOCKDO
   Bu F, 2020, LONELINESS LOCKDOWN
   Cacioppo JT, 2010, PSYCHOL AGING, V25, P453, DOI 10.1037/a0017216
   Cohen-Mansfield J, 2016, INT PSYCHOGERIATR, V28, P557, DOI 10.1017/S1041610215001532
   Cowan K, 2020, SURVEY RESULTS UNDER, P1
   Deckx L, 2014, EUR J ONCOL NURS, V18, P466, DOI 10.1016/j.ejon.2014.05.002
   Devaraj S, 2020, 3603746 SPEC SCI RES
   DiGiovanni C, 2004, BIOSECUR BIOTERROR, V2, P265, DOI 10.1089/bsp.2004.2.265
   Donovan NJ, 2020, AM J GERIATR PSYCHIA
   Entstehung der Die, 2013, JUD BOHEM, V48, P5
   Griffin SC, 2020, HEALTH PSYCHOL OPEN, V7, DOI 10.1177/2055102920913235
   Hansen T, 2016, SOC INDIC RES, V129, P445, DOI 10.1007/s11205-015-1111-6
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Hughes ME, 2004, RES AGING, V26, P655, DOI 10.1177/0164027504268574
   In Q, 2007, INTERNAL MED, V146, P317
   Jeste DV, 2020, JAMA PSYCHIAT
   Jia R, 2020, MENTAL HLTH UK COVID, DOI [10.1101/2020.05.14.20102012, DOI 10.1101/2020.05.14.20102012]
   Kang LJ, 2020, LANCET PSYCHIAT, V7, pE14, DOI 10.1016/S2215-0366(20)30047-X
   Kantor BN, 2020, MENTAL HLTH OUTCOMES
   Kaufman EA, 2016, J PSYCHOPATHOL BEHAV, V38, P443, DOI 10.1007/s10862-015-9529-3
   Kertz S, 2013, CLIN PSYCHOL PSYCHOT, V20, P456, DOI 10.1002/cpp.1802
   Killgore WDS, 2020, PSYCHIAT RES
   Kliem S, 2015, J CLIN EPIDEMIOL, V68, P551, DOI 10.1016/j.jclinepi.2014.11.003
   Kokou-Kpolou CK, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113128
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lasgaard M, 2016, SOC PSYCH PSYCH EPID, V51, P1373, DOI 10.1007/s00127-016-1279-3
   Lee B, 2019, PSYCHIAT CLIN PSYCH, V29, P864, DOI 10.1080/24750573.2019.1691320
   Lee EE, 2019, INT PSYCHOGERIATR, V31, P1447, DOI 10.1017/S1041610218002120
   Lee PW, 2007, J AFFECT DISORDERS, V99, P139, DOI 10.1016/j.jad.2006.09.002
   Li LZ, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113267
   Lin ECL, 2010, AM J INFECT CONTROL, V38, P302, DOI 10.1016/j.ajic.2009.09.008
   Lin MY, 2019, PSYCHOL ASSESSMENT, V31, P609, DOI 10.1037/pas0000686
   Loades ME, 2020, J AM ACAD CHILD ADOL
   Losada-Baltar A, 2020, J GERONTOL B
   Luchetti M, 2020, AM PSYCHOL
   Luo Y, 2012, SOC SCI MED, V74, P907, DOI 10.1016/j.socscimed.2011.11.028
   Mann F, 2017, SOC PSYCH PSYCH EPID, V52, P627, DOI 10.1007/s00127-017-1392-y
   Matthews T, 2016, SOC PSYCH PSYCH EPID, V51, P339, DOI 10.1007/s00127-016-1178-7
   Menec VH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230673
   Mujica-Mota RE, 2015, QUAL LIFE RES, V24, P909, DOI 10.1007/s11136-014-0820-7
   Mullen RA, 2019, ANN FAM MED, V17, P108, DOI 10.1370/afm.2358
   Murphy D, 2017, EUR J PSYCHOTRAUMATO, V8, DOI 10.1080/20008198.2017.1398001
   Mushtaq R, 2014, J CLIN DIAGN RES, V8, pWE01, DOI 10.7860/JCDR/2014/10077.4828
   Nyqvist F, 2017, SCAND J PUBLIC HEALT, V45, P411, DOI 10.1177/1403494817697511
   Okruszek L, 2020, PSYARXIV
   Peters M, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1103-3
   Pinquart M, 2001, BASIC APPL SOC PSYCH, V23, P245, DOI 10.1207/S15324834BASP2304_2
   Reynolds DL, 2008, EPIDEMIOL INFECT, V136, P997, DOI 10.1017/S0950268807009156
   Rosenberg M, 2020, DEPRESSION LONELINES
   Rutter LA, 2017, J PSYCHOPATHOL BEHAV, V39, P140, DOI 10.1007/s10862-016-9571-9
   Savikko N, 2005, ARCH GERONTOL GERIAT, V41, P223, DOI 10.1016/j.archger.2005.03.002
   Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676
   Shiovitz-Ezra S, 2010, INT PSYCHOGERIATR, V22, P455, DOI 10.1017/S1041610209991426
   Shovestul B, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229087
   Silva CJ, 2015, CULT CIENC DEPORTE, V10, P227, DOI 10.12800/ccd.v10i30.591
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Steptoe A, 2013, P NATL ACAD SCI USA, V110, P5797, DOI 10.1073/pnas.1219686110
   Stickley A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191651
   Stickley A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067978
   The Lancet Hiv null, 2020, LANCET HIV, V7, pe75
   Theeke LA, 2010, RES GERONTOL NURS, V3, P113, DOI 10.3928/19404921-20091103-99
   Theeke LA, 2009, ARCH PSYCHIAT NURS, V23, P387, DOI 10.1016/j.apnu.2008.11.002
   Titov Nickolai, 2011, Cognitive Behaviour Therapy, V40, P126, DOI 10.1080/16506073.2010.550059
   Trauer JM, 2015, ANN INTERN MED, V163, P191, DOI 10.7326/M14-2841
   Tull MT, 2020, PSYCHIAT RES
   Victor CR, 2012, J PSYCHOL, V146, P85, DOI 10.1080/00223980.2011.613875
   Victor CR, 2011, J PSYCHOL, DOI [10.1080/00223980.2011.613875?casa_token=FiyKOZi7o94AAAAA:Tdubr-aq-i4nihreqY0XIFltsz_d0ND26-vzHNS6g-U9Kn8xV1mOMxkIY8OXJTg1JOdoT9JcSDgc, DOI 10.1080/00223980.2011.613875?]
   Voitsidis P, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113076
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   Wang JY, 2020, SOC PSYCH PSYCH EPID, V55, P811, DOI 10.1007/s00127-019-01734-6
   Wong SY, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-119
   World Health Organization, 2020, MENT HLTH PSYCH CONS
   Wortmann JH, 2016, PSYCHOL ASSESSMENT, V28, P1392, DOI 10.1037/pas0000260
   Young JL, 2013, 2013 5TH IEEE INTERNATIONAL SYMPOSIUM ON MICROWAVE, ANTENNA, PROPAGATION AND EMC TECHNOLOGIES FOR WIRELESS COMMUNICATIONS (MAPE), P2, DOI 10.1109/MAPE.2013.6689923
NR 83
TC 1
Z9 1
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2020
VL 15
IS 9
AR e0239698
DI 10.1371/journal.pone.0239698
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NY2ZZ
UT WOS:000576265600022
PM 32970764
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hoffman, BU
AF Hoffman, Benjamin U.
TI Significant relaxation of SARS-CoV-2-targeted non-pharmaceutical
   interventions may result in profound mortality: A New York state
   modelling study
SO PLOS ONE
LA English
DT Article
ID CORONAVIRUS; CHINA
AB Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is the most significant global health crisis of the 21(st)century. The aim of this study was to develop a model to simulate the effect of undocumented infections, seasonal infectivity, immunity, and non-pharmaceutical interventions (NPIs) on the transmission, morbidity, and mortality of SARS-CoV-2 in New York State (NYS) based on data collected between March 4 and April 28, 2020. Simulations predict that undocumented infections significantly contribute to infectivity, NPIs are effective in reducing morbidity and mortality, and relaxation >50% of NPIs from initial lock-down levels may result in tens-of-thousands more deaths. Endemic infection is likely to occur in the absence of sustained immunity. As a result, until an effective vaccine or other effective pharmaceutical intervention is developed, the risks of significantly reducing NPIs should be carefully considered. This study employs modelling to simulate fundamental characteristics of SARS-CoV-2 transmission, which can help policymakers navigate combating this virus in the coming years.
C1 [Hoffman, Benjamin U.] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY 10027 USA.
   [Hoffman, Benjamin U.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
RP Hoffman, BU (corresponding author), Columbia Univ, Vagelos Coll Phys & Surg, New York, NY 10027 USA.; Hoffman, BU (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM Benjamin.Hoffman@ucsf.edu
OI Hoffman, Benjamin/0000-0002-9831-4061
FU NIH MSTP training grant (National Institute of General Medical Sciences)
   [T32GM007367]
FX BUH was funded by a NIH MSTP training grant (National Institute of
   General Medical Sciences T32GM007367; https://www.nigms.nih.gov).The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   [Anonymous], 2020, NAT RESP ENT VIR SUR
   [Anonymous], 2020, GOVERNOR CUOMO SIGNS
   [Anonymous], 2019, BMJ, V2020, pm792
   [Anonymous], 2018, FLUVIEW INTERACTIVE
   [Anonymous], 2019, QUICKFACTS US
   [Anonymous], 2020, NEW YORK STATE STATE
   Bendavid E, 2020, COVID 19 ANTIBODY SE, DOI [10.1101/2020.04.14.20062463, DOI 10.1101/2020.04.14.20062463]
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Chin AWH, 2020, LANCET MICROBE, V1, pe10, DOI [DOI 10.1101/2020.03.15.20036673, heresAdoi. moll 0.10161 S2666-5247(20130003-3, 10.1016/S2666-5247(20)130003-3]
   Coleman TF, 1994, MATH PROGRAM, V67, P189, DOI DOI 10.1007/BF01582221
   Cuomo A., 2020, AMID ONGOING COVID 1
   Cuomo A, 2020, VIDEO AUDIO PHOTOS R
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Ferguson NM, 2003, NATURE, V425, P681, DOI 10.1038/nature02007
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Ficetola G.F., 2020, CLIMATE AFFECTS GLOB, DOI [10.1101/2020.03.23.20040501, DOI 10.1101/2020.03.23.20040501]
   Goldstein E, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001051
   Haffajee RL, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006740
   Health CaCoSFDoP, 2020, ORC1907 HLTH CACOSFD
   Islam N, 2020, TEMPERATURE HUMIDITY, V2020, P2020, DOI [10.1101/2020.03.27.20045658, DOI 10.1101/2020.03.27.20045658]
   Kennedy J, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1-6, P1942, DOI 10.1109/icnn.1995.488968
   Killerby ME, 2018, J CLIN VIROL, V101, P52, DOI 10.1016/j.jcv.2018.01.019
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Koo JR, 2020, LANCET INFECT DIS, V20, P678, DOI 10.1016/S1473-3099(20)30162-6
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   National Academies of Sciences E Medicine, 2020, RAP EXP CONS SARS CO
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Qi HC, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138778
   Radcliffe J, 1977, J R STAT SOC C, V26, P85, DOI [10.2307/2346882, DOI 10.1057/JORS.1977.92]
   Richard AN, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20224
   Rocklov J, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa038
   Sajadi Mohammad M, 2020, SSRN, P3550308, DOI 10.2139/ssrn.3550308
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   Tang B, 2020, INT J INFECT DIS, V95, P288, DOI 10.1016/j.ijid.2020.03.018
   Tillett HE, 1992, EPIDEMIOL INFECT, V108, P211, DOI DOI 10.1017/S0950268800059896
   Wang J, 2020, HIGH TEMP-HIGH PRESS, DOI [10.2139/ssrn.3551767, DOI 10.2139/SSRN.3551767]
   White-House, 2020, OP AM WASH DC
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Wu P, 2020, EUROSURVEILLANCE, V25, P4, DOI 10.2807/1560-7917.ES.2020.25.3.2000044
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 47
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2020
VL 15
IS 9
AR e0239647
DI 10.1371/journal.pone.0239647
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NY2ZZ
UT WOS:000576265600057
PM 32970745
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kim, S
   Ko, Y
   Kim, YJ
   Jung, E
AF Kim, Soyoung
   Ko, Youngsuk
   Kim, Yae-Jean
   Jung, Eunok
TI The impact of social distancing and public behavior changes on COVID-19
   transmission dynamics in the Republic of Korea
SO PLOS ONE
LA English
DT Article
AB Background In the Republic of Korea (ROK), social distancing and public behavior changes mitigated COVID-19 spread. However, a second wave of the epidemic is expected in the fall if neither vaccine nor antiviral drugs become available. This study investigated the impact of non-pharmaceutical measures on short- and long-term outbreak dynamics. Methods A mathematical model based on Susceptible-Exposed-Infectious-Recovered model is developed considering isolated and behavior-changed groups. Using the least-squares fitting method, transmission and behavior change rates were estimated using cases reported from February 16 to April 20, 2020. Findings The estimated transmission rate of COVID-19 was 4 center dot 6180 and behavior change rate was 2 center dot 6044. The model predicted the number of new cases to continuously decrease, with less than one case expected after May 6, 2020. Concurrently, a 25% reduction in behavioral changes during the outbreak would increase the case count by 60,000, resulting in 4,000 cases at maximum, exceeding the medical system's capacity. As behavioral restrictions are eased, local transmission will likely increase, with forecasted second wave peak in October 2020. Interpretation Social distancing and public behavior changes have curbed the spread of COVID-19 in the ROK. Mathematical modeling demonstrates the importance of these measures in reducing and delaying outbreaks. Nevertheless, non-pharmaceutical interventions cannot eliminate the disease. In the future, vaccines and antiviral treatments combined with social distancing and public behavior changes will be paramount to ending COVID-19 epidemic.
C1 [Kim, Soyoung; Ko, Youngsuk; Jung, Eunok] Konkuk Univ, Dept Math, Seoul, South Korea.
   [Kim, Yae-Jean] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pediat, Sch Med, Seoul, South Korea.
RP Jung, E (corresponding author), Konkuk Univ, Dept Math, Seoul, South Korea.
EM junge@konkuk.ac.kr
FU Korea National Research Foundation (NRF) - Korean government (MEST)
   [NRF-2019R1A6A3A01091838, NRF-2017R1A2B2004651]
FX S. Kim's work is supported by the Korea National Research Foundation
   (NRF) grant funded by the Korean government (MEST; grant No.
   NRF-2019R1A6A3A01091838). E. Jung's work is supported by the Korea
   National Research Foundation (NRF) grant conferred by the Korean
   government (MEST; grant No. NRF-2017R1A2B2004651). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR [Anonymous], 2020, KOR SIT REP COVID 19
   [Anonymous], 2020, J KOREAN MED SCI, V35, pe112
   [Anonymous], 2020, CORONAVIRUS DIS COVI
   Coyne M, 2020, FORBES
   Ki M, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020007
   Kissler SM, 2020, SOCIAL DISTANCING ST
   Korean Statistical Information Service, RES REG POP ADM DIST
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Perra N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023084
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   World Health Organization, 2020, 2 M INT HLTH REG 200
NR 11
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2020
VL 15
IS 9
AR e0238684
DI 10.1371/journal.pone.0238684
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NY2ZZ
UT WOS:000576265600073
PM 32970716
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shan, WY
   Hong, DS
   Zhu, JQ
   Zhao, QW
AF Shan, Wenya
   Hong, Dongsheng
   Zhu, Jieqiang
   Zhao, Qingwei
TI Assessment of the Potential Adverse Events Related to
   Ribavirin-Interferon Combination for Novel Coronavirus Therapy
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article
ID PEGYLATED INTERFERON; SIGNAL-DETECTION; PEGINTERFERON ALPHA-2B;
   REPORTING SYSTEM; SAFETY; CHILDREN; EFFICACY; PATIENT
AB Purpose. We aimed to analyze and evaluate the safety signals of ribavirin-interferon combination through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS), so as to provide reference for the rationale use of these agents in the management of relevant toxicities emerging in patients with novel coronavirus pneumonia (COVID-19).Methods. Reports to the FAERS from 1 January 2004 to 8 March 2020 were analyzed. The proportion of report ratio (PRR), reporting odds ratio (ROR), and Bayesian confidence interval progressive neural network (BCPNN) method were used to detect the safety signals.Results. A total of 55 safety signals were detected from the top 250 adverse event reactions in 2200 reports, but 19 signals were not included in the drug labels. All the detected adverse event reactions were associated with 13 System Organ Classes (SOC), such as gastrointestinal, blood and lymph, hepatobiliary, endocrine, and various nervous systems. The most frequent adverse events were analyzed, and the results showed that females were more likely to suffer from anemia, vomiting, neutropenia, diarrhea, and insomnia.Conclusion. The ADE (adverse drug event) signal detection based on FAERS is helpful to clarify the potential adverse events related to ribavirin-interferon combination for novel coronavirus therapy; clinicians should pay attention to the adverse reactions of gastrointestinal and blood systems, closely monitor the fluctuations of the platelet count, and carry out necessary mental health interventions to avoid serious adverse events.
C1 [Shan, Wenya; Hong, Dongsheng; Zhao, Qingwei] Zhejiang Univ, Affiliated Hosp 1, Dept Clin Pharm, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhu, Jieqiang] Zhejiang Univ Technol, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhao, Qingwei] Zhejiang Prov Key Lab Drug Evaluat & Clin Res, Hangzhou 310003, Zhejiang, Peoples R China.
RP Zhao, QW (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Dept Clin Pharm, Hangzhou 310003, Zhejiang, Peoples R China.; Zhao, QW (corresponding author), Zhejiang Prov Key Lab Drug Evaluat & Clin Res, Hangzhou 310003, Zhejiang, Peoples R China.
EM qwzhao@zju.edu.cn
FU Zhejiang Medical and Health Foundation [2019KY385]; Zhejiang Medical and
   Health Innovation Talent Project [2021438228]
FX This research was supported by the Zhejiang Medical and Health
   Foundation (grant number 2019KY385) and Zhejiang Medical and Health
   Innovation Talent Project (grant number 2021438228).
CR Chinese National Health Committee, 2020, DIAGN TREATM NOV COR
   Evans SJW, 2001, PHARMACOEPIDEM DR S, V10, P483, DOI 10.1002/pds.677
   Georgiopoulos G, 2019, HELL J CARDIOL, V60, P143, DOI 10.1016/j.hjc.2018.07.001
   Gross BN, 2009, PHARMACOTHERAPY, V29, P121, DOI 10.1592/phco.29.1.121
   Hassaan SH, 2019, INT J PSYCHIAT MED, V54, P424, DOI 10.1177/0091217419858277
   Hesamizadeh Khashayar, 2019, Med J Islam Repub Iran, V33, P63, DOI 10.34171/mjiri.33.63
   Noguchi Y, 2019, PHARMAZIE, V74, P570, DOI 10.1691/ph.2019.9426
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Rosen I, 2013, WORLD J GASTROENTERO, V19, P1098, DOI 10.3748/wjg.v19.i7.1098
   Santos M, 2013, AN BRAS DERMATOL, V88, P109, DOI 10.1590/abd1806-4841.20131986
   Simin M, 2007, ALIMENT PHARM THER, V25, P1153, DOI 10.1111/j.1365-2036.2007.03294.x
   Smolders EJ, 2018, TROP MED INT HEALTH, V23, P295, DOI 10.1111/tmi.13027
   Taha AA, 2010, CAN J GASTROENTEROL, V24, P597, DOI 10.1155/2010/717845
   van Puijenbroek EP, 2003, DRUG SAFETY, V26, P293, DOI 10.2165/00002018-200326050-00001
   van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668
   Wirth S, 2010, J HEPATOL, V52, P501, DOI 10.1016/j.jhep.2010.01.016
   Xu R, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-17
   Yu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep24955
   Zhao WX, 2014, BRAZ J INFECT DIS, V18, P110, DOI 10.1016/j.bjid.2013.05.014
   Zorych I, 2013, STAT METHODS MED RES, V22, P39, DOI 10.1177/0962280211403602
NR 20
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748-670X
EI 1748-6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD SEP 24
PY 2020
VL 2020
AR 1391583
DI 10.1155/2020/1391583
PG 7
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA OB2NK
UT WOS:000578310100002
PM 33029193
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Adam, EH
   Schmid, B
   Sonntagbauer, M
   Kranke, P
   Zacharowski, K
   Meybohm, P
AF Adam, Elisabeth H.
   Schmid, Benedikt
   Sonntagbauer, Michael
   Kranke, Peter
   Zacharowski, Kai
   Meybohm, Patrick
TI Fibrin-derived peptide B beta 15-42 (FX06) as salvage treatment in
   critically ill patients with COVID-19-associated acute respiratory
   distress syndrome
SO CRITICAL CARE
LA English
DT Article
DE Critical care; Respiratory distress syndrome; adult; COVID-19;
   Therapies; investigational; Pulmonary edema; Immunomodulatory agents
C1 [Adam, Elisabeth H.; Sonntagbauer, Michael; Zacharowski, Kai] Goethe Univ, Univ Hosp Frankfurt, Dept Anaesthesiol Intens Care Med & Pain Therapy, Frankfurt, Germany.
   [Schmid, Benedikt; Kranke, Peter; Meybohm, Patrick] Julius Maximilians Univ, Univ Hosp Wuerzburg, Dept Anaesthesiol & Crit Care, Wurzburg, Germany.
RP Adam, EH (corresponding author), Goethe Univ, Univ Hosp Frankfurt, Dept Anaesthesiol Intens Care Med & Pain Therapy, Frankfurt, Germany.
EM Elisabeth.adam@kgu.de
CR Atar D, 2009, J AM COLL CARDIOL, V53, P720, DOI 10.1016/j.jacc.2008.12.017
   Groger M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005391
   Henning R, 2006, DRUG FUTURE, V31, P811, DOI 10.1358/dof.2006.031.09.1025670
   Jensen T, 2007, THROMB HAEMOSTASIS, V97, P822, DOI 10.1160/TH07-01-0039
   Pawlinski R, 2010, THROMB RES, V125, pS70, DOI 10.1016/j.thromres.2010.01.042
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 6
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD SEP 24
PY 2020
VL 24
IS 1
AR 574
DI 10.1186/s13054-020-03293-8
PG 4
WC Critical Care Medicine
SC General & Internal Medicine
GA NY1AJ
UT WOS:000576130600002
PM 32972429
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mansour, OY
   Malik, AM
   Linfante, I
AF Mansour, Ossama Yassin
   Malik, Amer M.
   Linfante, Italo
TI Mechanical Thrombectomy of COVID-19 positive acute ischemic stroke
   patient: a case report and call for preparedness
SO BMC NEUROLOGY
LA English
DT Article
DE Acute ischemic stroke; Mechanical thrombectomy; COVID-19; Coronavirus;
   SARS-CoV-2; Stroke workflow; Personal protective equipment; Large vessel
   occlusion
ID C-REACTIVE PROTEIN
AB Background The novel coronavirus (COVID-19) global pandemic is associated with an increased incidence of acute ischemic stroke (AIS) secondary to large vessel occlusion (LVO). The treatment of these patients poses unique and significant challenges to health care providers requiring changes in existing protocols. Case presentation A 54-year-old COVID-19 positive patient developed sudden onset left hemiparesis secondary to an acute right middle cerebral artery occlusion (National Institutes of Health Stroke Scale (NIHSS) score = 11). Mechanical thrombectomy (MT) was performed under a new protocol specifically designed to maximize protective measures for the team involved in the care of the patient. Mechanical Thrombectomy was performed successfully under general anesthesia resulting in TICI 3 recanalization. With regards to time metrics, time from door to reperfusion was 60 mins. The 24-h NIHSS score decreased to 2. Patient was discharged after 19 days after improvement of her pulmonary status with modified Rankin Scale = 1. Conclusion Patients infected by COVID-19 can develop LVO that is multifactorial in etiology. Mechanical thrombectomy in a COVID-19 confirmed patient presenting with AIS due to LVO is feasible with current mechanical thrombectomy devices. A change in stroke workflow and protocols is now necessary in order to deliver the appropriate life-saving therapy for COVID-19 positive patients while protecting medical providers.
C1 [Mansour, Ossama Yassin] Alexandria Univ, Stroke & Neurointervent Unit, Neurol Dept, Fac Med, Alexandria, Egypt.
   [Malik, Amer M.] Univ Miami, Miller Sch Med, Dept Neurol, Vasc Neurol Div, Miami, FL 33136 USA.
   [Linfante, Italo] Florida Int Univ, Miami Cardiac & Vasc Inst, Baptist Neurosci Inst, Miami, FL 33199 USA.
RP Mansour, OY (corresponding author), Alexandria Univ, Stroke & Neurointervent Unit, Neurol Dept, Fac Med, Alexandria, Egypt.
EM yassinossama@yahoo.com
RI mansour, ossama/F-4592-2010
OI mansour, ossama/0000-0001-8814-6431
CR [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   [Anonymous], 2020, UPD OUTBR COR DIS 20
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Horvei LD, 2016, J THROMB HAEMOST, V14, P1561, DOI 10.1111/jth.13369
   Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399
   Ji Y, 2014, J THROMB HAEMOST, V12, P1667, DOI 10.1111/jth.12680
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li Y, ACUTE CEREBROVASCULA
   Powers WJ, 2019, STROKE, V50, pE344, DOI 10.1161/STR.0000000000000211
   Rodrigues GM, 2019, J NEUROINTERV SURG
   Wang AR, 2020, J NEUROINTERV SURG, V12, P648, DOI [10.1136/neurintsurg-2020-016220, 10.1136/neurintsurg-2019-015702]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, 67 WHO
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
NR 14
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2377
J9 BMC NEUROL
JI BMC Neurol.
PD SEP 24
PY 2020
VL 20
IS 1
AR 358
DI 10.1186/s12883-020-01930-x
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA NY1CR
UT WOS:000576136700001
PM 32972381
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Canevelli, M
   Remoli, G
   Trentin, F
   Riccardi, G
   Tariciotti, L
   Risoleo, G
   Ancidoni, A
   Bruno, G
   Cesari, M
   Vanacore, N
   Raparelli, V
AF Canevelli, Marco
   Remoli, Giulia
   Trentin, Federica
   Riccardi, Gabriele
   Tariciotti, Leonardo
   Risoleo, Giovanni
   Ancidoni, Antonio
   Bruno, Giuseppe
   Cesari, Matteo
   Vanacore, Nicola
   Raparelli, Valeria
TI The Pipeline of Therapeutics Testing During the Emergency Phase of the
   COVID-19 Outbreak
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; clinical trials; antivirals; immunomodulators;
   research protocols; drug development
AB The coronavirus disease 19 (COVID-19) pandemic poses a serious threat to the sustainability of healthcare systems and is currently having a significant effect on living conditions worldwide. No therapeutic agent has yet proven to be effective for the treatment of COVID-19. The management of this disease currently relies on supportive care and the off-label and compassionate use of antivirals and immunomodulators. Nevertheless, there has been a great worldwide effort to progress research and test the efficacy and safety/tolerability profiles of numerous candidate agents that may positively affect the various clinical syndromes associated with COVID-19. In parallel, vaccination and chemoprophylaxis strategies are being investigated. This article provides a summary of interventional studies targeting COVID-19 during the emergency phase of the outbreak to broadly inform clinicians and researchers on what happened and what they can expect in upcoming months. Thedatabase and thewere investigated on March 31, 2020, to identify all ongoing phase 1-4 research protocols testing pharmacological interventions targeting SARS-CoV-2 infection and/or clinical syndromes associated with COVID-19. Overall, six phase 1, four phase 1-2, 14 phase 2, ten phase 2-3, 19 phase 3, and nine phase 4 studies were identified, and the features of these studies are described in the present review. We also provide an updated overview of the change overtime in the pipeline following this emergency phase and based on the current epidemiology of the COVID-19 pandemic.
C1 [Canevelli, Marco; Ancidoni, Antonio; Vanacore, Nicola] Italian Natl Inst Hlth, Natl Ctr Dis Prevent & Hlth Promot, Rome, Italy.
   [Canevelli, Marco; Remoli, Giulia; Trentin, Federica; Bruno, Giuseppe] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy.
   [Riccardi, Gabriele] Sapienza Univ Rome, Dept Sense Organ, Rome, Italy.
   [Tariciotti, Leonardo] Univ Milan, IRCSS Fdn Ca Granda Osped Maggiore Policlin, Unit Neurosurg, Milan, Italy.
   [Risoleo, Giovanni] Univ Milan, ASTT Grande Osped Metropolitano Niguarda, Dept Radiol, Milan, Italy.
   [Cesari, Matteo] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Cesari, Matteo] IRCCS Ist Clin Sci Maugeri, Geriatr Unit, Milan, Italy.
   [Raparelli, Valeria] Sapienza Univ Rome, Dept Expt Med, Rome, Italy.
RP Canevelli, M (corresponding author), Italian Natl Inst Hlth, Natl Ctr Dis Prevent & Hlth Promot, Rome, Italy.; Canevelli, M (corresponding author), Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy.
EM marco.canevelli@iss.it
FU Italian Ministry of HealthMinistry of Health, Italy [GR-2016-02364975];
   Italian Ministry of Education, University and Research (MIUR), Rome,
   ItalyMinistry of Education, Universities and Research (MIUR)
   [RBSI14HNVT]
FX MCa is supported by a research grant of the Italian Ministry of Health
   for the project Dementia in immigrants and ethnic minorities living in
   Italy: clinical-epidemiological aspects and public health perspectives
   (ImmiDem) (GR-2016-02364975). VR was supported by the Scientific
   Independence of Young Researchers Program (RBSI14HNVT), Italian Ministry
   of Education, University and Research (MIUR), Rome, Italy.
CR [Anonymous], 2020, PEDIATR MED RODZ, V16, P9, DOI 10.15557/PiMR.2020.0003
   [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   [Anonymous], COVID 19 MAP
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   COVID-19 Clinical Res Coalition, 2020, LANCET, V395, P1322, DOI 10.1016/S0140-6736(20)30798-4
   European Medicines Agency, 2020, POINTS CONS IMPL COR
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kabir MT, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00616
   Kalil AC, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.4742., DOI 10.1001/JAMA.2020.4742.]
   Maguire Brittany J, 2020, Wellcome Open Res, V5, P60, DOI 10.12688/wellcomeopenres.15821.1
   Poston JT, 2020, JAMA-J AM MED ASSOC, DOI [10.1001/jama.2020.4914., DOI 10.1001/JAMA.2020.4914.]
   Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207
   Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 19
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD SEP 24
PY 2020
VL 7
AR 552991
DI 10.3389/fmed.2020.552991
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA NX9HK
UT WOS:000576012600001
PM 33072781
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bergasa-Caceres, F
   Rabitz, HA
AF Bergasa-Caceres, Fernando
   Rabitz, Herschel A.
TI Interdiction of Protein Folding for Therapeutic Drug Development in SARS
   CoV-2
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; SEQUENTIAL COLLAPSE MODEL;
   BETA-LACTOGLOBULIN; CONSERVED DOMAIN; ALPHA-SYNUCLEIN; RECEPTOR;
   PATHWAY; IDENTIFICATION; REPLICATION; MECHANISMS
AB In this article, we predict the folding initiation events of the ribose phosphatase domain of protein Nsp3 and the receptor binding domain of the spike protein from the severe acute respiratory syndrome (SARS) coronavirus-2. The calculations employ the sequential collapse model and the crystal structures to identify the segments involved in the initial contact formation events of both viral proteins. The initial contact locations may provide good targets for therapeutic drug development. The proposed strategy is based on a drug binding to the contact location, thereby aiming to prevent protein folding. Peptides are suggested as a natural choice for such protein folding interdiction drugs.
C1 [Bergasa-Caceres, Fernando; Rabitz, Herschel A.] Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.
RP Bergasa-Caceres, F (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.
EM Bergasa@Princeton.edu
FU NSFNational Science Foundation (NSF) [CHE1763198]
FX The authors acknowledge support from NSF grant CHE1763198.
CR Alm E, 1999, P NATL ACAD SCI USA, V96, P11305, DOI 10.1073/pnas.96.20.11305
   Berezovsky IN, 2001, J MOL BIOL, V307, P1419, DOI 10.1006/jmbi.2001.4554
   Bergasa-Caceres F, 2003, J PHYS CHEM B, V107, P3606, DOI 10.1021/jp030087l
   Bergasa-Caceres F, 1999, J PHYS CHEM B, V103, P9749, DOI 10.1021/jp990090y
   Bergasa-Caceres F, 2001, J PHYS CHEM B, V105, P2874, DOI 10.1021/jp004421e
   Bergasa-Caceres F, 2019, J PHYS CHEM B, V123, P4463, DOI 10.1021/acs.jpcb.8b11634
   Bergasa-Caceres F, 2018, BBA-PROTEINS PROTEOM, V1866, P1201, DOI 10.1016/j.bbapap.2018.09.006
   Bergasa-Caceres F, 2016, J PHYS CHEM B, V120, P11093, DOI 10.1021/acs.jpcb.6b05696
   Bergasa-Caceres F, 2010, J PHYS CHEM A, V114, P6978, DOI 10.1021/jp909944p
   Broglia R. A., 2007, PROTEIN FOLDING DRUG
   Broglia RA, 2005, PROTEIN SCI, V14, P2668, DOI 10.1110/ps.051670905
   Clementi C, 2000, P NATL ACAD SCI USA, V97, P5871, DOI 10.1073/pnas.100547897
   CONRAD JC, 1976, MACROMOLECULES, V9, P41, DOI 10.1021/ma60049a007
   Das A., 2020, RATIONAL DESIGN PROT
   DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8
   Egloff MP, 2006, J VIROL, V80, P8493, DOI 10.1128/JVI.00713-06
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Eriksson KK, 2008, J VIROL, V82, P12325, DOI 10.1128/JVI.02082-08
   FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369
   Fehr AR, 2016, MBIO, V7, DOI 10.1128/mBio.01721-16
   GOLDENBERG DM, 1978, NEW ENGL J MED, V298, P1384, DOI 10.1056/NEJM197806222982503
   GORBALENYA AE, 1991, FEBS LETT, V288, P201, DOI 10.1016/0014-5793(91)81034-6
   Han DP, 2007, J VIROL, V81, P12029, DOI 10.1128/JVI.00315-07
   Han WD, 2011, MUTAT RES-REV MUTAT, V727, P86, DOI 10.1016/j.mrrev.2011.03.001
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu HB, 2005, J COMB CHEM, V7, P648, DOI 10.1021/cc0500607
   ITTAH V, 1995, BIOCHEMISTRY-US, V34, P4493, DOI 10.1021/bi00013a042
   JACOBSON H, 1950, J CHEM PHYS, V18, P1600, DOI 10.1063/1.1747547
   KARPLUS M, 1979, BIOPOLYMERS, V18, P1421, DOI 10.1002/bip.1979.360180608
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lee ACL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102383
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2004, J VIROL, V78, P11429, DOI 10.1128/JVI.78.20.11429-11433.2004
   Makarov DE, 2003, PROTEIN SCI, V12, P17, DOI 10.1110/ps.0220003
   Moreland JL, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-21
   Motta A, 2005, BIOCHEMISTRY-US, V44, P14170, DOI 10.1021/bi050658v
   Munoz V, 1999, P NATL ACAD SCI USA, V96, P11311, DOI 10.1073/pnas.96.20.11311
   Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07
   Neuman BW, 2016, ANTIVIR RES, V135, P97, DOI 10.1016/j.antiviral.2016.10.005
   Ozkan SB, 2007, P NATL ACAD SCI USA, V104, P11987, DOI 10.1073/pnas.0703700104
   Plotkin SS, 2002, J CHEM PHYS, V116, P5263, DOI 10.1063/1.1449866
   PRESS OW, 1995, LANCET, V346, P336, DOI 10.1016/S0140-6736(95)92225-3
   Putics A, 2005, J VIROL, V79, P12721, DOI 10.1128/JVI.79.20.12721-12731.2005
   Ruzza P, 2014, ACS CHEM NEUROSCI, V5, P30, DOI 10.1021/cn400149k
   Saikatendu KS, 2005, STRUCTURE, V13, P1665, DOI 10.1016/j.str.2005.07.022
   SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   SHIRAKI K, 1995, J MOL BIOL, V245, P180, DOI 10.1006/jmbi.1994.0015
   Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166
   Vendruscolo M, 2001, NATURE, V409, P641, DOI 10.1038/35054591
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu YY, 2009, J VIROL, V83, P1083, DOI 10.1128/JVI.01862-08
   Yang Nicole J, 2015, Methods Mol Biol, V1266, P29, DOI 10.1007/978-1-4939-2272-7_3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 63
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
EI 1520-5207
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD SEP 24
PY 2020
VL 124
IS 38
BP 8201
EP 8208
DI 10.1021/acs.jpcb.0c03716
PG 8
WC Chemistry, Physical
SC Chemistry
GA NX6LA
UT WOS:000575819100001
PM 32790379
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Huang, Y
   Zheng, WJ
   Ni, YS
   Li, MS
   Chen, JK
   Liu, XH
   Tan, XH
   Li, JQ
AF Huang, Ying
   Zheng, Wen-jiang
   Ni, Yong-shi
   Li, Mian-sha
   Chen, Jian-kun
   Liu, Xiao-hong
   Tan, Xing-hua
   Li, Ji-qiang
TI Therapeutic mechanism of Toujie Quwen granules in COVID-19 based on
   network pharmacology
SO BIODATA MINING
LA English
DT Article
DE COVID-19; Toujie Quwen granule; Potential therapeutic targets; Signaling
   pathways; Network pharmacology
ID ACUTE LUNG INJURY; GENE ONTOLOGY; UMBELLIPRENIN; PATHWAY; CYTOKINES;
   DIAGNOSIS; RECEPTOR; DATABASE; VIRUS; BCL-2
AB Background Chinese medicine Toujie Quwen granule (TJQW) has proven to be effective in the treatment of mild coronavirus disease 2019 (COVID-19) cases by relieving symptoms, slowing the progression of the disease, and boosting the recovery of patients. But the bioactive compounds and potential mechanisms of TJQW for COVID-19 prevention and treatment are unclear. This study aimed to explore the potential therapeutic mechanism of TJQW in coronavirus disease 2019 (COVID-19) based on an integrated network pharmacology approach. Methods TCMSP were used to search and screen the active ingredients in TJQW. The Swiss TargetPrediction was used to predict the potential targets of active ingredients. Genes co-expressed with ACE2 were considered potential therapeutic targets on COVID-19. Venn diagram was created to show correlative targets of TJQW against COVID-19. Cytoscape was used to construct a "drug-active ingredient-potential target" network, STRING were used to construct protein-protein interaction network, and cytoHubba performed network topology analysis. Enrichment of biological functions and signaling pathways of core targets was performed by using the clusterProfiler package in R software and ClueGO with CluePedia plugins in Cytoscape. Results A total of 156 active ingredients were obtained through oral bioavailability and drug-likeness screenings. Two hundred twenty-seven potential targets of TJQW were related to COVID-19. The top ten core targets are EGFR, CASP3, STAT3, ESR1, FPR2, F2, BCL2L1, BDKRB2, MPO, and ACE. Based on that, we obtained 19 key active ingredients: umbelliprenin, quercetin, kaempferol, luteolin, praeruptorin E, stigmasterol, and oroxylin A. And the enrichment analysis obtained multiple related gene ontology functions and signaling pathways. Lastly, we constructed a key network of "drug-component-target-biological process-signaling pathway". Our findings suggested that TJQW treatment for COVID-19 was associated with elevation of immunity and suppression of inflammatory stress, including regulation of inflammatory response, viral process, neutrophil mediated immunity, PI3K-Akt signaling pathway, MAPK signaling pathway, Jak-STAT signaling pathway, Complement and coagulation cascades, and HIF-1 signaling pathway. Conclusions Our study uncovered the pharmacological mechanism underlying TJQW treatment for COVID-19. These results should benefit efforts for people around the world to gain more knowledge about Chinese medicine TJQW in the treatment of this vicious epidemic COVID-19, and help to address this pressing problem currently facing the world.
C1 [Huang, Ying; Zheng, Wen-jiang; Liu, Xiao-hong] Guangzhou Univ Chinese Med, Coll Clin Med 1, Guangzhou, Peoples R China.
   [Huang, Ying; Chen, Jian-kun; Li, Ji-qiang] Guangdong Prov Hosp Chinese Med, Integrat Dept 3, Geriatr Dept, Guangzhou, Peoples R China.
   [Ni, Yong-shi] Guangzhou Univ Chinese Med, Coll Clin Med 2, Guangzhou, Peoples R China.
   [Li, Mian-sha] Tianhe Shadong St Community Healthcare Serv Ctr, Guangzhou, Peoples R China.
   [Tan, Xing-hua] Guangzhou Eighth Peoples Hosp, Dept Tradit Chinese Med, Guangzhou, Peoples R China.
RP Li, JQ (corresponding author), Guangdong Prov Hosp Chinese Med, Integrat Dept 3, Geriatr Dept, Guangzhou, Peoples R China.
EM lijiqiangjizhen@163.com
FU Department of Science and Technology of Guangdong Province
   [2020B111110001]; COVID-19 Epidemic Prevention and Control Special
   Research Fund of the Department of Education of Guangdong Province
   [2020KZDZX1054]; Student Learning Team Incubation Project of the First
   Affiliated Hospital of Guangzhou University of Traditional Chinese
   Medicine [2018XXTD003]; 2020 National College Student Innovation and
   Entrepreneurship Training Program of Guangzhou University of Chinese
   Medicine [202010572001]
FX \This work is supported by Department of Science and Technology of
   Guangdong Province (No. 2020B111110001), COVID-19 Epidemic Prevention
   and Control Special Research Fund of the Department of Education of
   Guangdong Province (No. 2020KZDZX1054), Student Learning Team Incubation
   Project of the First Affiliated Hospital of Guangzhou University of
   Traditional Chinese Medicine (No.2018XXTD003) and 2020 National College
   Student Innovation and Entrepreneurship Training Program of Guangzhou
   University of Chinese Medicine (No. 202010572001).
CR Alqahtani S, 2017, EXPERT OPIN DRUG MET, V13, P1147, DOI 10.1080/17425255.2017.1389897
   Aratani Yasuaki, 2012, Med Mycol J, V53, P123, DOI 10.3314/mmj.53.123
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Aziz N, 2018, J ETHNOPHARMACOL, V225, P342, DOI 10.1016/j.jep.2018.05.019
   Bindea G, 2013, BIOINFORMATICS, V29, P661, DOI 10.1093/bioinformatics/btt019
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Brasseur K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135106
   Bruey JM, 2007, CELL, V129, P45, DOI 10.1016/j.cell.2007.01.045
   Casalino-Matsuda SM, 2015, J IMMUNOL, V194, P5388, DOI 10.4049/jimmunol.1500150
   Cava C, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040404
   Chen T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15009-1
   Chi HB, 2006, P NATL ACAD SCI USA, V103, P2274, DOI 10.1073/pnas.0510965103
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Datta PK, 2020, THERANOSTICS, V10, P7448, DOI 10.7150/thno.48076
   Devi KP, 2015, PHARMACOL RES, V99, P1, DOI 10.1016/j.phrs.2015.05.002
   Eickmeier O, 2013, MUCOSAL IMMUNOL, V6, P256, DOI 10.1038/mi.2012.66
   [傅晓霞 Fu Xiaoxia], 2020, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V26, P44
   [傅晓霞 Fu Xiaoxia], 2020, [暨南大学学报. 自然科学与医学版, Journal of Jinan University. Natural Science & Medicine Edition], V41, P151
   Gansukh E, 2021, FOOD CHEM, V334, DOI 10.1016/j.foodchem.2020.127508
   Garvin MR, 2020, ELIFE, V9, DOI 10.7554/eLife.59177
   Hirano T, 2020, IMMUNITY, V52, P731, DOI 10.1016/j.immuni.2020.04.003
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Huang XF, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106727
   Huang YF, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104939
   Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063
   Kar P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1780947
   Khaghanzadeh N, 2017, IRAN J BASIC MED SCI, V20, P829, DOI 10.22038/IJBMS.2017.9021
   Khan MA, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106642
   Kharkar PS, 2010, CURR TOP MED CHEM, V10, P116, DOI 10.2174/156802610790232224
   Kim MJ, 2020, MOL CELLS, V43, P264, DOI 10.14348/molcells.2020.2197
   Kirk SG, 2020, LIFE SCI, V241, DOI 10.1016/j.lfs.2019.117157
   Kong J, 2013, MOL ENDOCRINOL, V27, P2116, DOI 10.1210/me.2013-1146
   Li LZ, 2016, J LEUKOCYTE BIOL, V99, P425, DOI 10.1189/jlb.2RI0815-354RR
   Li R, 2019, MOL MED REP, V20, P5041, DOI 10.3892/mmr.2019.10743
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875-5364(13)60037-0]
   Liu M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104896
   Luo W, 2020, TRENDS PHARMACOL SCI, V41, P531, DOI 10.1016/j.tips.2020.06.007
   Madoiwa S, 2001, BLOOD, V97, P3783, DOI 10.1182/blood.V97.12.3783
   Marchetti M, 2020, ANN HEMATOL, V99, P1701, DOI 10.1007/s00277-020-04138-8
   Marcinkiewicz J, 2020, CURR MED CHEM, V27, P2840, DOI [10.2174/092986732666619190819123300, 10.2174/0929867326666190819123300]
   Mokuda S, 2020, J RHEUMATOL, V47, P1593, DOI 10.3899/jrheum.200547
   Oh WJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/485262
   Park CM, 2013, NUTR RES PRACT, V7, P423, DOI 10.4162/nrp.2013.7.6.423
   Rabe SZT, 2016, J IMMUNOTOXICOL, V13, P209, DOI 10.3109/1547691X.2015.1043606
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Sala A, 2018, BIOCHEM PHARMACOL, V158, P161, DOI 10.1016/j.bcp.2018.10.007
   Shakeri A, 2014, J ASIAN NAT PROD RES, V16, P884, DOI 10.1080/10286020.2014.917630
   Song P, 2020, J TRADIT CHIN MED, V40, P497, DOI 10.19852/j.cnki.jtcm.2020.03.019
   Su Gang, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi0813s47
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tseng TL, 2020, TOXICOL APPL PHARM, V400, DOI 10.1016/j.taap.2020.115070
   Vavougios GD, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109759
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang J, 2020, ACE2 EXPRESSION COLO, DOI [10.1101/2020.02.05.20020545, DOI 10.1101/2020.02.05.20020545]
   Yamaguchi N, 2017, J BIOL CHEM, V292, P8136, DOI 10.1074/jbc.M116.763276
   Yang ZG, 2020, AGING-US, V12, P6037, DOI 10.18632/aging.102999
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu PJ, 2013, EUR J PHARMACOL, V710, P39, DOI 10.1016/j.ejphar.2013.03.050
   Zhang CJ, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.08.113
   Zhao ZH, 2020, AM J CHINESE MED, V48, P1035, DOI 10.1142/S0192415X20500500
NR 62
TC 1
Z9 1
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-0381
J9 BIODATA MIN
JI BioData Min.
PD SEP 24
PY 2020
VL 13
IS 1
AR 15
DI 10.1186/s13040-020-00225-8
PG 21
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA NX3WX
UT WOS:000575643500001
PM 32983259
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tabish, M
   Khatoon, A
   Alkahtani, S
   Alkahtane, A
   Alghamdi, J
   Ahmed, SA
   Mir, SS
   Albasher, G
   Almeer, R
   Al-Sultan, NK
   Aljarba, NH
   Al-Qahtani, WS
   AL-Zharani, M
   Nayak, AK
   Hasnain, MS
AF Tabish, Mohammad
   Khatoon, Aisha
   Alkahtani, Saad
   Alkahtane, Abdullah
   Alghamdi, Jawahir
   Ahmed, Syed Anees
   Mir, Snober S.
   Albasher, Gadah
   Almeer, Rafa
   Al-Sultan, Nouf K.
   Aljarba, Nada H.
   Al-Qahtani, Wedad Saeed
   AL-Zharani, Mohammed
   Nayak, Amit Kumar
   Hasnain, Md Saquib
TI Approaches for prevention and environmental management of novel COVID-19
SO ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
LA English
DT Article; Early Access
DE Severe acute respiratory syndrome; Environment; Waste management; Novel
   coronavirus; COVID-19
ID WASTE MANAGEMENT; REMDESIVIR; HEALTH
AB The World Health Organization (WHO) recognized a novel coronavirus as the causative agent of a new form of pneumonia. It was subsequently named COVID-19 and reported as the source of a respiratory disease occurrence starting in December 2019 in Wuhan, Hubei Province, China. It has been affirmed a public health emergency of international significance by the World Health Organization. It is regarded as a subset of the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS); COVID-19 is triggered by a betacoronavirus called SARS-CoV-2, which affects the lower respiratory tract and occurs in humans as pneumonia. A variety of drugs, such as remdesivir and favipiravir, are currently undergoing clinical trials to evaluate for the management of COVID-19. The effect of the pandemic as well as the epidemic that follows through the life cycles of various recycled plastic is evaluated, particularly those required for personal safety and health care. In response to the growth in COVID-19 cases worldwide, the energy and environmental impacts of these lifecycle management have risen rapidly. However, significant hazardous waste management concerns arise due to the need to assure the elimination of residual pathogens in household and medical wastes. This review article summarizes the preventive and environmental management of COVID-19.
C1 [Tabish, Mohammad] Shaqra Univ, Dept Pharmacol, Coll Med, Shaqra, Saudi Arabia.
   [Khatoon, Aisha] Integral Univ, Integral Informat & Res Ctr 4 IIRC 4, Fac Sci, Mol Cell Biol Lab,Dept Biosci, Kursi Rd, Lucknow 226026, Uttar Pradesh, India.
   [Alkahtani, Saad; Alkahtane, Abdullah; Alghamdi, Jawahir; Albasher, Gadah; Almeer, Rafa; Al-Sultan, Nouf K.] King Saud Univ, Coll Sci, Dept Zool, POB 2455, Riyadh 11451, Saudi Arabia.
   [Ahmed, Syed Anees] Hygia Inst Pharmaceut Educ & Res, Dept Pharmacol, Lucknow, UP, India.
   [Mir, Snober S.] Integral Univ, Integral Informat & Res Ctr 4 IIRC 4, Fac Engn, Mol Cell Biol Lab,Dept Bioengn, Kursi Rd, Lucknow 226026, Uttar Pradesh, India.
   [Aljarba, Nada H.] Princess Nourah bint Abdulrahman Univ, Biol Dept, Coll Sci, Riyadh, Saudi Arabia.
   [Al-Qahtani, Wedad Saeed] Naif Arab Univ Secur Sci, Dept Forens Sci, Coll Criminal Justice, Riyadh, Saudi Arabia.
   [AL-Zharani, Mohammed] Imam Muhammad Ibn Saud Islamic Univ, Dept Biol, Coll Sci, Riyadh, Saudi Arabia.
   [Nayak, Amit Kumar] Seemanta Inst Pharmaceut Sci, Dept Pharmaceut, Mayurbhanj, Odisha, India.
   [Hasnain, Md Saquib] ShriVenkateshwara Univ, Dept Pharm, Amroha, UP, India.
RP Alkahtani, S (corresponding author), King Saud Univ, Coll Sci, Dept Zool, POB 2455, Riyadh 11451, Saudi Arabia.; Hasnain, MS (corresponding author), ShriVenkateshwara Univ, Dept Pharm, Amroha, UP, India.
EM salkahtani@ksu.edu.sa; msaquibhasnain@gmail.com
RI Al-Qahtani, Wedad Saeed/ABH-7132-2020; Tabish, Mohammad/AAH-6504-2020
OI Tabish, Mohammad/0000-0001-8737-4088; Al-Qahtani, Wedad
   Saeed/0000-0002-7347-9804
FU Deanship of Scientific Research at Princess Nourah bint Abdulrahman
   University through the Fast-track Research Funding Program
FX The authors received support from The Deanship of Scientific Research at
   Princess Nourah bint Abdulrahman University through the Fast-track
   Research Funding Program.
CR [Anonymous], 2020, COVID W 19AD CORONAV
   [Anonymous], 2020, AUSTR NZ INT CAR SOC
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cascella M, 2020, FEATURES EVALUATION
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Klemes JJ, 2020, RENEW SUST ENERG REV, V127, DOI 10.1016/j.rser.2020.109883
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Liu HC, 2015, RENEW SUST ENERG REV, V41, P932, DOI 10.1016/j.rser.2014.08.061
   Liu MZ, 2020, J ENVIRON MANAGE, V255, DOI 10.1016/j.jenvman.2019.109859
   Lucrezi S, 2016, OCEAN COAST MANAGE, V121, P1, DOI 10.1016/j.ocecoaman.2015.12.003
   Ma BL, 2019, J CLEAN PROD, V206, P870, DOI 10.1016/j.jclepro.2018.09.063
   MacKenzie D, 2020, COVID 19 GOES GLOBAL
   Martinez M.A., 2020, ANTIMICROB AGENTS CH, V64
   Messner W, 2020, I CULTURAL CONTEXT C
   Morens DM, 2018, NEW ENGL J MED, V379, P2285, DOI 10.1056/NEJMp1814447
   Mourad M, 2016, J CLEAN PROD, V126, P461, DOI 10.1016/j.jclepro.2016.03.084
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Partelow S, 2015, MAR POLLUT BULL, V100, P352, DOI 10.1016/j.marpolbul.2015.08.026
   Prevention J, 2020, PRINC PSYCH CRIS INT
   Rajmohan Kunju Vaikarar Soundararajan, 2019, Current Opinion in Environmental Science & Health, V12, P72, DOI 10.1016/j.coesh.2019.08.006
   Schanes K, 2018, J CLEAN PROD, V182, P978, DOI 10.1016/j.jclepro.2018.02.030
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Tschudin S, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20298
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Varotto A, 2017, J ENVIRON PSYCHOL, V51, P168, DOI 10.1016/j.jenvp.2017.03.011
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 2020, CLIN MAN SEV AC RESP
   Windfeld ES, 2015, J ENVIRON MANAGE, V163, P98, DOI 10.1016/j.jenvman.2015.08.013
   World Health Organization, 2020, COR DIS 2019 COVID 1, P72
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zambrano-Monserrate MA, 2019, LAND USE POLICY, V87, DOI 10.1016/j.landusepol.2019.104059
   Zambrano-Monserrate MA, 2018, OCEAN COAST MANAGE, V157, P193, DOI 10.1016/j.ocecoaman.2018.02.020
   Zhang Y, 2020, CHINA CDC WEEKLY, V2, P123, DOI DOI 10.46234/CCDCW2020.033
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 40
TC 0
Z9 0
U1 6
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0944-1344
EI 1614-7499
J9 ENVIRON SCI POLLUT R
JI Environ. Sci. Pollut. Res.
DI 10.1007/s11356-020-10640-3
EA SEP 2020
PG 11
WC Environmental Sciences
SC Environmental Sciences & Ecology
GA NS9XN
UT WOS:000572607400011
PM 32970259
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Melmed, KR
   Cao, M
   Dogra, S
   Zhang, RN
   Yaghi, S
   Lewis, A
   Jain, R
   Bilaloglu, S
   Chen, J
   Czeisler, BM
   Raz, E
   Lord, A
   Berger, JS
   Frontera, JA
AF Melmed, Kara R.
   Cao, Meng
   Dogra, Siddhant
   Zhang, Ruina
   Yaghi, Shadi
   Lewis, Ariane
   Jain, Rajan
   Bilaloglu, Seda
   Chen, Ji
   Czeisler, Barry M.
   Raz, Eytan
   Lord, Aaron
   Berger, Jeffrey S.
   Frontera, Jennifer A.
TI Risk factors for intracerebral hemorrhage in patients with COVID-19
SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS
LA English
DT Article; Early Access
DE Anticoagulation; COVID-19; Hemorrhagic stroke; Intracerebral hemorrhage;
   Mechanical ventilation
ID ORAL ANTICOAGULANT-THERAPY; ATRIAL-FIBRILLATION; INTRACRANIAL
   HEMORRHAGE; STROKE; METAANALYSIS; INFECTION; SCORE
AB Intracerebral hemorrhage (ICH) can be a devastating complication of coronavirus disease (COVID-19). We aimed to assess risk factors associated with ICH in this population. We performed a retrospective cohort study of adult patients admitted to NYU Langone Health system between March 1 and April 27 2020 with a positive nasopharyngeal swab polymerase chain reaction test result and presence of primary nontraumatic intracranial hemorrhage or hemorrhagic conversion of ischemic stroke on neuroimaging. Patients with intracranial procedures, malignancy, or vascular malformation were excluded. We used regression models to estimate odds ratios and 95% confidence intervals (OR, 95% CI) of the association between ICH and covariates. We also used regression models to determine association between ICH and mortality. Among 3824 patients admitted with COVID-19, 755 patients had neuroimaging and 416 patients were identified after exclusion criteria were applied. The mean (standard deviation) age was 69.3 (16.2), 35.8% were women, and 34.9% were on therapeutic anticoagulation. ICH occurred in 33 (7.9%) patients. Older age, non-Caucasian race, respiratory failure requiring mechanical ventilation, and therapeutic anticoagulation were associated with ICH on univariate analysis (p < 0.01 for each variable). In adjusted regression models, anticoagulation use was associated with a five-fold increased risk of ICH (OR 5.26, 95% CI 2.33-12.24, p < 0.001). ICH was associated with increased mortality (adjusted OR 2.6, 95 % CI 1.2-5.9). Anticoagulation use is associated with increased risk of ICH in patients with COVID-19. Further investigation is required to elucidate underlying mechanisms and prevention strategies in this population.
C1 [Melmed, Kara R.; Yaghi, Shadi; Lewis, Ariane; Czeisler, Barry M.; Lord, Aaron; Frontera, Jennifer A.] New York Univ Langone Hlth, Dept Neurol, New York, NY 10016 USA.
   [Melmed, Kara R.; Lewis, Ariane; Jain, Rajan; Czeisler, Barry M.] New York Univ Langone Hlth, Dept Neurosurg, New York, NY 10016 USA.
   [Cao, Meng; Zhang, Ruina] New York Univ Langone Hlth, Dept Med, New York, NY USA.
   [Dogra, Siddhant; Jain, Rajan; Raz, Eytan] New York Univ Langone Hlth, Dept Radiol, New York, NY USA.
   [Bilaloglu, Seda; Chen, Ji] New York Univ Langone Hlth, Dept Populat Hlth, New York, NY USA.
   [Berger, Jeffrey S.] New York Univ Langone Hlth, Dept Cardiol, New York, NY USA.
RP Melmed, KR (corresponding author), New York Univ Langone Hlth, Dept Neurol, New York, NY 10016 USA.; Melmed, KR (corresponding author), New York Univ Langone Hlth, Dept Neurosurg, New York, NY 10016 USA.
EM kara.melmed@nyulangone.org
RI Melmed, Kara/AAS-3287-2020
OI Melmed, Kara/0000-0003-4084-8586; Lewis, Ariane/0000-0002-0756-7320;
   Czeisler, Barry/0000-0002-7888-0373; Jain, Rajan/0000-0002-4879-0457;
   Dogra, Siddhant/0000-0003-2386-7849; Lord, Aaron/0000-0001-8755-7773
FU NIH/NIAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [3P30AG066512-01S1]
FX JAF reports grant funding from NIH/NIA grant 3P30AG066512-01S1 for
   investigation into impact of age on COVID related neurologic
   complications.
CR Ackermann M, 2020, N ENGL J MED
   Agarwal S, 2020, STROKE, V51, P2649, DOI 10.1161/STROKEAHA.120.030940
   An SJ, 2017, J STROKE, V19, P3, DOI 10.5853/jos.2016.00864
   Arabi YM, 2015, INFECTION, V43, P495, DOI 10.1007/s15010-015-0720-y
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Arbour N, 1999, J VIROL, V73, P3338, DOI 10.1128/JVI.73.4.3338-3350.1999
   Becker RC, 2020, J THROMB THROMBOLYS, V50, P54, DOI 10.1007/s11239-020-02134-3
   Benger M, 2020, BRAIN BEHAV IMMUN, V88, P940, DOI 10.1016/j.bbi.2020.06.005
   Bilaloglu S, 2020, JAMA
   Carod-Artal FJ, 2020, REV NEUROLOGIA, V70, P311, DOI 10.33588/rn.7009.2020179
   Carroll E, 2020, NEUROCRIT CARE, DOI 10.1007/s12028-020-00993-5
   Charidimou A, 2017, J NEUROL SCI, V378, P102, DOI 10.1016/j.jns.2017.04.042
   Connors JM, 2020, BLOOD, V7, pe362
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   da Silva IRF, 2017, CURR TREAT OPTION NE, V19, DOI 10.1007/s11940-017-0477-y
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Dogra S, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104984
   Essien UR, 2018, JAMA CARDIOL, V3, P1174, DOI 10.1001/jamacardio.2018.3945
   Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754
   Gurol ME, 2018, STROKE, V49, P247, DOI 10.1161/STROKEAHA.117.017081
   Hanley JA, 1997, ACAD RADIOL, V4, P49, DOI 10.1016/S1076-6332(97)80161-4
   Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007
   Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891
   Hsu JC, 2016, JAMA CARDIOL, V1, P55, DOI 10.1001/jamacardio.2015.0374
   Jain R, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116923
   Javalkar V, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2019.104583
   JimenezRuiz A., 2020, GAC MED MEX, V156
   Kandemirli SG, 2020, RADIOLOGY, V297, pE232, DOI 10.1148/radiol.2020201697
   Klok FA, 2020, THROMB RES
   Koch S, 2016, NEUROLOGY, V87, P786, DOI 10.1212/WNL.0000000000002962
   Kvernland A, 2020, NEUROCRIT CARE, DOI 10.1007/s12028-020-01077-0
   Radmanesh A, 2020, RADIOLOGY, V297, pE223, DOI 10.1148/radiol.2020202040
   Riech S, 2015, CRIT CARE MED, V43, pE386, DOI 10.1097/CCM.0000000000001150
   Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880
   Sharifi-Razavi A, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100669
   Shen AYJ, 2007, J AM COLL CARDIOL, V50, P309, DOI 10.1016/j.jacc.2007.01.098
   Steiner T, 2006, STROKE, V37, P256, DOI 10.1161/01.STR.0000196989.09900.f8
   Tawfik A, 2016, CLIN PHARMACOL-ADV A, V8, P93, DOI 10.2147/CPAA.S105165
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Tsai Li-Kai, 2005, Acta Neurol Taiwan, V14, P113
   Turshudzhyan A, 2020, CUREUS, V12, DOI 10.7759/cureus.8150
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Yaghi S, 2020, STROKE, V51, P2002, DOI 10.1161/STROKEAHA.120.030335
NR 43
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-5305
EI 1573-742X
J9 J THROMB THROMBOLYS
JI J. Thromb. Thrombolysis
DI 10.1007/s11239-020-02288-0
EA SEP 2020
PG 8
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease
SC Cardiovascular System & Cardiology; Hematology
GA NS6AW
UT WOS:000572342900001
PM 32968850
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Maestro, IM
   Merino, LP
   del Tanago, BUG
   Gonzalez, AA
   Sopena, AO
   De Vicente, JS
   Nieto, JAR
   Marinas, EA
   Garcia, JG
AF Mendez Maestro, Irune
   Pena Merino, Lander
   Udondo Gonzalez del Tanago, Begona
   Aramburu Gonzalez, Aida
   Orbea Sopena, Ana
   Sanchez De Vicente, Javier
   Raton Nieto, Juan A.
   Acebo Marinas, Elvira
   Gardeazabal Garcia, Jesus
TI Skin manifestations in patients hospitalized with confirmed COVID-19
   disease: a cross-sectional study in a tertiary hospital
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Article
AB Background COVID-19 cutaneous manifestations have been recently described and classified in five different clinical patterns, including acral erythema-edema (pseudo-chilblain), maculopapular exanthemas, vesicular eruptions, urticarial lesions, and livedo or necrosis. Objectives The objective of this study was to examine the skin of hospitalized patients with a confirmed diagnosis of COVID-19 disease and describe the real prevalence of skin manifestations. Methods A cross-sectional study, which included hospitalized patients in Cruces University Hospital from April 14-30, 2020, with a laboratory-confirmed diagnosis of COVID-19 (with polymerase chain reaction and/or serology tests), was conducted. Entire body surface examination was performed by experienced dermatologists to search for cutaneous manifestations related to COVID-19 disease. Results From a sample of 75 patients, 14 (18.7%) developed cutaneous manifestations possibly related to COVID-19. We found six patients with acral erythema-edema (pseudo-chilblain) (42.8%), four patients with maculopapular exanthemas (28.6%), two patients with urticarial lesions (14.3%), one patient with livedo reticularis-like lesions (7.15%), and one patient with vesicular eruption (7.15%). Conclusions Our study provides a more plausible relationship between the main cutaneous patterns and COVID-19 in hospitalized patients as all of them had a confirmatory laboratory test. Skin manifestations are frequent but mild with spontaneous resolution. These findings are nonspecific and can be similar to other viral infections and adverse drug reactions in hospitalized patients.
C1 [Mendez Maestro, Irune; Pena Merino, Lander; Udondo Gonzalez del Tanago, Begona; Aramburu Gonzalez, Aida; Orbea Sopena, Ana; Raton Nieto, Juan A.; Acebo Marinas, Elvira; Gardeazabal Garcia, Jesus] Cruces Univ Hosp, Dept Dermatol, Baracaldo, Spain.
   [Sanchez De Vicente, Javier] Cruces Univ Hosp, Dept Allergol, Baracaldo, Spain.
RP Maestro, IM (corresponding author), Cruces Univ Hosp, Pl Cruces S-N, Baracaldo 48903, Vizcaya, Spain.
EM irune.mendez@gmail.com
OI Pena Merino, Lander/0000-0002-8679-7756
CR Ahouach B, 2020, BRIT J DERMATOL, V183, pE31, DOI 10.1111/bjd.19168
   Alramthan A, 2020, CLIN EXP DERMATOL, V45, P746, DOI 10.1111/ced.14243
   Bouaziz JD, 2020, J EUR ACAD DERMATOL, V34, pE451, DOI 10.1111/jdv.16544
   Estebanez A, 2020, J EUR ACAD DERMATOL, V34, pE250, DOI 10.1111/jdv.16474
   European Centre for Disease Prevention and Control, 2020, CAS DEF EUR SURV COV
   Fernandez-Nieto D, 2020, J EUR ACAD DERMATOL, V34, pE252, DOI 10.1111/jdv.16470
   Fernandez-Nieto D, 2020, J AM ACAD DERMATOL, V83, pE61, DOI 10.1016/j.jaad.2020.04.093
   Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163
   Hedou M, 2020, J EUR ACAD DERMATOL, V34, pE299, DOI 10.1111/jdv.16519
   Henry D, 2020, J EUR ACAD DERMATOL, V34, pE244, DOI 10.1111/jdv.16472
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Landa N, 2020, INT J DERMATOL, V59, P739, DOI 10.1111/ijd.14937
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE346, DOI 10.1111/jdv.16533
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Su CJ, 2020, J EUR ACAD DERMATOL, V34, pE251, DOI 10.1111/jdv.16469
   van Damme C, 2020, J EUR ACAD DERMATOL, V34, pE300, DOI 10.1111/jdv.16523
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 19
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
EI 1365-4632
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD NOV
PY 2020
VL 59
IS 11
BP 1353
EP 1357
DI 10.1111/ijd.15180
EA SEP 2020
PG 5
WC Dermatology
SC Dermatology
GA OE6TY
UT WOS:000572248300001
PM 32970840
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Verma, BK
   Verma, M
   Verma, VK
   Abdullah, RB
   Nath, DC
   Khan, HTA
   Verma, A
   Vishwakarma, RK
   Verma, V
AF Verma, Bhupendra Kumar
   Verma, Mamta
   Verma, Vikash Kumar
   Abdullah, Rifah B.
   Nath, Dilip C.
   Khan, Hafiz T. A.
   Verma, Anita
   Vishwakarma, Ramesh K.
   Verma, Vivek
TI Global lockdown: An effective safeguard in responding to the threat
   ofCOVID-19
SO JOURNAL OF EVALUATION IN CLINICAL PRACTICE
LA English
DT Article
DE credible interval; marginal distribution; posterior distribution; social
   distancing
ID INTERNATIONAL-LAW; INFLUENZA
AB Rationale, aims, and objectives The recent outbreak of coronavirus (COVID-19) has infected around 1 560 000 individuals till 10 April 2020, which has resulted in 95 000 deaths globally. While no vaccine or anti-viral drugs for COVID-19 are available, lockdown acts as a protective public health measures to reduce human interaction and lower transmission. The study aims to explore the impact of delayed planning or lack of planning for the lockdown and inadequate implementation of the lockdown, on the transmission rate of COVID-19. Method Epidemiological data on the incidence and mortality of COVID-19 cases as reported by public health authorities were accessed from six countries based on total number of infected cases, namely, United States and Italy (more than 100 000 cases); United Kingdom, and France (50 000-100 000 cases), and India and Russia (6000-10 000 cases). The Bayesian inferential technique was used to observe the changes (three points) in pattern of number of cases on different duration of exposure (in days) in these selected countries 1 month after World Health Organization (WHO) declaration about COVID-19 as a global pandemic. Results On comparing the pattern of transmission rates observed in these six countries at posterior estimated change points, it is found that partial implementation of lockdown (in the United States), delayed planning in lockdown (Russia, United Kingdom, and France), and inadequate implementation of the lockdown (in India and Italy) were responsible to the spread of infections. Conclusions In order to control the spreading of COVID-19, like other national and international laws, lockdown must be implemented and enforced. It is suggested that on-time or adequate implementation of lockdown is a step towards social distancing and to control the spread of this pandemic.
C1 [Verma, Bhupendra Kumar] Bimal Chandra Coll Law, Kandi, W Bengal, India.
   [Verma, Mamta] Kazi Nazrul Univ, Dept Law, Asansol, W Bengal, India.
   [Verma, Vikash Kumar] Sidho Kanho Birsha Univ, Dept Econ, Lagda, W Bengal, India.
   [Abdullah, Rifah B.] Univ Glasgow, Sch Psychol, Glasgow, Lanark, Scotland.
   [Nath, Dilip C.] Assam Univ, Silchar, Assam, India.
   [Khan, Hafiz T. A.] Univ West London, Coll Nursing Midwifery & Healthcare, Brentford, England.
   [Verma, Anita; Verma, Vivek] All India Inst Med Sci AIIMS, Dept Neurol, New Delhi 110029, India.
   [Vishwakarma, Ramesh K.] King Abdullah Int Med Res Ctr, Dept Biostat, Riyadh, Saudi Arabia.
   [Vishwakarma, Ramesh K.] King Saud bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia.
   [Vishwakarma, Ramesh K.] Minist Natl Guard Hlth Affairs, Riyadh, Saudi Arabia.
RP Verma, V (corresponding author), All India Inst Med Sci AIIMS, Dept Neurol, New Delhi 110029, India.
EM viv_verma456@yahoo.com
OI VERMA, VIVEK/0000-0003-2537-4431; Abdullah, Rifah B./0000-0001-8966-2171
CR Aginam O, 2002, B WORLD HEALTH ORGAN, V80, P946
   [Anonymous], HINDU
   [Anonymous], GUARDIAN
   Centers for Disease Control and Prevention, 1918, 1918 PAND H1N1 VIR
   Centers for Disease Control and Prevention, 2020, COVID 19 SPREADS
   Drone Association of Kerala, EC TIMES
   Fearnhead P, 2006, STAT COMPUT, V16, P203, DOI 10.1007/s11222-006-8450-8
   Ferguson N.M., 2020, PREPRINT, P16, DOI [DOI 10.25561/77482, 10.25561/77482]
   Fernandes N., 2020, EC EFFECTS CORONAVIR
   Fidler DP, 1996, EMERG INFECT DIS, V2, P77, DOI 10.3201/eid0202.960201
   Gentile L, 2020, J PUBLIC HEALTH-HEID, DOI 10.1007/s10389-019-01171-4
   Gostin LO, 2007, ADMIN LAW REV, V59, P121
   Gostin LO, 2020, JAMA-J AM MED ASSOC, V323, P1131, DOI 10.1001/jama.2020.2025
   Gostin LO, 2009, JAMA-J AM MED ASSOC, V301, P2376, DOI 10.1001/jama.2009.849
   Kidambi P, 2004, URBAN HIST, V31, P249
   Lai TL, 2011, STAT SINICA, V21, P539, DOI 10.5705/ss.2011.025a
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Magnusson RS, 2017, ADV RIGHT HLTH VITAL
   Parmet WE, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2004211
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Rakesh P S, 2016, Indian J Med Ethics, V1, P156
   Rasmussen P, 2001, WATER RESOUR RES, V37, P2723, DOI 10.1029/2001WR000311
   Semenza JC, 2012, EUR J PUBLIC HEALTH, V22, P5, DOI 10.1093/eurpub/ckr212
   Smith KM, 2019, ONE HEALTH-AMSTERDAM, V7, DOI 10.1016/j.onehlt.2018.100080
   Stoeva P, 2020, BMC INT HEALTH HUM R, V20, DOI 10.1186/s12914-020-00239-7
   Suhrcke M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020724
   Verma V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233074
   World Health Organization, Q A COR COVID 19
NR 30
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1356-1294
EI 1365-2753
J9 J EVAL CLIN PRACT
JI J. Eval. Clin. Pract.
PD DEC
PY 2020
VL 26
IS 6
BP 1592
EP 1598
DI 10.1111/jep.13483
EA SEP 2020
PG 7
WC Health Care Sciences & Services; Medical Informatics; Medicine, General
   & Internal
SC Health Care Sciences & Services; Medical Informatics; General & Internal
   Medicine
GA OQ2VL
UT WOS:000572172500001
PM 32970386
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Parida, PK
   Paul, D
   Chakravorty, D
AF Parida, Pratap Kumar
   Paul, Dipak
   Chakravorty, Debamitra
TI The natural way forward: Molecular dynamics simulation analysis of
   phytochemicals from Indian medicinal plants as potential inhibitors
   ofSARS-CoV-2 targets
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE India; main protease; molecular dynamics; phytochemicals; relative free
   binding energy; SARS-CoV-2; simulation; spike
ID WEB SERVER; P38 MAPK; PROTEIN; CORONAVIRUS; BINDING; COMPLEX
AB The pandemic COVID-19 has become a global panic-forcing life towards a compromised "new normal." Antiviral therapy against SARS-CoV-2 is still lacking. Thus, development of natural inhibitors as a prophylactic measure is an attractive strategy. In this context, this work explored phytochemicals as potential inhibitors for SARS-CoV-2 by performing all atom molecular dynamics simulations using high performance computing for 8 rationally screened phytochemicals fromWithania somniferaandAzadirachta indicaand two repurposed drugs docked with the spike glycoprotein and the main protease of SARS-CoV-2. These phytochemicals were rationally screened from 55 Indian medicinal plants in our previous work. MM/PBSA, principal component analysis (PCA), dynamic cross correlation matrix (DCCM) plots and biological pathway enrichment analysis were performed to reveal the therapeutic efficacy of these phytochemicals. The results revealed that Withanolide R (-141.96 KJ/mol) and 2,3-Dihydrowithaferin A (-87.60 KJ/mol) were with the lowest relative free energy of binding for main protease and the spike proteins respectively. It was also observed that the phytochemicals exhibit a remarkable multipotency with the ability to modulate various human biological pathways especially pathways in cancer. Conclusively we suggest that these compounds need further detailedin vivoexperimental evaluation and clinical validation to implement them as potent therapeutic agents for combating SARS-CoV-2.
C1 [Parida, Pratap Kumar; Paul, Dipak] Noor Enzymes Private Ltd, Kolkata, India.
   [Chakravorty, Debamitra] Novel Techsci OPC Private Ltd, Kolkata, India.
RP Chakravorty, D (corresponding author), Novel Techsci OPC Private Ltd, Project Lead Computat Biol, 37-B Darga Rd,1st Floor, Kolkata 700017, W Bengal, India.
EM dc@noveltechsciences.com
RI Parida, Pratap/J-6727-2015
OI Parida, Pratap/0000-0002-8193-335X; Chakravorty,
   Debamitra/0000-0002-1520-0780
FU COVID-19 HPC Consortium
FX This work used resources services, and support provided via the COVID-19
   HPC Consortium (https://covid19-hpc-consortium.org/), which is a unique
   private-public effort to bring together government, industry, and
   academic leaders who are volunteering free compute time and resources in
   support of COVID-19 research. We would also like to acknowledge Noor
   Enzymes Private Limited for providing us with the human resources needed
   to successfully complete this work. We would also like to specially
   thank Linda Hedges (HPC Solutions architect at Amazon Web Services),
   Tara Madhyastha (Principal research scientist at Amazon Web Services),
   Nathan Albrighton (Founder & CEO at RONIN) and Don Hancock (Co-Founder
   at RONIN) who provided us with timely guidance and assistance to
   complete this work.
CR Adem S., 2020, IDENTIFICATION POTEN, V46, P1, DOI [10.20944/preprints202003.0333.v1., 10.20944/preprints202003.0333.v1, DOI 10.20944/PREPRINTS202003.0333.V1]
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1742792
   AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Cascella M, 2020, FEATURES EVALUATION
   Chakrabarty B., 2020, NETWORK BASED ANAL F, DOI [10.26434/chemrxiv.12136470, DOI 10.26434/CHEMRXIV.12136470]
   Chandel V., 2020, PREPRINTS, DOI [10.20944/preprints202003.0349.v1, DOI 10.20944/PREPRINTS202003.0349.V1]
   Chatr-aryamontri A, 2009, NUCLEIC ACIDS RES, V37, pD669, DOI 10.1093/nar/gkn739
   Chaturvedi UC, 2005, FEMS IMMUNOL MED MIC, V43, P105, DOI 10.1016/j.femsim.2004.11.004
   Chen JJ, 2009, CURR PROTEOMICS, V6, P228, DOI 10.2174/157016409789973734
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Chikhale RV, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1784289
   Dai WW, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070625
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Doniach S, 1999, CURR OPIN STRUC BIOL, V9, P157, DOI 10.1016/S0959-440X(99)80022-0
   Dubey KD, 2013, CURR COMPUT-AID DRUG, V9, P518, DOI 10.2174/15734099113096660036
   Efferth T, 2011, CURR DRUG TARGETS, V12, P122, DOI 10.2174/138945011793591626
   Sousa da Silva Alan W, 2012, BMC Res Notes, V5, P367, DOI [10.1186/1756-0500-5-185, 10.1186/1756-0500-5-367]
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Gonzalez-Paz L. A., 2020, RES SQUARE, DOI [10.21203/rs.3.rs-21206/v1, DOI 10.21203/RS.3.RS-21206/V1]
   Grant BJ, 2006, BIOINFORMATICS, V22, P2695, DOI 10.1093/bioinformatics/btl461
   Grimes JM, 2020, J MOL CELL CARDIOL, V144, P63, DOI 10.1016/j.yjmcc.2020.05.007
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   Hegab Z, 2012, WORLD J CARDIOL, V4, P90, DOI 10.4330/wjc.v4.i4.90
   HUNENBERGER PH, 1995, J MOL BIOL, V252, P492, DOI 10.1006/jmbi.1995.0514
   Islam MJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52308-0
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kadioglu O, 2020, B WORLD HEALTH ORGAN, DOI [10.2471/BLT.20.255943, DOI 10.2471/BLT.20.255943]
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kono M, 2008, ANTIVIR RES, V77, P150, DOI 10.1016/j.antiviral.2007.10.011
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Kumar V, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1775704, 10.1080/07391102.2020.1772108]
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Lindahl A., 2020, ZENODO
   Lung JH, 2020, J MED VIROL, V92, P693, DOI 10.1002/jmv.25761
   Martens H., 1992, MULTIVARIATE CALIBRA
   MCCAMMON JA, 1984, REP PROG PHYS, V47, P1, DOI 10.1088/0034-4885/47/1/001
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Moghaddam E, 2014, SCI REP-UK, V4, DOI 10.1038/srep05452
   Montopoli M, 2020, ANN ONCOL, V31, P1040, DOI 10.1016/j.annonc.2020.04.479
   Parida P. K., 2020, NATURE NURTUREIDENTI, DOI [10.26434/chemrxiv.12355937, DOI 10.26434/CHEMRXIV.12355937]
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   RStudio Team, 2020, RSTUDIO INT DEV R
   Shang J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008392
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sharma A. D., 2020, EUCALYPTOL 1 8 CINEO, DOI [10.20944/preprints202003.0455.v1, DOI 10.20944/PREPRINTS202003.0455.V1]
   Sun N., 2020, PREDICTION POTENTIAL, DOI [10.20944/preprints202003.0247.v1, DOI 10.20944/PREPRINTS202003.0247.V1]
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Huynh T, 2020, J PHYS CHEM LETT, V11, P4413, DOI 10.1021/acs.jpclett.0c00994
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   WHO, 2020, INT CLIN TRIALS REG
   World Health Organization, 2020, COVID 19 SIGN IMP HL
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao X, 2008, J BIOL CHEM, V283, P3272, DOI 10.1074/jbc.M708033200
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 66
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD DEC
PY 2020
VL 34
IS 12
BP 3420
EP 3433
DI 10.1002/ptr.6868
EA SEP 2020
PG 14
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PC4GH
UT WOS:000572166300001
PM 32969524
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Deng, ZQ
   Chen, JS
   Wang, T
AF Deng, Ziqin
   Chen, Junsheng
   Wang, Ting
TI Bibliometric and Visualization Analysis of Human Coronaviruses:
   Prospects and Implications for COVID-19 Research
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article
DE human coronavirus; COVID-19; SARS-CoV-2; bibliometric; visualization
ID DISEASE; VIRUS; TRANSMISSION; OUTBREAKS; WUHAN
AB Human coronaviruses, which can cause a range of infectious diseases, have been studied for nearly 60 years. The field has gained renewed interest from researchers around the world due to the COVID-19 outbreak in late 2019. Despite a large amount of research, little is known about the knowledge structure and developing trends of this topic. Here, we apply bibliometric analysis along with visualization tools to analyze 15,207 publications related to human coronavirus from the Scopus database, using indicators on publication and citation, journal, country or territory, affiliation and international cooperation, author, and keyword co-occurrence cluster. The results show that research on human coronavirus is dominated by SARS-CoV. Although there have been many publications, only 626 publications (4.1% of total) have more than 100 citations. The top 20 journals with most publications account for 20.6% of total publications and 41% of total citations. In addition to the United States and some European countries, many Asian and African countries are involved in this research, with China holding an important position in this area. Leading researchers from various fields of human coronavirus research are listed to facilitate collaboration and promote effective disease prevention and control. The keywords co-occurrence analysis reveals that the research focus on virology, public health, drugs and other hotspot fields, and uncovers changes in the direction of coronavirus research. The research map on human coronavirus obtained by our analysis are expected to help researchers to efficiently and effectively explore COVID-19.
C1 [Deng, Ziqin; Chen, Junsheng; Wang, Ting] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China.
RP Wang, T (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China.
EM wangting139@hust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81000738]; National Undergraduate Innovation
   Funding of Huazhong University of Science and Technology [201910487117,
   2019A0199]
FX This work was supported by the National Natural Science Foundation of
   China (81000738 to TW) and the National Undergraduate Innovation Funding
   of Huazhong University of Science and Technology (201910487117 to TW,
   2019A0199 to TW).
CR Aggarwal A, 2016, J THORAC ONCOL, V11, P1040, DOI 10.1016/j.jtho.2016.03.010
   Almeida J D, 1967, J Gen Virol, V1, P175, DOI 10.1099/0022-1317-1-2-175
   Alsibai KD, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109893
   Annan A, 2016, CLIN MICROBIOL INFEC, V22, P340, DOI 10.1016/j.cmi.2015.11.002
   Azhar EI, 2014, NEW ENGL J MED, V370, P2499, DOI 10.1056/NEJMoa1401505
   BRADBURNE AF, 1967, BMJ-BRIT MED J, V3, P767, DOI 10.1136/bmj.3.5568.767
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Ciotti M, 2020, CHEMOTHERAPY, V64, P215, DOI [10.1159/000507423, 10.1080/10408363.2020.1783198]
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Deng ZQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00259
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Durieux V, 2010, RADIOLOGY, V255, P342, DOI 10.1148/radiol.09090626
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   ESTOLA T, 1970, AVIAN DIS, V14, P330, DOI 10.2307/1588476
   Fiala D, 2012, INFORM PROCESS MANAG, V48, P242, DOI 10.1016/j.ipm.2011.10.001
   Gasmi A, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108409
   Geller C, 2012, VIRUSES-BASEL, V4, P3044, DOI 10.3390/v4113044
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hurtado C, 2018, INT J INFECT DIS, V77, P29, DOI 10.1016/j.ijid.2018.09.027
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Bonilla-Aldana DK, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101566
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mackay IM, 2012, VIRUSES-BASEL, V4, P637, DOI 10.3390/v4040637
   MCINTOSH K, 1967, P NATL ACAD SCI USA, V57, P933, DOI 10.1073/pnas.57.4.933
   Muniz FWMG, 2018, J EVID-BASED DENT PR, V18, P110, DOI 10.1016/j.jebdp.2017.08.003
   Owusu M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099782
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Podsakoff PM, 2008, J MANAGE, V34, P641, DOI 10.1177/0149206308319533
   Romero L, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00564
   Saif LJ, 2004, REV SCI TECH OIE, V23, P643, DOI 10.20506/rst.23.2.1513
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Sweileh WM, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-017-0233-9
   Takahashi-Omoe H., 2012, INSIGHT CONTROL INFE, P121, DOI [10.5772/32096, DOI 10.5772/32096]
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Unkel S, 2012, J R STAT SOC A STAT, V175, P49, DOI 10.1111/j.1467-985X.2011.00714.x
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang LF, 2020, LANCET, V395, pE33, DOI 10.1016/S0140-6736(20)30350-0
   Wang XY, 2019, J CANCER, V10, P2643, DOI 10.7150/jca.32739
   Wong B, 2012, NAT METHODS, V9, P1131, DOI 10.1038/nmeth.2258
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhuang Y, 2014, INFORM SCIENCES, V263, P60, DOI 10.1016/j.ins.2013.10.013
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 58
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD SEP 23
PY 2020
VL 10
AR 581404
DI 10.3389/fcimb.2020.581404
PG 13
WC Immunology; Microbiology
SC Immunology; Microbiology
GA NX2BT
UT WOS:000575520900001
PM 33072630
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pirau, L
   Ottenhoff, L
   Williamson, CA
   Ahmad, SN
   Wabl, R
   Nguyen, A
   Faiver, L
   Rajajee, V
AF Pirau, Letitia
   Ottenhoff, Lauren
   Williamson, Craig A.
   Ahmad, Shahid N.
   Wabl, Rafael
   Nguyen, Andrew
   Faiver, Laura
   Rajajee, Venkatakrishna
TI Case Series: Evidence of Borderzone Ischemia in Critically-Ill COVID-19
   Patients Who "Do Not Wake Up"
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE COVID-19 (2019-nCoV); encephalopathy; coma; magnetic resonance imaging;
   cerebral ischemia; borderzone infarction
AB This article describes the clinical course, radiological findings, and outcome of two patients with the novel 2019 coronavirus disease (COVID-19) who remained comatose for a prolonged duration following discontinuation of all sedation. These two male patients, one aged 59-years and another aged 53-years, both with a history of hypertension and neurologically intact on admission, developed worsening COVID-19 associated acute respiratory distress syndrome (ARDS). Both required benzodiazepine, opioid, neuromuscular blockade, therapeutic anticoagulation, and vasopressor infusions in addition to renal replacement therapy. Echocardiography demonstrated normal chamber size and systolic function in both cases. Each patient demonstrated only trace flexion to pain 7-10 days following discontinuation of all sedation. Magnetic Resonance Imaging on both patients demonstrated multifocal lesions on diffusion weighted imaging with apparent diffusion coefficient correlate in bilateral middle/anterior cerebral artery borderzones, and no large-vessel occlusion or severe stenosis. In both patients, continuous electroencephalography demonstrated no seizures. Neither patient had any documented period of sustained hypotension (mean arterial pressure <60 mmHg) or hypoxia (SpO(2)<90%). Ninety days following initial presentation, the 59-years-old man was oriented, with fluent speech and able to ambulate with assistance, while the other 53-years-old man was at home and independent, undertaking the basic activities required by daily living. We conclude that critically-ill COVID-19 patients with prolonged coma following sedation discontinuation may demonstrate imaging features of ischemic injury in borderzone regions despite the absence of documented sustained hypotension or hypoxia. However, substantial neurological recovery is possible despite these findings.
C1 [Pirau, Letitia; Ottenhoff, Lauren; Williamson, Craig A.; Ahmad, Shahid N.; Wabl, Rafael; Nguyen, Andrew; Faiver, Laura; Rajajee, Venkatakrishna] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.
   [Ottenhoff, Lauren; Williamson, Craig A.; Ahmad, Shahid N.; Rajajee, Venkatakrishna] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.
RP Rajajee, V (corresponding author), Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.; Rajajee, V (corresponding author), Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA.
EM vrajajee@yahoo.com
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Filatov A, 2020, CUREUS, V12, DOI 10.7759/cureus.7352
   Hurley D, 2020, WASHINGTON POST
   Kandemirli SG, 2020, RADIOLOGY, V297, pE232, DOI 10.1148/radiol.2020201697
   Kremer S, 2020, RADIOLOGY, V297, pE242, DOI [10.1148/radiol.2020202222, 10.1148/radiol.202020222]
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Phend C, 2020, COVID 19 PUTS ICU SE
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Yong SW, 2006, STROKE, V37, P841, DOI 10.1161/01.STR.0000202590.75972.39
NR 18
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD SEP 23
PY 2020
VL 11
AR 964
DI 10.3389/fneur.2020.00964
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NX1IZ
UT WOS:000575472100001
PM 33071927
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, Q
   Ran, QS
   Sun, LD
   Yin, J
   Luo, T
   Liu, L
   Zhao, Z
   Yang, Q
   Li, YJ
   Chen, Y
   Weng, XG
   Wang, YJ
   Cai, WY
   Zhu, XX
AF Li, Qi
   Ran, Qingsen
   Sun, Lidong
   Yin, Jie
   Luo, Ting
   Liu, Li
   Zhao, Zheng
   Yang, Qing
   Li, Yujie
   Chen, Ying
   Weng, Xiaogang
   Wang, Yajie
   Cai, Weiyan
   Zhu, Xiaoxin
TI Lian Hua Qing Wen Capsules, a Potent Epithelial Protector in Acute Lung
   Injury Model, Block Proapoptotic Communication Between Macrophages, and
   Alveolar Epithelial Cells
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Lian Hua Qing Wen capsule; acute lung injury; macrophages and epithelial
   cells; endoplasmic reticulum stress; tumor necrosis factor-related
   apoptosis-inducing ligand
ID ENDOPLASMIC-RETICULUM STRESS; RESOLUTION; APOPTOSIS; TRAIL; MECHANISMS;
   CROSSTALK; PATHWAY
AB Besides pathogen evading, Acute Lung Injury (ALI), featuring the systematic inflammation and severe epithelial damages, is widely believed to be the central non-infectious factor controlling the progression of infectious diseases. ALI is partly caused by host immune responses. Under the inspiration of unsuccessful treatment in COVID-19, recent insights into pathogen-host interactions are leading to identification and development of a wide range of host-directed therapies with different mechanisms of action. The interaction unit consisting of macrophages and the alveolar epithelial cells has recently revealed as the therapeutic basis targeting ALI. Lian Hua Qing Wen capsule is the most effective and commonly-used clinical formula in treating respiratory infection for thousands of years in China. However, little is known about its relevance with ALI, especially its protective role against ALI-induced alveolar tissue damages. Aiming to evaluate its contribution in antibiotics-integrating therapies, this study pharmacologically verified whether LHQW could alleviate lipopolysaccharide (LPS)-induced ALI and explore its potential mechanisms in maintaining the physiology of macrophage-epithelial unit. In ALI mouse model, the pathological parameters, including the anal temperature, inflammation condition, lung edema, histopathological structures, have all been systematically analyzed. Results consistently supported the effectiveness of the combined strategy for LHQW and low-dose antibiotics. Furthermore, we established the macrophages-alveolar epithelial cells co-culture model and firstly proved that LHQW inhibited LPS-induced ER stress and TRAIL secretion in macrophages, thereby efficiently protected epithelial cells against TRAIL-induced apoptosis. Mechanistically, results showed that LHQW significantly deactivated NF-kappa B and reversed the SOCS3 expression in inflammatory macrophages. Furthermore, we proved that the therapeutic effects of LHQW were highly dependent on JNK-AP1 regulation. In conclusion, our data proved that LHQW is an epithelial protector in ALI, implying its promising potential in antibiotic alternative therapy.
C1 [Li, Qi; Ran, Qingsen; Sun, Lidong; Yin, Jie; Luo, Ting; Liu, Li; Zhao, Zheng; Yang, Qing; Li, Yujie; Chen, Ying; Weng, Xiaogang; Wang, Yajie; Cai, Weiyan; Zhu, Xiaoxin] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.
   [Yin, Jie] Capital Med Univ, Sch Chinese Mat Med, Beijing, Peoples R China.
RP Zhu, XX (corresponding author), China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.
EM zhuxiaoxin@icmm.ac.cn
FU National High Technology Research and Development Program of
   ChinaNational High Technology Research and Development Program of China
   [2017ZX09101002-002-002]; Institute of Traditional Chinese Medicine
   internal project-the research on reevaluating traditional Chinese
   medicine based on antibiotic substitution [Z2017019-03]; "Belt and Road"
   cooperation project of China academy of traditional Chinese medicine
   [GH201914]; General Programs of the National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China (NSFC)
   [8157141621]; Special training program for outstanding young scientific
   and technological talents of China academy of Chinese Medical Science
   [ZZ13-YQ-044]; Independent topic selection project China Academy of
   Chinese Medical Science [ZXKT17010]; China Academy of Traditional
   Chinese Medicine internal project-Construction of China-European
   research center for traditional Chinese medicine and natural products
   [GH2017-01]
FX This work was supported by grants from the National High Technology
   Research and Development Program of China (2017ZX09101002-002-002); the
   Institute of Traditional Chinese Medicine internal project-the research
   on reevaluating traditional Chinese medicine based on antibiotic
   substitution (No. Z2017019-03); "the Belt and Road" cooperation project
   of China academy of traditional Chinese medicine (No. GH201914); The
   General Programs of the National Natural Science Foundation of China
   (8157141621); Special training program for outstanding young scientific
   and technological talents of China academy of Chinese Medical Science
   (ZZ13-YQ-044); Independent topic selection project China Academy of
   Chinese Medical Science (ZXKT17010); China Academy of Traditional
   Chinese Medicine internal project-Construction of China-European
   research center for traditional Chinese medicine and natural products
   (No. GH2017-01).
CR Alessandri AL, 2013, PHARMACOL THERAPEUT, V139, P189, DOI 10.1016/j.pharmthera.2013.04.006
   Chen FL, 2015, INT J MOL SCI, V16, P19780, DOI 10.3390/ijms160819780
   Cheng GY, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00217
   Condamine T, 2014, J CLIN INVEST, V124, P2626, DOI 10.1172/JCI74056
   Dong L, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/637969
   Freire MO, 2013, PERIODONTOL 2000, V63, P149, DOI 10.1111/prd.12034
   Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620
   Hamid T, 2011, CARDIOVASC RES, V89, P129, DOI 10.1093/cvr/cvq274
   Headland SE, 2015, SEMIN IMMUNOL, V27, P149, DOI 10.1016/j.smim.2015.03.014
   Hogner K, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003188
   Huang Q, 2007, MED RES REV, V27, P609, DOI 10.1002/med.20094
   Huang Y, 2015, FEBS J, V282, P2361, DOI 10.1111/febs.13284
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Jia Weina, 2015, ScientificWorldJournal, V2015, P731765, DOI 10.1155/2015/731765
   Kim HJ, 2013, SCI REP-UK, V3, DOI 10.1038/srep01142
   Korkina L, 2011, MINI-REV MED CHEM, V11, P823, DOI 10.2174/138955711796575489
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu FF, 2016, CLIN EXP PHARMACOL P, V43, P543, DOI 10.1111/1440-1681.12561
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Oflazoglu E, 2009, J IMMUNOL, V183, P3770, DOI 10.4049/jimmunol.0901637
   Peteranderl C, 2016, J CLIN INVEST, V126, P1566, DOI 10.1172/JCI83931
   Petronelli A, 2009, ANTI-CANCER DRUG, V20, P880, DOI 10.1097/CAD.0b013e328330fd90
   Quartin AA, 2009, CHEST, V135, P261, DOI 10.1378/chest.08-0280
   Ren WY, 2003, MED RES REV, V23, P519, DOI 10.1002/med.10033
   Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333
   Seimon TA, 2010, CELL METAB, V12, P467, DOI 10.1016/j.cmet.2010.09.010
   Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675
   Tiwary R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011865
   Togno-Peirce C, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/570158
   YAMAZAKI M, 1994, BIOL PHARM BULL, V17, P1604, DOI 10.1248/bpb.17.1604
   Yang M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.144
   Zumla A, 2016, LANCET INFECT DIS, V16, pE47, DOI 10.1016/S1473-3099(16)00078-5
NR 32
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 23
PY 2020
VL 11
AR 522729
DI 10.3389/fphar.2020.522729
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NX1QX
UT WOS:000575492700001
PM 33071777
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shiau, S
   Bender, AA
   O'Halloran, JA
   Sundermann, E
   Aggarwal, J
   Althoff, KN
   Baker, JV
   Deeks, S
   Fried, LP
   Karpiak, S
   Karris, MY
   Marcotte, TD
   Nachega, JB
   Margolick, JB
   Erlandson, KM
   Moore, DJ
AF Shiau, Stephanie
   Bender, Alexis A.
   O'Halloran, Jane A.
   Sundermann, Erin
   Aggarwal, Juhi
   Althoff, Keri N.
   Baker, Jason V.
   Deeks, Steven
   Fried, Linda P.
   Karpiak, Stephen
   Karris, Maile Y.
   Marcotte, Thomas D.
   Nachega, Jean B.
   Margolick, Joseph B.
   Erlandson, Kristine M.
   Moore, David J.
TI The Current State of HIV and Aging: Findings Presented at the 10th
   International Workshop on HIV and Aging
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
DE HIV; aging; comorbidities; multidisciplinary
ID OLDER-ADULTS; CARDIOVASCULAR-DISEASE; SOCIAL-ISOLATION; UNITED-STATES;
   FRAILTY; LONELINESS; INFLAMMATION; MORTALITY; COAGULATION; INFECTION
AB With increasing effectiveness of antiretroviral therapy, people with HIV (PWH) are living longer and the prevalence of older PWH continues to increase. Accordingly, PWH are experiencing an increased burden of age-related comorbidities. With this shifting demographics, clinicians and researchers face additional challenges in how to identify, address, and manage the complex intersections of HIV- and aging-related conditions. Established in 2009, the International Workshop on HIV and Aging brings together clinicians and researchers in cross-disciplinary fields along with community advocates and PWH to address the multidisciplinary nature of HIV and aging. This article summarizes plenary talks from the 10th Annual International Workshop on HIV and Aging, which took place in New York City on October 10 and 11, 2019. Presentation topics included the following: the burdens of HIV-associated comorbidities, aging phenotypes, community engagement, and loneliness; these issues are especially important for older PWH, considering the current COVID-19 pandemic. We also discuss broad questions and potential directions for future research necessary to better understand the interaction between HIV and aging.
C1 [Shiau, Stephanie; Aggarwal, Juhi] Rutgers Sch Publ Hlth, Dept Biostat & Epidemiol, Piscataway, NJ USA.
   [Bender, Alexis A.] Emory Univ, Sch Med, Dept Med, Div Gen Med & Geriatr, Atlanta, GA USA.
   [O'Halloran, Jane A.] Washington Univ, Dept Med, Div Infect Dis, St Louis, MO USA.
   [Sundermann, Erin; Marcotte, Thomas D.; Moore, David J.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.
   [Althoff, Keri N.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Baker, Jason V.] Hennepin Hlth Care, Div Infect Dis, Minneapolis, MN USA.
   [Deeks, Steven] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Fried, Linda P.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
   [Fried, Linda P.] Columbia Univ, Mailman Sch Publ Hlth, Robert N Butler Columbia Aging Ctr, New York, NY USA.
   [Karpiak, Stephen] NYU, ACRIA Ctr HIV & Aging Gay Mens Hlth Crisis GMHC, New York, NY USA.
   [Karpiak, Stephen] NYU, Coll Nursing, New York, NY USA.
   [Karris, Maile Y.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   [Nachega, Jean B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
   [Margolick, Joseph B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA.
   [Erlandson, Kristine M.] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA.
RP Moore, DJ (corresponding author), Univ Calif San Diego, Dept Psychiat, HIV Neurobehav Res Program, 220 Dickinson St,Suite B,MC8231, La Jolla, CA 92103 USA.
EM djmoore@ucsd.edu
RI Karris, Maile/ABH-6856-2020
FU NIAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [AG054366];  [R25MH108389];  [R01HL126542];  [U01HL146201]
FX S.S.: R25MH108389; A.A.B.: R25MH108389; J.H.: R25MH108389; E.S.:
   R25MH108389; J.V.B.: R01HL126542; J. B.M.: U01HL146201; K.M. E.: NIA
   AG054366; and J.A., K.N. A., S.D., L.P.F., M.Y.K., S.K., T.D.M., J.B.N.,
   and D.J.M.: none associated.
CR Abrams DI, 2007, NEUROLOGY, V68, P515, DOI 10.1212/01.wnl.0000253187.66183.9c
   Althoff KN, 2019, AM J EPIDEMIOL, V188, P2097, DOI 10.1093/aje/kwz232
   Althoff KN, 2019, LANCET HIV, V6, pE93, DOI 10.1016/S2352-3018(18)30295-9
   Althoff KN, 2019, 41 ANN N AM M SOC ME
   Autenrieth CS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207005
   Azeem MM, 2020, INT J INNOV MANAG, V24, DOI 10.1142/S1363919620500632
   Baker JV, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000264
   Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262
   Bandeen-Roche K, 2015, J GERONTOL A-BIOL, V70, P1427, DOI 10.1093/gerona/glv133
   Bellantuono I, 2018, NATURE, V554, P293, DOI 10.1038/d41586-018-01668-0
   Bigna JJ, 2018, LANCET GLOB HEALTH, V6, pE182, DOI 10.1016/S2214-109X(17)30451-5
   Bourgi K, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25484
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brummel-Ziedins KE, 2018, RES PRACT THROMB HAE, V2, P708, DOI 10.1002/rth2.12147
   Cacioppo JT, 2002, PSYCHOSOM MED, V64, P407, DOI 10.1097/00006842-200205000-00005
   Castilho JL, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25233
   Cigna U, 2018, LONELINESS INDEX
   Cole MB, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz124
   Cole SW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r189
   Cole SW, 2015, PSYCHONEUROENDOCRINO, V62, P11, DOI 10.1016/j.psyneuen.2015.07.001
   De Francesco D, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy272
   Deren S, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00094
   Duprez DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044454
   Emlet CA, 2006, HEALTH SOC WORK, V31, P299, DOI 10.1093/hsw/31.4.299
   Erlandson KM, 2019, INFECT DIS CLIN N AM, V33, P769, DOI 10.1016/j.idc.2019.04.005
   Fauci AS, 2019, JAMA-J AM MED ASSOC, V321, P844, DOI 10.1001/jama.2019.1343
   Freeman ML, 2016, CLIN INFECT DIS, V62, P392, DOI 10.1093/cid/civ840
   Fried L, 1998, PRINCIPLES GERIATRIC, P1998
   Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Funderburg NT, 2010, BLOOD, V115, P161, DOI 10.1182/blood-2009-03-210179
   GLASER R, 1985, J BEHAV MED, V8, P249, DOI 10.1007/BF00870312
   Gouws E, 2017, ROLE CITIES ENDING A
   Greene M, 2018, AIDS BEHAV, V22, P1475, DOI 10.1007/s10461-017-1985-1
   Grund B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155100
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Hart BB, 2018, JAIDS-J ACQ IMM DEF, V77, P1, DOI 10.1097/QAI.0000000000001554
   Hawkley LC, 2010, ANN BEHAV MED, V40, P218, DOI 10.1007/s12160-010-9210-8
   Henrich T, 2019, C RETR OPP INF SEATT
   Ho C, 2019, INVEST OPHTH VIS SCI, V60
   Holt-Lunstad J, 2015, PERSPECT PSYCHOL SCI, V10, P227, DOI 10.1177/1745691614568352
   Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316
   Hontelez JAC, 2011, AIDS, V25, P1665, DOI 10.1097/QAD.0b013e32834982ea
   Jaremka LM, 2013, PSYCHOL SCI, V24, P1089, DOI 10.1177/0956797612464059
   Katoto PDMC, 2018, TROP MED INT HEALTH, V23, P795, DOI 10.1111/tmi.13073
   Keating R, 2013, NAT IMMUNOL, V14, P1266, DOI 10.1038/ni.2741
   Kennedy BK, 2014, CELL, V159, P708, DOI 10.1016/j.cell.2014.10.039
   KIECOLTGLASER JK, 1984, PSYCHOSOM MED, V46, P15, DOI 10.1097/00006842-198401000-00004
   Klinenberg E., 2018, NY TIMES
   Kong AM, 2019, AIDS PATIENT CARE ST, V33, P93, DOI 10.1089/apc.2018.0190
   Kooij KW, 2016, AIDS, V30, P241, DOI 10.1097/QAD.0000000000000910
   Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203
   Lagathu C, 2017, AIDS, V31, pS105, DOI [10.1097/QAD.0000000000001441, 10.1097/qad.0000000000001441]
   Lee EE, 2019, INT PSYCHOGERIATR, V31, P1447, DOI 10.1017/S1041610218002120
   Lee SA, 2016, AIDS, V30, P1807, DOI 10.1097/QAD.0000000000001124
   Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6
   Lorenz David R, 2019, EClinicalMedicine, V7, P55, DOI 10.1016/j.eclinm.2019.01.003
   Lucar J, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy017
   Mahale P, 2018, CLIN INFECT DIS, V67, P50, DOI 10.1093/cid/ciy012
   Mannick JB, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1564
   Meisner BA, 2020, CAN J AGING, V39, P333, DOI 10.1017/S0714980820000203
   National Academies of Sciences Engineering and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda, 2017, HLTH EFF CANN CANN C
   Neuhaus J, 2010, J INFECT DIS, V201, P1788, DOI 10.1086/652749
   Norwood J, 2017, JAIDS-J ACQ IMM DEF, V76, P527, DOI [10.1097/QAI.0000000000001525, 10.1097/qai.0000000000001525]
   Onen NF, 2014, J FRALITY AGING, V3, P158, DOI 10.14283/jfa.2014.18
   Park LS, 2018, ANN INTERN MED, V169, P87, DOI [10.7326/M16-2094, 10.7326/m16-2094]
   Pedicord VA, 2015, J IMMUNOL, V194, P2089, DOI 10.4049/jimmunol.1402390
   Pence BW, 2018, JAMA PSYCHIAT, V75, P379, DOI 10.1001/jamapsychiatry.2017.4726
   Piggott DA, 2020, AIDS, V34, P1217, DOI 10.1097/QAD.0000000000002527
   Rebeiro PF, 2019, OPEN FORUM INFECT S2, V6, pS996
   Saloner R, 2019, J INT NEUROPSYCH SOC, V25, P507, DOI 10.1017/S1355617719000018
   Sax PE, 2020, CLIN INFECT DIS, V71, P1379, DOI 10.1093/cid/ciz999
   Schacker T, 2008, AIDS, V22, pS13, DOI 10.1097/01.aids.0000327511.76126.b5
   Schrack JA, 2015, JAIDS-J ACQ IMM DEF, V70, P370, DOI 10.1097/QAI.0000000000000731
   Shah ASV, 2018, CIRCULATION, V138, P1100, DOI 10.1161/CIRCULATIONAHA.117.033369
   Shiau S, 2013, AIDS, V27, P1949, DOI 10.1097/QAD.0b013e328361d241
   Shiels MS, 2018, ANN INTERN MED, V168, P866, DOI [10.7326/M17-2499, 10.7326/m17-2499]
   Shippy RA, 2005, AGING MENT HEALTH, V9, P246, DOI 10.1080/13607860412331336850
   Shpacovitch V, 2008, J LEUKOCYTE BIOL, V83, P1309, DOI 10.1189/jlb.0108001
   Siedner MJ, 2019, J AGING HEALTH, V31, P109, DOI 10.1177/0898264317724549
   Sierra F, 2017, GEROSCIENCE, V39, P1, DOI 10.1007/s11357-016-9954-6
   Sierra F, 2016, J GERONTOL A-BIOL, V71, P1385, DOI 10.1093/gerona/glw087
   Smit M, 2015, LANCET INFECT DIS, V15, P810, DOI 10.1016/S1473-3099(15)00056-0
   So-Armah K, 2014, CURR OPIN HIV AIDS, V9, P346, DOI 10.1097/COH.0000000000000065
   Sparkenbaugh EM, 2014, BLOOD, V123, P1747, DOI 10.1182/blood-2013-08-523936
   Sun-Suslow N, 2020, JAIDS-J ACQ IMM DEF, V84, P522, DOI 10.1097/QAI.0000000000002391
   Sundermann EE, 2019, AIDS RES HUM RETROV, V35, P985, DOI [10.1089/AID.2019.0100, 10.1089/aid.2019.0100]
   The Lancet Haematology, 2018, LANCET HAEMATOL, V5, pe127
   Trickey A, 2017, LANCET HIV, V4, pE349, DOI 10.1016/S2352-3018(17)30066-8
   Varadhan R, 2019, J FRALITY AGING, V8, P162, DOI 10.14283/jfa.2019.21
   Varadhan R, 2008, J GERONTOL A-BIOL, V63, P190, DOI 10.1093/gerona/63.2.190
   Venter WDF, 2019, NEW ENGL J MED, V381, P803, DOI 10.1056/NEJMoa1902824
   Verheij E, 2020, J INFECT DIS, V222, P919, DOI 10.1093/infdis/jiaa010
   Wallace M, 2007, ANESTHESIOLOGY, V107, P785, DOI 10.1097/01.anes.0000286986.92475.b7
   Walston J, 2002, ARCH INTERN MED, V162, P2333, DOI 10.1001/archinte.162.20.2333
   Watson CWM, 2020, JAIDS-J ACQ IMM DEF, V83, P56, DOI 10.1097/QAI.0000000000002211
   Wilkerson WR, 2002, SEMIN THROMB HEMOST, V28, P555, DOI 10.1055/s-2002-36700
   Williams EC, 2018, DRUG ALCOHOL DEPEN, V189, P21, DOI 10.1016/j.drugalcdep.2018.04.022
   Wilsey B, 2013, J PAIN, V14, P136, DOI 10.1016/j.jpain.2012.10.009
   Wing EJ, 2016, INT J INFECT DIS, V53, P61, DOI 10.1016/j.ijid.2016.10.004
   Womack JA, 2019, JAIDS-J ACQ IMM DEF, V82, P305, DOI 10.1097/QAI.0000000000002130
   World Health Organization, 2017, GLOB HEP REP
   World Health Organization, 2018, HIV ASS TUB
   Zhou XY, 2008, PSYCHOL SCI, V19, P1023, DOI 10.1111/j.1467-9280.2008.02194.x
NR 103
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC 1
PY 2020
VL 36
IS 12
BP 973
EP 981
DI 10.1089/aid.2020.0128
EA SEP 2020
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA PA8MS
UT WOS:000574523500001
PM 32847368
DA 2021-01-01
ER

PT J
AU Sumirtanurdin, R
   Barliana, MI
AF Sumirtanurdin, Riyadi
   Barliana, Melisa Intan
TI Coronavirus Disease 2019 Vaccine Development: An Overview
SO VIRAL IMMUNOLOGY
LA English
DT Article; Early Access
DE SARS-CoV-2; challenges; platforms; progress
ID RECEPTOR-BINDING DOMAIN; MESSENGER-RNA VACCINES; DENDRITIC CELLS; VIRAL
   VECTORS; VIRUS; SPIKE; PARTICLES; 2019-NCOV
AB To this day, the coronavirus disease 2019 (COVID-19) pandemic has not shown signs of abating. Moreover, the virus responsible for the pandemic, severe acute respiratory syndrome coronavirus 2, has evolved into three different variants. This phenomenon highlights an even greater need to develop drugs and vaccines to control the rate of infection and spread of the disease. As of July 7, 2020, at least 160 vaccine candidates, 21 of which have entered the clinical trial phase, have been developed. This article describes the latest advances in development, reliable platforms, strategies used, and challenges that remain in developing COVID-19 vaccines.
C1 [Sumirtanurdin, Riyadi] Univ Padjadjaran, Fac Pharm, Educ, Bandung, Indonesia.
   [Sumirtanurdin, Riyadi; Barliana, Melisa Intan] Univ Padjadjaran, Dept Biol Pharm, Biotechnol Pharm Lab, Fac Pharm, Bandung, Indonesia.
   [Barliana, Melisa Intan] Univ Padjadjaran, Ctr Excellence Higher Educ Pharmaceut Care Innova, Bandung, Indonesia.
RP Barliana, MI (corresponding author), Univ Padjadjaran, Fac Pharm, Dept Biol Pharm, Jl Raya Bandung Sumedang KM 21, Jatinangor 45363, Indonesia.
EM melisa.barliana@unpad.ac.id
CR Adolph DW, 1997, J MOL BIOL, V109, P345
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Ambuhl PM, 2007, J HYPERTENS, V25, P63, DOI 10.1097/HJH.0b013e32800ff5d6
   [Anonymous], 2020, SIGN STEP COVID 19 V
   Anthony SJ, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex012
   Azmi F, 2014, HUM VACC IMMUNOTHER, V10, P778, DOI 10.4161/hv.27332
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Clover Biopharmaceuticals, 2020, CLOVER GSK ANNOUNCE
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fidler DP, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000247
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Gouglas D, 2018, LANCET GLOB HEALTH, V6, pE1386, DOI 10.1016/S2214-109X(18)30346-2
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   HARDING CV, 1994, J IMMUNOL, V153, P4925
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   INOVIO Pharmaceuticals, 2020, IN IN PHAS 1 CLIN TR
   Jahanafrooz Z, 2020, DRUG DISCOV TODAY, V25, P552, DOI 10.1016/j.drudis.2019.12.003
   Johnson JE, 2007, VIROLOGY, V360, P36, DOI 10.1016/j.virol.2006.10.026
   Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737
   Khudyakov Y., 2016, VIRAL NANOTECHNOLOGY
   Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821
   Kumar Swatantra, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00571-5
   Kupferschmidt K, 2020, SCIENCE, V367, P610, DOI 10.1126/science.367.6478.610
   Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Liniger M, 2007, EXPERT REV VACCINES, V6, P255, DOI 10.1586/14760584.6.2.255
   Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lu S, 2020, EMERG MICROBES INFEC, V9, P542, DOI 10.1080/22221751.2020.1737580
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Moderna Inc, 2020, DRUG DES STUD DIG DE
   Okba NMA, 2017, CURR OPIN VIROL, V23, P49, DOI 10.1016/j.coviro.2017.03.007
   Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243
   Parrino J, 2006, J ALLERGY CLIN IMMUN, V118, P1320, DOI 10.1016/j.jaci.2006.09.037
   Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231
   Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862
   Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039
   Pulendran B, 2010, NAT IMMUNOL, V11, P647, DOI 10.1038/ni.1894
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Robert-Guroff M, 2007, CURR OPIN BIOTECH, V18, P546, DOI 10.1016/j.copbio.2007.10.010
   Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278
   Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008
   Sedwick Caitlin E, 2002, Sci STKE, V2002, pre2, DOI 10.1126/stke.2002.122.re2
   Sharma A, 2011, HUM VACCINES, V7, P999, DOI 10.4161/hv.7.10.16369
   Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Toumi M, 2015, J MARKET ACCESS HLTH, V3, P29204
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   World Health Organization, 2020, TYPES VACC ADV REACT
   World Health Organization, 2020, COR COVID 19
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zabel F, 2014, J IMMUNOL, V192, P5499, DOI 10.4049/jimmunol.1400065
   Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
   Zuniga A, 2007, VACCINE, V25, P2974, DOI 10.1016/j.vaccine.2007.01.064
NR 60
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0882-8245
EI 1557-8976
J9 VIRAL IMMUNOL
JI Viral Immunol.
DI 10.1089/vim.2020.0119
EA SEP 2020
PG 11
WC Immunology; Virology
SC Immunology; Virology
GA NV6YA
UT WOS:000574463100001
PM 32985963
OA Bronze
DA 2021-01-01
ER

PT J
AU Zhang, LB
   Pang, RR
   Qiao, QH
   Wang, ZH
   Xia, XY
   Wang, CJ
   Xu, XL
AF Zhang, Li-Bo
   Pang, Rong-Rong
   Qiao, Qing-Hua
   Wang, Zhi-Hua
   Xia, Xin-Yi
   Wang, Chang-Jun
   Xu, Xiao-Li
TI Successful recovery of COVID-19-associated recurrent diarrhea and
   gastrointestinal hemorrhage using convalescent plasma
SO MILITARY MEDICAL RESEARCH
LA English
DT Article
DE Coronavirus disease 2019 (COVID-19); Convalescent plasma; SARS-CoV-2
   virus; Gastrointestinal symptoms
ID COVID-19
AB Background Gastrointestinal symptoms are not rare among coronavirus disease 2019 (COVID-19) patients, but there have been no reports regarding convalescent plasma therapy for the recovery of gastrointestinal problems in COVID-19 patients. Case presentation We present two cases of patients with COVID-19-associated recurrent diarrhea and positive fecal occult blood who successfully recovered after a one-time convalescent plasma administration. Conclusion When COVID-19 patients develop recurrent or refractory gastrointestinal symptoms and fail to respond to the available treatment, alternative therapy with convalescent plasma administration may be considered.
C1 [Zhang, Li-Bo; Pang, Rong-Rong; Xia, Xin-Yi] Southern Med Univ, Sch Clin Med 1, Sch Med, COVID 19 Res Ctr,Inst Lab Med,Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China.
   [Zhang, Li-Bo; Pang, Rong-Rong] Nanjing Red Cross Blood Ctr, Dept Lab Med, Nanjing 210003, Jiangsu, Peoples R China.
   [Qiao, Qing-Hua] 989th Hosp, Med & Tech Support Dept, Pingdingshan 467000, Henan, Peoples R China.
   [Qiao, Qing-Hua; Wang, Zhi-Hua; Xia, Xin-Yi] Wuhan Huoshenshan Hosp, Dept Lab Med & Blood Transfus, Wuhan 430100, Hubei, Peoples R China.
   [Wang, Zhi-Hua] 907th Hosp, Dept Lab Med & Blood Transfus, Nanping 350702, Fujian, Peoples R China.
   [Wang, Zhi-Hua; Xia, Xin-Yi; Wang, Chang-Jun; Xu, Xiao-Li] Wuhan Huoshenshan Hosp, Joint Expert Grp COVID 19, Wuhan 430100, Hubei, Peoples R China.
   [Wang, Chang-Jun] Ctr Dis Control & Prevent PLA, 20 Dongda St, Beijing 100071, Peoples R China.
   [Xu, Xiao-Li] Nanjing Univ, Jinling Hosp, Sch Med, Dept Med Adm, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.
RP Xia, XY (corresponding author), Southern Med Univ, Sch Clin Med 1, Sch Med, COVID 19 Res Ctr,Inst Lab Med,Jinling Hosp, Nanjing 210002, Jiangsu, Peoples R China.; Wang, CJ; Xu, XL (corresponding author), Wuhan Huoshenshan Hosp, Joint Expert Grp COVID 19, Wuhan 430100, Hubei, Peoples R China.
EM xinyixia@nju.edu.cn; science2008@hotmail.com; xxl2019kt@sina.com
OI Wang, Zhihua/0000-0002-8658-4697; Zhang, Libo/0000-0002-2972-5174; Reis,
   AlessanRSS/0000-0001-8486-7469
FU Key Foundation of Wuhan Huoshenshan Hospital [2020 [18]]; Key Research &
   Development Program of Jiangsu Province [BE2018713]; Medical Innovation
   Project of Logistics Service [18JS005]; Foundation of Jiangsu Population
   Association [JSPA2019017]; Medical Science and Technology Development
   Foundation, Nanjing Department of Health [YKK18179]
FX This work was supported by the Key Foundation of Wuhan Huoshenshan
   Hospital (2020 [18]), Key Research & Development Program of Jiangsu
   Province (BE2018713), Medical Innovation Project of Logistics Service
   (18JS005), the Foundation of Jiangsu Population Association
   (JSPA2019017), and Medical Science and Technology Development
   Foundation, Nanjing Department of Health (YKK18179).
CR BAJ J, 2020, J CLIN MED, V9, DOI DOI 10.3390/JCM90617537356953
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Blanco-Colino R, 2020, CIR ESPAN, V98, P295, DOI 10.1016/j.ciresp.2020.03.006
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen YF, 2020, J MED VIROL, V92, P833, DOI 10.1002/jmv.25825
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hosoda T, 2020, INFECT CONT HOSP EP, V41, P753, DOI 10.1017/ice.2020.87
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Liu Q, 2020, Fa Yi Xue Za Zhi, V36, P21, DOI 10.12116/j.issn.1004-5619.2020.01.005
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Nobel YR, 2020, GASTROENTEROLOGY, V159, P373, DOI 10.1053/j.gastro.2020.04.017
   Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tullie L, 2020, LANCET CHILD ADOLESC, V4, pE19, DOI 10.1016/S2352-4642(20)30165-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zhang H, 2020, INT J INFECT DIS, V96, P19, DOI 10.1016/j.ijid.2020.04.027
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
   Zhang TQ, 2020, J MED VIROL, V92, P909, DOI 10.1002/jmv.25795
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-7467
EI 2054-9369
J9 MILITARY MED RES
JI MILITARY MED. RES.
PD SEP 23
PY 2020
VL 7
IS 1
AR 45
DI 10.1186/s40779-020-00273-5
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA NV4JW
UT WOS:000574291100001
PM 32962760
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kumar, BK
   Faheem
   Sekhar, KVGC
   Ojha, R
   Prajapati, VK
   Pai, A
   Murugesan, S
AF Kumar, Banoth Karan
   Faheem
   Sekhar, Kondapalli Venkata Gowri Chandra
   Ojha, Rupal
   Prajapati, Vijay Kumar
   Pai, Aravinda
   Murugesan, Sankaranarayanan
TI Pharmacophore based virtual screening, molecular docking, molecular
   dynamics and MM-GBSA approach for identification of prospective
   SARS-CoV-2 inhibitor from natural product databases
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Covid-19; main protease; pharmacophore; virtual screening; molecular
   docking; molecular dynamics; MM-GBSA
ID COV 3CL PROTEASE; MORINDA-OFFICINALIS; OLIGOSACCHARIDES; ESTERS;
   GLYCOSIDES; EXTRACT; ROOTS; MODEL; COLOR; L.
AB COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily appeared in Wuhan, China, in December 2019. At present, no proper therapy and vaccinations are available for the disease, and it is increasing day by day with a high mortality rate. Pharmacophore based virtual screening of the selected natural product databases followed by Glide molecular docking and dynamics studies against SARS-CoV-2 main protease was investigated to identify potential ligands that may act as inhibitors. The moleculesSN00293542andSN00382835revealed the highest docking score of-14.57and-12.42 kcal/mol,respectively, when compared with the co-crystal ligands of PDB-6Y2F (O6K) and 6W63 (X77) of the SARS-CoV-2 M-pro. To further validate the interactions of top scored moleculesSN00293542andSN00382835,molecular dynamics study of 100 ns was carried out. This indicated that the protein-ligand complex was stable throughout the simulation period, and minimal backbone fluctuations have ensued in the system. Post-MM-GBSA analysis of molecular dynamics data showed free binding energy-71.7004 +/- 7.98, -56.81+/- 7.54 kcal/mol,respectively. The computational study identified several ligands that may act as potential inhibitors of SARS-CoV-2 M-pro. The top-ranked moleculesSN00293542,andSN00382835occupied the active site of the target, the main protease like that of the co-crystal ligand. These molecules may emerge as a promising ligands against SARS-CoV-2 and thus needs further detailed investigations. Communicated by Ramaswamy H. Sarma
C1 [Kumar, Banoth Karan; Faheem; Murugesan, Sankaranarayanan] Birla Inst Technol & Sci Pilani, Dept Pharm, Med Chem Res Lab, Pilani Campus, Pilani 333031, Rajasthan, India.
   [Sekhar, Kondapalli Venkata Gowri Chandra] Birla Inst Technol & Sci Pilani, Dept Chem, Hyderabad, India.
   [Ojha, Rupal; Prajapati, Vijay Kumar] Cent Univ Rajasthan, Sch Life Sci, Dept Biochem, Kishangarh, India.
   [Pai, Aravinda] Manipal Coll Pharmaceut Sci MCOPS, Dept Pharmaceut Chem, Manipal, Karnataka, India.
   [Pai, Aravinda] MAHE, Manipal, Karnataka, India.
RP Murugesan, S (corresponding author), Birla Inst Technol & Sci Pilani, Dept Pharm, Med Chem Res Lab, Pilani Campus, Pilani 333031, Rajasthan, India.
EM murugesan@pilani.bits-pilani.ac.in
RI KUMAR, BANOTH KARAN/AAQ-5523-2020
OI KUMAR, BANOTH KARAN/0000-0002-9615-6944; Prajapati,
   Vijay/0000-0001-6510-0596; Sankaranarayanan,
   Murugesan/0000-0002-3680-1577; Ojha, Rupal/0000-0002-2581-0187; ,
   Faheem/0000-0002-2306-3050
FU Department of Biotechnology, Indo-Spain, New Delhi
   [BT/IN/Spain/39/SM/2017-2018]; Ministry of Tribal affairs, Government of
   India [201920-NFST-TEL-01497]
FX Authors Banoth Karan Kumar, Faheem and Sankaranarayanan Murugesan
   gratefully acknowledge to the Department of Biotechnology, Indo-Spain,
   New Delhi. (Ref. No: BT/IN/Spain/39/SM/2017-2018). Additionally, Banoth
   Karan Kumar thankful to the Ministry of Tribal affairs, Government of
   India for providing financial assistance (Award
   no-201920-NFST-TEL-01497).
CR ADHIKARI SP, 2020, INFECT DIS POVERTY, V9, DOI DOI HTTPS://DOI.ORG/10.1186/S40249-020-00646-X
   AID, 2012, 651697 AID
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2015, QIKPROP DESCRIPTORS, P2
   [Anonymous], 2019, DESM MOL DYN SYST MA
   [Anonymous], 2019, SCHROD REL 2019 1 MA
   [Anonymous], 2019, SCHROD REL 2019 1 LI
   [Anonymous], 2019, SCHROD REL 2019 1 QI
   [Anonymous], 2019, SCHROD REL 2019 1 SC
   Bestle D., 2020, BIORXIV, DOI [10.1101/2020.04.15.042085, DOI 10.1101/2020.04.15.042085]
   Cebadera-Miranda L, 2019, FOOD CHEM, V270, P395, DOI 10.1016/j.foodchem.2018.07.094
   Chang HT, 2007, HELV CHIM ACTA, V90, P944, DOI 10.1002/hlca.200790095
   Chiow KH, 2016, ASIAN PAC J TROP MED, V9, P1, DOI 10.1016/j.apjtm.2015.12.002
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Crasci L, 2017, PLANTA MED, V83, P901, DOI 10.1055/s-0043-104775
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Hidaka H., 1986, Bifidobacteria and Microflora, V5, P37
   HISAMATSU M, 1985, AGR BIOL CHEM TOKYO, V49, P1447, DOI 10.1080/00021369.1985.10866904
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Inoue T, 2002, BIOL PHARM BULL, V25, P256, DOI 10.1248/bpb.25.256
   ISLAM MT, 2020, PHYTOTHER RES 0417, DOI DOI https://doi.org/10.1002/ptr.6700
   JIN Z, 2020, NATURE 0409, DOI DOI https://doi.org/10.1101/2020.02.26.964882
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Jung HA, 2011, FOOD CHEM TOXICOL, V49, P376, DOI 10.1016/j.fct.2010.11.012
   Kalibaeva G, 2003, MOL PHYS, V101, P765, DOI 10.1080/0026897021000044025
   Kazuma K, 2003, PHYTOCHEMISTRY, V64, P1133, DOI 10.1016/S0031-9422(03)00504-1
   KEYHAN SO, 2020, MAX PLAST RECONSTR S, V42, DOI DOI https://doi.org/10.1186/s40902-020-00254-7
   Li J, 2005, J NAT PROD, V68, P739, DOI 10.1021/np050023x
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Mani JS, 2020, VIRUS RES, V284, DOI 10.1016/j.virusres.2020.197989
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   MASETTI M, 2020, MOLECULES, V25, DOI DOI https://doi.org/10.3390/molecules25122911
   MITSUOKA T, 1987, NAHRUNG, V31, P427
   Miyase T, 1999, J NAT PROD, V62, P993, DOI 10.1021/np990084t
   Miyase Toshio, 1993, Shoyakugaku Zasshi, V47, P267
   Orhan F, 2016, MED CHEM RES, V25, P2567, DOI 10.1007/s00044-016-1681-0
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Qiu ZK, 2016, METAB BRAIN DIS, V31, P1143, DOI 10.1007/s11011-016-9853-7
   Rocchetti G, 2017, FOOD CHEM, V228, P367, DOI 10.1016/j.foodchem.2017.01.142
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sabater-Molina M, 2009, J PHYSIOL BIOCHEM, V65, P315, DOI 10.1007/BF03180584
   Schrodinger, 2019, SCHROD REL 2019 1 LI
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Sunseri J, 2016, NUCLEIC ACIDS RES, V44, pW442, DOI 10.1093/nar/gkw287
   WALKER MS, 1970, J BIOL CHEM, V245, P6683
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu XY, 2011, FOOD CHEM, V129, P443, DOI 10.1016/j.foodchem.2011.04.097
   XIA S, 2020, CELL MOL IMMUNO 0211, DOI DOI https://doi.org/10.1038/s41423-020-s0374-2
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Zhang JH, 2018, J ETHNOPHARMACOL, V213, P230, DOI 10.1016/j.jep.2017.10.028
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang ZQ, 2002, PHARMACOL BIOCHEM BE, V72, P39, DOI 10.1016/S0091-3057(01)00730-4
   Zhu XF, 2004, J AGR FOOD CHEM, V52, P7272, DOI 10.1021/jf0490192
NR 59
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1824814
EA SEP 2020
PG 24
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NT8BI
UT WOS:000573158700001
PM 32981461
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Head, KJ
   Kasting, ML
   Sturm, LA
   Hartsock, JA
   Zimet, GD
AF Head, Katharine J.
   Kasting, Monica L.
   Sturm, Lynne A.
   Hartsock, Jane A.
   Zimet, Gregory D.
TI A National Survey Assessing SARS-CoV-2 Vaccination Intentions:
   Implications for Future Public Health Communication Efforts
SO SCIENCE COMMUNICATION
LA English
DT Article
DE vaccination intentions; COVID-19; SARS-CoV-2; perceived threat; provider
   recommendation
ID HUMAN-PAPILLOMAVIRUS VACCINATION; INFLUENZA VACCINATION; PROVIDER
   RECOMMENDATION; HPV VACCINATION; HERD-IMMUNITY; BELIEF MODEL; HESITANCY;
   METAANALYSIS; BEHAVIOR; WOMEN
AB With SARS-CoV-2 vaccines under development, research is needed to assess intention to vaccinate. We conducted a survey (N= 3,159) with U.S. adults in May 2020 assessing SARS-CoV-2 vaccine intentions, intentions with a provider recommendation, and sociodemographic and psychosocial variables. Participants had high SARS-CoV-2 vaccine intentions (M= 5.23/7-point scale), which increased significantly with a provider recommendation (M= 5.47). Hierarchical linear regression showed that less education and working in health care were associated with lower intent, and liberal political views, altruism, and COVID-19-related health beliefs were associated with higher intent. This work can inform interventions to increase vaccine uptake, ultimately reducing COVID-19-related morbidity and mortality.
C1 [Head, Katharine J.; Hartsock, Jane A.] Indiana Univ Purdue Univ Indianapolis, Indianapolis, IN USA.
   [Kasting, Monica L.] Purdue Univ, Dept Publ Hlth, W Lafayette, IN 47907 USA.
   [Sturm, Lynne A.] Indiana Univ Sch Med, Pediat Clin, Indianapolis, IN 46202 USA.
   [Zimet, Gregory D.] Indiana Univ Sch Med, Clin Psychol, Indianapolis, IN 46202 USA.
RP Head, KJ (corresponding author), Indiana Univ Purdue Univ Indianapolis, Dept Commun Studies, IU Sch Liberal Arts, 450 Univ Blvd, Indianapolis, IN 46256 USA.
EM headkj@iupui.edu
OI Head, Katharine/0000-0001-8946-1716
FU Department of Communication Studies, IUPUI; Department of Public Health,
   Purdue University; Department of Pediatrics, IU School of Medicine;
   Department of Clinical Ethics, IU Health
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The study
   team is thankful to their individual departments for providing monetary
   support for this survey project (Department of Communication Studies,
   IUPUI; Department of Public Health, Purdue University; Department of
   Pediatrics, IU School of Medicine; and Department of Clinical Ethics, IU
   Health).
CR Abbas KM, 2018, PEERJ, V6, DOI 10.7717/peerj.5171
   Almario CV, 2016, AM J INFECT CONTROL, V44, P1004, DOI 10.1016/j.ajic.2016.03.064
   Bakshy E, 2015, SCIENCE, V348, P1130, DOI 10.1126/science.aaa1160
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Bloom BR, 2014, SCIENCE, V344, P339, DOI 10.1126/science.1254834
   Boboltz S., 2020, HUFFINGTON POST
   Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Burchell K, 2013, J CONSUM BEHAV, V12, P1, DOI 10.1002/cb.1395
   Cahyanto I, 2016, TOUR MANAG PERSPECT, V20, P195, DOI 10.1016/j.tmp.2016.09.004
   Cameron KA, 2009, HEALTH COMMUN, V24, P316, DOI 10.1080/10410230902889258
   Campo S, 2004, COMMUN MONOGR, V71, P448, DOI 10.1080/0363452042000307498
   Centers for Disease Control and Prevention, 2016, AD VACC INF HEALTHC
   Centers for Disease Control and Prevention, 2019, INFL FLU FLU VACC CO
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention, 2020, CORONAVIRUS DIS 2019
   Centers for Disease Control and Prevention, 2018, TALK PAR VACC INF
   Champion V. L., 2008, HLTH BEHAV HLTH ED T, P45
   Chen MF, 2011, J COMMUN HEALTH NURS, V28, P29, DOI 10.1080/07370016.2011.539087
   Coe Antoinette B, 2012, Innov Pharm, V3, P1
   Collange F, 2016, HUM VACC IMMUNOTHER, V12, P1282, DOI 10.1080/21645515.2015.1138024
   Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312
   de Visser R, 2011, SEX HEALTH, V8, P330, DOI 10.1071/SH10155
   Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041
   Eller NM, 2019, HEALTH EDUC BEHAV, V46, P445, DOI 10.1177/1090198118819716
   Fan H, 2018, AIDS CARE, V30, P1062, DOI 10.1080/09540121.2018.1442555
   Galarce EM, 2011, VACCINE, V29, P5284, DOI 10.1016/j.vaccine.2011.05.014
   Gerend MA, 2012, ANN BEHAV MED, V44, P171, DOI 10.1007/s12160-012-9366-5
   Gilkey MB, 2016, VACCINE, V34, P1187, DOI 10.1016/j.vaccine.2016.01.023
   Gore TD, 2005, HEALTH EDUC BEHAV, V32, P27, DOI 10.1177/1090198104266901
   Gorman JR, 2012, VACCINE, V31, P213, DOI 10.1016/j.vaccine.2012.10.064
   Iyengar S, 2009, J COMMUN, V59, P19, DOI 10.1111/j.1460-2466.2008.01402.x
   Jackson DN, 2019, AM J HEALTH PROMOT, V33, P1187, DOI 10.1177/0890117119861280
   Juraskova I, 2011, WOMEN HEALTH ISS, V21, P71, DOI 10.1016/j.whi.2010.08.004
   Korn L, 2020, P NATL ACAD SCI USA, V117, P14890, DOI 10.1073/pnas.1919666117
   Krawczyk AL, 2012, HEALTH PSYCHOL, V31, P685, DOI 10.1037/a0027012
   Kriss JL, 2017, VACCINE, V35, P1551, DOI 10.1016/j.vaccine.2017.01.037
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lee J. C., 2020, SEE ALL 50 STATES AR
   Li M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159780
   Liau A, 1998, SEX TRANSM DIS, V25, P76, DOI 10.1097/00007435-199802000-00004
   Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Minor DS, 2010, AM J MED, V123, P1031, DOI 10.1016/j.amjmed.2010.06.017
   Moss JL, 2016, SOC SCI MED, V159, P100, DOI 10.1016/j.socscimed.2016.04.030
   Paasche-Orlow MK, 2005, J GEN INTERN MED, V20, P175, DOI 10.1111/j.1525-1497.2005.40245.x
   Paulsen C., 2006, NCES 2006 483
   Prati G, 2012, HEALTH COMMUN, V27, P413, DOI 10.1080/10410236.2011.606523
   Quadri-Sheriff M, 2012, PEDIATRICS, V130, P522, DOI 10.1542/peds.2012-0140
   Quick BL, 2018, HEALTH COMMUN, V33, P379, DOI 10.1080/10410236.2016.1266738
   Quinn SC, 2019, VACCINE, V37, P1168, DOI 10.1016/j.vaccine.2019.01.033
   Rahman M, 2015, CLIN PEDIATR, V54, P371, DOI 10.1177/0009922814551135
   Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043
   Reiter PL, 2013, VACCINE, V31, P2816, DOI 10.1016/j.vaccine.2013.04.010
   RUSHTON JP, 1981, PERS INDIV DIFFER, V2, P293
   Schwenk G, 2009, QUAL QUANT, V43, P743, DOI 10.1007/s11135-007-9162-7
   Sobo EJ, 2016, SOC SCI MED, V165, P187, DOI 10.1016/j.socscimed.2016.06.015
   Stockwell MS, 2012, JAMA-J AM MED ASSOC, V307, P1702, DOI 10.1001/jama.2012.502
   Sturm L, 2017, J ADOLESCENT HEALTH, V61, P246, DOI 10.1016/j.jadohealth.2017.02.006
   Thigpen C., 2020, MOST AM EXPECT COVID
   Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018
   Vietri JT, 2012, MED DECIS MAKING, V32, P447, DOI 10.1177/0272989X11427762
   Vorpahl MM, 2018, HEALTH COMMUN, V33, P620, DOI 10.1080/10410236.2017.1289436
   Webb TL, 2006, PSYCHOL BULL, V132, P249, DOI 10.1037/0033-2909.132.2.249
   WITTE K, 1992, COMMUN MONOGR, V59, P329, DOI 10.1080/03637759209376276
   World Health Organization, 2019, 10 THREATS GLOBAL HL
   Yang ZJ, 2015, J HEALTH COMMUN, V20, P69, DOI 10.1080/10810730.2014.904023
NR 68
TC 0
Z9 0
U1 4
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1075-5470
EI 1552-8545
J9 SCI COMMUN
JI Sci. Commun.
PD OCT
PY 2020
VL 42
IS 5
SI SI
BP 698
EP 723
AR 1075547020960463
DI 10.1177/1075547020960463
EA SEP 2020
PG 26
WC Communication
SC Communication
GA OD5CK
UT WOS:000572744400001
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Themans, P
   Belkhir, L
   Dauby, N
   Yombi, JC
   De Greef, J
   Delongie, KA
   Vandeputte, M
   Nasreddine, R
   Wittebole, X
   Wuillaume, F
   Lescrainier, C
   Verlinden, V
   Kiridis, S
   Dogne, JM
   Hamdani, J
   Wallemacq, P
   Musuamba, FT
AF Themans, Pauline
   Belkhir, Leila
   Dauby, Nicolas
   Yombi, Jean-Cyr
   De Greef, Julien
   Delongie, Kevin-Alexandre
   Vandeputte, Martin
   Nasreddine, Rakan
   Wittebole, Xavier
   Wuillaume, Francoise
   Lescrainier, Cecile
   Verlinden, Veerle
   Kiridis, Sophie
   Dogne, Jean-Michel
   Hamdani, Jamila
   Wallemacq, Pierre
   Musuamba, Flora T.
TI Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients:
   Implications for Dose Optimization
SO EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
LA English
DT Article
AB Background and Objective In the absence of characterization on pharmacokinetics and reference concentrations for hydroxychloroquine in COVID-19 patients, the dose and treatment duration for hydrochloroquine are currently empirical, mainly based on in vitro data, and may vary across national guidelines and clinical study protocols. The aim of this paper is to describe the pharmacokinetics of hydroxychloroquine in COVID-19 patients, considered to be a key step toward its dosing optimization. Methods We have developed a population pharmacokinetic model for hydroxychloroquine in COVID-19 patients using prospectively collected pharmacokinetic data from patients either enrolled in a clinical trial or treated with hydroxychloroquine as part of standard of care in two tertiary Belgian hospitals. Results The final population pharmacokinetic model was a one-compartment model with first-order absorption and elimination. The estimated parameter values were 9.3/h, 860.8 L, and 15.7 L/h for the absorption rate constant, the central compartment volume, and the clearance, respectively. The bioavailability factor was fixed to 0.74 based on previously published models. Model validations by bootstraps, prediction corrected visual predictive checks, and normalized prediction distribution errors gave satisfactory results. Simulations were performed to compare the exposure obtained with alternative dosing regimens. Conclusion The developed models provide useful insight for the dosing optimization of hydroxychloroquine in COVID-19 patients. The present results should be used in conjunction with exposure-efficacy and exposure-safety data to inform optimal dosing of hydroxychloroquine in COVID-19.
C1 [Themans, Pauline] Univ Namur, Namur Inst Complex Syst naXys, Namur, Belgium.
   [Themans, Pauline] Univ Namur, Dept Math, Namur, Belgium.
   [Belkhir, Leila; Yombi, Jean-Cyr; De Greef, Julien; Wittebole, Xavier] Catholic Univ Louvain, Dept Internal Med & Infect Dis, Clin Univ St Luc, Brussels, Belgium.
   [Dauby, Nicolas; Nasreddine, Rakan] Univ Libre Bruxelles ULB, Ctr Hosp St Pierre, Dept Infect Dis, Brussels, Belgium.
   [Dauby, Nicolas; Vandeputte, Martin; Wuillaume, Francoise] Univ Libre Bruxelles ULB, Sch Publ Hlth, Environm Hlth Res Ctr, Brussels, Belgium.
   [Delongie, Kevin-Alexandre; Wallemacq, Pierre] Catholic Univ Louvain, Clin Univ St Luc, Dept Clin Chem, Brussels, Belgium.
   [Lescrainier, Cecile; Verlinden, Veerle; Kiridis, Sophie; Dogne, Jean-Michel; Hamdani, Jamila; Musuamba, Flora T.] Belgian Fed Agcy Med & Hlth Prod, B-1060 Brussels, Belgium.
   [Dogne, Jean-Michel] Univ Namur, Dept Pharm, Namur Thrombosis & Hemostasis Ctr, Namur, Belgium.
   [Musuamba, Flora T.] Univ Lubumbashi, Fac Pharmaceut Sci, Lubumbashi, DEM REP CONGO.
RP Musuamba, FT (corresponding author), Belgian Fed Agcy Med & Hlth Prod, B-1060 Brussels, Belgium.; Musuamba, FT (corresponding author), Univ Lubumbashi, Fac Pharmaceut Sci, Lubumbashi, DEM REP CONGO.
EM Flora.MusuambaTshinanu@fagg-afmps.be
RI Dauby, Nicolas/F-1235-2011
OI Dauby, Nicolas/0000-0002-7697-6849
CR Balevic SJ, 2019, CLIN PHARMACOKINET, V58, P525, DOI 10.1007/s40262-018-0712-z
   Blanchet B, 2019, ARTHRITIS RHEUMATOL, V71
   Carmichael SJ, 2003, THER DRUG MONIT, V25, P671, DOI 10.1097/00007691-200312000-00005
   Catteau L, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106144
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Garcia-Cremades M, 2020, CLIN PHARMACOL THER, V108, P253, DOI 10.1002/cpt.1856
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Grassin-Delyle Stanislas, 2020, Clin Infect Dis, V71, P2265, DOI 10.1093/cid/ciaa546
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   Martin-Blondel G, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa558
   MCLACHLAN AJ, 1993, EUR J CLIN PHARMACOL, V44, P481, DOI 10.1007/BF00315548
   Morita S, 2016, THER DRUG MONIT, V38, P259, DOI 10.1097/FTD.0000000000000261
   Morrisette T, 2020, INFECT DIS THER, V9, P561, DOI 10.1007/s40121-020-00325-2
   Sciensano, 2020, INT CLIN GUID AD SUS
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   Themans P, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14436
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, SOL CLIN TRIAL COVID
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 25
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 0378-7966
EI 2107-0180
J9 EUR J DRUG METAB PH
JI Eur. J. Drug Metabol. Pharmacokinet.
PD DEC
PY 2020
VL 45
IS 6
BP 703
EP 713
DI 10.1007/s13318-020-00648-y
EA SEP 2020
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OT6CV
UT WOS:000572330900001
PM 32968954
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kalhor, H
   Sadeghi, S
   Abolhasani, H
   Kalhor, R
   Rahimi, H
AF Kalhor, Hourieh
   Sadeghi, Solmaz
   Abolhasani, Hoda
   Kalhor, Reyhaneh
   Rahimi, Hamzeh
TI Repurposing of the approved small molecule drugs in order to inhibit
   SARS-CoV-2 S protein and human ACE2 interaction through virtual
   screening approaches
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE ACE2; Covid-19; molecular docking; SARS-CoV-2; structure-based virtual
   screening
ID ACTIVE COMPONENT; NUCLEAR IMPORT; LICORICE ROOTS; GLYCYRRHIZIN;
   REPLICATION; HEPATITIS; MECHANISM; INFECTION; CELLS; HIV-1
AB Most recently, the new coronavirus (SARS-CoV-2) has been recognized as a pandemic by the World Health Organization (WHO) while this virus shares substantial similarity with SARS-CoV. So far, no definitive vaccine or drug has been developed to cure Covid-19 disease, since many important aspects about Covid-19 such as pathogenesis and proliferation pathways are still unclear. It was proven that human ACE2 is the main receptor for the entry of Covid-19 into lower respiratory tract epithelial cells through interaction with SARS-CoV-2 S protein. Based on this observation, it is expected that the virus infection can be inhibited if protein-protein interaction is prevented. In this study, using structure-based virtual screening of FDA databases, several lead drugs were discovered based on the ACE2-binding pocket of SARS-CoV-2 S protein. Then, binding affinity, binding modes, critical interactions, and pharmaceutical properties of the lead drugs were evaluated. Among the previously approved drugs, Diammonium Glycyrrhizinate, Digitoxin, Ivermectin, Rapamycin, Rifaximin, and Amphotericin B represented the most desirable features, and can be possible candidates for Covid-19 therapies. Furthermore, molecular dynamics (MD) simulation was accomplished for three S protein/drug complexes with the highest binding affinity and best conformation and binding free energies were also computed with the Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) method. Results demonstrated the stable binding of these compounds to the S protein; however, in order to confirm the curative effect of these drugs, clinical trials must be done.
C1 [Kalhor, Hourieh; Abolhasani, Hoda; Kalhor, Reyhaneh] Qom Univ Med Sci, Cellular & Mol Res Ctr, Qom, Iran.
   [Kalhor, Hourieh; Rahimi, Hamzeh] Pasteur Inst Iran, Biotechnol Res Ctr, Mol Med Dept, 69,12th Farwardin St, Tehran, Iran.
   [Sadeghi, Solmaz] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Med Biotechnol, Tehran, Iran.
   [Abolhasani, Hoda] Qom Univ Med Sci, Spiritual Hlth Res Ctr, Qom, Iran.
   [Abolhasani, Hoda] Qom Univ Med Sci, Sch Med, Dept Pharmacol, Qom, Iran.
   [Kalhor, Reyhaneh] Islamic Azad Univ, Dept Genet, Kazerun Branch, Colleague Sci, Kazerun, Iran.
RP Rahimi, H (corresponding author), Pasteur Inst Iran, Biotechnol Res Ctr, Mol Med Dept, 69,12th Farwardin St, Tehran, Iran.
EM rahimi.h1981@gmail.com
OI Abolhasani, Hoda/0000-0001-9174-5304
FU Pasteur Institute of Iran [1852]
FX This study has been supported by Pasteur Institute of Iran (Grant
   Number: 1852).
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Alobid I, 2001, AM J RHINOL, V15, P327, DOI 10.1177/194589240101500508
   AMARELLE L, 2018, INT J MOL SCI, V19, DOI DOI https://doi.org/10.3390/ijms19082154
   Arase Y, 1997, CANCER, V79, P1494, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1494::AID-CNCR8>3.0.CO;2-B
   Athanasios T., 2020, NS8C7ERN MEDICINAL C, V8, DOI [https://doi.org/10.12970/2308-8044.2020.08.01, DOI 10.12970/2308-8044.2020.08.01]
   BABA M, 1987, ANTIVIR RES, V7, P99, DOI 10.1016/0166-3542(87)90025-8
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   Cinatl J, 2003, LANCET, V361, P2045, DOI 10.1016/S0140-6736(03)13615-X
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   DEOLIVEIRA OV, 2020, J BIOMOL STRUCT 0601, DOI DOI https://doi.org/10.1080/07391102.2020.1772885
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Feng C, 2007, INT IMMUNOPHARMACOL, V7, P1292, DOI 10.1016/j.intimp.2007.05.011
   Gotz V, 2016, SCI REP-UK, V6, DOI 10.1038/srep23138
   HACKETT AJ, 1972, P NATL ACAD SCI USA, V69, P3653, DOI 10.1073/pnas.69.12.3653
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   ITO M, 1988, ANTIVIR RES, V10, P289, DOI 10.1016/0166-3542(88)90047-2
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kalhor H, 2020, IRAN J PHARM RES, V19, P160, DOI 10.22037/ijpr.2019.15297.13037
   Kalhor H, 2020, J BIOMOL STRUCT DYN, V38, P791, DOI 10.1080/07391102.2019.1588784
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Koes DR, 2013, J CHEM INF MODEL, V53, P1893, DOI 10.1021/ci300604z
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Laskowski RA, 2009, NUCLEIC ACIDS RES, V37, pD355, DOI 10.1093/nar/gkn860
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001
   Lin JC, 2003, ANTIVIR RES, V59, P41, DOI 10.1016/S0166-3542(03)00030-5
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lundberg L, 2013, ANTIVIR RES, V100, P662, DOI 10.1016/j.antiviral.2013.10.004
   Mohammadi K, 2001, J BIOL CHEM, V276, P42050, DOI 10.1074/jbc.M107892200
   Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mukhtar F, 2020, J AYUB MED COLL ABBO, V32, P1
   NUMAZAKI K, 1994, J LEUKOCYTE BIOL, V55, P24
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pollard H. B., 2020, BIORXIV, DOI [https://doi.org/10.1101/2020.04.09.034983, DOI 10.1101/2020.04.09.034983]
   RISMANBAF A, 2020, ARCH ACAD EMERG MED, V8
   Roggo S, 2007, CHIMIA, V61, P312, DOI 10.2533/chimia.2007.312
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Sato H, 1996, ANTIVIR RES, V30, P171, DOI 10.1016/0166-3542(96)00942-4
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Sekhar T., 2020, PREPRINTS, DOI [10.20944/ preprints202002.0418.v2, DOI 10.20944/PREPRINTS202002.0418.V2, 10.20944/preprints202002.0418.v2]
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   SHANMUGARAJ B, 2020, PATHOGENS, V9, DOI DOI https://doi.org/10.3390/pathogens9020148
   Shayto RH, 2016, WORLD J GASTROENTERO, V22, P6638, DOI 10.3748/wjg.v22.i29.6638
   Shiri F, 2019, J BIOMOL STRUCT DYN, V37, P1800, DOI 10.1080/07391102.2018.1468281
   Shiri F, 2018, J RECEPT SIG TRANSD, V38, P37, DOI 10.1080/10799893.2017.1414844
   SIDDELL SG, 1983, INTERVIROLOGY, V20, P181, DOI 10.1159/000149390
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Stohr S, 2016, GUT, V65, P2017, DOI 10.1136/gutjnl-2014-308971
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Thakur A., 2017, J ANAL PHARM RES, V5, P156, DOI DOI 10.15406/JAPLR.2017.05.00156
   Tinku Gupta M. M., 2018, AJPER, V7
   Utsunomiya T, 1997, ANTIMICROB AGENTS CH, V41, P551, DOI 10.1128/AAC.41.3.551
   UTSUNOMIYA T, 1995, IMMUNOL LETT, V44, P59, DOI 10.1016/0165-2478(94)00183-R
   van Tilbeurgh H, 1999, BBA-MOL CELL BIOL L, V1441, P173, DOI 10.1016/S1388-1981(99)00149-3
   Visualizer B. D. S., 2017, VERSION 4 5 SOFTWARE
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yu XF, 2013, MOLECULES, V18, P6230, DOI 10.3390/molecules18066230
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 70
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1824816
EA SEP 2020
PG 17
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NS8CJ
UT WOS:000572483600001
PM 32969333
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wrigge, H
   Glien, C
AF Wrigge, H.
   Glien, C.
TI Specific treatment of acute lung failure
SO ANAESTHESIST
LA German
DT Article
DE Acute respiratory distress syndrome; PEEP titration; Lung recruitment
   maneuver; Prone position; COVID-19
ID RESPIRATORY-DISTRESS-SYNDROME; PRESSURE RELEASE VENTILATION; MECHANICAL
   VENTILATION; RECRUITMENT MANEUVERS; EARLY MOBILIZATION; PROPHYLAXIS;
   THERAPY; CARE
AB Due to a high heterogeneity and dynamic changes in the course of acute respiratory distress syndrome (ARDS), intensive care physicians are faced with extraordinary challenges. While the current definition, pathophysiology and differential diagnoses were previously addressed in this journal, this article focuses on some specific and individualized treatment options. Ventilation treatment with limitation of tidal volumes and pressure amplitudes has been shown to be advantageous with respect to mortality. Nevertheless, because of the multifactorial etiology of ARDS in the context of individual circumstances, this strategy needs to be adjusted to each patient's needs. In recent years it has become increasingly evident that prone positioning, early spontaneous breathing and early mobilization improve the course of the disease. Therefore, an individualized treatment should consider these issues and take the characteristics of the patient and the specific disease progression into account.
C1 [Wrigge, H.; Glien, C.] BG Klinikum Bergmannstrost Halle gGmbH, Klin Anasthesiol Intens & Notfallmed Schmerzthera, Merseburger Str 165, D-06112 Halle, Saale, Germany.
RP Wrigge, H (corresponding author), BG Klinikum Bergmannstrost Halle gGmbH, Klin Anasthesiol Intens & Notfallmed Schmerzthera, Merseburger Str 165, D-06112 Halle, Saale, Germany.
EM hermann.wrigge@bergmannstrost.de
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Amato MBP, 2015, NEW ENGL J MED, V372, P747, DOI 10.1056/NEJMsa1410639
   Balzer F, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0929-2
   Bein T, 2015, ANAESTHESIST, V64, P596, DOI 10.1007/s00101-015-0060-4
   Bein T, 2015, ANAESTHESIST, V64, pS1, DOI 10.1007/s00101-015-0071-1
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291
   Brower RG, 2004, NEW ENGL J MED, V351, P327
   Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171
   Dembinski R, 2020, ANAESTHESIST, V69, P439, DOI 10.1007/s00101-020-00789-4
   Fichtner F, 2018, DTSCH ARZTEBL INT, V115, P840, DOI 10.3238/arztebl.2018.0840
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Kluge S, 2020, MED KLIN-INTENSIVMED, P1
   Laffey JG, 2016, INTENS CARE MED, V42, P1865, DOI 10.1007/s00134-016-4571-5
   Lim SC, 2004, CRIT CARE MED, V32, P2378, DOI 10.1097/01.CCM.0000147444.58070.72
   Moss M, 2019, NEW ENGL J MED, V380, P1997, DOI 10.1056/NEJMoa1901686
   Munshi L, 2017, ANN AM THORAC SOC, V14, pS280, DOI 10.1513/AnnalsATS.201704-343OT
   Nestler C, 2017, BRIT J ANAESTH, V119, P1194, DOI 10.1093/bja/aex192
   Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9
   Suzumura EA, 2014, INTENS CARE MED, V40, P1227, DOI 10.1007/s00134-014-3413-6
   Varpula T, 2003, ACTA ANAESTH SCAND, V47, P516, DOI 10.1034/j.1399-6576.2003.00109.x
   Zhou YF, 2017, INTENS CARE MED, V43, P1648, DOI 10.1007/s00134-017-4912-z
NR 22
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0003-2417
EI 1432-055X
J9 ANAESTHESIST
JI Anaesthesist
PD NOV
PY 2020
VL 69
IS 11
SI SI
BP 847
EP 856
DI 10.1007/s00101-020-00844-0
EA SEP 2020
PG 10
WC Anesthesiology
SC Anesthesiology
GA OI1MJ
UT WOS:000572307000002
PM 32965509
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Pandey, P
   Prasad, K
   Prakash, A
   Kumar, V
AF Pandey, Preeti
   Prasad, Kartikay
   Prakash, Amresh
   Kumar, Vijay
TI Insights into the biased activity of dextromethorphan and haloperidol
   towards SARS-CoV-2 NSP6: in silico binding mechanistic analysis
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Article
DE COVID-19; NSP6; Haloperidol; Dextromethorphan; Molecular docking;
   Molecular dynamics
ID TOOL; REPLICATION; RECOGNITION; FRUSTRATION; POTENTIALS; MOLECULES;
   INFECTION; PROTEINS; DOCKING
AB The outbreak of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus continually led to infect a large population worldwide. SARS-CoV-2 utilizes its NSP6 and Orf9c proteins to interact with sigma receptors that are implicated in lipid remodeling and ER stress response, to infect cells. The drugs targeting the sigma receptors, sigma-1 and sigma-2, have emerged as effective candidates to reduce viral infectivity, and some of them are in clinical trials against COVID-19. The antipsychotic drug, haloperidol, exerts remarkable antiviral activity, but, at the same time, the sigma-1 benzomorphan agonist, dextromethorphan, showed pro-viral activity. To explore the potential mechanisms of biased binding and activity of the two drugs, haloperidol and dextromethorphan towards NSP6, we herein utilized molecular docking-based molecular dynamics simulation studies. Our extensive analysis of the protein-drug interactions, structural and conformational dynamics, residual frustrations, and molecular switches of NSP6-drug complexes indicates that dextromethorphan binding leads to structural destabilization and increase in conformational dynamics and energetic frustrations. On the other hand, the strong binding of haloperidol leads to minimal structural and dynamical perturbations to NSP6. Thus, the structural insights of stronger binding affinity and favorable molecular interactions of haloperidol towards viral NSP6 suggests that haloperidol can be potentially explored as a candidate drug against COVID-19. Key messages center dot Inhibitors of sigma receptors are considered as potent drugs against COVID-19. center dot Antipsychotic drug, haloperidol, binds strongly to NSP6 and induces the minimal changes in structure and dynamics of NSP6. center dot Dextromethorphan, agonist of sigma receptors, binding leads to overall destabilization of NSP6. center dot These two drugs bind with NSP6 differently and also induce differences in the structural and conformational changes that explain their different mechanisms of action. center dot Haloperidol can be explored as a candidate drug against COVID-19.
C1 [Pandey, Preeti] Univ Oklahoma, Dept Chem & Biochem, 101 Stephenson Pkwy, Norman, OK 73019 USA.
   [Prasad, Kartikay; Kumar, Vijay] Amity Univ, Amity Inst Neuropsychol & Neurosci, Noida 201303, UP, India.
   [Prakash, Amresh] Amity Univ Haryana, Amity Inst Integrat Sci & Hlth, Gurgaon 122413, India.
RP Kumar, V (corresponding author), Amity Univ, Amity Inst Neuropsychol & Neurosci, Noida 201303, UP, India.; Prakash, A (corresponding author), Amity Univ Haryana, Amity Inst Integrat Sci & Hlth, Gurgaon 122413, India.
EM aprakash@ggn.amity.edu; vkumar33@amity.edu
RI Prasad, Kartikay/AAS-1028-2020
OI Prasad, Kartikay/0000-0002-8730-0967; Reis,
   AlessanRSS/0000-0001-8486-7469
FU Science and Engineering Research Board (SERB), Government of India
   [YSS/2015/000228/LS]
FX The authors sincerely thank the Amity University, Noida, for providing
   facilities. Authors gratefully acknowledge the computational facility
   funded by Science and Engineering Research Board (SERB), Government of
   India (Ref. No.: YSS/2015/000228/LS).
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Barnard Dale L, 2008, Future Virol, V3, P119, DOI 10.2217/17460794.3.2.119
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   Cascella M, 2020, FEATURES EVALUATION
   Chen JZ, 2014, SCI REP-UK, V4, DOI 10.1038/srep06872
   Chen JZ, 2013, J COMPUT AID MOL DES, V27, P965, DOI 10.1007/s10822-013-9693-z
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Comentale G, 2020, J MOL MED, V98, P1053, DOI 10.1007/s00109-020-01945-4
   Cottam EM, 2014, AUTOPHAGY, V10, P1426, DOI 10.4161/auto.29309
   Cottam EM, 2011, AUTOPHAGY, V7, P1335, DOI 10.4161/auto.7.11.16642
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Enkirch T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01097
   Ferreiro DU, 2007, P NATL ACAD SCI USA, V104, P19819, DOI 10.1073/pnas.0709915104
   Fishback JA, 2010, PHARMACOL THERAPEUT, V127, P271, DOI 10.1016/j.pharmthera.2010.04.003
   Parra RG, 2016, NUCLEIC ACIDS RES, V44, pW356, DOI 10.1093/nar/gkw304
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   He YN, 2016, VIROL SIN, V31, P57, DOI 10.1007/s12250-015-3696-y
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hossein-khannazer N, 2020, J MOL MED, V98, P789, DOI 10.1007/s00109-020-01927-6
   Husain S, 2018, J THEOR BIOL, V449, P14, DOI 10.1016/j.jtbi.2018.04.016
   Jendele L, 2019, NUCLEIC ACIDS RES, V47, pW345, DOI 10.1093/nar/gkz424
   Joung IS, 2008, J PHYS CHEM B, V112, P9020, DOI 10.1021/jp8001614
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Kalita P, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104236
   Khatoon F, 2020, J NEUROVIROL, V26, P619, DOI 10.1007/s13365-020-00895-4
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Kumar N, 2020, J BIOMOL STRUCT DYN, V38, P3396, DOI 10.1080/07391102.2019.1657499
   Kumar V, 2019, BIOPHYS CHEM, V250, DOI 10.1016/j.bpc.2019.106174
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lauterbach EC, 2012, MED HYPOTHESES, V78, P693, DOI 10.1016/j.mehy.2012.02.012
   Maier HJ, 2013, MBIO, V4, DOI 10.1128/mBio.00801-13
   Matsumoto RR, 2014, ADV PHARMACOL, V69, P323, DOI 10.1016/B978-0-12-420118-7.00009-3
   McGibbon RT, 2015, BIOPHYS J, V109, P1528, DOI 10.1016/j.bpj.2015.08.015
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nguyen L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089985
   Olwenyi OA, 2020, J MOL MED, V98, P1369, DOI 10.1007/s00109-020-01961-4
   Oudshoorn D, 2017, MBIO, V8, DOI 10.1128/mBio.01658-17
   Pandey P, 2017, BIOINFORMATION, V13, P144, DOI 10.6026/97320630013144
   PARRINELLO M, 1980, PHYS REV LETT, V45, P1196, DOI 10.1103/PhysRevLett.45.1196
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Prakash A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1714481
   Prasad K, 2020, INT J BIOL MACROMOL, V163, P1, DOI 10.1016/j.ijbiomac.2020.06.228
   Rodrigues CHM, 2018, NUCLEIC ACIDS RES, V46, pW350, DOI 10.1093/nar/gky300
   Seeliger D, 2010, J COMPUT AID MOL DES, V24, P417, DOI 10.1007/s10822-010-9352-6
   Senior AW, 2020, NATURE, V577, P706, DOI 10.1038/s41586-019-1923-7
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Touma M, 2020, J MOL MED, V98, P947, DOI 10.1007/s00109-020-01931-w
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tulgar S, 2020, TURK J ANAESTHESIOL, V48, P256, DOI 10.5152/TJAR.2020.662
   van der Hoeven B, 2016, VIRUS RES, V220, P70, DOI 10.1016/j.virusres.2016.04.001
   Werling LL, 2007, EXP NEUROL, V207, P248, DOI 10.1016/j.expneurol.2007.06.013
   Yang JY, 2013, BIOINFORMATICS, V29, P2588, DOI 10.1093/bioinformatics/btt447
   Zalinger ZB, 2015, J VIROL, V89, P12330, DOI 10.1128/JVI.01470-15
   Zhang CX, 2020, J PROTEOME RES, V19, P1351, DOI 10.1021/acs.jproteome.0c00129
   Zheng W, 2019, PROTEINS, V87, P1149, DOI 10.1002/prot.25792
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
NR 60
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD DEC
PY 2020
VL 98
IS 12
BP 1659
EP 1673
DI 10.1007/s00109-020-01980-1
EA SEP 2020
PG 15
WC Genetics & Heredity; Medicine, Research & Experimental
SC Genetics & Heredity; Research & Experimental Medicine
GA OT9GX
UT WOS:000572322900001
PM 32965508
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Martin-Broto, J
   Hindi, N
   Aguiar, S
   Badilla-Gonzalez, R
   Castro-Oliden, V
   Chacon, M
   Correa-Generoso, R
   de Alava, E
   Donati, DM
   Eriksson, M
   Falla-Jimenez, M
   German, G
   Silva, MLG
   Gouin, F
   Gronchi, A
   Haro-Varas, JC
   Jimenez-Brenes, N
   Kasper, B
   de Mello, CAL
   Maki, R
   Martinez-Delgado, P
   Martinez-Said, H
   Martinez-Tlahuel, JL
   Morales-Perez, JM
   Munoz-Casares, FC
   Nakagawa, SA
   Ortiz-Cruz, EJ
   Palmerini, E
   Patel, S
   Moura, DS
   Stacchiotti, S
   Sunyach, MP
   Valverde, CM
   Waisberg, F
   Blay, JY
AF Martin-Broto, Javier
   Hindi, Nadia
   Aguiar, Samuel, Jr.
   Badilla-Gonzalez, Ronald
   Castro-Oliden, Victor
   Chacon, Matias
   Correa-Generoso, Raquel
   de alava, Enrique
   Donati, Davide Maria
   Eriksson, Mikael
   Falla-Jimenez, Martin
   German, Gisela
   Gobo Silva, Maria Leticia
   Gouin, Francois
   Gronchi, Alessandro
   Haro-Varas, Juan Carlos
   Jimenez-Brenes, Natalia
   Kasper, Bernd
   Lopes de Mello, Celso Abdon
   Maki, Robert
   Martinez-Delgado, Paula
   Martinez-Said, Hector
   Martinez-Tlahuel, Jorge Luis
   Morales-Perez, Jose Manuel
   Munoz-Casares, Francisco Cristobal
   Nakagawa, Suely A.
   Ortiz-Cruz, Eduardo Jose
   Palmerini, Emanuela
   Patel, Shreyaskumar
   Moura, David S.
   Stacchiotti, Silvia
   Sunyach, Marie Pierre
   Valverde, Claudia M.
   Waisberg, Federico
   Blay, Jean-Yves
TI Sarcoma European and Latin American Network (SELNET) Recommendations on
   Prioritization in Sarcoma Care During the COVID-19 Pandemic
SO ONCOLOGIST
LA English
DT Article
DE COVID-19; Sarcoma; Guidelines; Patient care; Multidisciplinary
ID SOFT-TISSUE SARCOMAS; GASTROINTESTINAL STROMAL TUMOR; HIGH-DOSE
   IFOSFAMIDE; CLINICAL-PRACTICE GUIDELINES; RANDOMIZED PHASE-II; STANDARD
   CHEMOTHERAPY; RETROSPECTIVE ANALYSIS; ADJUVANT CHEMOTHERAPY; SPANISH
   GROUP; HIGH-GRADE
AB Background The COVID-19 outbreak has resulted in collision between patients infected with SARS-CoV-2 and those with cancer on different fronts. Patients with cancer have been impacted by deferral, modification, and even cessation of therapy. Adaptive measures to minimize hospital exposure, following the precautionary principle, have been proposed for cancer care during COVID-19 era. We present here a consensus on prioritizing recommendations across the continuum of sarcoma patient care. Material and Methods A total of 125 recommendations were proposed in soft-tissue, bone, and visceral sarcoma care. Recommendations were assigned as higher or lower priority if they cannot or can be postponed at least 2-3 months, respectively. The consensus level for each recommendation was classified as "strongly recommended" (SR) if more than 90% of experts agreed, "recommended" (R) if 75%-90% of experts agreed and "no consensus" (NC) if fewer than 75% agreed. Sarcoma experts from 11 countries within the Sarcoma European-Latin American Network (SELNET) consortium participated, including countries in the Americas and Europe. The European Society for Medical Oncology-Magnitude of clinical benefit scale was applied to systemic-treatment recommendations to support prioritization. Results There were 80 SRs, 35 Rs, and 10 NCs among the 125 recommendations issued and completed by 31 multidisciplinary sarcoma experts. The consensus was higher among the 75 higher-priority recommendations (85%, 12%, and 3% for SR, R, and NC, respectively) than in the 50 lower-priority recommendations (32%, 52%, and 16% for SR, R, and NC, respectively). Conclusion The consensus on 115 of 125 recommendations indicates a high-level of convergence among experts. The SELNET consensus provides a tool for sarcoma multidisciplinary treatment committees during the COVID-19 outbreak. Implications for Practice The Sarcoma European-Latin American Network (SELNET) consensus on sarcoma prioritization care during the COVID-19 era issued 125 pragmatical recommendations distributed as higher or lower priority to protect critical decisions on sarcoma care during the COVID-19 pandemic. A multidisciplinary team from 11 countries reached consensus on 115 recommendations. The consensus was lower among lower-priority recommendations, which shows reticence to postpone actions even in indolent tumors. The European Society for Medical Oncology-Magnitude of Clinical Benefit scale was applied as support for prioritizing systemic treatment. Consensus on 115 of 125 recommendations indicates a high level of convergence among experts. The SELNET consensus provides a practice tool for guidance in the decisions of sarcoma multidisciplinary treatment committees during the COVID-19 outbreak.
C1 [Martin-Broto, Javier; Hindi, Nadia; Martinez-Delgado, Paula; Moura, David S.] Univ Seville, Inst Biomed Seville IBIS, HUVR, Grp Adv Therapies & Biomarkers Sarcoma,CSIC, Seville, Spain.
   [Martin-Broto, Javier; Hindi, Nadia] Univ Hosp Virgen Rocio, Dept Med Oncol, Seville, Spain.
   [Aguiar, Samuel, Jr.] AC Camargo Canc Ctr, Dept Pelv Surg, Sao Paulo, Brazil.
   [Gobo Silva, Maria Leticia] AC Camargo Canc Ctr, Dept Radiat Therapy, Sao Paulo, Brazil.
   [Lopes de Mello, Celso Abdon] AC Camargo Canc Ctr, Dept Med Oncol, Sao Paulo, Brazil.
   [Nakagawa, Suely A.] AC Camargo Canc Ctr, Dept Orthped, Sao Paulo, Brazil.
   [Badilla-Gonzalez, Ronald] Rafael Angel Calderon Guardia Hosp, Dept Med Oncol, San Jose, Costa Rica.
   [Castro-Oliden, Victor; Haro-Varas, Juan Carlos] Inst Nacl Enfermedades Neoplast, Dept Med Oncol, Lima, Peru.
   [Falla-Jimenez, Martin] Inst Nacl Enfermedades Neoplast, Dept iBreast & Soft Tissues Surg, Lima, Peru.
   [Chacon, Matias; Waisberg, Federico] Alexander Fleming Canc Inst, Dept Med Oncol, Buenos Aires, Argentina.
   [Correa-Generoso, Raquel] Virgen Victoria Univ Hosp, Radiotherapy Dept, Malaga, Spain.
   [de alava, Enrique] Univ Hosp Virgen Rocio, Pathol Dept, Seville, Spain.
   [de alava, Enrique] CIBERONC, Madrid, Spain.
   [de alava, Enrique] Univ Seville, Dept Normal & Pathol Cytol & Histol, Sch Med, Seville, Spain.
   [Donati, Davide Maria] Rizzoli Orthped Inst, Unit Orthoped Pathol & Osteoarticular Tissue Reg, Bologna, Italy.
   [Eriksson, Mikael] Skane Univ Hosp, Dept Med Oncol, Lund, Sweden.
   [German, Gisela] Hosp Onclg Prov, Dept Med Oncol, Cordoba, Argentina.
   [Gouin, Francois] Ctr Leon Berard, Dept Orthped Surg, Lyon, France.
   [Gronchi, Alessandro] Fdn IRCCS Ist Nazl Tumori, Dept Surg, Milan, Italy.
   [Stacchiotti, Silvia] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy.
   [Stacchiotti, Silvia] Univ Milan, Milan, Italy.
   [Jimenez-Brenes, Natalia] San Vicente Paul Hosp, Dept Med Oncol, Heredia, Costa Rica.
   [Kasper, Bernd] Mannheim Univ, Dept Med Oncol, Med Ctr, Mannheim, Germany.
   [Maki, Robert] Univ Penn, Abramson Canc Ctr, Dept Med Oncol, Perelman Sch Med, Philadelphia, PA USA.
   [Martinez-Said, Hector] Inst Nacl Cancerol, Dept Med Oncol, Mexico City, DF, Mexico.
   [Martinez-Tlahuel, Jorge Luis] Inst Nacl Cancerol, Dept Surg, Mexico City, DF, Mexico.
   [Morales-Perez, Jose Manuel] Univ Hosp Virgen Rocio, Radiol Dept, Seville, Spain.
   [Munoz-Casares, Francisco Cristobal] Univ Hosp Virgen Rocio, Dept Surg, Seville, Spain.
   [Ortiz-Cruz, Eduardo Jose] La Paz Univ Hosp, Orthoped Surg & Traumatol Dept, Madrid, Spain.
   [Palmerini, Emanuela] Rizzoli Orthped Inst, Dept Med Oncol, Bologna, Italy.
   [Patel, Shreyaskumar] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA.
   [Sunyach, Marie Pierre] Centre Leon Berard, Dept Radiat Therapy, Lyon, France.
   [Blay, Jean-Yves] Centre Leon Berard, Dept Med Oncol, Lyon, France.
   [Valverde, Claudia M.] Vall d'Hebron Hosp, Dept Med Oncol, Barcelona, Spain.
RP Martin-Broto, J (corresponding author), Univ Hosp Virgen Rocio, Dept Med Oncol, Inst Biomed Sevilla, LAB 214,C Antonio Maura Montaner S-N, Seville 41013, Spain.
EM jmartin@mustbesevilla.org
RI Palmerini, Emanuela/AAB-5920-2019; Maki, Robert G/J-9145-2019;
   Palmerini, Emanuela/ABE-6468-2020
OI Palmerini, Emanuela/0000-0003-3406-6705; Maki, Robert
   G/0000-0002-9853-2528; Reis, AlessanRSS/0000-0001-8486-7469;
   Martin-Broto, Javier/0000-0001-7350-6916; Moura,
   David/0000-0002-6514-2419; Nakagawa, Suely/0000-0002-9195-2087
FU European UnionEuropean Union (EU) [825806]
FX The authors would like to thank the SELNET project. SELNET has received
   funding from the European Union's Horizon 2020 research and innovation
   programme under grant agreement No. 825806.
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, pE936, DOI 10.1634/theoncologist.2020-0213
   [Anonymous], RES MAN OPT SAR COVI
   Bauer HCF, 2001, ACTA ORTHOP SCAND, V72, P150, DOI 10.1080/000164701317323408
   BENJAMIN R S, 1975, Medical and Pediatric Oncology, V1, P63, DOI 10.1002/mpo.2950010109
   Bernthal NM, 2012, CANCER-AM CANCER SOC, V118, P5888, DOI 10.1002/cncr.27651
   Berrak SG, 2005, PEDIATR BLOOD CANCER, V44, P215, DOI 10.1002/pbc.20228
   Bisogno G, 2018, LANCET ONCOL, V19, P1061, DOI 10.1016/S1470-2045(18)30337-1
   Buesa JM, 1998, ANN ONCOL, V9, P871, DOI 10.1023/A:1008474802882
   Burki TK, 2020, LANCET ONCOL, V21, P629, DOI 10.1016/S1470-2045(20)30217-5
   Casali PG, 2018, ANN ONCOL, V29, P51, DOI 10.1093/annonc/mdy096
   Casali PG, 2018, ANN ONCOL, V29, P79, DOI 10.1093/annonc/mdy310
   Casali PG, 2018, ANN ONCOL, V29, P267, DOI 10.1093/annonc/mdy320
   Cherny NI, 2017, ANN ONCOL, V28, P2340, DOI 10.1093/annonc/mdx310
   Cherny NI, 2015, ANN ONCOL, V26, P1547, DOI 10.1093/annonc/mdv249
   de Joode K, 2020, EUR J CANCER, V136, P132, DOI 10.1016/j.ejca.2020.06.019
   Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4
   Demetri GD, 2016, J CLIN ONCOL, V34, P786, DOI 10.1200/JCO.2015.62.4734
   Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1
   Demetri GD, 2012, CLIN CANCER RES, V18, P3170, DOI 10.1158/1078-0432.CCR-11-3005
   Diamond IR, 2014, J CLIN EPIDEMIOL, V67, P401, DOI 10.1016/j.jclinepi.2013.12.002
   Dinmohamed AG, 2020, LANCET ONCOL, V21, P750, DOI 10.1016/S1470-2045(20)30265-5
   Duffaud F, 2019, LANCET ONCOL, V20, P120, DOI 10.1016/S1470-2045(18)30742-3
   EILBER F, 1987, J CLIN ONCOL, V5, P21, DOI 10.1200/JCO.1987.5.1.21
   Frustaci S, 2001, J CLIN ONCOL, V19, P1238, DOI 10.1200/JCO.2001.19.5.1238
   Garcia-del-Muro X, 2011, J CLIN ONCOL, V29, P2528, DOI 10.1200/JCO.2010.33.6107
   Gentet JC, 1997, EUR J CANCER, V33, P232, DOI 10.1016/S0959-8049(96)00439-X
   Grier HE, 2003, NEW ENGL J MED, V348, P694, DOI 10.1056/NEJMoa020890
   Grignani G, 2015, LANCET ONCOL, V16, P98, DOI 10.1016/S1470-2045(14)71136-2
   Gronchi A, 2020, J CLIN ONCOL, V38, P2178, DOI 10.1200/JCO.19.03289
   Gronchi A, 2017, LANCET ONCOL, V18, P812, DOI 10.1016/S1470-2045(17)30334-0
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Hoekstra HJ, 2017, ANN SURG ONCOL, V24, P3279, DOI 10.1245/s10434-017-6003-3
   Hompland I, 2017, ACTA ONCOL, V56, P1317, DOI 10.1080/0284186X.2017.1330555
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Joensuu H, 2012, JAMA-J AM MED ASSOC, V307, P1265, DOI 10.1001/jama.2012.347
   Kamboj M, 2009, LANCET ONCOL, V10, P589, DOI 10.1016/S1470-2045(09)70069-5
   Kawai A, 2015, LANCET ONCOL, V16, P406, DOI 10.1016/S1470-2045(15)70098-7
   Lazzerini M, 2020, LANCET GLOB HEALTH, V8, pE641, DOI 10.1016/S2214-109X(20)30110-8
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lindner LH, 2018, INT J CANCER, V142, P2610, DOI 10.1002/ijc.31286
   Maki RG, 2007, J CLIN ONCOL, V25, P2755, DOI 10.1200/JCO.2006.10.4117
   Martin-Broto J, 2019, ONCOLOGIST, V24, pE338, DOI 10.1634/theoncologist.2018-0121
   Mathoulin-Pelissier S, 2014, ANN ONCOL, V25, P225, DOI 10.1093/annonc/mdt407
   McCabe MG, 2019, J CLIN ONCOL, V37
   Meazza C, 2010, PEDIATR BLOOD CANCER, V55, P617, DOI 10.1002/pbc.22596
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meyers PA, 2008, J CLIN ONCOL, V26, P633, DOI 10.1200/JCO.2008.14.0095
   Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004
   Mora J, 2017, BRIT J CANCER, V117, P767, DOI 10.1038/bjc.2017.252
   Moujaess E, 2020, CRIT REV ONCOL HEMAT, V150, DOI 10.1016/j.critrevonc.2020.102972
   National Institute for Health and Care Excellence, COVID 19 RAP GUID DE
   Oberlin O, 2012, J CLIN ONCOL, V30, P2457, DOI 10.1200/JCO.2011.40.3287
   OCHS JJ, 1978, CANCER TREAT REP, V62, P239
   Pautier P, 2012, ONCOLOGIST, V17, P1213, DOI 10.1634/theoncologist.2011-0467
   Ray-Coquard I, 2004, ANN ONCOL, V15, P307, DOI 10.1093/annonc/mdh058
   Rothermundt C, 2014, BRIT J CANCER, V110, P2420, DOI 10.1038/bjc.2014.200
   Rutkowski P, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0765-7
   Schoffski P, 2016, LANCET, V387, P1629, DOI 10.1016/S0140-6736(15)01283-0
   van de Haar J, 2020, NAT MED, V26, P665, DOI [10.1038/s41591-020-0874-8, 10.1038/s41591-020-0948-7]
   van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5
   van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7
   von Mehren M, 2019, ANN ONCOL, V30, pv851
   Voute PA, 1999, ANN ONCOL, V10, P1211, DOI 10.1023/A:1008361612767
   Waggoner J, 2016, ACAD MED, V91, P663, DOI 10.1097/ACM.0000000000001092
   Wheatley K, 2019, CTOS ANN M TOK JAP N, P48
   Williamson EJ, 2020, NATURE, DOI 10.1038/s41586-020-2521-4
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
NR 68
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD OCT
PY 2020
VL 25
IS 10
BP E1562
EP E1573
DI 10.1634/theoncologist.2020-0516
EA SEP 2020
PG 12
WC Oncology
SC Oncology
GA NX8OW
UT WOS:000571970000001
PM 32888360
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Masset, C
   Ville, S
   Halary, F
   Gaborit, B
   Bressolette-Bodin, C
   Deltombe, C
   Dujardin, A
   Jacquemont, L
   Lebot, S
   Kervella, D
   Figueres, L
   Cantarovich, D
   Giral, M
   Hourmant, M
   Blancho, G
   Garandeau, C
   Meurette, A
   Dantal, J
AF Masset, Christophe
   Ville, Simon
   Halary, Franck
   Gaborit, Benjamin
   Bressolette-Bodin, Celine
   Deltombe, Clement
   Dujardin, Amaury
   Jacquemont, Lola
   Lebot, Sabine
   Kervella, Delphine
   Figueres, Lucille
   Cantarovich, Diego
   Giral, Magali
   Hourmant, Maryvonne
   Blancho, Gilles
   Garandeau, Claire
   Meurette, Aurelie
   Dantal, Jacques
TI Resurgence of BK virus following Covid-19 in kidney transplant
   recipients
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article; Early Access
DE BK virus; Covid-19; kidney transplantation
ID POLYOMAVIRUS
AB Kidney transplant recipients have been supposed vulnerable to severe Covid-19 infection, due to their comorbidities and immunosuppressive therapies. Mild-term complications of Covid-19 are currently unknown, especially in this population. Herein, we report two cases of BKV replication after non-severe SARS-CoV-2 infection. The first case was a 59-year-old man, transplanted 3 months ago, with recent history of slight BKV viremia (3.3 log(10)DNA copies/ml). Despite strong reduction of maintenance immunosuppression (interruption of mycophenolic acid and important decrease of calcineurin inhibitors), BKV replication largely increased after Covid-19 and viremia persisted at 4.5 log copy/ml few months later. The second case was a 53-year-old woman, transplanted 15 years ago. She had a recent history of BKV cystitis, which resolved with a decrease of MPA dosage. Few weeks after SARS-CoV-2 infection, she presented recurrence of lower urinary tract symptoms. Our reports highlight that SARS-CoV-2 infection, even without severity, could disrupt immune system and particularly lymphocytes, thus leading to viral replication. Monitoring of viral replications after Covid-19 in kidney transplant recipients could permit to confirm these preliminary observations.
C1 [Masset, Christophe; Ville, Simon; Deltombe, Clement; Dujardin, Amaury; Jacquemont, Lola; Lebot, Sabine; Kervella, Delphine; Figueres, Lucille; Cantarovich, Diego; Giral, Magali; Hourmant, Maryvonne; Blancho, Gilles; Garandeau, Claire; Meurette, Aurelie; Dantal, Jacques] CHU Nantes, Nephrol & Transplantat Dept, 30 Bd Jean Monnet, Nantes 01, France.
   [Ville, Simon; Halary, Franck; Jacquemont, Lola; Kervella, Delphine; Figueres, Lucille; Cantarovich, Diego; Giral, Magali; Hourmant, Maryvonne; Blancho, Gilles; Dantal, Jacques] Univ Nantes, INSERM, UMR 1064, Ctr Rech Transplantat & Immunol, Nantes, France.
   [Gaborit, Benjamin] CHU Nantes, Infect Dis Dept, Nantes, France.
   [Bressolette-Bodin, Celine] CHU Nantes, Serv Virol, Nantes, France.
RP Masset, C (corresponding author), CHU Nantes, Nephrol & Transplantat Dept, 30 Bd Jean Monnet, Nantes 01, France.
EM christophe.masset@chu-nantes.fr
OI Masset, Christophe/0000-0002-7442-2164
FU  [CNIL 914184]
FX The authors would like to thank all medical staff healing patients
   during this particularly hard time of Covid-19 pandemic. Data were
   collected from the French DIVAT prospective cohort of kidney and/or
   pancreatic transplant recipients (, no. CNIL 914184). The analysis and
   interpretation of these data are the responsibility of the authors.
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Alattar R, 2020, J MED VIROL, V92, P2042, DOI 10.1002/jmv.25964
   Bethge T, 2015, J VIROL, V89, P3396, DOI 10.1128/JVI.03625-14
   Bressollette-Bodin C, 2005, AM J TRANSPLANT, V5, P1926, DOI 10.1111/j.1600-6143.2005.00934.x
   Chen YP, 2006, J VIROL, V80, P3495, DOI 10.1128/JVI.80.7.3495-3505.2006
   Drake KA, 2013, PEDIATR TRANSPLANT, V17, pE9, DOI 10.1111/petr.12026
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fishman JA, 2020, J AM SOC NEPHROL, V31, P1147, DOI 10.1681/ASN.2020040416
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Gardiner BJ, 2018, CLIN INFECT DIS, V67, P1395, DOI 10.1093/cid/ciy295
   Hotchkiss RS, 2009, NAT MED, V15, P496, DOI 10.1038/nm0509-496
   Ji D, 2020, CLIN INFECT DIS, V71, P1393, DOI 10.1093/cid/ciaa414
   Kamal M, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12814
   Limaye AP, 2008, JAMA-J AM MED ASSOC, V300, P413, DOI 10.1001/jama.300.4.413
   Liu ZM, 2020, J INFECTION, V81, P331, DOI 10.1016/j.jinf.2020.03.054
   Sawinski D, 2015, NEPHROL DIAL TRANSPL, V30, P209, DOI 10.1093/ndt/gfu023
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   XU B, 2020, J INFECTION, V81, pE51, DOI 10.1016/j.jinf.2020.04.012
NR 18
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
AR e13465
DI 10.1111/tid.13465
EA SEP 2020
PG 4
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA NS0TY
UT WOS:000571973800001
PM 32939955
OA Bronze
DA 2021-01-01
ER

PT J
AU Zhao, Q
   Seredych, M
   Precetti, E
   Shuck, CE
   Harhay, M
   Pang, R
   Shan, CX
   Gogotsi, Y
AF Zhao, Qi
   Seredych, Mykola
   Precetti, Eliot
   Shuck, Christopher E.
   Harhay, Meera
   Pang, Rui
   Shan, Chong-Xin
   Gogotsi, Yury
TI Adsorption of Uremic Toxins Using Ti3C2Tx MXene for Dialysate
   Regeneration
SO ACS NANO
LA English
DT Article
DE MXene; adsorption; kinetics; uremic toxins; dialysate
ID CARBON NANOTUBES; BIOSORPTION; BED; PREDICTION; NANOSHEETS; SORBENTS;
   BEHAVIOR; MODEL; BLUE
AB The COVID-19 pandemic has become a major worldwide crisis. Although respiratory symptoms are a key feature of the disease, many people who are hospitalized with COVID-19 also suffer acute kidney injury, a condition that exacerbates patient mortality and may have to be treated through renal replacement therapy. Much of the focus on hospital capacity during the pandemic has centered on the availability of ventilators. However, supplies for dialysis treatment, including dialysate, have also run dangerously low in hospitals at the epicenter of the pandemic. Therefore, there is an urgent need to develop materials that can efficiently and rapidly regenerate dialysate, removing toxins and restoring electrolyte concentrations so that this vital resource remains readily available. In this work, Ti3C2Tx a two-dimensional transition-metal carbide (MXene) that is known to efficiently adsorb urea, was used to remove creatinine and uric acid from an aqueous solution and dialysate, with a maximum adsorption capacity of 45.7 and 17.0 mg/g, respectively. We systematically analyzed and modeled the adsorption kinetics, isotherms, and thermodynamics, thus determining the rate-limiting step and adsorption mechanism. A fixed-bed column loaded with Ti3C2Tx was designed to further evaluate the adsorption performance under continuous fluid-flow conditions, mirroring conditions of continuous renal replacement therapy modalities. The maximum capacity and 50% breakthrough volume were calculated to further approach the practical application of Ti3C2Tx for removal of uremic toxins. Our findings suggest that Ti(3)C(2)T(x )has the potential to be used as an efficient sorbent for the regeneration of dialysate, allowing for accelerated dialysate regeneration by removing filtered toxins and leading to more portable dialysis devices.
C1 [Zhao, Qi; Seredych, Mykola; Precetti, Eliot; Shuck, Christopher E.; Gogotsi, Yury] Drexel Univ, AJ Drexel Nanomat Inst, Philadelphia, PA 19104 USA.
   [Zhao, Qi; Seredych, Mykola; Precetti, Eliot; Shuck, Christopher E.; Gogotsi, Yury] Drexel Univ, Mat Sci & Engn Dept, Philadelphia, PA 19104 USA.
   [Zhao, Qi] Chinese Acad Sci, Tech Inst Phys & Chem, Key Lab Photochem Convers & Optoelect Mat, Beijing 100190, Peoples R China.
   [Zhao, Qi; Pang, Rui; Shan, Chong-Xin] Zhengzhou Univ, Sch Phys & Microelect, Henan Key Lab Diamond Optoelect Mat & Devices, Key Lab Mat Phys,Minist Educ, Zhengzhou 450052, Peoples R China.
   [Harhay, Meera] Drexel Univ, Dept Med, Coll Med, Philadelphia, PA 19129 USA.
   [Harhay, Meera] Drexel Univ, Dept Epidemiol & Biostat, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA.
   [Harhay, Meera] Tower Hlth Syst, Tower Hlth Transplant Inst, W Reading, PA 19104 USA.
RP Gogotsi, Y (corresponding author), Drexel Univ, AJ Drexel Nanomat Inst, Philadelphia, PA 19104 USA.; Gogotsi, Y (corresponding author), Drexel Univ, Mat Sci & Engn Dept, Philadelphia, PA 19104 USA.
EM gogotsi@drexel.edu
RI ; Gogotsi, Yury/B-2167-2008
OI Shuck, Christopher/0000-0002-1274-8484; Gogotsi,
   Yury/0000-0001-9423-4032
FU U.S. National Science FoundationNational Science Foundation (NSF)
   [2035007]; Coulter-Drexel Translational Research Partnership; Office of
   the Director of National Intelligence (ODNI), Intelligence Advanced
   Research Projects Activity (IARPA) [2018-18071700007]; China Scholarship
   Council (CSC)China Scholarship Council; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [K23DK105207, R01DK124388]
FX Research on uremic toxins adsorption at Drexel University was supported
   by the U.S. National Science Foundation under grant no. 2035007 and
   Coulter-Drexel Translational Research Partnership. MXene development was
   supported by the Office of the Director of National Intelligence (ODNI),
   Intelligence Advanced Research Projects Activity (IARPA) (contract
   number 2018-18071700007). The views and conclusions contained herein are
   those of the authors and should not be interpreted as necessarily
   representing the official policies or endorsements, either expressed or
   implied, of the ODNI, IARPA, or the U.S. Government. The U.S. Government
   is authorized to reproduce and distribute reprints for Governmental
   purposes notwithstanding any copyright annotation thereon. Q.Z. was
   sponsored by the China Scholarship Council (CSC). M.H. is supported by
   NIH grants K23DK105207 and R01DK124388. We also thank Tyler Mathis for
   the SEM analysis. The calculations were performed at the Supercomputer
   Center in Zhengzhou University.
CR Aksu Z, 2004, PROCESS BIOCHEM, V39, P599, DOI 10.1016/S0032-9592(03)00132-8
   Alhabeb M, 2017, CHEM MATER, V29, P7633, DOI 10.1021/acs.chemmater.7b02847
   ANASORI B, 2017, NAT REV, V2, P2, DOI DOI 10.1038/NATREVMATS.2016.98
   Anasori B., 2019, 2D METAL CARBIDES NI
   Ash SR, 2009, SEMIN DIALYSIS, V22, P615, DOI 10.1111/j.1525-139X.2009.00657.x
   Bazaev N., 2018, WEARABLE TECHNOLOGIE, P91
   Cheah WK, 2017, J BIOMED MATER RES B, V105, P1232, DOI 10.1002/jbm.b.33475
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Ciou JH, 2019, SMALL, V15, DOI 10.1002/smll.201903281
   Dai C, 2017, CHEM MATER, V29, P8637, DOI 10.1021/acs.chemmater.7b02441
   Deysher G, 2020, ACS NANO, V14, P204, DOI 10.1021/acsnano.9b07708
   Field M. J., 2010, RENAL SYSTEM, P15
   Gogotsi Y, 2019, ACS NANO, V13, P8491, DOI 10.1021/acsnano.9b06394
   Halim J, 2016, APPL SURF SCI, V362, P406, DOI 10.1016/j.apsusc.2015.11.089
   Han RP, 2009, DESALINATION, V245, P284, DOI 10.1016/j.desal.2008.07.013
   Hayward D. O., 1964, CHEMISORPTION
   Ho YS, 1999, PROCESS BIOCHEM, V34, P451, DOI 10.1016/S0032-9592(98)00112-5
   Kabbashi NA, 2009, J ENVIRON SCI, V21, P539, DOI 10.1016/S1001-0742(08)62305-0
   Kooman JP, 2015, EXPERT REV MED DEVIC, V12, P373, DOI 10.1586/17434440.2015.1053466
   Levi MD, 2015, ADV ENERGY MATER, V5, DOI 10.1002/aenm.201400815
   Lima E., 2015, CARBON NANOMATERIALS, P33, DOI DOI 10.1007/978-3-319-18875-1_3
   Lin H, 2017, NANO LETT, V17, P384, DOI 10.1021/acs.nanolett.6b04339
   Liu Y, 2003, J BIOTECHNOL, V102, P233, DOI 10.1016/S0168-1656(03)00030-0
   Liu Y, 2008, SEP PURIF TECHNOL, V61, P229, DOI 10.1016/j.seppur.2007.10.002
   Liu Y, 2007, BIOCHEM ENG J, V35, P174, DOI 10.1016/j.bej.2007.01.020
   Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9
   Lukatskaya MR, 2013, SCIENCE, V341, P1502, DOI 10.1126/science.1241488
   Ma Y, 2020, COVID 19 HEMODIALYSI, DOI [10.1101/2020.02.24.20027201, DOI 10.1101/2020.02.24.20027201]
   Machado FM, 2012, PHYS CHEM CHEM PHYS, V14, P11139, DOI 10.1039/c2cp41475a
   Mashtalir O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2664
   Meng FY, 2018, ACS NANO, V12, P10518, DOI 10.1021/acsnano.8b06494
   MURISASCO A, 1986, CLIN NEPHROL, V26, pS53
   Naguib M, 2011, ADV MATER, V23, P4248, DOI 10.1002/adma.201102306
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   Peng QM, 2014, J AM CHEM SOC, V136, P4113, DOI 10.1021/ja500506k
   Plazinski W, 2009, ADV COLLOID INTERFAC, V152, P2, DOI 10.1016/j.cis.2009.07.009
   Regazzoni AE, 1998, LANGMUIR, V14, P868, DOI 10.1021/la970665n
   Ren CE, 2015, J PHYS CHEM LETT, V6, P4026, DOI 10.1021/acs.jpclett.5b01895
   Sag Y, 2000, BIOCHEM ENG J, V6, P145, DOI 10.1016/S1369-703X(00)00083-8
   Seredych M., 2018, ACS APPL BIOMATER, V1, P436
   Seredych M, 2019, CHEM MATER, V31, P3324, DOI 10.1021/acs.chemmater.9b00397
   Sokol M, 2019, TRENDS CHEM, V1, P210, DOI 10.1016/j.trechm.2019.02.016
   Vanholder R, 2003, KIDNEY INT, V63, P1934, DOI 10.1046/j.1523-1755.2003.00924.x
   Wang HW, 2016, CHEM MATER, V28, P349, DOI 10.1021/acs.chemmater.5b04250
   Wang JL, 2020, J HAZARD MATER, V390, DOI 10.1016/j.jhazmat.2020.122156
   Weber WJ, 1963, J SANIT ENG DIV ASCE, V89, P31, DOI DOI 10.1080/002689796173345
   Worch E, 2008, J WATER SUPPLY RES T, V57, P171, DOI 10.2166/aqua.2008.100
NR 47
TC 0
Z9 0
U1 26
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD SEP 22
PY 2020
VL 14
IS 9
BP 11787
EP 11798
DI 10.1021/acsnano.0c04546
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA NZ2WR
UT WOS:000576958900066
PM 32830949
DA 2021-01-01
ER

PT J
AU Laurini, E
   Marson, D
   Aulic, S
   Fermeglia, M
   Pricl, S
AF Laurini, Erik
   Marson, Domenico
   Aulic, Suzana
   Fermeglia, Maurizio
   Pricl, Sabrina
TI Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2
   Spike Protein/Angiotensin-Converting Enzyme 2 Complex
SO ACS NANO
LA English
DT Article
DE SARS-CoV-2 spike protein; ACE2; receptor-binding domain; molecular
   dynamics; computational alanine-scanning mutagenesis; molecular
   mechanics/Poisson-Boltzmann surface area; free energy of binding
ID INTERACTION ENTROPY; KIT MUTATIONS; BCR-ABL; INHIBITOR; RECEPTOR;
   RESISTANCE; BINDING; GIST; CORONAVIRUS; DASATINIB
AB The recent emergence of the pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent for the coronavirus disease 2019 (COVID-19), is causing a global pandemic that poses enormous challenges to global public health and economies. SARS-CoV-2 host cell entry is mediated by the interaction of the viral transmembrane spike glycoprotein (S-protein) with the angiotensin-converting enzyme 2 gene (ACE2), an essential counter-regulatory carboxypeptidase of the renin-angiotensin hormone system that is a critical regulator of blood volume, systemic vascular resistance, and thus cardiovascular homeostasis. Accordingly, this work reports an atomistic-based, reliable in silico structural and energetic framework of the interactions between the receptor-binding domain of the SARS-CoV-2 S-protein and its host cellular receptor ACE2 that provides qualitative and quantitative insights into the main molecular determinants in virus/receptor recognition. In particular, residues D38, K31, E37, K353, and Y41 on ACE2 and Q498, T500, and R403 on the SARS-CoV-2 S-protein receptor-binding domain are determined as true hot spots, contributing to shaping and determining the stability of the relevant protein-protein interface. Overall, these results could be used to estimate the binding affinity of the viral protein to different allelic variants of ACE2 receptors discovered in COVID-19 patients and for the effective structure-based design and development of neutralizing antibodies, vaccines, and protein/protein inhibitors against this terrible new coronavirus.
C1 [Laurini, Erik; Marson, Domenico; Aulic, Suzana; Fermeglia, Maurizio; Pricl, Sabrina] Univ Trieste, Mol Biol & Nanotechnol Lab MolBNL UniTS, DEA, I-34127 Trieste, Italy.
   [Pricl, Sabrina] Univ Lodz, Fac Biol & Environm Protect, Dept Gen Biophys, PL-90136 Lodz, Poland.
RP Pricl, S (corresponding author), Univ Trieste, Mol Biol & Nanotechnol Lab MolBNL UniTS, DEA, I-34127 Trieste, Italy.; Pricl, S (corresponding author), Univ Lodz, Fac Biol & Environm Protect, Dept Gen Biophys, PL-90136 Lodz, Poland.
EM sabrina.pricl@di3.units.it
RI Pricl, Sabrina/M-7493-2015
OI Pricl, Sabrina/0000-0001-8380-4474
FU CINECA Supercomputing CenterCINECA, Italy [HP10C9HMOT]
FX We acknowledge CINECA Supercomputing Center for awarding us access to
   Marconi100 based at CINECA (Bologna, Italy) (COVID19 Computational
   Alanine Scanning to Discover Genetic Susceptibility (CovAdis), HPC
   access Grant No. HP10C9HMOT).
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Bozzi F., 2013, LAB INVEST
   Brambilla L, 2015, MOL ONCOL, V9, P1194, DOI 10.1016/j.molonc.2015.02.012
   Brune S, 2014, BIOCHEMISTRY-US, V53, P2993, DOI 10.1021/bi401575g
   Case D. A., 2019, AMBER 2019
   Cavanagh D, 2005, BIRK ADV INFECT DIS, P1
   Colombo C, 2017, MOL ONCOL, V11, P1495, DOI 10.1002/1878-0261.12101
   Conca E, 2013, MOL ONCOL, V7, P756, DOI 10.1016/j.molonc.2013.02.019
   Conca E, 2009, MOL CANCER THER, V8, P2491, DOI 10.1158/1535-7163.MCT-09-0662
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Dileo P, 2011, INT J CANCER, V128, P983, DOI 10.1002/ijc.25418
   Ferrone M, 2006, MOL CANCER THER, V5, P1467, DOI 10.1158/1535-7163.MCT-06-0012
   Genini D, 2017, P NATL ACAD SCI USA, V114, pE4924, DOI 10.1073/pnas.1615730114
   Gibbons DL, 2014, P NATL ACAD SCI USA, V111, P3550, DOI 10.1073/pnas.1321173111
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Greger M, 2007, CRIT REV MICROBIOL, V33, P243, DOI 10.1080/10408410701647594
   Hajer Z, 2017, ONCOTARGET, V8, P77317, DOI 10.18632/oncotarget.20469
   Han YX, 2020, ACS NANO, V14, P5143, DOI 10.1021/acsnano.0c02857
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Laurini E, 2013, MOL ONCOL, V7, P968, DOI 10.1016/j.molonc.2013.06.001
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2013, ANTIVIR RES, V100, P246, DOI 10.1016/j.antiviral.2013.08.014
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu X, 2018, J CHEM THEORY COMPUT, V14, P1772, DOI 10.1021/acs.jctc.7b01295
   McAuliffe JC, 2008, MOL ONCOL, V2, P161, DOI 10.1016/j.molonc.2008.05.002
   Morgan Anna, 2015, Mutat Res, V781, P32, DOI 10.1016/j.mrfmmm.2015.09.002
   Negri T, 2009, JNCI-J NATL CANCER I, V101, P194, DOI 10.1093/jnci/djn477
   Perfetti V, 2017, ONCOTARGET, V8, P56158, DOI 10.18632/oncotarget.19341
   Pierotti MA, 2011, NAT REV CLIN ONCOL, V8, P161, DOI 10.1038/nrclinonc.2011.3
   Pricl S, 2005, MOL CANCER THER, V4, P1167, DOI 10.1158/1535-7163.MCT-05-0101
   Pricl S, 2015, MOL ONCOL, V9, P389, DOI 10.1016/j.molonc.2014.09.003
   Qiu L. Q., 2018, REV COMPUT MOL SCI, V8
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Simoes ICM, 2017, J CHEM INF MODEL, V57, P60, DOI 10.1021/acs.jcim.6b00378
   Sun ZX, 2017, J CHEM PHYS, V146, DOI 10.1063/1.4978893
   Tamborini E, 2006, ONCOGENE, V25, P6140, DOI 10.1038/sj.onc.1209639
   Towler P, 2004, J BIOL CHEM, V279, P17996, DOI 10.1074/jbc.M311191200
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang EC, 2019, CHEM REV, V119, P9478, DOI 10.1021/acs.chemrev.9b00055
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Woodman SE, 2009, MOL CANCER THER, V8, P2079, DOI 10.1158/1535-7163.MCT-09-0459
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yan Y, 2017, J CHEM INF MODEL, V57, P1112, DOI 10.1021/acs.jcim.6b00734
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 48
TC 1
Z9 1
U1 5
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD SEP 22
PY 2020
VL 14
IS 9
BP 11821
EP 11830
DI 10.1021/acsnano.0c04674
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA NZ2WR
UT WOS:000576958900069
PM 32833435
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Borquaye, LS
   Gasu, EN
   Ampomah, GB
   Kyei, LK
   Amarh, MA
   Mensah, CN
   Nartey, D
   Commodore, M
   Adomako, AK
   Acheampong, P
   Mensah, JO
   Mormor, DB
   Aboagye, CI
AF Borquaye, Lawrence Sheringham
   Gasu, Edward Ntim
   Ampomah, Gilbert Boadu
   Kyei, Lois Kwane
   Amarh, Margaret Amerley
   Mensah, Caleb Nketia
   Nartey, Daniel
   Commodore, Michael
   Adomako, Abigail Kusiwaa
   Acheampong, Philipina
   Mensah, Jehoshaphat Oppong
   Mormor, David Batsa
   Aboagye, Caleb Impraim
TI Alkaloids from Cryptolepis sanguinolenta as Potential Inhibitors of
   SARS-CoV-2 Viral Proteins: An In Silico Study
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID ANTIPLASMODIAL ACTIVITY; SIMULATION; BINDING; SARS
AB The ongoing global pandemic caused by the human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions of people and claimed hundreds of thousands of lives. The absence of approved therapeutics to combat this disease threatens the health of all persons on earth and could cause catastrophic damage to society. New drugs are therefore urgently required to bring relief to people everywhere. In addition to repurposing existing drugs, natural products provide an interesting alternative due to their widespread use in all cultures of the world. In this study, alkaloids fromCryptolepis sanguinolentahave been investigated for their ability to inhibit two of the main proteins in SARS-CoV-2, the main protease and the RNA-dependent RNA polymerase, usingin silicomethods. Molecular docking was used to assess binding potential of the alkaloids to the viral proteins whereas molecular dynamics was used to evaluate stability of the binding event. The results of the study indicate that all 13 alkaloids bind strongly to the main protease and RNA-dependent RNA polymerase with binding energies ranging from -6.7 to -10.6 kcal/mol. In particular, cryptomisrine, cryptospirolepine, cryptoquindoline, and biscryptolepine exhibited very strong inhibitory potential towards both proteins. Results from the molecular dynamics study revealed that a stable protein-ligand complex is formed upon binding. Alkaloids fromCryptolepis sanguinolentatherefore represent a promising class of compounds that could serve as lead compounds in the search for a cure for the corona virus disease.
C1 [Borquaye, Lawrence Sheringham; Gasu, Edward Ntim; Ampomah, Gilbert Boadu; Amarh, Margaret Amerley; Mensah, Caleb Nketia; Nartey, Daniel; Commodore, Michael; Adomako, Abigail Kusiwaa; Acheampong, Philipina; Mensah, Jehoshaphat Oppong; Mormor, David Batsa; Aboagye, Caleb Impraim] Kwame Nkrumah Univ Sci & Technol, Dept Chem, Kumasi, Ghana.
   [Borquaye, Lawrence Sheringham; Gasu, Edward Ntim; Kyei, Lois Kwane] Kwame Nkrumah Univ Sci & Technol, Cent Lab, Kumasi, Ghana.
RP Borquaye, LS (corresponding author), Kwame Nkrumah Univ Sci & Technol, Dept Chem, Kumasi, Ghana.; Borquaye, LS (corresponding author), Kwame Nkrumah Univ Sci & Technol, Cent Lab, Kumasi, Ghana.
EM lsborquaye.sci@knust.edu.gh
OI Nketia Mensah, Caleb/0000-0002-2290-3230; Mensah,
   Jehoshaphat/0000-0003-4676-9299
FU Department of Chemistry, Kwame Nkrumah University of Science and
   Technology, Kumasi; Central Laboratory, Kwame Nkrumah University of
   Science and Technology, Kumasi
FX The authors acknowledge the Department of Chemistry and the Central
   Laboratory, Kwame Nkrumah University of Science and Technology, Kumasi,
   for their support for this study.
CR Ajayi A. F., 2012, International Journal of Medicine and Biomedical Research, V1, P62
   Ansah C., 2008, Journal of Pharmacology and Toxicology, V3, P335
   Ansah C, 2013, Ghana Med J, V47, P137
   Ansah C, 2002, TOXICOL SCI, V70, P245, DOI 10.1093/toxsci/70.2.245
   Ansah C., 2009, J VET MED ANIMAL HLT, V1, P11
   Antunes DA, 2017, CANCER RES, V77, pE55, DOI 10.1158/0008-5472.CAN-17-0511
   Bierer DE, 1998, J MED CHEM, V41, P2754, DOI 10.1021/jm970735n
   Boakye-Yiadom K., 2008, Q J CRUDE DRUG RES, V17, P78, DOI 10.3109/13880207909067453
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chen G, 2005, J COMB CHEM, V7, P398, DOI 10.1021/cc049866h
   Cimanga K, 1997, J NAT PROD, V60, P688, DOI 10.1021/np9605246
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dong J, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0283-x
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gyebi GA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764868
   Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Karageorgis G, 2020, NAT CHEM, V12, P227, DOI 10.1038/s41557-019-0411-x
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Laskowski RA, 2001, NUCLEIC ACIDS RES, V29, P221, DOI 10.1093/nar/29.1.221
   Lehmann KC, 2015, NUCLEIC ACIDS RES, V43, P8416, DOI 10.1093/nar/gkv838
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Monto A.S., 2014, INFECT HUM EPIDEMIOL, V199, P223, DOI [10.1007/978-1-4899-7448-81-0, DOI 10.1007/978-1-4899-7448-81-0]
   Osafo N, 2017, ADV PHARMACOL SCI, V2017, DOI 10.1155/2017/3026370
   Pantsar T, 2018, MOLECULES, V23, DOI 10.3390/molecules23081899
   Park M, 2020, EUR J IMMUNOL, V50, P308, DOI 10.1002/eji.202070035
   Paulo A, 2000, PLANTA MED, V66, P30, DOI 10.1055/s-2000-11106
   PAULO A, 1994, J ETHNOPHARMACOL, V44, P73, DOI 10.1016/0378-8741(94)90071-X
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Silva O, 1997, INT J PHARMACOGN, V35, P12, DOI 10.1076/phbi.35.1.12.13264
   Swanson JMJ, 2004, BIOPHYS J, V86, P67, DOI 10.1016/S0006-3495(04)74084-9
   Huynh T, 2020, J PHYS CHEM LETT, V11, P4413, DOI 10.1021/acs.jpclett.0c00994
   Tona L, 1998, J ETHNOPHARMACOL, V61, P57, DOI 10.1016/S0378-8741(98)00015-4
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   World Health Organization, 2005, NAT POL TRAD MED REG
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   Yang Jing-Fang, 2020, Brief Bioinform, V21, P2206, DOI 10.1093/bib/bbz141
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhang L., 2020, BINDING MECH REMDESI, DOI [10. 20944/preprints202003.0267.v1., DOI 10.20944/PREPRINTS202003.0267.V1]
NR 53
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD SEP 22
PY 2020
VL 2020
AR 5324560
DI 10.1155/2020/5324560
PG 14
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA OB2FS
UT WOS:000578289700002
PM 33029513
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dearlove, B
   Lewitus, E
   Bai, HJ
   Li, YF
   Reeves, DB
   Joyce, MG
   Scott, PT
   Amare, MF
   Vasan, S
   Michael, NL
   Modjarrad, K
   Rolland, M
AF Dearlove, Bethany
   Lewitus, Eric
   Bai, Hongjun
   Li, Yifan
   Reeves, Daniel B.
   Joyce, M. Gordon
   Scott, Paul T.
   Amare, Mihret F.
   Vasan, Sandhya
   Michael, Nelson L.
   Modjarrad, Kayvon
   Rolland, Morgane
TI A SARS-CoV-2 vaccine candidate would likely match all currently
   circulating variants
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE SARS-CoV-2; evolution; vaccine
ID CORONAVIRUS; MODEL; TRANSMISSION; GLYCOPROTEIN; MUTATIONS; DIVERSITY;
   ALGORITHM; EVOLUTION; INFECTION; GENOME
AB The magnitude of the COVID-19 pandemic underscores the urgency for a safe and effective vaccine. Many vaccine candidates focus on the Spike protein, as it is targeted by neutralizing antibodies and plays a key role in viral entry. Here we investigate the diversity seen in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequences and compare it to the sequence on which most vaccine candidates are based. Using 18,514 sequences, we perform phylogenetic, population genetics, and structural bioinformatics analyses. We find limited diversity across SARS-CoV-2 genomes: Only 11 sites show polymorphisms in >5% of sequences; yet two mutations, including the D614G mutation in Spike, have already become consensus. Because SARS-CoV-2 is being transmitted more rapidly than it evolves, the viral population is becoming more homogeneous, with a median of seven nucleotide substitutions between genomes. There is evidence of purifying selection but little evidence of diversifying selection, with substitution rates comparable across structural versus nonstructural genes. Finally, the Wuhan-Hu-1 reference sequence for the Spike protein, which is the basis for different vaccine candidates, matches optimized vaccine inserts, being identical to an ancestral sequence and one mutation away from the consensus. While the rapid spread of the D614G mutation warrants further study, our results indicate that drift and bottleneck events can explain the minimal diversity found among SARS-CoV-2 sequences. These findings suggest that a single vaccine candidate should be efficacious against currently circulating lineages.
C1 [Dearlove, Bethany; Lewitus, Eric; Bai, Hongjun; Li, Yifan; Joyce, M. Gordon; Scott, Paul T.; Amare, Mihret F.; Modjarrad, Kayvon; Rolland, Morgane] Walter Reed Army Inst Res, Emerging Infect Dis Branch, Silver Spring, MD 20910 USA.
   [Dearlove, Bethany; Lewitus, Eric; Bai, Hongjun; Li, Yifan; Vasan, Sandhya; Rolland, Morgane] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA.
   [Dearlove, Bethany; Lewitus, Eric; Bai, Hongjun; Li, Yifan; Joyce, M. Gordon; Amare, Mihret F.; Vasan, Sandhya; Rolland, Morgane] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA.
   [Dearlove, Bethany; Lewitus, Eric; Bai, Hongjun; Li, Yifan; Vasan, Sandhya; Michael, Nelson L.; Modjarrad, Kayvon; Rolland, Morgane] Walter Reed Army Inst Res, Ctr Infect Dis Res, Silver Spring, MD 20910 USA.
   [Reeves, Daniel B.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA.
RP Modjarrad, K; Rolland, M (corresponding author), Walter Reed Army Inst Res, Emerging Infect Dis Branch, Silver Spring, MD 20910 USA.; Rolland, M (corresponding author), Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA.; Rolland, M (corresponding author), Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA.; Modjarrad, K; Rolland, M (corresponding author), Walter Reed Army Inst Res, Ctr Infect Dis Res, Silver Spring, MD 20910 USA.
EM kayvon.modjarrad.civ@mail.mil; mrolland@hivresearch.org
OI Bai, Hongjun/0000-0002-3501-3974; Reeves, Daniel/0000-0001-5684-9538;
   Michael, Nelson/0000-0001-5882-5548; Dearlove,
   Bethany/0000-0003-3653-4592
FU US Department of Defense Health AgencyUnited States Department of
   Defense; US Department of the Army; Henry M. Jackson Foundation for the
   Advancement of Military Medicine, Inc. [W81XWH-18-2-0040]; US Department
   of the Army [W81XWH-18-2-0040]
FX We gratefully acknowledge the authors and originating and submitting
   laboratories of the sequences from GISAID's EpiCov Database on which
   this research is based. We thank Lionel Conde, Robert Gramzinski, Joshua
   Herbeck, Melanie Merbah, Thembi Mdluli, Lydie Trautmann, Douglas Whalin,
   and Suzanne Wollen-Roberts. We also thank two reviewers for critical
   improvements of the original manuscript. This work was funded by US
   Department of Defense Health Agency and the US Department of the Army
   and a cooperative agreement between The Henry M. Jackson Foundation for
   the Advancement of Military Medicine, Inc., and the US Department of the
   Army (W81XWH-18-2-0040). The views expressed are those of the authors
   and should not be construed to represent the positions of the US Army,
   the Department of Defense, or the Department of Health and Human
   Services.
CR Andersen KG, 2015, CELL, V162, P738, DOI 10.1016/j.cell.2015.07.020
   Colijn C, 2018, SYST BIOL, V67, P113, DOI 10.1093/sysbio/syx046
   Dearlove BL, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004312
   Dietzel E., 2017, J VIROL, V91, DOI DOI 10.1128/JVI.01913-16
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Duchene S, 2020, BIORXIV, DOI [DOI 10.1101/2020.05.04.077735, 10.1101/2020.05.04.077735]
   Duchene S, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.0732
   Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Fonville JM, 2014, SCIENCE, V346, P996, DOI 10.1126/science.1256427
   Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441
   Hu J., 2020, BIORXIV, DOI [10.1101/2020.06.20.161323, DOI 10.1101/2020.06.20.161323]
   Hurley CK, 2020, HLA, V95, P516, DOI 10.1111/tan.13811
   Jost L, 2008, MOL ECOL, V17, P4015, DOI 10.1111/j.1365-294X.2008.03887.x
   Kalyaanamoorthy S, 2017, NAT METHODS, V14, P587, DOI [10.1038/NMETH.4285, 10.1038/nmeth.4285]
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kryazhimskiy S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000304
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300
   Latinne Alice, 2020, bioRxiv, DOI 10.1101/2020.05.31.116061
   Law JLM, 2018, J VIROL, V92, DOI 10.1128/JVI.02141-17
   Lee JM, 2019, ELIFE, V8, DOI 10.7554/eLife.49324
   Lewitus E, 2019, VIRUS EVOL, V5, DOI 10.1093/ve/vez044
   Lewitus E, 2016, SYST BIOL, V65, P495, DOI 10.1093/sysbio/syv116
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Luksza M, 2014, NATURE, V507, P57, DOI 10.1038/nature13087
   Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725
   Marzi A, 2018, CELL REP, V23, P1806, DOI 10.1016/j.celrep.2018.04.027
   Morlon H, 2016, METHODS ECOL EVOL, V7, P589, DOI 10.1111/2041-210X.12526
   Murrell B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002764
   Neher RA, 2014, ELIFE, V3, DOI 10.7554/eLife.03568
   NEI M, 1973, P NATL ACAD SCI USA, V70, P3321, DOI 10.1073/pnas.70.12.3321
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Ozono S, 2020, BIORXIV, DOI [10.1101/2020.06.15.151779, DOI 10.1101/2020.06.15.151779]
   Pages H., 2018, BIOSTRINGS EFFICIENT
   Paradis E, 2019, BIOINFORMATICS, V35, P526, DOI 10.1093/bioinformatics/bty633
   Park DJ, 2015, CELL, V161, P1516, DOI 10.1016/j.cell.2015.06.007
   Pond SLK, 2011, MOL BIOL EVOL, V28, P3033, DOI 10.1093/molbev/msr125
   Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   Pupko T, 2000, MOL BIOL EVOL, V17, P890, DOI 10.1093/oxfordjournals.molbev.a026369
   Rambaut A, 2020, DYNAMIC NOMENCLATURE, DOI [10.1101/2020.04.17.046086, DOI 10.1101/2020.04.17.046086]
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   Ueda MT, 2017, GENES CELLS, V22, P148, DOI 10.1111/gtc.12463
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang L, 2018, J VIROL, V92, DOI 10.1128/JVI.01060-18
   Wang MK, 2017, CELL HOST MICROBE, V21, P367, DOI 10.1016/j.chom.2017.02.002
   Whitlock MC, 2011, MOL ECOL, V20, P1083, DOI 10.1111/j.1365-294X.2010.04996.x
   Winter DJ, 2012, MOL ECOL RESOUR, V12, P1158, DOI 10.1111/j.1755-0998.2012.03174.x
   Worobey Michael, 2020, bioRxiv, DOI 10.1101/2020.05.21.109322
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiao KP, 2020, NATURE, V583, P286, DOI 10.1038/s41586-020-2313-x
   Yu GC, 2018, MOL BIOL EVOL, V35, P3041, DOI 10.1093/molbev/msy194
   Yurkovetskiy L., 2020, STRUCTURAL FUNCTIONA, DOI DOI 10.1101/2020.07.04.187757V2
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
   Zhao ZM, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-21
   Zhou H, 2020, CURR BIOL, V30, P2196, DOI 10.1016/j.cub.2020.05.023
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 65
TC 1
Z9 1
U1 2
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 22
PY 2020
VL 117
IS 38
BP 23652
EP 23662
DI 10.1073/pnas.2008281117
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NX7LF
UT WOS:000575887200001
PM 32868447
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Khrustalev, VV
   Giri, R
   Khrustaleva, TA
   Kapuganti, SK
   Stojarov, AN
   Poboinev, VV
AF Khrustalev, Vladislav Victorovich
   Giri, Rajanish
   Khrustaleva, Tatyana Aleksandrovna
   Kapuganti, Shivani Krishna
   Stojarov, Aleksander Nicolaevich
   Poboinev, Victor Vitoldovich
TI Translation-Associated Mutational U-Pressure in the First ORF of
   SARS-CoV-2 and Other Coronaviruses
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE COVID-19; SARS; MERS; mutational pressure; cytosine deamination
ID CYTOSINE-DEAMINATION; RNA; TRANSCRIPTION; REPLICATION; OXIDATION; CELLS
AB Within 4 months of the ongoing COVID-19 pandemic caused by SARS-CoV-2, more than 250 nucleotide mutations have been detected in ORF1ab of the virus isolated from infected persons from different parts of the globe. These observations open up an obvious question about the rate and direction of mutational pressure for further vaccine and therapeutics designing. In this study, we did a comparative analysis of ORF1a and ORF1b by using the first isolate (Wuhan strain) as the parent sequence. We observed that most of the nucleotide mutations are C to U transitions. The rate of synonymous C to U transitions is significantly higher than the rate of non-synonymous ones, indicating negative selection on amino acid substitutions. Further, trends in nucleotide usage bias have been investigated in 49 coronaviruses species. A strong bias in nucleotide usage in fourfold degenerate sites toward uracil residues is seen in ORF1ab of all the studied coronaviruses: both in the ORF1a and in the ORF1b translated thanks to the programmed ribosomal frameshifting that has an efficiency of 14 - 45% in different species. A more substantial mutational U-pressure is observed in ORF1a than in ORF1b perhaps because ORF1a is translated more frequently than ORF1b. Mutational U-pressure is there even in ORFs that are not translated from genomic RNA plus strands, but the bias is weaker than in ORF1ab. Unlike other nucleotide mutations, mutational U-pressure caused by cytosine deamination, mostly occurring during the RNA plus strand replication and also translation, cannot be corrected by the proof-reading machinery of coronaviruses. The knowledge generated on the mutational U-pressure that becomes stronger during translation of viral RNA plus strands has implications for vaccine and nucleoside analog development for treating COVID-19 and other coronavirus infections.
C1 [Khrustalev, Vladislav Victorovich; Poboinev, Victor Vitoldovich] Belarusian State Med Univ, Dept Gen Chem, Minsk, BELARUS.
   [Giri, Rajanish; Kapuganti, Shivani Krishna] Indian Inst Technol Mandi, Sch Basic Sci, Mandi, Himachal Prades, India.
   [Khrustaleva, Tatyana Aleksandrovna] Natl Acad Sci Belarus, Inst Physiol, Biochem Grp Multidisciplinary Diagnost Lab, Minsk, BELARUS.
   [Stojarov, Aleksander Nicolaevich] Belarusian State Med Univ, Dept Radiat Med & Ecol, Minsk, BELARUS.
RP Khrustalev, VV (corresponding author), Belarusian State Med Univ, Dept Gen Chem, Minsk, BELARUS.
EM vvkhrustalev@mail.ru
OI Poboinev, Victor/0000-0002-5092-0249
CR Agostini ML, 2019, J VIROL, V93, DOI 10.1128/JVI.01348-19
   [Anonymous], 2020, WHO SIT REP
   Baranov PV, 2005, VIROLOGY, V332, P498, DOI 10.1016/j.virol.2004.11.038
   Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501
   Bouvet M, 2012, P NATL ACAD SCI USA, V109, P9372, DOI 10.1073/pnas.1201130109
   BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4
   Chi PB, 2015, STAT APPL GENET MOL, V14, P375, DOI 10.1515/sagmb-2014-0078
   Diaz-Lopez I, 2019, ELIFE, V8, DOI 10.7554/eLife.48246
   Fidaleo M, 2016, ONCOTARGET, V7, P28711, DOI 10.18632/oncotarget.7377
   FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015
   Gros L, 2002, ONCOGENE, V21, P8905, DOI 10.1038/sj.onc.1206005
   Hendriks G, 2010, CELL CYCLE, V9, P2300, DOI 10.4161/cc.9.12.11987
   HEROLD J, 1993, NUCLEIC ACIDS RES, V21, P5838
   Hu HT, 2016, NUCLEIC ACIDS RES, V44, P256, DOI 10.1093/nar/gkv1307
   Huang C, 2011, J VIROL, V85, P638, DOI 10.1128/JVI.01806-10
   Irigoyen N, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005473
   Joffe A, 2003, CHEM RES TOXICOL, V16, P1528, DOI 10.1021/tx034142t
   Kandeel M, 2020, J MED VIROL, V92, P660, DOI 10.1002/jmv.25754
   Kelly JA, 2020, J BIOL CHEM, V295, P10741, DOI 10.1074/jbc.AC120.013449
   Khrustalev VV, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00044
   Khrustalev VV, 2020, INFECT GENET EVOL, V77, DOI 10.1016/j.meegid.2019.104100
   Khrustalev VV, 2019, MUTAT RES-FUND MOL M, V815, P1, DOI 10.1016/j.mrfmmm.2019.03.001
   Khrustalev VV, 2012, TUBERCULOSIS, V92, P333, DOI 10.1016/j.tube.2012.03.004
   Khrustalev VV, 2010, IMMUNOL INVEST, V39, P551, DOI 10.3109/08820131003706313
   Lauber C, 2012, ARCH VIROL, V157, P1623, DOI 10.1007/s00705-012-1295-x
   Lobry JR, 2002, GENOME BIOL, V3
   Mauger DM, 2019, P NATL ACAD SCI USA, V116, P24075, DOI 10.1073/pnas.1908052116
   Nijmeijer BM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01599
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Nga PT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002215
   Plant EP, 2013, VIRUSES-BASEL, V5, P279, DOI 10.3390/v5010279
   Polak P, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-187
   Qu XH, 2012, P NATL ACAD SCI USA, V109, P14458, DOI 10.1073/pnas.1208950109
   Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10
   Sato K, 2009, NUCLEIC ACIDS RES, V37, pW277, DOI 10.1093/nar/gkp367
   Sharma S, 2017, PEERJ, V5, DOI 10.7717/peerj.4136
   Sheikh A, 2020, J VIROL METHODS, V277, DOI 10.1016/j.jviromet.2019.113806
   Shen Z, 2019, J BIOL CHEM, V294, P13606, DOI 10.1074/jbc.RA119.009713
   Smith EC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003565
   Smith HC, 2017, RNA BIOL, V14, P1153, DOI 10.1080/15476286.2016.1259783
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Sola I, 2005, J VIROL, V79, P2506, DOI 10.1128/JVI.79.4.2506-2516.2005
   Stewart H, 2018, J VIROL, V92, DOI 10.1128/JVI.00589-18
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sueoka N, 2002, GENE, V300, P141, DOI 10.1016/S0378-1119(02)01046-6
   Tanaka T, 2012, J VIROL, V86, P11128, DOI 10.1128/JVI.01700-12
   Xie P, 2017, INT J BIOL SCI, V13, P712, DOI 10.7150/ijbs.19508
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
   Zuniga S, 2004, J VIROL, V78, P980, DOI 10.1128/JVI.78.2.980-994.2004
NR 49
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD SEP 22
PY 2020
VL 11
AR 559165
DI 10.3389/fmicb.2020.559165
PG 13
WC Microbiology
SC Microbiology
GA NW6TM
UT WOS:000575148100001
PM 33072018
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Goyal, DK
   Mansab, F
AF Goyal, Daniel Kumar
   Mansab, Fatma
TI The CHIR Score for Evaluating the Hyperimmune Response in COVID-19: A
   Preliminary Concept
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE COVID-19; SARS-CoV-2; 2019-nCov; hyperimmune; cytokine storm;
   corticosteroids; treatment; inflammation
ID DIAGNOSIS; THERAPY; SARS
AB Similar to SARS and MERS, the host immune response to COVID-19 is implicated in the severity of the disease itself. Here, we investigate the possible use of scoring systems to help guide clinicians in their determination as to when to commence immunosuppressive treatment in COVID-19. We utilized the relatively established clinical and biochemical severity indicators from large cohort studies to develop a potential scoring system for the hyperimmune response in COVID-19.
C1 [Goyal, Daniel Kumar] Univ Gibraltar, Gibraltar COVID 19 Res Grp, Gibraltar, Gibraltar.
   [Goyal, Daniel Kumar; Mansab, Fatma] St Bernards Hosp, Acute Gen Med, Dept Med, Gibraltar Hlth Author, Gibraltar, Gibraltar.
   [Mansab, Fatma] Publ Hlth Gibraltar, Hlth Advisory Unit, Gibraltar, Gibraltar.
RP Goyal, DK (corresponding author), Univ Gibraltar, Gibraltar COVID 19 Res Grp, Gibraltar, Gibraltar.; Goyal, DK (corresponding author), St Bernards Hosp, Acute Gen Med, Dept Med, Gibraltar Hlth Author, Gibraltar, Gibraltar.
EM daniel.goyal@unigib.edu.gi
CR Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Carr E, 2020, SUPPLEMENTING NATL E, DOI [10.1101/2020.04.24.20078006, DOI 10.1101/2020.04.24.20078006]
   Covington EW, 2018, PHARMACOTHERAPY, V38, P569, DOI 10.1002/phar.2112
   Cron RQ, 2020, J RHEUMATOL, V47, P1723, DOI [10.3899/jrheum.200744, 10.3899/jrheum.200334]
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Qin YY, 2020, CHINESE MED J-PEKING, V133, P1080, DOI 10.1097/CM9.0000000000000791
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Stawicki SP, 2020, J GLOB INFECT DIS, V12, P47, DOI 10.4103/jgid.jgid_86_20
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wang Y., 2020, EARLY LOW DOSE SHORT, DOI [10.1101/2020.03.06.20032342., DOI 10.1101/2020.03.06.20032342, 10.1101/2020.03.06. 20032342.]
   Xu TM, 2020, INT J INFECT DIS, V94, P68, DOI 10.1016/j.ijid.2020.03.022
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yu FT, 2020, CLIN INFECT DIS, V71, P793, DOI 10.1093/cid/ciaa345
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 21
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD SEP 22
PY 2020
VL 8
AR 550933
DI 10.3389/fpubh.2020.550933
PG 4
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NW6SY
UT WOS:000575146600001
PM 33072695
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Yao, T
   Gao, Y
   Cui, Q
   Peng, B
   Chen, Y
   Li, JS
   Huang, C
   He, CP
   Pu, J
   Wei, JJ
   Zhan, YQ
   Yan, J
   Tian, JH
   Zhang, ZH
   Liu, ZC
AF Yao, Tao
   Gao, Yan
   Cui, Qin
   Peng, Bo
   Chen, Yan
   Li, Jiansheng
   Huang, Chao
   He, Chunping
   Pu, Jie
   Wei, Jiajun
   Zhan, Yanqiang
   Yan, Jie
   Tian, Jinghua
   Zhang, Zhaohui
   Liu, Zhichao
TI Clinical characteristics of a group of deaths with COVID-19 pneumonia in
   Wuhan, China: a retrospective case series
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Characteristics; COVID-19; Pneumonia; Death
ID CRITICALLY-ILL PATIENTS; INFECTION; OUTCOMES; SARS
AB BackgroundWith the widespread outbreak of novel coronavirus diseases 2019(COVID-19), more and more death cases were reported, however, limited data are available for the patients who died. We aimed to explore the clinical characteristics of deaths with COVID-19 pneumonia.MethodsWe abstracted and analyzed epidemiological, demographic, clinical, and laboratory data from 83 death cases with COVID-19 pneumonia in East Hospital of Wuhan University Renmin Hospital, between January 26, 2020, and February 28, 2020.ResultsOf the 83 deaths, none was the medical staff. The mean age was 71.8years (SD 13.2; range, 34-97years) and 53(63.9%) were male. The median from onset to admission was 10days (IQR 7-14: range, 2-43days), to death was 17days (IQR 14-21: range, 6-54days). Most deaths (66[80%]) had underlying comorbid diseases, the most of which was hypertension [47(57%)]. The main initial symptoms of these 83 deaths were shortness of breath(98.8%), fever(94%), and myalgia or fatigue(90.4%). Laboratory analyses showed the lymphocytopenia in 69(83%) deaths, hypoalbuminemia in 77(93%) deaths, the elevation of lactate dehydrogenase in 79(95%) deaths, procalcitonin in 69(83%) deaths and C-reactive protein in 79(95%) deaths. All 83 patients received antiviral treatment, 81(97.6%) deaths received antibiotic therapy, 54(65.1%) deaths received glucocorticoid therapy, and 20(24.1%) patients received invasive mechanical ventilation.ConclusionMost of the deaths with COVID-19 pneumonia were elderly patients with underlying comorbid diseases, especially those over 70years of age. The time of death after the onset of the disease was mostly 15-21days. More care should be given to the elderly in further prevention and control strategies of COVID-19.
C1 [Yao, Tao; Gao, Yan; Cui, Qin; Peng, Bo; Chen, Yan; Li, Jiansheng; Huang, Chao; He, Chunping; Pu, Jie; Wei, Jiajun; Zhan, Yanqiang; Yan, Jie; Tian, Jinghua; Zhang, Zhaohui; Liu, Zhichao] Wuhan Univ, Renmin Hosp, Union Dept Infect Dis, Wuhan 430060, Peoples R China.
   [Yao, Tao; Gao, Yan; Cui, Qin; Peng, Bo; Chen, Yan; Li, Jiansheng; Pu, Jie; Wei, Jiajun; Zhan, Yanqiang; Zhang, Zhaohui; Liu, Zhichao] Wuhan Univ, Dept Neurol, Renmin Hosp, Wuhan 430060, Peoples R China.
   [Huang, Chao; He, Chunping] Wuhan Univ, Dept Gastroenterol, Renmin Hosp, Wuhan 430060, Peoples R China.
   [Yan, Jie] Wuhan Univ, Dept Crit Care Med, Renmin Hosp, Wuhan 430060, Peoples R China.
   [Tian, Jinghua] Wuhan Univ, Dept Obstet & Gynecol, Renmin Hosp, Wuhan 430060, Peoples R China.
RP Zhang, ZH; Liu, ZC (corresponding author), Wuhan Univ, Renmin Hosp, Union Dept Infect Dis, Wuhan 430060, Peoples R China.
EM zhangzhaohui2020@126.com; zhichao.liu@whu.edu.cn
OI Reis, AlessanRSS/0000-0001-8486-7469; Cui, Qin/0000-0002-8165-246X
CR Anesi GL, 2020, CORONAVIRUS DIS 2019
   [Anonymous], 2020, LAB TEST 2019 NOV CO
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Avramovski P, 2016, J OSTEOPOROS, V2016, DOI 10.1155/2016/7030272
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Colson PW, 2020, AIDS BEHAV, V24, P3436, DOI 10.1007/s10461-020-02901-6
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m757
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jernigan DB, 2020, MMWR-MORBID MORTAL W, V69, P216, DOI 10.15585/mmwr.mm6908e1
   Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374
   Li Q, 2020, J VASC ACCESS, DOI 10.1177/1129729820938201
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025
   Ng DL, 2016, AM J PATHOL, V186, P652, DOI 10.1016/j.ajpath.2015.10.024
   NHCo China, 2020, NEW COR PNEUM PREV C
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   World Health Organization, COR DIS 2019 COVID 1
   World Health Organization, WHO COR DIS COVID 19
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 31
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD SEP 22
PY 2020
VL 20
IS 1
AR 695
DI 10.1186/s12879-020-05423-7
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA NV9SS
UT WOS:000574652200003
PM 32962639
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shapira, G
   Shomron, N
   Gurwitz, D
AF Shapira, Guy
   Shomron, Noam
   Gurwitz, David
TI Ethnic differences in alpha-1 antitrypsin deficiency allele frequencies
   may partially explain national differences in COVID-19 fatality rates
SO FASEB JOURNAL
LA English
DT Article
DE alpha-1 antitrypsin; COVID-19; rs17580; rs28929474; SERPINA1
AB Infection rates, severity, and fatalities due to COVID-19, the pandemic mediated by SARS-CoV-2, vary greatly between countries. With few exceptions, these are lower in East and Southeast Asian and Sub-Saharan African countries compared with other regions. Epidemiological differences may reflect differences in border closures, lockdowns, and social distancing measures taken by each county, and by cultural differences, such as common use of face masks in East and Southeast Asian countries. The plasma serine protease inhibitor alpha-1 antitrypsin was suggested to protect from COVID-19 by inhibiting TMPRSS2, a cell surface serine protease essential for the SARS-CoV-2 cell entry. Here, we present evidence that population differences in alpha-1 antitrypsin deficiency allele frequencies may partially explain national differences in the COVID-19 epidemiology. Our study compared reported national estimates for the major alpha-1 antitrypsin deficiency alleles PiZ and PiS (SERPINA1rs28929474 and rs17580, respectively) with the Johns Hopkins University Coronavirus Resource Center dataset. We found a significant positive correlation (R = .54,P = 1.98e-6) between the combined frequencies of the alpha-1 antitrypsin PiZ and PiS deficiency alleles in 67 countries and their reported COVID-19 mortality rates. Our observations suggest that alpha-1 antitrypsin deficiency alleles may contribute to national differences in COVID-19 infection, severity, and mortality rates. Population-wide screening for carriers of alpha-1 antitrypsin deficiency alleles should be considered for prioritizing individuals for stricter social distancing measures and for receiving a SARS-CoV-2 vaccine once it becomes available.
C1 [Shapira, Guy; Shomron, Noam; Gurwitz, David] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
   [Shomron, Noam; Gurwitz, David] Tel Aviv Univ, Sagol Sch Neurosci, Tel Aviv, Israel.
   [Shomron, Noam] Tel Aviv Univ, Edmond J Safra Ctr Bioinformat, Tel Aviv, Israel.
RP Shomron, N; Gurwitz, D (corresponding author), Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
EM nshomron@tauex.tau.ac.il; gurwitz@tauex.tau.ac.il
RI Gurwitz, David/E-7642-2013
OI Gurwitz, David/0000-0002-9363-1869; Reis,
   AlessanRSS/0000-0001-8486-7469; Shapira, Guy/0000-0001-9376-4955
FU Yoran Institute for Human Genome Research at Tel Aviv University; Adelis
   Foundation
FX D. Gurwitz is supported by the Yoran Institute for Human Genome Research
   at Tel Aviv University. The N. Shomron lab is partially supported by the
   Adelis Foundation. The authors thank Cindy Cohen for professional
   editorial assistance.
CR Azouz Nurit P, 2020, bioRxiv, DOI 10.1101/2020.05.04.077826
   Blanco I, 2017, INT J CHRONIC OBSTR, V12, P1683, DOI 10.2147/COPD.S137852
   Cirovic B, 2020, CELL HOST MICROBE, V28, P322, DOI 10.1016/j.chom.2020.05.014
   de Loyola MB, 2020, REV MED VIROL, DOI 10.1002/rmv.2157
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Gaye B, 2020, NAT MED, DOI 10.1038/s41591-020-0960-y
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwasaki A, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012481
   Lindley VM, 2020, J AM COLL NUTR, DOI 10.1080/07315724.2020.1740629
   McElvaney OJ, 2020, AM J RESP CRIT CARE, V202, P812, DOI 10.1164/rccm.202005-1583OC
   Meltzer DO, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.19722
   Mitchell EL, 2018, CURR PATHOBIOL REP, V6, P97, DOI 10.1007/s40139-018-0164-z
   Pacha O, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0328-z
   Pervakova MY, 2020, PULM MED, V2020, DOI 10.1155/2020/9738032
   Schuster R, 2020, CELL IMMUNOL, V356, DOI 10.1016/j.cellimm.2020.104177
   Vaidyanathan G, 2020, NATURE, V585, P167, DOI 10.1038/d41586-020-02507-x
   Vianello A, 2020, ARCH BRONCONEUMOL, V56, P609, DOI 10.1016/j.arbres.2020.05.015
   Wettstein L, 2020, ALPHA 1 ANTITRYPSIN, DOI [10.1101/2020.07.02.183764, DOI 10.1101/2020.07.02.183764]
   Yamamoto M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060629
   Yi R, 2004, PROTEOMICS, V4, P3477, DOI 10.1002/pmic.200400897
   Yitbarek K, 2020, VACCINE, V38, P6374, DOI 10.1016/j.vaccine.2020.08.018
NR 21
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD NOV
PY 2020
VL 34
IS 11
BP 14160
EP 14165
DI 10.1096/fj.202002097
EA SEP 2020
PG 6
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA OP5RX
UT WOS:000573862800001
PM 32960480
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Berger, MM
   Hackett, PH
   Bartsch, P
AF Berger, Marc Moritz
   Hackett, Peter H.
   Baertsch, Peter
TI No Relevant Analogy Between COVID-19 and Acute Mountain Sickness
SO HIGH ALTITUDE MEDICINE & BIOLOGY
LA English
DT Article; Early Access
DE coronavirus disease; high-altitude cerebral edema; high-altitude
   pulmonary edema; high altitude; hypoxemia; SARS-CoV-2
ID ALTITUDE PULMONARY-EDEMA; LUNG; DEXAMETHASONE; PREVENTION;
   SUSCEPTIBILITY; INTERLEUKIN-6; PERMEABILITY; CYTOKINES; INCREASE; ASCENT
AB Clinicians and scientists have suggested therapies for coronavirus disease-19 (COVID-19) that are known to be effective for other medical conditions. A recent publication suggests that pathophysiological mechanisms underlying acute mountain sickness (a syndrome of nonspecific neurological symptoms typically experienced by nonacclimatized individuals at altitudes >2500 m) may overlap with the mechanisms causing COVID-19. In this short review, we briefly evaluate this mistaken analogy and demonstrate that this concept is not supported by scientific evidence.
C1 [Berger, Marc Moritz] Univ Hosp Essen, Dept Anesthesiol & Intens Care Med, Hufelandstr 55, D-45147 Essen, Germany.
   [Hackett, Peter H.] Univ Colorado, Dept Med, Div Pulm Sci & Crit Care Med, Altitude Res Ctr, Anschutz Med Campus, Aurora, CO USA.
   [Baertsch, Peter] Heidelberg Univ, Dept Internal Med, Heidelberg, Germany.
RP Berger, MM (corresponding author), Univ Hosp Essen, Dept Anesthesiol & Intens Care Med, Hufelandstr 55, D-45147 Essen, Germany.
EM marc.berger@uk-essen.de
OI Berger, Marc Moritz/0000-0001-6771-3193
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Bartsch P, 2013, NEW ENGL J MED, V368, P2294, DOI 10.1056/NEJMcp1214870
   Bartsch P, 2004, HIGH ALT MED BIOL, V5, P110, DOI 10.1089/1527029041352108
   Bartsch P, 2002, HIGH ALT MED BIOL, V3, P361, DOI 10.1089/15270290260512846
   BARTSCH P, 1991, NEW ENGL J MED, V325, P1284, DOI 10.1056/NEJM199110313251805
   Berger MM, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00982-2017
   Berger MM, 2019, J APPL PHYSL 1985, V128, P952
   Boos CJ, 2016, HIGH ALT MED BIOL, V17, P25, DOI 10.1089/ham.2015.0098
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cremona G, 2002, LANCET, V359, P303, DOI 10.1016/S0140-6736(02)07496-2
   Dehnert C, 2010, EUR RESPIR J, V35, P812, DOI 10.1183/09031936.00185808
   Dekker Marieke Cornelia Johanna, 2019, Pract Neurol, V19, P404, DOI 10.1136/practneurol-2017-001783
   Devaux CA, 2020, J MICROBIOL IMMUNOL, V53, P425, DOI 10.1016/j.jmii.2020.04.015
   HACKETT PH, 1988, AVIAT SPACE ENVIR MD, V59, P950
   Hackett PH, 1998, JAMA-J AM MED ASSOC, V280, P1920, DOI 10.1001/jama.280.22.1920
   Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206
   Hartmann G, 2000, CYTOKINE, V12, P246, DOI 10.1006/cyto.1999.0533
   Heo K, 2014, J KOREAN MED SCI, V29, P416, DOI 10.3346/jkms.2014.29.3.416
   HONIGMAN B, 1993, ANN INTERN MED, V118, P587, DOI 10.7326/0003-4819-118-8-199304150-00003
   Hu BY, 2020, J MED VIROL, DOI 10.1002/jmv.26232
   Jeong SK, 2010, CARDIOVASC DRUG THER, V24, P151, DOI 10.1007/s10557-010-6239-7
   JOHNSON TS, 1984, NEW ENGL J MED, V310, P683, DOI 10.1056/NEJM198403153101103
   JOHNSON TS, 1988, AVIAT SPACE ENVIR MD, V59, P208
   Julian CG, 2011, J APPL PHYSIOL, V111, P392, DOI 10.1152/japplphysiol.00391.2011
   Kleger GR, 1996, J APPL PHYSIOL, V81, P1917
   LEVINE BD, 1989, NEW ENGL J MED, V321, P1707, DOI 10.1056/NEJM198912213212504
   Li X, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02911-9
   Lipman GS, 2018, AM J MED, V131, DOI 10.1016/j.amjmed.2017.05.034
   Luks AM, 2020, ANN AM THORAC SOC, V17, P918, DOI 10.1513/AnnalsATS.202004-327CME
   Luks AM, 2020, HIGH ALT MED BIOL, V21, P192, DOI 10.1089/ham.2020.0055
   Lundeberg J, 2018, HIGH ALT MED BIOL, V19, P249, DOI 10.1089/ham.2017.0144
   MacInnis MJ, 2016, HIGH ALT MED BIOL, V17, P281, DOI 10.1089/ham.2016.0024
   Maggiorini M, 2001, CIRCULATION, V103, P2078
   Maggiorini M, 2006, ANN INTERN MED, V145, P497, DOI 10.7326/0003-4819-145-7-200610030-00007
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richalet JP, 2012, AM J RESP CRIT CARE, V185, P192, DOI 10.1164/rccm.201108-1396OC
   Roach RC, 2018, HIGH ALT MED BIOL, V19, P4, DOI 10.1089/ham.2017.0164
   Rocha PAS, 2020, HEADACHE, V60, P1797, DOI 10.1111/head.13941
   Schneider M, 2002, MED SCI SPORT EXER, V34, P1886, DOI 10.1097/00005768-200212000-00005
   SCHOENE RB, 1988, J APPL PHYSIOL, V64, P2605
   Senn O, 2006, MED SCI SPORT EXER, V38, P1565, DOI 10.1249/01.mss.0000229102.37359.af
   Solaimanzadeh I, 2020, CUREUS, V12, DOI 10.7759/cureus.7343
   Soliz J, 2020, RESP PHYSIOL NEUROBI, V279, DOI 10.1016/j.resp.2020.103476
   Strapazzon G, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01362-2020
   Swenson ER, 1997, AVIAT SPACE ENVIR MD, V68, P499
   Tolksdorf K, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.11.2000258
   Wang C, 2018, HIGH ALT MED BIOL, V19, P170, DOI 10.1089/ham.2017.0126
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wilson MH, 2014, HIGH ALT MED BIOL, V15, P123, DOI 10.1089/ham.2013.1151
   Wilson MH, 2009, LANCET NEUROL, V8, P175, DOI 10.1016/S1474-4422(09)70014-6
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 51
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1527-0297
EI 1557-8682
J9 HIGH ALT MED BIOL
JI High Alt. Med. Biol.
DI 10.1089/ham.2020.0147
EA SEP 2020
PG 4
WC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
SC Biophysics; Public, Environmental & Occupational Health; Sport Sciences
GA NV5LO
UT WOS:000574363100001
PM 32970479
OA Bronze
DA 2021-01-01
ER

PT J
AU Tomita, Y
   Sato, R
   Ikeda, T
   Sakagami, T
AF Tomita, Yusuke
   Sato, Ryo
   Ikeda, Tokunori
   Sakagami, Takuro
TI BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In
   silico analyses and a hypothesis
SO VACCINE
LA English
DT Article
DE Bacillus Calmette-Guerin (BCG); COVID-19; Human leukocyte antigen (HLA);
   Pandemic; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
AB The world is facing the rising emergency of SARS-CoV-2. The outbreak of COVID-19 has caused a global public health and economic crisis. Recent epidemiological studies have shown that a possible association of BCG vaccination program with decreased COVID-19-related risks, suggesting that BCG may provide protection against COVID-19. Non-specific protection against viral infections is considered as a main mechanism of BCG and clinical trials to determine whether BCG vaccine can protect healthcare workers from the COVID-19 are currently underway. We hypothesized that BCG may carry similar T cell epitopes with SARS-CoV-2 and evaluated the hypothesis by utilizing publicly available database and computer algorithms predicting human leukocyte antigen (HLA) class I-binding peptides. We found that BCG contains similar 9-amino acid sequences with SARS-CoV-2. These closely-related peptides had moderate to high binding affinity for multiple common HLA class I molecules, suggesting that cross-reactive T cells against SARS-CoV-2 could be generated by BCG vaccination. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Tomita, Yusuke; Sakagami, Takuro] Kumamoto Univ, Grad Sch Med Sci, Dept Resp Med, Kumamoto, Kumamoto, Japan.
   [Sato, Ryo] NHLBI, Lab Stem Cell & Neurovasc Biol, Genet & Dev Biol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Ikeda, Tokunori] Sojo Univ, Fac Pharmaceut Sci, Lab Clin Pharmacol & Therapeut, Kumamoto, Japan.
   [Ikeda, Tokunori] Kumamoto Univ Hosp, Dept Med Informat Sci & Adm Planning, Kumamoto, Japan.
RP Tomita, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Resp Med, Chuo Ku, Honjo 1-1-1, Kumamoto, Kumamoto 8608556, Japan.
EM y-tomita@kumadai.jp
OI Tomita, Yusuke/0000-0002-9680-7559
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP18K15928];
   Takeda Science FoundationTakeda Science Foundation (TSF)
FX This work was supported by JSPS KAKENHI Grant Number JP18K15928 and
   Takeda Science Foundation.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   Dendrou CA, 2018, NAT REV IMMUNOL, V18, P325, DOI 10.1038/nri.2017.143
   Fast E, POTENTIAL T CELL B C, DOI [10.1101/2020.02.19.9554841, DOI 10.1101/2020.02.19.9554841]
   Frankild S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001831
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hamiel U, 2020, JAMA
   Hoft DF, 2018, MUCOSAL IMMUNOL, V11, P486, DOI 10.1038/mi.2017.67
   Hohn H, 2003, EUR J IMMUNOL, V33, P1613, DOI 10.1002/eji.200323480
   Horwitz MA, 2009, VACCINE, V27, P441, DOI 10.1016/j.vaccine.2008.10.058
   Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Kaveh DA, 2014, VACCINE, V32, P6911, DOI 10.1016/j.vaccine.2014.10.041
   Kerboua KE, 2020, J MED VIROL, V92, P1858, DOI 10.1002/jmv.26083
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Meena J, 2020, INDIAN J PEDIAT
   Miller A, 2020, CORRELATION UNIVERSA, DOI [10.1101/2020.03.24.20042937, DOI 10.1101/2020.03.24.20042937, 10. 1101/2020.03.24.20042937]
   Miyasaka M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012661
   Moratto D, 2020, EUR J IMMUNOL, V50, P1412, DOI 10.1002/eji.202048724
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Redelman-Sidi G, 2020, NAT REV UROL, V17, P316, DOI 10.1038/s41585-020-0325-9
   Sala G, 2020, ASS BCG VACCINATION, DOI [10.1101/2020.03.30.20048165, DOI 10.1101/2020.03.30.20048165]
   ten Doesschate T, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04389-w
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Welsh RM, 2004, ANNU REV IMMUNOL, V22, P711, DOI 10.1146/annurev.immunol.22.012703.104527
   Yoshimoto FK, 2020, PROTEIN J, V39, P198, DOI 10.1007/s10930-020-09901-4
NR 27
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 22
PY 2020
VL 38
IS 41
BP 6352
EP 6356
DI 10.1016/j.vaccine.2020.08.045
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA NT3MH
UT WOS:000572848900004
PM 32863070
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Goldman, A
   Bomze, D
   Dankner, R
   Hod, H
   Meirson, T
   Boursi, B
   Maor, E
AF Goldman, Adam
   Bomze, David
   Dankner, Rachel
   Hod, Hanoch
   Meirson, Tomer
   Boursi, Ben
   Maor, Elad
TI Cardiovascular adverse events associated with hydroxychloroquine and
   chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19
   reports
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article; Early Access
DE cardiovascular adverse events; chloroquine; COVID-19; FDA adverse events
   reporting system (FAERS); hydroxychloroquine; pharmacovigilance
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; SIGNAL-DETECTION; HEART-FAILURE;
   DISPROPORTIONALITY; CARDIOTOXICITY; CARDIOMYOPATHY; AZITHROMYCIN; SAFETY
AB Aim There is a clinical need for safety data regarding hydroxychloroquine (HCQ) and chloroquine (CQ) during the coronavirus (COVID-19) pandemic. We analysed real-world data using the U.S. Food and Drug Administration Adverse Events Reporting System (FAERS) database to assess HCQ/CQ-associated cardiovascular adverse events (CVAEs) in pre-COVID-19 reports. Methods We conducted disproportionality analysis of HCQ/CQ in the FAERS database (07/2014-9/2019), using reporting odds ratio (ROR) and the lower bound of the information component 95% credibility interval (IC025). Results The full database contained 6 677 225 reports with a mean (+/- SD) age of 53 (+/- 17) years and 74% females. We identified 4895 reports of HCQ/CQ related adverse events, of which 696 (14.2%) were CVAEs. Compared with the full database, HCQ/CQ use was associated with a higher reporting rate of major CVAEs, including cardiomyopathy (n = 86 [1.8%], ROR = 29.0 [23.3-35.9]), QT prolongation (n = 43 [0.9%], ROR = 4.5 [3.3-6.1]), cardiac arrhythmias (n = 117 [2.4%], ROR = 2.2 [1.8-2.7]) and heart failure (n = 136 [2.8%], ROR = 2.2 [1.9-2.7], all ICx2080;x2082;x2085; > 0). No statistically significant differences were observed between sex and age groups. CVAEs were reported more often in patients with systemic lupus erythematosus and Sjogren's syndrome. HCQ/CQ-associated CVAEs demonstrated subsequent hospitalization and mortality rates of 39% and 8%, respectively. Overdose reports demonstrated an increased frequency of QT prolongation and ventricular arrhythmias (35% and 25%, respectively). Conclusion In a real-world setting, HCQ/CQ treatment is associated with higher reporting rates of various CVAEs, particularly cardiomyopathy, QT prolongation, cardiac arrhythmias and heart failure. HCQ/CQ-associated CVAEs result in high rates of severe outcomes and should be carefully considered as an off-label indication, especially for patients with cardiac disorders.
C1 [Goldman, Adam; Bomze, David; Dankner, Rachel] Tel Aviv Univ, Dept Epidemiol & Prevent Med, Sch Publ Hlth, Sackler Sch Med, Tel Aviv, Israel.
   [Goldman, Adam; Bomze, David; Hod, Hanoch; Boursi, Ben; Maor, Elad] Tel Aviv Univ, Sch Med, Sackler Fac Med, Tel Aviv, Israel.
   [Bomze, David] Univ Hosp Zurich, Dept Dermatol, Zurich, Switzerland.
   [Dankner, Rachel] Gertner Inst Epidemiol & Hlth Policy Res, Unit Cardiovasc Epidemiol, Ramat Gan, Israel.
   [Hod, Hanoch; Maor, Elad] Sheba Med Ctr, Leviev Heart Ctr, Ramat Gan, Israel.
   [Meirson, Tomer] Bar Ilan Univ, Azrieli Fac Med, Ramat Gan, Israel.
   [Boursi, Ben] Sheba Med Ctr, Dept Oncol, Tel Hashomer, Israel.
   [Boursi, Ben] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
RP Maor, E (corresponding author), Sheba Med Ctr, Cardiol, IL-52621 Tel Hashomer, Israel.; Maor, E (corresponding author), Tel Aviv Univ, IL-52621 Tel Hashomer, Israel.
EM elad.maor@sheba.health.gov.il
OI Goldman, Adam/0000-0001-5035-100X; Reis, AlessanRSS/0000-0001-8486-7469
CR Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Bate A, 2009, PHARMACOEPIDEM DR S, V18, P427, DOI 10.1002/pds.1742
   Bate A, 1998, EUR J CLIN PHARMACOL, V54, P315, DOI 10.1007/s002280050466
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   HAEUSLER IL, 2018, BMC MED, V16, DOI DOI 10.1186/S12916-018-1,188-2
   Harpaz R, 2013, CLIN PHARMACOL THER, V93, P539, DOI 10.1038/clpt.2013.24
   Harpaz R, 2012, CLIN PHARMACOL THER, V91, P1010, DOI 10.1038/clpt.2012.50
   Heeley E, 2001, LANCET, V358, P1872, DOI 10.1016/S0140-6736(01)06898-2
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]
   Joyce E, 2013, EUR HEART J-ACUTE CA, V2, P77, DOI 10.1177/2048872612471215
   Juurlink DN, 2020, CAN MED ASSOC J, V192, pE450, DOI 10.1503/cmaj.200528
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Li CJ, 2008, PHARMACOEPIDEM DR S, V17, P593, DOI 10.1002/pds.1601
   Manohar VA, 2009, J RHEUMATOL, V36, P440, DOI 10.3899/jrheum.080305
   Mazzanti A, 2020, CIRCULATION, V142, P513, DOI 10.1161/CIRCULATIONAHA.120.048476
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Montastruc JL, 2011, BRIT J CLIN PHARMACO, V72, P905, DOI 10.1111/j.1365-2125.2011.04037.x
   Mubagwa K, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106057
   Nardotto GHB, 2017, EUR J PHARM SCI, V109, pS108, DOI 10.1016/j.ejps.2017.05.033
   Newton-Cheh C, 2011, NEW ENGL J MED, V364, P1450, DOI 10.1056/NEJMcpc1011319
   Nord JE, 2004, SEMIN ARTHRITIS RHEU, V33, P336, DOI 10.1016/j.semarthrit.2003.09.012
   OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327
   Ohyama K, 2000, BRIT J CLIN PHARMACO, V49, P244, DOI 10.1046/j.1365-2125.2000.00134.x
   Page RL, 2016, CIRCULATION, V134, pE32, DOI 10.1161/CIR.0000000000000426
   Paton NI, 2005, HIV MED, V6, P13, DOI 10.1111/j.1468-1293.2005.00259.x
   Raschi E, 2018, NUTR METAB CARDIOVAS, V28, P533, DOI 10.1016/j.numecd.2018.02.014
   Roden DM, 2020, J AM COLL CARDIOL, V75, P2623, DOI 10.1016/j.jacc.2020.04.016
   Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470-2045(18)30608-9
   Skipper CP, 2020, ANN INTERN MED, DOI [10.7326/m20-4.207, DOI 10.7326/M20-4.207]
   SPERBER K, 1993, J RHEUMATOL, V20, P803
   Tonnesmann E, 2013, IMMUNOPHARM IMMUNOT, V35, P434, DOI 10.3109/08923973.2013.780078
   van Puijenbroek EP, 2002, PHARMACOEPIDEM DR S, V11, P3, DOI 10.1002/pds.668
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 41
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
DI 10.1111/bcp.14546
EA SEP 2020
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NR7NL
UT WOS:000571747400001
PM 32964535
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kandwal, S
   Fayne, D
AF Kandwal, Shubhangi
   Fayne, Darren
TI Repurposing drugs for treatment of SARS-CoV-2 infection: computational
   design insights into mechanisms of action
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; drug repurposing; pharmacophore; virtual
   screening; nucleocapsid protein; non-structural proteins
ID SARS-CORONAVIRUS; EBOLA-VIRUS; PROTEIN; IDENTIFICATION;
   ENDORIBONUCLEASE; ANTIBIOTICS; REPLICATION; CHALLENGES; STRATEGIES;
   COMPLEX
AB The COVID-19 pandemic has negatively affected human life globally. It has led to economic crises and health emergencies across the world, spreading rapidly among the human population and has caused many deaths. Currently, there are no treatments available for COVID-19 so there is an urgent need to develop therapeutic interventions that could be used against the novel coronavirus infection. In this research, we used computational drug design technologies to repurpose existing drugs as inhibitors of SARS-CoV-2 viral proteins. The Broad Institute's Drug Repurposing Hub consists of in-development/approved drugs and was computationally screened to identify potential hits which could inhibit protein targets encoded by the SARS-CoV-2 genome. By virtually screening the Broad collection, using rationally designed pharmacophore features, we identified molecules which may be repurposed against viral nucleocapsid and non-structural proteins. The pharmacophore features were generated after careful visualisation of the interactions between co-crystalised ligands and the protein binding site. The ChEMBL database was used to determine the compound's level of inhibition of SARS-CoV-2 and correlate the predicted viral protein target with whole virusin vitrodata. The results from this study may help to accelerate drug development against COVID-19 and the hit compounds should be progressed through furtherin vitroandin vivostudies on SARS-CoV-2.
C1 [Kandwal, Shubhangi] Trinity Coll Dublin, Trinity Translat Med Inst, Dept Clin Med, Dublin, Ireland.
   [Fayne, Darren] Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Mol Design Grp, Dublin 2, Ireland.
RP Fayne, D (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Mol Design Grp, Dublin 2, Ireland.
EM fayned@tcd.ie
OI Reis, AlessanRSS/0000-0001-8486-7469
FU Cycle 5 of the Irish Higher Education Authority's Programme for Research
   in Third Level Institutions (PRTLI); Dell Ireland; Trinity College
   Dublin MSc in Molecular Medicine
FX The Trinity Biomedical Sciences Institute (TBSI) is supported by a
   capital infrastructure investment from Cycle 5 of the Irish Higher
   Education Authority's Programme for Research in Third Level Institutions
   (PRTLI). We thank the software vendors for their continuing support of
   academic research efforts, in particular the contributions of the
   Chemical Computing Group, Biovia and OpenEye Scientific. The support and
   provisions of Dell Ireland is also acknowledged. The Trinity College
   Dublin MSc in Molecular Medicine is also gratefully acknowledged for
   supporting this work.
CR Akram M, 2018, PHYTOTHER RES, V32, P811, DOI 10.1002/ptr.6024
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Ashraf MU, 2019, MED RES REV, V39, P1091, DOI 10.1002/med.21554
   Astuti I, 2020, DIABETES METAB SYND, V14, P407, DOI 10.1016/j.dsx.2020.04.020
   Berman H. M., 2000, NUCL ACIDS RES, V28, pD235, DOI DOI HTTPS://DOI.ORG/10.1093/NAR/28.1.235
   Bhardwaj K, 2006, J MOL BIOL, V361, P243, DOI 10.1016/j.jmb.2006.06.021
   Bisson J, 2016, J MED CHEM, V59, P1671, DOI 10.1021/acs.jmedchem.5b01009
   Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Bouvet M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000863
   Brimacombe Kyle R, 2020, bioRxiv, DOI 10.1101/2020.06.04.135046
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cascella M, 2020, FEATURES EVALUATION
   Cavalla D, 2017, COMPREHENSIVE MEDICINAL CHEMISTRY III, VOL 1: GENERAL PERSPECTIVE - THE FUTURE OF DRUG DISCOVERY, P11, DOI 10.1016/B978-0-12-409547-2.12283-8
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Clark A, 2020, LANCET GLOB HEALTH, V8, P1003, DOI 10.1016/S2214-109X(20)30264-3
   Colson P, 2016, INT J ANTIMICROB AG, V48, P349, DOI 10.1016/j.ijantimicag.2016.07.004
   Deng XF, 2018, VIROLOGY, V517, P157, DOI 10.1016/j.virol.2017.12.024
   Ellinger B, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-23951/v1, DOI 10.21203/RS.3.RS-23951/V1]
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ganeshpurkar A, 2017, SAUDI PHARM J, V25, P149, DOI 10.1016/j.jsps.2016.04.025
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ge Y, 2020, BIORXIV, DOI [10.1101/2020.03.11.986836, DOI 10.1101/2020.03.11.986836]
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Hackbart M, 2020, P NATL ACAD SCI USA, V117, P8094, DOI 10.1073/pnas.1921485117
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsieh PK, 2005, J VIROL, V79, P13848, DOI 10.1128/JVI.79.22.13848-13855.2005
   Ispas G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126959
   Ivashchenko Andrey A, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1176
   Jimenez-Alberto A, 2020, COMPUT BIOL CHEM, V88, DOI 10.1016/j.compbiolchem.2020.107325
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Ke M, 2012, VIRUS RES, V167, P322, DOI 10.1016/j.virusres.2012.05.017
   Kesel Andreas J, 2014, Antivir Chem Chemother, V23, P197, DOI 10.3851/IMP2568
   Kim Y., 2020, BIORXIV, P17387, DOI [10.1101/2020.06.26.173872, DOI 10.1101/2020.06.26.173872]
   Kumar V, 2020, RES SQ, DOI [10.21203/rs.3.rs-31775/v1, DOI 10.21203/RS.3.RS-31775/V1]
   Kumar Y, 2020, J INFECT PUBLIC HEAL, V13, P1210, DOI 10.1016/j.jiph.2020.06.016
   Ladbury JE, 1996, CHEM BIOL, V3, P973, DOI 10.1016/S1074-5521(96)90164-7
   Leach AR, 2010, J MED CHEM, V53, P539, DOI 10.1021/jm900817u
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Long D, 2009, BIOPHYS J, V96, P1482, DOI 10.1016/j.bpj.200X.10.049
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Martin W. R., 2020, REPURPOSING FDA APPR, DOI [10.26434/CHEMRXIV.12431966.V1, DOI 10.26434/CHEMRXIV.12431966.V1]
   Masters P. S., 1990, ADV EXPT MED BIOL, V276, DOI [10.1007/978-1-4684-5823-7_32, DOI 10.1007/978-1-4684-5823-7_32]
   Mawhinney L, 2014, MOL MED, V20, P729, DOI 10.2119/molmed.2014.00136
   McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991
   McInnes C, 2007, CURR OPIN CHEM BIOL, V11, P494, DOI 10.1016/j.cbpa.2007.08.033
   McKay PB, 2012, MOL INFORM, V31, P246, DOI 10.1002/minf.201100127
   Menachery VD, 2017, MBIO, V8, DOI 10.1128/mBio.00665-17
   Molecular Operating Environment (MOE), 2020, 2019 01 CHEM COMP GR, pH3A
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929
   Muthas D, 2008, J MOL GRAPH MODEL, V26, P1237, DOI 10.1016/j.jmgm.2007.11.005
   Najmanovich R, 2000, PROTEINS, V39, P261, DOI 10.1002/(SICI)1097-0134(20000515)39:3<261::AID-PROT90>3.0.CO;2-4
   Nevin DK, 2012, J MED CHEM, V55, P4978, DOI 10.1021/jm300068n
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   OMEGA, 2019, OMEGA 3 1 1 2
   Pacios O, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9020065
   Pan JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003299
   Pandey A, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117883
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   Par A, 2018, ORVOSI HETILAP, V159, P455, DOI 10.1556/650.2018.30997
   Patskovsky Yuriy V., 1996, Biopolimery i Kletka, V12, P74
   Peele K Abraham, 2020, Inform Med Unlocked, V19, P100345, DOI 10.1016/j.imu.2020.100345
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Qadir A, 2018, EUR J MED CHEM, V156, P444, DOI 10.1016/j.ejmech.2018.07.014
   Sanders MPA, 2012, MEDCHEMCOMM, V3, P28, DOI 10.1039/c1md00210d
   Santibanez-Moran M. G., 2020, CONSENSUS VIRTUAL SC, DOI [10.26434/chemrxiv.12420860.v1, DOI 10.26434/CHEMRXIV.12420860.V1]
   Schiebel J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05769-2
   Schneider G, 2018, NAT REV DRUG DISCOV, V17, P97, DOI 10.1038/nrd.2017.232
   Schneider P, 2018, MOL INFORM, V37, DOI 10.1002/minf.201800050
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9
   Snijder EJ, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000715
   Su H., 2020, BIORXIV, DOI [10.1101/2020.04.13.038687, DOI 10.1101/2020.04.13.038687]
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Surjit M, 2006, J BIOL CHEM, V281, P10669, DOI 10.1074/jbc.M509233200
   Talevi A, 2020, EXPERT OPIN DRUG DIS, V15, P397, DOI 10.1080/17460441.2020.1704729
   Tazikeh-Lemeski E, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779133
   von Brunn A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000459
   Wagner MCE, 2011, CURR HIV RES, V9, P209, DOI 10.2174/157016211796320289
   Walters WP, 1998, DRUG DISCOV TODAY, V3, P160, DOI 10.1016/S1359-6446(97)01163-X
   World Health Organisation, 2020, WHO DIR GEN STAT IHR
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xiong H.-L., 2020, BIORXIV, DOI [10.1101/2020.06.05.135996, DOI 10.1101/2020.06.05.135996]
   Yamaguchi K, 2002, ANTIVIR RES, V53, P19, DOI 10.1016/S0166-3542(01)00189-9
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 92
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1825232
EA SEP 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NS4KV
UT WOS:000572233300001
PM 32964805
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Jacobs, W
   Lammens, M
   Kerckhofs, A
   Voets, E
   Van San, E
   Van Coillie, S
   Peleman, C
   Mergeay, M
   Sirimsi, S
   Matheeussen, V
   Jansens, H
   Baar, I
   Vanden Berghe, T
   Jorens, PG
AF Jacobs, Werner
   Lammens, Martin
   Kerckhofs, Annelies
   Voets, Evy
   Van San, Emily
   Van Coillie, Samya
   Peleman, Cedric
   Mergeay, Matthias
   Sirimsi, Sabriya
   Matheeussen, Veerle
   Jansens, Hilde
   Baar, Ingrid
   Vanden Berghe, Tom
   Jorens, Philippe G.
TI Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19):
   autopsy reveals a ferroptosis signature
SO ESC HEART FAILURE
LA English
DT Article; Early Access
DE Lymphocytic myocarditis; SARS-CoV-2-infection; COVID-19; Autopsy; Renal
   failure; Ferroptosis
ID DEATH; MYOCARDITIS
AB Aims Cardiovascular complications, including myocarditis, are observed in coronavirus disease 2019 (COVID-19). Major cardiac involvement is a potentially lethal feature in severe cases. We sought to describe the underlying pathophysiological mechanism in COVID-19 lethal cardiogenic shock.
   Methods and results We report on a 48-year-old male COVID-19 patient with cardiogenic shock; despite extracorporeal life support, dialysis, and massive pharmacological support, this rescue therapy was not successful. Severe acute respiratory syndrome coronavirus 2 RNA was detected at autopsy in the lungs and myocardium. Histopathological examination revealed diffuse alveolar damage, proliferation of type II pneumocytes, lymphocytes in the lung interstitium, and pulmonary microemboli. Moreover, patchy muscular, sometimes perivascular, interstitial mononuclear inflammatory infiltrates, dominated by lymphocytes, were seen in the cardiac tissue. The lymphocytes 'interlocked' the myocytes, resulting in myocyte degeneration and necrosis. Predominantly, T-cell lymphocytes with a CD4:CD8 ratio of 1.7 infiltrated the interstitial myocardium, reflecting true myocarditis. The myocardial tissue was examined for markers of ferroptosis, an iron-catalysed form of regulated cell death that occurs through excessive peroxidation of polyunsaturated fatty acids. Immunohistochemical staining with E06, a monoclonal antibody binding to oxidized phosphatidylcholine (reflecting lipid peroxidation during ferroptosis), was positive in morphologically degenerating and necrotic cardiomyocytes adjacent to the infiltrate of lymphocytes, near arteries, in the epicardium and myocardium. A similar ferroptosis signature was present in the myocardium of a COVID-19 subject without myocarditis. In a case of sudden death due to viral myocarditis of unknown aetiology, however, immunohistochemical staining with E06 was negative. The renal proximal tubuli stained positively for E06 and also hydroxynonenal (4-HNE), a reactive breakdown product of the lipid peroxides that execute ferroptosis. In the case of myocarditis of other aetiology, the renal tissue displayed no positivity for E06 or 4-HNE.
   Conclusions The findings in this case are unique as this is the first report on accumulated oxidized phospholipids (or their breakdown products) in myocardial and renal tissue in COVID-19. This highlights ferroptosis, proposed to detrimentally contribute to some forms of ischaemia-reperfusion injury, as a detrimental factor in COVID-19 cardiac damage and multiple organ failure.
C1 [Jacobs, Werner; Kerckhofs, Annelies] Univ Antwerp, Antwerp Univ Hosp, Dept Forens Med, Edegem, Belgium.
   [Jacobs, Werner] Belgian Def, Crisis Unit, Mil Hosp Queen Astrid, Brussels, Belgium.
   [Lammens, Martin; Sirimsi, Sabriya] Univ Antwerp, Antwerp Univ Hosp, Dept Pathol, Edegem, Belgium.
   [Voets, Evy; Mergeay, Matthias] Gen Hosp Sint Dimpna, Dept Anesthesia & Crit Care Med, Geel, Belgium.
   [Van San, Emily; Van Coillie, Samya; Vanden Berghe, Tom] VIB Ctr Inflammat Res, Ghent, Belgium.
   [Van San, Emily; Van Coillie, Samya; Vanden Berghe, Tom] Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium.
   [Peleman, Cedric; Jorens, Philippe G.] Univ Antwerp, Infla Med Res Consortium Excellence, Antwerp, Belgium.
   [Peleman, Cedric; Jorens, Philippe G.] Univ Antwerp, Lab Expt Med & Pediat LEMP, Dept Med & Hlth Sci, Antwerp, Belgium.
   [Matheeussen, Veerle; Jansens, Hilde] Univ Antwerp, Antwerp Univ Hosp, Cent Lab, Dept Microbiol, Edegem, Belgium.
   [Baar, Ingrid; Jorens, Philippe G.] Univ Antwerp, Antwerp Univ Hosp, Dept Intens Care Med, Wilrijkstr 10, B-2650 Edegem, Belgium.
   [Vanden Berghe, Tom] Univ Antwerp, Dept Biomed Sci, Antwerp, Belgium.
RP Jorens, PG (corresponding author), Univ Antwerp, Antwerp Univ Hosp, Dept Intens Care Med, Wilrijkstr 10, B-2650 Edegem, Belgium.
EM philippe.jorens@uza.be
RI ; Vanden Berghe, Tom/C-4916-2009
OI Reis, AlessanRSS/0000-0001-8486-7469; Vanden Berghe,
   Tom/0000-0002-1633-0974
FU Excellence of Science [EOS 30826052 MODEL-IDI]; Research Foundation
   FlandersFWO [FWO G0B7118N]; VLIR-UOS [TEAM2018-SEL018]; Charcot
   Foundation; Stichting Tegen Kanker [FAFC/2018/1250]; Ghent
   UniversityGhent University; VIB; FWO Kom op tegen Kanker [G049720N];
   IOF; TOP-BOF [32254]; FWOFWO [G0C0119N]
FX Vanden Berghe lab at VIB-UGent Center for Inflammatin Research is
   supported by Excellence of Science (EOS 30826052 MODEL-IDI), Research
   Foundation Flanders (FWO G0B7118N), VLIR-UOS (grant number:
   TEAM2018-SEL018), Charcot Foundation, Stichting Tegen Kanker
   (FAFC/2018/1250), Ghent University, and VIB. Vanden Berghe lab at the
   University of Antwerp is part of a consortium of excellence focusing on
   inflammation (INFLA-MED), is supported by FWO Kom op tegen Kanker
   (G049720N), IOF, TOP-BOF (32254) and FWO (G0C0119N) and has frequent
   partnerships with international pharma.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   [Anonymous], 2020, 2019 NOVEL CORONAVIR
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Bayir H, 2020, CELL CHEM BIOL, V27, P387, DOI 10.1016/j.chembiol.2020.03.014
   Caforio ALP, 2013, EUR HEART J, V34, P2636, DOI 10.1093/eurheartj/eht210
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Corman VM, 2019, EUROSURVEILLANCE, V2020, P25, DOI DOI 10.2807/1560-7917.ES.202025.3.2000045
   Devisscher L, 2018, J MED CHEM, V61, P10126, DOI 10.1021/acs.jmedchem.8b01299
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Escher F, 2020, ESC HEART FAIL, V7, P2440, DOI 10.1002/ehf2.12805
   Feng H, 2020, CELL REP, V30, P3411, DOI 10.1016/j.celrep.2020.02.049
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128
   Hassannia B, 2018, J CLIN INVEST, V128, P3341, DOI 10.1172/JCI99032
   Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533
   Hu Hongde, 2020, Eur Heart J, DOI 10.1093/eurheartj/ehaa190
   Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Linkermann A, 2014, P NATL ACAD SCI USA, V111, P16836, DOI 10.1073/pnas.1415518111
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Rosario C, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-185
   Sala S, 2020, EUR HEART J, V41, P1861, DOI 10.1093/eurheartj/ehaa286
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505
   Veronese G, 2018, ANATOL J CARDIOL, V19, P279, DOI 10.14744/AnatolJCardiol.2017.8170
   Wenzel SE, 2017, CELL, V171, P628, DOI 10.1016/j.cell.2017.09.044
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zeng J, 2020, INTENS CARE MED, V46, P1111, DOI 10.1007/s00134-020-05993-9
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 30
TC 1
Z9 1
U1 2
U2 2
PU WILEY PERIODICALS, INC
PI SAN FRANCISCO
PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA
SN 2055-5822
J9 ESC HEART FAIL
JI ESC Heart Fail.
DI 10.1002/ehf2.12958
EA SEP 2020
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NR4HB
UT WOS:000571524000001
PM 32959998
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Omotuyi, IO
   Nash, O
   Ajiboye, BO
   Olumekun, VO
   Oyinloye, BE
   Osuntokun, OT
   Olonisakin, A
   Ajayi, AO
   Olusanya, O
   Akomolafe, FS
   Adelakun, N
AF Omotuyi, I. Olaposi
   Nash, Oyekanmi
   Ajiboye, Basiru O.
   Olumekun, Victor O.
   Oyinloye, Babatunji E.
   Osuntokun, Oludare T.
   Olonisakin, Adebisi
   Ajayi, A. Olajide
   Olusanya, Olasehinde
   Akomolafe, Funmilola S.
   Adelakun, Niyi
TI Aframomum meleguetasecondary metabolites exhibit polypharmacology
   againstSARS-CoV-2 drug targets: in vitro validation of furin inhibition
SO PHYTOTHERAPY RESEARCH
LA English
DT Article; Early Access
DE Aframomum melegueta; COVID-19; Diarylheptanoid; flavonoids;
   phenylpropanoid; SARS-COV-2
ID RNA CAPPING MACHINERY; FLAVONOIDS; PROTEASE; GLYCOPROTEIN
AB COVID-19 pandemic is currently decimating the world's most advanced technologies and largest economies and making its way to the continent of Africa. Weak medical infrastructure and over-reliance on medical aids may eventually predict worse outcomes in Africa. To reverse this trend, Africa must re-evaluate the only area with strategic advantage; phytotherapy. One of the many plants with previous antiviral potency is against RNA viruses isAframomum melegueta. In this study, one hundred (100)A. meleguetasecondary metabolites have been mined and computational evaluated for inhibition of host furin, and SARS-COV-2 targets including 3C-like proteinase (M-pro/3CL(pro)), 2 '-O-ribose methyltransferase (nsp16) and surface glycoprotein/ACE2 receptor interface. Silica-gel column partitioning ofA. meleguetafruit/seed resulted in 6 fractions tested against furin activity. Diarylheptanoid (Letestuianin A), phenylpropanoid (4-Cinnamoyl-3-hydroxy-spiro[furan-5,2 '-(1 ' H)-indene]-1 ',2,3 '(2 ' H,5H)-trione), flavonoids (Quercetin, Apigenin and Tectochrysin) have been identified as high-binding compounds to SARS-COV-2 targets in a polypharmacology manner. Di-ethyl-ether (IC50= 0.03 mg/L), acetone (IC50= 1.564 mg/L), ethyl-acetate (IC50= 0.382 mg/L) and methanol (IC50= 0.438 mg/L) fractions demonstrated the best inhibition in kinetic assay while DEF, ASF and MEF completely inhibited furin-recognition sequence containing Ebola virus-pre-glycoprotein. In conclusion,A. meleguetaand its secondary metabolites have potential for addressing the therapeutic needs of African population during the COVID-19 pandemic.
C1 [Omotuyi, I. Olaposi] Adekunle Ajasin Univ, Dept Biochem, Chemogenom Res Unit, Akungba, Ondo State, Nigeria.
   [Omotuyi, I. Olaposi; Adelakun, Niyi] Mols & Sims, Chemoinformat Unit, Ado Ekiti, Nigeria.
   [Nash, Oyekanmi] Natl Biotechnol Dev Agcy, Ctr Genom Res & Innovat, Abuja, Nigeria.
   [Ajiboye, Basiru O.; Oyinloye, Babatunji E.] Afe Babalola Univ, Phytomed Biochem Toxicol & Biotechnol Res Labs, Dept Biochem, Coll Sci, Ado Ekiti, Nigeria.
   [Olumekun, Victor O.] Adekunle Ajasin Univ, Dept Plant Sci & Biotechnol, Akungba, Nigeria.
   [Oyinloye, Babatunji E.] Univ Zululand, Dept Biochem & Microbiol, Biotechnol & Struct Biol BSB Grp, Kwa Dlangezwa, South Africa.
   [Osuntokun, Oludare T.; Olonisakin, Adebisi] Adekunle Ajasin Univ, Dept Chem Sci, Akungba, Nigeria.
   [Ajayi, A. Olajide] Adekunle Ajasin Univ, Dept Microbiol, Akungba, Nigeria.
   [Olusanya, Olasehinde] Univ Benin, Dept Biochem, Fac Life Sci, Benin, Nigeria.
   [Akomolafe, Funmilola S.] Ekiti State Univ, Dept Biochem, Ado Ekiti, Nigeria.
RP Omotuyi, IO (corresponding author), Adekunle Ajasin Univ, Dept Biochem, Chemogenom Res Unit, Akungba, Ondo State, Nigeria.
EM olaposi.omotuyi@aaua.edu.ng
RI Ajayi, Adedayo Olajide/ABD-8707-2020; TEMITOPE, OSUNTOKUN
   OLUDARE/L-4314-2016; OLASEHINDE, OLUSANYA/ABG-9481-2020; Olumekun,
   Victor/AAQ-3459-2020
OI TEMITOPE, OSUNTOKUN OLUDARE/0000-0002-3954-6778; OLASEHINDE,
   OLUSANYA/0000-0003-0480-5634; Reis, AlessanRSS/0000-0001-8486-7469
CR Adefegha Stephen A., 2012, Journal of Basic and Clinical Physiology and Pharmacology, V23, P153, DOI 10.1515/jbcpp-2012-0029
   Ahmed-Belkacem A, 2005, CANCER RES, V65, P4852, DOI 10.1158/0008-5472.CAN-04-1817
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Esimone C. O., 2006, Nigerian Journal of Natural Products and Medicine, V10, P51
   Fatiregun Akinola Ayoola, 2017, Niger Med J, V58, P1, DOI 10.4103/0300-1652.218414
   Ferraro F, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004834
   Ferron F, 2012, ANTIVIR RES, V96, P21, DOI 10.1016/j.antiviral.2012.07.007
   Gbodossou E. V. A., 2012, U.S. Patent Application, Patent No. [12/997,413, 12997413]
   Ghorai N., 2012, PROTOCOL EXCHANGE, P5, DOI [10.1038/protex.2012.055, DOI 10.1038/PROTEX.2012.055]
   Gigante A, 2017, ANTIVIR RES, V144, P216, DOI 10.1016/j.antiviral.2017.06.003
   Gire SK, 2014, SCIENCE, V345, P1369, DOI 10.1126/science.1259657
   He B, 2019, EUR J PHARMACOL, V842, P365, DOI 10.1016/j.ejphar.2018.11.002
   Hellinger R, 2019, DRUG DISCOV TODAY, V24, P1877, DOI 10.1016/j.drudis.2019.05.026
   Hossain MU, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3187647
   Hou R, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700288
   Ibekwe Hyacinth, 2019, Int J Biochem Mol Biol, V10, P9
   Imran M, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11111011
   Issur M, 2011, WIRES RNA, V2, P184, DOI 10.1002/wrna.43
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Joseph OA, 2019, DRUG RES, V69, P451, DOI 10.1055/a-0849-9377
   Kamnaing P, 2003, J NAT PROD, V66, P364, DOI 10.1021/np020362f
   KAUL TN, 1985, J MED VIROL, V15, P71, DOI 10.1002/jmv.1890150110
   Kibirev V K, 2010, Ukr Biokhim Zh (1999), V82, P15
   Kouretova J, 2017, J ENZYM INHIB MED CH, V32, P712, DOI 10.1080/14756366.2017.1306521
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Majumdar S, 2010, CURR MED CHEM, V17, P2049, DOI 10.2174/092986710791233643
   Gonzalez CM, 2019, FOOD SCI NUTR, V7, P3853, DOI 10.1002/fsn3.1211
   Mohammed A, 2015, J ETHNOPHARMACOL, V175, P518, DOI 10.1016/j.jep.2015.10.011
   Ojo O. O., 2009, African Journal of Plant Science, V3, P157
   Olaposi OI, 2019, DRUG RES, V69, P643, DOI 10.1055/a-0807-8640
   Omotuyi IO, 2015, J BIOMOL STRUCT DYN, V33, P461, DOI 10.1080/07391102.2014.981207
   Omotuyi O.I., 2020, DARUNAVIR DISRUPTS C, DOI DOI 10.20944/PREPRINTS202003.0125.V1
   Onwuatuegwu J., 2017, INT DIGITAL ORG SCI, V2, P33
   Qian K, 2009, MED RES REV, V29, P369, DOI 10.1002/med.20138
   Ramos RTM, 2017, PHARMACOGN RES, V9, P253, DOI 10.4103/pr.pr_143_16
   Ringeard M, 2019, NATURE, V565, P500, DOI 10.1038/s41586-018-0841-4
   Saddi Manuela, 2007, Ann Clin Microbiol Antimicrob, V6, P10, DOI 10.1186/1476-0711-6-10
   Sander T, 2015, J CHEM INF MODEL, V55, P460, DOI 10.1021/ci500588j
   Sharp PM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006841
   Sofowora A, 2013, AFR J TRADIT COMPLEM, V10, P210, DOI 10.4314/ajtcam.v10i5.2
   Spychalski P, 2020, LANCET INFECT DIS, V20, P774, DOI [10.1016/S1473-3099(20)30246-2, 10.1016/S1473-3099(20)30245-0]
   Srikanth S, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00470
   Tambunana U., 2016, AIP C P, P1862
   Van TVL, 2019, CHEMMEDCHEM, V14, P673, DOI 10.1002/cmdc.201800807
   Tu YY, 2016, ANGEW CHEM INT EDIT, V55, P10210, DOI 10.1002/anie.201601967
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang Yu, 2019, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V35, P283, DOI 10.12047/j.cjap.5754.2019.059
   Xavier KNF, 2019, ANDROLOGIA, V51, DOI 10.1111/and.13306
   Xu HX, 2000, BIOL PHARM BULL, V23, P1072, DOI 10.1248/bpb.23.1072
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zeng C, 2016, J VIROL, V90, P6675, DOI 10.1128/JVI.00658-16
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
NR 58
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
DI 10.1002/ptr.6843
EA SEP 2020
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NR5WX
UT WOS:000571634800001
PM 32964551
DA 2021-01-01
ER

PT J
AU Esmail, S
   Danter, WR
AF Esmail, Sally
   Danter, Wayne R.
TI Viral pandemic preparedness: A pluripotent stem cell-based
   machine-learning platform for simulatingSARS-CoV-2 infection to enable
   drug discovery and repurposing
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article; Early Access
DE antiviral; DeepNEU; drug discovery and repurposing; pandemic
   preparedness; SARS-CoV-2; unsupervised learning
ID IMMUNE-RESPONSES; CORONAVIRUS; SARS; COVID-19; IPSCS
AB Infection with the SARS-CoV-2 virus has rapidly become a global pandemic for which we were not prepared. Several clinical trials using previously approved drugs and drug combinations are urgently underway to improve our current situation. Unfortunately, a vaccine option is optimistically at least a year away. It is imperative that for future viral pandemic preparedness, we have a rapid screening technology for drug discovery and repurposing. The primary purpose of this research project was to evaluate the DeepNEU stem-cell based platform by creating and validating computer simulations of artificial lung cells infected with SARS-CoV-2 to enable the rapid identification of antiviral therapeutic targets and drug repurposing. The data generated from this project indicate that (a) human alveolar type lung cells can be simulated by DeepNEU (v5.0), (b) these simulated cells can then be infected with simulated SARS-CoV-2 virus, (c) the unsupervised learning system performed well in all simulations based on available published wet lab data, and (d) the platform identified potentially effective anti-SARS-CoV2 combinations of known drugs for urgent clinical study. The data also suggest that DeepNEU can identify potential therapeutic targets for expedited vaccine development. We conclude that based on published data plus current DeepNEU results, continued development of the DeepNEU platform will improve our preparedness for and response to future viral outbreaks. This can be achieved through rapid identification of potential therapeutic options for clinical testing as soon as the viral genome has been confirmed.
C1 [Esmail, Sally; Danter, Wayne R.] 123Genetix, 1309 Dyer Dr, London, ON N6G0T7, Canada.
RP Danter, WR (corresponding author), 123Genetix, 1309 Dyer Dr, London, ON N6G0T7, Canada.
EM wdanter@123genetix.com
OI Esmail, Sally/0000-0001-9595-4779; Danter, Wayne/0000-0002-9297-4405
CR Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Barkauskas CE, 2017, DEVELOPMENT, V144, P986, DOI 10.1242/dev.140103
   Callaway E, 2020, NATURE, V579, P482, DOI 10.1038/d41586-020-00758-2
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chua KB, 2012, CURR TOP MICROBIOL, V359, P1, DOI 10.1007/82_2012_218
   Danter WR, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-018-0983-3
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Dodds W, 2019, WORLDS WORST PROBLEM, P31
   Elitt MS, 2018, HUM MOL GENET, V27, pR89, DOI 10.1093/hmg/ddy186
   Esmail S, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00325
   Frank DB, 2019, P NATL ACAD SCI USA, V116, P4362, DOI 10.1073/pnas.1813952116
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ghaedi M, 2018, J TISSUE ENG REGEN M, V12, pE1623, DOI 10.1002/term.2589
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Groumpos PP, 2016, IFAC PAPERSONLINE, V49, P180, DOI 10.1016/j.ifacol.2016.11.099
   Han C, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00047
   Jacob A, 2017, CELL STEM CELL, V21, P472, DOI 10.1016/j.stem.2017.08.014
   Kao RY, 2004, CHEM BIOL, V11, P1293, DOI 10.1016/j.chembiol.2004.07.013
   Li CG, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020384
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Majolo F, 2019, J MED VIROL, V91, P525, DOI 10.1002/jmv.25345
   Mehand MS, 2018, ANTIVIR RES, V159, P63, DOI 10.1016/j.antiviral.2018.09.009
   Mehand MS, 2018, EMERG INF DIS, V24, pe1, DOI 10.3201/eid2409.171427
   Mitchell A, 2017, DIFFERENTIATION, V96, P62, DOI 10.1016/j.diff.2017.08.001
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Rajsbaum R, 2013, TRENDS MICROBIOL, V21, P421, DOI 10.1016/j.tim.2013.06.006
   Sen N, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007419
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Simmons G, 2013, ANTIVIR RES, V100, P605, DOI 10.1016/j.antiviral.2013.09.028
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   TAM L, 2018, AM J PHYSIOL-CELL PH, V315, pL921
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Trevisan M, 2015, VIRUSES-BASEL, V7, P3835, DOI 10.3390/v7072800
   von Brunn A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000459
   Wenzhong L, 2019, PREPRINT, DOI [10.26434/chemrxiv.11938173.v9, DOI 10.26434/CHEMRXIV.11938173.V9]
   Wong AP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45195-y
   Woo B, 2019, CYTOKINE GROWTH F R, V48, P40, DOI 10.1016/j.cytogfr.2019.06.001
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
   Young W., 2012, J STEM CELL RES TH S, V10, P2, DOI DOI 10.1021/ACS.JMEDCHEM.5B00789
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 44
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
DI 10.1002/sctm.20-0181
EA SEP 2020
PG 12
WC Cell & Tissue Engineering
SC Cell Biology
GA NR5FY
UT WOS:000571589100001
PM 32961040
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, N
   Zhao, LF
   Zhan, XQ
AF Li, Na
   Zhao, Lingfeng
   Zhan, Xianquan
TI Quantitative proteomics reveals a broad-spectrum antiviral property of
   ivermectin, benefiting for COVID-19 treatment
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article; Early Access
DE ivermectin; quantitative proteomics; SARS-CoV-2; COVID-19; stable
   isotope labeling by amino acids in cell culture; virus-related pathways
ID SAFETY; DRUG; MECHANISMS; DISORDERS; INFECTION; CELLS
AB Viruses such as human cytomegalovirus (HCMV), human papillomavirus (HPV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) represent a great burden to human health worldwide. FDA-approved anti-parasite drug ivermectin is also an antibacterial, antiviral, and anticancer agent, which offers more potentiality to improve global public health, and it can effectively inhibit the replication of SARS-CoV-2 in vitro. This study sought to identify ivermectin-related virus infection pathway alterations in human ovarian cancer cells. Stable isotope labeling by amino acids in cell culture (SILAC) quantitative proteomics was used to analyze human ovarian cancer cells TOV-21G treated with and without ivermectin (20 mu mol/L) for 24 h, which identified 4447 ivermectin-related proteins in ovarian cancer cells. Pathway network analysis revealed four statistically significant antiviral pathways, including HCMV, HPV, EBV, and HIV1 infection pathways. Interestingly, compared with the reported 284 SARS-CoV-2/COVID-19-related genes from GencLip3, we identified 52 SARS-CoV-2/COVID-19-related protein alterations when treated with and without ivermectin. Protein-protein network (PPI) was constructed based on the interactions between 284 SARS-CoV-2/COVID-19-related genes and between 52 SARS-CoV-2/COVID-19-related proteins regulated by ivermectin. Molecular complex detection analysis of PPI network identified three hub modules, including cytokines and growth factor family, MAP kinase and G-protein family, and HLA class proteins. Gene Ontology analysis revealed 10 statistically significant cellular components, 13 molecular functions, and 11 biological processes. These findings demonstrate the broad-spectrum antiviral property of ivermectin benefiting for COVID-19 treatment in the context of predictive, preventive, and personalized medicine in virus-related diseases.
C1 [Li, Na; Zhan, Xianquan] Shandong First Med Univ, Univ Creat Res Initiat Ctr, 6699 Qingdao Rd, Jinan 250117, Shandong, Peoples R China.
   [Li, Na; Zhan, Xianquan] Cent South Univ, Xiangya Hosp, Key Lab Canc Prote, Chinese Minist Hlth, Changsha, Hunan, Peoples R China.
   [Li, Na; Zhan, Xianquan] Cent South Univ, Xiangya Hosp, State Local Joint Engn Lab Anticanc Drugs, Changsha, Hunan, Peoples R China.
   [Zhao, Lingfeng] Sothern Med Univ, Affiliated Hosp 3, Dept Obstet & Gynecol, Guangzhou, Guangdong, Peoples R China.
   [Zhan, Xianquan] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China.
   [Zhan, Xianquan] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Hunan, Peoples R China.
RP Zhan, XQ (corresponding author), Shandong First Med Univ, Univ Creat Res Initiat Ctr, 6699 Qingdao Rd, Jinan 250117, Shandong, Peoples R China.
EM yjzhan2011@gmail.com
OI Reis, AlessanRSS/0000-0001-8486-7469
FU Hunan Provincial Hundred Talent Plan; Shandong First Medical University
   Talent Introduction Funds
FX Hunan Provincial Hundred Talent Plan (to X.Z.); Shandong First Medical
   University Talent Introduction Funds (to X.Z.)
CR Abdeltawab MSA, 2020, PARASITOL RES, V119, P55, DOI 10.1007/s00436-019-06539-9
   Almeida AM, 2019, DRUG DISCOV TODAY, V24, P2044, DOI 10.1016/j.drudis.2019.07.011
   AlpalhAo M., 2020, MED HYPOTHESES, V143
   Andoniou CE, 2006, IMMUNOL CELL BIOL, V84, P99, DOI 10.1111/j.1440-1711.2005.01412.x
   Ashour DS, 2019, INT J ANTIMICROB AG, V54, P134, DOI 10.1016/j.ijantimicag.2019.05.003
   Athanasiou A, 2020, BEST PRACT RES CL OB, V65, P109, DOI 10.1016/j.bpobgyn.2020.02.009
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Boussinesq M, 2005, Med Trop (Mars), V65, P69
   Britt W, 2008, CURR TOP MICROBIOL, V325, P417
   Buechner SA, 2002, BJU INT, V90, P498, DOI 10.1046/j.1464-410X.2002.02962.x
   BURG RW, 1979, ANTIMICROB AGENTS CH, V15, P361, DOI 10.1128/AAC.15.3.361
   Buxmann H, 2017, DTSCH ARZTEBL INT, V114, P45, DOI 10.3238/arztebl.2017.0045
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   CHABALA JC, 1980, J MED CHEM, V23, P1134, DOI 10.1021/jm00184a014
   Chaccour C, 2020, AM J TROP MED HYG, V102, P1156, DOI 10.4269/ajtmh.20-0271
   Crump A, 2017, J ANTIBIOT, V70, P495, DOI 10.1038/ja.2017.11
   Csoka B, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99431
   Deng FM, 2019, J CELL BIOCHEM, V120, P1702, DOI 10.1002/jcb.27490
   Develoux M, 2004, ANN DERMATOL VENER, V131, P561, DOI 10.1016/S0151-9638(04)93668-X
   Diao HX, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2026-2
   Dou QH, 2016, CANCER RES, V76, P4457, DOI 10.1158/0008-5472.CAN-15-2887
   Gallardo F, 2018, DRUG DES DEV THER, V12, P2805, DOI 10.2147/DDDT.S172538
   Guzzo CA, 2002, J CLIN PHARMACOL, V42, P1122, DOI 10.1177/009127002401382731
   He L, 2006, J PATHOL, V210, P288, DOI 10.1002/path.2067
   Holder KA, 2019, J LEUKOCYTE BIOL, V106, P447, DOI 10.1002/JLB.2AB0418-158RR
   Hoppe-Seyler K, 2018, TRENDS MICROBIOL, V26, P158, DOI 10.1016/j.tim.2017.07.007
   Huynh K., 2020, HIV PREVENTION
   Jiang L., 2019, J EXP CLIN CANC RES, V38, P1
   Juarez M, 2018, AM J CANCER RES, V8, P317
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Laing R, 2017, TRENDS PARASITOL, V33, P463, DOI 10.1016/j.pt.2017.02.004
   Lee JY, 2019, PESTIC BIOCHEM PHYS, V159, P144, DOI 10.1016/j.pestbp.2019.06.009
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Levy M, 2020, BRIT J DERMATOL, V182, P1003, DOI 10.1111/bjd.18369
   Li HO, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00483-20
   Li N, 2020, EPMA J, V11, P289, DOI 10.1007/s13167-020-00209-y
   Lv CJ, 2018, ANTIVIR RES, V159, P55, DOI 10.1016/j.antiviral.2018.09.010
   Marques-Piubelli ML, 2020, PATHOLOGY, V52, P40, DOI 10.1016/j.pathol.2019.09.006
   Nash D, 2019, CURR HIV-AIDS REP, V16, P304, DOI 10.1007/s11904-019-00452-7
   Nicolas P, 2020, LANCET GLOB HEALTH, V8, pE92, DOI 10.1016/S2214-109X(19)30453-X
   Nussinovitch M, 2003, CLIN PEDIATR, V42, P581, DOI 10.1177/000992280304200702
   Patri A, 2020, J AM ACAD DERMATOL, V82, pE221, DOI 10.1016/j.jaad.2020.04.017
   Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i
   Rehwinkel J., 2020, NAT REV IMMUNOL, V20, P1
   Rezk SA, 2018, HUM PATHOL, V79, P18, DOI 10.1016/j.humpath.2018.05.020
   Schaller M, 2017, J EUR ACAD DERMATOL, V31, P1907, DOI 10.1111/jdv.14437
   Shannon-Lowe C, 2014, CURR OPIN VIROL, V4, P78, DOI 10.1016/j.coviro.2013.12.001
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   VANWYK JA, 1988, VET REC, V123, P226, DOI 10.1136/vr.123.9.226
   Varghese FS, 2016, ANTIVIR RES, V126, P117, DOI 10.1016/j.antiviral.2015.12.012
   Wagstaff KM, 2012, BIOCHEM J, V443, P851, DOI 10.1042/BJ20120150
   Wang JH, 2020, BIOINFORMATICS, V36, P1973, DOI 10.1093/bioinformatics/btz807
   Wei JG, 2020, DEV COMP IMMUNOL, V111, DOI 10.1016/j.dci.2020.103744
   Yang SNY, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104760
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zavattoni M, 2014, EARLY HUM DEV, V90, pS29, DOI 10.1016/S0378-3782(14)70010-6
   Zhang JX, 2013, 2013 IEEE WIRELESS COMMUNICATIONS AND NETWORKING CONFERENCE WORKSHOPS (WCNCW), P1, DOI [10.1109/PLASMA.2013.6633336, 10.1109/WCNCW.2013.6533305]
   Zhang XM, 2009, INT IMMUNOPHARMACOL, V9, P354, DOI 10.1016/j.intimp.2008.12.016
NR 62
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
DI 10.1002/jcp.30055
EA SEP 2020
PG 17
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA NR3VH
UT WOS:000571490800001
PM 32959892
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Genzel, L
   Adan, R
   Berns, A
   van den Beucken, J
   Blokland, A
   Boddeke, EHWGM
   Bogers, WM
   Bontrop, R
   Bulthuis, R
   Bousema, T
   Clevers, H
   Coenen, TCJJ
   van Dam, AM
   Deen, PMT
   van Dijk, KW
   Eggen, BJL
   Elgersma, Y
   Erdogan, I
   Englitz, B
   van Vlissingen, JMF
   la Fleur, S
   Fouchier, R
   Fitzsimons, CP
   Frieling, W
   Haagmans, B
   Heesters, BA
   Henckens, M
   Herfst, S
   Hol, E
   van den Hove, D
   de Jonge, MI
   Jonkers, J
   Joosten, LAB
   Kalsbeek, A
   Kamermans, M
   Kampinga, HH
   Kas, MJ
   Keijer, J
   Kersten, S
   Kiliaan, AJ
   Kooij, TWA
   Kooijman, S
   Koopman, WJH
   Korosi, A
   Krugers, HJ
   Kuiken, T
   Kushner, SA
   Langermans, JAM
   Lesscher, H
   Lucassen, PJ
   Lutgens, E
   Netea, MG
   Noldus, LPJJ
   van der Meer, JWM
   Meye, FJ
   Mul, JD
   van Oers, K
   Olivier, JDA
   Pasterkamp, RJ
   Philippens, IHCHM
   Prickaerts, J
   Pullox, BJA
   Rensen, PCN
   Van Rheenen, J
   van Rij, RP
   Ritsma, L
   Rockx, BHG
   Roozendaal, B
   van Schothorst, EM
   Stittelaar, K
   Stockhofe, N
   Swaab, DF
   de Swart, RL
   Vanderschuren, LJMJ
   de Vries, T
   de Vrij, F
   van Wezel, R
   Wierenga, CJ
   Wiesmann, M
   Willuhn, I
   de Zeeuw, CI
   Homberg, JR
AF Genzel, Lisa
   Adan, Roger
   Berns, Anton
   van den Beucken, Jeroen
   Blokland, Arjan
   Boddeke, Erik H. W. G. M.
   Bogers, Willy M.
   Bontrop, Ronald
   Bulthuis, R.
   Bousema, Teun
   Clevers, Hans
   Coenen, Tineke C. J. J.
   van Dam, Anne-Marie
   Deen, Peter M. T.
   van Dijk, K. W.
   Eggen, Bart J. L.
   Elgersma, Ype
   Erdogan, Izel
   Englitz, Bernard
   van Vlissingen, J. Martje Fentener
   la Fleur, Susanne
   Fouchier, Ron
   Fitzsimons, Carlos P.
   Frieling, Wilbert
   Haagmans, Bart
   Heesters, Balthasar A.
   Henckens, Marloes
   Herfst, Sander
   Hol, Elly
   van den Hove, Daniel
   de Jonge, Marien I.
   Jonkers, Jos
   Joosten, Leo A. B.
   Kalsbeek, Andries
   Kamermans, Maarten
   Kampinga, Harm H.
   Kas, Martien J.
   Keijer, J.
   Kersten, Sander
   Kiliaan, Amanda J.
   Kooij, Taco W. A.
   Kooijman, Sander
   Koopman, Werner J. H.
   Korosi, Aniko
   Krugers, Harm J.
   Kuiken, Thijs
   Kushner, Steven A.
   Langermans, Jan A. M.
   Lesscher, Heidi
   Lucassen, Paul J.
   Lutgens, Esther
   Netea, Mihai G.
   Noldus, Lucas P. J. J.
   van der Meer, Jos W. M.
   Meye, Frank J.
   Mul, Joram D.
   van Oers, Kees
   Olivier, Jocelien D. A.
   Pasterkamp, R. Jeroen
   Philippens, Ingrid H. C. H. M.
   Prickaerts, Jos
   Pullox, Bart J. A.
   Rensen, Patrick C. N.
   Van Rheenen, Jacco
   van Rij, Ronald P.
   Ritsma, Laila
   Rockx, Barry. H. G.
   Roozendaal, Benno
   van Schothorst, Evert M.
   Stittelaar, K.
   Stockhofe, Norbert
   Swaab, Dick F.
   de Swart, Rik L.
   Vanderschuren, Louk J. M. J.
   de Vries, Taco
   de Vrij, Femke
   van Wezel, Richard
   Wierenga, Corette J.
   Wiesmann, Maximilian
   Willuhn, Ingo
   de Zeeuw, Chris I.
   Homberg, Judith R.
TI How the COVID-19 pandemic highlights the necessity of animal research
SO CURRENT BIOLOGY
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; INFECTION; VACCINE; MICE
AB Recently, a petition was offered to the European Commission calling for an immediate ban on animal testing. Although a Europe-wide moratorium on the use of animals in science is not yet possible, there has been a push by the non-scientific community and politicians for a rapid transition to animal-free innovations. Although there are benefits for both animal welfare and researchers, advances on alternative methods have not progressed enough to be able to replace animal research in the foreseeable future. This trend has led first and foremost to a substantial increase in the administrative burden and hurdles required to make timely advances in research and treatments for human and animal diseases. The current COVID-19 pandemic clearly highlights how much we actually rely on animal research. COVID-19 affects several organs and systems, and the various animal-free alternatives currently available do not come close to this complexity. In this Essay, we therefore argue that the use of animals is essential for the advancement of human and veterinary health.
C1 [Genzel, Lisa; Deen, Peter M. T.; Englitz, Bernard; Noldus, Lucas P. J. J.; van Wezel, Richard] Radboud Univ Nijmegen, NL-6525 XZ Nijmegen, Netherlands.
   [Adan, Roger; Hol, Elly; Meye, Frank J.; Pasterkamp, R. Jeroen] Univ Utrecht, Univ Med Ctr, Utrecht Brain Ctr, NL-3584 CG Utrecht, Netherlands.
   [Berns, Anton; Jonkers, Jos; Van Rheenen, Jacco] Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands.
   [van den Beucken, Jeroen; Bousema, Teun; Erdogan, Izel; Henckens, Marloes; de Jonge, Marien I.; Joosten, Leo A. B.; Kiliaan, Amanda J.; Kooij, Taco W. A.; Koopman, Werner J. H.; Netea, Mihai G.; van der Meer, Jos W. M.; van Rij, Ronald P.; Roozendaal, Benno; Wiesmann, Maximilian; Homberg, Judith R.] Radboud Univ Nijmegen, Med Ctr, NL-6525 GA Nijmegen, Netherlands.
   [Blokland, Arjan; van den Hove, Daniel; Prickaerts, Jos] Maastricht Univ, NL-6211 LK Maastricht, Netherlands.
   [Boddeke, Erik H. W. G. M.; Eggen, Bart J. L.; Kas, Martien J.; Olivier, Jocelien D. A.] Univ Groningen, NL-9712 CP Groningen, Netherlands.
   [Boddeke, Erik H. W. G. M.; Eggen, Bart J. L.; Kampinga, Harm H.] Univ Groningen, Univ Med Ctr, NL-9713 GZ Groningen, Netherlands.
   [Bogers, Willy M.; Bontrop, Ronald; Langermans, Jan A. M.; Philippens, Ingrid H. C. H. M.] Biomed Primate Res Ctr, NL-2288 GJ Rijswijk, Netherlands.
   [Bulthuis, R.] Metris BV, NL-2132 NG Hoofddorp, Netherlands.
   [Clevers, Hans] Univ Med Ctr, NL-3584 CX Utrecht, Netherlands.
   [Coenen, Tineke C. J. J.; van Dijk, K. W.; Kooijman, Sander; Rensen, Patrick C. N.; Ritsma, Laila] Leiden Univ, Med Ctr, NL-2333 ZA Leiden, Netherlands.
   [van Dam, Anne-Marie; la Fleur, Susanne; Heesters, Balthasar A.; Kamermans, Maarten; Lutgens, Esther; de Vries, Taco; Willuhn, Ingo] Univ Amsterdam, Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
   [Elgersma, Ype; van Vlissingen, J. Martje Fentener; Fouchier, Ron; Haagmans, Bart; Herfst, Sander; Kuiken, Thijs; Kushner, Steven A.; Rockx, Barry. H. G.; de Swart, Rik L.; de Vrij, Femke; de Zeeuw, Chris I.] Erasmus MC, NL-3015 GD Rotterdam, Netherlands.
   [la Fleur, Susanne; Kalsbeek, Andries; Kamermans, Maarten; Swaab, Dick F.; Willuhn, Ingo; de Zeeuw, Chris I.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, NL-1105 BA Amsterdam, Netherlands.
   [Fitzsimons, Carlos P.; Korosi, Aniko; Krugers, Harm J.; Lucassen, Paul J.; Mul, Joram D.] Univ Amsterdam, Swammerdam Inst Life Sci, NL-1098 XH Amsterdam, Netherlands.
   [Frieling, Wilbert] Charles River, NL-5231 DD Den Bosch, Netherlands.
   [Jonkers, Jos] Oncode Inst, NL-3521 AL Utrecht, Netherlands.
   [Keijer, J.; Kersten, Sander; van Oers, Kees; Pullox, Bart J. A.; van Schothorst, Evert M.; Stockhofe, Norbert] Wageningen Univ, NL-6708 PB Wageningen, Netherlands.
   [Langermans, Jan A. M.; Lesscher, Heidi; Vanderschuren, Louk J. M. J.; Wierenga, Corette J.] Univ Utrecht, NL-3512 JE Utrecht, Netherlands.
   [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst, D-53115 Bonn, Germany.
   [van Oers, Kees] Wageningen Univ, Netherlands Inst Ecol, NL-6708 PB Wageningen, Netherlands.
   [Stittelaar, K.] Viroclin Xplore, NL-5374 RE Schaijk, Netherlands.
   [Stockhofe, Norbert] Wageningen Bioveterinary Res, NL-8221 RA Lelystad, Netherlands.
RP Genzel, L (corresponding author), Radboud Univ Nijmegen, NL-6525 XZ Nijmegen, Netherlands.; Homberg, JR (corresponding author), Radboud Univ Nijmegen, Med Ctr, NL-6525 GA Nijmegen, Netherlands.
EM l.genzel@donders.ru.nl; Judith.Homberg@radboudumc.nl
RI Kiliaan, Amanda J/D-8778-2012; Genzel, Lisa/B-5716-2017; Joosten, Leo
   AB/H-3138-2015; Wierenga, Corette J./H-2749-2019; van Wezel, Richard R
   J/G-4455-2011; Henckens, Marloes J.A.G./J-7132-2015; Kooijman,
   Sander/S-3857-2016; Koopman, Werner/AAC-9668-2020; Kas, Martien
   J./G-8269-2018; De Swart, Rik/E-6508-2011
OI Genzel, Lisa/0000-0001-9537-7959; Joosten, Leo AB/0000-0001-6166-9830;
   Wierenga, Corette J./0000-0001-9073-4099; van Wezel, Richard R
   J/0000-0001-5753-7069; Henckens, Marloes J.A.G./0000-0002-2375-1611;
   Kooijman, Sander/0000-0002-0014-5571; Koopman,
   Werner/0000-0002-5340-6747; Kas, Martien J./0000-0002-4471-8618;
   Haagmans, Bart/0000-0001-6221-2015; Langermans, Jan/0000-0002-4806-4412;
   Olivier, Jocelien/0000-0003-4654-9763; De Swart, Rik/0000-0003-3599-8969
CR Bao L, 2020, REINFECTION COULD NO, DOI [10.1101/2020.03.13.990226, DOI 10.1101/2020.03.13.990226, 10.1101/2020.03.13.990226.]
   Cohen J, 2020, SCIENCE, V368, P221, DOI 10.1126/science.368.6488.221
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Gerdts V, 2007, FUTURE MICROBIOL, V2, P667, DOI 10.2217/17460913.2.6.667
   Hozain AE, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0971-8
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Stanley DA, 2014, NAT MED, V20, P1126, DOI 10.1038/nm.3702
   Weingartl H, 2004, J VIROL, V78, P12672, DOI 10.1128/JVI.78.22.12672-12676.2004
   Williamson Brandi N, 2020, bioRxiv, DOI 10.1101/2020.04.15.043166
   Zuo T, 2020, GASTROENTEROLOGY, V159, P944, DOI 10.1053/j.gastro.2020.05.048
NR 17
TC 1
Z9 1
U1 8
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD SEP 21
PY 2020
VL 30
IS 18
BP R1014
EP R1018
PG 5
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA NW4JR
UT WOS:000574975200003
PM 32961149
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ji, JJ
   Zhang, JX
   Shao, ZY
   Xie, QF
   Zhong, L
   Liu, ZF
AF Ji, Jingjing
   Zhang, Jinxia
   Shao, Ziyun
   Xie, Qifeng
   Zhong, Li
   Liu, Zhifeng
TI Glucocorticoid therapy does not delay viral clearance in COVID-19
   patients
SO CRITICAL CARE
LA English
DT Letter
DE Glucocorticoid; COVID-19; Viral clearance
C1 [Ji, Jingjing; Liu, Zhifeng] Southern Theater Command PLA, Gen Hosp, Dept Crit Care Med, Guangzhou 510010, Peoples R China.
   [Zhang, Jinxia] Southern Theater Command PLA, Gen Hosp, Cardiovasc Dept, Guangzhou 510010, Peoples R China.
   [Shao, Ziyun] Cent Theater Command PLA, Gen Hosp, Dept Nephrol, Wuhan 430070, Peoples R China.
   [Xie, Qifeng] Southern Theater Command PLA, Gen Hosp, Dept Urol Surg, Guangzhou 510010, Peoples R China.
   [Zhong, Li] Guizhou Univ Chinese Med, Affiliated Hosp 1, Dept Crit Care Med, Guiyang 550001, Peoples R China.
   [Liu, Zhifeng] Southern Med Univ, Gen Hosp, Southern Theater Command PLA, Dept Crit Care Med, Guangzhou 510010, Peoples R China.
RP Liu, ZF (corresponding author), Southern Theater Command PLA, Gen Hosp, Dept Crit Care Med, Guangzhou 510010, Peoples R China.; Liu, ZF (corresponding author), Southern Med Univ, Gen Hosp, Southern Theater Command PLA, Dept Crit Care Med, Guangzhou 510010, Peoples R China.
EM Zhifengliu7797@163.com
OI Reis, AlessanRSS/0000-0001-8486-7469
FU PLA Logistics Research Project of China [18CXZ030, 17CXZ008]
FX This work was supported by grants from the PLA Logistics Research
   Project of China [18CXZ030, 17CXZ008]. The funder of the study had no
   role in study design, data collection, data analysis, data
   interpretation, or writing of the report. The corresponding author had
   full access to all the data in the study and had final responsibility
   for the decision to submit for publication.
CR [Anonymous], 2020, CHIN REC DIAGN TREAT
   Fang X, 2020, J INFECTION, V133, P1039
   Fang XZ, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106257
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
NR 5
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1466-609X
EI 1364-8535
J9 CRIT CARE
JI Crit. Care
PD SEP 21
PY 2020
VL 24
IS 1
AR 565
DI 10.1186/s13054-020-03287-6
PG 4
WC Critical Care Medicine
SC General & Internal Medicine
GA NV9UD
UT WOS:000574655900003
PM 32958060
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Henderson, JA
   Verma, N
   Harris, RC
   Liu, RB
   Shen, J
AF Henderson, Jack A.
   Verma, Neha
   Harris, Robert C.
   Liu, Ruibin
   Shen, Jana
TI Assessment of proton-coupled conformational dynamics of SARS and MERS
   coronavirus papain-like proteases: Implication for designing
   broad-spectrum antiviral inhibitors
SO JOURNAL OF CHEMICAL PHYSICS
LA English
DT Article
ID PH MOLECULAR-DYNAMICS; RESPIRATORY SYNDROME CORONAVIRUS; PARTICLE MESH
   EWALD; PROTEINS; COV; SIMULATIONS; PREDICTION; PARAMETERS; SOLVENT;
   PK(A)
AB Broad-spectrum antiviral drugs are urgently needed to stop the Coronavirus Disease 2019 pandemic and prevent future ones. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is related to the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), which have caused the previous outbreaks. The papain-like protease (PLpro) is an attractive drug target due to its essential roles in the viral life cycle. As a cysteine protease, PLpro is rich in cysteines and histidines, and their protonation/deprotonation modulates catalysis and conformational plasticity. Here, we report the pK(a) calculations and assessment of the proton-coupled conformational dynamics of SARS-CoV-2 in comparison to SARS-CoV and MERS-CoV PLpros using the recently developed graphical processing unit (GPU)-accelerated implicit-solvent continuous constant pH molecular dynamics method with a new asynchronous replica-exchange scheme, which allows computation on a single GPU card. The calculated pK(a)'s support the catalytic roles of the Cys-His-Asp triad. We also found that several residues can switch protonation states at physiological pH among which is C270/271 located on the flexible blocking loop 2 (BL2) of SARS-CoV-2/CoV PLpro. Simulations revealed that the BL2 can open and close depending on the protonation state of C271/270, consistent with the most recent crystal structure evidence. Interestingly, despite the lack of an analogous cysteine, BL2 in MERS-CoV PLpro is also very flexible, challenging a current hypothesis. These findings are supported by the all-atom fixed-charge simulations and provide a starting point for more detailed studies to assist the structure-based design of broad-spectrum inhibitors against CoV PLpros.
C1 [Henderson, Jack A.; Verma, Neha; Harris, Robert C.; Liu, Ruibin; Shen, Jana] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
   [Harris, Robert C.] Aerial Applicat, Washington, DC 20036 USA.
   [Liu, Ruibin] ComputChem LLC, Baltimore, MD 21202 USA.
RP Shen, J (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
EM jana.shen@rx.umaryland.edu
OI VERMA, NEHA/0000-0002-3277-0937
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [GM098818]
FX We acknowledge financial support from the National Institutes of Health
   (Grant No. GM098818).
CR Alexov E, 2011, PROTEINS, V79, P3260, DOI 10.1002/prot.23189
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Case D., 2018, AMBER 2018
   Clementz MA, 2010, J VIROL, V84, P4619, DOI 10.1128/JVI.02406-09
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Ellis CR, 2016, J PHYS CHEM LETT, V7, P944, DOI 10.1021/acs.jpclett.6b00137
   Ellis CR, 2015, J AM CHEM SOC, V137, P9543, DOI 10.1021/jacs.5b05891
   Gallicchio E, 2015, COMPUT PHYS COMMUN, V196, P236, DOI 10.1016/j.cpc.2015.06.010
   Gotz AW, 2012, J CHEM THEORY COMPUT, V8, P1542, DOI 10.1021/ct200909j
   Grum-Tokars V, 2008, VIRUS RES, V133, P63, DOI 10.1016/j.virusres.2007.02.015
   Nguyen H, 2014, J AM CHEM SOC, V136, P13959, DOI 10.1021/ja5032776
   Han YS, 2005, BIOCHEMISTRY-US, V44, P10349, DOI 10.1021/bi0504761
   Harris RC, 2020, J CHEM THEORY COMPUT, V16, P3689, DOI 10.1021/acs.jctc.0c00258
   Harris RC, 2019, J CHEM INF MODEL, V59, P4821, DOI 10.1021/acs.jcim.9b00754
   Harris RC, 2017, J PHYS CHEM LETT, V8, P4832, DOI 10.1021/acs.jpclett.7b02309
   Henderson JA, 2018, J PHYS CHEM LETT, V9, P5440, DOI 10.1021/acs.jpclett.8b02440
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang YD, 2018, J CHEM INF MODEL, V58, P1372, DOI 10.1021/acs.jcim.8b00227
   Huang YD, 2016, J CHEM THEORY COMPUT, V12, P5411, DOI 10.1021/acs.jctc.6b00552
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Khandogin J, 2005, BIOPHYS J, V89, P141, DOI 10.1529/biophysj.105.061341
   Khandogin J, 2006, BIOCHEMISTRY-US, V45, P9363, DOI 10.1021/bi060706r
   Lee H, 2015, ACS CHEM BIOL, V10, P1456, DOI 10.1021/cb500917m
   Lee MS, 2004, PROTEINS, V56, P738, DOI 10.1002/prot.20128
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Lei J, 2017, FEBS LETT, V591, P3190, DOI 10.1002/1873-3468.12827
   Lei J, 2014, ANTIVIR RES, V109, P72, DOI 10.1016/j.antiviral.2014.06.011
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Liu RB, 2019, J AM CHEM SOC, V141, P6553, DOI 10.1021/jacs.8b13248
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Mielech AM, 2014, VIROLOGY, V450, P64, DOI 10.1016/j.virol.2013.11.040
   Mongan J, 2007, J CHEM THEORY COMPUT, V3, P156, DOI 10.1021/ct600085e
   Nguyen H, 2013, J CHEM THEORY COMPUT, V9, P2020, DOI 10.1021/ct3010485
   Pahari S, 2018, PROTEINS, V86, P1277, DOI 10.1002/prot.25608
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Wallace JA, 2011, J CHEM THEORY COMPUT, V7, P2617, DOI 10.1021/ct200146j
   Wang L, 2016, BIOINFORMATICS, V32, P614, DOI 10.1093/bioinformatics/btv607
   Wang L, 2015, PROTEINS, V83, P2186, DOI 10.1002/prot.24935
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
NR 47
TC 1
Z9 1
U1 2
U2 2
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 0021-9606
EI 1089-7690
J9 J CHEM PHYS
JI J. Chem. Phys.
PD SEP 21
PY 2020
VL 153
IS 11
AR 115101
DI 10.1063/5.0020458
PG 10
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA NU1XP
UT WOS:000573435300001
PM 32962355
OA Green Published
DA 2021-01-01
ER

PT J
AU Gonzalez, AJC
   Montenegro-Idrogo, JJ
   Vadillo, ARV
   Torres, MS
   Matos, IV
   Delgado, CPR
AF Chiappe Gonzalez, Alfredo Juan
   Montenegro-Idrogo, Juan Jose
   Vargas Vadillo, Ademir Roberto
   Slee Torres, Milagros
   Vargas Matos, Ivan
   Resurreccion Delgado, Cristhian Pedro
TI Hospital-acquired SARS-CoV-2 pneumonia in a person living with HIV
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE Combination ART (cART); HIV (Human immunodeficiency virus); Location;
   Other; South America; Viral disease
AB We report the case of a 38 year-old man living with well-controlled HIV on antiretroviral therapy who developed cerebellar symptoms and was admitted to hospital for management of an intraventricular cryptococcoma. During his hospital stay he contracted SARS CoV-2 infection within the hospital setting with a fatal outcome.
C1 [Chiappe Gonzalez, Alfredo Juan; Montenegro-Idrogo, Juan Jose; Vargas Vadillo, Ademir Roberto; Slee Torres, Milagros; Resurreccion Delgado, Cristhian Pedro] Hosp Nacl Dos Mayo, Lima, Peru.
   [Vargas Matos, Ivan] Clin Angloamer, Lima, Peru.
RP Gonzalez, AJC (corresponding author), Av 237,Dpto 203, Lima 33, Peru.
EM alfredochiappe911@hotmail.com
OI Chiappe, Alfredo/0000-0003-0687-3112
CR Blanco J, 2020, LANCET HIV
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Ip V, 2020, ANESTH ANALG, V10
   Klompas M, 2020, ANN INTERN MED, V172, P619, DOI 10.7326/M20-0751
   Lu D, 2020, J HOSP INFECT, V104, P454, DOI 10.1016/j.jhin.2020.02.018
   Mungmunpuntipantip R, 2020, INFECT CONTROL HOSP, V1
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101613
   Shiau S, 2020, AIDS BEHAV, V24, P2244, DOI 10.1007/s10461-020-02871-9
NR 8
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD NOV
PY 2020
VL 31
IS 13
BP 1320
EP 1322
AR 0956462420957528
DI 10.1177/0956462420957528
EA SEP 2020
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA OK4EJ
UT WOS:000572119500001
PM 32951564
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Biswas, SK
   Ghosh, JK
   Sarkar, S
   Ghosh, U
AF Biswas, Sudhanshu Kumar
   Ghosh, Jayanta Kumar
   Sarkar, Susmita
   Ghosh, Uttam
TI COVID-19 pandemic in India: a mathematical model study
SO NONLINEAR DYNAMICS
LA English
DT Article
DE Basic reproduction number; COVID-19; Asymptomatic class; Quarantine;
   Sensitivity analysis; Prevention measure
ID DYNAMICS; DISEASE; DENGUE; OUTBREAK; WUHAN; CHINA
AB The present novel coronavirus (SARS-CoV-2) infection has created a global emergency situation by spreading all over the world in a large scale within very short time period. But there is no vaccine, anti-viral medicine for such infection. So at this moment, a major worldwide problem is that how we can control this pandemic. On the other hand, India is high population density country, where the coronavirus infection disease (COVID-19) has started from 1 March 2020. Due to high population density, human to human social contact rate is very high in India. So controlling pandemic COVID-19 in early stage is very urgent and challenging problem of India. Mathematical models are employed to study the disease dynamics, identify the influential parameters and access the proper prevention strategies for reduction outbreak size. In this work, we have formulated a deterministic compartmental model to study the spreading of COVID-19 and estimated the model parameters by fitting the model with reported data of ongoing pandemic in India. Sensitivity analysis has been done to identify the influential model parameters. The basic reproduction number has been estimated from actual data and the effective basic reproduction number has been studied on the basis of reported cases. Some effective preventive measures and their impact have also been studied. Prediction are given on the future trends of the virus transmission under some control measures. Finally, the positive measures to control the disease have been summarized in the conclusion section.
C1 [Biswas, Sudhanshu Kumar] Sripat Singh Coll, Murshidabad, W Bengal, India.
   [Ghosh, Jayanta Kumar; Sarkar, Susmita; Ghosh, Uttam] Univ Calcutta, Dept Appl Math, Kolkata, India.
RP Ghosh, U (corresponding author), Univ Calcutta, Dept Appl Math, Kolkata, India.
EM uttam_math@yahoo.co.in
CR Biswas SK, 2020, INFECT DIS MODEL, V5, P23, DOI 10.1016/j.idm.2019.12.001
   Bogoch II, 2020, J TRAVEL MED, DOI [10.1056/NEJMoa2002032, DOI 10.1056/NEJMOA2002032]
   Brauer F., 2001, MATH MODELS POPULATI
   Chitnis N, 2008, B MATH BIOL, V70, P1272, DOI 10.1007/s11538-008-9299-0
   Chowell G., 2003, LAUR032653
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Favier C, 2006, TROP MED INT HEALTH, V11, P332, DOI 10.1111/j.1365-3156.2006.01560.x
   Hethcote HW, 2000, SIAM REV, V42, P599, DOI 10.1137/S0036144500371907
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Lakshmikantham V., 1989, STABILITY ANAL NONLI
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Ma Z, 2009, DYNAMICAL MODELING A
   Martcheva M., 2015, INTRO MATH EPIDEMIOL
   Massad E, 2010, TROP MED INT HEALTH, V15, P120, DOI 10.1111/j.1365-3156.2009.02413.x
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   National Centre for Disease Control, COVID 19 OUTBR CHIN
   National Centre for Disease Control, 2020, TRAV ADV
   Pinho STR, 2010, PHILOS T R SOC A, V368, P5679, DOI 10.1098/rsta.2010.0278
   Sardar T, 2015, MATH BIOSCI, V263, P18, DOI 10.1016/j.mbs.2015.01.009
   Social distancing, 2020, SOC DIST QUAR IS CDC
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   Wallinga J, 2007, P ROY SOC B-BIOL SCI, V274, P599, DOI 10.1098/rspb.2006.3754
   WHO, 2019, MIDDL E RESP SYNDR C
   WHO, 2020, PNEUM UNK CAUS CHIN
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, UPD WHO ADV INT TRAF
   Worldometer, 2020, COVID 19 COR PAND
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
NR 30
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0924-090X
EI 1573-269X
J9 NONLINEAR DYNAM
JI Nonlinear Dyn.
PD SEP
PY 2020
VL 102
IS 1
BP 537
EP 553
DI 10.1007/s11071-020-05958-z
EA SEP 2020
PG 17
WC Engineering, Mechanical; Mechanics
SC Engineering; Mechanics
GA OG5NP
UT WOS:000571729000002
PM 32982061
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Haghani, M
   Bliemer, MCJ
AF Haghani, Milad
   Bliemer, Michiel C. J.
TI Covid-19 pandemic and the unprecedented mobilisation of scholarly
   efforts prompted by a health crisis: Scientometric comparisons across
   SARS, MERS and 2019-nCoV literature
SO SCIENTOMETRICS
LA English
DT Article; Early Access
DE Scientometrics; Bibliometrics; Research synthesis; Coronaviruses; Viral
   respiratory diseases
ID CORONAVIRUSES
AB During the current century, each major coronavirus outbreak has triggered a quick and immediate surge of academic publications on its respective topic. The spike in research publications following the 2019 Novel Coronavirus (Covid-19) outbreak, however, has been like no other. The global crisis caused by the Covid-19 pandemic has mobilised scientific efforts at an unprecedented scale. In less than 5 months, more than 12,000 research items and in less than seven months, more than 30,000 items were indexed, while it is projected that the number could exceed 80,000 by the end of 2020, should the current trend continues. With the health crisis affecting all aspects of life, research on Covid-19 seems to have become a focal point of interest across many academic disciplines. Here, scientometric aspects of the Covid-19 literature are analysed and contrasted with those of the two previous major coronavirus diseases, i.e., Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). The focus is on the co-occurrence of key-terms, bibliographic coupling and citation relations of journals and collaborations between countries. Interesting recurring patterns across all three literatures were discovered. All three outbreaks have commonly generated three distinct cohorts of studies: (i) studies linked to public health response and epidemic control, (ii) studies on chemical constitution of the virus; and (iii) studies related to treatment, vaccine and clinical care. While studies affiliated with category (i) seem to have been relatively earliest to emerge, they have overall received relatively smaller number of citations compared to publications the two other categories. Covid-19 studies seem to have been disseminated across a broader variety of journals and across a more diverse range of subject areas. Clear links are observed between the geographical origins of each outbreak as well as the local geographical severity of each outbreak and the magnitude of research originated from regions. Covid-19 studies also display the involvement of authors from a broader variety of countries compared to SARS and MERS. Considering the speed at which the Covid-19-related literature is accumulating, an interesting dimension that warrants further exploration could be to assess if the quality and rigour of these publications have been affected.
C1 [Haghani, Milad; Bliemer, Michiel C. J.] Univ Sydney, Business Sch, Inst Transport & Logist Studies, Sydney, NSW, Australia.
RP Haghani, M (corresponding author), Univ Sydney, Business Sch, Inst Transport & Logist Studies, Sydney, NSW, Australia.
EM Milad.haghani@sydney.edu.au
CR Almeida JD, 1968, NATURE, V220, P650
   Anggraeni S., 2020, INDONESIAN J SCI TEC, V5, P18
   Barmparis GD, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109842
   Bekiros S, 2020, CHAOS SOLITON FRACT, V136, DOI 10.1016/j.chaos.2020.109828
   Boccaletti S, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109794
   Brainard J., 2020, SCIENCE, DOI [10.1126/science.abc7839, DOI 10.1126/SCIENCE.ABC7839]
   Bychkova OV, 2020, SOC ANTHROPOL, V28, P233, DOI 10.1111/1469-8676.12884
   Cavanagh D, 2005, BIRK ADV INFECT DIS, P1
   Chahrour M, 2020, CUREUS, V12, DOI 10.7759/cureus.7357
   Chang L, 2020, TRANSFUS MED REV, V34, P75, DOI 10.1016/j.tmrv.2020.02.003
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cherry JD, 2004, PEDIATR RES, V56, P1, DOI 10.1203/01.PDR.0000129184.87042.FC
   Colavizza G, 2020, A SCIENTOMETRIC OVER, V3, P993
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Ribeiro MHD, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109853
   Dandekar A, 2020, ECON POLIT WEEKLY, V55, P28
   De Vos J., 2020, TRANSP RES INTERDISC, V5, P100121, DOI DOI 10.1016/J.TRIP.2020.100121
   Dehghanbanadaki Hojat, 2020, Med J Islam Repub Iran, V34, P51, DOI 10.34171/mjiri.34.51
   Golinelli D, 2020, IMPACT EARLY SCI LIT, DOI [10.1101/2020.04.15.20066183, DOI 10.1101/2020.04.15.20066183]
   Haghani M, 2020, SAFETY SCI, V129, DOI 10.1016/j.ssci.2020.104806
   Hossain M. M., 2020, SSRN, DOI [10.2139/ssrn.3547824, DOI 10.2139/SSRN.3547824]
   Jarvis C, 2020, J PEER REV COPE SURG
   Kagan D, 2020, SCIENTOMETRIC TRENDS, V46, P416
   Karaseva A, 2020, SOC ANTHROPOL, V28, P294, DOI 10.1111/1469-8676.12825
   Bonilla-Aldana DK, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101566
   KNIGHT CA, 1954, ADV VIRUS RES, V2, P153, DOI 10.1016/S0065-3527(08)60532-1
   Kostoff RN, 2011, SCIENTOMETRICS, V86, P195, DOI 10.1007/s11192-010-0240-6
   Kumar K, 2020, AUTHOR PRODUCTIVITY, DOI [10.2139/ssrn.3603889, DOI 10.2139/SSRN.3603889]
   Le Bras P., 2020, ARXIV200506380
   LEE D, 2020, J MECH SCI TECH 0303, DOI DOI 10.1016/j.trip.2020.100111
   Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026
   McIntosh K., 1974, Current Topics in Microbiology and Immunology, V63, P85
   Mulchandani P, 2020, ECON POLIT WEEKLY, DOI [10.2139/ssrn.3663113, DOI 10.2139/SSRN.3663113]
   MYINT SH, 1994, REV MED VIROL, V4, P35, DOI 10.1002/rmv.1980040108
   Ndairoua F, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109846
   Olijnyk NV, 2015, SCIENTOMETRICS, V105, P623, DOI 10.1007/s11192-015-1688-1
   Postnikov EB, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109841
   Reardon Thomas, 2020, EC POLITIC WKLY, V55, P18
   Sedaju A, 2020, INT J ADV SCI TECHNO, V29, P3914
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Tian DQ, 2015, SCIENTOMETRICS, V105, P485, DOI 10.1007/s11192-015-1681-8
   Torres-Salinas D, 2020, BIORXIV, V26, P420
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wesemann C, 2020, MATERIALS, V13, DOI 10.3390/ma13081997
   Zhang XL, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109829
NR 46
TC 0
Z9 0
U1 16
U2 16
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0138-9130
EI 1588-2861
J9 SCIENTOMETRICS
JI Scientometrics
DI 10.1007/s11192-020-03706-z
EA SEP 2020
PG 32
WC Computer Science, Interdisciplinary Applications; Information Science &
   Library Science
SC Computer Science; Information Science & Library Science
GA NR6SE
UT WOS:000571691800007
PM 32981988
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rayman, G
   Lumb, AN
   Kennon, B
   Cottrell, C
   Nagi, D
   Page, E
   Voigt, D
   Courtney, HC
   Atkins, H
   Higgins, K
   Platts, J
   Dhatariya, K
   Patel, M
   Newland-Jones, P
   Narendran, P
   Kar, P
   Burr, O
   Thomas, S
   Stewart, R
AF Rayman, G.
   Lumb, A. N.
   Kennon, B.
   Cottrell, C.
   Nagi, D.
   Page, E.
   Voigt, D.
   Courtney, H. C.
   Atkins, H.
   Higgins, K.
   Platts, J.
   Dhatariya, K.
   Patel, M.
   Newland-Jones, P.
   Narendran, P.
   Kar, P.
   Burr, O.
   Thomas, S.
   Stewart, R.
TI Dexamethasone therapy in COVID-19 patients: implications and guidance
   for the management of blood glucose in people with and without diabetes
SO DIABETIC MEDICINE
LA English
DT Letter; Early Access
C1 [Rayman, G.] East Suffolk & North Essex NHS Fdn Trust, Ipswich Diabet Ctr, Colchester, Essex, England.
   [Lumb, A. N.] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Oxford, England.
   [Kennon, B.] Queen Elizabeth Univ Hosp, Dept Diabet, Glasgow, Lanark, Scotland.
   [Cottrell, C.] Swansea Bay Univ Hlth Board, Port Talbot, Wales.
   [Nagi, D.] Mid Yorkshire Hosp NHS Trust, Wakefield, England.
   [Page, E.] Ipswich Hosp NHS Trust, Diabet Ctr, Ipswich, Suffolk, England.
   [Voigt, D.] NHS Tayside, Ninewells Hosp, Dundee, Scotland.
   [Courtney, H. C.] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Atkins, H.; Higgins, K.] Univ Hosp Leicester NHS Trust, Leicester, Leics, England.
   [Platts, J.] Cardiff & Vale Univ Hlth Board, Cardiff, Wales.
   [Dhatariya, K.] Norfolk & Norwich Univ Hosp NHS Trust, Diabet Ctr, Norwich, Norfolk, England.
   [Patel, M.; Newland-Jones, P.] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England.
   [Narendran, P.] Queen Elizabeth Hosp Birmingham, Birmingham, W Midlands, England.
   [Kar, P.] NHS England, NHS Diabet Programme, London, England.
   [Burr, O.] Diabet UK, London, England.
   [Thomas, S.] Kings Coll Hosp London, Diabet Ctr, London, England.
   [Stewart, R.] Wrexham Maelor Hosp, Gladstone Ctr, Wrexham, Wales.
RP Rayman, G (corresponding author), East Suffolk & North Essex NHS Fdn Trust, Ipswich Diabet Ctr, Colchester, Essex, England.
OI Lumb, Alistair/0000-0001-7041-9534; Narendran,
   Parth/0000-0002-4583-8793; Page, Emma/0000-0002-6998-7064; Dhatariya,
   Ketan/0000-0003-3619-9579
CR Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Dashora UK, 2003, DIABETIC MED, V21, P297
   Rayman G, 2020, DIABETIC MED, V37, P1214, DOI 10.1111/dme.14328
   Roberts A, 2018, DIABETIC MED, V35, P1011, DOI 10.1111/dme.13675
NR 4
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
AR e14378
DI 10.1111/dme.14378
EA SEP 2020
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NR5OA
UT WOS:000571611100001
PM 32740972
OA Green Published
DA 2021-01-01
ER

PT J
AU Blum, K
   Cadet, JL
   Baron, D
   Badgaiyan, RD
   Brewer, R
   Modestino, EJ
   Gold, MS
AF Blum, Kenneth
   Cadet, Jean Lud
   Baron, David
   Badgaiyan, Rajendra D.
   Brewer, Raymond
   Modestino, Edward J.
   Gold, Mark S.
TI Putative COVID-19 Induction of Reward Deficiency Syndrome (RDS) and
   Associated Behavioral Addictions with Potential Concomitant Dopamine
   Depletion: Is COVID-19 Social Distancing a Double Edged Sword?
SO SUBSTANCE USE & MISUSE
LA English
DT Article
DE COVID-19 pandemic; epigenetic insults; mental illness; stress;
   immunologic function; dopamine homeostasis; behavioral addiction
ID ALCOHOL-CONSUMPTION; STRESS; EXPOSURE
AB Background The overwhelming fatalities of the global COVID-19 Pandemic will have daunting epigenetic sequala that can translate into an array of mental health issues, including panic, phobia, health anxiety, sleep disturbances to dissociative like symptoms including suicide.Method:We searched PUBMED for articles listed using the search terms "COVID 19 Pandemic", COVID19 and genes," "stress and COVID 19", Stress and Social distancing:Results:Long-term social distancing may be neurologically harmful, the consequence of epigenetic insults to the gene encoding the primary receptor for SARS-CoV2, and COVID 19. The gene is Angiotensin I Converting-Enzyme 2 (ACE2). According to the multi-experiment matrix (MEM), the gene exhibiting the most statistically significant co-expression link to ACE2 is Dopa Decarboxylase (DDC). DDC is a crucial enzyme that participates in the synthesis of both dopamine and serotonin. SARS-CoV2-induced downregulation of ACE2 expression might reduce dopamine and serotonin synthesis, causing hypodopaminergia.Discussion:Indeed, added to the known reduced dopamine function during periods of stress, including social distancing the consequence being both genetic and epigenetic vulnerability to all Reward Deficiency Syndrome (RDS) addictive behaviors. Stress seen in PTSD can generate downstream alterations in immune functions by reducing methylation levels of immune-related genes.Conclusion:Mitigation of these effects by identifying subjects at risk and promoting dopaminergic homeostasis to help regulate stress-relative hypodopaminergia, attenuate fears, and prevent subsequent unwanted drug and non-drug RDS type addictive behaviors seems prudent.
C1 [Blum, Kenneth; Baron, David] Western Univ Hlth Sci, Grad Coll, Pomona, CA 91766 USA.
   [Blum, Kenneth] Wright Univ, Boonshoff Sch Med, Dept Psychiat, Dayton, OH USA.
   [Blum, Kenneth; Brewer, Raymond] Geneus Hlth LLC, Div Nutrigen, Geneus Genom Testing Ctr, San Antonio, TX USA.
   [Blum, Kenneth] Eotvos Lorand Univ, Inst Psychol, Budapest, Hungary.
   [Cadet, Jean Lud] NIDA, Mol Neuropsychiat Res Branch, NIH, Bethesda, MD 20892 USA.
   [Badgaiyan, Rajendra D.] Univ Texas Hlth Sci Ctr San Antonio, Long Sch Med, Dept Psychiat, San Antonio, TX 78229 USA.
   [Modestino, Edward J.] Curry Coll, Dept Psychol, Milton, MA USA.
   [Gold, Mark S.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
RP Blum, K (corresponding author), Western Univ Hlth Sci, Grad Coll, Pomona, CA 91766 USA.
EM drd2gene@gmail.com
OI Blum, Kenneth/0000-0001-6727-803X; Modestino,
   Edward/0000-0001-7611-5144; Reis, AlessanRSS/0000-0001-8486-7469
CR Adler P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-12-r139
   AHORSU DK, 2020, INT J MENT HEAL 0327, DOI DOI https://doi.org/10.1007/s11469-020-00270-8
   [Anonymous], 2013, Sci News, V184, P18, DOI 10.1002/scin.5591841312
   Arreola R, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/3160486
   Banday AA, 2019, AM J PHYSIOL-RENAL, V317, pF949, DOI 10.1152/ajprenal.00135.2019
   Banerjee D, 2020, ASIAN J PSYCHIATR, V50, DOI 10.1016/j.ajp.2020.102014
   Beseler CL, 2011, ALCOHOL CLIN EXP RES, V35, P1004, DOI 10.1111/j.1530-0277.2010.01431.x
   Blum K, 2019, J Syst Integr Neurosci, V5, P1
   Blum K, 2018, Open Access J Behav Sci Psychol, V1, P1
   BLUM K, 2018, FRONT PSYCHIATRY, V9, DOI DOI https://doi.org/10.3389/fpsyt.2018.00548
   Blum K., 2020, CURRENT PSYCHOPHARMA, V9, DOI [https://doi.org/10.2174/2211556008666191111103152, DOI 10.2174/2211556008666191111103152]
   Blum K, 2015, J BEHAV ADDICT, V4, P1
   Cabot PJ, 2001, PAIN, V93, P207, DOI 10.1016/S0304-3959(01)00322-0
   Clay JM, 2020, LANCET PUBLIC HEALTH, V5, pE259, DOI 10.1016/S2468-2667(20)30088-8
   Courtemanche C, 2020, HEALTH AFFAIR, V39, P1237, DOI 10.1377/hlthaff.2020.00608
   Davis C, 2013, ADDICT BEHAV, V38, P2306, DOI 10.1016/j.addbeh.2013.02.012
   Edwards Drew, 2020, J Addict Sci, V6, P1
   Fineberg NA, 2018, EUR NEUROPSYCHOPHARM, V28, P1232, DOI 10.1016/j.euroneuro.2018.08.004
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Hasin DS, 2007, AM J PUBLIC HEALTH, V97, P2268, DOI 10.2105/AJPH.2006.100057
   KIRALY O, 2020, COMPR PSYCHIAT, V100, DOI DOI https://doi.org/10.1016/j.comppsych.2020.152180
   Klempin F, 2018, CELL MOL LIFE SCI, V75, P3625, DOI 10.1007/s00018-018-2815-y
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kar SK, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102064
   Leece P, 2015, J SUBST ABUSE TREAT, V57, P30, DOI 10.1016/j.jsat.2015.04.008
   Li JH, 2004, J NEUROCHEM, V90, P1117, DOI 10.1111/j.1471-4159.2004.02569.x
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Lin X, 2020, CELL MICROBIOL, V22, DOI 10.1111/cmi.13150
   Mackenzie JS, 2020, MICROBIOL AUST, V41, P45, DOI 10.1071/MA20013
   McLaughlin Thomas, 2016, J Reward Defic Syndr Addict Sci, V2, P3, DOI 10.17756/jrdsas.2016-022
   Morens DM, 2020, NEW ENGL J MED, V382, P1293, DOI 10.1056/NEJMp2002106
   Park S, 2010, NANO, V5, P1, DOI 10.1142/S1793292010001822
   Pawlak R, 2001, BRAIN RES BULL, V54, P689, DOI 10.1016/S0361-9230(01)00489-0
   Peeters M, 2019, J BEHAV ADDICT, V8, P574, DOI 10.1556/2006.8.2019.55
   Smith ACW, 2018, GENES BRAIN BEHAV, V17, DOI 10.1111/gbb.12424
   SMITH DE, 1969, AM J PUBLIC HEALTH N, V59, P2046, DOI 10.2105/AJPH.59.11.2046
   Uddin M, 2010, P NATL ACAD SCI USA, V107, P9470, DOI 10.1073/pnas.0910794107
   Van Rooij AJ, 2018, J BEHAV ADDICT, V7, P1, DOI 10.1556/2006.7.2018.19
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Welch AE, 2014, DRUG ALCOHOL DEPEN, V140, P1, DOI 10.1016/j.drugalcdep.2014.04.013
   YAO H, 2020, ASIAN J PSYCHIATR, V50
   Zhang DD, 2015, PLANT SCI, V237, P24, DOI 10.1016/j.plantsci.2015.05.002
   Zieker J, 2007, MOL PSYCHIATR, V12, P116, DOI 10.1038/sj.mp.4001905
NR 43
TC 0
Z9 0
U1 7
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6084
EI 1532-2491
J9 SUBST USE MISUSE
JI Subst. Use Misuse
PD SEP 21
PY 2020
VL 55
IS 14
BP 2438
EP 2442
DI 10.1080/10826084.2020.1817086
EA SEP 2020
PG 5
WC Substance Abuse; Psychiatry; Psychology
SC Substance Abuse; Psychiatry; Psychology
GA OH5UM
UT WOS:000571563300001
PM 32957797
DA 2021-01-01
ER

PT J
AU Kneitz, C
   Muller-Ladner, U
AF Kneitz, C.
   Mueller-Ladner, U.
TI Most important vaccinations in patients with rheumatological diseases
   and why
SO ZEITSCHRIFT FUR RHEUMATOLOGIE
LA German
DT Article
DE Immunosuppressive therapy; Risk of infection; Immunity;
   Multidrug-resistant pathogen; Herd immunity
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; PNEUMOCOCCAL
   VACCINES; OPEN-LABEL; LONG-TERM; INFLUENZA; IMMUNOGENICITY; COVERAGE;
   IMPACT
AB For a long time, most of the infectious diseases seemed to have become under control. In particular, vaccinations have contributed to this development. In recent years newly occurring bacterial infections caused by multidrug-resistant pathogens and viral infections, such as the chikungunya virus, influenza epidemics and currently the COVID-19 pandemic, are endangering the world population. This specifically affects patients with rheumatological diseases, who often require immunosuppressive therapy and are thus at risk for infections. Vaccinations can protect those affected, both individually and by generating herd immunity, and are thus an important instrument to reduce morbidity and mortality from infections. Knowledge of the indications and application of the individual vaccinations is particularly important for consistent implementation of the current recommendations.
C1 [Kneitz, C.] Rheumatol Schwerpunktpraxis Schwerin, Beethovenstr 3, D-19053 Schwerin, Germany.
   [Mueller-Ladner, U.] Justus Liebig Univ Giessen, Abt Rheumatol & Klin Immunol, Campus Kerckhoff, Bad Nauheim, Germany.
RP Kneitz, C (corresponding author), Rheumatol Schwerpunktpraxis Schwerin, Beethovenstr 3, D-19053 Schwerin, Germany.
EM christian.kneitz@rheuma-schwerin.de
CR [Anonymous], 2019, EPIDEMIOLOGISCHES B, V34
   Bingham CO, 2015, ANN RHEUM DIS, V74, P818, DOI 10.1136/annrheumdis-2013-204427
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Brisson M, 2020, LANCET, V395, P575, DOI 10.1016/S0140-6736(20)30068-4
   Chehab G, 2018, RHEUMATOLOGY, V57, P1439, DOI 10.1093/rheumatology/key120
   Cooper S, 2019, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD013265, DOI 10.1002/14651858.CD013265]
   Feuchtenberger M, 2012, RHEUMATOL INT, V32, P1533, DOI 10.1007/s00296-011-1808-z
   Furer V, 2019, ANN RHEUM DIS, DOI [10.1136/annrheumdis-2019-21588, DOI 10.1136/ANNRHEUMDIS-2019-21588]
   Hertzell KB, 2016, VACCINE, V34, P650, DOI 10.1016/j.vaccine.2015.12.029
   Hmamouchi I, 2015, VACCINE, V33, P1446, DOI 10.1016/j.vaccine.2015.01.065
   Holvast A, 2009, RHEUMATOLOGY, V48, P1294, DOI 10.1093/rheumatology/kep200
   Huang YF, 2017, CURR MED RES OPIN, V33, P1901, DOI 10.1080/03007995.2017.1329140
   Intongkam S, 2019, JCR-J CLIN RHEUMATOL, V25, P329, DOI 10.1097/RHU.0000000000000877
   Izumi Y, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-016-1207-7
   Kaine JL, 2007, J RHEUMATOL, V34, P272
   Kobashigawa T, 2013, SCAND J RHEUMATOL, V42, P445, DOI 10.3109/03009742.2013.788733
   Lindsey NP, 2008, VACCINE, V26, P6077, DOI 10.1016/j.vaccine.2008.09.009
   Mok CC, 2018, VACCINE, V36, P3301, DOI 10.1016/j.vaccine.2018.04.056
   Niehues T, 2017, BUNDESGESUNDHEITSBLA, V60, P674, DOI 10.1007/s00103-017-2555-4
   Park JK, 2018, ANN RHEUM DIS, V77, P898, DOI 10.1136/annrheumdis-2018-213222
   Pleguezuelos O, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0174-9
   Puges M, 2016, RHEUMATOLOGY, V55, P1664, DOI 10.1093/rheumatology/kew211
   Rondaan C, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-001035
   Rosdahl A, 2018, TRAVEL MED INFECT DI, V21, P43, DOI 10.1016/j.tmaid.2017.12.004
   Schulte K, 2019, DTSCH ARZTEBL INT, V116, P413, DOI 10.3238/arztebl.2019.0413
   Vu T, 2002, VACCINE, V20, P1831, DOI 10.1016/S0264-410X(02)00041-5
   Wagner N, 2019, BUNDESGESUNDHEITSBLA, V62, P494, DOI 10.1007/s00103-019-02905-1
   Walker UA, 2016, ARTHRITIS RHEUMATOL, V68, P516, DOI 10.1002/art.39482
   Whittembury A, 2009, VACCINE, V27, P5974, DOI 10.1016/j.vaccine.2009.07.082
NR 29
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-1855
EI 1435-1250
J9 Z RHEUMATOL
JI Z. Rheumatol.
PD NOV
PY 2020
VL 79
IS 9
SI SI
BP 855
EP 864
DI 10.1007/s00393-020-00875-3
EA SEP 2020
PG 10
WC Rheumatology
SC Rheumatology
GA OO1BB
UT WOS:000571668300002
PM 32955610
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Baicus, C
   Pinte, L
   Stoichitoiu, LE
   Badea, C
AF Baicus, Cristian
   Pinte, Larisa
   Stoichitoiu, Laura E.
   Badea, Camelia
TI Hydroxychloroquine for prophylaxis ofCOVID-19 physicians survey: Despite
   lack of evidence, many would take or give to dear ones, and despite the
   perceived necessity of anRCT, few would participate
SO JOURNAL OF EVALUATION IN CLINICAL PRACTICE
LA English
DT Article
DE COVID-19; hydroxychloroquine; physicians; prophylaxis; randomized
   controlled trial; survey
AB Introduction There was no evidence concerning the prophylaxis with hydroxychloroquine, and only low-grade evidence regarding the use of hydroxychloroquine as a treatment for COVID-19 patients. We performed a survey among Romanian physicians in order to see how many of them would administer prophylactically hydroxychloroquine to themselves or to people close to them, and if they would participate to a randomized controlled trial. Methods Between March 30 and April 02, 2020, a 16-item questionnaire was shared in a Romanian Facebook group of 2645 physicians dedicated to COVID-19 information, asking to be completed by physicians who could be directly involved in the care of these patients. Results A total of 785 answers were collected. Nine physicians (1.1%) thought that there was clear evidence on prescribing hydroxychloroquine prophylaxis, 375 (48%) considered the evidence acceptable, 348 (44.3%) considered it weak, whereas 53 (6.8%) answered there was no evidence. 59 (7.5%) respondents were determined to take it (of which 31 = 4% already took), 192 (24.5%) were inclined to take, 271 (34.5%) were not decided yet. 175 (22.3%) of respondents declared they (would) give the treatment to their close ones, and this decision was associated with a higher age (P= 0.003), and the opinion that there was evidence (P < 0.001). When asked about the source of the treatment regimen, 286 (36.4%) indicated a scientific paper, while no scientific paper about the prophylaxis with hydroxychloroquine existed at that time. 718 (91.5%) considered a randomized clinical trial necessary (RCT), but only 333 (42.4%) answered they would enrol in such a trial. There was only a very weak correlation (Kendall's tau _b = 0.255,P < 0.001) between the belief that an RCT is necessary and the willingness to enrol in such an RCT. Conclusions Despite the lack of evidence, many physicians considered the evidence as existing, and were ready to take or to give hydroxychloroquine prophylactically to family. They considered an RCT necessary, but they were not willing to participate.
C1 [Baicus, Cristian; Pinte, Larisa; Stoichitoiu, Laura E.; Badea, Camelia] Colentina Hosp, Dept Internal Med, Soseaua Stefan Cel Mare 19-21,Sect 2, Bucharest 020125, Romania.
   [Baicus, Cristian; Pinte, Larisa; Badea, Camelia] Univ Med & Pharm Carol Davila Bucharest, Bucharest, Romania.
   [Baicus, Cristian; Pinte, Larisa; Stoichitoiu, Laura E.] Reseau Epidemiol Clin Int Francophone, Clin Res Unit, Bucharest, Romania.
RP Stoichitoiu, LE (corresponding author), Colentina Hosp, Dept Internal Med, Soseaua Stefan Cel Mare 19-21,Sect 2, Bucharest 020125, Romania.
EM laura.elena.stoich@gmail.com
OI Stoichitoiu, Laura Elena/0000-0002-0234-0856
CR [Anonymous], 2020, BMJ, V369, pm2170, DOI 10.1136/bmj.m2170
   Baicus C, 2017, EUR J CLIN INVEST, V47, P649, DOI 10.1111/eci.12786
   Chatterjee P, 2020, INDIAN J MED RES, V151, P459, DOI 10.4103/ijmr.IJMR_2234_20
   ClinicalTrials.gov, SEARCH PLAQ COVID ST
   Gangopadhyay KK, 2020, DIABETES METAB SYND, V14, P1413, DOI 10.1016/j.dsx.2020.07.040
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gendelman O, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102566
   Grau-Pujol B, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04621-7
   Lofgren Sarah M, 2020, medRxiv, DOI 10.1101/2020.07.16.20155531
   NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X
   Qaseem A, 2020, ANN INTERN MED, V173, pW88, DOI 10.7326/L20-1007
   Rakedzon S, 2020, RAMBAM MAIMONIDES ME, V11, DOI 10.5041/RMMJ.10416
   Shah SK, 2020, INT J RHEUM DIS, V23, P613, DOI 10.1111/1756-185X.13842
   Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980
   Swennen MHJ, 2013, ACAD MED, V88, P1384, DOI 10.1097/ACM.0b013e31829ed3cc
   Ubel PA, 2011, ARCH INTERN MED, V171, P630, DOI 10.1001/archinternmed.2011.91
NR 16
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1356-1294
EI 1365-2753
J9 J EVAL CLIN PRACT
JI J. Eval. Clin. Pract.
PD DEC
PY 2020
VL 26
IS 6
BP 1579
EP 1582
DI 10.1111/jep.13484
EA SEP 2020
PG 4
WC Health Care Sciences & Services; Medical Informatics; Medicine, General
   & Internal
SC Health Care Sciences & Services; Medical Informatics; General & Internal
   Medicine
GA OQ2VL
UT WOS:000571282700001
PM 32955801
OA Green Published
DA 2021-01-01
ER

PT J
AU Daniell, H
AF Daniell, Henry
TI From conception to COVID-19: an arduous journey of tribulations of
   racism and triumphs
SO PLANT BIOTECHNOLOGY JOURNAL
LA English
DT Article
DE biopharmaceuticals; chloroplast; enzymes; genetic engineering; genome;
   vaccines
ID ORAL TOLERANCE INDUCTION; CHLOROPLAST GENOME; EXPRESSION; TOBACCO; GENE;
   CELLS; OVEREXPRESSION; TRANSFORMATION; PROTOPLASTS; GENERATION
AB Growing up in a densely wooded tropical forest enhanced my curiosity in plants and reading biography of Marie Curie profoundly influenced pursuit of my research career. Early in my career, I developed in vitro functional chloroplasts, capable of expressing foreign genes and this laid the foundation for the chloroplast genetic engineering field. Four decades of research has advanced chloroplast bioreactors for production of industrial enzymes or biopharmaceuticals by small or large companies. Because I experienced firsthand horrors of expensive vaccines or medicines, I devoted most of my career to develop affordable therapeutics. During this long journey, I suffered institutional racial discrimination but was rescued by several guardian angels. This biography gives readers a glimpse of tribulations and triumphs of my journey and recognizes important contributions made by my mentees.
C1 [Daniell, Henry] Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA.
RP Daniell, H (corresponding author), Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA.
EM hdaniell@upenn.edu
OI Daniell, Henry/0000-0003-4485-1176
CR [Anonymous], 2020, CELL, V181, P1443, DOI 10.1016/j.cell.2020.06.009
   BONNETT HT, 1976, PLANTA, V131, P229, DOI 10.1007/BF00385420
   BONNETT HT, 1974, PLANTA, V120, P71, DOI 10.1007/BF00388272
   Chan HT, 2016, PLANT BIOTECHNOL J, V14, P2190, DOI 10.1111/pbi.12575
   Chan HT, 2015, PLANT BIOTECHNOL J, V13, P1056, DOI 10.1111/pbi.12471
   DANIELL H, 1986, MOL GEN GENET, V204, P243, DOI 10.1007/BF00425505
   Daniell H, 2001, J MOL BIOL, V311, P1001, DOI 10.1006/jmbi.2001.4921
   Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345
   DANIELL H, 1990, P NATL ACAD SCI USA, V87, P88, DOI 10.1073/pnas.87.1.88
   DANIELL H, 1987, P NATL ACAD SCI USA, V84, P6349, DOI 10.1073/pnas.84.18.6349
   DANIELL H, 1986, BIOCHEM BIOPH RES CO, V135, P248, DOI 10.1016/0006-291X(86)90969-1
   DANIELL H, 1986, P NATL ACAD SCI USA, V83, P2546, DOI 10.1073/pnas.83.8.2546
   Daniell H., 1988, US patents, Patent No. [5,693,507, 5693507]
   Daniell H., 1988, US patents, Patent No. [7,135,620, 7135620]
   Daniell H., 1988, US patents, Patent No. [6,680,426, 6680426]
   Daniell H., 1988, US patents, Patent No. [5,932,479, 5932479]
   Daniell H., 1988, US patents, Patent No. [6,642,053, 6642053]
   Daniell H, 2020, BIOMATERIALS, V233, DOI 10.1016/j.biomaterials.2019.119750
   Daniell H, 2019, BIOTECHNOL ADV, V37, DOI 10.1016/j.biotechadv.2019.06.012
   Daniell H, 2019, PLANT BIOTECHNOL J, V17, P1154, DOI 10.1111/pbi.13119
   Daniell H, 2019, PLANT BIOTECHNOL J, V17, P1357, DOI 10.1111/pbi.13060
   Daniell H, 2016, ANNU REV GENET, V50, P595, DOI 10.1146/annurev-genet-120215-035349
   Daniell H, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1004-2
   De Cosa B, 2001, NAT BIOTECHNOL, V19, P71, DOI 10.1038/83559
   DiMaggio P.J., 1991, NEW I ORG ANAL, P1, DOI DOI 10.1075/TSL.19.1.02CLO
   Dufourmantel N, 2005, PLANT MOL BIOL, V58, P659, DOI 10.1007/s11103-005-7405-3
   Dufourmantel N, 2007, PLANT BIOTECHNOL J, V5, P118, DOI 10.1111/j.1467-7652.2006.00226.x
   GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083
   Herzog RW, 2017, MOL THER, V25, P512, DOI 10.1016/j.ymthe.2016.11.009
   Jin SX, 2015, TRENDS PLANT SCI, V20, P622, DOI 10.1016/j.tplants.2015.07.004
   Kota M, 1999, P NATL ACAD SCI USA, V96, P1840, DOI 10.1073/pnas.96.5.1840
   Kumar S, 2004, PLANT PHYSIOL, V136, P2843, DOI 10.1104/pp.104.045187
   Kumari U, 2019, PLANT BIOTECHNOL J, V17, P1167, DOI 10.1111/pbi.13122
   Kwon KC, 2018, PLANT BIOTECHNOL J, V16, P1148, DOI 10.1111/pbi.12859
   Kwon KC, 2016, PLANT PHYSIOL, V172, P62, DOI 10.1104/pp.16.00981
   Park J, 2020, BIOMATERIALS, V233, DOI 10.1016/j.biomaterials.2019.119591
   Ruhlman T, 2010, PLANT PHYSIOL, V152, P2088, DOI 10.1104/pp.109.152017
   Su J, 2015, BIOMATERIALS, V70, P84, DOI 10.1016/j.biomaterials.2015.08.004
   SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913
   Viitanen PV, 2004, PLANT PHYSIOL, V136, P4048, DOI 10.1104/pp.104.050054
NR 40
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1467-7644
EI 1467-7652
J9 PLANT BIOTECHNOL J
JI Plant Biotechnol. J.
PD NOV
PY 2020
VL 18
IS 11
BP 2147
EP 2154
DI 10.1111/pbi.13468
EA SEP 2020
PG 8
WC Biotechnology & Applied Microbiology; Plant Sciences
SC Biotechnology & Applied Microbiology; Plant Sciences
GA OH4FP
UT WOS:000571307100001
PM 32799416
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hedde, PN
   Abram, TJ
   Jain, A
   Nakajima, R
   de Assis, RR
   Pearce, T
   Jasinskas, A
   Toosky, MN
   Khan, S
   Felgner, PL
   Gratton, E
   Zhao, WA
AF Hedde, Per Niklas
   Abram, Timothy J.
   Jain, Aarti
   Nakajima, Rie
   de Assis, Rafael Ramiro
   Pearce, Trevor
   Jasinskas, Algis
   Toosky, Melody N.
   Khan, Saahir
   Felgner, Philip L.
   Gratton, Enrico
   Zhao, Weian
TI A modular microarray imaging system for highly specific COVID-19
   antibody testing
SO LAB ON A CHIP
LA English
DT Article
AB To detect the presence of antibodies in blood against SARS-CoV-2 in a highly sensitive and specific manner, here we describe a robust, inexpensive ($200), 3D-printable portable imaging platform (TinyArray imager) that can be deployed immediately in areas with minimal infrastructure to read coronavirus antigen microarrays (CoVAMs) that contain a panel of antigens from SARS-CoV-2, SARS-1, MERS, and other respiratory viruses. Application includes basic laboratories and makeshift field clinics where a few drops of blood from a finger prick could be rapidly tested in parallel for the presence of antibodies to SARS-CoV-2 with a test turnaround time of only 2-4 h. To evaluate our imaging device, we probed and imaged coronavirus microarrays with COVID-19-positive and negative sera and achieved a performance on par with a commercial microarray reader 100x more expensive than our imaging device. This work will enable large scale serosurveillance, which can play an important role in the months and years to come to implement efficient containment and mitigation measures, as well as help develop therapeutics and vaccines to treat and prevent the spread of COVID-19.
C1 [Hedde, Per Niklas; Zhao, Weian] Univ Calif Irvine, Dept Pharmaceut Sci, Irvine, CA 92697 USA.
   [Hedde, Per Niklas; Pearce, Trevor; Gratton, Enrico; Zhao, Weian] Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA.
   [Hedde, Per Niklas; Gratton, Enrico] Univ Calif Irvine, Lab Fluorescence Dynam, Irvine, CA 92697 USA.
   [Abram, Timothy J.; Toosky, Melody N.] Velox Biosyst, Irvine, CA USA.
   [Jain, Aarti; Nakajima, Rie; de Assis, Rafael Ramiro; Jasinskas, Algis; Felgner, Philip L.] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92717 USA.
   [Khan, Saahir] Univ Calif Irvine Hlth, Dept Med, Div Infect Dis, Orange, CA USA.
   [Zhao, Weian] Univ Calif Irvine, Sue & Bill Gross Stem Cell Res Ctr, Irvine, CA USA.
   [Zhao, Weian] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA.
   [Zhao, Weian] Univ Calif Irvine, Edwards Life Sci Ctr Adv Cardiovasc Technol, Irvine, CA USA.
   [Zhao, Weian] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.
RP Hedde, PN (corresponding author), Univ Calif Irvine, Dept Pharmaceut Sci, Irvine, CA 92697 USA.; Hedde, PN (corresponding author), Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA.; Hedde, PN (corresponding author), Univ Calif Irvine, Lab Fluorescence Dynam, Irvine, CA 92697 USA.
EM phedde@uci.edu
OI Hedde, Per Niklas/0000-0002-2994-369X; Khan, Saahir/0000-0001-6732-768X
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P41 GM103540, R01
   AI117061]; UC Irvine CRAFT-COVID grant
FX We thank Byron Shen from Velox Biosystems for help with providing
   materials. This work was supported by National Institutes of Health
   grants P41 GM103540, R01 AI117061, and a UC Irvine CRAFT-COVID grant.
CR Adams E.R., 2020, EVALUATION ANTIBODY, DOI [10.1101/2020.04.15.20066407, DOI 10.1101/2020.04.15.20066407]
   Anfinrud P, 2020, NEW ENGL J MED, V382, P2061, DOI 10.1056/NEJMc2007800
   Bacarese-Hamilton T, 2004, J APPL MICROBIOL, V96, P10, DOI 10.1046/j.1365-2672.2003.02111.x
   Breslauer DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006320
   Collins JT, 2020, BIOMED OPT EXPRESS, V11, P2447, DOI 10.1364/BOE.385729
   de Assis Rafael R, 2020, bioRxiv, DOI 10.1101/2020.04.15.043364
   Furukawa Nathan W, 2020, Emerg Infect Dis, V26, DOI 10.3201/eid2607.201595
   Hindson J, 2020, NAT REV GASTRO HEPAT, V17, P259, DOI 10.1038/s41575-020-0295-7
   Jain A, 2016, PROTEOMICS, V16, P1271, DOI 10.1002/pmic.201500375
   Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000
   Khan Saahir, 2020, bioRxiv, DOI 10.1101/2020.03.24.006544
   Khan S, 2019, JOVE-J VIS EXP, DOI 10.3791/59973
   Kupferschmidt K, 2020, SCIENCE, V368, P218, DOI 10.1126/science.368.6488.218
   Leung Nancy H L, 2020, Nat Med, V26, P676, DOI 10.1038/s41591-020-0843-2
   Liu Y., 2020, AERODYNAMIC CHARACTE, DOI [10.1101/2020.03.08.982637, DOI 10.1101/2020.03.08.982637]
   Loreck K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217290
   Nakajima R, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00592-18
   Santarpia JL, 2020, TRANSMISSION POTENTI, DOI [10.1101/2020.03.23.20039446, DOI 10.1101/2020.03.23.20039446]
   Selvarajah S, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/820304
   Sung YL, 2017, BIOMED OPT EXPRESS, V8, P5075, DOI 10.1364/BOE.8.005075
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wei QS, 2013, ACS NANO, V7, P9147, DOI 10.1021/nn4037706
   Yelleswarapu VR, 2017, LAB CHIP, V17, P1083, DOI 10.1039/c6lc01489e
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhu HY, 2011, IEEE ENG MED BIO, P6801, DOI 10.1109/IEMBS.2011.6091677
   Zhu SW, 2020, ENVIRON INT, V137, DOI 10.1016/j.envint.2020.105537
NR 28
TC 1
Z9 1
U1 13
U2 13
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1473-0197
EI 1473-0189
J9 LAB CHIP
JI Lab Chip
PD SEP 21
PY 2020
VL 20
IS 18
BP 3302
EP 3309
DI 10.1039/d0lc00547a
PG 8
WC Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry,
   Analytical; Nanoscience & Nanotechnology; Instruments & Instrumentation
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics; Instruments & Instrumentation
GA NO5ER
UT WOS:000569507600021
PM 32743622
OA Other Gold
DA 2021-01-01
ER

PT J
AU Mohamed, TA
   Elshamy, AI
   Ibrahim, MAA
   Zellagui, A
   Moustafa, MF
   Abdelrahman, AHM
   Ohta, S
   Pare, PW
   Hegazy, MEF
AF Mohamed, Tarik A.
   Elshamy, Abdelsamed, I
   Ibrahim, Mahmoud A. A.
   Zellagui, Ammar
   Moustafa, Mahmoud F.
   Abdelrahman, Alaa H. M.
   Ohta, Shinji
   Pare, Paul W.
   Hegazy, Mohamed-Elamir F.
TI Carotane sesquiterpenes fromFerula vesceritensis:in silicoanalysis as
   SARS-CoV-2 binding inhibitors
SO RSC ADVANCES
LA English
DT Article
ID DAUCANE ESTERS; FERULA-COMMUNIS; ROOTS; COUMARINS; CORONAVIRUS;
   SINKIANGENSIS; ANTIOXIDANT; APOPTOSIS
AB Two sesquiterpenes, 8 alpha-anisate-dauc-4-ene-3,9-dione (webiol anisate) (1) and 10 alpha-acetoxy-6 alpha-benzoate-jaeschkeanadiol (2) as well as, ten known analogues (3-10), and two sesquiterpene coumarins (11-12) were isolated from an organic root extract ofFerula vesceritensis(Fam. Apiaceae). Chemical structures were elucidated based on IR, 1D- and 2D-NMR and HRMS, spectroscopic analyses. With molecular overlap observed between two protease inhibitors that are being examined as anti-COVID-19 drugs, and sesquiterpenes isolated here, metabolite molecular docking calculations were made using the main protease (M-pro), which is required for viral multiplication as well as RNA-dependent RNA polymerase (RdRp).In silicobinding-inhibition analysis predicted that selectF. vesceritensissesquiterpenes can bind to these enzymes required for viral replication. Structures of the isolated constituents were also consistent with the chemo-systematic grouping ofF. vesceritensissecondary metabolites with otherFerulaspecies.
C1 [Mohamed, Tarik A.; Hegazy, Mohamed-Elamir F.] Natl Res Ctr, Chem Med Plants Dept, 33 El Bohouth St, Giza 12622, Egypt.
   [Elshamy, Abdelsamed, I] Natl Res Ctr, Chem Nat Cpds Dept, 33 El Bohouth St, Giza 12622, Egypt.
   [Ibrahim, Mahmoud A. A.; Abdelrahman, Alaa H. M.] Menia Univ, Fac Sci, Chem Dept, Computat Chem Lab, Al Minya 61519, Egypt.
   [Zellagui, Ammar] Univ Larbi Ben Mhidi, Fac Exact Sci & Life Sci & Nat, Life Sci & Nat Dept, Lab Biomol & Plant Breeding, Oum El Bouaghi 4000, Algeria.
   [Moustafa, Mahmoud F.] King Khalid Univ, Coll Sci, Dept Biol, Abha 9004, Saudi Arabia.
   [Moustafa, Mahmoud F.] South Valley Univ, Fac Sci, Dept Bot & Microbiol, Qena, Egypt.
   [Ohta, Shinji] Hiroshima Univ, Grad Sch Integrated Sci Life, 1-7-1 Kagamiyama, Higashihiroshima 7398521, Japan.
   [Pare, Paul W.] Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA.
RP Hegazy, MEF (corresponding author), Natl Res Ctr, Chem Med Plants Dept, 33 El Bohouth St, Giza 12622, Egypt.; Pare, PW (corresponding author), Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA.
EM paul.pare@ttu.edu; me.fathy@nrc.sci.eg
RI Ibrahim, Mahmoud/J-2936-2014; Pare, Paul/E-3055-2013; Hegazy, Mohamed
   Elamir/AAA-3454-2019
OI Ibrahim, Mahmoud/0000-0003-4819-2040; Pare, Paul/0000-0003-1644-723X;
   Hegazy, Mohamed Elamir/0000-0002-0343-4969
FU Deanship of Scientific Research at King Khalid University [R.G.P2/90/41]
FX The authors extend their appreciation to the Deanship of Scientific
   Research at King Khalid University for funding this work under grant no.
   (R.G.P2/90/41).
CR Ahmed AA, 2001, PHYTOCHEMISTRY, V57, P513, DOI 10.1016/S0031-9422(01)00115-7
   Ahmed AA, 1999, PHYTOCHEMISTRY, V50, P109, DOI 10.1016/S0031-9422(98)00489-0
   Ahmed AA, 2007, PHYTOCHEMISTRY, V68, P680, DOI 10.1016/j.phytochem.2006.12.011
   Al-Ja'fari AH, 2011, PHYTOCHEMISTRY, V72, P1406, DOI 10.1016/j.phytochem.2011.04.013
   Amin A, 2016, MOLECULES, V21, DOI 10.3390/molecules21101287
   Appendino G, 1997, PHYTOCHEMISTRY, V45, P1639, DOI 10.1016/S0031-9422(97)00250-1
   Auzi AA, 2008, J ASIAN NAT PROD RES, V10, P701, DOI 10.1080/10286020802016040
   Boulos L., 1983, MED PLANTS N AFRICA, P183
   Dall'Acqua S, 2011, BIOORGAN MED CHEM, V19, P5876, DOI 10.1016/j.bmc.2011.08.021
   El-Razek MHA, 2001, PHYTOCHEMISTRY, V58, P1289, DOI 10.1016/S0031-9422(01)00246-1
   Gamal-Eldeen AM, 2010, NAT PROD RES, V24, P246, DOI 10.1080/14786410802685398
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Ghanbari M., 2012, J MED PLANTS, V3, P62
   Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464
   Harrison C, 2020, NAT BIOTECHNOL, V38, P379, DOI 10.1038/d41587-020-00003-1
   Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ibraheim ZZ, 2012, PHYTOTHER RES, V26, P579, DOI 10.1002/ptr.3609
   Iranshahi M, 2010, PHYTOMEDICINE, V17, P269, DOI 10.1016/j.phymed.2009.05.020
   Jabrane A, 2010, CHEM BIODIVERS, V7, P392, DOI 10.1002/cbdv.200900025
   JIN Z, 2020, NATURE 0409, DOI DOI 10.1101/2020.02.26.964882
   Kurimoto S, 2012, PHYTOCHEM LETT, V5, P729, DOI 10.1016/j.phytol.2012.08.001
   Kurimoto S, 2012, CHEM PHARM BULL, V60, P913, DOI 10.1248/cpb.c12-00350
   LAMNAOUER D, 1989, PHYTOCHEMISTRY, V28, P2711, DOI 10.1016/S0031-9422(00)98073-7
   Lhuillier A, 2005, J NAT PROD, V68, P468, DOI 10.1021/np049652h
   Li R, 2019, J CELL BIOCHEM, V120, P11265, DOI 10.1002/jcb.28404
   Liu T, 2015, CHEM BIODIVERS, V12, P599, DOI 10.1002/cbdv.201400150
   MISKI M, 1985, PHYTOCHEMISTRY, V24, P1735, DOI 10.1016/S0031-9422(00)82543-1
   Mohammadhosseini M, 2019, IND CROP PROD, V129, P350, DOI 10.1016/j.indcrop.2018.12.012
   Moradzadeh M, 2017, CELL MOL BIOL, V63, P17, DOI 10.14715/cmb/2017.63.11.4
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Motai T, 2004, CHEM PHARM BULL, V52, P1215, DOI 10.1248/cpb.52.1215
   Nazari ZE, 2011, PHYTOTHER RES, V25, P315, DOI 10.1002/ptr.3311
   Oughlissi-Dehak K, 2008, PHYTOCHEMISTRY, V69, P1933, DOI 10.1016/j.phytochem.2008.03.010
   Paydar M, 2013, J MED SCI, V13, P236
   PINAR M, 1977, PHYTOCHEMISTRY, V16, P1987, DOI 10.1016/0031-9422(77)80109-X
   Poli F, 2005, PHYTOTHER RES, V19, P152, DOI 10.1002/ptr.1443
   Sayah M., 2003, IRAN BIOMED J, V7, P139
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   SINGH MM, 1988, PLANTA MED, P492, DOI 10.1055/s-2006-962526
   Suzuki K, 2007, J NAT PROD, V70, P1915, DOI 10.1021/np0703996
   Tamemoto K, 2001, PHYTOCHEMISTRY, V58, P763, DOI 10.1016/S0031-9422(01)00307-7
   UPADHYAY PK, 2017, INT J GREEN PHARM, V11, P240, DOI DOI 10.22377/IJGP.V11I02.1033
   Venkataraman T, 2017, ANTIVIR RES, V143, P142, DOI 10.1016/j.antiviral.2017.03.022
   Yang JR, 2006, CHEM PHARM BULL, V54, P1595, DOI 10.1248/cpb.54.1595
   Yaqoob U, 2017, J KING SAUD UNIV SCI, V29, P19, DOI 10.1016/j.jksus.2015.10.002
   Zhang HY, 2015, INT J CLIN EXP MED, V8, P20845
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 49
TC 0
Z9 0
U1 2
U2 2
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD SEP 20
PY 2020
VL 10
IS 57
BP 34541
EP 34548
DI 10.1039/d0ra06901a
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA NS5KI
UT WOS:000572299600023
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Fernandez-Aranda, F
   Munguia, L
   Mestre-Bach, G
   Steward, T
   Etxandi, M
   Baenas, I
   Granero, R
   Sanchez, I
   Ortega, E
   Andreu, A
   Moize, VL
   Fernandez-Real, JM
   Tinahones, FJ
   Dieguez, C
   Fruhbeck, G
   Le Grange, D
   Tchanturia, K
   Karwautz, A
   Zeiler, M
   Favaro, A
   Claes, L
   Luyckx, K
   Shekriladze, I
   Serrano-Troncoso, E
   Rangil, T
   Meler, MEL
   Soriano-Pacheco, J
   Carceller-Sindreu, M
   Bujalance-Arguijo, S
   Lozano, M
   Linares, R
   Gudiol, C
   Carratala, J
   Sanchez-Gonzalez, J
   Machado, PP
   Hakansson, A
   Tury, F
   Paszthy, B
   Stein, D
   Papezova, H
   Bax, B
   Borisenkov, MF
   Popov, SV
   Kim, YR
   Nakazato, M
   Godart, N
   van Voren, R
   Ilnytska, T
   Chen, J
   Rowlands, K
   Treasure, J
   Jimenez-Murcia, S
AF Fernandez-Aranda, Fernando
   Munguia, Lucero
   Mestre-Bach, Gemma
   Steward, Trevor
   Etxandi, Mikel
   Baenas, Isabel
   Granero, Roser
   Sanchez, Isabel
   Ortega, Emilio
   Andreu, Alba
   Moize, Violeta L.
   Fernandez-Real, Jose M.
   Tinahones, Francisco J.
   Dieguez, Carlos
   Fruhbeck, Gema
   Le Grange, Daniel
   Tchanturia, Kate
   Karwautz, Andreas
   Zeiler, Michael
   Favaro, Angela
   Claes, Laurence
   Luyckx, Koen
   Shekriladze, Ia
   Serrano-Troncoso, Eduardo
   Rangil, Teresa
   Meler, Maria Eulalia Loran
   Soriano-Pacheco, Jose
   Carceller-Sindreu, Mar
   Bujalance-Arguijo, Sara
   Lozano, Meritxell
   Linares, Raquel
   Gudiol, Carlota
   Carratala, Jordi
   Sanchez-Gonzalez, Jessica
   Machado, Paulo P. P.
   Hakansson, Anders
   Tury, Ferenc
   Paszthy, Bea
   Stein, Daniel
   Papezova, Hana
   Bax, Brigita
   Borisenkov, Mikhail F.
   Popov, Sergey V.
   Kim, Youl-Ri
   Nakazato, Michiko
   Godart, Nathalie
   van Voren, Robert
   Ilnytska, Tetiana
   Chen, Jue
   Rowlands, Katie
   Treasure, Janet
   Jimenez-Murcia, Susana
TI COVID Isolation Eating Scale (CIES): Analysis of the impact of
   confinement in eating disorders and obesity-A collaborative
   international study
SO EUROPEAN EATING DISORDERS REVIEW
LA English
DT Article
DE COVID Isolation Eating Scale; COVID-19; eating disorders; obesity
ID VALIDATION
AB Confinement during the COVID-19 pandemic is expected to have a serious and complex impact on the mental health of patients with an eating disorder (ED) and of patients with obesity. The present manuscript has the following aims: (1) to analyse the psychometric properties of the COVID Isolation Eating Scale (CIES), (2) to explore changes that occurred due to confinement in eating symptomatology; and (3) to explore the general acceptation of the use of telemedicine during confinement. The sample comprised 121 participants (87 ED patients and 34 patients with obesity) recruited from six different centres. Confirmatory Factor Analyses (CFA) tested the rational-theoretical structure of the CIES. Adequate goodness-of-fit was obtained for the confirmatory factor analysis, and Cronbach alpha values ranged from good to excellent. Regarding the effects of confinement, positive and negative impacts of the confinement depends of the eating disorder subtype. Patients with anorexia nervosa (AN) and with obesity endorsed a positive response to treatment during confinement, no significant changes were found in bulimia nervosa (BN) patients, whereas Other Specified Feeding or Eating Disorder (OSFED) patients endorsed an increase in eating symptomatology and in psychopathology. Furthermore, AN patients expressed the greatest dissatisfaction and accommodation difficulty with remote therapy when compared with the previously provided face-to-face therapy. The present study provides empirical evidence on the psychometric robustness of the CIES tool and shows that a negative confinement impact was associated with ED subtype, whereas OSFED patients showed the highest impairment in eating symptomatology and in psychopathology.
C1 [Fernandez-Aranda, Fernando; Munguia, Lucero; Mestre-Bach, Gemma; Etxandi, Mikel; Baenas, Isabel; Sanchez, Isabel; Sanchez-Gonzalez, Jessica; Jimenez-Murcia, Susana] Bellvitge Univ Hosp IDIBELL, Dept Psychiat, C FeixaLlarga S-N, Barcelona 08907, Spain.
   [Fernandez-Aranda, Fernando; Baenas, Isabel; Granero, Roser; Sanchez, Isabel; Fernandez-Real, Jose M.; Tinahones, Francisco J.; Dieguez, Carlos; Fruhbeck, Gema; Jimenez-Murcia, Susana] Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CIBERobn, Barcelona, Spain.
   [Fernandez-Aranda, Fernando; Munguia, Lucero; Gudiol, Carlota; Carratala, Jordi; Jimenez-Murcia, Susana] Univ Barcelona, Sch Med & Hlth Sci, Dept Clin Sci, Barcelona, Spain.
   [Mestre-Bach, Gemma] Univ Int La Rioja, La Rioja, Spain.
   [Steward, Trevor] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia.
   [Granero, Roser] Univ Autonoma Barcelona, Sch Psychol, Dept Psychobiol & Methodol, Barcelona, Spain.
   [Ortega, Emilio; Andreu, Alba; Moize, Violeta L.] Hosp Clin Barcelona, Endocrinol & Nutr Div, Barcelona, Spain.
   [Ortega, Emilio; Andreu, Alba; Moize, Violeta L.] Inst Invest Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain.
   [Ortega, Emilio; Moize, Violeta L.] Ctr Invest Biomed Red Diabet & Enfermedades Metab, Madrid, Spain.
   [Fernandez-Real, Jose M.] Hosp Girona Dr Josep Trueta, Unit Diabet Endocrinol & Nutr, Girona, Spain.
   [Fernandez-Real, Jose M.] Inst Invest Biomed Girona IDIBGI, Girona, Spain.
   [Tinahones, Francisco J.] Virgen Victoria Univ Hosp, Dept Endocrinol & Nutr, Malaga, Spain.
   [Tinahones, Francisco J.] Inst Invest Biomed Malaga IBIMA, Malaga, Spain.
   [Dieguez, Carlos] Univ Santiago de Compostela, CIMUS, Inst Invest Sanitaria, Dept Physiol, Santiago De Compostela, Spain.
   [Fruhbeck, Gema] Univ Navarra IdiSNA, Clin Univ Navarra, Metabol Res Lab, Pamplona, Spain.
   [Le Grange, Daniel] Univ Calif San Francisco, Dept Psychiat, Eating Disorders Program, San Francisco, CA USA.
   [Tchanturia, Kate; Rowlands, Katie; Treasure, Janet] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, Sect Eating Disorders, London, England.
   [Tchanturia, Kate; Shekriladze, Ia] Ilia State Univ, D Uznadze Inst Psychol, Tbilisi, Georgia.
   [Karwautz, Andreas; Zeiler, Michael] Med Univ Vienna, Dept Child & Adolescent Psychiat, Eating Disorders Unit, Vienna, Austria.
   [Favaro, Angela] Univ Padua, Dept Neurosci, Padua, Italy.
   [Favaro, Angela] Neurosci Ctr PNC, Padua, Italy.
   [Claes, Laurence] Katholieke Univ Leuven, Fac Psychol & Educ Sci, Leuven, Belgium.
   [Claes, Laurence; Luyckx, Koen] Univ Antwerp, Fac Med & Hlth Sci, Antwerp, Belgium.
   [Luyckx, Koen] Univ Free State, UNIBS, Bloemfontein, South Africa.
   [Serrano-Troncoso, Eduardo] Hosp St Joan de Deu, Child & Adolescent Psychiat & Psychol Dept, Esplugas de Llobregat, Spain.
   [Serrano-Troncoso, Eduardo] Inst Recerca St Joan de Deu, Esplugas de Llobregat, Spain.
   [Rangil, Teresa; Meler, Maria Eulalia Loran] Germans Trias & Pujol Univ Hosp IGTP, Dept Psychiat, Barcelona, Spain.
   [Rangil, Teresa] Univ Autonoma Barcelona, Dept Psychiat & Legal Med, Barcelona, Spain.
   [Soriano-Pacheco, Jose; Carceller-Sindreu, Mar] Univ Autonoma Barcelona UAB, Hosp Santa Creu & St Pau, Dept Psychiat, Barcelona, Spain.
   [Soriano-Pacheco, Jose; Carceller-Sindreu, Mar] Univ Autonoma Barcelona UAB, Inst Invest Biomed St Pau IIB St Pau, Barcelona, Spain.
   [Soriano-Pacheco, Jose; Carceller-Sindreu, Mar] ISCIII, Ctr Invest Biomed Red Salud Mental CIBERSAM, Madrid, Spain.
   [Bujalance-Arguijo, Sara] Assoc Anorexia & Bulimia ACAB, Barcelona, Spain.
   [Lozano, Meritxell; Linares, Raquel] FITA Fdn, Barcelona, Spain.
   [Gudiol, Carlota; Carratala, Jordi] Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge IDIBELL, Infect Dis Dept, Barcelona, Spain.
   [Gudiol, Carlota; Carratala, Jordi] IDIBELL, Inst Catala Oncol Hosp, Barcelona, Spain.
   [Gudiol, Carlota; Carratala, Jordi] Inst Salud Carlos III, REIPI Spanish Network Res Infect Dis, Madrid, Spain.
   [Machado, Paulo P. P.] Univ Minho, Sch Psychol, Psychotherapy & Psychopathol Res Unit, Psychol Res Ctr, Braga, Portugal.
   [Hakansson, Anders] Lund Univ, Fac Med, Dept Clin Sci Lund, Psychiat, Lund, Sweden.
   [Hakansson, Anders; Bax, Brigita] Malmo Addict Ctr, Gambling Disorder Unit, Malmo, Sweden.
   [Tury, Ferenc; Paszthy, Bea] Semmelweis Univ, Inst Behav Sci, Budapest, Hungary.
   [Paszthy, Bea] Semmelweis Univ, Dept Paediat 1, Budapest, Hungary.
   [Stein, Daniel] Chaim Sheba Med Ctr, Safra Childrens Hosp, Tel Hashomer, Israel.
   [Papezova, Hana] Charles Univ Prague, Fac Med 1, Dept Psychiat, Prague, Czech Republic.
   [Bax, Brigita] Vilnius Univ, Eating Disorders Ctr, Vilnius, Lithuania.
   [Borisenkov, Mikhail F.; Popov, Sergey V.] RAS, Inst Physiol, Komi Sci Ctr UB, Syktyvkar, Russia.
   [Kim, Youl-Ri] Inje Univ, Seoul Paik Hosp, Dept Psychiat, Seoul, South Korea.
   [Nakazato, Michiko] Int Univ Hlth & Welf Psychiat, Narita, Japan.
   [Godart, Nathalie] Univ Paris Saclay, Univ Paris Sud, INSERM U 1178, UVSQ,CESP, Villejuif, France.
   [Godart, Nathalie] Univ Paris 05, Inst Mutualiste Montsouris, Sch Med, Dept Psychiat, Paris, France.
   [Godart, Nathalie] Praticienne Hosp, Fondat Sante Etudiants France, UFR Sci Sante Simone Veil UVSQ, Paris, France.
   [van Voren, Robert] Vytautas Magnus Univ, Kaunas, Lithuania.
   [Ilnytska, Tetiana] Natl Univ Kyiv, Inst Psychiat Taras Shevchenko, Kiev, Ukraine.
   [Chen, Jue] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Dept Clin Psychol, Shanghai, Peoples R China.
RP Fernandez-Aranda, F (corresponding author), Bellvitge Univ Hosp IDIBELL, Dept Psychiat, C FeixaLlarga S-N, Barcelona 08907, Spain.; Fernandez-Aranda, F (corresponding author), CIBEROBN, C FeixaLlarga S-N, Barcelona 08907, Spain.
EM ffernandez@bellvitgehospital.cat
RI Ilnytska, Tetiana/ABB-5813-2020; Fernandez-Aranda, Fernando/L-9762-2014;
   Borisenkov, Mikhail/H-7169-2019; Mestre-Bach, Gemma/Q-1695-2015;
   Carratala, Jordi/B-8410-2011; Machado, Paulo/B-3358-2008; Granero,
   Roser/F-9492-2016
OI Fernandez-Aranda, Fernando/0000-0002-2968-9898; Borisenkov,
   Mikhail/0000-0002-4310-2010; karwautz, andreas/0000-0001-9053-998X;
   Munguia, Lucero/0000-0002-9751-810X; Baenas Soto, Isabel
   Maria/0000-0001-7415-0616; Mestre-Bach, Gemma/0000-0001-5345-0484;
   Zeiler, Michael/0000-0002-7087-6134; Rowlands, Katie
   Paige/0000-0002-9671-4344; Ortega Martinez de Victoria,
   Emilio/0000-0002-2217-8905; Andreu, Alba/0000-0001-9854-1531;
   Tchanturia, Kate/0000-0001-8988-3265; Carratala,
   Jordi/0000-0003-3209-2563; Machado, Paulo/0000-0003-4277-9203; Granero,
   Roser/0000-0001-6308-3198
FU Fondo Investigacion Sanitario-FIS [INT19/00046, PI17/01167]; Ministerio
   de Economia y CompetitividadSpanish Government [PSI2015-68701-R];
   Portuguese Foundation for Science and TechnologyPortuguese Foundation
   for Science and Technology [POCI-01-0145-FEDER-028145]; Consejo Nacional
   de Ciencia y TecnologiaConsejo Nacional de Ciencia y Tecnologia
   (CONACyT); Generalitat de CatalunyaGeneralitat de Catalunya; European
   Regional Development FundEuropean Union (EU)
FX Fondo Investigacion Sanitario-FIS, Grant/Award Numbers: FIS,
   INT19/00046, PI17/01167; Ministerio de Economia y Competitividad,
   Grant/Award Number: PSI2015-68701-R; Portuguese Foundation for Science
   and Technology grant, Grant/Award Number: POCI-01-0145-FEDER-028145;
   Consejo Nacional de Ciencia y Tecnologia; Generalitat de Catalunya;
   European Regional Development Fund
CR Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   Baenas I, 2020, EUR EAT DISORD REV, V28, P855, DOI 10.1002/erv.2771
   Barrett P, 2007, PERS INDIV DIFFER, V42, P815, DOI 10.1016/j.paid.2006.09.018
   Brown M, 2017, EUR EAT DISORD REV, V25, P329, DOI 10.1002/erv.2523
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Chandu Viswa Chaitanya, 2020, Indian J Public Health, V64, pS201, DOI 10.4103/ijph.IJPH_492_20
   Claes L, 2019, EUR EAT DISORD REV, V27, P410, DOI 10.1002/erv.2681
   Bryan DC, 2020, EUR EAT DISORD REV, V28, P826, DOI 10.1002/erv.2762
   COHEN J, 1988, NEW YORK TIMES BK R, P26
   Columb D, 2020, IRISH J PSYCHOL MED, V37, P164, DOI 10.1017/ipm.2020.47
   Cooper M, 2020, EAT DISORD, DOI 10.1080/10640266.2020.1790271
   Cornejo-Pareja I.M., 2020, EUROPEAN EATING DISO, V28
   Costantini A, 2020, RIV PSICHIATR, V55, P145, DOI 10.1708/3382.33570
   Darrow SM, 2017, EUR EAT DISORD REV, V25, P389, DOI 10.1002/erv.2531
   de Girolamo G, 2020, JAMA PSYCHIAT, V77, P974, DOI 10.1001/jamapsychiatry.2020.1276
   Fernandez-Aranda F., 2020, J EATING DISORDERS A, V28, P239, DOI [10.1002/erv.2738, DOI 10.1002/erv.2738]
   Forte G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17114151
   Graell M, 2020, EUR EAT DISORD REV, V28, P864, DOI 10.1002/erv.2763
   Granero R, 2020, EUR EAT DISORD REV, V28, P483, DOI 10.1002/erv.2782
   Hakansson Anders, 2020, J Addict Med, V14, pe10, DOI 10.1097/ADM.0000000000000690
   Hewlett Bonnie L, 2005, J Transcult Nurs, V16, P289, DOI 10.1177/1043659605278935
   Inchausti F, 2020, CLIN SALUD, V31, P105, DOI 10.5093/clysa2020a11
   Kannarkat JT, 2020, ADM POLICY MENT HLTH, V47, P489, DOI 10.1007/s10488-020-01044-z
   Kaufman J, 2020, CORONAVIRUS IMPACT S
   Kelley K, 2012, PSYCHOL METHODS, V17, P137, DOI 10.1037/a0028086
   King DL, 2020, J BEHAV ADDICT, V9, P184, DOI 10.1556/2006.2020.00016
   Kinsman J, 2012, GLOBALIZATION HEALTH, V8, DOI 10.1186/1744-8603-8-15
   Kiraly O, 2020, COMPR PSYCHIAT, V100, DOI 10.1016/j.comppsych.2020.152180
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Li YX, 2018, TRANSL CANCER RES, V7, P1, DOI 10.21037/tcr.2017.10.26
   Linardon J, 2020, INT J EAT DISORDER, V53, P907, DOI 10.1002/eat.23268
   Main A, 2011, J COUNS PSYCHOL, V58, P410, DOI 10.1037/a0023632
   Mallorqui-Bague N, 2018, EUR EAT DISORD REV, V26, P53, DOI 10.1002/erv.2570
   Marsden J, 2020, ADDICTION, V115, P1007, DOI 10.1111/add.15080
   McDonnell WM, 2012, AM J EMERG MED, V30, P275, DOI 10.1016/j.ajem.2010.11.027
   Mestre-Bach G, 2020, J BEHAV ADDICT, V9, P181, DOI 10.1556/2006.2020.00015
   Mihashi M, 2009, HEALTH PSYCHOL, V28, P91, DOI 10.1037/a0013674
   Papandreou C, 2020, EUR EAT DISORD REV, V28, P836, DOI 10.1002/erv.2772
   Pierce M, 2020, LANCET PSYCHIAT, V7, P883, DOI 10.1016/S2215-0366(20)30308-4
   Raven J, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3072-3
   Riesco N, 2018, EUR PSYCHIAT, V54, P109, DOI 10.1016/j.eurpsy.2018.08.001
   Rodgers RF, 2020, INT J EAT DISORDER, V53, P1166, DOI 10.1002/eat.23318
   Rossi R, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.10185
   Rundle AG, 2020, OBESITY, V28, P1008, DOI 10.1002/oby.22813
   Sakib N, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00289-x
   Smith K, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/21108
   Soraci P, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00277-1
   Stata Press, 2019, STAT STAT SOFTW REL
   Strand M, 2019, EUR EAT DISORD REV, V27, P236, DOI 10.1002/erv.2653
   Sun Y, 2020, AM J ADDICTION, V29, P268, DOI 10.1111/ajad.13066
   Taylor S, 2020, J ANXIETY DISORD, V72, DOI 10.1016/j.janxdis.2020.102232
   Termorshuizen JD, 2020, INT J EAT DISORDER, V53, P1780, DOI 10.1002/eat.23353
   Todisco P, 2020, EAT WEIGHT DISORD-ST, DOI 10.1007/s40519-020-00938-z
   Treasure J, 2003, EUR EAT DISORD REV, V11, P25, DOI 10.1002/erv.485
   Vanzhula IA, 2019, EUR EAT DISORD REV, V27, P147, DOI 10.1002/erv.2634
   Vintro-Alcaraz C, 2018, EUR EAT DISORD REV, V26, P329, DOI 10.1002/erv.2604
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang YN, 2020, PSYCHOL HEALTH MED, DOI 10.1080/13548506.2020.1746817
   Wu P, 2009, CAN J PSYCHIAT, V54, P302, DOI 10.1177/070674370905400504
NR 60
TC 1
Z9 1
U1 8
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1072-4133
EI 1099-0968
J9 EUR EAT DISORD REV
JI Eur. Eat. Disord. Rev.
PD NOV
PY 2020
VL 28
IS 6
BP 871
EP 883
DI 10.1002/erv.2784
EA SEP 2020
PG 13
WC Psychology, Clinical
SC Psychology
GA OI3VE
UT WOS:000571616200001
PM 32954595
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ibrahim, D
   Dulipsingh, L
   Zapatka, L
   Eadie, R
   Crowell, R
   Williams, K
   Wakefield, DB
   Cook, L
   Puff, J
   Hussain, SA
AF Ibrahim, Danyal
   Dulipsingh, Latha
   Zapatka, Lisa
   Eadie, Reginald
   Crowell, Rebecca
   Williams, Kendra
   Wakefield, Dorothy B.
   Cook, Lisa
   Puff, Jennifer
   Hussain, Syed A.
TI Factors Associated with Good Patient Outcomes Following Convalescent
   Plasma in COVID-19: A Prospective Phase II Clinical Trial
SO INFECTIOUS DISEASES AND THERAPY
LA English
DT Article
DE Adult respiratory distress syndrome; COVID-19; COVID-19 serotherapy;
   Hospital mortality; Length of stay; Phase II clinical trial; Plasma;
   Prospective studies; Severe acute respiratory syndrome coronavirus 2;
   Ventilation
AB Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus was discovered in Wuhan City, Hubei Province, China, in December 2019. As of September 6, 2020, confirmed cases have risen to more than 27,000,000 worldwide and more than 885,000 people have died. Currently, no cure or standard treatment for COVID-19 exists. We conducted a prospective single-arm open-label phase II clinical trial assessing the safety and efficacy of convalescent plasma in hospitalized patients with COVID-19. Methods Convalescent plasma with sufficient total anti-SARS-CoV-2 IgG titer (1:320) obtained from recovered donors was administered to adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of stay, and hospital discharge. Results Of the 38 patients included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients who received convalescent plasma early in the disease course (severe illness group) as compared to the patients that received convalescent plasma later in the disease progression (critical illness group) had significantly lower hospital mortality 13% vs 55% (p < 0.02) and shorter mean hospital length of stay 15.4 vs 33 days (p < 0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed. Conclusions Our results suggest that convalescent plasma with adequate anti-SARS-CoV-2 antibody titer is safe and has the potential for positive impact on clinical outcomes including recovery and survival if given to patients early in the course of COVID-19 disease.
C1 [Ibrahim, Danyal; Zapatka, Lisa; Eadie, Reginald; Hussain, Syed A.] Trinity Hlth New England, Hartford, CT 06105 USA.
   [Dulipsingh, Latha; Cook, Lisa; Puff, Jennifer] St Francis Hosp & Med Ctr, Diabet Ctr, Hartford, CT USA.
   [Crowell, Rebecca; Williams, Kendra; Wakefield, Dorothy B.] St Francis Hosp & Med Ctr, Res Dept, Hartford, CT USA.
RP Ibrahim, D (corresponding author), Trinity Hlth New England, Hartford, CT 06105 USA.
EM dibrahim@trinityhealthofne.org
OI Ibrahim, Danyal/0000-0003-1359-0014
FU Trinity Health of New England
FX This study was supported by funds from Trinity Health of New England, a
   not-forprofit healthcare organization. The Rapid Service Fees were
   funded by the authors.
CR [Anonymous], 2020, COVID 19 DEV DRUGS B
   ARMSTRONG RA, 2020, ANAESTHESIA 0715, DOI DOI 10.1111/ANAE.15201
   Bonow RO, 2020, JAMA CARDIOL, V5, P986, DOI 10.1001/jamacardio.2020.1782
   Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004
   Deng Y, 2020, CHINESE MED J-PEKING, V133, P1261, DOI 10.1097/CM9.0000000000000824
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Gautier JF, 2020, OBESITY, V28, P848, DOI 10.1002/oby.22809
   Grasselli G, 2020, JAMA INTERN MED, P3539
   Gupta Shruti, 2020, JAMA Intern Med, DOI 10.1001/jamainternmed.2020.3596
   Hartman William R, 2020, Res Sq, DOI 10.21203/rs.3.rs-39447/v1
   He JJ, 2020, J MED VIROL, DOI 10.1002/jmv.26326
   ICNARC, 2020, ICNARC REP COVID 19
   Johns Hopkins University of Medicine, COVID 19 DASHB CTR S
   Joyner MJ, 2020, MAYO CLIN PROC, V95, P1888, DOI 10.1016/j.mayocp.2020.06.028
   Joyner Michael J, 2020, medRxiv, DOI 10.1101/2020.08.12.20169359
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Karagiannidis C, 2020, LANCET RESP MED, VS2213-2600, P30316
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Liu W, 2020, CHINESE MED J-PEKING, V133, P1032, DOI 10.1097/CM9.0000000000000775
   Lu LG, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00677
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Park M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040967
   Perotti C, 2020, HAEMATOLOGICA
   Quah P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03006-1
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Salazar E, 2020, AM J PATHOL
   Salazar E, 2020, AM J PATHOL, V190, P1680, DOI 10.1016/j.ajpath.2020.05.014
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sun MY, 2020, INT J INFECT DIS, V98, P334, DOI 10.1016/j.ijid.2020.06.107
   U.S. Food and Drug Administration, 2020, INV COVID 19 CONV PL
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
NR 33
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 2193-8229
EI 2193-6382
J9 INFECT DIS THER
JI Infect. Dis. Ther.
PD DEC
PY 2020
VL 9
IS 4
BP 913
EP 926
DI 10.1007/s40121-020-00341-2
EA SEP 2020
PG 14
WC Infectious Diseases
SC Infectious Diseases
GA OU0TA
UT WOS:000571359500001
PM 32951151
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dai, W
   Chen, XM
   Xu, XT
   Leng, ZF
   Yu, WW
   Lin, H
   Li, HY
   Lin, J
   Qiu, ZW
   Dai, YR
AF Dai, Wei
   Chen, Xinmiao
   Xu, Xiaoting
   Leng, Zhefeng
   Yu, Wenwen
   Lin, Hui
   Li, Huiying
   Lin, Jie
   Qiu, Zhangwei
   Dai, Yuanrong
TI Clinical Characteristics of Asymptomatic Patients with SARS-CoV-2 in
   Zhejiang: An Imperceptible Source of Infection
SO CANADIAN RESPIRATORY JOURNAL
LA English
DT Article
ID CORONAVIRUS; PNEUMONIA; WUHAN
AB Objective. Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, was first identified in December 2019 in Wuhan, China, and has since spread globally, resulting in an ongoing pandemic. However, the study of asymptomatic patients is still rare, and the understanding of its potential transmission risk is still insufficient. In this study, epidemiological investigations were conducted in the Zhejiang province to understand the epidemiology and clinical characteristics of asymptomatic patients with COVID-19.Methods. This retrospective study was carried out on 22 asymptomatic patients and 234 symptomatic patients with COVID-19 who were hospitalized in Zhejiang Duodi Hospital from January 21 to March 16, 2020. The characteristics of epidemiology, demography, clinical manifestations, and laboratory data of mild patients were compared and analyzed.Results. The median age was 28 years in asymptomatic patients and 48 years in symptomatic patients. The proportion who were female was 77.3% in asymptomatic patients and 36.3% in symptomatic patients (p<0.001). The proportion of patients with coexisting diseases was 4.5% in asymptomatic patients and 38.0% in symptomatic patients (p=0.002). The proportion of patients with increased CRP was 13.6% in the asymptomatic group and 61.1% in the symptomatic group (p<0.001). The proportion of patients received antiviral therapy was 45.5% in the asymptomatic group and 97.9% in the symptomatic group (p<0.001). The proportion of patients received oxygen therapy was 22.7% in the asymptomatic group and 99.1% in symptomatic patients (p<0.001). By March 16, 2020, all patients were discharged from the hospital, and no symptoms had appeared in the asymptomatic patients during hospitalization. The median course of infection to discharge was 21.5 days in asymptomatic patients and 22 days in symptomatic patients.Conclusions. Asymptomatic patients are also infectious; relying only on clinical symptoms, blood cell tests, and radiology examination will lead to misdiagnosis of most patients, leading to the spread of the virus. Investigation of medical history is the best strategy for screening asymptomatic patients, especially young people, women, and people without coexisting disease, who are more likely to be asymptomatic when infected. Although the prognosis is good, isolation is critical for asymptomatic patients, and it is important not to end isolation early before a nucleic acid test turns negative.
C1 [Dai, Wei] Wenzhou Med Univ, Dept Neurorehabil, Affiliated Hosp 2, Wenzhou 325027, Peoples R China.
   [Chen, Xinmiao; Xu, Xiaoting; Leng, Zhefeng; Yu, Wenwen; Lin, Hui; Li, Huiying; Lin, Jie; Qiu, Zhangwei; Dai, Yuanrong] Wenzhou Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp 2, Wenzhou 325027, Peoples R China.
RP Dai, YR (corresponding author), Wenzhou Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp 2, Wenzhou 325027, Peoples R China.
EM daiyr@126.com
FU  [NSFC81800028];  [81570027]
FX This study was supported by the NSFC81800028 and 81570027). The authors
   acknowledge all the patients involved in this study and all the
   healthcare workers involved in treatment and diagnosis of patients in
   Zhejiang.
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Craig A T, 2020, Epidemiol Infect, V148, pe71, DOI 10.1017/S0950268820000710
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lee S, 2020, CAN J ANESTH, V67, P1424, DOI 10.1007/s12630-020-01729-x
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 18
TC 1
Z9 1
U1 4
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1198-2241
EI 1916-7245
J9 CAN RESPIR J
JI Can. Respir. J.
PD SEP 19
PY 2020
VL 2020
AR 2045341
DI 10.1155/2020/2045341
PG 5
WC Respiratory System
SC Respiratory System
GA NY0TU
UT WOS:000576113100001
PM 33005276
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Daniela, M
   Felipe, S
   Van Nicolette, SJ
   Tomas, R
   Eli, V
   Jorge, R
   Christian, F
   Roberto, C
   Jose, I
   Luisa, D
   Rodrigo, D
AF Daniela, Martinez
   Felipe, Salech
   Van Nicolette, Sint Jan
   Tomas, Regueira
   Eli, Villalabeitia
   Jorge, Rufs
   Christian, Fajardo
   Roberto, Castillo
   Jose, Iniguez
   Luisa, Duran
   Rodrigo, Diaz
TI Mobile ECMO in COVID-19 patient: case report
SO JOURNAL OF ARTIFICIAL ORGANS
LA English
DT Article; Early Access
DE COVID-19; ECMO; Mobile ECMO; ARDS; Personal protective equipment
ID EXTRACORPOREAL MEMBRANE-OXYGENATION; CORONAVIRUS; ARDS
AB At July 25, 2020, WHO had recorded more than 16.1 million confirmed COVID-19 cases, 1% of them developed critical illness. These patients can experience rapid progression to profound hypoxemia and severe acute respiratory distress syndrome (ARDS). Some patients, despite receiving lung-protective ventilation and maximal medical therapy, develop refractory hypoxemia, rendering candidates for extracorporeal membrane oxygenation (ECMO) support. Centers with experience in this technique are available only in a few reference hospitals and some patients are too ill to be transferred with conventional mechanical ventilation so they need mobile ECMO (interhospital transport under ECMO). Here we report the first interhospital extracorporeal membrane oxygenation transport of a COVID-19 patient in Chile, showing that it is feasible and safe to transfer a COVID-19 patient under ECMO support if a mobile ECMO program is correctly implemented and the particularities of protective measures are properly taken.
C1 [Daniela, Martinez] Hosp San Borja Arriaran, Unidad Infectol Pediat, Santiago, Chile.
   [Daniela, Martinez] Clin Las Condes, Ctr Pacientes Crit Pediat, Las Condes, Chile.
   [Felipe, Salech] Hosp Clin Univ Chile, Ctr Invest Clin Avanzada, Independencia, Chile.
   [Felipe, Salech; Luisa, Duran] Clin Las Condes, Dept Med Interna, Las Condes, Chile.
   [Van Nicolette, Sint Jan; Tomas, Regueira] Clin Las Condes, Ctr Pacientes Crit, Las Condes, Chile.
   [Van Nicolette, Sint Jan; Eli, Villalabeitia; Christian, Fajardo] Clin Las Condes, Dept Cirugia Cardiovasc, Las Condes, Chile.
   [Van Nicolette, Sint Jan; Eli, Villalabeitia; Jorge, Rufs; Christian, Fajardo; Rodrigo, Diaz] Clin Las Condes, Unidad ECMO, Las Condes, Chile.
   [Jorge, Rufs; Roberto, Castillo; Rodrigo, Diaz] Clin Las Condes, Dept Anestesia, ECMO Unit, Estoril 450, Santiago, Chile.
   [Jose, Iniguez] Hosp Clin Magallanes, Serv Urgencias, Punta Arenas, Chile.
RP Rodrigo, D (corresponding author), Clin Las Condes, Unidad ECMO, Las Condes, Chile.; Rodrigo, D (corresponding author), Clin Las Condes, Dept Anestesia, ECMO Unit, Estoril 450, Santiago, Chile.
EM rdiaz@clc.cl
FU FONDECYTComision Nacional de Investigacion Cientifica y Tecnologica
   (CONICYT)CONICYT FONDECYT [11190882] Funding Source: Medline
CR Alshahrani MS, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-017-0350-x
   Bartlett RH, 2020, ASAIO J, V66, pE113, DOI 10.1097/MAT.0000000000001219
   Brodie D, 2011, NEW ENGL J MED, V365, P1905, DOI 10.1056/NEJMct1103720
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Diaz R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165824
   Henry BM, 2020, J CRIT CARE, V58, P27, DOI 10.1016/j.jcrc.2020.03.011
   Japan ECMOnet COVID-19, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00440-9
   Sorbello M, 2020, ANAESTHESIA, V75, P724, DOI 10.1111/anae.15049
   Squiccimarro E, 2020, ASAIO J, V66, P841, DOI 10.1097/MAT.0000000000001199
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zeng YC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2840-8
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 12
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 1434-7229
EI 1619-0904
J9 J ARTIF ORGANS
JI J. Artif. Organs
DI 10.1007/s10047-020-01209-5
EA SEP 2020
PG 6
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA NQ7AR
UT WOS:000571022800001
PM 32949269
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Shamir, I
   Abutbul-Amitai, M
   Abbas-Egbariya, H
   Pasmanik-Chor, M
   Paret, G
   Nevo-Caspi, Y
AF Shamir, Inbal
   Abutbul-Amitai, Mor
   Abbas-Egbariya, Haya
   Pasmanik-Chor, Metsada
   Paret, Gideon
   Nevo-Caspi, Yael
TI STAT3 isoforms differentially affect ACE2 expression: A potential target
   for COVID-19 therapy
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE ACE2; COVID-19; SARS-CoV-2; STAT3 isoforms; STAT3 alpha; STAT3 beta
ID CORONAVIRUS
AB The SARS-coronavirus 2 is the aetiologic agent COVID-19. ACE2 has been identified as a cell entry receptor for the virus. Therefore, trying to understand how the gene is controlled has become a major goal. We silenced the expression of STAT3 alpha and STAT3 beta, and found that while silencing STAT3 alpha causes an increase in ACE2 expression, silencing STAT3 beta causes the opposite effect. Studying the role of STAT3 in ACE2 expression will shed light on the molecular events that contribute to the progression of the disease and that the different roles of STAT3 alpha and STAT3 beta in that context must be taken in consideration. Our results place STAT3 in line with additional potential therapeutic targets for treating COVID-19 patients.
C1 [Shamir, Inbal; Abutbul-Amitai, Mor; Abbas-Egbariya, Haya; Paret, Gideon; Nevo-Caspi, Yael] Sheba Med Ctr, Safra Childrens Hosp, Dept Pediat Crit Care Med, Tel Hashomer, Israel.
   [Pasmanik-Chor, Metsada] Tel Aviv Univ, George S Wise Fac Life Sci, Bioinformat Unit, Tel Aviv, Israel.
   [Paret, Gideon] Tel Aviv Univ, Sackler Med Sch, Tel Aviv, Israel.
RP Nevo-Caspi, Y (corresponding author), Sheba Med Ctr, Safra Childrens Hosp, Dept Pediat Crit Care Med, Tel Hashomer, Israel.
EM yael.caspi@sheba.health.gov.il
CR Aigner P, 2019, CYTOKINE, V118, P27, DOI 10.1016/j.cyto.2018.07.014
   Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Bharadwaj U, 2014, CANCERS, V6, P2012, DOI 10.3390/cancers6042012
   Clarke NE, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/307315
   Dewilde S, 2008, FRONT BIOSCI-LANDMRK, V13, P6501, DOI 10.2741/3170
   Dreos R, 2015, NUCLEIC ACIDS RES, V43, pD92, DOI 10.1093/nar/gku1111
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Maritano D, 2004, NAT IMMUNOL, V5, P401, DOI 10.1038/ni1052
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Zhang HF, 2016, CLIN CANCER RES, V22, P691, DOI 10.1158/1078-0432.CCR-15-1253
   Zhang HX, 2019, INT J BIOCHEM CELL B, V110, P130, DOI 10.1016/j.biocel.2019.02.006
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 15
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD NOV
PY 2020
VL 24
IS 21
BP 12864
EP 12868
DI 10.1111/jcmm.15838
EA SEP 2020
PG 5
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA OV1EP
UT WOS:000570683200001
PM 32949179
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Copcu, HE
AF Copcu, H. Eray
TI New normal: two aspects of adipose tissue in COVID-19-treat and threat?
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Article
DE Adipose tissue; COVID19; stromal cells; MSC; ADSC; hypertrophied; ACE2
ID STROMAL-VASCULAR FRACTION; RENIN-ANGIOTENSIN SYSTEM; CELL DELIVERY;
   INFLAMMATION; DYSFUNCTION; THERAPIES; HEALTH; SCARS; WHITE
AB Introduction Adipose-derived stromal cells (ADSCs) can be an important alternative in COVID-19 prevention, treatment, and subsequent sequelae repair. However, ACE-2 plays a common role in the pathogenesis of adipocyte hypertrophy and COVID 19. Areas covered In this 'Perspective,' the author would like to emphasize the use of adipose tissue-derived stromal cells in COVID 19 and the issues that clinicians should pay attention to in fat graft applications in terms of adipose tissue-RAS relationship. The new normal for adipose tissue in COVID 19 will be highlighted. Expert Opinion ADSCs may potentially be used in COVID-19. However, it has been speculated that ACE2 receptors are responsible for the pathogenesis of adipose tissue overgrowth and may be a potential danger in terms of the relationship between ACE2 receptors and COVID19. We speculate that reducing the size of overgrown fat tissue by ultra-sharp blades and using near-normal adipocytes will create a 'new normal.'
C1 [Copcu, H. Eray] MEST Hlth Serv, Dept Aesthet Plast Surg, Izmir, Turkey.
RP Copcu, HE (corresponding author), MEST Hlth Serv, Aesthet & Plast Surg, Izmir, Turkey.
EM ecopcu@gmail.com
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Al-Ghadban S, 2020, PHYSIOLOGY, V35, P125, DOI 10.1152/physiol.00021.2019
   Americo ALV, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215896
   Andia I, 2019, EXPERT OPIN BIOL TH, V19, P1289, DOI 10.1080/14712598.2019.1671970
   Bari E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040924
   Bourin P, 2013, CYTOTHERAPY, V15, P641, DOI 10.1016/j.jcyt.2013.02.006
   Cervelli V, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/434191
   CHANG YS, 2014, J PEDIAT, V164
   Copcu HE, 2020, AESTHETIC SURG J OPE, V2, DOI [10.1093/asjof/ojaa035, DOI 10.1093/ASJ0F/0JAA035]
   Frantz ED, 2018, CLIN SCI, V132, P1487, DOI 10.1042/CS20180276
   Fukui E, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/5179172
   Gan Rosemary, 2020, Med Hypotheses, V144, P110024, DOI 10.1016/j.mehy.2020.110024
   Garg RK, 2014, STEM CELL TRANSL MED, V3, P1079, DOI 10.5966/sctm.2014-0007
   GENTILE P, 2019, CELLS-BASEL, V8, DOI DOI 10.3390/CELLS8030282
   Gentile P, 2019, INT J MOL SCI, V2, P20
   Gentile P, 2019, J CLIN MED, V15, P8
   Gentile P, 2019, J CLIN MED, V12, P8
   Gentile P, 2020, AGING DIS, V11, P1191, DOI 10.14336/AD.2020.0711
   Gentile P, 2020, AGING DIS, V11, P465, DOI 10.14336/AD.2020.0422
   Gentile P, 2020, EXPERT OPIN BIOL TH, V20, P711, DOI 10.1080/14712598.2020.1761322
   Gentile P, 2017, REGEN MED, V12, P939, DOI 10.2217/rme-2017-0076
   Gentile P, 2014, J CRANIOFAC SURG, V25, P267, DOI 10.1097/01.scs.0000436746.21031.ba
   Ghiasloo M, 2020, AESTHET SURG J, V40, pNP546, DOI 10.1093/asj/sjaa111
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Hoogduijn MJ, 2019, STEM CELL TRANSL MED, V8, P1126, DOI 10.1002/sctm.19-0073
   Ji FP, 2020, STEM CELL TRANSL MED, V9, P813, DOI 10.1002/sctm.20-0083
   Jia X, 2020, 2 THINGS COVID 19 MI, DOI [10.20944/preprints202002.0315.v1, DOI 10.20944/PREPRINTS202002.0315.V1]
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Kloting N, 2014, REV ENDOCR METAB DIS, V15, P277, DOI 10.1007/s11154-014-9301-0
   Lee JC, 2009, EPLASTY, V9, pe14
   Li MO, 2008, IMMUNITY, V28, P468, DOI 10.1016/j.immuni.2008.03.003
   Lopes-Pacheco M, 2020, CELL BIOL TOXICOL, V36, P83, DOI 10.1007/s10565-019-09493-5
   Morestin H, 1915, B MEM SOC CHIR PARIS, V41, P1631
   OON CJ, 1975, CLIN EXP IMMUNOL, V20, P1
   Pahlavani M, 2017, COMPR PHYSIOL, V7, P1137, DOI 10.1002/cphy.c160031
   Patel VB, 2016, ADIPOCYTE, V5, P306, DOI 10.1080/21623945.2015.1131881
   Rohrich RJ, 2019, PLAST RECONSTR SURG, V143, DOI 10.1097/PRS.0000000000005561
   Ryan PM, 2020, OBESITY, V28, P1191, DOI 10.1002/oby.22843
   Schildberg FA, 2018, CYTOM PART A, V93A, P871, DOI 10.1002/cyto.a.23600
   Sese B, 2019, PLAST RECONSTR SURG, V144, P1079, DOI 10.1097/PRS.0000000000006155
   Shetty AK, 2020, AGING DIS, V11, P200, DOI 10.14336/AD.2020.0103
   Shetty Rohit, 2020, Indian J Ophthalmol, V68, P693, DOI 10.4103/ijo.IJO_639_20
   Silva JD, 2018, CRIT CARE MED, V46, pE132, DOI 10.1097/CCM.0000000000002833
   Slamkova M, 2016, Endocr Regul, V50, P229, DOI 10.1515/enr-2016-0025
   Sun ZW, 2018, J THORAC DIS, V10, P1084, DOI 10.21037/jtd.2018.01.46
   Taghavi-Farahabadi M, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106463
   Tonnard P, 2013, PLAST RECONSTR SURG, V132, P1017, DOI 10.1097/PRS.0b013e31829fe1b0
   Ullah M, 2019, ISCIENCE, V15, P421, DOI 10.1016/j.isci.2019.05.004
   Urbanek K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158746
   Zimmerlin L, 2013, CYTOTHERAPY, V15, P102, DOI 10.1016/j.jcyt.2012.10.009
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 50
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD NOV 1
PY 2020
VL 20
IS 11
BP 1283
EP 1292
DI 10.1080/14712598.2020.1822812
EA SEP 2020
PG 10
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA OK3HN
UT WOS:000570285100001
PM 32910704
OA Bronze
DA 2021-01-01
ER

PT J
AU Palermo, S
AF Palermo, Sara
TI Covid-19 Pandemic: Maximizing Future Vaccination Treatments Considering
   Aging and Frailty
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; ageotype; frailty; vaccination; adherence to treatment;
   immunosenecence; inflammaging; immunology
ID MENTAL-HEALTH; INFLUENZA VACCINATION; COGNITIVE IMPAIRMENT; OLDER;
   COMMUNITY; ADHERENCE; EFFICACY; VACCINES; INFLAMMATION; ASSOCIATION
AB The COVID-19 pandemic is proving to be a multiplier of inequalities. Especially toward the elderly population. A voiceless scream that comes from geriatrics, nursing homes, hospices from all over Italy. They call it the silent massacre: from North to South, the bulletin of coronavirus positive-or already deceased-elderly people continues to grow exponentially without a chance to counter it. Population aging and chronicity are a question that needs to be addressed. Frailty is the most challenging expression of population aging, with major consequences for public health and clinical practice. It is a geriatric syndrome which consists in a state of higher vulnerability to stressors attributed to a lower homeostatic reserve due to an age-related multisystem physiological change. People over 60, and especially over 80, are particularly vulnerable to severe or fatal infection. Moreover, the age-related dysregulation of the immune system in the elderly (i.e., immunosenescence and inflammaging) results in poorer responses to vaccination. Physical frailty is an effective health indicator and it has previously shown to predict the response to the seasonal flu vaccine. These findings suggest that assessing frailty in the elderly may identify those who are less likely to respond to immunization and be at higher risk for COVID-19 and its complications. Moreover, cognitive frailty and neurocognitive disorders, mental health and reduced awareness of illness negatively impact on adherence to complex medication regimens among elderly patients. A worldwide research and development blueprint have been initiated to accelerate the development of vaccines and therapeutics for the COVID-19 outbreak. Considered the above, I suggest the importance to consider aging in thinking about future Civud-19 vaccination and treatment, focusing on the possible impact of physical and cognitive frailty.
C1 [Palermo, Sara] Univ Turin, Dept Psychol, Turin, Italy.
   [Palermo, Sara] European Innovat Partnership Act & Hlth Aging, Brussels, Belgium.
RP Palermo, S (corresponding author), Univ Turin, Dept Psychol, Turin, Italy.; Palermo, S (corresponding author), European Innovat Partnership Act & Hlth Aging, Brussels, Belgium.
EM sara.palermo@unito.it
RI Palermo, Sara/M-7102-2013
OI Palermo, Sara/0000-0002-1451-3793
CR Ahadi S, 2020, NAT MED, V26, P83, DOI 10.1038/s41591-019-0719-5
   Andrew MK, 2007, CAN J AGING, V26, P33, DOI 10.3138/8774-758W-702Q-2531
   Andrew MK, 2017, J INFECT DIS, V216, P405, DOI 10.1093/infdis/jix282
   Anisman H, 2018, IMMUNE SYSTEM MENTAL, P186
   Beard JR, 2016, LANCET, V387, P2145, DOI 10.1016/S0140-6736(15)00516-4
   Bellelli G, 2020, INTENS CARE MED, V46, P1634, DOI 10.1007/s00134-020-06087-2
   Bennett FC, 2019, CLIN EXP IMMUNOL, V197, P294, DOI 10.1111/cei.13334
   Bilotta C, 2010, AGING MENT HEALTH, V14, P1024, DOI 10.1080/13607863.2010.508772
   Bodeker B, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1970-4
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Brummel NE, 2017, AM J RESP CRIT CARE, V196, P64, DOI 10.1164/rccm.201605-0939OC
   Calder PC, 2017, AGEING RES REV, V40, P95, DOI 10.1016/j.arr.2017.09.001
   Chan TC, 2013, J GERONTOL A-BIOL, V68, P324, DOI 10.1093/gerona/gls175
   Chao CT, 2016, PEERJ, V4, DOI 10.7717/peerj.2122
   Chudiak A, 2018, CLIN INTERV AGING, V13, P1409, DOI 10.2147/CIA.S162701
   Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010
   Committee for Medicinal Products for Human Use (CHMP), 2018, REFL PAP PHYS FRAILT
   Costa A, 2017, HORIZONS NEUROSCIENC, V28, P137
   D'Acquisto F, 2017, DIALOGUES CLIN NEURO, V19, P9
   de Meijer C, 2013, EUR J AGEING, V10, P353, DOI 10.1007/s10433-013-0280-x
   Del Giudice G, 2017, NPJ AGING MECH DIS, V4, DOI 10.1038/s41514-017-0020-0
   Dolansky MA, 2016, CIRC-HEART FAIL, V9, DOI 10.1161/CIRCHEARTFAILURE.116.002475
   Duggal NA, 2018, AGING CELL, V17, DOI 10.1111/acel.12750
   Ecarnot Fiona, 2020, Interdiscip Top Gerontol Geriatr, V43, P234, DOI 10.1159/000504486
   Elliott RA, 2015, CURR CLIN PHARMACOL, V10, P213, DOI 10.2174/1574884710666150812141525
   Elomaa AP, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-2
   Eurostat, POP STRUCT AG
   Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2
   Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016
   Franceschi C, 2018, NAT REV ENDOCRINOL, V14, P576, DOI 10.1038/s41574-018-0059-4
   Fried L, 2009, HAZZARDS GERIATRIC M, P631
   Gobbens RJJ, 2010, J AM MED DIR ASSOC, V11, P338, DOI 10.1016/j.jamda.2009.09.015
   Gobbens RJJ, 2010, J AM MED DIR ASSOC, V11, P356, DOI 10.1016/j.jamda.2009.11.008
   GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661
   Holt E, 2013, J AM GERIATR SOC, V61, P558, DOI 10.1111/jgs.12171
   Hoogendijk EO, 2019, LANCET, V394, P1365, DOI 10.1016/S0140-6736(19)31786-6
   ISS, 2020, SURV NAZ CONT COVID
   Jankowska-Polanska B, 2016, EUR J CARDIOVASC NUR, V15, P559, DOI 10.1177/1474515115626878
   Jankowska-Polanska B, 2016, CLIN INTERV AGING, V11, P1781, DOI 10.2147/CIA.S113994
   Jeste DV, 2019, INT PSYCHOGERIATR, V31, P755, DOI 10.1017/S1041610219000863
   Kelaiditi E, 2013, J NUTR HEALTH AGING, V17, P726, DOI 10.1007/s12603-013-0367-2
   LaFon DC, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00189-7
   Longobucco Yari, 2019, Acta Biomed, V90, P364, DOI 10.23750/abm.v90i2.8419
   Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4
   Lundstrom K, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050109
   Ma Lina, 2020, J Gerontol A Biol Sci Med Sci, DOI 10.1093/gerona/glaa156
   Maltese G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072106
   McElhaney JE, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00181-1
   Medaglini D, 2018, VACCINE, V36, P1136, DOI 10.1016/j.vaccine.2017.11.069
   Mercatelli D, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01800
   Mhaolain AMN, 2012, INT PSYCHOGERIATR, V24, P1265, DOI 10.1017/S1041610211002110
   Morese R, 2019, NEW FORMS SOCIAL EXC, P1
   Morese R, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02010
   Nishiguchi S, 2015, J AM MED DIR ASSOC, V16, P120, DOI 10.1016/j.jamda.2014.07.010
   Ogura S, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00335
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Pariante CM, 2016, EPIDEMIOL PSYCH SCI, V25, P101, DOI 10.1017/S204579601500089X
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Pinti M, 2016, EUR J IMMUNOL, V46, P2286, DOI 10.1002/eji.201546178
   Pinti M, 2014, EUR J IMMUNOL, V44, P1552, DOI 10.1002/eji.201343921
   Pivetta NRS, 2020, ARCH GERONTOL GERIAT, V86, DOI 10.1016/j.archger.2019.103931
   Pop-Vicas A, 2011, GERONTOLOGY, V57, P397, DOI 10.1159/000319033
   Qiu TY, 2020, J GENET GENOMICS, V47, P115, DOI 10.1016/j.jgg.2020.01.003
   Rappuoli R, 2014, P NATL ACAD SCI USA, V111, P12288, DOI 10.1073/pnas.1402981111
   Robertson DA, 2014, J AM GERIATR SOC, V62, P2118, DOI 10.1111/jgs.13111
   Rodgers JE, 2018, MED CARE RES REV, V75, P746, DOI 10.1177/1077558717696992
   Rosado-Artalejo C, 2017, J NUTR HEALTH AGING, V21, P980, DOI 10.1007/s12603-017-0895-2
   Ruan HH, 2020, MENOPAUSE, V27, P1185, DOI 10.1097/GME.0000000000001612
   Smith D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170651
   Smith GE, 2013, MILD COGNITIVE IMPAI
   Sourial N, 2010, J CLIN EPIDEMIOL, V63, P647, DOI 10.1016/j.jclinepi.2009.08.007
   Stilley CS, 2010, HEALTH PSYCHOL, V29, P50, DOI 10.1037/a0016940
   Talegawkar SA, 2012, J NUTR, V142, P2161, DOI 10.3945/jn.112.165498
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   United Nations Department of Economic and Social Affairs Population Division, 2019, WORLD POP PROSP 2019
   Van Epps P, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00498-16
   Vatic M, 2020, EXP GERONTOL, V133, DOI 10.1016/j.exger.2020.110858
   Vetrano DL, 2019, J GERONTOL A-BIOL, V74, P659, DOI 10.1093/gerona/gly110
   Villacampa-Fernandez P, 2017, MATURITAS, V95, P31, DOI 10.1016/j.maturitas.2016.10.008
   Wang GC, 2014, TRANSL MED UNISA, V9, P1
   Ward L, 2008, J CLIN NURS, V17, P5, DOI 10.1111/j.1365-2702.2006.01861.x
   Wheelock A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113503
   Wilson D, 2017, AGEING RES REV, V36, P1, DOI 10.1016/j.arr.2017.01.006
   Wise DA, 2005, ANAL EC AGING
   Wrapp D, 2020, CELL, V181, P1436, DOI 10.1016/j.cell.2020.05.047
   Wu YH, 2015, J AM MED DIR ASSOC, V16, DOI 10.1016/j.jamda.2015.07.013
   Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071
   Yao X, 2011, VACCINE, V29, P5015, DOI 10.1016/j.vaccine.2011.04.077
NR 88
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD SEP 18
PY 2020
VL 7
AR 558835
DI 10.3389/fmed.2020.558835
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ1CK
UT WOS:000576829300001
PM 33072783
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Keiffer, G
   French, Z
   Wilde, L
   Filicko-O'Hara, J
   Gergis, U
   Binder, AF
AF Keiffer, Gina
   French, Zachary
   Wilde, Lindsay
   Filicko-O'Hara, Joanne
   Gergis, Usama
   Binder, Adam F.
TI Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a
   Patient With Aplastic Anemia
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; tocilizumab; cytokine storm; aplastic anemia
ID ANTI-IL-6 RECEPTOR ANTIBODY; INTERLEUKIN-6; BLOCKADE; COVID-19; THERAPY;
   IL-6
AB While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm resolved, and the patient was ultimately safely discharged from the hospital.
C1 [Keiffer, Gina; Wilde, Lindsay; Filicko-O'Hara, Joanne; Gergis, Usama; Binder, Adam F.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   [French, Zachary] Thomas Jefferson Univ Hosp, Dept Med, Philadelphia, PA 19107 USA.
RP Keiffer, G (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
EM gina.keiffer@jefferson.edu
FU Sidney Kimmel Cancer Center
FX Publication of this manuscript was funded as part of employment of the
   authors at Sidney Kimmel Cancer Center.
CR Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Grupp SA, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.221.221
   Guo C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17834-w
   Gupta V, 2017, J PEDIAT HEMATOL ONC, V39, P214, DOI 10.1097/MPH.0000000000000724
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Lu SL, 2017, J PEDIAT HEMATOL ONC, V39, P614, DOI 10.1097/MPH.0000000000000942
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Madkaikar M, 2007, ACTA HAEMATOL-BASEL, V118, P153, DOI 10.1159/000108630
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   Roumier M, 2020, INTERLEUKIN 6 BLOCKA, DOI [10.1101/2020.04.20.20061861, 10.1101/2020.04.20.20061861., DOI 10.1101/2020.04.20.20061861]
   Ruan QR, 2020, INTENS CARE MED, V46, P1294, DOI 10.1007/s00134-020-06028-z
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tanaka T, 2014, SEMIN IMMUNOL, V26, P88, DOI 10.1016/j.smim.2014.01.009
   Teachey DT, 2016, CANCER DISCOV, V6, P664, DOI 10.1158/2159-8290.CD-16-0040
   Uchiyama Y, 2008, INT IMMUNOPHARMACOL, V8, P1595, DOI 10.1016/j.intimp.2008.07.002
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zeng Y, 2015, CLIN EXP IMMUNOL, V180, P361, DOI 10.1111/cei.12605
   Zhang SY, 2020, CLIN DRUG INVEST, V40, P511, DOI 10.1007/s40261-020-00917-3
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD SEP 18
PY 2020
VL 10
AR 562625
DI 10.3389/fonc.2020.562625
PG 6
WC Oncology
SC Oncology
GA NY6DG
UT WOS:000576477000001
PM 33072589
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fang, J
   Li, H
   Du, W
   Yu, P
   Guan, YY
   Ma, SY
   Liu, D
   Chen, W
   Shi, GC
   Bian, XL
AF Fang, Jie
   Li, Hui
   Du, Wei
   Yu, Ping
   Guan, Ying-Yun
   Ma, Shi-Yu
   Liu, Dong
   Chen, Wei
   Shi, Guo-Chao
   Bian, Xiao-Lan
TI Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in
   Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Arbidol; Lianhuaqingwen; combination therapy
ID INFLUENZA-A VIRUS; CHINESE MEDICINE; SARS-COV-2
AB Objective Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan City, China, coronavirus disease 2019 (COVID-19) has become a global pandemic. However, no special therapeutic drugs have been identified for COVID-19. The aim of this study was to search for drugs to effectively treat COVID-19. Materials and Methods We conducted a retrospective cohort study with a total of 162 adult inpatients (>= 18 years old) from Ruijin Hospital (Shanghai, China) and Tongji Hospital (Wuhan, China) between January 27, 2020, and March 10, 2020. The enrolled COVID-19 patients were first divided into the Lianhuaqingwen (LHQW) monotherapy group and the LHQW + Arbidol combination therapy group. Then, these two groups were further classified into moderate and severe groups according to the clinical classification of COVID-19. Results The early combined usage of LHQW and Arbidol can significantly accelerate the recovery of patients with moderate COVID-19 by reducing the time to conversion to nucleic acid negativity, the time to chest CT improvement, and the length of hospital stay. However, no benefit was observed in severe COVID-19 patients treated with the combination of LHQW + Arbidol. In this study, both Arbidol and LHQW were well tolerated without serious drug-associated adverse events. Conclusion The early combined usage of LHQW and Arbidol may accelerate recovery and improve the prognosis of patients with moderate COVID-19.
C1 [Fang, Jie; Li, Hui; Yu, Ping; Guan, Ying-Yun; Ma, Shi-Yu; Bian, Xiao-Lan] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pharm, Shanghai, Peoples R China.
   [Du, Wei; Liu, Dong; Chen, Wei; Shi, Guo-Chao] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Resp & Crit Care Dis, Shanghai, Peoples R China.
   [Du, Wei; Liu, Dong; Chen, Wei; Shi, Guo-Chao] Shanghai Jiao Tong Univ, Inst Resp Dis, Sch Med, Shanghai, Peoples R China.
RP Bian, XL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pharm, Shanghai, Peoples R China.; Chen, W; Shi, GC (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Resp & Crit Care Dis, Shanghai, Peoples R China.; Chen, W; Shi, GC (corresponding author), Shanghai Jiao Tong Univ, Inst Resp Dis, Sch Med, Shanghai, Peoples R China.
EM monbox007@hotmail.com; shiguochao@hotmail.com; bxl40338@rjh.com.cn
FU Shanghai Jiao Tong University of Medicine [JDYX2020KYZX011]
FX This study was supported by Shanghai Jiao Tong University of Medicine
   Special Scientific Research Fund for Pharmacy Administration and
   rational drug use of COVID-19 (JDYX2020KYZX011).
CR Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Ding YW, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1585-7
   Dong L, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/637969
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Duan ZP, 2011, CHINESE MED J-PEKING, V124, P2925, DOI 10.3760/cma.j.issn.0366-6999.2011.18.024
   Global Times, 2020, GLOBAL TIMES
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hansell DM, 2008, RADIOLOGY, V246, P697, DOI 10.1148/radiol.2462070712
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu K. E., 2020, PHYTOMEDICINE, P153242, DOI [10.1016/j.phymed.2020.153242, DOI 10.1016/J.PHYMED.2020.153242]
   Jia Weina, 2015, ScientificWorldJournal, V2015, P731765, DOI 10.1155/2015/731765
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Liu Q, 2013, ACTA PHARMACOL SIN, V34, P1075, DOI 10.1038/aps.2013.54
   Luo H, 2020, CHIN J INTEGR MED, V26, P243, DOI 10.1007/s11655-020-3192-6
   Pecheur EI, 2016, J VIROL, V90, P3086, DOI 10.1128/JVI.02077-15
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Shi L, 2007, ARCH VIROL, V152, P1447, DOI 10.1007/s00705-007-0974-5
   Teissier E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015874
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wang CH, 2016, MOL BIOSYST, V12, P606, DOI 10.1039/c5mb00448a
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   World Health Organization, 2020, ROLL UPD COR DIS COV
   Wu J, 2020, J INTERN MED, V288, P128, DOI 10.1111/joim.13063
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   [姚开涛 Yao Kaitao], 2020, [中国实验方剂学杂志, Chinese Journal of Experimental Traditional Medical Formulae], V26, P8
   Zhang GM, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01338-8
   Zhao P, 2014, ALTERN THER HEALTH M, V20, P25
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
NR 35
TC 0
Z9 0
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 18
PY 2020
VL 11
AR 560209
DI 10.3389/fphar.2020.560209
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY6JF
UT WOS:000576492500001
PM 33071781
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bertin, P
   Nera, K
   Delouvee, S
AF Bertin, Paul
   Nera, Kenzo
   Delouvee, Sylvain
TI Conspiracy Beliefs, Rejection of Vaccination, and Support for
   hydroxychloroquine: A Conceptual Replication-Extension in the COVID-19
   Pandemic Context
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE vaccination; chloroquine; conspiracy beliefs; conspiracy mentality;
   attitude toward science; pandemic (COVID-19); COVID-19; vaccination
   intention
AB Many conspiracy theories appeared along with the COVID-19 pandemic. Since it is documented that conspiracy theories negatively affect vaccination intentions, these beliefs might become a crucial matter in the near future. We conducted two cross-sectional studies examining the relationship between COVID-19 conspiracy beliefs, vaccine attitudes, and the intention to be vaccinated against COVID-19 when a vaccine becomes available. We also examined how these beliefs predicted support for a controversial medical treatment, namely, chloroquine. In an exploratory study 1 (N= 409), two subdimensions of COVID-19 conspiracy beliefs were associated with negative attitudes toward vaccine science. These results were partly replicated and extended in a pre-registered study 2 (N= 396). Moreover, we found that COVID-19 conspiracy beliefs (among which, conspiracy beliefs about chloroquine), as well as a conspiracy mentality (i.e., predisposition to believe in conspiracy theories) negatively predicted participants' intentions to be vaccinated against COVID-19 in the future. Lastly, conspiracy beliefs predicted support for chloroquine as a treatment for COVID-19. Interestingly, none of the conspiracy beliefs referred to the dangers of the vaccines. Implications for the pandemic and potential responses are discussed.
C1 [Bertin, Paul] Univ Cote Azur, LAPCOS, Nice, France.
   [Nera, Kenzo] Univ Libre Bruxelles, Ctr Social & Cultural Psychol, Brussels, Belgium.
   [Nera, Kenzo] Fonds Rech Sci FRS, Brussels, Belgium.
   [Delouvee, Sylvain] Univ Rennes, EA1285 Lab Psychol Cognit Comportement Commun LP3, Rennes, France.
RP Bertin, P (corresponding author), Univ Cote Azur, LAPCOS, Nice, France.
EM pbertin@unice.fr
FU l'Agence Nationale de la Recherche (ANR)French National Research Agency
   (ANR) [ANR-17-CE39-0010-01]
FX The open access publication fees was supported by l'Agence Nationale de
   la Recherche (ANR) for the Project CONSPIRACY (ANR-17-CE39-0010-01).
CR Anvari F, 2018, COMPREHENSIVE RESULT, V3, P266, DOI DOI 10.1080/23743603.2019.1684822
   Bangerter A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049806
   Blanca MJ, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02558
   Bogart LM, 2010, JAIDS-J ACQ IMM DEF, V53, P648, DOI 10.1097/QAI.0b013e3181c57dbc
   Bruder M, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00225
   Chen L, 2020, HEALTH COMMUN, DOI 10.1080/10410236.2020.1751384
   Cichocka A, 2016, BRIT J PSYCHOL, V107, P556, DOI 10.1111/bjop.12158
   Conspiracy Watch, 2019, ENQ COMPL VAG 2
   Conspiracy Watch, 2020, FRANC QUATR EST TORT
   COronavirus et CONfinement: Enquete Longitudinale (COCONEL), 2020, CORONAVIRUS CONFINEM
   Douglas KM, 2019, POLIT PSYCHOL, V40, P3, DOI 10.1111/pops.12568
   Douglas KM, 2017, CURR DIR PSYCHOL SCI, V26, P538, DOI 10.1177/0963721417718261
   Franks B, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00424
   GOERTZEL T, 1994, POLIT PSYCHOL, V15, P731, DOI 10.2307/3791630
   Goldberg Z. J., 2020, WORLD AFFAIR, V183, P105, DOI [10.1177/0043820020920554, DOI 10.1177/0043820020920554]
   Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586
   IJzerman H., 2020, PSYCHOL SCI IS NOT Y
   Imhoff R, 2018, EUR J SOC PSYCHOL, V48, P909, DOI 10.1002/ejsp.2494
   Imhoff R, 2014, EUR J PERSONALITY, V28, P25, DOI 10.1002/per.1930
   Institut francais d'opinion publique [IFOP], 2020, CHLOR MIR OP FRANC C
   Institut National de la Statistique et des Etudes Economiques [INSEE], 2019, PERS 6 UT INT PLUS U
   Jolley D, 2017, J APPL SOC PSYCHOL, V47, P459, DOI 10.1111/jasp.12453
   Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177
   Kouzy R, 2020, CUREUS, V12, DOI 10.7759/cureus.7255
   Krueger J, 2001, AM PSYCHOL, V56, P16, DOI 10.1037//0003-066X.56.1.16
   Lamberty P, 2018, SOC PSYCHOL-GERMANY, V49, P255, DOI 10.1027/1864-9335/a000347
   Lantian A, 2016, INT REV SOC PSYCHOL, V29, P1, DOI 10.5334/irsp.8
   Le Point, 2020, LE POINT
   Lewandowsky S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075637
   Lyons B, 2019, HEALTH COMMUN, V34, P1741, DOI 10.1080/10410236.2018.1530526
   Martinez-Berman Lisset, 2020, Psychol Health Med, P1, DOI 10.1080/13548506.2020.1778754
   Moscovici S., 1987, CHANGING CONCEPTIONS, P151, DOI [10.1007/978-1-4612-4618-3, DOI 10.1007/978-1-4612-4618-3_9]
   Rosenfeld D. L., 2020, CONDUCTING SOCIAL PS, DOI [10.31234/osf.io/6gjfm, DOI 10.31234/OSF.IO/6GJFM]
   Rozbroj T, 2019, PATIENT EDUC COUNS, V102, P172, DOI 10.1016/j.pec.2018.08.027
   Schonbrodt FD, 2013, J RES PERS, V47, P609, DOI 10.1016/j.jrp.2013.05.009
   Spinney L., 2017, PALE RIDER SPANISH F
   Swami V, 2011, BRIT J PSYCHOL, V102, P443, DOI 10.1111/j.2044-8295.2010.02004.x
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z
   van Prooijen JW, 2018, EUR J SOC PSYCHOL, V48, P897, DOI 10.1002/ejsp.2530
   van Prooijen JW, 2017, MEM STUD, V10, P323, DOI 10.1177/1750698017701615
   Ward JK, 2019, NAT IMMUNOL, V20, P1257, DOI 10.1038/s41590-019-0488-9
   WHO, 2020, PUBL STAT COLL COVID
   Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7
NR 44
TC 0
Z9 0
U1 7
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD SEP 18
PY 2020
VL 11
AR 565128
DI 10.3389/fpsyg.2020.565128
PG 9
WC Psychology, Multidisciplinary
SC Psychology
GA NW6TZ
UT WOS:000575149500001
PM 33071892
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gordon, JL
   Balsom, AA
AF Gordon, Jennifer L.
   Balsom, Ashley A.
TI The psychological impact of fertility treatment suspensions during the
   COVID-19 pandemic
SO PLOS ONE
LA English
DT Article
ID INFERTILE WOMEN; DEFENSIVE PESSIMISM; SOCIAL SUPPORT; CHRONIC PAIN;
   PREVALENCE; ACCEPTANCE; ANXIETY; ADJUSTMENT; DEPRESSION; THERAPY
AB Purpose To examine the psychological impact of fertility treatment suspensions resulting from the COVID-19 pandemic and to clarify psychosocial predictors of better or worse mental health. Methods 92 women from Canada and the United States (ages 20-45 years) whose fertility treatments had been cancelled were recruited via social media. Participants completed a battery of questionnaires assessing depressive symptoms, perceived mental health impact, and change in quality of life related to treatment suspensions. Potential predictors of psychological outcomes were also examined, including several personality traits, aspects of social support, illness cognitions, and coping strategies. Results 52% of respondents endorsed clinical levels of depressive symptoms. On a 7-point scale, participants endorsed a significant decline in overall quality of life (M(SD) = -1.3(1.3), p < .0001) as well as a significant decline in mental health related to treatment suspensions on a scale from -5 to +5 (M(SD) = -2.1(2.1), p < .001). Several psychosocial variables were found to positively influence these outcomes: lower levels of defensive pessimism (r = -.25, p < .05), greater infertility acceptance (r = .51, p < .0001), better quality social support (r = .31, p < .01), more social support seeking (r = .35, p < .001) and less avoidance of infertility reminders (r = -.23, p = .029). Conclusion Fertility treatment suspensions have had a considerable negative impact on women's mental health and quality of life. However, these findings point to several protective psychosocial factors that can be fostered in the future to help women cope.
C1 [Gordon, Jennifer L.; Balsom, Ashley A.] Univ Regina, Dept Psychol, Regina, SK, Canada.
RP Gordon, JL (corresponding author), Univ Regina, Dept Psychol, Regina, SK, Canada.
EM jennifer.gordon@uregina.ca
RI Balsom, Ashley/AAS-1161-2020
OI Balsom, Ashley/0000-0002-1795-8093
FU Saskatchewan Health Research Foundation [4577]; Canadian Institutes of
   Health Research, Tier II Canada Research ChairCanadian Institutes of
   Health Research (CIHR)
FX JLG: Saskatchewan Health Research Foundation, grant #4577, www.shrf.ca
   JLG: Canadian Institutes of Health Research, Tier II Canada Research
   Chair, https://cihr-irsc.gc.ca/The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR American Society for Reproductive Medicine, 2020, PAT MAN CLIN REC COR
   [Anonymous], 2020, CFAS COMM COVID 19
   Bromham D.R., 1989, J REPROD INFANT PSYC, V7, P195, DOI DOI 10.1080/02646838908403594
   Bushnik T, 2012, HUM REPROD, V27, P738, DOI 10.1093/humrep/der465
   Carleton RN, 2007, J ANXIETY DISORD, V21, P105, DOI 10.1016/j.janxdis.2006.03.014
   Chen TH, 2004, HUM REPROD, V19, P2313, DOI 10.1093/humrep/deh414
   DOMAR AD, 1993, J PSYCHOSOM OBST GYN, V14, P45
   Driscoll MA, 2016, ANN BEHAV MED, V50, P272, DOI 10.1007/s12160-015-9750-z
   Esteve R, 2007, ANN BEHAV MED, V33, P179, DOI 10.1007/BF02879899
   Faramarzi M, 2008, J AFFECT DISORDERS, V108, P159, DOI 10.1016/j.jad.2007.09.002
   HAYES SC, 1994, BEHAV ANALYST, V17, P289, DOI 10.1007/BF03392677
   HYNES GJ, 1992, BRIT J MED PSYCHOL, V65, P269, DOI 10.1111/j.2044-8341.1992.tb01707.x
   Kee BS, 2000, J ASSIST REPROD GEN, V17, P445
   Kemp B., 2001, TOP SPINAL CORD INJU, V6, P116
   Koszycki D, 2012, ARCH WOMEN MENT HLTH, V15, P193, DOI 10.1007/s00737-012-0277-z
   Lauwerier E, 2010, INT J BEHAV MED, V17, P90, DOI 10.1007/s12529-009-9059-z
   Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006
   Lund R, 2009, HUM REPROD, V24, P2810, DOI 10.1093/humrep/dep257
   Martins MV, 2014, HUM REPROD, V29, P83, DOI 10.1093/humrep/det403
   McCracken LA, 2008, HEALTH PSYCHOL, V27, P215, DOI 10.1037/0278-6133.27.2.215
   Mindes EJ, 2003, SOC SCI MED, V56, P2165, DOI 10.1016/S0277-9536(02)00221-6
   Myers LB, 1996, AM J FAM THER, V24, P9, DOI 10.1080/01926189508251012
   Nelson CJ, 2008, J SEX MED, V5, P1907, DOI 10.1111/j.1743-6109.2008.00880.x
   NOREM JK, 1986, J PERS SOC PSYCHOL, V51, P1208, DOI 10.1037/0022-3514.51.6.1208
   Peterson BD, 2006, HUM REPROD, V21, P2443, DOI 10.1093/humrep/del145
   Peterson BD, 2011, COGN BEHAV PRACT, V18, P577, DOI 10.1016/j.cbpra.2010.03.004
   Ruiz F. J., 2012, INT J PSYCHOL PSYCHO, V12, P333, DOI DOI 10.1016/J.BETH.2011.07.004
   SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063
   Spencer SM, 1996, PERS SOC PSYCHOL B, V22, P354, DOI 10.1177/0146167296224003
   Turocy JM, 2020, EMOTIONAL IMPACT ASR
   Van den Broeck U, 2010, PATIENT EDUC COUNS, V81, P422, DOI 10.1016/j.pec.2010.10.009
   Viane I, 2003, PAIN, V106, P65, DOI 10.1016/S0304-3959(03)00291-4
   Volgsten H, 2008, HUM REPROD, V23, P2056, DOI 10.1093/humrep/den154
   Yu YJ, 2014, PSYCHIAT RES, V215, P401, DOI 10.1016/j.psychres.2013.10.032
NR 34
TC 1
Z9 1
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 18
PY 2020
VL 15
IS 9
AR e0239253
DI 10.1371/journal.pone.0239253
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NU7WV
UT WOS:000573851100030
PM 32946479
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jillella, DV
   Janocko, NJ
   Nahab, F
   Benameur, K
   Greene, JG
   Wright, WL
   Obideen, M
   Rangaraju, S
AF Jillella, Dinesh, V
   Janocko, Nicholas J.
   Nahab, Fadi
   Benameur, Karima
   Greene, James G.
   Wright, Wendy L.
   Obideen, Mahmoud
   Rangaraju, Srikant
TI Ischemic stroke in COVID-19: An urgent need for early identification and
   management
SO PLOS ONE
LA English
DT Article
AB Objective In the setting of the Coronavirus Disease 2019 (COVID-19) global pandemic caused by SARS-CoV-2, a potential association of this disease with stroke has been suggested. We aimed to describe the characteristics of patients who were admitted with COVID-19 and had an acute ischemic stroke (AIS). Methods This is a case series of PCR-confirmed COVID-19 patients with ischemic stroke admitted to an academic health system in metropolitan Atlanta, Georgia (USA) between March 24(th), 2020 and July 17(th), 2020. Demographic, clinical, and radiographic characteristics were described. Results Of 396 ischemic stroke patients admitted during this study period, 13 (2.5%) were also diagnosed with COVID-19. The mean age of patients was 61.6 +/- 10.8 years, 10 (76.9%) male, 8 (61.5%) were Black Americans, mean time from last normal was 4.97 +/- 5.1 days, and only one received acute reperfusion therapy. All 13 patients had at least one stroke-associated co-morbidity. The predominant pattern of ischemic stroke was embolic with 4 explained by atrial fibrillation. COVID-19 patients had a significantly higher rate of cryptogenic stroke than non-COVID-19 patients during the study period (69% vs 17%, p = 0.0001). Conclusions In our case series, ischemic stroke affected COVID-19 patients with traditional stroke risk factors at an age typically seen in non-COVID populations, and mainly affecting males and Black Americans. We observed a predominantly embolic pattern of stroke with a higher than expected rate of cryptogenic strokes, a prolonged median time to presentation and symptom recognition limiting the use of acute reperfusion treatments. These results highlight the need for increased community awareness, early identification, and management of AIS in COVID-19 patients.
C1 [Jillella, Dinesh, V; Janocko, Nicholas J.; Nahab, Fadi; Benameur, Karima; Greene, James G.; Wright, Wendy L.; Obideen, Mahmoud; Rangaraju, Srikant] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
   [Jillella, Dinesh, V; Janocko, Nicholas J.; Rangaraju, Srikant] Grady Mem Hosp, Atlanta, GA 30303 USA.
RP Jillella, DV (corresponding author), Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.; Jillella, DV (corresponding author), Grady Mem Hosp, Atlanta, GA 30303 USA.
EM dineshvinayakjillella@gmail.com
RI Rangaraju, S/Q-1924-2018
OI Rangaraju, S/0000-0003-2765-1500; Benameur, Karima/0000-0002-4599-5705;
   Jillella, Dinesh/0000-0002-5399-0170
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Avula A, 2020, BRAIN BEHAV IMMUN
   Fang L, 2020, LANCET RESP MED, V8, ppe21, DOI 10.1016/S2223-2600(20)301136-8
   Jillella DV, 2019, CURR OPIN INFECT DIS, V32, P285, DOI 10.1097/QCO.0000000000000547
   Kansagra AP, 2020, N ENGL J MED
   Kuipers S, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0688-5
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Mao L, 2020, JAMA NEUROL
   Oxley JMT.J., 2020, N ENGL J MED
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Saver JL, 2016, NEW ENGL J MED, V374, P2065, DOI 10.1056/NEJMcp1503946
   Seecheran R, 2020, J INVEST MED HIGH IM, V8, DOI 10.1177/2324709620925571
   Spiezia L, 2020, THROMB HAEMOST
   Yaghi S, 2020, STROKE, V51, P2002, DOI 10.1161/STROKEAHA.120.030335
NR 14
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 18
PY 2020
VL 15
IS 9
AR e0239443
DI 10.1371/journal.pone.0239443
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NU7WV
UT WOS:000573851100018
PM 32946512
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Huang, PH
   Tsai, HH
   Liao, BH
   Lin, YL
   Jan, JT
   Tao, MH
   Chou, YC
   Hu, CMJ
   Chen, HW
AF Huang, Ping-Han
   Tsai, Hsiao-Han
   Liao, Bo-Hung
   Lin, Yi-Ling
   Jan, Jia-Tsrong
   Tao, Mi-Hua
   Chou, Yu-Chi
   Hu, Che-Ming Jack
   Chen, Hui-Wen
TI Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding
   domain
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE SARS-CoV-2; receptor-binding domain; vaccine; neutralizing antibodies
AB A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.
C1 [Huang, Ping-Han; Chen, Hui-Wen] Natl Taiwan Univ, Dept Vet Med, Taipei 10617, Taiwan.
   [Tsai, Hsiao-Han; Liao, Bo-Hung; Lin, Yi-Ling; Tao, Mi-Hua; Hu, Che-Ming Jack] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.
   [Tsai, Hsiao-Han] Natl Yang Ming Univ, Taiwan Int Grad Program Mol Med, Taipei, Taiwan.
   [Tsai, Hsiao-Han] Acad Sinica, Taipei, Taiwan.
   [Jan, Jia-Tsrong] Acad Sinica, Genom Res Ctr, Taipei, Taiwan.
   [Chou, Yu-Chi] Acad Sinica, RNAi Core Facil, Taipei, Taiwan.
RP Chen, HW (corresponding author), Natl Taiwan Univ, Dept Vet Med, Taipei 10617, Taiwan.
EM winnichen@ntu.edu.tw
OI CHEN, HUI-WEN/0000-0002-0595-3420
FU Ministry of Science and Technology [MOST-109-3114-Y-001-001,
   MOST-109-2327-B-002-009]; National Taiwan UniversityNational Taiwan
   University; Academia Sinica, TaiwanAcademia Sinica - Taiwan
FX This study was supported by the Ministry of Science and Technology
   (MOST-109-3114-Y-001-001 and MOST-109-2327-B-002-009), National Taiwan
   University and Academia Sinica, Taiwan.
CR [Anonymous], 2020, REC INV COVID 19 CON
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Czajkowsky DM, 2012, EMBO MOL MED, V4, P1015, DOI 10.1002/emmm.201201379
   Diamond MS, 2020, CELL HOST MICROBE, V27, P699, DOI 10.1016/j.chom.2020.04.021
   European Commission, 2020, EU PROGR COVID 19 CO
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Lan JM, 2015, EBIOMEDICINE, V2, P1438, DOI 10.1016/j.ebiom.2015.08.031
   Lin LCW, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201807616
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
NR 10
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1814098
EA SEP 2020
PG 2
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA NU4ZU
UT WOS:000573652300001
PM 32991231
DA 2021-01-01
ER

PT J
AU Asakura, H
   Ogawa, H
AF Asakura, Hidesaku
   Ogawa, Haruhiko
TI Perspective on fibrinolytic therapy in COVID-19: the potential of
   inhalation therapy against suppressed-fibrinolytic-type DIC
SO JOURNAL OF INTENSIVE CARE
LA English
DT Letter
DE COVID-19; Thrombosis; Fibrinolytic therapy
ID TISSUE-PLASMINOGEN ACTIVATOR
AB A high rate of thrombotic complications, such as pulmonary embolism, has been linked to mortality in COVID-19, and appropriate treatment of thrombosis is important for lifesaving. Although heparin is frequently used to treat thrombotic pathology in COVID-19, pulmonary embolism is still seen in severe cases. Although systemic fibrinolytic therapy is a focus of attention because a thrombotic pathology is the cause of death in severe COVID-19, it should be kept in mind that fibrinolytic therapy might be harmful at advanced stage of COVID-19 where the status of disseminated intravascular coagulation (DIC) has been transmitted from suppressed-fibrinolytic to enhanced-fibrinolytic in disease progression of COVID-19. In this respect, inhalation therapy with fibrinolytic substances might be a safe and promising treatment.
C1 [Asakura, Hidesaku] Kanazawa Univ Hosp, Dept Hematol, Takaramachi 13-1, Kanazawa, Ishikawa 9208640, Japan.
   [Ogawa, Haruhiko] Kanazawa Univ, Dept Environm & Prevent Med, Takaramachi 13-1, Kanazawa, Ishikawa 9208640, Japan.
RP Asakura, H (corresponding author), Kanazawa Univ Hosp, Dept Hematol, Takaramachi 13-1, Kanazawa, Ishikawa 9208640, Japan.
EM hasakura@staff.kanazawa-u.ac.jp
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Asakura H, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-20
   Carsana L, 2020, PULMONARY POSTMORTEM, DOI [10.1101/2020.04.19.20054262, DOI 10.1101/2020.04.19.20054262]
   Choudhury R, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00305-4
   Christie DB, 2020, J TRAUMA ACUTE CARE, V89, P448, DOI 10.1097/TA.0000000000002787
   Fox SE., PULMONARY CARDIAC PA, DOI [10.1101/2020.04.06.20050575, DOI 10.1101/2020.04.06.20050575]
   Mahmoud AAA, 2020, J CARDIOTHOR VASC AN, V34, P436, DOI 10.1053/j.jvca.2019.05.035
   Mantuano E, 2017, BLOOD, V130, P1364, DOI 10.1182/blood-2017-04-780205
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Nougier C, 2020, J THROMB HAEMOST, V18, P2215, DOI 10.1111/jth.15016
   Stringer KA, 2008, CLIN EXP PHARMACOL P, V35, P1454, DOI 10.1111/j.1440-1681.2008.05011.x
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Whyte CS, 2020, J THROMB HAEMOST, V18, P1548, DOI 10.1111/jth.14872
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wu Y, 2020, QJM-INT J MED, V113, P539, DOI 10.1093/qjmed/hcaa121
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zalfa C, 2019, J LEUKOCYTE BIOL, V105, P729, DOI 10.1002/JLB.3A0818-329RRR
   Zenz W, 2004, CRIT CARE MED, V32, P1777, DOI 10.1097/01.CCM.0000133667.86429.5D
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 19
TC 3
Z9 3
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2052-0492
J9 J INTENSIVE CARE
JI J. Intensive Care
PD SEP 18
PY 2020
VL 8
IS 1
AR 71
DI 10.1186/s40560-020-00491-y
PG 4
WC Critical Care Medicine
SC General & Internal Medicine
GA NU7OJ
UT WOS:000573829100001
PM 32959003
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hsieh, CL
   Goldsmith, JA
   Schaub, JM
   DiVenere, AM
   Kuo, HC
   Javanmardi, K
   Le, KC
   Wrapp, D
   Lee, AG
   Liu, YT
   Chou, CW
   Byrne, PO
   Hjorth, CK
   Johnson, NV
   Ludes-Meyers, J
   Nguyen, AW
   Park, J
   Wang, NS
   Amengor, D
   Lavinder, JJ
   Ippolito, GC
   Maynard, JA
   Finkelstein, IJ
   McLellan, JS
AF Hsieh, Ching-Lin
   Goldsmith, Jory A.
   Schaub, Jeffrey M.
   DiVenere, Andrea M.
   Kuo, Hung-Che
   Javanmardi, Kamyab
   Le, Kevin C.
   Wrapp, Daniel
   Lee, Alison G.
   Liu, Yutong
   Chou, Chia-Wei
   Byrne, Patrick O.
   Hjorth, Christy K.
   Johnson, Nicole, V
   Ludes-Meyers, John
   Nguyen, Annalee W.
   Park, Juyeon
   Wang, Nianshuang
   Amengor, Dzifa
   Lavinder, Jason J.
   Ippolito, Gregory C.
   Maynard, Jennifer A.
   Finkelstein, Ilya J.
   McLellan, Jason S.
TI Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
SO SCIENCE
LA English
DT Article
ID CRYO-EM STRUCTURE; CORONAVIRUS; GLYCOPROTEIN; VACCINE; NEUTRALIZATION;
   PROTEIN; ENTRY; RSV
AB The coronavirus disease 2019 (COVID-19) pandemic has led to accelerated efforts to develop therapeutics and vaccines. A key target of these efforts is the spike (S) protein, which is metastable and difficult to produce recombinantly. We characterized 100 structure-guided spike designs and identified 26 individual substitutions that increased protein yields and stability. Testing combinations of beneficial substitutions resulted in the identification of HexaPro, a variant with six beneficial proline substitutions exhibiting higher expression than its parental construct (by a factor of 10) as well as the ability to withstand heat stress, storage at room temperature, and three freeze-thaw cycles. A cryo-electron microscopy structure of HexaPro at a resolution of 3.2 angstroms confirmed that it retains the prefusion spike conformation. High-yield production of a stabilized prefusion spike protein will accelerate the development of vaccines and serological diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
C1 [Hsieh, Ching-Lin; Goldsmith, Jory A.; Schaub, Jeffrey M.; Kuo, Hung-Che; Javanmardi, Kamyab; Wrapp, Daniel; Lee, Alison G.; Chou, Chia-Wei; Byrne, Patrick O.; Hjorth, Christy K.; Johnson, Nicole, V; Ludes-Meyers, John; Park, Juyeon; Wang, Nianshuang; Amengor, Dzifa; Lavinder, Jason J.; Ippolito, Gregory C.; Finkelstein, Ilya J.; McLellan, Jason S.] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.
   [DiVenere, Andrea M.; Le, Kevin C.; Liu, Yutong; Nguyen, Annalee W.; Lavinder, Jason J.; Maynard, Jennifer A.] Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA.
   [Ippolito, Gregory C.] Univ Texas Austin, Dell Med Sch, Dept Oncol, Austin, TX 78712 USA.
   [Finkelstein, Ilya J.] Univ Texas Austin, Ctr Syst & Synthet Biol, Austin, TX 78712 USA.
RP Finkelstein, IJ; McLellan, JS (corresponding author), Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.; Maynard, JA (corresponding author), Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA.; Finkelstein, IJ (corresponding author), Univ Texas Austin, Ctr Syst & Synthet Biol, Austin, TX 78712 USA.
EM maynard@che.utexas.edu; ilya@finkelsteinlab.org;
   jmclellan@austin.utexas.edu
OI Wrapp, Daniel/0000-0002-0538-9647; Javanmardi,
   Kamyab/0000-0002-6449-6709; Nguyen, Annalee/0000-0003-1268-7164;
   Johnson, Nicole/0000-0003-4351-125X; Ippolito,
   Gregory/0000-0002-7565-7002; Le, Kevin-Phu/0000-0001-5098-7737; Schaub,
   Jeffrey/0000-0002-1130-2675
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01-AI127521, GM120554, GM124141,
   AI122753, 75N93019C00050]; Bill & Melinda Gates FoundationBill & Melinda
   Gates Foundation; Welch FoundationThe Welch Foundation [F-1808, F-1767];
   NSFNational Science Foundation (NSF) [1453358]; National Cancer
   Institute's National Cryo-EM Facility at the Frederick National
   Laboratory for Cancer Research [HSSN261200800001E]; University of Texas
   College of Natural Sciences; CPRIT [RR160023]
FX Supported by NIH grants or contracts R01-AI127521 (J.S.M.), GM120554 and
   GM124141 (I.J.F.), AI122753 (J.A.M.), and 75N93019C00050 (J.J.L. and
   G.C.I.); the Bill & Melinda Gates Foundation (J.A.M., I.J.F., and
   J.S.M.); Welch Foundation grants F-1808 (I.J.F.) and F-1767 (J.A.M.);
   NSF grant 1453358 (I.J.F.); and the National Cancer Institute's National
   Cryo-EM Facility at the Frederick National Laboratory for Cancer
   Research under contract HSSN261200800001E. I.J.F. is a Cancer Prevention
   and Research Institute of Texas (CPRIT) Scholar in Cancer Research. The
   Sauer Structural Biology Laboratory is supported by the University of
   Texas College of Natural Sciences and by award RR160023 from CPRIT.
CR BATTLES MB, 2017, NAT COMMUN, V8, DOI DOI 10.1038/S41467-
   Battles MB, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01708-9
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Crank MC, 2019, SCIENCE, V365, P505, DOI 10.1126/science.aav9033
   Croll TI, 2018, ACTA CRYSTALLOGR D, V74, P519, DOI 10.1107/S2059798318002425
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Hastie KM, 2017, SCIENCE, V356, P923, DOI 10.1126/science.aam7260
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2004, J VIROL, V78, P6134, DOI 10.1128/JVI.78.12.6134-6142.2004
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Krarup A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9143
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li ZJ, 2019, ELIFE, V8, DOI 10.7554/eLife.51230
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Qiao H, 1998, J CELL BIOL, V141, P1335, DOI 10.1083/jcb.141.6.1335
   Ramirez-Aportela E, 2020, BIOINFORMATICS, V36, P765, DOI 10.1093/bioinformatics/btz671
   Rutten L, 2020, CELL REP, V30, P4540, DOI 10.1016/j.celrep.2020.03.025
   Rutten L, 2018, CELL REP, V23, P584, DOI 10.1016/j.celrep.2018.03.061
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Tegunov D, 2019, NAT METHODS, V16, P1146, DOI 10.1038/s41592-019-0580-y
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang NS, 2019, CELL REP, V28, P3395, DOI 10.1016/j.celrep.2019.08.052
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 35
TC 17
Z9 16
U1 11
U2 11
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD SEP 18
PY 2020
VL 369
IS 6510
BP 1501
EP +
DI 10.1126/science.abd0826
PG 28
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NU8RF
UT WOS:000573904400037
PM 32703906
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lv, Z
   Deng, YQ
   Ye, Q
   Cao, L
   Sun, CY
   Fan, CF
   Huang, WJ
   Sun, SH
   Sun, Y
   Zhu, L
   Chen, Q
   Wang, N
   Nie, JH
   Cui, Z
   Zhu, DD
   Shaw, N
   Li, XF
   Li, QQ
   Xie, LZ
   Wang, YC
   Rao, ZH
   Qin, CF
   Wang, XX
AF Lv, Zhe
   Deng, Yong-Qiang
   Ye, Qing
   Cao, Lei
   Sun, Chun-Yun
   Fan, Changfa
   Huang, Weijin
   Sun, Shihui
   Sun, Yao
   Zhu, Ling
   Chen, Qi
   Wang, Nan
   Nie, Jianhui
   Cui, Zhen
   Zhu, Dandan
   Shaw, Neil
   Li, Xiao-Feng
   Li, Qianqian
   Xie, Liangzhi
   Wang, Youchun
   Rao, Zihe
   Qin, Cheng-Feng
   Wang, Xiangxi
TI Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a
   potent therapeutic antibody
SO SCIENCE
LA English
DT Article
ID HUMAN MONOCLONAL-ANTIBODY; CRYO-EM STRUCTURE; MERS-COV; SPIKE;
   CORONAVIRUS; BINDING; PROTEIN; VALIDATION; REFINEMENT
AB The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. There are no approved vaccines or therapeutics for treating COVID-19. Here we report a humanized monoclonal antibody, H014, that efficiently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2 at nanomolar concentrations by engaging the spike (S) receptor binding domain (RBD). H014 administration reduced SARS-CoV-2 titers in infected lungs and prevented pulmonary pathology in a human angiotensin-converting enzyme 2 mouse model. Cryo-electron microscopy characterization of the SARS-CoV-2 S trimer in complex with the H014 Fab fragment unveiled a previously uncharacterized conformational epitope, which was only accessible when the RBD was in an open conformation. Biochemical, cellular, virological, and structural studies demonstrated that H014 prevents attachment of SARS-CoV-2 to its host cell receptors. Epitope analysis of available neutralizing antibodies against SARS-CoV and SARS-CoV-2 uncovered broad cross-protective epitopes. Our results highlight a key role for antibody-based therapeutic interventions in the treatment of COVID-19.
C1 [Lv, Zhe; Cao, Lei; Sun, Yao; Zhu, Ling; Wang, Nan; Cui, Zhen; Zhu, Dandan; Shaw, Neil; Rao, Zihe; Wang, Xiangxi] Chinese Acad Sci, Inst Biophys, CAS Key Lab Infect & Immun, Natl Lab Macromol, Beijing 100101, Peoples R China.
   [Lv, Zhe; Wang, Nan; Cui, Zhen; Wang, Xiangxi] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Deng, Yong-Qiang; Ye, Qing; Sun, Shihui; Chen, Qi; Li, Xiao-Feng; Qin, Cheng-Feng] Acad Mil Med Sci, Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.
   [Sun, Chun-Yun; Xie, Liangzhi] Sinocelltech Ltd, Beijing Prot & Antibody RandD Engn Ctr, Beijing 100176, Peoples R China.
   [Fan, Changfa] Natl Inst Food & Drug Control NIFDC, Inst Lab Anim Resources, Div Anim Model Res, Beijing 102629, Peoples R China.
   [Huang, Weijin; Nie, Jianhui; Li, Qianqian; Wang, Youchun] Natl Inst Food & Drug Control NIFDC, Inst Biol Prod Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, Beijing 102629, Peoples R China.
   [Xie, Liangzhi] Sino Biol Inc, BDA, Beijing Antibody Res Key Lab, Bldg 9,Jing Dong Bei Technol Pk, Beijing 100176, Peoples R China.
   [Xie, Liangzhi] Chinese Acad Med Sci & Peking Union Med Coll, Cell Culture Engn Ctr, Beijing 100005, Peoples R China.
RP Rao, ZH; Wang, XX (corresponding author), Chinese Acad Sci, Inst Biophys, CAS Key Lab Infect & Immun, Natl Lab Macromol, Beijing 100101, Peoples R China.; Wang, XX (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Qin, CF (corresponding author), Acad Mil Med Sci, Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.; Xie, LZ (corresponding author), Sinocelltech Ltd, Beijing Prot & Antibody RandD Engn Ctr, Beijing 100176, Peoples R China.; Wang, YC (corresponding author), Natl Inst Food & Drug Control NIFDC, Inst Biol Prod Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, Beijing 102629, Peoples R China.; Xie, LZ (corresponding author), Sino Biol Inc, BDA, Beijing Antibody Res Key Lab, Bldg 9,Jing Dong Bei Technol Pk, Beijing 100176, Peoples R China.; Xie, LZ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Cell Culture Engn Ctr, Beijing 100005, Peoples R China.
EM liangzhi@yahoo.com; wangyc@nifdc.org.cn; raozh@tsinghua.edu.cn;
   qincf@bmi.ac.cn; xiangxi@ibp.ac.cn
RI Qin, Cheng-Feng/I-6839-2019
OI Qin, Cheng-Feng/0000-0002-0632-2807; sun, chunyun/0000-0002-1839-8737;
   Huang, Weijin/0000-0002-4246-8889; LV, zhe/0000-0001-5777-1605; Cao,
   Lei/0000-0003-4289-4025; Sun, Shihui/0000-0002-2623-9939
FU National Key Research and Development Program [2020YFA0707500,
   2018YFA0900801]; National Science and Technology Major Projects of
   Infectious Disease funds [2017ZX103304402]; Beijing Municipal Science
   and Technology Project [Z201100005420017]; Zhejiang Provincial Basic
   Public Welfare Research Project [LED20C010001]; Ten Thousand Talent
   Program; NSFS Innovative Research Group [81921005]; Strategic Priority
   Research ProgramChinese Academy of Sciences [XDB29010000]; National
   Science Fund for Distinguished Young ScholarNational Natural Science
   Foundation of China (NSFC)National Science Fund for Distinguished Young
   Scholars [81925025]; Innovative Research Group from the NSFC [81621005];
   Innovation Fund for Medical Sciences from the Chinese Academy of Medical
   Sciences [2019-I2M-5-049]
FX We thank X. Huang, B. Zhu, and G. Ji for cryo-EM data collection and the
   Center for Biological imaging (CBI) at the Institute of Biophysics for
   EM work. This study was supported by the National Key Research and
   Development Program (2020YFA0707500, 2018YFA0900801), the Strategic
   Priority Research Program (XDB29010000), National Science and Technology
   Major Projects of Infectious Disease funds (grants 2017ZX103304402),
   Beijing Municipal Science and Technology Project (Z201100005420017), and
   Zhejiang Provincial Basic Public Welfare Research Project
   (LED20C010001). X.W. was supported by the Ten Thousand Talent Program
   and the NSFS Innovative Research Group (no. 81921005). C.-F.Q. was
   supported by the National Science Fund for Distinguished Young Scholar
   (no. 81925025) and the Innovative Research Group (no. 81621005) from the
   NSFC, and the Innovation Fund for Medical Sciences (no. 2019-I2M-5-049)
   from the Chinese Academy of Medical Sciences. L.X. and C.-Y.S. are
   inventors on patent application (202010219867.1) submitted by
   Sinocelltech Ltd. that covers the intellectual property of H014.
CR Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308
   Berry JD, 2004, J VIROL METHODS, V120, P87, DOI 10.1016/j.jviromet.2004.04.009
   Brown A, 2015, ACTA CRYSTALLOGR D, V71, P136, DOI 10.1107/S1399004714021683
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Corti D, 2015, P NATL ACAD SCI USA, V112, P10473, DOI 10.1073/pnas.1510199112
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Kucukelbir A, 2014, NAT METHODS, V11, P63, DOI [10.1038/NMETH.2727, 10.1038/nmeth.2727]
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Ou Z. Z. Junxian, 2020, BIORXIV 2020 03 15 9, DOI [10.1101/2020.03.15.991844., DOI 10.1101/2020.03.15.991844]
   Ou Z. Z. Junxian, 2020, RBD MUTATIONS CIRCUL
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto D., 2020, BIORXIV 2020 04 07 0, DOI DOI 10.1101/2020.04.07.023903
   Pinto Dora, 2020, bioRxiv, DOI 10.1101/2020.04.07.023903
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Scheres SHW, 2016, METHOD ENZYMOL, V579, P125, DOI 10.1016/bs.mie.2016.04.012
   Scheres SHW, 2012, NAT METHODS, V9, P853, DOI 10.1038/nmeth.2115
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   van den Brink EN, 2005, J VIROL, V79, P1635, DOI 10.1128/JVI.79.3.1635-1644.2005
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang N, 2020, PROTEIN CELL, V11, P366, DOI 10.1007/s13238-020-00711-z
   Wang N, 2019, SCIENCE, V366, P640, DOI 10.1126/science.aaz1439
   Wang XX, 2017, P NATL ACAD SCI USA, V114, P770, DOI 10.1073/pnas.1616502114
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang YX, 2020, PROTEIN CELL, V11, P339, DOI 10.1007/s13238-020-00710-0
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 43
TC 17
Z9 16
U1 15
U2 15
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD SEP 18
PY 2020
VL 369
IS 6510
BP 1505
EP +
DI 10.1126/science.abc5881
PG 33
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NU8RF
UT WOS:000573904400038
PM 32703908
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Glowacki, EM
   Wilcox, GB
   Glowacki, JB
AF Glowacki, Elizabeth M.
   Wilcox, Gary B.
   Glowacki, Joseph B.
TI Identifying #addiction concerns on twitter during the COVID-19 pandemic:
   A text mining analysis
SO SUBSTANCE ABUSE
LA English
DT Article; Early Access
DE Addiction; COVID-19; text mining analysis; social media; health
   communication
ID FOR-DISEASE-CONTROL; LIVE; CRISIS
AB Background The 2019 Novel Coronavirus (COVID-19) is responsible for thousands of deaths and hospitalizations. To curb the spread of this highly transmissible disease, governments enacted protective guidelines for its citizens, including social distancing and stay-at-home orders. These restrictions on social interactions can be especially problematic for individuals managing or recovering from addiction given that treatment often involves access to services and resources that became limited or even unavailable at this time. Social media sites like Twitter serve as a space for users to post questions and concerns about timely topics and allow for researchers to track common themes among the public. The goal of this study was to identify how the public was discussing addiction on Twitter during the COVID pandemic.Methods:We performed a text mining analysis to analyze tweets that contained "addiction" and "covid" to capture posts from the public that illustrated comments and concerns about addiction during the COVID-19 pandemic. We report on 3,301 tweets captured between January 31 and April 23, 2020. The study was conducted in the United States, but contained tweets from multiple countries.Results:The most prevalent topics had to do with services offered by Acadia Healthcare and Serenity Healthcare Centers, attempts to manage time while home, difficulties of coping with alcoholism amidst rising sales of alcohol, and attention to ongoing health crises (e.g.,., opioids, vaping). Additional topics included affordable telehealth services, research from France on the relationship between nicotine and COVID-19, concerns about gambling addiction, and changing patterns in substance misuse as drug availability varies.Conclusions:Analyzing Twitter content enables health professionals to identify the public's concerns about addiction during the COVID-19 pandemic. Findings from text mining studies addressing timely health topics can serve as preliminary analyses for building more comprehensive models, which can then be used to generate recommendations for the larger public and inform policy.
C1 [Glowacki, Elizabeth M.] Northeastern Univ, Bouve Coll Hlth Sci, Coll Arts Media & Design, 360 Huntington Ave,216 Lake Hall, Boston, MA 02115 USA.
   [Wilcox, Gary B.] Univ Texas Austin, Stan Richards Sch Advertising & Publ Relat, Austin, TX 78712 USA.
   [Glowacki, Joseph B.] Rowan Univ, Sch Osteopath Med, Stratford, NJ USA.
RP Glowacki, EM (corresponding author), Northeastern Univ, Bouve Coll Hlth Sci, Coll Arts Media & Design, 360 Huntington Ave,216 Lake Hall, Boston, MA 02115 USA.
EM e.glowacki@northeastern.edu
OI Glowacki, Elizabeth M./0000-0001-7870-3206
CR Acadia Healthcare, 2020, FREQ ASK QUEST COVID
   Adams D., 2020, BOSTON GLOBE
   Animosa LH, 2018, YOUTH SOC, V50, P49, DOI 10.1177/0044118X15586146
   Bary A., NASDAQ
   Bennett J., 2020, NY TIMES
   Bernhardt JM, 2004, AM J PUBLIC HEALTH, V94, P2051, DOI 10.2105/AJPH.94.12.2051
   Centers for Disease Control and Prevention, 2019, CULT HLTH LIT
   Centers for Disease Control and Prevention, SOC DIST KEEP YOUR D
   Chakraborty G., 2013, TEXT MINING ANAL PRA
   Choliz M, 2016, J GAMBL STUD, V32, P749, DOI 10.1007/s10899-015-9558-6
   Clay RA., ADVICE TREATING PREV
   Crook B, 2016, COMMUN RES REP, V33, P349, DOI 10.1080/08824096.2016.1224171
   Estrin D., 2020, NATL PUBLIC RADIO
   Ferrara E, 2016, COMMUN ACM, V59, P96, DOI 10.1145/2818717
   Glantz SA., REDUCE YOUR RISK OF
   Glowacki EM, 2019, AM J INFECT CONTROL, V47, P1280, DOI 10.1016/j.ajic.2019.04.004
   Glowacki EM, 2018, SUBST ABUS, V39, P129, DOI 10.1080/08897077.2017.1356795
   Glowacki EM, 2016, AM J INFECT CONTROL, V44, P1709, DOI 10.1016/j.ajic.2016.05.025
   Glowacki EM, 2020, QUAL HLTH RES
   Gotts JE, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l5275
   Henry TA., COVID 19 MAKES TELEM, DOI [10.1177/1049732320916466, DOI 10.1177/1049732320916466]
   Joob B, 2016, AM J INFECT CONTROL, V44, P1756, DOI 10.1016/j.ajic.2016.08.019
   Jordan SE, 2018, DATA, V4, DOI 10.3390/data4010006
   Kim S, 2018, 2018 INTERNATIONAL CONFERENCE ON CONTROL AND ROBOTS (ICCR), P78, DOI 10.1109/ICCR.2018.8534487
   King DL, 2020, J BEHAV ADDICT, V9, P1, DOI 10.1556/2006.2020.00001
   Lazard AJ, 2017, TOB CONTROL, V26, pe112, DOI 10.1136/tobaccocontrol-2016-053295
   Lazard AJ, 2015, AM J INFECT CONTROL, V43, P1109, DOI 10.1016/j.ajic.2015.05.025
   Lee K, 2009, ULTRASOUND MED BIOL, V35, pS50
   Li H, 2020, WILEY INTERDISCIP RE, V5, pe1465
   Magua W, 2017, J WOMENS HEALTH, V26, P560, DOI 10.1089/jwh.2016.6021
   Mian A, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01556-3
   National Council on Problem Gambling, COVID 19 PROBL GAMBL
   National Institute of Drug Abuse, 2020, COVID 19 POT IMPL IN
   Owusu-Dabo E, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-1
   Parmer J, 2016, HEALTH COMMUN, V31, P1215, DOI 10.1080/10410236.2015.1049728
   Polakovic G., PANDEMIC DRIVES ALCO
   Pretorius KA, 2018, JMIR PEDIAT PARENT, V1, DOI DOI 10.2196/10435]
   Raja Uzma, 2008, J Healthc Inf Manag, V22, P52
   Sanawi JB, 2017, INT J BUS SOC, V18, P718
   Scott C., 2020, CNN
   Singh N., 2007, INT J HOSP MANAG, V26, P131, DOI DOI 10.1016/J.IJHM.2005.10.002
   Snider M., 2020, USA TODAY
   Snider M., 2019, USA TODAY
   University of Texas at Austin Office of Research Support and Compliance, EX ACT THAT MAY MAY
   van der Linden S, 2017, GLOB CHALL, V1, DOI 10.1002/gch2.201600008
   van Schalkwyk MC, BMJ OPINION
   Vraga EK, 2017, SCI COMMUN, V39, P621, DOI 10.1177/1075547017731776
   WHO Timeline - COVID-19, WHO TIM COVID 19
   World Health Organization, ROLL UPD COR DIS COV
   Yates D, 2011, INT J INFORM MANAGE, V31, P6, DOI 10.1016/j.ijinfomgt.2010.10.001
   Young KS, 2004, AM BEHAV SCI, V48, P402, DOI 10.1177/0002764204270278
NR 51
TC 0
Z9 0
U1 17
U2 17
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0889-7077
EI 1547-0164
J9 SUBST ABUS
JI Subst. Abus.
DI 10.1080/08897077.2020.1822489
EA SEP 2020
PG 8
WC Substance Abuse
SC Substance Abuse
GA NS8MV
UT WOS:000572510800001
PM 32970973
DA 2021-01-01
ER

PT J
AU Wainwright, JJ
   Mikre, M
   Whitley, P
   Dawson, E
   Huskey, A
   Lukowiak, A
   Giroir, BP
AF Wainwright, Jacob J.
   Mikre, Meriam
   Whitley, Penn
   Dawson, Eric
   Huskey, Angela
   Lukowiak, Andrew
   Giroir, Brett P.
TI Analysis of Drug Test Results Before and After the US Declaration of a
   National Emergency Concerning the COVID-19 Outbreak
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
AB This substance use epidemiology study uses a commercial urine drug testing (UDT) service's data to compare UDT results for cocaine, fentanyl, heroin, and methamphetamine before vs after US declaration of coronavirus disease 2019 (COVID-19) as a national emergency among patients diagnosed with or at risk of substance use disorders.
C1 [Wainwright, Jacob J.; Mikre, Meriam; Giroir, Brett P.] Off Assistant Secretary Hlth, Washington, DC USA.
   [Whitley, Penn; Dawson, Eric; Huskey, Angela; Lukowiak, Andrew] Millennium Hlth LLC, San Diego, CA USA.
RP Giroir, BP (corresponding author), US PHS, US Dept HHS, 200 Independence Ave SW, Washington, DC 20201 USA.
EM ashmedia@hhs.gov
FU Millennium Health LLC
FX This study was supported by Millennium Health LLC.
CR Panchal N, 2020, IMPLICATIONS COVID 1
   Substance Abuse and Mental Health Services Administration, 2019, KEY SUBST US MENT HL
   Twillman RK, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.18514
NR 3
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 27
PY 2020
VL 324
IS 16
BP 1674
EP 1677
DI 10.1001/jama.2020.17694
EA SEP 2020
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA OZ8NK
UT WOS:000572361700003
PM 32945855
OA Bronze
DA 2021-01-01
ER

PT J
AU Surendran, H
   Nandakumar, S
   Pal, R
AF Surendran, Harshini
   Nandakumar, Swapna
   Pal, Rajarshi
TI Human Induced Pluripotent Stem Cell-Derived Lung Epithelial System for
   SARS-CoV-2 Infection Modeling and Its Potential in Drug Repurposing
SO STEM CELLS AND DEVELOPMENT
LA English
DT Letter
DE human induced pluripotent stem cells; lung epithelium; respiratory
   disease; SARS-CoV-2; drug repurposing
AB The lung is the most vulnerable target for the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, and respiratory failure causing acute respiratory distress syndrome is its foremost outcome. However, the current primary in vitro models in use for SARS-CoV-2 display apparent limitations for modeling such complex human respiratory disease. Although patient cells can directly model the effects of a drug, their availability and capacity for expansion are limited compared with transformed/immortalized cells or tumor-derived cell lines. An additional caveat is that the latter may harbor genetic and metabolic abnormalities making them unsuitable for drug screening. Therefore, it is important to create physiologically relevant human-cell models that can replicate the pathophysiology of SARS-CoV-2, thus facilitating drug testing. In this study, we show preliminary data on how human induced pluripotent stem cells-derived lung epithelial cell system could emerge as a relevant and sensitive platform for modeling SARS-CoV-2 infection and drug screening.
C1 [Surendran, Harshini; Pal, Rajarshi] Univ Transdisciplinary Hlth Sci & Technol, Bengaluru, India.
   [Nandakumar, Swapna; Pal, Rajarshi] Ctr Cellular & Mol Platforms C CAMP, Eyestem Res, NCBS TIFR Campus, Bengaluru 560065, Karnataka, India.
RP Pal, R (corresponding author), Ctr Cellular & Mol Platforms C CAMP, Eyestem Res, NCBS TIFR Campus, Bengaluru 560065, Karnataka, India.
EM rajarshi.pal@eyestem.com
FU Department of Biotechnology (DBT), Ministry of Science and Technology,
   Govt. of IndiaDepartment of Biotechnology (DBT) India
   [BT/PR14341/MED/31/303/2015]; Biotechnology Industry Research Assistance
   Council (BIRAC), a Govt. of India Enterprise [BT/COVID0046/01/20]
FX This study was jointly funded by the Department of Biotechnology (DBT),
   Ministry of Science and Technology, Govt. of India (no.
   BT/PR14341/MED/31/303/2015) and Biotechnology Industry Research
   Assistance Council (BIRAC), a Govt. of India Enterprise (no.
   BT/COVID0046/01/20).
CR Banerjee P, 2018, STEM CELLS, V36, P218, DOI 10.1002/stem.2740
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Han Y, 2020, IDENTIFICATION CANDI, VDOI, P10
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang Jessie, 2020, bioRxiv, DOI 10.1101/2020.06.30.175695
   Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Nikolic MZ, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.163485
   Surendran Harshini, 2019, Curr Protoc Stem Cell Biol, V49, pe86, DOI 10.1002/cpsc.86
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 10
TC 0
Z9 0
U1 2
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
EI 1557-8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD NOV 1
PY 2020
VL 29
IS 21
BP 1365
EP 1369
DI 10.1089/scd.2020.0152
EA SEP 2020
PG 5
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA OS8NV
UT WOS:000572335700001
PM 32867617
OA Bronze
DA 2021-01-01
ER

PT J
AU Kouznetsova, VL
   Zhang, AD
   Tatineni, M
   Miller, MA
   Tsigelny, IF
AF Kouznetsova, Valentina L.
   Zhang, Aidan
   Tatineni, Mahidhar
   Miller, Mark A.
   Tsigelny, Igor F.
TI Potential COVID-19 papain-like protease PL(pr)o inhibitors: repurposing
   FDA-approved drugs
SO PEERJ
LA English
DT Article
DE COVID-19; Papain-like protease; Computational drug design; Drugs
   repurposing
ID CORONAVIRUS
AB Using the crystal structure of SARS-CoV-2 papain-like protease (PLpro) as a template, we developed a pharmacophore model of functional centers of the PLpro inhibitor-binding pocket. With this model, we conducted data mining of the conformational database of FDA-approved drugs. This search identified 147 compounds that can be potential inhibitors of SARS-CoV-2 PLpro. The conformations of these compounds underwent 3D fingerprint similarity clusterization, followed by docking of possible conformers to the binding pocket of PLpro. Docking of random compounds to the binding pocket of protease was also done for comparison. Free energies of the docking interaction for the selected compounds were lower than for random compounds. The drug list obtained includes inhibitors of HIV, hepatitis C, and cytomegalovirus (CMV), as well as a set of drugs that have demonstrated some activity in MERS, SARS-CoV, and SARS-CoV-2 therapy. We recommend testing of the selected compounds for treatment of COVID-19
C1 [Kouznetsova, Valentina L.; Tatineni, Mahidhar; Miller, Mark A.; Tsigelny, Igor F.] Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92093 USA.
   [Zhang, Aidan] Univ Calif San Diego, REHS Program, San Diego Dupercomp Ctr, La Jolla, CA 92093 USA.
   [Tsigelny, Igor F.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
   [Tsigelny, Igor F.] CureMatch Inc, Sci, San Diego, CA 92121 USA.
RP Tsigelny, IF (corresponding author), Univ Calif San Diego, San Diego Supercomp Ctr, La Jolla, CA 92093 USA.; Tsigelny, IF (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.; Tsigelny, IF (corresponding author), CureMatch Inc, Sci, San Diego, CA 92121 USA.
EM itsigeln@ucsd.edu
OI Tsigelny, Igor/0000-0002-7155-8947
FU NSFNational Science Foundation (NSF) [1341698]; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R01 GM126463]
FX The SDSC Comet supercomputer is supported by the NSF grant: ACI #1341698
   Gateways to Discovery: Cyberinfrastructure for the Long Tail of Science.
   Mark Miller was supported by NIH R01 GM126463. Other authors received no
   funding for this work. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abruzzese E, 2020, MEDITERR J HEMATOL I, V12, DOI 10.4084/MJHID.2020.031
   Akaji K, 2011, J MED CHEM, V54, P7962, DOI 10.1021/jm200870n
   Alamri M. A., 2020, PHARMACOINFORMATICS, DOI [10.20944/preprints202002.0308.v1., DOI 10.20944/PREPRINTS202002.0308.V1]
   Andersen PI, 2020, INT J INFECT DIS, V93, P268, DOI 10.1016/j.ijid.2020.02.018
   Anderson Jeffrey, 2009, V189, P85, DOI 10.1007/978-3-540-79086-0_4
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Arya R, 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11860011.v2, DOI 10.26434/CHEMRXIV.11860011.V2, 10.26434/chemrxiv.11860011.v2.]
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Devaraj SG, 2007, J BIOL CHEM, V282, P32208, DOI 10.1074/jbc.M704870200
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kouznetsova V., 2020, POTENTIAL COVID 19 P, DOI [10.26434/chemrxiv.12093900.v1., DOI 10.26434/CHEMRXIV.12093900.V1, 10.26434/chemrxiv.12093900.v1]
   Lee H, 2015, ACS CHEM BIOL, V10, P1456, DOI 10.1021/cb500917m
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Lei J, 2014, ANTIVIR RES, V109, P72, DOI 10.1016/j.antiviral.2014.06.011
   Liu X., 2020, POTENTIAL INHIBITORS, DOI [10.1101/2020.01.29.924100, DOI 10.1101/2020.01.29.924100]
   Ma C, 2020, BIORXIV, DOI [10.1101/2020.04.20.051581.2020., DOI 10.1101/2020.04.20.051581.2020]
   Moore RL, 2014, P 2014 ANN C EXTR SC, P1
   Neuman BW, 2016, ANTIVIR RES, V135, P97, DOI 10.1016/j.antiviral.2016.10.005
   Osipiuk J, 2020, CRYSTAL STRUCTURE PA
   Plewczynski D, 2007, CHEM BIOL DRUG DES, V69, P269, DOI 10.1111/j.1747-0285.2007.00475.x
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Tan ELC, 2004, EMERG INFECT DIS, V10, P581, DOI 10.3201/eid1004.030458
   Vuong W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18096-2
   WHO, 2020, 171 WHO
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 31
TC 0
Z9 0
U1 1
U2 1
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD SEP 18
PY 2020
VL 8
AR e9965
DI 10.7717/peerj.9965
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NQ6JX
UT WOS:000570978600012
PM 32999768
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ticinesi, A
   Cerundolo, N
   Parise, A
   Nouvenne, A
   Prati, B
   Guerra, A
   Lauretani, F
   Maggio, M
   Meschi, T
AF Ticinesi, Andrea
   Cerundolo, Nicoletta
   Parise, Alberto
   Nouvenne, Antonio
   Prati, Beatrice
   Guerra, Angela
   Lauretani, Fulvio
   Maggio, Marcello
   Meschi, Tiziana
TI Delirium in COVID-19: epidemiology and clinical correlations in a large
   group of patients admitted to an academic hospital
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Coronavirus pneumonia; SARS-CoV-2; Delirium; Multimorbidity; Dementia
ID CONFUSION ASSESSMENT METHOD; INCIDENT DELIRIUM; ELDERLY-PATIENTS;
   DEMENTIA; RISK
AB Background Delirium incidence and clinical correlates in coronavirus disease-19 (COVID-19) pneumonia are still poorly investigated. Aim To describe the epidemiology of delirium in patients hospitalized for suspect COVID-19 pneumonia during the pandemic peak in an academic hospital of Northern Italy, identify its clinical correlations and evaluate the association with mortality. Methods The clinical records of 852 patients admitted for suspect COVID-19 pneumonia, defined as respiratory symptoms or fever or certain history of contact with COVID-19 patients, plus chest CT imaging compatible with alveolar-interstitial pneumonia, were retrospectively analyzed. Delirium was defined after careful revision of daily clinical reports in accordance with the Confusion Assessment Method criteria. Data on age, clinical presentation, comorbidities, drugs, baseline lab tests and outcome were collected. The factors associated with delirium, and the association of delirium with mortality, were evaluated through binary logistic regression models. Results Ninety-four patients (11%) developed delirium during stay. They were older (median age 82, interquartile range, IQR 78-89, vs 75, IQR 63-84,p < 0.001), had more neuropsychiatric comorbidities and worse respiratory exchanges at baseline. At multivariate models, delirium was independently and positively associated with age [odds ratio (OR) 1.093, 95% confidence interval (CI) 1.046-1.143,p < 0.001], use of antipsychotic drugs (OR 4.529, 95% CI 1.204-17.027,p = 0.025), serum urea and lactate-dehydrogenase at admission. Despite a higher mortality in patients with delirium (57% vs 30%), this association was not independent of age and respiratory parameters. Conclusions Delirium represents a common complication of COVID-19 and a marker of severe disease course, especially in older patients with neuropsychiatric comorbidity.
C1 [Ticinesi, Andrea; Cerundolo, Nicoletta; Parise, Alberto; Nouvenne, Antonio; Prati, Beatrice; Lauretani, Fulvio; Maggio, Marcello; Meschi, Tiziana] Azienda Osped Univ Parma, Geriatr Rehabil Dept, Via Antonio Gramsci 14, I-43126 Parma, Italy.
   [Guerra, Angela; Lauretani, Fulvio; Maggio, Marcello; Meschi, Tiziana] Univ Parma, Dept Med & Surg, Parma, Italy.
RP Ticinesi, A (corresponding author), Azienda Osped Univ Parma, Geriatr Rehabil Dept, Via Antonio Gramsci 14, I-43126 Parma, Italy.
EM aticinesi@ao.pr.it
RI Ticinesi, Andrea/K-5017-2016
OI Ticinesi, Andrea/0000-0001-9171-8592
FU Universita degli Studi di Parma within the CRUI-CARE Agreement
FX Open access funding provided by Universita degli Studi di Parma within
   the CRUI-CARE Agreement.
CR Ahmed S, 2014, AGE AGEING, V43, P326, DOI 10.1093/ageing/afu022
   Alkeridy WA, 2020, J AM GERIATR SOC, V68, P1382, DOI 10.1111/jgs.16536
   Beach SR, 2020, GEN HOSP PSYCHIAT, V65, P47, DOI 10.1016/j.genhosppsych.2020.05.008
   Bellelli G, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0649-8
   Benussi Alberto, 2020, Neurology, V95, pe910, DOI 10.1212/WNL.0000000000009848
   Bianchetti A, 2020, J NUTR HEALTH AGING, V24, P560, DOI 10.1007/s12603-020-1389-1
   Bowman K, 2020, AGE AGEING, V49, P374, DOI 10.1093/ageing/afaa006
   Dosa D, 2007, J AM GERIATR SOC, V55, P1099, DOI 10.1111/j.1532-5415.2007.01239.x
   Faverio P, 2014, EUR J INTERN MED, V25, P312, DOI 10.1016/j.ejim.2013.12.001
   Fortini A, 2014, INTERN EMERG MED, V9, P435, DOI 10.1007/s11739-013-0968-0
   Girard TD, 2018, LANCET RESP MED, V6, P213, DOI 10.1016/S2213-2600(18)30062-6
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Inouye SK, 2014, LANCET, V383, P911, DOI 10.1016/S0140-6736(13)60688-1
   INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941
   Koeberle S, 2020, FRENCH EXAMPLE AGE A, V49, P516, DOI [10.1093/ageing/afaa092, DOI 10.1093/AGEING/AFAA092]
   Krewulak KD, 2018, CRIT CARE MED, V46, P2029, DOI 10.1097/CCM.0000000000003402
   Lauretani F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072397
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Lovell N, 2020, J PAIN SYMPTOM MANAG, V60, pE77, DOI 10.1016/j.jpainsymman.2020.04.015
   Magny E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193034
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Meschi T, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13250
   Morandi A, 2020, EUR GERIATR MED, V11, P53, DOI 10.1007/s41999-019-00261-6
   Morandi A, 2017, J AM MED DIR ASSOC, V18, P12, DOI 10.1016/j.jamda.2016.07.014
   O'Hanlon S, 2020, AGE AGEING, V49, P497, DOI 10.1093/ageing/afaa094
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Perrotta F, 2020, AGING CLIN EXP RES, V32, P1599, DOI 10.1007/s40520-020-01631-y
   Sverzellati N, 2020, J THORAC IMAG, V35, P228, DOI 10.1097/RTI.0000000000000516
   Tay HS, 2020, AGE AGEING, V49, P523, DOI 10.1093/ageing/afaa068
   Witlox J, 2010, JAMA-J AM MED ASSOC, V304, P443, DOI 10.1001/jama.2010.1013
NR 32
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1594-0667
EI 1720-8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD OCT
PY 2020
VL 32
IS 10
SI SI
BP 2159
EP 2166
DI 10.1007/s40520-020-01699-6
EA SEP 2020
PG 8
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA NW1CN
UT WOS:000570850400001
PM 32946031
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Kanduc, D
   Shoenfeld, Y
AF Kanduc, Darja
   Shoenfeld, Yehuda
TI Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian
   proteomes: implications for the vaccine
SO IMMUNOLOGIC RESEARCH
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; SIMILARITY; PEPTIDES; MODEL
C1 [Kanduc, Darja] Univ Bari, Dept Biosci Biotechnol & Biopharmaceut, Via Orabona 4, I-70125 Bari, Italy.
   [Shoenfeld, Yehuda] Tel Aviv Univ, Sch Med, Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, Tel Hashomer, Israel.
   [Shoenfeld, Yehuda] Sechenov Univ, IM Sechenov First Moscow State Med Univ, Minist Hlth Russian Federat, Moscow, Russia.
RP Kanduc, D (corresponding author), Univ Bari, Dept Biosci Biotechnol & Biopharmaceut, Via Orabona 4, I-70125 Bari, Italy.
EM dkanduc@gmail.com; Yehuda.Shoenfeld@sheba.health.gov.il
OI Kanduc, Darja/0000-0003-2111-4608
CR Almendros A, 2020, VET REC, V186, P419, DOI [10.1136/vr.m1322, 10.1136/vr.m1302, 10.1136/vr.m1194]
   Cappello F, 2020, J CLIN NEUROSCI, V77, P246, DOI 10.1016/j.jocn.2020.05.015
   Chen CM, 2013, BIOINFORMATICS, V29, P2808, DOI 10.1093/bioinformatics/btt484
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Hogan RJ, 2006, PLOS MED, V3, P1656, DOI 10.1371/journal.pmed.0030411
   Kanduc D., 2018, OPEN IMMUNOL J, V8, P11, DOI [10.2174/1874226201808010016, DOI 10.2174/1874226201808010016]
   Kanduc D, 2020, PATHOBIOLOGY, V87, P268, DOI 10.1159/000508903
   Kanduc D, 2020, ANTIBODIES, V9, DOI 10.3390/antib9030033
   Kanduc D, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108426
   Kanduc D, 2016, AUTOIMMUN REV, V15, P1054, DOI 10.1016/j.autrev.2016.07.030
   Kanduc D, 2015, ANTI-CANCER AGENT ME, V15, P1264, DOI 10.2174/1871520615666150716105543
   Kanduc D, 2013, CURR PROTEIN PEPT SC, V14, P111, DOI 10.2174/1389203711314020003
   Kanduc D, 2012, J PEPT SCI, V18, P487, DOI 10.1002/psc.2419
   Kanduc Darja, 2012, Front Biosci (Schol Ed), V4, P1393
   Kanduc D, 2009, EXPERT OPIN BIOL TH, V9, P45, DOI [10.1517/14712590802614041, 10.1517/14712590802614041 ]
   Kanduc D, 2009, CURR PHARM DESIGN, V15, P3283, DOI 10.2174/138161209789105135
   Lawler JV, 2006, PLOS MED, V3, P677, DOI 10.1371/journal.pmed.0030149
   Li XD, 2020, VET REC, V186, P457, DOI 10.1136/vr.m1455
   Lowenstine LJ, 2012, NONHUMAN PRIMATES BI, V2
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   Nagata N, 2010, VET PATHOL, V47, P881, DOI 10.1177/0300985810378760
   Oldstone Michael B. A., 2014, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V33, P158, DOI 10.1089/mab.2013.0090
   Parry N.M.A., 2020, FORENSIC SCI INT REP, V2, DOI [10.1016/j.fsir.2020.100090, DOI 10.1016/J.FSIR.2020.100090]
   Pieczenik George, 2003, Reprod Biomed Online, V6, P154
   Roberts A, 2005, J VIROL, V79, P5833, DOI 10.1128/JVI.79.9.5833-5838.2005
   Rowe T, 2004, J VIROL, V78, P11401, DOI 10.1128/JVI.78.20.11401-11404.2004
   Vlasova AN, 2007, J VIROL, V81, P13365, DOI 10.1128/JVI.01169-07
   Vojdani A, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108480
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
NR 30
TC 1
Z9 1
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0257-277X
EI 1559-0755
J9 IMMUNOL RES
JI Immunol. Res.
PD OCT
PY 2020
VL 68
IS 5
BP 310
EP 313
DI 10.1007/s12026-020-09152-6
EA SEP 2020
PG 4
WC Immunology
SC Immunology
GA NT0MJ
UT WOS:000570821300001
PM 32946016
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Martino, M
   Aboud, N
   Cola, MF
   Giancola, G
   Ciarloni, A
   Salvio, G
   Arnaldi, G
AF Martino, M.
   Aboud, N.
   Cola, M. F.
   Giancola, G.
   Ciarloni, A.
   Salvio, G.
   Arnaldi, G.
TI Impact of COVID-19 pandemic on psychophysical stress in patients with
   adrenal insufficiency: the CORTI-COVID study
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Article; Early Access
DE SARS-CoV-2; Adrenal crisis; Addison; Hypopituitarism; AddiQoL;
   Telemedicine COVID
ID QUALITY-OF-LIFE; ADDISONS-DISEASE; HEALTH SURVEY; QUESTIONNAIRE;
   ENDOCRINOLOGY; MORTALITY; THERAPY; SF-36
AB Purpose COVID-19 is a novel threat to patients with adrenal insufficiency (AI), whose life expectancy and quality (QoL) are impaired by an increased risk of infections and stress-triggered adrenal crises (AC). If infected, AI patients require prompt replacement tailoring. We assessed, in a cohort of AI patients: prevalence and clinical presentation of COVID-19; prevalence of AC and association with intercurrent COVID-19 or pandemic-related psychophysical stress; lockdown-induced emotional burden, and health-related QoL. Methods In this monocentric (Ancona University Hospital, Italy), cross-sectional study covering February-April 2020, 121 (40 primary, 81 secondary) AI patients (59 males, 55 +/- 17 years) completed telematically three questionnaires: the purpose-built "CORTI-COVID", assessing medical history and concern for COVID-19-related global health, AI-specific personal health, occupational, economic, and social consequences; the AddiQoL-30; the Short-Form-36 (SF-36) Health Survey. Results COVID-19 occurred in one (0 center dot 8% prevalence) 48-year-old woman with primary AI, who promptly tailored her replacement. Dyspnea lasted three days, without requiring hospitalization. Secondary AI patients were not involved. No AC were experienced, but pandemic-related stress accounted for 6/14 glucocorticoid up-titrations. Mean CORTI-COVID was similar between groups, mainly depending on "personal health" in primary AI (rho = 0.888,p < 0.0001) and "economy" in secondary AI (rho = 0.854,p < 0.0001). Working restrictions increased occupational concern. CORTI-COVID correlated inversely with QoL. AddiQoL-30 and SF-36 correlated strongly. Comorbidities worsened patients' QoL. Conclusion If educational efforts are made in preventing acute events, AI patients seem not particularly susceptible to COVID-19. The novel "CORTI-COVID" questionnaire reliably assesses the pandemic-related emotional burden in AI. Even under unconventional stress, educated AI patients preserve a good QoL.
C1 [Martino, M.; Aboud, N.; Cola, M. F.; Giancola, G.; Ciarloni, A.; Salvio, G.; Arnaldi, G.] Polytech Univ Marche, Dept Endocrinol & Metab Dis DISCLIMO, Via Conca 71, I-60126 Ancona, Italy.
RP Arnaldi, G (corresponding author), Polytech Univ Marche, Dept Endocrinol & Metab Dis DISCLIMO, Via Conca 71, I-60126 Ancona, Italy.
EM g.arnaldi@staff.univpm.it
OI Arnaldi, Giorgio/0000-0002-6204-3423
FU MIUR (Ministero dell'Istruzione dell'Universita e della Ricerca)Ministry
   of Education, Universities and Research (MIUR) [HRTZYA_005]
FX This work was supported by the MIUR (Ministero dell'Istruzione
   dell'Universita e della Ricerca, grant number HRTZYA_005, 2017).
CR Allolio B, 2015, EUR J ENDOCRINOL, V172, pR115, DOI 10.1530/EJE-14-0824
   Apolone G, 1998, J CLIN EPIDEMIOL, V51, P1025, DOI 10.1016/S0895-4356(98)00094-8
   Arlt W, 2020, EUR J ENDOCRINOL, V183, pG25, DOI 10.1530/EJE-20-0361
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Bergthorsdottir R, 2006, J CLIN ENDOCR METAB, V91, P4849, DOI 10.1210/jc.2006-0076
   Bornstein SR, 2016, J CLIN ENDOCR METAB, V101, P364, DOI 10.1210/jc.2015-1710
   Fleseriu M, 2016, J CLIN ENDOCR METAB, V101, P3888, DOI 10.1210/jc.2016-2118
   Hahner S, 2007, J CLIN ENDOCR METAB, V92, P3912, DOI 10.1210/jc.2007-0685
   Hahner S, 2015, J CLIN ENDOCR METAB, V100, P407, DOI 10.1210/jc.2014-3191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Isidori AM, 2020, J ENDOCRINOL INVEST, V43, P1141, DOI 10.1007/s40618-020-01266-w
   Isidori AM, 2018, LANCET DIABETES ENDO, V6, P173, DOI 10.1016/S2213-8587(17)30398-4
   Lovas K, 2010, J CLIN ENDOCR METAB, V95, P545, DOI 10.1210/jc.2009-1711
   Mazziotti G, 2017, EUR J ENDOCRINOL, V177, pR231, DOI 10.1530/EJE-17-0154
   Meyer G, 2018, ENDOCRINE, V60, P355, DOI 10.1007/s12020-017-1513-0
   Oksnes M, 2012, J CLIN ENDOCR METAB, V97, P568, DOI 10.1210/jc.2011-1901
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Sherlock M, 2010, ENDOCR REV, V31, P301, DOI 10.1210/er.2009-0033
   Teblick A, 2019, NAT REV ENDOCRINOL, V15, P417, DOI 10.1038/s41574-019-0185-7
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 23
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0391-4097
EI 1720-8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
DI 10.1007/s40618-020-01422-2
EA SEP 2020
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NQ4HD
UT WOS:000570823600002
PM 32946078
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kostenberger, M
   Hasibeder, W
   Dankl, D
   Germann, R
   Hormann, C
   Joannidis, M
   Markstaller, K
   Muller-Muttonen, SO
   Neuwersch-Sommeregger, S
   Schaden, E
   Staudinger, T
   Ullrich, R
   Valentin, A
   Likar, R
AF Koestenberger, Markus
   Hasibeder, Walter
   Dankl, Daniel
   Germann, Reinhard
   Hoermann, Christoph
   Joannidis, Michael
   Markstaller, Klaus
   Mueller-Muttonen, Steve-Oliver
   Neuwersch-Sommeregger, Stefan
   Schaden, Eva
   Staudinger, Thomas
   Ullrich, Roman
   Valentin, Andreas
   Likar, Rudolf
TI SARS-CoV-2: recommendations for treatment in intensive care medicine
SO WIENER KLINISCHE WOCHENSCHRIFT
LA English
DT Article
DE SARS-CoV-2; COVID-19; ARDS; Personal protective equipment; Respiratory
   therapy
ID CORONAVIRUS; REMDESIVIR
AB Coronavirus disease 2019 (COVID-19) progresses mildly in most of the cases; however, about 5% of the patients develop a severe acute respiratory distress syndrome (ARDS). Of all COVID-19 patients 3% need intensive care treatment, which becomes a great challenge for anesthesiology and intensive care medicine, medically, hygienically and for technical safety requirements. For these reasons, only experienced medical and nursing staff in the smallest grouping possible should be assigned. For these team members, a consistent use of personal protective equipment (PPE) is essential. Due to the immense medical challenges, the following treatment guidelines were developed by the oGARI (osterreichische Gesellschaft fur Anasthesiologie, Reanimation und Intensivmedizin), FASIM (Federation of Austrian Societies of Intensive Care Medicine) and oGIAIN (osterreichische Gesellschaft fur Internistische und Allgemeine Intensivmedizin und Notfallmedizin). The recommendations given in this article are to be understood as short snapshots of the moment; all basic guidelines are works in progress and will be regularly updated as evidence levels, new study results and additional experience are gathered.
C1 [Koestenberger, Markus; Neuwersch-Sommeregger, Stefan; Likar, Rudolf] Klinikum Klagenfurt Worthersee, Dept Anaesthesiol & Crit Care Med, Feschnigstr 11, A-9020 Klagenfurt, Austria.
   [Hasibeder, Walter] Hosp Zams, Dept Anaesthesiol & Crit Care Med, Zams, Austria.
   [Dankl, Daniel] Univ Hosp Salzburg, Dept Anaesthesiol & Crit Care Med, Salzburg, Austria.
   [Germann, Reinhard] Hosp Feldkirch, Dept Anaesthesiol & Crit Care Med, Feldkirch, Austria.
   [Hoermann, Christoph] Univ Hosp St Polten, Dept Anaesthesiol & Crit Care Med, St Polten, Austria.
   [Joannidis, Michael] Med Univ Innsbruck, Dept Internal Med, Div Intens Care & Emergency Med, Univ Hosp Innsbruck, Innsbruck, Austria.
   [Markstaller, Klaus; Schaden, Eva] Med Univ Vienna, Dept Anaesthesia Intens Care Med & Pain Med, Vienna, Austria.
   [Mueller-Muttonen, Steve-Oliver] Hosp Villach, Dept Anaesthesiol & Crit Care Med, Villach, Austria.
   [Staudinger, Thomas; Ullrich, Roman] Med Univ Vienna, Dept Internal & Crit Care Med, Vienna, Austria.
   [Valentin, Andreas] Hosp Schwarzach, Dept Internal & Crit Care Med, Schwarzach, Austria.
RP Kostenberger, M (corresponding author), Klinikum Klagenfurt Worthersee, Dept Anaesthesiol & Crit Care Med, Feschnigstr 11, A-9020 Klagenfurt, Austria.
EM markus.koestenberger@kabeg.at
RI Kostenberger, Markus/AAL-1020-2020; Taha, Samy/N-4620-2019
OI Kostenberger, Markus/0000-0002-7205-6818; Taha, Samy/0000-0003-0284-7806
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Bi Q, 2020, EPIDEMIOLOGY TRANSMI, DOI [10.1101/2020.03.03.20028423, DOI 10.1101/2020.03.03.20028423]
   Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Deutsche Rontgengesellschaft, 2020, COVID 19
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Jean SS, 2020, J MICROBIOL IMMUNOL, V53, P436, DOI 10.1016/j.jmii.2020.03.034
   Joannidis M, 2020, INTENS CARE MED, V46, P654, DOI 10.1007/s00134-019-05869-7
   Johnson RM, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2648
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
   Kostenberger M, 2020, ICU THERAPY GUIDELIN
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   National Health Commission of China (NHC), 2020, DIAGN TREATM PROT NO
   Papazian L, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0540-9
   Peng PWH, 2020, BRIT J ANAESTH, V124, P497, DOI 10.1016/j.bja.2020.02.008
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Robert Koch Institut, 2019, SARS COV 2 STECKBR C
   Schebesta K, 2020, HYGIENERICHTLINIE CO
   Sharma R, 2020, CORONAVIRUS DIS 2019
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Federation of Societies of Anaesthesiologists, COR GUID AN PER PROV
   World Health Organization, SIT REP
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang JW, 2020, CLIN MICROBIOL INFEC, V26, P1171, DOI 10.1016/j.cmi.2020.06.020
   Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
NR 39
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0043-5325
EI 1613-7671
J9 WIEN KLIN WOCHENSCHR
JI Wien. Klin. Wochen.
PD NOV
PY 2020
VL 132
IS 21-22
SI SI
BP 664
EP 670
DI 10.1007/s00508-020-01734-6
EA SEP 2020
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA PD0SK
UT WOS:000570828500003
PM 32948888
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Efe, C
   Simsek, C
   Batibay, E
   Caliskan, AR
   Wahlin, S
AF Efe, Cumali
   Simsek, Cem
   Batibay, Ersin
   Caliskan, Ali Riza
   Wahlin, Staffan
TI Feasibility of telehealth in the management of autoimmune hepatitis
   before and during the COVID-19 pandemic
SO EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Article
DE Autoimmunity; immunosuppression; corticosteroids; azathioprine;
   telehealth; liver failure; liver transplant
ID CARE; TELEMEDICINE
AB Objectives We aimed to evaluate the feasibility of telehealth in the management of patients with autoimmune hepatitis (AIH). The COVID-19 outbreak during the study period provided an opportunity to evaluate any pandemic influence on how telehealth was perceived by patients and physicians. Methods We included patients with AIH who were followed in the Harran University hospital, Turkey. Patients were managed by either remote telehealth or standard care. Results A total of 46 (telehealth, n=19 and standard care, n= 27) patients (40 female) with a median age of 32 (range 17-74) years at diagnosis were included in the study. Until the start of the COVID-19 pandemic, the rates of biochemical remission and relapse after remission were similar in the telehealth and standard care groups (89.5% vs. 89.1% and 15.8% vs. 25.9%, p=ns, for both). The telehealth group maintained remission significantly better than the standard care group (100% vs. 77.3%, p=0.035) during the COVID-19 period. All relapses were due to non-adherence to therapy. Psychiatric problems, pregnancy-related issues and drug side-effects could all be managed remotely by telehealth. Conclusions In this study, we show for the first time that telehealth is a feasible alternative for managing AIH, both under normal circumstances and during the COVID-19 pandemic. Expert opinion Autoimmune hepatitis (AIH) requires long-life lifelong immunosuppression and follow-up for most patients. The use of telehealth may be an alternative way to evaluate these patients remotely. We show for the first time that telehealth is effective and useful in the management of AIH in regular time as well during COVID-19. We hope that our study can extend use of telehealth in the evaluation of patients with other causes of chronic liver disease.
C1 [Efe, Cumali; Batibay, Ersin] Harran Univ, Dept Gastroenterol, TR-63100 Sanliurfa, Turkey.
   [Simsek, Cem] Hacettepe Univ, Dept Gastroenterol, Ankara, Turkey.
   [Caliskan, Ali Riza] Adiyaman Univ, Dept Gastroenterol, Adiyaman, Turkey.
   [Wahlin, Staffan] Karolinska Inst, Ctr Digest Dis, Hepatol Div, Stockholm, Sweden.
   [Wahlin, Staffan] Karolinska Univ Hosp, Stockholm, Sweden.
RP Efe, C (corresponding author), Harran Univ, Dept Gastroenterol, TR-63100 Sanliurfa, Turkey.
EM drcumi21@hotmail.com
CR Arora S, 2011, NEW ENGL J MED, V364, P2199, DOI 10.1056/NEJMoa1009370
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   Demir N, 2019, TURK J GASTROENTEROL, DOI [10.5152/tjg.2020.19866, DOI 10.5152/TJG.2020.19866]
   Elkjaer M, 2010, GUT, V59, P1652, DOI 10.1136/gut.2010.220160
   Gerussi A, 2020, HEPATOL COMMUN, V4, P1257, DOI 10.1002/hep4.1557
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Hennes EM, 2008, HEPATOLOGY, V48, P169, DOI 10.1002/hep.22322
   John BV, 2020, CLIN GASTROENTEROL H, V18, P1822, DOI 10.1016/j.cgh.2019.12.021
   Le LB, 2019, DIGEST DIS SCI, V64, P1150, DOI 10.1007/s10620-018-5397-5
   Lleo A, 2020, J HEPATOL, V73, P453, DOI 10.1016/j.jhep.2020.04.002
   Lohse AW, 2015, J HEPATOL, V63, P971, DOI 10.1016/j.jhep.2015.06.030
   Mack CL, 2020, HEPATOLOGY, V72, P671, DOI 10.1002/hep.31065
   Piao C, 2019, HEPATOL COMMUN, V3, P716, DOI 10.1002/hep4.1340
   SALAMI AC, 2014, J ONCOL PRACT, V11
   Serper M, 2020, HEPATOLOGY, V72, P723, DOI 10.1002/hep.31276
   Serper M, 2018, CLIN GASTROENTEROL H, V16, P157, DOI 10.1016/j.cgh.2017.10.004
   Tuckson RV, 2017, NEW ENGL J MED, V377, P1585, DOI 10.1056/NEJMsr1503323
   van Gerven NMF, 2013, J HEPATOL, V58, P141, DOI 10.1016/j.jhep.2012.09.009
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
NR 20
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1747-4124
EI 1747-4132
J9 EXPERT REV GASTROENT
JI Expert Rev. Gastroenterol. Hepatol.
PD DEC 1
PY 2020
VL 14
IS 12
BP 1215
EP 1219
DI 10.1080/17474124.2020.1822734
EA SEP 2020
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OU3GC
UT WOS:000570292100001
PM 32909852
OA Bronze
DA 2021-01-01
ER

PT J
AU Stefely, JA
   Christensen, BB
   Gogakos, T
   Sullivan, JKC
   Montgomery, GG
   Barranco, JP
   Van Cott, EM
AF Stefely, Jonathan A.
   Christensen, Bianca B.
   Gogakos, Tasos
   Cone Sullivan, Jensyn K.
   Montgomery, Gabriella G.
   Barranco, John P.
   Van Cott, Elizabeth M.
TI Marked factor V activity elevation in severeCOVID-19 is associated with
   venous thromboembolism
SO AMERICAN JOURNAL OF HEMATOLOGY
LA English
DT Article
ID WAVE-FORM; COAGULATION; THROMBOSIS; EVENTS; RISK
AB Coagulopathy causes morbidity and mortality in patients with coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Yet, the mechanisms are unclear and biomarkers are limited. Early in the pandemic, we observed markedly elevated factor V activity in a patient with COVID-19, which led us to measure factor V, VIII, and X activity in a cohort of 102 consecutive inpatients with COVID-19. Contemporaneous SARS-CoV-2-negative controls (n = 17) and historical pre-pandemic controls (n = 260-478) were also analyzed. This cohort represents severe COVID-19 with high rates of ventilator use (92%), line clots (47%), deep vein thrombosis or pulmonary embolism (DVT/PE) (23%), and mortality (22%). Factor V activity was significantly elevated in COVID-19 (median 150 IU/dL, range 34-248 IU/dL) compared to contemporaneous controls (median 105 IU/dL, range 22-161 IU/dL) (P< .001)-the strongest association with COVID-19 of any parameter studied, including factor VIII, fibrinogen, and D-dimer. Patients with COVID-19 and factor V activity >150 IU/dL exhibited significantly higher rates of DVT/PE (16/49, 33%) compared to those with factor V activity <= 150 IU/dL (7/53, 13%) (P= .03). Within this severe COVID-19 cohort, factor V activity associated with SARS-CoV-2 load in a sex-dependent manner. Subsequent decreases in factor V were linked to progression toward DIC and mortality. Together, these data reveal marked perturbations of factor V activity in severe COVID-19, provide links to SARS-CoV-2 disease biology and clinical outcomes, and nominate a candidate biomarker to investigate for guiding anticoagulation therapy in COVID-19.
C1 Massachusetts Gen Hosp, Dept Pathol, Coagulat Lab, Boston, MA 02114 USA.
   Harvard Med Sch, Boston, MA 02115 USA.
RP Van Cott, EM (corresponding author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM evancott@mgh.harvard.edu
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barrett CD, 2020, J THROMB HAEMOST, V18, P2060, DOI 10.1111/jth.14860
   Bowles L, 2020, NEW ENGL J MED, V383, P288, DOI 10.1056/NEJMc2013656
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Connors JM, 2020, J THROMB HAEMOST, V18, P1559, DOI 10.1111/jth.14849
   Escher R, 2020, THROMB RES, V190, P62, DOI 10.1016/j.thromres.2020.04.014
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jackson SP, 2019, BLOOD, V133, P906, DOI 10.1182/blood-2018-11-882993
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Lowe GDO, 1997, BRIT J HAEMATOL, V97, P775, DOI 10.1046/j.1365-2141.1997.1222936.x
   Marchandot B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061651
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Rapkiewicz Amy V, 2020, EClinicalMedicine, V24, P100434, DOI 10.1016/j.eclinm.2020.100434
   ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504
   Saliba W, 2018, THROMB RES, V168, P14, DOI 10.1016/j.thromres.2018.05.030
   Sevenet PO, 2017, INT J LAB HEMATOL, V39, P561, DOI 10.1111/ijlh.12724
   Smith EY, 2004, AM J CLIN PATHOL, V121, P138, DOI 10.1309/W4F7892WJE6Y1W7Y
   Song J, 2015, CLIN EXP THROMB HEMO, V2, P29
   Suzuki K, 2019, THROMB J, V17, DOI 10.1186/s12959-019-0201-0
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang Y, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, pE006, DOI [10.3760/cma.j.issn.0253-2727.2020.008, 10.3760/cma.j.issn.0253-2727.2020.0006]
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 39
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0361-8609
EI 1096-8652
J9 AM J HEMATOL
JI Am. J. Hematol.
PD DEC
PY 2020
VL 95
IS 12
BP 1522
EP 1530
DI 10.1002/ajh.25979
EA SEP 2020
PG 9
WC Hematology
SC Hematology
GA OS0RA
UT WOS:000570260400001
PM 32833259
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Pike, A
   Muus, P
   Munir, T
   Mitchell, L
   Arnold, L
   Riley, K
   Houghton, N
   Forrest, B
   Gachev, J
   Hillmen, P
   Griffin, M
AF Pike, Alexandra
   Muus, Petra
   Munir, Tahla
   Mitchell, Lindsay
   Arnold, Louise
   Riley, Kathryn
   Houghton, Nicola
   Forrest, Briony
   Gachev, Jeanifer
   Hillmen, Peter
   Griffin, Morag
TI COVID-19 infection in patients on anti-complement therapy: The Leeds
   National Paroxysmal Nocturnal Haemoglobinuria service experience
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Letter
C1 [Pike, Alexandra; Muus, Petra; Munir, Tahla; Arnold, Louise; Riley, Kathryn; Houghton, Nicola; Forrest, Briony; Gachev, Jeanifer; Hillmen, Peter; Griffin, Morag] Leeds Teaching Hosp NHS Trust, Dept Haematol, Leeds, W Yorkshire, England.
   [Pike, Alexandra; Hillmen, Peter] Univ Leeds, Sch Med, Leeds Inst Med Res St Jamess, Sect Expt Haematol, Leeds, W Yorkshire, England.
   [Mitchell, Lindsay] Univ Hosp Monklands, Dept Haematol, Airdrie, Lanark, Scotland.
RP Pike, A (corresponding author), Leeds Teaching Hosp NHS Trust, Dept Haematol, Leeds, W Yorkshire, England.; Pike, A (corresponding author), Univ Leeds, Sch Med, Leeds Inst Med Res St Jamess, Sect Expt Haematol, Leeds, W Yorkshire, England.
EM alexandra.pike@nhs.net
OI Pike, Alexandra/0000-0002-6115-421X
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Diurno F, 2020, EUR REV MED PHARMACO, V24, P4040, DOI 10.26355/eurrev_202004_20875
   Fletcher-Sandersjoo A, 2020, THROMB RES, V194, P36, DOI 10.1016/j.thromres.2020.06.027
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   HILLMEN P, 1995, NEW ENGL J MED, V333, P1253, DOI 10.1056/NEJM199511093331904
   Kulasekararaj AG, 2020, BRIT J HAEMATOL, V190, pE141, DOI 10.1111/bjh.16916
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Risitano AM, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0320-7
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 10
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD OCT
PY 2020
VL 191
IS 1
BP E1
EP E4
DI 10.1111/bjh.17097
EA SEP 2020
PG 4
WC Hematology
SC Hematology
GA NU0ET
UT WOS:000570222600001
PM 32945525
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Goldman, M
   Silva, M
AF Goldman, Michel
   Silva, Mitchell
TI Reflections on the Collaborative Fight Against COVID-19
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE patient; trial; partnership; regulation; COVID-19
ID TRIALS
AB Clinical trials to identify efficient treatments against COVID-19 flourish worldwide without much attention to patients' voice so far. As therapeutic interventions in the early phase of the disease are attracting more and more interest, we argue that now is the time to involve patients' organizations in the design of clinical protocols in order to define the most relevant end-points and assess the risk-benefit balance of new therapies.
C1 [Goldman, Michel] Univ Libre Bruxelles, Inst Interdisciplinary Innovat Healthcare I3h, Brussels, Belgium.
   [Silva, Mitchell] EUPATI Belgium Vzw, Brussels, Belgium.
RP Goldman, M (corresponding author), Univ Libre Bruxelles, Inst Interdisciplinary Innovat Healthcare I3h, Brussels, Belgium.
EM mgoldman@i3health.eu
CR Aiyegbusi OL, 2020, LANCET, V396, P531, DOI 10.1016/S0140-6736(20)31724-4
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Collins FS, 2020, JAMA-J AM MED ASSOC, V323, P2455, DOI 10.1001/jama.2020.8920
   Eichler HG, 2020, CLIN PHARMACOL THER, V108, P730, DOI 10.1002/cpt.1891
   Geissler J, 2017, THER INNOV REGUL SCI, V51, P612, DOI 10.1177/2168479017706405
   Lane H Clifford, 2020, N Engl J Med, DOI 10.1056/NEJMe2024638
   Levitan B, 2018, THER INNOV REGUL SCI, V52, P220, DOI 10.1177/2168479017716715
   Mullard A, 2020, LANCET, V395, P1245, DOI 10.1016/S0140-6736(20)30894-1
   North CM, 2020, NEW ENGL J MED, V383, P1406, DOI 10.1056/NEJMp2019989
   Park JH, 2020, LANCET GLOB HEALTH, V8, pE1249, DOI 10.1016/S2214-109X(20)30365-X
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Stergiopoulos S, 2020, THER INNOV REGUL SCI, V54, P103, DOI 10.1007/s43441-019-00034-0
   Wason JMS, 2015, BRIT J CANCER, V113, P699, DOI 10.1038/bjc.2015.278
NR 13
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD SEP 17
PY 2020
VL 7
AR 565
DI 10.3389/fmed.2020.00565
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ1BY
UT WOS:000576828100001
PM 33043032
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Madubueze, CE
   Dachollom, S
   Onwubuya, IO
AF Madubueze, Chinwendu E.
   Dachollom, Sambo
   Onwubuya, Isaac Obiajulu
TI Controlling the Spread of COVID-19: Optimal Control Analysis
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article
ID SENSITIVITY-ANALYSIS; CORONAVIRUS; WUHAN; MODEL; TRANSMISSION
AB Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV-2). It was declared on March 11, 2020, by the World Health Organization as pandemic disease. The disease has neither approved medicine nor vaccine and has made governments and scholars search for drastic measures in combating the pandemic. Regrettably, the spread of the virus and mortality due to COVID-19 has continued to increase daily. Hence, it is imperative to control the spread of the disease particularly using nonpharmacological strategies such as quarantine, isolation, and public health education. This work studied the effect of these different control strategies as time-dependent interventions using mathematical modeling and optimal control approach to ascertain their contributions in the dynamic transmission of COVID-19. The model was proven to have an invariant region and was well-posed. The basic reproduction number and effective reproduction numbers were computed with and without interventions, respectively, and were used to carry out the sensitivity analysis that identified the critical parameters contributing to the spread of COVID-19. The optimal control analysis was carried out using the Pontryagin's maximum principle to figure out the optimal strategy necessary to curtail the disease. The findings of the optimal control analysis and numerical simulations revealed that time-dependent interventions reduced the number of exposed and infected individuals compared to time-independent interventions. These interventions were time-bound and best implemented within the first 100 days of the outbreak. Again, the combined implementation of only two of these interventions produced a good result in reducing infection in the population. While, the combined implementation of all three interventions performed better, even though zero infection was not achieved in the population. This implied that multiple interventions need to be deployed early in order to reduce the virus to the barest minimum.
C1 [Madubueze, Chinwendu E.] Univ Agr Makurdi, Dept Math Stat Comp Sci, PMB 2373, Markurdi, Nigeria.
   [Dachollom, Sambo] Akanu Ibiam Fed Polytech, Dept Math Stat, PMB 1007 Afikpo, Unwana, Ebonyi State, Nigeria.
   [Onwubuya, Isaac Obiajulu] Airforce Inst Technol, Dept Math, Kaduna, Nigeria.
RP Madubueze, CE (corresponding author), Univ Agr Makurdi, Dept Math Stat Comp Sci, PMB 2373, Markurdi, Nigeria.
EM ce.madubueze@gmail.com
CR Al-Asuoad N, 2017, BIOMATH, V5, DOI 10.11145/j.biomath.2016.12.141
   [Anonymous], 2020, 51 WHO
   Carlos WG, 2020, AM J RESP CRIT CARE, V201, pP7, DOI 10.1164/rccm.2014P7
   Chen TM, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00640-3
   Chitnis N, 2008, B MATH BIOL, V70, P1272, DOI 10.1007/s11538-008-9299-0
   Djidjou-Demasse Ramses, 2020, OPTIMAL COVID 19 EPI
   Edward S., 2017, INT J SCI BASIC APPL, V33, P112
   Edward S, 2015, APPL COMPUTATIONAL M, V4, P53
   Gjorgjieva J, 2005, MATH BIOSCI ENG, V2, P753
   Gumel AB, 2004, P ROY SOC B-BIOL SCI, V271, P2223, DOI 10.1098/rspb.2004.2800
   He S, 2020, MATH BIOSCI ENG, V17, P2792, DOI 10.3934/mbe.2020153
   Imai N., 2020, 3 IMP COLL LOND, DOI [10.25561/77148., DOI 10.25561/77148, 10.25561/77148]
   Kamyad AV, 2014, COMPUT MATH METHOD M, DOI 10.1155/2014/475451
   Kim Yunhwan, 2016, Osong Public Health Res Perspect, V7, P49, DOI 10.1016/j.phrp.2016.01.001
   Lenhart S., 2007, OPTIMAL CONTROL APPL, DOI [10.1201/9781420011418, DOI 10.1201/9781420011418]
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Madubueze CE, 2018, APPL APPL MATH, V13, P382
   Moore S. E., CONTROLLING TRANSMIS
   Nigerian Centre for Disease Control (NCDC), 1 NCDC
   Rabajante J. F., 2020, INSIGHTS EARLY MATH
   Sadiq S. F., 2014, Annual Research & Review in Biology, V4, P560, DOI 10.9734/ARRB/2014/6378
   Sanchez MA, 1997, AM J EPIDEMIOL, V145, P1127
   Shen M., 2020, MODELLING EPIDEMIC T
   Surico P., 2020, WHEELER I BUSINESS J
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   World Health Organization, 25 WHO
   World Health Organization, 2020, 73 WHO
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Yan X, 2008, MATH COMPUT MODEL, V47, P235, DOI 10.1016/j.mcm.2007.04.003
   Yang CY, 2020, MATH BIOSCI ENG, V17, P2708, DOI 10.3934/mbe.2020148
   Zhao S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020388
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 35
TC 1
Z9 1
U1 2
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748-670X
EI 1748-6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD SEP 17
PY 2020
VL 2020
AR 6862516
DI 10.1155/2020/6862516
PG 14
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA NY0NH
UT WOS:000576096200001
PM 32963585
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jang, M
   Park, YI
   Cha, YE
   Park, R
   Namkoong, S
   Lee, JI
   Park, J
AF Jang, Minsu
   Park, Yea-In
   Cha, Yeo-Eun
   Park, Rackhyun
   Namkoong, Sim
   Lee, Jin, I
   Park, Junsoo
TI Tea Polyphenols EGCG and Theaflavin Inhibit the Activity of SARS-CoV-2
   3CL-Protease In Vitro
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID GREEN TEA; 3CL PROTEASE; BLACK TEA; VIRUS; CYTOTOXICITY;
   (-)-EPIGALLOCATECHIN-3-GALLATE; EPIGALLOCATECHIN-3-GALLATE; PROTEINASE;
   MECHANISMS; CATECHINS
AB COVID-19, a global pandemic, has caused over 750,000 deaths worldwide as of August 2020. A vaccine or remedy for SARS-CoV-2, the virus responsible for COVID-19, is necessary to slow down the spread and lethality of COVID-19. However, there is currently no effective treatment available against SARS-CoV-2. In this report, we demonstrated that EGCG and theaflavin, the main active ingredients of green tea and black tea, respectively, are potentially effective to inhibit SARS-CoV-2 activity. Coronaviruses require the 3CL-protease for the cleavage of its polyprotein to make individual proteins functional. EGCG and theaflavin showed inhibitory activity against the SARS-CoV-2 3CL-protease in a dose-dependent manner, and the half inhibitory concentration (IC50) was 7.58 mu g/ml for EGCG and 8.44 mu g/ml for theaflavin. In addition, we did not observe any cytotoxicity for either EGCG or theaflavin at the concentrations tested up to 40 mu g/ml in HEK293T cells. These results suggest that upon further study, EGCG and theaflavin can be potentially useful to treat COVID-19.
C1 [Jang, Minsu; Park, Yea-In; Cha, Yeo-Eun; Park, Rackhyun; Namkoong, Sim; Park, Junsoo] Yonsei Univ, Div Biol Sci & Technol, Wonju, South Korea.
   [Lee, Jin, I] Kangwon Natl Univ, Dept Biochem, Chunchon, South Korea.
RP Park, J (corresponding author), Yonsei Univ, Div Biol Sci & Technol, Wonju, South Korea.
EM junsoo@yonsei.ac.kr
OI Park, Junsoo/0000-0002-2355-6760
FU National Research Foundation of Korea (NRF) - Korean government
   [2019R1A2C1006511]
FX This study was supported by a National Research Foundation of Korea
   (NRF) grant funded by the Korean government (2019R1A2C1006511).
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Babich H, 2006, TOXICOL IN VITRO, V20, P677, DOI 10.1016/j.tiv.2005.09.017
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Carneiro BM, 2016, VIROLOGY, V496, P215, DOI 10.1016/j.virol.2016.06.012
   Chen CN, 2005, EVID-BASED COMPL ALT, V2, P209, DOI 10.1093/ecam/neh081
   Chen LR, 2005, BIOORG MED CHEM LETT, V15, P3058, DOI 10.1016/j.bmcl.2005.04.027
   Chung WG, 2007, BRAIN RES, V1176, P133, DOI 10.1016/j.brainres.2007.07.083
   Ciesek S, 2011, HEPATOLOGY, V54, P1947, DOI 10.1002/hep.24610
   Clark KJ, 1998, VET MICROBIOL, V63, P147, DOI 10.1016/S0378-1135(98)00242-9
   Ghosh R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779818
   GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Herold J, 1998, J VIROL, V72, P910, DOI 10.1128/JVI.72.2.910-918.1998
   Hsu JTA, 2004, FEBS LETT, V574, P116, DOI 10.1016/j.febslet.2004.08.015
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   Isaacs CE, 2013, ANTIMICROB AGENTS CH, V57, P3806, DOI 10.1128/AAC.00659-13
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Kaihatsu K, 2018, MOLECULES, V23, DOI 10.3390/molecules23102475
   Kim Y, 2013, ANTIVIR RES, V97, P161, DOI 10.1016/j.antiviral.2012.11.005
   Lambert JD, 2010, ARCH BIOCHEM BIOPHYS, V501, P65, DOI 10.1016/j.abb.2010.06.013
   Leung LK, 2001, J NUTR, V131, P2248
   Lin LC, 2004, J CHROMATOGR A, V1032, P125, DOI 10.1016/j.chroma.2003.08.077
   Mulder TPJ, 2001, J CHROMATOGR B, V760, P271, DOI 10.1016/S0378-4347(01)00285-7
   Nakagawa K, 1997, J NUTR SCI VITAMINOL, V43, P679, DOI 10.3177/jnsv.43.679
   Peele K. A., 2020, INFORM MED UNLOCKED, V76
   Reusser P, 1996, J HOSP INFECT, V33, P235, DOI 10.1016/S0195-6701(96)90010-9
   Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093
   Song JM, 2005, ANTIVIR RES, V68, P66, DOI 10.1016/j.antiviral.2005.06.010
   Steinmann J., 2020, BRIT J PHARMACOL, V168, P1059
   Tsai JP, 2019, PATHOLOGY, V51, P86, DOI 10.1016/j.pathol.2018.10.005
   Weber JM, 2003, ANTIVIR RES, V58, P167, DOI 10.1016/S0166-3542(02)00212-7
   Wei YQ, 2016, FOOD CHEM, V204, P218, DOI 10.1016/j.foodchem.2016.02.134
   Yang S, 2006, J MED CHEM, V49, P4971, DOI 10.1021/jm0603926
   Zhang L., 2020, SCIENCE, V49
   Zhao Y, 2014, J INTERCULT ETHNOPHA, V3, P68, DOI 10.5455/jice.20140123040224
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zu M, 2012, ANTIVIR RES, V94, P217, DOI 10.1016/j.antiviral.2012.04.001
NR 37
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD SEP 17
PY 2020
VL 2020
AR 5630838
DI 10.1155/2020/5630838
PG 7
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA NX9YW
UT WOS:000576058700004
PM 32963564
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khatri, I
   Staal, FJT
   van Dongen, JJM
AF Khatri, Indu
   Staal, Frank J. T.
   van Dongen, Jacques J. M.
TI Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2
   Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity
   Antibodies: An Immune Perspective
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE ACE2; SARS-CoV; interaction-synapse; antibody; binding-affinity;
   felines; interface; IgA dimer
ID RECEPTOR-BINDING DOMAIN; SARS CORONAVIRUS; HYDROGEN-BONDS; INFECTION;
   THERAPY; CATS; COV
AB The pandemic of Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2 has induced global eagerness to develop vaccines and therapeutics for treating COVID-19, including neutralizing antibodies. To develop effective therapeutic antibodies against SARS-CoV-2, it is critical to understand the interaction between viral and host's proteins. The human ACE2 ((h)ACE2) protein is the crucial target for the SARS-CoV's Spike protein that allows the virus to adhere to host epithelial cells. X-ray crystal structures and biophysical properties of protein-protein interactions reveal a large interaction surface with high binding-affinity between SARS-CoV-2 and(h)ACE2 (18 interactions), at least 15-fold stronger than between SARS-CoV-1 and(h)ACE2 (eight interactions). This suggests that antibodies against CoV-1 infection might not be very efficient against CoV-2. Furthermore, interspecies comparisons indicate that ACE2 proteins of man and cat are far closer than dog, ferret, mouse, and rat with significant differences in binding-affinity between Spike and ACE2 proteins. This strengthens the notion of productive SARS-CoV-2 transmission between felines and humans and that classical animal models are not optimally suited for evaluating therapeutic antibodies. The large interaction surface with strong affinity between SARS-CoV-2 and(h)ACE2 (dG-12.4) poses a huge challenge to develop reliable antibody therapy that truly blocks SARS-CoV-2 adherence and infection. We gauge that single antibodies against single epitopes might not sufficiently interfere with the strong interaction-synapse between Spike and(h)ACE2 proteins. Instead, appropriate combinations of high-affinity neutralizing antibodies against different epitopes might be needed, preferably of IgA-class for optimal and prolonged activity at epithelial layers of respiratory and intestine tracts.
C1 [Khatri, Indu; Staal, Frank J. T.; van Dongen, Jacques J. M.] Leiden Univ, Med Ctr, Dept Immunol, Leiden, Netherlands.
   [Khatri, Indu] Leiden Univ, Med Ctr, Leiden Computat Biol Ctr, Leiden, Netherlands.
RP Khatri, I; van Dongen, JJM (corresponding author), Leiden Univ, Med Ctr, Dept Immunol, Leiden, Netherlands.; Khatri, I (corresponding author), Leiden Univ, Med Ctr, Leiden Computat Biol Ctr, Leiden, Netherlands.
EM i.khatri@lumc.nl; j.j.m.van_dongen@lumc.nl
FU European UnionEuropean Union (EU) [707404]
FX IK was supported by the European Union's Horizon 2020 research and
   innovation program under the Marie Sklodowska-Curie grant agreement No.
   707404.
CR Ainai A, 2013, HUM VACC IMMUNOTHER, V9, P1962, DOI 10.4161/hv.25458
   Almendros A, 2020, VET REC, V186, P419, DOI [10.1136/vr.m1322, 10.1136/vr.m1302, 10.1136/vr.m1194]
   Asahi-Ozaki Y, 2004, J MED VIROL, V74, P328, DOI 10.1002/jmv.20173
   Bonam Srinivasa Reddy, 2020, Cell Rep Med, V1, P100016, DOI 10.1016/j.xcrm.2020.100016
   Brielle ES, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050497
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen YQ, 2013, J VIROL, V87, P10777, DOI 10.1128/JVI.01756-13
   Chu CM, 2005, EMERG INFECT DIS, V11, P1882
   Damas Joana, 2020, bioRxiv, DOI 10.1101/2020.04.16.045302
   DeLano W.L, PYMOL MOL GRAPHICS S
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Florindo HF, 2020, NAT NANOTECHNOL, V15, P630, DOI 10.1038/s41565-020-0732-3
   Goumenou M, 2020, MOL MED REP, V21, P2293, DOI 10.3892/mmr.2020.11037
   Grubaugh ND, 2020, CELL, V182, P794, DOI 10.1016/j.cell.2020.06.040
   Gussow AB, 2020, P NATL ACAD SCI USA, V117, P15193, DOI 10.1073/pnas.2008176117
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Hurlburt Nicholas K, 2020, bioRxiv, DOI 10.1101/2020.06.12.148692
   Hussain M, 2020, J MED VIROL, V92, P1580, DOI 10.1002/jmv.25832
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Jiang L, 2002, J BIOL CHEM, V277, P37732, DOI 10.1074/jbc.M204514200
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kim MH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220196
   Koide S, 2009, ACS CHEM BIOL, V4, P325, DOI 10.1021/cb800314v
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Liu L, 2011, J VIROL, V85, P4025, DOI 10.1128/JVI.02292-10
   Liu LM, 2015, J PHARM SCI-US, V104, P1866, DOI 10.1002/jps.24444
   Liu ZX, 2020, J MED VIROL, V92, P595, DOI 10.1002/jmv.25726
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a
   Maya EAL, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00613
   McCloskey B, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000254
   OIE1, 2020, 1 OIE1
   OIE2, 2020, IMM NOT 06 04 2020 M
   Paulo AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011655
   Richard M., 2020, SARS COV 2 IS TRANSM, DOI [10.1101/2020.04.16.044503, DOI 10.1101/2020.04.16.044503]
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Shen M, 2020, SARS COV 2 INFECT CA
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Sterlin D, 2020, IGA DOMINATES EARLY, DOI [10.1101/2020.06.10.20126532, DOI 10.1101/2020.06.10.20126532]
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Van den Brand JMA, 2008, VET PATHOL, V45, P551, DOI 10.1354/vp.45-4-551
   Vangone A, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2124
   Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037
   Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xu D, 1997, PROTEIN ENG, V10, P999, DOI 10.1093/protein/10.9.999
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Yuan Meng, 2020, bioRxiv, DOI 10.1101/2020.06.08.141267
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
NR 68
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 17
PY 2020
VL 11
AR 570018
DI 10.3389/fimmu.2020.570018
PG 9
WC Immunology
SC Immunology
GA NY4KK
UT WOS:000576360300001
PM 33042151
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ara, T
   Rahman, MM
   Hossain, MA
   Ahmed, A
AF Ara, Tasnim
   Rahman, Md Mahabubur
   Hossain, Md Abir
   Ahmed, Amir
TI Identifying the Associated Risk Factors of Sleep Disturbance During the
   COVID-19 Lockdown in Bangladesh: A Web-Based Survey
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE COVID-19; lock down; home confinement; sleep disturbance; anxiety; AOR;
   AUC
ID GENERALIZED ANXIETY; INTERNET ADDICTION; PSYCHIATRIC-DISORDERS;
   POSTTRAUMATIC-STRESS; MENTAL-HEALTH; INSOMNIA; DEPRESSION; PREVALENCE;
   DURATION; THERAPY
AB Background Bangladesh, a developing country with a lower-middle-income and one of the world's most densely populated areas, has been severely affected by COVID-19. This global epidemic is not only affecting the physical health of the patients but also causing severe psychological effects among those who have not yet been infected. Sleep disturbance is one of the key symptoms of major depression and one of the proven risk factors for suicide. The objective of this study is to identify the risk factors associated with sleep disturbance which has developed as a general impact of COVID-19 and new normal life during the lockdown (a measure to control the spread of COVID-19) in Bangladesh. Methods Demographic characteristics, COVID-19, and lockdown related information have been collected from 1,128 individuals by conducting a web-based survey. Respondent's perspective regarding sleep disturbance during COVID-19 lockdown is considered as the outcome of interest which is dichotomous. Descriptive statistics methods have been applied to explore the distribution of respondent's demographic characteristics. Pearson's chi-square tests have been performed to relate the sleep disturbance status of the respondents to their demographic, personal, and COVID-19 related information. Furthermore, a multivariable logistic regression model has been adopted to identify the significant association of sleep disturbance with the demographic, COVID-19, and lockdown related information of respondents during the COVID-19 lockdown in Bangladesh. Findings The prevalence of sleep disturbance during the COVID-19 lockdown is found to be higher among participants aged 31-40 years. Gender disparity has also been observed in favor of male participants, whereas no significant regional heterogeneity has been found. Working from home or doing online classes during the lockdown has been found as a potential predictive factor of sleep disturbance. Losing a job has been considered as an adverse economic effect of COVID-19, which also induces sleep disturbance. Perception regarding the risk of getting infected and anxiety triggered the chance of developing sleep disturbance. The sleeping schedule is also found as a risk factor for sleep disturbance. Conclusion Evidence-based policies are required to combat psychological challenges that have arisen due to COVID-19, primarily targeting the groups who are largely suffering from sleep disturbance.
C1 [Ara, Tasnim; Rahman, Md Mahabubur] Univ Dhaka, Inst Stat Res & Training, Dhaka, Bangladesh.
   [Hossain, Md Abir] Dhaka Univ Engn & Technol, Dept Chem & Food Engn, Gazipur, Bangladesh.
   [Ahmed, Amir] Daffodil Int Univ, Dept Nutr & Food Engn, Dhaka, Bangladesh.
RP Ara, T (corresponding author), Univ Dhaka, Inst Stat Res & Training, Dhaka, Bangladesh.
EM tara@isrl.ac.bd
CR Agargun MY, 1997, J CLIN PSYCHIAT, V58, P249
   Agresti A, 2007, CATEGORICAL DATA ANA, P211
   Ahmed HU, 2011, MANAGEMENT PSYCHOTIC, pSS46
   Altena E, 2020, J SLEEP RES, V29, DOI 10.1111/jsr.13052
   ANDERSON DJ, 1984, AM J PSYCHIAT, V141, P572
   Anner M, IMPACT COVID 19 WORK
   [Anonymous], 2020, DHAKA TRIBUNE
   Anwar S, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00154
   Baird J, 2020, ABC NEWS
   Bakken IJ, 2009, SCAND J PSYCHOL, V50, P121, DOI 10.1111/j.1467-9450.2008.00685.x
   Bass JK, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001159
   Baum KT, 2014, J CHILD PSYCHOL PSYC, V55, P180, DOI 10.1111/jcpp.12125
   Bernert Rebecca A, 2007, Neuropsychiatr Dis Treat, V3, P735
   Bradshaw S., 2015, HAZARDS RISKS DISAST, P233, DOI DOI 10.1016/B978-0-12-396451-9.00014-7
   Bradshaw S, 2015, DISASTERS, V39, pS54, DOI 10.1111/disa.12111
   Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Buxton OM, 2010, DIABETES, V59, P2126, DOI 10.2337/db09-0699
   Canan F, 2013, SLEEP BIOL RHYTHMS, V11, P210, DOI 10.1111/sbr.12022
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Casagrande M, 2020, SLEEP MED, V75, P12, DOI 10.1016/j.sleep.2020.05.011
   Chang PP, 1997, AM J EPIDEMIOL, V146, P105
   Cheng SH, 2012, PSYCHIAT RES, V197, P270, DOI 10.1016/j.psychres.2011.08.011
   Cheung LM, 2011, J SLEEP RES, V20, P311, DOI 10.1111/j.1365-2869.2010.00883.x
   Chien KL, 2010, SLEEP, V33, P177, DOI 10.1093/sleep/33.2.177
   Choi K, 2009, PSYCHIAT CLIN NEUROS, V63, P455, DOI 10.1111/j.1440-1819.2009.01925.x
   Cramer JS, 2002, ORIGINS LOGISTIC REG
   Das J, 2007, SOC SCI MED, V65, P467, DOI 10.1016/j.socscimed.2007.02.037
   Drake CL, 2004, SLEEP, V27, P1453, DOI 10.1093/sleep/27.8.1453
   Espie CA, 2001, BEHAV RES THER, V39, P45, DOI 10.1016/S0005-7967(99)00157-6
   Firoz A. H. M., 2006, BANGLADESH J PSYCHIA, V20, P9
   Fischer A, 2015, BRAIN BEHAV, V5, DOI 10.1002/brb3.365
   Fogarty J, 2005, P GRAPHICS INTERFACE, P129
   FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479
   Fu WN, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-00913-3
   Gamaldo CE, 2012, NEUROL CLIN, V30, P1313, DOI 10.1016/j.ncl.2012.08.007
   Garbarino S, 2002, SLEEP, V25, P648
   Goldstein TR, 2008, J CONSULT CLIN PSYCH, V76, P84, DOI 10.1037/0022-006X.76.1.84
   Graves L, 2020, WOMENS DOMESTIC BURD
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Harvey AG, 2011, CLIN PSYCHOL REV, V31, P225, DOI 10.1016/j.cpr.2010.04.003
   Hock RS, 2012, LANCET, V379, P1367, DOI 10.1016/S0140-6736(12)60243-8
   Hossain MD, 2014, BMC PSYCHIATRY, V14, DOI 10.1186/s12888-014-0216-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Institute of Epidemiology Disease Control and Research (IEDCR), 2020, BANGL COV 19 UPD
   Irwin M, 2002, BRAIN BEHAV IMMUN, V16, P503, DOI 10.1016/S0889-1591(02)00003-X
   Islam MS, 2020, J AFFECT DISORDERS, V276, P30, DOI 10.1016/j.jad.2020.06.049
   Jansson M, 2006, PSYCHOL HEALTH, V21, P383, DOI 10.1080/14768320500129015
   Kahn M, 2013, INT J PSYCHOPHYSIOL, V89, P218, DOI 10.1016/j.ijpsycho.2013.05.010
   Kaneita Y, 2009, SLEEP MED, V10, P780, DOI 10.1016/j.sleep.2008.06.014
   LeBlanc M, 2009, SLEEP, V32, P1027, DOI 10.1093/sleep/32.8.1027
   Li YP, 2014, CIRCULATION, V129, P737, DOI 10.1161/CIRCULATIONAHA.113.004500
   Lin Li-Yu, 2020, Sleep Med, DOI 10.1016/j.sleep.2020.05.018
   Lora A, 2020, EPIDEMIOL PSYCH SCI, V29, DOI 10.1017/S2045796017000075
   Lucassen EA, 2012, ANN NY ACAD SCI, V1264, P110, DOI 10.1111/j.1749-6632.2012.06655.x
   Magee CA, 2013, SLEEP MED, V14, P591, DOI 10.1016/j.sleep.2013.02.002
   McLaren H.J., 2020, SOCIAL SCI, V9, DOI [DOI 10.3390/SOCSCI9050087, 10.3390/socsci9050087]
   Mehnert A, 2010, EUR J CANCER CARE, V19, P736, DOI 10.1111/j.1365-2354.2009.01117.x
   Mitchell MD, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-40
   Mohit MA, 2011, BMJ-BRIT MED J, V40, P53, DOI DOI 10.3329/bmj.v40i1.9966
   Mondal S. H, 2014, GLOBAL J HUMAN SOCIA, V14, P46
   Monti JM, 2000, SLEEP MED REV, V4, P263, DOI 10.1053/smrv.1999.0096
   Moser C, 2012, GENDER PLANNING DEV, P15, DOI [10.4324/9780203411940, DOI 10.4324/9780203411940]
   Ohayon MM, 1997, J PSYCHIATR RES, V31, P333, DOI 10.1016/S0022-3956(97)00002-2
   Ohayon MM, 2002, J PSYCHOSOM RES, V53, P577, DOI 10.1016/S0022-3999(02)00438-5
   Okajima I, 2011, SLEEP BIOL RHYTHMS, V9, P24, DOI 10.1111/j.1479-8425.2010.00481.x
   Ortega-Montiel J, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2112-8
   Papadimitriou GN, 2005, INT REV PSYCHIATR, V17, P229, DOI 10.1080/09540260500104524
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Pearson K, 1900, PHILOS MAG, V50, P157, DOI 10.1080/14786440009463897
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Roberts RE, 2000, AM J PSYCHIAT, V157, P81, DOI 10.1176/ajp.157.1.81
   Saxena S, 2007, LANCET, V370, P878, DOI 10.1016/S0140-6736(07)61239-2
   Shen L, 2018, J YOUTH ADOLESCENCE, V47, P2584, DOI 10.1007/s10964-018-0899-1
   Sher L, 2020, SLEEP MED, V70, P124, DOI 10.1016/j.sleep.2020.04.019
   Shimizu Tetsuo, 2012, Nihon Rinsho, V70, P1206
   Soares CN, 2006, PSYCHIAT CLIN N AM, V29, P1095, DOI 10.1016/j.psc.2006.09.002
   Staner Luc, 2003, Dialogues Clin Neurosci, V5, P249
   Stemple L, 2016, HUM RIGHTS QUART, V38, P993, DOI 10.1353/hrq.2016.0054
   Su TP, 2007, J PSYCHIATR RES, V41, P119, DOI 10.1016/j.jpsychires.2005.12.006
   Tavernier R, 2015, J YOUTH ADOLESCENCE, V44, P317, DOI 10.1007/s10964-014-0107-x
   The Business Standard, 2020, BUSINESS STANDARD
   The Financial Express, 2020, FINANCIAL EXPRESS
   UNB, 2020, COR TRANSP WORK UN B
   Walker MP, 2009, PSYCHOL BULL, V135, P731, DOI 10.1037/a0016570
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   White K, 2015, AM J MED SCI, V350, P290, DOI 10.1097/MAJ.0000000000000554
   World Health Organization, COP STRESS 2019 NCOV
   World Health Organization, 2020, WHO TIM COVID 19
   World Health Organization, MENT HLTH ATL 2017 C
   World Health Organization, DOING WHAT MATT TIM
   World Health Organization (WHO), WHO DIR GEN OP REM M
   Worldometer, COR UPD
   Worldometers, BANGLADESHCORONAVIRU
   Wu KK, 2005, J TRAUMA STRESS, V18, P39, DOI 10.1002/jts.20004
   Xiao H, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923921
   Yen CF, 2008, SLEEP, V31, P1515, DOI 10.1093/sleep/31.11.1515
   Yeo Yohwan, 2013, J Prev Med Public Health, V46, P271, DOI 10.3961/jpmph.2013.46.5.271
   Younes F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161126
NR 101
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD SEP 17
PY 2020
VL 11
AR 580268
DI 10.3389/fpsyt.2020.580268
PG 11
WC Psychiatry
SC Psychiatry
GA NY4VF
UT WOS:000576388500001
PM 33093839
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chukwudozie, OS
   Chukwuanukwu, RC
   Iroanya, OO
   Eze, DM
   Duru, VC
   Dele-Alimi, TO
   Kehinde, BD
   Bankole, TT
   Obi, PC
   Okinedo, EU
AF Chukwudozie, Onyeka S.
   Chukwuanukwu, Rebecca C.
   Iroanya, Onyekachi O.
   Eze, Daniel M.
   Duru, Vincent C.
   Dele-Alimi, Temiloluwa O.
   Kehinde, Busuyi D.
   Bankole, Taiwo T.
   Obi, Perpetua C.
   Okinedo, Elizabeth U.
TI Attenuated Subcomponent Vaccine Design Targeting the SARS-CoV-2
   Nucleocapsid Phosphoprotein RNA Binding Domain: In Silico Analysis
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID PROTEIN; EPITOPES; ANTIBODIES; RESPONSES; WEB
AB The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has previously never been identified with humans, thereby creating devastation in public health. The need for an effective vaccine to curb this pandemic cannot be overemphasized. In view of this, we designed a subcomponent antigenic peptide vaccine targeting the N-terminal (NT) and C-terminal (CT) RNA binding domains of the nucleocapsid protein that aid in viral replication. Promising antigenic B cell and T cell epitopes were predicted using computational pipelines. The peptides "RIRGGDGKMKDL" and "AFGRRGPEQTQGNFG" were the B cell linear epitopes with good antigenic index and nonallergenic property. Two CD8(+)and Three CD4(+)T cell epitopes were also selected considering their safe immunogenic profiling such as allergenicity, antigen level conservancy, antigenicity, peptide toxicity, and putative restrictions to a number of MHC-I and MHC-II alleles. With these selected epitopes, a nonallergenic chimeric peptide vaccine incapable of inducing a type II hypersensitivity reaction was constructed. The molecular interaction between the Toll-like receptor-5 (TLR5) which was triggered by the vaccine was analyzed by molecular docking and scrutinized using dynamics simulation. Finally,in silicocloning was performed to ensure the expression and translation efficiency of the vaccine, utilizing the pET-28a vector. This research, therefore, provides a guide for experimental investigation and validation.
C1 [Chukwudozie, Onyeka S.; Iroanya, Onyekachi O.; Bankole, Taiwo T.; Okinedo, Elizabeth U.] Univ Lagos, Dept Cell Biol & Genet, Akoka, Lagos State, Nigeria.
   [Chukwuanukwu, Rebecca C.] Nnamdi Azikiwe Univ, Med Lab Sci Dept, Immunol Unit, Nnewi Campus, Awka, Nigeria.
   [Eze, Daniel M.; Duru, Vincent C.; Dele-Alimi, Temiloluwa O.] Univ Ibadan, Univ Coll Hosp, Inst Child Hlth, Publ Hlth Biotechnol Unit, Ibadan, Nigeria.
   [Kehinde, Busuyi D.] Ladoke Akintola Univ Technol, Dept Biochem, Ogbomosho, Oyo State, Nigeria.
   [Obi, Perpetua C.] Fed Polytech, Microbiol Unit, Dept Sci Lab & Technol, Oko, Anambra State, Nigeria.
RP Chukwudozie, OS (corresponding author), Univ Lagos, Dept Cell Biol & Genet, Akoka, Lagos State, Nigeria.
EM solomononyeka84@gmail.com; rc.chukwuanukwu@unizik.edu.ng;
   onyiiog@yahoo.com; eze_d@yahoo.com; chiagozieduru@gmail.com;
   delealimitemi@gmail.com; kehindebd20@gmail.com; ttbankole@unilag.edu.ng;
   obipchisom@gmail.com; uokinedo@unilag.edu.ng
RI Chukwudozie, Onyeka/ABD-1140-2020
OI Chukwudozie, Onyeka/0000-0002-0814-6798
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Amanna IJ, 2011, VIROLOGY, V411, P206, DOI 10.1016/j.virol.2010.12.016
   Berry JD, 2010, MABS-AUSTIN, V2, P53, DOI 10.4161/mabs.2.1.10788
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chang CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065045
   Chang CK, 2006, J BIOMED SCI, V13, P59, DOI 10.1007/s11373-005-9035-9
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Dawood AA, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100673
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Doytchinova I. A, 2008, OPEN VACCINE J, V1, P4, DOI DOI 10.2174/1875035400801010022
   El-Manzalawy Y, 2008, J MOL RECOGNIT, V21, P243, DOI 10.1002/jmr.893
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   ICHIYE T, 1991, PROTEINS, V11, P205, DOI 10.1002/prot.340110305
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kim TW, 2004, J VIROL, V78, P4638, DOI 10.1128/JVI.78.9.4638-4645.2004
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kozakov D, 2013, PROTEINS, V81, P2159, DOI 10.1002/prot.24403
   Liang SD, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-302
   Liu SJ, 2006, VACCINE, V24, P3100, DOI 10.1016/j.vaccine.2006.01.058
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Okoye IS, 2011, IMMUNOLOGY, V134, P368, DOI 10.1111/j.1365-2567.2011.03497.x
   Oyarzun P, 2015, INT J IMMUNOGENET, V42, P313, DOI 10.1111/iji.12214
   Padron-Regalado E, 2020, INFECT DIS THER, V9, P255, DOI 10.1007/s40121-020-00300-x
   Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036
   Peters B, 2005, PLOS BIOL, V3, P379, DOI 10.1371/journal.pbio.0030091
   Pourseif MM, 2019, BIOIMPACTS, V9, P131, DOI 10.15171/bi.2019.18
   Ramaiah A., 2020, INSIGHTS CROSS SPECI, DOI [10.1101/2020.01.29.925867, DOI 10.1101/2020.01.29.925867]
   Shang B, 2005, BIOCHEM BIOPH RES CO, V336, P110, DOI 10.1016/j.bbrc.2005.08.032
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Surjit M, 2008, INFECT GENET EVOL, V8, P397, DOI 10.1016/j.meegid.2007.07.004
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Van Regenmortal Marc H. V., 1996, Methods (Orlando), V9, P465, DOI 10.1006/meth.1996.0054
   Wang Jingqiang, 2003, Genomics Proteomics & Bioinformatics, V1, P145
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   WHO, 2020, 88 WHO
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Yang Jianyi, 2015, Curr Protoc Bioinformatics, V52, DOI 10.1002/0471250953.bi0508s52
   Yu IM, 2006, J BIOL CHEM, V281, P17134, DOI 10.1074/jbc.M602107200
   Zhang Y, 2005, NUCLEIC ACIDS RES, V33, P2302, DOI 10.1093/nar/gki524
   Zhao P, 2005, VIROLOGY, V331, P128, DOI 10.1016/j.virol.2004.10.016
   Zhao X, 2008, J BIOL CHEM, V283, P3272, DOI 10.1074/jbc.M708033200
NR 42
TC 0
Z9 0
U1 3
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PD SEP 17
PY 2020
VL 2020
AR 2837670
DI 10.1155/2020/2837670
PG 17
WC Immunology
SC Immunology
GA NY0IN
UT WOS:000576083800001
PM 32964056
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jackson, LA
   Roberts, PC
   Graham, BS
AF Jackson, Lisa A.
   Roberts, Paul C.
   Graham, Barney S.
TI A SARS-CoV-2 mRNA Vaccine - Preliminary Report
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Jackson, Lisa A.] Kaiser Permanente Washington Hlth Res Inst, Seattle, WA 98101 USA.
   [Roberts, Paul C.; Graham, Barney S.] NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Jackson, LA (corresponding author), Kaiser Permanente Washington Hlth Res Inst, Seattle, WA 98101 USA.
EM lisa.a.jackson@kp.org
CR Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035
   Barouch DH, 2003, J VIROL, V77, P7367, DOI 10.1128/JVI.77.13.7367-7375.2003
   Bines JE, 2020, LANCET INFECT DIS, V20, P762, DOI 10.1016/S1473-3099(20)30151-1
   Chumakov K, 2020, SCIENCE, V368, P1187, DOI 10.1126/science.abc4262
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Heaton PM, 2020, NEW ENGL J MED, V383, P1986, DOI 10.1056/NEJMe2025111
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Niezold T, 2015, IMMUNOLOGY, V145, P519, DOI 10.1111/imm.12467
   Scheiblhofer S, 2018, PEDIAT ALLERG IMM-UK, V29, P679, DOI 10.1111/pai.12964
   Su Y, 2017, HUM VACC IMMUNOTHER, V13, P2804, DOI 10.1080/21645515.2017.1329070
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
NR 11
TC 3
Z9 3
U1 1
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 17
PY 2020
VL 383
IS 12
BP 1190
EP 1192
DI 10.1056/NEJMc2026616
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA NU8QD
UT WOS:000573901600022
PM 32813942
OA Bronze
DA 2021-01-01
ER

PT J
AU Kaufman, HW
   Niles, JK
   Kroll, MH
   Bi, CX
   Holick, MF
AF Kaufman, Harvey W.
   Niles, Justin K.
   Kroll, Martin H.
   Bi, Caixia
   Holick, Michael F.
TI SARS-CoV-2 positivity rates associated with circulating
   25-hydroxyvitamin D levels
SO PLOS ONE
LA English
DT Article
ID VITAMIN-D; PREVENTION
AB Until treatment and vaccine for coronavirus disease-2019 (COVID-19) becomes widely available, other methods of reducing infection rates should be explored. This study used a retrospective, observational analysis of deidentified tests performed at a national clinical laboratory to determine if circulating 25-hydroxyvitamin D (25(OH)D) levels are associated with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) positivity rates. Over 190,000 patients from all 50 states with SARS-CoV-2 results performed mid-March through mid-June, 2020 and matching 25(OH)D results from the preceding 12 months were included. Residential zip code data was required to match with US Census data and perform analyses of race/ethnicity proportions and latitude. A total of 191,779 patients were included (median age, 54 years [interquartile range 40.4-64.7]; 68% female. The SARS-CoV-2 positivity rate was 9.3% (95% C.I. 9.2-9.5%) and the mean seasonally adjusted 25(OH)D was 31.7 (SD 11.7). The SARS-CoV-2 positivity rate was higher in the 39,190 patients with "deficient" 25(OH)D values (<20 ng/mL) (12.5%, 95% C.I. 12.2-12.8%) than in the 27,870 patients with "adequate" values (30-34 ng/mL) (8.1%, 95% C.I. 7.8-8.4%) and the 12,321 patients with values >= 55 ng/mL (5.9%, 95% C.I. 5.5-6.4%). The association between 25(OH)D levels and SARS-CoV-2 positivity was best fitted by the weighted second-order polynomial regression, which indicated strong correlation in the total population (R-2= 0.96) and in analyses stratified by all studied demographic factors. The association between lower SARS-CoV-2 positivity rates and higher circulating 25(OH)D levels remained significant in a multivariable logistic model adjusting for all included demographic factors (adjusted odds ratio 0.984 per ng/mL increment, 95% C.I. 0.983-0.986; p<0.001). SARS-CoV-2 positivity is strongly and inversely associated with circulating 25(OH)D levels, a relationship that persists across latitudes, races/ethnicities, both sexes, and age ranges. Our findings provide impetus to explore the role of vitamin D supplementation in reducing the risk for SARS-CoV-2 infection and COVID-19 disease.
C1 [Kaufman, Harvey W.; Niles, Justin K.; Kroll, Martin H.; Bi, Caixia] Quest Diagnost, Med Informat, Secaucus, NJ USA.
   [Holick, Michael F.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
RP Holick, MF (corresponding author), Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
EM mfholick@bu.edu
CR Berry DJ, 2011, BRIT J NUTR, V106, P1433, DOI 10.1017/S0007114511001991
   Bhala N, 2020, LANCET, V395, P1673, DOI 10.1016/S0140-6736(20)31102-8
   Centers for Disease Control and Prevention, COVID 19 REC ETHN MI
   D'Avolio A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051359
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Gunville Cameron F., 2013, Inflammation & Allergy Drug Targets, V12, P239
   Hastie CE, 2020, DIABETES METAB SYND, V14, P561, DOI 10.1016/j.dsx.2020.04.050
   Holick MF, 2011, J CLIN ENDOCR METAB, V96, P1911, DOI 10.1210/jc.2011-0385
   Ingham TR, 2014, EUR RESPIR J, V44
   Kohlmeier Martin, 2020, BMJ Nutr Prev Health, V3, P67, DOI 10.1136/bmjnph-2020-000096
   Kroll MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118108
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Panarese A, 2020, ALIMENT PHARM THER, V51, P993, DOI 10.1111/apt.15752
   Rhodes Jonathan, 2020, BMJ Nutr Prev Health, V3, P118, DOI 10.1136/bmjnph-2020-000110
   Sabetta JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011088
   U.S. Census Bureau; American Community Survey, 2020, AM COMM SURV 2018 AM
   U.S. Food and Drug Administration, PANTH FUS SARS COV 2
   United States Food and Drug Administration, COB SARS COV 2
   United States Food and Drug Administration, APT SARS COV 2 ASS I
   United States Food and Drug Administration, QUEST SARS COV 2 RRT
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Zdrenghea MT, 2017, REV MED VIROL, V27, DOI 10.1002/rmv.1909
NR 23
TC 6
Z9 6
U1 3
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 17
PY 2020
VL 15
IS 9
AR e0239252
DI 10.1371/journal.pone.0239252
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NU7VY
UT WOS:000573848800072
PM 32941512
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Madsen, AMR
   Schaltz-Buchholzer, F
   Benfield, T
   Bjerregaard-Andersen, M
   Dalgaard, LS
   Dam, C
   Ditlev, SB
   Faizi, G
   Johansen, IS
   Kofoed, PE
   Kristensen, GS
   Loekkegaard, ECL
   Mogensen, CB
   Mohamed, L
   Ostenfeld, A
   Oedegaard, ES
   Soerensen, MK
   Wejse, C
   Jensen, AKG
   Nielsen, S
   Krause, TG
   Netea, MG
   Aaby, P
   Benn, CS
AF Madsen, Anne Marie Rosendahl
   Schaltz-Buchholzer, Frederik
   Benfield, Thomas
   Bjerregaard-Andersen, Morten
   Dalgaard, Lars Skov
   Dam, Christine
   Ditlev, Sisse Bolm
   Faizi, Gulia
   Johansen, Isik Somuncu
   Kofoed, Poul-Erik
   Kristensen, Gitte Schultz
   Loekkegaard, Ellen Christine Leth
   Mogensen, Christian Backer
   Mohamed, Libin
   Ostenfeld, Anne
   Oedegaard, Emilie Sundhaugen
   Soerensen, Marcus Kjaer
   Wejse, Christian
   Jensen, Aksel Karl Georg
   Nielsen, Sebastian
   Krause, Tyra Grove
   Netea, Mihai G.
   Aaby, Peter
   Benn, Christine Stabell
TI Using BCG vaccine to enhance non-specific protection of health care
   workers during the COVID-19 pandemic: A structured summary of a study
   protocol for a randomised controlled trial in Denmark
SO TRIALS
LA English
DT Letter
C1 [Madsen, Anne Marie Rosendahl; Schaltz-Buchholzer, Frederik; Oedegaard, Emilie Sundhaugen; Soerensen, Marcus Kjaer; Nielsen, Sebastian; Aaby, Peter; Benn, Christine Stabell] Univ Southern Denmark, Odense Univ Hosp, Dept Clin Res, Bandim Hlth Project,OPEN, Odense, Denmark.
   [Benfield, Thomas] Copenhagen Univ Hosp, Amager & Hvidovre Hosp, Dept Infect Dis, Ctr Res & Disrupt Infect Dis CREDID, Hvidovre, Denmark.
   [Bjerregaard-Andersen, Morten; Faizi, Gulia] Sydvestjysk Hosp, Dept Med, Esbjerg, Denmark.
   [Dalgaard, Lars Skov] Herning Hosp, Dept Med, Herning, Denmark.
   [Dam, Christine] Bispebjerg & Frederiksberg Hosp, Dept Resp Med, Copenhagen, Denmark.
   [Ditlev, Sisse Bolm] Bispebjerg Hosp, Copenhagen Ctr Translat Res CCTR, Copenhagen, Denmark.
   [Johansen, Isik Somuncu] Odense Univ Hosp, Dept Infect Dis, Odense, Denmark.
   [Kofoed, Poul-Erik; Mohamed, Libin] Lillebaelt Hosp, Dept Pediat, Kolding, Denmark.
   [Kristensen, Gitte Schultz; Mogensen, Christian Backer] Soenderjylland Hosp, Dept Med, Aabenraa, Denmark.
   [Loekkegaard, Ellen Christine Leth; Ostenfeld, Anne] Nordsjaellands Hosp, Dept Gynaecol & Obstet, Hillerod, Denmark.
   [Wejse, Christian] Aarhus Univ Hosp, Dept Infect Dis, Skejby, Denmark.
   [Jensen, Aksel Karl Georg] Univ Copenhagen, Dept Publ Hlth, Sect Biostat, Copenhagen, Denmark.
   [Krause, Tyra Grove] Statens Serum Inst, Copenhagen, Denmark.
   [Netea, Mihai G.] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands.
   [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst LIMES, Dept Genom & Immunoregulat, Bonn, Germany.
RP Madsen, AMR (corresponding author), Univ Southern Denmark, Odense Univ Hosp, Dept Clin Res, Bandim Hlth Project,OPEN, Odense, Denmark.
EM arosendahl@health.sdu.dk
OI Kristensen, Gitte Schultz/0000-0002-0238-5675; johansen, isik
   somuncu/0000-0002-2189-9823; Schaltz-Buchholzer,
   Frederik/0000-0001-7643-8322; Nielsen, Sebastian/0000-0003-3384-7489;
   Benfield, Thomas/0000-0003-0698-9385; Mogensen, Christian
   Backer/0000-0002-8254-089X
FU Torben and Alice Frimodts Fund [CVR 11592333]
FX We have received a grant of 30,000 DKK (approx. 4,000 euros) from
   "Torben and Alice Frimodts Fund" (Danish tax number/CVR 11592333) to
   cover running costs. AJ Vaccines, Copenhagen, Denmark, have donated the
   BCG vaccines for the trial. Statens Serum Institut, Copenhagen, Denmark,
   has kindly provided rapid tests for COVID-19 antibody testing.; None of
   the parties in the study group have any economic interest in the company
   or in the production of BCG vaccines. The funders have had no influence
   on the design of the study and will not have influence on any aspect of
   the analysis, interpretation or reporting of the study results. We are
   currently applying for further funding from foundations that support
   projects aiming to mitigate the effect of the COVID-19 pandemic.
NR 0
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 17
PY 2020
VL 21
IS 1
AR 799
DI 10.1186/s13063-020-04714-3
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NU4LD
UT WOS:000573613700003
PM 32943115
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chen, J
   Malone, B
   Llewellyn, E
   Grasso, M
   Shelton, PMM
   Olinares, PDB
   Maruthi, K
   Eng, ET
   Vatandaslar, H
   Chait, BT
   Kapoor, TM
   Darst, SA
   Campbell, EA
AF Chen, James
   Malone, Brandon
   Llewellyn, Eliza
   Grasso, Michael
   Shelton, Patrick M. M.
   Olinares, Paul Dominic B.
   Maruthi, Kashyap
   Eng, Edward T.
   Vatandaslar, Hasan
   Chait, Brian T.
   Kapoor, Tarun M.
   Darst, Seth A.
   Campbell, Elizabeth A.
TI Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2
   Replication-Transcription Complex
SO CELL
LA English
DT Article
ID RNA-POLYMERASE; CRYO-EM; ARTERIVIRUS HELICASE; ENZYMATIC-ACTIVITIES;
   CORONAVIRUS; VIRUS; FIDELITY; PROTEIN; DNA; SARS
AB SARS-CoV-2 is the causative agent of the 2019-2020 pandemic. The SARS-CoV-2 genome is replicated and transcribed by the RNA-dependent RNA polymerase holoenzyme (subunits nsp7/nsp82/nsp12) along with a cast of accessory factors. One of these factors is the nsp13 helicase. Both the holo-RdRp and nsp13 are essential for viral replication and are targets for treating the disease COVID-19. Here we present cryoelectron microscopic structures of the SARS-CoV-2 holo-RdRp with an RNA template product in complex with two molecules of the nsp13 helicase. The Nidovirales order-specific N-terminal domains of each nsp13 interact with the N-terminal extension of each copy of nsp8. One nsp13 also contacts the nsp12 thumb. The structure places the nucleic acid-binding ATPase domains of the helicase directly in front of the replicating-transcribing holo-RdRp, constraining models for nsp13 function. We also observe ADP-Mg2+ bound in the nsp12 N-terminal nidovirus RdRp-associated nucleotidyltransferase domain, detailing a new pocket for anti-viral therapy development.
C1 [Chen, James; Malone, Brandon; Llewellyn, Eliza; Darst, Seth A.; Campbell, Elizabeth A.] Rockefeller Univ, Lab Mol Biophys, New York, NY 10065 USA.
   [Grasso, Michael; Shelton, Patrick M. M.; Kapoor, Tarun M.] Rockefeller Univ, Lab Chem & Cell Biol, New York, NY 10065 USA.
   [Olinares, Paul Dominic B.; Chait, Brian T.] Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10065 USA.
   [Maruthi, Kashyap; Eng, Edward T.] New York Struct Biol Ctr, Simons Electron Microscopy Ctr, Natl Resource Automated Mol Microscopy, New York, NY 10027 USA.
   [Vatandaslar, Hasan] Swiss Fed Inst Technol, Inst Mol Hlth Sci, CH-8093 Zurich, Switzerland.
RP Darst, SA; Campbell, EA (corresponding author), Rockefeller Univ, Lab Mol Biophys, New York, NY 10065 USA.
EM darst@rockefeller.edu; campbee@rockefeller.edu
OI Chait, Brian/0000-0003-3524-557X; Olinares, Paul
   Dominic/0000-0002-3429-6618; Malone, Brandon/0000-0001-7752-9824; Eng,
   Edward/0000-0002-8014-7269; Chen, James/0000-0002-2311-003X; Maruthi,
   Kashyap/0000-0001-5290-4413
FU NIH National Institute of General Medical SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS) [P41
   GM103310]; NYSTAR; Simons Foundation [SF349247]; NIH Common Fund
   Transformative High Resolution Cryo-Electron Microscopy ProgramUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [U24 GM129539]; NY State Assembly Majority; Pels
   Family Center for Biochemistry and Structural Biology (The Rockefeller
   University); NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P41 GM109824, P41
   GM103314, R35 GM130234, R35 GM118130, R01 GM114450]
FX We thank A. Aher, J. Berger, R. Landick, and C. Rice for helpful
   discussions and suggestions; L. Urnavicius (Laboratory of Cell Biology
   and Laboratory of Chemistry and Cell Biology); M. Ebrahim (The
   Rockefeller University Evelyn Gruss Lipper Cryo-electron Microscopy
   Resource Center) and H. Kuang (New York Structural Biology Center
   [NYSBC]) for help with cryo-EM data collection; T. Tuschl for support;
   and members of the Chait, Darst/Campbell, and Kapoor laboratories for
   helpful discussions. We thank B.R. tenOever for SARS-CoV-2 RNA. Some of
   the work reported here was conducted at the Simons Electron Microscopy
   Center (SEMC) and the National Resource for Automated Molecular
   Microscopy (NRAMM) and National Center for CryoEM Access and Training
   (NCCAT) located at the NYSBC, supported by grants from the NIH National
   Institute of General Medical Sciences (P41 GM103310), NYSTAR, the Simons
   Foundation (SF349247), the NIH Common Fund Transformative High
   Resolution Cryo-Electron Microscopy Program (U24 GM129539), and NY State
   Assembly Majority. This work was supported by the Pels Family Center for
   Biochemistry and Structural Biology (The Rockefeller University) and NIH
   grants P41 GM109824 and P41 GM103314 (to B.T.C.), R35 GM130234 (to
   T.K.), R35 GM118130 (to S.A.D.), and R01 GM114450 (to E.A.C.).
CR Abdelkareem M, 2019, MOL CELL, V75, P298, DOI 10.1016/j.molcel.2019.04.029
   Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Adedeji AO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036521
   Afonine PV, 2018, ACTA CRYSTALLOGR D, V74, P814, DOI 10.1107/S2059798318009324
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Alonso S, 2002, J VIROL, V76, P1293, DOI 10.1128/JVI.76.3.1293-1308.2002
   [Anonymous], 2012, FAMILY CORONAVIRIDAE, P806, DOI [10.1016/B978-0-12-384684-6.00068-9., DOI 10.1016/B978-0-12-384684-6.00068-9]
   Bautista EM, 2002, VIROLOGY, V298, P258, DOI 10.1006/viro.2002.1495
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6
   Bouhaddou M, 2020, CELL, V182, P685, DOI 10.1016/j.cell.2020.06.034
   Bouvet M, 2012, P NATL ACAD SCI USA, V109, P9372, DOI 10.1073/pnas.1201130109
   Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277
   Cardone G, 2013, J STRUCT BIOL, V184, P226, DOI 10.1016/j.jsb.2013.08.002
   CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T
   Chen James, 2019, J Struct Biol X, V1, DOI 10.1016/j.yjsbx.2019.100005
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Cheung ACM, 2011, NATURE, V471, P249, DOI 10.1038/nature09785
   Cupido T, 2019, NAT CHEM BIOL, V15, P444, DOI 10.1038/s41589-019-0225-6
   D.E. Shaw Research, 2020, MOL DYN SIM REL SARS
   Deng ZQ, 2014, NUCLEIC ACIDS RES, V42, P3464, DOI 10.1093/nar/gkt1310
   Denison MR, 2011, RNA BIOL, V8, P270, DOI 10.4161/rna.8.2.15013
   Dudkiewicz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032138
   Dulin D, 2017, CELL REP, V21, P1063, DOI 10.1016/j.celrep.2017.10.005
   Dulin D, 2015, NUCLEIC ACIDS RES, V43, P10421, DOI 10.1093/nar/gkv1098
   Eckerle LD, 2007, J VIROL, V81, P12135, DOI 10.1128/JVI.01296-07
   Eckerle LD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000896
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Enjuanes L, 2006, ANNU REV MICROBIOL, V60, P211, DOI 10.1146/annurev.micro.60.080805.142157
   ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608
   Fish RN, 2002, BBA-GENE STRUCT EXPR, V1577, P287, DOI 10.1016/S0167-4781(02)00459-1
   Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Hao W, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006474
   Hilgenfeld R, 2013, ANTIVIR RES, V100, P286, DOI 10.1016/j.antiviral.2013.08.015
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   Holm L, 2016, NUCLEIC ACIDS RES, V44, pW351, DOI 10.1093/nar/gkw357
   Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004
   Ivanov KA, 2004, J VIROL, V78, P7833, DOI 10.1128/JVI.78.14.7833-7838.2004
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Kang JY, 2017, ELIFE, V6, DOI 10.7554/eLife.25478
   Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1
   Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329
   Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755
   Lane WJ, 2010, J MOL BIOL, V395, P686, DOI 10.1016/j.jmb.2009.10.063
   Lee NR, 2010, NUCLEIC ACIDS RES, V38, P7626, DOI 10.1093/nar/gkq647
   Lehmann KC, 2015, NUCLEIC ACIDS RES, V43, P8416, DOI 10.1093/nar/gkv838
   Lehmann KC, 2015, VIRUS RES, V202, P12, DOI 10.1016/j.virusres.2014.12.001
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Marty MT, 2015, ANAL CHEM, V87, P4370, DOI 10.1021/acs.analchem.5b00140
   Minskaia E, 2006, P NATL ACAD SCI USA, V103, P5108, DOI 10.1073/pnas.0508200103
   Mohni KN, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003652
   Morin A, 2013, ELIFE, V2, DOI 10.7554/eLife.01456
   Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4
   Nudler E, 2012, CELL, V149, P1438, DOI 10.1016/j.cell.2012.06.003
   Olinares P.D.B., 2019, METHOD MOL BIOL, V2062, P357
   Opalka N, 2003, CELL, V114, P335, DOI 10.1016/S0092-8674(03)00600-7
   Pasternak AO, 2001, EMBO J, V20, P7220, DOI 10.1093/emboj/20.24.7220
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Nga PT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002215
   Pisa R, 2019, CELL CHEM BIOL, V26, P1263, DOI 10.1016/j.chembiol.2019.06.001
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Reid DJ, 2019, J AM SOC MASS SPECTR, V30, P118, DOI 10.1007/s13361-018-1951-9
   Saberi A, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007314
   Saikrishnan K, 2009, CELL, V137, P849, DOI 10.1016/j.cell.2009.03.036
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006
   SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097
   Seybert A, 2000, J VIROL, V74, P9586, DOI 10.1128/JVI.74.20.9586-9593.2000
   Seybert A, 2000, RNA, V6, P1056, DOI 10.1017/S1355838200000728
   Seybert A, 2005, J VIROL, V79, P696, DOI 10.1128/JVI.79.2.696-704.2005
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Singleton MR, 2007, ANNU REV BIOCHEM, V76, P23, DOI 10.1146/annurev.biochem.76.052305.115300
   Smith EC, 2014, ANNU REV VIROL, V1, P111, DOI 10.1146/annurev-virology-031413-085507
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218
   Sreelatha A, 2018, CELL, V175, P809, DOI 10.1016/j.cell.2018.08.046
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010
   Tan YZ, 2017, NAT METHODS, V14, P793, DOI [10.1038/NMETH.4347, 10.1038/nmeth.4347]
   Tanner JA, 2003, J BIOL CHEM, V278, P39578, DOI 10.1074/jbc.C300328200
   Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5
   Tvarogova J, 2019, J VIROL, V93, DOI 10.1128/JVI.00291-19
   US Food and Drug Administration, 2020, REMD EUA LETT AUTH R
   van Dinten LC, 2000, J VIROL, V74, P5213, DOI 10.1128/JVI.74.11.5213-5223.2000
   van Marle G, 1999, J VIROL, V73, P5274, DOI 10.1128/JVI.73.7.5274-5281.1999
   vanDinten LC, 1996, J VIROL, V70, P6625, DOI 10.1128/JVI.70.10.6625-6633.1996
   von Brunn A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000459
   Wang D, 2009, SCIENCE, V324, P1203, DOI 10.1126/science.1168729
   Wang Q., 2020, CELL, V368, P1499
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Westover KD, 2004, CELL, V119, P481, DOI 10.1016/j.cell.2004.10.016
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao YB, 2012, J VIROL, V86, P4444, DOI 10.1128/JVI.06635-11
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9
   Zhang R, 2015, J VIROL, V89, P3598, DOI 10.1128/JVI.03535-14
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zirkel F, 2011, MBIO, V2, DOI 10.1128/mBio.00077-11
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
   Zuniga S, 2004, J VIROL, V78, P980, DOI 10.1128/JVI.78.2.980-994.2004
NR 105
TC 2
Z9 2
U1 7
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD SEP 17
PY 2020
VL 182
IS 6
BP 1560
EP +
DI 10.1016/j.cell.2020.07.033
PG 27
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NR3DQ
UT WOS:000571443300018
PM 32783916
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU De, P
   Bhayye, S
   Kumar, V
   Roy, K
AF De, Priyanka
   Bhayye, Sagar
   Kumar, Vinay
   Roy, Kunal
TI In silicomodeling for quick prediction of inhibitory activity against
   3CL(pro)enzyme in SARS CoV diseases
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS CoV-2; Covid-19; coronavirus; in silico; QSAR
ID ACUTE RESPIRATORY SYNDROME; SUBSTRATE-SPECIFICITY; ISATIN DERIVATIVES;
   VALIDATION; CORONAVIRUS; PROTEASE; DOCKING; TOOL; GROMACS; BIOLOGY
AB As of 2 September 2020, the 2019 novel coronavirus or SARS CoV-2 has been responsible for more than 2,56,02,665 infections and 8,52,768 deaths worldwide. There has been an urgent need of newer drug discovery to tackle the situation. Severe acute respiratory syndrome-associated coronavirus 3C-like protease (or 3CL(pro)) is a potential target as anti-SARS agents as it plays a vital role in the viral life cycle. This study aims at developing a quantitative structure-activity relationship (QSAR) model against a group of 3CL(pro)inhibitors to study their structural requirements for their inhibitory activity. Further, molecular docking studies were carried out which helped in the justification of the QSAR findings. Moreover, molecular dynamics simulation study was performed for selected compounds to check the stability of interactions as suggested by the docking analysis. The current QSAR model was further used in the prediction and screening of large databases within a short time. Communicated by Ramaswamy H. Sarma
C1 [De, Priyanka; Kumar, Vinay; Roy, Kunal] Jadavpur Univ, Dept Pharmaceut Technol, Drug Theoret & Cheminformat Lab, Kolkata 700032, India.
   [Bhayye, Sagar] Shiv Nadar Univ, Ctr Informat, Dadri, Uttar Pradesh, India.
RP Roy, K (corresponding author), Jadavpur Univ, Dept Pharmaceut Technol, Drug Theoret & Cheminformat Lab, Kolkata 700032, India.
EM kunalroy_in@yahoo.com
RI Roy, Kunal/B-1673-2009
OI Roy, Kunal/0000-0003-4486-8074; Kumar, Vinay/0000-0002-6809-7633
FU Indian Council of Medical Research, New DelhiIndian Council of Medical
   Research (ICMR); Indian Council of Medical Research (ICMR), New
   DelhiIndian Council of Medical Research (ICMR)
   [5/3/8/27/ITR-F/2018-ITR]; SERB, Govt. of India under the MATRICS scheme
   [MTR/2019/000008]; Science and Engineering Research Board (SERB),
   IndiaDepartment of Science & Technology (India)Science Engineering
   Research Board (SERB), India [EMR/2016/002141]
FX PD thanks Indian Council of Medical Research, New Delhi, for awarding
   with a Senior Research Fellowship, Financial assistance from the Indian
   Council of Medical Research (ICMR), New Delhi in the form of a senior
   research fellowship (File No: 5/3/8/27/ITR-F/2018-ITR; dated:
   18.05.2018) to VK is thankfully acknowledged, KR thanks SERB, Govt. of
   India for financial assistance under the MATRICS scheme
   (MTR/2019/000008). SB likes to acknowledge financial support from the
   Science and Engineering Research Board (SERB), India, under grant
   EMR/2016/002141.
CR Akarachantachote N, 2014, INT J PURE APPL MATH, V94, P307, DOI DOI 10.12732/IJPAM.V94I3.2
   Chen LR, 2005, BIOORG MED CHEM LETT, V15, P3058, DOI 10.1016/j.bmcl.2005.04.027
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   De P, 2018, RSC ADV, V8, P4662, DOI 10.1039/c7ra13159c
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   Devillers J, 1996, GENETIC ALGORITHMS M
   Domling A, 2020, CHEM-US, V6, P1283, DOI 10.1016/j.chempr.2020.04.023
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   GADALETA D, 2016, INT J QUANT STRUCT P, V1, P45, DOI DOI 10.4018/IJQSPR.2016010102
   Goetz DH, 2007, BIOCHEMISTRY-US, V46, P8744, DOI 10.1021/bi0621415
   Gramatica P, 2020, IJQSPR, V5, P1, DOI [10.4018/IJQSPR.20200701.oa1, DOI 10.4018/IJQSPR.20200701.OA1]
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jackson J.E., 2005, USERS GUIDE PRINCIPA, V587
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kumar V, 2020, SAR QSAR ENVIRON RES, V31, P511, DOI 10.1080/1062936X.2020.1776388
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Liu W, 2014, BIOORGAN MED CHEM, V22, P292, DOI 10.1016/j.bmc.2013.11.028
   Lu IL, 2006, J MED CHEM, V49, P5154, DOI 10.1021/jm060207o
   MAKOV G, 1995, PHYS REV B, V51, P4014, DOI 10.1103/PhysRevB.51.4014
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   Niu C, 2008, BIOORGAN MED CHEM, V16, P293, DOI 10.1016/j.bmc.2007.09.034
   Ojha PK, 2011, CHEMOMETR INTELL LAB, V107, P194, DOI 10.1016/j.chemolab.2011.03.011
   Park HS, 2009, EXPERT SYST APPL, V36, P3336, DOI 10.1016/j.eswa.2008.01.039
   Park JY, 2012, BIOORGAN MED CHEM, V20, P5928, DOI 10.1016/j.bmc.2012.07.038
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   PETERSEN HG, 1995, J CHEM PHYS, V103, P3668, DOI 10.1063/1.470043
   Rizvi SMD, 2013, EXCLI J, V12, P831
   Roy K., 2015, QUANTITATIVE STRUCTU
   Roy K, 2018, J INDIAN CHEM SOC, V95, P1497
   Roy K, 2018, ACS OMEGA, V3, P11392, DOI 10.1021/acsomega.8b01647
   Roy K, 2016, CHEMOMETR INTELL LAB, V159, P108, DOI 10.1016/j.chemolab.2016.10.009
   Roy K, 2016, CHEMOMETR INTELL LAB, V152, P18, DOI 10.1016/j.chemolab.2016.01.008
   Roy K, 2011, COMB CHEM HIGH T SCR, V14, P450, DOI 10.2174/138620711795767893
   Roy K, 2010, CURR PHARM DESIGN, V16, P2625, DOI 10.2174/138161210792389270
   Roy PP, 2008, CHEMOMETR INTELL LAB, V90, P31, DOI 10.1016/j.chemolab.2007.07.004
   Gutierrez IS, 2016, BIOORGAN MED CHEM, V24, P4812, DOI 10.1016/j.bmc.2016.06.034
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   TOPLISS JG, 1979, J MED CHEM, V22, P1238, DOI 10.1021/jm00196a017
   Toropova MA, 2017, CURR DRUG METAB, V18, P1123, DOI 10.2174/1389200218666171010124733
   Tsai KC, 2006, J MED CHEM, V49, P3485, DOI 10.1021/jm050852f
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1
   Yap CW, 2011, J COMPUT CHEM, V32, P1466, DOI 10.1002/jcc.21707
   Zhavoronkov A., 2020, POTENTIAL NONCOVALEN, DOI [10.26434/chemrxiv.12301457.v1, DOI 10.26434/CHEMRXIV.12301457.V1]
NR 48
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1821779
EA SEP 2020
PG 27
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NR4SP
UT WOS:000571554400001
PM 32954984
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hong, RM
   Zhao, HL
   Wang, YY
   Chen, Y
   Cai, HL
   Hu, YX
   Wei, GQ
   Huang, H
AF Hong, Ruimin
   Zhao, Houli
   Wang, Yiyun
   Chen, Yu
   Cai, Hongliu
   Hu, Yongxian
   Wei, Guoqing
   Huang, He
TI Clinical characterization and risk factors associated with cytokine
   release syndrome induced by COVID-19 and chimeric antigen receptor
   T-cell therapy
SO BONE MARROW TRANSPLANTATION
LA English
DT Article; Early Access
ID MANAGEMENT; SARS
AB An excessive immune response during coronavirus disease (COVID-19) can induce cytokine release syndrome (CRS), which is associated with life-threatening complications and disease progression. This retrospective study evaluated the clinical characteristics of severe CRS (sCRS, grade 3-4) induced by severe COVID-19 (40 patients) or chimeric antigen receptor T-cell (CAR-T) therapy as a comparator (41 patients). Grade 4 CRS was significantly more common in the COVID-19 group (15/40 (35.7%) vs. 5/41 (12.2%),P = 0.008). The CAR-T group had more dramatic increase in cytokines, including IL-2, IL-6, IL-10, and IFN-gamma. Interestingly, COVID-19 group had significantly higher levels for TNF-alpha (31.1 pg/ml (16.1-70.0) vs. 3.3 (1.8-9.6),P < 0.001) and lg viral loads were correlated with lg IL-6 (R-2 = 0.101;P < 0.001) and lg IL-10 (R-2 = 0.105;P < 0.001). The independent risk factor for COVID-19-related sCRS was hypertension history (OR: 4.876, 95% CI: 2.038-11.668;P < 0.001). Our study demonstrated that there were similar processes but different intensity of inflammatory responses of sCRS in COVID-19 and CAR-T group. The diagnose and management of severe COVID-19-related sCRS can learn lessons from treatment of sCRS induced by CAR-T therapy.
C1 [Hong, Ruimin; Zhao, Houli; Wang, Yiyun; Hu, Yongxian; Wei, Guoqing; Huang, He] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China.
   [Hong, Ruimin; Zhao, Houli; Wang, Yiyun; Hu, Yongxian; Wei, Guoqing; Huang, He] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China.
   [Hong, Ruimin; Zhao, Houli; Wang, Yiyun; Hu, Yongxian; Wei, Guoqing; Huang, He] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China.
   [Hong, Ruimin; Zhao, Houli; Wang, Yiyun; Hu, Yongxian; Wei, Guoqing; Huang, He] Zhejiang Univ, Zhejiang Lab Syst Precis Med, Med Ctr, Hangzhou, Peoples R China.
   [Chen, Yu] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Clin Lab, Hangzhou, Peoples R China.
   [Cai, Hongliu] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Surg Intens Care Unit SICU, Hangzhou, Peoples R China.
RP Hu, YX; Wei, GQ; Huang, H (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China.; Hu, YX; Wei, GQ; Huang, H (corresponding author), Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China.; Hu, YX; Wei, GQ; Huang, H (corresponding author), Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China.; Hu, YX; Wei, GQ; Huang, H (corresponding author), Zhejiang Univ, Zhejiang Lab Syst Precis Med, Med Ctr, Hangzhou, Peoples R China.
EM huyongxian2000@aliyun.com; Weiguoqing2000@sina.com; huanghe@zju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81230014, 81470341, 81520108002]; Key
   Project of Science and Technology Department of Zhejiang Province
   [2018C03016-2]; Key Research and Development Program of Zhejiang
   Province [2019C03016]
FX The authors would like to thank the patients and families for
   participating in this study, the help of medical and nurse team on
   patients' care and department of laboratory for their help in analyzing
   the viral load. This work was supported by grants from the National
   Natural Science Foundation of China (81230014, 81470341, 81520108002),
   the Key Project of Science and Technology Department of Zhejiang
   Province (2018C03016-2), and the Key Research and Development Program of
   Zhejiang Province (2019C03016).
CR Agarwal S, 2020, CANCER DISCOV, V10, P775, DOI 10.1158/2159-8290.CD-20-0473
   Ali SA, 2016, BLOOD, V128, P1688, DOI 10.1182/blood-2016-04-711903
   [Anonymous], 2020, CHIN J INTEGR MED, V40, P136
   [Anonymous], 2017, COMMON TERMINOLOGY C
   Bhattacharyya S, 2007, BLOOD, V109, P4313, DOI 10.1182/blood-2006-10-048215
   Boni C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112754
   Busillo JM, 2013, TRENDS ENDOCRIN MET, V24, P109, DOI 10.1016/j.tem.2012.11.005
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   England JT, 2020, BLOOD REV, DOI [10.1016/j.blre.2020.100707., DOI 10.1016/J.BLRE.2020.100707.]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105
   Hay KA, 2018, BRIT J HAEMATOL, V183, P364, DOI 10.1111/bjh.15644
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hunter BD, 2019, JNCI-J NATL CANCER I, V111, P646, DOI 10.1093/jnci/djz017
   Jamilloux Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102567
   Kirkpatrick CT, 2018, MBIO, V9, DOI 10.1128/mBio.00696-18
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729
   Leiva-Juarez MM, 2018, MUCOSAL IMMUNOL, V11, P21, DOI 10.1038/mi.2017.71
   Majzner RG, 2019, NAT MED, V25, P1341, DOI 10.1038/s41591-019-0564-6
   Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035
   McDermott JE, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0336-6
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148
   Oldstone MBA, 2014, CURR TOP MICROBIOL, V378, P129, DOI 10.1007/978-3-319-05879-5_6
   Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919
   Pascarella G, 2020, J INTERN MED, V288, P192, DOI 10.1111/joim.13091
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Qin YY, 2020, CHINESE MED J-PEKING, V133, P1080, DOI 10.1097/CM9.0000000000000791
   Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980
   Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9
   Wei J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000862
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   XU B, 2020, J INFECTION, V81, pE51, DOI 10.1016/j.jinf.2020.04.012
   Xu YX, 2020, CURR RES TRANSL MED, V68, P111, DOI 10.1016/j.retram.2020.06.003
   Yanez L, 2019, HEMASPHERE, V3, DOI 10.1097/HS9.0000000000000186
   Yang Z, 2020, J INFECTION, DOI [10.1016/j.jinf.2020.03.062., DOI 10.1016/J.JINF.2020.03.062., 10.1016/j.jinf.2020.03.062]
   Zhang SY, 2020, CLIN DRUG INVEST, V40, P511, DOI 10.1007/s40261-020-00917-3
NR 40
TC 1
Z9 1
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
DI 10.1038/s41409-020-01060-5
EA SEP 2020
PG 11
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA NR5UQ
UT WOS:000571628900001
PM 32943758
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Ribaudo, G
   Ongaro, A
   Oselladore, E
   Zagotto, G
   Memo, M
   Gianoncelli, A
AF Ribaudo, Giovanni
   Ongaro, Alberto
   Oselladore, Erika
   Zagotto, Giuseppe
   Memo, Maurizio
   Gianoncelli, Alessandra
TI A computational approach to drug repurposing against SARS-CoV-2 RNA
   dependent RNA polymerase (RdRp)
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; RdRp; remdesivir; molecular modelling; repurposing
ID KINASE INHIBITORS; CORONAVIRUS; DISCOVERY; PNEUMONIA; WUHAN; CHINA
AB The spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) caused a worldwide outbreak of coronavirus disease 19 (COVID-19), which rapidly evolved as a global concern. The efforts of the scientific community are pointed towards the identification of promptly available therapeutic options. RNA-dependent RNA polymerase (RdRp) is a promising target for developing small molecules to contrast SARS-CoV-2 replication. Modern computational tools can boost identification and repurposing of known drugs targeting RdRp. We here report the results regarding the screening of a database containing more than 8800 molecules, including approved, experimental, nutraceutical, illicit, withdrawn and investigational compounds. The molecules were docked against the cryo-electron microscopy structure of SARS-CoV-2 RdRp, optimized by means of molecular dynamics (MD) simulations. The adopted three-stageensembledocking study underline that compounds formerly developed as kinase inhibitors may interact with RdRp. Communicated by Ramaswamy H. Sarma
C1 [Ribaudo, Giovanni; Ongaro, Alberto; Memo, Maurizio; Gianoncelli, Alessandra] Univ Brescia, Dept Mol & Translat Med, I-25121 Brescia, Italy.
   [Oselladore, Erika; Zagotto, Giuseppe] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Padua, Italy.
RP Gianoncelli, A (corresponding author), Univ Brescia, Dept Mol & Translat Med, I-25121 Brescia, Italy.
EM alessandra.gianoncelli@unibs.it
OI Oselladore, Erika/0000-0002-2546-1343
FU University of Brescia
FX This work was granted by University of Brescia.
CR Abedi F, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104808
   [Anonymous], 2020, SCHROD REL 2020 1 SI
   [Anonymous], 2020, SCHROD REL 2020 1 PR
   [Anonymous], 2020, SCHROD REL 2020 1 LI
   [Anonymous], 2020, SCHROD REL 2020 1 GL
   [Anonymous], 2020, SCHROD REL 2020 1 QI
   Encinar JA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050525
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bettiol A, 2018, CLIN DRUG INVEST, V38, P837, DOI 10.1007/s40261-018-0676-7
   Bhardwaj VK, 2020, COMPUT METH PROG BIO, V194, DOI 10.1016/j.cmpb.2020.105494
   BHARDWAJ VK, 2020, J BIOMOL STRUCT 0520, DOI DOI https://doi.org/10.1080/07391102.2020.1766572
   CALLIGARI P, 2020, VIRUSES BASEL, V12, DOI DOI https://doi.org/10.3390/v12040445
   Cazzola M, 2012, PHARMACOL REV, V64, P450, DOI 10.1124/pr.111.004580
   Cha Y, 2018, BRIT J PHARMACOL, V175, P168, DOI 10.1111/bph.13798
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   D.E. Shaw Research, 2020, MOL DYN SIM REL SARS
   Dong WY, 2020, ANTIVIR RES, V173, DOI 10.1016/j.antiviral.2019.104651
   ELFIKY AA, 2020, J BIOMOL STRUCT 0505, DOI DOI https://doi.org/10.1080/07391102.2020.1761882
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fachi MM, 2018, EUR J CANCER, V104, P9, DOI 10.1016/j.ejca.2018.08.016
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Greenidge PA, 2013, J CHEM INF MODEL, V53, P201, DOI [10.1021/ci300425v, 10.1021/cI300025v]
   Gupta AK, 2019, CHEM BIOL DRUG DES, V94, P1441, DOI 10.1111/cbdd.13519
   Hillen HS, 2020, NATURE, V584, P154, DOI 10.1038/s41586-020-2368-8
   HUANG JS, 2020, J CLIN MED, V9, DOI DOI https://doi.org/10.3390/jcm9041131
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Khatik Gopal L, 2018, Curr Drug Discov Technol, V15, P163, DOI 10.2174/1570163814666170915134018
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lung JH, 2020, J MED VIROL, V92, P693, DOI 10.1002/jmv.25761
   Oprea Tudor I, 2011, Drug Discov Today Ther Strateg, V8, P61
   PARK M, 2020, J CLIN MED, V9, DOI DOI https://doi.org/10.3390/jcm9040967
   Perwitasari O, 2015, ASSAY DRUG DEV TECHN, V13, P638, DOI 10.1089/adt.2015.0003.drrr
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Queirolo P, 2017, EXPERT REV ANTICANC, V17, P985, DOI 10.1080/14737140.2017.1374177
   Roos K, 2019, J CHEM THEORY COMPUT, V15, P1863, DOI 10.1021/acs.jctc.8b01026
   Roschewski M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd0110
   Schor S, 2018, DNA CELL BIOL, V37, P63, DOI 10.1089/dna.2017.4033
   Schrodinger, 2020, SCHROD REL 2020 1 EP
   Schrodinger Release 2020-1: Maestro, 2020, SCHROD REL 2020 1 MA
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Shaw DE, 2014, INT CONF HIGH PERFOR, P41, DOI 10.1109/SC.2014.9
   Spellberg B, 2020, JAMA-J AM MED ASSOC, V323, P1966, DOI 10.1001/jama.2020.4958
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   TCHESNOKOV EP, 2019, VIRUSES BASEL, V11, DOI DOI https://doi.org/10.3390/v11040326
   Tee AKH, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001281.pub2
   Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wishart DS, 2006, NUCLEIC ACIDS RES, V34, pD668, DOI 10.1093/nar/gkj067
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xue Q, 2008, CANCER RES, V68, P9551, DOI 10.1158/0008-5472.CAN-08-2058
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 64
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1822209
EA SEP 2020
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NR0TE
UT WOS:000571275700001
PM 32948103
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Sen, D
   Debnath, P
   Debnath, B
   Bhaumik, S
   Debnath, S
AF Sen, Debanjan
   Debnath, Pradip
   Debnath, Bimal
   Bhaumik, Samhita
   Debnath, Sudhan
TI Identification of potential inhibitors of SARS-CoV-2 main protease and
   spike receptor from 10 important spices through structure-based virtual
   screening and molecular dynamic study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Spices; SARS-CoV-2; main protease; spike receptor; virtual screening;
   molecular dynamics; ADME filtration
ID RESPIRATORY SYNDROME CORONAVIRUS; GARLIC ALLIUM-SATIVUM; CUMINUM-CYMINUM
   L.; CHEMICAL-COMPOSITION; NIGELLA-SATIVA; ESSENTIAL OILS; ANTIOXIDANT
   PROPERTIES; ACCURATE DOCKING; SEED; GLIDE
AB The outbreak of novel coronavirus disease (COVID-19) caused by SARS-CoV-2 poses a serious threat to human health and world economic activity. There is no specific drug for the treatment of COVID-19 patients at this moment. Traditionally, people have been using spices like ginger, fenugreek and onion, etc. for the remedy of a common cold. This work identifies the potential inhibitors of the main protease (M-pro) and spike (S) receptor of SARS-CoV-2 from 10 readily available spices. These two proteins, S and M-pro, play an important role during the virus entry into the host cell, and replication and transcription processes of the virus, respectively. To identify potential molecules an in-house databank containing 1040 compounds was built-up from the selected spices. Structure-based virtual screening of this databank was performed with two important SARS-CoV-2 proteins using Glide. Top hits resulted from virtual screening (VS) were subjected to molecular docking using AutoDock 4.2 and AutoDock Vina to eliminate false positives. The top six hits against M(pro)and top five hits against spike receptor subjected to 130 ns molecular dynamic simulation using GROMACS. Finally, the compound1-, 2-, 3- and5-M(pro)complexes, and compound17-,18-,19-,20-and21- spike receptor complexes showed stability throughout the simulation time. The ADME values also supported the drug-like nature of the selected hits. These nine compounds are available in onion, garlic, ginger, peppermint, chili and fenugreek. All the spices are edible and might be used as home remedies against COVID-19 after proper biological evaluation.
C1 [Sen, Debanjan] BCDA Coll Pharm & Technol, Kolkata, W Bengal, India.
   [Debnath, Pradip; Debnath, Sudhan] Maharaja Bir Bikram Coll, Dept Chem, Agartala 799004, Tripura, India.
   [Debnath, Bimal] Tripura Univ, Dept Forestry & Biodivers, Suryamaninagar, Tripura, India.
   [Bhaumik, Samhita] Womens Coll, Dept Chem, Agartala, Tripura, India.
RP Debnath, S (corresponding author), Maharaja Bir Bikram Coll, Dept Chem, Agartala 799004, Tripura, India.
EM bcsdebnath@gmail.com
CR Aanouz I, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758790
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Ahmad Aftab, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P337, DOI 10.1016/S2221-1691(13)60075-1
   Amin G, 2012, WOODHEAD PUBL FOOD S, P250
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Antonio AS, 2018, RSC ADV, V8, P25767, DOI 10.1039/c8ra02067a
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Brahmi F., 2017, AROMATIC MED PLANTS, P47, DOI [10.5772/67291, DOI 10.5772/67291]
   Bystricka J, 2013, ACTA ALIMENT HUNG, V42, P11, DOI 10.1556/AAlim.42.2013.1.2
   Chatterjee S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1787228
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen Z, 2004, PHYTOTHER RES, V18, P592, DOI 10.1002/ptr.1485
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Ee GCL, 2009, NAT PROD RES, V23, P1416, DOI 10.1080/14786410902757998
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Farag MA, 2017, MOLECULES, V22, DOI 10.3390/molecules22050761
   Fehr AR, 2018, TRENDS MICROBIOL, V26, P598, DOI 10.1016/j.tim.2017.11.011
   Feng T, 2011, J AGR FOOD CHEM, V59, P11690, DOI 10.1021/jf202544w
   Fischer A, 2020, INHIBITORS NOVEL COR, DOI [10.26434/chemrxiv.11923239.v1, DOI 10.26434/CHEMRXIV.11923239.V1]
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gachkar L, 2007, FOOD CHEM, V102, P898, DOI 10.1016/j.foodchem.2006.06.035
   Gohari A. R., 2011, Pharmacognosy Journal, V3, P1, DOI 10.5530/pj.2011.25.1
   Hajlaoui H, 2010, FOOD CHEM TOXICOL, V48, P2186, DOI 10.1016/j.fct.2010.05.044
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Han YM, 2001, PHYTOCHEMISTRY, V58, P577, DOI 10.1016/S0031-9422(01)00273-4
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Imran M, 2018, 2018 INTERNATIONAL CONFERENCE ON ENGINEERING & EMERGING TECHNOLOGIES (ICEET), P1
   Islam MT, 2019, ORIENTAL PHARM EXP M, V19, P115, DOI 10.1007/s13596-019-00363-3
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Israeli Eitan, 2020, Harefuah, V159, P70
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kamel A. S., 2000, STUDIES NATURAL PROD, P455, DOI DOI 10.1016/S1572-5995(00)80135-0
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kim DE, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110696
   Kokoska L, 2008, J FOOD PROTECT, V71, P2475, DOI 10.4315/0362-028X-71.12.2475
   Kufareva Irina, 2012, Methods Mol Biol, V857, P231, DOI 10.1007/978-1-61779-588-6_10
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lanzotti V, 2012, PHYTOCHEM REV, V11, P179, DOI 10.1007/s11101-012-9247-3
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li R, 2004, FLAVOUR FRAG J, V19, P311, DOI 10.1002/ffj.1302
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li Y., 2020, BIORXIV, DOI [10.1101/2020.01.28.922922, DOI 10.1101/2020.01.28.922922]
   Liu W, 2020, CURR TOP MED CHEM, V20, P603, DOI 10.2174/1568026620999200305145032
   Mahboubi M., 2019, Clinical Phytoscience, V5, DOI [10.1186/s40816-019-0121-3, 10.1186/s40816-018-0097-4]
   Mandal M., 2016, ESSENTIAL OILS FOOD, DOI [10.1016/b978-0-12-416641-7.00047-x, DOI 10.1016/B978-0-12-416641-7.00047-X, 10.1016/B978-0-12-416641-7.00047-X]
   Martins N, 2016, FOOD CHEM, V211, P41, DOI 10.1016/j.foodchem.2016.05.029
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Meng FC, 2018, HANDB FOOD BIOENG, V7, P299, DOI 10.1016/B978-0-12-811518-3.00010-7
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Mohd HA, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0544-0
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Mukhtar H, 2019, J ESSENT OIL RES, V31, P171, DOI 10.1080/10412905.2018.1562388
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Omezzine F, 2017, ARAB J CHEM, V10, pS3622, DOI 10.1016/j.arabjc.2014.03.013
   Oroojalian F, 2010, FOOD CHEM, V120, P765, DOI 10.1016/j.foodchem.2009.11.008
   Pancharoen O., 2000, STUDIES NATURAL PROD, V23, P797
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Ramajayam R, 2010, BIOORGAN MED CHEM, V18, P7849, DOI 10.1016/j.bmc.2010.09.050
   Reddy DN, 2019, J KING SAUD UNIV SCI, V31, P528, DOI 10.1016/j.jksus.2017.07.013
   Saharkhiz Mohammad Jamal, 2012, ISRN Pharm, V2012, P718645, DOI 10.5402/2012/718645
   Salehi B, 2019, MOLECULES, V24, DOI 10.3390/molecules24071364
   Sampangi-Ramaiah MH, 2020, CURR SCI INDIA, V118, P1087, DOI 10.18520/cs/v118/i7/1087-1092
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Schreiner W, 2012, COMPUT MATH METHOD M, DOI 10.1155/2012/173521
   Siddiqui BS, 2005, NAT PROD RES, V19, P703, DOI 10.1080/14786410512331330657
   Singh R. P., 2017, Pharmacognosy Journal, V9, P292, DOI 10.5530/pj.2017.3.51
   Sokovic MD, 2009, MOLECULES, V14, P238, DOI 10.3390/molecules14010238
   Srinivasan K, 2018, FOOD QUAL SAF-OXFORD, V2, P1, DOI 10.1093/fqsafe/fyx031
   Su HX, 2020, ACTA PHARMACOL SIN, V41, P1167, DOI 10.1038/s41401-020-0483-6
   Takooree H, 2019, CRIT REV FOOD SCI, V59, pS210, DOI 10.1080/10408398.2019.1565489
   Teshika JD, 2019, CRIT REV FOOD SCI, V59, pS39, DOI 10.1080/10408398.2018.1499074
   Thomson M, 2003, CURR CANCER DRUG TAR, V3, P67, DOI 10.2174/1568009033333736
   Tian W, 2018, NUCLEIC ACIDS RES, V46, pW363, DOI 10.1093/nar/gky473
   Topal U, 2008, INT J FOOD SCI NUTR, V59, P619, DOI 10.1080/09637480701553816
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Tundis R, 2011, PLANT FOOD HUM NUTR, V66, P261, DOI 10.1007/s11130-011-0248-y
   Umesh, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763202
   Wang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30250-6
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z., 2020, BIORXIV, DOI [10.1101/2020.01.27.921627., DOI 10.1101/2020.01.27.921627]
   Yoshikawa M, 1997, CHEM PHARM BULL, V45, P81, DOI 10.1248/cpb.45.81
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhang HP, 2020, INTERDISCIP SCI, V12, P368, DOI 10.1007/s12539-020-00376-6
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu Z., 2020, D3SIMILARITY LIGAND, DOI [10.26434/chemrxiv.11959323.v1, DOI 10.26434/CHEMRXIV.11959323.V1]
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 105
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1819883
EA SEP 2020
PG 22
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NR1CK
UT WOS:000571299700001
PM 32948116
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mahalingam, R
   Dharmalingam, P
   Santhanam, A
   Kotla, S
   Davuluri, G
   Karmouty-Quintana, H
   Ashrith, G
   Thandavarayan, RA
AF Mahalingam, Rajasekaran
   Dharmalingam, Prakash
   Santhanam, Abirami
   Kotla, Sivareddy
   Davuluri, Gangarao
   Karmouty-Quintana, Harry
   Ashrith, Guha
   Thandavarayan, Rajarajan A.
TI Single-cell RNA sequencing analysis of SARS-CoV-2 entry receptors in
   human organoids
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article; Early Access
DE ACE2; COVID-19; human organoids; SARS-CoV-2; scRNA sequencing; TMPRSS2
ID CULTURE; DIVERSITY; MODELS
AB Coronavirus disease-2019 (COVID-19) is a global pandemic and caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has resulted in millions of deaths worldwide. Reports denote SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2), transmembrane serine protease 2 (TMPRSS2) as its primary entry point into the host cell. However, understanding the biology behind this viral replication, disease mechanism and drug discovery efforts are limited due to the lack of a suitable experimental model. Here, we used single-cell RNA sequencing data of human organoids to analyze expressions of ACE2 and TMPRSS2, in addition to an array of RNA receptors to examine their role in SARS-CoV-2 pathogenesis. ACE2 is abundant in all organoids, except the prostate and brain, and TMPRSS2 is omnipresent. Innate immune pathways are upregulated in ACE2(+) cells of all organoids, except the lungs. Besides this, the expression of low-density lipoprotein receptor is highly enriched in ACE2(+) cells in intestinal, lung, and retinal organoids, with the highest expression in lung organoids. Collectively, this study demonstrates that the organoids can be used as an experimental platform to explore this novel virus disease mechanism and for drug development.
C1 [Mahalingam, Rajasekaran] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Lab Neuroimmunol, Houston, TX 77030 USA.
   [Dharmalingam, Prakash] Clonegene Biosyst, Chennai, Tamil Nadu, India.
   [Santhanam, Abirami] Univ Texas Hlth Sci Ctr Houston, Ophthalmol & Visual Sci, Houston, TX 77030 USA.
   [Kotla, Sivareddy] Univ Texas MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA.
   [Davuluri, Gangarao] Pennington Biomed Res Ctr, Integrated Physiol & Mol Metab, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.
   [Karmouty-Quintana, Harry; Thandavarayan, Rajarajan A.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
   [Karmouty-Quintana, Harry; Thandavarayan, Rajarajan A.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Div Crit Care, Houston, TX 77030 USA.
   [Karmouty-Quintana, Harry; Thandavarayan, Rajarajan A.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Div Pulm & Sleep Med, Houston, TX 77030 USA.
   [Karmouty-Quintana, Harry] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Internal Med, Houston, TX 77030 USA.
   [Ashrith, Guha; Thandavarayan, Rajarajan A.] Houston Methodist Hosp, Dept Cardiol, Houston, TX 77030 USA.
RP Thandavarayan, RA (corresponding author), Houston Methodist Hosp, Dept Cardiol, Houston, TX 77030 USA.
EM atrajarajan@gmail.com
RI Karmouty-Quintana, Harry/ABC-9144-2020
OI Karmouty-Quintana, Harry/0000-0003-4753-9823; Amirthalingam
   Thandavarayan, Rajarajan/0000-0001-8452-2903
FU American Heart AssociationAmerican Heart Association [19TPA34880039,
   18IPA34170497]; Roswell and Ann Vaughan Fund
FX This study was supported by grants from the American Heart Association
   (19TPA34880039 and 18IPA34170497 to Rajarajan A. Thandavarayan) and the
   Roswell and Ann Vaughan Fund to Guha Ashrith.
CR Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Cleary SJ, 2020, BRIT J PHARMACOL, V177, P4851, DOI 10.1111/bph.15143
   Clevers H, 2020, NAT REV MOL CELL BIO, V21, P355, DOI 10.1038/s41580-020-0258-4
   Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082
   Day CW, 2009, VIROLOGY, V395, P210, DOI 10.1016/j.virol.2009.09.023
   Didangelos A, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00367-20
   DiMarco RL, 2014, INTEGR BIOL-UK, V6, P127, DOI 10.1039/c3ib40188j
   Domansky K, 2010, LAB CHIP, V10, P51, DOI 10.1039/b913221j
   Duque-Correa MA, 2020, TRENDS PARASITOL, V36, P170, DOI 10.1016/j.pt.2019.10.013
   Dutta D, 2017, ELSEVIER CURRENT TRE, V48, P15, DOI [10.1016/j.coi.2017.07.012, DOI 10.1016/J.COI.2017.07.012]
   Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002
   Ettayebi K, 2016, SCIENCE, V353, P1387, DOI 10.1126/science.aaf5211
   Fujii M, 2018, CELL STEM CELL, V23, P787, DOI 10.1016/j.stem.2018.11.016
   Grabinger T, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.183
   Grassi L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1453-0
   Harrison C, 2020, NAT BIOTECHNOL, V38, P659, DOI 10.1038/d41587-020-00013-z
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jensen C, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00033
   Kruger J., 2020, BIORXIV
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125
   Lee DW, 2017, BIOMED MICRODEVICES, V19, DOI 10.1007/s10544-017-0242-8
   Maenhoudt N, 2020, STEM CELL REP, V14, P717, DOI 10.1016/j.stemcr.2020.03.004
   Mahe Maxime M, 2013, Curr Protoc Mouse Biol, V3, P217, DOI 10.1002/9780470942390.mo130179
   McCray T, 2019, AM J CLIN EXP UROL, V7, P123
   Mead BE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1677-4
   Miller AJ, 2020, DEV CELL, V53, P117, DOI 10.1016/j.devcel.2020.01.033
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Peng Y., 2020, CHOLESTEROL METABOLI, DOI [10.1101/2020.04.16.20068528, DOI 10.1101/2020.04.16.20068528]
   Platt DJ, 2017, CURR OPIN VIROL, V27, P1, DOI 10.1016/j.coviro.2017.09.005
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Sasai Y, 2013, NATURE, V493, P318, DOI 10.1038/nature11859
   Shamir ER, 2014, NAT REV MOL CELL BIO, V15, P647, DOI 10.1038/nrm3873
   Shi YL, 2020, ACTA PHARMACOL SIN B, V10, P1239, DOI 10.1016/j.apsb.2020.04.006
   Sridhar A, 2020, CELL REP, V30, P1644, DOI 10.1016/j.celrep.2020.01.007
   Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031
   Suzuki T., 2020, GENERATION HUMAN BRO, DOI [10.1101/2020.05.25.115600, DOI 10.1101/2020.05.25.115600]
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Takahashi T, 2019, ANNU REV PHARMACOL, V59, P447, DOI 10.1146/annurev-pharmtox-010818-021108
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   TRINKAUS JP, 1955, P NATL ACAD SCI USA, V41, P787, DOI 10.1073/pnas.41.10.787
   Tsai S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4238-4
   Velasco S, 2019, NATURE, V570, P523, DOI 10.1038/s41586-019-1289-x
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Wu HJ, 2018, CELL STEM CELL, V23, P869, DOI 10.1016/j.stem.2018.10.010
   Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zervantonakis IK, 2012, P NATL ACAD SCI USA, V109, P13515, DOI 10.1073/pnas.1210182109
   Zhang QZ, 2020, NANO LETT, V20, P5570, DOI 10.1021/acs.nanolett.0c02278
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 52
TC 1
Z9 1
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
DI 10.1002/jcp.30054
EA SEP 2020
PG 9
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA NP4OJ
UT WOS:000570156800001
PM 32944935
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tremblay, D
   Seah, C
   Schneider, T
   Bhalla, S
   Feld, J
   Naymagon, L
   Wang, B
   Patel, V
   Jun, T
   Jandl, T
   Rahman, F
   Liu, STH
   Aberg, JA
   Bouvier, N
AF Tremblay, Douglas
   Seah, Carina
   Schneider, Thomas
   Bhalla, Sheena
   Feld, Jonathan
   Naymagon, Leonard
   Wang, Bo
   Patel, Vaibhav
   Jun, Tomi
   Jandl, Thomas
   Rahman, Farah
   Liu, Sean T. H.
   Aberg, Judith A.
   Bouvier, Nicole
CA Mt Sinai Hlth Syst Convalescent
TI Convalescent Plasma for the Treatment of Severe COVID-19 Infection in
   Cancer Patients
SO CANCER MEDICINE
LA English
DT Article
DE cancer; convalescent plasma; COVID-19; malignancy; SARS-CoV-2
AB Background Patients with malignancy are particularly vulnerable to infection with Severe Acute Respiratory Disease-Coronavirus-2 (SARS-CoV-2) given their immunodeficiency secondary to their underlying disease and cancer-directed therapy. We report a case series of patients with cancer who received convalescent plasma, an investigational therapy for severe Coronavirus Disease 2019 (COVID-19). Methods Patients with cancer were identified who received convalescent plasma. Enrolled patients had confirmed COVID-19 with severe or life-threatening disease and were transfused with convalescent plasma from donors with a SARS-CoV-2 anti-spike antibody titer of >= 1:320 dilution. Oxygen requirements and clinical outcomes of interests were captured as well as laboratory parameters at baseline and 3 days after treatment. Results We identified 24 patients with cancer, 14 of whom had a hematological malignancy, who were treated with convalescent plasma. Fifteen patients (62.5%) were on cancer-directed treatment at the time of COVID-19 infection. After a median of hospital duration of 9 days, 13 patients (54.2%) had been discharged home, 1 patient (4.2%) was still hospitalized, and 10 patients had died (41.7%). Non-intubated patients, particularly those on nasal cannula alone, had favorable outcomes. Three mild febrile non-hemolytic transfusion reactions were observed. C-reactive protein significantly decreased after 3 days of treatment, while other laboratory parameters including ferritin and D-dimer remained unchanged. Conclusions Convalescent plasma may be a promising therapy in cancer patients with COVID-19.
C1 [Tremblay, Douglas; Bhalla, Sheena; Feld, Jonathan; Naymagon, Leonard; Wang, Bo; Patel, Vaibhav; Jun, Tomi; Jandl, Thomas] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA.
   [Seah, Carina] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.
   [Schneider, Thomas] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA.
   [Rahman, Farah; Liu, Sean T. H.; Aberg, Judith A.; Bouvier, Nicole] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA.
RP Tremblay, D (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, Dept Med, One Gustave L Levy Pl, New York, NY 10029 USA.
EM douglas.tremblay@mountsinai.org
RI Wang, Bo/ABC-5571-2020
OI , Douglas/0000-0002-4719-7192; Jandl, Thomas/0000-0002-9481-4229
CR Allegra A, 2020, CANCERS, V12, DOI 10.3390/cancers12061581
   Aries JA, 2020, BRIT J HAEMATOL, V190, pE64, DOI 10.1111/bjh.16852
   Beigel J. H., 2020, N ENGL J MED
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Dai M, 2020, CANCER DISCOV
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Emami A, 2020, ARCH ACAD EMERG MED, V8
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Hegerova L, 2020, BLOOD, V136, P759, DOI 10.1182/blood.2020006964
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   La Rosee F, 2020, LEUKEMIA, V34, P1805, DOI 10.1038/s41375-020-0891-0
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Lip GYH, 2002, LANCET ONCOL, V3, P27, DOI 10.1016/S1470-2045(01)00619-2
   Liu STH, 2020, CONVALESCENT PLASMA
   Martin-Moro F, 2020, BRIT J HAEMATOL, V190, pE16, DOI 10.1111/bjh.16801
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   National Healthcare Safety Network Biovigilance Component, 2018, HEM MOD SURV PROT
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roche, 2020, ROCH PROV UPD PHAS 3
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Salazar E, 2020, AM J PATHOL, V190, P1680, DOI 10.1016/j.ajpath.2020.05.014
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shishido SN, 2012, CLIN IMMUNOL, V144, P142, DOI 10.1016/j.clim.2012.06.002
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organisation, R D BLUEPR COVID 19
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
NR 35
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD NOV
PY 2020
VL 9
IS 22
BP 8571
EP 8578
DI 10.1002/cam4.3457
EA SEP 2020
PG 8
WC Oncology
SC Oncology
GA OR0QH
UT WOS:000570008400001
PM 32945149
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zhao, HJ
   Yang, XM
   Wang, AH
   Li, Y
AF Zhao, Hong-Jin
   Yang, Xiao-Mei
   Wang, Ai-Hong
   Li, Yan
TI Pharmacological rationale for antihypertensive drug choice on
   COVID-19-affected patients: ACEI/ARB might not increase their
   susceptibility
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Letter
ID ANGIOTENSIN-CONVERTING ENZYME; ACE2; HYPERTENSION
C1 [Zhao, Hong-Jin; Wang, Ai-Hong] Shandong First Med Univ, Shandong Prov Hosp, Dept Cardiol, Jinan, Peoples R China.
   [Yang, Xiao-Mei] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Anesthesiol, Jinan, Peoples R China.
   [Li, Yan] Shandong Univ, Cheeloo Coll Med, Sch Med, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
RP Li, Y (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Med, 44 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.; Wang, AH (corresponding author), Shandong Prov Hosp, Dept Cardiol, 324 Jing Wu Rd, Jinan 250021, Shandong, Peoples R China.
EM yanli.sdu@gmail.com; yanli.sdu@gmail.com
OI Zhao, Hong-Jin/0000-0001-5296-2293; Li, Yan/0000-0003-1813-8115
FU Fundamental Research Funds of Shandong University [21520079614029];
   Shandong Provincial Natural Science Foundation of ChinaNatural Science
   Foundation of Shandong Province [ZR2015PH036]; China Scholarship
   CouncilChina Scholarship Council [201706225023]
FX This work was supported by the Fundamental Research Funds of Shandong
   University (21520079614029), Shandong Provincial Natural Science
   Foundation of China (Grant number ZR2015PH036) and China Scholarship
   Council (No.201706225023).
CR Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Flack JM, 2020, TRENDS CARDIOVAS MED, V30, P160, DOI 10.1016/j.tcm.2019.05.003
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hilliard LM, 2013, CURR HYPERTENS REP, V15, P71, DOI 10.1007/s11906-012-0319-y
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Johnson K, 2020, ASS RATE ANGIOTENSIN, DOI [10.1101/2020.05.31.20118802, DOI 10.1101/2020.05.31.20118802]
   Kaparianos A, 2011, CURR MED CHEM, V18, P3506, DOI 10.2174/092986711796642562
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lakshmanan AP, 2012, MOL CELL ENDOCRINOL, V348, P104, DOI 10.1016/j.mce.2011.07.041
   Li YC, 2017, INT J CARDIOL, V227, P516, DOI 10.1016/j.ijcard.2016.10.110
   Liang WN, 2004, EMERG INFECT DIS, V10, P25, DOI 10.3201/eid1001.030553
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xie XD, 2006, LIFE SCI, V78, P2166, DOI 10.1016/j.lfs.2005.09.038
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
NR 17
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD NOV
PY 2020
VL 24
IS 21
BP 12879
EP 12881
DI 10.1111/jcmm.15850
EA SEP 2020
PG 3
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA OV1EP
UT WOS:000569981600001
PM 32942339
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Jeste, S
   Hyde, C
   Distefano, C
   Halladay, A
   Ray, S
   Porath, M
   Wilson, RB
   Thurm, A
AF Jeste, S.
   Hyde, C.
   Distefano, C.
   Halladay, A.
   Ray, S.
   Porath, M.
   Wilson, R. B.
   Thurm, A.
TI Changes in access to educational and healthcare services for individuals
   with intellectual and developmental disabilities during COVID-19
   restrictions
SO JOURNAL OF INTELLECTUAL DISABILITY RESEARCH
LA English
DT Article
DE Autism; COVID-19; Genetics; Intellectual disability; Parents
ID DE-NOVO MUTATIONS; AUTISM; CHILDREN
AB Background COVID-19 restrictions have significantly limited access to in-person educational and healthcare services for all, including individuals with intellectual and developmental disabilities (IDDs). The objectives of this online survey that included both national and international families were to capture changes in access to healthcare and educational services for individuals with IDDs that occurred shortly after restrictions were initiated and to survey families on resources that could improve services for these individuals. Methods This was an online survey for caregivers of individuals with (1) a genetic diagnosis and (2) a neurodevelopmental diagnosis, including developmental delay, intellectual disability, autism spectrum disorder or epilepsy. The survey assessed (1) demographics, (2) changes in access to educational and healthcare services and (3) available and preferred resources to help families navigate the changes in service allocation. Results Of the 818 responses (669 within the USA and 149 outside of the USA), most families reported a loss of at least some educational or healthcare services. Seventy-four per cent of parents reported that their child lost access to at least one therapy or education service, and 36% of respondents lost access to a healthcare provider. Only 56% reported that their child received at least some continued services through tele-education. Those that needed to access healthcare providers did so primarily through telemedicine. Telehealth (both tele-education and telemedicine) was reported to be helpful when available, and caregivers most often endorsed a need for an augmentation of these remote delivery services, such as 1:1 videoconference sessions, as well as increased access to 1:1 aides in the home. Conclusions COVID-19 restrictions have greatly affected access to services for individuals with syndromic IDDs. Telehealth may provide opportunities for delivery of care and education in a sustainable way, not only as restrictions endure but also after they have been lifted.
C1 [Jeste, S.; Hyde, C.; Distefano, C.; Wilson, R. B.] Univ Calif Los Angeles, Semel Inst Neurosci, 760 Westwood Plaza,Room A7-489, Los Angeles, CA 90095 USA.
   [Halladay, A.] Autism Sci Fdn, New York, NY USA.
   [Halladay, A.] Rutgers State Univ, Dept Pharmacol & Toxicol, Newark, NJ USA.
   [Ray, S.; Porath, M.] The Mighty, Glendale, CA USA.
   [Thurm, A.] NIMH, Neurodev & Behav Phenotyping Serv, NIH, DHHS, Bethesda, MD 20892 USA.
RP Jeste, S (corresponding author), Univ Calif Los Angeles, Semel Inst Neurosci, 760 Westwood Plaza,Room A7-489, Los Angeles, CA 90095 USA.
EM sjeste@mednet.ucla.edu
OI Thurm, Audrey/0000-0002-0489-9485; Hyde, Carly/0000-0001-7935-5784
CR Aman MG, 2020, J CHILD ADOL PSYCHOP, V30, P280, DOI 10.1089/cap.2020.0081
   Arora S, 2011, NEW ENGL J MED, V364, P2199, DOI 10.1056/NEJMoa1009370
   Boulet SL, 2009, ARCH PEDIAT ADOL MED, V163, P19, DOI 10.1001/archpediatrics.2008.506
   Centers for Disease Control and Prevention, 2020, COR DIS PEOPL DEV BE
   CRISIS AFAR, 2020, CORONAVIRUS HLTH IMP
   Dibner K. A., 2020, JAMA-J AM MED ASSOC, P833
   Eshraghi AA, 2020, LANCET PSYCHIAT, V7, P481, DOI 10.1016/S2215-0366(20)30197-8
   Fernandez BA, 2017, DIALOGUES CLIN NEURO, V19, P353
   Jeste SS, 2011, CURR OPIN NEUROL, V24, P132, DOI 10.1097/WCO.0b013e3283446450
   Jeste SS, 2015, J CHILD NEUROL, V30, P1963, DOI 10.1177/0883073815601501
   Liptak GS, 2006, J AUTISM DEV DISORD, V36, P871, DOI 10.1007/s10803-006-0119-9
   Mazurek MO, 2016, PEDIATRICS, V56, P247, DOI DOI 10.1177/0009922816648288
   Muhle R, 2004, PEDIATRICS, V113, pE472, DOI 10.1542/peds.113.5.e472
   Neale BM, 2012, NATURE, V485, P242, DOI 10.1038/nature11011
   Rametta S., 2020, NEUROLOGY, P1257
   Rodriguez K, 2020, BEHAV ANAL PRACT, V13, P291, DOI 10.1007/s40617-020-00429-8
   Sanders SJ, 2012, NATURE, V485, P237, DOI 10.1038/nature10945
   The Mighty, 2020, MAK HLTH PEOPL
   Tye C, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00438
NR 19
TC 0
Z9 0
U1 7
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0964-2633
EI 1365-2788
J9 J INTELL DISABIL RES
JI J. Intell. Disabil. Res.
PD NOV
PY 2020
VL 64
IS 11
BP 825
EP 833
DI 10.1111/jir.12776
EA SEP 2020
PG 9
WC Education, Special; Genetics & Heredity; Clinical Neurology; Psychiatry;
   Rehabilitation
SC Education & Educational Research; Genetics & Heredity; Neurosciences &
   Neurology; Psychiatry; Rehabilitation
GA OB9LU
UT WOS:000569833500001
PM 32939917
OA Bronze
DA 2021-01-01
ER

PT J
AU Loft, ND
   Halling, AS
   Iversen, L
   Vestergaard, C
   Deleuran, M
   Rasmussen, MK
   Zachariae, C
   Thyssen, JP
   Skov, L
AF Loft, N. D.
   Halling, A. -S.
   Iversen, L.
   Vestergaard, C.
   Deleuran, M.
   Rasmussen, M. K.
   Zachariae, C.
   Thyssen, J. P.
   Skov, L.
TI Concerns related to the coronavirus disease 2019 pandemic in adult
   patients with atopic dermatitis and psoriasis treated with systemic
   immunomodulatory therapy: a Danish questionnaire survey
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Letter; Early Access
C1 [Loft, N. D.; Halling, A. -S.; Zachariae, C.; Thyssen, J. P.; Skov, L.] Univ Copenhagen, Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Hellerup, Denmark.
   [Loft, N. D.; Halling, A. -S.; Zachariae, C.; Thyssen, J. P.; Skov, L.] Herlev & Gentofte Hosp, Copenhagen Res Grp Inflammatory Skin CORGIS, Hellerup, Denmark.
   [Iversen, L.; Vestergaard, C.; Deleuran, M.; Rasmussen, M. K.] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark.
RP Loft, ND (corresponding author), Univ Copenhagen, Herlev & Gentofte Hosp, Dept Dermatol & Allergy, Hellerup, Denmark.; Loft, ND (corresponding author), Herlev & Gentofte Hosp, Copenhagen Res Grp Inflammatory Skin CORGIS, Hellerup, Denmark.
EM nikolai.dyrberg.loft@regionh.dk
RI Thyssen, Jacob/ABD-8517-2020
OI Vestergaard, Christian/0000-0001-6485-3158; Skov,
   Lone/0000-0002-4784-9680; Iversen, Lars/0000-0003-1816-4508; Rasmussen,
   Mads Kirchheiner/0000-0001-8242-9377; Loft, Nikolai
   Dyrberg/0000-0002-2950-3280; Thyssen, Jacob
   Pontoppidan/0000-0003-3770-1743
CR Burlando M, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1770165
   Carugno A, 2020, J EUR ACAD DERMATOL, V34, pE433, DOI 10.1111/jdv.16552
   Conforti C, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13298
   Fougerousse AC, 2020, J EUR ACAD DERMATOL, DOI 10.1111/jdv.16761
   Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Ricardo JW, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13687
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
NR 8
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
DI 10.1111/jdv.16863
EA SEP 2020
PG 3
WC Dermatology
SC Dermatology
GA NP1SY
UT WOS:000569962200001
PM 32780487
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kasilingam, D
   Prabhakaran, SPS
   Rajendran, DK
   Rajagopal, V
   Kumar, TS
   Soundararaj, A
AF Kasilingam, Dharun
   Sathiya Prabhakaran, Sakthivel Puvaneswaran
   Rajendran, Dinesh Kumar
   Rajagopal, Varthini
   Santhosh Kumar, Thangaraj
   Soundararaj, Ajitha
TI Exploring the growth of COVID-19 cases using exponential modelling
   across 42 countries and predicting signs of early containment using
   machine learning
SO TRANSBOUNDARY AND EMERGING DISEASES
LA English
DT Article; Early Access
DE coronavirus; COVID-19; exponential growth model; machine learning;
   pandemic; SARS-CoV-2
ID INFLUENZA; CHINA
AB The coronavirus disease 2019 (COVID-19) pandemic spread by the single-stranded RNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to the seventh generation of the coronavirus family. Following an unusual replication mechanism, its extreme ease of transmissivity has put many countries under lockdown. With the uncertainty of developing a cure/vaccine for the infection in the near future, the onus currently lies on healthcare infrastructure, policies, government activities, and behaviour of the people to contain the virus. This research uses exponential growth modelling studies to understand the spreading patterns of SARS-CoV-2 and identifies countries that showed early signs of containment until March 26, 2020. Predictive supervised machine learning models are built using infrastructure, environment, policies, and infection-related independent variables to predict early containment. COVID-19 infection data across 42 countries are used. Logistic regression results show a positive significant relationship between healthcare infrastructure and lockdown policies, and signs of early containment. Machine learning models based on logistic regression, decision tree, random forest, and support vector machines are developed and show accuracies between 76.2% and 92.9% to predict early signs of infection containment. Other policies and the decisions taken by countries to contain the infection are also discussed.
C1 [Kasilingam, Dharun] MICA Sch Ideas, Mkt Analyt, Digital Platform & Strategies, Ahmadabad, Gujarat, India.
   [Sathiya Prabhakaran, Sakthivel Puvaneswaran] Natl Inst Technol, Energy & Environm Engn, Tiruchirappalli, India.
   [Rajendran, Dinesh Kumar] Natl Inst Technol, Dept Mech Engn, Ponda, Goa, India.
   [Rajagopal, Varthini] Govt Coll Engn, Dept Mech Engn, Srirangam, India.
   [Santhosh Kumar, Thangaraj] JIPMER, Dept Paediat, Pondicherry, India.
   [Soundararaj, Ajitha] SRM Univ AP, Sch Management, Amaravati, India.
RP Rajendran, DK (corresponding author), Natl Inst Technol, Dept Mech Engn, Ponda, Goa, India.
EM dineshrd453@gmail.com
OI RAJENDRAN, DINESH KUMAR/0000-0003-1801-805X; Kasilingam, Dharun
   Lingam/0000-0003-0624-7971; Soundararaj, Ajitha/0000-0003-2072-9280;
   Prabhakaran, Sathiya/0000-0003-2991-372X
CR Actuaries M. B. A., 2010, POTENTIAL IMPACT PAN
   Bambas A., 2000, HLTH HUMAN DEV NEW G
   Barbiere C., 2020, EURACTIV COVID 19 FR
   BBC, 2020, BBC
   Beaubien J., 2020, GOATS SODA S KOREA R
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Breiman L., 1984, INT GROUP, V432, P151
   Brittany Shammas E., 2020, WASHINGTON POST
   Callaway B. E., 2020, NATURE, V576, P482
   Carstensen T., 2020, WORLD DENMARK TAKES
   CDCP, 2020, CDCP TRAV HLTH NOT
   Chen WH, 2020, PHYTOKEYS, P1, DOI 10.3897/phytokeys.157.56842
   Chowell G, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0659
   Daw MA, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101634
   Dey SK, 2020, J MED VIROL, V92, P632, DOI 10.1002/jmv.25743
   Dhungana HN, 2020, INT J INFECT DIS, V94, P72, DOI 10.1016/j.ijid.2020.02.024
   Dicker RC, 2006, PRINCIPLES EPIDEMIOL
   Dietz K, 2002, MATH BIOSCI, V180, P1, DOI 10.1016/S0025-5564(02)00122-0
   Dincer I., 2010, GREEN ENERGY TECHNOL, V31, P643, DOI [10.1007/978-1-4419-1017-2, DOI 10.1007/978-1-4419-1017-2]
   Diwanji S., 2020, STATISTICA PRECAUTIO
   Duddu P., 2020, FOCUS COVID 19 IRAN
   East M., 2020, ECLINICALMEDICINE, V19, P100300
   Euractiv, 2020, EUR GREE TOT LOCJD A
   Fihlani P., 2020, BBC CORONAVIRUS AFRI
   Fisher D., 2020, WHY SINGAPORE ISNT C
   Fisher D., 2020, PRINT WHY SINGAPORE
   Flake GW, 2002, MACH LEARN, V46, P271, DOI 10.1023/A:1012474916001
   Garda World, 2020, GARD WORLD MAL NEW T
   Garda World, 2020, GARD WORLD NETH GOV
   Gary R. S., 2020, HBR LESSONS ITALYS R
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   GC, 2020, GC PRIM MIN ANN NEW
   Gesley J., 2020, LIB C EM MAN EP GOV
   Gherasim C., 2020, EUOBSERVER ROMANIAS
   Grafton, 2020, GRAFT GRAFT RESP COV
   Hastie T., 2009, ELEMENTS STAT LEARNI, V2nd, DOI 10.1007/b94608
   Itzwerth R., 2013, THESIS
   Kate Mayberry T. V., 2020, ALJAZEERA WHO TEST E
   Keeling MJ, 2009, BRIT MED BULL, V92, P33, DOI 10.1093/bmb/ldp038
   Kerkhove M. D. V., 2020, EPIDEMIC INTERVENTIO, P1, DOI 10.2471/BLT.11.097949
   Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118
   Keystone F., 2020, SWISSINFO CORONAVIRU
   Kondofersky I., 2018, BIOMETRICS, V74, P769
   Kyzer L., 2020, ICELAND REV STEPS TA
   LECESSIE S, 1992, APPL STAT-J ROY ST C, V41, P191
   Leung KY, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2018.0296
   Library Of Congress, 2020, AUSTR GOV TIGHT RULE
   Lin QY, 2020, INT J INFECT DIS, V93, P211, DOI 10.1016/j.ijid.2020.02.058
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Lomas N., 2020, TECH CRUNCH ISRAEL P
   Lowen AC, 2014, J VIROL, V88, P7692, DOI 10.1128/JVI.03544-13
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Ma JL, 2020, INFECT DIS MODEL, V5, P129, DOI 10.1016/j.idm.2019.12.009
   Ma YL, 2020, SCI TOTAL ENVIRON, V724, DOI 10.1016/j.scitotenv.2020.138226
   Maharaj S., 2012, CONTROLLING EPIDEMIC
   Master of Public Health, 2020, STAT QAT COR DIS 201
   Miller G, 2008, INFECT CONT HOSP EP, V29, P320, DOI 10.1086/529212
   MOH, 2014, MOH PAND READ RES PL
   Murrin S., 2018, OFFICE INSPECTOR GEN
   National Research Council, 2001, UND WEATH CLIM EC IN
   Nishiura H, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-15
   Norway Panorama, 2020, NORD PAG NORW GOV TA
   NPR, 2020, S KOR REIN OUTB WITH
   Nuzzo JB, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7707-z
   Nyoman Sutarsa A. P., 2020, CHANNEL NEWS ASIA CO
   Oliveira I., 2020, POLOLITICO PORTUGAL
   Pakistan, 2020, GULF NEWS 10 STEPS P
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Paweska JT, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005665
   Persoff J, 2018, J HOSP MED, V13, P713, DOI 10.12788/jhm.3073
   Petrosillo N., 2020, JANUARY 2020 ELSEVIE
   Pi B. R., 2020, LIFE LESSONS HIST LO, P1
   Piscitelli C., 2020, MSAN MEASURES TAKEN
   Porta M, 2008, DICT EPIDEMIOLOGY, P179
   Prem K., 2020, LANCET, V2667, P1
   Rajendran Dinesh Kumar, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00604-z
   Rashid H., SOCIAL DISTANCING EV
   Richard, 2020, UPS BATTERY CTR CORO
   Rodeny R., 2020, AM SOC MICROBIOLOGY, V24, P1
   Salute M. D., 2020, NUOVO CORONAVIRUS CO, P1
   Sameni R., 2020, MATH MODELING EPIDEM, P1
   Sattar S.B.A., 2020, BACTERIAL PNEUMONIA
   Sepkowitz K., 2020, CNN
   Sexton NR, 2016, J VIROL, V90, P7415, DOI 10.1128/JVI.00080-16
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Siettos CI, 2013, VIRULENCE, V4, P295, DOI 10.4161/viru.24041
   Silverman E. D., 2020, STATNEWS ECUADOR BEC
   Slovenija R., 2020, GOV SLOVENIJA
   The World Bank, 2020, PHYS PER 1000 PEOPL
   Thompson RN, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2019.0038
   Tosepu R, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138436
   U.S Embassy in Chile, 2020, US EMB CJIL GLOB LEV
   US Embassy, 2020, COVID 19
   Victor A. O., 2020, MATHEMATICAL PREDICT, DOI 10.13140/RG.2.2.12081.53600
   Weather Underground, 2020, WUND
   WHO, 2020, REP WHO CHIN JOINT M
   WHO, 2014, INF PREV CONTR EPID
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wimberly A., 2018, PANDEMIC PLANNING ES
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Wuhan L., 2020, LOCKED WUHAN WHY WE, P1
   Yong EL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.19706
   Yu D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180545
   Zhang J., 2020, INT J INFECT DIS, V75, P1
   Zhang S, 2020, INT J INFECT DIS, V93, P201, DOI 10.1016/j.ijid.2020.02.033
NR 105
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1865-1674
EI 1865-1682
J9 TRANSBOUND EMERG DIS
JI Transbound. Emerg. Dis.
DI 10.1111/tbed.13764
EA SEP 2020
PG 18
WC Infectious Diseases; Veterinary Sciences
SC Infectious Diseases; Veterinary Sciences
GA NP1EA
UT WOS:000569923400001
PM 32749759
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Tarfaoui, M
   Nachtane, M
   Goda, I
   Qureshi, Y
   Benyahia, H
AF Tarfaoui, M.
   Nachtane, M.
   Goda, I.
   Qureshi, Y.
   Benyahia, H.
TI Additive manufacturing in fighting against novel coronavirus COVID-19
SO INTERNATIONAL JOURNAL OF ADVANCED MANUFACTURING TECHNOLOGY
LA English
DT Article
DE COVID-19; Coronavirus; PPE; Frontline healthcare workers; Additive
   manufacturing; Face mask; Ventilators
ID RESPIRATORY VIRUSES; INFLUENZA-VIRUS; FACE SHIELDS; TRANSMISSION;
   EFFICACY; MASKS
AB Nowadays, COVID-19 also known as novel coronavirus has become a global pandemic by causing severe respiratory tract infections in humans without any definite treatment or vaccine. Therefore, disease control measures include slowing down or averting the transfer of this viral infection from person to person. Continuous efforts are carried out to avoid the transmission of this disease to frontline healthcare personnel using single-use personal protective equipment (PPE). However, a critical shortage in this equipment around the world is becoming an alarming concern. Therefore, it is vital to present a possible alternative to overcome the acute shortage of protective gear such as face masks against this infectious disease which can have universal accessibility and is easily available. Additive manufacturing (AM), also known as 3D printing, is a possible solution to overcome the shortage of protective gear and can play a vital role in supporting their conventional production supplies during this global pandemic situation. In this context, this paper provides a brief background study of COVID-19, its conventional preventive measure, and a detailed overview regarding the latest AM efforts including designers' providers and makers in the 3D printing community. Moreover, numerous inquiries and questions such as technical factors, testing recommendations and characterization methods and biological concerns such as biocompatibility and sterilization for the AM manufactured medical devices are addressed in this paper. In the end, two examples of AM medical devices, i.e., face mask and Ambu bag ventilator, are presented and studied through numerical simulations.
C1 [Tarfaoui, M.; Qureshi, Y.; Benyahia, H.] ENSTA Bretagne, IRDL UMR CNRS 6027, F-29200 Brest, France.
   [Nachtane, M.; Goda, I.] HESAM Univ, I2M Bordeaux, Arts & Metiers Inst Technol, Univ Bordeaux,CNRS,Bordeaux INP,INRAE, F-33400 Talence, France.
RP Tarfaoui, M (corresponding author), ENSTA Bretagne, IRDL UMR CNRS 6027, F-29200 Brest, France.; Nachtane, M (corresponding author), HESAM Univ, I2M Bordeaux, Arts & Metiers Inst Technol, Univ Bordeaux,CNRS,Bordeaux INP,INRAE, F-33400 Talence, France.
EM mostapha.tarfaoui@ensta-bretagne.fr; mourad.nachtane@u-bordeaux.fr;
   ibrahim.goda@u-bordeaux.fr; yumna.qureshi@ensta-bretagne.org;
   h.benyahia.dms@gmail.com
OI nachtane, mourad/0000-0001-7381-2331
CR [Anonymous], 2009, DIGIMAT USER DOCUMEN
   [Anonymous], 1997, DES CONTR GUID MED D
   [Anonymous], 2020, COVID 19 DIS NOV COR
   [Anonymous], 2014, PUBL WORKSH AMOF MED
   [Anonymous], 2020, APPL HAND SAN
   [Anonymous], 1998, FED REGISTER, V63, P64625
   [Anonymous], 2020, NAT I OCC SAF HLTH N
   Armani AM, 2020, NAT REV MATER, V5, P403, DOI 10.1038/s41578-020-0205-1
   Belhouideg S, 2020, INT J HEALTH PLAN M, V35, P1014, DOI 10.1002/hpm.3009
   BENTLEY CD, 1994, J AM DENT ASSOC, V125, P579, DOI 10.14219/jada.archive.1994.0093
   Centers for Disease Control and Prevention, 2020, SIT SUMM
   Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1073
   Choong YYC, 2020, NATURE REV MAT, P1
   CHRISTENSEN R P, 1991, General Dentistry, V39, P414
   Clifton W, 2020, CONSIDERATIONS CAUTI
   Cowling BJ, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.6.2000110
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1039, DOI 10.1001/jama.2020.1490
   Di Prima Matthew, 2015, 3D Print Med, V2, P1, DOI 10.1186/s41205-016-0005-9
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Farrier SL, 2006, BRIT DENT J, V200, P218, DOI 10.1038/sj.bdj.4813257
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Flanagan ST, 2020, ACAD RADIOL, V27, P905, DOI 10.1016/j.acra.2020.04.020
   Food and Drug Administration (FDA), 2017, TECHN CONS ADD MAN M
   Gerke S, 2020, NAT MED, V26, P1176, DOI 10.1038/s41591-020-0994-1
   Gondi S, 2020, LANCET, V395, pE90, DOI 10.1016/S0140-6736(20)31038-2
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   HAERI GB, 1980, CLIN ORTHOP RELAT R, P160
   Han QM, 2020, INFLUENZA OTHER RESP, V14, P470, DOI 10.1111/irv.12735
   Hand hygiene, HAND HYG
   Hu G, 2020, REGULATORY CONSIDERA
   HuiDS IAE, 2020, INT J INFECT DIS, V91, P264, DOI [10.1016/j.ijid.2020.01.009, DOI 10.1016/J.IJID.2020.01.009]
   International Organization for Standardization: ISO/IEC JTC 1, 2013, 109932013 ISOIEC
   Ishack S, 2020, AM J MED, V133, pE385, DOI 10.1016/j.amjmed.2020.04.002
   Jiang JC, 2020, MICROMACHINES-BASEL, V11, DOI 10.3390/mi11070633
   Jiang JC, 2018, J MANUF MATER PROC, V2, DOI 10.3390/jmmp2040064
   Johnson DF, 2009, CLIN INFECT DIS, V49, P275, DOI 10.1086/600041
   Kutter JS, 2018, CURR OPIN VIROL, V28, P142, DOI 10.1016/j.coviro.2018.01.001
   Larraneta E, 2020, 3D PRINTING ADDITIVE
   Leung NHL, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0843-2
   Lindsley WG, 2014, J OCCUP ENVIRON HYG, V11, P509, DOI 10.1080/15459624.2013.877591
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   Maclntyre CR, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h694
   Mehrotra P, 2020, JAMA HLTH FOR, V1, pe200553
   Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205
   Mueller T, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10124135
   Nachtane M, 2020, COMPOS STRUCT, V247, DOI 10.1016/j.compstruct.2020.112474
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Otter JA, 2016, J HOSP INFECT, V92, P235, DOI 10.1016/j.jhin.2015.08.027
   Patel RB, 2016, J OCCUP ENVIRON HYG, V13, P569, DOI 10.1080/15459624.2015.1043050
   Roosa K, 2020, INFECT DIS MODEL, V5, P256, DOI 10.1016/j.idm.2020.02.002
   Shiu EYC, 2019, CURR OPIN INFECT DIS, V32, P372, DOI 10.1097/QCO.0000000000000563
   Sophie Gallagher, 2020, INDEPENDENT
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Swennen GRJ, 2019, INT J ORAL MAXILLOFA
   Taledo J, 2020, INFECT PREVENTION CO
   Tellier R, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3707-y
   Tino R, 2020, COVID 19 ROLE 3D PRI
   U.S. Department of Health and Human Services, ISO10993 US DEP HHS
   Vordos N, 2020, SAFETY SCI, V130, DOI 10.1016/j.ssci.2020.104870
   WHO, 2020, MOD TRANSM VIR CAUS
   WHO, 2020, DIS OUTBREAK NE 0208
   WHO, 2020, SEV AC RESP SYNDR SA
   World Health Organization, 2020, RAT US PERS PROT EQ
   World Health Organization, 2020, MIDDL E RESP SYNDR C
   World Health Organization, 2020, ROLL UPD COR DIS COV
   Xiao JY, 2020, EMERG INFECT DIS, V26, P967, DOI 10.3201/eid2605.190994
   Xu X, 2020, EUR J NUCL MED MOL I, V47, P1275, DOI 10.1007/s00259-020-04735-9
   Zhang Y, 2020, IEEE J EM SEL TOP P, V8, P124, DOI 10.1109/JESTPE.2019.2946340
NR 69
TC 1
Z9 1
U1 5
U2 5
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268-3768
EI 1433-3015
J9 INT J ADV MANUF TECH
JI Int. J. Adv. Manuf. Technol.
PD OCT
PY 2020
VL 110
IS 11-12
BP 2913
EP 2927
DI 10.1007/s00170-020-06077-0
EA SEP 2020
PG 15
WC Automation & Control Systems; Engineering, Manufacturing
SC Automation & Control Systems; Engineering
GA NU0BQ
UT WOS:000570482300002
PM 32963417
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Peng, LH
   Tian, XF
   Shen, L
   Kuang, M
   Li, TB
   Tian, G
   Yang, JL
   Zhou, LQ
AF Peng, Lihong
   Tian, Xiongfei
   Shen, Ling
   Kuang, Ming
   Li, Tianbao
   Tian, Geng
   Yang, Jialiang
   Zhou, Liqian
TI Identifying Effective Antiviral Drugs Against SARS-CoV-2 by Drug
   Repositioning Through Virus-Drug Association Prediction
SO FRONTIERS IN GENETICS
LA English
DT Article
DE SARS-CoV-2; antiviral drugs; drug repositioning; virus-drug association;
   regularized least square; bipartite local model; neighbor association
   information
ID TARGET INTERACTION PREDICTION; INFECTION; COV
AB A new coronavirus called SARS-CoV-2 is rapidly spreading around the world. Over 16,558,289 infected cases with 656,093 deaths have been reported by July 29th, 2020, and it is urgent to identify effective antiviral treatment. In this study, potential antiviral drugs against SARS-CoV-2 were identified by drug repositioning through Virus-Drug Association (VDA) prediction. 96 VDAs between 11 types of viruses similar to SARS-CoV-2 and 78 small molecular drugs were extracted and a novel VDA identification model (VDA-RLSBN) was developed to find potential VDAs related to SARS-CoV-2. The model integrated the complete genome sequences of the viruses, the chemical structures of drugs, a regularized least squared classifier (RLS), a bipartite local model, and the neighbor association information. Compared with five state-of-the-art association prediction methods, VDA-RLSBN obtained the best AUC of 0.9085 and AUPR of 0.6630. Ribavirin was predicted to be the best small molecular drug, with a higher molecular binding energy of -6.39 kcal/mol with human angiotensin-converting enzyme 2 (ACE2), followed by remdesivir (-7.4 kcal/mol), mycophenolic acid (-5.35 kcal/mol), and chloroquine (-6.29 kcal/mol). Ribavirin, remdesivir, and chloroquine have been under clinical trials or supported by recent works. In addition, for the first time, our results suggested several antiviral drugs, such as FK506, with molecular binding energies of -11.06 and -10.1 kcal/mol with ACE2 and the spike protein, respectively, could be potentially used to prevent SARS-CoV-2 and remains to further validation. Drug repositioning through virus-drug association prediction can effectively find potential antiviral drugs against SARS-CoV-2.
C1 [Peng, Lihong; Tian, Xiongfei; Shen, Ling; Kuang, Ming; Zhou, Liqian] Hunan Univ Technol, Sch Comp Sci, Zhuzhou, Peoples R China.
   [Li, Tianbao; Tian, Geng; Yang, Jialiang] Geneis Beijing Co Ltd, Beijing, Peoples R China.
RP Peng, LH; Zhou, LQ (corresponding author), Hunan Univ Technol, Sch Comp Sci, Zhuzhou, Peoples R China.; Yang, JL (corresponding author), Geneis Beijing Co Ltd, Beijing, Peoples R China.
EM plhhnu@163.com; yanji@geneis.cn; zhoulq11@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [61803151]; Natural Science Foundation of
   Hunan ProvinceNatural Science Foundation of Hunan Province [2018JJ3570,
   2018JJ2461]
FX This research was funded by the National Natural Science Foundation of
   China (Grant No. 61803151) and Natural Science Foundation of Hunan
   Province (Grant Nos. 2018JJ3570 and 2018JJ2461).
CR Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bleakley K, 2009, BIOINFORMATICS, V25, P2397, DOI 10.1093/bioinformatics/btp433
   Bonaparte MI, 2005, P NATL ACAD SCI USA, V102, P10652, DOI 10.1073/pnas.0504887102
   Canese K., 2013, NCBI HDB
   Chen X, 2016, BRIEF BIOINFORM, V17, P696, DOI 10.1093/bib/bbv066
   Chen X, 2012, MOL BIOSYST, V8, P1970, DOI 10.1039/c2mb00002d
   Cobbs CS, 2002, CANCER RES, V62, P3347
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   de Ruyck Jerome, 2016, Adv Appl Bioinform Chem, V9, P1, DOI 10.2147/AABC.S105289
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Gao HN, 2013, NEW ENGL J MED, V368, P2277, DOI 10.1056/NEJMoa1305584
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0
   Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507
   Hayden FG, 2020, J INFECT DIS, V222, P1417, DOI 10.1093/infdis/jiaa029
   Hu H, 2018, RNA BIOL, V15, P797, DOI 10.1080/15476286.2018.1457935
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912
   Kaiser UB, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa148
   Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496
   Lan W, 2018, IEEE ACM T COMPUT BI, V15, P1774, DOI 10.1109/TCBB.2016.2586190
   Lan W, 2017, BIOINFORMATICS, V33, P458, DOI 10.1093/bioinformatics/btw639
   Lan W, 2016, NEUROCOMPUTING, V206, P50, DOI 10.1016/j.neucom.2016.03.080
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li J, 2016, ONCOTARGET, V7, P45584, DOI 10.18632/oncotarget.10052
   Liu HS, 2020, KNOWL-BASED SYST, V191, DOI 10.1016/j.knosys.2019.105261
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Peng L., 2017, SCI REP, V7, P1
   Peng LH, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00040
   Peng LH, 2017, IEEE J BIOMED HEALTH, V21, P561, DOI 10.1109/JBHI.2015.2513200
   Permpalung N, 2020, TRANSPLANTATION, V104, P1280, DOI 10.1097/TP.0000000000002985
   Sanche S, 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.02.07.20021154, DOI 10.1101/2020.02.07.20021154]
   Sayers EW, 2020, NUCLEIC ACIDS RES, V48, pD9, DOI 10.1093/nar/gkz899
   Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393
   van Laarhoven T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066952
   Wang C., 2020, BIORXIV, DOI [10.1101/2020.03.29.013490, DOI 10.1101/2020.03.29.013490]
   Wang F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08127-2
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689
   WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Xia Z, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S2-S6
   Zhang H., 2020, DEEP LEARNING BASED, DOI DOI 10.20944/PREPRINTS202002.0061.V1
   Zhang Z, 2020, VIROL SIN, V35, P330, DOI 10.1007/s12250-020-00203-8
   Zhao Q, 2018, MOL THER-NUCL ACIDS, V13, P464, DOI 10.1016/j.omtn.2018.09.020
   Zheng X., 2013, P 19 ACM SIGKDD INT
NR 49
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD SEP 16
PY 2020
VL 11
AR 577387
DI 10.3389/fgene.2020.577387
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA NY3CA
UT WOS:000576270900001
PM 33193695
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Calles, A
   Aparicio, MI
   Alva, M
   Bringas, M
   Gutierrez, N
   Soto, J
   Arregui, M
   Tirado, VC
   Alvarez, EL
   del Monte-Millan, M
   Massarrah, T
   Galera, M
   Alvarez, R
   Martin, M
AF Calles, Antonio
   Inmaculada Aparicio, Maria
   Alva, Manuel
   Bringas, Marianela
   Gutierrez, Natalia
   Soto, Javier
   Arregui, Marta
   Clara Tirado, Victoria
   Luis Alvarez, Enrique
   del Monte-Millan, Maria
   Massarrah, Tatiana
   Galera, Mar
   Alvarez, Rosa
   Martin, Miguel
TI Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary
   Hospital in Madrid
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE COVID-19; coronavirus; SARS-CoV-2; lung cancer; tocilizumab;
   multivariate; immunotherapy; targeted therapy
AB Background:Cancer patients represent a vulnerable population for COVID-19 illness. We aimed to analyze outcomes of lung cancer patients affected by COVID-19 in a tertiary hospital of a high-incidence region during the pandemic. Methods:We annotated 23 lung cancer patients consecutively diagnosed with COVID-19 at our institution (HGUGM; Madrid, Spain) between March 4th, 2020 and May 12th, 2020. Only patients with a confirmatory SARS-CoV-2 RT-PCR were included in the study. Results:All patients had at least 1 COVID-19 related symptom; cough (48%), shortness of breath (48%), fever (39%), and low-grade fever (30%) were the most common. Time from symptoms onset to first positive SARS-CoV-2 PCR was 5.5 days (range 1-17), with 13% of cases needed from a 2nd PCR to confirm diagnosis. There was a high variability on thoracic imaging findings, with multilobar pneumonia as the most commonly found pattern (74%). Main lab test abnormalities were low lymphocytes count (87%), high neutrophil to lymphocyte ratio -NLR- (78%), and elevated inflammatory markers: fibrinogen (91%), c-reactive protein -CRP- (87%), and D-dimer (70%). In our series, hospitalization rate was 74%, 39% of patients developed acute respiratory distress syndrome (ARDS), and the case-fatality rate was 35% (8/23). 87% of patients received anti-viral treatment (87% hydroxychloroquine, 74% lopinavir/ritonavir, 13% azithromycin), 43% corticosteroids, 26% interferon-beta, 4% tocilizumab, and 82% of hospitalized patients received anticoagulation. High-oxygen requirements were needed in 39% of patients, but only 1 pt was admitted for invasive MV and was discharged 42 days after admission. Multiple variables related to tumor status, clinical baseline conditions, and inflammation markers were associated with mortality but did not remain statistically significant in a multivariate model. In patients with lung cancer receiving systemic therapy (n= 242) incidence and mortality from COVID-19 were 4.5, and 2.1%, respectively, with no differences found by type of treatment. Conclusions:Lung cancer patients represent a vulnerable population for COVID-19, according to the high rate of hospitalization, onset of ARDS, and high mortality rate. Although larger series are needed, no differences in mortality were found by type of cancer treatment. Measures to minimize the risk of SARS-CoV-2 infection remain key to protect lung cancer patients.
C1 [Calles, Antonio; Inmaculada Aparicio, Maria; Alva, Manuel; Bringas, Marianela; Gutierrez, Natalia; Soto, Javier; Arregui, Marta; Clara Tirado, Victoria; Luis Alvarez, Enrique; del Monte-Millan, Maria; Massarrah, Tatiana; Galera, Mar; Alvarez, Rosa; Martin, Miguel] Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain.
   [Calles, Antonio; Luis Alvarez, Enrique; del Monte-Millan, Maria; Massarrah, Tatiana; Galera, Mar; Alvarez, Rosa; Martin, Miguel] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
   [del Monte-Millan, Maria; Massarrah, Tatiana; Martin, Miguel] CiberOnc, Madrid, Spain.
RP Calles, A (corresponding author), Hosp Gen Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain.; Calles, A (corresponding author), Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
EM antonio.calles@live.com
RI Calles, Antonio/O-4527-2018
OI Calles, Antonio/0000-0002-2547-1947
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Barlesi F, 2020, CANCER RES, V80, pCT403
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Cai H, 2020, LANCET RESP MED, V8, pE20, DOI 10.1016/S2213-2600(20)30117-X
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   del Amo J, 2020, ANN INTERN MED, pM20, DOI 10.7326/M20-3689
   Direccion General de Salud Publica, 2020, ACT 104 ENF COR COVI
   Fratino L, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00648
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Instituto de Salud Carlos III, 2020, MIN SAN EST ENE COVI
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Luo J, 2020, ANN ONCOL, V31, P1386, DOI 10.1016/j.annonc.2020.06.007
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zahorec R, 2001, Bratisl Lek Listy, V102, P5
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 34
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD SEP 16
PY 2020
VL 10
AR 1777
DI 10.3389/fonc.2020.01777
PG 12
WC Oncology
SC Oncology
GA NY2UG
UT WOS:000576250400001
PM 33042826
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ge, CL
   He, Y
AF Ge, Chenliang
   He, Yan
TI In Silico Prediction of Molecular Targets of Astragaloside IV for
   Alleviation of COVID-19 Hyperinflammation by Systems Network
   Pharmacology and Bioinformatic Gene Expression Analysis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; Astragaloside IV; hyperinflammation; network pharmacological;
   cytokine storms
ID CYTOKINE STORM; CELLS; SUPPRESSION; ACTIVATION; APOPTOSIS; SAPONINS;
   ADHESION; UPDATE
AB Introduction The overproduction of cytokines and chemokines caused by excessive and uncontrolled inflammation contributes to the development of COVID-19. Astragaloside IV is considered as an anti-inflammatory and antioxidant agent. This study aimed at undertaking a network pharmacology approach and bioinformatics analysis to uncover the pharmacological mechanisms of Astragaloside IV on COVID-19. Methods Potential targets of Astragaloside IV were screened from public databases. Differentially expressed genes (DEGs) in SARS-CoV-2 were screened using bioinformatics analysis on the Gene Expression Omnibus (GEO) datasets GSE147507. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were subsequently performed. The overlapping genes, GO terms and KEGG pathways between Astragaloside IV targets and SARS-CoV-2 DEGs were confirmed, and the location of overlapping targets in the key pathways was queried using KEGG Mapper. Results A total of 425 potential targets of Astragaloside IV were screened. Besides, a total of 546 DEGs were identified between SARS-CoV-2 infected samples and control samples, including 380 up-regulated and 166 down-regulated genes. There was a significant overlap in GO terms and KEGG pathways between Astragaloside IV targets and SARS-CoV-2 DEGs. The shared genes included MMP13, NLRP3, TRIM21, GBP1, ADORA2A, PTAFR, TNF, MLNR, IL1B, NFKBIA, ADRB2, and IL6. Conclusions This study is the first to propose Astragaloside IV as a new drug candidate for alleviating hyper-inflammation in COVID-19 patients. Besides, the key targets and pathways may reveal the main pharmacological mechanism of Astragaloside IV in the treatment of COVID-19.
C1 [Ge, Chenliang; He, Yan] Guangxi Med Univ, Affiliated Hosp 1, Dept Geriatr Cardiol, Nanning, Peoples R China.
   [Ge, Chenliang] Univ South China, Affiliated Hosp 1, Dept Cardiol, Hengyang, Peoples R China.
RP He, Y (corresponding author), Guangxi Med Univ, Affiliated Hosp 1, Dept Geriatr Cardiol, Nanning, Peoples R China.
EM hyxjwxy@126.com
CR Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Cao Qing-Wei, 2019, Zhongguo Zhong Yao Za Zhi, V44, P2813, DOI 10.19540/j.cnki.cjcmm.20190412.201
   Chen P, 2011, EUR J PHARMACOL, V658, P168, DOI 10.1016/j.ejphar.2011.02.040
   Chen ZX, 2007, BIOINFORMATICS, V23, P321, DOI 10.1093/bioinformatics/btl609
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Davis AP, 2019, NUCLEIC ACIDS RES, V47, pD948, DOI 10.1093/nar/gky868
   Gong Amy G W, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5020046
   Howell MD, 2018, JAMA-J AM MED ASSOC, V319, P711, DOI 10.1001/jama.2018.0307
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang XP, 2017, CHIN J INTEGR MED, V23, P445, DOI 10.1007/s11655-015-1965-0
   Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766
   Jordan F, 2012, BRIEF FUNCT GENOMICS, V11, P497, DOI 10.1093/bfgp/els035
   Leng B, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/1082497
   Leng B, 2018, LIFE SCI, V209, P111, DOI 10.1016/j.lfs.2018.07.053
   Li L, 2017, FUND CLIN PHARMACOL, V31, P17, DOI 10.1111/fcp.12232
   Li M, 2013, EUR J PHARMACOL, V715, P189, DOI 10.1016/j.ejphar.2013.05.022
   Li M, 2012, NEUROCHEM INT, V60, P458, DOI 10.1016/j.neuint.2012.01.026
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Liu QS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101504
   Liu TL, 2019, EXP ANIM TOKYO, V68, P549, DOI 10.1538/expanim.19-0037
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794
   Murakami M, 2019, IMMUNITY, V50, P812, DOI 10.1016/j.immuni.2019.03.027
   Otasek D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1758-4
   Qi LW, 2006, J CHROMATOGR A, V1134, P162, DOI 10.1016/j.chroma.2006.08.085
   Ramanathan K, 2020, LANCET RESP MED, V8, P518, DOI 10.1016/S2213-2600(20)30121-1
   Ren S, 2013, J TRADIT CHIN MED, V33, P413, DOI 10.1016/S0254-6272(13)60189-2
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Shang L, 2011, J PHARM PHARMACOL, V63, P688, DOI 10.1111/j.2042-7158.2011.01258.x
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shen YC, 1998, EUR J PHARMACOL, V343, P79, DOI 10.1016/S0014-2999(97)01519-7
   Song MT, 2018, ACTA PHARMACOL SIN, V39, P1559, DOI 10.1038/aps.2017.208
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang CJ, 2020, PHYTOMEDICINE, V67, DOI 10.1016/j.phymed.2019.153155
   Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019
   Wang X, 2017, NUCLEIC ACIDS RES, V45, pW356, DOI 10.1093/nar/gkx374
   Wang XL, 2018, DRUG DES DEV THER, V12, P2971, DOI 10.2147/DDDT.S174058
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xie WD, 2012, J ETHNOPHARMACOL, V140, P345, DOI 10.1016/j.jep.2012.01.027
   Xu MJ, 2013, PHYTOMEDICINE, V20, P1105, DOI 10.1016/j.phymed.2013.05.004
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang QY, 2012, CHIN J INTEGR MED, V18, P235, DOI 10.1007/s11655-012-1022-1
   Yao ZJ, 2016, J COMPUT AID MOL DES, V30, P413, DOI 10.1007/s10822-016-9915-2
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang J, 2020, FEMS MICROBIOL LETT, V367, DOI 10.1093/femsle/fnaa007
   Zhang YY, 2006, J CARDIOVASC PHARM, V47, P190, DOI 10.1097/01.fjc.0000199683.43448.64
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
   Zhuang Z, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01388
NR 54
TC 0
Z9 0
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 16
PY 2020
VL 11
AR 556984
DI 10.3389/fphar.2020.556984
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY2XQ
UT WOS:000576259500001
PM 33041797
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Garcia-Menaya, JM
   Cordobes-Duran, C
   Rangel-Mayoral, JF
   Garcia-Martin, E
   Agundez, JAG
AF Miguel Garcia-Menaya, Jesus
   Cordobes-Duran, Concepcion
   Francisco Rangel-Mayoral, Juan
   Garcia-Martin, Elena
   Agundez, Jose A. G.
TI Outcomes and Laboratory and Clinical Findings of Asthma and Allergic
   Patients Admitted With Covid-19 in a Spanish University Hospital
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE coronavirus disease 2019; severe acute respiratory syndrome coronavirus
   2; asthma; allergy; clinical outcome
ID CORONAVIRUS; PNEUMONIA
AB Individual susceptibility and clinical outcome of Covid-19 are variable and mortality is also very variable across countries, being particularly high in Spain. Comorbidities might increase the risk for less favourable outcomes, but it has been reported that patients with antecedents of asthma or allergic diseases were under-represented among hospitalized Covid-19 patients. Aiming to compare the clinical evolution of patients with antecedents of asthma or allergic diseases and patients without these antecedents, we analyzed a series of 113 consecutive patients with Covid-19 in a regional hospital in Spain. We collected and analyzed the putative effect of the 16 most common co-morbidities, previous treatment with 33 drug classes, symptoms, radiological, and laboratory findings at admission and drug therapy after admission. Predictors of long hospital stays were older age (P = 0.002), low oxygen saturation (P = 0.001) and bilateral radiological findings at admission (P = 0.023). Predictors of Intensive Care Unit (ICU) admission were the previous use of calcium-channel blockers (P = 0.005), proton pump inhibitors (P = 0.017), low oxygen saturation (P = 0.002), high leukocyte count (P = 0.011), and high D-dimer values (P = 0.005). Predictors of mortality were older age (P = 0.001), antecedents of cerebrovascular disorders (P = 0.034), previous use of oral anticoagulants (P = 0.009) or selective serotonin reuptake inhibitors (P = 0.003), and increased levels of interleukin-6 (P = 0.001). Patients with antecedents of allergic diseases were about ten years younger (P = 0.003) and had fewer comorbidities (P = 0.026) than the rest of the patients. In conclusion, antecedents of allergic diseases might influence hospitalization risk in relatively young patients.
C1 [Miguel Garcia-Menaya, Jesus] ARADyAL Inst Salud Carlos III, Allergy Serv, Badajoz Univ Hosp, Badajoz, Spain.
   [Cordobes-Duran, Concepcion] ARADyAL Inst Salud Carlos III, Allergy Serv, Hosp Don Benito, Don Benito, Spain.
   [Francisco Rangel-Mayoral, Juan] Badajoz Univ Hosp, Hosp Pharm Serv, Badejoz, Spain.
   [Garcia-Martin, Elena; Agundez, Jose A. G.] ARADyAL Inst Salud Carlos III, Univ Inst Mol Pathol Biomarkers, UNEx, Caceres, Spain.
RP Garcia-Menaya, JM (corresponding author), ARADyAL Inst Salud Carlos III, Allergy Serv, Badajoz Univ Hosp, Badajoz, Spain.
EM jesusmiguelgarciamenaya@gmail.com
RI Garcia-Martin, Elena/H-9828-2016
OI Garcia-Martin, Elena/0000-0002-8094-046X
FU Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Madrid,
   SpainInstituto de Salud Carlos III [RETICS RD16/0006/0004, PI15/00303,
   PI18/00540]; Junta de Extremadura, Merida, Spain [GR18145, IB16170];
   FEDER fundsEuropean Union (EU)
FX This work was supported in part by Grants RETICS RD16/0006/0004
   (ARADyAL), PI15/00303, and PI18/00540 from Fondo de Investigacion
   Sanitaria, Instituto de Salud Carlos III, Madrid, Spain and GR18145 and
   IB16170 from Junta de Extremadura, Me ' rida, Spain. Partially funded
   with FEDER funds.
CR Bradding P, 2020, J ALLERGY CLIN IMMUN, V146, P208, DOI 10.1016/j.jaci.2020.05.013
   Ceylan Z, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.138817
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Gaig P, 2004, ALERGOL INMUNOL CLIN, V19, P68
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106
   Halpin DMG, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01009-2020
   Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3
   Hegde S, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0324-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009
   Johnston SL, 2020, ALLERGY, V75, P1543, DOI 10.1111/all.14348
   Lechien JR, 2020, J INTERN MED, V288, P335, DOI 10.1111/joim.13089
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Lindsley AW, 2020, J ALLERGY CLIN IMMUN, V146, P1, DOI 10.1016/j.jaci.2020.04.021
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Liu F, 2020, INT J INFECT DIS, V95, P183, DOI 10.1016/j.ijid.2020.03.013
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maes T, 2020, AM J RESP CRIT CARE, V202, P8, DOI 10.1164/rccm.202005-1651ED
   Mahdavinia M, 2020, J ALLER CL IMM-PRACT, V8, P2388, DOI 10.1016/j.jaip.2020.05.006
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Moorthy A, 2020, INT J RHEUM DIS, V23, P849, DOI 10.1111/1756-185X.13883
   Niedzwiedz CL, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01640-8
   Pennington Emily, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc002
   Peters MC, 2020, AM J RESP CRIT CARE, V202, P83, DOI 10.1164/rccm.202003-0821OC
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Quirce S, 2011, J INVEST ALLERG CLIN, V21, P466
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sajuthi Satria P, 2020, bioRxiv, DOI 10.1101/2020.04.09.034454
   Solaimanzadeh I, 2020, CUREUS, V12, DOI 10.7759/cureus.8069
   Sotgiu G, 2020, ALLERGY, V75, P1813, DOI 10.1111/all.14327
   Spiteri G, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.9.2000178
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Wang DW, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02895-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhao XY, 2020, BMC INFECT DIS, V20, DOI [10.1186/s12872-020-01652-5, 10.1186/s12879-020-05010-w]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 48
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 16
PY 2020
VL 11
AR 570721
DI 10.3389/fphar.2020.570721
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY2WY
UT WOS:000576257700001
PM 33041811
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mandal, N
   De, NY
   Jana, P
   Sannigrahi, A
   Chattopadhyay, K
AF Mandal, Narattam
   De, Nayan
   Jana, Pulak
   Sannigrahi, Achinta
   Chattopadhyay, Krishnananda
TI Correlation between CNS Tuberculosis and the COVID-19 Pandemic: The
   Neurological and Therapeutic Insights
SO ACS CHEMICAL NEUROSCIENCE
LA English
DT Article
DE SARS-CoV-2; neuroinvasivness; trained immunity; CNS tuberculosis
AB The recent outbreak of Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) from Wuhan, China, was caused by a single-stranded RNA virus which has kept the entire world stranded. The outbreak was first diagnosed with respiratory illness, but recent findings of acute necrotizing hemorrhage of brain, brain encephalopathy, and the presence of the virus in the cerebrospinal fluid (CSF) have unveiled its neuroinvasivness. Various clinical features related to the central nervous system (CNS) and peripheral nervous system (PNS) due to COVID-19 infection are now identified. We demonstrate here an apparent similarity in neurological disorders of COVID-19 with CNS tuberculosis, which suggests that some anti-tubercular drugs may be used as therapeutic agents against COVID-19 infection.
C1 [Mandal, Narattam; De, Nayan; Jana, Pulak; Sannigrahi, Achinta; Chattopadhyay, Krishnananda] CSIR Indian Inst Chem Biol, Struct Biol & Bioinformat Div, Kolkata 700032, India.
RP Sannigrahi, A; Chattopadhyay, K (corresponding author), CSIR Indian Inst Chem Biol, Struct Biol & Bioinformat Div, Kolkata 700032, India.
EM sannigrahiachinta@gmail.com; krish@iicb.res.in
OI Chattopadhyay, Krishnananda/0000-0002-1449-8909
CR Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Rock RB, 2008, CLIN MICROBIOL REV, V21, P243, DOI 10.1128/CMR.00042-07
   Sannigrahi A, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-1115-x
   Sannigrahi A, 2019, ACS CHEM BIOL, V14, P1601, DOI 10.1021/acschembio.9b00327
   Sharma A, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2720-9
NR 6
TC 0
Z9 0
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7193
J9 ACS CHEM NEUROSCI
JI ACS Chem. Neurosci.
PD SEP 16
PY 2020
VL 11
IS 18
BP 2789
EP 2792
DI 10.1021/acschemneuro.0c00546
PG 4
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences
   & Neurology
GA NU0ZU
UT WOS:000573370200003
PM 32880441
DA 2021-01-01
ER

PT J
AU ul Qamar, MT
   Shahid, F
   Aslam, S
   Ashfaq, UA
   Aslam, S
   Fatima, I
   Fareed, MM
   Zohaib, A
   Chen, LL
AF Tahir ul Qamar, Muhammad
   Shahid, Farah
   Aslam, Sadia
   Ashfaq, Usman Ali
   Aslam, Sidra
   Fatima, Israr
   Fareed, Muhammad Mazhar
   Zohaib, Ali
   Chen, Ling-Ling
TI Reverse vaccinology assisted designing of multiepitope-based subunit
   vaccine against SARS-CoV-2
SO INFECTIOUS DISEASES OF POVERTY
LA English
DT Article
DE SARS-CoV-2; COVID-19; Structural protein; Epitope; Vaccine;
   Multiepitope-based subunit vaccine; Immunoinformatics
ID RESPIRATORY SYNDROME CORONAVIRUS; EPITOPE-BASED DIAGNOSTICS; CODON
   USAGE; MERS-COV; DE-NOVO; PROTEIN; PREDICTION; WEB; SERVER; SARS
AB Background Coronavirus disease 2019 (COVID-19) linked with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause severe illness and life-threatening pneumonia in humans. The current COVID-19 pandemic demands an effective vaccine to acquire protection against the infection. Therefore, the present study was aimed to design a multiepitope-based subunit vaccine (MESV) against COVID-19. Methods Structural proteins (Surface glycoprotein, Envelope protein, and Membrane glycoprotein) of SARS-CoV-2 are responsible for its prime functions. Sequences of proteins were downloaded from GenBank and several immunoinformatics coupled with computational approaches were employed to forecast B- and T- cell epitopes from the SARS-CoV-2 highly antigenic structural proteins to design an effective MESV. Results Predicted epitopes suggested high antigenicity, conserveness, substantial interactions with the human leukocyte antigen (HLA) binding alleles, and collective global population coverage of 88.40%. Taken together, 276 amino acids long MESV was designed by connecting 3 cytotoxic T lymphocytes (CTL), 6 helper T lymphocyte (HTL) and 4 B-cell epitopes with suitable adjuvant and linkers. The MESV construct was non-allergenic, stable, and highly antigenic. Molecular docking showed a stable and high binding affinity of MESV with human pathogenic toll-like receptors-3 (TLR3). Furthermore, in silico immune simulation revealed significant immunogenic response of MESV. Finally, MEV codons were optimized for its in silico cloning into theEscherichia coliK-12 system, to ensure its increased expression. Conclusion The MESV developed in this study is capable of generating immune response against COVID-19. Therefore, if designed MESV further investigated experimentally, it would be an effective vaccine candidate against SARS-CoV-2 to control and prevent COVID-19.
C1 [Tahir ul Qamar, Muhammad; Chen, Ling-Ling] Guangxi Univ, Coll Life Sci & Technol, Nanning, Peoples R China.
   [Shahid, Farah; Ashfaq, Usman Ali; Aslam, Sidra; Fatima, Israr; Fareed, Muhammad Mazhar] Govt Coll Univ Faisalabad GCUF, Dept Bioinformat & Biotechnol, Faisalabad, Pakistan.
   [Aslam, Sadia] Jinnah Hosp, Lahore, Pakistan.
   [Zohaib, Ali] Natl Univ Sci & Technol NUST, Atta ur Rahman Sch Appl Biosci ASAB, Dept Healthcare Biotechnol, Islamabad, Pakistan.
RP Chen, LL (corresponding author), Guangxi Univ, Coll Life Sci & Technol, Nanning, Peoples R China.; Ashfaq, UA (corresponding author), Govt Coll Univ Faisalabad GCUF, Dept Bioinformat & Biotechnol, Faisalabad, Pakistan.
EM usmancemb@gmail.com; llchen@mail.hzau.edu.cn
RI aslam, sidra/AAT-4467-2020; Qamar, Muhammad Tahir ul/E-5803-2015
OI Qamar, Muhammad Tahir ul/0000-0003-4832-4250
FU Starting Research Grant for High-level Talents from Guangxi University
   and Postdoctoral research platform grant of Guangxi University
FX This work was supported by the Starting Research Grant for High-level
   Talents from Guangxi University and Postdoctoral research platform grant
   of Guangxi University.
CR Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   Adhikari UK, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6718083
   Ahmad B, 2019, MICROB PATHOGENESIS, V132, P243, DOI 10.1016/j.micpath.2019.05.010
   Alamri MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1782768
   Alsaadi EAJ, 2019, FUTURE VIROL, V14, P275, DOI 10.2217/fvl-2018-0144
   Amer H, 2018, INT J INFECT DIS, V71, P113, DOI 10.1016/j.ijid.2018.04.001
   Arai R, 2001, PROTEIN ENG, V14, P529, DOI 10.1093/protein/14.8.529
   Ashfaq UA, 2016, VIRAL IMMUNOL, V29, P436, DOI 10.1089/vim.2016.0033
   Bacchetta R, 2005, AUTOIMMUN REV, V4, P491, DOI 10.1016/j.autrev.2005.04.005
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Benson DA, 2008, NUCLEIC ACIDS RES, V36, pD25, DOI 10.1093/nar/gkm929
   Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163
   Blaszczyk M, 2013, NUCLEIC ACIDS RES, V41, pW406, DOI 10.1093/nar/gkt462
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cockrell AS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28900-1
   COOPER NR, 1984, J INVEST DERMATOL, V83, pS121, DOI 10.1111/1523-1747.ep12281847
   Cotten M, 2014, MBIO, V5, DOI 10.1128/mBio.01062-13
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   DeLano W.L., 2002, PYMOL OPEN SOURCE MO, P82
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4
   Douglas MG, 2018, VIROLOGY, V517, P98, DOI 10.1016/j.virol.2017.12.006
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Durdagi S, 2018, J MOL GRAPH MODEL, V85, P122, DOI 10.1016/j.jmgm.2018.07.010
   FIESER TM, 1987, P NATL ACAD SCI USA, V84, P8568, DOI 10.1073/pnas.84.23.8568
   Gasteiger E., 2005, PROTEOMICS PROTOCOLS
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458
   Hoover DM, 2003, ANTIMICROB AGENTS CH, V47, P2804, DOI 10.1128/AAC.47.9.2804-2809.2003
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085
   Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200
   Laskowski RA, 2018, PROTEIN SCI, V27, P129, DOI 10.1002/pro.3289
   신웅희, 2014, Biodesign, V2, P1
   Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51
   Lengths MC, 2018, QUICK GUIDELINE COMP, V16, P75
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Mahram A, 2010, FAST ACCURATE NCBI B, P73
   Meza B, 2017, INFECT GENET EVOL, V49, P309, DOI 10.1016/j.meegid.2017.02.007
   Mishra S, 2020, T CELL EPITOPE BASED
   Mukherjee S., 2020, FORTUNE
   Nain Z, 2020, MOL IMMUNOL, V120, P146, DOI 10.1016/j.molimm.2020.02.009
   Pandey R., 2018, CURR PERS MED AROMA, V1, P1
   Pandey RK, 2017, J BIOMOL STRUCT DYN, V35, P791, DOI 10.1080/07391102.2016.1161560
   Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pohl R, 2013, ANNU REV NUCL PART S, V63, P175, DOI 10.1146/annurev-nucl-102212-170627
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   SHAMMAH A, 2018, KNE LIFE SCI, V4, P98, DOI DOI 10.18502/KLS.V4I6.3094
   SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281
   Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08
   SMITH CL, 1987, SCIENCE, V236, P1448, DOI 10.1126/science.3296194
   Song HC, 2004, J VIROL, V78, P10328, DOI 10.1128/JVI.78.19.10328-10335.2004
   Sun PP, 2013, COMPUT MATH METHOD M, DOI 10.1155/2013/943636
   ul Qamar MT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020288
   Tang X, 2020, NATL SCI REV, V6, P6
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tovchigrechko A, 2006, NUCLEIC ACIDS RES, V34, pW310, DOI 10.1093/nar/gkl206
   ul Qamar M.T., 2020, DESIGNING NEXT GENER, DOI [10.1101/2020.02.28.970343, DOI 10.1101/2020.02.28.970343]
   ul Qamar MT, 2019, SCI REP, V9, P1
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Webb B, 2014, METHODS MOL BIOL, V1137, P1, DOI 10.1007/978-1-4939-0366-5_1
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Xu D, 2011, BIOPHYS J, V101, P2525, DOI 10.1016/j.bpj.2011.10.024
   Yadav R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060785
   Zhang LF, 2018, CELL MOL IMMUNOL, V15, P182, DOI 10.1038/cmi.2017.92
   Zhang MX, 2004, IMMUNOLOGY, V112, P567, DOI 10.1111/j.1365-2567.2004.01916.x
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 91
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-5162
EI 2049-9957
J9 INFECT DIS POVERTY
JI Infect. Dis. Poverty
PD SEP 16
PY 2020
VL 9
IS 1
AR 132
DI 10.1186/s40249-020-00752-w
PG 14
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA NT6JN
UT WOS:000573044800003
PM 32938504
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mishra, S
AF Mishra, Seema
TI Designing of cytotoxic and helper T cell epitope map provides insights
   into the highly contagious nature of the pandemic novel coronavirus
   SARS-CoV-2
SO ROYAL SOCIETY OPEN SCIENCE
LA English
DT Article
DE SARS-CoV-2; SARS-CoV-2 proteome; T cell epitopes; immunoinformatics;
   immunopathology; cytokine storm
ID SARS CORONAVIRUS; RESPONSES; PREDICTION; SPIKE
AB Novel coronavirus, SARS-CoV-2, has emerged as one of the deadliest pathogens of this century, creating an unprecedented pandemic. Belonging to the betacoronavirus family, it primarily spreads through human contact via symptomatic and asymptomatic transmission. Despite several attempts since it emerged, there is no known treatment in the form of drugs or vaccines. Hence, work on developing a potential multi-subunit vaccine is the need of the hour. In this study, attempts have been made to find globally conserved epitopes from the entire set of SARS-CoV-2 proteins as there is as yet, no clear information on the immunogenicity of these proteins. Using diverse computational tools, a ranked list of probable immunogenic, promiscuous epitopes generated through all the three main stages of antigen processing and presentation pathways has been prioritized. Moreover, several useful insights were gleaned during these analyses. One of the most important insights is that all of the proteins in this pathogen present unique epitopes, so that the targeting of a few specific viral proteins is not likely to result in an effective immune response in humans. Due to the presence of these unique epitopes in all of the SARS-CoV-2 proteins, stronger immune responses generated by T cell hyperactivation may lead to cytokine storm and immunopathology and consequently, remote chances of human survival. These epitopes, after due validation in vitro, may thus need to be presented to the human body in that form of multi-subunit epitope-based vaccine that avoids such immunopathologies.
C1 [Mishra, Seema] Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad, Telangana, India.
RP Mishra, S (corresponding author), Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad, Telangana, India.
EM seema_uoh@yahoo.com
CR Calis J., 2013, PLOS COMPUT BIOL, V8, P361
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   Dhanda SK, 2018, IMMUNOLOGY, V155, P331, DOI 10.1111/imm.12984
   Dhanda SK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01369
   Diez-Rivero CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043674
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Haveri A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.11.2000266
   Karosiene E, 2013, IMMUNOGENETICS, V65, P711, DOI 10.1007/s00251-013-0720-y
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mishra S, 2020, T CELL EPITOPE BASED, DOI DOI 10.26434/CHEMRXIV.12029523.V2
   Mishra S, 2020, DESIGNING CYTOTOXIC, DOI DOI 10.26434/CHEMRXIV.12253463.V1
   Mishra S, 2006, J BIOMOL STRUCT DYN, V24, P109, DOI 10.1080/07391102.2006.10507104
   Mishra S, 2009, J BIOMOL STRUCT DYN, V27, P293, DOI 10.1080/07391102.2009.10507317
   Narayanan K, 2008, VIRUS RES, V133, P113, DOI 10.1016/j.virusres.2007.10.009
   Nayak JL, 2013, J INFECT DIS, V207, P297, DOI 10.1093/infdis/jis684
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26
   Oh HLJ, 2011, J VIROL, V85, P10464, DOI 10.1128/JVI.05039-11
   Quinlan B. D., 2020, BIORXIV, DOI [10.1101/2020.04.10.036418, DOI 10.1101/2020.04.10.036418]
   Schneidman-Duhovny D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206654
   Shi JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144475
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Stranzl T, 2010, IMMUNOGENETICS, V62, P357, DOI 10.1007/s00251-010-0441-4
   Vartak A, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020012
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang YD, 2004, J VIROL, V78, P5612, DOI 10.1128/JVI.78.11.5612-5618.2004
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   World Health Organization, 2020, DRAFT LANDSCAPE COVI
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Zhang H, 2009, BIOINFORMATICS, V25, P1293, DOI 10.1093/bioinformatics/btp137
NR 38
TC 1
Z9 1
U1 0
U2 0
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 2054-5703
J9 ROY SOC OPEN SCI
JI R. Soc. Open Sci.
PD SEP 16
PY 2020
VL 7
IS 9
AR 201141
DI 10.1098/rsos.201141
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NV8ES
UT WOS:000574548200001
PM 33047062
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bermejo, ACF
   Ruiz-Antoran, B
   Cruz, AF
   Sempere, ED
   Diaz, AC
   Rubio, EM
   Avendano-Sola, C
   Martinez, AR
   Lopez, AS
AF Caballero Bermejo, Antonio F.
   Ruiz-Antoran, Belen
   Fernandez Cruz, Ana
   Diago Sempere, Elena
   Callejas Diaz, Alejandro
   Munez Rubio, Elena
   Avendano-Sola, Cristina
   Ramos Martinez, Antonio
   Sancho Lopez, Aranzazu
CA Puerta Hierro Covid-19 Study Grp
TI Sarilumab versus standard of care for the early treatment of COVID-19
   pneumonia in hospitalized patients: SARTRE: a structured summary of a
   study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; SARS-CoV-2; Randomised controlled trial; protocol; sarilumab;
   anti-IL6 inhibitor; severe interstitial pneumonia; corticosteroids;
   early intervention
AB Objectives In some patients, acute, life-threatening respiratory injury produced by viruses such as SARS-CoV and other viral pneumonia are associated with an over-exuberant cytokine release. Elevated levels of blood IL-6 had been identified as a one of the risk factors associated with severe COVID-19 disease. Anti-IL6 inhibitors are among the therapeutic armamentarium for preventing the fatal consequences of acute respiratory and multi organ failure in around 20% of the COVID-19 infected patients. At present, their use is prioritized to patients with severe interstitial pneumonia (Brescia-COVID Scale-COVID 2-3) with hyperinflammation as determined by the presence of elevated IL6 and/or d-dimer, or progressive d-dimer increase, in patients who otherwise are subsidiary to ICU admission. However, many uncertainties remain on the actual role of anti-IL6 inhibitors in this setting, and whether current use and timing is the right one. There is the hypothesis that the use of anti-IL6 inhibitors at an earlier state during the hyperinflammatory syndrome would be beneficial and may avoid progressing to ARDS. On the other hand, the standard of care has changed and nowadays the use of corticosteroids has become part of the SOC in the treatment of COVID-19 pneumonia. Our limited experience suggests that better treatment outcomes can be achieved when combining IL6-inhibitors (e.g. sarilumab) with corticosteroids. The aim of the present study is to evaluate if an earlier therapeutic intervention with sarilumab plus SOC (including corticosteroids) may be more effective than current standard of care alone, in preventing progression to respiratory failure in COVID-19 infected patients with interstitial pneumonia. This study will also provide supportive evidence to that provided by currently ongoing studies on the efficacy and safety of sarilumab in this clinical context. Trial design A phase two multi-center randomised controlled trial (RCT) with two parallel arms (1:1 ratio). Participants They will be hospitalized patients, of at least 18 years of age, with severe COVID-19 who have positive RT-PCR test and have radiographic evidence of pulmonary infiltrates by imaging or rales/crackles on exam and SpO2 <= 94% on room air that requires supplemental oxygen. Patients must present elevation of inflammatory parameters (IL-6 > 40 pg/mL or d-dimer >1.0 mcg/ml) or, alternatively, progressive worsening in at least two of these inflammatory parameters in the prior 24-48h: CRP, LDH, serum ferritin, lymphopenia, or d-dimer. Exclusion criteria: high oxygen requirements (including face mask with reservoir, non-invasive mechanical ventilation or high flow nasal cannula, or mechanical ventilation), admission to ICU, pregnancy or lactation, allergy or hypersensitivity to sarilumab or corticoesteroids, immunosuppressive antibody therapy within the past 5 months, AST/ALT values > 10 x ULN, neutropenia (< 0.5 x 109/L), severe thrombocytopenia (< 50 x 109/L), sepsis caused by an alternative pathogen, diverticulitis with risk of perforation or ongoing infectious dermatitis. The study will be conducted in several hospitals in Spain. Intervention and comparator Patients randomised to the experimental arm will receive sarilumab + methylprednisolone plus SOC for COVID-19. Patients included in the control arm will receive methylprednisolone plus SOC for COVID-19. Corticosteroids will be given to all patients at a 1mg/kg/d of methylprednisolone for at least 3 days. Clinical follow-up visits will be performed at 3, 5, and 15 days after treatment randomization.
   Patients in the control group (SOC group without sarilumab) progressing to Brescia- COVID 2-3 plus inflammatory markers, will be given the option to be rescued with sarilumab at the same doses and, in that case, be included in an open-label phase and be followed up for additional weeks (with visits at 3, 7 and 15 days after sarilumab rescue administration). Patients randomly assigned to sarilumab therapy at baseline progressing to Brescia-COVID 2-3 will be rescued according to local clinical practice protocols. A final follow-up visit will be conducted for all patients at day 29 from randomization, regardless of initial treatment assignment. Main outcomes Primary end point is the proportion of patients progressing to either severe respiratory failure (Brescia-COVID >= 2), ICU admission, or death. Randomization Randomization codes were produced by means of the PROC PLAN of the SAS system, with a 1:1 assignment ratio, stratifying by centre and using blocks multiple of 2 elements. The randomization schedule will be managed through the eCRF in a concealed manner. Blinding (masking) All study drugs will be administered as open label. No blinding methods will be used in this trial. Numbers to be randomised (simple size) The target sample size will be 200 COVID-19 patients, who will be allocated randomly to control arm (100) and treatment arm (100). Trial status Protocol Code: SARTRE Protocol Date: May 05th 2020. Version: 2.0 The study has been approved by the Spanish Competent Authority (AEMPS) as a low intervention clinical trial. Start of recruitment: August, 2020 End of recruitment: May, 2021 Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file2).
C1 [Caballero Bermejo, Antonio F.; Ruiz-Antoran, Belen; Diago Sempere, Elena; Avendano-Sola, Cristina; Sancho Lopez, Aranzazu] Hosp Univ Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Clin Pharmacol Dept, Madrid, Spain.
   [Fernandez Cruz, Ana; Callejas Diaz, Alejandro; Munez Rubio, Elena; Ramos Martinez, Antonio] Hosp Univ Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Internal Med Dept, Infect Dis Unit, Madrid, Spain.
RP Ruiz-Antoran, B (corresponding author), Hosp Univ Puerta Hierro Majadahonda, Inst Invest Sanitaria Puerta Hierro Segovia Arana, Clin Pharmacol Dept, Madrid, Spain.
EM mariabelen.ruiz@salud.madrid.org
RI ; Ruiz-Antoran, Belen/F-3580-2017
OI Caballero Bermejo, Antonio F/0000-0002-8113-2085; Ruiz-Antoran,
   Belen/0000-0002-2020-9077
FU Sanofi
FX The trial is partially funded by Sanofi : Sanofi will provide sarilumab
   free of charge to the study centers and finances the eCRF. Sanofi will
   have no role in the study's design, collection, management, analysis and
   interpretation of data, writing of the report and the decision to submit
   the report for publication.
NR 0
TC 1
Z9 1
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 16
PY 2020
VL 21
IS 1
AR 794
DI 10.1186/s13063-020-04633-3
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NT6VR
UT WOS:000573076400001
PM 32938496
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pavel, STI
   Yetiskin, H
   Aydin, G
   Holyavkin, C
   Uygut, MA
   Dursun, ZB
   Celik, I
   Cevik, C
   Ozdarendeli, A
AF Pavel, Shaikh Terkis Islam
   Yetiskin, Hazel
   Aydin, Gunsu
   Holyavkin, Can
   Uygut, Muhammet Ali
   Dursun, Zehra Bestepe
   Celik, Ilhami
   Cevik, Ceren
   Ozdarendeli, Aykut
TI Isolation and characterization of severe acute respiratory syndrome
   coronavirus 2 in Turkey
SO PLOS ONE
LA English
DT Article
ID SARS; ALIGNMENT; CHINA; WUHAN
AB Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and associated with severe respiratory illness emerged in Wuhan, China, in late 2019. The virus has been able to spread promptly across all continents in the world. The current pandemic has posed a great threat to public health concern and safety. Currently, there are no specific treatments or licensed vaccines available for COVID-19. We isolated SARS-CoV-2 from the nasopharyngeal sample of a patient in Turkey with confirmed COVID-19. We determined that the Vero E6 and MA-104 cell lines are suitable for supporting SARS-CoV-2 that supports viral replication, development of cytopathic effect (CPE) and subsequent cell death. Phylogenetic analyses of the whole genome sequences showed that the hCoV-19/Turkey/ERAGEM-001/2020 strain clustered with the strains primarily from Australia, Canada, England, Iran and Kuwait and that the cases in the nearby clusters were reported to have travel history to Iran and to share the common unique nucleotide substitutions.
C1 [Pavel, Shaikh Terkis Islam; Yetiskin, Hazel; Aydin, Gunsu; Ozdarendeli, Aykut] Erciyes Univ, Med Fac, Dept Microbiol, Kayseri, Turkey.
   [Pavel, Shaikh Terkis Islam; Yetiskin, Hazel; Aydin, Gunsu; Uygut, Muhammet Ali; Ozdarendeli, Aykut] Erciyes Univ, Vaccine Res Dev & Applicat Ctr, Kayseri, Turkey.
   [Holyavkin, Can; Cevik, Ceren] Gen Era Diagnost Inc Barbaros, Istanbul, Turkey.
   [Dursun, Zehra Bestepe; Celik, Ilhami] Kayseri City Training & Res Hosp, Dept Microbiol & Infect Dis, Kayseri, Turkey.
RP Ozdarendeli, A (corresponding author), Erciyes Univ, Med Fac, Dept Microbiol, Kayseri, Turkey.; Ozdarendeli, A (corresponding author), Erciyes Univ, Vaccine Res Dev & Applicat Ctr, Kayseri, Turkey.
EM aozdarendeli@erciyes.edu.tr
OI Ozdarendeli, Aykut/0000-0002-6950-8545
FU Health Institutes of Turkey (TUSEB) [2020-AG/Ar-Ge ID-7112]; Erciyes
   University Scientific Research FoundationErciyes University
   [TSG-2019-9644]
FX The present study was financially supported by Health Institutes of
   Turkey (TUSEB) (Project No: 2020-AG/Ar-Ge ID-7112) and Erciyes
   University Scientific Research Foundation (Project No: TSG-2019-9644).
   Gen Era Diagnostics Inc. provided support in the form of salaries for
   authors [CH and CC], but did not have any additional role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The specific roles of these authors are
   articulated in the `author contributions' section.
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Ayittey FK, 2020, J MED VIROL, V92, P473, DOI 10.1002/jmv.25706
   Berber E, 2013, J VIROL METHODS, V187, P26, DOI 10.1016/j.jviromet.2012.07.025
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chu DKW, 2014, EMERG INFECT DIS, V20, P1049, DOI 10.3201/eid2006.140299
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Contini C, 2020, J INFECT DEV COUNTR, V14, P254, DOI 10.3855/jidc.12671
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   DeDiego ML, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002315
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Eden JS, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa027
   Fehr AR, 2017, ANNU REV MED, V68, P387, DOI 10.1146/annurev-med-051215-031152
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Guo Q., 2020, BIORXIV, P1, DOI [10.1101/2020.01.21.914044, DOI 10.1101/2020.01.21.914044]
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Haveri A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.11.2000266
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496
   Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Masters PS, 2013, FIELDS VIROLOGY, P58
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Mossel EC, 2005, J VIROL, V79, P3846, DOI 10.1128/JVI.79.6.3846-3850.2005
   Narasimhan V, 2016, BIOINFORMATICS, V32, P1749, DOI 10.1093/bioinformatics/btw044
   Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018
   Nuttall I, 2013, SCIENCE, V339, P1287, DOI 10.1126/science.1236434
   Ozdarendeli A, 2001, J VIROL, V75, P7362, DOI 10.1128/JVI.75.16.7362-7374.2001
   Park WB, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e84
   Sola I, 2015, ANNU REV VIROL, V2, P265, DOI 10.1146/annurev-virology-100114-055218
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   WHO, NAM NEW PNEUM COVID
   World Health Organization, NOV COR 2019 NCOV SI
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu HY, 2006, J VIROL, V80, P2183, DOI 10.1128/JVI.80.5.2183-2193.2006
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 45
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 16
PY 2020
VL 15
IS 9
AR e0238614
DI 10.1371/journal.pone.0238614
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NU5BZ
UT WOS:000573658000011
PM 32936826
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mansour, MA
   AboulMagd, AM
   Abdel-Rahman, HM
AF Mansour, Mostafa A.
   AboulMagd, Asmaa M.
   Abdel-Rahman, Hamdy M.
TI Quinazoline-Schiff base conjugates:in silicostudy and ADMET predictions
   as multi-target inhibitors of coronavirus (SARS-CoV-2) proteins
SO RSC ADVANCES
LA English
DT Article
ID PHOSPHODIESTERASE-4 INHIBITORS; ACE2
AB The 2019 coronavirus (COVID-19) pandemic is spreading worldwide, with a dramatic increase in death without any effective therapeutic treatment available up to now. We previously reported quinazoline-trihydroxyphenyl Schiff base conjugates as phosphodiesterase 4B (PDE 4B) inhibitors (an enzyme that plays an essential role in the early stages of COVID-19 pneumonia). Additionally, the structural similarity between these conjugates and identified anti-severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2 flavonoids inspired us toin silicostudy their possible binding interactions with essential SARS-CoV-2 proteins. Thus, this study provides an insight into the potential bindings between quinazoline-Schiff base conjugates and SARS-CoV-2 proteins, including spike glycoprotein (SGp), main protease (M-pro) and RNA-dependent RNA polymerase (RdRp), to offer an opportunity to find an effective therapy. Besides this, based on the role that COVID-19 plays in iron dysmetabolism, the conjugate trihydroxyphenyl moiety should be reconsidered as an iron chelator. Moreover, molecular dynamics simulations of quinazoline derivativeIcbound to the mentioned targets were carried out. Finally, ADMET calculations were performed for the studied compounds to predict their pharmacokinetic profiles.
C1 [Mansour, Mostafa A.; AboulMagd, Asmaa M.; Abdel-Rahman, Hamdy M.] Nahda Univ NUB, Fac Pharm, Pharmaceut Chem Dept, Beni Suet, Egypt.
   [Abdel-Rahman, Hamdy M.] Assiut Univ, Fac Pharm, Med Chem Dept, Assiut 71526, Egypt.
RP Abdel-Rahman, HM (corresponding author), Nahda Univ NUB, Fac Pharm, Pharmaceut Chem Dept, Beni Suet, Egypt.; Abdel-Rahman, HM (corresponding author), Assiut Univ, Fac Pharm, Med Chem Dept, Assiut 71526, Egypt.
EM hamdy.abdelrahman@nub.edu.eg
RI Abdel-Rahman, Hamdy/ABE-6386-2020
OI Abdel-Rahman, Hamdy/0000-0003-1355-8380; Mansour,
   Mostafa/0000-0002-0179-8398
FU Nahda University in Beni Suef (NUB)
FX The authors thank Nahda University in Beni Suef (NUB) for supporting
   this work.
CR Abdel-Rahman HM, 2014, ARCH PHARM, V347, P650, DOI 10.1002/ardp.201400083
   Ahmad M., 2020, ACS OMEGA, DOI [10.31219/osf.io/fjnzc, DOI 10.31219/OSF.IO/FJNZC]
   Alexpandi R, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01796
   Cavezzi A, 2020, CLINICS PRACT, V10, P24, DOI 10.4081/cp.2020.1271
   Clarke NE, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/307315
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Dalamaga M, 2020, METABOLISM, V109, DOI 10.1016/j.metabol.2020.154282
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Ekins S, 2020, DRUG DISCOV TODAY, V25, P928, DOI 10.1016/j.drudis.2020.03.019
   El-Menshawe SF, 2020, J DRUG DELIV SCI TEC, V56, DOI 10.1016/j.jddst.2020.101569
   Ferraz WR, 2020, FUTURE MED CHEM, V12, P1815, DOI 10.4155/fmc-2020-0165
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Hagar M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113922
   Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646
   Hao W, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006474
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Hirschhorn T, 2019, FREE RADICAL BIO MED, V133, P130, DOI 10.1016/j.freeradbiomed.2018.09.043
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Jo S, 2019, CHEM BIOL DRUG DES, V94, P2023, DOI 10.1111/cbdd.13604
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kodimuthali A, 2008, J MED CHEM, V51, P5471, DOI 10.1021/jm800582j
   Kumar KS, 2010, EUR J MED CHEM, V45, P5474, DOI 10.1016/j.ejmech.2010.07.058
   Kumar Y, 2020, J INFECT PUBLIC HEAL, V13, P1210, DOI 10.1016/j.jiph.2020.06.016
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li H, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01048
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11110979
   Liu W, 2020, CURR CLIN MICROBIOL, V7, P13, DOI [10.1080/15384101.2020.1731644, 10.1007/s40588-020-00140-w]
   Luan JW, 2020, BIOCHEM BIOPH RES CO, V526, P165, DOI 10.1016/j.bbrc.2020.03.047
   Mansour M., 2020, EGYPT J CHEM, DOI [10.21608/ejchem.2020.28992.2624, DOI 10.21608/EJCHEM.2020.28992.2624]
   Ngo Son Tung, 2020, J Chem Inf Model, DOI 10.1021/acs.jcim.0c00491
   Olubiyi OO, 2020, MOLECULES, V25, DOI 10.3390/molecules25143193
   Phillips JE, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00259
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Sayed AM, 2020, RSC ADV, V10, P19790, DOI 10.1039/d0ra04199h
   Shahinshavali S., 2020, TETRAHEDRON LETT
   Sunke R, 2019, EUR J MED CHEM, V174, P198, DOI 10.1016/j.ejmech.2019.04.020
   Tang DL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008536
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Vardhan S, 2020, COMPUT BIOL MED, V124, DOI 10.1016/j.compbiomed.2020.103936
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Yazdanian M, 1998, PHARMACEUT RES, V15, P1490, DOI 10.1023/A:1011930411574
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 51
TC 0
Z9 0
U1 1
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD SEP 16
PY 2020
VL 10
IS 56
BP 34033
EP 34045
DI 10.1039/d0ra06424f
PG 13
WC Chemistry, Multidisciplinary
SC Chemistry
GA NR7SM
UT WOS:000571760600039
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Yang, MX
   Ng, PK
AF Yang, Michael X.
   Ng, Philip K.
TI Central Venous Catheter Insertion in the Prone Position-A Last Resort in
   Critically Ill COVID-19 Patients
SO JOURNAL OF INTENSIVE CARE MEDICINE
LA English
DT Article; Early Access
DE central venous catheter insertion; vascular access; prone position;
   ultrasound guidance; COVID; ARDS
AB Background: In the setting of the COVID pandemic, many patients falling ill with acute respiratory distress syndrome eventually require prone positioning for gas exchange. Traditionally, central venous catheters are inserted with patient in the supine or Trendelenburg position. However, when a patient cannot tolerate supine position and the need for central venous access is urgent, catheter placement may be considered with the patient in the prone position. Case Summary: A 69-year-old male with rapidly declining respiratory status secondary to COVID pneumonia quickly developed acute respiratory distress syndrome, was rapidly intubated, and then placed in the prone position. Patient could not tolerate the supine position even briefly and required a central venous catheter insertion for continuous renal replacement therapy. We kept the patient in the prone position and successfully inserted a central venous catheter in such position with real-time ultrasound guidance and using micropuncture technique. Conclusion: In the setting of the COVID pandemic, many cases of acute respiratory distress syndrome require patients to be prone in order to improve gas exchange. In the most severe situations, these patients would not be able to tolerate rotating back to the supine position but would still require central venous catheter insertion urgently. We demonstrated feasibility of central venous catheter insertion in the prone position in these severely ill patients.
C1 [Yang, Michael X.; Ng, Philip K.] Cedars Sinai Med Ctr, Dept Med, Procedure Ctr, COVID 19 Line Team, 8700 Beverly Blvd,Becker B-113, Los Angeles, CA 90048 USA.
   [Ng, Philip K.] Cedars Sinai Med Ctr, Med Intens Care Unit, Saperstein Critical Care Tower, Los Angeles, CA 90048 USA.
RP Yang, MX (corresponding author), Cedars Sinai Med Ctr, Dept Med, Procedure Ctr, COVID 19 Line Team, 8700 Beverly Blvd,Becker B-113, Los Angeles, CA 90048 USA.
EM michael.yang2@cshs.org
CR Lazzari A, 2017, J VASC ACCESS, V18, pE95, DOI 10.5301/jva.5000754
   Sofi K, 2010, SAUDI J ANAESTH, V4, P28, DOI 10.4103/1658-354X.62612
NR 2
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0885-0666
EI 1525-1489
J9 J INTENSIVE CARE MED
JI J. Intensive Care Med.
AR 0885066620959649
DI 10.1177/0885066620959649
EA SEP 2020
PG 3
WC Critical Care Medicine
SC General & Internal Medicine
GA NQ1OK
UT WOS:000570636000001
PM 32935610
OA Bronze
DA 2021-01-01
ER

PT J
AU Kim, HN
   Park, HH
   Lim, W
   Hong, KS
   Ahn, JH
   Na, DH
   Kim, IS
   Jang, JG
   Bae, JS
   Lee, W
AF Kim, Hong Nam
   Park, Hee Ho
   Lim, Wonhee
   Hong, Kyung Soo
   Ahn, June Hong
   Na, Dong Hee
   Kim, In-San
   Jang, Jong Geol
   Bae, Jong-Sup
   Lee, Wonhwa
TI Ferritin Nanocage-Based Methyltransferase SETD6 for COVID-19 Therapy
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE COVID-19; cytokine storm; ferritin; NF-kappa B signaling; SETD6
ID NF-KAPPA-B; OXIDATIVE STRESS; CYTOKINE STORM; SEPSIS; PHOSPHORYLATION;
   RELA; METHYLATION; CHROMATIN; SARS
AB The transcription factor nuclear factor-kappa B (NF-kappa B) signaling is a mediator of viral infection-mediated inflammation and SET-domain containing 6 (SETD6) is known as a methyltransferase that suppresses the activity of NF-kappa B signaling. However, the downside of the SETD6 is that it cannot be directly utilized as an inflammatory regulator due to the short half-life and poor intracellular delivery. Here, a ferritin nanocage-based delivery system is presented that can maintain the activity of SETD6 in vivo. According to the analysis of severe COVID-19 patients' peripheral blood mononuclear cells (PBMCs), the SETD6 expression is downregulated while that of NF-kappa B is upregulated. By engineering the structure of ferritin, a protein scaffold is fabricated in which short ferritin is decorated with cell-penetrating peptide and nuclear-localizing TAT-NBD peptide together with SETD6, termed TFS. The TFS enhances the SETD6 level and reduces the NF-kappa B signaling in PBMCs of severe COVID-19 patients and subsequently suppresses the cytokine storm. When the TFS is intravenously administered in the cytokine storm mouse model, the survival rate is rescued and the lung tissue damage and cytokine expression are also inhibited. These results indicate that the ferritin nanocage-based peptide delivery system allows stable in vivo delivery and efficient suppression of NF-kappa B signaling-mediated inflammation.
C1 [Kim, Hong Nam] Korea Inst Sci & Technol KIST, Brain Sci Inst, Ctr BioMicrosyst, Seoul 02792, South Korea.
   [Kim, Hong Nam] Korea Univ Sci & Technol, KIST Sch, Div Biomed Sci & Technol, Seoul 02792, South Korea.
   [Park, Hee Ho] Kangwon Natl Univ, Dept Biotechnol & Bioengn, Chunchon 24341, Gangwon Do, South Korea.
   [Lim, Wonhee] Korea Res Inst Biosci & Biotechnol, Rare Dis Res Ctr, Daejeon 34141, South Korea.
   [Lim, Wonhee] Univ Sci & Technol, Dept Funct Genom, Daejeon 34141, South Korea.
   [Hong, Kyung Soo; Ahn, June Hong; Jang, Jong Geol] Yeungnam Univ, Coll Med, Dept Internal Med, Div Pulmonol & Allergy, Daegu 42415, South Korea.
   [Hong, Kyung Soo; Ahn, June Hong; Jang, Jong Geol] Yeungnam Univ, Med Ctr, Reg Ctr Resp Dis, Daegu 42415, South Korea.
   [Na, Dong Hee] Chung Ang Univ, Coll Pharm, Seoul 06974, South Korea.
   [Kim, In-San] Korea Inst Sci & Technol, Biomed Res Inst, Seoul 02792, South Korea.
   [Kim, In-San] Korea Univ, KU KIST Grad Sch Converging Sci & Technol, Seoul 02841, South Korea.
   [Bae, Jong-Sup] Kyungpook Natl Univ, Plus KNU Multiom Based Creat Drug Res Team BK21, Res Inst Pharmaceut Sci, Coll Pharm,CMRI, Daegu 41566, South Korea.
   [Lee, Wonhwa] Korea Res Inst Biosci & Biotechnol, Aging Res Ctr, Daejeon 34141, South Korea.
RP Jang, JG (corresponding author), Yeungnam Univ, Coll Med, Dept Internal Med, Div Pulmonol & Allergy, Daegu 42415, South Korea.; Jang, JG (corresponding author), Yeungnam Univ, Med Ctr, Reg Ctr Resp Dis, Daegu 42415, South Korea.; Bae, JS (corresponding author), Kyungpook Natl Univ, Plus KNU Multiom Based Creat Drug Res Team BK21, Res Inst Pharmaceut Sci, Coll Pharm,CMRI, Daegu 41566, South Korea.; Lee, W (corresponding author), Korea Res Inst Biosci & Biotechnol, Aging Res Ctr, Daejeon 34141, South Korea.
EM jang83@ynu.ac.kr; baejs@knu.ac.kr; wonhwalee@kribb.re.kr
RI Bae, Jong-Sup/AAU-9724-2020; Kim, Hong Nam/D-2922-2015
OI Kim, Hong Nam/0000-0002-0329-0029; Lee, Wonhwa/0000-0003-4336-5221
FU National Research Foundation of Korea (NRF) - Korean Government (MSIT)
   [2018R1A2A3075013, 2020R1A2C1004131, 2020R1A4A3078645,
   2020R1A4A4079817]; Korea Health Technology RAMP;D Project through the
   Korea Health Industry Development Institute (KHIDI) - Ministry of Health
   AMP; Welfare, Republic of Korea [HI15C0001]
FX This work was supported by a grant from the National Research Foundation
   of Korea (NRF) funded by the Korean Government (MSIT) (grant nos.
   2018R1A2A3075013, 2020R1A2C1004131, 2020R1A4A3078645, and
   2020R1A4A4079817). This research was supported by a grant of the Korea
   Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI), funded by the Ministry of Health &
   Welfare, Republic of Korea (grant number: HI15C0001).
CR Abraham E, 2003, J INFECT DIS, V187, pS364, DOI 10.1086/374750
   Cecchini R, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.110102
   Chen A, 2016, BBA-GENE REGUL MECH, V1859, P420, DOI 10.1016/j.bbagrm.2016.01.003
   Choi H, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6980
   Dai SB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11554-6
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Delgado-Roche L, 2020, ARCH MED RES, V51, P384, DOI 10.1016/j.arcmed.2020.04.019
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Dosch SF, 2009, VIRUS RES, V142, P19, DOI 10.1016/j.virusres.2009.01.005
   Duan Q, 2008, J BIOL CHEM, V283, P33585, DOI 10.1074/jbc.M803312200
   Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370
   Fan YM, 2014, BBA-MOL CELL RES, V1843, P2775, DOI 10.1016/j.bbamcr.2014.06.015
   Fang L, 2014, MOL CELL, V55, P537, DOI 10.1016/j.molcel.2014.06.018
   Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423
   Guidotti G, 2017, TRENDS PHARMACOL SCI, V38, P406, DOI 10.1016/j.tips.2017.01.003
   Guo LP, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/1594726
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jang JG, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e234
   Lee W, 2015, ADV MATER, V27, P6637, DOI 10.1002/adma.201503093
   Levy D, 2011, NAT IMMUNOL, V12, P29, DOI 10.1038/ni.1968
   Li WZ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau7566
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Luo Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00604
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1071
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Somers Emily C, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa954
   Sun F, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2287
   Teusch N, 2004, J IMMUNOL, V173, P507, DOI 10.4049/jimmunol.173.1.507
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wen Haitao, 2013, Methods Mol Biol, V1031, P117, DOI 10.1007/978-1-62703-481-4_15
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Xu JJ, 2014, J MOL MED, V92, P77, DOI 10.1007/s00109-013-1081-6
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhang H., 2020, BIORXIV
   Zhao Y., 2020, BIORXIV
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 42
TC 0
Z9 0
U1 2
U2 2
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616-301X
EI 1616-3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD NOV
PY 2020
VL 30
IS 48
SI SI
AR 2006110
DI 10.1002/adfm.202006110
EA SEP 2020
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA PA7CW
UT WOS:000569966900001
OA Bronze
DA 2021-01-01
ER

PT J
AU Bersanelli, M
   Zielli, T
   Perrone, F
   Casartelli, C
   Prattico, F
   Rapacchi, E
   Camisa, R
   Tognetto, M
   Clemente, A
   Giannarelli, D
   Rebuzzi, SE
   Leonetti, A
   Bordi, P
   Tiseo, M
   Buti, S
AF Bersanelli, Melissa
   Zielli, Teresa
   Perrone, Fabiana
   Casartelli, Chiara
   Prattico, Fabiana
   Rapacchi, Elena
   Camisa, Roberta
   Tognetto, Michele
   Clemente, Alberto
   Giannarelli, Diana
   Rebuzzi, Sara Elena
   Leonetti, Alessandro
   Bordi, Paola
   Tiseo, Marcello
   Buti, Sebastiano
TI Clinical impact of COVID-19 in a single-center cohort of a prospective
   study in cancer patients receiving immunotherapy
SO IMMUNOTHERAPY
LA English
DT Article
DE anti-PD-1; cancer patients; COVID-19; immune checkpoint inhibitors;
   immunotherapy; influenza vaccine; interstitial pneumonia; SARS-CoV2
AB Aim:Evaluating the incidence and course of COVID-19 in cancer patients treated with immunotherapy.Patients & methods:We reported the influenza-like illness events with diagnosis of COVID-19 within the patient cohort enrolled in the prospective observational multicenter INVIDIa-2 study in the single center of Parma.Results:Among 53 patients, eight experienced influenza-like illness during the influenza season 2019/2020, and three of them had diagnosis of COVID-19. They were males, elderly, with cardiovascular disease. Radiological features of COVID-19 pneumonitis were found in all of three cases, although the pharyngeal swab resulted positive in only two. Two of these three patients died due to respiratory failure.Conclusion:Cancer patients are at high risk of severe events from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
C1 [Rapacchi, Elena; Camisa, Roberta; Tognetto, Michele; Clemente, Alberto; Rebuzzi, Sara Elena; Leonetti, Alessandro; Bordi, Paola; Buti, Sebastiano] Univ Parma, Med Oncol Unit, I-43126 Parma, Italy.
   [Bersanelli, Melissa; Prattico, Fabiana; Leonetti, Alessandro; Tiseo, Marcello] Univ Parma, Med & Surg Dept, Parma, Italy.
   [Clemente, Alberto] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Biostat & Clin Res Unit, I-47014 Meldola, Italy.
   [Giannarelli, Diana] IRCCS, Regina Elena Natl Canc Inst, Biostat Unit, I-00144 Rome, Italy.
EM fabiana.perrone89@libero.it
RI Rebuzzi, Sara Elena/ABI-2839-2020
OI Perrone, Fabiana/0000-0001-8090-770X; Bersanelli,
   Melissa/0000-0002-6527-6281
FU Roche S.p.A.; Seqirus UK unlimited; Seqirus; RocheRoche Holding;
   Astra-ZenecaAstraZeneca; Boehringer IngelheimBoehringer Ingelheim
FX The authors thank Roche S.p.A. (Gold sponsor), and Seqirus UK unlimited
   (Silver sponsor) for providing the funding for the INVIDIa-2 study. S
   Buti received honoraria for advisory role and as speaker at scientific
   events by Bristol-Myers Squibb (BMS), Pfizer; MSD, Ipsen, AstraZeneca
   and Novartis. M Bersanelli, through FICOG as Institution, received
   funding for the INVIDIa-2 study by Seqirus and Roche. She also received,
   outside the present work, research funding from Pfizer and Novartis,
   honoraria as speaker at scientific events by Astra Zeneca, Bristol-Myers
   Squibb (BMS), Novartis and Pfizer; as consultant for advisory role by
   Novartis, BMS and Pfizer. M Tiseo received honoraria for advisory role
   and as speaker at scientific events by Astra-Zeneca, BMS, MSD,
   Boehringer Ingelheim, Takeda; he also received research grants by
   Astra-Zeneca, Boehringer Ingelheim. The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Adhanom Ghebreyesus T, 2020, WHO DIRECTOR GEN OPE
   [Anonymous], 2020, COR DIS COVID 19 WEE
   Barlesi F, 2020, VIRT ANN M 2020 PHIL
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P105, DOI 10.2217/imt-2019-0200
   Casalegno J, 2017, EUROSURVEILLANCE, V22, P26, DOI [10.2807/1560-7917.es.2017.22.14.30504, 10.2807/1560-7917.ES.2017.22.14.30504]
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Finelli C, 2020, IMMUNOTHERAPY-UK, V12, P541, DOI 10.2217/imt-2019-0143
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Li H, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105951
   Mehraeen E, 2020, EUR ARCH OTO-RHINO-L, DOI 10.1007/s00405-020-06120-6
   Protezione Civile Italia, COR IER 285 VITT NON
   Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060
   Robinson AG, 2020, NAT REV CLIN ONCOL, V17, P386, DOI 10.1038/s41571-020-0394-y
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Shi HS, 2020, RADIOLOGY, V295, P20, DOI 10.1148/radiol.2020200269
   Solomon DA, 2020, JAMA
   Sverzellati N, 2020, J THORAC IMAG, V35, P228, DOI 10.1097/RTI.0000000000000516
   Szabados B, 2020, EUR UROL, V78, P276, DOI 10.1016/j.eururo.2020.05.024
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Trapani D, 2020, EUR J CANCER, V132, P199, DOI 10.1016/j.ejca.2020.04.017
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 31
TC 1
Z9 1
U1 1
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-743X
EI 1750-7448
J9 IMMUNOTHERAPY-UK
JI Immunotherapy
PD OCT
PY 2020
VL 12
IS 15
BP 1139
EP 1148
DI 10.2217/imt-2020-0211
EA SEP 2020
PG 10
WC Immunology
SC Immunology
GA NU8CD
UT WOS:000569363600001
PM 32933369
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Waterer, GW
   Rello, J
AF Waterer, Grant W.
   Rello, Jordi
TI Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits
   All
SO INFECTIOUS DISEASES AND THERAPY
LA English
DT Article
DE ARDS; Coronavirus; Covid-19; Pneumonia; Precision medicine; RCT; SARS;
   Therapy
AB COVID-19 is a new infectious disease causing severe respiratory failure and death for which optimal treatment is currently unclear. Many therapies have been proven to be ineffective; however, promising findings related to corticosteroid therapy have been published. Analysis of published data including in this issue suggests that therapy with corticosteroids in the range of 6 mg of dexamethasone (or equivalent) per day likely has a positive effect in patients requiring mechanical ventilation but there remains considerable doubt in patients over the age of 70, in patients with diabetes and patients with milder disease. Clinicians must consider the individual potential risks and benefits of corticosteroid in patients with COVID-19 rather than routinely using them until more data is available.
C1 [Waterer, Grant W.] Univ Western Australia, Perth, WA, Australia.
   [Waterer, Grant W.] Northwestern Univ, Chicago, IL 60611 USA.
   [Rello, Jordi] Inst Salud Carlos III, Ctr Invest Biomed Red CIBERES, Madrid, Spain.
   [Rello, Jordi] Vall dHebron Inst Res VHIR, Barcelona, Spain.
   [Rello, Jordi] Univ Montpellier Nimes, Clin Res, CHU Nimes, Nimes, France.
RP Waterer, GW (corresponding author), Univ Western Australia, Perth, WA, Australia.
EM grant.waterer@uwa.edu.au
CR Barrasa H, 2020, ANAESTH CRIT CARE PA, V39, P553, DOI 10.1016/j.accpm.2020.04.001
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   COVID-19 National Incident Room Surveillance Team, 2018, COMMUN DIS INTELL, V2020, P44
   Fadel Raef, 2020, Clin Infect Dis, V71, P2114, DOI 10.1093/cid/ciaa601
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Jeronimo Christiane Maria Prado, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1177
   Li Q, 2020, INFECT DIS THER, V9, P823, DOI 10.1007/s40121-020-00332-3
   Liu J, 2020, J ALLERGY CLIN IMMUN, V146, P325, DOI 10.1016/j.jaci.2020.05.021
   Martin-Loeches I, 2011, INTENS CARE MED, V37, P272, DOI 10.1007/s00134-010-2078-z
   Moreno G, 2018, INTENS CARE MED, V44, P1470, DOI 10.1007/s00134-018-5332-4
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rello J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01028-2020
   Roche, ROCH PROV UPD PHAS 3
   Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349
   WALJEE AK, 2017, BMJ-BRIT MED J, V357, DOI DOI 10.1136/BMJ.J1415
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Waterer GW, 2020, AM J RESP CRIT CARE, V201, P1324, DOI 10.1164/rccm.202004-1153ED
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 21
TC 1
Z9 1
U1 1
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 2193-8229
EI 2193-6382
J9 INFECT DIS THER
JI Infect. Dis. Ther.
PD DEC
PY 2020
VL 9
IS 4
BP 701
EP 705
DI 10.1007/s40121-020-00338-x
EA SEP 2020
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA OU0TA
UT WOS:000570026900001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mathpal, S
   Joshi, T
   Sharma, P
   Joshi, T
   Pundir, H
   Pande, V
   Chandra, S
AF Mathpal, Shalini
   Joshi, Tushar
   Sharma, Priyanka
   Joshi, Tanuja
   Pundir, Hemlata
   Pande, Veena
   Chandra, Subhash
TI A dynamic simulation study of FDA drug from zinc database against
   COVID-19 main protease receptor
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; FDA drugs; zinc database; main protease; molecular dynamic
   simulation; molecular docking
ID SARS; DESIGN
AB The sudden outbreak of COVID-19 has been responsible for several deaths across the globe. Due to its high contagious nature, it spreads from one human to another very quickly. Now it becomes a global public health threat with no approved treatments. In silico techniques can accelerate the drug development process. Our research aimed to identify the novel drugs for inhibition of Main protease (Mpro) enzyme of COVID-19 by performing in silico approach. In this context, a library consisting of 3180 FDA-approved drugs from 'the ZINC database' was used to identify novel drug candidates against 'the Mpro' of SARS-CoV-2. Initially, the top 10 drugs out of 3180 drugs were selected by molecular docking according to their binding score. Among 10 selected drugs; seven drugs that showed binding with Mpro enzyme residue Glu166 were subjected to100 ns Molecular dynamics (MD) simulation. Out of seven compounds, four namely, ZINC03831201, ZINC08101052, ZINC01482077, and ZINC03830817 were found significant based on MD simulation results. Furthermore, RMSD, RMSF, RG, SASA, PCA, MMPBSA (for last 40 ns) were calculated for the 100 ns trajectory period. Currently, the world needs potent drugs in a short period and this work suggests that these four drugs could be used as novel drugs against COVID-19 and it also provides new lead compounds for further in vitro, in vivo, and ongoing clinical studies against SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Mathpal, Shalini; Joshi, Tushar; Pande, Veena] Kumaun Univ, Dept Biotechnol, Bhimtal, Uttarakhand, India.
   [Sharma, Priyanka; Joshi, Tanuja; Pundir, Hemlata; Chandra, Subhash] Kumaun Univ, Dept Bot, SSJ Campus, Almora, Uttarakhand, India.
   [Joshi, Tanuja; Chandra, Subhash] Soban Singh Jeena Univ, Dept Bot, Computat Biol & Biotechnol Lab, Almora, Uttarakhand, India.
RP Chandra, S (corresponding author), Soban Singh Jeena Univ, Dept Bot, Almora 263601, Uttarakhand, India.
EM scjnu@yahoo.co.in
RI Joshi, Tushar/AAJ-9626-2020
OI Chandra, Subhash/0000-0002-8978-5427
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   CALY L, 2020, ANTIVIR RES, V178, DOI DOI https://doi.org/10.1016/j.antiviral.2020.104787
   Chen DL, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501240
   David CC, 2014, METHODS MOL BIOL, V1084, P193, DOI 10.1007/978-1-62703-658-0_11
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   ElHefnawi M, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S17-S5
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Fuster V, 2011, CIRCULATION, V123, P768, DOI 10.1161/CIRCULATIONAHA.110.963843
   Ghasemi F, 2016, J MOL GRAPH MODEL, V68, P39, DOI 10.1016/j.jmgm.2016.05.011
   Ghofrani HA, 2006, NAT REV DRUG DISCOV, V5, P689, DOI 10.1038/nrd2030
   Gimeno A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061375
   GRALINSKI LE, 2020, VIRUSES BASEL, V12, DOI DOI https://doi.org/10.3390/v12020135
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646
   Khan SA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751298
   Kuzmanic A, 2010, BIOPHYS J, V98, P861, DOI 10.1016/j.bpj.2009.11.011
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Liu B, 2005, J COMPUT CHEM, V26, P484, DOI 10.1002/jcc.20186
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   PALOS I, 2017, MOLECULES, V22, DOI DOI https://doi.org/10.3390/molecules22061015
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Sargsyan K, 2017, J CHEM THEORY COMPUT, V13, P1518, DOI 10.1021/acs.jctc.7b00028
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Sirois S, 2004, J CHEM INF COMP SCI, V44, P1111, DOI 10.1021/ci034270n
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vanommeslaeghe K, 2010, J COMPUT CHEM, V31, P671, DOI 10.1002/jcc.21367
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu Canrong, 2020, ACTA PHARM SIN B
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 38
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1821785
EA SEP 2020
PG 17
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NP2HL
UT WOS:000570001400001
PM 32940134
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rout, J
   Swain, BC
   Tripathy, U
AF Rout, Janmejaya
   Swain, Bikash Chandra
   Tripathy, Umakanta
TI In silicoinvestigation of spice molecules as potent inhibitor of
   SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; receptor-binding domain; spike proteins; main
   protease; spice molecules; inhibition
ID DRUG DISCOVERY; ANTIVIRAL ACTIVITY; BETA-LACTOGLOBULIN; SOLUBILITY;
   PREDICTION; DYNAMICS; DOCKING; EWALD; TOOL
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel infectious disease that is in rapid growth. Several trials are going on worldwide to find a solution for this pandemic. The viral replication can be blocked by inhibiting the receptor-binding domain (RBD) of SARS-CoV-2 spike protein (SARS-CoV-2 RBD Spro) and the SARS-CoV-2 main protease (SARS-CoV-2 Mpro). The binding of potential small molecules to these proteins can inhibit the replication and transcription of the virus. The spice molecules that are used in our food have antiviral, antifungal and antimicrobial properties. As spice molecules are consumed in the diet, hence its antiviral properties against SARS-CoV-2 will benefit in a significant manner. Therefore, in this work, the molecular docking of 30 selected spice molecules (screened through ADME property) was performed to identify the potential inhibitors for the RBD Spro and Mpro of SARS-CoV-2. We have found that though all the molecules bind actively with the SARS-CoV-2 RBD Spro and Mpro, but Piperine has the highest binding affinity among the 30 screened molecules. Besides, the comparative study between Piperine and currently used drugs show that Piperine is more effective. The interaction of Piperine with RBD Spro and Mpro is further validated by the molecular dynamics (MD) simulation studies. The free energy landscape and binding free energy results also, support for the stable complex formation of Piperine with RBD Spro and Mpro. We anticipate immediate wet-lab experiments and clinical trials in support of this computational study that might help to inhibit the SARS-CoV-2 virus. Communicated by Ramaswamy H. Sarma
C1 [Rout, Janmejaya; Swain, Bikash Chandra; Tripathy, Umakanta] Indian Sch Mines, Indian Inst Technol, Dept Phys, Dhanbad 826004, Jharkhand, India.
RP Tripathy, U (corresponding author), Indian Sch Mines, Indian Inst Technol, Dept Phys, Dhanbad 826004, Jharkhand, India.
EM utripathy@iitism.ac.in
RI Swain, Bikash Chandra/ABE-7255-2020
FU Ministry of Human Resource Development (MHRD), New Delhi
   [(FDC)/2015-2016/438/INST]
FX The authors are thankful to the Ministry of Human Resource Development
   (MHRD), New Delhi, for financial assistance
   (MHRD/(FDC)/2015-2016/438/INST) to establish the computational facility.
   We are also extremely grateful to Dr. Anand Kant Das, New York
   University, Abu Dhabi, for a fruitful scientific discussion.
CR Aboubakr HA, 2016, J FOOD PROTECT, V79, P1001, DOI 10.4315/0362-028X.JFP-15-593
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Al-Khafaji K, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1764392
   Al-Shabib NA, 2020, SAUDI PHARM J, V28, P238, DOI 10.1016/j.jsps.2020.01.002
   Al-Shabib NA, 2018, J MOL LIQ, V269, P511, DOI 10.1016/j.molliq.2018.07.122
   Ali J, 2012, J CHEM INF MODEL, V52, P420, DOI 10.1021/ci200387c
   [Anonymous], 2017, PYMOL MOL GRAPHICS S
   Anurag A., 2020, MOL DOCKING STUDY ID, DOI [10.26434/chemrxiv.12170904.v1, DOI 10.26434/CHEMRXIV.12170904.V1]
   Arnott JA, 2012, EXPERT OPIN DRUG DIS, V7, P863, DOI 10.1517/17460441.2012.714363
   Astani A, 2010, PHYTOTHER RES, V24, P673, DOI 10.1002/ptr.2955
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bergstrom CAS, 2018, INT J PHARMACEUT, V540, P185, DOI 10.1016/j.ijpharm.2018.01.044
   BROCHOT A, 2017, MICROBIOLOGYOPEN, V6, DOI DOI https://doi.org/10.1002/mbo3.459
   Thuy BTP, 2020, ACS OMEGA, V5, P8312, DOI 10.1021/acsomega.0c00772
   Chang JS, 2013, J ETHNOPHARMACOL, V145, P146, DOI 10.1016/j.jep.2012.10.043
   Cheng TJ, 2007, J CHEM INF MODEL, V47, P2140, DOI 10.1021/ci700257y
   Choi Hwa-Jung, 2016, Osong Public Health Res Perspect, V7, P400, DOI 10.1016/j.phrp.2016.11.003
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   CONSTANTINESCU T, 2019, MOLECULES, V24, DOI DOI https://doi.org/10.3390/molecules24081505
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Daina A, 2016, CHEMMEDCHEM, V11, P1117, DOI 10.1002/cmdc.201600182
   Daina A, 2014, J CHEM INF MODEL, V54, P3284, DOI 10.1021/ci500467k
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Das S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1763201
   Delaney JS, 2004, J CHEM INF COMP SCI, V44, P1000, DOI 10.1021/ci034243x
   Discovery Studio Visualizer, 2005, DISC STUD VIS, P2
   GUPTA MK, 2020, J BIOMOL STRUCT 0413, DOI DOI https://doi.org/10.1080/07391102.2020.1751300
   GYEBI GA, 2020, J BIOMOL STRUCT 0514, DOI DOI https://doi.org/10.1080/07391102.2020.1764868
   Hasan A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1754293
   Huang J, 2013, J COMPUT CHEM, V34, P2135, DOI 10.1002/jcc.23354
   Jang GR, 2001, MED RES REV, V21, P382, DOI 10.1002/med.1015
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   Kumar A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772112
   Kumar D, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1779131
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Liang D, 2014, PROCEEDINGS OF THE 11TH INTERNATIONAL CONFERENCE ON INNOVATION AND MANAGEMENT, VOLS I AND II, P152
   Lindsley C. W., 2010, ENCY PSYCHOPHARMACOL
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   MAIR CE, 2016, PLANTA MED S1, V82, DOI DOI https://doi.org/10.1055/s-0036-1596830
   Millan S, 2018, J PHOTOCH PHOTOBIO B, V179, P23, DOI 10.1016/j.jphotobiol.2017.12.019
   MORIGUCHI I, 1992, CHEM PHARM BULL, V40, P127
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   POLITZER P, 1985, ENVIRON HEALTH PERSP, V61, P191, DOI 10.2307/3430072
   Price DJ, 2004, J CHEM PHYS, V121, P10096, DOI 10.1063/1.1808117
   Savjani Ketan T, 2012, ISRN Pharm, V2012, P195727, DOI 10.5402/2012/195727
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   UMESH, 2020, J BIOMOL STRUCT 0512, DOI DOI https://doi.org/10.1080/07391102.2020.1763202
   Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3144, DOI 10.1021/ci300363c
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wildman SA, 1999, J CHEM INF COMP SCI, V39, P868, DOI 10.1021/ci990307l
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 60
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1819879
EA SEP 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NP2HM
UT WOS:000570001500001
PM 32938313
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cohen, JB
   Hanff, TC
   Corrales-Medina, V
   William, P
   Renna, N
   Rosado-Santander, NR
   Rodriguez-Mori, JE
   Spaak, J
   Andrade-Villanueva, J
   Chang, TI
   Barbagelata, A
   Alfonso, CE
   Bernales-Salas, E
   Coacalla, J
   Castro-Callirgos, CA
   Tupayachi-Venero, KE
   Medina, C
   Valdivia, R
   Villavicencio, M
   Vasquez, CR
   Harhay, MO
   Chittams, J
   Sharkoski, T
   Byrd, JB
   Edmonston, DL
   Sweitzer, N
   Chirinos, JA
AF Cohen, Jordana B.
   Hanff, Thomas C.
   Corrales-Medina, Vicente
   William, Preethi
   Renna, Nicolas
   Rosado-Santander, Nelson R.
   Rodriguez-Mori, Juan E.
   Spaak, Jonas
   Andrade-Villanueva, Jaime
   Chang, Tara I.
   Barbagelata, Alejandro
   Alfonso, Carlos E.
   Bernales-Salas, Eduardo
   Coacalla, Johanna
   Castro-Callirgos, Carlos Augusto
   Tupayachi-Venero, Karen E.
   Medina, Carola
   Valdivia, Renzo
   Villavicencio, Mirko
   Vasquez, Charles R.
   Harhay, Michael O.
   Chittams, Jesse
   Sharkoski, Tiffany
   Byrd, James Brian
   Edmonston, Daniel L.
   Sweitzer, Nancy
   Chirinos, Julio A.
TI Randomized elimination and prolongation of ACE inhibitors and ARBs in
   coronavirus 2019 (REPLACE COVID) Trial Protocol
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
DE angiotensin receptor blocker; angiotensin-converting enzyme inhibitor;
   angiotensin-converting enzyme inhibitor 2; clinical trial; coronavirus;
   COVID-19; hypertension
ID ANGIOTENSIN-CONVERTING ENZYME-2; MYOCARDIAL-INFARCTION; HEART-FAILURE;
   ANTIHYPERTENSIVE MEDICATION; CLINICAL-TRIALS; DOUBLE-BLIND; END-POINT;
   BLOCKADE; EXPRESSION; OUTCOMES
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), is associated with high incidence of multiorgan dysfunction and death. Angiotensin-converting enzyme 2 (ACE2), which facilitates SARS-CoV-2 host cell entry, may be impacted by angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), two commonly used antihypertensive classes. In a multicenter, international randomized controlled trial that began enrollment on March 31, 2020, participants are randomized to continuation vs withdrawal of their long-term outpatient ACEI or ARB upon hospitalization with COVID-19. The primary outcome is a hierarchical global rank score incorporating time to death, duration of mechanical ventilation, duration of renal replacement or vasopressor therapy, and multiorgan dysfunction severity. Approval for the study has been obtained from the Institutional Review Board of each participating institution, and all participants will provide informed consent. A data safety monitoring board has been assembled to provide independent oversight of the project.
C1 [Cohen, Jordana B.] Univ Penn, Perelman Sch Med, Renal Electrolyte & Hypertens Div, 423 Guardian Dr,831 Blockley, Philadelphia, PA 19104 USA.
   [Cohen, Jordana B.; Hanff, Thomas C.; Vasquez, Charles R.; Harhay, Michael O.; Chittams, Jesse] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA.
   [Hanff, Thomas C.; Sharkoski, Tiffany; Chirinos, Julio A.] Hosp Univ Penn, Div Cardiovasc Med, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Hanff, Thomas C.; Sharkoski, Tiffany; Chirinos, Julio A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Corrales-Medina, Vicente] Univ Ottawa, Div Infect Dis, Ottawa, ON, Canada.
   [Corrales-Medina, Vicente] Ottawa Hosp Res Inst, Ottawa, ON, Canada.
   [William, Preethi; Sweitzer, Nancy] Univ Arizona, Div Cardiol, Tucson, AZ USA.
   [Renna, Nicolas] Natl Univ Cuyo, CONICET, Hosp Espanol Mendoza, Hypertens Unit,Dept Pathol,IMBECU, Mendoza, Argentina.
   [Rosado-Santander, Nelson R.; Bernales-Salas, Eduardo; Coacalla, Johanna] Hosp Nacl Carlos Alberto Seguin Escobedo, Dept Med, Arequipa, Peru.
   [Rodriguez-Mori, Juan E.; Castro-Callirgos, Carlos Augusto; Tupayachi-Venero, Karen E.] Hosp Nacl Alberto Sabogal Sologuren, EsSalud, Dept Nephrol, Lima, Peru.
   [Spaak, Jonas] Karolinska Inst, Danderyd Univ Hosp, Dept Clin Sci, Stockholm, Sweden.
   [Andrade-Villanueva, Jaime] Univ Guadalajara, Guadalajara, Mexico.
   [Chang, Tara I.] Stanford Univ, Sch Med, Div Nephrol, Stanford, CA 94305 USA.
   [Barbagelata, Alejandro] Univ Catolica Buenos Aires, Buenos Aires, DF, Argentina.
   [Barbagelata, Alejandro] Duke Univ, Sch Med, Dept Med, Div Cardiol, Durham, NC 27706 USA.
   [Alfonso, Carlos E.] Univ Miami, Miller Sch Med, Cardiol Div, Miami, FL 33136 USA.
   [Medina, Carola; Valdivia, Renzo; Villavicencio, Mirko] Hosp Nacl Edgardo Rebagliati Martins, EsSalud, Dept Nephrol, Lima, Peru.
   [Vasquez, Charles R.] Univ Penn, Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA.
   [Harhay, Michael O.] Univ Penn, Perelman Sch Med, Palliat & Adv Illness Res PAIR Ctr, Philadelphia, PA 19104 USA.
   [Harhay, Michael O.] Univ Penn, Perelman Sch Med, Dept Med, Crit Care Div, 17, Philadelphia, PA 19104 USA.
   [Byrd, James Brian] Univ Michigan, Med Sch, Div Cardiovasc Med, Ann Arbor, MI 48109 USA.
   [Edmonston, Daniel L.] Duke Univ, Sch Med, Dept Med, Div Nephrol, Durham, NC 27706 USA.
RP Cohen, JB (corresponding author), Univ Penn, Perelman Sch Med, Renal Electrolyte & Hypertens Div, 423 Guardian Dr,831 Blockley, Philadelphia, PA 19104 USA.
EM jco@pennmedicine.upenn.edu
RI Cohen, Jordana/S-5435-2016
OI Cohen, Jordana/0000-0003-4649-079X; Renna, Nicolas/0000-0003-2257-4243;
   Valdivia-Vega, Renzo P./0000-0002-8718-4361
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R56 HL136730, T32 HL007891, R01 HL153646, R01
   HL121510, R03 HL146874, R61 HL146390, K23 HL133843, P01 HL094307, R01
   HL104106, R00 HL141678] Funding Source: Medline; NIA NIH HHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG058969]
   Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T32
   DK007785] Funding Source: Medline; NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [R56-HL136730, R61-HL-146390, T32-HL007891, R01-AG058969,
   R03-HL146874-01, K23-HL133843, T32-DK07785, R01-HL 121510-01A1,
   P01-HL094307, 1R01-HL104106, R00-HL141678] Funding Source: Medline
CR [Anonymous], 2018, PASS 16 POW AN SAMPL
   Beeftink MMA, 2017, HYPERTENSION, V69, P927, DOI 10.1161/HYPERTENSIONAHA.116.08793
   BROWN BW, 1980, BIOMETRICS, V36, P69, DOI 10.2307/2530496
   Burchill LJ, 2012, CLIN SCI, V123, P649, DOI 10.1042/CS20120162
   Burrell LM, 2005, EUR HEART J, V26, P369, DOI 10.1093/eurheartj/ehi114
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cohen JB, 2020, CIRC RES, V126, pE140, DOI 10.1161/CIRCRESAHA.120.317205
   Diaz JH, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa041
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Felker GM, 2010, CIRC-HEART FAIL, V3, P643, DOI 10.1161/CIRCHEARTFAILURE.109.926030
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Grissom CK, 2010, DISASTER MED PUBLIC, V4, P277, DOI 10.1001/dmp.2010.40
   GRIZZLE JE, 1965, BIOMETRICS, V21, P467, DOI 10.2307/2528104
   Gu QP, 2012, CIRCULATION, V126, P2105, DOI 10.1161/CIRCULATIONAHA.112.096156
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hanff TC, 2020, CLIN INFECT DIS, V71, P870, DOI 10.1093/cid/ciaa329
   Harhay MN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156532
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Julious SA, 2004, STAT MED, V23, P1921, DOI 10.1002/sim.1783
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   LITTLE RJA, 1995, J AM STAT ASSOC, V90, P1112, DOI 10.2307/2291350
   Margulies KB, 2016, JAMA-J AM MED ASSOC, V316, P500, DOI 10.1001/jama.2016.10260
   O'Connor CM, 2017, J AM COLL CARDIOL, V69, P1577, DOI 10.1016/j.jacc.2017.01.041
   OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   Ocaranza MP, 2006, HYPERTENSION, V48, P572, DOI 10.1161/01.HYP.0000237862.94083.45
   Peterson RL, 2019, CONT CLIN TRIAL COMM, V15, DOI 10.1016/j.conctc.2019.100401
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   PFLUGFELDER PW, 1993, J AM COLL CARDIOL, V22, P1557, DOI 10.1016/0735-1097(93)90578-O
   Ramchand J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198144
   Senchenkova EY, 2014, MICROCIRCULATION, V21, P401, DOI 10.1111/micc.12120
   Smith DHG, 2003, J HYPERTENS, V21, P1291, DOI 10.1097/00004872-200307000-00016
   Soler MJ, 2009, AM J PHYSIOL-RENAL, V296, pF398, DOI 10.1152/ajprenal.90488.2008
   Sommerstein R, 2020, BMJ-BRIT MED J, V368, pm810, DOI [10.1136/bmj.m810, DOI 10.1136/BMJ.M810]
   Sparks M. A., CORONAVIRUS CONUNDRU
   Therneau TM, 2001, MODELING SURVIVAL DA
   Walters TE, 2017, EUROPACE, V19, P1280, DOI 10.1093/europace/euw246
   WILLAN AR, 1986, BIOMETRICS, V42, P593, DOI 10.2307/2531209
   Wilson FP, 2015, LANCET, V385, P1966, DOI 10.1016/S0140-6736(15)60266-5
   Wilson FP, 2014, CLIN TRIALS, V11, P521, DOI 10.1177/1740774514542619
   Wright JT, 2005, JAMA-J AM MED ASSOC, V293, P1595, DOI 10.1001/jama.293.13.1595
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Wysocki J, 2020, J AM SOC NEPHROL
   Xie XD, 2006, LIFE SCI, V78, P2166, DOI 10.1016/j.lfs.2005.09.038
NR 50
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD OCT
PY 2020
VL 22
IS 10
BP 1780
EP 1788
DI 10.1111/jch.14011
EA SEP 2020
PG 9
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA OI4CY
UT WOS:000569487700001
PM 32937008
OA Bronze
DA 2021-01-01
ER

PT J
AU Shekh, S
   Reddy, KKA
   Gowd, KH
AF Shekh, Shamasoddin
   Reddy, K. Kasi Amarnath
   Gowd, Konkallu Hanumae
TI In silicoallicin inducedS-thioallylation of SARS-CoV-2 main protease
SO JOURNAL OF SULFUR CHEMISTRY
LA English
DT Article; Early Access
DE Allicin; SARS-CoV-2 main protease; virtual screening; S-thioallylation;
   COVID-19
ID ANTIBACTERIAL PRINCIPLE; ALLICIN; CORONAVIRUS
AB Coronavirus disease 2019 (COVID-19) is an ongoing pandemic caused due to new coronavirus infection with(3)716075 deaths across the world as reported by the World Health Organization (WHO). SARS-CoV-2 main protease (M-pro) plays a vital role in the replication of coronavirus and thus an attractive target for the screening of inhibitors for the therapy of COVID-19. The preclinical drugs ebselen and PX-12 are potent inhibitors of SARS-CoV-2 M(pro)and covalently modifies the active site Cys-145 residue of M(pro)through selenosulfide/disulfide. In the current report, using virtual screening methods, reactive sulfur species allicin is subjecting for covalent docking at the active site of SARS-CoV-2 M(pro)using PX-12 as a benchmark reference compound. The results indicate that allicin induces dual S-thioallylation of Cys-145 and Cys-85/ Cys-156 residues of SARS-CoV-2 M-pro. Using density functional theory (DFT), Gibbs free energy change (DG) is calculated for the putative reactions between N-acetylcysteine amide thiol and allicin/allyl sulfenic acid. The overall reaction is exergonic and allyl disulfide of Cys-145 residue of M(pro)is involved in a sulfur mediated hydrogen bond. The results indicate that allicin causes dual S-thioallylation of SARS-CoV-2 M(pro)which may be of interest for treatment and attenuation of ongoing coronavirus infection.
C1 [Shekh, Shamasoddin; Reddy, K. Kasi Amarnath; Gowd, Konkallu Hanumae] Cent Univ Karnataka, Sch Chem Sci, Dept Chem, Kalaburagi 585367, Karnataka, India.
RP Gowd, KH (corresponding author), Cent Univ Karnataka, Sch Chem Sci, Dept Chem, Kalaburagi 585367, Karnataka, India.
EM khgowd@cuk.ac.in
FU Government of Karnataka; DST-SERB-ECR research grant
FX We acknowledge Dr. Pritesh Bhat and Dr. Sudharsan Pandiyan from
   Schrodinger for guiding in executing the current research work. Mr.
   Shamasoddin Shekh is the recipient of a Ph.D. fellowship from the
   directorate of minorities from the Government of Karnataka. This
   research work is funded by the DST-SERB-ECR research grant. We also
   acknowledge Dr. Harish Holla, Department of Chemistry, CUK.
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   [Anonymous], 2020, 201 WHO
   Arreola R, 2015, J IMMUNOL RES, V14
   Biswal HS, 2015, NONCOVALENT FORCES
   Borlinghaus J, 2014, MOLECULES, V19, P12591, DOI 10.3390/molecules190812591
   Thuy BTP, 2020, ACS OMEGA, V5, P8312, DOI 10.1021/acsomega.0c00772
   Cavallito CJ, 1944, J AM CHEM SOC, V66, P1950, DOI 10.1021/ja01239a048
   Cavallito CJ, 1944, J AM CHEM SOC, V66, P1952, DOI 10.1021/ja01239a049
   Chand A, 2020, ACCOUNTS CHEM RES, V53, P1580, DOI 10.1021/acs.accounts.0c00289
   Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   Chung LY, 2006, J MED FOOD, V9, P205, DOI 10.1089/jmf.2006.9.205
   Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W
   Gruhlke MCH, 2019, FREE RADICAL BIO MED, V131, P144, DOI 10.1016/j.freeradbiomed.2018.11.022
   Han J, 2020, SCIENCE, V368, DOI 10.1126/science.abc1767
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Lawson LD, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070812
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Muller A, 2016, J BIOL CHEM, V291, P11477, DOI 10.1074/jbc.M115.702308
   Mundlapati VR, 2015, J PHYS CHEM LETT, V6, P1385, DOI 10.1021/acs.jpclett.5b00491
   Rut W, 2020, ACTIVITY PROFILING S
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 29
TC 0
Z9 0
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1741-5993
EI 1741-6000
J9 J SULFUR CHEM
JI J. Sulfur Chem.
DI 10.1080/17415993.2020.1817457
EA SEP 2020
PG 12
WC Chemistry, Multidisciplinary
SC Chemistry
GA NO4FO
UT WOS:000569441100001
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ahmed, E
   Matouk, AE
AF Ahmed, Elsayd
   Matouk, Ahmed E.
TI Complex dynamics of some models of antimicrobial resistance on complex
   networks
SO MATHEMATICAL METHODS IN THE APPLIED SCIENCES
LA English
DT Article
DE 0-1 test; antimicrobial resistance (AMR) models; basin sets of
   attraction; bifurcations; complex networks; fractional order
AB Studying the spread of epidemics and diseases is a worldwide problem especially during the current time where the whole world is suffering from COVID-19 pandemic. Antimicrobial resistance (AMR) and waning vaccination are classified as worldwide problems. Both depend on the exposure time to antibiotic and vaccination. Here, a simple model for competition between drug-resistant and drug-sensitive bacteria is given. Conditions for local stability are investigated, which agree with observation. Existence of positive solution in the AMR complex networks is proved. Dynamics of the identical AMR models are explored with different topologies of complex networks such as global, star, line, and unidirectional line networks coupled through their susceptible states. Chaotic attractors are shown to exist as the AMR models are located on all these topologies of complex networks. Thus, it is found that the dynamics of the AMR model become more complicated as it is located on either integer-order or fractional-order complex networks. Furthermore, a discretized version of the fractional AMR model is presented. Complex dynamics such as existence of Neimark-Sacker, flip bifurcations, coexistence of multiple attractors, homoclinic connections, and multiple closed invariant curves are investigated. Basin sets of attraction are also computed. Finally, the discretized system is located on complex networks with different topologies which show rich variety of complex dynamics. Also, 0-1 test is used to verify the existence of unpredictable dynamics. So, studying the dynamics of AMR models on complex networks is very helpful to understand the mechanism of spread of diseases.
C1 [Ahmed, Elsayd] Mansoura Univ, Fac Sci, Math Dept, Mansoura, Egypt.
   [Matouk, Ahmed E.] Majmaah Univ, Coll Sci Al Zulfi, Dept Math, Al Majmaah 11952, Saudi Arabia.
   [Matouk, Ahmed E.] Majmaah Univ, Coll Engn, Al Majmaah, Saudi Arabia.
RP Matouk, AE (corresponding author), Majmaah Univ, Coll Sci Al Zulfi, Dept Math, Al Majmaah 11952, Saudi Arabia.
EM aematouk@hotmail.com
OI Matouk, Ahmed/0000-0001-5834-4234
FU Majmaah University [1440-42]
FX Majmaah University, Grant/Award Number: 1440-42
CR Ahmed E, 2007, PHYSICA A, V379, P607, DOI 10.1016/j.physa.2007.01.010
   Ahmed E, 2020, J FRACTIONAL CALCULU, V11, P22, DOI DOI 10.1016/J.PHYSLETA.2006.04.087
   Ahmed EM, 2017, J FRACT CALCULUS APP, V8, P118
   Al-khedhairi A, 2018, COMPLEXITY, DOI 10.1155/2018/6719341
   Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI [10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2019.02.033]
   Ameen I, 2020, COMPLEXITY, V2020, DOI 10.1155/2020/9823753
   Ameen I, 2017, APPL MATH MODEL, V43, P78, DOI 10.1016/j.apm.2016.10.054
   Ameen I., 2018, WJMS, V14, P30
   Blanquart F, 2019, EVOL APPL, V12, P365, DOI 10.1111/eva.12753
   Capponetto R, 2010, WORLD SCI SERIES NON, V72
   Edelstein-Keshet L, 2005, MATH MODELS BIOL
   El-Sayed AMA, 2013, J FRACT CALC APPL, V4, P251
   El-Shahed M, 2011, MATH PROBL ENG, V2011, DOI 10.1155/2011/480378
   Elettreby MF, 2017, MATH PROBL ENG, V2017, DOI 10.1155/2017/6714538
   Elsadany AA, 2015, J APPL MATH COMPUT, V49, P269, DOI 10.1007/s12190-014-0838-6
   Gottwald GA, 2009, SIAM J APPL DYN SYST, V8, P129, DOI 10.1137/080718851
   Hirsch MW, 1974, DIFF EQUAT, P239
   Kostova T, 2007, MATH BIOSCI, V206, P309, DOI 10.1016/j.mbs.2005.08.003
   Kuznetsov Y. A., 1998, ELEMENTS APPL BIFURC
   Lewnard JA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5945
   Massad E, 2008, APPL MATH COMPUT, V201, P161, DOI 10.1016/j.amc.2007.12.007
   Matignon D., 1996, Symposium on Control, Optimization and Supervision. CESA '96 IMACS Multiconference. Computational Engineering in Systems Applications, P963
   Matouk AE, 2016, NONLINEAR DYNAM, V85, P1597, DOI 10.1007/s11071-016-2781-6
   Matouk AE, 2015, COMMUN NONLINEAR SCI, V27, P153, DOI 10.1016/j.cnsns.2015.03.004
   Podlubny I., 1999, FRACTIONAL DIFFERENT
   Podlubny I, 2008, GEOMETRIC PHYS INTER
   Vargas-De-Leon C, 2015, COMMUN NONLINEAR SCI, V24, P75, DOI 10.1016/j.cnsns.2014.12.013
   WHO, 2018, WHOEMPIAU201806
NR 28
TC 0
Z9 0
U1 6
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0170-4214
EI 1099-1476
J9 MATH METHOD APPL SCI
JI Math. Meth. Appl. Sci.
PD JAN 30
PY 2021
VL 44
IS 2
BP 1896
EP 1912
DI 10.1002/mma.6889
EA SEP 2020
PG 17
WC Mathematics, Applied
SC Mathematics
GA PA8TR
UT WOS:000569526300001
DA 2021-01-01
ER

PT J
AU Kalkowska, DA
   Thompson, KM
AF Kalkowska, Dominika A.
   Thompson, Kimberly M.
TI Expected Implications of Globally Coordinated Cessation of Serotype 3
   Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV
SO RISK ANALYSIS
LA English
DT Article; Early Access
DE Dynamic modeling; eradication; oral poliovirus vaccine; polio
AB Globally coordinated cessation of all three serotypes of oral poliovirus vaccine (OPV) represents a critical part of a successful polio endgame, which the Global Polio Eradication Initiative (GPEI) plans to conduct in phases, with serotype 2 OPV cessation completed in mid 2016. Although in 2016 the GPEI expected to globally coordinate cessation of the remaining OPV serotypes (1 and 3) by 2021, continuing transmission of serotype 1 wild polioviruses to date makes those plans obsolete. With increasing time since the last reported polio case caused by serotype 3 wild poliovirus (in November 2012) leading to high confidence about its successful global eradication, the Global Commission for the Certification of Poliomyelitis Eradication recently certified its eradication. Questions now arise about the optimal timing of serotype 3 OPV (OPV3) cessation. Using an integrated global model that characterizes the risks, costs, and benefits of global polio policy and risk management options, we explored the implications of different options for coordinated cessation of OPV3 prior to COVID-19. Globally coordinating cessation of OPV3 as soon as possible offers the opportunity to reduce cases of vaccine-associated paralytic polio globally. In addition, earlier cessation of OPV3 should reduce the risks of creating serotype 3 circulating vaccine-derived polioviruses after OPV3 cessation, which represents a significant threat to the polio endgame given current GPEI plans to reduce preventive OPV supplemental immunization activities starting in 2019.
C1 [Kalkowska, Dominika A.; Thompson, Kimberly M.] Kid Risk Inc, 7512 Dr Phillips Blvd 50-523, Orlando, FL 32819 USA.
RP Thompson, KM (corresponding author), Kid Risk Inc, 7512 Dr Phillips Blvd 50-523, Orlando, FL 32819 USA.
EM kimt@kidrisk.org
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [5NU2RGH001913-03-00]
FX This publication was supported by Cooperative Agreement Number
   5NU2RGH001913-03-00 funded by the Centers for Disease Control and
   Prevention. Its contents are solely the responsibility of the authors
   and do not necessarily represent the official views of the Centers for
   Disease Control and Prevention or the Department of Health and Human
   Services.
CR Hampton LM, 2016, MMWR-MORBID MORTAL W, V65, P934, DOI 10.15585/mmwr.mm6535a3
   Kalkowska DA, 2020, RISK ANAL, DOI 10.1111/risa.13555
   Kalkowska DA, 2020, RISK ANAL, DOI 10.1111/risa.13486
   Kalkowska DA, 2020, RISK ANAL, DOI 10.1111/risa.13447
   Kalkowska DA, 2019, RISK ANAL, V39, P402, DOI 10.1111/risa.13214
   Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, 2019, WORLD POP PROSP 2019
   Tebbens RJD, 2017, EPIDEMIOL INFECT, V145, P217, DOI 10.1017/S0950268816002302
   Tebbens RJD, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023938
   Tebbens RJD, 2018, FUTURE VIROL, V13, P617, DOI 10.2217/fvl-2018-0079
   Tebbens RJD, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3074-0
   Tebbens Radboud J Duintjer, 2016, J Vaccines Vaccin, V7, DOI 10.4172/2157-7560.1000340
   Tebbens RJD, 2017, EXPERT REV VACCINES, V16, P577, DOI 10.1080/14760584.2017.1322514
   Tebbens RJD, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1537-8
   Tebbens RJD, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1536-9
   Tebbens RJD, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1465-7
   Tebbens RJD, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1114-6
   Thompson KM, 2020, EXPERT REV VACCINES, V19, P661, DOI 10.1080/14760584.2020.1791093
   Thompson KM, 2019, EXPERT REV VACCINES, V18, P725, DOI 10.1080/14760584.2019.1635463
   Thompson KM, 2017, J INFECT DIS, V216, pS176, DOI 10.1093/infdis/jix108
   Thompson KM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1113-7
   Thompson KM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1116-4
   Thompson KM, 2014, LANCET, V384, P1480, DOI 10.1016/S0140-6736(14)60983-1
   Thompson KM, 2014, J INFECT DIS, V210, pS475, DOI 10.1093/infdis/jit845
   UNICEF, 2019, MARK UPD OR POL VACC
   WHO, 2019, 2 OUT 3 WILD POL STR
   World Bank, 2019, WORLD BANK LIST EC J
   World Health Organization, 2018, 18 M GLOB COMM CERT
   World Health Organization, 2020, POL THIS WEEK 19 FEB
   World Health Organization, 2013, YEAR TYP 3 COULD TYP
   World Health Organization and UNICEF, 2018, 17 WHO UNICEF CONS O
   World Health Organization Global Polio Eradication Initiative, 2015, WHOPOLIO1504
   World Health Organization Global Polio Eradication Initiative, 2019, WHOPOLIO1904
NR 32
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4332
EI 1539-6924
J9 RISK ANAL
JI Risk Anal.
DI 10.1111/risa.13590
EA SEP 2020
PG 8
WC Public, Environmental & Occupational Health; Mathematics,
   Interdisciplinary Applications; Social Sciences, Mathematical Methods
SC Public, Environmental & Occupational Health; Mathematics; Mathematical
   Methods In Social Sciences
GA NO4ZN
UT WOS:000569493100001
PM 32936466
DA 2021-01-01
ER

PT J
AU Sorokina, M
   Teixeira, JMC
   Barrera-Vilarmau, S
   Paschke, R
   Papasotiriou, I
   Rodrigues, JPGLM
   Kastritis, PL
AF Sorokina, Marija
   M. C. Teixeira, Joao
   Barrera-Vilarmau, Susana
   Paschke, Reinhard
   Papasotiriou, Ioannis
   Rodrigues, Joao P. G. L. M.
   Kastritis, Panagiotis L.
TI Structural models of human ACE2 variants with SARS-CoV-2 Spike protein
   for structure-based drug design
SO SCIENTIFIC DATA
LA English
DT Article; Data Paper
ID DETERMINANTS; ENTRY
AB Emergence of coronaviruses poses a threat to global health and economy. The current outbreak of SARS-CoV-2 has infected more than 28,000,000 people and killed more than 915,000. To date, there is no treatment for coronavirus infections, making the development of therapies to prevent future epidemics of paramount importance. To this end, we collected information regarding naturally-occurring variants of the Angiotensin-converting enzyme 2 (ACE2), an epithelial receptor that both SARS-CoV and SARS-CoV-2 use to enter the host cells. We built 242 structural models of variants of human ACE2 bound to the receptor binding domain (RBD) of the SARS-CoV-2 surface spike glycoprotein (S protein) and refined their interfaces with HADDOCK. Our dataset includes 140 variants of human ACE2 representing missense mutations found in genome-wide studies, 39 mutants with reported effects on the recognition of the RBD, and 63 predictions after computational alanine scanning mutagenesis of ACE2-RBD interface residues. This dataset will help accelerate the design of therapeutics against SARS-CoV-2, as well as contribute to prevention of possible future coronaviruses outbreaks.
C1 [Sorokina, Marija; Kastritis, Panagiotis L.] Martin Luther Univ Halle Wittenberg, Inst Biochem & Biotechnol, Kurt Mothes Str 3, D-06120 Halle, Germany.
   [Sorokina, Marija; Papasotiriou, Ioannis] RGCC Int GmbH, Baarerstr 95, CH-6300 Zug, Switzerland.
   [Sorokina, Marija; Paschke, Reinhard] BioSolut GmbH, Weinbergweg 22, D-06120 Halle, Germany.
   [M. C. Teixeira, Joao] Hosp Sick Children, Program Mol Med, Toronto, ON M5G 0A4, Canada.
   [Barrera-Vilarmau, Susana] CSIC, Inst Adv Chem Catalonia IQAC, Jordi Girona 18-26, Barcelona 08034, Spain.
   [Paschke, Reinhard; Kastritis, Panagiotis L.] Martin Luther Univ Halle Wittenberg, Biozentrum, Weinbergweg 22, D-06120 Halle, Germany.
   [Rodrigues, Joao P. G. L. M.] Stanford Univ, Dept Struct Biol, Stanford, CA 94305 USA.
   [Kastritis, Panagiotis L.] Martin Luther Univ Halle Wittenberg, Interdisciplinary Res Ctr HALOmem, Charles Tanford Prot Ctr, Kurt Mothes Str 3a, D-06120 Halle, Germany.
RP Kastritis, PL (corresponding author), Martin Luther Univ Halle Wittenberg, Inst Biochem & Biotechnol, Kurt Mothes Str 3, D-06120 Halle, Germany.; Kastritis, PL (corresponding author), Martin Luther Univ Halle Wittenberg, Biozentrum, Weinbergweg 22, D-06120 Halle, Germany.; Kastritis, PL (corresponding author), Martin Luther Univ Halle Wittenberg, Interdisciplinary Res Ctr HALOmem, Charles Tanford Prot Ctr, Kurt Mothes Str 3a, D-06120 Halle, Germany.
EM panagiotis.kastritis@bct.uni-halle.de
RI Teixeira, Joao Miguel Correia/ABD-1037-2020; Barrera-Vilarmau,
   Susana/ABD-1039-2020; Rodrigues, Joao/J-6579-2013
OI Teixeira, Joao Miguel Correia/0000-0002-9113-0622; Barrera-Vilarmau,
   Susana/0000-0003-4868-6593; Kastritis, Panagiotis/0000-0002-1463-8422;
   Rodrigues, Joao/0000-0001-9796-3193; PAPASOTIRIOU,
   IOANNIS/0000-0002-6145-946X
FU Federal Ministry for Education and Research (BMBF, ZIK program)Federal
   Ministry of Education & Research (BMBF) [03Z22HN23]; European Regional
   Development Funds for Saxony-Anhalt [EFRE: ZS/2016/04/78115]; Deutsche
   Forschungsgemeinschaft (DFG, German Research Foundation)German Research
   Foundation (DFG) [RTG 2467, 391498659]; R.G.C.C. International GmbH;
   BioSolutions GmbH; Martin Luther University Halle-Wittenberg; Projekt
   DEAL
FX This work was supported by the Federal Ministry for Education and
   Research (BMBF, ZIK program) [grant number 03Z22HN23 (to P.L.K.)]; the
   European Regional Development Funds for Saxony-Anhalt [grant number
   EFRE: ZS/2016/04/78115 (to P.L.K.)], the Deutsche Forschungsgemeinschaft
   (DFG, German Research Foundation), RTG 2467, project number 391498659
   (to P.L.K.), R.G.C.C. International GmbH (to M.S.), BioSolutions GmbH
   (to M.S.) and the Martin Luther University Halle-Wittenberg. Open access
   funding provided by Projekt DEAL.
CR Ali F., 2020, BIORXIV PREPRINT, DOI [10.1101/2020.05.08.084384, DOI 10.1101/2020.05.08.084384]
   [Anonymous], 2020, FIGSHARE, DOI [10.6084/m9.figshare.12458591, DOI 10.6084/M9.FIGSHARE.12458591]
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Benetti E, 2020, EUR J HUM GENET, V28, P1602, DOI 10.1038/s41431-020-0691-z
   Chen YY, 2018, J CLIN PHARM THER, V43, P189, DOI 10.1111/jcpt.12625
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Fokkema IFAC, 2011, HUM MUTAT, V32, P557, DOI 10.1002/humu.21438
   Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57
   Han DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/j.virol.2006.01.029
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussain M, 2020, J MED VIROL, V92, P1580, DOI 10.1002/jmv.25832
   Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7
   Kastritis PL, 2014, J MOL BIOL, V426, P2632, DOI 10.1016/j.jmb.2014.04.017
   Kastritis PL, 2013, PROTEINS, V81, P510, DOI 10.1002/prot.24210
   Kastritis PL, 2010, J PROTEOME RES, V9, P2216, DOI 10.1021/pr9009854
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Procko Erik, 2020, bioRxiv, DOI 10.1101/2020.03.16.994236
   Rushworth CA, 2008, FEBS J, V275, P6033, DOI 10.1111/j.1742-4658.2008.06733.x
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sorokina M, 2020, SBGRID, DOI [10.15785/SBGRID/791, DOI 10.15785/SBGRID/791]
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   Vangone A, 2017, PROTEINS, V85, P417, DOI 10.1002/prot.25198
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
NR 34
TC 1
Z9 1
U1 1
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2052-4463
J9 SCI DATA
JI Sci. Data
PD SEP 16
PY 2020
VL 7
IS 1
AR 309
DI 10.1038/s41597-020-00652-6
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NP0HB
UT WOS:000569863700001
PM 32938937
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wendel, S
   Kutner, JM
   Machado, R
   Fontao-Wendel, R
   Bub, C
   Fachini, R
   Yokoyama, A
   Candelaria, G
   Sakashita, A
   Achkar, R
   Hamerschlak, N
   Scuracchio, P
   Amaral, M
   Dal Ben, M
   Araujo, D
   Soares, C
   Camargo, A
   Kallas, E
   Durigon, E
   Reis, LF
   Rizzo, LV
AF Wendel, Silvano
   Kutner, Jose Mauro
   Machado, Rafael
   Fontao-Wendel, Rita
   Bub, Carolina
   Fachini, Roberta
   Yokoyama, Ana
   Candelaria, Gabriela
   Sakashita, Araci
   Achkar, Ruth
   Hamerschlak, Nelson
   Scuracchio, Patricia
   Amaral, Marcelo
   Dal Ben, Mirian
   Araujo, Danielle
   Soares, Camila
   Camargo, Anamaria
   Kallas, Esper
   Durigon, Edison
   Reis, Luiz Fernando
   Rizzo, Luiz Vicente
TI Screening forSARS-CoV-2 antibodies in convalescent plasma in Brazil:
   Preliminary lessons from a voluntary convalescent donor program
SO TRANSFUSION
LA English
DT Article
DE convalescent plasma therapy; COVID-19; passive immune therapy;
   SARS-COV-2; coronavirus
ID NEUTRALIZING ANTIBODIES; CORONAVIRUS; INFECTION; IMMUNOTHERAPY;
   SARS-COV-2; PROTECTION; COVID-19; OBESITY; DISEASE; BLOOD
AB Background Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) collection began in two Brazilian hospitals for treatment of severe/critical patients. Methods and Materials Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence of symptoms for >= 14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus-1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT-PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect-based virus neutralization test neutralizing antibody) and anti-nucleocapsid protein SARS-CoV-2 IgM, IgG, and IgA enzyme-linked immunosorbent assays. Results Among 271 donors (41 females, 230 males), 250 presented with neutralizing antibodies. Final RT-PCR was negative on swab (77.0%) or blood (88.4%;P= .46). Final definition of RT-PCR was only defined at more than 28 days after full recovery in 59 of 174 (33.9%) RT-PCR -ve, and 25/69 RT-PCR +ve (36.2%; 13 between 35 and 48 days). Neutralizing antibody titers of 160 or greater were found in 63.6%. Correlation between IgG signal/cutoff of 5.0 or greater and neutralizing antibody of 160 or greater was 82.4%. Combination of final RT-PCR -ve with neutralizing antibody >= 160 was 41.3% (112/271). Serial plasma collection showed decline in neutralizing antibody titers and IgA levels (P< .05), probably denoting a "golden period" for CCP collection (<= 28 days after joining the program); IgA might have an important role as neutralizing antibody. Donor's weight, days between disease onset and serial plasma collection, and IgG and IgM levels are important predictors for neutralizing antibody titer. Conclusions RT-PCR +ve cases are still detected in 36.2% within 28 to 48 days after recovery. High anti-nucleocapsid protein IgG levels may be used as a surrogate marker to neutralizing antibody.
C1 [Wendel, Silvano; Fontao-Wendel, Rita; Fachini, Roberta; Candelaria, Gabriela; Achkar, Ruth; Scuracchio, Patricia; Amaral, Marcelo] Hosp Sirio Libanes Blood Bank, Rua Adma Jafet 91, BR-01308050 Sao Paulo, Brazil.
   [Kutner, Jose Mauro; Bub, Carolina; Yokoyama, Ana; Sakashita, Araci; Hamerschlak, Nelson] Hosp Israelita Albert Einstein Blood Bank, Sao Paulo, Brazil.
   [Machado, Rafael; Araujo, Danielle; Soares, Camila; Durigon, Edison] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo, Brazil.
   [Dal Ben, Mirian; Camargo, Anamaria; Reis, Luiz Fernando] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Rizzo, Luiz Vicente] Albert Einstein Jewish Inst Educ & Res, Sao Paulo, Brazil.
   [Kallas, Esper] Univ Sao Paulo, Sch Med, Infectious Dis Dept, Sao Paulo, Brazil.
RP Wendel, S (corresponding author), Hosp Sirio Libanes Blood Bank, Rua Adma Jafet 91, BR-01308050 Sao Paulo, Brazil.
EM snwendel@terra.com.br
RI Bub, Carolina/N-8010-2018
OI Bub, Carolina/0000-0001-5103-4970
FU Fundacao de. Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo
   a Pesquisa do Estado de Sao Paulo (FAPESP) [2018/23680-0, 2017/24769-2];
   Coordenacao de Aperfeicoamento de Pessoal de. Nivel Superior -
   CAPESCAPES [88 887.131387/2016-00]; Fundacao de Amparo a Pesquisa do
   Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2016/20045-7, 2020/06409-1]
FX C.P.S. is funded by Grant 2018/23680-0 (Fundacao de. Amparo a Pesquisa
   do Estado de Sao Paulo); D.B.A. by Grant 88 887.131387/2016-00
   (Coordenacao de Aperfeicoamento de Pessoal de. Nivel Superior - CAPES),
   R.R.G.M. by Grant 2017/24769-2 (Fundacao de. Amparo a Pesquisa do Estado
   de Sao Paulo) and E.L.D. by Grants 2016/20045-7 and 2020/06409-1
   (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo). All other
   authors have no conflict of interest.
CR Almeida FJ, 2020, PEDIATR INFECT DIS J, V39, pE161, DOI 10.1097/INF.0000000000002737
   [Anonymous], 2020, REC INV COVID 19 CON
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Araujo DB, 2020, MEM I OSWALDO CRUZ, V115, DOI 10.1590/0074-02760200342
   Barone P, 2020, TRANSFUSION, V60, P1123, DOI 10.1111/trf.15843
   Bloch Evan M, 2020, Vox Sang, DOI 10.1111/vox.12970
   Blutt SE, 2012, MUCOSAL IMMUNOL, V5, P712, DOI 10.1038/mi.2012.51
   Brazilian Ministry of Health, 192020SEIGSTCODIRE1A
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Casadevall A, 2020, JAMA-J AM MED ASSOC, V324, P455, DOI 10.1001/jama.2020.10218
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Caussy C, 2020, LANCET DIABETES ENDO, V8, P562, DOI [10.1016/S2213-8587(20)30160-0, 10.1016/S2213-8587(20)30160-1]
   Cervia C, 2020, BIORXIV, DOI [10.1101/2020.05.21.108308, DOI 10.1101/2020.05.21.108308]
   Chang L, 2020, EMERG INFECT DIS, V26, P1631, DOI 10.3201/eid2607.200839
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Dzik S, 2020, TRANSFUS MED REV, V34, P141, DOI 10.1016/j.tmrv.2020.04.002
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Epstein J, 2020, VOX SANG, DOI 10.1111/vox.12964
   Epstein J, 2020, VOX SANG, V115, P485, DOI 10.1111/vox.12939
   European Commission Directorate-General For Health And Food Safety, EU PROGR COVID 19 CO
   Gallup JL, 2019, STATA J, V19, P598, DOI 10.1177/1536867X19874236
   Gniadek TJ, 2020, TRANSFUSION, V60, P1643, DOI 10.1111/trf.15871
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jin YJ, 2020, INT J INFECT DIS, V94, P49, DOI 10.1016/j.ijid.2020.03.065
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Kass DA, 2020, LANCET, V395, P1544, DOI 10.1016/S0140-6736(20)31024-2
   Keil SD, 2020, VOX SANG, V115, P495, DOI 10.1111/vox.12937
   Knudson CM, 2020, TRANSFUSION, V60, P1332, DOI 10.1111/trf.15842
   Kwon SY, 2020, VOX SANG, V115, P601, DOI 10.1111/vox.12925
   Lanteri MC, 2020, TRANSFUSION, V60, P1319, DOI 10.1111/trf.15807
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li N, 2020, J MED VIROL, V92, P2286, DOI 10.1002/jmv.25952
   Li TS, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000024
   Liu STH, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.05.20.20102236, DOI 10.1101/2020.05.20.20102236]
   Liu WD, 2020, J INFECTION, V81, P329, DOI 10.1016/j.jinf.2020.03.063
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Luchsinger Larry L, 2020, medRxiv, DOI 10.1101/2020.06.08.20124792
   Luke TC, 2010, CRIT CARE MED, V38, pE66, DOI 10.1097/CCM.0b013e3181d44c1e
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   McGuire LW, 1919, J AMER MED ASSOC, V72, P709, DOI 10.1001/jama.1919.02610100017007
   Meyer B, 2014, VIRUS RES, V194, P175, DOI 10.1016/j.virusres.2014.03.018
   Mupapa K, 1999, J INFECT DIS, V179, pS18, DOI 10.1086/514298
   Nurtop E, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1105-5
   Oliveira DBL, 2016, NEW ENGL J MED, V375, P1202, DOI 10.1056/NEJMc1607583
   Park WH, 1932, J AMER MED ASSOC, V99, P1050, DOI 10.1001/jama.1932.02740650008003
   Park WH, 1926, J AMER MED ASSOC, V87, P556, DOI 10.1001/jama.1926.02680080022009
   RAMBAR AC, 1946, AM J DIS CHILD, V71, P1
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Robbiani Davide F, 2020, bioRxiv, DOI 10.1101/2020.05.13.092619
   Sahr F, 2017, J INFECTION, V74, P302, DOI 10.1016/j.jinf.2016.11.009
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   STINEBAUGH BJ, 1966, AM J MED, V40, P217, DOI 10.1016/0002-9343(66)90103-3
   Tan CW, 2020, NAT RES
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Tu CC, 2004, EMERG INFECT DIS, V10, P2244, DOI 10.3201/eid1012.040520
   Valk SJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600
   Walsh EE, 2004, J INFECT DIS, V190, P373, DOI 10.1086/421524
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wong HK, 2020, VOX SANG, V115, P545, DOI 10.1111/vox.12927
   World Health Organization, NAM COR DIS COVID 19
   World Health Organization (WHO), 2020, LAB TEST COR DIS 201, P1
   World Health Organization (WHO), 2020, 2020WHO2019NCOVCLINI
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yan HM, 2002, J VIROL, V76, P10972, DOI 10.1128/JVI.76.21.10972-10979.2002
   Yang JR, 2020, J MED VIROL, V92, P1681, DOI 10.1002/jmv.25940
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang JS, 2005, J MED VIROL, V77, P147, DOI 10.1002/jmv.20431
   Zhang Q, 2020, SARS COV 2 NEUTRALIZ
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11080743
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
NR 80
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD DEC
PY 2020
VL 60
IS 12
BP 2938
EP 2951
DI 10.1111/trf.16065
EA SEP 2020
PG 14
WC Hematology
SC Hematology
GA PB1EO
UT WOS:000569937100001
PM 32935877
OA Other Gold
DA 2021-01-01
ER

PT J
AU Molaei, H
   Khedmat, L
   Nemati, E
   Rostami, Z
   Saadat, SH
AF Molaei, Hamideh
   Khedmat, Leila
   Nemati, Eghlim
   Rostami, Zohreh
   Saadat, Seyed Hassan
TI Iranian kidney transplant recipients with COVID-19 infection: Clinical
   outcomes and cytomegalovirus coinfection
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article; Early Access
DE COVID-19; cytomegalovirus; kidney transplantation; renal disease; viral
   coinfection
AB Background There is a high risk of COVID-19 in kidney transplant recipients (KTRs) because of chronic immunosuppression and severe cytomegalovirus (CMV) pneumonitis. Case presentation A case series of 10 KTRs with COVID-19 in Iran was developed. Participants consisted of two female and eight male patients, aged 46-68 years old. The data related to clinical laboratory tests, outcomes, diagnosis, and drug treatments were collected. The RT-PCR confirmed the COVID-19 infection in KTRs. The assessment of serum biochemical and blood hematological factors showed that there was a strong correlation between COVID-19 intensity and high serum Cr, BUN, and ALT levels, high CRP concentration, and lower lymphocyte and platelet counts in male KTRs. Ground-glass opacity (GGO) was the main radiologic pattern visible on both chest radiographs of computed tomography scans. The COVID-19 and CMV coinfection in KTRs resulted in large-size kidneys with severe parenchymal echogenicity and hydronephrosis. The combined use of effective antibiotic and antiviral drugs was suitable to prevent COVID-19 progression in KTRs. Conclusions The coincidence of COVID-19 and CMV in KTRs may potentially increase the mortality risk of patients. The levels of Cr, BUN, ALT, and CRP as well as lymphocytes count in these patients should be continuously controlled.
C1 [Molaei, Hamideh] Baqiyatallah Univ Med Sci, Trauma Res Ctr, Tehran, Iran.
   [Khedmat, Leila] Baqiyatallah Univ Med Sci, Hlth Management Res Ctr, Tehran, Iran.
   [Nemati, Eghlim; Rostami, Zohreh] Baqiyatallah Univ Med Sci, Nephrol & Urol Res Ctr, Tehran, Iran.
   [Saadat, Seyed Hassan] Baqiyatallah Univ Med Sci, Behav Sci Res Ctr, Tehran, Iran.
RP Khedmat, L (corresponding author), Baqiyatallah Univ Med Sci, Hlth Management Res Ctr, Tehran, Iran.
EM lkhedmat@yahoo.com
CR Abu Jawdeh Bassam G, 2020, Adv Chronic Kidney Dis, V27, P383, DOI 10.1053/j.ackd.2020.07.004
   Alberici F, 2020, KIDNEY INT REP, V5, P580, DOI 10.1016/j.ekir.2020.04.001
   Babazadeh A, 2017, CASP J INTERN MED, V8, P23
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Bartiromo M, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13286
   Billah M, 2020, TRANSPL INT, V33, P1140, DOI 10.1111/tri.13635
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Chun J, 2015, INTEST RES, V13, P50, DOI 10.5217/ir.2015.13.1.50
   Dangi A, 2020, KIDNEY INT, V98, P147, DOI 10.1016/j.kint.2020.01.034
   Gandolfini I, 2020, AM J TRANSPLANT, V20, P1941, DOI 10.1111/ajt.15891
   Gotoh Y, 2020, TRANSPL INFECT DIS, V22, DOI 10.1111/tid.13271
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Hashemifesharaki R, 2020, NUTRIRE, V45, DOI [10.1186/s41110-020-00122-4, DOI 10.1186/S41110-020-00122-4]
   Jehn U, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010252
   Johnson KM, 2020, PHARMACOTHERAPY, V40, P517, DOI 10.1002/phar.2410
   Khedmat L, 2020, INT J TRAVEL MED GLO, V8, P44
   Li Z, 2020, CAUTION KIDNEY DYSFU, DOI [10.1101/2020.02.08.20021212, DOI 10.1101/2020.02.08.20021212]
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Marx D, 2020, AM J TRANSPLANT, V20, P1944, DOI 10.1111/ajt.15919
   Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2
   Mirzadeh M, 2020, J MATERN-FETAL NEO M, DOI 10.1080/14767058.2020.1749257
   Osman NM, 2014, EGYPT J CHEST DIS TU, V63, P239, DOI 10.1016/j.ejcdt.2013.09.022
   Rahbar M, 2019, FUTURE VIROL, V14, P419, DOI 10.2217/fvl-2018-0192
   Shaiegan M, 2015, IRAN J BASIC MED SCI, V18, P627
   Shingare A, 2020, AM J TRANSPLANT, V20, P3206, DOI 10.1111/ajt.16120
   Tan CC, 2020, J MED VIROL, V92, P856, DOI 10.1002/jmv.25871
   Tang Bin, 2020, Kidney Med, V2, P354, DOI 10.1016/j.xkme.2020.03.001
   Taylor DM, 2019, DEV CELL, V49, P10, DOI 10.1016/j.devcel.2019.03.001
   Thammathiwat T, 2020, TRANSPL INFECT DIS, DOI 10.1111/tid.13388
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang H, 2020, EUR UROL, V77, P742, DOI 10.1016/j.eururo.2020.03.030
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 37
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
AR e13455
DI 10.1111/tid.13455
EA SEP 2020
PG 9
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA NO4WQ
UT WOS:000569485600001
PM 32881220
OA Bronze
DA 2021-01-01
ER

PT J
AU Spinner, CD
   Gottlieb, RL
   Criner, GJ
   Lopez, JRA
   Cattelan, AM
   Viladomiu, AS
   Ogbuagu, O
   Malhotra, P
   Mullane, KM
   Castagna, A
   Chai, LYA
   Roestenberg, M
   Tsang, OTY
   Bernasconi, E
   Le Turnier, P
   Chang, SC
   SenGupta, D
   Hyland, RH
   Osinusi, AO
   Cao, HY
   Blair, C
   Wang, HY
   Gaggar, A
   Brainard, DM
   McPhail, MJ
   Bhagani, S
   Ahn, Y
   Sanyal, AJ
   Huhn, G
   Marty, FM
AF Spinner, Christoph D.
   Gottlieb, Robert L.
   Criner, Gerard J.
   Arribas Lopez, Jose Ramon
   Cattelan, Anna Maria
   Soriano Viladomiu, Alex
   Ogbuagu, Onyema
   Malhotra, Prashant
   Mullane, Kathleen M.
   Castagna, Antonella
   Chai, Louis Yi Ann
   Roestenberg, Meta
   Tsang, Owen Tak Yin
   Bernasconi, Enos
   Le Turnier, Paul
   Chang, Shan-Chwen
   SenGupta, Devi
   Hyland, Robert H.
   Osinusi, Anu O.
   Cao, Huyen
   Blair, Christiana
   Wang, Hongyuan
   Gaggar, Anuj
   Brainard, Diana M.
   McPhail, Mark J.
   Bhagani, Sanjay
   Ahn, Young
   Sanyal, Arun J.
   Huhn, Gregory
   Marty, Francisco M.
CA GS-US-540-5774 Investigators
TI Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in
   Patients With Moderate COVID-19 A Randomized Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
AB IMPORTANCE Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown.
   OBJECTIVE To determine the efficacy of 5 or 10 days of remdesivir treatment compared with standard care on clinical status on day 11 after initiation of treatment.
   DESIGN, SETTING, AND PARTICIPANTS Randomized, open-label trial of hospitalized patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and moderate COVID-19 pneumonia (pulmonary infiltrates and room-air oxygen saturation >94%) enrolled from March 15 through April 18, 2020, at 105 hospitals in the United States, Europe, and Asia. The date of final follow-up was May 20, 2020.
   INTERVENTIONS Patients were randomized in a 1:1:1 ratio to receive a 10-day course of remdesivir (n = 197), a 5-day course of remdesivir (n = 199), or standard care (n = 200). Remdesivir was dosed intravenously at 200 mg on day 1 followed by 100 mg/d.
   MAIN OUTCOMES AND MEASURES The primary end point was clinical status on day 11 on a 7-point ordinal scale ranging from death (category 1) to discharged (category 7). Differences between remdesivir treatment groups and standard care were calculated using proportional odds models and expressed as odds ratios. An odds ratio greater than 1 indicates difference in clinical status distribution toward category 7 for the remdesivir group vs the standard care group.
   RESULTS Among 596 patients who were randomized, 584 began the study and received remdesivir or continued standard care (median age, 57 [interquartile range, 46-66] years; 227 [39%] women; 56% had cardiovascular disease, 42% hypertension, and 40% diabetes), and 533 (91%) completed the trial. Median length of treatment was 5 days for patients in the 5-day remdesivir group and 6 days for patients in the 10-day remdesivir group. On day 11, patients in the 5-day remdesivir group had statistically significantly higher odds of a better clinical status distribution than those receiving standard care (odds ratio, 1.65; 95% CI, 1.09-2.48; P =.02). The clinical status distribution on day 11 between the 10-day remdesivir and standard care groups was not significantly different (P =.18 by Wilcoxon rank sum test). By day 28, 9 patients had died: 2 (1%) in the 5-day remdesivir group, 3 (2%) in the 10-day remdesivir group, and 4 (2%) in the standard care group. Nausea (10% vs 3%), hypokalemia (6% vs 2%), and headache (5% vs 3%) were more frequent among remdesivir-treated patients compared with standard care.
   CONCLUSIONS AND RELEVANCE Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clinical status compared with standard care at 11 days after initiation of treatment. Patients randomized to a 5-day course of remdesivir had a statistically significant difference in clinical status compared with standard care, but the difference was of uncertain clinical importance.
C1 [Spinner, Christoph D.] Sch Med, Univ Hosp Rechts Isar, Tech Univ Munich, Munich, Germany.
   [Gottlieb, Robert L.] Baylor Univ, Med Ctr, Dallas, TX USA.
   [Criner, Gerard J.] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.
   [Arribas Lopez, Jose Ramon] Inst Invest Hosp Univ La Paz, Madrid, Spain.
   [Cattelan, Anna Maria] Azienda Osped Padova, Padua, Italy.
   [Soriano Viladomiu, Alex] IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain.
   [Ogbuagu, Onyema] Yale Sch Med, New Haven, CT USA.
   [Malhotra, Prashant] North Shore Univ Hosp, Manhasset, NY USA.
   [Mullane, Kathleen M.] Univ Chicago, Chicago, IL 60637 USA.
   [Castagna, Antonella] IRCCS San Raffaele Hosp, Milan, Italy.
   [Castagna, Antonella] Univ Vita Salute San Raffaele, Milan, Italy.
   [Chai, Louis Yi Ann] Natl Univ Hlth Syst, Singapore, Singapore.
   [Roestenberg, Meta] Leiden Univ, Med Ctr, Leiden, Netherlands.
   [Tsang, Owen Tak Yin] Princess Margaret Hosp, Hong Kong, Peoples R China.
   [Bernasconi, Enos] Ente Osped Cantonale, Bellinzona, Switzerland.
   [Le Turnier, Paul] Univ Nantes, Nantes, France.
   [Chang, Shan-Chwen] Natl Taiwan Univ Hosp, Taipei, Taiwan.
   [SenGupta, Devi; Hyland, Robert H.; Osinusi, Anu O.; Cao, Huyen; Blair, Christiana; Wang, Hongyuan; Gaggar, Anuj; Brainard, Diana M.] Gilead Sci, 333 Lakeside Dr, Foster City, CA 94404 USA.
   [McPhail, Mark J.] Kings Coll London, London, England.
   [Bhagani, Sanjay] Royal Free Hosp, London, England.
   [Ahn, Young] Seoul Med Ctr, Seoul, South Korea.
   [Sanyal, Arun J.] Virginia Commonwealth Univ, Richmond, VA USA.
   [Huhn, Gregory] Cook Cty Hlth, Chicago, IL USA.
   [Marty, Francisco M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Marty, Francisco M.] Harvard Med Sch, Boston, MA 02115 USA.
RP Brainard, DM (corresponding author), Gilead Sci, 333 Lakeside Dr, Foster City, CA 94404 USA.
EM diana.brainard@gilead.com
RI Le Turnier, Paul/AAF-1879-2019; Marty, Francisco M./H-7088-2019;
   Gottlieb, Robert L/AAM-8310-2020; Haddad, Esther Isabel
   Arbona/AAX-4726-2020
OI Marty, Francisco M./0000-0002-3708-8734; Gottlieb, Robert
   L/0000-0001-8376-8709; Haddad, Esther Isabel Arbona/0000-0001-6264-423X;
   Spinner, Christoph/0000-0002-3875-5367
FU Gilead SciencesGilead Sciences
FX This study was sponsored by Gilead Sciences.
CR Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Cohen PA, 2020, MAYO CLIN PROC, V95, P1124, DOI 10.1016/j.mayocp.2020.04.010
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   European Medicines Agency, 2020, 1 COVID 19 TREATM RE
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa20201436, DOI 10.1056/NEJMOA20201436]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Peterson RL, 2017, CLIN TRIALS, V14, P264, DOI 10.1177/1740774517697919
   Pizzorno A, 2020, ANTIVIR RES, V181, DOI 10.1016/j.antiviral.2020.104878
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   US Food and Drug Administration, 2020, COR COVID 19 UPD FDA
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   World Health Organization, 2020, 202 WHO
   World Health Organization, 2020, COVID 19 THER TRIAL
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI DOI 10.1001/JAMA.2013.281053
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 34
Z9 34
U1 4
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD SEP 15
PY 2020
VL 324
IS 11
BP 1048
EP 1057
DI 10.1001/jama.2020.16349
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA OF2XM
UT WOS:000581077300019
PM 32821939
OA Bronze
DA 2021-01-01
ER

PT J
AU Shi, D
   Wu, WR
   Wang, Q
   Xu, KJ
   Xie, JJ
   Wu, JJ
   Lv, LX
   Sheng, JF
   Guo, J
   Wang, KC
   Fang, DQ
   Li, YT
   Li, LJ
AF Shi, Ding
   Wu, Wenrui
   Wang, Qing
   Xu, Kaijin
   Xie, Jiaojiao
   Wu, Jingjing
   Lv, Longxian
   Sheng, Jifang
   Guo, Jing
   Wang, Kaicen
   Fang, Daiqiong
   Li, Yating
   Li, Lanjuan
TI Clinical Characteristics and Factors Associated With Long-Term Viral
   Excretion in Patients With Severe Acute Respiratory Syndrome Coronavirus
   2 Infection: a Single-Center 28-Day Study
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE SARS-CoV-2; viral excretion; disease severity; risk factors; lymphocyte
   function
ID SARS; THERAPY
AB Background. Despite the ongoing spread of coronavirus disease 2019 (COVID-19), knowledge about factors affecting prolonged viral excretion is limited.
   Methods. In this study, we retrospectively collected data from 99 hospitalized patients with coronavirus disease 2019 (COVID-19) between 19 January and 17 February 2020 in Zhejiang Province, China. We classified them into 2 groups based on whether the virus test results eventually became negative. Cox proportional hazards regression was used to evaluate factors associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shedding.
   Results. Among 99 patients, 61 patients had SARS-CoV-2 clearance (virus-negative group), but 38 patients had sustained positive results (virus-positive group). The median duration of SARS-CoV-2 excretion was 15 (interquartile range, 12-19) days among the virus-negative patients. The shedding time was significantly increased if the fecal SARS-CoV-2 RNA test result was positive. Male sex (hazard ratio [HR], 0.58 [95% confidence interval {CI}, .35-.98]), immunoglobulin use (HR, 0.42 [95% CI, .24-.76]), APACHE II score (HR, 0.89 [95% CI, .84-.96]), and lymphocyte count (HR, 1.81 [95% CI, 1.05-3.1]) were independent factors associated with a prolonged duration of SARS-CoV-2 shedding. Antiviral therapy and corticosteroid treatment were not independent factors.
   Conclusions. SARS-CoV-2 RNA clearance time was associated with sex, disease severity, and lymphocyte function. The current antiviral protocol and low-to-moderate dosage of corticosteroid had little effect on the duration of viral excretion.
C1 [Shi, Ding; Wu, Wenrui; Wang, Qing; Xu, Kaijin; Xie, Jiaojiao; Wu, Jingjing; Lv, Longxian; Sheng, Jifang; Guo, Jing; Wang, Kaicen; Li, Yating; Li, Lanjuan] Zhejiang Univ, Affiliated Hosp 1, Coll Med,Collaborat Innovat Ctr Diag & Treatment, State Key Lab Diag & Treatment Infect Dis,Natl Cl, Hangzhou, Peoples R China.
   [Fang, Daiqiong] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Endocrinol & Metab, Hangzhou, Peoples R China.
RP Li, LJ (corresponding author), Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Affiliated Hosp 1, Coll Med, 79 Qingchun Rd, Hangzhou 310003, Peoples R China.
EM ljli@zju.edu.cn
FU Science and Technology Department of Zhejiang Province [2020c03123-1];
   Zhejiang Provincial Natural Science Foundation of ChinaNatural Science
   Foundation of Zhejiang Province [LQ20H030010]; National Key Research and
   Development Program of China [2018YFC2000500]
FX This study was funded by Science and Technology Department of Zhejiang
   Province (grant number 2020c03123-1); the Zhejiang Provincial Natural
   Science Foundation of China (grant number LQ20H030010); and the National
   Key Research and Development Program of China (grant number
   2018YFC2000500). We thank all patients involved in the study and all the
   front-line medical staff in the First Affiliated Hospital, School of
   Medicine, Zhejiang University.
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Clotet-Freixas S, 2018, LAB INVEST, V98, P1237, DOI 10.1038/s41374-018-0084-x
   Collins AR, 2002, CLIN DIAGN LAB IMMUN, V9, P1392, DOI 10.1128/CDLI.9.6.1392-1395.2002
   Corman VM, 2016, CLIN INFECT DIS, V62, P477, DOI 10.1093/cid/civ951
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Khamitov R. A., 2008, Voprosy Virusologii, V53, P9
   Ko JH, 2016, J INFECTION, V73, P468, DOI 10.1016/j.jinf.2016.08.005
   Lang ZW, 2003, PATHOLOGY, V35, P526, DOI 10.1080/00313020310001619118
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Leong HN, 2006, ANN ACAD MED SINGAP, V35, P326
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535
   Liu W, 2004, EMERG INFECT DIS, V10, P1841, DOI 10.3201/eid1010.040297
   McGeer A, 2007, CLIN INFECT DIS, V45, P1568, DOI 10.1086/523584
   Min CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep25359
   MOFENSON LM, 1992, JAMA-J AM MED ASSOC, V268, P483, DOI 10.1001/jama.268.4.483
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Park WB, 2018, INT J INFECT DIS, V72, P8, DOI 10.1016/j.ijid.2018.05.003
   Raboud J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010717
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sung JJY, 2004, THORAX, V59, P414, DOI 10.1136/thx.2003.014076
   Wan S, 2020, CHARACTERISTICS LYMP, DOI [10.1101/2020.02.10.20021832v1, DOI 10.1101/2020.02.10.20021832V1]
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou XY, 2015, INT J INFECT DIS, V30, P144, DOI 10.1016/j.ijid.2014.11.005
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 34
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 15
PY 2020
VL 222
IS 6
BP 910
EP 918
DI 10.1093/infdis/jiaa388
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5WB
UT WOS:000577174800008
PM 32614392
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Xiang, DC
   Xiang, X
   Zhang, W
   Yi, SD
   Zhang, JX
   Gu, XL
   Xu, YW
   Huang, K
   Su, X
   Yu, B
   Wang, Y
   Fang, WY
   Huo, Y
   Ge, JB
AF Xiang, Dingcheng
   Xiang, Xin
   Zhang, Wei
   Yi, Shaodong
   Zhang, Jinxia
   Gu, Xiaolong
   Xu, Yawei
   Huang, Kai
   Su, Xi
   Yu, Bo
   Wang, Yan
   Fang, Weiyi
   Huo, Yong
   Ge, Junbo
TI Management and Outcomes of Patients With STEMI During the COVID-19
   Pandemic in China
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE chest pain center; COVID-19; primary percutaneous coronary intervention;
   ST-segment elevation myocardial infarction; thrombolysis
AB BACKGROUND ST-segment elevation myocardial infarction (STEMI) is a fatal cardiovascular emergency requiring rapid reperfusion treatment. During the coronavirus disease-2019 (COVID-19) pandemic, medical professionals need to strike a balance between providing timely treatment for STEMI patients and implementing infection control procedures to prevent nosocomial spread of COVID-19 among health care workers and other vulnerable cardiovascular patients.
   OBJECTIVES This study evaluates the impact of the COVID-19 outbreak and China Chest Pain Center's modified STEMI protocol on the treatment and prognosis of STEMI patients in China.
   METHODS Based on the data of 28,189 STEMI patients admitted to 1,372 Chest Pain Centers in China between December 27, 2019 and February 20, 2020, the study analyzed how the COVID-19 outbreak and China Chest Pain Center's modified STEMI protocol influenced the number of admitted STEMI cases, reperfusion strategy, key treatment time points, and in-hospital mortality and heart failure for STEMI patients.
   RESULTS The COVID-19 outbreak reduced the number of STEMI cases reported to China Chest Pain Centers. Consistent with China Chest Pain Center's modified STEMI protocol, the percentage of patients undergoing primary percutaneous coronary intervention declined while the percentage of patients undergoing thrombolysis increased. With an average delay of approximately 20 min for reperfusion therapy, the rate of in-hospital mortality and in-hospital heart failure increased during the outbreak, but the rate of in-hospital hemorrhage remained stable.
   CONCLUSIONS There were reductions in STEMI patients' access to care, delays in treatment timelines, changes in reperfusion strategies, and an increase of in-hospital mortality and heart failure during the COVID-19 pandemic in China. (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
C1 [Xiang, Dingcheng; Yi, Shaodong; Zhang, Jinxia; Gu, Xiaolong] PLA, Dept Cardiol, Gen Hosp, Southern Theatre Command, Liuhua Rd 111, Guangzhou 510010, Peoples R China.
   [Xiang, Xin] Harvard Univ, Grad Sch Arts & Sci, Cambridge, MA 02138 USA.
   [Zhang, Wei] Fudan Univ, Sch Publ Hlth, Dept Biostat, Shanghai, Peoples R China.
   [Xu, Yawei] Tongji Univ, Dept Cardiol, Hosp 10, Shanghai, Peoples R China.
   [Huang, Kai] Huazhong Univ Sci & Technol, Dept Cardiol, Union Hosp, Wuhan, Peoples R China.
   [Su, Xi] Wuhan Asia Heart Hosp, Dept Cardiol, Wuhan, Peoples R China.
   [Yu, Bo] Harbin Med Univ, Dept Cardiol, Educ Minist Myocardial Ischemia Mech & Treatment, Key Labs,Affiliated Hosp 2, Harbin, Peoples R China.
   [Wang, Yan] Xiamen Heart Ctr, Dept Cardiol, Xiamen, Peoples R China.
   [Fang, Weiyi] Shanghai Dongfang Hosp, Dept Cardiol, Shanghai, Peoples R China.
   [Huo, Yong] Peking Univ First Hosp, Dept Cardiol, 8 St Xishiku, Beijing, Peoples R China.
   [Ge, Junbo] Fudan Univ, Zhongshan Hosp, Dept Cardiol, Shanghai, Peoples R China.
RP Xiang, DC (corresponding author), PLA, Dept Cardiol, Gen Hosp, Southern Theatre Command, Liuhua Rd 111, Guangzhou 510010, Peoples R China.; Huo, Y (corresponding author), Peking Univ First Hosp, Dept Cardiol, 8 St Xishiku, Beijing, Peoples R China.
EM dcxiang@foxmail.com; drhuoyong@163.com
FU Ministry of Science and Technology of the People's Republic of
   ChinaMinistry of Science and Technology, China [2016YFC1301201]
FX Drs. Dingcheng Xiang and Xin Xiang contributed equally to this work.
   This study is supported by Ministry of Science and Technology of the
   People's Republic of China (2016YFC1301201). The authors have reported
   that they have no relationships relevant to the contents of this paper
   to disclose.
CR Al-Azizi K, 2020, CURR CARDIOL REP, V22, DOI 10.1007/s11886-020-01301-5
   Ardati AK, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006661
   Daniels MJ, 2020, CIRCULATION, V141, P1948, DOI 10.1161/CIRCULATIONAHA.120.047122
   Daralammouri Y, 2020, PALEST MED PHARM J, V5, P65
   di Uccio FS, 2020, G ITAL CARDIOL, V21, P332, DOI 10.1714/3343.33129
   Dingcheng X., 2017, CARDIOL PLUS, V2, P18
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Ibanez B, 2018, EUR HEART J, V39, P119, DOI 10.1093/eurheartj/ehx393
   Mahmud E, 2020, J AM COLL CARDIOL, V76, P1375, DOI 10.1016/j.jacc.2020.04.039
   Rodriguez-Leor O, 2020, REC INTERV CARDIOL, V2, P82, DOI DOI 10.24875/RECIC.M20000120
   Rodriguez- Leor O, 2020, J AM COLL CARDIOL CA
   Sadeghipour P, 2020, CATHETER CARDIOVASC
   Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631
   Xiang D, 2020, CARDIOL PLUS, V5, P21
   Zaman S, 2020, MED J AUSTRALIA, DOI 10.5694/mja2.50714
   Zhang Y, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026362
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 18
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD SEP 15
PY 2020
VL 76
IS 11
BP 1318
EP 1324
DI 10.1016/j.jacc.2020.06.039
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OA6XJ
UT WOS:000577925000007
PM 32828614
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Faguer, S
   Del Bello, A
   Abravanel, F
   Nicolau-Travers, ML
   Kamar, N
AF Faguer, Stanislas
   Del Bello, Arnaud
   Abravanel, Florence
   Nicolau-Travers, Marie-Laure
   Kamar, Nassim
TI Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient
   With COVID-19
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
ID THERAPY
C1 [Faguer, Stanislas; Del Bello, Arnaud; Abravanel, Florence; Nicolau-Travers, Marie-Laure; Kamar, Nassim] Univ Hosp Toulouse, Toulouse, France.
RP Faguer, S (corresponding author), Hop Rangueil, Dept Nephrol & Transplantat Organes, Unite Reanimat, INSERM,U1048,Equipe 12,I2MC, 1 Ave Jean Poulhes, F-31059 Toulouse, France.
EM faguer.s@chu-toulouse.fr
CR Faguer S, 2016, HEMATOL ONCOL, V34, P55, DOI 10.1002/hon.2174
   Fardet L, 2014, ARTHRITIS RHEUMATOL, V66, P2613, DOI 10.1002/art.38690
   Fitzgerald JC, 2017, CRIT CARE MED, V45, pE124, DOI 10.1097/CCM.0000000000002053
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 5
TC 4
Z9 4
U1 1
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD SEP 15
PY 2020
VL 173
IS 6
BP 501
EP +
DI 10.7326/L20-0419
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA NX3SZ
UT WOS:000575633300030
PM 32432518
OA Green Published
DA 2021-01-01
ER

PT J
AU Li, DM
   Liu, CM
   Liu, JH
   Hu, JF
   Yang, YL
   Zhou, YF
AF Li, Dianming
   Liu, Chuanmiao
   Liu, Jiahui
   Hu, Junfeng
   Yang, Yanli
   Zhou, Yufu
TI Analysis of Risk Factors for 24 Patients With COVID-19 Developing From
   Moderate to Severe Condition
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Article
DE COVID-19; moderate; severe; risk factors; IL-6
AB Objective:The present study aimed at investigating the clinical risk factors for COVID-19 patients developing from moderate condition to severe condition, and providing reference for early intervention and prognosis. Methods:We collected the clinical data of 24 patients with moderate-to-severe COVID-19 who were admitted to the isolation ward of the First Affiliated Hospital of Bengbu Medical College from January, 2020 to February 20, 2020, and evaluated the data of clinical characteristics, blood test results, inflammatory index, chest CT imaging characteristics, and antiviral treatment, comparing this with the clinical data of 41 patients with moderate condition in the same period. From this comparison we thus summarized the current knowledge of potential risk factors for COVID-19 patients developing from moderate to severe condition. Results:(1) Clinical characteristics: The moderate-to-severe group and the moderate group in terms of combined common underlying diseases and respiratory frequency showed significant difference statistically (t-value were 13.32, 6.17, respectively,P< 0.05), while no significant difference between the two groups in gender, age, or clinical symptoms was statistically observed(P> 0.05). (2) Analysis of blood test results: The lymphocyte count and plasma albumin of the moderate-to-severe group were significantly lower than those of the moderate group (t-values were 4.16, 4.11, respectively,P< 0.05), and the blood glucose and urea of the moderate-to-severe group were significantly higher than those of the moderate group (t-value were 3.27, 4.19, respectively,P< 0.05). However, there was no significant difference in terms of white blood cell count (WBC), platelet count (PLT), and glutamic-pyruvic transaminase (GPT) (P> 0.05). (3) Comparison of inflammatory indicators: The level of IL-6 and CRP of the moderate-to-severe group were significantly higher than those of the moderate group (t-values were 2.84, 4.88, respectively,P< 0.05). (4) Imaging comparison: As for patients with moderate COVID-19, the imaging manifestations were the concurrence of ground-glass opacity, patchy shadow, and consolidation shadow in both lungs, diffuse ground-glass opacity in both lungs accompanied by air bronchogram, and large area consolidation of both lungs with pulmonary interstitial changes. The possibility for these patients to develop into severe condition increased, and the differences were statistically significant (t= 10.92,P< 0.05). (5) Clinical antiviral treatment: There was no statistically significant difference in the combination of two or three antiviral drugs between the two groups (chi(2)= 0.05,P> 0.05). Conclusion:Current evidence suggested that the combination of common underlying diseases, respiratory frequency, lymphocyte count, blood glucose, albumin, urea level, inflammatory factors (CRP, IL-6), and imaging manifestations collectively contributed to the potential risk factors for the development of COVID-19 from moderate condition to severe condition. Particular attention should be paid to early detection and intervention during clinical work, which will be of vital significance to the ascent of the recovery rate as well as the reduction of mortality.
C1 [Li, Dianming; Liu, Jiahui; Hu, Junfeng] Bengbu Med Coll, Affiliated Hosp 1, Dept Resp & Crit Care Med, Bengbu, Peoples R China.
   [Liu, Chuanmiao] Bengbu Med Coll, Affiliated Hosp 1, Dept Infect Dis, Bengbu, Peoples R China.
   [Yang, Yanli] Bengbu Med Coll, Affiliated Hosp 1, Dept Hematol, Bengbu, Peoples R China.
   [Zhou, Yufu] Bengbu Med Coll, Affiliated Hosp 1, Dept Tumor Radiotherapy, Bengbu, Peoples R China.
RP Yang, YL (corresponding author), Bengbu Med Coll, Affiliated Hosp 1, Dept Hematol, Bengbu, Peoples R China.
EM yangyanli0702@126.com
CR Castrucci MR, 2018, HUM VACC IMMUNOTHER, V14, P637, DOI 10.1080/21645515.2017.1338547
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen L., 2020, CHIN J TUBERC RESP D, DOI [10.3760/cma.j.issn.1001-0939.2020.0005., DOI 10.3760/CMA.J.ISSN.1001-0939.2020.0005.]
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   La Gruta NL, 2007, IMMUNOL CELL BIOL, V85, P85, DOI 10.1038/sj.icb.7100026
   Medical Expert Group of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science Technology, 2020, QUICK GUID NOV COR I
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang P, 2020, EPIDEMIOLOGICAL CLIN, DOI [10.1101/2020.02.28.20028068, DOI 10.1101/2020.02.28.20028068]
NR 11
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD SEP 15
PY 2020
VL 10
AR 548582
DI 10.3389/fcimb.2020.548582
PG 7
WC Immunology; Microbiology
SC Immunology; Microbiology
GA NY1UZ
UT WOS:000576184600001
PM 33042873
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mantovani, E
   Zucchella, C
   Bottiroli, S
   Federico, A
   Giugno, R
   Sandrini, G
   Chiamulera, C
   Tamburin, S
AF Mantovani, Elisa
   Zucchella, Chiara
   Bottiroli, Sara
   Federico, Angela
   Giugno, Rosalba
   Sandrini, Giorgio
   Chiamulera, Cristiano
   Tamburin, Stefano
TI Telemedicine and Virtual Reality for Cognitive Rehabilitation: A Roadmap
   for the COVID-19 Pandemic
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE augmented reality; cognitive; COVID-19; rehabilitation; telemedicine;
   virtual reality
ID THERAPY; TELEREHABILITATION; NEUROREHABILITATION; NEUROLOGY; DISEASE
AB The current COVID-19 pandemic presents unprecedented new challenges to public health and medical care delivery. To control viral transmission, social distancing measures have been implemented all over the world, interrupting the access to routine medical care for many individuals with neurological diseases. Cognitive disorders are common in many neurological conditions, e.g., stroke, traumatic brain injury, Alzheimer's disease, and other types of dementia, Parkinson's disease and parkinsonian syndromes, and multiple sclerosis, and should be addressed by cognitive rehabilitation interventions. To be effective, cognitive rehabilitation programs must be intensive and prolonged over time; however, the current virus containment measures are hampering their implementation. Moreover, the reduced access to cognitive rehabilitation might worsen the relationship between the patient and the healthcare professional. Urgent measures to address issues connected to COVID-19 pandemic are, therefore, needed. Remote communication technologies are increasingly regarded as potential effective options to support health care interventions, including neurorehabilitation and cognitive rehabilitation. Among them, telemedicine, virtual reality, augmented reality, and serious games could be in the forefront of these efforts. We will briefly review current evidence-based recommendations on the efficacy of cognitive rehabilitation and offer a perspective on the role of tele- and virtual rehabilitation to achieve adequate cognitive stimulation in the era of social distancing related to COVID-19 pandemic. In particular, we will discuss issues related to their diffusion and propose a roadmap to address them. Methodological and technological improvements might lead to a paradigm shift to promote the delivery of cognitive rehabilitation to people with reduced mobility and in remote regions.
C1 [Mantovani, Elisa; Federico, Angela; Tamburin, Stefano] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy.
   [Zucchella, Chiara] Verona Univ Hosp, Neurol Sect, Dept Neurosci, Verona, Italy.
   [Bottiroli, Sara] Giustino Fortunato Univ, Benevento, Italy.
   [Bottiroli, Sara; Sandrini, Giorgio] IRCCS Mondino Fdn, Pavia, Italy.
   [Giugno, Rosalba] Univ Verona, Dept Comp Sci, Verona, Italy.
   [Sandrini, Giorgio] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy.
   [Chiamulera, Cristiano] Univ Verona, Dept Diagnost & Publ Hlth, Verona, Italy.
RP Tamburin, S (corresponding author), Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy.
EM stefano.tamburin@univr.it
OI Mantovani, Elisa/0000-0003-3717-7697
CR Alzahrani H, 2018, J PARKINSON DIS, V8, P233, DOI 10.3233/JPD-171250
   Bahar-Fuchs A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003260.pub2
   Bartolo M, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00423
   Bergquist TF, 1997, NEUROREHABILITATION, V8, P49, DOI 10.3233/NRE-1997-8107
   Bird KT, 1975, TELEMEDICINE EXPLORA, P89
   Bloem BR, 2020, JAMA NEUROL, V77, P927, DOI 10.1001/jamaneurol.2020.1452
   Bowen A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003586.pub3
   Brennan D, 2010, INT J TELEREHABILITA, V2, P31, DOI [10.5195/ijt.2010.6063, 10.5195/IJT.2010.6063]
   Burdea G., 2003, PRESENCE-TELEOP VIRT, V12, P663, DOI DOI 10.1162/105474603322955950
   Cappa SF, 2005, EUR J NEUROL, V12, P665
   Centers for Disease Control and Prevention, 2020, PUBL HLTH REC COMM R
   Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240
   Cicerone KD, 2019, ARCH PHYS MED REHAB, V100, P1515, DOI 10.1016/j.apmr.2019.02.011
   Cotelli M, 2019, J TELEMED TELECARE, V25, P67, DOI 10.1177/1357633X17740390
   Danzl Megan M, 2012, J Allied Health, V41, P35
   Dial HR, 2019, CLIN INTERV AGING, V14, P453, DOI 10.2147/CIA.S178878
   Duncan C, 2010, SCOT MED J, V55, P3, DOI 10.1258/rsmsmj.55.1.3
   Ferguson C, 2020, AM J HOSP PALLIAT ME, V37, P809, DOI 10.1177/1049909120901525
   Ferrer-Garcia M, 2013, J CONTEMP PSYCHOTHER, V43, P207, DOI 10.1007/s10879-013-9240-1
   Gaggioli A, 2009, ADV TECHNOLOGIES REH
   Gamito P, 2014, INT J DISABIL HUM DE, V13, P337, DOI DOI 10.1515/IJDHD-2014-0325
   Gamito P, 2017, DISABIL REHABIL, V39, P385, DOI 10.3109/09638288.2014.934925
   Gamito P, 2011, VIRTUAL REALITY, P515
   Giglioli IAC, 2015, COMPUT MATH METHOD M, DOI 10.1155/2015/862942
   Griffiths PC, 2018, AM J ALZHEIMERS DIS, V33, P269, DOI 10.1177/1533317518755331
   Grossman SN, 2020, NEUROLOGY, V94, P1077, DOI 10.1212/WNL.0000000000009677
   Hopwood J, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9548
   Isernia S, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01206
   Khademi M, 2013, IEEE ENG MED BIO, P4613, DOI 10.1109/EMBC.2013.6610575
   Kovaleva M, 2019, J APPL GERONTOL, V38, P159, DOI 10.1177/0733464817705958
   Kumar KS, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007935.pub2
   Lange B, 2012, DISABIL REHABIL, V34, P1863, DOI 10.3109/09638288.2012.670029
   Laver KE, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010255.pub3
   Laver KE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008349.pub2
   Li JH, 2014, CYBERPSYCH BEH SOC N, V17, P519, DOI 10.1089/cyber.2013.0481
   Lohse KR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093318
   Lopes S, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01712
   Lupinacci G, 2018, DISABIL REHABIL-ASSI, V13, P234, DOI 10.1080/17483107.2017.1306592
   Maggio MG, 2020, EXPERT REV MED DEVIC, V17, P473, DOI 10.1080/17434440.2020.1776607
   Maggio MG, 2019, J NATL MED ASSOC, V111, P457, DOI 10.1016/j.jnma.2019.01.003
   Manera V, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01243
   Manera V, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00024
   Matamala-Gomez M, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00354
   McCallum Simon, 2013, Serious Games Development and Applications. 4th International Conference, SGDA 2013. Proceedings: LNCS 8101, P15, DOI 10.1007/978-3-642-40790-1_2
   McCann RA, 2014, J ANXIETY DISORD, V28, P625, DOI 10.1016/j.janxdis.2014.05.010
   Mishkind MC, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0836-0
   Montaner J, 2020, STROKE, V51, P2307, DOI 10.1161/STROKEAHA.120.030106
   Moreno Alexander, 2019, Alzheimers Dement (N Y), V5, P834, DOI 10.1016/j.trci.2019.09.016
   Moyle W, 2018, GERONTOLOGIST, V58, P478, DOI 10.1093/geront/gnw270
   Nesbitt TS, 2000, WESTERN J MED, V173, P169, DOI 10.1136/ewjm.173.3.169-a
   Platz T, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00349
   Riva G, 2016, FRONT PSYCHIATRY, V7, DOI 10.3389/fpsyt.2016.00164
   Robert PH, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00054
   Rogers JM, 2018, NEUROPSYCHOL REV, V28, P285, DOI 10.1007/s11065-018-9378-4
   Rosti-Otajarvi EM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009131.pub3
   Rouse R, 2015, DIGIT CREAT, V26, P175, DOI 10.1080/14626268.2015.1100123
   Sokolov AA, 2020, CURR OPIN NEUROL, V33, P239, DOI 10.1097/WCO.0000000000000791
   Solomon MD, 2020, NEW ENGL J MED, V383, P691, DOI 10.1056/NEJMc2015630
   Tarr MJ, 2002, NAT NEUROSCI, V5, P1089, DOI 10.1038/nn948
   Tchero H, 2018, J MED INTERNET RES, V20, DOI 10.2196/10867
   Teo WP, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00284
   Tieri G, 2018, EXPERT REV MED DEVIC, V15, P107, DOI 10.1080/17434440.2018.1425613
   Triberti S, 2014, CYBERPSYCH BEH SOC N, V17, P335, DOI 10.1089/cyber.2014.0054
   Turner-Stokes L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub3
   Valimaki M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009928.pub2
   van den Berg ME, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00424
   van der Linden SD, 2018, J NEURO-ONCOL, V137, P523, DOI 10.1007/s11060-017-2738-8
   Weiss PL, 2006, TXB NEURAL REPAIR RE, P182, DOI [DOI 10.1017/CB09780511545078.015, 10.1017/CBO9780511545078.015.]
   Wiederhold BK, 2019, CYBERPSYCH BEH SOC N, V22, P3, DOI 10.1089/cyber.2018.29136.bkw
   Wiederhold BK, 2018, CYBERPSYCH BEH SOC N, V21, P341, DOI 10.1089/cyber.2018.29114.bkw
   Wiley E, 2020, DISABIL REHABIL-ASSI, DOI 10.1080/17483107.2020.1755376
   Winters JM, 2002, ANNU REV BIOMED ENG, V4, P287, DOI 10.1146/annurev.bioeng.4.112801.121923
   Wolf SL, 2002, NEUROLOGIST, V8, P325, DOI 10.1097/00127893-200211000-00001
   Wollersheim D. M, 2010, INT J EMERGING TECHN, V8, P85
   World Health Organization (WHO), 2010, TEL OPP DEV MEMB STA
   Yeroushalmi S, 2020, J TELEMED TELECARE, V26, P400, DOI 10.1177/1357633X19840097
   Zhou RJ, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00597
   Zucchella C, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01058
   Zyda M, 2005, COMPUTER, V38, P25, DOI 10.1109/MC.2005.297
NR 79
TC 1
Z9 1
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD SEP 15
PY 2020
VL 11
AR 926
DI 10.3389/fneur.2020.00926
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NY2AD
UT WOS:000576198100001
PM 33041963
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, C
   Huang, YH
   Qin, TY
   Guo, ES
   Wu, P
   Sun, CY
   Chen, G
AF Liu, Chen
   Huang, Yuhan
   Qin, Tianyu
   Guo, Ensong
   Wu, Peng
   Sun, Chaoyang
   Chen, Gang
TI Six Gynecological Cancer Patients Infected With SARS-CoV-2 After Surgery
   or Radio-/Chemo-Therapy Treatment: Case Series
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; gynecological cancer; treatment; suggestions
ID COVID-19; PNEUMONIA; WUHAN; CHINA
AB Objective Recently, the number of gynecological cancer patients infected with SARS-CoV-2 has been increasing. This article was committed to studying the influence of gynecological tumor treatment history compared to the Coronavirus Disease 2019 (COVID-19), which was of great significance for the treatment of gynecological cancer patients during the outbreak of COVID-19. Methods We retrospectively analyzed the diagnosis and treatment of six gynecological cancer patients infected with SARS-CoV-2 in Tongji Hospital in Wuhan from January 30 to March 25, 2020. To better explain the treatment of gynecological cancer patients during the epidemic of COVID-19, we summarized the case characteristics, auxiliary examination, treatment plan, and outcome of these six patients. Results We observed a high rate of nosocomial SARS-CoV-2 infection among these six gynecological cancer patients, who were in a low immune state. Also, due to the influence of cancer treatment history, COVID-19-related atypical symptoms became the first symptom of COVID-19 in some cases, which increased the difficulty of diagnosis. Furthermore, in terms of treatment for these cases, immune boosters and reagents that raised white blood cells were applied, except for in symptomatic antiviral treatment. At present, all patients in this study were discharged from the hospital with a good prognosis. Conclusion After cancer-related treatment, the gynecological cancer patients became more susceptible to COVID-19. Besides, the history of cancer treatment made the diagnosis of COVID-19 difficult, which also affected the treatment of COVID-19. Therefore, we put forward the corresponding therapy suggestions for gynecological cancer patients during the outbreak of COVID-19.
C1 [Liu, Chen; Huang, Yuhan; Qin, Tianyu; Guo, Ensong; Wu, Peng; Sun, Chaoyang; Chen, Gang] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Wuhan, Peoples R China.
RP Wu, P; Sun, CY; Chen, G (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Obstet & Gynecol, Wuhan, Peoples R China.
EM pengwu8626@tjh.tjmu.edu.cn; suncydoctor@gmail.com;
   tjchengang@hust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [NFSC 81874106]; National Clinical Research
   Center of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical
   College, Huazhong University of Science and Technology, Wuhan, China
FX This work was supported by the National Natural Science Foundation of
   China under grant number NFSC 81874106, as well as the National Clinical
   Research Center of Gynecology and Obstetrics, Tongji Hospital, Tongji
   Medical College, Huazhong University of Science and Technology, Wuhan,
   China.
CR Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P269, DOI 10.2217/imt-2020-0067
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cortiula F, 2020, ANN ONCOL, V31, P553, DOI 10.1016/j.annonc.2020.03.286
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Jazieh AR, 2020, JCO GLOB ONCOL, V6, P471, DOI 10.1200/GO.20.00064
   Jin XH, 2020, LANCET HAEMATOL, V7, pE351, DOI 10.1016/S2352-3026(20)30074-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Oh WK, 2020, ANN ONCOL, V31, P838, DOI 10.1016/j.annonc.2020.03.297
   Price KN, 2020, J AM ACAD DERMATOL, V82, pE173, DOI 10.1016/j.jaad.2020.03.046
   Schonrich G, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00207
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Wang ZJ, 2020, JAMA ONCOL, V6, P631, DOI 10.1001/jamaoncol.2020.1198
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu YT, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30557-2
   You B, 2020, LANCET ONCOL, V21, P619, DOI 10.1016/S1470-2045(20)30204-7
   Zhang HY, 2020, J THORAC ONCOL, V15, pE63, DOI 10.1016/j.jtho.2020.02.025
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 18
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD SEP 15
PY 2020
VL 10
AR 1606
DI 10.3389/fonc.2020.01606
PG 9
WC Oncology
SC Oncology
GA NY1LH
UT WOS:000576159300001
PM 33042803
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Liu, TW
   Guo, YH
   Zhao, JX
   He, SS
   Bai, YJ
   Wang, N
   Lin, Y
   Liu, QQ
   Xu, XL
AF Liu, Tengwen
   Guo, Yuhong
   Zhao, Jingxia
   He, Shasha
   Bai, Yunjing
   Wang, Ning
   Lin, Yan
   Liu, Qingquan
   Xu, Xiaolong
TI Systems Pharmacology and Verification of ShenFuHuang Formula in
   Zebrafish Model Reveal Multi-Scale Treatment Strategy for Septic
   Syndrome in COVID-19
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE COVID-19; sepsis; traditional Chinese medicine; systems pharmacology;
   zebrafish
ID INFECTION; SEPSIS
AB The outbreak of coronavirus disease 2019 (COVID-19) has affected millions of people worldwide. Critically ill COVID-19 patients develop viral septic syndrome, including inflammatory damage, immune dysfunction, and coagulation disorder. In this study, we investigated ShenFuHuang formula (SFH), a traditional Chinese medicine, which has been widely used as complementary therapy for clinical treatment of COVID-19 in Wuhan, to understand its pharmacological properties. Results of systems pharmacology identified 49 active compounds of SFH and their 69 potential targets, including GSK3 beta, ESR1, PPARG, PTGS2, AKR1B10, and MAPK14. Network analysis illustrated that the targets of SFH may be involved in viral disease, bacterial infection/mycosis, and metabolic disease. Moreover, signaling pathway analysis showed that Toll-like receptors, MAPK, PPAR, VEGF, NOD-like receptor, and NF-kappa B signaling pathways are highly connected with the potential targets of SFH. We further employed multiple zebrafish models to confirm the pharmacological effects of SFH. Results showed that SFH treatment significantly inhibited the inflammatory damage by reducing the generation of neutrophils in Poly (I:C)-induced viral infection model. Moreover, SFH treatment could improve the phagocytosis of macrophages and enhance the expression of immune genes in an immune deficiency model. Furthermore, SFH treatment exhibited promising anti-thrombosis effect in a thrombus model. This study provided additional evidence of SFH formula for treating COVID-19 patients with septic syndrome using multiple-scale estimation.
C1 [Liu, Tengwen] Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong, Peoples R China.
   [Guo, Yuhong; Zhao, Jingxia; He, Shasha; Bai, Yunjing; Wang, Ning; Lin, Yan; Liu, Qingquan; Xu, Xiaolong] Capital Med Univ, Beijing Inst Tradit Chinese Med, Beijing Hosp Tradit Chinese Med, Beijing, Peoples R China.
   [Guo, Yuhong; Zhao, Jingxia; He, Shasha; Bai, Yunjing; Wang, Ning; Lin, Yan; Liu, Qingquan; Xu, Xiaolong] Beijing Key Lab Basic Res Tradit Chinese Med Infe, Beijing, Peoples R China.
RP Xu, XL (corresponding author), Capital Med Univ, Beijing Inst Tradit Chinese Med, Beijing Hosp Tradit Chinese Med, Beijing, Peoples R China.; Xu, XL (corresponding author), Beijing Key Lab Basic Res Tradit Chinese Med Infe, Beijing, Peoples R China.
EM xiaolong_xu3013@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81673934, 62041701, 81973608]; National
   Major Scientific and Technological Project [2017ZX10305501]; Beijing
   Natural Science FoundationBeijing Natural Science Foundation [7192083]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81673934, 62041701, 81973608), the National Major
   Scientific and Technological Project (2017ZX10305501), the Beijing
   Natural Science Foundation (No. 7192083).
CR Guevara-Noriega KA, 2020, ANN CLIN LAB SCI, V50, P295
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bellinvia S, 2020, INFLAMM RES, V69, P757, DOI 10.1007/s00011-020-01366-6
   Cecconi M, 2018, LANCET, V392, P75, DOI 10.1016/S0140-6736(18)30696-2
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Didangelos A, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00367-20
   Dong XX, 2016, PHYTOTHER RES, V30, P1207, DOI 10.1002/ptr.5631
   Drescher B, 2013, VIRUS RES, V171, P1, DOI 10.1016/j.virusres.2012.11.002
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   He YL, 2018, J CELL BIOL, V217, P315, DOI 10.1083/jcb.201701049
   Hsieh YH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091208
   Hu K. E., 2020, PHYTOMEDICINE, P153242, DOI [10.1016/j.phymed.2020.153242, DOI 10.1016/J.PHYMED.2020.153242]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jakubzick CV, 2017, NAT REV IMMUNOL, V17, P349, DOI 10.1038/nri.2017.28
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kobayashi M, 2003, BURNS, V29, P37, DOI 10.1016/S0305-4179(02)00248-6
   Kumaki Y, 2017, ANTIVIR RES, V139, P1, DOI 10.1016/j.antiviral.2016.12.007
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Lin GL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02147
   Liu GW, 2018, HUM CELL, V31, P189, DOI 10.1007/s13577-017-0189-3
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Majithia AR, 2016, NAT GENET, V48, P1570, DOI 10.1038/ng.3700
   Mehrdana F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181277
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Munoz AC, 2020, NEW ENGL J MED, V382, pE49, DOI 10.1056/NEJMc2010614
   Nemmar A, 2015, CELL PHYSIOL BIOCHEM, V36, P1517, DOI 10.1159/000430315
   Patel P, 2017, CURR TOP DEV BIOL, V123, P277, DOI 10.1016/bs.ctdb.2016.11.011
   Pence BD, 2020, GEROSCIENCE, V42, P1051, DOI 10.1007/s11357-020-00213-0
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Sanchez-Cerrillo Ildefonso, 2020, medRxiv, DOI 10.1101/2020.05.13.20100925
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   SUZUKI Y, 1994, PLANTA MED, V60, P391, DOI 10.1055/s-2006-959516
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36
   Van Wyngene L, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708712
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu W, 2019, REDOX BIOL, V22, DOI 10.1016/j.redox.2019.101137
   Xie L, 2019, J PHARM PHARMACOL, V71, P1475, DOI 10.1111/jphp.13143
   Xu HY, 2019, NUCLEIC ACIDS RES, V47, pD976, DOI 10.1093/nar/gky987
   Xu XL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00818
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Yang LL, 2014, MOLECULES, V19, P2390, DOI 10.3390/molecules19022390
   Zheng CL, 2015, SCI REP-UK, V5, DOI 10.1038/srep11970
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu XY, 2016, ZEBRAFISH, V13, P335, DOI 10.1089/zeb.2016.1263
NR 48
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 15
PY 2020
VL 11
AR 584057
DI 10.3389/fphar.2020.584057
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NY2BX
UT WOS:000576202700001
PM 33041827
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Selvaraj, S
   Greene, SJ
   Khatana, SAM
   Nathan, AS
   Solomon, SD
   Bhatt, DL
AF Selvaraj, Senthil
   Greene, Stephen J.
   Khatana, Sameed Ahmed M.
   Nathan, Ashwin S.
   Solomon, Scott D.
   Bhatt, Deepak L.
TI The Landscape of Cardiovascular Clinical Trials in the United States
   Initiated Before and During COVID-19
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE biomarker; clinical trial; COVID-19; renin-angiotensin system; troponin
C1 [Selvaraj, Senthil; Khatana, Sameed Ahmed M.; Nathan, Ashwin S.] Hosp Univ Penn, Dept Med, Div Cardiol, Philadelphia, PA 19104 USA.
   [Greene, Stephen J.] Duke Univ, Sch Med, Div Cardiol, Duke Clin Res Inst, Durham, NC USA.
   [Solomon, Scott D.] Brigham & Womens Hosp, Dept Med, Div Cardiol, 75 Francis St, Boston, MA 02115 USA.
   [Bhatt, Deepak L.] Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, Boston, MA 02115 USA.
RP Selvaraj, S (corresponding author), 3400 Civ Ctr Blvd,PCAM 11-134, Philadelphia, PA 19103 USA.
EM senthil.selvaraj@pennmedicine.upenn.edu
RI Bhatt, Deepak/Y-3070-2019
OI Bhatt, Deepak/0000-0002-1278-6245; Selvaraj, Senthil/0000-0001-8418-7623
CR Bagiella E, 2020, J AM COLL CARDIOL, V76, P342, DOI 10.1016/j.jacc.2020.05.041
   Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
NR 4
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD SEP 15
PY 2020
VL 9
IS 18
AR e018274
DI 10.1161/JAHA.120.018274
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NU8KQ
UT WOS:000573887300019
PM 32713281
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Joshi, MG
   Kshersagar, J
   Desai, SR
   Sharma, S
AF Joshi, Meghnad G.
   Kshersagar, Jeevitaa
   Desai, Shashikant R.
   Sharma, Shimpa
TI Antiviral properties of placental growth factors: A novel therapeutic
   approach for COVID-19 treatment
SO PLACENTA
LA English
DT Article
DE Novel coronavirus COVID-19; Placental extract; Immunomodulatory;
   Anti-inflammatory; Cellular proliferation; Tissue regeneration
ID MESENCHYMAL STEM-CELLS; REGULATORY T-CELLS; IMMUNE-RESPONSES; FACTOR
   RECEPTOR; LUNG; EXPRESSION; VIRUS; EXTRACT; TH17; PROTECTION
AB The current challenge of the COVID-19 pandemic is complicated by the limited therapeutic options against the virus, with many being anecdotal or still undergoing confirmatory trials, underlining the urgent need for novel strategies targeting the virus. The pulmotropic virus causes loss of oxygenation in severe cases with acute respiratory distress syndrome (ARDS) and need for mechanical ventilation. This work seeks to introduce placental extract-derived biologically active components as a therapeutic option and highlights their mechanism of action relevant to COVID-19 virus. Human placenta has been used in clinical practice for over a century and there is substantial experience in clinical applications of placental extract for different indications. Aqueous extract of human placentacontains growth factors, cytokines/chemokines, natural metabolic and other compounds, antioxidants, amino acids, vitamins, trace elements and biomolecules, which individually or in combination show accelerated cellular metabolism, immunomodulatory and anti-inflammatory effects, cellular proliferation and stimulation of tissue regeneration processes.
   Placental extract treatment is proposed as a suitable therapeutic approach consideringthe above properties which could protect against initial viral entry and acute inflammation of alveolar epithelial cells, reconstitute pulmonary microenvironment and regenerate the lung. We reviewed useful therapeutic information of placental biomolecules in relation to COVID-19 treatment. We propose the new approach of using placental growth factors, chemokines and cytokine which will execute antiviral activity in coordination with innate and humoral immunity and improve patient's immunological responses to COVID-19. Executing a clinical trial using placental extract as preventive, protective and/or therapeutic approach for COVID-19treatment could advance the development of a most promising therapeutic candidate that can join the armamentaria against the COVID-19 virus.
C1 [Joshi, Meghnad G.; Kshersagar, Jeevitaa] DY Patil Educ Soc, Dept Stem Cells & Regenerat Med, E 869 DY Patil Vidyanagar, Kolhapur 416006, Maharashtra, India.
   [Desai, Shashikant R.] Stem Plus Fdn, CTS 648 A-1, Sangli 416415, MS, India.
   [Sharma, Shimpa] DY Patil Educ Soc, DY Patil Med Coll, Dept Med, E 869 DY Patil Vidyanagar, Kolhapur 416006, Maharashtra, India.
RP Joshi, MG (corresponding author), DY Patil Educ Soc, Dept Stem Cells & Regenerat Med, E 869 DY Patil Vidyanagar, Kolhapur 416006, Maharashtra, India.
EM drmeghnadjoshi@gmail.com
RI Sharma, Shimpa R/B-7290-2016; Sharma, Shimpa/ABC-5731-2020
OI Sharma, Shimpa R/0000-0001-8888-272X; 
CR Afzali B, 2007, CLIN EXP IMMUNOL, V148, P32, DOI 10.1111/j.1365-2249.2007.03356.x
   Akamura B.T.N., 2010, LIFE SCI CLIN MED, V86, P588
   Almeida J D, 1967, J Gen Virol, V1, P175, DOI 10.1099/0022-1317-1-2-175
   Aloe L., 2016, J EXP CLIN CANC RES, P1
   Alothaimeen T., 2020, MACROPHAGES EXHIBIT, P1
   Andreakos E, 2019, CURR OPIN IMMUNOL, V56, P67, DOI 10.1016/j.coi.2018.10.007
   Andres G, 2009, J CELL MOL MED, V13, P2083, DOI 10.1111/j.1582-4934.2008.00415.x
   [Anonymous], 2019, S REPORT CORONAVIRUS, P2020
   Bailey MJ, 2011, IMMUNOL CELL BIOL, V89, P283, DOI 10.1038/icb.2010.92
   Barrow AD, 2019, CURR OPIN IMMUNOL, V56, P82, DOI 10.1016/j.coi.2018.11.004
   Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008
   Bayer A, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.07.060
   Bhandari V, 2006, P NATL ACAD SCI USA, V103, P11021, DOI 10.1073/pnas.0601057103
   Bicknell BA, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.183
   Bolat F, 2010, PATHOL RES PRACT, V206, P19, DOI 10.1016/j.prp.2009.07.017
   Bosca A.B., 2018, MIHU CM, V59, P1220
   Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697
   Braciale TJ, 2012, NAT REV IMMUNOL, V12, P295, DOI 10.1038/nri3166
   Broggi A, 2020, J EXP MED, V217, DOI 10.1084/jem.20190295
   Burgel PR, 2008, EUR RESPIR J, V32, P1068, DOI 10.1183/09031936.00172007
   Cameron MJ, 2008, VIRUS RES, V133, P13, DOI 10.1016/j.virusres.2007.02.014
   Chakraborty D, 2012, PROC INT CONF EMERG, P77, DOI 10.1109/EAIT.2012.6407866
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chatterjee P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00253
   Chen GX, 2016, J NANOMATER, V2016, DOI 10.1155/2016/1683416
   Chen JC, 2016, PHYSIOL REV, V96, P1025, DOI 10.1152/physrev.00030.2015
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen SJ, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/258391
   Choi JH, 2014, STEM CELLS DEV, V23, P132, DOI 10.1089/scd.2012.0674
   Chousterman BG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01015
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P333, DOI 10.23812/Editorial-Conti-2
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Corry J., 2017, P NATL ACAD SCI USA, P2
   De D, 2009, J CHROMATOGR B, V877, P2435, DOI 10.1016/j.jchromb.2009.05.018
   de Witte SFH, 2018, STEM CELLS, V36, P602, DOI 10.1002/stem.2779
   Deng Y., 2016, ADV ENERGY MATER, V6, P1
   Ding BS, 2011, CELL, V147, P539, DOI 10.1016/j.cell.2011.10.003
   Duan K Bc, 2020, P NATL ACAD SCI USA, P1
   Edwin Francis, 2006, V327, P1
   El-Shewy HM, 2009, VITAM HORM, V80, P667, DOI 10.1016/S0083-6729(08)00624-9
   Favre L., 2020, J IMMUNOL, V175, P2793
   Finetti F, 2009, CIRC RES, V105, P657, DOI 10.1161/CIRCRESAHA.109.203760
   Fleetwood AJ, 2007, J IMMUNOL, V178, P5245, DOI 10.4049/jimmunol.178.8.5245
   Franco G.R., 2000, PLACENTA, V1999, P189
   Gomezlopez W.F.N., 2018, AM J REPROD IMMUNOL, P1
   Goncalves F.C., 2017, SCI REP, V7, P1
   Grant RF, 2004, TREE PHYSIOL, V24, P1
   Greter M, 2012, IMMUNITY, V36, P1031, DOI 10.1016/j.immuni.2012.03.027
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guglani L, 2010, CURR OPIN HIV AIDS, V5, P120, DOI 10.1097/COH.0b013e328335c2f6
   Hamilton J.A., 2008, IMMUNOLOGY, V8, P11
   Hart D.A., 2017, TARGETING MAST CELLS, P76
   Hemmi Hiroaki, 2005, V86, P120, DOI 10.1159/000086657
   Hoeksema M, 2015, INNATE IMMUN-LONDON, V21, P736, DOI 10.1177/1753425915593794
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Hong JW, 2010, ANN PLAS SURG, V65, P96, DOI 10.1097/SAP.0b013e3181b0bb67
   Huang C, 2020, LANCET, V395, P496, DOI 10.1016/S0140-6736(20)30252-X
   Hunt KJ, 2010, BIOL RES NURS, V11, P245, DOI 10.1177/1099800409352237
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   Jang JY, 2017, EMBO MOL MED, V9, P750, DOI 10.15252/emmm.201607341
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Jogie-Brahim S, 2009, ENDOCR REV, V30, P417, DOI 10.1210/er.2008-0028
   Johannesson B, 2014, DIS MODEL MECH, V7, P977, DOI 10.1242/dmm.015362
   Johnson EL, 2016, CURR OPIN INFECT DIS, V29, P248, DOI 10.1097/QCO.0000000000000267
   Joshi M, 2012, CYTOTHERAPY, V14, P657, DOI 10.3109/14653249.2012.663526
   Jung J, 2011, INT IMMUNOPHARMACOL, V11, P976, DOI 10.1016/j.intimp.2011.02.012
   Kao C, 2011, NAT IMMUNOL, V12, P663, DOI 10.1038/ni.2046
   Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259
   Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737, DOI 10.1164/ajrccm.163.3.2002117
   Kearley J, 2011, AM J RESP CRIT CARE, V183, P865, DOI 10.1164/rccm.200909-1462OC
   Khader SA, 2005, J IMMUNOL, V175, P788, DOI 10.4049/jimmunol.175.2.788
   Kim MJ, 2011, CELL TISSUE RES, V346, P53, DOI 10.1007/s00441-011-1249-8
   Kim YS, 2010, INT IMMUNOPHARMACOL, V10, P1177, DOI 10.1016/j.intimp.2010.06.024
   Kong M., 2012, EVID BASE COMPL ALTE, P1
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Kramann R, 2013, J PATHOL, V231, P273, DOI 10.1002/path.4253
   Kreijtz JHCM, 2011, VIRUS RES, V162, P19, DOI 10.1016/j.virusres.2011.09.022
   Kumar PA, 2011, CELL, V147, P525, DOI 10.1016/j.cell.2011.10.001
   Lambiase A, 2004, CURR OPIN ALLERGY CL, V4, P425, DOI 10.1097/00130832-200410000-00015
   Lee H, 2014, AM J RESP CELL MOL, V50, P667, DOI 10.1165/rcmb.2013-0397TR
   Lee KH, 2011, NAT PROD RES, V25, P1090, DOI 10.1080/14786419.2010.489050
   Lei JQ, 2020, RADIOLOGY, V295, P18, DOI 10.1148/radiol.2020200236
   Li GP, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02541
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308
   lijima, 2017, Patent No. 0326214
   Liu XF, 2015, ADV METEOROL, V2015, DOI 10.1155/2015/950262
   Loffredo S, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00443
   Luk F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01042
   Lutsenko GV, 2018, BIOCHEM MOSC SUPPL S, V12, P239, DOI 10.1134/S1990747818030066
   Malek TR, 2010, IMMUNITY, V33, P153, DOI 10.1016/j.immuni.2010.08.004
   Malik YS, 2020, VET QUART, V40, P68, DOI 10.1080/01652176.2020.1727993
   Marleau AM, 2012, ANTICANCER RES, V32, P1153
   MEISEL R, 2004, IMMUNOBIOLOGY, V103, P4619, DOI DOI 10.1182/BLOOD-2003-11-3909
   Melief S.M., 2013, HAEMATOL, V98, P1
   Melief SM, 2013, STEM CELLS, V31, P1980, DOI 10.1002/stem.1432
   Mizuno S, 2005, AM J PATHOL, V166, P1895, DOI 10.1016/S0002-9440(10)62498-4
   Mu MM, 2019, MOL MED REP, V20, P2381, DOI 10.3892/mmr.2019.10456
   Muller T, 2005, AM J RESP CELL MOL, V33, P601, DOI 10.1165/rcmb.2005-0181OC
   Nakajima D, 2019, J HEART LUNG TRANSPL, V38, P1214, DOI 10.1016/j.healun.2019.07.006
   Nordisk N., 2001, BIOCHEM SOC T, V29, P513
   Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5
   Organi W.H., 2020, NEW ENGL J MED, P1
   Ouyang YS, 2016, PLACENTA, V47, P86, DOI 10.1016/j.placenta.2016.09.008
   Pan SY, 2017, J MED THERAPEUTICS, V1, P1
   Park KM, 2017, J INTEGR MED-JIM, V15, P135, DOI 10.1016/S2095-4964(17)60316-9
   Presneill JJ, 2002, AM J RESP CRIT CARE, V166, P138, DOI 10.1164/rccm.2009005
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ramasamy S.K., 2014, TRENDS CELL BIOL, V2, P1
   Rao P, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.46
   Redington AE, 2001, J ALLERGY CLIN IMMUN, V107, P384, DOI 10.1067/mai.2001.112268
   Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722
   Ribatti D., 2019, MAST CELL
   Ribatti D, 2008, ANGIOGENESIS, V11, P215, DOI 10.1007/s10456-008-9114-4
   Schafer R, 2003, AM J PHYSIOL-LUNG C, V285, pL376, DOI 10.1152/ajplung.00447.2002
   Shi Q., 2020, RETROSPECTIVE STUDY
   Shigemura N, 2005, CIRCULATION, V111, P1407, DOI 10.1161/01.CIR.0000158433.89103.85
   Shukla V K, 2004, J Wound Care, V13, P177
   Singer NG, 2011, ANNU REV PATHOL-MECH, V6, P457, DOI 10.1146/annurev-pathol-011110-130230
   Skaper S., 2017, NERVE GROWTH FACTOR, V1
   Sone Y, 2017, PHARMACOLOGY, V99, P57, DOI 10.1159/000450582
   Sozzani S, 2007, TRENDS IMMUNOL, V28, P385, DOI 10.1016/j.it.2007.07.006
   Sponsor S., 2020, OVERVIEW PLANNED ONG, V19, P1
   Stolarczyk M, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1067134
   Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002
   Thebaud B, 2005, CIRCULATION, V112, P2477, DOI 10.1161/CIRCULATIONAHA.105.541524
   Tough D.F., 2009, LEUKEMIA LYMPHOMA, V45, P257
   TYRRELL DA, 1966, LANCET, V1, P76
   TYRRELL DAJ, 1975, INTERVIROLOGY, V5, P76, DOI 10.1159/000149883
   Ungvari Z, 2018, NAT REV CARDIOL, V15, P555, DOI 10.1038/s41569-018-0030-z
   Ushach I., 2016, BIOL ROLE GRANULOCYT, V100, P1
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Virag JAI, 2007, AM J PATHOL, V171, P1431, DOI 10.2353/ajpath.2007.070003
   Voelkel NF, 2006, AM J PHYSIOL-LUNG C, V290, pL209, DOI 10.1152/ajplung.00185.2005
   Wang J, 2016, INT C PAR DISTRIB SY, P24, DOI [10.1109/ICPADS.2016.11, 10.1109/ICPADS.2016.0013]
   Wang K, 2018, CANCER BIOL THER, V19, P809, DOI 10.1080/15384047.2018.1472192
   Wang LJ, 2018, ONCOL LETT, V15, P4711, DOI 10.3892/ol.2018.7982
   Wang W, 2012, CLIN EXP ALLERGY, V42, P1604, DOI 10.1111/j.1365-2222.2012.04062.x
   Wang Z., 2018, BIOMED RES INT, V17-9
   Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052
   Williams AE, 2014, AM J PHYSIOL-LUNG C, V306, pL217, DOI 10.1152/ajplung.00311.2013
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Wu F., 2016, J MED SCI, V9, P151
   Wu Y., 2017, EVID-BASED COMPL ALT, V2017, P1, DOI DOI 10.1080/20961790.2017.1319785
   Yanez R, 2010, EXP CELL RES, V316, P3109, DOI 10.1016/j.yexcr.2010.08.008
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Young H., 2010, INT ARCH ALLERGY IMM, V155, P12
   Zhang N, 2011, IMMUNITY, V35, P161, DOI 10.1016/j.immuni.2011.07.010
   Zhang S., 2020, STEM CELL TRANSL MED, P1
   Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zheng GP, 2018, CELL TISSUE RES, V374, P1, DOI 10.1007/s00441-018-2871-5
NR 154
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0143-4004
EI 1532-3102
J9 PLACENTA
JI Placenta
PD SEP 15
PY 2020
VL 99
BP 117
EP 130
DI 10.1016/j.placenta.2020.07.033
PG 14
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA NV9LQ
UT WOS:000574633800015
PM 32798764
OA Green Published
DA 2021-01-01
ER

PT J
AU Safa, O
   Hassani-Azad, M
   Farashahinejad, M
   Davoodian, P
   Dadvand, H
   Hassanipour, S
   Fathalipour, M
AF Safa, Omid
   Hassani-Azad, Mehdi
   Farashahinejad, Mehdi
   Davoodian, Parivash
   Dadvand, Habib
   Hassanipour, Soheil
   Fathalipour, Mohammad
TI Effects of Licorice on clinical symptoms and laboratory signs in
   moderately ill patients with pneumonia from COVID-19: A structured
   summary of a study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomized controlled trial; Protocol; Liquorice; Clinical
   symptoms; Laboratory signs
AB Objectives: We investigate the effects of Licorice (Glycyrrhiza glabra L.) root extract, an anti-inflammatory natural medicine, compared to the usual therapeutic regimen on clinical symptoms and laboratory signs in patients with confirmed COVID-19 that are moderately ill.
   Trial design: This is a single-center, open-label, randomized, clinical trial with parallel-group design. This study is being conducted at Shahid Mohammadi Hospital, Bandar Abbas, Iran.
   Participants: Both male and female patients with >= 18 years of age (>= 35 kg of weight), admitted at the Shahid Mohammadi Hospital, Hormozgan University of Medical Sciences, Bandar Abbas for treatment, screened for the following criteria.
   Inclusion criteria:
   1. Confirmed diagnosis of SARS-CoV-2 infection (via polymerase chain reaction [PCR] and/or antibody test).
   2. Presenting as moderate COVID-19 pneumonia (via chest computed tomography (CT) and/or X-ray) requiring hospitalization.
   3. Hospitalized <= 48 hours.
   4. Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm.
   Exclusion criteria:
   1. Underlying diseases, including chronic heart disease, chronic hypertension, severe renal failure, severe liver failure, and thyroid disorders.
   2. Severe and critical COVID-19 pneumonia.
   3. Use of warfarin, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), diuretics, corticosteroids, and antiarrhythmic drugs.
   4. Treatment with Investigational and antiviral therapy in a clinical study within one month before randomization.
   5. History of allergy to Licorice.
   6. Pregnancy and breastfeeding.
   Intervention and comparator
   Intervention group: The standard treatment regimen for COVID-19 along with a Licorice-based herbal preparation (D-Reglis (R), Irandarouk Pharmaceutical Company, Iran) at a dose of 760 mg three times a day for a period of seven days.Control group: The standard treatment for COVID-19 based on the Iranian Ministry of Health and Medical Education's protocol for a period of seven days.
   Main outcomes: The recovery rate of clinical symptoms, including fever, dry cough, and tiredness, as well as paraclinical features, including thrombocytopenia, lymphocytopenia, and C-reactive protein, are evaluated as primary outcomes within seven days of randomization.Time to improvement of clinical and paraclinical features and length of stay in a hospital, along with the incidence of adverse reactions are also evaluated as the secondary outcomes within seven days of randomization.
   Randomization: An electronic table of random numbers will be used to allocate the included participants into either control or intervention groups (in a 1:1 ratio) using the simple randomization method.
   Blinding (masking): This is an open-label trial without blinding and placebo control.Numbers to be randomized (sample size)A total of 60 participants randomizes (30 patients allocated to the intervention group and 30 patients allocated to the control group).
   Trial Status: The protocol is Version 1.0, May 31, 2020. Recruitment began July 30, 2020, and is anticipated to be completed by October 30, 2020.
   Trial registration: This clinical trial has been registered in the Iranian Registry of Clinical Trials (IRCT). The registration number is "IRCT20200506047323N2", https://www.irct.ir/trial/47990. The registration date is 31 May 2020.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Safa, Omid] Hormozgan Univ Bandar Abbas, Fac Pharm, Dept Clin Pharm, Bandar Abbas, Iran.
   [Hassani-Azad, Mehdi; Farashahinejad, Mehdi; Davoodian, Parivash; Dadvand, Habib] Hormozgan Univ Med Sci, Hormozgan Hlth Inst, Infect & Trop Dis Res Ctr, Bandar Abbas, Iran.
   [Hassanipour, Soheil] Guilan Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Rasht, Iran.
   [Fathalipour, Mohammad] Hormozgan Univ Med Sci, Fac Pharm, Dept Pharmacol & Toxicol, Bandar Abbas, Iran.
   [Fathalipour, Mohammad] Hormozgan Univ Med Sci, Endocrinol & Metab Res Ctr, Bandar Abbas, Iran.
RP Fathalipour, M (corresponding author), Hormozgan Univ Med Sci, Fac Pharm, Dept Pharmacol & Toxicol, Bandar Abbas, Iran.; Fathalipour, M (corresponding author), Hormozgan Univ Med Sci, Endocrinol & Metab Res Ctr, Bandar Abbas, Iran.
EM M.fathalipour@hums.ac.ir
RI Hassanipour, Soheil/Y-7903-2019; Fathalipour, Mohammad/L-9204-2016
OI Fathalipour, Mohammad/0000-0002-4568-7024
FU Hormozgan University of Medical Sciences, Bandar Abbas, Iran [990061]
FX This trial has been supported by Hormozgan University of Medical
   Sciences, Bandar Abbas, Iran (grant no. 990061). The funders have no
   role in the design of the trial, the intervention procedures,
   collection, evaluation, and analysis of data.
NR 0
TC 0
Z9 0
U1 4
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 15
PY 2020
VL 21
IS 1
AR 790
DI 10.1186/s13063-020-04706-3
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NT9TJ
UT WOS:000573284300001
PM 32933552
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Diener, M
   Adamcik, J
   Mezzenga, R
AF Diener, Michael
   Adamcik, Jozef
   Mezzenga, Raffaele
TI Formation of Higher Structural Levels in lambda-Carrageenan Induced by
   the Antimalarial Drug Chloroquine
SO ACS MACRO LETTERS
LA English
DT Article
ID METHYLENE-BLUE; PHARMACEUTICAL APPLICATIONS; POLYSACCHARIDE HYDROGELS;
   MARINE POLYSACCHARIDES; PROTEIN INTERACTIONS; DELIVERY; SYSTEM; COIL;
   DNA
AB The linear polysaccharide lambda-carrageenan is the only one among the carrageenans not forming secondary, tertiary, and quaternary structures in the presence of inorganic ions. Chloroquine (CQ) is a well-established antimalaria drug also recently discussed in therapeutics against the COVID-19 pandemic. The interaction of this polysaccharide-ionic drug pair was investigated by combining UV-vis spectrophotometry and atomic force microscopy (AFM) imaging. A decrease of the UV peak assigned to free CQ and the occurrence of isosbestic points indicate the formation of complexes. High-resolution AFM height images revealed an increasing height of the single polysaccharide chains in the random coil state upon addition of CQ, indicating the formation of a secondary structure, followed by higher hierarchical aggregates. The disappearance of higher-ordered structures and the recovery of polysaccharide chains with primary structure were observed by introducing inorganic cations (Na+, K+, Ca2+), replacing the condensed CQ and paving the way to reversible ion-induced drug release.
C1 [Diener, Michael; Adamcik, Jozef; Mezzenga, Raffaele] Swiss Fed Inst Technol Zurich, Dept Hlth Sci & Technol, CH-8092 Zurich, Switzerland.
   [Mezzenga, Raffaele] Swiss Fed Inst Technol Zurich, Dept Mat, CH-8092 Zurich, Switzerland.
RP Mezzenga, R (corresponding author), Swiss Fed Inst Technol Zurich, Dept Hlth Sci & Technol, CH-8092 Zurich, Switzerland.; Mezzenga, R (corresponding author), Swiss Fed Inst Technol Zurich, Dept Mat, CH-8092 Zurich, Switzerland.
EM raffaele.mezzenga@hest.ethz.ch
OI Diener, Michael/0000-0003-0919-9434
CR Adamcik J, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/38/384016
   Agougui H, 2017, J APPL POLYM SCI, V134, DOI 10.1002/app.45385
   Agrawal P, 2007, BIOMATERIALS, V28, P3349, DOI 10.1016/j.biomaterials.2007.04.004
   Alvarez-Lorenzo C, 2013, ADV DRUG DELIVER REV, V65, P1148, DOI 10.1016/j.addr.2013.04.016
   Bajpai AK, 2006, J MATER SCI-MATER M, V17, P345, DOI 10.1007/s10856-006-8235-9
   Bonferoni MC, 2004, PHARM DEV TECHNOL, V9, P155, DOI 10.1081/PDT-120027428
   Campo VL, 2009, CARBOHYD POLYM, V77, P167, DOI 10.1016/j.carbpol.2009.01.020
   Cao YP, 2020, NAT FOOD, V1, P106, DOI 10.1038/s43016-019-0009-x
   Cao YP, 2015, J PHYS CHEM B, V119, P9982, DOI 10.1021/acs.jpcb.5b05002
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Coviello T, 2007, J CONTROL RELEASE, V119, P5, DOI 10.1016/j.jconrel.2007.01.004
   Cunha L, 2016, MAR DRUGS, V14, DOI 10.3390/md14030042
   Deshpande S, 2016, MED CHEM, V6, P1, DOI DOI 10.4172/2161-0444.1000315
   Diener M, 2020, ACS MACRO LETT, V9, P115, DOI 10.1021/acsmacrolett.9b00824
   Diener M, 2019, BIOMACROMOLECULES, V20, P1731, DOI 10.1021/acs.biomac.9b00087
   Djabourov M., 2013, PHYS GELS BIOL SYNTH, DOI [10.1017/CBO9781139024136, DOI 10.1017/CBO9781139024136]
   JACKSON RL, 1991, PHYSIOL REV, V71, P481
   Japaridze A, 2017, NANO LETT, V17, P1938, DOI 10.1021/acs.nanolett.6b05294
   Laurienzo P, 2010, MAR DRUGS, V8, P2435, DOI 10.3390/md8092435
   Li L, 2014, CARBOHYD POLYM, V103, P1, DOI 10.1016/j.carbpol.2013.12.008
   Ling YP, 2013, AIP CONF PROC, V1571, P717, DOI 10.1063/1.4858739
   Lyubchenko YL, 1997, P NATL ACAD SCI USA, V94, P496, DOI 10.1073/pnas.94.2.496
   Matricardi P, 2013, ADV DRUG DELIVER REV, V65, P1172, DOI 10.1016/j.addr.2013.04.002
   Michon C, 2002, FOOD HYDROCOLLOID, V16, P613, DOI 10.1016/S0268-005X(02)00024-3
   Moles E, 2015, J CONTROL RELEASE, V210, P217, DOI 10.1016/j.jconrel.2015.05.284
   Nzekwe I. T., 2015, Journal of Chemical and Pharmaceutical Research, V7, P932
   Otelo VA, 2011, BIOORG MED CHEM LETT, V21, P250, DOI 10.1016/j.bmcl.2010.11.019
   Pavli M, 2011, INT J PHARMACEUT, V421, P110, DOI 10.1016/j.ijpharm.2011.09.019
   Rinaudo M., 1993, J INTEL MAT SYST STR, V4, P210, DOI DOI 10.1177/1045389X9300400210
   Rohart A, 2015, FOOD HYDROCOLLOID, V43, P769, DOI 10.1016/j.foodhyd.2014.08.007
   Schefer L, 2015, NANOSCALE, V7, P16182, DOI 10.1039/c5nr04525h
   Schefer L, 2015, BIOMACROMOLECULES, V16, P985, DOI 10.1021/bm501874k
   Schefer L, 2014, ANGEW CHEM INT EDIT, V53, P5376, DOI 10.1002/anie.201402855
   Shi QM, 2017, CARBOHYD RES, V453-454, P1, DOI 10.1016/j.carres.2017.10.020
   Srivastava V, 2015, EUR J PHARMACOL, V762, P472, DOI 10.1016/j.ejphar.2015.04.048
   SWINGLE KF, 1974, BIOCHEM PHARMACOL, V23, P1669, DOI 10.1016/0006-2952(74)90393-1
   van de Velde F., 2005, BIOSYS HERMES 2005 C, P1, DOI 10.1002/3527600035.bpol6009
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yegappan R, 2018, CARBOHYD POLYM, V198, P385, DOI 10.1016/j.carbpol.2018.06.086
   Yu Y, 2018, CARBOHYD POLYM, V183, P91, DOI 10.1016/j.carbpol.2017.12.009
   Ziolkowska D, 2017, CARBOHYD POLYM, V165, P1, DOI 10.1016/j.carbpol.2017.02.029
NR 41
TC 0
Z9 0
U1 5
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
EI 2161-1653
J9 ACS MACRO LETT
JI ACS Macro Lett.
PD SEP 15
PY 2020
VL 9
IS 9
BP 1310
EP 1317
DI 10.1021/acsmacrolett.0c00501
PG 8
WC Polymer Science
SC Polymer Science
GA NT3JA
UT WOS:000572840300016
DA 2021-01-01
ER

PT J
AU Madariaga, A
   McMullen, M
   Sheikh, S
   Kumar, R
   Liu, FF
   Zimmermann, C
   Husain, S
   Zadeh, G
   Oza, AM
AF Madariaga, Ainhoa
   McMullen, Michelle
   Sheikh, Semira
   Kumar, Rajat
   Liu, Fei-Fei
   Zimmermann, Camilla
   Husain, Shahid
   Zadeh, Gelareh
   Oza, Amit M.
TI COVID-19 Testing in Patients with Cancer: Does One Size Fit All?
SO CLINICAL CANCER RESEARCH
LA English
DT Article
AB The COVID-19 global pandemic has drastically impacted cancer care, posing challenges in treatment and diagnosis. There is increasing evidence that cancer patients, particularly those who have advanced age, significant comorbidities, metastatic disease, and/or are receiving active immunosuppressive therapy may be at higher risk of COVID-19 severe complications. Controlling viral spread from asymptomatic carriers in cancer centers is paramount, and appropriate screening methods need to be established. Universal testing of asymptomatic cancer patients may be key to ensure safe continuation of treatment and appropriate hospitalized patients cohorting during the pandemic. Here we perform a comprehensive review of the available evidence regarding SARS-CoV-2 testing in asymptomatic cancer patients, and describe the approach adopted at Princess Margaret Cancer Centre (Toronto, Canada) as a core component of COVID-19 control.
C1 [Madariaga, Ainhoa; McMullen, Michelle; Sheikh, Semira; Kumar, Rajat; Oza, Amit M.] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada.
   [Liu, Fei-Fei] Univ Hlth Network, Princess Margaret Canc Ctr, Div Radiat Oncol, Toronto, ON, Canada.
   [Zimmermann, Camilla] Univ Hlth Network, Princess Margaret Canc Ctr, Div Palliat Care, Toronto, ON, Canada.
   [Husain, Shahid] Univ Hlth Network, Toronto Gen Hosp, Div Infect Dis, Toronto, ON, Canada.
   [Zadeh, Gelareh] Univ Hlth Network, Toronto Gen Hosp, Div Surg, Toronto, ON, Canada.
RP Oza, AM (corresponding author), Princess Margaret Canc Ctr, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.
EM amit.oza@uhn.ca
RI Madariaga, Ainhoa/ABG-9146-2020
OI Madariaga, Ainhoa/0000-0001-7166-9762; Zimmermann,
   Camilla/0000-0003-4889-0244
CR Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Basile C, 2020, NEPHROL DIAL TRANSPL, V35, P737, DOI 10.1093/ndt/gfaa069
   Cancer Care Ontario, 2020, PAND PLANN CLIN GUID
   Corman VM, 2019, EUROSURVEILLANCE, V2020, P25, DOI DOI 10.2807/1560-7917.ES.202025.3.2000045
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Dohla M, 2020, PUBLIC HEALTH, V182, P170, DOI 10.1016/j.puhe.2020.04.009
   European Centre for Disease Prevention and Control (ECDC), CAS DEF EUR SURV COV
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Huang WE, 2020, MICROB BIOTECHNOL, V13, P950, DOI 10.1111/1751-7915.13586
   IDSA, COVID 19 PRIOR DIAGN
   Infectious Diseases Society of America, IDSA REL ANT TEST PR
   Iwen PC, 2020, LAB MED, V51, P239, DOI 10.1093/labmed/lmaa018
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li YF, 2020, J MED VIROL, V92, P903, DOI 10.1002/jmv.25786
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Ontario Ministry of Health, 2020, COV 19 PROV TEST GUI
   Ooi EE, 2020, LANCET INFECT DIS, V20, P996, DOI 10.1016/S1473-3099(20)30460-6
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Rubin GD, 2020, CHEST, V158, P106, DOI 10.1016/j.chest.2020.04.003
   Simpson S, 2020, J THORAC IMAG, V35, P219, DOI 10.1097/RTI.0000000000000524
   SONG Y, 2020, J CLIN MICROBIOL, P20, DOI DOI 10.1007/S42770-020-00345-7
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   To KKW, 2019, CLIN MICROBIOL INFEC, V25, P372, DOI 10.1016/j.cmi.2018.06.009
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Uyeki TM, 2017, ANN INTERN MED, V167, pITC33, DOI 10.7326/AITC201709050
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Wilder-Smith A, 2020, LANCET INFECT DIS, V20, pE102, DOI 10.1016/S1473-3099(20)30129-8
   Williams E, 2020, J CLIN MICROBIOL
   Williams M, 2020, ESTIMATING RISKS COV, DOI [10.1101/2020.03.18., DOI 10.1101/2020.03.18]
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   World Health Organization, 2020, LAB TEST COR DIS 201
   Xiao AT, 2020, J MED VIROL, V92, P1755, DOI 10.1002/jmv.25855
   Yang Y, 2020, LAB DIAGNOSIS MONITO, V39, pe95
   Young S, 2020, J CLIN PATHOL, V73, P328, DOI 10.1136/jclinpath-2019-206242
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao QW, 2020, INT J INFECT DIS, V96, P131, DOI 10.1016/j.ijid.2020.04.086
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 45
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 15
PY 2020
VL 26
IS 18
BP 4737
EP 4742
DI 10.1158/1078-0432.CCR-20-2224
PG 6
WC Oncology
SC Oncology
GA NT3DN
UT WOS:000572826000004
PM 32616498
OA Bronze
DA 2021-01-01
ER

PT J
AU Xi, YZ
AF Xi, Yongzhi
TI Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
SO SIGNAL TRANSDUCTION AND TARGETED THERAPY
LA English
DT Article
ID IMMUNOTHERAPY; INFLUENZA
C1 [Xi, Yongzhi] Chinese Peoples Liberat Army Gen Hosp, Dept Immunol, Med Ctr 5, 8 Dongda Ave, Beijing 100071, Peoples R China.
   [Xi, Yongzhi] Chinese Peoples Liberat Army Gen Hosp, Natl Ctr Biomed Anal, Med Ctr 5, 8 Dongda Ave, Beijing 100071, Peoples R China.
RP Xi, YZ (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Immunol, Med Ctr 5, 8 Dongda Ave, Beijing 100071, Peoples R China.; Xi, YZ (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Natl Ctr Biomed Anal, Med Ctr 5, 8 Dongda Ave, Beijing 100071, Peoples R China.
EM xiyz@yahoo.com
CR Baden LR, 2020, NEW ENGL J MED, V382, P1851, DOI 10.1056/NEJMe2005477
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Dean NE, 2020, NEW ENGL J MED, V382, P1366, DOI 10.1056/NEJMsb1905390
   Eroshenko N, 2020, NAT BIOTECHNOL, V38, P789, DOI 10.1038/s41587-020-0577-1
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Luke TC, 2010, CRIT CARE MED, V38, pE66, DOI 10.1097/CCM.0b013e3181d44c1e
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Mupapa K, 1999, J INFECT DIS, V179, pS18, DOI 10.1086/514298
   Naranjo-Gomez M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97339
   Nasser R, 2013, BLOOD, V121, P1102, DOI 10.1182/blood-2012-06-432153
   National Health Commission of the People's Republic of China, 2020, OFF GUID PREV CONTR
   National Institutes of Health, 2020, COR DIS 2019 COVID 1
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Pelegrin M, 2015, TRENDS MICROBIOL, V23, P653, DOI 10.1016/j.tim.2015.07.005
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991
   Ulrich H, 2020, CYTOM PART A, V97, P662, DOI 10.1002/cyto.a.24047
   VON BEHRING H, 1954, Dtsch Med J, V5, P172
   WHO, 2020, 209 WHO
   Who Mers-Cov Research Group, 2013, PLoS Curr, V5, DOI 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8
   Wong HK, 2010, TRANSFUSION, V50, P1967, DOI 10.1111/j.1537-2995.2010.02651.x
   Yeh KM, 2005, J ANTIMICROB CHEMOTH, V56, P919, DOI 10.1093/jac/dki346
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
NR 23
TC 1
Z9 1
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095-9907
EI 2059-3635
J9 SIGNAL TRANSDUCT TAR
JI Signal Transduct. Target. Ther.
PD SEP 15
PY 2020
VL 5
IS 1
AR 203
DI 10.1038/s41392-020-00310-8
PG 4
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NT6XA
UT WOS:000573079900001
PM 32934211
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

EF